PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mishra, DP; Shaha, C				Mishra, DP; Shaha, C			Estrogen-induced spermatogenic cell apoptosis occurs via the mitochondrial pathway - Role of superoxide and nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS LIGAND EXPRESSION; SEMINIFEROUS TUBULES; BISPHENOL-A; IN-VITRO; RECEPTOR; TESTIS; 17-BETA-ESTRADIOL; DEATH; PROLIFERATION; FERTILITY	The detrimental effects of estrogen on testicular function provide a conceptual basis to examine the speculative link between increased exposure to estrogens and spermatogenic cell death. Using an in vitro model, we provide an understanding of the events leading to estrogen-induced apoptosis in cells of spermatogenic lineage. Early events associated with estrogen exposure were up-regulation of FasL and increased generation of H2O2, superoxide, and nitric oxide. The ability of anti-FasL antibodies to prevent several downstream biochemical changes and cell death induced by 17beta-estradiol substantiates the involvement of the cell death receptor pathway. Evidence for the amplification of the death-inducing signals through mitochondria was obtained from the transient mitochondrial hyperpolarization observed after estradiol exposure resulting in cytochrome c release. A combination of nitric oxide and superoxide but not H2O2 was responsible for the mitochondrial hyperpolarization. Mn(III) tetrakis(4-benzoic acid)porphyrin chloride, an intracellular peroxynitrite scavenger, was able to reduce mitochondrial hyperpolarization and cell death. Although nitric oxide augmentation occurred through an increase in the expression of inducible nitric-oxide synthase, superoxide up-regulation was a product of estradiol metabolism. All of the above changes were mediated through an estrogen receptor-based mechanism because tamoxifen, the estrogen receptor modulator, was able to rescue the cells from estrogen-induced alterations. This study establishes the importance of the independent capability of cells of the spermatogenic lineage to respond to estrogens and most importantly suggests that low dose estrogens can potentially cause severe spermatogenic cellular dysfunction leading to impaired fertility even without interference of the hypothalamo-hypophyseal axis.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Shaha, C (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	cshaha@nii.res.in						Akingbemi BT, 2004, P NATL ACAD SCI USA, V101, P775, DOI 10.1073/pnas.0305977101; Amant C, 2001, CIRCULATION, V104, P2576, DOI 10.1161/hc4601.099406; ARAVINDA S, 1995, J BIOL CHEM, V270, P15675, DOI 10.1074/jbc.270.26.15675; Atanassova N, 2000, ENDOCRINOLOGY, V141, P3898, DOI 10.1210/en.141.10.3898; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; CORADINI D, 1994, ANTICANCER RES, V14, P1779; Denning TL, 2002, FREE RADICAL BIO MED, V33, P1641, DOI 10.1016/S0891-5849(02)01141-3; Devadas S, 2003, FREE RADICAL BIO MED, V35, P648, DOI 10.1016/S0891-5849(03)00391-5; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Farinati F, 2002, MOL CELL ENDOCRINOL, V193, P85, DOI 10.1016/S0303-7207(02)00100-4; Fukuzawa NH, 2003, TOXICOL IN VITRO, V17, P259, DOI 10.1016/S0887-2333(03)00011-0; Hess Rex A, 2003, Reprod Biol Endocrinol, V1, P52, DOI 10.1186/1477-7827-1-52; Hikim APS, 2003, J STEROID BIOCHEM, V85, P175, DOI 10.1016/S0960-0760(03)00193-6; Iida H, 2003, REPROD TOXICOL, V17, P457, DOI 10.1016/S0890-6238(03)00034-0; Johnson L, 1999, BIOL REPROD, V61, P927, DOI 10.1095/biolreprod61.4.927; Kabuto H, 2004, LIFE SCI, V74, P2931, DOI 10.1016/j.lfs.2003.07.060; Kang YC, 2004, IN VIVO, V18, P367; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Knox PG, 2003, J IMMUNOL, V170, P677, DOI 10.4049/jimmunol.170.2.677; Koji T, 2003, ARCH HISTOL CYTOL, V66, P1, DOI 10.1679/aohc.66.1; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KUSHNER PJ, 1990, MOL ENDOCRINOL, V4, P1465, DOI 10.1210/mend-4-10-1465; Liang BC, 1999, APOPTOSIS, V4, P89, DOI 10.1023/A:1009610625150; Liu H, 2003, J NATL CANCER I, V95, P1586, DOI 10.1093/jnci/djg080; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; Mor G, 2003, J IMMUNOL, V170, P114, DOI 10.4049/jimmunol.170.1.114; Nair R, 2003, J BIOL CHEM, V278, P6470, DOI 10.1074/jbc.M209319200; Nandi S, 1999, BIOL REPROD, V61, P70, DOI 10.1095/biolreprod61.1.70; Nilsson S, 2002, CRIT REV BIOCHEM MOL, V37, P1, DOI 10.1080/10409230290771438; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; Ohta S, 2003, CURR MED CHEM, V10, P2485, DOI 10.2174/0929867033456440; Perez-Cruz I, 2003, BLOOD, V102, P336, DOI 10.1182/blood-2002-11-3559; Print CG, 2000, BIOESSAYS, V22, P423, DOI 10.1002/(SICI)1521-1878(200005)22:5&lt;423::AID-BIES4&gt;3.0.CO;2-0; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Rao AVSK, 2000, FREE RADICAL BIO MED, V29, P1015, DOI 10.1016/S0891-5849(00)00408-1; Sapi E, 2002, J SOC GYNECOL INVEST, V9, P243, DOI 10.1016/S1071-5576(02)00162-4; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; Song RXD, 2003, APOPTOSIS, V8, P55, DOI 10.1023/A:1021649019025; Toppari J, 1998, BAILLIERE CLIN ENDOC, V12, P143, DOI 10.1016/S0950-351X(98)80529-6; WEICHSELBAUM RR, 1978, CANCER RES, V38, P2339; You HJ, 2003, BIOCHEM BIOPH RES CO, V303, P1129, DOI 10.1016/S0006-291X(03)00477-7	47	93	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6181	6196		10.1074/jbc.M405970200	http://dx.doi.org/10.1074/jbc.M405970200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15545282	hybrid			2022-12-25	WOS:000227217100125
J	Jiang, BH; Liu, WB; Qu, H; Meng, L; Song, SM; Tao, OY; Shou, CC				Jiang, BH; Liu, WB; Qu, H; Meng, L; Song, SM; Tao, OY; Shou, CC			A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; PROTEIN; RECEPTOR; VACCINE; CELL; ANTIBODY	Trastuzumab, a humanized antibody to HER-2, has been shown to be effective in the treatment of breast cancer in which HER-2 overexpression and metastasis occurs. In our search for an effective mimic epitope of HER-2 binding with trastuzumab and to develop HER-2 peptide vaccine, we screened a phage display 12-mer peptide library with trastuzumab as the target. A mimetic peptide (mimotope) H98 (LLGPYELWELSH) that could specifically recognize trastuzumab was isolated. The DNA encoding peptide H98 was cloned and expressed as the fusion protein GST-H98 in Escherichia coli BL21. The purified GST-H98 could specifically bind to trastuzumab and block the binding of trastuzumab to HER-2 protein. Moreover, H98 could significantly block the function of trastuzumab inhibiting the growth of cancer cells. Mice that were immunized with GST-H98 made specific antibody to H98 as well as to HER-2. In addition, T-cell proliferation occurred in mice immunized with GST-H98. Although no sequence homology was found between H98 and HER-2, through the use of structure analysis we were able to determine that peptide H98 contributed to a conformational epitope of HER-2. Furthermore, we determined that the last two amino acids at the C terminus, and the third together with the fourth amino acid at the N terminus of peptide H98 are critical to the binding of H98 to trastuzumab. As a result, we conclude that peptide H98 has potential for being developed as a HER-2 vaccine for biotherapy of cancer with HER-2 overexpression.	Peking Univ, Sch Oncol, Beijing Inst Canc Res, Dept Biochem & Mol Biol, Beijing 100034, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Beijing Canc Hosp, Breast Canc Ctr, Beijing 100036, Peoples R China	Peking University; Peking University; Peking University	Shou, CC (corresponding author), Peking Univ, Sch Oncol, Beijing Inst Canc Res, Dept Biochem & Mol Biol, Da Hong Luo Chang St 1, Beijing 100034, Peoples R China.	cshou@vip.sina.com						Aina OH, 2002, BIOPOLYMERS, V66, P184, DOI 10.1002/bip.10257; Baral RN, 2003, CANCER IMMUNOL IMMUN, V52, P317, DOI 10.1007/s00262-002-0351-x; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Dakappagari NK, 2000, CANCER RES, V60, P3782; Dakappagari NK, 2003, J IMMUNOL, V170, P4242, DOI 10.4049/jimmunol.170.8.4242; Disis ML, 1997, J CLIN ONCOL, V15, P3363, DOI 10.1200/JCO.1997.15.11.3363; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; DISIS ML, 1994, CANCER RES, V54, P16; Liu RW, 2003, EXP HEMATOL, V31, P11, DOI 10.1016/S0301-472X(02)01008-1; Nabholtz Jean-Marc, 2002, Clin Breast Cancer, V3 Suppl 2, pS75; Nahta R, 2003, ONCOLOGIST, V8, P5, DOI 10.1634/theoncologist.8-1-5; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Riemer AB, 2004, J IMMUNOL, V173, P394, DOI 10.4049/jimmunol.173.1.394; Romanov VI, 2003, CURR CANCER DRUG TAR, V3, P119, DOI 10.2174/1568009033482010; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Wang SC, 2001, SEMIN ONCOL, V28, P21, DOI 10.1053/sonc.2001.29724; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yip YL, 2001, J IMMUNOL, V166, P5271, DOI 10.4049/jimmunol.166.8.5271; Yip Yum L., 2002, Current Pharmaceutical Biotechnology, V3, P29, DOI 10.2174/1389201023378472	24	48	165	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4656	4662		10.1074/jbc.M411047200	http://dx.doi.org/10.1074/jbc.M411047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15536075	hybrid			2022-12-25	WOS:000227096600081
J	Konno, D; Yoshimura, S; Hori, K; Maruoka, H; Sobue, K				Konno, D; Yoshimura, S; Hori, K; Maruoka, H; Sobue, K			Involvement of the phosphatidylinositol 3-kinase/Rac1 and cdc42 pathways in radial migration of cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; INTEGRIN; POLARITY; RAC; PHOSPHORYLATION; ORGANIZATION; EXPRESSION; RECEPTORS; EFFECTOR; MOTILITY	During cortical development, newly generated neurons migrate radially toward their final positions. Although several candidate genes essential for this radial migration have been reported, the signaling pathways regulating it are largely unclear. Here we studied the role of phosphatidylinositol (PI) 3-kinase and its downstream signaling molecules in the radial migration of cortical neurons in vivo and in vitro. The expression of constitutively active and dominant-negative PI 3-kinases markedly inhibited radial migration. In the neocortical slice culture, a PI 3-kinase inhibitor suppressed the formation of GTP-bound Rac1 and Cdc42 and radial migration. Constitutively active and dominant-negative forms of Rac1 and Cdc42 but not Akt also significantly inhibited radial migration. In migrating neurons, wild-type Rac1 and Cdc42 showed different localizations; Rac1 localized to the plasma membrane and Cdc42 to the perinuclear region on the side of the leading processes. These results suggest that both the PI 3-kinase/Rac1 and Cdc42 pathways are involved in the radial migration of cortical neurons and that they have different roles.	Osaka Univ, Dept Neurosci D13, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University	Sobue, K (corresponding author), Osaka Univ, Dept Neurosci D13, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sobue@nbiochem.med.osaka-u.ac.jp		Maruoka, Hisato/0000-0002-7185-3356				Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; FISHMAN RB, 1993, J NEUROSCI, V13, P3485; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gleeson JG, 2000, TRENDS NEUROSCI, V23, P352, DOI 10.1016/S0166-2236(00)01607-6; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Hatanaka Y, 2002, J COMP NEUROL, V454, P1, DOI 10.1002/cne.10421; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Kawauchi T, 2003, EMBO J, V22, P4190, DOI 10.1093/emboj/cdg413; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; LIESI P, 1985, EMBO J, V4, P1163, DOI 10.1002/j.1460-2075.1985.tb03755.x; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Morris NR, 1998, TRENDS CELL BIOL, V8, P467, DOI 10.1016/S0962-8924(98)01389-0; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohkawa Y, 2003, BIOCHEM BIOPH RES CO, V301, P78, DOI 10.1016/S0006-291X(02)02965-0; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Tabata H, 2002, J NEUROSCI RES, V69, P723, DOI 10.1002/jnr.10345; Tanaka T, 2004, NEURON, V41, P215, DOI 10.1016/S0896-6273(03)00852-3; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	32	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5082	5088		10.1074/jbc.M408251200	http://dx.doi.org/10.1074/jbc.M408251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557338	hybrid			2022-12-25	WOS:000227096600130
J	She, HY; Xiong, SG; Hazra, S; Tsukamoto, H				She, HY; Xiong, SG; Hazra, S; Tsukamoto, H			Adipogenic transcriptional regulation of hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA ACTIVITY; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; X-RECEPTOR; RAT-LIVER; BINDING; PROTEIN; ALPHA; METABOLISM; IDENTIFICATION	Hepatic stellate cells (HSC undergo transdifferentiation (activation) from lipid-storing pericytes to myofibroblastic cells to participate in liver fibrogenesis. Our recent work demonstrates that depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) constitutes one of the key molecular events for HSC activation and that ectopic expression of this nuclear receptor achieves the phenotypic reversal of activated HSC to the quiescent cells. The present study extends these findings to test a novel hypothesis that adipogenic transcriptional regulation is required for the maintenance of HSC quiescence. Comparative analysis of quiescent and activated HSC in culture reveals higher expression of putative adipogenic transcription factors such as CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBP)beta, C/EBPdelta, PPARgamma, liver X receptor a, sterol regulatory element-binding protein 1c and of adipocyte-specific genes in the quiescent cells. Conversely, activated HSC have increased expression of PPARbeta, a transcription factor known to promote fatty acid oxidation. A treatment of activated HSC with the adipocyte differentiation mixture (isobutylmethylxanthine, dexamethasone, and insulin) or ectopic expression of PPARgamma or SREBP-1c in these cells, induces a panel of adipogenic transcription factors, reduces PPARbeta, and causes the phenotypic reversal to quiescent HSC. These results support the importance of adipogenic transcriptional regulation in HSC quiescence and provide a new framework for identifying novel molecular targets for the treatment of liver cirrhosis.	Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; Dept Vet Affairs Greater Los Angeles Healthcare S, Los Angeles, CA 90073 USA	University of Southern California	Tsukamoto, H (corresponding author), Univ So Calif, Keck Sch Med, 1333 San Pablo St,MMR 402, Los Angeles, CA 90033 USA.	htsukamo@usc.edu			NIAAA NIH HHS [R24 AA12885, R37 AA006603, P50 AA11999] Funding Source: Medline; NIDDK NIH HHS [P30 DK48522] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999, R37AA006603, R24AA012885] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abderrahim-Ferkoune A, 2004, EXP CELL RES, V293, P219, DOI 10.1016/j.yexcr.2003.10.020; Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Bostrom K, 2000, J CELL BIOCHEM, V78, P210, DOI 10.1002/(SICI)1097-4644(20000801)78:2<210::AID-JCB4>3.0.CO;2-Z; Camp HS, 1997, J BIOL CHEM, V272, P10811; Cassiman D, 1999, AM J PATHOL, V155, P1831, DOI 10.1016/S0002-9440(10)65501-0; Cassiman D, 2001, HEPATOLOGY, V33, P148, DOI 10.1053/jhep.2001.20793; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ENZAN H, 1994, VIRCHOWS ARCH, V424, P249; Friedman SL, 2003, J HEPATOL, V38, pS38, DOI 10.1016/S0168-8278(02)00429-4; FRIEDMAN SL, 1993, AM J PHYSIOL, V264, pG947, DOI 10.1152/ajpgi.1993.264.5.G947; Galli A, 2002, GASTROENTEROLOGY, V122, P1924, DOI 10.1053/gast.2002.33666; GARD AL, 1985, J NEUROIMMUNOL, V8, P359, DOI 10.1016/S0165-5728(85)80073-4; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hazra S, 2004, J BIOL CHEM, V279, P11392, DOI 10.1074/jbc.M310284200; Hellemans K, 2003, J LIPID RES, V44, P280, DOI 10.1194/jlr.M200376-JLR200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; ITO T, 1952, Okajimas Folia Anat Jpn, V24, P243; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Li JP, 2003, P NATL ACAD SCI USA, V100, P9476, DOI 10.1073/pnas.1133426100; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Pinzani M, 2001, SEMIN LIVER DIS, V21, P397, DOI 10.1055/s-2001-17554; RAMADORI G, 1990, VIRCHOWS ARCH B, V59, P349, DOI 10.1007/BF02899424; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430-3444.2004; Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Sung CK, 2004, AM J PHYSIOL-GASTR L, V286, pG722, DOI 10.1152/ajpgi.00411.2003; Suskind DL, 2004, J HEPATOL, V40, P261, DOI 10.1016/j.jhep.2003.11.007; Trim N, 2000, AM J PATHOL, V156, P1235, DOI 10.1016/S0002-9440(10)64994-2; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	47	226	243	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4959	4967		10.1074/jbc.M410078200	http://dx.doi.org/10.1074/jbc.M410078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15537655	hybrid			2022-12-25	WOS:000227096600117
J	Ewart, MA; Clarke, M; Kane, S; Chamberlain, LH; Gould, GW				Ewart, MA; Clarke, M; Kane, S; Chamberlain, LH; Gould, GW			Evidence for a role of the exocyst in insulin-stimulated Glut4 trafficking in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; FACTOR-II RECEPTORS; PLASMA-MEMBRANE; SEC6/8 COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSFERRIN RECEPTORS; CELL-SURFACE; EXOCYTOSIS; RESISTANCE; VESICLES	Insulin stimulates glucose transport in adipocytes and muscle by inducing the redistribution of Glut4 from intracellular locations to the plasma membrane. The fusion of Glut4-containing vesicles at the plasma membrane is known to involve the target SNAREs syntaxin 4 and SNAP-23 and the vesicle SNARE VAMP2. Little is known about the initial docking of Glut4 vesicles with the plasma membrane. A recent report has implicated Exo70, a component of the mammalian exocyst complex, in the initial interaction of Glut4 vesicles with the adipocyte plasma membrane. Here, we have examined the role of two other exocyst components, rsec6 and rsec8. We show that insulin promotes a redistribution of rsec6 and rsec6 to the plasma membrane and to cytoskeletal fractions within 3T3-L1 adipocytes but does not modulate levels of these proteins co-localized with Glut4. We further show that adenoviral-mediated overexpression of either rsec6 or rsec8 increases the magnitude of insulin-stimulated glucose transport in 3T3-L1 adipocytes. By contrast, overexpression of rsec6 or rsec8 did not increase the extent of the secretion of adipsin or ACRP30 from adipocytes and had no discernible effect on transferrin receptor traffic. Collectively, our data support a role for the exocyst in insulin-stimulated glucose transport and suggest a model by which insulin-dependent relocation of the exocyst to the plasma membrane may contribute to the specificity of Glut4 vesicle docking and fusion with the adipocyte plasma membrane.	Univ Glasgow, Fac Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Gould, GW (corresponding author), Univ Glasgow, Fac Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	G.Gould@bio.gla.ac.uk		Gould, Gwyn/0000-0001-6571-2875; Clarke, Mairi/0000-0002-9658-4308	Biotechnology and Biological Sciences Research Council [REI18423] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BRANT AM, 1993, BIOCHEM BIOPH RES CO, V192, P1297, DOI 10.1006/bbrc.1993.1557; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; EauClaire S, 2003, NEURON, V37, P369, DOI 10.1016/S0896-6273(03)00059-X; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; Matern HT, 2001, P NATL ACAD SCI USA, V98, P9648, DOI 10.1073/pnas.171317898; Millar CA, 2000, TRAFFIC, V1, P141, DOI 10.1034/j.1600-0854.2000.010206.x; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Murthy M, 2003, NEURON, V37, P433, DOI 10.1016/S0896-6273(03)00031-X; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; REAVEN GM, 1989, DIABETES, V38, P1155, DOI 10.2337/diabetes.38.9.1155; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088	30	40	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3812	3816		10.1074/jbc.M409928200	http://dx.doi.org/10.1074/jbc.M409928200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550383	hybrid			2022-12-25	WOS:000226983900083
J	Ferreri-Jacobia, M; Mak, DOD; Foskett, JK				Ferreri-Jacobia, M; Mak, DOD; Foskett, JK			Translational mobility of the type 3 inositol 1,4,5-trisphosphate receptor Ca2+ release channel in endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; PANCREATIC ACINAR-CELLS; XENOPUS-LAEVIS OOCYTES; IP3 RECEPTORS; TRISPHOSPHATE RECEPTOR; LATERAL DIFFUSION; COMPLEX-FORMATION; GATED CHANNELS; CYTOSOLIC CA2+; LIVING CELLS	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) is an integral membrane protein in the endoplasmic reticulum. (ER) which functions as a ligand-gated Ca2+ release channel. InsP(3)-mediated Ca2+ release modulates the cytoplasmic free Ca2+ concentration ([Ca2+](i)), providing a ubiquitous intracellular signal with high temporal and spatial specificity. Precise localization of the InsP,R is believed to be important for providing local [Ca2+] regulation and for ensuring efficient functional coupling between Ca2+ release sites by enabling graded recruitment of channels with increasing stimulus strength in the face of the intrinsically unstable regenerative process of Ca2+-induced Ca2+ release. Highly localized Ca2+ release has been attributed to the ability of the InsP3R channels to cluster and to be localized to discrete areas, suggesting that mechanisms may exist to restrict their movement. Here, we examined the lateral mobility of the type 3 isoform of the InsP(3)R (InsP(3)R3) in the ER membrane by performing confocal fluorescence recovery after photobleaching of an InSP(3)R3 with green fluorescent protein fused to its N terminus. In Chinese hamster ovary and COS-7 cells, the diffusion coefficient D was similar to4 x 10(-10) cm(2)/s at room temperature, a value similar to that determined for other ER-localized integral membrane proteins, with a high fraction (similar to75%) of channels mobile. D was modestly increased at 37 degreesC, and it as well as the mobile fraction were reversibly reduced by ATP depletion. Although disruption of the actin cytoskeleton (latrunculin) was without effect, disruption,of microtubules (nocodazole) reduced D by half without affecting the mobile fraction. We conclude that the entire ER is continuous in these cells, with the large majority of InSP(3)R3 channels free to diffuse throughout it, at rates that are comparable with those measured for other polytopic ER integral membrane proteins. The observed InsP(3)R3 mobility may be higher than its intrinsic diffusional mobility because of additional ATPand microtubule-facilitated motility of the channel.	Univ Penn, Dept Physiol, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Foskett, JK (corresponding author), Univ Penn, Dept Physiol, Sch Med, B-39 Anat Chem Bldg, Philadelphia, PA 19104 USA.	foskett@mail.med.upenn.edu	Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059937] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL007027] Funding Source: Medline; NIMH NIH HHS [R01 MH059937, MH59937] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J EXP BIOL, V200, P315; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Bootman MD, 2001, J CELL SCI, V114, P2213; Bootman MD, 1996, CURR BIOL, V6, P855, DOI 10.1016/S0960-9822(02)00609-7; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Bruce JIE, 2004, J BIOL CHEM, V279, P12909, DOI 10.1074/jbc.M309070200; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; Duesbery NS, 1996, ZYGOTE, V4, P21, DOI 10.1017/S0967199400002859; Fogarty KE, 2000, J BIOL CHEM, V275, P22487, DOI 10.1074/jbc.M909402199; FUJIMOTO T, 1995, J CELL SCI, V108, P7; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Haggie PM, 2002, J BIOL CHEM, V277, P16419, DOI 10.1074/jbc.M112361200; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; Hattori M, 2004, J BIOL CHEM, V279, P11967, DOI 10.1074/jbc.M311456200; HIROSE K, 1994, NATURE, V372, P791; Horne JH, 1997, SCIENCE, V276, P1690, DOI 10.1126/science.276.5319.1690; Imreh G, 2003, EXP CELL RES, V284, P173, DOI 10.1016/S0014-4827(02)00034-4; Joseph SK, 2000, J BIOL CHEM, V275, P16084, DOI 10.1074/jbc.M000506200; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Levin MH, 2001, J BIOL CHEM, V276, P21331, DOI 10.1074/jbc.M101901200; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; Mak DOD, 2003, J GEN PHYSIOL, V122, P569, DOI 10.1085/jgp.200308808; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; Marchant JS, 2000, J GEN PHYSIOL, V116, P691, DOI 10.1085/jgp.116.5.691; Marchant JS, 2002, AM J PHYSIOL-CELL PH, V282, pC1374, DOI 10.1152/ajpcell.00446.2001; Marchant JS, 2001, EMBO J, V20, P65, DOI 10.1093/emboj/20.1.65; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; Maximov A, 2003, MOL CELL NEUROSCI, V22, P271, DOI 10.1016/S1044-7431(02)00027-1; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Morita T, 2002, CELL CALCIUM, V31, P59, DOI 10.1054/ceca.2001.0262; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nikonov AV, 2002, J CELL BIOL, V158, P497, DOI 10.1083/jcb.200201116; Olveczky BP, 1998, BIOPHYS J, V74, P2722, DOI 10.1016/S0006-3495(98)77978-0; Ostlund C, 1999, J CELL SCI, V112, P1709; Parker AKT, 2004, J BIOL CHEM, V279, P23797, DOI 10.1074/jbc.M402098200; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SASAKI T, 1994, AM J PHYSIOL, V267, pL152, DOI 10.1152/ajplung.1994.267.2.L152; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; SCHINDLER M, 1985, J CELL BIOL, V100, P1408, DOI 10.1083/jcb.100.5.1408; Spiliotis ET, 2002, MOL BIOL CELL, V13, P1566, DOI 10.1091/mbc.01-07-0322; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; Sugiyama T, 2000, FEBS LETT, V466, P29, DOI 10.1016/S0014-5793(99)01732-9; Sun XP, 1998, J PHYSIOL-LONDON, V509, P67, DOI 10.1111/j.1469-7793.1998.067bo.x; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; TASAKA K, 1991, SKIN PHARMACOL, V4, P43; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Thomas D, 1998, J BIOL CHEM, V273, P27130, DOI 10.1074/jbc.273.42.27130; Thomas D, 2000, CURR BIOL, V10, P8, DOI 10.1016/S0960-9822(99)00258-4; THORN P, 1993, J EXP BIOL, V184, P129; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Vermassen E, 2003, J CELL SCI, V116, P1269, DOI 10.1242/jcs.00354; Walker DS, 2002, CURR BIOL, V12, P951, DOI 10.1016/S0960-9822(02)00868-0; Yamamoto-Hino M, 1998, J CELL BIOL, V141, P135, DOI 10.1083/jcb.141.1.135; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	77	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3824	3831		10.1074/jbc.M409462200	http://dx.doi.org/10.1074/jbc.M409462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15537642	hybrid			2022-12-25	WOS:000226983900085
J	Bussiere, FI; Chaturvedi, R; Cheng, YL; Gobert, AP; Asim, M; Blumberg, DR; Xu, HX; Kim, PY; Hacker, A; Casero, RA; Wilson, KT				Bussiere, FI; Chaturvedi, R; Cheng, YL; Gobert, AP; Asim, M; Blumberg, DR; Xu, HX; Kim, PY; Hacker, A; Casero, RA; Wilson, KT			Spermine causes loss of innate immune response to Helicobacter pylori by inhibition of inducible nitric-oxide synthase translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE; MACROPHAGE APOPTOSIS; SURFACE-PROTEINS; CUTTING EDGE; EXPRESSION; INDUCTION; MECHANISM; CELLS; ACTIVATION; ARGININE	Helicobacter pylori infection of the stomach elicits a vigorous but ineffective host immune and inflammatory response, resulting in persistence of the bacterium for the life of the host. We have reported that in macrophages, H. pylori up-regulates inducible NO synthase (iNOS) and antimicrobial NO production, but in parallel there is induction of arginase 11, generating ornithine, and of ornithine decarboxylase (ODC), generating polyamines. Spermine, in particular, has been shown to restrain immune response in activated macrophages by inhibiting proinflammatory gene expression. We hypothesized that spermine could prevent the antimicrobial effects of NO by inhibiting iNOS in macrophages activated by H. pylori. Spermine did not affect the upregulation of iNOS mRNA levels but in a concentration-dependent manner significantly attenuated iNOS protein levels and NO production. Reduction in iNOS protein was due to inhibition of iNOS translation and not due to iNOS degradation. ODC knockdown with small interfering (si) RNA resulted in increased H. pylori-stimulated iNOS protein expression and NO production without altering iNOS mRNA levels. When macrophages were cocultured with H. pylori, killing of bacteria was enhanced by transfection of ODC siRNA and prevented by addition of spermine. These results identify a mechanism of immune dysregulation induced by H. pylori in which stimulated spermine synthesis by the arginase-ODC pathway inhibits iNOS translation and NO production, leading to persistence of the bacterium and risk for peptic ulcer disease and gastric cancer.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Wilson, KT (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, 22 S Greene St,Rm N3W62, Baltimore, MD 21201 USA.	kwilson@umaryland.edu	Gobert, Alain P/AHB-1368-2022; Kim, Paul/GYV-3258-2022	Kim, Paul/0000-0003-0943-4924; Casero, Robert/0000-0001-5653-3306; Bussiere, Francoise I/0000-0001-9365-6831; Wilson, Keith/0000-0003-4421-1830	NATIONAL CANCER INSTITUTE [R01CA098454, R01CA051085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK063626, R01DK053620] Funding Source: NIH RePORTER; NCI NIH HHS [CA51085, CA98454] Funding Source: Medline; NIDDK NIH HHS [DK53620, DK63626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baydoun AR, 1998, BRIT J PHARMACOL, V125, P1511, DOI 10.1038/sj.bjp.0702231; Casero RA, 2003, BIOCHEM SOC T, V31, P361, DOI 10.1042/BST0310361; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1991, J BIOL CHEM, V266, P810; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; El-Gayar S, 2003, J IMMUNOL, V171, P4561, DOI 10.4049/jimmunol.171.9.4561; FAUVE RM, 1983, J IMMUNOL METHODS, V64, P345, DOI 10.1016/0022-1759(83)90442-8; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; Gobert AP, 2002, J IMMUNOL, V168, P6002, DOI 10.4049/jimmunol.168.12.6002; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; Kuwahara H, 2000, INFECT IMMUN, V68, P4378, DOI 10.1128/IAI.68.8.4378-4383.2000; Lee J, 2003, P NATL ACAD SCI USA, V100, P4843, DOI 10.1073/pnas.0735876100; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; Meyer F, 2003, J IMMUNOL, V171, P3913, DOI 10.4049/jimmunol.171.8.3913; MORGAN DML, 1994, BIOCHEM SOC T, V22, pS389, DOI 10.1042/bst022389s; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; SZABO C, 1994, BRIT J PHARMACOL, V112, P355, DOI 10.1111/j.1476-5381.1994.tb13078.x; SZABO C, 1994, BRIT J PHARMACOL, V113, P757, DOI 10.1111/j.1476-5381.1994.tb17058.x; Varanasi RV, 1998, HELICOBACTER, V3, P188, DOI 10.1046/j.1523-5378.1998.08001.x; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wang YL, 2001, CANCER RES, V61, P5370; Wilson KT, 1996, GASTROENTEROLOGY, V111, P1524, DOI 10.1016/S0016-5085(96)70014-8; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511; Zhang MH, 1997, J EXP MED, V185, P1759, DOI 10.1084/jem.185.10.1759	28	104	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2409	2412		10.1074/jbc.C400498200	http://dx.doi.org/10.1074/jbc.C400498200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548540	hybrid, Green Submitted			2022-12-25	WOS:000226449100005
J	Chen, L; Trujillo, KM; Van Komen, S; Roh, DH; Krejci, L; Lewis, LK; Resnick, MA; Sung, P; Tomkinson, AE				Chen, L; Trujillo, KM; Van Komen, S; Roh, DH; Krejci, L; Lewis, LK; Resnick, MA; Sung, P; Tomkinson, AE			Effect of amino acid substitutions in the Rad50 ATP binding domain on DNA double strand break repair in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEASE ACTIVITIES; PROTEIN COMPLEX; MRE11; RECOMBINATION; IDENTIFICATION; PATHWAY; LIGASE; PHOSPHORYLATION; EXONUCLEASE	The Saccharomyces cerevisiae Rad50-Mre11-Xrs2 complex plays a central role in the cellular response to DNA double strand breaks. Rad50 has a globular ATPase head domain with a long coiled-coil tail. DNA binding by Rad50 is ATP-dependent and the Rad50-Mre11-Xrs2 complex possesses DNA unwinding and endonuclease activities that are regulated by ATP. Here we have examined the role of the Rad50 Walker type A ATP binding motif in DNA double strand break repair by a combination of genetic and biochemical approaches. Replacement of the conserved lysine residue within the Walker A motif with alanine, glutamate, or arginine results in the same DNA damage sensitivity and homologous recombination defect as the rad50 deletion mutation. The Walker A mutations also cause a deficiency in non-homologous end-joining. As expected, complexes containing the rad50 Walker A mutant proteins are defective in ATPase, ATP-dependent DNA unwinding, and ATP-stimulated endonuclease activities. Although the DNA end-bridging activity of the Rad50-Mre11-Xrs2 complex is ATP-independent, the end-bridging activity of complexes containing the rad50 Walker A mutant proteins is salt-sensitive. These results provide a molecular explanation for the observed in vivo defects of the rad50 Walker mutant strains and reveal a novel ATP-independent function for Rad50 in DNA end-bridging.	Univ Maryland, Sch Med, Dept Radiat Oncol, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; SW Texas State Univ, Dept Chem & Biochem, San Marcos, TX 78666 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Health San Antonio; Yale University; Texas State University System; Texas State University San Marcos; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Tomkinson, AE (corresponding author), Univ Maryland, Sch Med, Dept Radiat Oncol, Radiat Oncol Res Lab, 655 W Baltimore St, Baltimore, MD 21201 USA.	atomkinson@som.umaryland.edu	Krejci, Lumir/B-7842-2009; resnick, Michael/F-1668-2019	Krejci, Lumir/0000-0002-4732-1405; resnick, Michael/0000-0002-8473-7506	NIEHS NIH HHS [R01 ES07061] Funding Source: Medline; NIGMS NIH HHS [R01 GM47251] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021016, R01ES007061, ZIAES021016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047251] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Anderson DE, 2001, J BIOL CHEM, V276, P37027, DOI 10.1074/jbc.M106179200; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis LK, 2004, GENETICS, V166, P1701, DOI 10.1534/genetics.166.4.1701; Lewis LK, 2002, GENETICS, V160, P49; Lewis LK, 2000, MUTAT RES-FUND MOL M, V451, P71, DOI 10.1016/S0027-5107(00)00041-5; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Moncalian G, 2004, J MOL BIOL, V335, P937, DOI 10.1016/j.jmb.2003.11.026; Moreau S, 1999, MOL CELL BIOL, V19, P556; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SIKORSKI RS, 1989, GENETICS, V122, P19; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Trujillo KM, 2003, J BIOL CHEM, V278, P48957, DOI 10.1074/jbc.M309877200; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	47	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2620	2627		10.1074/jbc.M410192200	http://dx.doi.org/10.1074/jbc.M410192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15546877	hybrid			2022-12-25	WOS:000226449100031
J	Kiel, JAKW; Emmrich, K; Meyer, HE; Kunau, WH				Kiel, JAKW; Emmrich, K; Meyer, HE; Kunau, WH			Ubiquitination of the peroxisomal targeting signal type 1 receptor, Pex5p, suggests the presence of a quality control mechanism during peroxisomal matrix protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PTS1 RECEPTOR; CONJUGATING ENZYME; BIOGENESIS FACTORS; SHUTTLE VECTORS; YEAST; MACHINERY; STABILITY; MEMBRANE; PEX4P	PEX genes encode proteins (peroxins) that are required for the biogenesis of peroxisomes. One of these peroxins, Pex5p, is the receptor for matrix proteins with a type 1 peroxisomal targeting signal (PTS1), which shuttles newly synthesized proteins from the cytosol into the peroxisome matrix. We observed that in various Saccharomyces cerevisiae pex mutants disturbed in the early stages of PTS1 import, the steady-state levels of Pex5p are enhanced relative to wild type controls. Furthermore, we identified ubiquitinated forms of Pex5p in deletion mutants of those PEX genes that have been implicated in recycling of Pex5p from the peroxisomal membrane into the cytosol. Pex5p ubiquitination required the presence of the ubiquitin-conjugating enzyme Ubc4p and the peroxins that are required during early stages of PTS1 protein import. Finally, we provide evidence that the proteasome is involved in the turnover of Pex5p in wild type yeast cells, a process that requires Ubc4p and occurs at the peroxisomal membrane. Our data suggest that during receptor recycling a portion of Pex5p becomes ubiquitinated and degraded by the proteasome. We propose that this process represents a conserved quality control mechanism in peroxisome biogenesis.	Ruhr Univ Bochum, Fak Med, Med Proteom Ctr, D-44780 Bochum, Germany; Ruhr Univ Bochum, Abt Zellbiochem, D-44780 Bochum, Germany	Ruhr University Bochum; Ruhr University Bochum	Kiel, JAKW (corresponding author), Univ Groningen, GBB, Kerklaan 30, NL-9751 NN Haren, Netherlands.	J.A.K.W.Kiel@Biol.RUG.nl						Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; Birschmann I, 2003, MOL BIOL CELL, V14, P2226, DOI 10.1091/mbc.E02-11-0752; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hazra PP, 2002, TRAFFIC, V3, P560, DOI 10.1034/j.1600-0854.2002.30806.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; KRAUSE T, 1994, YEAST, V10, P1613, DOI 10.1002/yea.320101210; Matsumoto N, 2003, NAT CELL BIOL, V5, P454, DOI 10.1038/ncb982; Oliveira ME, 2003, J BIOL CHEM, V278, P39483, DOI 10.1074/jbc.M305089200; Platta H, 2004, BIOCHEM J, V384, P37, DOI 10.1042/BJ20040572; Purdue PE, 2001, J BIOL CHEM, V276, P47684, DOI 10.1074/jbc.M106823200; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; SIKORSKI RS, 1989, GENETICS, V122, P19; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Titorenko VI, 2002, J CELL BIOL, V156, P481, DOI 10.1083/jcb.200111075; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; Wang DY, 2003, J BIOL CHEM, V278, P43340, DOI 10.1074/jbc.M307789200; Weller S, 2003, ANNU REV GENOM HUM G, V4, P165, DOI 10.1146/annurev.genom.4.070802.110424; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; Yang XD, 2001, EUR J CELL BIOL, V80, P126, DOI 10.1078/0171-9335-00144; Zolman BK, 2004, P NATL ACAD SCI USA, V101, P1786, DOI 10.1073/pnas.0304368101	40	126	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1921	1930		10.1074/jbc.M403632200	http://dx.doi.org/10.1074/jbc.M403632200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15536088	hybrid			2022-12-25	WOS:000226341700026
J	Kilic, N; Oliveira-Ferrer, L; Wurmbach, JH; Loges, S; Chalajour, F; Vahid, SN; Weil, J; Fernando, M; Ergun, S				Kilic, N; Oliveira-Ferrer, L; Wurmbach, JH; Loges, S; Chalajour, F; Vahid, SN; Weil, J; Fernando, M; Ergun, S			Pro-angiogenic signaling by the endothelial presence of CEACAM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; BILIARY GLYCOPROTEIN; C-CAM; TUMOR ANGIOGENESIS; GROWTH; VEGF; ANGIOPOIETIN-1; ANTIGEN; INTERLEUKIN-8; CARCINOMA	Here, we demonstrate the expression of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) in angiogenic sprouts but not in large mother blood vessels within tumor tissue. Correspondingly, only human microvascular endothelial cells involved in in vitro tube formation exhibit CEACAM1. CEACAM1-overexpressing versus CEACAM1-silenced human microvascular endothelial cells were used in migration and tube formation assays. CEACAM1-overexpressing microvascular endothelial cells showed prolonged survival and increased tube formation when they were stimulated with vascular endothelial growth factor ( VEGF), whereas CEACAM1 silencing via small interfering RNA blocks these effects. Gene array and LightCycler analyses show an up-regulation of angiogenic factors such as VEGF, VEGF receptor 2, angiopoietin-1, angiopoietin-2, tie-2, angiogenin, and interleukin-8 but a down-regulation of collagen XVIII/endostatin and Tie-1 in CEACAM1-overexpressing microvascular endothelial cells. Western blot analyses confirm these results for VEGF and endostatin at the protein level. These results suggest that constitutive expression of CEACAM1 in microvascular endothelial cells switches them to an angiogenic phenotype, whereas CEACAM1 silencing apparently abrogates the VEGF-induced morphogenetic effects during capillary formation. Thus, strategies targeting the endothelial up-regulation of CEACAM1 might be promising for antiangiogenic tumor therapy.	Univ Hosp Eppendorf, Inst Anat, D-20246 Hamburg, Germany; Univ Hosp Eppendorf, Med Clin 1, D-20246 Hamburg, Germany; Univ Hosp Eppendorf, Dept Hematol Oncol, D-20246 Hamburg, Germany; Univ Hosp Regensburg, Dept Cardiol, D-93042 Regensburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg	Ergun, S (corresponding author), Univ Hosp Hamburg Eppendorf, Inst Anat 1, Ctr Med Expt, Martinistr 52, D-20246 Hamburg, Germany.	erguen@uke.uni-hamburg.de	Loges, Sonja/ABE-9868-2021	Loges, Sonja/0000-0002-7650-8527				Bancroft CC, 2001, CLIN CANCER RES, V7, P435; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BRUMMER J, 1995, ONCOGENE, V11, P1649; Brummer J, 2001, AM J PATHOL, V159, P537, DOI 10.1016/S0002-9440(10)61725-7; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Byrne GJ, 2000, J NATL CANCER I, V92, P1329, DOI 10.1093/jnci/92.16.1329; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chalajour F, 2004, EXP CELL RES, V298, P455, DOI 10.1016/j.yexcr.2004.04.034; DAVIDOFF M, 1990, HISTOCHEMISTRY, V93, P531, DOI 10.1007/BF00266413; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; DRZENIEK Z, 1991, CANCER LETT, V56, P173, DOI 10.1016/0304-3835(91)90093-W; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Ergun S, 2001, ANGIOGENESIS, V4, P193, DOI DOI 10.1023/A:1014027218980; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 2003, J MOL MED, V81, P20, DOI 10.1007/s00109-002-0397-4; Gho YS, 2001, CANCER RES, V61, P4253; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Iijima H, 2004, J EXP MED, V199, P471, DOI 10.1084/jem.20030437; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; KILIC N, 2001, METHODS MOL MED META, P125; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; Koch AE, 2001, ARTHRITIS RHEUM-US, V44, P31, DOI 10.1002/1529-0131(200101)44:1<31::AID-ANR5>3.0.CO;2-4; Langley RR, 2003, CANCER RES, V63, P2971; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lin SH, 1999, SEMIN ONCOL, V26, P227; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Melero I, 2002, CANCER RES, V62, P3167; Mercurio AM, 2004, SEMIN CANCER BIOL, V14, P115, DOI 10.1016/j.semcancer.2003.09.016; Nollau P, 1997, AM J PATHOL, V151, P521; Nor JE, 2001, CANCER RES, V61, P2183; Obrink B, 2002, ANN NY ACAD SCI, V971, P597; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OLIVEIRAFERRER L, 2005, IN PRESS CANC RES; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Risau W., 1991, DEV VASCULAR SYSTEM, P58; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Singer BB, 2000, CANCER RES, V60, P1236; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Stocks SC, 1996, EUR J IMMUNOL, V26, P2924, DOI 10.1002/eji.1830261218; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Vallee BL, 1997, CELL MOL LIFE SCI, V53, P803, DOI 10.1007/s000180050101; Volpert O, 2002, J BIOL CHEM, V277, P35696, DOI 10.1074/jbc.M205319200; Wagener C, 2000, EXP CELL RES, V261, P19, DOI 10.1006/excr.2000.5038; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02	59	52	53	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2361	2369		10.1074/jbc.M409407200	http://dx.doi.org/10.1074/jbc.M409407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15536067	hybrid			2022-12-25	WOS:000226341700073
J	Attwooll, C; Oddi, S; Cartwright, P; Prosperini, E; Agger, K; Steensgaard, P; Wagener, C; Sardet, C; Moroni, MC; Helin, K				Attwooll, C; Oddi, S; Cartwright, P; Prosperini, E; Agger, K; Steensgaard, P; Wagener, C; Sardet, C; Moroni, MC; Helin, K			A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITHORAX-GROUP; GROUP GENE; AXIAL SKELETON; TRANSCRIPTIONAL REPRESSOR; CHROMATIN MODIFIERS; TARGETED DELETION; BINDING-PROTEIN; DROSOPHILA; ENHANCER; YEAST	The transcriptional repressor E2F6 has been identified as a component of two distinct polycomb group protein (PcG)-containing complexes, suggesting a mechanism for the recruitment of repressive complexes to target sequences in DNA. Whereas one complex is involved in the repression of classic E2F target genes in G(0), a role for E2F6 within the cell cycle has yet to be defined. We searched for novel E2F6-binding proteins using a yeast two-hybrid screen and identified the PcG protein, EPC1. We showed that, both in vitro and in vivo, E2F6, DP1, and EPC1 form a stable core complex with repressive activity. Furthermore, we identified the proliferation-specific PcG, EZH2, as an EPC1-interacting protein. Using affinity purification, we showed that E2F6, DP1, EPC1, EZH2, and Sin3B co-elute, suggesting the identification of a novel E2F6 complex that exists in vivo in both normal and transformed human cell lines. EZH2 is required for cellular proliferation and consistent with this, EZH2 elutes with the E2F6-EPC1 complex only in proliferating cells. Thus we have identified a novel E2F6-PcG complex (E2F6-EPC1) that interacts with EZH2 and may regulate genes required for cell cycle progression.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Inst Genet Mol, UMR5535, F-34293 Montpellier, France; Biotech Res & Innovat Ctr, DK-2100 Copenhagen, Denmark	IRCCS European Institute of Oncology (IEO); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	kristian.helin@bric.dk	Moroni, Maria Cristina/H-7044-2018; Helin, Kristian/K-2526-2019; PROSPERINI, ELENA/AAB-1952-2021; Helin, Kristian/HDM-8306-2022; Oddi, Sergio/B-6668-2009	Moroni, Maria Cristina/0000-0003-2409-5764; Helin, Kristian/0000-0003-1975-6097; Oddi, Sergio/0000-0002-6217-698X				Akasaka T, 1996, DEVELOPMENT, V122, P1513; Akasaka T, 1997, IMMUNITY, V7, P135, DOI 10.1016/S1074-7613(00)80516-6; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Core N, 1997, DEVELOPMENT, V124, P721; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gildea JJ, 2000, GENETICS, V156, P645; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; Lorente MD, 2000, DEVELOPMENT, V127, P5093; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 1997, MOL CELL BIOL, V17, P5508; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pasini D, 2004, CELL CYCLE, V3, P396; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; SATO T, 1984, DEV GENET, V4, P185; SATO T, 1983, GENETICS, V105, P357; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Stankunas K, 1998, DEVELOPMENT, V125, P4055; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321	44	89	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1199	1208		10.1074/jbc.M412509200	http://dx.doi.org/10.1074/jbc.M412509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536069	Green Published, hybrid			2022-12-25	WOS:000226195200042
J	Lewis, HA; Zhao, X; Wang, C; Sauder, JM; Rooney, I; Noland, BW; Lorimer, D; Kearins, MC; Conners, K; Condon, B; Maloney, PC; Guggino, WB; Hunt, JF; Emtage, S				Lewis, HA; Zhao, X; Wang, C; Sauder, JM; Rooney, I; Noland, BW; Lorimer, D; Kearins, MC; Conners, K; Condon, B; Maloney, PC; Guggino, WB; Hunt, JF; Emtage, S			Impact of the Delta F508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING; MOLECULAR-BASIS; TRANSPORTER; STABILITY; MECHANISM; CASSETTE; RESCUE; CFTR; HALF	Cystic fibrosis is caused by defects in the cystic fibrosis transmembrane conductance regulator ( CFTR), commonly the deletion of residue Phe-508 (DeltaF508) in the first nucleotide-binding domain (NBD1), which results in a severe reduction in the population of functional channels at the epithelial cell surface. Previous studies employing incomplete NBD1 domains have attributed this to aberrant folding of DeltaF508 NBD1. We report structural and biophysical studies on complete human NBD1 domains, which fail to demonstrate significant changes of in vitro stability or folding kinetics in the presence or absence of the DeltaF508 mutation. Crystal structures show minimal changes in protein conformation but substantial changes in local surface topography at the site of the mutation, which is located in the region of NBD1 believed to interact with the first membrane spanning domain of CFTR. These results raise the possibility that the primary effect of DeltaF508 is a disruption of proper interdomain interactions at this site in CFTR rather than interference with the folding of NBD1. Interestingly, increases in the stability of NBD1 constructs are observed upon introduction of second-site mutations that suppress the trafficking defect caused by the DeltaF508 mutation, suggesting that these suppressors might function indirectly by improving the folding efficiency of NBD1 in the context of the full-length protein. The human NBD1 structures also solidify the understanding of CFTR regulation by showing that its two protein segments that can be phosphorylated both adopt multiple conformations that modulate access to the ATPase active site and functional interdomain interfaces.	Struct GenomiX Inc, San Diego, CA 92121 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Columbia University; Johns Hopkins University	Lewis, HA (corresponding author), Struct GenomiX Inc, San Diego, CA 92121 USA.	hal_lewis@stromix.com		Sauder, J Michael/0000-0002-0254-4955				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bass RB, 2003, FEBS LETT, V555, P111, DOI 10.1016/S0014-5793(03)01126-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang G, 2003, FEBS LETT, V555, P102, DOI 10.1016/S0014-5793(03)01085-8; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; deCarvalho ACV, 2002, J BIOL CHEM, V277, P35896, DOI 10.1074/jbc.M205644200; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Pace C. N., 1989, MEASURING CONFORMATI, P311; Ratjen F, 2003, LANCET, V361, P681, DOI 10.1016/S0140-6736(03)12567-6; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; Teem JL, 1996, RECEPTOR CHANNEL, V4, P63; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; WARD CL, 1994, J BIOL CHEM, V269, P25710; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhang XM, 2003, J BIOL CHEM, V278, P51232, DOI 10.1074/jbc.M309076200; [No title captured]	31	230	236	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1346	1353		10.1074/jbc.M410968200	http://dx.doi.org/10.1074/jbc.M410968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528182	hybrid			2022-12-25	WOS:000226195200060
J	McGoldrick, HM; Roessner, CA; Raux, E; Lawrence, AD; McLean, KJ; Munro, AW; Santabarbara, S; Rigby, SEJ; Heathcote, P; Scott, AI; Warren, MJ				McGoldrick, HM; Roessner, CA; Raux, E; Lawrence, AD; McLean, KJ; Munro, AW; Santabarbara, S; Rigby, SEJ; Heathcote, P; Scott, AI; Warren, MJ			Identification and characterization of a novel vitamin B-12 (Cobalamin) biosynthetic enzyme (CobZ) from Rhodobacter capsulatus, containing flavin, heme, and Fe-S cofactors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PSEUDOMONAS-DENITRIFICANS; SALMONELLA-TYPHIMURIUM; RING CONTRACTION; TIGHT REGULATION; COENZYME B-12; INSERTION; CLUSTERS; LIGANDS; GENES	One of the most intriguing steps during cobalamin (vitamin B-12) biosynthesis is the ring contraction process that leads to the extrusion of one of the integral macrocyclic carbon atoms from the tetrapyrrole-derived framework. The aerobic cobalamin pathway requires the action of a monooxygenase called CobG (precorrin-3B synthase), which generates a hydroxylactone intermediate that is subsequently ring-contracted by CobJ. However, in the photosynthetic bacterium Rhodobacter capsulatus, which harbors an aerobic-like pathway, there is no cobG in the main cobalamin biosynthetic operon although it does contain an additional uncharacterized gene called orf663. To demonstrate the involvement of Orf663 in cobalamin synthesis, the first dedicated 10 genes of the B-12 pathway (including orf663), encoding enzymes for the transformation of uroporphyrinogen III into hydrogenobyrinic acid (HBA), were sequentially cloned into a plasmid to generate an artificial operon, which, when transformed into Escherichia coli, endowed the host with the ability to make HBA. Deletion of orf663 from this operon prevented HBA synthesis, demonstrating that it was essential for corrin construction. HBA synthesis was restored to this recombinant strain either by returning orf663 or by substituting it with cobG. Recombinant overproduction of Orf663, now renamed CobZ, allowed the characterization of a novel cofactor-rich protein, housing two Fe-S centers, a flavin, and a heme group, which like B-12 itself is a modified tetrapyrrole. A mechanism for Orf663 (CobZ) in cobalamin biosynthesis is proposed.	Univ London Queen Mary & Westfield Coll, Sch Biol Sci, London E1 4NS, England; Texas A&M Univ, Dept Chem, Ctr Biol NMR, College Stn, TX 77843 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of London; Queen Mary University London; Texas A&M University System; Texas A&M University College Station; University of Leicester	Warren, MJ (corresponding author), Univ London Queen Mary & Westfield Coll, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	m.j.warren@qmul.ac.uk	Munro, Andrew/G-5639-2019; Heathcote, Peter/B-3749-2011; McLean, Kirsty J/GXI-2853-2022	Munro, Andrew/0000-0002-4642-180X; Warren, Martin/0000-0002-6028-6456; McLean, Kirsty/0000-0002-7193-5044; Santabarbara, Stefano/0000-0002-7993-2614				Bartlett GJ, 2003, J MOL BIOL, V331, P829, DOI 10.1016/S0022-2836(03)00734-4; BLANCHE F, 1993, ANGEW CHEM INT EDIT, V32, P1651, DOI 10.1002/anie.199316511; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; Chapman SK, 1999, BIOCHEM SOC T, V27, P185, DOI 10.1042/bst0270185; Dalton L. R., 1985, EPR ADV EPR STUDIES; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEBUSSCHE L, 1993, J CHEM SOC CHEM COMM, P1100, DOI 10.1039/c39930001100; DEBUSSCHE L, 1993, J BACTERIOL, V175, P7430, DOI 10.1128/JB.175.22.7430-7440.1993; DEBUSSCHE L, 1992, J BACTERIOL, V174, P7445, DOI 10.1128/jb.174.22.7445-7451.1992; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Dutton P L, 1978, Methods Enzymol, V54, P411; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; Gough SP, 2000, P NATL ACAD SCI USA, V97, P6908, DOI 10.1073/pnas.97.12.6908; GUIGLIARELLI B, 1993, J BIOL CHEM, V268, P900; GUTNICK D, 1969, J BACTERIOL, V100, P215, DOI 10.1128/JB.100.1.215-219.1969; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Lewis JA, 2004, J BACTERIOL, V186, P1629, DOI 10.1128/JB.186.6.1629-1637.2004; LOVENBERG W, 1973, IRON SULFUR PROTEINS, V2, P285; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; MORE C, 1996, J BIOL INORG CHEM, V1, P52; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; Raux E, 1996, J BACTERIOL, V178, P753, DOI 10.1128/jb.178.3.753-767.1996; Rodionov DA, 2003, J BIOL CHEM, V278, P41148, DOI 10.1074/jbc.M305837200; Roessner C A, 1994, Chem Biol, V1, P119; Roessner CA, 1999, BIOORGAN MED CHEM, V7, P2215, DOI 10.1016/S0968-0896(99)00154-6; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; SCOTT AI, 1993, FEBS LETT, V331, P105, DOI 10.1016/0014-5793(93)80306-F; Strand A, 2003, NATURE, V421, P79, DOI 10.1038/nature01204; SWEENEY WV, 1980, ANNU REV BIOCHEM, V49, P139, DOI 10.1146/annurev.bi.49.070180.001035; Vassiliev IR, 2001, BBA-BIOENERGETICS, V1507, P139, DOI 10.1016/S0005-2728(01)00197-9; Vlcek C, 1997, P NATL ACAD SCI USA, V94, P9384, DOI 10.1073/pnas.94.17.9384; Wang JJ, 1996, P NATL ACAD SCI USA, V93, P14320, DOI 10.1073/pnas.93.25.14320; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P486, DOI 10.1016/0968-0004(90)90304-T	36	40	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1086	1094		10.1074/jbc.M411884200	http://dx.doi.org/10.1074/jbc.M411884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15525640	hybrid			2022-12-25	WOS:000226195200029
J	Torigoe, T; Izumi, H; Wakasugi, T; Niina, I; Igarashi, T; Yoshida, T; Shibuya, I; Chijiiwa, K; Matsuo, K; Itoh, H; Kohno, K				Torigoe, T; Izumi, H; Wakasugi, T; Niina, I; Igarashi, T; Yoshida, T; Shibuya, I; Chijiiwa, K; Matsuo, K; Itoh, H; Kohno, K			DNA topoisomerase II poison TAS-103 transactivates GC-Box-dependent transcription via acetylation of Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; CANCER-CELL-LINES; BINDING-PROTEIN; CISPLATIN RESISTANCE; DRUG-RESISTANCE; GENE; PROMOTER; AGENTS; P300; ACIDIFICATION	Drug-induced modifications of transcription factors play important roles in both apoptosis and survival signaling. The data presented here show that the DNA topoisomerase II poison TAS-103 transactivated the SV40 promoter in a GC-box-dependent manner and induced Sp1 acetylation in cells expressing p300. This activity was not observed in cells lacking p300. TAS-103 treatment also enhanced the p300 content of the nucleus and the interaction of p300 with Sp1. Cellular susceptibility to TAS-103 was correlated with p300 expression but not with topoisomerase II expression. Furthermore, the presence of p300 significantly sensitized cancer cells to TAS-103 but not to cisplatin. Taken together, these findings demonstrate novel genomic responses to anticancer agents that modulate Sp1 acetylation and Sp1-dependent transcription in an apoptotic pathway.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 1, Yahatanishi Ku, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Physiol 1, Yahatanishi Ku, Fukuoka 8078555, Japan; Miyazaki Univ, Dept Surg 1, Miyazaki 8891692, Japan; Taiho Pharmaceut Co Ltd, Hanno Res Ctr, Hanno, Saitama 3578527, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; University of Miyazaki; Taiho Pharmaceutical	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp		Shibuya, Izumi/0000-0003-4137-5856				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Chan HM, 2001, J CELL SCI, V114, P2363; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; Goodman RH, 2000, GENE DEV, V14, P1553; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; Ishiguchi H, 2004, INT J CANCER, V111, P900, DOI 10.1002/ijc.20358; Izumi H, 2003, CANCER TREAT REV, V29, P541, DOI 10.1016/S0305-7372(03)00106-3; Izumi H, 2003, BBA-GENE STRUCT EXPR, V1628, P97, DOI 10.1016/S0167-4781(03)00119-2; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; Klochendler-Yeivin A, 2001, BBA-REV CANCER, V1551, pM1, DOI 10.1016/S0304-419X(01)00021-X; Kluza J, 2000, CANCER RES, V60, P4077; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; LAURENCOT CM, 1995, ONCOL RES, V7, P363; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Martens JHA, 2002, MOL CELL BIOL, V22, P2598, DOI 10.1128/MCB.22.8.2598-2606.2002; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; TAKANO H, 1992, ANTI-CANCER DRUG, V3, P323, DOI 10.1097/00001813-199208000-00002; Tanabe M, 2003, CANCER RES, V63, P8592; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Torigoe T, 2003, NUCLEIC ACIDS RES, V31, P4523, DOI 10.1093/nar/gkg487; Torigoe T, 2002, ANTI-CANCER DRUG, V13, P237, DOI 10.1097/00001813-200203000-00005; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Tsunoda T, 2001, ANTICANCER RES, V21, P3897; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yoshida Y, 2003, CANCER RES, V63, P3729	36	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1179	1185		10.1074/jbc.M410499200	http://dx.doi.org/10.1074/jbc.M410499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15533934	hybrid			2022-12-25	WOS:000226195200039
J	Lu, ZF; Ku, L; Chen, Y; Feng, Y				Lu, ZF; Ku, L; Chen, Y; Feng, Y			Developmental abnormalities of myelin basic protein expression in fyn knock-out brain reveal a role of Fyn in posttranscriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; TYROSINE KINASE; GENE-EXPRESSION; MUTANT MICE; MORPHOLOGICAL-DIFFERENTIATION; OLIGODENDROCYTES; CNS; PHOSPHORYLATION; DYSMYELINATION; ASSOCIATION	Fyn protein-tyrosine kinase (PTK), a member of the Src-PTK family, is essential for myelin development in the central nervous system (CNS). The absence of Fyn activity results in defects in the morphogenesis of oligodendrocyte precursors (OPCs) and CNS hypomyelination. However, molecular mechanisms for Fyn to control CNS myelinogenesis remain elusive. Here we show that Fyn-PTK is significantly up-regulated in early OPC differentiation, concentrated in the compact myelin, and declines during myelin development. Despite the high levels of Fyn-PTK expression during early OPC differentiation, Fyn deficiency does not affect the expression of mRNAs that encode myelin structural proteins, including that for the myelin basic protein (MBP), until postnatal day 13 (P13). However, the accumulation rate of MBP mRNA is significantly attenuated during the most active period of myelinogenesis (P13 and P20). Interestingly, the absence of Fyn causes a preferential reduction of the exon-2 containing MBP mRNA isoforms derived from alternative splicing, providing the first evidence that Fyn is required for posttranscriptional regulation of MBP. Consistent with this idea, Fyn phosphorylates the selective RNA-binding protein QKI, which likely modulates the activity of QKI in binding and stabilizing the MBP mRNA. Furthermore, Fyn deficiency exerts an opposing influence on MBP isoform patterning in comparison to that by QKI deficiency. These observations collectively suggest that Fyn plays critical roles in promoting accelerated MBP expression during myelinogenesis in a MBP isoform-preferential manner, and QKI may act in the same pathway downstream of Fyn for MBP mRNA homeostasis.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Feng, Y (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	yfeng@emory.edu		Feng, Yue/0000-0002-7905-2182	NINDS NIH HHS [1R01 NS39551] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039551] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bedell MA, 1996, NAT GENET, V12, P229, DOI 10.1038/ng0396-229; Biffiger K, 2000, J NEUROSCI, V20, P7430; BILLINGSGAGLIARDI S, 1980, BRAIN RES, V194, P325, DOI 10.1016/0006-8993(80)91215-9; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; Cohen RI, 2003, J NEUROCHEM, V85, P1262, DOI 10.1046/j.1471-4159.2003.01722.x; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; Frederick TJ, 2004, MOL CELL NEUROSCI, V25, P480, DOI 10.1016/j.mcn.2003.11.015; Goto J, 2004, CELL MOL NEUROBIOL, V24, P149, DOI 10.1023/B:CEMN.0000012720.71630.14; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; Li ZZ, 2000, J NEUROSCI, V20, P4944; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Lu ZF, 2003, NUCLEIC ACIDS RES, V31, P4616, DOI 10.1093/nar/gkg635; MACKLIN WB, 1991, J NEUROCHEM, V56, P163, DOI 10.1111/j.1471-4159.1991.tb02576.x; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Nakahara J, 2003, DEV CELL, V4, P841, DOI 10.1016/S1534-5807(03)00155-2; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Scarlato M, 2000, J NEUROSCI RES, V59, P430, DOI 10.1002/(SICI)1097-4547(20000201)59:3<430::AID-JNR18>3.0.CO;2-7; Seiwa C, 2000, NEUROSCI RES, V37, P21, DOI 10.1016/S0168-0102(00)00100-0; Sperber BR, 2001, J NEUROSCI RES, V63, P303, DOI 10.1002/1097-4547(20010215)63:4<303::AID-JNR1024>3.0.CO;2-A; Sperber BR, 2001, J NEUROSCI, V21, P2039, DOI 10.1523/JNEUROSCI.21-06-02039.2001; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Umemori H, 1999, J NEUROSCI, V19, P1393; Wolf RM, 2001, J NEUROBIOL, V49, P62, DOI 10.1002/neu.1066; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171; Zhang YY, 2001, J NEUROCHEM, V77, P165, DOI 10.1046/j.1471-4159.2001.00224.x	30	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					389	395		10.1074/jbc.M405973200	http://dx.doi.org/10.1074/jbc.M405973200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15528192	hybrid			2022-12-25	WOS:000226025100047
J	Stupina, VA; Wang, JC				Stupina, VA; Wang, JC			Viability of Escherichia coli topA mutants lacking DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III-BETA; SCHIZOSACCHAROMYCES-POMBE; SALMONELLA-TYPHIMURIUM; SUPERCOILED DNA; GYRASE GENES; MICE LACKING; SUPX LOCUS; MUTATIONS; RECOMBINATION; REPLICATION	The viability of the topA mutants lacking DNA topoisomerase I was thought to depend on the presence of compensatory mutations in Escherichia coli but not Salmonella typhimurium or Shigella flexneri. This apparent discrepancy in topA requirements in different bacteria prompted us to reexamine the topA requirements in E. coli. We find that E. coli strains bearing topA mutations, introduced into the strains by DNA-mediated gene replacement, are viable at 37 or 42 degreesC without any compensatory mutations. These topA(-) cells exhibit cold sensitivity in their growth, however, and this cold sensitivity phenotype appears to be caused by excessive negative supercoiling of intracellular DNA. In agreement with previous results (Zhu, Q., Pongpech, P., and DiGate, R. J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 9766-9771), E. coli cells lacking both type IA DNA topoisomerases I and III are found to be nonviable, indicating that the two type IA enzymes share a critical cellular function.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	jcwang@fas.harvard.edu			NCI NIH HHS [CA94584] Funding Source: Medline; NIGMS NIH HHS [GM14621, GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Dabert P, 1997, GENETICS, V145, P877; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DORMAN CJ, 1989, MOL MICROBIOL, V3, P531, DOI 10.1111/j.1365-2958.1989.tb00199.x; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DUBNAU E, 1973, MOL GEN GENET, V126, P191, DOI 10.1007/BF00267530; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HIASA H, 1994, J BIOL CHEM, V269, P32655; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; Kwan KY, 2003, P NATL ACAD SCI USA, V100, P2526, DOI 10.1073/pnas.0437998100; Kwan KY, 2001, P NATL ACAD SCI USA, V98, P5717, DOI 10.1073/pnas.101132498; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; LUTTINGER A, 1995, MOL MICROBIOL, V15, P601, DOI 10.1111/j.1365-2958.1995.tb02369.x; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; MARGOLIN P, 1985, P NATL ACAD SCI USA, V82, P5437, DOI 10.1073/pnas.82.16.5437; NIBHRIAIN N, 1993, MOL MICROBIOL, V7, P351; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Oakley TJ, 2002, DNA REPAIR, V1, P463, DOI 10.1016/S1568-7864(02)00032-0; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RAJI A, 1985, J BACTERIOL, V162, P1173, DOI 10.1128/JB.162.3.1173-1179.1985; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; Shor E, 2002, GENETICS, V162, P647; Silhavy T. J., 1984, EXPT GENE FUSIONS, P107; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Stupina VA, 2004, P NATL ACAD SCI USA, V101, P8608, DOI 10.1073/pnas.0402849101; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; TRUCKSIS M, 1981, J BACTERIOL, V147, P679, DOI 10.1128/JB.147.2.679-681.1981; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WANG JC, 1993, CURR OPIN GENET DEV, V3, P764, DOI 10.1016/S0959-437X(05)80096-6; WANG JC, 1983, NUCLEIC ACIDS RES, V11, P1773, DOI 10.1093/nar/11.6.1773; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang Y, 2002, J BIOL CHEM, V277, P1203, DOI 10.1074/jbc.M109436200; Wilson TM, 2000, J BIOL CHEM, V275, P1533, DOI 10.1074/jbc.275.3.1533; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103; ZENGEL JM, 1981, J BACTERIOL, V145, P459, DOI 10.1128/JB.145.1.459-465.1981; ZHU CX, 1995, J MOL BIOL, V250, P609, DOI 10.1006/jmbi.1995.0402; Zhu Q, 2001, P NATL ACAD SCI USA, V98, P9766, DOI 10.1073/pnas.171579898; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	51	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					355	360		10.1074/jbc.M411924200	http://dx.doi.org/10.1074/jbc.M411924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15522872	hybrid			2022-12-25	WOS:000226025100043
J	Granda, TG; Liu, XH; Smaaland, R; Cermakian, N; Filipski, E; Sassone-Corsi, P; Levi, F				Granda, TG; Liu, XH; Smaaland, R; Cermakian, N; Filipski, E; Sassone-Corsi, P; Levi, F			Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor	FASEB JOURNAL			English	Article						clock genes; mammary cancer; BCL-2; BAX	DNA-SYNTHESIS; CANCER-CELLS; CLOCK GENES; IN-VIVO; EXPRESSION; MICE; CHRONOTHERAPY; AGENTS; STAGE; P53	Proapoptotic drugs such as docetaxel displayed least toxicity and highest antitumor efficacy following dosing during the circadian rest phase in mice, suggesting that cell cycle and apoptotic processes could be regulated by the circadian clock. In study 1, mouse bone marrow and/or tumor were obtained every 4 h for 24 h in C3H/HeN mice with or without MA13/C mammary adenocarcinoma in order to determine the circadian patterns in cell-cycle phase distribution and BCL-2 anti-apoptotic protein expression. In study 2, mouse bone marrow from B6D2F(1) mice was sampled every 3 h for 24 h in order to confirm the BCL-2 rhythm and to study its relation with 24 h changes in the expression of proapoptotic BCL-2-associated X protein (BAX) protein and clock genes mPer2, mBmal1, mClock, and mTim mRNAs. The rhythms in G1-, S- or G2/M-phase cells were shifted in tumor compared with bone marrow. In the tumor, the mean proportion of G2/M-phase cells increased by 75% from late rest to late activity span ( P from cosinor = 0.001). No 24 h rhythm was found for BCL-2 in tumors. In contrast to this, in the bone marrow, mean BCL-2 expression varied 2.8-fold in B6D2F1 mice (P = 0.025) and 3- or 4.5-fold in tumor-bearing and nontumor-bearing C3H/HeN mice, with a peak during the early rest span (P = 0.024 and P < 0.001, respectively). BAX varied fivefold during the 24 h span with a major peak occurring near mid-activity (P = 0.007). The mean mRNAs of mPer2, mClock, and mBmal1 varied twofold to threefold over the 24 h, with high values during the activity span (P < 0.05). In the tumor, the circadian organization in cell-cycle phase distribution was shifted and BCL2 rhythm was ablated. Conversely, a molecular circadian clock likely regulated BCL-2 and BAX expression in the bone marrow, increasing cellular protection against apoptosis during the rest span.	Hop Paul Brousse, INSERM, E Chronotherapeut Canc 0354, F-94800 Villejuif, France; Univ Paris 11, Hop Paul Brousse, F-94800 Villejuif, France; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Haukeland Hosp, Dept Oncol & Med Phys, N-5021 Bergen, Norway	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Bergen; Haukeland University Hospital	Levi, F (corresponding author), Hop Paul Brousse, INSERM, E Chronotherapeut Canc 0354, 14 Ave PV Couturier, F-94800 Villejuif, France.	levi-f@vjf.inserm.fr	Smaaland, Rune/AAH-2149-2021	Granda, Teresa/0000-0002-7490-5932; Cermakian, Nicolas/0000-0003-4517-9131				Abrahamsen JF, 1997, EUR J HAEMATOL, V58, P333; Abrahamsen JF, 1998, EUR J HAEMATOL, V60, P7; Asainz R. M., 1999, FASEB J, V13, P1547; Backus HHJ, 2003, EUR J CANCER, V39, P1310, DOI 10.1016/S0959-8049(03)00204-1; Bjarnason G A, 2000, Prog Cell Cycle Res, V4, P193; Bjarnason GA, 2001, AM J PATHOL, V158, P1793, DOI 10.1016/S0002-9440(10)64135-1; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Canaple L, 2003, CANCER RES, V63, P7545; Cermakian N, 2000, NAT REV MOL CELL BIO, V1, P59, DOI 10.1038/35036078; Chen YG, 2000, BIOCHEM BIOPH RES CO, V276, P724, DOI 10.1006/bbrc.2000.3536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0; Ezzat A, 1997, ANN ONCOL, V8, P663, DOI 10.1023/A:1008228121390; Filipski E, 1999, J PHARMACOL EXP THER, V289, P231; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Granda TG, 2002, CHRONOBIOL INT, V19, P21, DOI 10.1081/CBI-120002589; Granda TG, 2001, CANCER RES, V61, P1996; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1997, CANCER RES, V57, P229; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; KLEVECZ RR, 1987, CANCER RES, V47, P6267; Levi F, 1997, LANCET, V350, P681, DOI 10.1016/S0140-6736(97)03358-8; Levi F, 2001, LANCET ONCOL, V2, P307, DOI 10.1016/S1470-2045(00)00326-0; Li XM, 2000, AM J PHYSIOL-REG I, V278, pR924, DOI 10.1152/ajpregu.2000.278.4.R924; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Maestroni GJM, 1998, ANN NY ACAD SCI, V840, P411, DOI 10.1111/j.1749-6632.1998.tb09579.x; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; Mormont MC, 2003, CANCER-AM CANCER SOC, V97, P155, DOI 10.1002/cncr.11040; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Ohdo S, 1997, J PHARMACOL EXP THER, V283, P1383; Oishi K, 1998, BIOCHEM BIOPH RES CO, V253, P199, DOI 10.1006/bbrc.1998.9779; OLTVAI ZN, 1993, CELL, V74, P619; Osaki M, 1997, APOPTOSIS, V2, P221, DOI 10.1023/A:1026476801463; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; SCHEVING LE, 1984, CELL CYCLE CLOCKS, P455; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; SMAALAND R, 1993, CANCER RES, V53, P3129; SMAALAND R, 1992, BLOOD, V79, P2281; SMAALAND R, 1991, JNCI-J NATL CANCER I, V83, P1092, DOI 10.1093/jnci/83.15.1092; Tampellini M, 1998, CANCER RES, V58, P3896; Vijayalaxmi, 2002, J CLIN ONCOL, V20, P2575, DOI 10.1200/JCO.2002.11.004; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitmore D, 1998, NAT NEUROSCI, V1, P701, DOI 10.1038/3703; Workman P, 1998, BRIT J CANCER, V77, P1; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; ZHANG RW, 1993, CANCER RES, V53, P2816	49	118	122	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					304	+		10.1096/fj.04-2665fje	http://dx.doi.org/10.1096/fj.04-2665fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545298				2022-12-25	WOS:000225482100018
J	Burkhart, BA; Hebbar, PB; Trotter, KW; Archer, TK				Burkhart, BA; Hebbar, PB; Trotter, KW; Archer, TK			Chromatin-dependent E1A activity modulates NF-kappa B RelA-mediated repression of glucocorticoid receptor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR VIRUS PROMOTER; HISTONE ACETYLTRANSFERASE ACTIVITY; THYROID-HORMONE RECEPTOR; CREB-BINDING-PROTEIN; HUMAN BREAST-CANCER; CELL-CYCLE ARREST; IN-VIVO; COREPRESSOR CTBP; MMTV PROMOTER; CROSS-TALK	The role of chromatin-dependent regulatory mechanisms in the repression of glucocorticoid-dependent transcription from the murine mammary tumor virus (MMTV) promoter by p65 and E1A was investigated by using chromatin and transiently transfected reporters. The p65 RelA subunit of NF-kappaB represses MMTV expression on either transient or integrated reporters. In contrast, the viral oncoprotein E1A represses a transient but not an integrated MMTV. E1A repression is attenuated by chromatin, suggesting p65 but not E1A manipulates chromatin appropriately to inhibit the GR. Coexpression of p65 and E1A additively represses the transient NMTV but restores the transcriptional activation of the chromatin MMTV in response to glucocorticoids. This indicates that E1A has a dominant chromatin-dependent activity that attenuates repression by p65. E1A, p65, and GR bind the MMTV promoter, and chromatin remodeling enhances binding on both repressed and activated promoters. In addition, p65 requires Brg for repression of the integrated NMTV. This suggests that neither p65 repression nor E1A attenuation of repression results from an inhibition of remodeling that prevents transcription factor binding. Furthermore, p300/CBP is also required for both repression and attenuation by p65 and E1A. E1A and p65 mutants that do not bind p300/CBP are inactive, indicative of a requirement for p300/CBP-dependent complex formation for both repression and attenuation with chromatin. These data suggest that both the p65-dependent repression and the E1A-mediated attenuation of repression require the Brg1 dependent chromatin remodeling function and p300/CBP-dependent complex formation at a promoter assembled within chromatin.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA.	archer1@niehs.nih.gov	Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES071006, Z01ES071006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Archer TK, 1997, METHODS, V11, P235, DOI 10.1006/meth.1996.0410; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CEREGHINI S, 1984, EUR J BIOCHEM, V144, P545, DOI 10.1111/j.1432-1033.1984.tb08500.x; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Deroo BJ, 2001, ONCOGENE, V20, P3039, DOI 10.1038/sj.onc.1204328; Eckey M, 2003, MOL CELL ENDOCRINOL, V213, P13, DOI 10.1016/j.mce.2003.10.026; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fryer CJ, 2000, J BIOL CHEM, V275, P17771, DOI 10.1074/jbc.M908729199; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Gaston K, 2003, CELL MOL LIFE SCI, V60, P721, DOI 10.1007/s00018-003-2260-3; Grigoryev SA, 2004, FEBS LETT, V564, P4, DOI 10.1016/S0014-5793(04)00258-3; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hsiao PW, 2002, BIOCHEM CELL BIOL, V80, P343, DOI 10.1139/O02-082; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Keeton EK, 2002, J BIOL CHEM, V277, P28247, DOI 10.1074/jbc.M203898200; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kino T, 2002, J VIROL, V76, P9724, DOI 10.1128/JVI.76.19.9724-9734.2002; Kinyamu HK, 2004, BBA-GENE STRUCT EXPR, V1677, P30, DOI 10.1016/j.bbaexp.2003.09.015; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Miller ME, 1996, MOL CELL BIOL, V16, P5737; Moazed D, 2004, NOVART FDN SYMP, V259, P163; MOAZED D, 2004, NOVART FDN SYMP, V256, P48; Mulholland NM, 2003, ONCOGENE, V22, P4807, DOI 10.1038/sj.onc.1206722; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; OEDENTLICH P, 2001, CURR TOP MICROBIOL, V254, P101; Periyasamy S, 2002, INT J BIOCHEM CELL B, V34, P1571, DOI 10.1016/S1357-2725(02)00057-2; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Poole JC, 2004, CELL CYCLE, V3, P931; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shuen M, 2002, J BIOL CHEM, V277, P30844, DOI 10.1074/jbc.M201877200; Soeth E, 2002, J BIOL CHEM, V277, P19847, DOI 10.1074/jbc.M200629200; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Stoecklin E, 1999, J STEROID BIOCHEM, V69, P195, DOI 10.1016/S0960-0760(99)00052-7; Subramanian T, 2003, FEBS LETT, V540, P255, DOI 10.1016/S0014-5793(03)00275-8; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; Ugai H, 1999, J MOL MED, V77, P481, DOI 10.1007/s001099900021; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; WOLFFE AP, 1993, COLD SPRING HARB SYM, V58, P225, DOI 10.1101/SQB.1993.058.01.027; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	75	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6349	6358		10.1074/jbc.M411147200	http://dx.doi.org/10.1074/jbc.M411147200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15556937	hybrid			2022-12-25	WOS:000227332700015
J	Desagher, S; Severac, D; Lipkin, A; Bernis, C; Ritchie, W; Le Digarcher, A; Journot, L				Desagher, S; Severac, D; Lipkin, A; Bernis, C; Ritchie, W; Le Digarcher, A; Journot, L			Genes regulated in neurons undergoing transcription-dependent apoptosis belong to signaling pathways rather than the apoptotic machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; ENDOPLASMIC-RETICULUM STRESS; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBER; GROWTH-FACTOR-I; MESSENGER-RNA; JNK PATHWAY; SURVIVAL; INDUCTION	Neuronal apoptosis has been shown to require de novo RNA/protein synthesis. However, very few genes whose expression is necessary for inducing apoptosis have been identified so far. To systematically identify such genes, we have used genome-scale, long oligonucleotide microarrays and characterized the gene expression profile of cerebellar granule neurons in the early phase of apoptosis elicited by KCl deprivation. We identified 368 significantly differentially expressed genes, including most of the genes previously reported to be transcriptionally regulated in this paradigm. In addition, we identified several hundreds of genes whose transcriptional regulation has never been associated with neuronal apoptosis. We used automated Gene Ontology annotation, analysis of promoter sequences, and statistical tools to characterize these regulations. Although differentially expressed genes included some components of the apoptotic machinery, this functional category was not significantly over-represented among regulated genes. On the other hand, categories related to signal transduction were the most significantly over-represented group. This indicates that the apoptotic machinery is mainly constitutive, whereas molecular pathways that lead to the activation of apoptotic components are transcriptionally regulated. In particular, we show for the first time that signaling pathways known to be involved in the control of neuronal survival are regulated at the transcriptional level and not only by post-translational mechanisms. Moreover, our approach provides insights into novel transcription factors and novel mechanisms, such as the unfolded protein response and cell adhesion, that may contribute to the induction of neuronal apoptosis.	CNRS, Inst Genom Fonct, UMR 5203, F-34094 Montpellier, France; CNRS, Montpellier Genopole Microarray Facil, F-34094 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Desagher, S (corresponding author), CNRS, Inst Genet Mol Montpellier, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.	solange.desagher@igmm.enrs.fr	Lipkin, Alexey V/F-9028-2014; Journot, Laurent/T-9652-2018	Lipkin, Alexey V/0000-0001-7624-8529; Journot, Laurent/0000-0003-3499-8887				Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Catania MV, 1999, NEUROSCIENCE, V91, P1529, DOI 10.1016/S0306-4522(98)00544-2; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DeGregorio-Rocasolano N, 2001, J BIOL CHEM, V276, P796, DOI 10.1074/jbc.M007967200; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Ginham R, 2001, NEUROSCI LETT, V302, P113, DOI 10.1016/S0304-3940(01)01687-1; Hallmann D, 2003, J BIOL CHEM, V278, P5099, DOI 10.1074/jbc.M208451200; Harris CA, 2001, J BIOL CHEM, V276, P37754; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Imaizumi K, 2004, J NEUROSCI, V24, P3721, DOI 10.1523/JNEUROSCI.5101-03.2004; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jabado O, 2004, CELL DEATH DIFFER, V11, P618, DOI 10.1038/sj.cdd.4401397; Kane MD, 2000, NUCLEIC ACIDS RES, V28, P4552, DOI 10.1093/nar/28.22.4552; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Lauritzen I, 2003, J BIOL CHEM, V278, P32068, DOI 10.1074/jbc.M302631200; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J BIOL CHEM, V272, P9847; Nardi N, 1997, J NEUROCHEM, V68, P750; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Roschier M, 2001, J NEUROCHEM, V76, P11, DOI 10.1046/j.1471-4159.2001.00002.x; Saitoh T, 2001, J NEUROCHEM, V78, P1267, DOI 10.1046/j.1471-4159.2001.00505.x; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Villalba M, 1997, NEUROREPORT, V8, P981, DOI 10.1097/00001756-199703030-00032; Watson A, 1998, J NEUROSCI, V18, P751; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	52	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5693	5702		10.1074/jbc.M408971200	http://dx.doi.org/10.1074/jbc.M408971200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15542599	hybrid, Green Published			2022-12-25	WOS:000227217100071
J	Garnon, J; Lachance, C; Di Marco, S; Hel, Z; Marion, D; Ruiz, MC; Newkirk, MM; Khandjian, EW; Radzioch, D				Garnon, J; Lachance, C; Di Marco, S; Hel, Z; Marion, D; Ruiz, MC; Newkirk, MM; Khandjian, EW; Radzioch, D			Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MENTAL-RETARDATION PROTEIN; ALPHA MESSENGER-RNA; AU-RICH-ELEMENT; TNF-ALPHA; 3'-UNTRANSLATED REGION; BINDING PROTEIN; GENE; IDENTIFICATION; TRANSLATION; FMR1	Tumor necrosis factor (TNF) is regulated post-transcriptionally by the AU-rich element (ARE) within the 3'-untranslated region of its mRNA. This regulation modulates translational efficacy and mRNA stability. By using a cRNA probe containing the TNF ARE sequence, we screened a macrophage protein expression library and identified FXR1P. Macrophages that we generated from FXR1 knock-out mice had enhanced TNF protein production compared with wild type macrophages following activation. Expression of several other proteins that are regulated by ARE sequences was also affected by FXR1P deficiency. A GFP-ARE reporter that has green fluorescent protein (GFP) expression under control of the 3'-untranslated region of TNF mRNA had enhanced expression in transfected macrophages deficient in FXR1P. Finally, we found that the ablation of FXR1P led to a dramatically enhanced association of the TNF mRNA with polyribosomes demonstrating the important role of FXR1P in the post-transcriptional regulation of TNF expression. Our data suggest that release of this repression by FXR1P occurs during lipopolysaccharideinduced macrophage activation. Finally, complementation of the knock-out macrophages with recombinant FXR1P resulted in decreased TNF protein production, supporting our findings that FXR1P operates as a repressor of TNF translation.	McGill Univ, Dept Expt Med, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1L 3L5, Canada; Hop St Francois Assise, Unite Rech Genet Humaine & Mol, Quebec City, PQ G1L 3L5, Canada	McGill University; McGill University; Laval University; Laval University	Radzioch, D (corresponding author), McGill Univ, Dept Expt Med, Ctr Hlth, 1650 Cedar Ave,L11-218, Montreal, PQ H3G 1A4, Canada.	danuta.radzioch@muhc.mcgill.ca	Lachance, Claude/A-4214-2012	Lachance, Claude/0000-0002-1974-1787; Radzioch, Danuta/0000-0002-1601-2757; Hel, Zdenek/0000-0002-4923-4794; Di Marco, Sergio/0000-0002-4039-0600				Bardoni B, 2001, BRAIN RES BULL, V56, P375, DOI 10.1016/S0361-9230(01)00647-5; BEUTLER B, 1995, J INVEST MED, V43, P227; BLASI E, 1987, CELL IMMUNOL, V104, P334, DOI 10.1016/0008-8749(87)90035-9; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; Bolivar J, 1998, J BIOL CHEM, V273, P17122, DOI 10.1074/jbc.273.27.17122; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Ceman S, 1999, MOL CELL BIOL, V19, P7925; Ceman S, 2003, HUM MOL GENET, V12, P3295, DOI 10.1093/hmg/ddg350; Chen L, 2003, NEUROSCIENCE, V120, P1005, DOI 10.1016/S0306-4522(03)00406-8; Corbin F, 1997, HUM MOL GENET, V6, P1465, DOI 10.1093/hmg/6.9.1465; COY JF, 1995, HUM MOL GENET, V4, P2209, DOI 10.1093/hmg/4.12.2209; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; Dolzhanskaya N, 2003, BIOCHEM BIOPH RES CO, V305, P434, DOI 10.1016/S0006-291X(03)00766-6; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Hasegawa M, 1997, J RHEUMATOL, V24, P663; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Hel Z, 1998, NUCLEIC ACIDS RES, V26, P2803, DOI 10.1093/nar/26.11.2803; Huot ME, 2001, HUM MOL GENET, V10, P2803, DOI 10.1093/hmg/10.24.2803; Khandjian EW, 1998, HUM MOL GENET, V7, P2121, DOI 10.1093/hmg/7.13.2121; Kirkpatrick LL, 1999, GENOMICS, V59, P193, DOI 10.1006/geno.1999.5868; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; RADZIOCH D, 1987, J IMMUNOL, V139, P805; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; RENIER G, 1994, J LIPID RES, V35, P271; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI MC, 1995, EMBO J, V14, P2401, DOI 10.1002/j.1460-2075.1995.tb07237.x; Siomi MC, 2002, MOL CELL BIOL, V22, P8438, DOI 10.1128/MCB.22.24.8438-8447.2002; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Tamanini F, 1999, BIOCHEM J, V343, P517, DOI 10.1042/0264-6021:3430517; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X	47	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5750	5763		10.1074/jbc.M401988200	http://dx.doi.org/10.1074/jbc.M401988200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15548538	hybrid			2022-12-25	WOS:000227217100077
J	Qian, KC; Wang, L; Hickey, ER; Studts, J; Barringer, K; Peng, C; Kronkaitis, A; Li, J; White, A; Mische, S; Farmer, B				Qian, KC; Wang, L; Hickey, ER; Studts, J; Barringer, K; Peng, C; Kronkaitis, A; Li, J; White, A; Mische, S; Farmer, B			Structural basis of constitutive activity and a unique nucleotide binding mode of human PIM-1 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; C-MYC; PHOSPHORYLASE-KINASE; INHIBITOR; LYMPHOMAGENESIS; PHOSPHATASE; ACTIVATION; MECHANISMS	Pim-1 kinase is a member of a distinct class of serine/threonine kinases consisting of Pim-1, Pim-2, and Pim-3. Pim kinases are highly homologous to one another and share a unique consensus hinge region sequence, ERPXPX, with its two proline residues separated by a non-conserved residue, but they (Pim kinases) have <30% sequence identity with other kinases. Pim-1 has been implicated in both cytokine-induced signal transduction and the development of lymphoid malignancies. We have determined the crystal structures of apo Pim-1 kinase and its AMP-PNP (5'-adenylyl-beta,gamma-imidodiphosphate) complex to 2.1-Angstrom resolutions. The structures reveal the following. 1) The kinase adopts a constitutively active conformation, and extensive hydrophobic and hydrogen bond interactions between the activation loop and the catalytic loop might be the structural basis for maintaining such a conformation. 2) The hinge region has a novel architecture and hydrogen-bonding pattern, which not only expand the ATP pocket but also serve to establish unambiguously the alignment of the Pim-1 hinge region with that of other kinases. 3) The binding mode of AMP-PNP to Pim-1 kinase is unique and does not involve a critical hinge region hydrogen bond interaction. Analysis of the reported Pim-1 kinase-domain structures leads to a hypothesis as to how Pim kinase activity might be regulated in vivo.	Boehringer Ingelheim Pharmaceut Inc, Res & Dev, Dept Med Chem, Ridgefield, CT 06877 USA; Boehringer Ingelheim Pharmaceut Inc, Res & Dev, Dept Immunol & Inflammat, Ridgefield, CT 06877 USA	Boehringer Ingelheim; Boehringer Ingelheim	Qian, KC (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Res & Dev, Dept Med Chem, 175 Briar Ridge Rd, Ridgefield, CT 06877 USA.	kqian@rdg.boehringer-ingelheim.com	Studts, Jamie L/A-4634-2008	Studts, Jamie L/0000-0003-3922-3597; Mische, Sheenah/0000-0002-6055-5564				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Cherry M, 2004, CURR MED CHEM, V11, P663, DOI 10.2174/0929867043455792; CUYPERS HT, 1984, CELL, V37, P141; DASGUPTA M, 1995, J BIOL CHEM, V270, P22283, DOI 10.1074/jbc.270.38.22283; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Losman JA, 2003, J BIOL CHEM, V278, P4800, DOI 10.1074/jbc.M208246200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; *MOL SIM INC, 1997, QUANT 97; Narayana N, 1997, STRUCTURE, V5, P921, DOI 10.1016/S0969-2126(97)00246-3; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Palaty CK, 1997, J BIOL CHEM, V272, P10514; QIAN KC, 2005, IN PRESS ACTA CRYS F, V61; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	36	212	228	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6130	6137		10.1074/jbc.M409123200	http://dx.doi.org/10.1074/jbc.M409123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15525646	hybrid			2022-12-25	WOS:000227217100120
J	Hill, K; Krugmann, S; Andrews, SR; Coadwell, WJ; Finan, P; Welch, HCE; Hawkins, PT; Stephens, LR				Hill, K; Krugmann, S; Andrews, SR; Coadwell, WJ; Finan, P; Welch, HCE; Hawkins, PT; Stephens, LR			Regulation of P-Rex1 by phosphatidylinositol (3,4,5)-trisphosphate and G beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHOINOSITIDE 3-KINASE; DEPENDENT ACTIVATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; RHO-GTPASES; RAC; DBL; COMPLEX	P-Rex1 is a guanine-nucleotide exchange factor (GEF) for the small GTPase Rac. We have investigated here the mechanisms of stimulation of P-Rex1 Rac-GEF activity by the lipid second messenger phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P-3) and the Goy subunits of heterotrimeric G proteins. We show that a P-Rex1 mutant lacking the PH domain (DeltaPH) cannot be stimulated by PtdIns(3,4,5)P-3, which implies that the PH domain confers Ptdlns(3,4,5)P-3 regulation of P-Rex1 Rac-GEF activity. Consistent with this, we found that Ptdlns(3,4,5)P-3 binds to the PH domain of P-Rex1 and that the DH/PH domain tandem is sufficient for Ptdlns(3,4,5)P-3-stimulated P-Rex1 activity. The Rac-GEF activities of the DeltaPH mutant and the DH/PH domain tandem can both be stimulated by Gbetagamma subunits, which infers that Gbetagamma subunits regulate P-Rex1 activity by binding to the catalytic DH domain. Deletion of the DEP, PDZ, or inositol polyphosphate 4-phosphatase homology domains has no major consequences on the abilities of either Ptdlns(3,4,5)P-3 or Gbetagamma subunits to stimulate P-Rex1 Rac-GEF activity. However, the presence of any of these domains impacts on the levels of basal and/or stimulated P-Rex1 Rac-GEF activity, suggesting that there are important functional interactions between the DH/PH domain tandem and the DEP, PDZ, and inositol polyphosphate 4-phosphatase homology domains of P-Rex1.	Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England; Babraham Inst, Bioinformat Grp, Cambridge CB2 4AT, England; Novartis Inst BioMed Res, Horsham RH12 5AB, W Sussex, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Novartis	Welch, HCE (corresponding author), Babraham Inst, Inositide Lab, Babraham Res Campus, Cambridge CB2 4AT, England.	heidi.welch@bbsre.ac.uk	Vermeren, Sonja/AAK-7442-2020	Vermeren, Sonja/0000-0002-8460-0884; stephens, len/0000-0002-2771-3487; Hawkins, Phillip/0000-0002-6979-0464; Welch, Heidi/0000-0001-7865-7000				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Gaffney PRJ, 1997, BIOORG MED CHEM LETT, V7, P3171, DOI 10.1016/S0960-894X(97)10166-4; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Martemyanov KA, 2003, J NEUROSCI, V23, P10175; Niu JX, 2003, CIRC RES, V93, P848, DOI 10.1161/01.RES.0000097607.14733.0C; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Nystuen A, 2001, NEURON, V32, P203, DOI 10.1016/S0896-6273(01)00468-8; Painter GF, 1999, J CHEM SOC PERK T 1, P923, DOI 10.1039/a900278b; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zimmermann P, 2002, MOL CELL, V9, P1215, DOI 10.1016/S1097-2765(02)00549-X	38	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4166	4173		10.1074/jbc.M411262200	http://dx.doi.org/10.1074/jbc.M411262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15545267	hybrid			2022-12-25	WOS:000227096600022
J	Kim, WS; Fitzgerald, ML; Kang, KW; Okuhira, K; Bell, SA; Manning, JJ; Koehn, SL; Lu, NF; Moore, KJ; Freeman, MW				Kim, WS; Fitzgerald, ML; Kang, KW; Okuhira, K; Bell, SA; Manning, JJ; Koehn, SL; Lu, NF; Moore, KJ; Freeman, MW			Abca7 null mice retain normal macrophage phosphatidyleholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER 1; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; CELLULAR CHOLESTEROL; APOA-I; BINDING; MUTATIONS; DIFFERENTIATION; DEFICIENCY	Mutations in the A class of ATP-binding cassette transporters (ABCA) are causally implicated in three human diseases: Tangier disease (ABCA1), Stargadt's macular degeneration (ABCA4), and neonatal respiratory failure (ABCA3). Both ABCA1 and ABCA4 have been shown to transport lipids across cellular membranes, and ABCA3 may play a similar role in transporting pulmonary surfactant. Although the functions of the other 10 ABCA class transporters identified in the human genome remain obscure, ABCA7-transfected cells have been shown to efflux lipids in response to stimulation by apolipoprotein A-I. In an effort to elucidate the physiologic role of ABCA7, we generated mice lacking. this transporter (Abca7(-/-) mice). Homozygous null mice were produced from intercrosses of heterozygous null mice at the expected Mendelian frequency and developed normally without any obvious phenotypic abnormalities. Cholesterol and phospholipid efflux stimulated by apolipoprotein A-1 from macrophages isolated from wild type and Abca7(-/-) mice did not differ, suggesting that these activities may not be central to the physiological role of the transporter in vivo. Abca7(-/-) females, but not males, had significantly less visceral fat and lower total serum and high density lipoprotein cholesterol levels than wild type, gender-matched littermates. ABCA7 expression was detected in hippocampal and cortical neurons by in situ hybridization and in brain and white adipose tissue by Western blotting. Induction of adipocyte differentiation from 3T3 fibroblasts in culture led to a marked increase in ABCA7 expression. These studies suggest that ABCA7 plays a novel role in lipid and fat metabolism that Abca7(-/-) mice can be used to elucidate.	Harvard Univ, Lipid Metab Unit, Massachusetts Gen Hosp, Dept Med,Sch Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Freeman, MW (corresponding author), Harvard Univ, Lipid Metab Unit, Massachusetts Gen Hosp, Dept Med,Sch Med, Boston, MA 02114 USA.	freeman@molbio.mgh.harvard.edu	Moore, Kathryn/ABE-6416-2020	Moore, Kathryn/0000-0003-2505-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098, R01HL072358, R01HL068988] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL72358, HL68988, HL45098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe-Dohmae S, 2004, J BIOL CHEM, V279, P604, DOI 10.1074/jbc.M309888200; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Dean M, 2001, J LIPID RES, V42, P1007; Fitzgerald ML, 2004, J BIOL CHEM, V279, P48477, DOI 10.1074/jbc.M409848200; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Kielar D, 2003, J INVEST DERMATOL, V121, P465, DOI 10.1046/j.1523-1747.2003.12404.x; Lefevre C, 2003, HUM MOL GENET, V12, P2369, DOI 10.1093/hmg/ddg235; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sasaki M, 2003, BIOCHEM BIOPH RES CO, V304, P777, DOI 10.1016/S0006-291X(03)00659-4; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	26	112	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3989	3995		10.1074/jbc.M412602200	http://dx.doi.org/10.1074/jbc.M412602200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550377	hybrid			2022-12-25	WOS:000226983900102
J	Matsui, T; Furukawa, M; Unno, M; Tomita, T; Ikeda-Saito, M				Matsui, T; Furukawa, M; Unno, M; Tomita, T; Ikeda-Saito, M			Roles of distal asp in heme oxygenase from Corynebacterium diphtheriae, HmuO - A water-driven oxygen activation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RESONANCE RAMAN; IRON SOURCES; RAT HEME; COMPLEX; DEGRADATION; EXPRESSION; SITE; BIOSYNTHESIS; MENINGITIDIS	Heme oxygenases found in mammals, plants, and bacteria catalyze degradation of heme using the same mechanism. Roles of distal Asp (Asp-136) residue in HmuO, a heme oxygenase of Corynebacterium diphtheriae, have been investigated by site-directed mutagenesis, enzyme kinetics, resonance Raman spectroscopy, and x-ray crystallography. Replacements of the Asp-136 by Ala and Phe resulted in reduced heme degradation activity due to the formation of ferryl heme, showing that the distal Asp is critical in HmuO heme oxygenase activity. D136N HmuO catalyzed heme degradation at a similar efficiency to wild type and D136E HmuO, implying that the carboxylate moiety is not required for the heme catabolism by HmuO. Resonance Raman results suggest that the inactive ferryl heme formation in the HmuO mutants is induced by disruption of the interaction between a reactive Fe-OOH species and an adjacent distal pocket water molecule. Crystal structural analysis of the HmuO mutants confirms partial disappearance of this nearby water in D136A HmuO. Our results provide the first experimental evidence for the catalytic importance of the nearby water molecule that can be universally critical in heme oxygenase catalysis and propose that the distal Asp helps in positioning the key water molecule at a position suitable for efficient activation of the Fe-OH species.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Matsui, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan.	matsui@tagen.tohoku.ac.jp; mis2@tagen.tohoku.ac.jp	Matsui, Toshitaka/B-1570-2008; Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008	Matsui, Toshitaka/0000-0003-3865-8468; Tomita, Takeshi/0000-0001-6815-2244				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEALE SI, 1984, ARCH BIOCHEM BIOPHYS, V235, P371, DOI 10.1016/0003-9861(84)90210-8; BENKO B, 1983, P NATL ACAD SCI USA, V80, P7042, DOI 10.1073/pnas.80.22.7042; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caignan GA, 2002, J AM CHEM SOC, V124, P14879, DOI 10.1021/ja0274960; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; Coyle CM, 2003, BIOCHEMISTRY-US, V42, P4896, DOI 10.1021/bi026395b; Davis SJ, 1999, P NATL ACAD SCI USA, V96, P6541, DOI 10.1073/pnas.96.11.6541; Davydov R, 2003, J AM CHEM SOC, V125, P16208, DOI 10.1021/ja038923s; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; Friedman J, 2004, BIOCHEMISTRY-US, V43, P5239, DOI 10.1021/bi049687g; Friedman J, 2003, J BIOL CHEM, V278, P34654, DOI 10.1074/jbc.M302985200; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; Hirotsu S, 2004, J BIOL CHEM, V279, P11937, DOI 10.1074/jbc.M311631200; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Li YM, 2003, J BIOL CHEM, V278, P6651, DOI 10.1074/jbc.M211249200; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P34501, DOI 10.1074/jbc.M004245200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; POULOS TL, 1980, J BIOL CHEM, V255, P8199; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sharma PK, 2004, ANGEW CHEM INT EDIT, V43, P1129, DOI 10.1002/anie.200352943; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2003, BIOCHEMISTRY-US, V42, P9898, DOI 10.1021/bi027268i; Syvitski RT, 2002, J AM CHEM SOC, V124, P14296, DOI 10.1021/ja028108x; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1140, DOI 10.1021/bi00535a005; Unno M, 2004, J BIOL CHEM, V279, P21055, DOI 10.1074/jbc.M400491200; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Zhu WM, 2000, J BACTERIOL, V182, P439, DOI 10.1128/JB.182.2.439-447.2000	46	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2981	2989		10.1074/jbc.M410263200	http://dx.doi.org/10.1074/jbc.M410263200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15528205	hybrid			2022-12-25	WOS:000226449100074
J	Saito, H; Maeda, A; Ohtomo, S; Hirata, M; Kusano, K; Kato, S; Ogata, E; Segawa, H; Miyamoto, K; Fukushima, N				Saito, H; Maeda, A; Ohtomo, S; Hirata, M; Kusano, K; Kato, S; Ogata, E; Segawa, H; Miyamoto, K; Fukushima, N			Circulating FGF-23 is regulated by 1 alpha,25-dihydroxyvitamin D-3 and phosphorus in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOPHOSPHATEMIC RICKETS; ONCOGENIC OSTEOMALACIA; PROTEOLYTIC CLEAVAGE; PHOSPHATE; BONE; EXPRESSION; GENE; FIBROBLAST-GROWTH-FACTOR-23; TUMORS; FGF23	Fibroblast growth factor-23 (FGF-23), a novel phosphate-regulating factor, was elevated in hypophosphatemic patients with X-linked hypophosphatemic rickets/osteomalacia and also in patients with chronic kidney disease. These observations suggested the pathophysiological importance of FGF-23 on phosphate homeostasis. However, regulation of FGF-23 production is still unclear. We investigated effects of both dietary phosphorus and 1alpha,25-dihydroxyvitamin D-3 (1alpha,25(OH)(2)D-3) on circulating FGF-23 in vivo. Administration of 1alpha,25(OH)(2)D-3 dose-dependently increased serum FGF-23 in thyroparathyroidectomized rats without correlating with serum inorganic phosphorus or serum parathyroid hormone. On the other hand, vitamin D receptor null mice had very low serum FGF-23 and did not respond to the 1alpha,25(OH)(2)D-3 administration. These observations suggested la,25(OH)2D3 directly or indirectly regulates circulating FGF-23. Serum FGF-23 had a strong correlation with serum inorganic phosphorus controlled by dietary phosphorus in 5/6 nephrectomized rats. High phosphate diet elicited a 5-fold increase in serum FGF-23 compared with sham-operated rats, whereas serum FGF-23 did not correlate with serum calcium or serum creatinine in 5/6 nephrectomized rats. Administration of 1alpha,25-dihydroxyvitamin D-3 also elicited a severalfold increase in serum FGF-23 in the uremic rats. Taken together, this shows that both serum phosphorus and 1alpha,25(OH)(2)D-3 regulate circulating FGF-23 independent of each other. Therefore, we proposed there was a feedback loop existing among serum phosphorus, 1alpha,25(OH)(2)D-3, and FGF-23, in which the novel phosphate-regulating bone-kidney axis integrated with the parathyroid hormone-vitamin D-3 axis in regulating phosphate homeostasis.	Chugai Pharmaceut Co Ltd, Pharmaceut Res Dept 2, Shizuoka 4128513, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Canc Inst Hosp, Toshima Ku, Tokyo 1708455, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Mol Nutr, Tokushima 7708503, Japan	Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tokyo; Japanese Foundation for Cancer Research; Tokushima University	Saito, H (corresponding author), Chugai Pharmaceut Co Ltd, Pharmaceut Res Dept 2, Shizuoka 4128513, Japan.	saitohts@chugai-pharm.co.jp	Saito, Hitoshi/A-5844-2016	Saito, Hitoshi/0000-0001-5316-2079				Argiro L, 2001, GENOMICS, V74, P342, DOI 10.1006/geno.2001.6553; Bai XY, 2003, J BIOL CHEM, V278, P9843, DOI 10.1074/jbc.M210490200; Berndt T, 2003, J CLIN INVEST, V112, P785, DOI 10.1172/JC1200318563; Brewer AJ, 2004, AM J PHYSIOL-RENAL, V286, pF739, DOI 10.1152/ajprenal.00321.2003; De Beur SMJ, 2002, J BONE MINER RES, V17, P1102, DOI 10.1359/jbmr.2002.17.6.1102; Ecarot B, 1999, ENDOCRINOLOGY, V140, P1192, DOI 10.1210/en.140.3.1192; Gowen LC, 2003, J BIOL CHEM, V278, P1998, DOI 10.1074/jbc.M203250200; Imanishi Y, 2004, KIDNEY INT, V65, P1943, DOI 10.1111/j.1523-1755.2004.00604.x; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Katai K, 1999, BIOCHEM J, V343, P705, DOI 10.1042/0264-6021:3430705; Katai K, 1997, J BIOCHEM-TOKYO, V121, P50, DOI 10.1093/oxfordjournals.jbchem.a021569; Larsson T, 2003, KIDNEY INT, V64, P2272, DOI 10.1046/j.1523-1755.2003.00328.x; Liu SG, 2003, J BIOL CHEM, V278, P37419, DOI 10.1074/jbc.M304544200; Quarles LD, 2003, J CLIN INVEST, V112, P642, DOI 10.1172/JC1200319687; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899; Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235; Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200; Shigematsu T, 2004, AM J KIDNEY DIS, V44, P250, DOI 10.1053/j.ajkd.2004.04.029; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shimada T, 2004, BIOCHEM BIOPH RES CO, V314, P409, DOI 10.1016/j.bbrc.2003.12.102; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179; Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264; Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227; White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002-021105; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	30	348	367	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2543	2549		10.1074/jbc.M408903200	http://dx.doi.org/10.1074/jbc.M408903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15531762	hybrid			2022-12-25	WOS:000226449100022
J	Bertrand, C; Benhamed, M; Li, YF; Ayadi, M; Lemonnier, G; Renou, JP; Delarue, M; Zhou, DX				Bertrand, C; Benhamed, M; Li, YF; Ayadi, M; Lemonnier, G; Renou, JP; Delarue, M; Zhou, DX			Arabidopsis HAF2 gene encoding TATA-binding protein (TBP)-associated factor TAF1, is required to integrate light signals to regulate gene expression and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISRUPTS CIRCADIAN-RHYTHMS; HISTONE ACETYLTRANSFERASE; BZIP PROTEIN; PHYTOCHROME; TRANSCRIPTION; TAF(II)250; PROMOTER; HY5; ACETYLATION; PERCEPTION	Plant growth and development are sensitive to light. Light-responsive DNA-binding transcription factors have been functionally identified. However, how transcription initiation complex integrates light signals from enhancer-bound transcription factors remains unknown. In this work, we characterized mutations within the Arabidopsis HAF2 gene encoding TATA-binding protein-associated factor TAF1 (or TAF(II)250). The mutation of HAF2 induced decreases on chlorophyll accumulation, light-induced mRNA levels, and promoter activity. Genetic analysis indicated that HAF2 is involved in the pathways of both red/far-red and blue light signals. Double mutants between haf2-1 and hy5-1, a mutation of a light signaling positive DNA-binding transcription factor gene, had a synergistic effect on photomorphogenic traits and light-activated gene expression under different light wavelengths, suggesting that HAF2 is required for interaction with additional light-responsive DNA-binding transcription factors to fully respond to light induction. Chromatin immunoprecipitation assays showed that the mutation of HAF2 reduced acetylation of histone H3 in light-responsive promoters. In addition, transcriptome analysis showed that the mutation altered the expression of about 9% of genes in young leaves. These data indicate that TAF1 encoded by the Arabidopsis HAF2 gene functions as a coactivator capable of integrating light signals and acetylating histones to activate light-induced gene transcription.	Univ Paris 11, Inst Biotechnol Plantes, UMR8618, F-91405 Orsay, France; Univ Picardie, Fac Sci, F-80039 Amiens, France; INRA, Unite Rech Genom Vegetale, F-91057 Evry, France	UDICE-French Research Universities; Universite Paris Saclay; Picardie Universites; Universite de Picardie Jules Verne (UPJV); INRAE; UDICE-French Research Universities; Universite Paris Saclay	Zhou, DX (corresponding author), Univ Paris 11, Inst Biotechnol Plantes, UMR8618, Bat 425, F-91405 Orsay, France.	zhou@ibp.u-psud.fr		Zhou Li, Youfang/0000-0002-0390-8925; Zhou, Dao-Xiu/0000-0002-1540-0598; Ayadi, Mira/0000-0002-4019-2858				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Anderson SL, 1997, PLANT CELL, V9, P1727, DOI 10.1105/tpc.9.10.1727; Ballesteros ML, 2001, GENE DEV, V15, P2613, DOI 10.1101/gad.915001; Bertrand C, 2003, J BIOL CHEM, V278, P28246, DOI 10.1074/jbc.M302787200; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Carre IA, 1995, PLANT CELL, V7, P2039, DOI 10.2307/3870149; Chattopadhyay S, 1998, PLANT CELL, V10, P673, DOI 10.1105/tpc.10.5.673; Chua YL, 2003, PLANT CELL, V15, P1468, DOI 10.1105/tpc.011825; Chua YL, 2001, PLANT CELL, V13, P599, DOI 10.1105/tpc.13.3.599; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Fairchild CD, 2000, GENE DEV, V14, P2377; Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950; Halliday KJ, 1999, P NATL ACAD SCI USA, V96, P5832, DOI 10.1073/pnas.96.10.5832; Holm M, 2002, GENE DEV, V16, P1247, DOI 10.1101/gad.969702; Le Gourrierec J, 1999, PLANT J, V18, P663, DOI 10.1046/j.1365-313x.1999.00482.x; Li YF, 2001, FEBS LETT, V489, P187, DOI 10.1016/S0014-5793(01)02101-9; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Lin CT, 2002, PLANT CELL, V14, pS207, DOI 10.1105/tpc.000646; Ma LG, 2001, PLANT CELL, V13, P2589, DOI 10.1105/tpc.13.12.2589; Martinez E, 2002, PLANT MOL BIOL, V50, P925, DOI 10.1023/A:1021258713850; Martinez-Garcia JF, 2000, SCIENCE, V288, P859, DOI 10.1126/science.288.5467.859; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Muramoto T, 1999, PLANT CELL, V11, P335, DOI 10.1105/tpc.11.3.335; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Oyama T, 1997, GENE DEV, V11, P2983, DOI 10.1101/gad.11.22.2983; Pandey R, 2002, NUCLEIC ACIDS RES, V30, P5036, DOI 10.1093/nar/gkf660; Quail PH, 2002, CURR OPIN CELL BIOL, V14, P180, DOI 10.1016/S0955-0674(02)00309-5; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Schoof H, 2002, NUCLEIC ACIDS RES, V30, P91, DOI 10.1093/nar/30.1.91; Schroeder DF, 2002, CURR BIOL, V12, P1462, DOI 10.1016/S0960-9822(02)01106-5; Schwechheimer C, 2000, SEMIN CELL DEV BIOL, V11, P495, DOI 10.1006/scdb.2000.0203; Smith H, 2000, NATURE, V407, P585, DOI 10.1038/35036500; Soh MS, 2000, PLANT CELL, V12, P2061, DOI 10.1105/tpc.12.11.2061; Spiegelman JI, 2000, PLANT CELL, V12, P2485, DOI 10.1105/tpc.12.12.2485; Tepperman JM, 2001, P NATL ACAD SCI USA, V98, P9437, DOI 10.1073/pnas.161300998; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Vlachonasios KE, 2003, PLANT CELL, V15, P626, DOI 10.1105/tpc.007922; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Wassarman DA, 2000, P NATL ACAD SCI USA, V97, P1154, DOI 10.1073/pnas.97.3.1154; Wassarman DA, 2001, J CELL SCI, V114, P2895	43	95	104	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1465	1473		10.1074/jbc.M409000200	http://dx.doi.org/10.1074/jbc.M409000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15525647	hybrid, Green Published			2022-12-25	WOS:000226195200075
J	Miao, H; Strebhardt, K; Pasquale, EB; Shen, TL; Guan, JL; Wang, BC				Miao, H; Strebhardt, K; Pasquale, EB; Shen, TL; Guan, JL; Wang, BC			Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase - Role of RHO family small GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE LIGANDS; INDEPENDENT FUNCTIONS; CROSS-LINKING; EPHRINS; BINDING; RAC; MORPHOGENESIS; PROTRUSION; ACTIVATION; ATTACHMENT	Genetic studies have shown that Eph receptor tyrosine kinases have both kinase-dependent and kinase-independent functions through incompletely understood mechanisms. We report here that ephrin-B1 stimulation of endogenous EphB kinases in LS174T colorectal epithelial cells inhibited integrin-mediated adhesion and HGF/SF-induced directional cell migration. Using 293 cells stably transfected with wild type (WT)- or kinase-deficient (KD-EphB3), we found that inhibition of integrin-mediated cell adhesion and induction of cell rounding was kinase-dependent. Unexpectedly, in two independent assays, both KD- and WT-EphB3 significantly inhibited directional cell migration. Upon ephrin-B1 stimulation, the activities of Rac1 and Cdc42 were reduced in both WT- and KD- EphB3-expressing cells that were induced to migrate. Pharmacological evidence demonstrates that a relative increase in RhoA signaling as a result of decreased Rac1/ Cdc42 activities contributes to the inhibitory effects. Furthermore, EphB3-mediated inhibitory effect on cell adhesion but not migration was abolished by the integrin activating antibodies, suggesting that the inhibition of cell migration is not because of down-regulation of integrin function. These results uncover a differential requirement for EphB3 catalytic activity in the regulation of cell adhesion and migration, and suggest that while catalytic activity of EphB3 is required for inhibition of integrin-mediated cell adhesion, a distinct signaling pathway to Rho GTPases shared by WT- and KD- EphB3 receptor mediates inhibition of directional cell migration.	Case Western Reserve Univ, Metrohlth Med Ctr, Sch Med, Rammelkamp Ctr Res, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44109 USA; Goethe Univ Frankfurt, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Goethe University Frankfurt; Sanford Burnham Prebys Medical Discovery Institute; Cornell University	Wang, BC (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Sch Med, Rammelkamp Ctr Res, Metrohlth Campus,R421,2500 Metrohlth Dr, Cleveland, OH 44109 USA.	bxw14@case.edu	Strebhardt, Klaus/E-8765-2011; Shen, Tang-Long/C-7460-2011	Strebhardt, Klaus/0000-0003-2173-9763; Shen, Tang-Long/0000-0001-6264-3608	NCI NIH HHS [CA96533, CA92259] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092259, R01CA096533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Caenepeel S, 2004, P NATL ACAD SCI USA, V101, P11707, DOI 10.1073/pnas.0306880101; Caron E, 2003, NAT CELL BIOL, V5, P185, DOI 10.1038/ncb0303-185; Chin-Sang ID, 1999, CELL, V99, P781, DOI 10.1016/S0092-8674(00)81675-X; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1997, CELL TISSUE RES, V290, P227, DOI 10.1007/s004410050927; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Gurniak CB, 1996, ONCOGENE, V13, P777; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Luo HY, 2002, J CLIN INVEST, V110, P1141, DOI 10.1172/JCI200215883; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Miao H, 2003, J CELL BIOL, V162, P1281, DOI 10.1083/jcb.200304018; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Smith LM, 2004, EXP CELL RES, V292, P295, DOI 10.1016/j.yexcr.2003.08.021; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wang XM, 1999, MOL CELL, V4, P903, DOI 10.1016/S1097-2765(00)80220-8; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	57	81	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					923	932		10.1074/jbc.M411383200	http://dx.doi.org/10.1074/jbc.M411383200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536074	hybrid, Green Published			2022-12-25	WOS:000226195200011
J	Salaun, C; Gould, GW; Chamberlain, LH				Salaun, C; Gould, GW; Chamberlain, LH			The SNARE proteins SNAP-25 and SNAP-23 display different affinities for lipid rafts in PC12 cells - Regulation by distinct cysteine-rich domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; PLASMA-MEMBRANE; EXOCYTOSIS; PALMITOYLATION; VESICLE; LOCALIZATION; CHOLESTEROL; DOCKING; PATHWAY; BINDING	SNAP-25 and its ubiquitously expressed homologue, SNAP-23, are SNARE proteins that are essential for regulated exocytosis in diverse cell types. Recent work has shown that SNAP-25 and SNAP-23 are partly localized in sphingolipid/cholesterol-rich lipid raft domains of the plasma membrane and that the integrity of these domains is important for exocytosis. Here, we show that raft localization is mediated by a 36-amino-acid region of SNAP-25 that is also the minimal sequence required for membrane targeting; this domain contains 4 closely spaced cysteine residues that are sites for palmitoylation. Analysis of endogenous levels of SNAP-25 and SNAP-23 present in lipid rafts in PC12 cells revealed that SNAP-23 (54% raft-associated) was almost 3-fold more enriched in rafts when compared with SNAP-25 (20% raft-associated). We report that the increased raft association of SNAP-23 occurs due to the substitution of a highly conserved phenylalanine residue present in SNAP-25 with a cysteine residue. Intriguingly, although the extra cysteine in SNAP-23 enhances its raft association, the phenylalanine at the same position in SNAP-25 acts to repress the raft association of this protein. These different raft-targeting signals within SNAP-25 and SNAP-23 are likely important for fine-tuning the exocytic pathways in which these proteins operate.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Chamberlain, LH (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	l.chamberlain@bio.gla.ac.uk	Gould, Gwyn/AAF-6721-2019	Gould, Gwyn/0000-0001-6571-2875; Salaun, Christine/0000-0003-3002-6810	Biotechnology and Biological Sciences Research Council [C16435] Funding Source: Medline; Wellcome Trust [070835] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bacia K, 2004, J BIOL CHEM, V279, P37951, DOI 10.1074/jbc.M407020200; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chamberlain LH, 2001, J CELL SCI, V114, P445; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Koticha DK, 1999, J BIOL CHEM, V274, P9053, DOI 10.1074/jbc.274.13.9053; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lane SR, 1997, J NEUROCHEM, V69, P1864; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Pombo I, 2003, FEBS LETT, V550, P144, DOI 10.1016/S0014-5793(03)00864-0; RAVICHANDRAN V, 1996, J BIOL CHEM, V268, P24408; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; Saslowsky DE, 2003, J MEMBRANE BIOL, V194, P153, DOI 10.1007/s00232-003-2035-7; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Taverna E, 2004, J BIOL CHEM, V279, P5127, DOI 10.1074/jbc.M308798200; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Wang GY, 1997, J CELL SCI, V110, P505; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200	28	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1236	1240		10.1074/jbc.M410674200	http://dx.doi.org/10.1074/jbc.M410674200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15542596	Green Accepted, hybrid			2022-12-25	WOS:000226195200047
J	Motterlini, R; Sawle, P; Bains, S; Hammad, J; Alberto, R; Foresti, R; Green, CJ				Motterlini, R; Sawle, P; Bains, S; Hammad, J; Alberto, R; Foresti, R; Green, CJ			CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule	FASEB JOURNAL			English	Article						sodium boranocarbonate; CO electrode; vascular tone; blood pressure; heme oxygenase-1	HEME OXYGENASE-1; SMOOTH-MUSCLE; NITRIC-OXIDE; VASOACTIVE PROPERTIES; CO; SUPPRESSES; INDUCTION; CELLS; INHIBITION; REJECTION	Carbon monoxide (CO) is emerging as an important and versatile mediator of physiological processes to the extent that treatment of animals with exogenous CO gas has beneficial effects in a range of vascular- and inflammatory-related disease models. The recent discovery that certain transition metal carbonyls function as CO-releasing molecules (CO-RMs) in biological systems highlighted the potential of exploiting this and similar classes of compounds as a stratagem to deliver CO for therapeutic purposes. Here we describe the biochemical features and pharmacological actions of a newly identified water-soluble CO releaser (CORM-A1) that, unlike the first prototypic molecule recently described (CORM-3), does not contain a transition metal and liberates CO at a much slower rate under physiological conditions. Using a myoglobin assay and an amperometric CO electrode, we demonstrated that the release of CO from CORM-A1 is both pH- and temperature-dependent with a half-life of similar to21 min at 37degreesC and pH 7.4. In isolated aortic rings, CORM-A1 promoted a gradual but profound concentration-dependent vasorelaxation over time, which was highly amplified by YC-1 (1 muM) and attenuated by ODQ, a stimulator and inhibitor of guanylate cyclase, respectively. Similarly, administration of CORM-A1 (30 mumol/kg i.v.) in vivo produced a mild decrease in mean arterial pressure, which was markedly potentiated by pretreatment with YC-1 (1.2 mumol/kg i.v.). Interestingly, an inactive form of CORM-A1 that is incapable of releasing CO failed to promote both vasorelaxation and hypotension, thus directly implicating CO as the mediator of the observed pharmacological effects. Our results reveal that the bioactivities exerted by CORM-A1 reflect its intrinsic biochemical behavior of a slow CO releaser, which may be advantageous in the treatment of chronic conditions that require CO to be delivered in a carefully controlled manner.	Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow, Middx, England; Univ Zurich, Dept Chem, CH-8006 Zurich, Switzerland	Imperial College London; University of Zurich	Motterlini, R (corresponding author), Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow, Middx, England.	r.motterlini@imperial.ac.uk	Alberto, Roger/S-6405-2019; Motterlini, Roberto/G-2489-2013; Motterlini, Roberto/Q-1890-2019	Alberto, Roger/0000-0001-5978-3394; Motterlini, Roberto/0000-0003-2684-2612; Motterlini, Roberto/0000-0003-2684-2612; foresti, roberta/0000-0002-0836-7937				Alberto R, 1998, J AM CHEM SOC, V120, P7987, DOI 10.1021/ja980745t; Alberto R, 2001, J AM CHEM SOC, V123, P3135, DOI 10.1021/ja003932b; Arregui B, 2004, KIDNEY INT, V65, P564, DOI 10.1111/j.1523-1755.2004.00409.x; Bak I, 2003, FASEB J, V17, P2133, DOI 10.1096/fj.03-0032fje; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chapman JT, 2001, AM J PHYSIOL-LUNG C, V281, pL209, DOI 10.1152/ajplung.2001.281.1.L209; Chatterjee PK, 2004, BRIT J PHARMACOL, V142, P391, DOI 10.1038/sj.bjp.0705826; Choi BM, 2003, FREE RADICAL BIO MED, V34, P1136, DOI 10.1016/S0891-5849(03)00064-9; Choi BM, 2003, HEPATOLOGY, V37, P810, DOI 10.1053/jhep.2003.50114; Clark JE, 2003, CIRC RES, V93, pE2, DOI 10.1161/01.RES.0000084381.86567.08; Fiumana E, 2003, AM J PHYSIOL-HEART C, V284, pH1073, DOI 10.1152/ajpheart.00881.2002; Foresti R, 2004, BIOCHEM SOC SYMP, V71, P177, DOI 10.1042/bss0710177; Foresti R, 2004, BRIT J PHARMACOL, V142, P453, DOI 10.1038/sj.bjp.0705825; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Guo YR, 2004, AM J PHYSIOL-HEART C, V286, pH1649, DOI 10.1152/ajpheart.00971.2003; Johnson TR, 2003, ANGEW CHEM INT EDIT, V42, P3722, DOI 10.1002/anie.200301634; Jozkowicz A, 2003, ANTIOXID REDOX SIGN, V5, P155, DOI 10.1089/152308603764816514; Koneru P, 2004, AM J PHYSIOL-HEART C, V286, pH304, DOI 10.1152/ajpheart.00810.2003; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; Motterlini R, 2002, BIOMED PHARMACOTHER, V56, P349; Motterlini R, 2003, CURR PHARM DESIGN, V9, P2525, DOI 10.2174/1381612033453785; Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530; Motterlini R, 2002, ANTIOXID REDOX SIGN, V4, P615, DOI 10.1089/15230860260220111; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Motterlini R, 1998, CIRC RES, V83, P568, DOI 10.1161/01.RES.83.5.568; Motterlini R., 2002, CARBON MONOXIDE CARD, P249; Naughton P, 2002, J BIOL CHEM, V277, P40666, DOI 10.1074/jbc.M203863200; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; Rattan S, 2004, AM J PHYSIOL-GASTR L, V287, pG605, DOI 10.1152/ajpgi.00070.2004; RYTER SW, 2004, SCI STKE, pRE6; Sacerdoti D, 2004, J PHARMACOL EXP THER, V308, P636, DOI 10.1124/jpet.103.057315; Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Stanford SJ, 2003, EUR J PHARMACOL, V473, P135, DOI 10.1016/S0014-2999(03)02001-6; Tongers J, 2004, CARDIOVASC RES, V63, P545, DOI 10.1016/j.cardiores.2004.04.015; Vannacci A, 2004, INFLAMM RES, V53, pS9, DOI 10.1007/s00011-003-0303-8; Waibel R, 1999, NAT BIOTECHNOL, V17, P897, DOI 10.1038/12890; Wakabayaski Y, 1999, AM J PHYSIOL-GASTR L, V277, pG1088, DOI 10.1152/ajpgi.1999.277.5.G1088; Wang R, 1998, CAN J PHYSIOL PHARM, V76, P1; Wang R, 1997, BRIT J PHARMACOL, V121, P927, DOI 10.1038/sj.bjp.0701222; Xi Q, 2004, AM J PHYSIOL-HEART C, V286, pH610, DOI 10.1152/ajpheart.00782.2003	49	334	353	1	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					284	+		10.1096/fj.04-2169fje	http://dx.doi.org/10.1096/fj.04-2169fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15556971	Green Accepted			2022-12-25	WOS:000225482100006
J	Comini, M; Menge, U; Wissing, J; Flohe, L				Comini, M; Menge, U; Wissing, J; Flohe, L			Trypanothione synthesis in Crithidia revisited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; ALANYL-D-ALANINE; GLUTATHIONE SYNTHETASE; PEROXIDE METABOLISM; KINETIC MECHANISM; CRYSTAL-STRUCTURE; FLEXIBLE LOOP; TRYPANOSOMA; GLUTATHIONYLSPERMIDINE; REDUCTASE	In Crithidia fasciculata the biosynthesis of trypanothione (N-1,N-8-bis(glutathionyl)spermidine; reduced trypanothione), a redox mediator unique to and essential for pathogenic trypanosomatids, was assumed to be achieved by two distinct enzymes, glutathionylspermidine synthetase and trypanothione synthetase (TryS), and only the first one was adequately characterized. We here report that the TryS of C. fasciculata, like that of Trypanosoma species, catalyzes the entire synthesis of trypanothione, whereas its glutathionylspermidine synthetase appears to be specialized for Gsp synthesis. A gene (GenBank(TM) accession number AY603101) implicated in reduced trypanothione synthesis of C. fasciculata was isolated from genomic DNA and expressed in Escherichia coli as His-tagged or Nus fusion proteins. The expression product proved to be a trypanothione synthetase (Cf-TryS) that also displayed a glutathionylspermidine synthetase, an amidase, and marginal ATPase activity. The dual specificity of the Cf-TryS preparations was not altered by removal of the tags. Steady-state kinetic analysis of Cf-TryS yielded a pattern that was compatible with a concerted substitution mechanism, wherein the enzyme forms a ternary complex with Mg2+-ATP and GSH to phosphorylate GSH and then ligates the glutathionyl residue to glutathionylspermidine. Limiting K-m values for GSH, Mg2+-ATP, and glutathionylspermidine were 407, 222, and 480 mum, respectively, and the k(cat) was 8.7 s(-1) for the TryS reaction. Mutating Arg-553 or Arg-613 to Lys, Leu, Gln, or Glu resulted in marked reduction or abrogation (R553E) of activity. Limited proteolysis with factor Xa or trypsin resulted in cleavage at Arg-556 that was accompanied by loss of activity. The presence of substrates, in particular of ATP and GSH alone or in combination, delayed proteolysis of wild-type Cf-TryS and Cf-TryS R553Q but not in Cf-TryS R613Q, which suggests dynamic interactions of remote domains in substrate binding and catalysis.	MOLISA GmbH, D-39106 Magdeburg, Germany; Tech Univ Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany; German Res Ctr Biotechnol, D-38124 Braunschweig, Germany	Braunschweig University of Technology; Helmholtz Association; Helmholtz-Center for Infection Research	Flohe, L (corresponding author), MOLISA GmbH, Univ Pl 2, D-39106 Magdeburg, Germany.	l.flohe@t-online.de		Comini, Marcelo/0000-0001-5000-1333				Ariyanayagam MR, 1997, MOL BIOCHEM PARASIT, V84, P111, DOI 10.1016/S0166-6851(96)02788-0; Artymiuk PJ, 1996, NAT STRUCT BIOL, V3, P128, DOI 10.1038/nsb0296-128; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; COLANDUONI J, 1987, J BIOL CHEM, V262, P3037; Comini M, 2003, BIOL CHEM, V384, P653, DOI 10.1515/BC.2003.072; Comini MA, 2004, FREE RADICAL BIO MED, V36, P1289, DOI 10.1016/j.freeradbiomed.2004.02.008; DALZIEL K, 1969, BIOCHEM J, V114, P547, DOI 10.1042/bj1140547; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; FAIRLAMB AH, 1985, MOL BIOCHEM PARASIT, V14, P187, DOI 10.1016/0166-6851(85)90037-4; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; Flohe L, 2001, SELENIUM: ITS MOLECULAR BIOLOGY AND ROLE IN HUMAN HEALTH, P157; Grishin NV, 1999, J MOL BIOL, V291, P239, DOI 10.1006/jmbi.1999.2973; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hofmann B, 2001, BIOL CHEM, V382, P459, DOI 10.1515/BC.2001.056; KATO H, 1994, BIOCHEMISTRY-US, V33, P4995, DOI 10.1021/bi00183a001; Koenig K, 1997, J BIOL CHEM, V272, P11908, DOI 10.1074/jbc.272.18.11908; Krauth-Siegel RL, 2003, BIOL CHEM, V384, P539, DOI 10.1515/BC.2003.062; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Mannervik B., 1989, COENZYMES COFACTORS, VVolume 3A, P475; Mastri C, 2001, BIOCHEM BIOPH RES CO, V282, P1177, DOI 10.1006/bbrc.2001.4704; Mauri P, 2003, BIOL CHEM, V384, P575, DOI 10.1515/BC.2003.065; MEEK TD, 1980, BIOCHEMISTRY-US, V19, P5513, DOI 10.1021/bi00565a008; MEISTER A, 1974, ENZYMES, V10, P699; Meister A., 1974, ENZYMES, V10, P671; MULLINS LS, 1990, J BIOL CHEM, V265, P8993; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Oza SL, 2002, BIOCHEM J, V364, P679, DOI 10.1042/BJ20011370; Oza SL, 2002, J BIOL CHEM, V277, P35853, DOI 10.1074/jbc.M204403200; Oza SL, 2003, MOL BIOCHEM PARASIT, V131, P25, DOI 10.1016/S0166-6851(03)00176-2; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; Rabilloud T, 2001, PROTEOMICS, V1, P699, DOI 10.1002/1615-9861(200104)1:5<699::AID-PROT699>3.3.CO;2-3; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; SCHECHTER P J, 1986, Parasitology Today, V2, P223, DOI 10.1016/0169-4758(86)90087-6; Schirmer R. H., 1989, GLUTATHIONE CHEM B A, P553; SHI Y, 1995, BIOCHEMISTRY-US, V34, P2768, DOI 10.1021/bi00009a005; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1975, J BIOL CHEM, V250, P2648; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; Tetaud E, 1998, J BIOL CHEM, V273, P19383, DOI 10.1074/jbc.273.31.19383; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WENDEL A, 1972, H-S Z PHYSIOL CHEM, V353, P523, DOI 10.1515/bchm2.1972.353.1.523; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2003, J BIOL CHEM, V278, P31640, DOI 10.1074/jbc.M303035200; WRIGHT GD, 1993, PROTEIN SCI, V2, P1765, DOI 10.1002/pro.5560021020; XIAOLIN S, 1998, P NATL ACAD SCI USA, V95, P6647	55	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6850	6860		10.1074/jbc.M404486200	http://dx.doi.org/10.1074/jbc.M404486200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15537651	hybrid			2022-12-25	WOS:000227332700074
J	Chen, CY; Brodsky, FM				Chen, CY; Brodsky, FM			Huntingtin-interacting protein 1 (Hip1) and Hip1-related protein (Hip1R) bind the conserved sequence of clathrin light chains and thereby influence clathrin assembly in vitro and actin distribution in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED PITS; MEDIATED ENDOCYTOSIS; RECEPTOR; LOCALIZATION; EXPRESSION; SLA2P; CORTACTIN; COMPONENT; HOMOLOGY; REGION	Clathrin heavy and light chains form triskelia, which assemble into polyhedral coats of membrane vesicles that mediate transport for endocytosis and organelle biogenesis. Light chain subunits regulate clathrin assembly in vitro by suppressing spontaneous self-assembly of the heavy chains. The residues that play this regulatory role are at the N terminus of a conserved 22-amino acid sequence that is shared by all vertebrate light chains. Here we show that these regulatory residues and others in the conserved sequence mediate light chain interaction with Hip1 and Hip1R. These related proteins were previously found to be enriched in clathrin-coated vesicles and to promote clathrin assembly in vitro. We demonstrate Hip1R binding preference for light chains associated with clathrin heavy chain and show that Hip1R stimulation of clathrin assembly in vitro is blocked by mutations in the conserved sequence of light chains that abolish interaction with Hip1 and Hip1R. In vivo overexpression of a fragment of clathrin light chain comprising the Hip1R-binding region affected cellular actin distribution. Together these results suggest that the roles of Hip1 and Hip1R in affecting clathrin assembly and actin distribution are mediated by their interaction with the conserved sequence of clathrin light chains.	Univ Calif San Francisco, George Williams Hooper Fdn, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Brodsky, FM (corresponding author), Univ Calif San Francisco, George Williams Hooper Fdn, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA.	fmarbro@itsa.ucs.edu		Brodsky, Frances/0000-0002-1334-9258	NCI NIH HHS [CA09043] Funding Source: Medline; NIGMS NIH HHS [GM38093] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038093] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; ACTON SL, 1993, MOL BIOL CELL, V4, P647, DOI 10.1091/mbc.4.6.647; Bennett EM, 2001, TRAFFIC, V2, P851, DOI 10.1034/j.1600-0854.2001.21114.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BRODSKY FM, 1991, TRENDS BIOCHEM SCI, V16, P208, DOI 10.1016/0968-0004(91)90087-C; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Carreno S, 2004, J CELL BIOL, V165, P781, DOI 10.1083/jcb.200403120; Chen CY, 2002, EMBO J, V21, P6072, DOI 10.1093/emboj/cdf594; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Engqvist-Goldstein AEY, 2004, MOL BIOL CELL, V15, P1666, DOI 10.1091/mbc.E03-09-0639; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Greene B, 2000, TRAFFIC, V1, P69, DOI 10.1034/j.1600-0854.2000.010110.x; Henry KR, 2002, MOL BIOL CELL, V13, P2607, DOI 10.1091/mbc.E02-01-0012; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Hyun TS, 2004, J BIOL CHEM, V279, P14294, DOI 10.1074/jbc.M312645200; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; Legendre-Guillemin V, 2002, J BIOL CHEM, V277, P19897, DOI 10.1074/jbc.M112310200; Legendre-Guillemin V, 2005, J BIOL CHEM, V280, P6101, DOI 10.1074/jbc.M408430200; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Nossal R, 2001, TRAFFIC, V2, P138, DOI 10.1034/j.1600-0854.2001.020208.x; PLEY UM, 1995, J BIOL CHEM, V270, P2395, DOI 10.1074/jbc.270.5.2395; Towler MC, 2004, MOL BIOL CELL, V15, P3181, DOI 10.1091/mbc.E04-03-0249; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; Wakeham DE, 2003, EMBO J, V22, P4980, DOI 10.1093/emboj/cdg511; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297	42	83	90	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6109	6117		10.1074/jbc.M408454200	http://dx.doi.org/10.1074/jbc.M408454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15533940	hybrid			2022-12-25	WOS:000227217100118
J	Bonnal, S; Pileur, F; Orsini, C; Parker, F; Pujol, F; Prats, AC; Vagner, S				Bonnal, S; Pileur, F; Orsini, C; Parker, F; Pujol, F; Prats, AC; Vagner, S			Heterogeneous nuclear ribonucleoprotein A1 is a novel internal ribosome entry site trans-acting factor that modulates alternative initiation of translation of the fibroblast growth factor 2 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; GROWTH-FACTOR 2; HUMAN FIBROBLAST GROWTH-FACTOR-2; HNRNP A1; FUNCTIONAL-CHARACTERIZATION; GENE-EXPRESSION; SPLICING FACTOR; LA AUTOANTIGEN; SR PROTEINS; IN-VIVO	Alternative initiation of translation of the human fibroblast growth factor 2 (FGF-2) mRNA at five in-frame CUG or AUG translation initiation codons requires various RNA cis-acting elements, including an internal ribosome entry site (IRES). Here we describe the purification of a trans-acting factor controlling FGF-2 mRNA translation achieved by several biochemical purification approaches. We have identified the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) as a factor that binds to the FGF-2 5'-leader RNA and that also complements defective FGF-2 translation in vitro in rabbit reticulocyte lysate. Recombinant hnRNP A1 stimulates in vitro translation at the four IRES-dependent initiation codons but has no effect on the cap-dependent initiation codon. Consistent with a role of hnRNP A1 in the control of alternative initiation of translation, short interfering RNA-mediated knock down of hnRNP A1 specifically inhibits translation at the four IRES-dependent initiation codons. Furthermore, hnRNP A1 binds to the FGF-2 IRES, implicating this interaction in the control of alternative initiation of translation.	Hop Rangueil, Inst Louis Bugnard, INSERM, U589,TSA 50032, F-31059 Toulouse 9, France; Sanofi Aventis CRVA, F-94403 Vitry Sur Seine, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis; Sanofi France	Vagner, S (corresponding author), Inst Claude Regaud, INSERM, U563, Rue Pont Sain Pierre, F-31052 Toulouse, France.	vagner@toulouse.inserm.fr	Prats, Anne-Catherine/E-5051-2016; Vagner, Stephan/G-3664-2013	Prats, Anne-Catherine/0000-0002-5282-3776; vagner, stephan/0000-0003-1452-7164				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BIAMONTI G, 1993, J MOL BIOL, V230, P77, DOI 10.1006/jmbi.1993.1127; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CamachoVanegas O, 1997, NUCLEIC ACIDS RES, V25, P3950, DOI 10.1093/nar/25.19.3950; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Galy B, 1999, CANCER RES, V59, P165; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; Hanamura A, 1998, RNA, V4, P430; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lemaire R, 2002, GENE DEV, V16, P594, DOI 10.1101/gad.939502; Mili S, 2001, MOL CELL BIOL, V21, P7307, DOI 10.1128/MCB.21.21.7307-7319.2001; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Odreman-Macchioli FE, 2000, NUCLEIC ACIDS RES, V28, P875, DOI 10.1093/nar/28.4.875; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; Pilipenko EV, 2000, GENE DEV, V14, P2028; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PONTIUS BW, 1993, TRENDS BIOCHEM SCI, V18, P181, DOI 10.1016/0968-0004(93)90111-Y; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Shiroki K, 2002, NUCLEIC ACIDS RES, V30, P2851, DOI 10.1093/nar/gkf408; Spangberg K, 1999, J GEN VIROL, V80, P1371, DOI 10.1099/0022-1317-80-6-1371; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248-4900(03)00033-9; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0	49	114	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4144	4153		10.1074/jbc.M411492200	http://dx.doi.org/10.1074/jbc.M411492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15525641	Green Submitted, hybrid			2022-12-25	WOS:000227096600020
J	Casarosa, P; Waldhoer, M; LiWang, PJ; Vischer, HF; Kledal, T; Timmerman, H; Schwartz, TW; Smit, MJ; Leurs, R				Casarosa, P; Waldhoer, M; LiWang, PJ; Vischer, HF; Kledal, T; Timmerman, H; Schwartz, TW; Smit, MJ; Leurs, R			CC and CX3C chemokines differentially interact with the N terminus of the human cytomegalovirus-encoded US28 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TYROSINE SULFATION; RANTES; FRACTALKINE; DOMAIN; BETA; MIP-1-BETA; ACTIVATION; ADHESION	Human cytomegalovirus (HCMV) is the causative agent of life-threatening systemic diseases in immunocompromised patients as well as a risk factor for vascular pathologies, like atherosclerosis, in immunocompetent individuals. HCMV encodes a G-protein-coupled receptor (GPCR), referred to as US28, that displays homology to the human chemokine receptor CCR1 and binds several chemokines of the CC family as well as the CX3C chemokine fractalkine with high affinity. Most importantly, following HCMV infection, US28 activates several intracellular pathways, either constitutively or in a chemokine-dependent manner. In this study, our goal was to understand the molecular interactions between chemokines and the HCMV-encoded US28 receptor. To achieve this goal, a double approach has been used, consisting in the analysis of both receptor and ligand mutants. This approach has led us to identify several amino acids located in the N terminus of US28 that differentially contribute to the high affinity binding of CC versus CX3C chemokines. Additionally, our results highlight the importance of secondary modifications occurring at US28, such as sulfation, for ligand recognition. Finally, the effects of chemokine dimerization and interaction with glycosaminoglycans (GAGs) on chemokine binding and activation of US28 were investigated as well using CCL4 as model ligand. In line with the two-state model describing chemokine/receptor interaction, we show that an aromatic residue in the N-loop region of CCL4 promotes tight binding to US28, whereas receptor activation depends on the presence of the N terminus of CCL4, as shown previously for CCR5.	Leiden Amsterdam Ctr Durg Res, Fac Chem, Div Med Chem, NL-1081 HV Amsterdam, Netherlands; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, San Francisco, CA 94608 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Copenhagen, Hvidovre Hosp, DK-2650 Hvidovre, Denmark; Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, DK-2100 Copenhagen, Denmark; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; Texas A&M University System; Texas A&M University College Station; University of Copenhagen; University of Copenhagen	Leurs, R (corresponding author), Leiden Amsterdam Ctr Durg Res, Fac Chem, Div Med Chem, De Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	leurs@few.vu.nl	Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021; Waldhoer, Maria/HDO-0619-2022	Leurs, Rob/0000-0003-1354-2848; Waldhoer, Maria/0000-0003-3534-1959; Schwartz, Thue W./0000-0002-0261-6904; Smit, Martine/0000-0003-2713-0238				Adam E, 1997, Cent Eur J Public Health, V5, P99; Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Ali S, 2002, GLYCOBIOLOGY, V12, P535, DOI 10.1093/glycob/cwf069; BAEUERLE PA, 1985, J BIOL CHEM, V260, P6434; Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Beisser PS, 2001, J VIROL, V75, P5949, DOI 10.1128/JVI.75.13.5949-5957.2001; Billstrom MA, 1999, AM J RESP CELL MOL, V21, P163, DOI 10.1165/ajrcmb.21.2.3673; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Blanpain C, 2001, J LEUKOCYTE BIOL, V69, P977; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Bondue A, 2002, BIOCHEMISTRY-US, V41, P13548, DOI 10.1021/bi026087d; Bruggeman Cathrien A, 2000, Herpes, V7, P51; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Casarosa P, 2003, J BIOL CHEM, V278, P5172, DOI 10.1074/jbc.M210033200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Christlet THT, 2001, BIOPHYS J, V80, P952, DOI 10.1016/S0006-3495(01)76074-2; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; EPSTEIN SE, 1996, LANCET S, V348, P13; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; Hengel H, 1998, TRENDS MICROBIOL, V6, P190, DOI 10.1016/S0966-842X(98)01255-4; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; KUNA P, 1993, J IMMUNOL, V150, P1932; Laurence JS, 1998, BIOCHEMISTRY-US, V37, P9346, DOI 10.1021/bi980329l; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Lin HC, 2003, BIOCHEM BIOPH RES CO, V312, P1154, DOI 10.1016/j.bbrc.2003.11.047; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma YQ, 2002, J IMMUNOL, V168, P1690, DOI 10.4049/jimmunol.168.4.1690; McCornack MA, 2003, J BIOL CHEM, V278, P1946, DOI 10.1074/jbc.M207440200; Melnick Joseph L., 1996, Archivum Immunologiae et Therapiae Experimentalis, V44, P297; Minisini R, 2003, J VIROL, V77, P4489, DOI 10.1128/JVI.77.8.4489-4501.2003; Mizoue LS, 2001, J BIOL CHEM, V276, P33906, DOI 10.1074/jbc.M101348200; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; MURPHY PM, 2000, PHARMACOL REV, V54, P227; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Qian YQ, 1999, J MOL BIOL, V294, P1065, DOI 10.1006/jmbi.1999.3333; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Seibert C, 2002, P NATL ACAD SCI USA, V99, P11031, DOI 10.1073/pnas.172380899; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Smit MJ, 2003, CURR DRUG TARGETS, V4, P431; Sorlie PD, 2000, ARCH INTERN MED, V160, P2027, DOI 10.1001/archinte.160.13.2027; Streblow DN, 2003, J BIOL CHEM, V278, P50456, DOI 10.1074/jbc.M307936200; Streblow DN, 2001, J NUTR, V131, p2798S, DOI 10.1093/jn/131.10.2798S; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Struyf S, 1999, J IMMUNOL, V162, P4903; Sweet C, 1999, FEMS MICROBIOL REV, V23, P457, DOI 10.1111/j.1574-6976.1999.tb00408.x; Umehara H, 2001, IMMUNOL CELL BIOL, V79, P298, DOI 10.1046/j.1440-1711.2001.01004.x; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Wang DZ, 2003, BIOCHEMISTRY-US, V42, P1071, DOI 10.1021/bi026425a; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	80	57	61	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3275	3285		10.1074/jbc.M407536200	http://dx.doi.org/10.1074/jbc.M407536200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15546882	hybrid			2022-12-25	WOS:000226983900020
J	Eschenburg, S; Priestman, M; Schonbrunn, E				Eschenburg, S; Priestman, M; Schonbrunn, E			Evidence that the fosfomycin target Cys(115) in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHEDRAL INTERMEDIATE; BACTERIAL PEPTIDOGLYCAN; ANTIBIOTIC FOSFOMYCIN; STEREOCHEMICAL COURSE; 3-PHOSPHATE SYNTHASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ENZYME; BIOSYNTHESIS; GLYPHOSATE	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase, EC 2.5.1.7) is an essential enzyme in the biosynthesis of the peptidoglycan layer of the bacterial cell. It provides an attractive template for the design of novel antibiotic drugs and is the target of the naturally occurring antibiotic fosfomycin, which covalently attaches to Cys(115) in the active site of the enzyme. Mutations of Cys(115) to Asp exist in pathogens such as Mycobacteria or Chlamydia rendering these organisms resistant to fosfomycin. Thus, there is a need for the elucidation of the role of this cysteine in the MurA reaction. We determined the x-ray structure of the C115S mutant of Enterobacter cloacae MurA, which was crystallized in the presence of the substrates of MurA. The structure depicts the product state of the enzyme with enolpyruvyl-UDP-N-acetylglucosamine and inorganic phosphate trapped in the active site. Kinetic analysis revealed that the Cys-to-Ser mutation results in an enzyme that appears to perform a single turnover of the reaction. Opposing the common view of Cys(115) as a key residue in the chemical reaction of enolpyruvyl transfer, we now conclude that the wild-type cysteine is essential for product release only. On the basis of a detailed comparison of the product state with the intermediate state and an unliganded state of MurA, we propose that dissociation of the products is an ordered event with inorganic phosphate leaving first. Phosphate departure appears to trigger a suite of conformational changes, which finally leads to opening of the two-domain structure of MurA and the release of the second product enolpyruvyl-UDP-N-acetylglucosamine.	Univ Kansas, Dept Med Chem, Lawrence, KS 66049 USA; Max Planck Inst Med Res, Dept Biophys, D-69120 Heidelberg, Germany	University of Kansas; Max Planck Society	Schonbrunn, E (corresponding author), Univ Kansas, Dept Med Chem, 4040A Malott Hall, Lawrence, KS 66049 USA.	eschoenb@ku.edu		Schonbrunn, Ernst/0000-0002-3589-3510	NCRR NIH HHS [P20 RR16443-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016443] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERG DG, 1992, J AM CHEM SOC, V114, P3535, DOI 10.1021/ja00035a058; An M, 2003, J AM CHEM SOC, V125, P12759, DOI 10.1021/ja036627+; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Byczynski B, 2003, J AM CHEM SOC, V125, P12541, DOI 10.1021/ja0349655; De Smet KAL, 1999, MICROBIOL-UK, V145, P3177, DOI 10.1099/00221287-145-11-3177; El Zoeiby A, 2003, MOL MICROBIOL, V47, P1, DOI 10.1046/j.1365-2958.2003.03289.x; Eschenburg S, 2002, PLANTA, V216, P129, DOI 10.1007/s00425-002-0908-0; Eschenburg S, 2003, J BIOL CHEM, V278, P49215, DOI 10.1074/jbc.M309741200; Eschenburg S, 2000, PROTEINS, V40, P290, DOI 10.1002/(SICI)1097-0134(20000801)40:2<290::AID-PROT90>3.0.CO;2-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Green David W, 2002, Expert Opin Ther Targets, V6, P1, DOI 10.1517/14728222.6.1.1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAHAN FM, 1974, ANN NY ACAD SCI, V235, P364, DOI 10.1111/j.1749-6632.1974.tb43277.x; Katz AH, 2003, CURR PHARM DESIGN, V9, P857, DOI 10.2174/1381612033455305; Kim DH, 1996, BIOCHEMISTRY-US, V35, P4923, DOI 10.1021/bi952937w; Kim DH, 1996, BIOCHEMISTRY-US, V35, P5435, DOI 10.1021/bi952978s; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar S, 2002, BIOPHYS J, V83, P1595, DOI 10.1016/S0006-3495(02)73929-5; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARQUARDT JL, 1994, BIOCHEMISTRY-US, V33, P10646, DOI 10.1021/bi00201a011; McCoy AJ, 2003, J BACTERIOL, V185, P1218, DOI 10.1128/JB.185.4.1218-1228.2003; McDevitt D, 2002, J APPL MICROBIOL, V92, p28S, DOI 10.1046/j.1365-2672.92.5s1.16.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schonbrunn E, 1998, EUR J BIOCHEM, V253, P406, DOI 10.1046/j.1432-1327.1998.2530406.x; Schonbrunn E, 2001, P NATL ACAD SCI USA, V98, P1376, DOI 10.1073/pnas.98.4.1376; Schonbrunn E, 1996, STRUCTURE, V4, P1065, DOI 10.1016/S0969-2126(96)00113-X; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; Schonbrunn E, 2000, BIOCHEMISTRY-US, V39, P2164, DOI 10.1021/bi991091j; Skarzynski T, 1998, BIOCHEMISTRY-US, V37, P2572, DOI 10.1021/bi9722608; Skarzynski T, 1996, STRUCTURE, V4, P1465, DOI 10.1016/S0969-2126(96)00153-0; STALLINGS WC, 1991, P NATL ACAD SCI USA, V88, P5046, DOI 10.1073/pnas.88.11.5046; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; VANHEIJENOORT J, 1994, N COMP BIOC, V27, P39; Walsh CT, 1996, CHEM BIOL, V3, P83, DOI 10.1016/S1074-5521(96)90282-3; WANKE C, 1993, EUR J BIOCHEM, V218, P861, DOI 10.1111/j.1432-1033.1993.tb18442.x	38	97	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3757	3763		10.1074/jbc.M411325200	http://dx.doi.org/10.1074/jbc.M411325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15531591	hybrid			2022-12-25	WOS:000226983900076
J	Fukuhara-Takaki, K; Sakai, M; Sakamoto, YI; Takeya, M; Horiuchi, S				Fukuhara-Takaki, K; Sakai, M; Sakamoto, YI; Takeya, M; Horiuchi, S			Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; GLYCATION END-PRODUCTS; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; ATHEROSCLEROTIC LESIONS; CARDIOVASCULAR-DISEASE; PERITONEAL-MACROPHAGES; LOX-1 EXPRESSION; CD36	In the early stage of atherosclerosis, macrophages take up chemically modified low density lipoproteins (LDL) through the scavenger receptors, leading to foam cell formation in atherosclerotic lesions. To get insight into a role of the scavenger receptors in diabetes-enhanced atherosclerotic complications, the effects on class A scavenger receptor (SR-A) of high glucose exposure in vitro as well as the diabetic conditions in vivo were determined in the present study. The in vitro experiments demonstrated that high glucose exposure to human monocyte-derived macrophages led to an increased SR-A expression with a concomitant increase in the endocytic uptake of acetylated LDL and oxidized LDL. The endocytic process was significantly suppressed by an anti-SR-A neutralizing antibody. Stability analyses revealed a significant increased stability of SR-A at a mRNA level but not a protein level, indicating that high glucose-induced up-regulation of SR-A is due largely to increased stability of SR-A mRNA. High glucose-enhanced SR-A expression was prevented by protein kinase C and NAD(P)H oxidase inhibitors as well as antioxidants. High glucose-enhanced production of intracellular peroxides was visualized in these cells, which was attenuated by an antioxidant. The in vivo experiments demonstrated that peritoneal macrophages from streptozotocin-induced diabetic mice increased SR-A expression when compared with those from nondiabetic mice. Endocytic degradation of acetylated LDL and oxidized LDL were also increased with these macrophages but not with the corresponding macrophages from diabetic SR-A knock-out mice. These in vitro and in vivo results probably suggest that reactive oxygen species generated from a protein kinase C-dependent NAD(P)H oxidase pathway plays a role in the high glucose-induced up-regulation of SR-A, leading to the increased endocytic degradation of modified LDL for foam cell formation. This could be one mechanism for an increased rate of atherosclerosis in patients with diabetes.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Biochem Med, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Cellular Pathol, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Horiuchi, S (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Biochem Med, Honjo 1-1-1, Kumamoto 8608556, Japan.	horiuchi@gpo.kumamoto-u.ac.jp						ACTON SL, 1994, J BIOL CHEM, V269, P21003; Babaev VR, 2000, ARTERIOSCL THROM VAS, V20, P2593, DOI 10.1161/01.ATV.20.12.2593; Bendriss-Vermare N, 2001, J CLIN INVEST, V107, P835, DOI 10.1172/JCI11734; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; CONNOR RI, 1990, J IMMUNOL, V145, P1483; De Kimpe SJ, 1998, MOL PHARMACOL, V53, P1076; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fitzgerald ML, 2000, J IMMUNOL, V164, P2692, DOI 10.4049/jimmunol.164.5.2692; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Gough PJ, 1999, ARTERIOSCL THROM VAS, V19, P461, DOI 10.1161/01.ATV.19.3.461; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; HAKAMATA H, 1995, FEBS LETT, V363, P29, DOI 10.1016/0014-5793(95)00273-C; Heine RJ, 2002, DIABETOLOGIA, V45, P461, DOI 10.1007/s00125-001-0726-0; HUNT JV, 1994, BIOCHEM J, V300, P243, DOI 10.1042/bj3000243; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Iwashima Y, 2000, BIOCHEM BIOPH RES CO, V277, P368, DOI 10.1006/bbrc.2000.3685; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Laakso M, 1999, DIABETES, V48, P937, DOI 10.2337/diabetes.48.5.937; Lafuse WP, 2002, CELL IMMUNOL, V215, P195, DOI 10.1016/S0008-8749(02)00026-6; Li L, 2004, CIRC RES, V94, P892, DOI 10.1161/01.RES.0000124920.09738.26; Li L, 2003, DIABETES, V52, P1843, DOI 10.2337/diabetes.52.7.1843; Li YM, 1997, J IMMUNOL METHODS, V201, P183, DOI 10.1016/S0022-1759(96)00224-4; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MIYAZAKI A, 1994, J BIOL CHEM, V269, P5264; MIYAZAKI A, 1991, BIOCHIM BIOPHYS ACTA, V1082, P143; Miyazaki A, 2002, TRENDS CARDIOVAS MED, V12, P258, DOI 10.1016/S1050-1738(02)00171-8; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; Sakai M, 1996, ARTERIOSCL THROM VAS, V16, P600, DOI 10.1161/01.ATV.16.4.600; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Svensson L, 2002, J INTERN MED, V251, P437, DOI 10.1046/j.1365-2796.2002.00983.x; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tomokiyo R, 2002, ATHEROSCLEROSIS, V161, P123, DOI 10.1016/S0021-9150(01)00624-4; VLASSARA H, 1997, DIABETES S2, V46, P19; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	46	68	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3355	3364		10.1074/jbc.M408715200	http://dx.doi.org/10.1074/jbc.M408715200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15556945	hybrid			2022-12-25	WOS:000226983900029
J	Lluis, JM; Morales, A; Blasco, C; Colell, A; Mari, M; Garcia-Ruiz, C; Fernandez-Checa, JC				Lluis, JM; Morales, A; Blasco, C; Colell, A; Mari, M; Garcia-Ruiz, C; Fernandez-Checa, JC			Critical role of mitochondrial glutathione in the survival of hepatocytes during hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT CHAIN; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; OXIDATIVE STRESS; RAT HEPATOCYTES; HEPG2 CELLS; PERMEABILITY TRANSITION; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; GENE-EXPRESSION	Hypoxia is known to stimulate reactive oxygen species (ROS) generation. Because reduced glutathione (GSH) is compartmentalized in cytosol and mitochondria, we examined the specific role of mitochondrial GSH (mGSH) in the survival of hepatocytes during hypoxia (5% O-2). 5% O-2 stimulated ROS in HepG2 cells and cultured rat hepatocytes. Mitochondrial complex I and II inhibitors prevented this effect, whereas inhibition of nitric oxide synthesis with N-omega-nitro-L-arginine methyl ester hydrochloride or the peroxynitrite scavenger uric acid did not. Depletion of GSH stores in both cytosol and mitochondria enhanced the susceptibility of HepG2 cells or primary rat hepatocytes to 5% O-2 exposure. However, this sensitization was abrogated by preventing mitochondrial ROS generation by complex I and II inhibition. Moreover, selective mGSH depletion by (R,S)-3-hydroxy-4-pentenoate that spared cytosol GSH levels sensitized rat hepatocytes to hypoxia because of enhanced ROS generation. GSH restoration by GSH ethyl ester or by blocking mitochondrial electron flow at complex I and II rescued (R,S)-3-hydroxy-4-pentenoate-treated hepatocytes to hypoxia-induced cell death. Thus, mGSH controls the survival of hepatocytes during hypoxia through the regulation of mitochondrial generation of oxidative stress.	Inst Invest Biomed August Pi & Sunyer, Hosp Clin & Prov Barcelona, Inst Malaties Digest, Liver Unit, Barcelona 08036, Spain; CSIC, Inst Invest Biomed, Dept Expt Pathol, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)	Fernandez-Checa, JC (corresponding author), Inst Invest Biomed August Pi & Sunyer, Hosp Clin & Prov Barcelona, Inst Malaties Digest, Liver Unit, C Villarroel 170, Barcelona 08036, Spain.	checa229@yahoo.com	MARI, MONTSERRAT/M-2871-2019; Garcia-Ruiz, Carmen/L-8211-2014; Mari, Montserrat/A-7376-2013; Fernández-Checa, José Carlos/L-8342-2014; Morales, Albert/E-2988-2013; Colell, Anna/N-8710-2014	Garcia-Ruiz, Carmen/0000-0002-2652-6102; Mari, Montserrat/0000-0002-6116-3247; Fernández-Checa, José Carlos/0000-0003-3422-2990; Morales, Albert/0000-0001-8702-2269; Colell, Anna/0000-0001-5236-1834	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999, R21AA014135] Funding Source: NIH RePORTER; NIAAA NIH HHS [1R21 AA014135-01, P50 AA 11999] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 2000, J IMMUNOL, V165, P1013, DOI 10.4049/jimmunol.165.2.1013; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FEO F, 1975, BIOCHIM BIOPHYS ACTA, V413, P116, DOI 10.1016/0005-2736(75)90063-2; Fernandez-Checa JC, 2003, BIOCHEM BIOPH RES CO, V304, P471, DOI 10.1016/S0006-291X(03)00619-3; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; FERNANDEZCHECA JC, 2005, IN PRESS TOXICOL APP; French SW, 2004, HEPATOL RES, V29, P69, DOI 10.1016/j.hepres.2004.02.006; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; ISRAEL Y, 1975, P NATL ACAD SCI USA, V72, P1137, DOI 10.1073/pnas.72.3.1137; JAESCHKE H, 1989, BIOCHEM BIOPH RES CO, V160, P140, DOI 10.1016/0006-291X(89)91632-X; JI SC, 1982, P NATL ACAD SCI-BIOL, V79, P5415, DOI 10.1073/pnas.79.17.5415; Khan S, 1997, BIOCHEM BIOPH RES CO, V238, P320, DOI 10.1006/bbrc.1997.7281; LITTLE C, 1970, J BIOL CHEM, V245, P3632; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lluis JM, 2003, GASTROENTEROLOGY, V124, P708, DOI 10.1053/gast.2003.50089; Mansfield KD, 2004, J APPL PHYSIOL, V97, P1358, DOI 10.1152/japplphysiol.00449.2004; Mari M, 2002, FREE RADICAL BIO MED, V32, P73, DOI 10.1016/S0891-5849(01)00759-6; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Paris R, 2002, J BIOL CHEM, V277, P49870, DOI 10.1074/jbc.M208303200; Pastorino JG, 2000, HEPATOLOGY, V31, P1141, DOI 10.1053/he.2000.7013; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Schild L, 2003, FASEB J, V17, P2194, DOI 10.1096/fj.02-1170com; Schumacker PT, 2002, AM J PHYSIOL-LUNG C, V283, pL918, DOI 10.1152/ajplung.00205.2002; Sekhar KR, 1997, RADIAT RES, V147, P592, DOI 10.2307/3579626; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; SHAN XQ, 1993, CHEM RES TOXICOL, V6, P75, DOI 10.1021/tx00031a012; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; STRUBELT O, 1994, PHARMACOL TOXICOL, V75, P280, DOI 10.1111/j.1600-0773.1994.tb00361.x; TRIBBLE DL, 1988, MOL PHARMACOL, V34, P413; UMEKI S, 1990, BIOCHEM PHARMACOL, V40, P559, DOI 10.1016/0006-2952(90)90556-Z; Walford GA, 2004, J BIOL CHEM, V279, P4425, DOI 10.1074/jbc.M310582200; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WISSEMANN D-H, 1991, Hepatology, V13, P297; ZHANG J, 1992, J CLIN INVEST, V90, P1193, DOI 10.1172/JCI115980; ZHANG WW, 1989, CANCER RES, V49, P2433	49	80	85	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3224	3232		10.1074/jbc.M408244200	http://dx.doi.org/10.1074/jbc.M408244200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548523	hybrid			2022-12-25	WOS:000226983900014
J	Matsuda, O; Sakamoto, H; Hashimoto, T; Iba, K				Matsuda, O; Sakamoto, H; Hashimoto, T; Iba, K			A temperature-sensitive mechanism that regulates post-translational stability of a plastidial omega-3 fatty acid desaturase (FAD8) in Arabidopsis leaf tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID COMPOSITION; CHLOROPLAST OMEGA-3 DESATURASE; STEAROYL-COA DESATURASE; ENVELOPE MEMBRANES; RAPID DEGRADATION; GENE; THALIANA; EXPRESSION; CLONING; PLANTS	Trienoic fatty acids (TAs) are the major constituents in plant membrane lipids. In Arabidopsis, two plastidial isozymes of omega-3 fatty acid desaturase, FAD7 and FAD8, are the major contributors for TA production in leaf tissues. Despite a high degree of structural relatedness, activities of these two isozymes are regulated differentially in response to temperature. Elevated temperatures lead to decreases in leaf TA level due to temperature sensitivity of FAD8 activity. A series of FAD7-FAD8 chimeric genes, each encoding a functional plastidial w-3 desaturase, were introduced into the Arabidopsis fad7fad8 double mutant. Constructs with or without a c-Myc epitope tag were tested. Functionality of each chimeric gene in response to temperature was assayed by Northern and Western analyses and by examining the fatty acid composition. All transformants harboring a chimeric gene containing the FAD8-derived C-terminal coding region (44 amino acids) showed a marked decrease in TA level when exposed to high temperature, similarly as transgenic lines complemented with the native form of FAD8. The reduction of TA level was accompanied by a decrease in the amount of omega-3 desaturase protein but not necessarily by a decrease in its transcript level. Analysis of the decay of c-Myc-tagged products after inhibiting protein synthesis revealed that the FAD8-derived C-terminal region acts in an autoregulatory fashion to destabilize the protein at high temperature. This suggests that the regulation of post-translational stability of FADS provides an important regulatory mechanism for modifying its activity in response to temperature, mediating a decrease in TA level at elevated temperatures.	Kyushu Univ, Fac Sci, Dept Biol, Higashi, Fukuoka 8128581, Japan	Kyushu University	Iba, K (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Higashi, Fukuoka 8128581, Japan.	koibascb@mbox.ne.kyushu-u.ac.jp						AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Bevington P. R., 2003, DATA REDUCTION ERROR, DOI 10.2307/2284752; BROWSE J, 1993, J BIOL CHEM, V268, P16345; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; Dyer JM, 2001, BIOCHEM BIOPH RES CO, V282, P1019, DOI 10.1006/bbrc.2001.4667; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Froehlich JE, 2003, J PROTEOME RES, V2, P413, DOI 10.1021/pr034025j; GIBSON S, 1994, PLANT PHYSIOL, V106, P1615, DOI 10.1104/pp.106.4.1615; Harwood J. L., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P1; Heinemann FS, 2003, J BIOL CHEM, V278, P42966, DOI 10.1074/jbc.M306240200; HEINEMANN FS, 2003, FATTY ACIDS, V68, P123; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Horiguchi G, 2000, PLANT J, V24, P805, DOI 10.1046/j.1365-313x.2000.00925.x; Horiguchi G, 1996, PLANTA, V199, P439, DOI 10.1007/BF00195737; IBA K, 1993, J BIOL CHEM, V268, P24099; JagerVottero P, 1997, P NATL ACAD SCI USA, V94, P1597, DOI 10.1073/pnas.94.4.1597; KODAMA H, 1994, PLANT PHYSIOL, V105, P601, DOI 10.1104/pp.105.2.601; Kusumi J, 1998, J PLANT RES, V111, P87, DOI 10.1007/BF02507153; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; Los DA, 1998, BBA-LIPID LIPID MET, V1394, P3, DOI 10.1016/S0005-2760(98)00091-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Margulis L, 1970, ORIGIN EUKARYOTIC CE; Martinez-Garcia JF, 1999, PLANT J, V20, P251, DOI 10.1046/j.1365-313x.1999.00579.x; Matsuda O, 2001, PLANTA, V213, P833, DOI 10.1007/s004250100575; MCCONN M, 1994, PLANT PHYSIOL, V106, P1609, DOI 10.1104/pp.106.4.1609; Murakami Y, 2000, SCIENCE, V287, P476, DOI 10.1126/science.287.5452.476; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Mziaut H, 2000, P NATL ACAD SCI USA, V97, P8883, DOI 10.1073/pnas.97.16.8883; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Ramos JA, 2001, PLANT CELL, V13, P2349, DOI 10.1105/tpc.13.10.2349; Reed DW, 2000, PLANT PHYSIOL, V122, P715, DOI 10.1104/pp.122.3.715; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT H, 1994, PLANT MOL BIOL, V26, P631, DOI 10.1007/BF00013749; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SMOLENSKA G, 1977, PHYSIOL PLANTARUM, V41, P29, DOI 10.1111/j.1399-3054.1977.tb01517.x; SOMERVILLE C, 1995, P NATL ACAD SCI USA, V92, P6215, DOI 10.1073/pnas.92.14.6215; Stumpf P. K., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P177; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILLEMOT C, 1977, CRYOBIOLOGY, V14, P87, DOI 10.1016/0011-2240(77)90126-2	45	96	107	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3597	3604		10.1074/jbc.M407226200	http://dx.doi.org/10.1074/jbc.M407226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15545277	hybrid			2022-12-25	WOS:000226983900058
J	Dronadula, N; Liu, ZM; Wang, CM; Cao, HQ; Rao, GN				Dronadula, N; Liu, ZM; Wang, CM; Cao, HQ; Rao, GN			STAT-3-dependent cytosolic phospholipase A(2) expression is required for thrombin-induced vascular smooth muscle cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ARACHIDONIC-ACID; STIMULATES PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INDUCED GROWTH; INHIBITION; MIGRATION; PROLIFERATION; METABOLITES; DIFFERENTIATION	Vascular smooth muscle cell (VSMC) migration from media to intima and its multiplication in intima is a contributing factor in the pathogenesis of atherosclerosis and restenosis after angioplasty. Previously, we have demonstrated that STAT-3-dependent cytosolic phospholipase A, (cPLA,) expression is needed for VSMC motility induced by platelet-derived growth factor-BB, a receptor tyrosine kinase agonist (Neeli et aL (2005) J. BioL Chem. 279, 46122-46128). In order to learn more about the STAT-3-cPLA(2) axis in motogenic signaling, here we have studied its role in VSMC motility in response to a G protein-coupled receptor (GPCR) agonist, thrombin. Thrombin induced VSMC motility in a dose-dependent manner with a maximum effect at 0.5 units/ ml. Thrombin activated STAT-3 as measured by its tyrosine phosphorylation and translocation from the cytoplasm to the nucleus. Forced expression of a dominant negative mutant of STAT-3 reduced thrombin-induced STAT-3 tyrosine phosphorylation and its translocation from the cytoplasm to the nucleus. Thrombin stimulated STAT-3-DNA binding and reporter gene activities in VSMC, and these responses were blocked by FS3DM, a dominant negative mutant of STAT-3. FS3DM also attenuated thrombin-induced VSMC motility. Thrombin induced the expression of cPLA(2) in a time- and STAT-3-dependent manner. In addition, pharmacological inhibition of cPLA(2) blocked thrombin-induced VSMC motility. Furthermore, exogenous addition of arachidonic acid rescued thrombin-induced VSMC motility from inhibition by blockade of STAT-3 activation. Forced expression of cPLA(2) also surpassed the inhibitory effect of dominant negative STAT-3 on thrombin-induced VSMC motility. Together, these results show that thrombin-induced VSMC motility requires STAT-3-dependent induction of expression of cPLA(2).	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu			NHLBI NIH HHS [HL64165, HL69908] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069908, R01HL064165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Butenas S, 2004, J BIOL CHEM, V279, P22875, DOI 10.1074/jbc.M400531200; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; Goetze S, 1999, HYPERTENSION, V33, P183, DOI 10.1161/01.HYP.33.1.183; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; Maddox JF, 1998, FASEB J, V12, P487, DOI 10.1096/fasebj.12.6.487; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Mezentsev A, 2002, J BIOL CHEM, V277, P18670, DOI 10.1074/jbc.M201143200; Neeli I, 2004, J BIOL CHEM, V279, P46122, DOI 10.1074/jbc.M406922200; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; Rauch BH, 2004, CIRC RES, V94, P340, DOI 10.1161/01.RES.0000111805.09592.D8; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Stockton RA, 2001, MOL BIOL CELL, V12, P1937, DOI 10.1091/mbc.12.7.1937; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TAY A, 1994, BBA-GENE STRUCT EXPR, V1217, P345, DOI 10.1016/0167-4781(94)90299-2; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; Yellaturu CR, 2003, J BIOL CHEM, V278, P9986, DOI 10.1074/jbc.M211276200; Zhuang DM, 2004, AM J PHYSIOL-HEART C, V286, pH2103, DOI 10.1152/ajpheart.01118.2003	64	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3112	3120		10.1074/jbc.M409739200	http://dx.doi.org/10.1074/jbc.M409739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548519	hybrid			2022-12-25	WOS:000226449100088
J	Xu, DZ; Makkinje, A; Kyriakis, JM				Xu, DZ; Makkinje, A; Kyriakis, JM			Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GLUCOCORTICOID RECEPTOR; RAT-LIVER; EXPRESSION; INSULIN; CELLS; INDUCTION; PROLIFERATION; STIMULATION; HEPATOCYTES	We report a mechanism by which the adapter protein Gene 33 (also called RALT and MIG6) regulates epidermal growth factor receptor (EGFR) signaling. We find that Gene 33 inhibits EGFR autophosphorylation and specifically blunts epidermal growth factor (EGF)-induced activation and/or phosphorylation of Ras, ERK, JNK, Akt/PKB, and retinoblastoma protein. The Ack homology domain of Gene 33, which contains the previously identified EGFR binding domain, is both necessary and sufficient for this inhibition of EGFR autophosphorylation. The endogenous Gene 33 polypeptide is induced by EGF, platelet-derived growth factor, serum, and dexamethasone (Dex) in Rat 2 rat fibroblasts. Dex induces Gene 33 expression and inhibits EGFR phosphorylation and EGF signaling. RNA interference-mediated silencing of Gene 33 significantly reverses this effect. Overexpression of Gene 33 completely blocks EGF-induced protein and DNA synthesis in Rat 2 cells, whereas gene 33 RNA interference substantially enhances EGF-induced protein and DNA synthesis in Rat 2 cells. Our results indicate that Gene 33 is a physiological feedback inhibitor of the EGFR, functioning to inhibit EGFR phosphorylation and all events induced by EGFR activation. Our results also indicate a role for Gene 33 in the suppression, by Dex, of EGF signaling pathways. We propose that Gene 33 may function in the cross-talk between EGF signaling and other mitogenic and/or stress signaling pathways.	Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Xu, DZ (corresponding author), Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	dxu@tufts-nemc.org		Xu, Dazhong/0000-0001-9264-3342	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK062680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32-DK62680] Funding Source: Medline; NIGMS NIH HHS [R01-GM46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Baus E, 1996, J IMMUNOL, V156, P4555; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Buren J, 2002, EUR J ENDOCRINOL, V146, P419, DOI 10.1530/eje.0.1460419; Byon JCH, 2001, MOL CELL BIOCHEM, V218, P131, DOI 10.1023/A:1007204508882; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Hulley PA, 1998, ENDOCRINOLOGY, V139, P2423, DOI 10.1210/en.139.5.2423; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KARASIK A, 1988, ENDOCRINOLOGY, V123, P2214, DOI 10.1210/endo-123-5-2214; Kato-Stankiewicz J, 2001, BIOCHEM BIOPH RES CO, V284, P470, DOI 10.1006/bbrc.2001.5004; KENT TA, 1994, ENDOCRINOLOGY, V134, P2237, DOI 10.1210/en.134.5.2237; LEE KL, 1985, J BIOL CHEM, V260, P6433; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; Messina Joseph L., 1994, P263; MOHN KL, 1990, J BIOL CHEM, V265, P21914; Nagy P, 1998, HEPATOLOGY, V28, P423, DOI 10.1002/hep.510280220; Pesesse X, 2001, J BIOL CHEM, V276, P28348, DOI 10.1074/jbc.M103537200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Reuther-Madrid JY, 2002, MOL CELL BIOL, V22, P8175, DOI 10.1128/MCB.22.23.8175-8183.2002; Romero N, 1999, P R Health Sci J, V18, P257; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; WEINSTOCK RS, 1992, BIOCHEM BIOPH RES CO, V189, P931, DOI 10.1016/0006-291X(92)92293-7; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Xu DZ, 2003, J BIOL CHEM, V278, P39349, DOI 10.1074/jbc.M302771200; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; ZENDEGUI J G, 1988, Journal of Cellular Physiology, V136, P257, DOI 10.1002/jcp.1041360207	36	80	86	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2924	2933		10.1074/jbc.M408907200	http://dx.doi.org/10.1074/jbc.M408907200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15556944	hybrid			2022-12-25	WOS:000226449100068
J	Lakshmi, VM; Nauseef, WM; Zenser, TV				Lakshmi, VM; Nauseef, WM; Zenser, TV			Myeloperoxidase potentiates nitric oxide-mediated nitrosation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDASE-CATALYZED OXIDATION; INFLAMMATORY-BOWEL-DISEASE; R569W MISSENSE MUTATION; IN-VIVO; NO; OXYGEN; NITROTYROSINE; SUPEROXIDE; PEROXYNITRITE; NEUTROPHILS	Nitrosation is an important reaction elicited by nitric oxide ( NO). To better understand how nitrosation occurs in biological systems, we assessed the effect of myeloperoxidase (MPO), a mediator of inflammation, on nitrosation observed during NO autoxidation. Nitrosation of 2-amino-3-methylimidazo[4,5-f]quinoline ( IQ; 10 muM) to 2-nitrosoamino-3-methylimidazo[4,5-f]quinoline (N-NO-IQ) was monitored by HPLC. Using the NO donor spermine NONOate at pH 7.4, MPO potentiated N-NO-IQ formation. The minimum effective quantity of necessary components was 8.5 nM MPO, 0.25 muM H2O2/min, and 0.024 muM NO/min. Autoxidation was only detected at greater than or equal to1.2 muM NO/min. MPO potentiation was not affected by a 40-fold excess flux of H2O2 over NO or less than a 2.4-fold excess flux of NO over H2O2. Potentiation was due to an 8.8-fold increased affinity of MPO-derived nitrosating species for IQ. Autoxidation was inhibited by azide, suggesting involvement of the nitrosonium ion, NO+. MPO potentiation was inhibited by NADH, but not azide, suggesting oxidative nitrosylation with NO2. or an NO2.-like species. MPO nonnitrosative oxidation of IQ with 0.3 mM NO2- at pH 5.5 was inhibited by azide, but not NADH, demonstrating differences between MPO oxidation of IQ with NO compared with NO2-. Using phorbol ester-stimulated human neutrophils, N-NO-IQ formation was increased with superoxide dismutase and inhibited by catalase and NADH, but not NaN3. This is consistent with nitrosation potentiation by MPO, not peroxynitrite. Increased N-NO-IQ formation was not detected with polymorphonuclear neutrophils from two unrelated MPO-deficient patients. Results suggest that the highly diffusible stable gas NO could initiate nitrosation at sites of neutrophil infiltration.	Vet Adm Med Ctr, St Louis, MO 63125 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63125 USA; St Louis Univ, Sch Med, Div Geriatr Med, St Louis, MO 63125 USA; Univ Iowa, Inflammat Program, Iowa City, IA 52241 USA; Univ Iowa, Dept Med, Iowa City, IA 52241 USA; Vet Adm Med Ctr, Iowa City, IA 52241 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Saint Louis University; Saint Louis University; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Zenser, TV (corresponding author), Vet Adm Med Ctr, 11G-JB, St Louis, MO 63125 USA.	zensertv@slu.edu		Nauseef, William/0000-0003-4032-757X	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020579] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA072613] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NCI NIH HHS [CA72613] Funding Source: Medline; NCRR NIH HHS [RR-00954] Funding Source: Medline; NIADDK NIH HHS [AM-20579] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Veterans Affairs(US Department of Veterans Affairs); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P11866, DOI 10.1021/bi011206v; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Dijkstra G, 1998, J PATHOL, V186, P416, DOI 10.1002/(SICI)1096-9896(199812)186:4<416::AID-PATH201>3.0.CO;2-U; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Espey MG, 2002, P NATL ACAD SCI USA, V99, P11127, DOI 10.1073/pnas.152157599; Espey MG, 2002, ANN NY ACAD SCI, V962, P195, DOI 10.1111/j.1749-6632.2002.tb04068.x; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Goldstein S, 2000, CHEM RES TOXICOL, V13, P736, DOI 10.1021/tx000099n; Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315; Hussain SP, 2000, CANCER RES, V60, P3333; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; JOSEPHY PD, 1982, J BIOL CHEM, V257, P3669; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Lakshmi VM, 2004, CHEM RES TOXICOL, V17, P709, DOI 10.1021/tx030042b; Lakshmi VM, 2002, CHEM RES TOXICOL, V15, P1059, DOI 10.1021/tx020008h; Lakshmi VM, 2000, CHEM RES TOXICOL, V13, P891, DOI 10.1021/tx000115g; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MOTTLEY C, 1989, BIOL MAGN RESON, V8, P489; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; Nauseef WM, 1998, J LEUKOCYTE BIOL, V63, P264, DOI 10.1002/jlb.63.2.264; O'Donnell VB, 2000, J BIOL CHEM, V275, P38239, DOI 10.1074/jbc.M001802200; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Rettori D, 2002, FREE RADICAL BIO MED, V33, P685, DOI 10.1016/S0891-5849(02)00953-X; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387; TSUDA M, 1985, MUTAT RES, V147, P335, DOI 10.1016/0165-1161(85)90002-0; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Wink DA, 1996, METHOD ENZYMOL, V268, P120; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003	40	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1746	1753		10.1074/jbc.M411263200	http://dx.doi.org/10.1074/jbc.M411263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15531583	hybrid			2022-12-25	WOS:000226341700007
J	Ameen, C; Edvardsson, U; Ljungberg, A; Asp, L; Akerblad, P; Tuneld, A; Olofsson, SO; Linden, D; Oscarsson, J				Ameen, C; Edvardsson, U; Ljungberg, A; Asp, L; Akerblad, P; Tuneld, A; Olofsson, SO; Linden, D; Oscarsson, J			Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-B; GROWTH-HORMONE; IN-VIVO; GENE-EXPRESSION; FATTY-ACIDS; SECRETION; DEGRADATION; B-100; MICE	Microsomal triglyceride transfer protein (MTP) is rate-limiting in the assembly and secretion of lipoproteins containing apolipoprotein (apo) B. Previously we demonstrated that Wy 14,643 (Wy), a peroxisome proliferator-activated receptor (PPAR) alpha agonist, increases apoB-100 secretion despite decreased triglyceride synthesis. In this study, we sought to determine whether PPARalpha activation increases MTP expression and activity. Treatment with Wy increased hepatic MTP expression and activity in rats and mice and increased MTP expression in primary cultures of rat and mouse hepatocytes. Addition of actinomycin D blocked this increase and the MTP promoter (-136 to +67) containing a conserved DR1 element was activated by Wy, showing that PPARalpha activates transcription of the gene. Wy did not affect MTP expression in the intestine or in cultured hepatocytes from PPARalpha-null mice. A retinoid X receptor agonist (9-cis-retinoic acid), but not a PPARgamma agonist (rosiglitazone), increased MTP mRNA expression in cultured hepatocytes from both wild type and PPAR alpha-null mice. In rat hepatocytes incubated with Wy, MTP mRNA levels increased between 6 and 24 h, and MTP protein expression and apoB-100 secretion increased between 24 and 72 h. In conclusion, PPARalpha activation stimulates hepatic MTP expression via increased transcription of the Mtp gene. This effect is paralleled by a change in apoB-100 secretion, indicating that the effect of Wy on apoB-100 secretion is mediated by increased expression of MTP.	AstraZeneca R&D, Dept Integrat Pharmacol, S-43183 Molndal, Sweden; Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Physiol, S-40530 Gothenburg, Sweden	AstraZeneca; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Oscarsson, J (corresponding author), AstraZeneca R&D, Dept Integrat Pharmacol, HE 119, S-43183 Molndal, Sweden.	jan.oscarsson@astrazeneca.com	Adiels, Martin/C-9278-2011					Ameen C, 2003, ENDOCRINOLOGY, V144, P3914, DOI 10.1210/en.2003-0518; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Carlsson L, 1998, ENDOCRINOLOGY, V139, P2699, DOI 10.1210/en.139.6.2699; Carpentier A, 2002, J BIOL CHEM, V277, P28795, DOI 10.1074/jbc.M204568200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Fu T, 2004, J BIOL CHEM, V279, P28662, DOI 10.1074/jbc.M403271200; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; Haghpassand M, 1996, J LIPID RES, V37, P1468; Hirokane H, 2004, J BIOL CHEM, V279, P45685, DOI 10.1074/jbc.M404255200; IJpenberg A, 2004, EMBO J, V23, P2083, DOI 10.1038/sj.emboj.7600209; Kang S, 2003, J BIOL CHEM, V278, P30478, DOI 10.1074/jbc.M304201200; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; LIN MCM, 1994, J BIOL CHEM, V269, P29138; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; Linden D, 2001, J LIPID RES, V42, P1831; Linden D, 2000, AM J PHYSIOL-ENDOC M, V279, pE1335, DOI 10.1152/ajpendo.2000.279.6.E1335; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Packard CJ, 2003, BIOCHEM SOC T, V31, P1066; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Phillips C, 2002, METABOLISM, V51, P847, DOI 10.1053/meta.2002.33350; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Ritchie PJ, 1999, BIOCHEM J, V338, P305, DOI 10.1042/0264-6021:3380305; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; SJOBERG A, 1992, ENDOCRINOLOGY, V130, P3356, DOI 10.1210/en.130.6.3356; SJOBERG A, 1994, ENDOCRINOLOGY, V135, P1415, DOI 10.1210/en.135.4.1415; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Taguchi H, 2002, J NUTR BIOCHEM, V13, P678, DOI 10.1016/S0955-2863(02)00212-7; Tietge UJF, 1999, J LIPID RES, V40, P2134; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	38	107	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1224	1229		10.1074/jbc.M412107200	http://dx.doi.org/10.1074/jbc.M412107200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15537571	hybrid			2022-12-25	WOS:000226195200045
J	Keramaris, E; Vanderluit, JL; Bahadori, M; Mousavi, K; Davis, RJ; Flavell, R; Slack, RS; Park, DS				Keramaris, E; Vanderluit, JL; Bahadori, M; Mousavi, K; Davis, RJ; Flavell, R; Slack, RS; Park, DS			c-Jun N-terminal kinase 3 deficiency protects neurons from axotomy-induced death in vivo through mechanisms independent of c-Jun phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TRANSCRIPTION FACTOR; CELL-DEATH; INDUCED APOPTOSIS; CORTICAL-NEURONS; SIGNAL-TRANSDUCTION; FACIAL MOTONEURONS; ACTIVATION; SURVIVAL; P53	Both the transcription factor c-Jun and the c-Jun N-terminal kinases (JNKs) have been associated with neuronal loss in several death paradigms. JNK are key regulators of c-Jun and a common accepted model has been that JNKs mediate neuronal death through modulation of c-Jun activation. In the present study, we examined whether JNK2 and -3 (JNK members most associated with neuronal loss) deficiency can rescue neuronal loss caused by facial and sciatic nerve axotomy in the neonate in vivo. JNK2, JNK3, and JNK2/3 double-deficient neurons displayed significantly less death in the facial nerves of the CNS when compared with controls. JNK2 and JNK2/3 double-deficient animals also showed reduced c-Jun phosphorylation and induction following axotomy, consistent with the model that JNK acts to regulate death by activating c-Jun. Of significance, however, protection of facial nerves in JNK3-deficient animals was not accompanied by reduction in c-Jun activation. These results suggest that JNKs can mediate death independently of c-Jun. Importantly, the lack of correlation between JNK3 deficiency and c-Jun induction was not universal. In a sciatic axotomy model of neuronal injury in the neonate, death of DRG neurons was also reduced by JNK3 deficiency. However, in this case, c-Jun activation was also eliminated.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Cellular Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Worcester, MA 01605 USA; Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Yale University	Park, DS (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1H 8M5, Canada.	dpark@uottawa.ca		Slack, Ruth/0000-0002-1552-2835; Park, David/0000-0002-4490-3784				Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bruckner SR, 2001, J NEUROCHEM, V78, P298, DOI 10.1046/j.1471-4159.2001.00400.x; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Cesari F, 2004, MOL CELL BIOL, V24, P294, DOI 10.1128/MCB.24.1.294-305.2004; Coffey ET, 2000, J NEUROSCI, V20, P7602; Crocker SJ, 2003, J NEUROSCI, V23, P4081; Crocker SJ, 2001, P NATL ACAD SCI USA, V98, P13385, DOI 10.1073/pnas.231177098; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Hayley S, 2004, J NEUROSCI, V24, P2045, DOI 10.1523/JNEUROSCI.4564-03.2004; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Martin-Villalba A, 1998, MOL BRAIN RES, V62, P158, DOI 10.1016/S0169-328X(98)00239-3; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Morrison RS, 1996, J NEUROSCI, V16, P1337; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sedarous M, 2003, J BIOL CHEM, V278, P26031, DOI 10.1074/jbc.M302833200; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Sun W, 2003, MOL CELL NEUROSCI, V24, P875, DOI 10.1016/S1044-7431(03)00219-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; Vanderluit JL, 2000, EUR J NEUROSCI, V12, P3469, DOI 10.1046/j.1460-9568.2000.00241.x; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Watson A, 1998, J NEUROSCI, V18, P751; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	56	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1132	1141		10.1074/jbc.M410127200	http://dx.doi.org/10.1074/jbc.M410127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528206	hybrid			2022-12-25	WOS:000226195200034
J	Shen, SS; Tucker, WC; Chapman, ER; Steinhardt, RA				Shen, SS; Tucker, WC; Chapman, ER; Steinhardt, RA			Molecular regulation of membrane resealing in 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM C2 DOMAINS; SYNAPTOTAGMIN-I; CA2+ SENSOR; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; EXOCYTOSIS; FUSION; VII; BINDING; MECHANISM	Membrane resealing in mammalian cells after injury depends on Ca2+-dependent fusion of intracellular vesicles with the plasma membrane. When cells are wounded twice, the subsequent resealing is generally faster. Physiological and biochemical studies have shown the initiation of two different repair signaling pathways, which are termed facilitated and potentiated responses. The facilitated response is dependent on the generation and recruitment of new vesicles, whereas the potentiated response is not. Here, we report that the two responses can be differentially defined molecularly. Using recombinant fragments of synaptobrevin-2 and synaptotagmin C2 domains we were able to dissociate the molecular requirements of vesicle exocytosis for initial membrane resealing and the facilitated and potentiated responses. The initial resealing response was blocked by fragments of synaptobrevin-2 and the C2B domain of synaptotagmin VII. Both the facilitated and potentiated responses were also blocked by the C2B domain of synaptotagmin VII. Although the initial resealing response was not blocked by the C2AB domain of synaptotagmin I or the C2A domain of synaptotagmin VII, recruitment of new vesicles for the facilitated response was inhibited. We also used Ca2+ binding mutant studies to show that the effects of synaptotagmins on membrane resealing are Ca2+-dependent. The pattern of inhibition by synaptotagmin C2 fragments that we observed cannot be used to specify a vesicle compartment, such as lysosomes, in membrane repair.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA; Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	University of California System; University of California Berkeley; Iowa State University; University of Wisconsin System; University of Wisconsin Madison	Steinhardt, RA (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	rsteinha@socrates.berkeley.edu		Chapman, Edwin/0000-0001-9787-8140	NEI NIH HHS [EY 13436] Funding Source: Medline; NIGMS NIH HHS [GM 56827] Funding Source: Medline; NIMH NIH HHS [MH 61876] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061876] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; Bai JH, 2004, NEURON, V41, P929, DOI 10.1016/S0896-6273(04)00117-5; Bai JH, 2004, TRENDS BIOCHEM SCI, V29, P143, DOI 10.1016/j.tibs.2004.01.008; Baram D, 2001, IMMUNOL REV, V179, P25, DOI 10.1034/j.1600-065X.2001.790103.x; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; Caler EV, 2001, J EXP MED, V193, P1097, DOI 10.1084/jem.193.9.1097; Cerny J, 2004, EMBO REP, V5, P883, DOI 10.1038/sj.embor.7400243; Chakrabarti S, 2003, J CELL BIOL, V162, P543, DOI 10.1083/jcb.200305131; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Earles CA, 2001, J CELL BIOL, V154, P1117, DOI 10.1083/jcb.200105020; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 2004, BIOCHEM J, V380, P875, DOI 10.1042/BJ20040096; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Gut A, 2001, J CELL SCI, V114, P1709; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jaiswal JK, 2004, PLOS BIOL, V2, P1224, DOI 10.1371/journal.pbio.0020233; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Rickman C, 2004, BIOCHEM J, V378, P681, DOI 10.1042/BJ20031407; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Rossetto O, 1996, J CELL BIOL, V132, P167, DOI 10.1083/jcb.132.1.167; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Stevens CF, 2003, NEURON, V39, P299, DOI 10.1016/S0896-6273(03)00432-X; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Togo T, 2003, MOL BIOL CELL, V14, P93, DOI 10.1091/mbc.E02-01-0056; Togo T, 1999, J CELL SCI, V112, P719; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100	60	38	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1652	1660		10.1074/jbc.M410136200	http://dx.doi.org/10.1074/jbc.M410136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536080	hybrid			2022-12-25	WOS:000226195200096
J	Carmiel-Haggai, M; Cederbaum, AI; Nieto, N				Carmiel-Haggai, M; Cederbaum, AI; Nieto, N			A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats	FASEB JOURNAL			English	Article						oxidative stress; fa/fa	HIGH GLUCOSE; LIPID-PEROXIDATION; PROTEIN OXIDATION; ACTIVATION; EXPRESSION; OXIDASE; LEPTIN; STEATOHEPATITIS; PATHOGENESIS; GLUTATHIONE	Fatty livers of obese fa/fa rats are vulnerable to injury when challenged by insults such as endotoxin, ischemia-reperfusion or acute ethanol treatment. The objective of this study was to evaluate whether a high-fat diet can act as a "second hit" and cause progression to liver injury in obese fa/fa rats compared with lean Fa/? rats. Accordingly, obese fa/fa rats and their lean littermates were fed a diet low in fat (12% of total calories) or a diet with 60% calories as lard for 8 weeks. Hyperglycemia and steatohepatitis occurred in the fa/fa rats fed the high-fat diet. This was accompanied by liver injury as assessed by alanine aminotransferase, hematoxilin and eosin staining, increased TNFalpha and stellate cell-derived TGFbeta, collagen deposition, and up-regulation of alpha-smooth muscle actin. Active MMP13 decreased in fa/fa rats independently of the diet, and TIMP1 expression increased with the high-fat diet, especially in fa/fa rats. Although UCP2 expression was higher in fa/fa rats regardless of the diet, minor changes in ATP levels were observed. Oxidative stress occurred in the fa/fa rats fed the high-fat diet as lipid peroxidation and protein carbonyls were elevated, while glutathione and antioxidant enzymes were very low. Expression and activity of cytochrome P450 2E1 and xanthine oxidase activity were down-regulated in fa/fa compared with Fa/? rats, and no effect was seen by the high-fat diet. However, NADPH oxidase activity increased 2.5-fold in fa/fa rats fed with the high-fat diet. In summary, a high-fat diet induces liver injury in fa/fa rats leading to periportal fibrosis. A role for oxidative stress is suggested via increased NADPH oxidase activity, lipid peroxidation, protein carbonyl formation, and low antioxidant defense.	CUNY, Mt Sinai Med Ctr, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; CUNY, Mt Sinai Med Ctr, Div Liver Dis, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nieto, N (corresponding author), CUNY, Mt Sinai Med Ctr, Dept Pharmacol & Biol Chem, 1 Gustave L Levy Pl,Box 1603, New York, NY 10029 USA.	ny2000@hotmail.com			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA003312, R01AA006610, R37AA006610, R01AA003312] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 06610, AA 03312] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Amet Y, 1995, BIOCHEM PHARMACOL, V50, P1775, DOI 10.1016/0006-2952(95)02040-3; Angulo P, 2002, J GASTROEN HEPATOL, V17, pS186, DOI 10.1046/j.1440-1746.17.s1.10.x; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Bailey SM, 2001, ALCOHOL CLIN EXP RES, V25, P726, DOI 10.1111/j.1530-0277.2001.tb02273.x; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Carmiel-Haggai M, 2003, GASTROENTEROLOGY, V125, P1818, DOI 10.1053/j.gastro.2003.09.019; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; De Keulenaer GW, 1998, BIOCHEM J, V329, P653; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Enriquez A, 1999, BIOCHEM BIOPH RES CO, V255, P300, DOI 10.1006/bbrc.1999.0202; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Hoffman BB, 1998, KIDNEY INT, V54, P1107, DOI 10.1046/j.1523-1755.1998.00119.x; Iredale JP, 1997, INT J BIOCHEM CELL B, V29, P43, DOI 10.1016/S1357-2725(96)00118-5; Jaeschke H, 2002, HEPATOLOGY, V36, P761, DOI 10.1053/jhep.2002.36038; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Lardinois OM, 1996, BBA-PROTEIN STRUCT M, V1298, P180, DOI 10.1016/S0167-4838(96)00130-6; Lardinois OM, 1996, BBA-PROTEIN STRUCT M, V1295, P222, DOI 10.1016/0167-4838(96)00043-X; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4; Lieber C S, 1997, Adv Pharmacol, V38, P601; Lieber CS, 2002, AM J CLIN NUTR, V76, p1183S, DOI 10.1093/ajcn/76.5.1183S; LOMBARDI B, 1966, LAB INVEST, V15, P1; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ludwig J, 1997, J GASTROEN HEPATOL, V12, P398, DOI 10.1111/j.1440-1746.1997.tb00450.x; Maddox DA, 2002, KIDNEY INT, V62, P208, DOI 10.1046/j.1523-1755.2002.00412.x; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Matsuda S, 1999, KIDNEY INT, V56, pS150, DOI 10.1046/j.1523-1755.1999.07138.x; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Raner GM, 1997, BIOCHEMISTRY-US, V36, P4895, DOI 10.1021/bi9630568; Ratziu V, 2000, GASTROENTEROLOGY, V118, P1117, DOI 10.1016/S0016-5085(00)70364-7; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Robertson Graham, 2001, American Journal of Physiology, V281, pG1135; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tofovic SP, 2003, METH MOLEC MED, V86, P29; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; Woodcroft KJ, 1997, CHEM-BIOL INTERACT, V107, P75, DOI 10.1016/S0009-2797(97)00075-6; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Yang SQ, 2001, AM J PHYSIOL-GASTR L, V281, pG382, DOI 10.1152/ajpgi.2001.281.2.G382	57	240	256	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					136	+		10.1096/fj.04-2291fje	http://dx.doi.org/10.1096/fj.04-2291fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522905				2022-12-25	WOS:000225482100027
J	Ideo, H; Seko, A; Yamashita, K				Ideo, H; Seko, A; Yamashita, K			Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on the cell surface of human colon adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; HUMAN NEUROBLASTOMA-CELLS; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; HIGH-AFFINITY; SUGAR CHAIN; CARBOHYDRATE; LECTIN; PROTEINS; RECEPTOR	Galectin-4, a member of the galectin family, is expressed in the epithelium of the alimentary tract. It has two tandemly repeated carbohydrate recognition domains and specifically binds to an SO3--->3Galbeta1-->3GalNAc pyranoside with high affinity (Ideo, H., Seko, A., Ohkura, T., Matta, K. L., and Yamashita, K. (2002) Glycobiology 12,199-208). In this study, we found that galectin-4 binds to glycosphingolipids carrying 3-O-sulfated Gal residues, such as SB1a, SM3, SM4s, SB2, SM2a, and GM1, but not to glycosphingolipids with 3-O-sialylated Gal, such as sLc4Cer, snLc4Cer, GM3, GM2, and GM4, using both an enzyme-linked immunosorbent assay and a surface plasmon resonance assay. A confocal immunocytochemical assay showed that galectin-4 was colocalized with SB1a, GM1, and carcinoembryonic antigen (CEA) in the patches on the cell surface of human colon adenocarcinoma CCK-81 and LS174T cells. This localization was distinct from caveolin/VIP21 localization. Furthermore, immobilized galectin-4 promoted adhesion of CCK-81 cells through the sulfated glycosphingolipid, SB1a. CEA also bound to galectin-4 with K, value of 2 x 10(-8 M) by surface plasmon resonance and coimmunoprecipitated with galectin-4 in LS174T cell lysates. These findings suggest that SB1a and CEA in the patches on the cell surface of human colon adenocarcinoma cells could be biologically important ligands for galectin-4.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Japan Science & Technology Agency (JST)	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2,Kanda Surugadai, Tokyo 1010062, Japan.	yamashita@sasaki.or.jp						BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Braccia A, 2003, J BIOL CHEM, V278, P15679, DOI 10.1074/jbc.M211228200; BRENNAN MJ, 1991, J BIOL CHEM, V266, P18827; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Catimel B, 1998, GLYCOBIOLOGY, V8, P927, DOI 10.1093/glycob/8.9.927; CRITTENDEN SL, 1984, MOL CELL BIOL, V4, P1252, DOI 10.1128/MCB.4.7.1252; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; DITTMER JC, 1964, J LIPID RES, V5, P126; FUKUSHIMA K, 1995, GLYCOBIOLOGY, V5, P105, DOI 10.1093/glycob/5.1.105; FUKUSHIMA K, 1993, ARCH BIOCHEM BIOPHYS, V304, P144, DOI 10.1006/abbi.1993.1332; GOUIN E, 1993, ARCH BIOCHEM BIOPHYS, V306, P125, DOI 10.1006/abbi.1993.1489; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hansen GH, 2001, J BIOL CHEM, V276, P32338, DOI 10.1074/jbc.M102667200; Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081; HIRAIWA N, 1988, CANCER RES, V48, P6769; HIRAIWA N, 1990, CANCER RES, V50, P2917; Hokama A, 2004, IMMUNITY, V20, P681, DOI 10.1016/j.immuni.2004.05.009; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; ICHIKI S, 1986, JPN J CANCER RES, V77, P462; Ideo H, 2003, GLYCOBIOLOGY, V13, P713, DOI 10.1093/glycob/cwg094; Ideo H, 2002, GLYCOBIOLOGY, V12, P199, DOI 10.1093/glycob/12.3.199; IIDA N, 1989, J BIOL CHEM, V264, P5974; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; ODA Y, 1993, J BIOL CHEM, V268, P5929; OHANNESIAN DW, 1994, CANCER RES, V54, P5992; OHANNESIAN DW, 1995, CANCER RES, V55, P2191; Rechreche H, 1997, EUR J BIOCHEM, V248, P225, DOI 10.1111/j.1432-1033.1997.00225.x; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; SIMONS K, 1993, J BIOL CHEM, V272, P29947; Suzuki T, 1996, BIOCHEM J, V318, P389, DOI 10.1042/bj3180389; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; Teneberg S, 1997, J BIOL CHEM, V272, P19067, DOI 10.1074/jbc.272.30.19067; VonKleist S, 1995, ANTICANCER RES, V15, P1889; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145	41	95	97	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4730	4737		10.1074/jbc.M410362200	http://dx.doi.org/10.1074/jbc.M410362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15546874	hybrid			2022-12-25	WOS:000227096600089
J	Reyes, A; Yang, MY; Bowmaker, M; Holt, IJ				Reyes, A; Yang, MY; Bowmaker, M; Holt, IJ			Bidirectional replication initiates at sites throughout the mitochondrial genome of birds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; DIHYDROFOLATE-REDUCTASE DOMAIN; DNA-REPLICATION; GENE ORGANIZATION; START SITES; ORIGIN; YEAST; SEQUENCE; CELLS; ZONE	Analysis of mitochondrial replication intermediates of Gallus gallus on fork-direction gels indicates that replication occurs in both directions around circular mitochondrial DNA. This finding was corroborated by a study of chick mitochondrial DNA on standard neutral two-dimensional agarose gels, which yielded archetypal initiation arcs in fragments covering the entire genome. There was, however, considerable variation in initiation arc intensity. The majority of initiation events map to regions flanking the major non-coding region, in particular the NADH dehydrogenase subunit 6 (ND6) gene. Initiation point mapping of the ND6 gene identified prominent free 5' ends of DNA, which are candidate start sites for DNA synthesis. Therefore we propose that the initiation zone of G. gallus mitochondrial DNA encompasses most, if not all, of the genome, with preferred initiation sites in regions flanking the major non-coding region. Comparison with mammals suggests a common mechanism of initiation of mitochondrial DNA replication in higher vertebrates.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; CNR, Ist Tecnol Biomed, Sez Bioinformat & Genom Bari, I-70126 Bari, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Holt, IJ (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	holt@mrc-dunn.cam.ac.uk	Yang, Mingyao/AAX-9927-2020	Yang, Mingyao/0000-0001-6508-2738; holt, ian/0000-0001-5468-0193	Medical Research Council [MC_U105663140] Funding Source: Medline; MRC [MC_U105663140] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; Aladjem MI, 2002, MOL CELL BIOL, V22, P442, DOI 10.1128/MCB.22.2.442-452.2002; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4; Boore JL, 1999, NUCLEIC ACIDS RES, V27, P1767, DOI 10.1093/nar/27.8.1767; Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BRUN C, 1995, CHROMOSOMA, V104, P92; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; DESJARDINS P, 1990, J MOL BIOL, V212, P599, DOI 10.1016/0022-2836(90)90225-B; Dijkwel PA, 1997, METHODS, V13, P235, DOI 10.1006/meth.1997.0523; Dijkwel PA, 2002, MOL CELL BIOL, V22, P3053, DOI 10.1128/MCB.22.9.3053-3065.2002; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; Gerbi SA, 1997, METHODS, V13, P271, DOI 10.1006/meth.1997.0526; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; HAN ZY, 1994, CHROMOSOMA, V103, P162, DOI 10.1007/BF00368008; HIXSON JE, 1986, J BIOL CHEM, V261, P2384; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; Kang DC, 1997, J BIOL CHEM, V272, P15275, DOI 10.1074/jbc.272.24.15275; KASAMATSU H, 1971, P NATL ACAD SCI USA, V68, P2252, DOI 10.1073/pnas.68.9.2252; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; KORNBERG A, 1992, DNA REPLICATION, P51; LEU TH, 1989, MOL CELL BIOL, V9, P523, DOI 10.1128/MCB.9.2.523; Lewis DL, 1995, INSECT MOL BIOL, V4, P263, DOI 10.1111/j.1365-2583.1995.tb00032.x; Ling F, 2004, MOL BIOL CELL, V15, P310, DOI 10.1091/mbc.E03-07-0508; LITTLE RD, 1995, MOL CELL BIOL, V15, P2893; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MALESZKA R, 1991, EMBO J, V10, P3923, DOI 10.1002/j.1460-2075.1991.tb04962.x; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MAYHOOK AG, 1992, P ROY SOC B-BIOL SCI, V248, P85, DOI 10.1098/rspb.1992.0046; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NASS MMK, 1995, CURR GENET, V28, P401, DOI 10.1007/BF00310807; Preiser PR, 1996, EMBO J, V15, P684, DOI 10.1002/j.1460-2075.1996.tb00401.x; Saccone C, 1999, GENE, V238, P195, DOI 10.1016/S0378-1119(99)00270-X; Santamaria D, 2000, NUCLEIC ACIDS RES, V28, P2099, DOI 10.1093/nar/28.10.2099; SLATKO B, 1999, CURRENT PROTOCOLS MO, P9; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9; Yokobori S, 1999, GENETICS, V153, P1851; Zhou J, 2002, P NATL ACAD SCI USA, V99, P13693, DOI 10.1073/pnas.212392399	46	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3242	3250		10.1074/jbc.M411916200	http://dx.doi.org/10.1074/jbc.M411916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557283	hybrid			2022-12-25	WOS:000226983900016
J	Agbottah, E; de la Fuente, C; Nekhai, S; Barnett, A; Gianella-Borradori, A; Pumfery, A; Kashanchi, F				Agbottah, E; de la Fuente, C; Nekhai, S; Barnett, A; Gianella-Borradori, A; Pumfery, A; Kashanchi, F			Antiviral activity of CYC202 in HIV-1-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT KINASE INHIBITORS; HERPES-SIMPLEX-VIRUS; CARBOXYL-TERMINAL DOMAIN; VARICELLA-ZOSTER-VIRUS; SMALL INTERFERING RNA; DYNAMICS IN-VIVO; HIV-1 TAT; T-CELLS; REVERSE-TRANSCRIPTASE	There are currently 40 million individuals in the world infected with human immunodeficiency virus (HIV. The introduction of highly active antiretroviral therapy (HAART) has led to a significant reduction in AIDS-related morbidity and mortality. Unfortunately, up to 25% of patients discontinue their initial HAART regimen. Current HIV-1 inhibitors target the fusion of the virus to the cell and two viral proteins, reverse transcriptase and protease. Here, we examined whether other targets, such as an activated transcription factor, could be targeted to block HIV-1 replication. We specifically asked whether we could target a cellular kinase needed for HIV-1 transcription using CYC202 (R-roscovitine), a pharmacological cyclin-dependent kinase inhibitor. We targeted the cdk2-cyclin E complex in HIV-1-infected cells because both cdk2 and cyclin E are nonessential during mammalian development and are likely replaced by other kinases. We found that CYC202 effectively inhibits wild type and resistant HIV-1 mutants in T-cells, monocytes, and peripheral blood mononuclear cells at a low IC50 and sensitizes these cells to enhanced apoptosis resulting in a dramatic drop in viral titers. Interestingly, the effect of CYC202 is independent of cell cycle stage and more specific for the cdk2-cyclin E complex. Finally, we show that cdk2-cyclin E is loaded onto the HIV-1 genome in vivo and that CYC202 is able to inhibit the uploading of this cdk-cyclin complex onto HIV-1 DNA. Therefore, targeting cellular enzymes necessary for HIV-1 transcription, which are not needed for cell survival, is a compelling strategy to inhibit wild type and mutant HIV-1 strains.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; Cyclacel Ltd, Dundee Technopole, Dundee DD1 5JJ, Scotland; Inst Genom Res, Rockville, MD 20850 USA; Howard Univ, Ctr Sickle Cell Dis, Washington, DC 20059 USA	George Washington University; Cyclacel Pharmaceuticals Inc.; J. Craig Venter Institute; Howard University	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St NW,Ross Hall,Rm 551, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	, nekhai/AAW-3105-2021; , nekhai/AFO-2652-2022	Barnett, Anna/0000-0002-6345-0194	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056973] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI056973, R21 AI056973-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Advani SJ, 2001, J VIROL, V75, P10326, DOI 10.1128/JVI.75.21.10326-10333.2001; Amara RR, 2002, J VIROL, V76, P7625, DOI 10.1128/JVI.76.15.7625-7631.2002; Anderson J, 2003, OLIGONUCLEOTIDES, V13, P303, DOI 10.1089/154545703322616989; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Boden D, 2004, MOL THER, V9, P396, DOI 10.1016/j.ymthe.2003.11.025; Bresnahan WA, 1997, VIROLOGY, V231, P239, DOI 10.1006/viro.1997.8489; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Chen GX, 2000, DIABETES, V49, P562, DOI 10.2337/diabetes.49.4.562; Chiu YL, 2004, J VIROL, V78, P2517, DOI 10.1128/JVI.78.5.2517-2529.2004; Chun TW, 1997, J VIROL, V71, P4436, DOI 10.1128/JVI.71.6.4436-4444.1997; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Davido DJ, 2002, J VIROL, V76, P1077, DOI 10.1128/JVI.76.3.1077-1088.2002; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; de la Fuente C, 2003, CURR HIV RES, V1, P131; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Deng LW, 2001, VIROLOGY, V289, P312, DOI 10.1006/viro.2001.1129; Dunn SJ, 2004, VIROLOGY, V321, P260, DOI 10.1016/j.virol.2004.01.010; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; GARTNER S, 1986, JAMA-J AM MED ASSOC, V256, P2365, DOI 10.1001/jama.256.17.2365; GENDELMAN HE, 1990, CURR OPIN IMMUNOL, V2, P414, DOI 10.1016/0952-7915(89)90152-0; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Ghedin Elodie, 2004, Retrovirology, V1, P10, DOI 10.1186/1742-4690-1-10; Ghose R, 2001, J VIROL, V75, P11336, DOI 10.1128/JVI.75.23.11336-11343.2001; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; Hu WY, 2004, VIRUS RES, V102, P59, DOI 10.1016/j.virusres.2004.01.016; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; Kashanchi F, 1997, J MED VIROL, V52, P179, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;179::AID-JMV11&gt;3.0.CO;2-G; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Kijak GH, 2002, J VIROL, V76, P7000, DOI 10.1128/JVI.76.14.7000-7009.2002; Kim J, 2003, MICROBIOL IMMUNOL, V47, P959, DOI 10.1111/j.1348-0421.2003.tb03470.x; Kim TA, 2003, J IMMUNOL, V170, P2629, DOI 10.4049/jimmunol.170.5.2629; Kootstra NA, 1998, AIDS RES HUM RETROV, V14, P339, DOI 10.1089/aid.1998.14.339; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; Kudoh A, 2004, J VIROL, V78, P104, DOI 10.1128/JVI.78.1.104-115.2004; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lee NS, 2004, VIRUS RES, V102, P53, DOI 10.1016/j.virusres.2004.01.015; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; Mendez J, 2003, CELL, V114, P398, DOI 10.1016/S0092-8674(03)00649-4; MIKOVITS JA, 1992, J CLIN INVEST, V90, P1486, DOI 10.1172/JCI116016; Moffat JF, 2004, BBA-PROTEINS PROTEOM, V1697, P225, DOI 10.1016/j.bbapap.2003.11.026; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nekhai S, 1997, J VIROL, V71, P7436, DOI 10.1128/JVI.71.10.7436-7441.1997; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Nelson PJ, 2001, J AM SOC NEPHROL, V12, P2827, DOI 10.1681/ASN.V12122827; NICHOLSON JKA, 1986, J IMMUNOL, V137, P323; Nijhuis M, 2001, CURR OPIN INFECT DIS, V14, P23, DOI 10.1097/00001432-200102000-00005; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OBEYESEKERE MN, 1995, ONCOGENE, V11, P1199; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POTTS BJ, 1990, VIROLOGY, V175, P465, DOI 10.1016/0042-6822(90)90431-P; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Roebuck KA, 1996, AIDS, V10, P819, DOI 10.1097/00002030-199607000-00004; Sadaie AR, 2004, ANTIVIR RES, V61, P1, DOI 10.1016/j.antiviral.2003.09.004; Schang LM, 2004, BBA-PROTEINS PROTEOM, V1697, P197, DOI 10.1016/j.bbapap.2003.11.024; Schang LM, 2002, J ANTIMICROB CHEMOTH, V50, P779, DOI 10.1093/jac/dkf227; Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002; Schang LM, 1998, J VIROL, V72, P5626, DOI 10.1128/JVI.72.7.5626-5637.1998; Schang LM, 2000, J VIROL, V74, P2107, DOI 10.1128/JVI.74.5.2107-2120.2000; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUITEMAKER H, 1994, EMBO J, V13, P5929, DOI 10.1002/j.1460-2075.1994.tb06938.x; SHARPLESS N, 1992, VIROLOGY, V191, P813, DOI 10.1016/0042-6822(92)90257-P; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002; Takahashi Y, 2000, GENE DEV, V14, P804; Taylor SL, 2004, J VIROL, V78, P2853, DOI 10.1128/JVI.78.6.2853-2862.2004; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TONGSTARKSEN SE, 1990, J IMMUNOL, V145, P4348; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; van de Wijgert Janneke, 2002, BETA, V15, P23; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Wang L, 2002, MOL CELL BIOCHEM, V237, P137, DOI 10.1023/A:1016555821581; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; *WHO, 2000, JOINT UN PROGR HIV A; *WHO, 2001, JOINT UN PROGR HIV A; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhou MS, 2003, P NATL ACAD SCI USA, V100, P12666, DOI 10.1073/pnas.1835726100	95	65	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3029	3042		10.1074/jbc.M406435200	http://dx.doi.org/10.1074/jbc.M406435200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15531588	hybrid			2022-12-25	WOS:000226449100079
J	Augustin, S; Nolden, M; Muller, S; Hardt, O; Arnold, I; Langer, T				Augustin, S; Nolden, M; Muller, S; Hardt, O; Arnold, I; Langer, T			Characterization of peptides released from mitochondria - Evidence for constant proteolysis and peptide efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; TRANSPORTER MDL1; INNER MEMBRANE; AAA PROTEASE; YEAST; ATP; DEGRADATION; PROTEINS; PROTEOME	Conserved ATP-dependent proteases ensure the quality control of mitochondrial proteins and control essential steps in mitochondrial biogenesis. Recent studies demonstrated that non-assembled mitochondrially encoded proteins are degraded to peptides and amino acids that are released from mitochondria. Here, we have characterized peptides extruded from mitochondria by mass spectrometry and identified 270 peptides that are exported in an ATP- and temperature-dependent manner. The peptides originate from 51 mitochondrially and nuclearly encoded proteins localized mainly in the matrix and inner membrane, indicating that peptides generated by the activity of all known mitochondrial ATP-dependent proteases can be released from the organelle. Pulse-labeling experiments in logarithmically growing yeast cells revealed that similar to6-12% of preexisting and newly imported proteins is degraded and contribute to this peptide pool. Under respiring conditions, we observed an increased proteolysis of newly imported proteins that suggests a higher turnover rate of respiratory chain components and thereby rationalizes the predominant appearance of representatives of this functional class in the detected peptide pool. These results demonstrated a constant efflux of peptides from mitochondria and provided new insight into the stability of the mitochondrial proteome and the efficiency of mitochondrial biogenesis.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Univ Cologne, Zentrum Mol Med, D-50674 Cologne, Germany	University of Cologne; University of Cologne	Langer, T (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.	Thomas.Langer@uni-koeln.de		Langer, Thomas/0000-0003-1250-1462				Andreoli C, 2004, NUCLEIC ACIDS RES, V32, pD459, DOI 10.1093/nar/gkh137; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2001, MITOCHONDRION, V1, P33, DOI 10.1016/S1567-7249(01)00005-8; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chloupkova M, 2003, J MOL BIOL, V331, P155, DOI 10.1016/S0022-2836(03)00666-1; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DEAN M, 1994, YEAST, V10, P377, DOI 10.1002/yea.320100310; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Galluhn D, 2004, J BIOL CHEM, V279, P38338, DOI 10.1074/jbc.M405871200; Korbel D, 2004, EMBO REP, V5, P698, DOI 10.1038/sj.embor.7400186; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; PEARCE DA, 1995, J BIOL CHEM, V270, P1; Prokisch H, 2004, PLOS BIOL, V2, P795, DOI 10.1371/journal.pbio.0020160; Serizawa A, 1997, BIOM HLTH R, V13, P248; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Stahl A, 2002, J BIOL CHEM, V277, P41931, DOI 10.1074/jbc.M205500200; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; Wipf D, 2002, TRENDS BIOCHEM SCI, V27, P139, DOI 10.1016/S0968-0004(01)02054-0; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	30	80	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2691	2699		10.1074/jbc.M410609200	http://dx.doi.org/10.1074/jbc.M410609200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15556950	hybrid			2022-12-25	WOS:000226449100040
J	Auluck, PK; Meulener, MC; Bonini, NM				Auluck, PK; Meulener, MC; Bonini, NM			Mechanisms of suppression of alpha-synuclein neurotoxicity by geldanamycin in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY FORMATION; PARKINSONS-DISEASE; HEAT-SHOCK; LEWY BODIES; MOLECULAR CHAPERONES; IN-VITRO; AGGREGATION; HSP70; NEURODEGENERATION; TOXICITY	Parkinson's disease is a common neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of the protein alpha-synuclein into aggregates called Lewy bodies and Lewy neurites. Parkinson's disease can be modeled in Drosophila where directed expression of alpha-synuclein induces compromise of dopaminergic neurons and the formation of Lewy body-like aggregates. The molecular chaperone Hsp70 protects cells from the deleterious effects of alpha-synuclein, indicating a potential therapeutic approach to enhance neuron survival in Parkinson's disease. We have now investigated the molecular mechanisms by which the drug geldanamycin protects neurons against alpha-synuclein toxicity. Our studies show that geldanamycin sensitizes the stress response within normal physiological parameters to enhance chaperone activation, offering protection against alpha-synuclein neurotoxicity. Further, geldanamycin uncouples neuronal toxicity from Lewy body and Lewy neurite formation such that dopaminergic neurons are protected from the effects of alpha-synuclein expression despite the continued presence of (and even increase in) inclusion pathology. These studies indicate that compounds that modulate the stress response are a promising approach to treat Parkinson's disease.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Bonini, NM (corresponding author), 415 S Univ Ave,305 Leidy Labs, Philadelphia, PA 19104 USA.	nbonini@sas.upenn.edu	Auluck, Pavan K/A-1160-2010	Bonini, Nancy/0000-0003-0226-5291				Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Bagatell R, 2000, CLIN CANCER RES, V6, P3312; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Campbell BCV, 2000, NEUROBIOL DIS, V7, P192, DOI 10.1006/nbdi.2000.0286; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Driscoll M, 2003, NAT REV GENET, V4, P181, DOI 10.1038/nrg1018; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Friggi-Grelin F, 2003, J NEUROBIOL, V54, P618, DOI 10.1002/neu.10185; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Helfand SL, 2002, SCIENCE, V295, P809, DOI 10.1126/science.1069544; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Li H, 2000, CURR BIOL, V10, P211, DOI 10.1016/S0960-9822(00)00340-7; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi M, 2003, NEUROSCI LETT, V336, P155, DOI 10.1016/S0304-3940(02)01258-2; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wu YR, 2004, HUM GENET, V114, P236, DOI 10.1007/s00439-003-1050-1; Zhou Y, 2004, J BIOL CHEM, V279, P39155, DOI 10.1074/jbc.M405456200; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	42	168	178	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2873	2878		10.1074/jbc.M412106200	http://dx.doi.org/10.1074/jbc.M412106200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15556931	hybrid			2022-12-25	WOS:000226449100062
J	Mostecki, J; Showalter, BM; Rothman, PB				Mostecki, J; Showalter, BM; Rothman, PB			Early growth response-1 regulates lipopolysaccharide-induced suppressor of cytokine signaling-1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA PROMOTER; HUMAN MONOCYTIC CELLS; GENE-EXPRESSION; MICE LACKING; KAPPA-B; NEGATIVE REGULATOR; DOWN-REGULATION; NUCLEAR-FACTOR; TISSUE FACTOR; SOCS BOX	Suppressor of cytokine signaling (SOCS)-1 is a critical regulator of lipopolysaccharide (LPS) tolerance and LPS-induced cytokine production. The mechanisms regulating the transcription of SOCS-1 in response to LPS are not entirely understood. Functional analysis of the SOCS-1 promoter demonstrates that early growth response-1 (Egr-1) is an important transcriptional regulator of SOCS-1. Two Egr-1 binding sites are present within the SOCS-1 promoter as shown by EMSA and supershift analysis. Further, mutation of the Egr-1 binding sites significantly reduces both the basal and LPS-induced transcriptional activity of the promoter. Chromatin immunoprecipitation experiments confirm LPS-induced binding of Egr-1 to the SOCS-1 promoter in vivo. Additionally, Egr-1(-/-) macrophages show reduced levels of LPS-induced SOCS-1 expression in comparison with macrophages derived from Egr-1(+/+) littermate controls. These results demonstrate an important role for Egr-1 in regulating both the basal and LPS-induced activity of the SOCS-1 promoter.	Columbia Univ, Dept Med, Div Pulmonary Allergy & Crit Care, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Dept Microbiol, Coll Phys & Surg, New York, NY 10032 USA	Columbia University; Columbia University	Rothman, PB (corresponding author), Columbia Univ, Dept Med, Div Pulmonary Allergy & Crit Care, Coll Phys & Surg, P&S Bldg,Rm 8-425,630 W 168th St, New York, NY 10032 USA.	pbr3@columbia.edu						Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Chadjichristos C, 2003, J BIOL CHEM, V278, P39762, DOI 10.1074/jbc.M303541200; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Crespo A, 2000, BIOCHEM J, V349, P99, DOI 10.1042/0264-6021:3490099; Cuesta N, 2003, J IMMUNOL, V170, P5739, DOI 10.4049/jimmunol.170.11.5739; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Davis W, 2003, NUCLEIC ACIDS RES, V31, P1097, DOI 10.1093/nar/gkg192; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Fukada T, 2001, J BIOL CHEM, V276, P25512, DOI 10.1074/jbc.M101354200; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; Jegalian AG, 2002, J BIOL CHEM, V277, P2345, DOI 10.1074/jbc.M105575200; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; MCMAHON SB, 1995, J IMMUNOL METHODS, V179, P251, DOI 10.1016/0022-1759(94)00292-5; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pawlinski R, 2003, BLOOD, V101, P3940, DOI 10.1182/blood-2002-07-2303; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	56	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2596	2605		10.1074/jbc.M408938200	http://dx.doi.org/10.1074/jbc.M408938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15545275	hybrid			2022-12-25	WOS:000226449100028
J	Ungefroren, H; Groth, S; Ruhnke, M; Kalthoff, H; Fandrich, F				Ungefroren, H; Groth, S; Ruhnke, M; Kalthoff, H; Fandrich, F			Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45 beta gene mediates the induction of biglycan expression by TGF-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; PROTEOGLYCAN EXPRESSION; PANCREATIC-CANCER; TUMOR SUPPRESSION; RECEPTOR; DOWNSTREAM; PHENOTYPE; DECORIN; CLONING; ARREST	We have recently shown that induction of biglycan (BGN) expression by transforming growth factor-beta1 (TGF-beta1) required sequential activation of both Smad and p38 mitogen-activated protein kinase signaling (Ungefroren, H., Lenschow, W., Chen, W.-B., and Kalthoff, H. (2003) J. Biol. Chem. 278, 11041-11049). Here, we have analyzed the receptors through which TGF-beta1 controls expression of BGN and GADD45beta, the latter of which is postulated to link early Smad signaling to delayed activation of p38. Ectopic expression of a dominant-negative mutant of the TGF-beta type II receptor in PANC-1 cells abrogated TGF-beta-induced BGN up-regulation. Similarly, inhibition of the TGF-beta type I receptor/ALK5 with either SB431542 or by enforced stable expression of a kinase-dead mutant greatly attenuated the TGF-beta effect on both BGN and GADD45beta expression in PANC-1 and MG-63 cells. The enhancing effect of ALK5 on TGF-beta-mediated GADD45beta and BGN expression and on GADD45beta promoter activity was also dependent on its ability to activate Smad signaling, because an ALK5 mutant defective in Smad activation (TbetaIlmL45) but with an otherwise functional kinase domain failed to mediate these responses. The TGF-beta/ALK5 effect on p38 activation and BGN expression was mimicked by overexpression of GADD45beta alone (in the absence of TGF-beta stimulation) and suppressed upon antisense inhibition of GADD45beta expression. These results show that TGF-beta induces BGN expression through (the Smad-activating function of) ALK5 and GADD45beta and suggest that the sensitivity of MyD118 to activation by TGF-beta, which varies between tissues, ultimately determines the strength of the TGF-beta effect on BGN.	Univ Hosp Schleswig Holstein, Dept Gen Surg & Thorac Surg, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Ungefroren, H (corresponding author), Univ Hosp Schleswig Holstein, Dept Gen Surg & Thorac Surg, Campus Kiel,Arnold Heller Str 7, D-24105 Kiel, Germany.	hungefroren@chirurgie-sh.de	Faendrich, Fred/B-1705-2010; Goletz, Stephanie/K-1358-2014; Kalthoff, Holger/B-1618-2010					Bakin AV, 2002, J CELL SCI, V115, P3193; Chakravarty D, 2002, AM J PHYSIOL-RENAL, V283, pF1020, DOI 10.1152/ajprenal.00118.2002; Chen WB, 2002, J BIOL CHEM, V277, P36118, DOI 10.1074/jbc.M203709200; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Dai JL, 1998, CANCER RES, V58, P4592; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Ellenrieder V, 2001, CANCER RES, V61, P4222; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200; GRESSNER AM, 1994, PATHOL RES PRACT, V190, P864; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Major MB, 2004, J BIOL CHEM, V279, P5278, DOI 10.1074/jbc.M311517200; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Schaefer L, 2001, FASEB J, V15, P559; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; Vincent F, 1997, ONCOGENE, V15, P117, DOI 10.1038/sj.onc.1201166; Weber CK, 2001, GASTROENTEROLOGY, V121, P657, DOI 10.1053/gast.2001.27222; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Young MF, 2002, GLYCOCONJUGATE J, V19, P257, DOI 10.1023/A:1025336114352; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	37	34	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2644	2652		10.1074/jbc.M411925200	http://dx.doi.org/10.1074/jbc.M411925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15546867	hybrid			2022-12-25	WOS:000226449100034
J	Bunda, S; Kaviani, N; Hinek, A				Bunda, S; Kaviani, N; Hinek, A			Fluctuations of intracellular iron modulate elastin production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PSEUDOXANTHOMA-ELASTICUM; GENE-EXPRESSION; DEVELOPMENTAL REGULATION; 3-UNTRANSLATED REGION; BETA-THALASSEMIA; TROPOELASTIN EXPRESSION; CELL-PROLIFERATION; MARKED LONGEVITY; BINDING PROTEIN	Production of insoluble elastin, the major component of elastic fibers, can be modulated by numerous intrinsic and exogenous factors. Because patients with hemolytic disorders characterized with fluctuations in iron concentration demonstrate defective elastic fibers, we speculated that iron might also modulate elastogenesis. In the present report we demonstrate that treatment of cultured human skin fibroblasts with low concentration of iron 2 - 20 muM ( ferric ammonium citrate) induced a significant increase in the synthesis of tropoelastin and deposition of insoluble elastin. Northern blot and real-time reverse transcription-PCR analysis revealed that treatment with 20 muM iron led to an increase of similar to3-fold in elastin mRNA levels. Because treatment with an intracellular iron chelator, desferrioxamine, caused a significant decrease in elastin mRNA level and consequent inhibition of elastin deposition, we conclude that iron facilitates elastin gene expression. Our experimental evidence also demonstrates the existence of an opposite effect, in which higher, but not cytotoxic concentrations of iron ( 100 - 400 muM) induced the production of intracellular reactive oxygen species that coincided with a significant decrease in elastin message stability and the disappearance of iron-dependent stimulatory effect on elastogenesis. This stimulatory elastogenic effect was reversed, however, in cultures simultaneously treated with high iron concentration ( 200 muM) and the intracellular hydroxyl radical scavenger, dimethylthiourea. Thus, presented data, for the first time, demonstrate the existence of two opposite iron-dependent mechanisms that may affect the steady state of elastin message. We speculate that extreme fluctuations in intracellular iron levels result in impaired elastic fiber production as observed in hemolytic diseases.	Hosp Sick Children, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Hinek, A (corresponding author), Hosp Sick Children, Cardiovasc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	alek.hinek@sickkids.on.ca	Hinek, Aleksander/V-8790-2019					ABRAHAM MK, 1999, BLOOD, V94, P2128; Aessopos A, 2002, BLOOD, V99, P30, DOI 10.1182/blood.V99.1.30; Aessopos A, 1998, ANGIOLOGY, V49, P137, DOI 10.1177/000331979804900206; ALCANTARA O, 1994, BLOOD, V84, P3510; AMARA FM, 1995, NUCLEIC ACIDS RES, V23, P1461, DOI 10.1093/nar/23.9.1461; Beck K, 2003, J HISTOCHEM CYTOCHEM, V51, P887, DOI 10.1177/002215540305100704; Bercovitch L, 2004, J AM ACAD DERMATOL, V51, pS13, DOI 10.1016/j.jaad.2004.01.015; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Boldt DH, 1999, AM J MED SCI, V318, P207, DOI 10.1097/00000441-199910000-00001; Brenneisen P, 1998, J BIOL CHEM, V273, P5279, DOI 10.1074/jbc.273.9.5279; Breuer W, 2000, TRANSFUS SCI, V23, P185, DOI 10.1016/S0955-3886(00)00087-4; Breuer W, 1996, FEBS LETT, V382, P304, DOI 10.1016/0014-5793(96)00190-1; Britton RS, 1996, SEMIN LIVER DIS, V16, P3, DOI 10.1055/s-2007-1007214; Browne P, 1998, FREE RADICAL BIO MED, V24, P1040, DOI 10.1016/S0891-5849(97)00391-2; CAZZOLA M, 1990, BLOOD, V75, P1903; CHRISTIANO AM, 1994, J INVEST DERMATOL, V103, pS53, DOI 10.1111/1523-1747.ep12399044; Cianciulli P, 2002, EUR J CLIN INVEST, V32, P700, DOI 10.1046/j.1365-2362.2002.01032.x; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; CzyzykKrzeska MF, 1997, KIDNEY INT, V51, P585, DOI 10.1038/ki.1997.84; DAVIDSON JM, 1997, ELASTIN ELASTIC TISS, P139; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Degterev A, 1999, MATRIX BIOL, V18, P295, DOI 10.1016/S0945-053X(99)00020-7; DeMoor JM, 2000, CELL MOL BIOL, V46, P367; Demple B, 2004, REDOX REP, V9, P3, DOI 10.1179/135100004225003932; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447, DOI 10.1165/ajrcmb.26.4.4473; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; Fraga CG, 2002, TOXICOLOGY, V180, P23, DOI 10.1016/S0300-483X(02)00379-7; Francke U, 1999, HUM MOL GENET, V8, P1947, DOI 10.1093/hmg/8.10.1947; Frenette PS, 2002, CURR OPIN HEMATOL, V9, P101, DOI 10.1097/00062752-200203000-00003; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; Hamlin N, 2003, BRIT J HAEMATOL, V122, P852, DOI 10.1046/j.1365-2141.2003.04484.x; Hardingham GE, 1999, MICROSC RES TECHNIQ, V46, P348, DOI 10.1002/(SICI)1097-0029(19990915)46:6<348::AID-JEMT3>3.3.CO;2-1; HERSHKO C, 1987, BRIT J HAEMATOL, V66, P149, DOI 10.1111/j.1365-2141.1987.tb01291.x; Hershko C, 1998, BRIT J HAEMATOL, V101, P399, DOI 10.1046/j.1365-2141.1998.00726.x; Hew Y, 2000, J BIOL CHEM, V275, P24857, DOI 10.1074/jbc.M002776200; Hinek A, 2000, AM J HUM GENET, V66, P859, DOI 10.1086/302829; Hinek A, 2000, AM J PATHOL, V156, P925, DOI 10.1016/S0002-9440(10)64961-9; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HINEK A, 1991, CONNECT TISSUE RES, V26, P155, DOI 10.3109/03008209109152434; Ilias A, 2002, J BIOL CHEM, V277, P16860, DOI 10.1074/jbc.M110918200; KAHARI VM, 1992, LAB INVEST, V66, P580; Kicic A, 2001, CANCER, V92, P3093, DOI 10.1002/1097-0142(20011215)92:12<3093::AID-CNCR10107>3.0.CO;2-B; Kielty CM, 2002, PHILOS T R SOC B, V357, P207, DOI 10.1098/rstb.2001.1029; Kielty CM, 2002, J CELL SCI, V115, P2817; Kucich U, 1997, AM J RESP CELL MOL, V17, P10, DOI 10.1165/ajrcmb.17.1.2816; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Lee DH, 2004, MED HYPOTHESES, V62, P442, DOI 10.1016/s0306-9877(03)00344-x; Li DY, 1997, HUM MOL GENET, V6, P1021, DOI 10.1093/hmg/6.7.1021; McGowan KM, 1997, J BIOL CHEM, V272, P1331, DOI 10.1074/jbc.272.2.1331; MCLANE NJ, 1984, AM J OPHTHALMOL, V97, P444, DOI 10.1016/S0002-9394(14)76127-6; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; NELDNER KH, 1988, CLIN DERMATOL, V6, pR8; OLSON TM, 1995, HUM MOL GENET, V4, P1677, DOI 10.1093/hmg/4.9.1677; Pang H, 2004, J BIOL CHEM, V279, P1491, DOI 10.1074/jbc.M310022200; Parkes JG, 2000, J MOL CELL CARDIOL, V32, P233, DOI 10.1006/jmcc.1999.1068; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PARKS WC, 1992, BIOCHEMISTRY-US, V31, P6639, DOI 10.1021/bi00144a003; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; Pietrangelo A, 2000, J HEPATOL, V32, P862, DOI 10.1016/S0168-8278(00)80258-5; PIETRANGELO A, 1990, HEPATOLOGY, V11, P798, DOI 10.1002/hep.1840110513; RICHARDSON D, 1994, CANCER RES, V54, P685; Ritz-Timme S, 2003, BRIT J DERMATOL, V149, P951, DOI 10.1111/j.1365-2133.2003.05618.x; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Rodems SM, 1998, J VIROL, V72, P2697, DOI 10.1128/JVI.72.4.2697-2707.1998; Rosenbloom J, 1995, CIBA F SYMP, V192, P59; ROTHMAN RJ, 1992, MOL PHARMACOL, V42, P703; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Ruiz IG, 2000, DNA CELL BIOL, V19, P167, DOI 10.1089/104454900314555; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; Sherer DW, 1999, DERMATOLOGY, V199, P3, DOI 10.1159/000018195; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; Templeton DM, 2003, BBA-GEN SUBJECTS, V1619, P113, DOI 10.1016/S0304-4165(02)00497-X; TRAORE HN, 2002, METHODS CELL SCI, V23, P175; Tsomi K, 2001, EUR J HAEMATOL, V67, P135, DOI 10.1034/j.1600-0609.2001.5790349.x; Uitto J, 1995, CIBA F SYMP, V192, P237; Urban Z, 2002, AM J HUM GENET, V71, P30, DOI 10.1086/341035; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Vulcano M, 1998, INT J IMMUNOPHARMACO, V20, P709, DOI 10.1016/S0192-0561(98)00055-1; Wendler WMF, 1997, J BIOL CHEM, V272, P8482, DOI 10.1074/jbc.272.13.8482; Ye Z, 2000, BIOCHEM BIOPH RES CO, V275, P223, DOI 10.1006/bbrc.2000.3282; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000; ZHANG MC, 1995, J CLIN INVEST, V95, P986, DOI 10.1172/JCI117808	88	27	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2341	2351		10.1074/jbc.M409897200	http://dx.doi.org/10.1074/jbc.M409897200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537639	hybrid			2022-12-25	WOS:000226341700071
J	Kandasamy, K; Joseph, K; Subramaniam, K; Raymond, JR; Tholanikunnel, BG				Kandasamy, K; Joseph, K; Subramaniam, K; Raymond, JR; Tholanikunnel, BG			Translational control of beta(2)-adrenergic receptor mRNA by T-cell-restricted intracellular antigen-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; BETA-ADRENERGIC-RECEPTOR; 3' UNTRANSLATED REGION; AGONIST-INDUCED DESTABILIZATION; 3'-UNTRANSLATED REGION; BINDING PROTEINS; BETA-2-ADRENERGIC RECEPTORS; 3-UNTRANSLATED REGION; GAMMA-INTERFERON; DOWN-REGULATION	Cellular expression of the beta(2)-adrenergic receptor (beta(2)-AR) is suppressed at the translational level by 3'-untranslated region (UTR) sequences. To test the possible role of 3'-UTR-binding proteins in translational suppression of beta(2)-AR mRNA, we expressed the full-length 3'-UTR or the adenylate/uridylate-rich (A + U-rich element (ARE)) RNA from the 3'-UTR sequences of beta(2)-AR in cell lines that endogenously express this receptor. Reversal of beta(2)-adrenergic receptor translational repression by retroviral expression of 3'-UTR sequences suggested that ARE RNA-binding proteins are involved in translational suppression of beta(2)-adrenergic receptor expression. Using a 20-nucleotide ARE RNA from the receptor 3'-UTR as an affinity ligand, we purified the proteins that bind to these sequences. T-cell-restricted intracellular antigen-related protein ( TIAR) was one of the strongly bound proteins identified by this method. UV-catalyzed cross-linking experiments using in vitro transcribed 3'-UTR RNA and glutathione S-transferase-TIAR demonstrated multiple binding sites for this protein on beta(2)-AR 3'-UTR sequences. The distal 340-nucleotide region of the 3'-UTR was identified as a target RNA motif for TIAR binding by both RNA gel shift analysis and immunoprecipitation experiments. Overexpression of TIAR resulted in suppression of receptor protein synthesis and a significant shift in endogenously expressed beta(2)-AR mRNA toward low molecular weight fractions in sucrose gradient polysome fractionation. Taken together, our results provide the first evidence for translational control of beta(2)-AR mRNA by TIAR.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Med Univ S Carolina, Div Pulm Crit Care Med Allergy & Clin Immunol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Tholanikunnel, BG (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.	tholanik@musc.edu			NIGMS NIH HHS [R01 GM 58740] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058740] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blaxall BC, 2000, J BIOL CHEM, V275, P4290, DOI 10.1074/jbc.275.6.4290; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; COLLINS S, 1988, J BIOL CHEM, V263, P9067; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; Duquette M, 2002, J BIOL CHEM, V277, P44631, DOI 10.1074/jbc.M207007200; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Grosset C, 2004, J BIOL CHEM, V279, P13354, DOI 10.1074/jbc.M308003200; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; GUINER CL, 2001, J BIOL CHEM, V276, P40638; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kirigiti P, 2001, MOL PHARMACOL, V60, P1308, DOI 10.1124/mol.60.6.1308; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Mazumder B, 1999, MOL CELL BIOL, V19, P6898; Mazumder B, 2003, CELL, V115, P187, DOI 10.1016/S0092-8674(03)00773-6; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P411; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Subramaniam K, 2004, J BIOL CHEM, V279, P27108, DOI 10.1074/jbc.M401352200; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tholanikunnel BG, 1999, BIOCHEMISTRY-US, V38, P15564, DOI 10.1021/bi9913348; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; THOLANIKUNNEL BG, 2000, REGULATION G PROTEIN, P273; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; Yu Q, 2003, J BIOL CHEM, V278, P1579, DOI 10.1074/jbc.M203526200; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	58	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1931	1943		10.1074/jbc.M405937200	http://dx.doi.org/10.1074/jbc.M405937200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15536087	hybrid			2022-12-25	WOS:000226341700027
J	Morimoto, S; Nishimura, N; Terai, T; Manabe, S; Yamamoto, Y; Shinahara, W; Miyake, H; Tashiro, S; Shimada, M; Sasaki, T				Morimoto, S; Nishimura, N; Terai, T; Manabe, S; Yamamoto, Y; Shinahara, W; Miyake, H; Tashiro, S; Shimada, M; Sasaki, T			Rab13 mediates the continuous endocytic recycling of occludin to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL ADHESION MOLECULE; POLARIZED EPITHELIAL-CELLS; COATED PIT FORMATION; TIGHT JUNCTION; E-CADHERIN; ENDOPLASMIC-RETICULUM; NONPOLARIZED CELLS; MEMBRANE-PROTEINS; BARRIER FUNCTION; PLASMA-MEMBRANE	During epithelial morphogenesis, adherens junctions (AJs) and tight junctions (TJs) undergo dynamic reorganization, whereas epithelial polarity is transiently lost and reestablished. Although ARF6-mediated endocytic recycling of E-cadherin has been characterized and implicated in the rapid remodeling of AJs, the molecular basis for the dynamic rearrangement of TJs remains elusive. Occludin and claudins are integral membrane proteins comprising TJ strands and are thought to be responsible for establishing and maintaining epithelial polarity. Here we investigated the intracellular transport of occludin and claudins to and from the cell surface. Using cell surface biotinylation and immunofluorescence, we found that a pool of occludin was continuously endocytosed and recycled back to the cell surface in both fibroblastic baby hamster kidney cells and epithelial MTD-1A cells. Biochemical endocytosis and recycling assays revealed that a Rab13 dominant active mutant (Rab13 Q67L) inhibited the postendocytic recycling of occludin, but not that of transferrin receptor and polymeric immunoglobulin receptor in MTD-1A cells. Double immunolabelings showed that a fraction of endocytosed occludin was colocalized with Rab13 in MTD-1A cells. These results suggest that Rab13 specifically mediates the continuous endocytic recycling of occludin to the cell surface in both fibroblastic and epithelial cells.	Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Biochem, Tokushima 7708503, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Digest & Pediat Surg, Tokushima 7708503, Japan	Tokushima University; Tokushima University	Sasaki, T (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Biochem, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	sasaki@basic.med.tokushima-u.ac.jp						Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Czekay RP, 1997, MOL BIOL CELL, V8, P517, DOI 10.1091/mbc.8.3.517; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; Hoekstra D, 2004, J CELL SCI, V117, P2183, DOI 10.1242/jcs.01217; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lecuit T, 2003, NAT CELL BIOL, V5, P103, DOI 10.1038/ncb0203-103; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Marzesco AM, 2002, MOL BIOL CELL, V13, P1819, DOI 10.1091/mbc.02-02-0029; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Rojas R, 2002, NAT REV MOL CELL BIO, V3, P944, DOI 10.1038/nrm972; Royle SJ, 2003, BIOESSAYS, V25, P39, DOI 10.1002/bies.10200; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Schock F, 2002, ANNU REV CELL DEV BI, V18, P463, DOI 10.1146/annurev.cellbio.18.022602.131838; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; Yamamoto Y, 2003, BIOCHEM BIOPH RES CO, V308, P270, DOI 10.1016/S0006-291X(03)01358-5; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; Zegers MMP, 2003, TRENDS CELL BIOL, V13, P169, DOI 10.1016/S0962-8924(03)00036-9; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	47	116	123	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2220	2228		10.1074/jbc.M406906200	http://dx.doi.org/10.1074/jbc.M406906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15528189	hybrid			2022-12-25	WOS:000226341700058
J	Shimizu, N; Dean, T; Tsang, JC; Khatri, A; Potts, JT; Gardella, TJ				Shimizu, N; Dean, T; Tsang, JC; Khatri, A; Potts, JT; Gardella, TJ			Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE RECEPTOR; PHOTOAFFINITY CROSS-LINKING; N-TERMINAL REGION; AMINO-TERMINUS; NONPEPTIDE ANTAGONISTS; CALCITONIN RECEPTOR; EXTRACELLULAR LOOP; LIGAND INTERACTION; COUPLED RECEPTORS; SECRETIN RECEPTOR	Current antagonists for the parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor (PTHR) are N-terminally truncated or N-terminally modified analogs of PTH(1-34) or PTHrP(1-34) and are thought to bind predominantly to the N-terminal extracellular (N) domain of the receptor. We hypothesized that ligands that bind only to PTHR region comprised of the extracellular loops and seven transmembrane helices (the juxtamembrane or J domain) could also antagonize the PTHR. To test this, we started with the J domain-selective agonists [Gln(10), Ala(12), Har(11), Trp(14), Arg(19) (M)]PTH(1-21), [M]PTH(1-15), and [M]PTH(1-14), and introduced substitutions at positions 1-3 that were predicted to dissociate PTHR binding and cAMP signaling activities. Strong dissociation was observed with the tri-residue sequence diethylglycine (Deg)(1)-para-benzoyl-L-phenylalanine (Bpa)(2)-Deg(3). In HKRK-B7 cells, which express the cloned human PTHR, [Deg(1,3), Bpa(2),M]PTH(1-21), [Deg(1,3),Bpa(2),M]PTH(1-15), and [Deg(1,3),Bpa(2),M]PTH(1-14) fully inhibited (IC(50)s = 100-700 nM) the binding of I-125-[alpha-aminoisobutyric acid(1,3),M]PTH(1-15) and were severely defective for stimulating cAMP accumulation. In ROS 17/2.8 cells, which express the native rat PTHR, [Deg(1,3),Bpa(2),M]PTH(1-21) and [Deg(1,3),Bpa(2),M]PTH(1-15) antagonized the cAMP-agonist action of PTH(1-34), as did PTHrP(5-36) (IC(50)s = 0.7 muM, 2.6 muM, and 36 nM, respectively). In COS-7 cells expressing PTHR-delNt, which lacks the N domain of the receptor, [Deg(1,3),Bpa(2), M]PTH(1-21) and [Deg(1,3),Bpa(2),M]PTH(1-15) inhibited the agonist actions of [alpha-aminoisobutyric acid(1,3)]PTH(1-34) and [M]PTH(1-14) (IC(50)s similar to1 muM), whereas PTHrP(5-36) failed to inhibit. [Deg(1,3),Bpa(2),M]PTH(1-14) inhibited the constitutive cAMP-signaling activity of PTHR-tetherPTH-(1-9), in which the PTH(1-9) sequence is covalently linked to the PTHR J domain, as well as that of PTHR(cam)H223R. Thus, the J-domain-selective N-terminal PTH fragment analogs can function as antagonists as well as inverse agonists for the PTHR. The new ligands described should be useful for further studies of the ligand binding and activation mechanisms that operate in the critical PTHR J domain.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.	gardella@helix.mgh.harvard.edu			NIDDK NIH HHS [DK-11794] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Assil-Kishawi I, 2002, J BIOL CHEM, V277, P32558, DOI 10.1074/jbc.M204964200; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Bowen WP, 1995, TRENDS PHARMACOL SCI, V16, P413, DOI 10.1016/S0165-6147(00)89091-4; Carter PH, 2001, ENDOCRINOLOGY, V142, P1534, DOI 10.1210/en.142.4.1534; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; Cascieri MA, 1999, J BIOL CHEM, V274, P8694, DOI 10.1074/jbc.274.13.8694; COHEN FE, 1991, J BIOL CHEM, V266, P1997; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; Gensure RC, 2003, MOL ENDOCRINOL, V17, P2647, DOI 10.1210/me.2003-0275; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; Hoare SRJ, 2004, BIOCHEMISTRY-US, V43, P3996, DOI 10.1021/bi036110a; Hoare SRJ, 2003, MOL PHARMACOL, V63, P751, DOI 10.1124/mol.63.3.751; HORIUCHI N, 1983, SCIENCE, V220, P1053, DOI 10.1126/science.6302844; Jin L, 2000, J BIOL CHEM, V275, P27238; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; Juppner H, 2001, ENDOCRINOLOGY, P969; KENAKIN T, 1997, PHARM ANAL DRUG RECE, P331; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Mallee JJ, 2002, J BIOL CHEM, V277, P14294, DOI 10.1074/jbc.M109661200; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Monticelli L, 2002, BIOPHYS CHEM, V95, P165, DOI 10.1016/S0301-4622(02)00005-4; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; Pham V, 2004, J BIOL CHEM, V279, P6720, DOI 10.1074/jbc.M307214200; Piserchio A, 2002, BIOCHEMISTRY-US, V41, P13217, DOI 10.1021/bi0261600; Rolz C, 2001, BIOPHYS CHEM, V89, P119, DOI 10.1016/S0301-4622(00)00222-2; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; SHIGENO C, 1988, J BIOL CHEM, V263, P3864; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Shimizu M, 2000, J BIOL CHEM, V275, P19456, DOI 10.1074/jbc.M001596200; Shimizu M, 2002, BIOCHEMISTRY-US, V41, P13224, DOI 10.1021/bi026162k; Shimizu M, 2001, ENDOCRINOLOGY, V142, P3068, DOI 10.1210/en.142.7.3068; Shimizu N, 2004, J BONE MINER RES, V19, P2078, DOI 10.1359/JBMR.040914; Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; Takasu H, 1999, J BONE MINER RES, V14, P11, DOI 10.1359/jbmr.1999.14.1.11; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200; Tibaduiza EC, 2001, J BIOL CHEM, V276, P37787; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132	58	32	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1797	1807		10.1074/jbc.M408270200	http://dx.doi.org/10.1074/jbc.M408270200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15550385	hybrid			2022-12-25	WOS:000226341700013
J	Verbsky, JW; Chang, SC; Wilson, MP; Mochizukim, Y; Majerus, PW				Verbsky, JW; Chang, SC; Wilson, MP; Mochizukim, Y; Majerus, PW			The pathway for the production of inositol hexakisphosphate in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; 1,3,4-TRISPHOSPHATE 5/6-KINASE; PHOSPHATE MULTIKINASE; HUMAN HOMOLOG; DNA-PK; PROTEIN; 1,4,5-TRISPHOSPHATE; BINDING; KINASE; 1,3,4,6-TETRAKISPHOSPHATE	The yeast and Drosophila pathways leading to the production of inositol hexakisphosphate (InsP(6)) have been elucidated recently. The in vivo pathway in humans has been assumed to be similar. Here we show that overexpression of Ins(1,3,4) P-3 5/6-kinase in human cell lines results in an increase of inositol tetrakisphosphate (InsP(4)) isomers, inositol pentakisphosphate (InsP(5)) and InsP6, whereas its depletion by RNA interference decreases the amounts of these inositol phosphates. Expression of Ins(1,3,4,6)P-4 5-kinase does not increase the amount of InsP(5) and InsP(6), although its depletion does block InsP(5) and InsP(6) production, showing that it is necessary for production of InsP(5) and InsP(6). Expression of Ins(1,3,4,5,6)P-5 2-kinase increases the amount of InsP(6) by depleting the InsP(5) in the cell, and depletion of 2-kinase decreases the amount of InsP(6) and causes an increase in InsP(5). These results are consistent with a pathway that produces InsP(6) through the sequential action of Ins(1,3,4)P-3 5/6-kinase, Ins(1,3,4,6)P-4 5-kinase, and Ins(1,3,4,5,6) P5 2-kinase to convert Ins(1,3,4)P-3 to InsP(6). Furthermore, the evidence implicates 5/6-kinase as the rate-limiting enzyme in this pathway.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Mol Cell Biol Lab, Tokyo 1920392, Japan	Washington University (WUSTL); Tokyo University of Pharmacy & Life Sciences	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.	phil@im.wustl.edu			NHLBI NIH HHS [HL 55272, HL 16634] Funding Source: Medline; PHS HHS [H107088] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R37HL016634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; CHANDA VB, 1997, CURRENT PROTOCOLS MO; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Feng YC, 2001, P NATL ACAD SCI USA, V98, P875, DOI 10.1073/pnas.021558098; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Ho MWY, 2002, CURR BIOL, V12, P477, DOI 10.1016/S0960-9822(02)00713-3; Hoy M, 2002, P NATL ACAD SCI USA, V99, P6773, DOI 10.1073/pnas.102157499; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; Stevenson-Paulik J, 2002, J BIOL CHEM, V277, P42711, DOI 10.1074/jbc.M209112200; Sun Y, 2003, J BIOL CHEM, V278, P43645, DOI 10.1074/jbc.M300674200; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; WONG NS, 1992, BIOCHEM J, V286, P459, DOI 10.1042/bj2860459; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	32	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1911	1920		10.1074/jbc.M411528200	http://dx.doi.org/10.1074/jbc.M411528200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15531582	hybrid			2022-12-25	WOS:000226341700025
J	Suzuki, T; Ishihara, K; Migaki, H; Matsuura, W; Kohda, A; Okumura, K; Nagao, M; Yamaguchi-Iwai, Y; Kambe, T				Suzuki, T; Ishihara, K; Migaki, H; Matsuura, W; Kohda, A; Okumura, K; Nagao, M; Yamaguchi-Iwai, Y; Kambe, T			Zinc transporters, ZnT5 and ZnT7, are required for the activation of alkaline phosphatases, zinc-requiring enzymes that are glycosylphosphatidylinositol-anchored to the cytoplasmic membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SLC30 FAMILY; PROTEIN; IDENTIFICATION; RESOLUTION; BIOLOGY; CLONING; CANCER; GENES; DEATH	Numerous proteins are properly folded by binding with zinc during their itinerary in the biosynthetic-secretory pathway. Several transporters have been implicated in the zinc entry into secretory compartments from cytosol, but their precise roles are poorly understood. We report here that two zinc transporters (ZnT5 and ZnT7) localized in the secretory apparatus are responsible for loading zinc to alkaline phosphatases (ALPs) that are glycosylphosphatidylinositol-anchored membrane proteins exposed to the extracellular site. Disruption of the ZnT5 gene in DT40 cells decreased the ALP activity to 45% of that in the wild-type cells. Disruption of the ZnT7 gene lowered the ALP activity only by 20%. Disruption of both genes markedly decreased the ALP activity to <5%. Overexpression of human ZnT5 or ZnT7 in DT40 cells deficient in both ZnT5 and ZnT7 genes recovered the ALP activity to the level comparable to that in the wild-type cells. The inactive ALP protein in DT40 cells deficient in both ZnT5 and ZnT7 genes was transported to cytoplasmic membrane like the active ALP protein in the wild-type cells. Thus both ZnT5 and ZnT7 contribute to the conversion of apo-ALP to holo-ALP.	Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan; Mie Univ, Fac Bioresources, Dept Life Sci, Tsu, Mie 5148507, Japan	Kyoto University; Mie University	Kambe, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan.	kambe1@kais.kyoto-u.ac.jp						Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Boardman PE, 2002, CURR BIOL, V12, P1965, DOI 10.1016/S0960-9822(02)01296-4; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Chimienti F, 2003, CURR DRUG TARGETS, V4, P323, DOI 10.2174/1389450033491082; Chimienti F, 2004, DIABETES, V53, P2330, DOI 10.2337/diabetes.53.9.2330; CRAWFORD K, 1995, DEV DYNAM, V204, P48, DOI 10.1002/aja.1002040107; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Galperin MY, 2001, PROTEINS, V45, P318, DOI 10.1002/prot.1152; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775; Kambe T, 2004, CELL MOL LIFE SCI, V61, P49, DOI 10.1007/s00018-003-3148-y; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kilshtain-Vardi A, 2003, ACTA CRYSTALLOGR D, V59, P323, DOI 10.1107/S0907444902015706; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; Le Du MH, 2002, J BIOL CHEM, V277, P49808, DOI 10.1074/jbc.M207394200; Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402; Mann KJ, 2001, BIOCHEMISTRY-US, V40, P1205, DOI 10.1021/bi0024512; MILLAN JL, 1995, CRIT REV CL LAB SCI, V32, P1, DOI 10.3109/10408369509084680; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; Okumura K, 1998, BIOSCI BIOTECH BIOCH, V62, P1640, DOI 10.1271/bbb.62.1640; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Seve M, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-32; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1	33	129	135	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					637	643		10.1074/jbc.M411247200	http://dx.doi.org/10.1074/jbc.M411247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15525635	hybrid			2022-12-25	WOS:000226025100075
J	Jones, GLAH; Sang, E; Goddard, C; Mortishire-Smith, RJ; Sweatman, BC; Haselden, JN; Davies, K; Grace, AA; Clarke, K; Griffin, JL				Jones, GLAH; Sang, E; Goddard, C; Mortishire-Smith, RJ; Sweatman, BC; Haselden, JN; Davies, K; Grace, AA; Clarke, K; Griffin, JL			A functional analysis of mouse models of cardiac disease through metabolic profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCULAR-DYSTROPHY; PATTERN-RECOGNITION; NMR-SPECTRA; CLASSIFICATION; EXPRESSION; INVESTIGATE; DISRUPTION; PHENOTYPE; TOXICITY	Since the completion of the human and mouse genomes, the focus in mammalian biology has been on assessing gene function. Tools are needed for assessing the phenotypes of the many mouse models that are now being generated, where genes have been "knocked out," "knocked in," or mutated, so that gene expression can be understood in its biological context. Metabolic profiling of cardiac tissue through high resolution NMR spectroscopy in conjunction with multivariate statistics has been used to classify mouse models of cardiac disease. The data sets included metabolic profiles from mouse models of Duchenne muscular dystrophy, two models of cardiac arrhythmia, and one of cardiac hypertrophy. The metabolic profiles demonstrate that the strain background is an important component of the global metabolic phenotype of a mouse, providing insight into how a given gene deletion may result in very different responses in diverse populations. Despite these differences associated with strain, multivariate statistics were capable of separating each mouse model from its control strain, demonstrating that metabolic profiles could be generated for each disease. Thus, this approach is a rapid method of phenotyping mouse models of disease.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ Cambridge, Dept Physiol, Cambridge CB2 1QW, England; Merck Sharp & Dohme Ltd, Ctr Neurosci, Harlow CM20 2QR, Essex, England; GlaxoSmithKline, Metabon Grp, Ware SG12 0DP, Herts, England; Univ Oxford, Dept Genet, Oxford OX1 3QX, England	University of Cambridge; University of Oxford; University of Cambridge; Merck & Company; GlaxoSmithKline; University of Oxford	Griffin, JL (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England.	jlg40@mole.bio.cam.ac.uk		McKernan, Kevin/0000-0002-3908-1122	British Heart Foundation [PS/02/002/14893] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		ANTHONY ML, 1994, MOL PHARMACOL, V46, P199; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Beckwith-Hall BM, 1998, CHEM RES TOXICOL, V11, P260, DOI 10.1021/tx9700679; Bendall JK, 2002, J MOL CELL CARDIOL, V34, P1325, DOI 10.1006/jmcc.2002.2083; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Brindle JT, 2003, ANALYST, V128, P32, DOI 10.1039/b209155k; BRINDLE KM, 2003, BIOCHEMIST, V25, P15; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Burton EA, 2002, CELL, V108, P5, DOI 10.1016/S0092-8674(01)00626-2; Castrillo JI, 2003, PHYTOCHEMISTRY, V62, P929, DOI 10.1016/S0031-9422(02)00713-6; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; FELL D, 1996, UNDERSTANDING CONTRO; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; Gavaghan CL, 2000, FEBS LETT, V484, P169, DOI 10.1016/S0014-5793(00)02147-5; Griffin JL, 2002, FEBS LETT, V530, P109, DOI 10.1016/S0014-5793(02)03437-3; Griffin JL, 2001, ANAL BIOCHEM, V293, P16, DOI 10.1006/abio.2001.5096; Hintze TH, 2002, J MOL CELL CARDIOL, V34, P1283, DOI 10.1006/jmcc.2002.2103; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hoit BD, 2001, J MOL CELL CARDIOL, V33, P27, DOI 10.1006/jmcc.2000.1294; Holmes E, 2000, CHEM RES TOXICOL, V13, P471, DOI 10.1021/tx990210t; Holmes E, 1998, NMR BIOMED, V11, P235, DOI 10.1002/(SICI)1099-1492(199806/08)11:4/5<235::AID-NBM507>3.0.CO;2-V; Hongo M, 2000, BASIC RES CARDIOL, V95, P431, DOI 10.1007/s003950070018; Hough TA, 2002, MAMM GENOME, V13, P595, DOI 10.1007/s00335-002-2188-1; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Linder CC, 2001, LAB ANIMAL, V30, P34; McIntosh LM, 1998, ANAT RECORD, V252, P311, DOI 10.1002/(SICI)1097-0185(199810)252:2<311::AID-AR17>3.0.CO;2-Q; McIntosh LM, 1998, BIOCHEM CELL BIOL, V76, P532; Nicholson JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/nrd728; Oliver SG, 1998, TRENDS BIOTECHNOL, V16, P373, DOI 10.1016/S0167-7799(98)01214-1; Papadatos GA, 2002, P NATL ACAD SCI USA, V99, P6210, DOI 10.1073/pnas.082121299; Raamsdonk LM, 2001, NAT BIOTECHNOL, V19, P45, DOI 10.1038/83496; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803, DOI 10.1098/rspb.2001.1711; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wold S., 1999, INTRO MULTIMEGAVARIA	39	49	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7530	7539		10.1074/jbc.M410200200	http://dx.doi.org/10.1074/jbc.M410200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15546876	hybrid			2022-12-25	WOS:000227395700015
J	Narayan, S; Jaiswal, AS; Balusu, R				Narayan, S; Jaiswal, AS; Balusu, R			Tumor suppressor APC blocks DNA polymerase beta-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; COLON-CANCER CELLS; INDUCED CYTOTOXICITY; MAMMALIAN-CELLS; PCNA; INSTABILITY; INHIBITOR; MECHANISM; SELECTION; PATHWAYS	In the present investigation, we report a previously unsuspected function of the tumor suppressor protein, APC ((a) under bar denomatous (p) under bar olyposis (c) under bar oli), in the regulation of base excision repair (BER). We identified a proliferating cell nuclear antigen-interacting protein-like box sequence in APC that binds DNA polymerase beta and blocks DNA polymerase beta-mediated strand-displacement synthesis in long patch BER without affecting short patch BER. We further showed that the colon cancer cell line expressing the wild-type APC gene was more sensitive to a DNA-methylating agent due to decreased DNA repair by long patch BER than the cell line expressing the mutant A-PC gene lacking the proliferating cell nuclear antigen-interacting protein-like box. Experiments based on RNA interference showed that the wild-type APC gene expression is required for DNA methylation-induced sensitivity of colon cancer cells. Thus, APC may play a critical role in determining utilization of long versus short patch BER pathways and affect the susceptibility of colon cancer cells to carcinogenic and chemotherapeutic agents.	Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, Acad Res Bldg,R4-216,1600 SW Archer Rd, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu			NATIONAL CANCER INSTITUTE [R01CA100247, R01CA097031] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 100247, R01-CA 097031, R01 CA100247, R01 CA097031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY C, 1994, P INT C INT SYST MOL, V2, P28; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hanawalt PC, 2003, MUTAT RES-REV MUTAT, V544, P107, DOI 10.1016/j.mrrev.2003.06.002; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; Jaiswal AS, 2002, ONCOGENE, V21, P5912, DOI 10.1038/sj.onc.1205789; James P, 1996, GENETICS, V144, P1425; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; KOI M, 1994, CANCER RES, V54, P4308; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu LL, 2002, CLIN CANCER RES, V8, P2985; Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan Satya, 2003, Mol Cancer, V2, P41, DOI 10.1186/1476-4598-2-41; Petermann E, 2003, DNA REPAIR, V2, P1101, DOI 10.1016/S1568-7864(03)00117-4; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Verma UN, 2003, CLIN CANCER RES, V9, P1291; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8	30	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6942	6949		10.1074/jbc.M409200200	http://dx.doi.org/10.1074/jbc.M409200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15548520	hybrid			2022-12-25	WOS:000227332700084
J	Piper, DR; Hinz, WA; Tallurri, CK; Sanguinetti, MC; Tristani-Firouzi, M				Piper, DR; Hinz, WA; Tallurri, CK; Sanguinetti, MC; Tristani-Firouzi, M			Regional specificity of human ether-a'-go-go-related gene channel activation and inactivation gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; HERG POTASSIUM CHANNELS; VOLTAGE-DEPENDENT ACTIVATION; HUMAN INWARD RECTIFIER; XENOPUS-OOCYTES; S4-S5 LINKER; PORE DOMAIN; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE DOMAIN; PACEMAKER CHANNELS	Slow activation and rapid C-type inactivation produce inward rectification of the current-voltage relationship for human ether-a'-go-go-related gene (hERG) channels. To characterize the voltage sensor movement associated with hERG activation and inactivation, we performed an Ala scan of the 32 amino acids (Gly(514)- Tyr(545)) that comprise the S4 domain and the flanking S3-S4 and S4-S5 linkers. Gating and ionic currents of wild-type and mutant channels were measured using cut-open oocyte Vaseline gap and two microelectrode voltage clamp techniques to determine the voltage dependence of charge movement, activation, and inactivation. Mapping the position of the charge-perturbing mutations (defined as \DeltaDeltaG\ > 1.0 kcal/mol) on a three-dimensional S4 homology model revealed a spiral pattern. As expected, mutation of these residues also altered activation. However, mutation of residues in the S3-S4 and S4-S5 linkers and the C-terminal end of S4 perturbed activation (\DeltaDeltaG\ > 1.0 kcal/mol) without altering charge movement, suggesting that the native residues in these regions couple S4 movement to the opening of the activation gate or stabilize the open or closed state of the channel. Finally, mutation of a distinct set of residues impacted inactivation and mapped to a single face of the S4 helix that was devoid of activation-perturbing residues. These results define regions on the S4 voltage sensor that contribute differentially to hERG activation and inactivation gating.	Univ Utah, Dept Physiol, Nora Eccles Harrison CVRTI, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Piper, DR (corresponding author), Univ Utah, Dept Physiol, Nora Eccles Harrison CVRTI, 95 South 2000 East, Salt Lake City, UT 84112 USA.	piper@cvrti.utah.edu	Sanguinetti, Michael/AAN-2615-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075536, R01HL065299] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03816, HL65299, HL75536] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Bianchi L, 1998, CANCER RES, V58, P815; Broomand A, 2003, J GEN PHYSIOL, V122, P741, DOI 10.1085/jgp.200308927; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Chen J, 2001, P NATL ACAD SCI USA, V98, P11277, DOI 10.1073/pnas.201250598; Choe S, 1995, P NATL ACAD SCI USA, V92, P12046, DOI 10.1073/pnas.92.26.12046; Decher N, 2004, J BIOL CHEM, V279, P13859, DOI 10.1074/jbc.M313704200; Elinder F, 2001, J GEN PHYSIOL, V118, P1, DOI 10.1085/jgp.118.1.1; Elinder F, 2001, BIOPHYS J, V80, P1802, DOI 10.1016/S0006-3495(01)76150-4; Gandhi CS, 2000, NEURON, V27, P585, DOI 10.1016/S0896-6273(00)00068-4; Gandhi CS, 2003, NEURON, V40, P515, DOI 10.1016/S0896-6273(03)00646-9; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Johnson JP, 1999, J GEN PHYSIOL, V113, P565, DOI 10.1085/jgp.113.4.565; Johnson JP, 1999, BIOPHYS J, V77, P2534, DOI 10.1016/S0006-3495(99)77088-8; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Larsson HP, 2000, NEURON, V27, P573, DOI 10.1016/S0896-6273(00)00067-2; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Latorre R, 2001, BIOPHYS J, V80, p436A; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Liu J, 2003, J GEN PHYSIOL, V121, P599, DOI 10.1085/jgp.200308788; Loots E, 2000, J GEN PHYSIOL, V116, P623, DOI 10.1085/jgp.116.5.623; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; LYNCH JJ, 1994, J PHARMACOL EXP THER, V269, P541; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; Piper DR, 2003, P NATL ACAD SCI USA, V100, P10534, DOI 10.1073/pnas.1832721100; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez-Chapula JA, 2000, PFLUG ARCH EUR J PHY, V440, P264, DOI 10.1007/s004240051048; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schonherr R, 2002, NEURON, V35, P935, DOI 10.1016/S0896-6273(02)00869-3; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Silverman WR, 2000, J GEN PHYSIOL, V116, P663, DOI 10.1085/jgp.116.5.663; Silverman WR, 2003, P NATL ACAD SCI USA, V100, P2935, DOI 10.1073/pnas.0636603100; Smith PL, 2002, J GEN PHYSIOL, V119, P275, DOI 10.1085/jgp.119.3.275; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P421, DOI 10.1085/jgp.111.3.421; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Stefani E, 1998, METHOD ENZYMOL, V293, P300; STUEHMER W, 1992, METHOD ENZYMOL, V207, P319; Subbiah RN, 2004, J PHYSIOL-LONDON, V558, P417, DOI 10.1113/jphysiol.2004.062588; Tang CY, 2000, J GEN PHYSIOL, V115, P319, DOI 10.1085/jgp.115.3.319; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Zou AR, 1998, J PHYSIOL-LONDON, V509, P129, DOI 10.1111/j.1469-7793.1998.129bo.x	66	62	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7206	7217		10.1074/jbc.M411042200	http://dx.doi.org/10.1074/jbc.M411042200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15528201	hybrid			2022-12-25	WOS:000227332700112
J	He, B; Liu, L; Cook, GA; Grgurevich, S; Jennings, LK; Zhang, XA				He, B; Liu, L; Cook, GA; Grgurevich, S; Jennings, LK; Zhang, XA			Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha 6-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY-LIKE STRUCTURES; HUMAN-ENDOTHELIAL CELLS; PROSTATE-CANCER CELLS; HUMAN T-CELLS; METASTASIS-SUPPRESSOR; BASEMENT-MEMBRANE; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; PROTEINS; MIGRATION	Tetraspanin CD82 has been implicated in integrin-mediated functions such as cell motility and invasiveness. Although tetraspanins associate with integrins, it is unknown if and how CD82 regulates the functionality of integrins. In this study, we found that Du145 prostate cancer cells underwent morphogenesis on the reconstituted basement membrane Matrigel to form an anastomosing network of multicellular structures. This process entirely depends on integrin alpha6, a receptor for laminin. After CD82 is expressed in Du145 cells, this cellular morphogenesis was abolished, indicating a functional cross-talk between CD82 and alpha6 integrins. Interestingly, antibodies against other tetraspanins expressed in Du145 cells such as CD9, CD81, and CD151 did not block this integrin alpha6-dependent morphogenesis. We further found that CD82 significantly inhibited cell adhesion on laminin 1. Notably, the level of alpha6 integrins on the cell surface was down-regulated upon CD82 expression, although total cellular alpha6 protein levels remained unchanged in CD82-expressing cells. This down-regulation indicates that the diminished cell adhesiveness of CD82-expressing Dul.45 cells on laminin likely resulted from less cell surface expression of alpha6 integrins. As expected, CD82 physically associated with the integrin alpha6 in Du145-CD82 transfectant cells, suggesting that the formation of the CD82-integrin alpha6 complex reduces alpha6 integrin cell surface expression. Finally, the internalization of cell surface integrin alpha6 is significantly enhanced upon CD82 expression. In conclusion, our results indicate that 1) CD82 attenuates integrin alpha6 signaling during a cellular morphogenic process; 2) the decreased surface expression of alpha6 integrins in CD82-expressing cells is likely responsible for the diminished adhesiveness on laminin and, subsequently, results in the attenuation of alpha6 integrin-mediated cellular morphogenesis; and 3) the accelerated internalization of integrin alpha6 upon CD82 expression correlates with the down-regulation of cell surface integrin alpha6.	Univ Tennessee, Ctr Hlth Sci, Vasc Biol Ctr, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Zhang, XA (corresponding author), Univ Tennessee, Ctr Hlth Sci, Vasc Biol Ctr, Coleman H300,956 Court Ave, Memphis, TN 38163 USA.	xazhang@utmem.edu			NCI NIH HHS [CA-96991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER J, 1992, J CELL PHYSIOL, V153, P437, DOI 10.1002/jcp.1041530302; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2001, J CELL SCI, V114, P4143; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Davis TL, 2001, J BIOL CHEM, V276, P26099, DOI 10.1074/jbc.M102811200; Delaguillaumie A, 2002, J CELL SCI, V115, P433; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Fabbri M, 1999, EMBO J, V18, P4915, DOI 10.1093/emboj/18.18.4915; Feigelson SW, 2003, J BIOL CHEM, V278, P51203, DOI 10.1074/jbc.M303601200; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GAIETTA G, 1994, J CELL SCI, V107, P3339; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; GIL ML, 1992, J IMMUNOL, V148, P2826; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; Iwata S, 2002, EUR J IMMUNOL, V32, P1328, DOI 10.1002/1521-4141(200205)32:5<1328::AID-IMMU1328>3.0.CO;2-6; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; JENNINGS LK, 1994, ANN NY ACAD SCI, V714, P175, DOI 10.1111/j.1749-6632.1994.tb12042.x; Katz BZ, 1997, BIOCHIMIE, V79, P467, DOI 10.1016/S0300-9084(97)82738-1; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Kleinman HK, 2003, CURR OPIN BIOTECH, V14, P526, DOI 10.1016/j.copbio.2003.08.002; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lagaudriere-Gesbert C, 1998, EUR J IMMUNOL, V28, P4332, DOI 10.1002/(SICI)1521-4141(199812)28:12<4332::AID-IMMU4332>3.0.CO;2-8; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; Lee JH, 2003, CANCER RES, V63, P7247; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ono M, 1999, CANCER RES, V59, P2335; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; Sasaki T, 1999, GUIDEBOOK EXTRACELLU, P434; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Shibagaki N, 1998, EUR J IMMUNOL, V28, P1125, DOI 10.1002/(SICI)1521-4141(199804)28:04<1125::AID-IMMU1125>3.0.CO;2-C; Shibagaki N, 1999, EUR J IMMUNOL, V29, P4081, DOI 10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.3.CO;2-9; Stahl S, 1997, J CELL SCI, V110, P55; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Takaoka A, 1998, JPN J CANCER RES, V89, P397, DOI 10.1111/j.1349-7006.1998.tb00577.x; Testa JE, 1999, CANCER RES, V59, P3812; VERNON RB, 1992, LAB INVEST, V66, P536; VERNON RB, 1995, AM J PATHOL, V147, P873; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yang XH, 2001, CANCER RES, V61, P5284; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351; Zhang XA, 2003, CANCER RES, V63, P2665; Zhang XA, 2003, J BIOL CHEM, V278, P27319, DOI 10.1074/jbc.M303039200; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhang XA, 2002, MOL BIOL CELL, V13, P1, DOI 10.1091/mbc.01-10-0481; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	72	72	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3346	3354		10.1074/jbc.M406680200	http://dx.doi.org/10.1074/jbc.M406680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557282	hybrid			2022-12-25	WOS:000226983900028
J	Hsu, GW; Huang, XW; Luneva, NP; Geacintov, NE; Beese, LS				Hsu, GW; Huang, XW; Luneva, NP; Geacintov, NE; Beese, LS			Structure of a high fidelity DNA polymerase bound to a benzo[a]pyrene adduct that blocks replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; DIASTEREOMERIC BENZO<A>PYRENE 7,8-DIOL-9,10-EPOXIDES; EPOXIDE-DEOXYGUANOSINE ADDUCTS; TEMPLATE-PRIMER JUNCTION; PRONE LESION BYPASS; DIOL EPOXIDE; TRANSLESION SYNTHESIS; OPTICAL ENANTIOMERS; ACTIVE-SITE; SINGLE STEREOISOMER	Of the carcinogens to which humans are most frequently exposed, the polycyclic aromatic hydrocarbon benzo[a]pyrene (BP) is one of the most ubiquitous. BP is a byproduct of grilled foods and tobacco and fuel combustion and has long been linked to various human cancers, particularly lung and skin. BP is metabolized to diol epoxides that covalently modify DNA bases to form bulky adducts that block DNA synthesis by replicative or high fidelity DNA polymerases. Here we present the structure of a high fidelity polymerase from a thermo-stable strain of Bacillus stearothermophilus (Bacillus fragment) bound to the most common BP-derived N-2-guanine adduct base-paired with cytosine. The BP adduct adopts a conformation that places the polycyclic BP moiety in the nascent DNA minor groove and is the first structure of a minor groove adduct bound to a polymerase. Orientation of the BP moiety into the nascent DNA minor groove results in extensive disruption to the interactions between the adducted DNA duplex and the polymerase. The disruptions revealed by the structure of Bacillus fragment bound to a BP adduct provide a molecular basis for rationalizing the potent blocking effect on replication exerted by BP adducts.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; NYU, Dept Chem, New York, NY 10003 USA	Duke University; New York University	Beese, LS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	Isb@biochem.duke.edu	beese, lorena/G-4993-2010; Classen, Scott/AAY-8176-2020		NATIONAL CANCER INSTITUTE [P01CA092584, R01CA099194] Funding Source: NIH RePORTER; NCI NIH HHS [CA92584, CA 099194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alekseyev YO, 2000, BIOCHEMISTRY-US, V39, P10431, DOI 10.1021/bi000552u; Alekseyev YO, 2002, BIOCHEMISTRY-US, V41, P4467, DOI 10.1021/bi015850l; Alekseyev YO, 2001, BIOCHEMISTRY-US, V40, P2282, DOI 10.1021/bi002245u; BECKMAN RA, 1993, Q REV BIOPHYS, V26, P225, DOI 10.1017/S0033583500002869; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; CONNEY AH, 1982, CANCER RES, V42, P4875; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Feng BB, 1997, BIOCHEMISTRY-US, V36, P13769, DOI 10.1021/bi970069s; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; GEACINTOV NE, 1991, CARCINOGENESIS, V12, P2099, DOI 10.1093/carcin/12.11.2099; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347; Hsu GW, 2004, J BIOL CHEM, V279, P50280, DOI 10.1074/jbc.M409224200; Hsu GW, 2004, NATURE, V431, P217, DOI 10.1038/nature02908; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Jerina D M, 1991, Adv Exp Med Biol, V283, P533; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; KOREEDA M, 1978, SCIENCE, V199, P778, DOI 10.1126/science.622566; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Lipinski LJ, 1998, INT J ONCOL, V13, P269; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perlow RA, 2003, J MOL BIOL, V327, P797, DOI 10.1016/S0022-2836(03)00187-6; Perlow RA, 2002, J MOL BIOL, V322, P291, DOI 10.1016/S0022-2836(02)00751-9; Perlow-Poehnelt RA, 2004, J BIOL CHEM, V279, P36951, DOI 10.1074/jbc.M404332200; Pirogov N, 1998, CHEM RES TOXICOL, V11, P381, DOI 10.1021/tx980006q; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; Simhadri S, 2002, MUTAT RES-FUND MOL M, V508, P137, DOI 10.1016/S0027-5107(02)00211-7; SLAGA TJ, 1979, CANCER RES, V39, P67; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Washington MT, 2004, MOL CELL BIOL, V24, P5687, DOI 10.1128/MCB.24.13.5687-5693.2004; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; WOOD AW, 1977, BIOCHEM BIOPH RES CO, V77, P1389, DOI 10.1016/S0006-291X(77)80133-2; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhuang P, 2001, BIOCHEMISTRY-US, V40, P6660, DOI 10.1021/bi010005o	67	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3764	3770		10.1074/jbc.M411276200	http://dx.doi.org/10.1074/jbc.M411276200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548515	hybrid			2022-12-25	WOS:000226983900077
J	Liu, XH; Kirschenbaum, A; Yu, K; Yao, S; Levine, AC				Liu, XH; Kirschenbaum, A; Yu, K; Yao, S; Levine, AC			Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; GENE-EXPRESSION; GROWTH; ANGIOGENESIS; PROTEIN; MDM2; PHOSPHORYLATION; ACCUMULATION; DEGRADATION; MUTATIONS	Although p53-inactivating mutations have been described in the majority of human cancers, their role in prostate cancer is controversial as mutations are uncommon, particularly in early lesions. p53 is activated by hypoxia and other stressors and is primarily regulated by the Mdm2 protein. Cyclooxygenase (COX)-2, an inducible enzyme that catalyzes the conversion of arachidonic acid to prostaglandins and other eicosanoids, is also induced by hypoxia. COX-2 and resultant prostaglandins increase tumor cell proliferation, resistance to apoptosis, and angiogenesis. Previous reports indicate a complex, reciprocal relationship between p53 and COX-2. To elucidate the effects of COX-2 on p53 in response to hypoxia, we transfected the COX-2 gene into the p53-positive, COX-2-negative MDA-PCa-2b human prostate cancer cell line. The expression of functional p53 and Mdm2 was compared in COX-2(+) versus COX-2(-) cells under normoxic and hypoxic conditions. Our results demonstrated that hypoxia increases both COX-2 protein levels and p53 transcriptional activity in these cells. Forced expression of COX-2 increased tumor cell viability and decreased apoptosis in response to hypoxia. COX-2(+) cells had increased Mdm2 phosphorylation in either normoxic or hypoxic conditions. Overexpression of COX-2 abrogated hypoxia-induced p53 phosphorylation and promoted the binding of p53 to Mdm2 protein in hypoxic cells. In addition, COX-2-expressing cells exhibited decreased hypoxia-induced nuclear accumulation of p53 protein. Finally, forced expression of COX-2 suppressed both basal and hypoxia-induced p53 transcriptional activity, and this effect was mimicked by the addition of PGE, to wild-type cells. These results demonstrated a role for COX-2 in the suppression of hypoxia-induced p53 activity via both direct effects and indirect modulation of Mdm2 activity. These data imply that COX-2-positive prostate cancer cells can have impaired p53 function even in the presence of wild-type p53 and that p53 activity can be restored in these cells via inhibition of COX-2 activity.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Div Endocrinol & Metab, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Urol, New York, NY 10029 USA; Wenzhou Med Coll, Dept Hematol, Wenzhou 325003, Zhejiang, Peoples R China	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Wenzhou Medical University	Liu, XH (corresponding author), Mt Sinai Sch Med, Dept Med, Box 1055,Annenberg Bldg,Rm 23-78,1 Gustave L Levy, New York, NY 10029 USA.	Liu.Xinhua@doc.mssm.edu		Levine, Alice/0000-0002-0634-4133				Alarcon R, 1999, CANCER RES, V59, P6046; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Isaacs JS, 1998, CELL GROWTH DIFFER, V9, P545; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kirschenbaum A, 2001, UROLOGY, V58, P127, DOI 10.1016/S0090-4295(01)01255-9; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; Kunz Manfred, 2003, Mol Cancer, V2, P23, DOI 10.1186/1476-4598-2-23; Lane DP, 2004, NATURE, V427, P789, DOI 10.1038/427789a; Leung WK, 2001, BRIT J CANCER, V84, P335, DOI 10.1054/bjoc.2000.1607; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Liu XH, 1998, CANCER RES, V58, P4245; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ravi R, 2000, GENE DEV, V14, P34; Ristimaki A, 2002, CANCER RES, V62, P632; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Swamy MV, 2003, CANCER RES, V63, P5239; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805	44	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3817	3823		10.1074/jbc.M406577200	http://dx.doi.org/10.1074/jbc.M406577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550400	hybrid			2022-12-25	WOS:000226983900084
J	Ogg, D; Elleby, B; Norstrom, C; Stefansson, K; Abrahmsen, L; Oppermann, U; Svensson, S				Ogg, D; Elleby, B; Norstrom, C; Stefansson, K; Abrahmsen, L; Oppermann, U; Svensson, S			The crystal structure of guinea pig 11 beta-hydroxysteroid dehydrogenase type 1 provides a model for enzyme-lipid bilayer interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN DEHYDROGENASES/REDUCTASES; HYDROXYSTEROID DEHYDROGENASE; MACROMOLECULAR STRUCTURES; ALCOHOL-DEHYDROGENASE; ANGSTROM RESOLUTION; RECOGNITION; REFINEMENT; SDR	The metabolic reduction of 11-keto groups in glucocorticoid steroids such as cortisone leads to the nuclear receptor ligand cortisol. This conversion is an example of pre-receptor regulation and constitutes a novel pharmacological target for the treatment of metabolic disorders such as insulin resistance and possibly other derangements observed in the metabolic syndrome, such as hyperlipidemia, hypertension, and lowered insulin secretion. This reaction is carried out by the NADPH-dependent type 1 11beta-hydroxysteroia dehydrogenase (11beta-HSD1), an enzyme attached through an integral N-terminal transmembrane helix to the lipid bilayer and located with its active site within the lumen of the endoplasmic reticulum. Here we report,the crystal structure of recombinant guinea pig 11beta-HSD1. This variant was determined in complex with NADP at 2.5 A resolution and crystallized in the presence of detergent and guanidinium hydrochloride. The overall structure of guinea pig 11beta-HSD1 shows a clear relationship to other members of the superfamily of short-chain dehydrogenases/reductases but harbors a unique C-terminal helical segment that fulfills three essential functions and accordingly is involved in subunit interactions, contributes to active site architecture, and is necessary for lipid-membrane interactions. The structure provides a model for enzyme-lipid bilayer interactions and suggests a funneling of lipophilic substrates such as steroid hormones from the hydrophobic membrane environment to the enzyme active site.	Biovitrum, Dept Struct Chem, SE-11276 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Karolinska Institutet	Svensson, S (corresponding author), Biovitrum, Dept Struct Chem, SE-11276 Stockholm, Sweden.	Stefan.Svensson@biovitrum.com		Norstrom, Carina/0000-0002-5700-0496				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AGARWAL AK, 1995, BBA-PROTEIN STRUCT M, V1248, P70, DOI 10.1016/0167-4838(95)00005-F; Barf T, 2002, J MED CHEM, V45, P3813, DOI 10.1021/jm025530f; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; Benach J, 2002, BIOCHEMISTRY-US, V41, P14659, DOI 10.1021/bi0203684; Blum A, 2000, BIOCHEM BIOPH RES CO, V276, P428, DOI 10.1006/bbrc.2000.3491; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Davani B, 2000, J BIOL CHEM, V275, P34841, DOI 10.1074/jbc.C000600200; EKLUND H, 1974, FEBS LETT, V44, P200, DOI 10.1016/0014-5793(74)80725-8; Elleby B, 2004, BBA-PROTEINS PROTEOM, V1700, P199, DOI 10.1016/j.bbapap.2004.05.003; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Filling C, 2001, BIOCHEM BIOPH RES CO, V289, P712, DOI 10.1006/bbrc.2001.6032; Ghosh D, 2001, CHEM-BIOL INTERACT, V130, P637, DOI 10.1016/S0009-2797(00)00255-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1975, FEBS LETT, V54, P297, DOI 10.1016/0014-5793(75)80096-2; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nobel S, 2001, EUR J BIOCHEM, V268, P4113, DOI 10.1046/j.1432-1327.2001.02359.x; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; Oppermann UCT, 1997, BIOCHEMISTRY-US, V36, P34, DOI 10.1021/bi961803v; Oppermann UCT, 1997, EUR J BIOCHEM, V249, P355, DOI 10.1111/j.1432-1033.1997.t01-1-00355.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Shafqat N, 2003, J BIOL CHEM, V278, P2030, DOI 10.1074/jbc.M210135200; Stewart PM, 1999, VITAM HORM, V57, P249; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; VONRHEIN C, 2003, AUTOSHARP AUTOMATED; Walker BR, 2003, EXPERT OPIN THER TAR, V7, P771, DOI 10.1517/14728222.7.6.771; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811	35	42	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3789	3794		10.1074/jbc.M412463200	http://dx.doi.org/10.1074/jbc.M412463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15542590	hybrid			2022-12-25	WOS:000226983900080
J	van Riggelen, J; Buchwalter, G; Soto, U; Arce, JD; Hausen, HZ; Wasylyk, B; Rosl, F				van Riggelen, J; Buchwalter, G; Soto, U; Arce, JD; Hausen, HZ; Wasylyk, B; Rosl, F			Loss of net as repressor leads to constitutive increased c-fos transcription in cervical cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; SIGNAL-TRANSDUCTION PATHWAYS; TERNARY COMPLEX; SELECTIVE SUPPRESSION; PROTEIN PHOSPHATASE; AP-1 TRANSCRIPTION; BINDING PROTEIN; CARCINOMA CELLS; KINASE PATHWAY; CREB-BINDING	We have investigated the expression of c-fos in cervical carcinoma cells and in somatic cell hybrids derived therefrom. In malignant cells, c-fos was constitutively expressed even after serum starvation. Dissection of the c-fos promoter showed that expression was mainly controlled by the SRE motif, which was active in malignant cells, but repressed in their non-malignant counterparts. Constitutive SRE activity was not mediated by sustained mitogen-activated protein kinase activity but because of inefficient expression of the ternary complex factor Net, which was either very low or even barely discernible. Chromatin immunoprecipitation assays revealed that Net directly binds to the SRE nucleoprotein complex in non-tumorigenic cells, but not in malignant segregants. Small interfering RNA targeted against Net resulted in enhanced c-fos transcription, clearly illustrating its repressor function. Conversely, stable ectopic expression of Net in malignant cells negatively regulated endogenous c-fos, resulting in a disappearance of the c-Fos protein from the AP-1 transcription complex. These data indicate that loss of Net and constitutive c-fos expression appear to be a key event in the transformation of cervical cancer cells.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angewandte Tumorvirol, D-69120 Heidelberg, Germany; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Loma Linda Univ, Sch Med, Dept Biochem, Loma Linda, CA 92350 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Loma Linda University	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angewandte Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	F.Roesl@dkfz.de	Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Acquaviva C, 2001, BIOCHIMIE, V83, P357, DOI 10.1016/S0300-9084(01)01243-3; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bachmann A, 2002, J VIROL, V76, P280, DOI 10.1128/JVI.76.1.280-291.2002; BENHAM FJ, 1989, GENOMICS, V5, P209, DOI 10.1016/0888-7543(89)90048-7; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cahill MA, 1997, FEBS LETT, V400, P9, DOI 10.1016/S0014-5793(96)01349-X; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; Gille H, 1996, MOL CELL BIOL, V16, P1094; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Gonzales M, 2002, GENE, V293, P169, DOI 10.1016/S0378-1119(02)00723-0; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Mammas IN, 2004, GYNECOL ONCOL, V92, P941, DOI 10.1016/j.ygyno.2003.11.040; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mohr S, 2004, BIOCHIMIE, V86, P13, DOI 10.1016/j.biochi.2003.11.008; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; RIVERA V M, 1990, New Biologist, V2, P751; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; Rosl F, 1999, CONT CANC RES, P207; ROSL F, 1994, J VIROL, V68, P2142; Rosl F, 1997, J VIROL, V71, P362; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; STANBRIDGE EJ, 1984, CANCER SURV, V3, P335; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	65	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3286	3294		10.1074/jbc.M409915200	http://dx.doi.org/10.1074/jbc.M409915200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548518	hybrid			2022-12-25	WOS:000226983900021
J	Alekseev, OM; Widgren, EE; Richardson, RT; O'Rand, MG				Alekseev, OM; Widgren, EE; Richardson, RT; O'Rand, MG			Association of NASP with HSP90 in mouse spermatogenic cells - Stimulation of ATPase activity and transport of linker histones into nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TETRATRICOPEPTIDE REPEAT; PROTEIN; H1; CHROMATIN; BINDING; OVEREXPRESSION; PROGRESSION; TESTIS; CYCLE	NASP (nuclear autoantigenic sperm protein) is a linker histone-binding protein found in all dividing cells that is regulated by the cell cycle (Richardson, R. T., Batova, I. N., Widgren, E. E., Zheng, L. YL, Whitfield, M., Marzluff, W. F., and O'Rand, M. G. (2000) J. Biol. Chem. 275, 30378-30386), and in the nucleus linker histones not bound to DNA are bound to NASP (Alekseev, O. M., Bencieg D. C., Richardson R. T., Widgren E. E., and O'Rand, M. G. (2003) J. Biol. Chem. 278, 8846-8852). In mouse spermatogenic cells tNASP binds the testis-specific linker histone H1t. Utilizing a cross-linker, 3,3'-dithiobissulfosuceinimidyl propionate, and mass spectrometry, we have identified HSP90 as a testis/embryo form of NASP (tNASP)-binding partner. In vitro assays demonstrate that the association of tNASP with HSP90 stimulated the ATPase activity of HSP90 and increased the binding of H1t to tNASP. HSP90 and tNASP are present in both nuclear and cytoplasmic fractions of mouse spermatogenic cells; however, HSP90 bound to NASP only in the cytoplasm. In vitro nuclear import assays on permeabilized HeLa cells demonstrate that tNASP, in the absence of any other cytoplasmic factors, transports linker histones into the nucleus in an energy and nuclear localization signal-dependent manner. Consequently we hypothesize that in the cytoplasm linker histones are bound to a complex containing NASP and HSP90 whose ATPase activity is stimulated by binding NASP. NASP-H1 is subsequently released from the complex and translocates to the nucleus where the H1 is released for binding to the DNA.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	O'Rand, MG (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090, Chapel Hill, NC 27599 USA.	morand@unc.edu	, Proteomics Core UNC/AFQ-7201-2022		NICHD NIH HHS [U54HD35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD035041] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Alekseev OM, 2003, J BIOL CHEM, V278, P8846, DOI 10.1074/jbc.M210352200; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; BROWN DT, 1993, J BIOL CHEM, V268, P713; Caplan Avrom J., 2003, EMBO Reports, V4, P126, DOI 10.1038/sj.embor.embor742; Cheung E, 2002, MOL CELL BIOL, V22, P2463, DOI 10.1128/MCB.22.8.2463-2471.2002; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; CSERMELY P, 1994, BIOCHEM BIOPH RES CO, V202, P1657, DOI 10.1006/bbrc.1994.2124; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Drabent B, 1998, CELL TISSUE RES, V291, P127, DOI 10.1007/s004410050986; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; Grimes SR, 2003, GENE, V304, P13, DOI 10.1016/S0378-1119(02)01201-5; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Kim HR, 1999, J BIOCHEM-TOKYO, V126, P1025, DOI 10.1093/oxfordjournals.jbchem.a022546; Kurz M, 1997, J CELL BIOCHEM, V64, P573; Langer T, 2002, CELL BIOL INT, V26, P653, DOI 10.1006/cbir.2002.0882; Lea Isabel A, 2004, Reprod Biol Endocrinol, V2, P57, DOI 10.1186/1477-7827-2-57; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Lin QC, 2004, J BIOL CHEM, V279, P23525, DOI 10.1074/jbc.M400925200; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; Meyer P, 2004, EMBO J, V23, P511, DOI 10.1038/sj.emboj.7600060; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; NADEAU K, 1993, J BIOL CHEM, V268, P1479; O'Rand MG, 2000, SERONO SYMP, P143; OBRIEN DA, 1993, METHODS TOXICOL, V3, P246; Park M, 1998, MOL CELL BIOCHEM, V185, P33, DOI 10.1023/A:1006884306169; Richardson RT, 2000, J BIOL CHEM, V275, P30378, DOI 10.1074/jbc.M003781200; Richardson RT, 2001, GENE, V274, P67, DOI 10.1016/S0378-1119(01)00605-9; Shima JE, 2004, BIOL REPROD, V71, P319, DOI 10.1095/biolreprod.103.026880; Spector D. L., 1998, CELLS LAB MANUAL; van Holde KE., 1989, SPRINGER SERIES MOL; Wang ZF, 1997, J MOL BIOL, V271, P124, DOI 10.1006/jmbi.1997.1166; Zhao YG, 2001, J BIOL CHEM, V276, P32822, DOI 10.1074/jbc.M105562200	36	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2904	2911		10.1074/jbc.M410397200	http://dx.doi.org/10.1074/jbc.M410397200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15533935	hybrid			2022-12-25	WOS:000226449100066
J	Chen, CF; Lohnes, D				Chen, CF; Lohnes, D			Dominant-negative retinoic acid receptors elicit epidermal defects through a non-canonical pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; NUCLEAR HORMONE-RECEPTORS; TRANSGENIC MICE; P53 HOMOLOG; PPAR-ALPHA; DIFFERENTIAL REGULATION; BARRIER FUNCTION; GROWTH-FACTOR; EEC-SYNDROME; HUMAN SKIN	Previous work has shown that a dominant-negative retinoic acid receptor alpha (dnRARalpha), expressed under the K14 promoter, causes severe epidermal defects. Similar defects are, however, not seen in RARalphay double null mutant mice, which lack the entire complement of RARs expressed in the epidermis. To investigate the mechanism of action of these dominant-negative receptors, dnRARalpha or a DNA binding-deficient variant, dnRARalpha(DBD), were targeted to the basal epidermis. Expression of either receptor type led to similar epidermal phenotypes suggesting that both RAR mutants acted through a common mechanism. The epidermal phenotype was reminiscent of defects seen in p63(-/-) mice. Consistent with this, reduced p63 expression was observed in transgenic offspring expressing either RAR mutant, suggesting that down-regulation of p63 might underlie the effects of these receptors on epidermal development. By contrast, expression of p63 in the epidermis of RARalphagamma(-/-) offspring was unaffected, indicating that RARs were not essential for p63 expression. These findings suggest that dnRARs may impact on epidermal development through one or more non-canonical pathways, which are independent of receptor-DNA interaction.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ K1H 8M5, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal	Lohnes, D (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	dlohnes@uottawa.ca						Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; ANDERSEN B, 1995, NATURE, V374, P118, DOI 10.1038/374118a0; ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; Attar PS, 1997, MOL ENDOCRINOL, V11, P792, DOI 10.1210/me.11.6.792; Bakkers J, 2002, DEV CELL, V2, P617, DOI 10.1016/S1534-5807(02)00163-6; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chapellier B, 2002, EMBO J, V21, P3402, DOI 10.1093/emboj/cdf331; Chen CF, 2004, ONCOGENE, V23, P5350, DOI 10.1038/sj.onc.1207682; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Costa SL, 1996, EXP CELL RES, V225, P35, DOI 10.1006/excr.1996.0154; DARMON M, 1990, J LIPID MEDIATOR, V2, P247; DARWICHE N, 1995, CANCER RES, V55, P2774; DE LUCA LM, 1991, FASEB J, V5, P2924; ELIAS PM, 1981, LAB INVEST, V44, P531; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; FRAZIER G. N., 1931, Archives of Internal Medicine, V48, P507, DOI 10.1001/archinte.1931.00150030158012; FUTORYAN T, 1994, NUTR REV, V52, P299, DOI 10.1111/j.1753-4887.1994.tb01461.x; Ghyselinck NB, 2002, ANN DERMATOL VENER, V129, P793; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Goyette P, 2000, J BIOL CHEM, V275, P16497, DOI 10.1074/jbc.M909382199; Hanley K, 2000, J BIOL CHEM, V275, P11484, DOI 10.1074/jbc.275.15.11484; Hanley K, 1997, J CLIN INVEST, V100, P705, DOI 10.1172/JCI119583; Hanley K, 1998, J INVEST DERMATOL, V110, P368, DOI 10.1046/j.1523-1747.1998.00139.x; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hsu MH, 1998, J BIOL CHEM, V273, P27988, DOI 10.1074/jbc.273.43.27988; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; Iulianella A, 2002, DEV BIOL, V247, P62, DOI 10.1006/dbio.2002.0685; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Koide T, 2001, GENE DEV, V15, P2111, DOI 10.1101/gad.908801; Koster MI, 2002, J INVEST DERM SYMP P, V7, P41, DOI 10.1046/j.1523-1747.2002.19639.x; Lanctot C, 1999, ENDOCRINOLOGY, V140, P1416, DOI 10.1210/en.140.3.1416; Li M, 2001, DEVELOPMENT, V128, P675; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matheny KE, 2003, LARYNGOSCOPE, V113, P936, DOI 10.1097/00005537-200306000-00004; Matsushita A, 2000, J ENDOCRINOL, V167, P493, DOI 10.1677/joe.0.1670493; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nakamuta N, 2004, J VET MED SCI, V66, P681, DOI 10.1292/jvms.66.681; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; REICHRATH J, 1995, BRIT J DERMATOL, V133, P168, DOI 10.1111/j.1365-2133.1995.tb02612.x; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAITOU M, 1994, J BIOL CHEM, V269, P19101; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wei LN, 2003, ANNU REV PHARMACOL, V43, P47, DOI 10.1146/annurev.pharmtox.43.100901.140301; Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; Xiao JH, 1999, EMBO J, V18, P1539, DOI 10.1093/emboj/18.6.1539; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	67	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3012	3021		10.1074/jbc.M411522200	http://dx.doi.org/10.1074/jbc.M411522200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15528198	hybrid			2022-12-25	WOS:000226449100077
J	Chigorno, V; Giannotta, C; Ottico, E; Sciannamblo, M; Mikulak, J; Prinetti, A; Sonnino, S				Chigorno, V; Giannotta, C; Ottico, E; Sciannamblo, M; Mikulak, J; Prinetti, A; Sonnino, S			Sphingolipid uptake by cultured cells - Complex aggregates of cell sphingolipids with serum proteins and lipoproteins are rapidly catabolized	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; EXOGENOUS GANGLIOSIDE GM1; TUMOR GANGLIOSIDES; SACCHAROMYCES-CEREVISIAE; RECYCLING PATHWAYS; HUMAN FIBROBLASTS; KEY REGULATOR; RAT-LIVER; DE-NOVO; SPHINGOSINE	Human fibroblasts, rat neurons, and murine neuroblastoma cells, cultured in the presence of fetal calf serum, were fed with [1-H-3]sphingosine to radiolabel sphingolipids. The fate of cell sphingolipids, the release of sphingolipids in the culture medium, the interaction of sphingolipids with the proteins and lipoproteins of fetal calf serum, and the fate of sphingolipids taken up by the cells were investigated. For this latter purpose, the culture medium containing radioactive sphingolipids was delivered to nonlabeled cells. The presence of tritium at position 1 of sphingosine allowed us to follow the extent of sphingolipid catabolism by measuring the production of radioactive phosphatidylethanolamine and proteins by recycling the radioactive ethanolamine formed during sphingosine catabolism and the production of tritiated water. We confirmed that in cells the recycling of sphingosine occurred to a high extent and that only a minor portion of cell sphingolipids was catabolized to the small fragments of ethanolamine and water. Cell sphingolipids were released in the culture medium, where they formed large lipoproteic aggregates at a rate of about 12% per day. Released sphingolipids were taken up by the cells and catabolized to the sphingosine and then to ethanolamine, and recycling of sphingosine was not observed. This suggests that in the presence of fetal calf serum in the culture medium, exogenous sphingolipids directly reach the lysosomes, were they are entirely catabolized. Thus, the trafficking of sphingolipids from cells to the extracellular environment and from this to other cells does not allow the modification of the plasma membrane composition.	Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Med Chem Biochem & Biotechnol, I-20090 Segrate, Italy	University of Milan	Sonnino, S (corresponding author), Via Fratelli Cervi 93, I-20090 Segrate, Mi, Italy.	Sandro.Sonnino@unimi.it	mikulak, joanna/AAB-3070-2022; Sonnino, Sandro/R-4154-2017; Prinetti, Alessandro/R-4206-2017	mikulak, joanna/0000-0001-8310-9543; Sonnino, Sandro/0000-0001-8180-5908; Prinetti, Alessandro/0000-0003-0252-2593				CARTER HE, 1961, J LIPID RES, V2, P228; Chang FM, 1997, EXP CELL RES, V234, P341, DOI 10.1006/excr.1997.3619; Chester MA, 1997, PURE APPL CHEM, V69, P2475, DOI 10.1351/pac199769122475; Chigorno V, 2000, EUR J BIOCHEM, V267, P4187, DOI 10.1046/j.1432-1327.2000.01454.x; Chigorno V, 1997, EUR J BIOCHEM, V250, P661, DOI 10.1111/j.1432-1033.1997.00661.x; Chigorno V, 1985, GLYCOCONJUGATE J, VV2, P279; Cornish-Bowden A, 1998, CARBOHYD RES, V312, P167; COTTERCHIO M, 1994, J LIPID RES, V35, P10; FORMISANO S, 1979, BIOCHEMISTRY-US, V18, P1119, DOI 10.1021/bi00573a028; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; GIGLIONI A, 1990, CHEM PHYS LIPIDS, V55, P207, DOI 10.1016/0009-3084(90)90080-B; Gillard BK, 1998, EXP CELL RES, V242, P561, DOI 10.1006/excr.1998.4126; Gillard BK, 1998, GLYCOBIOLOGY, V8, P885, DOI 10.1093/glycob/8.9.885; HARPIN ML, 1990, IN VITRO CELL DEV B, V26, P217; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Kong Y, 1998, BBA-LIPID LIPID MET, V1394, P43, DOI 10.1016/S0005-2760(98)00096-4; LEROY JG, 1972, PEDIATR RES, V6, P752, DOI 10.1203/00006450-197210000-00002; LI RX, 1993, BIOCHIM BIOPHYS ACTA, V1170, P283, DOI 10.1016/0005-2760(93)90011-W; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mobius W, 1999, J HISTOCHEM CYTOCHEM, V47, P1005; MRAZ W, 1980, H-S Z PHYSIOL CHEM, V361, P177, DOI 10.1515/bchm2.1980.361.1.177; NAKAMURA O, 1991, ACTA NEUROCHIR, V109, P34, DOI 10.1007/BF01405694; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olshefski R, 1996, FEBS LETT, V386, P11, DOI 10.1016/0014-5793(96)00392-4; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; RIBONI L, 1990, NEUROCHEM RES, V15, P1175, DOI 10.1007/BF01208577; Riboni L, 1999, BIOCHEM J, V338, P147, DOI 10.1042/0264-6021:3380147; Riboni L, 1996, FEBS LETT, V391, P336, DOI 10.1016/0014-5793(96)00772-7; RIBONI L, 1994, FEBS LETT, V352, P323, DOI 10.1016/0014-5793(94)00984-8; RIBONI L, 1993, FEBS LETT, V322, P257, DOI 10.1016/0014-5793(93)81582-K; RUEDA R, 1993, FEBS LETT, V328, P13, DOI 10.1016/0014-5793(93)80955-T; SAQR HE, 1993, J NEUROCHEM, V61, P395; Schwarzmann G, 2001, SEMIN CELL DEV BIOL, V12, P163, DOI 10.1006/scdb.2000.0233; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; Sonnino S, 2000, METHOD ENZYMOL, V311, P639; SONNINO S, 1994, CHEM PHYS LIPIDS, V71, P21, DOI 10.1016/0009-3084(94)02304-2; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P635, DOI 10.1515/bchm2.1970.351.1.635; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; TAKI T, 1994, ANAL BIOCHEM, V223, P232, DOI 10.1006/abio.1994.1579; TOMASI M, 1980, EUR J BIOCHEM, V111, P315, DOI 10.1111/j.1432-1033.1980.tb04944.x; TOYOKUNI T, 1991, J LABELLED COMPD RAD, V29, P567, DOI 10.1002/jlcr.2580290508; TRINCHERA M, 1990, BIOCHEM J, V270, P815, DOI 10.1042/bj2700815; VALENTINO LA, 1994, BLOOD, V83, P2872, DOI 10.1182/blood.V83.10.2872.2872; VALENTINO LA, 1992, CANCER RES, V52, P810; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VENERANDO B, 1982, BIOCHIM BIOPHYS ACTA, V692, P18, DOI 10.1016/0005-2736(82)90497-7; Ziulkoski AL, 2001, BIOCHEM BIOPH RES CO, V281, P971, DOI 10.1006/bbrc.2001.4440	55	35	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2668	2675		10.1074/jbc.M407749200	http://dx.doi.org/10.1074/jbc.M407749200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548542	hybrid			2022-12-25	WOS:000226449100037
J	Harris, CL; Abbott, RJM; Smith, RA; Morgan, BP; Lea, SM				Harris, CL; Abbott, RJM; Smith, RA; Morgan, BP; Lea, SM			Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-B; CONFORMATIONAL-CHANGES; FACTOR-H; A DOMAIN; H-1-NMR SPECTROSCOPY; C-3 CONVERTASES; BINDING-SITES; C3 CONVERTASE; 3RD COMPONENT; COBRA VENOM	The complement regulatory protein decay accelerating factor (DAF; CD55), inhibits the alternative complement pathway by accelerating decay of the convertase enzymes formed by C3b and factor B. We show, using surface plasmon resonance, that in the absence of Mg2+, DAF binds C3b, factor B, and the Bb subunit with low affinity (K-D, 14 +/- 0.1, 44 +/- 10, and 20 +/- 7 muM, respectively). In the presence of Mg2+, DAF bound Bb or the von Willebrand factor type A subunit of Bb with higher affinities (K-D, 1.3 +/- 0.5 and 2.2 +/- 0.1 muM, respectively). Interaction with the proenzyme C3bB was investigated by flowing factor B across a C3b-coated surface in the absence of factor D. The dissociation rate was dependent on the time of incubation, suggesting that a time-dependent conformational transition stabilized the C3b-factor B interaction. Activation by factor D (forming C3bBb) increased the complex half-life; however, the enzyme became susceptible to rapid decay by DAF, unlike the proenzyme, which was unaffected. A convertase assembled with cobra venom factor and Bb was decayed by DAF, albeit far less efficiently than C3bBb. DAF did not bind cobra venom factor, implying that Bb decay is accelerated, at least in part, through DAF binding of this subunit. It is likely that DAF binds the complex with higher affinity/avidity, promoting a conformational change in either or both subunits accelerating decay. Such analysis of component and regulator interactions will inform our understanding of inhibitory mechanisms and the ways in which regulatory proteins cooperate to control the complement cascade.	Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Complement Biol Grp, Cardiff CF14 4XN, S Glam, Wales; Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Adprotech Ltd, Saffron Walden CB10 1XL, Essex, England	Cardiff University; University of Oxford	Harris, CL (corresponding author), Henry Wellcome Bldg,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	harriscl@cardiff.ac.uk	Lea, Susan M/B-7678-2009	Lea, Susan M/0000-0001-9287-8053; Morgan, Paul/0000-0003-4075-7676; Abbott, Rachel/0000-0003-1902-1429				Anderson KL, 2004, MOL CELL, V15, P647, DOI 10.1016/j.molcel.2004.08.003; Brodbeck WG, 2000, IMMUNOLOGY, V101, P104, DOI 10.1046/j.1365-2567.2000.00086.x; COOPER NR, 1973, J EXP MED, V137, P451, DOI 10.1084/jem.137.2.451; COYNE KE, 1992, J IMMUNOL, V149, P2906; FARRIES TC, 1990, COMPLEMENT INFLAMMAT, V7, P30, DOI 10.1159/000463124; FISHELSON Z, 1984, J IMMUNOL, V132, P1425; FISHELSON Z, 1983, J BIOL CHEM, V258, P7411; FUJITA T, 1987, J EXP MED, V166, P1221, DOI 10.1084/jem.166.5.1221; Harris CL, 2002, J IMMUNOL METHODS, V268, P245, DOI 10.1016/S0022-1759(02)00207-7; HARRISON RA, 1980, MOL IMMUNOL, V17, P9, DOI 10.1016/0161-5890(80)90119-4; HARRISON RA, 1996, WEIRS HDB EXPT IMMUN, V2; Hinshelwood J, 2000, J MOL BIOL, V301, P1267, DOI 10.1006/jmbi.2000.4044; Hinshelwood J, 2000, J MOL BIOL, V298, P135, DOI 10.1006/jmbi.2000.3632; HOLERS VM, 1985, IMMUNOL TODAY, V6, P188, DOI 10.1016/0167-5699(85)90114-8; Hourcade DE, 2002, J BIOL CHEM, V277, P1107, DOI 10.1074/jbc.M109322200; Hourcade DE, 1999, IMMUNOPHARMACOLOGY, V42, P167, DOI 10.1016/S0162-3109(99)00005-3; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1981, MOL IMMUNOL, V18, P331, DOI 10.1016/0161-5890(81)90057-2; Jokiranta TS, 2001, INT IMMUNOPHARMACOL, V1, P495, DOI 10.1016/S1567-5769(00)00042-4; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; KuttnerKondo L, 1996, PROTEIN ENG, V9, P1143, DOI 10.1093/protein/9.12.1143; Lambris JD, 1996, J IMMUNOL, V156, P4821; LAMBRIS JD, 1986, MOL IMMUNOL, V23, P1237, DOI 10.1016/0161-5890(86)90157-4; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; Lea S, 2002, BIOCHEM SOC T, V30, P1014, DOI 10.1042/bst0301014; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Loftus JC, 1997, J CLIN INVEST, V100, pS77; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; Morgan BP., 1999, COMPLEMENT REGULATOR; NICHOLSONWELLER A, 1992, CURR TOP MICROBIOL, V178, P7; NICOL PAE, 1973, IMMUNOLOGY, V24, P259; PANGBURN MK, 1986, J IMMUNOL, V136, P2216; PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; PRYZDIAL ELG, 1987, J BIOL CHEM, V262, P1519; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Tuckwell DS, 1997, BIOCHEMISTRY-US, V36, P6605, DOI 10.1021/bi963155l; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; VOGEL CW, 1982, J BIOL CHEM, V257, P8292; VOGT W, 1977, IMMUNOCHEMISTRY, V14, P201, DOI 10.1016/0019-2791(77)90195-1; Volanakis JE, 1996, PROTEIN SCI, V5, P553; White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604; Williams P, 2003, J BIOL CHEM, V278, P10691, DOI 10.1074/jbc.M212561200; Williams SC, 1999, BIOCHEM J, V342, P625, DOI 10.1042/0264-6021:3420625	46	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2569	2578		10.1074/jbc.M410179200	http://dx.doi.org/10.1074/jbc.M410179200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15536079	hybrid			2022-12-25	WOS:000226449100025
J	Kostenko, EV; Mahon, GM; Cheng, L; Whitehead, IP				Kostenko, EV; Mahon, GM; Cheng, L; Whitehead, IP			The Sec14 homology domain regulates the cellular distribution and transforming activity of the Rho-specific guanine nucleotide exchange factor Dbs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINALDEHYDE-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; EXPRESSION CLONING; FAMILY PROTEINS; ONCOGENIC DBL; CDNA CLONING; PH DOMAIN; ACTIVATION; YEAST; GENE	Dbs is a Rho-specific guanine nucleotide exchange factor that was identified in a screen for proteins whose overexpression cause deregulated growth in murine fibroblasts. Dbs contains multiple recognizable motifs including a centrally located Rho-specific guanine nucleotide exchange factor domain, a COOH-terminal Sre homology 3 domain, two spectrin-like repeats, and a recently identified NH2-terminal Sec14 homology domain. The transforming potential of Dbs is substantially activated by the removal of inhibitory sequences that lie outside of the core catalytic sequences, and in this current study we mapped this inhibition to the Sec14 domain. Surprisingly removal of the NH2 terminus did not alter the catalytic activity of Dbs in vivo but rather altered its subcellular distribution. Whereas full-length Dbs was distributed primarily in a perinuclear structure that coincides with a marker for the Golgi apparatus, removal of the Sec14 domain was associated with translocation of Dbs to the cell periphery where it accumulated within membrane ruffles and lamellipodia. However, translocation of Dbs and the concomitant changes in the actin cytoskeleton were not sufficient to fully activate Dbs transformation. The Sec14 domain also forms intramolecular contacts with the pleckstrin homology domain, and these contacts must also be relieved to achieve full transforming activity. Collectively these observations suggest that the Sec14 domain regulates Dbs transformation through at least two distinct mechanisms, neither of which appears to directly influence the in vivo exchange activity of the protein.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 225 Warren St, Newark, NJ 07103 USA.	whiteip@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA097066] Funding Source: NIH RePORTER; NCI NIH HHS [CA97066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; ARITA M, 1995, BIOCHEM J, V306, P437, DOI 10.1042/bj3060437; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; Cheng L, 2004, J BIOL CHEM, V279, P12786, DOI 10.1074/jbc.M313099200; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CRABB JW, 1988, J BIOL CHEM, V263, P18688; Curtis C, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-10; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Grewal S, 2003, J CELL SCI, V116, P2303, DOI 10.1242/jcs.00446; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; INTRES R, 1994, J BIOL CHEM, V269, P25411; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; Kin Y, 2001, J BIOL CHEM, V276, P39462, DOI 10.1074/jbc.M105484200; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Li XM, 2000, BBA-MOL CELL BIOL L, V1486, P55, DOI 10.1016/S1388-1981(00)00048-2; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Lu MJ, 2004, NAT STRUCT MOL BIOL, V11, P756, DOI 10.1038/nsmb800; Mahon GM, 2003, CURR BIOL, V13, P437, DOI 10.1016/S0960-9822(03)00090-3; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; ORCI L, 1991, CELL, V64, P1183; PASTERIS NG, 1994, CELL, V79, P669; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Qi Y, 2002, J CELL BIOCHEM, V86, P79, DOI 10.1002/jcb.10195; RON D, 1991, NEW BIOL, V3, P372; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; Solski PA, 2004, J BIOL CHEM, V279, P25226, DOI 10.1074/jbc.M313792200; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Ueda S, 2004, CELL SIGNAL, V16, P899, DOI 10.1016/j.cellsig.2004.01.007; VAN AL, 1997, GENE DEV, V11, P2295; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Zhao RX, 2003, J BIOL CHEM, V278, P22609, DOI 10.1074/jbc.M301560200; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001	63	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2807	2817		10.1074/jbc.M411139200	http://dx.doi.org/10.1074/jbc.M411139200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15531584	hybrid			2022-12-25	WOS:000226449100054
J	Burwick, NR; Wahl, ML; Fang, J; Zhong, Z; Moser, TL; Li, B; Capaldi, RA; Kenan, DJ; Pizzo, SV				Burwick, NR; Wahl, ML; Fang, J; Zhong, Z; Moser, TL; Li, B; Capaldi, RA; Kenan, DJ; Pizzo, SV			An inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; OXIDATIVE-PHOSPHORYLATION; PROTEIN; PH; BINDING; FAMILY; 5-TRIPHOSPHATASE; STOICHIOMETRY; F-1-ATPASE; RECEPTORS	Angiostatin binds to endothelial cell (EC) surface F-1-F-0 ATP synthase, leading to inhibition of EC migration and proliferation during tumor angiogenesis. This has led to a search for angiostatin mimetics specific for this enzyme. A naturally occurring protein that binds to the F1 subunit of ATP synthase and blocks ATP hydrolysis in mitochondria is inhibitor of F1 (IF1). The present study explores the effect of IF1 on cell surface ATP synthase. IF1 protein bound to purified F-1 ATP synthase and inhibited F-1-dependent ATP hydrolysis consistent with its reported activity in studies of mitochondria. Although exogenous IF1 did not inhibit ATP production on the surface of EC, it did conserve ATP on the cell surface, particularly at low extracellular pH. IF1 inhibited ATP hydrolysis but not ATP synthesis, in contrast to angiostatin, which inhibited both. In cell-based assays used to model angiogenesis in vitro, IF1 did not inhibit EC differentiation to form tubes and only slightly inhibited cell proliferation compared with angiostatin. From these data, we conclude that inhibition of ATP synthesis is necessary for an anti-angiogenic outcome in cell-based assays. We propose that IF1 is not an angiostatin mimetic, but it can serve a protective role for EC in the tumor microenvironment. This protection may be overridden in a concentration-dependent manner by angiostatin. In support of this hypothesis, we demonstrate that angiostatin blocks IF1 binding to ATP synthase and abolishes its ability to conserve ATP. These data suggest that there is a relationship between the binding sites of IF1 and angiostatin on ATP synthase and that IF1 could be employed to modulate angiogenesis.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27514 USA; Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27514 USA; Univ N Carolina, Dept Immunol, Chapel Hill, NC 27514 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Biol, Eugene, OR 97403 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Oregon; University of Oregon	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	Pizzo001@mc.duke.edu		Havener, Tammy/0000-0002-4613-0498	NCI NIH HHS [CA86344, CA-56690, R01 CA086344, P01 CA056690] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086344, P01CA056690] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; Arakaki N, 2003, MOL CANCER RES, V1, P931; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Cabezon E, 2001, EMBO J, V20, P6990, DOI 10.1093/emboj/20.24.6990; CASSEL D, 1988, J BIOL CHEM, V263, P6122; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; FOLKMAN J, 1986, CANCER RES, V46, P467; GONZALEZGRONOW M, 1994, J BIOL CHEM, V269, P4360; Graven KK, 1997, KIDNEY INT, V51, P426, DOI 10.1038/ki.1997.57; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS DA, 1979, BIOCHIM BIOPHYS ACTA, V548, P72, DOI 10.1016/0005-2728(79)90188-9; HASHIMOTO T, 1981, J BIOCHEM-TOKYO, V90, P1151, DOI 10.1093/oxfordjournals.jbchem.a133567; HORSTMAN LL, 1970, J BIOL CHEM, V245, P1336; JACKSON PJ, 1988, FEBS LETT, V229, P224, DOI 10.1016/0014-5793(88)80832-9; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; Li SG, 1996, BIOCHEM MOL BIOL INT, V40, P479; LIPPE G, 1988, BIOCHIM BIOPHYS ACTA, V933, P12, DOI 10.1016/0005-2728(88)90051-5; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 2002, THROMB HAEMOSTASIS, V87, P394; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PANCHENKO MV, 1985, FEBS LETT, V184, P226, DOI 10.1016/0014-5793(85)80611-6; PARIS S, 1983, J BIOL CHEM, V258, P3503; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Ralevic V, 1998, PHARMACOL REV, V50, P413; REINERTSEN KV, 1988, J BIOL CHEM, V263, P11117; ROUSLIN W, 1983, J BIOL CHEM, V258, P9657; ROUSLIN W, 1987, J BIOL CHEM, V262, P3472; ROUSLIN W, 1989, J BIOL CHEM, V264, P15224; SCHWERZMANN K, 1981, ARCH BIOCHEM BIOPHYS, V250, P1; Staerman F, 2000, ADV EXP MED BIOL, V486, P189; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; TSE CM, 1994, CELL PHYSIOL BIOCHEM, V4, P282, DOI 10.1159/000154731; Wahl ML, 2000, GEN PHARMACOL-VASC S, V35, P277, DOI 10.1016/S0306-3623(01)00115-X; Wahl ML, 2002, ENDOTHELIUM-J ENDOTH, V9, P205, DOI 10.1080/10623320213633; WAHL ML, 2001, P AM ASS CANC RES, V59; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920; Yamagata M, 1996, BRIT J CANCER, V73, P1328, DOI 10.1038/bjc.1996.254; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zheng JB, 1999, BIOCHEM BIOPH RES CO, V261, P499, DOI 10.1006/bbrc.1999.1063	48	67	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1740	1745		10.1074/jbc.M405947200	http://dx.doi.org/10.1074/jbc.M405947200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15528193	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000226341700006
J	Hess, JF; Budamagunta, MS; FitzGerald, PG; Voss, JC				Hess, JF; Budamagunta, MS; FitzGerald, PG; Voss, JC			Characterization of structural changes in vimentin bearing an epidermolysis bullosa simplex-like mutation using site-directed spin labeling and electron paramagnetic resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATIN INTERMEDIATE-FILAMENTS; MEESMANNS CORNEAL-DYSTROPHY; PREDICTING COILED COILS; ROD DOMAIN; ALEXANDER-DISEASE; POINT MUTATIONS; SKIN DISEASES; GENETIC-BASIS; IN-VITRO; PROTEIN	Mutations in intermediate filament protein genes are responsible for a number of inherited genetic diseases including skin blistering diseases, corneal opacities, and neurological degenerations. Mutation of the arginine (Arg) residue of the highly conserved LNDR motif has been shown to be causative in inherited disorders in at least four different intermediate filament ( IF) proteins found in skin, cornea, and the central nervous system. Thus this residue appears to be broadly important to IF assembly and/or function. While the genetic basis for these diseases has been clearly defined, the inability to determine crystal structure for IFs has precluded a determination of how these mutations affect assembly/structure/function of IFs. To investigate the impact of mutation at this site in IFs, we have mutated the LNDR to LNDS in vimentin, a Type III intermediate filament protein, and have examined the impact of this change on assembly using electron paramagnetic resonance. Compared with wild type vimentin, the mutant shows normal formation of the coiled coil dimer, with a slight reduction in the stability of the dimer in rod domain 1. Probing the dimer-dimer interactions shows the formation of normal dimer centered on residue 191 but a failure of dimerization at residue 348 in rod domain 2. These data point toward a specific stage of assembly at which a common disease-causing mutation in IF proteins interrupts assembly.	Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	FitzGerald, PG (corresponding author), Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA.	pgfitzgerald@ucdavis.edu	Budamagunta, Madhu S/C-4628-2011	Voss, John/0000-0001-9279-209X	NEI NIH HHS [R01 EY015560-02, R01 EY015560, R01 EY008747, R01 NEI EY08747] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015560, R01EY008747] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; Banwell BL, 1999, J NEUROPATH EXP NEUR, V58, P832, DOI 10.1097/00005072-199908000-00006; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; CHAN YM, 1993, P NATL ACAD SCI USA, V90, P7414, DOI 10.1073/pnas.90.15.7414; CHAN YM, 1994, GENE DEV, V8, P2574, DOI 10.1101/gad.8.21.2574; CHEN H, 1995, J INVEST DERMATOL, V105, P629, DOI 10.1111/1523-1747.ep12323846; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; Coleman CM, 1999, AM J OPHTHALMOL, V128, P687, DOI 10.1016/S0002-9394(99)00317-7; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Corden LD, 1998, HUM MUTAT, V11, P279, DOI 10.1002/(SICI)1098-1004(1998)11:4<279::AID-HUMU5>3.0.CO;2-E; Corden LD, 2000, BRIT J OPHTHALMOL, V84, P527, DOI 10.1136/bjo.84.5.527; COULOMBE PA, 1993, SEMIN DERMATOL, V12, P173; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FUCHS E, 1994, J CELL BIOL, V125, P511, DOI 10.1083/jcb.125.3.511; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1991, BIOCHEM SOC T, V19, P1112, DOI 10.1042/bst0191112; Gupta S K, 1999, Curr Opin Ophthalmol, V10, P234, DOI 10.1097/00055735-199908000-00003; Herrmann H, 2002, J STRUCT BIOL, V137, P82, DOI 10.1006/jsbi.2002.4466; Hess JF, 2004, J BIOL CHEM, V279, P44841, DOI 10.1074/jbc.M406257200; Hess JF, 1996, J BIOL CHEM, V271, P6729, DOI 10.1074/jbc.271.12.6729; HESS JF, 1993, CURR EYE RES, V12, P77, DOI 10.3109/02713689308999499; Hess JF, 2002, J BIOL CHEM, V277, P35516, DOI 10.1074/jbc.M206500200; Irvine AD, 1997, NAT GENET, V16, P184, DOI 10.1038/ng0697-184; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LEIGH IM, 1993, ARCH DERMATOL, V129, P1571, DOI 10.1001/archderm.129.12.1571; LETAI A, 1993, P NATL ACAD SCI USA, V90, P3197, DOI 10.1073/pnas.90.8.3197; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Ma LL, 2001, NAT CELL BIOL, V3, P503, DOI 10.1038/35074576; McLean WHI, 1996, GENE DEV, V10, P1724, DOI 10.1101/gad.10.14.1724; Mehrani T, 2001, J BIOL CHEM, V276, P2088, DOI 10.1074/jbc.M007260200; Nishida K, 1997, AM J HUM GENET, V61, P1268, DOI 10.1086/301650; Rodriguez D, 2001, AM J HUM GENET, V69, P1134, DOI 10.1086/323799; RUGG EL, 1993, NAT GENET, V5, P294, DOI 10.1038/ng1193-294; Shemanko CS, 1998, J INVEST DERMATOL, V111, P893, DOI 10.1046/j.1523-1747.1998.00388.x; Smith TA, 2004, PROTEINS, V55, P1043, DOI 10.1002/prot.20089; Strelkov SV, 2002, EMBO J, V21, P1255, DOI 10.1093/emboj/21.6.1255; Strelkov SV, 2001, J MOL BIOL, V306, P773, DOI 10.1006/jmbi.2001.4442; SYDER AJ, 1994, J CLIN INVEST, V93, P1533, DOI 10.1172/JCI117132; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Wawersik M, 1997, J BIOL CHEM, V272, P32557, DOI 10.1074/jbc.272.51.32557; Wu KC, 2000, MOL BIOL CELL, V11, P3539, DOI 10.1091/mbc.11.10.3539	44	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2141	2146		10.1074/jbc.M412254200	http://dx.doi.org/10.1074/jbc.M412254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15556930	Green Accepted, hybrid			2022-12-25	WOS:000226341700049
J	Laugel, B; Boulter, JM; Lissin, N; Vuidepot, A; Li, Y; Gostick, E; Crotty, LE; Douek, DC; Hemelaar, J; Price, DA; Jakobsen, BK; Sewell, AK				Laugel, B; Boulter, JM; Lissin, N; Vuidepot, A; Li, Y; Gostick, E; Crotty, LE; Douek, DC; Hemelaar, J; Price, DA; Jakobsen, BK; Sewell, AK			Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCR CROSS-REACTIVITY; MONOCLONAL-ANTIBODIES; LIGAND RECOGNITION; HIGH-AFFINITY; IN-VIVO; NEUROLOGICAL DISEASE; STRUCTURAL FEATURES; PHENOTYPIC ANALYSIS; MULTIPLE-SCLEROSIS; MOLECULAR MIMICRY	The use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered by the naturally low affinity of TCR interactions with peptide major histocompatibility complex ligands. Here, we use multimeric forms of soluble heterodimeric alphabeta TCRs for specific detection of target cells pulsed with cognate peptide, discrimination of quantitative changes in antigen display at the cell surface, identification of virus-infected cells, inhibition of antigen-specific cytotoxic T lymphocyte activation, and identification of cross-reactive peptides. Notably, the A6 TCR specific for the immunodominant HLA A2-restricted human T cell leukemia virus type 1 Tax(11-19) epitope bound to HLA A2-HuD(87-95) (K-D 120 muM by surface plasmon resonance), an epitope implicated as a causal antigen in the paraneoplastic neurological degenerative disorder anti-Hu syndrome. A mutant A6 TCR that exhibited dramatically increased affinity for cognate antigen (K-D 2.5 nM) without enhanced cross-reactivity was generated; this TCR demonstrated potent biological activity even as a monomeric molecule. These data provide insights into TCR repertoire selection and delineate a framework for the selective modification of TCRs in vitro that could enable specific therapeutic intervention in vivo.	Univ Oxford, T Cell Modulat Grp, Peter Medawar Bldg Pathogen Res, Oxford OX1 3SY, England; Univ Wales Coll Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales; Avidex Ltd, Abingdon OX14 4RX, Oxon, England; NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Oxford Magdalen Coll, Oxford OX1 4AU, England	University of Oxford; Cardiff University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Oxford	Sewell, AK (corresponding author), Univ Oxford, T Cell Modulat Grp, Peter Medawar Bldg Pathogen Res, S Parks Rd, Oxford OX1 3SY, England.	andy.sewell@ndm.ox.ac.uk	Alexander, Laura Crotty/AIC-1001-2022; Sewell, Andrew/GPT-4220-2022; Price, David A/C-7876-2013	Alexander, Laura Crotty/0000-0002-5091-2660; Sewell, Andrew/0000-0003-3194-3135; Price, David A/0000-0001-9416-2737; Hemelaar, Joris/0000-0003-3523-7457	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005033, Z01AI005031, ZIAAI005033, ZIAAI005031, Z01AI005066, ZIAAI005066] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARONI R, 1991, NATURE, V351, P147, DOI 10.1038/351147a0; Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Albert ML, 2004, NAT REV CANCER, V4, P36, DOI 10.1038/nrc1255; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; Biddison WE, 2003, J IMMUNOL, V171, P3064, DOI 10.4049/jimmunol.171.6.3064; Boulter JM, 2003, PROTEIN ENG, V16, P707, DOI 10.1093/protein/gzg087; Chung DH, 2001, J IMMUNOL, V167, P699, DOI 10.4049/jimmunol.167.2.699; Cohen CJ, 2003, J IMMUNOL, V170, P4349, DOI 10.4049/jimmunol.170.8.4349; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Crawford F, 2004, PLOS BIOL, V2, P523, DOI 10.1371/journal.pbio.0020090; Cull MG, 2000, METHOD ENZYMOL, V326, P430; Dadaglio G, 1997, IMMUNITY, V6, P727, DOI 10.1016/S1074-7613(00)80448-3; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Eastman S, 1996, EUR J IMMUNOL, V26, P385, DOI 10.1002/eji.1830260218; ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HAGERTY DT, 1995, J IMMUNOL, V155, P2993; Hausmann S, 1999, J IMMUNOL, V162, P5389; Hemmer B, 1998, IMMUNOL TODAY, V19, P163, DOI 10.1016/S0167-5699(97)01217-6; HENGEL H, 1994, J VIROL, V68, P289, DOI 10.1128/JVI.68.1.289-297.1994; Hiemstra HS, 2001, P NATL ACAD SCI USA, V98, P3988, DOI 10.1073/pnas.071050898; Hiemstra HS, 1999, EUR J IMMUNOL, V29, P2385, DOI 10.1002/(SICI)1521-4141(199908)29:08<2385::AID-IMMU2385>3.0.CO;2-B; Holler PD, 2000, P NATL ACAD SCI USA, V97, P5387, DOI 10.1073/pnas.080078297; Holler PD, 2004, MOL IMMUNOL, V40, P1027, DOI 10.1016/j.molimm.2003.11.013; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; Konig R, 2002, CURR OPIN IMMUNOL, V14, P75, DOI 10.1016/S0952-7915(01)00300-4; Lake DF, 1999, INT IMMUNOL, V11, P745, DOI 10.1093/intimm/11.5.745; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; LEHNER PJ, 1995, J EXP MED, V181, P79, DOI 10.1084/jem.181.1.79; Lev A, 2004, P NATL ACAD SCI USA, V101, P9051, DOI 10.1073/pnas.0403222101; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; McMichael AJ, 1998, J EXP MED, V187, P1367, DOI 10.1084/jem.187.9.1367; Messaoudi I, 1999, J IMMUNOL, V163, P3286; Morkowski S, 1997, EUR J IMMUNOL, V27, P609, DOI 10.1002/eji.1830270306; MURPHY DB, 1992, J IMMUNOL, V148, P3483; OHerrin SM, 1997, J EXP MED, V186, P1333, DOI 10.1084/jem.186.8.1333; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; Plaksin D, 1997, J IMMUNOL, V158, P2218; Plonquet A, 2003, J NEUROIMMUNOL, V142, P93, DOI 10.1016/S0165-5728(03)00269-8; Polakova K, 2000, J IMMUNOL, V165, P5703, DOI 10.4049/jimmunol.165.10.5703; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Puri J, 1997, J IMMUNOL, V158, P2471; QUARATINO S, 1995, P NATL ACAD SCI USA, V92, P10398, DOI 10.1073/pnas.92.22.10398; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; Reiser JB, 2003, NAT IMMUNOL, V4, P241, DOI 10.1038/ni891; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; Schodin BA, 1996, IMMUNITY, V5, P137, DOI 10.1016/S1074-7613(00)80490-2; Sewell AK, 1997, EUR J IMMUNOL, V27, P2323, DOI 10.1002/eji.1830270929; Shields MJ, 1998, J BIOL CHEM, V273, P28010, DOI 10.1074/jbc.273.43.28010; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; UTZ U, 1992, J IMMUNOL, V149, P214; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; Willcox BE, 1999, PROTEIN SCI, V8, P2418; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Yewdell JW, 2001, TRENDS CELL BIOL, V11, P294, DOI 10.1016/S0962-8924(01)02030-X; Zhong GM, 1997, P NATL ACAD SCI USA, V94, P13856, DOI 10.1073/pnas.94.25.13856	70	65	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1882	1892		10.1074/jbc.M409427200	http://dx.doi.org/10.1074/jbc.M409427200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15531581	hybrid			2022-12-25	WOS:000226341700022
J	Liu, F; Iqbal, K; Grundke-Iqbal, I; Rossie, S; Gong, CX				Liu, F; Iqbal, K; Grundke-Iqbal, I; Rossie, S; Gong, CX			Dephosphorylation of tau by protein phosphatase 5 - Impairment in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; ABNORMALLY PHOSPHORYLATED-TAU; ABERRANT GLYCOSYLATION; MICROTUBULE-BINDING; TRANSGENIC MICE; BRAIN; HYPERPHOSPHORYLATION; IDENTIFICATION; CALCINEURIN	Protein phosphatase ( PP) 5 is highly expressed in the mammalian brain, but few physiological substrates have yet been identified. Here, we investigated the kinetics of dephosphoryation of phospho-tau by PP5 and found that PP5 had a K-m of 8-13 muM toward tau, which is similar to that of PP2A, the major known tau phosphatase. This K-m value is within the range of intraneuronal tau concentration in human brain, suggesting that tau could be a physiological substrate of both PP5 and PP2A. PP5 dephosphorylated tau at all 12 Alzheimer's disease (AD)-associated abnormal phosphorylation sites studied, with different efficiency toward each site. Thr(205), Thr(212), and Ser(409) of tau were the most favorable sites; Ser(199), Ser(202), Ser(214), Ser(396), and Ser(404) were less favorable sites; and Ser(262) was the poorest site for PP5. Overexpression of PP5 in PC12 cells resulted in dephosphorylation of tau at multiple phosphorylation sites. The activity but not the protein level of PP5 was found to be decreased by similar to20% in AD neocortex. These results suggest that tau is probably a physiological substrate of PP5 and that the abnormal hyperphosphorylation of tau in AD might result in part from the decreased PP5 activity in the diseased brains.	New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Institute for Basic Research in Developmental Disabilities; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Gong, CX (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	cxgong@ultinet.net			NIA NIH HHS [AG16760, AG19157] Funding Source: Medline; NINDS NIH HHS [NS31221] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS031221, R01NS031221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016760] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonso AD, 2001, J BIOL CHEM, V276, P37967; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; Bahl R, 2001, MOL BRAIN RES, V90, P101, DOI 10.1016/S0169-328X(01)00089-4; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; Becker W, 1996, MOL BRAIN RES, V36, P23, DOI 10.1016/0169-328X(95)00233-I; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; Gong CX, 2004, J NEUROCHEM, V88, P298, DOI 10.1046/j.1471-4159.2003.02147.x; GONG CX, 1994, NEUROSCIENCE, V61, P765, DOI 10.1016/0306-4522(94)90400-6; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; Gong CX, 1996, BRAIN RES, V741, P95, DOI 10.1016/S0006-8993(96)00904-3; GONG CX, 1994, FEBS LETT, V341, P94, DOI 10.1016/0014-5793(94)80247-5; GONG CX, 1994, J NEUROCHEM, V62, P803; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GONG CX, 2005, IN PRESS J NEURAL TR; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; IQBAL K, 1986, LANCET, V2, P421; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; Jeong JY, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-3; KENESSEY A, 1993, BRAIN RES, V629, P40, DOI 10.1016/0006-8993(93)90478-6; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; Kins S, 2001, J BIOL CHEM, V276, P38193; KOPKE E, 1993, J BIOL CHEM, V268, P24374; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Liu F, 2002, NEUROSCIENCE, V115, P829, DOI 10.1016/S0306-4522(02)00510-9; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; Loring JF, 2001, DNA CELL BIOL, V20, P683, DOI 10.1089/10445490152717541; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pei JJ, 1998, J NEURAL TRANSM, V105, P69, DOI 10.1007/s007020050039; Ramsey AJ, 2002, BIOCHEMISTRY-US, V41, P5625, DOI 10.1021/bi016090h; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P287, DOI 10.1093/jnen/63.4.287; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Vogelsberg-Ragaglia V, 2001, EXP NEUROL, V168, P402, DOI 10.1006/exnr.2001.7630; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; YAMAMOTO H, 1988, J NEUROCHEM, V50, P1614, DOI 10.1111/j.1471-4159.1988.tb03051.x	57	175	186	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1790	1796		10.1074/jbc.M410775200	http://dx.doi.org/10.1074/jbc.M410775200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15546861	hybrid			2022-12-25	WOS:000226341700012
J	Nevins, AK; Thurmond, DC				Nevins, AK; Thurmond, DC			A direct interaction between Cdc42 and vesicle-associated membrane protein 2 regulates SNARE-dependent insulin exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ENDOCRINE-CELLS; NUCLEOTIDE EXCHANGE FACTOR; FACTOR ATTACHMENT PROTEIN; GTP-BINDING PROTEINS; MEMBRANE-FUSION; BETA-CELLS; GLUT4 TRANSLOCATION; DYNAMIC INTERPLAY; PLASMA-MEMBRANE; O-GLYCOSYLATION	In pancreatic beta cells, insulin granule exocytosis is regulated by SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein ( SNAP) receptor) proteins, and this is coupled to cortical F-actin reorganization via the Rho family GTPase Cdc42 by an unknown mechanism. We investigated interactions among the target SNARE protein Syntaxin 1A and the vesicle-associated membrane SNARE protein (VAMP2) with Cdc42 and compared these structural interactions with their functional importance to glucose-stimulated insulin secretion in MIN6 beta cells. Subcellular fractionation analyses revealed a parallel redistribution of Cdc42 and VAMP2 from the granule fraction to the plasma membrane in response to glucose that temporally corresponded with the glucose-induced activation of Cdc42. Moreover, within these fractions Cdc42 and VAMP2 were found to co-immunoprecipitate under basal and glucose-stimulated conditions, suggesting that they moved as a complex. Furthermore, VAMP2 bound both GST-Cdc42-GTPgammaS and GST-Cdc42-GDP, indicating that the Cdc42-VAMP2 complex could form under both cytosolic GDP-bound Cdc42 and plasma membrane GTP-bound Cdc42 conformational conditions. In vitro binding analyses showed that VAMP2 bound directly to Cdc42 and that a heterotrimeric complex with Syntaxin 1A could also be formed. Deletion analyses of VAMP2 revealed that only the N-terminal 28 residues were required for Cdc42 binding. Expression of this 28-residue VAMP2 peptide in MIN6 beta cells resulted in the specific impairment of glucose-stimulated insulin secretion, indicating a functional importance for the Cdc42-VAMP2 interaction. Taken together, these data suggest a mechanism whereby glucose activates Cdc42 to induce the targeting of intracellular Cdc42-VAMP2-insulin granule complexes to Syntaxin 1A at the plasma membrane.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Thurmond, DC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	dthurmon@iupui.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK064466] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK064466-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Daniel S, 2002, BIOCHEMISTRY-US, V41, P9663, DOI 10.1021/bi025604p; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; HUBBARD AL, 1983, J CELL BIOL, V96, P230, DOI 10.1083/jcb.96.1.230; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; KiralyBorri CE, 1996, BIOCHEM J, V314, P199, DOI 10.1042/bj3140199; Kowluru A, 1996, BIOCHEM J, V313, P97, DOI 10.1042/bj3130097; Kowluru A, 1996, J CLIN INVEST, V98, P540, DOI 10.1172/JCI118822; KOWLURU A, 1994, BBA-MOL CELL RES, V1222, P360, DOI 10.1016/0167-4889(94)90041-8; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lang JC, 1997, FEBS LETT, V419, P13, DOI 10.1016/S0014-5793(97)01411-7; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; LI GD, 1994, MOL BIOL CELL, V5, P1199, DOI 10.1091/mbc.5.11.1199; Li GD, 1996, BIOCHEM J, V316, P345, DOI 10.1042/bj3160345; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Meller N, 2004, J BIOL CHEM, V279, P37470, DOI 10.1074/jbc.M404535200; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Mitchell KJ, 2004, DIABETES, V53, P393, DOI 10.2337/diabetes.53.2.393; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; Nevins AK, 2003, AM J PHYSIOL-CELL PH, V285, pC698, DOI 10.1152/ajpcell.00093.2003; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Pennuto M, 2003, MOL BIOL CELL, V14, P4909, DOI 10.1091/mbc.E03-06-0380; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; Rhodes CJ., 2000, DIABETES MELLITUS FU, P20; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Saito T, 2003, J BIOL CHEM, V278, P36718, DOI 10.1074/jbc.M305114200; SATIN LS, 1985, PFLUG ARCH EUR J PHY, V404, P385, DOI 10.1007/BF00585354; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOMERS G, 1979, ENDOCRINOLOGY, V104, P255, DOI 10.1210/endo-104-1-255; Thurmond DC, 2003, MOL ENDOCRINOL, V17, P732, DOI 10.1210/me.2002-0333; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Wasmeier C, 1999, BIOCHEM J, V341, P563, DOI 10.1042/0264-6021:3410563; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Wilson JR, 2001, FEBS LETT, V492, P101, DOI 10.1016/S0014-5793(01)02241-4; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	62	80	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1944	1952		10.1074/jbc.M409528200	http://dx.doi.org/10.1074/jbc.M409528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537656	hybrid			2022-12-25	WOS:000226341700028
J	Sundberg-Smith, LJ; Doherty, JT; Mack, CP; Taylor, JM				Sundberg-Smith, LJ; Doherty, JT; Mack, CP; Taylor, JM			Adhesion stimulates direct PAK1/ERK2 association and leads to ERK-dependent PAK1 Thr(212) phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; NUCLEOTIDE-EXCHANGE FACTOR; CROSS-CASCADE ACTIVATION; SMOOTH-MUSCLE-CELLS; P21-ACTIVATED KINASE; RHO GTPASES; NUCLEOCYTOPLASMIC DISTRIBUTION; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOGENOUS INHIBITOR	The Rac1/Cdc42 effector p21-activated kinase (PAK) is activated by various signaling cascades including receptor-tyrosine kinases and integrins and regulates a number of processes such as cell proliferation and motility. PAK activity has been shown to be required for maximal activation of the canonical Ras/Raf/MEK/ERK Map kinase signaling cascade, likely because of PAK co-activation of Raf and MEK. Herein, we found that adhesion signaling also stimulates an association between PAK1 and ERK1/2. PAK1 and ERK1/2 co-immunoprecipitated from rat aortic smooth muscle cells (SMC) plated on fibronectin, and the two proteins colocalized in membrane ruffles and adhesion complexes following PDGF-BB or sphingosine 1-phosphate treatment, respectively. Far Western analysis demonstrated a direct association between the two proteins, and peptide mapping identified an ERK2 binding site within the autoinhibitory domain of PAK1. Interestingly, deletion of a major ERK binding site in PAK attenuates activation of an ERK-dependent serum-responsive element (SRE)-luciferase reporter gene, indicating that association between PAK and ERK is required to facilitate ERK signaling. We also show that ERK2 phosphorylates PAK1 on Thr(212) in vitro and that Thr(212) is phosphorylated in smooth muscle cells following PDGF-BB treatment in an adhesion- and MEK/ERK-dependent fashion. Expression of a phosphomimic variant, PAK-T212E, does not alter ERK association, but markedly attenuates downstream ERK signaling. Taken together, these data suggest that PAK1 may facilitate ERK signaling by serving as a scaffold to recruit Raf, MEK, and ERK to adhesion complexes, and that subsequent growth factor-stimulated phosphorylation of PAK-Thr(212) by ERK may serve to provide a negative feedback signal to control coordinate activation of ERK by growth factor- and matrix-induced signals.	Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Taylor, JM (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, 420 Brinkhous Bullitt Blvd CB 7525, Chapel Hill, NC 27599 USA.	jmt3x@med.unc.edu		Taylor, Joan/0000-0002-8794-5167	NHLBI NIH HHS [T32 HL-69768, R01 HL071054, R01 HL081844, R01 HL-071054] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071054, R01HL081844, T32HL069768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aplin AE, 2002, J CELL SCI, V115, P2781; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BOKOCH GM, 2003, ANNU REV BIOCHEM, V27, P27; Brennan JA, 2002, J BIOL CHEM, V277, P5369, DOI 10.1074/jbc.M109875200; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; CLOWES AW, 1983, LAB INVEST, V49, P327; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Elion EA, 2001, J CELL SCI, V114, P3967; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Howe AK, 2001, J BIOL CHEM, V276, P14541, DOI 10.1074/jbc.C000797200; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mayer G, 2001, P NATL ACAD SCI USA, V98, P4961, DOI 10.1073/pnas.091100698; Miao H, 2002, J CELL SCI, V115, P2199; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; Raska CS, 2003, J AM SOC MASS SPECTR, V14, P1076, DOI 10.1016/S1044-0305(03)00405-7; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zhong JL, 2003, DEV DYNAM, V228, P121, DOI 10.1002/dvdy.10351	57	49	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2055	2064		10.1074/jbc.M406013200	http://dx.doi.org/10.1074/jbc.M406013200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542607	Green Published, hybrid			2022-12-25	WOS:000226341700040
J	Fujii, M; York, JD				Fujii, M; York, JD			A role for rat inositol polyphosphate kinases rIPK2 and rIPK1 in inositol pentakisphosphate and inositol hexakisphosphate production in rat-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; ASSEMBLY IN-VITRO; V-SRC ONCOGENE; 1,3,4-TRISPHOSPHATE 5/6-KINASE; PHOSPHATE MULTIKINASE; HYPOOSMOTIC STRESS; MAMMALIAN-CELLS; HUMAN HOMOLOG; DNA-PK; BINDING	Over 30 inositol polyphosphates are known to exist in mammalian cells; however, the majority of them have uncharacterized functions. In this study we investigated the molecular basis of synthesis of highly phosphorylated inositol polyphosphates (such as inositol tetrakisphosphate, inositol pentakisphosphate (IP5), and inositol hexakisphosphate (IP6)) in rat cells. We report that heterologous expression of rat inositol polyphosphate kinases rIPK2, a dual specificity inositol trisphosphate/ inositol tetrakisphosphate kinase, and rIPK1, an IP5 2-kinase, were sufficient to recapitulate IP6 synthesis from inositol 1,4,5-trisphosphate in mutant yeast cells. Overexpression of rIPK2 in Rat-1 cells increased inositol 1,3,4,5,6-pentakisphosphate (I(1,3,4,5,6)P-5) levels about 2-3-fold compared with control. Likewise in Rat-1 cells, overexpression of rIPK1 was capable of completely converting I(1,3,4,5,6)P-5 to IP6. Simultaneous overexpression of both rIPK2 and rIPK1 in Rat-1 cells increased both IP5 and IP6 levels. To reduce IPK2 activity in Rat-1 cells, we introduced vector-based short interference RNA against rIPK2. Cells harboring the short interference RNA had a 90% reduction of mRNA levels and a 75% decrease of I(1,3,4,5,6)P-5. These data confirm the involvement of IPK2 and IPK1 in the conversion of inositol 1,4,5-trisphosphate to IP6 in rat cells. Furthermore these data suggest that rIPK2 and rIPK1 act as key determining steps in production of IP5 and IP6, respectively. The ability to modulate the intracellular inositol polyphosphate levels by altering IPK2 and IPK1 expression in rat cells will provide powerful tools to study the roles of I(1,3,4,5,6)P-5 and IP6 in cell signaling.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	York, JD (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.	yorkj@duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55672] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campbell S, 2001, P NATL ACAD SCI USA, V98, P10875, DOI 10.1073/pnas.191224698; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Chi HB, 2000, MOL CELL BIOL, V20, P6496, DOI 10.1128/MCB.20.17.6496-6507.2000; El Alami M, 2003, MOL MICROBIOL, V49, P457, DOI 10.1046/j.1365-2958.2003.03562.x; Fujii M, 1999, BIOCHEM BIOPH RES CO, V254, P284, DOI 10.1006/bbrc.1998.9936; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Ho MWY, 2002, CURR BIOL, V12, P477, DOI 10.1016/S0960-9822(02)00713-3; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; Jun KS, 1998, LEARN MEMORY, V5, P317; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Orchiston EA, 2004, J BIOL CHEM, V279, P1116, DOI 10.1074/jbc.M310933200; Perera NM, 2004, J BIOL CHEM, V279, P5216, DOI 10.1074/jbc.M305068200; Pouillon V, 2003, NAT IMMUNOL, V4, P1136, DOI 10.1038/ni980; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Stevenson-Paulik J, 2002, J BIOL CHEM, V277, P42711, DOI 10.1074/jbc.M209112200; Sun Y, 2002, J BIOL CHEM, V277, P45759, DOI 10.1074/jbc.M208709200; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wen BG, 2004, P NATL ACAD SCI USA, V101, P5604, DOI 10.1073/pnas.0306907101; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Woodring PJ, 1996, BIOCHEM J, V319, P73, DOI 10.1042/bj3190073; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X	51	42	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1156	1164		10.1074/jbc.M412006200	http://dx.doi.org/10.1074/jbc.M412006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528195	hybrid			2022-12-25	WOS:000226195200037
J	Gimelbrant, AA; Ensminger, AW; Qi, PM; Zucker, J; Chess, A				Gimelbrant, AA; Ensminger, AW; Qi, PM; Zucker, J; Chess, A			Monoallelic expression and asynchronous replication of p120 catenin in mouse and human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; ALLELIC EXCLUSION; EPITHELIAL-CELLS; GENE-EXPRESSION; HUMAN CANCER; CHROMOSOMES; ISOFORMS; INTERLEUKIN-2; INACTIVATION; ADHESION	The number of autosomal mammalian genes subject to random monoallelic expression has been limited to genes highly specific to the function of chemosensory neurons or lymphocytes, making this phenomenon difficult to address systematically. Here we demonstrate that asynchronous DNA replication can be used as a marker for the identification of novel genes with monoallelic expression and identify p120 catenin, a gene involved in cell adhesion, as belonging to this class. p120 is widely expressed; its presence in available cell lines allowed us to address quantitative aspects of monoallelic expression. We show that the epigenetic choice of active allele is clonally stable and that biallelic clones express p120 at twice the level of monoallelic clones. Unlike previous reports about genes of this type, we found that expression of p120 can be monoallelic in one cell type and strictly biallelic in another. We show that in human lymphoblasts, the silencing of one allele is incomplete. These unexpected properties are likely to be widespread, as we show that the Tlr4 gene shares them. Identification of monoallelic expression of a nearly ubiquitous gene indicates that this type of gene regulation is more common than previously thought. This has important implications for carcinogenesis and definition of cell identity.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Chess, A (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	chess@wi.mit.edu		Gimelbrant, Alexander/0000-0001-6986-0285; Ensminger, Alexander/0000-0003-0824-3704				Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Buetow KH, 2001, P NATL ACAD SCI USA, V98, P581, DOI 10.1073/pnas.021506298; Carrel L, 1999, P NATL ACAD SCI USA, V96, P7364, DOI 10.1073/pnas.96.13.7364; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Ensminger AW, 2004, HUM MOL GENET, V13, P651, DOI 10.1093/hmg/ddh062; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LATT SA, 1973, P NATL ACAD SCI USA, V70, P3395, DOI 10.1073/pnas.70.12.3395; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; LYON MF, 1986, NATURE, V320, P313, DOI 10.1038/320313b0; Mayerle J, 2003, GASTROENTEROLOGY, V124, P949, DOI 10.1053/gast.2003.50142; Mo YY, 1996, CANCER RES, V56, P2633; Montonen O, 2001, J HISTOCHEM CYTOCHEM, V49, P1487, DOI 10.1177/002215540104901202; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Ohlsson R, 1998, TRENDS GENET, V14, P435, DOI 10.1016/S0168-9525(98)01583-2; Ohlsson R, 2003, ADV CANCER RES, V88, P145, DOI 10.1016/S0065-230X(03)88306-9; Pereira JP, 2003, NAT IMMUNOL, V4, P464, DOI 10.1038/ni917; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rhoades KL, 2000, CURR BIOL, V10, P789, DOI 10.1016/S0960-9822(00)00565-0; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; Ross P, 2000, BIOTECHNIQUES, V29, P620, DOI 10.2144/00293rr05; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Singh N, 2003, NAT GENET, V33, P339, DOI 10.1038/ng1102; Tang K, 1999, P NATL ACAD SCI USA, V96, P10016, DOI 10.1073/pnas.96.18.10016; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Xiong ZG, 1998, NUCLEIC ACIDS RES, V26, P684, DOI 10.1093/nar/26.2.684	35	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1354	1359		10.1074/jbc.M411283200	http://dx.doi.org/10.1074/jbc.M411283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522875	hybrid			2022-12-25	WOS:000226195200061
J	Petitjean, A; Cavard, C; Shi, H; Tribollet, V; Hainaut, P; de Fromentel, CC				Petitjean, A; Cavard, C; Shi, H; Tribollet, V; Hainaut, P; de Fromentel, CC			The expression of TA and Delta Np63 are regulated by different mechanisms in liver cells	ONCOGENE			English	Article						p63; TP53 family; DNA-damage; liver; HCC; topoisomerase inhibitor	KINASE C-ABL; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; APOPTOTIC RESPONSE; P53 PROTEIN; P73; P63; FAMILY; GENE; CANCER	The TP63 gene, a member of the TP53 gene family, encodes several isoforms with (TAp63) or without (DeltaNp63) transactivating properties. Whereas the role of p63 in the normal development of squamous epithelia is well established, its function in other cell types remains to be elucidated. Here, we have analysed the expression of TA and DeltaNp63 isoforms in liver cells, by using both primary hepatocytes from wild type and p53-null mice and three human hepatocellular carcinoma (HCC) cell lines, according to the transformation state and the TP53 status of the cells. We observed the expression of DeltaNp63 isoforms only in a p53-null context. On the other hand, the expression of TAp63 isoforms was restricted to the HCC cell lines, whatever the TP53 status. We then studied the expression of TP63 upon genotoxic treatment. When treated with UVB or H2O2, hepatocytes did not exhibit any change in p63 mRNA level. At the opposite, upon treatment with topoisomerase II inhibitors ( doxorubicin or etoposide), the expression of TAp63 isoforms was clearly induced, independently of the TP53 status of cells. The same treatment did not induce any variation in the expression of DeltaNp63 isoforms, both at mRNA and protein levels. In HCC cell lines, doxorubicin or etoposide treatment also resulted in an increase of TAp63 transcripts only. This increase was accompanied by an increase in the intracellular level of TAp63 alpha protein. In parallel, we observed an upregulation of some p53-target genes related to cell cycle regulation, such as WAF1/CIP1, PIG3, 14-3-3sigma or GADD45, independently of the TP53 status of cells. In conclusion, we report for the first time that TA and DeltaNp63 alpha proteins are present in liver cells. Furthermore, our results suggest that p63 may partially substitute for wild-type p53, in counteracting uncontrolled liver cell proliferation in response to certain forms of DNA-damage.	Ctr Leon Berard, INSERM, U590, Unite Oncogenese & Progress Tumorale, F-69008 Lyon, France; Int Agcy Res Canc, F-69372 Lyon 08, France; Inst Cochin Genet Mol, CNRS, UMR 8104, INSERM,U567, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; World Health Organization; International Agency for Research on Cancer (IARC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	de Fromentel, CC (corresponding author), Ctr Leon Berard, INSERM, U590, Unite Oncogenese & Progress Tumorale, 28 Rue Laennec, F-69008 Lyon, France.	carondef@lyon.fnclcc.fr	de Fromentel, Claude Caron/Y-9715-2019; Hainaut, Pierre/B-6018-2012	de Fromentel, Claude Caron/0000-0001-7566-3958; Hainaut, Pierre/0000-0002-1303-1610				Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Chou YY, 1997, J GASTROEN HEPATOL, V12, P569, DOI 10.1111/j.1440-1746.1997.tb00487.x; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Gillet R, 2000, ONCOGENE, V19, P3498, DOI 10.1038/sj.onc.1203671; Gong JG, 1999, NATURE, V399, P806; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Mueller H, 1996, ANTICANCER RES, V16, P3845; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Staib F, 2003, HUM MUTAT, V21, P201, DOI 10.1002/humu.10176; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101	37	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					512	519		10.1038/sj.onc.1208215	http://dx.doi.org/10.1038/sj.onc.1208215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543231				2022-12-25	WOS:000226279700021
J	Soung, YH; Lee, JW; Kim, SY; Sung, YJ; Park, WS; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH				Soung, YH; Lee, JW; Kim, SY; Sung, YJ; Park, WS; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH			Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas	ONCOGENE			English	Article						caspase-8; mutation; hepatocellular carcinoma; apoptosis; caspases	CELL-DEATH; CANCER; APOPTOSIS; MECHANISMS	Evidence exists that alterations of the genes encoding apoptosis-related proteins contribute to either development or progression of human cancers. Caspase-8 plays a crucial role in the initiation phase of apoptosis. To explore the possibility that the genetic alteration of caspase-8 gene is involved in the development of hepatocellular carcinomas (HCCs), we have analysed the entire coding region of human caspase-8 gene for the detection of somatic mutations by polymerase chain reaction-single-strand conformation polymorphism in 69 HCCs with low-grade dysplastic nodule (LGDN, n = 2) or high-grade dysplastic nodule (HGDN, n = 2) or without any dysplastic nodules (n = 65). Overall, we detected a total of nine somatic mutations in 69 HCCs (13.0%). Interestingly, all of the nine mutations were an identical frameshift mutation with two base-pair deletion (1225_1226delTG), which would result in a premature termination of amino-acid synthesis in the p10 protease subunit. In a patient sample, we detected the 1225_1226delTG mutation both in HCC and LDGN lesions, suggesting that caspase-8 mutation could be involved in the early stage of HCC carcinogenesis. We expressed the tumor-derived caspase-8 mutant in the cells and found that the mutant abolished cell death activity of caspase-8. Our data indicate that caspase-8 gene is frequently mutated in HCC and the majority of the mutations may be the frameshift mutation 1225_1226delTG. Also, the data suggest that caspase-8 gene mutation might lead to the loss of its cell death function and contribute to the pathogenesis of HCC.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea	Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					BAE JM, 2002, CANC RES TREAT, V34, P708; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, CANCER RES, V59, P3068; Li SP, 2001, J HEPATOL, V34, P840, DOI 10.1016/S0168-8278(01)00047-2; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maggioni M, 2000, HEPATOLOGY, V32, P942, DOI 10.1053/jhep.2000.18425; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Soung YH, 2003, ONCOGENE, V22, P8048, DOI 10.1038/sj.onc.1206727; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341	26	82	89	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					141	147		10.1038/sj.onc.1208244	http://dx.doi.org/10.1038/sj.onc.1208244			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531912				2022-12-25	WOS:000226125800016
J	Esparza, J; Kruse, M; Lee, J; Michaud, M; Madri, JA				Esparza, J; Kruse, M; Lee, J; Michaud, M; Madri, JA			MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity	FASEB JOURNAL			English	Article						MMP-9; MT1-MMP; EAE; T lymphocyte	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; GELATINASE-B; T-CELLS; ALPHA-4 INTEGRIN; DEFICIENT MICE; G-PROTEIN; IN-VIVO; MIGRATION; ANGIOGENESIS; ARTHRITIS	Matrix metalloproteinase-2 (MMP-2; gelatinase A) is known to degrade a broad range of extracellular matrix components and chemokines, and has important roles in the processes of cell migration, invasion, and involution during development, as well as during tumor growth and metastasis and in inflammation and repair. To better elucidate the roles of this matrix metalloproteinase in the development and progression of experimental autoimmune encephalomyelitis, we used MMP-2-deficient (KO) mice. Surprisingly, we found that MMP-2 KO mice exhibited an earlier onset and more severe disease than did their wild-type (WT) counterparts. WT mice engrafted with MMP-2 KO bone marrow exhibited a similar earlier onset and more severe clinical disease score than WT mice engrafted with WT bone marrow. Lymphocytes derived from MMP-2 KO mice exhibited increased transmigration through endothelial cell monolayers as well as through collagen type IV and laminin-coated BD BIOCOAT inserts(R), which correlated with a 3-fold increase in expression of MMP-9 and was abrogated by inhibition of MMP activity. We demonstrated a correlation between expression levels of MMP-9 and MT1-MMP expression and suggest a signaling pathway involving tethering of MMP-2 to MT1-MMP as a modulator of MMP-9 expression. Last, we discuss other possible MMP-2-mediated mechanisms which may contribute to the observed phenotype.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06520 USA.	joseph.Madri@yale.edu		Michaud, Michael/0000-0001-7332-4987; Lee, Janet/0000-0002-3563-8843	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028373, R01HL051018] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL28373, R01-HL51018] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alt C, 2002, EUR J IMMUNOL, V32, P2133, DOI 10.1002/1521-4141(200208)32:8<2133::AID-IMMU2133>3.0.CO;2-W; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CID MC, 1994, EUR J IMMUNOL, V24, P1377, DOI 10.1002/eji.1830240621; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Duffy MJ, 2003, THROMB HAEMOSTASIS, V89, P622; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gepstein A, 2002, ARTHRITIS RHEUM-US, V46, P3240, DOI 10.1002/art.10690; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Graesser D, 2000, J NEUROIMMUNOL, V109, P121, DOI 10.1016/S0165-5728(00)00275-7; Graesser D, 1998, LAB INVEST, V78, P1445; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643; JAMES SP, 1994, MEASUREMENT BASIC IM, V2; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; Madri J A, 2000, Dev Immunol, V7, P103, DOI 10.1155/2000/79045; Mahooti S, 2000, AM J PATHOL, V157, P75, DOI 10.1016/S0002-9440(10)64519-1; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rozanov DV, 2002, FEBS LETT, V527, P51, DOI 10.1016/S0014-5793(02)03153-8; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; SOUNNI NE, 2004, IN PRESS J BIOL CHEM; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; SWANBORG RH, 1996, EXPT AUTOIMMUNE ENCE, V3; Tani Kenji, 2001, Journal of Medical Investigation, V48, P133; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; UEKITA T, 2004, IN PRESS J BIOL CHEM; Vajkoczy P, 2001, J CLIN INVEST, V108, P557; Van den Steen PE, 2003, EUR J BIOCHEM, V270, P3739, DOI 10.1046/j.1432-1033.2003.03760.x; Vu TH, 2001, NAT GENET, V28, P202, DOI 10.1038/90023; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	41	88	92	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1682	1691		10.1096/fj.04-2445com	http://dx.doi.org/10.1096/fj.04-2445com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522913				2022-12-25	WOS:000225482100036
J	Ding, Q; Grammer, JR; Nelson, MA; Guan, JL; Stewart, JE; Gladson, CL				Ding, Q; Grammer, JR; Nelson, MA; Guan, JL; Stewart, JE; Gladson, CL			P27(Kip) and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CDK INHIBITOR P27(KIP1); DEPENDENT KINASE; GLIOMA-CELLS; SIGNALING PATHWAY; MAP-KINASE; EXPRESSION; RAS; FAK; PHOSPHORYLATION	We have reported previously that the expression of focal adhesion kinase (FAK) is elevated in glioblastomas and that expression of FAK promotes the proliferation of glioblastoma cells propagated in either soft agar or in the C.B.17 severe combined immunodeficiency (scid) mouse brain. We therefore determined the effect of FAK on cell cycle progression in these cells. We found that overexpression of wild-type FAK promoted exit from G, in monolayer cultures of glioblastoma cells, enhanced the expression of cyclins D1 and E while reducing the expression of p27(Kip1) and p21(waf1) and enhanced the kinase activity of the cyclin D1-cyclin-dependent kinase-4 (cdk4) complex. Transfection of the monolayers with a FAK molecule in which the autophosphorylation site is mutated (FAK397F) inhibited exit from G, and reduced the expression of cyclins D1 and E while enhancing the expression of p27(Kip1) and p21(Waf1). Small interfering RNA (siRNA)-mediated down-regulation of cyclin D1 inhibited the enhancement of cell cycle progression observed on expression of wild-type FAK, whereas siRNA-mediated down-regulation of cyclin E had no effect. siRNA-mediated down-regulation of p27(Kip1) overcame the inhibition of cell cycle progression observed on expression of FAK397F, whereas down-regulation of p21(Waf1) had no effect. These results were confirmed in vivo in the scid mouse brain xenograft model in which propagation of glioblastoma cells expressing FAK397F resulted in a 50% inhibition of tumor growth and inhibited exit from G(1) Taken together, our results indicate that FAK promotes proliferation of glioblastoma cells by enhancing exit from G(1) through a mechanism that involves cyclin D1 and P27(Kip1).	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA; Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Arizona; Cornell University	Gladson, CL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, LHRB 567,701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu			NCI NIH HHS [CA70145, CA97110, CA59958] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070145, R01CA097110, R01CA070145, R01CA059958] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi J, 1999, J NEUROSURG, V91, P822, DOI 10.3171/jns.1999.91.5.0822; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Cavalla P, 1998, ACTA NEUROPATHOL, V95, P131, DOI 10.1007/s004010050776; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cheyney IW, 1999, CANCER RES, V59, P2318; Ding Q, 2003, J BIOL CHEM, V278, P39882, DOI 10.1074/jbc.M304685200; Fuse T, 2000, J NEUROCHEM, V74, P1393, DOI 10.1046/j.1471-4159.2000.0741393.x; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Hecker TP, 2002, CANCER RES, V62, P2699; Ilic D, 1998, J CELL BIOL, V143, P547; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Lang FF, 1998, J NEUROSURG, V89, P125, DOI 10.3171/jns.1998.89.1.0125; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Ling LX, 1999, J CELL BIOCHEM, V73, P533; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Nho Richard Seonghun, 2003, Prog Cell Cycle Res, V5, P249; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Piva R, 1997, NEUROSCI LETT, V234, P127, DOI 10.1016/S0304-3940(97)00688-5; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Tamiya T, 2001, ACTA NEUROPATHOL, V101, P334; Wang DY, 2000, J CELL SCI, V113, P4221; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Zagzag D, 2000, PEDIATR NEUROSURG, V33, P49, DOI 10.1159/000028975; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5	49	85	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6802	6815		10.1074/jbc.M409180200	http://dx.doi.org/10.1074/jbc.M409180200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15557280	hybrid			2022-12-25	WOS:000227332700069
J	Raux-Deery, E; Leech, HK; Nakrieko, KA; McLean, KJ; Munro, AW; Heathcote, P; Rigby, SEJ; Smith, AG; Warren, MJ				Raux-Deery, E; Leech, HK; Nakrieko, KA; McLean, KJ; Munro, AW; Heathcote, P; Rigby, SEJ; Smith, AG; Warren, MJ			Identification and characterization of the terminal enzyme of siroheme biosynthesis from Arabidopsis thaliana - A plastid-located sirohydrochlorin ferrochelatase containing a 2Fe-2S center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPORPHYRINOGEN-III METHYLTRANSFERASE; ADENOSYL-L-METHIONINE; PROSTHETIC GROUP; BACILLUS-MEGATERIUM; SULFITE REDUCTASES; ESCHERICHIA-COLI; REDOX CONTROL; HIGHER-PLANTS; TRANSFER-RNA; COBALAMIN	Higher plant sulfite and nitrite reductases contain siroheme as a prosthetic group. Siroheme is synthesized from the tetrapyrrole primogenitor uroporphyrinogen III in three steps involving methylation, oxidation, and ferrochelation reactions. In this paper we report on the Arabidopsis thaliana sirohydrochlorin ferrochelatase At-SirB. The complete precursor protein of 225 amino acids and shorter constructs in which the first 46 or 79 residues had been removed were shown to complement a defined Escherichia coli sirohydrochlorin ferrochelatase mutant. The mature form of the protein appeared to consist of only 150 amino acids, making it much smaller than previously characterized ferrochelatases. Green fluorescent protein tagging revealed that it is located in the chloroplast. The enzyme was easily produced in E. coli as a recombinant protein, and the isolated enzyme was found to have a specific activity of 48.5 nmol/min/mg. Significantly, the protein purified as a brown-colored solution with a UV-visible spectrum containing maxima at 415 and 455 nm, suggestive of an Fe-S center. EPR analysis of the recombinant protein produced a rhombic spectrum with G-values of 2.04, 1.94, and 1.90 and with temperature dependence consistent with a 2Fe-2S center. Redox titration demonstrated that the Fe-S center is highly unstable, with an apparent midpoint reduction potential of about -370 mV. This is the first Fe-S center to be reported in a higher plant ferrochelatase. The implications of the Fe-S center in an enzyme that is so closely associated with the metabolism of sulfur and iron are discussed.	Univ London Queen Mary & Westfield Coll, Sch Biol Sci, London E1 4NS, England; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of London; Queen Mary University London; University of Cambridge; University of Leicester	Warren, MJ (corresponding author), Univ London Queen Mary & Westfield Coll, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	mj.warren@qmul.ac.uk	McLean, Kirsty J/GXI-2853-2022; Munro, Andrew/G-5639-2019; Heathcote, Peter/B-3749-2011	Munro, Andrew/0000-0002-4642-180X; Warren, Martin/0000-0002-6028-6456; Smith, Alison Gail/0000-0001-6511-5704; McLean, Kirsty/0000-0002-7193-5044				Al-Karadaghi S, 1997, STRUCTURE, V5, P1501, DOI 10.1016/S0969-2126(97)00299-2; BLANCHE F, 1989, J BACTERIOL, V171, P4222, DOI 10.1128/JB.171.8.4222-4231.1989; BLANCHE F, 1991, J BACTERIOL, V173, P4637, DOI 10.1128/jb.173.15.4637-4645.1991; Brindley AA, 2003, J BIOL CHEM, V278, P22388, DOI 10.1074/jbc.M302468200; Cleary SP, 2002, J BIOL CHEM, V277, P5562, DOI 10.1074/jbc.M106532200; Cornah JE, 2003, TRENDS PLANT SCI, V8, P224, DOI 10.1016/S1360-1385(03)00064-5; Crane BR, 1996, CURR OPIN STRUC BIOL, V6, P744, DOI 10.1016/S0959-440X(96)80003-0; Crouse BR, 1996, BIOCHEMISTRY-US, V35, P16222, DOI 10.1021/bi9620114; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; Dailey HA, 2000, CELL MOL LIFE SCI, V57, P1909, DOI 10.1007/PL00000672; Dailey TA, 2002, J BACTERIOL, V184, P2460, DOI 10.1128/JB.184.9.2460-2464.2002; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; Dutton P L, 1978, Methods Enzymol, V54, P411; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; GRIFFITHS L, 1987, ARCH MICROBIOL, V147, P364, DOI 10.1007/BF00406134; Johansson P, 1999, MICROBIOL-SGM, V145, P529, DOI 10.1099/13500872-145-3-529; Leech HK, 2003, J BIOL CHEM, V278, P41900, DOI 10.1074/jbc.M306112200; Leustek T, 1997, J BIOL CHEM, V272, P2744, DOI 10.1074/jbc.272.5.2744; LOVENBERG W, 1973, IRON SULFUR PROTEINS, V2, P285; MINET M, 1992, PLANT J, V2, P417; Moser J, 2001, EMBO J, V20, P6583, DOI 10.1093/emboj/20.23.6583; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; MURPHY MJ, 1973, J BIOL CHEM, V248, P6911; MURPHY MJ, 1974, P NATL ACAD SCI USA, V71, P612, DOI 10.1073/pnas.71.3.612; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; Phillips JD, 2003, EMBO J, V22, P6225, DOI 10.1093/emboj/cdg606; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Raux E, 2003, BIOCHEM J, V370, P505, DOI 10.1042/BJ20021443; Raux E, 1999, BIOCHEM J, V338, P701, DOI 10.1042/0264-6021:3380701; ROBIN C, 1991, J BACTERIOL, V173, P4893, DOI 10.1128/jb.173.15.4893-4896.1991; Sakakibara H, 1996, PLANT J, V10, P883, DOI 10.1046/j.1365-313X.1996.10050883.x; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; Schubert HL, 1999, BIOCHEMISTRY-US, V38, P10660, DOI 10.1021/bi9906773; Schubert HL, 2002, EMBO J, V21, P2068, DOI 10.1093/emboj/21.9.2068; Sellers VM, 1998, J BIOL CHEM, V273, P22311, DOI 10.1074/jbc.273.35.22311; Stroupe ME, 2003, NAT STRUCT BIOL, V10, P1064, DOI 10.1038/nsb1007; WARREN MJ, 1990, FEBS LETT, V261, P76, DOI 10.1016/0014-5793(90)80640-5; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P486, DOI 10.1016/0968-0004(90)90304-T; ZANETTI G, 2001, HDB METALLOPROTEINS, P425	41	29	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4713	4721		10.1074/jbc.M411360200	http://dx.doi.org/10.1074/jbc.M411360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15545265	hybrid			2022-12-25	WOS:000227096600087
J	Seppala, U; Hagglund, P; Wurtzen, PA; Ipsen, H; Thorsted, P; Lenhard, T; Roepstorff, P; Spangfort, MD				Seppala, U; Hagglund, P; Wurtzen, PA; Ipsen, H; Thorsted, P; Lenhard, T; Roepstorff, P; Spangfort, MD			Molecular characterization of major cat allergen Fel d 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEL-D-I; MONOCLONAL-ANTIBODIES; SEQUENCE-ANALYSIS; CELL EPITOPES; EXPRESSION; PURIFICATION; IDENTIFICATION; IMMUNOASSAY; PEPTIDES; ORIGIN	Fel d 1 is a major cat allergen inducing allergic rhinitis and asthma in sensitized individuals. It has a more complex structure when compared with other allergens and therefore expression of recombinant Fel d 1 has been considered a challenge. The present study shows for the first time that a Baculovirus expression system is able to produce an intact rFel d 1 molecule that is glycosylated and structurally equivalent to the natural cat allergen, nFel d 1. Enzymatic digestion of rFel d 1 and further analysis by use of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) resulted in a complete coverage of the amino, acid sequence of rFel d 1. In addition, the three disulfide bridges at the positions alpha70-beta7, alpha44-beta48, and alpha3-beta73 were verified. The N-glycan structure of rFel d 1 was investigated by a combination of MALDI-TOF MS and monosaccharide analysis by high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAC). The N-glycosylation analyses of rFel d 1 refer to a pattern of glycoforms including core alpha1.3-fucosylation that is different from nFel d 1. Further characterization by use of human serum IgE, histamine release, and lymphocyte proliferation assays demonstrated that the immunological characteristics of rFel d 1 are similar to those of nFel d 1. Detailed characterization of both natural and recombinant allergens provides tools to explore immunological mechanisms associated with allergen sensitization and desensitization.	ALK Abello, Dept Vaccine Res, DK-2970 Horsholm, Denmark; ALK Abello, Dept Expt Immunol, DK-2970 Horsholm, Denmark; Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	ALK-Abello AS; ALK-Abello AS; University of Southern Denmark	Spangfort, MD (corresponding author), ALK Abello, Dept Vaccine Res, DK-2970 Horsholm, Denmark.	MSp@dk.alk-abello.com	Hägglund, Per/X-4881-2019	Hagglund, Per/0000-0002-6627-7518				Arentz-Hansen H, 2002, GASTROENTEROLOGY, V123, P803, DOI 10.1053/gast.2002.35381; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chen CL, 2003, J IMMUNOL, V170, P528, DOI 10.4049/jimmunol.170.1.528; Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; Dwek RA, 2002, NAT REV DRUG DISCOV, V1, P65, DOI 10.1038/nrd708; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Hilger C, 1996, GENE, V169, P295, DOI 10.1016/0378-1119(95)00851-9; Hsu TA, 1997, J BIOL CHEM, V272, P9062; Ichikawa K, 2001, CLIN EXP ALLERGY, V31, P1279, DOI 10.1046/j.1365-2222.2001.01169.x; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; KEATING KM, 1995, MOL IMMUNOL, V32, P287, DOI 10.1016/0161-5890(94)00140-V; KROLLKRISTENSEN AK, 1997, BIOL CHEM, V378, P899; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; OREILLY DR, 1994, BACULOVIRUS EXPRESSI, P135; Petersen AB, 2004, CLIN BIOCHEM, V37, P882, DOI 10.1016/j.clinbiochem.2004.06.010; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Reichert JM, 2003, CURR OPIN MOL THER, V5, P139; ROGERS BL, 1993, MOL IMMUNOL, V30, P559, DOI 10.1016/0161-5890(93)90030-F; ROGERS BL, 1994, MOL IMMUNOL, V31, P955, DOI 10.1016/0161-5890(94)90090-6; SCHOU C, 1996, ALLERGY ALLERGIC DIS, P900; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; Vailes LD, 2002, J ALLERGY CLIN IMMUN, V110, P757, DOI 10.1067/mai.2002.129035; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; VANTHOF W, 1993, ALLERGY, V48, P255; Walker CS, 2001, J BIOL CHEM, V276, P7769, DOI 10.1074/jbc.M009576200; Weintraub SJ, 2004, MECH AGEING DEV, V125, P255, DOI 10.1016/j.mad.2004.03.002; Wurtzen PA, 1999, CLIN EXP ALLERGY, V29, P1614, DOI 10.1046/j.1365-2222.1999.00652.x	41	19	20	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3208	3216		10.1074/jbc.M410668200	http://dx.doi.org/10.1074/jbc.M410668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15546862	hybrid			2022-12-25	WOS:000226983900012
J	Varshochi, R; Halim, F; Sunters, A; Alao, JP; Madureira, PA; Hart, SM; Ali, S; Vigushin, DM; Coombes, RC; Lam, EWF				Varshochi, R; Halim, F; Sunters, A; Alao, JP; Madureira, PA; Hart, SM; Ali, S; Vigushin, DM; Coombes, RC; Lam, EWF			ICI182,780 induces p21(Waf1) gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; REPRESS TRANSCRIPTION; NUCLEAR RECEPTORS; FAMILY-MEMBERS; OVALBUMIN GENE; PROMOTER; EXPRESSION; ACTIVATION; INHIBITOR; PROGRESSION	We used the estrogen-responsive MCF-7 breast cancer cell line as a relevant model to study the anti-proliferative effects of ICI182,780 and identified the negative cell cycle regulator p21(waf1) as a specific target of ICI182,780. Furthermore, silencing of the p21(waf1) expression by small interfering RNA overcame the G(0)/G(1) cell cycle arrest induced by ICI182,780, suggesting that the induction of p21(waf1) expression has a direct role in mediating the ICI182,780-induced G(0)/G(1) arrest. We further demonstrated that the induction of p21(waf1) by ICI182,780 is mediated at transcriptional and gene promoter levels through the proximal Sp1 sites located near the transcription start site. Co-immunoprecipitation, DNA "pulldown," and chromatin immunoprecipitation experiments together showed that in cycling cells, estrogen receptor a and histone deacetylase 1 (HDAC1) are recruited to the proximal Sp1 sites of the promoter to repress p21(waf1) expression. In the presence of ICI182,780, estrogen receptor alpha and HDACs are dissociated from Sp1, resulting in increased histone acetylation and de-repression of the p21(Waf1) promoter and induction of p21(waf1) expression. The fact that p21(Waf1) expression is normally repressed by HDAC activity in cycling cells is further demonstrated by the finding that p21(Waf1) transcription can be induced by the silencing of HDACs with small interfering RNA or treatment with HDAC inhibitors.	Univ London Imperial Coll Sci Technol & Med, Canc Res UK Labs, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Sect Canc Cell Biol, London W12 0NN, England	Cancer Research UK; Imperial College London; Imperial College London	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Canc Res UK Labs, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020; Alao, John-Patrick/AAY-8645-2021; Madureira, Patricia/F-4656-2012; Madureira, Patricia A/C-9666-2013; Ali, Simak/M-6912-2018	Lam, Eric W-F/0000-0003-1274-3576; Madureira, Patricia/0000-0002-4856-3908; Madureira, Patricia A/0000-0002-4856-3908; Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816				Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Brosens JJ, 2004, BEST PRACT RES CL OB, V18, P265, DOI 10.1016/j.bpobgyn.2004.01.006; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Cummings FJ, 2002, CLIN THER, V24, pC3, DOI 10.1016/S0149-2918(02)85158-X; Cunliffe VT, 2003, GENE, V305, P141, DOI 10.1016/S0378-1119(03)00386-X; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DUBIK D, 1992, ONCOGENE, V7, P1587; Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002-0323; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Gradishar William J, 2003, Int J Clin Oncol, V8, P239, DOI 10.1007/s10147-003-0338-4; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Han JW, 2000, CANCER RES, V60, P6068; Horwitz K B, 1980, Recent Results Cancer Res, V71, P45; Howell A, 1996, BRIT J CANCER, V74, P300, DOI 10.1038/bjc.1996.357; Jensen EV, 1996, ANN NY ACAD SCI, V784, P1, DOI 10.1111/j.1749-6632.1996.tb16223.x; Ju R, 2003, CANCER RES, V63, P2891; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Lai A, 2001, J BIOL CHEM, V276, P25823, DOI 10.1074/jbc.M100925200; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Maehara K, 2002, BIOCHEM BIOPH RES CO, V295, P187, DOI 10.1016/S0006-291X(02)00646-0; Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041; McKenna N, 2000, NAT MED, V6, P960, DOI 10.1038/79637; McKenna NJ, 2001, ANN NY ACAD SCI, V949, P3; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rosato RR, 2003, CANCER RES, V63, P3637; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Wang F, 2002, J CELL BIOCHEM, V84, P156, DOI 10.1002/jcb.1276; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; White JH, 2004, VITAM HORM, V68, P123; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Zou AH, 1999, MOL ENDOCRINOL, V13, P418, DOI 10.1210/me.13.3.418	50	60	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3185	3196		10.1074/jbc.M408063200	http://dx.doi.org/10.1074/jbc.M408063200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557281	hybrid			2022-12-25	WOS:000226983900010
J	Becker, KP; Kitatani, K; Idkowiak-Baldys, J; Bielawski, J; Hannun, YA				Becker, KP; Kitatani, K; Idkowiak-Baldys, J; Bielawski, J; Hannun, YA			Selective inhibition of juxtanuclear translocation of protein kinase C beta II by a negative feedback mechanism involving ceramide formed from the salvage pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; DE-NOVO; RECYCLING ENDOSOMES; INDUCED APOPTOSIS; PHOSPHOLIPASE-D; ACTIVATION; ALPHA; SPHINGOMYELINASES; MEMBRANE; SUBSET	In a previous study, we showed that protein kinase C betaII (PKC betaII) translocated to a novel juxtanuclear compartment as observed in several cell types (Becker, K. P., and Hannun, Y. A. (2003) J. BioL Chem. 278, 5274752754). In this study, we noted the absence of this translocation in MCF-7 breast cancer cells, and we examined the mechanisms underlying this selectivity of response. We show that sustained stimulation of PKC betaII with 4beta-phorbol 12-myristate 13-acetate (PMA) resulted in accumulation of ceramide in MCF-7 cells but not in those cells that showed juxtanuclear translocation of PKC betaII. Addition of exogenous ceramides or formation of endogenous ceramide by the action of bacterial sphingomyelinase prevented PMA-induced translocation of PKC betaII in HEK 293 cells. On the other hand, inhibition of ceramide accumulation with fumonisin B1 restored the ability of PMA to induce translocation of PKC betaII in MCF-7 cells. Taken together, the results showed that endogenous ceramide is both necessary and sufficient for preventing juxtanuclear translocation of PKC betaII in response to PMA. Investigation of the mechanisms of ceramide generation in response to PMA revealed that PMA activated the salvage pathway of ceramide formation and not the de novo pathway. This conclusion was based on the following: 1) the ability of fumonisin B1 but not myriocin to inhibit ceramide formation, 2) the ability of PMA to induce increases in palmitate-labeled ceramide only under chase labeling but not acute pulse labeling, 3) the induction of the levels of sphingosine but not dihydrosphingosine in response to PMA, and 4) induction of sphingomyelin hydrolysis in response to PMA. Together, these results define a novel pathway of regulated formation of ceramide, the salvage pathway, and they define a role for this pathway in regulating juxtanuclear translocation of PKC betaII.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43707] Funding Source: Medline; NIGMS NIH HHS [GM08716] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker KP, 2004, J BIOL CHEM, V279, P28251, DOI 10.1074/jbc.M400770200; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Garzotto M, 1998, CANCER RES, V58, P2260; Gillard BK, 1998, GLYCOBIOLOGY, V8, P885, DOI 10.1093/glycob/8.9.885; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hu TH, 2004, J BIOL CHEM, V279, P35702, DOI 10.1074/jbc.M402372200; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; Karakashian AA, 2004, FASEB J, V18, P968, DOI 10.1096/fj.03-0875fje; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Perry DK, 2000, ANN NY ACAD SCI, V905, P91; Signorelli P, 2001, FASEB J, V15, P2401, DOI 10.1096/fj.01-0244com	27	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2606	2612		10.1074/jbc.M409066200	http://dx.doi.org/10.1074/jbc.M409066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15546881	hybrid			2022-12-25	WOS:000226449100029
J	Renault, MA; Jalvy, S; Potier, M; Belloc, I; Genot, E; Dekker, LV; Desgranges, C; Gadeau, AP				Renault, MA; Jalvy, S; Potier, M; Belloc, I; Genot, E; Dekker, LV; Desgranges, C; Gadeau, AP			UTP induces osteopontin expression through a coordinate action of NF kappa B, activator protein-1, and upstream stimulatory factor in arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; CYCLE PROGRESSION; ANGIOTENSIN-II; GROWTH-FACTOR; KINASE; RECEPTOR; PROMOTER; GENE; IDENTIFICATION; INHIBITION	Osteopontin (OPN) is an important chemokinetic agent for several cell types. Our earlier studies have shown that its expression is essential for uridine triphosphate (UTP)-mediated migration of vascular smooth muscle cells. We demonstrated previously that the activation of an AP-1 binding site located 76 bp upstream of the transcription start in the rat OPN promoter is involved in the induction of OPN expression. In this work, using a luciferase promoter deletion assay, we identified a new region of the rat OPN promoter (-1837 to -1757) that is responsive to UTP. This region contains an NFkappaB site located at -1800 and an Ebox located at -1768. Supershift electrophoretic mobility shift assay and chromatin immunoprecipitation assays identified NFkappaB and USF-1/USF-2 as the DNA binding proteins induced by UTP, respectively, for these two sites. Using dominant negative mutants of IkappaB kinase and USF transcription factors, we confirmed that NFkappaB and USF-1/USF-2 are involved in the UTP-mediated expression of OPN. Using a pharmacological approach, we demonstrated that USF proteins are regulated by the extracellular signal-regulated kinase (ERK)1/2 pathway, just as the earlier discovered AP-1 complex, whereas NFkappaB is up-regulated through PKCS signals. Finally, our work suggests that the UTP-stimulated OPN expression involves a coordinate regulation of PKCdelta-NFkappaB, ERK1/2-USF, and ERK1/2/NAD(P)H oxidase AP-1 signaling pathways.	INSERM, U441 Atherosclerose, F-33600 Pessac, France; Univ Bordeaux 2, F-33076 Bordeaux, France; Univ Bordeaux 1, Inst Europeen Chim & Biol, F-33600 Pessac, France; Ionix Pharmaceut Ltd, Cambridge CB4 0PA, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Gadeau, AP (corresponding author), INSERM, U441 Atherosclerose, Ave Haut Leveque, F-33600 Pessac, France.	alain.gadeau@bordeaux.inserm.fr	Renault, Marie-Ange/J-4081-2016; Gadeau, Alain-Pierre/H-7889-2016; Genot, Elisabeth/G-8031-2014; Dekker, Lodewijk/J-6934-2013	Renault, Marie-Ange/0000-0002-5287-1540; Gadeau, Alain-Pierre/0000-0003-1312-6481; Dekker, Lodewijk/0000-0001-5247-3297				Abbott KL, 2000, MOL PHARMACOL, V58, P946, DOI 10.1124/mol.58.5.946; Asaumi S, 2003, J DIABETES COMPLICAT, V17, P34, DOI 10.1016/S1056-8727(02)00189-7; Asou Y, 2001, ENDOCRINOLOGY, V142, P1325, DOI 10.1210/en.142.3.1325; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Chaulet H, 2001, CIRC RES, V89, P772, DOI 10.1161/hh2101.098617; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; Fei JW, 2000, ARTERIOSCL THROM VAS, V20, P1244, DOI 10.1161/01.ATV.20.5.1244; Giachelli CM, 1998, AM J PATHOL, V152, P353; Gourdon L, 1999, FEBS LETT, V459, P9, DOI 10.1016/S0014-5793(99)01203-X; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Isoda K, 2002, CIRC RES, V91, P77, DOI 10.1161/01.RES.0000025268.10302.0C; Kim HJ, 2003, DEV DYNAM, V227, P335, DOI 10.1002/dvdy.10319; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; Liu YN, 2004, ONCOGENE, V23, P278, DOI 10.1038/sj.onc.1207022; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; MALAMSOULEY R, 1993, AM J PHYSIOL, V264, pC783, DOI 10.1152/ajpcell.1993.264.4.C783; MalamSouley R, 1996, J CELL PHYSIOL, V166, P57, DOI 10.1002/(SICI)1097-4652(199601)166:1<57::AID-JCP7>3.0.CO;2-F; Malyankar UM, 1999, EXP CELL RES, V250, P535, DOI 10.1006/excr.1999.4537; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matsui Y, 2003, ARTERIOSCL THROM VAS, V23, P1029, DOI 10.1161/01.ATV.0000074878.29805.D0; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Pfeilschifter J, 1996, J AUTON PHARMACOL, V16, P315, DOI 10.1111/j.1474-8673.1996.tb00043.x; Pillois X, 2002, CIRC RES, V90, P678, DOI 10.1161/01.RES.0000013700.98464.8E; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Ralevic V, 1998, PHARMACOL REV, V50, P413; Renault MA, 2003, CIRC RES, V93, P674, DOI 10.1161/01.RES.0000094747.05021.62; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Sauer H, 2001, FASEB J, V15, P2539, DOI 10.1096/fj.01-0360fje; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Senger DR, 1996, AM J PATHOL, V149, P293; Shi XM, 2001, J BIOL CHEM, V276, P850, DOI 10.1074/jbc.M005955200; Takeshita A, 1998, J BIOL CHEM, V273, P14738, DOI 10.1074/jbc.273.24.14738; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; Viedt C, 2000, ARTERIOSCL THROM VAS, V20, P940, DOI 10.1161/01.ATV.20.4.940; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wang DY, 2000, ONCOGENE, V19, P5801, DOI 10.1038/sj.onc.1203917; Xie ZL, 2001, J CELL PHYSIOL, V188, P132, DOI 10.1002/jcp.1104; Yamakawa T, 2002, ARTERIOSCL THROM VAS, V22, P752, DOI 10.1161/01.ATV.0000015903.02749.71	47	36	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2708	2713		10.1074/jbc.M411786200	http://dx.doi.org/10.1074/jbc.M411786200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15557322	hybrid			2022-12-25	WOS:000226449100042
J	Hagan, RM; Worner-Gibbs, J; Wilton, DC				Hagan, RM; Worner-Gibbs, J; Wilton, DC			Tryptophan insertion mutagenesis of liver fatty acid-binding protein - L28W mutant provides important insights into ligand binding and physiological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGE REVERSAL MUTATIONS; RAT-LIVER; PHOSPHOLIPID-MEMBRANES; HELICAL DOMAIN; BILE-SALTS; ACYL COAS; GENE; EXPRESSION; ADIPOCYTE; TITRATION	Liver fatty acid-binding protein (FABP) binds a variety of non-polar anionic ligands including fatty acids, fatty acyl CoAs, and bile acids. Previously we prepared charge reversal mutants and demonstrated the importance of lysine residues within the portal region in ligand and membrane binding. We have now prepared several tryptophan-containing mutants within the portal region, and one tryptophan at position 28 (L28W) has proved remarkably effective as an intrinsic probe to further study ligand binding. The fluorescence of the L28W mutant was very sensitive to fatty acid and bile acid binding where a large (up to 4-fold) fluorescence enhancement was obtained. In contrast, the binding of oleoyl CoA reduced tryptophan fluorescence. Positive cooperativity for fatty acid binding was observed while detailed information on the orientation of binding of bile acid derivatives was obtained. The ability of bound oleoyl CoA to reduce the fluorescence of L28W provided an opportunity to demonstrate that fatty acyl CoAs can compete with fatty acids for binding to liver FABP under physiological conditions, further highlighting the role of fatty acyl CoAs in modulating FABP function in the cell.	Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England	University of Southampton	Wilton, DC (corresponding author), Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	D.C.Wilton@soton.ac.uk						BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Beers SA, 2003, BIOCHEMISTRY-US, V42, P7326, DOI 10.1021/bi0343222; BORCHERS T, 1994, CURR TOP MEMBR, V40, P261, DOI 10.1016/S0070-2161(08)60984-3; Coe NR, 1998, BBA-LIPID LIPID MET, V1391, P287, DOI 10.1016/S0005-2760(97)00205-1; Corsico B, 2004, BIOCHEMISTRY-US, V43, P3600, DOI 10.1021/bi0357356; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; Davies JK, 1999, BIOCHEMISTRY-US, V38, P16932, DOI 10.1021/bi991926q; Davies JK, 2002, J BIOL CHEM, V277, P48395, DOI 10.1074/jbc.M208141200; DIETRICH A, 1995, J LIPID RES, V36, P1745; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Glatz JFC, 2001, CURR OPIN LIPIDOL, V12, P267, DOI 10.1097/00041433-200106000-00005; Hagan RM, 2002, MOL CELL BIOCHEM, V239, P55, DOI 10.1023/A:1020562808304; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Huang H, 2004, BIOCHEMISTRY-US, V43, P2484, DOI 10.1021/bi0352318; Jenkins AE, 2002, BIOCHEMISTRY-US, V41, P2022, DOI 10.1021/bi015769i; Lakowicz J. R., 1999, PRINC FLUORESC SPECT, P445, DOI [DOI 10.1007/978-1-4757-3061-6_16, 10.1007/978-1-4757-3061-6_16]; Martin GG, 2003, BIOCHEMISTRY-US, V42, P11520, DOI 10.1021/bi0346749; MILLER KR, 1993, MOL CELL BIOCHEM, V123, P29, DOI 10.1007/BF01076472; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; TAKIKAWA H, 1986, ARCH BIOCHEM BIOPHYS, V251, P385, DOI 10.1016/0003-9861(86)90086-X; Thompson J, 1999, MOL CELL BIOCHEM, V192, P9, DOI 10.1023/A:1006806616963; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; THUMSER AEA, 1994, BIOCHEM J, V300, P827, DOI 10.1042/bj3000827; Thumser AEA, 1996, BIOCHEM J, V320, P729, DOI 10.1042/bj3200729; Wang H, 2002, BIOCHEMISTRY-US, V41, P5453, DOI 10.1021/bi011914g; WILKINSON TCI, 1987, BIOCHEM J, V247, P485, DOI 10.1042/bj2470485; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; WORRALL AF, 1991, BIOCHEM J, V278, P365, DOI 10.1042/bj2780365; Wu F, 2001, BIOCHEMISTRY-US, V40, P1976, DOI 10.1021/bi002252i	33	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1782	1789		10.1074/jbc.M407131200	http://dx.doi.org/10.1074/jbc.M407131200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542605	hybrid			2022-12-25	WOS:000226341700011
J	Qing, Y; Costa-Pereira, AP; Watling, D; Stark, G				Qing, Y; Costa-Pereira, AP; Watling, D; Stark, G			Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CYTOKINE SIGNALING-3; IN-VIVO; SUPPRESSOR; BINDING; GP130; SOCS3; PHOSPHORYLATION; KINASE; IL-6	Suppressor of cytokine signaling (SOCS)-1, the key negative regulator of interferon (IFN)-gamma-dependent signaling, is induced in response to IFNgamma. SOCS-1 binds to and inhibits the IFNgamma receptor-associated kinase Janus-activated kinase (JAK) 2 and inhibits its function in vitro, but the mechanism by which SOCS-1 inhibits IFNgamma-dependent signaling in vivo is not clear. Upon stimulation, mouse IFNgamma receptor subunit 1 (IFNGR1) is phosphorylated on several cytoplasmic tyrosine residues, and Tyr(419) is required for signal transducer and activator of transcription ( STAT) 1 activation in mouse embryo fibroblasts. However, the functions of the other three cytoplasmic tyrosine residues are not known. Here we show that Tyr(441) is required to attenuate STAT1 activation in response to IFNgamma. Several tyrosine to phenylalanine mutants of IFNGR1, expressed at normal levels in stable pools of IFNGR1-null cells, were analyzed for the phosphorylation of STAT1 during a 48-h period, and antiviral activity in response to IFNgamma was also measured. Stronger activation of STAT1 was observed in cells expressing all IFNGR1 variants mutated at Tyr(441), and, consistently, stronger antiviral activity was also observed in these cells. Furthermore, constitutive overexpression of SOCS-1 inhibited IFNgamma-dependent signaling only in cells expressing IFNGR1 variants that included the Tyr(441) mutation. Mutation of Tyr(441) also blocked the ability of SOCS-1 to bind to IFNGR1 and JAK2 in response to IFNgamma and the normal down-regulation of STAT1 activation and antiviral activity. These results, together with data from the literature, suggest a model in which, in response to IFNgamma, phosphorylation of Tyr(441) creates a docking site for SOCS-1, which then binds to JAK2 within the receptor-JAK complex to partially inhibit JAK2 phosphorylation. Furthermore, the virtually complete blockade of STAT1 phosphorylation by overexpressed SOCS-1 in this experiment suggests that the binding of SOCS-1 to Tyr(441) also blocks the access of STAT1 to Tyr(419) and that this effect may be the principal mechanism of inhibition of downstream signaling.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Canc Res UK, London Res Inst, Lincolns Inn Labs, London WC2A 3PX, England	Cleveland Clinic Foundation; Case Western Reserve University; Cancer Research UK	Stark, G (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org	Costa-Pereira, Ana/AAE-8192-2020	Costa-Pereira, Ana/0000-0001-8265-8065	NCI NIH HHS [P01 CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JANSSEN JWG, 1986, CYTOMETRY, V7, P411, DOI 10.1002/cyto.990070504; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; KARNITZ LM, 1995, CURR OPIN IMMUNOL, V7, P320, DOI 10.1016/0952-7915(95)80105-7; KLINT P, 1999, FRONT BIOSCI, V4, P165; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mulcahy L, 2001, SEMIN ONCOL, V28, P19, DOI 10.1053/sonc.2001.25394; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Sporri B, 2001, BLOOD, V97, P221, DOI 10.1182/blood.V97.1.221; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Strobl B, 2001, EMBO J, V20, P5431, DOI 10.1093/emboj/20.19.5431; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Woldman I, 2001, J BIOL CHEM, V276, P45722, DOI 10.1074/jbc.M105320200; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3	53	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1849	1853		10.1074/jbc.M409863200	http://dx.doi.org/10.1074/jbc.M409863200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15522878	hybrid			2022-12-25	WOS:000226341700018
J	Amor, JC; Swails, J; Zhu, XJ; Roy, CR; Nagai, H; Ingmundson, A; Cheng, XD; Kahn, RA				Amor, JC; Swails, J; Zhu, XJ; Roy, CR; Nagai, H; Ingmundson, A; Cheng, XD; Kahn, RA			The structure of RalF, an ADP-ribosylation factor guanine nucleotide exchange factor from Legionella pneumophila, reveals the presence of a cap over the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC7 DOMAIN; FACTOR-I; AGROBACTERIUM-TUMEFACIENS; ARF; SYSTEM; ACTIVATION; APPENDAGE; GTPASE; MOTIFS; ARNO	The Legionella pneumophila protein RalF is secreted into host cytosol via the Dot/Icm type IV transporter where it acts to recruit ADP-ribosylation factor (Arf) to pathogen-containing phagosomes in the establishment of a replicative organelle. The presence in RalF of the Sec7 domain, present in all Arf guanine nucleotide exchange factors, has suggested that recruitment of Arf is an early step in pathogenesis. We have determined the crystal structure of RalF and of the isolated Sec7 domain and found that RalF is made up of two domains. The Sec7 domain is homologous to mammalian Sec7 domains. The C-terminal domain forms a cap over the active site in the Sec7 domain and contains a conserved folding motif, previously observed in adaptor subunits of vesicle coat complexes. The importance of the capping domain and of the glutamate in the "glutamic finger," conserved in all Sec7 domains, to RalF functions was examined using three different assays. These data highlight the functional importance of domains other than Sec7 in Arf guanine nucleotide exchange factors to biological activities and suggest novel mechanisms of regulation of those activities.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA	Emory University; Yale University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Cifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Nagai, Hiroki/G-4113-2015; Nagai, Hiroki/GXZ-7815-2022; Kahn, Richard/ABD-2666-2020	Nagai, Hiroki/0000-0003-1659-2197; Kahn, Richard/0000-0002-0259-0601; Roy, Craig/0000-0003-4490-440X	NIAID NIH HHS [AI41699] Funding Source: Medline; NIGMS NIH HHS [GM61355, GM49245, GM61268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041699, R01AI041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061355, R01GM061268, R01GM049245] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Austin C, 2000, J BIOL CHEM, V275, P21862, DOI 10.1074/jbc.M908875199; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Chen J, 2004, SCIENCE, V303, P1358, DOI 10.1126/science.1094226; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hoffman GR, 2003, MOL CELL, V12, P615, DOI 10.1016/j.molcel.2003.08.002; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORWITZ MA, 1983, J EXP MED, V158, P2108, DOI 10.1084/jem.158.6.2108; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kagan JC, 2004, J EXP MED, V199, P1201, DOI 10.1084/jem.20031706; Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; Kahn RA, 2002, TRENDS BIOCHEM SCI, V27, P308, DOI 10.1016/S0968-0004(02)02108-4; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Knodler LA, 2001, NAT REV MOL CELL BIO, V2, P578, DOI 10.1038/35085062; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Luo ZQ, 2004, P NATL ACAD SCI USA, V101, P841, DOI 10.1073/pnas.0304916101; Monier S, 1998, J CELL SCI, V111, P3427; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; Segal G, 1998, P NATL ACAD SCI USA, V95, P1669, DOI 10.1073/pnas.95.4.1669; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Simone M, 2001, MOL MICROBIOL, V41, P1283, DOI 10.1046/j.1365-2958.2001.02582.x; TERUI T, 1994, J BIOL CHEM, V269, P28130; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Vergunst AC, 2000, SCIENCE, V290, P979, DOI 10.1126/science.290.5493.979; Vergunst AC, 2003, PLANT PHYSIOL, V133, P978, DOI 10.1104/pp.103.029223; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	51	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1392	1400		10.1074/jbc.M410820200	http://dx.doi.org/10.1074/jbc.M410820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15520000	hybrid			2022-12-25	WOS:000226195200066
J	Harikumar, KG; Clain, J; Pinon, DI; Dong, MQ; Miller, LJ				Harikumar, KG; Clain, J; Pinon, DI; Dong, MQ; Miller, LJ			Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON EVOLUTIONARY ORIGIN; DIRECT IDENTIFICATION; LIGAND-BINDING; GASTRIN; SITE; BIOCHEMISTRY; COEVOLUTION; ACTIVATION; AFFINITY; DOMAINS	Fluorescence spectroscopy provides a direct method for evaluating the environment of a fluorescent ligand bound to its receptor. We utilized this methodology to determine the environment of Alexa within a cholecystokinin (CCK)-like probe (Alexa(488)-Gly-[(Nle(28,31)) CCK-26 - 33]; CCK-8 probe) bound to the type A CCK receptor (Harikumar, K. G., Pinon, D. L., Wessels, W. S., Prendergast, F. G., and Miller, L. J. ( 2002) J. Biol. Chem. 277, 18552 - 18560). Here, we study this probe at the type B CCK receptor and develop another probe with its fluorophore closer to the carboxyl-terminal pharmacophore of type B receptor ligands (Alexa(488)-Trp-Nle-Asp-Phe-NH2; CCK-4 probe). Both probes bound to type B CCK receptors in a saturable and specific manner and represented full agonists. Similar to the type A receptor, at the type B receptor these probes exhibited shorter lifetimes and lower anisotropy when the receptor was in the active conformation than when it was shifted to its inactive, G protein-uncoupled state using guanosine 5'-[beta,gamma-imido]triphosphate trisodium salt. Absolute values for lifetime and anisotropy were lower for the CCK-8 probe bound to the type B receptor than for this probe bound to the type A receptor, and Alexa fluorescence was more easily quenched by iodide at the type B receptor. This represents the first direct evidence that, despite having identical affinities for binding and potencies for activating type A and B receptors, CCK is docked via distinct mechanisms, with the amino terminus more exposed to the aqueous milieu when bound to the type B CCK receptor than to the type A CCK receptor. Of interest, despite this difference in binding, activation of both receptors results in analogous direction of movement of the fluorescent indicator probes.	Mayo Clin Scottsdale, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Miller, LJ (corresponding author), Mayo Clin Scottsdale, Ctr Canc, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NIDDK NIH HHS [DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anders J, 1999, BIOCHEMISTRY-US, V38, P6043, DOI 10.1021/bi990269z; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; Cheng ZJ, 2003, J BIOL CHEM, V278, P52972, DOI 10.1074/jbc.M310090200; Dawson ES, 2002, PHARMACOL TOXICOL, V91, P290, DOI 10.1034/j.1600-0773.2002.910605.x; Ding XQ, 2002, MOL PHARMACOL, V61, P1041, DOI 10.1124/mol.61.5.1041; DOUST TAM, 1984, BIOCHEM SOC T, V12, P630, DOI 10.1042/bst0120630; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Harikumar KG, 2004, MOL PHARMACOL, V65, P28, DOI 10.1124/mol.65.1.28; Harikumar KG, 2002, J BIOL CHEM, V277, P18552, DOI 10.1074/jbc.M201164200; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JOHNSEN AH, 1992, EUR J BIOCHEM, V207, P419, DOI 10.1111/j.1432-1033.1992.tb17065.x; Johnsen AH, 1997, P NATL ACAD SCI USA, V94, P10221, DOI 10.1073/pnas.94.19.10221; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; LARSSON LI, 1977, NATURE, V269, P335, DOI 10.1038/269335a0; Miller LJ, 2001, PANCREATOLOGY, V1, P336, DOI 10.1159/000055832; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Noble F, 1999, PROG NEUROBIOL, V58, P349, DOI 10.1016/S0301-0082(98)00090-2; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; QIAN JM, 1993, AM J PHYSIOL, V264, P718; Schmitz F, 1996, MOL PHARMACOL, V50, P436; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; vanKesteren RE, 1996, J BIOL CHEM, V271, P3619; VERNIER P, 1995, TRENDS PHARMACOL SCI, V16, P375, DOI 10.1016/S0165-6147(00)89078-1; VIGNA SR, 1986, P NATL ACAD SCI USA, V83, P4355, DOI 10.1073/pnas.83.12.4355	32	29	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1044	1050		10.1074/jbc.M409480200	http://dx.doi.org/10.1074/jbc.M409480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15520004	hybrid			2022-12-25	WOS:000226195200024
J	Munro, CA; Bates, S; Buurman, ET; Hughes, HB; MacCallum, DM; Bertram, G; Atrih, A; Ferguson, MAJ; Bain, JM; Brand, A; Hamilton, S; Westwater, C; Thomson, LM; Brown, AJP; Odds, FC; Gow, NAR				Munro, CA; Bates, S; Buurman, ET; Hughes, HB; MacCallum, DM; Bertram, G; Atrih, A; Ferguson, MAJ; Bain, JM; Brand, A; Hamilton, S; Westwater, C; Thomson, LM; Brown, AJP; Odds, FC; Gow, NAR			Mnt1p and Mnt2p of Candida albicans are partially redundant alpha-1,2-mannosyltransferases that participate in O-linked mannosylation and are required for adhesion and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST-CELL-WALL; MANNOSYLTRANSFERASE GENE FAMILY; BUCCAL EPITHELIAL-CELLS; WILD-TYPE CELLS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-CHARACTERIZATION; DEFECTIVE-MUTANTS; PICHIA-PASTORIS; N-GLYCOSYLATION; IN-VITRO	The MNT1 gene of the human fungal pathogen Candida albicans is involved in O-glycosylation of cell wall and secreted proteins and is important for adherence of C. albicans to host surfaces and for virulence. Here we describe the molecular analysis of CaMNT2, a second member of the MNT1-like gene family in C. albicans. Mnt2p also functions in O-glycosylation. Mnt1p and Mnt2p encode partially redundant alpha-1,2-mannosyltransferases that catalyze the addition of the second and third mannose residues in an O-linked mannose pentamer. Deletion of both copies of MNT1 and MNT2 resulted in reduction in the level of in vitro mannosyltransferase activity and truncation of O-mannan. Both the mnt2Delta and mnt1Delta single mutants were significantly reduced in adherence to human buccal epithelial cells and Matrigel-coated surfaces, indicating a role for O-glycosylated cell wall proteins or O-mannan itself in adhesion to host surfaces. The double mnt1Deltamnt2Delta mutant formed aggregates of cells that appeared to be the result of abnormal cell separation. The double mutant was attenuated in virulence, underlining the importance of O-glycosylation in pathogenesis of C. albicans infections.	Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen AB25 2ZD, Scotland; Univ Dundee, Sch Life Sci, Dundee DD1 4NH, Scotland	University of Aberdeen; University of Dundee	Gow, NAR (corresponding author), Univ Aberdeen, Inst Med Sci, Sch Med Sci, Foresterhill, Aberdeen AB25 2ZD, Scotland.	n.gow@abdn.ac.uk	Ferguson, Michael A. J./F-7829-2010; Brown, Alistair J.P./B-6627-2014; MacCallum, Donna M./D-7897-2011; Westwater, Caroline/AAZ-9217-2020; GOW, Neil/AAS-5323-2021; Munro, Carol A/A-5175-2011; Brand, Alexandra/P-7493-2018	Ferguson, Michael A. J./0000-0003-1321-8714; MacCallum, Donna M./0000-0003-4833-0378; Westwater, Caroline/0000-0001-9329-2513; GOW, Neil/0000-0002-2776-5850; Bates, Steven/0000-0003-0489-5705; Brand, Alexandra/0000-0002-7381-131X; Brown, Alistair JP/0000-0003-1406-4251; bain, judith/0000-0002-1060-0419; Munro, Carol/0000-0003-0761-1755	Wellcome Trust [063204] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brand A, 2004, EUKARYOT CELL, V3, P900, DOI 10.1128/EC.3.4.900-909.2004; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; Calderone RA., 2002, CANDIDA CANDIDIASIS; Calderone Richard A., 1993, Trends in Microbiology, V1, P55, DOI 10.1016/0966-842X(93)90033-N; CASANOVA M, 1992, INFECT IMMUN, V60, P4221, DOI 10.1128/IAI.60.10.4221-4229.1992; Cutler JE, 2001, MED MYCOL, V39, P75, DOI 10.1080/714030992; Dalle F, 2003, INFECT IMMUN, V71, P7061, DOI 10.1128/IAI.71.12.7061-7068.2003; Dallies N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; DOUGLAS LJ, 1981, FEMS MICROBIOL LETT, V12, P241; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FONZI WA, 1993, GENETICS, V134, P717; Frieman MB, 2002, MOL MICROBIOL, V46, P479, DOI 10.1046/j.1365-2958.2002.03166.x; Fukazawa Y, 1997, J MED VET MYCOL, V35, P87; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; Gaur NK, 2004, MICROBIOL-SGM, V150, P277, DOI 10.1099/mic.0.26738-0; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; GOW NAR, 1982, J GEN MICROBIOL, V128, P2187; Gow NAR, 1999, BIOCHEM SOC T, V27, P512, DOI 10.1042/bst0270512; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HERCOVICS A, 1999, BIOCHIM BIOPHYS ACTA, V1426, P275; Herrero AB, 2002, EUKARYOT CELL, V1, P420, DOI 10.1128/EC.1.3.420-431.2002; HILL K, 1992, GENETICS, V130, P273; Hobson RP, 2004, J BIOL CHEM, V279, P39628, DOI 10.1074/jbc.M405003200; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hughes HB, 1999, MICROBIOL-UK, V145, P1927, DOI 10.1099/13500872-145-8-1927; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KANBE T, 1994, INFECT IMMUN, V62, P1662, DOI 10.1128/IAI.62.5.1662-1668.1994; Kapteyn JC, 2000, MOL MICROBIOL, V35, P601, DOI 10.1046/j.1365-2958.2000.01729.x; Kapteyn JC, 1999, MOL MICROBIOL, V31, P1835, DOI 10.1046/j.1365-2958.1999.01320.x; KIMURA LH, 1978, INFECT IMMUN, V21, P64, DOI 10.1128/IAI.21.1.64-68.1978; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lobsanov YD, 2004, J BIOL CHEM, V279, P17921, DOI 10.1074/jbc.M312720200; Lussier M, 1997, YEAST, V13, P267, DOI 10.1002/(SICI)1097-0061(19970315)13:3<267::AID-YEA72>3.0.CO;2-K; Lussier M, 1997, J BIOL CHEM, V272, P15527, DOI 10.1074/jbc.272.24.15527; Lussier M, 1996, J BIOL CHEM, V271, P11001, DOI 10.1074/jbc.271.18.11001; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Maneu V, 1996, FEMS MICROBIOL LETT, V145, P157, DOI 10.1016/S0378-1097(96)00386-2; Munro CA, 2003, FUNGAL GENET BIOL, V40, P146, DOI 10.1016/S1087-1845(03)00083-5; NAKIJAMA T, 1977, P NATL ACAD SCI USA, V72, P3912; Odds FC., 1988, CANDIDA CANDIDOSIS; Pappas PG, 2003, CLIN INFECT DIS, V37, P634, DOI 10.1086/376906; Popolo L, 2001, MED MYCOL, V39, P111, DOI 10.1080/744118881; Romani Luigina, 2002, P223; Romero PA, 1999, GLYCOBIOLOGY, V9, P1045, DOI 10.1093/glycob/9.10.1045; Romero PA, 1997, BIOCHEM J, V321, P289, DOI 10.1042/bj3210289; Sandven Per, 2000, Revista Iberoamericana de Micologia, V17, P73; Schaller M, 1998, MOL MICROBIOL, V29, P605, DOI 10.1046/j.1365-2958.1998.00957.x; Seoighe C, 2000, P NATL ACAD SCI USA, V97, P14433, DOI 10.1073/pnas.240462997; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Sundstrom P, 1999, CURR OPIN MICROBIOL, V2, P353, DOI 10.1016/S1369-5274(99)80062-9; Thomson LM, 2000, J BIOL CHEM, V275, P18933, DOI 10.1074/jbc.M909699199; Timpel C, 2000, J BACTERIOL, V182, P3063, DOI 10.1128/JB.182.11.3063-3071.2000; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; Wang YY, 1998, INFECT IMMUN, V66, P1384, DOI 10.1128/IAI.66.4.1384-1391.1998; Watts HJ, 1998, FEMS MICROBIOL LETT, V159, P129, DOI 10.1111/j.1574-6968.1998.tb12851.x; WOOD PJ, 1980, CARBOHYD RES, V85, P271, DOI 10.1016/S0008-6215(00)84676-5	62	144	152	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1051	1060		10.1074/jbc.M411413200	http://dx.doi.org/10.1074/jbc.M411413200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15519997	Green Accepted, hybrid			2022-12-25	WOS:000226195200025
J	Young, RM; Zheng, XM; Holowka, D; Baird, B				Young, RM; Zheng, XM; Holowka, D; Baird, B			Reconstitution of regulated phosphorylation of Fc epsilon RI by a lipid raft-excluded protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; MEMBRANE DOMAINS; LYN KINASE; HISTAMINE-RELEASE; MAST-CELLS; PTP-ALPHA; ACTIVATION; SHP-1; CD45	To examine the exquisite regulation of IgE-FcepsilonRI tyrosine phosphorylation by Lyn kinase that is stimulated by antigen-mediated cross-linking, we utilized co-expression of FcepsilonRI and Lyn in Chinese hamster ovary cells, which results in high basal levels of Lyn kinase activity and spontaneous phosphorylation of FcepsilonRI. We found that co-expression of a lipid raft-excluded transmembrane tyrosine phosphatase, PTPalpha, suppresses Lyn kinase activity and markedly reduces the level of spontaneous phosphorylation of FcepsilonRI, while facilitating its antigen-stimulated phosphorylation. Other tyrosine phosphatases, including SHP-1, CD45, and a lipid raft-preferring chimeric version of PTPalpha fail to reconstitute antigen-dependent FcepsilonRI phosphorylation. We concluded that both substrate specificity and submembrane location are critical to phosphatase-mediated regulation of Lyn kinase activity that supports activation of FcepsilonRI.	Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University; Cornell University	Baird, B (corresponding author), Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	bab13@cornell.edu			NIAID NIH HHS [R01-AI22449] Funding Source: Medline; NIGMS NIH HHS [T32-GM07273] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007273] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER G, 1991, J BIOL CHEM, V266, P22613; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Coggeshall KM, 2002, MOL IMMUNOL, V39, P521, DOI 10.1016/S0161-5890(02)00209-2; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; He X, 2002, EUR J IMMUNOL, V32, P2578, DOI 10.1002/1521-4141(200209)32:9<2578::AID-IMMU2578>3.0.CO;2-3; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Holowka D, 2000, J CELL SCI, V113, P1009; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kosugi A, 2001, IMMUNITY, V14, P669, DOI 10.1016/S1074-7613(01)00146-7; Mao SY, 1997, J BIOL CHEM, V272, P14067, DOI 10.1074/jbc.272.22.14067; MENON AK, 1986, J CELL BIOL, V102, P541, DOI 10.1083/jcb.102.2.541; MENON AK, 1984, J CELL BIOL, V98, P577, DOI 10.1083/jcb.98.2.577; Metzger H, 2002, MOL IMMUNOL, V38, P1207, DOI 10.1016/S0161-5890(02)00065-2; Moretta A, 2000, SEMIN IMMUNOL, V12, P129, DOI 10.1006/smim.2000.0215; Murakami K, 2000, INT IMMUNOL, V12, P169, DOI 10.1093/intimm/12.2.169; Ng DHW, 1997, BIOCHEM J, V327, P867; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Peirce M, 2000, J BIOL CHEM, V275, P34976, DOI 10.1074/jbc.M005819200; POSNER RG, 1992, BIOCHEMISTRY-US, V31, P5350, DOI 10.1021/bi00138a015; Pyenta PS, 2001, BIOPHYS J, V80, P2120, DOI 10.1016/S0006-3495(01)76185-1; Repetto B, 1996, J IMMUNOL, V156, P4876; Rivera J, 2002, MOL IMMUNOL, V38, P1253, DOI 10.1016/S0161-5890(02)00072-X; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SCHNEIDER H, 1993, IMMUNOL INVEST, V22, P503, DOI 10.3109/08820139309084179; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Siminovitch KA, 1999, CURR TOP MICROBIOL, V246, P291; Siraganian RP, 2002, MOL IMMUNOL, V38, P1229, DOI 10.1016/S0161-5890(02)00068-8; Somani AK, 2001, J BIOL CHEM, V276, P1938, DOI 10.1074/jbc.M006820200; Su MWC, 2001, J IMMUNOL, V166, P3975, DOI 10.4049/jimmunol.166.6.3975; SWIETER M, 1995, J IMMUNOL, V155, P5330; Torigoe C, 2001, BIOCHEMISTRY-US, V40, P4016, DOI 10.1021/bi0027534; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Vonakis BM, 2001, J BIOL CHEM, V276, P1041, DOI 10.1074/jbc.M003397200; Wang LL, 1999, J IMMUNOL, V162, P1318; Xie ZH, 2000, J IMMUNOL, V164, P1521, DOI 10.4049/jimmunol.164.3.1521; Young RM, 2003, J BIOL CHEM, V278, P20746, DOI 10.1074/jbc.M211402200; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	43	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1230	1235		10.1074/jbc.M408339200	http://dx.doi.org/10.1074/jbc.M408339200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15537644	hybrid			2022-12-25	WOS:000226195200046
J	Zaric, J; Ruegg, C				Zaric, J; Ruegg, C			Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE-2 GENE-EXPRESSION; FLUID SHEAR-STRESS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCRIPTIONAL REGULATION; PROTEASOME INHIBITION; MC3T3-E1 OSTEOBLASTS; UP-REGULATION; ANGIOGENESIS; INDUCTION; KINASE	Cyclooxygenase-2 (COX-2), a key enzyme in prostaglandin synthesis, is highly expressed during inflammation and cellular transformation and promotes tumor progression and angiogenesis. We have previously demonstrated that endothelial cell COX-2 is required for integrin alpha(V)beta(3)-dependent activation of Rac-1 and Cdc-42 and for endothelial cell spreading, migration, and angiogenesis (Dormond, O., Foletti, A., Paroz, C., and Ruegg, C. (2001) Nat. Med. 7, 1041-1047; Dormond, O., Bezzi, M., Mariotti, A., and Ruegg, C. (2002) J. Biol. Chem. 277, 45838-45846). In this study, we addressed the question of whether integrin-mediated cell adhesion may regulate COX-2 expression in endothelial cells. We report that cell detachment from the substrate caused rapid degradation of COX-2 protein in human umbilical vein endothelial cells (HUVEC) independent of serum stimulation. This effect was prevented by broad inhibition of cellular proteinases and by neutralizing lysosomal activity but not by inhibiting the proteasome. HUVEC adhesion to laminin, collagen I, fibronectin, or vitronectin induced rapid COX-2 protein expression with peak levels reached within 2 h and increased COX-2-dependent prostaglandin E-2 production. In contrast, nonspecific adhesion to poly-L-lysine was ineffective in inducing COX-2 expression. Furthermore, the addition of matrix proteins in solution promoted COX-2 protein expression in suspended or poly-L-lysine-attached HUVEC. Adhesion-induced COX-2 expression was strongly suppressed by pharmacological inhibition of c-Src, phosphatidylinositol 3-kinase, p38, extracellular-regulated kinase 1/2, and, to a lesser extent, protein kinase C and by the inhibition of mRNA or protein synthesis. In conclusion, this work demonstrates that integrin-mediated cell adhesion and soluble integrin ligands contribute to maintaining COX-2 steady-state levels in endothelial cells by the combined prevention of lysosomal-dependent degradation and the stimulation of mRNA synthesis involving multiple signaling pathways.	Swiss Inst Expt Canc Res, Ctr Pluridisciplinaire Oncol, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, Natl Ctr Competence Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research; Swiss Institute Experimental Cancer Research	Ruegg, C (corresponding author), Swiss Inst Expt Canc Res, Ctr Pluridisciplinaire Oncol, 155 Chemin Boveresses, CH-1066 Epalinges, Switzerland.	curzio.ruegg@isrec.ch						Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Cho MK, 2004, BIOCHEM PHARMACOL, V67, P2239, DOI 10.1016/j.bcp.2004.02.024; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97; Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050; Dimberg J, 2001, ANTICANCER RES, V21, P911; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2003, THROMB HAEMOSTASIS, V90, P577, DOI 10.1160/TH03-03-0196; Dormond O, 2001, DRUG RESIST UPDATE, V4, P314, DOI 10.1054/drup.2001.0219; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Doroudi R, 2000, BIOCHEM BIOPH RES CO, V269, P257, DOI 10.1006/bbrc.2000.2279; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109-003-0422-2; Engelse MA, 2004, SEMIN THROMB HEMOST, V30, P71; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Figueiredo-Pereira ME, 2002, J BIOL CHEM, V277, P25283, DOI 10.1074/jbc.M109145200; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilroy DW, 2001, AM J PHYSIOL-CELL PH, V281, pC188, DOI 10.1152/ajpcell.2001.281.1.C188; Han SW, 2004, INT J CANCER, V111, P322, DOI 10.1002/ijc.20281; Hashimoto Y, 2004, HISTOPATHOLOGY, V44, P353, DOI 10.1111/j.1365-2559.2004.01853.x; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Jones MK, 1999, NAT MED, V5, P1418; Khan KMF, 2004, J BIOL CHEM, V279, P22039, DOI 10.1074/jbc.M312735200; Kim SJ, 2003, J BIOL CHEM, V278, P42448, DOI 10.1074/jbc.M304887200; Kirtikara K, 2000, MOL CELL BIOCHEM, V203, P41, DOI 10.1023/A:1007045600664; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Marnett LJ, 1999, TRENDS PHARMACOL SCI, V20, P465, DOI 10.1016/S0165-6147(99)01385-1; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murphy JF, 2003, BRIT J HAEMATOL, V121, P157, DOI 10.1046/j.1365-2141.2003.04247.x; Nakagawa T, 1999, J CELL PHYSIOL, V179, P226, DOI 10.1002/(SICI)1097-4652(199905)179:2<226::AID-JCP13>3.3.CO;2-H; Nina M, 2000, EUR BIOPHYS J BIOPHY, V29, P439, DOI 10.1007/PL00006649; Norvell SM, 2004, J APPL PHYSIOL, V96, P957, DOI 10.1152/japplphysiol.00869.2003; Okahara K, 1998, ARTERIOSCL THROM VAS, V18, P1922, DOI 10.1161/01.ATV.18.12.1922; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PAVALKO FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591, DOI DOI 10.1152/ajpcell.1998.275.6.C1591; Ponik SM, 2004, J APPL PHYSIOL, V97, P135, DOI 10.1152/japplphysiol.01260.2003; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Ruegg C, 2003, ANN MED, V35, P476, DOI 10.1080/07853890310017053; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Sawyer SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1038, DOI 10.1152/ajpcell.2001.281.3.C1038; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; SEGLEN PO, 1976, EXP CELL RES, V100, P276, DOI 10.1016/0014-4827(76)90148-8; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Smyth SS, 2002, J CELL BIOL, V158, P17, DOI 10.1083/jcb.200202100; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stinson MW, 2003, INFECT IMMUN, V71, P2365, DOI 10.1128/IAI.71.5.2365-2372.2003; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200; Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3504, DOI 10.1210/jc.87.7.3504; Tang QB, 2001, CANCER RES, V61, P4329; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Uracz W, 2002, J PHYSIOL PHARMACOL, V53, P643; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266; Weaver SA, 2001, GASTROENTEROLOGY, V120, P1117, DOI 10.1053/gast.2001.23257; Wickstrom SA, 2003, CANCER CELL, V3, P513, DOI 10.1016/S1535-6108(03)00143-0; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang CM, 2002, CELL SIGNAL, V14, P899, DOI 10.1016/S0898-6568(02)00037-2	81	50	52	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1077	1085		10.1074/jbc.M410006200	http://dx.doi.org/10.1074/jbc.M410006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15525653	hybrid			2022-12-25	WOS:000226195200028
J	Zhu, DG; Kosik, KS; Meigs, TE; Yanamadala, V; Denker, BM				Zhu, DG; Kosik, KS; Meigs, TE; Yanamadala, V; Denker, BM			G alpha(12) directly interacts with PP2A - Evidence for G alpha(12)-stimulated PP2A phosphatase activity and dephosphorylation of microtubuleassociated protein, Tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-ALPHA SUBUNITS; CYTOPLASMIC DOMAIN; 2A; PHOSPHORYLATION; ISOFORMS; FAMILY; MECHANISMS; EXPRESSION; STIMULATE; JUNCTIONS	The Galpha(12/13) family of heterotrimeric G proteins modulate multiple cellular processes including regulation of the actin cytoskeleton. Galpha(12/13) interact with several cytoskeletal/ scaffolding proteins, and in a yeast two-hybrid screen with Galpha(12), we detected an interaction with the scaffolding subunit (Aalpha) of the Ser/Thr phosphatase, protein phosphatase 2A (PP2A). PP2A dephosphorylates multiple substrates including tau, a microtubule-associated protein that is hyperphosphorylated in neurofibrillary tangles. The interaction of Aalpha and Galpha(12) was confirmed by coimmunoprecipitation studies in transfected COS cells and by glutathione S-transferase (GST)-Galpha(12) pull-downs from cell lysates of primary neurons. The interaction was specific for Aalpha and Galpha(12) and was independent of Galpha(12) conformation. Endogenous Aalpha and Galpha(12) colocalized by immunofluorescent microscopy in Caco-2 cells and in neurons. In vitro reconstitution of GST-Galpha(12) or recombinant Galpha(12) with PP2A core enzyme resulted in similar to300% stimulation of PP2A activity that was not detected with other Galpha subunits and was similar with GTPgammaS- and GDP-liganded Galpha(12). When tau and active kinase (Cdk5 and p25) were cotransfected in to COS cells, there was robust tau phosphorylation. Co-expression of wild type or QLalpha(12) with tau and the active kinase resulted in 60+/-15% reductions in tau phosphorylation. In primary cortical neurons stimulated with lysophosphatitic acid, a 50% decrease in tau phosphorylation was observed. The Galpha12 effect on tau phosphorylation was inhibited by the PP2A inhibitor, okadaic acid (50 nM), in COS cells and neurons. Taken together, these findings reveal novel, direct regulation of PP2A activity by Galpha(12) and potential in vivo modulation of PP2A target proteins including tau.	Harvard Univ, Inst Med, Brigham & Womens Hosp, Dept Med,Renal Div, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ N Carolina, Dept Biol, Asheville, NC 28804 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina - Asheville	Denker, BM (corresponding author), Harvard Univ, Inst Med, Brigham & Womens Hosp, Dept Med,Renal Div, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	bdenker@rics.bwh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA100869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055223, R29GM055223] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100869] Funding Source: Medline; NIGMS NIH HHS [GM 55223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Busconi L, 2000, J BIOL CHEM, V275, P1565, DOI 10.1074/jbc.275.3.1565; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; KOHZUKI M, 1995, J CARDIOVASC PHAR S3, V26, P329; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Lu M, 2001, MOL BIOL CELL, V12, P171, DOI 10.1091/mbc.12.1.171; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Meyer TN, 2003, AM J PHYSIOL-CELL PH, V285, pC1281, DOI 10.1152/ajpcell.00548.2002; Meyer TN, 2002, J BIOL CHEM, V277, P24855, DOI 10.1074/jbc.C200240200; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Sayas CL, 2002, J NEUROSCI, V22, P6863; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Yagami T, 2002, BRAIN RES, V948, P72, DOI 10.1016/S0006-8993(02)02951-7; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; ZHANG WW, 1994, J NEUROL SCI, V122, P90, DOI 10.1016/0022-510X(94)90057-4	30	36	37	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					54983	54986		10.1074/jbc.C400508200	http://dx.doi.org/10.1074/jbc.C400508200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15525651	hybrid			2022-12-25	WOS:000225960800002
J	Amarilio, R; Ramachandran, S; Sabanay, H; Lev, S				Amarilio, R; Ramachandran, S; Sabanay, H; Lev, S			Differential regulation of endoplasmic reticulum structure through VAP-Nir protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-DEGENERATION-B; MEMBRANE-PROTEIN; TRANSFER DOMAIN; MICROTUBULES; ORGANIZATION; OVEREXPRESSION; LOCALIZATION; BIOGENESIS; KARMELLAE; HOMOLOG	The endoplasmic reticulum (ER) exhibits a characteristic tubular structure that is dynamically rearranged in response to specific physiological demands. However, the mechanisms by which the ER maintains its characteristic structure are largely unknown. Here we show that the integral ER-membrane protein VAP-B causes a striking rearrangement of the ER through interaction with the Nir2 and Nir3 proteins. We provide evidence that Nir (Nir1, Nir2, and Nir3)-VAP-B interactions are mediated through the conserved FFAT (two phenylalanines (FF) in acidic tract) motif present in Nir proteins. However, each interaction affects the structural integrity of the ER differently. Whereas the Nir2-VAP-B interaction induces the formation of stacked ER membrane arrays, the Nir3-VAP-B interaction leads to a gross remodeling of the ER and the bundling of thick microtubules along the altered ER membranes. In contrast, the Nir1-VAP-B interaction has no apparent effect on ER structure. We also show that the Nir2-VAP-B interaction attenuates protein export from the ER. These results demonstrate new mechanisms for the regulation of ER structure, all of which are mediated through interaction with an identical integral ER-membrane protein.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, EM Unit, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Lev, S (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	sima.lev@weizmann.ac.il	Ramachandran, Sreekumar/H-4746-2019; Lev, Sima/AAP-7880-2020	Ramachandran, Sreekumar/0000-0002-6020-1344; Lev, Sima/0000-0002-2108-3330				Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Brosig B, 1998, PROTEIN SCI, V7, P1052; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Elagin VA, 2000, VISUAL NEUROSCI, V17, P303, DOI 10.1017/S095252380017213X; Foster LJ, 2000, TRAFFIC, V1, P512, DOI 10.1034/j.1600-0854.2000.010609.x; Fukuda M, 2001, J BIOL CHEM, V276, P41112, DOI 10.1074/jbc.M106209200; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gong FC, 1996, P NATL ACAD SCI USA, V93, P2219, DOI 10.1073/pnas.93.5.2219; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Kagiwada S, 1998, J BACTERIOL, V180, P1700, DOI 10.1128/JB.180.7.1700-1708.1998; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; Lapierre LA, 1999, J CELL SCI, V112, P3723; Lev S, 2004, EXP CELL RES, V297, P1, DOI 10.1016/j.yexcr.2004.02.033; Lev S, 1999, MOL CELL BIOL, V19, P2278; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Litvak V, 2002, CURR BIOL, V12, P1513, DOI 10.1016/S0960-9822(02)01107-7; Litvak V, 2002, MOL CELL BIOL, V22, P5064, DOI 10.1128/MCB.22.14.5064-5075.2002; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Nishimura Y, 1999, BIOCHEM BIOPH RES CO, V254, P21, DOI 10.1006/bbrc.1998.9876; PARRISH ML, 1995, MOL BIOL CELL, V6, P1535, DOI 10.1091/mbc.6.11.1535; Pennetta G, 2002, NEURON, V35, P291, DOI 10.1016/S0896-6273(02)00769-9; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Powell KS, 2000, TRAFFIC, V1, P689, DOI 10.1034/j.1600-0854.2000.010901.x; Profant DA, 1999, MOL BIOL CELL, V10, P3409, DOI 10.1091/mbc.10.10.3409; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SKEHEL A, 1995, NEUROPHARMACOLOGY, V34, P1379, DOI 10.1016/0028-3908(95)00149-Z; Skehel PA, 2000, P NATL ACAD SCI USA, V97, P1101, DOI 10.1073/pnas.97.3.1101; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; TERASAKI M, 1990, CELL MOTIL CYTOSKEL, V15, P71, DOI 10.1002/cm.970150203; Tian DH, 2002, MOL CELL BIOL, V22, P2650, DOI 10.1128/MCB.22.8.2650-2662.2002; VERGERES G, 1993, J CELL SCI, V106, P249; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; WEIDMANN B, 1993, BIOCHIM BIOPHYS ACTA, V1153, P267, DOI 10.1016/0005-2736(93)90415-V; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Weir ML, 2001, BIOCHEM BIOPH RES CO, V286, P616, DOI 10.1006/bbrc.2001.5437; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; WRIGHT R, 1990, New Biologist, V2, P915; Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200; Yamamoto A, 1996, J CELL SCI, V109, P1727	45	149	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5934	5944		10.1074/jbc.M409566200	http://dx.doi.org/10.1074/jbc.M409566200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15545272	hybrid			2022-12-25	WOS:000227217100100
J	Bardor, M; Nguyen, DH; Diaz, S; Varki, A				Bardor, M; Nguyen, DH; Diaz, S; Varki, A			Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANGANUTZIU-DEICHER ANTIGEN; ACETYLNEURAMINIC ACID; GLYCOLOYLNEURAMINIC ACID; GM3 GANGLIOSIDE; EXPRESSION; HYDROXYLASE; ACETYL; RAT; BIOSYNTHESIS; LYSOSOMES	N-Glycolylneuraminic acid (Neu5Gc) is a widely expressed sialic acid in mammalian cells. Although humans are genetically deficient in producing Neu5Gc, small amounts are present in human cells in vivo. A dietary origin was suggested by human volunteer studies and by observing that free Neu5Gc is metabolically incorporated into cultured human carcinoma cells by unknown mechanisms. We now show that free Neu5Ge uptake also occurs in other human and mammalian cells. Inhibitors of certain non-clathrin-mediated endocytic pathways reduce Neu5Gc accumulation. Studies with human mutant cells show that the lysosomal sialic acid transporter is required for metabolic incorporation of free Neu5Ge. Incorporation of glycosidically bound Neu5Gc from exogenous glycoconjugates (relevant to human gut epithelial exposure to dietary Neu5Gc) requires the transporter as well as the lysosomal sialidase, which presumably acts to release free Neu5Gc. Thus, exogenous Neu5Gc reaches lysosomes via pinocytic/endocytic pathways and is exported in free form into the cytosol, becoming available for activation and transfer to glycoconjugates. In contrast, N-glycolylmannosamine (ManNGc) apparently traverses the plasma membrane by passive diffusion and becomes available for conversion to Neu5Gc in the cytosol. This mechanism can also explain the metabolic incorporation of chemically synthesized unnatural sialic acids, as reported by others. Finally, to our knowledge, this is the first example of delivery to the cytosol of an extracellular small molecule that cannot cross the plasma membrane, utilizing fluid pinocytosis and a specific lysosomal transporter. The approach could, thus, potentially be generalized to any small molecule that has a specific lysosomal transporter but not a plasma membrane transporter.	Univ Calif San Diego, Sch Med, CMM East,Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Sch Med, CMM East,Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA.	a1varki@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM061894, R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32373, 5R24GM61894] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amyere M, 2002, INT J MED MICROBIOL, V291, P487; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Angata T, 2002, BBA-GEN SUBJECTS, V1572, P294, DOI 10.1016/S0304-4165(02)00316-1; Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820; Biancheri R, 2002, CLIN GENET, V61, P443, DOI 10.1034/j.1399-0004.2002.610608.x; BOUHOURS JF, 1989, J BIOL CHEM, V264, P16992; Carr A, 2000, HYBRIDOMA, V19, P241, DOI 10.1089/02724570050109639; Chefalo P, 2003, GLYCOCONJUGATE J, V20, P407, DOI 10.1023/B:GLYC.0000033997.01760.b9; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Chou HH, 2002, P NATL ACAD SCI USA, V99, P11736, DOI 10.1073/pnas.182257399; Collins BE, 2000, GLYCOBIOLOGY, V10, P11, DOI 10.1093/glycob/10.1.11; COMB DG, 1960, J BIOL CHEM, V235, P2529; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; DEVINE PL, 1991, CANCER RES, V51, P5826; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Gu XJ, 1998, BIOTECHNOL BIOENG, V58, P642, DOI 10.1002/(SICI)1097-0290(19980620)58:6<642::AID-BIT10>3.0.CO;2-9; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; Havelaar AC, 1998, J BIOL CHEM, V273, P34568, DOI 10.1074/jbc.273.51.34568; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HIGASHI H, 1988, JPN J CANCER RES, V79, P952, DOI 10.1111/j.1349-7006.1988.tb00060.x; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P251; HIRSCHBERG CB, 1977, J SUPRAMOL STR CELL, V6, P571, DOI 10.1002/jss.400060410; HIRSCHBERG CB, 1976, BIOCHEMISTRY-US, V15, P3591, DOI 10.1021/bi00661a029; HOWARD RJ, 1986, PARASITOLOGY, V92, P527, DOI 10.1017/S0031182000065422; Irie A, 1998, J BIOL CHEM, V273, P15866, DOI 10.1074/jbc.273.25.15866; Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600-0854.2002.30701.x; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; Jones MB, 2004, BIOTECHNOL BIOENG, V85, P394, DOI 10.1002/bit.10901; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; KAWACHI S, 1988, INT ARCH ALLER A IMM, V85, P381, DOI 10.1159/000234536; KAWANO T, 1995, J BIOL CHEM, V270, P16458, DOI 10.1074/jbc.270.27.16458; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; Klein A, 1997, GLYCOBIOLOGY, V7, P421, DOI 10.1093/glycob/7.3.421; Kleta R, 2003, AM J MED GENET A, V120A, P28, DOI 10.1002/ajmg.a.20024; LAKE JR, 1987, GASTROENTEROLOGY, V92, P1251, DOI 10.1016/S0016-5085(87)91085-7; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LEPERS A, 1990, EUR J BIOCHEM, V193, P715, DOI 10.1111/j.1432-1033.1990.tb19391.x; LEPERS A, 1989, FEBS LETT, V250, P245, DOI 10.1016/0014-5793(89)80731-8; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; Marquina G, 1996, CANCER RES, V56, P5165; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; MIYOSHI I, 1986, MOL IMMUNOL, V23, P631, DOI 10.1016/0161-5890(86)90100-8; Muchmore EA, 1998, AM J PHYS ANTHROPOL, V107, P187, DOI 10.1002/(SICI)1096-8644(199810)107:2<187::AID-AJPA5>3.3.CO;2-M; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; Oetke C, 2002, J BIOL CHEM, V277, P6688, DOI 10.1074/jbc.M109973200; Oetke C, 2001, EUR J BIOCHEM, V268, P4553, DOI 10.1046/j.1432-1327.2001.02379.x; Piemonti L, 1999, INT IMMUNOL, V11, P1519, DOI 10.1093/intimm/11.9.1519; Prescher JA, 2004, NATURE, V430, P873, DOI 10.1038/nature02791; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; SCHAUER R, 1980, H-S Z PHYSIOL CHEM, V361, P641, DOI 10.1515/bchm2.1980.361.1.641; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; Schlenzka W, 1996, FEBS LETT, V385, P197, DOI 10.1016/0014-5793(96)00384-5; Schmid JA, 1999, J BIOL CHEM, V274, P19063, DOI 10.1074/jbc.274.27.19063; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; Sieczkarski SB, 2002, J VIROL, V76, P10455, DOI 10.1128/JVI.76.20.10455-10464.2002; Sonnenburg JL, 2002, J BIOL CHEM, V277, P17502, DOI 10.1074/jbc.M110867200; Sonnenburg JL, 2004, GLYCOBIOLOGY, V14, P339, DOI 10.1093/glycob/cwh039; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Takahata N, 1997, P NATL ACAD SCI USA, V94, P4811, DOI 10.1073/pnas.94.9.4811; Tangvoranuntakul P, 2003, P NATL ACAD SCI USA, V100, P12045, DOI 10.1073/pnas.2131556100; TIETZE F, 1989, J BIOL CHEM, V264, P15316; TONDEUR M, 1982, EUR J PEDIATR, V139, P142, DOI 10.1007/BF00441499; Traving C, 1998, CELL MOL LIFE SCI, V54, P1330, DOI 10.1007/s000180050258; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; Varki A, 2001, YEARB PHYS ANTHROPOL, V44, P54, DOI 10.1002/ajpa.10018; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585	76	273	305	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4228	4237		10.1074/jbc.M412040200	http://dx.doi.org/10.1074/jbc.M412040200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557321	hybrid			2022-12-25	WOS:000227096600030
J	An, FQ; Compitello, N; Horwitz, E; Sramkoski, M; Knudsen, ES; Renne, R				An, FQ; Compitello, N; Horwitz, E; Sramkoski, M; Knudsen, ES; Renne, R			The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY EFFUSION LYMPHOMA; EPSTEIN-BARR-VIRUS; MULTICENTRIC CASTLEMANS-DISEASE; TERMINAL REPEAT; DNA-SEQUENCES; TRANSCRIPTIONAL ACTIVATION; ENDOTHELIAL-CELLS; SPINDLE CELLS; BETA-CATENIN; HUMAN-HERPESVIRUS-8	Latently infected Kaposi's sarcoma-associated herpesvirus (KSHV)-associated tumor cells have both endothelial and lymphoid origins and express a limited set of latent viral genes. One such gene, ORF73, encodes the latency-associated nuclear antigen (LANA), a multifunctional protein that plays roles in viral DNA replication, episome maintenance, and transcriptional regulation. LANA interacts with cellular proteins involved in transcriptional regulation such as the tumor suppressors, retinoblastoma (Rb) and p53, and RING3 family members. Although several reports about specific LANA-regulated promoters exist, only limited data are available that address how LANA expression in KSHV-infected cells globally affects cellular gene expression, thereby potentially contributing to KSHV pathogenicity. To investigate this question, we generated an Epstein-Barr virus-negative Burkitts lymphoma line that expresses LANA from a tetracycline-inducible promoter (BJAB/Tet-On/LANA), and we performed microarray-based gene expression profiling. Expression profiling at different time points post-induction revealed that 186 genes were activated or repressed over 2-fold in the presence of LANA. Of these genes, 41 are regulated in the Rb/E2F pathway, whereas 7 are related to p53 signaling. To determine whether these gene expression changes translate into LANA-dependent changes in cell cycle regulation, we overexpressed p16 INK4a, a CDK4/6 inhibitor that efficiently induces cell cycle arrest in Rb-positive cells. Under these conditions, LANA expression protects lymphoid cells from p16 INK4a-induced cell cycle arrest and induces S-phase entry.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Cincinnati, Dept Cell Biol, Cincinnati, OH 45229 USA	State University System of Florida; University of Florida; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University System of Ohio; University of Cincinnati	Renne, R (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.	rrenne@ufscc.ufl.edu			NATIONAL CANCER INSTITUTE [R01CA088763, R21CA097939] Funding Source: NIH RePORTER; NCI NIH HHS [CA88763, CA097939] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Ballestas ME, 2001, J VIROL, V75, P3250, DOI 10.1128/JVI.75.7.3250-3258.2001; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Cesarman Ethel, 2002, Recent Results Cancer Res, V159, P27; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Davis MA, 1997, J NATL CANCER I, V89, P1868, DOI 10.1093/jnci/89.24.1868; Dittmer D, 1999, J EXP MED, V190, P1857, DOI 10.1084/jem.190.12.1857; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; DYSON N, 1992, TUMOR SUPPRESSOR GEN, P161; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, J VIROL, V77, P8019, DOI 10.1128/JVI.77.14.8019-8030.2003; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Garber AC, 2001, J VIROL, V75, P7882, DOI 10.1128/JVI.75.17.7882-7892.2001; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grundhoff A, 2003, J VIROL, V77, P2779, DOI 10.1128/JVI.77.4.2779-2783.2003; Hu JH, 2002, J VIROL, V76, P11677, DOI 10.1128/JVI.76.22.11677-11687.2002; Hyun TS, 2001, J VIROL, V75, P8761, DOI 10.1128/JVI.75.18.8761-8771.2001; Jenner RG, 2003, P NATL ACAD SCI USA, V100, P10399, DOI 10.1073/pnas.1630810100; Jeong J, 2001, J VIROL, V75, P1798, DOI 10.1128/JVI.75.4.1798-1807.2001; Jeong JH, 2004, J BIOL CHEM, V279, P16822, DOI 10.1074/jbc.M312801200; Klein U, 2003, BLOOD, V101, P4115, DOI 10.1182/blood-2002-10-3090; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Krishnan HH, 2004, J VIROL, V78, P3601, DOI 10.1128/JVI.78.7.3601-3620.2004; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Liebowitz D, 1998, NEW ENGL J MED, V338, P1413, DOI 10.1056/NEJM199805143382003; Lim C, 2000, J GEN VIROL, V81, P2645, DOI 10.1099/0022-1317-81-11-2645; Lim C, 2001, J BIOL CHEM, V276, P31016, DOI 10.1074/jbc.M102431200; Markey MP, 2002, CANCER RES, V62, P6587; Moore PS, 2003, ANNU REV MICROBIOL, V57, P609, DOI 10.1146/annurev.micro.57.030502.090824; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nielsen JV, 2004, GENOMICS, V83, P181, DOI 10.1016/j.ygeno.2003.07.001; Paggi MG, 2001, CANCER RES, V61, P4651; Platt G, 2002, ONCOGENE, V21, P1823, DOI 10.1038/sj.onc.1205360; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Polakis P, 2000, GENE DEV, V14, P1837; Polson AG, 2002, CANCER RES, V62, P4525; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Renou JP, 2003, ONCOGENE, V22, P4594, DOI 10.1038/sj.onc.1206596; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Schwam DR, 2000, J VIROL, V74, P8532, DOI 10.1128/JVI.74.18.8532-8540.2000; Schwartz DR, 2003, CANCER RES, V63, P2913; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Staal FJT, 2004, J IMMUNOL, V172, P1099, DOI 10.4049/jimmunol.172.2.1099; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Van Dyk LF, 1999, J VIROL, V73, P5110, DOI 10.1128/JVI.73.6.5110-5122.1999; Watanabe T, 2003, J VIROL, V77, P6188, DOI 10.1128/JVI.77.11.6188-6196.2003; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	66	98	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3862	3874		10.1074/jbc.M407435200	http://dx.doi.org/10.1074/jbc.M407435200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15525642	hybrid			2022-12-25	WOS:000226983900089
J	Bollimuntha, S; Singh, BB; Shavali, S; Sharma, SK; Ebadi, M				Bollimuntha, S; Singh, BB; Shavali, S; Sharma, SK; Ebadi, M			TRPC1-mediated inhibition of 1-methyl-4-phenylpyridinium ion neurotoxicity in human SH-SY5Y neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-AMINOETHOXYDIPHENYL BORATE; OXIDATIVE STRESS; INTRACELLULAR CALCIUM; SUBSTANTIA-NIGRA; APOPTOSIS; CA2+; CHANNELS; NEURONS; DISEASE; 2-APB	Mammalian homologues of the Drosophila canonical transient receptor potential (TRP) proteins have been implicated to function as plasma membrane Ca2+ channels. This study examined the role of TRPC1 in human neuroblastoma (SH- SY5Y)cells. SH- SY5Y cells treated with an exogenous neurotoxin, 1-methyl-4-phenylpyridinium ion (MPP+) significantly decreased TRPC1 protein levels. Confocal microscopy on SH-SY5Y cells treatment with MPP+ showed decreased plasma membrane staining of TRPC1. Importantly, overexpression of TRPC1 reduced neurotoxicity induced by MPP+. MPP+-induced alpha-synuclein expression was also suppressed by TRPC1 overexpression. Protection of SH- SY5Y cells against MPP+ was significantly decreased upon the overexpression of antisense TRPC1 cDNA construct or the addition of a nonspecific transient receptor potential channel blocker lanthanum. Activation of TRPC1 by thapsigargin or carbachol decreased MPP+ neurotoxicity, which was partially dependent on external Ca2+. Staining of SH-SY5Y cells with an apoptotic marker (YO-PRO-1) showed that TRPC1 protects SH- SY5Y neuronal cells against apoptosis. Further, TRPC1 overexpression inhibited cytochrome c release and decreased Bax and Apaf-1 protein levels. Interpretation of the above data suggests that reduction in the cell surface expression of TRPC1 following MPP+ treatment may be involved in dopaminergic neurodegeneration. Furthermore, TRPC1 may inhibit degenerative apoptotic signaling to provide neuroprotection against Parkinson's disease-inducing agents.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; Univ N Dakota, Sch Med & Hlth Sci, Dept Pathol, Grand Forks, ND 58203 USA; Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58203 USA	University of North Dakota Grand Forks; University of North Dakota Grand Forks; University of North Dakota Grand Forks	Singh, BB (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA.	bsingh@medicine.nodak.edu		Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE017102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034566] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE017102, R01 DE017102-03, R01 DE017102-02, R01 DE017102-01A1, R01 DE017102-07, R01 DE017102-06A1, R01 DE017102-05, R01 DE017102-04] Funding Source: Medline; NINDS NIH HHS [2R01NS 34566-09, R01 NS034566] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P603; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BALLARD PA, 1985, NEUROLOGY, V35, P949, DOI 10.1212/WNL.35.7.949; Barnhill JC, 2004, J CELL BIOCHEM, V91, P808, DOI 10.1002/jcb.10775; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BELLOMO G, 1992, CANCER RES, V52, P1342; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Chen Q, 1999, EXP NEUROL, V159, P283, DOI 10.1006/exnr.1999.7135; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Choi HJ, 2003, EXP NEUROL, V181, P281, DOI 10.1016/S0014-4886(03)00054-2; DARREN B, 2003, NAT CELL BIOL, V5, P1051; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; FREI B, 1986, FEBS LETT, V198, P99, DOI 10.1016/0014-5793(86)81192-9; Harks EGA, 2003, FASEB J, V17, P941, DOI 10.1096/fj.02-0786fje; HIRSCH EC, 2003, J NEURAL TRANSM, V3, P89; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Kobayashi T, 1998, EUR J PHARMACOL, V363, P1, DOI 10.1016/S0014-2999(98)00774-2; Lee HS, 2000, EXP NEUROL, V165, P164, DOI 10.1006/exnr.2000.7460; Lehotsky J, 2003, PHYSIOL RES, V52, P269; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Meissner W, 2003, MOL NEUROBIOL, V28, P209, DOI 10.1385/MN:28:3:209; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; MONTELL C, 2001, SCI STKE, V90, P1; Moran MM, 2004, CURR OPIN NEUROBIOL, V14, P362, DOI 10.1016/j.conb.2004.05.003; MOSER A, 1992, LIFE SCI, V50, P1885, DOI 10.1016/0024-3205(92)90549-5; Muralikrishnan D, 2001, BRAIN RES, V892, P241, DOI 10.1016/S0006-8993(00)02994-2; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; SANDLER M, 1973, NATURE, V241, P439, DOI 10.1038/241439a0; SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x; Shavali S, 2004, J NEUROSCI RES, V76, P563, DOI 10.1002/jnr.20082; Sheehan JP, 1997, J NEUROCHEM, V68, P1221; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Tatton NA, 1997, NEUROSCIENCE, V77, P1037, DOI 10.1016/S0306-4522(96)00545-3; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Tompkins MM, 1997, AM J PATHOL, V150, P119; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Wang Y, 2002, CELL CALCIUM, V32, P209, DOI 10.1016/S0143416002001562; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3	57	89	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2132	2140		10.1074/jbc.M407384200	http://dx.doi.org/10.1074/jbc.M407384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542611	Green Accepted, hybrid			2022-12-25	WOS:000226341700048
J	Prenner, EJ; Kiricsi, M; Jelokhani-Niaraki, M; Lewis, RNAH; Hodges, RS; McElhaney, RN				Prenner, EJ; Kiricsi, M; Jelokhani-Niaraki, M; Lewis, RNAH; Hodges, RS; McElhaney, RN			Structure-activity relationships of diastereomeric lysine ring size analogs of the antimicrobial peptide gramicidin S - Mechanism of action and discrimination between bacterial and animal cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; REVERSED-PHASE CHROMATOGRAPHY; ACHOLEPLASMA-LAIDLAWII-B; LIPID-BILAYER MEMBRANES; HEMOLYTIC ACTIVITIES; RETENTION TIMES; CYCLIC-PEPTIDES; MOLECULAR-BASIS; P-31 NMR; X-RAY	Structure-activity relationships were examined in seven gramicidin S analogs in which the ring-expanded analog GS14 [cyclo-(VKLKVdYPLKVKLdYP)] is modified by enantiomeric inversions of its lysine residues. The conformation, amphiphilicity, and self-association propensity of these peptides were investigated by circular dichroism spectroscopy and reversed phase high performance liquid chromatography. P-31 nuclear magnetic resonance spectroscopic and dye leakage experiments were performed to evaluate the capacity of these peptides to induce inverse nonlamellar phases in, and to permeabilize phospholipid bilayers; their growth inhibitory activity against the cell wall-less mollicute Acholeplasma laidlawii B was also examined. The amount and stability of beta-sheet structure, effective hydrophobicity, propensity for self-association in water, ability to disrupt the organization of phospholipid bilayers, and ability to inhibit A. laidlawii B growth are strongly correlated with the facial amphiphilicity of these GS14 analogs. Also, the magnitude of the parameters segregate these peptides into three groups, consisting of GS14, the four single inversion analogs, and the two multiple inversion analogs. The capacity of these peptides to differentiate between bacterial and animal cell membranes exhibits a biphasic relationship with peptide amphiphilicity, suggesting that there may only be a narrow range of peptide amphiphilicity within which it is possible to achieve the dual therapeutic requirements of high antibiotic effectiveness and low hemolytic activity. These results were rationalized by considering how the physiochemical properties of these GS14 analogs are likely to be reflected in their partitioning into lipid bilayer membranes.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Ctr Excellence, Prot Engn Network, Edmonton, AB T6G 2H7, Canada; Univ Colorado, Hlth Sci Ctr, Fitzsimons Army Med Ctr, Dept Biochem & Mol Genet, Aurora, CO 80045 USA	University of Alberta; University of Alberta; University of Colorado System; University of Colorado Anschutz Medical Campus	McElhaney, RN (corresponding author), Univ Alberta, Dept Biochem, Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	rmcelhan@ualberta.ca	Prenner, Elmar J/E-5549-2011	Kiricsi, Monika/0000-0002-8416-2052	NIAID NIH HHS [R01 AI067296-01A2, R01 AI067296] Funding Source: Medline; NIGMS NIH HHS [R01 GM061885] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067296] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLANCO FJ, 1994, BIOCHEMISTRY-US, V33, P6004, DOI 10.1021/bi00185a041; CAGAS PM, 1995, PROT STRUCT FUNCT GE, V21, P141; CAMPBELL RF, 1979, J PHYS CHEM-US, V83, P525, DOI 10.1021/j100467a020; Cornut I., 1993, AMPHIPATHIC HELIX, P173; Gause GF, 1944, NATURE, V154, P703, DOI 10.1038/154703a0; Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284; GUO DC, 1986, J CHROMATOGR, V359, P499, DOI 10.1016/0021-9673(86)80102-9; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Izumiya N., 1979, SYNTHETIC ASPECTS BI; Jelokhani-Niaraki M, 2000, BIOCHEM J, V349, P747, DOI 10.1042/bj3490747; Jelokhani-Niaraki M, 2002, J PEPT RES, V60, P23, DOI 10.1034/j.1399-3011.2002.21003.x; Jelokhani-Niaraki M, 2001, J PEPT RES, V58, P293, DOI 10.1034/j.1399-3011.2001.00893.x; Kiricsi M, 2002, EUR J BIOCHEM, V269, P5911, DOI 10.1046/j.1432-1033.2002.03315.x; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; Kondejewski LH, 2002, J BIOL CHEM, V277, P67, DOI 10.1074/jbc.M107825200; Kondejewski LH, 1996, J BIOL CHEM, V271, P25261, DOI 10.1074/jbc.271.41.25261; Kondejewski LH, 1996, INT J PEPT PROT RES, V47, P460; Krause E, 1996, INT J PEPT PROT RES, V48, P559; KRIVANEK R, 2000, BIOCHIM BIOPHYS ACTA, V1510, P452; Lee DL, 2004, J PEPT RES, V63, P69, DOI 10.1046/j.1399-3011.2003.00106.x; Lee DL, 2003, J BIOL CHEM, V278, P22918, DOI 10.1074/jbc.M301777200; Lewis RNAH, 1999, BIOCHEMISTRY-US, V38, P15193, DOI 10.1021/bi9912342; Lewis RNAH, 2003, BIOCHEMISTRY-US, V42, P440, DOI 10.1021/bi026707a; Lohner Karl, 2001, P149; MANT CT, 1989, J CHROMATOGR, V476, P363, DOI 10.1016/S0021-9673(01)93882-8; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; McElhaney Ronald N., 1992, P113; McInnes C, 2000, J BIOL CHEM, V275, P14287, DOI 10.1074/jbc.275.19.14287; Nes W. R., 1977, BIOCH STEROIDS OTHER; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; Prenner EJ, 1999, BBA-BIOMEMBRANES, V1417, P211, DOI 10.1016/S0005-2736(99)00004-8; Prenner EJ, 1997, BIOCHEMISTRY-US, V36, P7906, DOI 10.1021/bi962785k; Prenner EJ, 1999, BBA-BIOMEMBRANES, V1462, P201, DOI 10.1016/S0005-2736(99)00207-2; Prenner EJ, 2001, BBA-BIOMEMBRANES, V1510, P83, DOI 10.1016/S0005-2736(00)00337-0; Rothemund S, 1996, PEPTIDE RES, V9, P79; Salgado J, 2001, J BIOMOL NMR, V21, P191, DOI 10.1023/A:1012946026231; SEELIG J, 1978, BIOCHIM BIOPHYS ACTA, V515, P105, DOI 10.1016/0304-4157(78)90001-1; SILVIUS JR, 1978, CAN J BIOCHEM CELL B, V56, P462, DOI 10.1139/o78-072; SILVIUS JR, 1985, BIOCHEMISTRY-US, V24, P5388, DOI 10.1021/bi00341a017; Smith Paul F., 1992, P79; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Staudegger E, 2000, BBA-BIOMEMBRANES, V1468, P213, DOI 10.1016/S0005-2736(00)00260-1; TYTLER EM, 1995, BIOCHEMISTRY-US, V34, P4393, DOI 10.1021/bi00013a031; WAKI M, 1990, BIOCH PEPTIDE ANTIBI, P205; Wishart DS, 1996, LETT PEPT SCI, V3, P53, DOI 10.1007/BF00131086; YEAGLE PL, 1988, BIOL CHOLESTEROL, P121	46	30	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2002	2011		10.1074/jbc.M406509200	http://dx.doi.org/10.1074/jbc.M406509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542606	Green Accepted, hybrid			2022-12-25	WOS:000226341700034
J	Kaplan, CD; Holland, MJ; Winston, F				Kaplan, CD; Holland, MJ; Winston, F			Interaction between transcription elongation factors and mRNA 3 '-end formation at the Saccharomyces cerevisiae GAL10-GAL7 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; HUMAN CSB GENE; IN-VIVO; HISTONE METHYLATION; PAF1 COMPLEX; TERMINAL DOMAIN; FUNCTIONAL INTERACTION; CHROMATIN-STRUCTURE; PROCESSING FACTORS; H3 METHYLATION	Spt6 is a conserved transcription factor that associates with RNA polymerase II (pol II) during elongation. Spt6 is essential for viability in Saccharomyces cerevisiae and regulates chromatin structure during pol II transcription. Here we present evidence that mutations that impair Spt6, a second elongation factor, Spt4, and pol II can affect 3 3'-end formation at GAL10. Additional analysis suggests that Spt6 is required for cotranscriptional association of the factor Ctr9, a member of the Paf1 complex, with GAL10 and GAL7, and that Ctr9 association with chromatin 3' of GAL10 is regulated by the GAL10 polyadenylation signal. Overall, these results provide new evidence for a connection between the transcription elongation factor Spt6 and 3'-end formation in vivo.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Calif Davis, Dept Biochem & Mol Biol, Davis, CA 95616 USA	Harvard University; Harvard Medical School; University of California System; University of California Davis	Kaplan, CD (corresponding author), Stanford Univ, Dept Biol Struct, Fairchild D-122,299 Campus Dr W, Stanford, CA 94305 USA.	cdkaplan@stanford.edu	Kaplan, Craig/AAO-4500-2021	Kaplan, Craig/0000-0002-7518-695X	NHGRI NIH HHS [HG001736] Funding Source: Medline; NIGMS NIH HHS [GM32967] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032967, R37GM032967] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Andrulis ED, 2002, NATURE, V420, P837, DOI 10.1038/nature01181; Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; CLARKADAMS CD, 1987, MOL CELL BIOL, V7, P679, DOI 10.1128/MCB.7.2.679; Costa PJ, 2000, GENETICS, V156, P535; Cui YJ, 2003, MOL CELL BIOL, V23, P7887, DOI 10.1128/MCB.23.21.7887-7901.2003; Denis CL, 2001, GENETICS, V158, P627; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Dichtl B, 2001, EMBO J, V20, P3197, DOI 10.1093/emboj/20.12.3197; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; DOUGLAS HC, 1964, GENETICS, V49, P837; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Endoh M, 2004, MOL CELL BIOL, V24, P3324, DOI 10.1128/MCB.24.8.3324-3336.2004; Formosa T, 2002, GENETICS, V162, P1557; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Greger IH, 1998, EMBO J, V17, P4771, DOI 10.1093/emboj/17.16.4771; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 2002, BBA-GENE STRUCT EXPR, V1577, P276, DOI 10.1016/S0167-4781(02)00458-X; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; Kang J J, 2000, Nucleic Acids Res, V28, pe2, DOI 10.1093/nar/28.2.e2; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Koch C, 1999, NUCLEIC ACIDS RES, V27, P2126, DOI 10.1093/nar/27.10.2126; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee SK, 2002, MOL CELL BIOL, V22, P4383, DOI 10.1128/MCB.22.12.4383-4389.2002; Lee SK, 2002, CELL, V109, P823, DOI 10.1016/S0092-8674(02)00795-X; Lee SK, 2001, MOL CELL BIOL, V21, P8651, DOI 10.1128/MCB.21.24.8651-8656.2001; Lei EP, 2002, GENE DEV, V16, P2761, DOI 10.1101/gad.1032902; Lennon JC, 1998, MOL CELL BIOL, V18, P5771, DOI 10.1128/MCB.18.10.5771; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Lindstrom DL, 2003, MOL CELL BIOL, V23, P1368, DOI 10.1128/MCB.23.4.1368-1378.2003; Lindstrom DL, 2001, GENETICS, V159, P487; MALONE EA, 1993, MOL GEN GENET, V237, P449, DOI 10.1007/BF00279450; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Mellor J, 2004, BBA-GENE STRUCT EXPR, V1677, P100, DOI 10.1016/j.bbaexp.2003.10.014; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; Mueller CL, 2004, MOL CELL, V14, P447, DOI 10.1016/S1097-2765(04)00257-6; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rondon AG, 2004, EMBO REP, V5, P47, DOI 10.1038/sj.embor.7400045; Rose MD., 1990, METHODS YEAST GENETI; Sadowski M, 2003, EMBO J, V22, P2167, DOI 10.1093/emboj/cdg200; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Schaft D, 2003, NUCLEIC ACIDS RES, V31, P2475, DOI 10.1093/nar/gkg372; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Shilatifard A, 2004, BBA-GENE STRUCT EXPR, V1677, P79, DOI 10.1016/j.bbaexp.2003.11.013; SIKORSKI RS, 1989, GENETICS, V122, P19; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Skaar DA, 2002, MOL CELL, V10, P1429, DOI 10.1016/S1097-2765(02)00731-1; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Steinmetz EJ, 2003, MOL CELL BIOL, V23, P6339, DOI 10.1128/MCB.23.18.6339-6349.2003; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; Wade PA, 1996, PROTEIN EXPRES PURIF, V8, P85, DOI 10.1006/prep.1996.0077; Wind-Rotolo M, 2001, J BIOL CHEM, V276, P11531, DOI 10.1074/jbc.M011322200; Winkler M, 2000, J VIROL, V74, P8053, DOI 10.1128/JVI.74.17.8053-8064.2000; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503	82	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					913	922		10.1074/jbc.M411108200	http://dx.doi.org/10.1074/jbc.M411108200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15531585	hybrid			2022-12-25	WOS:000226195200010
J	Ottolia, M; Nicoll, DA; Philipson, KD				Ottolia, M; Nicoll, DA; Philipson, KD			Mutational analysis of the alpha-1 repeat of the cardiac Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; SHAKER K+ CHANNELS; NA+/CA2+ EXCHANGER; DYNAMIC PROPERTIES; TOPOLOGICAL MODEL; MEMBRANE PATCHES; STEADY-STATE; INACTIVATION; EXPRESSION; CLONING	The Na+-Ca2+ exchanger contains internal regions of sequence homology known as the alpha repeats. The first region (alpha-1 repeat) includes parts of transmembrane segments (TMSs) 2 and 3 and a linker modeled to be a reentrant loop. To determine the involvement of the reentrant loop and TMS 3 portions of the alpha-1 repeat in exchanger function, we generated a series of mutants and examined ion binding and transport and regulatory properties. Mutations in the reentrant loop did not substantially modify transport properties of the exchanger though the Hill coefficient for Na+ and the rate of Na+-dependent inactivation were decreased. Mutations in TMS 3 had more striking effects on exchanger activity. Of mutations at 10 positions, 3 behaved like the wild-type exchanger (V137C, A141C, M144C). Mutants at two other positions expressed no activity (Ser(139)) or very low activity (Gly(138)). Six different mutations were made at position 143; only N143D was active, and it displayed wild-type characteristics. The highly specific requirement for an asparagine or aspartate residue at this position may indicate a key role for Asn(143) in the transport mechanism. Mutations at residues Ala(140) and Ile(147) decreased affinity for intracellular Na+, whereas mutations at Phe(145) increased Na+ affinity. The cooperativity of Na+ binding was also altered. In no case was Ca2+ affinity changed. TMS 3 may form part of a site that binds Na+ but not Ca2+. We conclude that TMS 3 is involved in Na+ binding and transport, but previously proposed roles for the reentrant loop need to be reevaluated.	Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, MRL 3-645, Los Angeles, CA 90095 USA.	kphilipson@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basso C, 1998, FEBS LETT, V429, P375, DOI 10.1016/S0014-5793(98)00635-8; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Fujiyoshi Y, 2002, CURR OPIN STRUC BIOL, V12, P509, DOI 10.1016/S0959-440X(02)00355-X; He ZP, 1998, J GEN PHYSIOL, V111, P857, DOI 10.1085/jgp.111.6.857; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Hille B, 1999, NAT MED, V5, P1105, DOI 10.1038/13415; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Kang TM, 2004, NATURE, V427, P544, DOI 10.1038/nature02271; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Loots E, 1998, J GEN PHYSIOL, V112, P377, DOI 10.1085/jgp.112.4.377; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 2002, ANN NY ACAD SCI, V976, P11; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; REEVES JP, 1983, J BIOL CHEM, V258, P3178; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Shigekawa M, 2002, ANN NY ACAD SCI, V976, P19	27	36	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1061	1069		10.1074/jbc.M411899200	http://dx.doi.org/10.1074/jbc.M411899200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15519995	hybrid			2022-12-25	WOS:000226195200026
J	Tiainen, P; Myllyharju, J; Koivunen, P				Tiainen, P; Myllyharju, J; Koivunen, P			Characterization of a second Arabidopsis thaliana prolyl 4-hydroxylase with distinct substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABINOGALACTAN-PROTEINS; PROLINE HYDROXYLATION; BINDING DOMAIN; ALPHA-SUBUNIT; HIF-ALPHA; COLLAGEN; HYDROXYPROLINE; IDENTIFICATION; ENZYMES; CLONING	4-Hydroxyproline is found in collagens, collagen-like proteins, elastin, and the hypoxia-inducible transcription factor in animals and in many hydroxyproline-rich glycoproteins in plants. We report here on the cloning and characterization of a second plant P4H (prolyl 4-hydroxylase), At-P4H-2, from Arabidopsis thaliana. It consists of 299 amino acids and shows 33% sequence identity to the first characterized isoenzyme, At-P4H-1. A characteristic feature of the At-P4H-2 polypeptide is a 49-amino-acid C-terminal toxin homology domain with 6 cysteines that is not found in At-P4H-1 but is present in a putative rice P4H homologue. At-P4H-2 differed distinctly from At-P4H-1 in its substrate specificity. Recombinant At-P4H-2 hydroxylated poly(L-proline) and extensin and arabinogalactan-like peptides effectively but with much higher Km values than At-P4H-1, suggesting different roles for the two At-P4Hs in the plant cell. Unlike At-P4H-1, At-P4H-2 hydroxylated collagen-like peptides only very inefficiently and did not hydroxylate hypoxia-inducible transcription factor alpha-like peptides at all. All the peptides efficiently hydroxylated by At-P4H-2 had at least 3 consecutive prolines, suggesting that these may represent a minimum requirement for efficient hydroxylation by this isoenzyme. N-terminal sequencing of an extensin-like peptide SPPPVYKSPPPPVKHYSPPPV indicated that At-P4H-2 preferentially hydroxylated the 3rd proline in the C-terminal PPP triplet. The K-m values of At-P4H-2 for the reaction cosubstrates Fe2+, 2-oxoglutarate, and ascorbate were similar to those of At-P4H-1 with the exception that the Km for iron was about 3-fold lower. Pyridine-2,4-dicarboxylate and pyridine-2,5-dicarboxylate, well known competitive inhibitors of the vertebrate P4Hs with respect to 2-oxoglutarate, were also competitive inhibitors of At-P4H-2 but with K-i values 5-100-fold higher than those of human type I collagen P4H. It thus seems that there are some distinct differences in the structure of the 2-oxoglutarate-binding site between At-P4H-2 and the animal collagen P4Hs.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu	Koivunen, P (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	peppi.koivunen@oulu.fi						Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; Gill AC, 2000, EMBO J, V19, P5324, DOI 10.1093/emboj/19.20.5324; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kieliszewski MJ, 2001, CELL MOL LIFE SCI, V58, P1386, DOI 10.1007/PL00000783; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Pan TL, 1998, DEV GENES EVOL, V208, P259, DOI 10.1007/s004270050180; Showalter AM, 2001, CELL MOL LIFE SCI, V58, P1399, DOI 10.1007/PL00000784; Shpak E, 2001, J BIOL CHEM, V276, P11272, DOI 10.1074/jbc.M011323200; Silvennoinen L, 2004, J BIOL CHEM, V279, P13607, DOI 10.1074/jbc.M313054200; TANAKA M, 1981, J BIOL CHEM, V256, P1397; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C	35	75	79	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1142	1148		10.1074/jbc.M411109200	http://dx.doi.org/10.1074/jbc.M411109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528200	hybrid			2022-12-25	WOS:000226195200035
J	Rudner, J; Jendrossek, V; Lauber, K; Daniel, PT; Wesselborg, S; Belka, C				Rudner, J; Jendrossek, V; Lauber, K; Daniel, PT; Wesselborg, S; Belka, C			Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies	ONCOGENE			English	Article						TRAIL; Bcl-2; apoptosis	TUMOR-NECROSIS-FACTOR; TYROSINE KINASE LCK; CD95 TYPE-I; CYTOCHROME-C; MEDIATED APOPTOSIS; CASPASE-8 ACTIVATION; IONIZING-RADIATION; SIGNALING COMPLEX; LIGAND TRAIL; SMAC/DIABLO RELEASE	Death receptor-induced apoptosis is paradigmatically mediated via the recruitment of FADD adapter molecule to the ligand/receptor complex and subsequent activation of caspase-8. However, several observations provided evidence that components of the mitochondrial apoptosis pathway are involved in death receptor-mediated apoptosis. In this regard, caspase-8-mediated activation of Bid induces the release of cytochrome c from the mitochondria, which, in turn, triggers the formation of the apoptosome protein complex, resulting in the activation of caspase-9. Whereas Bax or Bak were shown to be required for the proapoptotic effect of Bid, Bcl-2 was described to interfere with its action. Up to now, contradictory results regarding the role of Bcl-2 in TRAIL-induced apoptosis have been published. In order to study the influence of Bcl-2 on TRAIL-induced cell death more detailed, we utilized a tetracycline-regulated Bcl-2 expression system in Jurkat T cells. After having analysed the dose response for TRAIL-induced activation of caspase-8, -9, -3, breakdown of the mitochondrial membrane potential, and changes in the apoptotic morphology in cells expressing different Bcl-2 levels, we conclude that overexpression of Bcl-2 mediates a partial resistance towards lower doses of TRAIL that can be overcome when higher doses of TRAIL are applied. Thus, the requirement of the mitochondrial pathway for death receptor-induced apoptosis in type II cells should be reconsidered, since the protective effect of Bcl-2 is limited to lower TRAIL doses or early observation time points.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Humboldt Univ, Charite, Dept Mol Hematol & Oncol, D-13125 Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Rudner, Justine/ABD-1397-2021; Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107; Wesselborg, Sebastian/0000-0002-5236-942X				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 2003, STRAHLENTHER ONKOL, V179, P141, DOI 10.1007/s00066-003-1047-7; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 2000, NAT MED, V6, P502, DOI 10.1038/74972; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; RUFFOLO SC, 2003, J BIOL CHEM, V29, P29; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; SUN XM, 2002, J BIOL CHEM, V18, P18; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; TECCHIO C, 2004, BLOOD, V15, P15; Velthuis JHL, 2002, J BIOL CHEM, V277, P24631, DOI 10.1074/jbc.M111572200; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zhang XD, 2001, CANCER RES, V61, P7339	78	72	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					130	140		10.1038/sj.onc.1208191	http://dx.doi.org/10.1038/sj.onc.1208191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531922				2022-12-25	WOS:000226125800015
J	Miyazaki, H; Watabe, T; Kitamura, T; Miyazono, K				Miyazaki, H; Watabe, T; Kitamura, T; Miyazono, K			BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells	ONCOGENE			English	Article						PC-3; DU-145; p21(CIP1/WAF1); pRb	BONE MORPHOGENETIC PROTEIN; RETINOBLASTOMA PROTEIN; CANCER CELLS; II RECEPTOR; FACTOR-BETA; EXPRESSION; TGF-BETA-1; CYCLE; DIFFERENTIATION; TRANSDUCTION	Prostate cancer is one of the most common cancers in men. Several lines of evidence have suggested that bone morphogenetic protein (BMP) signals play important roles in the generation and progression of prostate cancers. In the present study, we show that BMP-7 inhibits the proliferation of androgen-insensitive PC-3 and DU-145 prostate cancer cells in a medium containing 1% fetal bovine serum, observed as decreased incorporation of [H-3] thymidine and decreased cell number. Cell cycle analysis by flow cytometry showed an increased fraction of cells in the G1 phase and subsequent decrease in both S and G2/M phase after BMP-7 stimulation. BMP-7 caused an upregulation of the cyclin-dependent kinase inhibitor (CDKI) p21(CIP1/WAF1), and decreased the activity of Cdk2, leading to hypophosphorylation of Rb proteins. Furthermore, in order to evaluate the impact of BMP signals on prostate tumor growth, we generated the PC-3 cell lines expressing a constitutively active BMP type I receptor (constitutively active (c.a.) activin receptor-like kinase (ALK)-6) in a tetracycline (Tet)-regulated manner. Tet/doxycycline-regulated expression of c.a.ALK-6 resulted in the inhibition of in vitro cell proliferation and reduction of the size of tumors derived from the PC-3 cells subcutaneously injected into immune-deficient mice. Collectively, these findings suggest that BMP signals inhibit growth and proliferation of prostate tumor cells through induction of CDKI. Furthermore, this is the first report of a role for BMP signaling in reducing growth kinetics of androgen-insensitive prostate tumors.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp	Kitamura, Toshio/AAA-2071-2021					Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Candia AF, 1997, DEVELOPMENT, V124, P4467; CLARKE NW, 1991, BRIT J UROL, V68, P74, DOI 10.1111/j.1464-410X.1991.tb15260.x; Ebisawa T, 1999, J CELL SCI, V112, P3519; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ide H, 1997, CANCER RES, V57, P5022; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; ISHIKAWA T, 1995, BIOCHEM BIOPH RES CO, V216, P26, DOI 10.1006/bbrc.1995.2587; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kim IY, 2000, CANCER RES, V60, P2840; Kim IY, 1996, CANCER RES, V56, P44; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIU F, 1995, MOL CELL BIOL, V15, P3479; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; Miyazono K, 2000, J CELL SCI, V113, P1101; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Park BJ, 2000, CANCER RES, V60, P3031; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SCHER HI, 1987, AM J MED, V82, P6, DOI 10.1016/0002-9343(87)90483-9; Thomas R, 1998, PROSTATE, V37, P236, DOI 10.1002/(SICI)1097-0045(19981201)37:4<236::AID-PROS5>3.0.CO;2-C; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong GA, 2003, AM J PHYSIOL-ENDOC M, V284, pE972, DOI 10.1152/ajpendo.00385.2002; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26	39	83	95	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9326	9335		10.1038/sj.onc.1208127	http://dx.doi.org/10.1038/sj.onc.1208127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531927				2022-12-25	WOS:000225764100004
J	Vey, N; Mozziconacci, MJ; Groulet-Martinec, A; Debono, S; Finetti, P; Carbuccia, N; Beillard, E; Devilard, E; Arnoulet, C; Coso, D; Sainty, D; Xerri, L; Stoppa, AM; Lafage-Pochitaloff, M; Nguyen, C; Houlgatte, R; Blaise, D; Maraninchi, D; Birg, F; Birnbaum, D; Bertucci, F				Vey, N; Mozziconacci, MJ; Groulet-Martinec, A; Debono, S; Finetti, P; Carbuccia, N; Beillard, E; Devilard, E; Arnoulet, C; Coso, D; Sainty, D; Xerri, L; Stoppa, AM; Lafage-Pochitaloff, M; Nguyen, C; Houlgatte, R; Blaise, D; Maraninchi, D; Birg, F; Birnbaum, D; Bertucci, F			Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling	ONCOGENE			English	Article						acute myelogenous leukaemia; gene expression; DNA microarrays; chemotherapy; normal karyotype; FLT3	ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TOPOISOMERASE-II; NITRIC-OXIDE; AML 10; CANCER; CHEMOTHERAPY; CYTOGENETICS; PREDICTION; SURVIVAL	Conventional cytogenetic analysis currently stratifies acute myelogenous leukaemia (AML) into prognostically relevant groups. However, approximately 50% of adult AMLs have normal cytogenetics (NC-AMLs), and represent a heterogeneous and poorly understood group. We analysed gene expression in 55 AML samples including 53 cases from adult patients with NC-AML (n=36), trisomy 8, t(15;17), t(8;21), t(11;19), 7q deletion, and two cell lines using 9000-gene DNA microarrays. Global hierarchical clustering showed that NC-AMLs are a heterogeneous group. Supervised analysis distinguished two subgroups of NC-AML: one subgroup constituted a homogeneous NC cluster ('pure NC-AML'), and the other NC-AMLs were close to the AML cases with translocations ('translocation like'). Gene expression signatures were also derived for patients with trisomy 8, as well as FLT3 and MLL gene duplications. Importantly, samples from 24 NC-AML patients who could be evaluated for clinical outcome were analysed. In all, 43 genes that discriminated two classes of patients with significantly different prognosis were identified. The poor prognosis class contained a majority of 'pure NC-AMLs', whereas the 'translocation-like' AMLs were in the good prognosis class. Discriminator genes included genes involved in drug resistance (TOP2B), protein transport (MTX2, SLC35A2), and cell signalling (MAPK1, PRKAB2). Our results demonstrate the transcriptional heterogeneity of NC-AMLs, and suggest the existence of 'translocation-like' NC-AMLs and of a gene expression signature that may predict response to chemotherapy.	Inst J Paoli I Calmettes, INSERM, UMR599, Dept Mol Oncol,Marseille Canc Inst, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM, UMR599, Dept Haematol,Marseille Canc Inst, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM, UMR599, Dept Biopathol,Marseille Canc Inst, F-13009 Marseille, France; IPSOGEN SAS, Marseille, France; ERT MEIDIA, Marseille, France; Univ Mediterranee, Marseille, France; ERM206, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, UMR599, Dept Mol Oncol,Marseille Canc Inst, 27 Bd Lei Roure,IFR137, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Blaise, Didier/R-2483-2016; Vey, Norbert/AGE-3573-2022; Carbuccia, Nadine/O-4459-2017; Houlgatte, Remi/P-3020-2017; Nguyen, Catherine/M-4119-2016; Finetti, Pascal/O-8669-2017	Blaise, Didier/0000-0002-5684-9447; Vey, Norbert/0000-0001-7027-040X; Carbuccia, Nadine/0000-0002-3561-4315; Nguyen, Catherine/0000-0001-9376-6360; Finetti, Pascal/0000-0002-2674-3123; Bertucci, Francois/0000-0002-0157-0959; Birnbaum, Daniel/0000-0001-7920-9883				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bonilla E, 2003, BIOCHEM PHARMACOL, V65, P1701, DOI 10.1016/S0006-2952(03)00119-9; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Dingemans AMC, 1999, CLIN CANCER RES, V5, P2048; Downing JR, 2002, CANCER CELL, V2, P437, DOI 10.1016/S1535-6108(02)00211-8; GOASGUEN JE, 1992, LEUKEMIA, V6, P520; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Haferlach T, 2003, SEMIN HEMATOL, V40, P281, DOI 10.1016/S0037-1963(03)00193-8; Haferlach T, 2003, J CLIN ONCOL, V21, P256, DOI 10.1200/JCO.2003.08.005; Iyer L, 1998, J CLIN INVEST, V101, P847, DOI 10.1172/JCI915; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kaufmann SH, 1998, LEUKEMIA LYMPHOMA, V29, P217, DOI 10.3109/10428199809068560; Kohlmann A, 2003, GENE CHROMOSOME CANC, V37, P396, DOI 10.1002/gcc.10225; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; LANOTTE M, 1991, BLOOD, V77, P1080; Marcucci G, 2000, CANCER INVEST, V18, P768, DOI 10.3109/07357900009012209; Noguera N, 2002, LEUKEMIA, V16, P2185, DOI 10.1038/sj.leu.2402723; Okutsu J, 2002, MOL CANCER THER, V1, P1035; Pinto A, 2001, CRIT REV ONCOL HEMAT, V39, P275, DOI 10.1016/S1040-8428(00)00122-0; Poirel H, 1996, BLOOD, V87, P2496, DOI 10.1182/blood.V87.6.2496.bloodjournal8762496; Reid HM, 2003, J BIOL CHEM, V278, P51190, DOI 10.1074/jbc.M309314200; Reiffers J, 1996, LEUKEMIA, V10, P389; Reiffers J, 1996, LEUKEMIA, V10, P1874; Sabatti C, 2002, MATH BIOSCI, V176, P17, DOI 10.1016/S0025-5564(01)00102-X; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Tanaka K, 2002, BIOCHEM BIOPH RES CO, V292, P776, DOI 10.1006/bbrc.2002.6713; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Wallqvist A, 2003, BIOINFORMATICS, V19, P2212, DOI 10.1093/bioinformatics/btg302; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	39	42	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9381	9391		10.1038/sj.onc.1207910	http://dx.doi.org/10.1038/sj.onc.1207910			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543237				2022-12-25	WOS:000225764100009
J	Vo, QN; Kim, WJ; Cvitanovic, L; Boudreau, DA; Ginzinger, DG; Brown, KD				Vo, QN; Kim, WJ; Cvitanovic, L; Boudreau, DA; Ginzinger, DG; Brown, KD			The ATM gene is a target for epigenetic silencing in locally advanced breast cancer	ONCOGENE			English	Article						ATM; epigenetics; promoter hypermethylation; breast cancer	PROMOTER; MUTATIONS; RADIATION; HYPERMETHYLATION; METHYLATION; WOMEN	Several epidemiological studies on ataxia-telangiectasia families indicate that obligate ATM heterozygotes display an elevated risk for developing breast cancer. However, a molecular basis for a potential link between diminished ATM function and sporadic breast malignancy remains elusive. Here, we show that 78% (18 out of a panel of 23) of surgically removed breast tumors (stage II or greater) displayed aberrant methylation of the ATM proximal promoter region as judged by methylation-specific PCR. Aberrant methylation of the ATM promoter was independently confirmed in several tumors by bisulfate sequencing. Moreover, bisulfate sequencing indicated that this region of the genome is subject to dense methylation. Further, we found a highly significant correlation (P = 0.0006) between reduced ATM mRNA abundance, as measured by real-time RT-PCR, and aberrant methylation of the ATM gene promoter. These findings indicate that epigenetic silencing of ATM expression occurs in locally advanced breast tumors, and establish a link at the molecular level between reduced ATM function and sporadic breast malignancy.	Dept Biochem & Mol Biol, New Orleans, LA USA; LSU Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA USA; Dept Surg, New Orleans, LA USA; Dept Pathol, New Orleans, LA USA; Univ Calif San Francisco, UCSF Comprehens Canc Ctr, San Francisco, CA 94143 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Brown, KD (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245,1600 Archer Rd, Gainesville, FL 32610 USA.	kdbrown1@ufl.edu						Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3; Angele S, 2000, CLIN CANCER RES, V6, P3536; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bebb DG, 1999, BRIT J CANCER, V80, P1979, DOI 10.1038/sj.bjc.6690630; Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Esteller M, 2001, CANCER RES, V61, P3225; Fang ZM, 2001, PATHOLOGY, V33, P30; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gueven N, 2003, GENE CHROMOSOME CANC, V38, P157, DOI 10.1002/gcc.10261; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kairouz R, 1999, J CLIN PATHOL-MOL PA, V52, P252, DOI 10.1136/mp.52.5.252; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Shafman TD, 2000, GENE CHROMOSOME CANC, V27, P124, DOI 10.1002/(SICI)1098-2264(200002)27:2<124::AID-GCC2>3.0.CO;2-M; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Vo QN, 2002, J CLIN PATHOL, V55, P669, DOI 10.1136/jcp.55.9.669	21	80	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9432	9437		10.1038/sj.onc.1208092	http://dx.doi.org/10.1038/sj.onc.1208092			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516988				2022-12-25	WOS:000225764100015
J	Legendre-Guillemin, V; Metzler, M; Lemaire, JF; Philie, J; Gan, L; Hayden, MR; McPherson, PS				Legendre-Guillemin, V; Metzler, M; Lemaire, JF; Philie, J; Gan, L; Hayden, MR; McPherson, PS			Huntingtin interacting protein 1 (HIP1) regulates clathrin assembly through direct binding to the regulatory region of the clathrin light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; AP180; RECEPTOR; ADAPTER; ACTIN; TRIMERIZATION; DOMAIN; ORGANIZATION; DISRUPTION; MEMBRANE	Huntingtin interacting protein 1 (HIP1) is a component of clathrin coats. We previously demonstrated that HIP1 promotes clathrin assembly through its central helical domain, which binds directly to clathrin light chains (CLCs). To better understand the relationship between CLC binding and clathrin assembly we sought to dissect this interaction. Using C-terminal deletion constructs of the HIP1 helical domain, we identified a region between residues 450 and 456 that is required for CLC binding. Within this region, point mutations showed the importance of residues Leu-451, Leu-452, and Arg-453. Mutants that fail to bind CLC are unable to promote clathrin assembly in vitro but still mediate HIP1 homodimerization and heterodimerization with the family member HIP12/HIP1R. Moreover, HIP1 binding to CLC is necessary for HIP1 targeting to clathrin-coated pits and clathrin-coated vesicles. Interestingly, HIPl binds to a highly conserved region of CLC previously demonstrated to regulate clathrin assembly. These results suggest a role for HIP1/CLC interactions in the regulation of clathrin assembly.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	McGill University; University of British Columbia	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.	peter.mcpherson@mcgill.ca	Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				BARIK S, 1995, MOL BIOTECHNOL, V3, P1, DOI 10.1007/BF02821329; BRODSKY FM, 1991, TRENDS BIOCHEM SCI, V16, P208, DOI 10.1016/0968-0004(91)90087-C; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Carreno S, 2004, J CELL BIOL, V165, P781, DOI 10.1083/jcb.200403120; Chen CY, 2002, EMBO J, V21, P6072, DOI 10.1093/emboj/cdf594; Chen CY, 2005, J BIOL CHEM, V280, P6109, DOI 10.1074/jbc.M408454200; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Engqvist-Goldstein AEY, 2004, MOL BIOL CELL, V15, P1666, DOI 10.1091/mbc.E03-09-0639; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Greene B, 2000, TRAFFIC, V1, P69, DOI 10.1034/j.1600-0854.2000.010110.x; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Henry KR, 2002, MOL BIOL CELL, V13, P2607, DOI 10.1091/mbc.E02-01-0012; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; KIRCHHAUSEN T, 1993, J BIOL CHEM, V268, P10268; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Legendre-Guillemin V, 2004, J CELL SCI, V117, P9, DOI 10.1242/jcs.00928; Legendre-Guillemin V, 2002, J BIOL CHEM, V277, P19897, DOI 10.1074/jbc.M112310200; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Metzler M, 2003, EMBO J, V22, P3254, DOI 10.1093/emboj/cdg334; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morgan JR, 2000, J NEUROSCI, V20, P8667; Morgan JR, 1999, J NEUROSCI, V19, P10201; Moskowitz HS, 2003, MOL BIOL CELL, V14, P4437, DOI 10.1091/mbc.e03-04-0230; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Nossal R, 2001, TRAFFIC, V2, P138, DOI 10.1034/j.1600-0854.2001.020208.x; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; Wakeham DE, 2003, EMBO J, V22, P4980, DOI 10.1093/emboj/cdg511; Wu XF, 2003, MOL BIOL CELL, V14, P516, DOI 10.1091/mbc.E02-06-0353; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297; Ybe JA, 2003, TRAFFIC, V4, P850, DOI 10.1046/j.1600-0854.2003.0139.x; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	46	83	87	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6101	6108		10.1074/jbc.M408430200	http://dx.doi.org/10.1074/jbc.M408430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15533941	Green Accepted, hybrid			2022-12-25	WOS:000227217100117
J	Choi, MY; Partridge, AW; Daniels, C; Du, K; Lukacs, GL; Deber, CM				Choi, MY; Partridge, AW; Daniels, C; Du, K; Lukacs, GL; Deber, CM			Destabilization of the transmembrane domain induces misfolding in a phenotypic mutant of cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL PORE; MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM; ANION-SELECTIVITY; MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; PROLINE RESIDUES; QUALITY-CONTROL; MILD-DISEASE; CFTR	Two phenotypic missense mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) channel pore (L346P and R347P in transmembrane (TM) segment 6) involve gain of a proline residue, but only L346P represents a significant loss of segment hydropathy. We show here that, for synthetic peptides corresponding to sequences of CFTR TM6 segments, circular dichroism spectra of wild type and R347P TM6 in membrane mimetic environments are virtually identical, but L346P loses similar to50% helicity, implying a membrane insertion defect in the latter mutant. A similar defect was observed in the corresponding double-spanning ("hairpin") TM5/6-L346P synthetic peptide. Examination of the biogenesis of CFTR revealed that the full-length protein harboring the L346P mutation is rapidly degraded at the endoplasmic reticulum (ER), whereas the wild type and the R347P protein process normally. Furthermore, a second site mutation (113471) that restores in vitro membrane insertion and folding of the TM5/6L346P peptide also rescues the folding and cell surface chloride channel function of full-length L346P CFTR. The correlated in vitro/in vivo results demonstrate that destabilizing local hydrophobic character represents a sufficient signal for marking CFTR as a non-native protein by the ER quality control, with accompanying deleterious consequences to global protein folding events.	Hosp Sick Children, Res Inst, Program Cell & Lung Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Lukacs, GL (corresponding author), Hosp Sick Children, Res Inst, Program Cell & Lung Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	glukacs@sickkids.ca; deber@sickkids.ca		Lukacs, Gergely/0000-0003-0900-0675				ADAIR BD, 1994, BIOCHEMISTRY-US, V33, P5539, DOI 10.1021/bi00184a024; Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Benharouga M, 2003, J BIOL CHEM, V278, P22079, DOI 10.1074/jbc.M301030200; BOTEVA K, 1994, HUM GENET, V93, P529; Carveth K, 2002, J BIOL CHEM, V277, P39507, DOI 10.1074/jbc.M205759200; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen JM, 2001, MOL BIOL EVOL, V18, P1771, DOI 10.1093/oxfordjournals.molbev.a003965; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Clain J, 2001, J BIOL CHEM, V276, P9045, DOI 10.1074/jbc.M008979200; Deber CM, 2002, NAT STRUCT BIOL, V9, P318, DOI 10.1038/nsb0502-318; Deber CM, 2001, PROTEIN SCI, V10, P212, DOI 10.1110/ps.30301; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gong XD, 2002, J PHYSIOL-LONDON, V540, P39, DOI 10.1113/jphysiol.2001.013235; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; HURLEY JH, 1992, BIOPOLYMERS, V32, P1443, DOI 10.1002/bip.360321104; Linsdell P, 2000, BIOPHYS J, V78, P2973, DOI 10.1016/S0006-3495(00)76836-6; Linsdell P, 2001, J PHYSIOL-LONDON, V531, P51, DOI 10.1111/j.1469-7793.2001.0051j.x; Liu LP, 1999, BIOORGAN MED CHEM, V7, P1, DOI 10.1016/S0968-0896(98)00233-8; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lu LP, 1998, BIOPOLYMERS, V47, P41, DOI 10.1002/(SICI)1097-0282(1998)47:1<41::AID-BIP6>3.0.CO;2-X; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Mohamed A, 1997, BIOCHEM J, V322, P259, DOI 10.1042/bj3220259; OBLATTMONTAL M, 1994, P NATL ACAD SCI USA, V91, P1495, DOI 10.1073/pnas.91.4.1495; Partridge AW, 2004, PROTEINS, V54, P648, DOI 10.1002/prot.10611; Partridge AW, 2002, BIOPOLYMERS, V66, P350, DOI 10.1002/bip.10313; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sanders CR, 2004, ANNU REV BIOPH BIOM, V33, P25, DOI 10.1146/annurev.biophys.33.110502.140348; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; Smith SS, 2001, J GEN PHYSIOL, V118, P407, DOI 10.1085/jgp.118.4.407; Tan ALC, 2002, ARCH BIOCHEM BIOPHYS, V401, P215, DOI 10.1016/S0003-9861(02)00057-7; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WARD CL, 1994, J BIOL CHEM, V269, P25710; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B; Yohannan S, 2004, J MOL BIOL, V341, P1, DOI 10.1016/j.jmb.2004.06.025; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	46	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4968	4974		10.1074/jbc.M410069200	http://dx.doi.org/10.1074/jbc.M410069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15537638	hybrid			2022-12-25	WOS:000227096600118
J	Starzynski, RR; Lipinski, P; Drapier, JC; Diet, A; Smuda, E; Bartlomiejezyk, T; Gralak, MA; Kruszewski, M				Starzynski, RR; Lipinski, P; Drapier, JC; Diet, A; Smuda, E; Bartlomiejezyk, T; Gralak, MA; Kruszewski, M			Down-regulation of iron regulatory protein 1 activities and expression in superoxide dismutase 1 knock-out mice is not associated with alterations in iron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; NITRIC-OXIDE; HYDROGEN-PEROXIDE; MAMMALIAN-CELLS; MESSENGER-RNAS; DEGRADATION; MODULATION; FERRITIN	Iron and oxygen (O-2) are intimately associated in many well characterized patho-physiological processes. These include oxidation of the [4Fe-4S] cluster of mitochondrial aconitase and inactivation of this Krebs cycle enzyme by the superoxide anion (O-2(.-)), a product of the one-electron reduction of O-2. In contrast to the apparent toxicity of this reaction, the biological consequences of O-2(.-)-mediated inactivation of the cytosolic counterpart of mitochondrial aconitase, commonly known as iron regulatory protein 1 (IRP1), are not clear. Apart from its ability to convert citrate to iso-citrate, IRP1 in its apo-form binds to iron-responsive elements in the untranslated regions of mRNAs coding for proteins involved in iron metabolism, to regulate their synthesis and thus control the cellular homeostasis of this metal. Here, we show that in superoxide dismutase 1 (SOD1) knock-out mice, lacking Cu,Zn-SOD, an enzyme that acts to reduce the concentration of 072 mainly in cytosol, not only is aconitase activity of IRP1 inhibited but the level of IRP1 is also strongly decreased. Despite such an evident alteration in IRP1 status, SOD1-deficient mice display a normal iron metabolism phenotype. Our findings clearly show that under conditions of O-2(.-) mediated oxidative stress, IRP1 is not essential for the maintenance of iron metabolism in mammals.	Polish Acad Sci, Inst Genet & Anim Breeding, Dept Mol Biol, PL-05552 Wolka Kosowska, Poland; CNRS, Inst Chim Subst Nat, F-91190 Gif Sur Yvette, France; Inst Nucl Chem & Technol, Dept Radiobiol & Hlth Protect, PL-03195 Warsaw, Poland; Agr Univ Warsaw, Fac Vet Med, Dept Physiol Sci, PL-02776 Warsaw, Poland	Institute of Genetics & Animal Biotechnology, Polish Academy of Sciences; Polish Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institute of Nuclear Chemistry Technology; Warsaw University of Life Sciences	Lipinski, P (corresponding author), Polish Acad Sci, Inst Genet & Anim Breeding, Dept Mol Biol, PL-05552 Wolka Kosowska, Poland.	P.Lipinski@ighz.pl	Gralak, Mikolaj/AAE-7916-2022; Gralak, Mikolaj/GLU-1208-2022; Kruszewski, Marcin/S-6095-2018	Gralak, Mikolaj/0000-0002-3008-4917; Kruszewski, Marcin/0000-0003-4554-8566; , Rafal/0000-0002-7470-0507				Andrews NC, 2000, ANNU REV GENOM HUM G, V1, P75, DOI 10.1146/annurev.genom.1.1.75; Andrews NC, 2002, SEMIN HEMATOL, V39, P227, DOI 10.1053/shem.2002.35632; Beyer W F Jr, 1988, Basic Life Sci, V49, P651; Bothwell, 1980, METHODS HEMATOLOGY, V1, P90; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403; BOUTON C, 2003, SCI STKE, V182, pPE17; Brown NM, 1998, P NATL ACAD SCI USA, V95, P15235, DOI 10.1073/pnas.95.26.15235; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; Caltagirone A, 2001, J BIOL CHEM, V276, P19738, DOI 10.1074/jbc.M100245200; Cuajungco MP, 2003, BRAIN RES REV, V41, P44, DOI 10.1016/S0165-0173(02)00219-9; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; Drapier JC, 1996, BIOESSAYS, V18, P549, DOI 10.1002/bies.950180706; DRAPIER JC, 2001, NITRIC OXIDE BIOL PA, P315; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Festa M, 2000, J BIOL CHEM, V275, P36708, DOI 10.1074/jbc.M004988200; Fillebeen C, 2003, MOL CELL BIOL, V23, P6973, DOI 10.1128/MCB.23.19.6973-6981.2003; Flohe L, 1988, Basic Life Sci, V49, P663; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gehring NH, 1999, J BIOL CHEM, V274, P6219, DOI 10.1074/jbc.274.10.6219; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Knutson M, 2003, CRIT REV BIOCHEM MOL, V38, P61, DOI 10.1080/713609210; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Liochev SI, 2003, FREE RADICAL BIO MED, V34, P1383, DOI 10.1016/S0891-5849(03)00153-9; Lipinski P, 2000, BLOOD, V95, P2960, DOI 10.1182/blood.V95.9.2960.009k13_2960_2966; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; Martelli A, 2004, J INORG BIOCHEM, V98, P1413, DOI 10.1016/j.jinorgbio.2004.04.011; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; Meyron-Holtz EG, 2004, EMBO J, V23, P386, DOI 10.1038/sj.emboj.7600041; Missirlis F, 2003, J BIOL CHEM, V278, P47365, DOI 10.1074/jbc.M307700200; Mueller S, 2001, J BIOL CHEM, V276, P23192, DOI 10.1074/jbc.M100654200; Oliveira L, 2000, P NATL ACAD SCI USA, V97, P6550, DOI 10.1073/pnas.120571797; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Recalcati S, 1999, EUR J BIOCHEM, V259, P304, DOI 10.1046/j.1432-1327.1999.00038.x; SALO DC, 1990, J BIOL CHEM, V265, P11919; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Simpson D, 2000, MOL VIS, V6, P178; Smith SR, 2004, ANN NY ACAD SCI, V1012, P65, DOI 10.1196/annals.1306.006; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; WATANABE H, 1990, FREE RADICAL BIO MED, V8, P507, DOI 10.1016/0891-5849(90)90150-H; Wawryn J, 2002, BBA-GEN SUBJECTS, V1570, P199, DOI 10.1016/S0304-4165(02)00197-6; Wei JPJ, 2001, J BIOL CHEM, V276, P44798, DOI 10.1074/jbc.M104708200	61	33	35	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4207	4212		10.1074/jbc.M411055200	http://dx.doi.org/10.1074/jbc.M411055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557328	hybrid			2022-12-25	WOS:000227096600027
J	Cheng, J; Wang, H; Guggino, WB				Cheng, J; Wang, H; Guggino, WB			Regulation of cystic fibrosis transmembrane regulator trafficking and protein expression by a rho family small GTPase TC10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDUCTANCE REGULATOR; PLASMA-MEMBRANE; GOLGI PROTEIN; BINDING PROTEINS; ENDOCYTOSIS; RECEPTOR; INSULIN; REQUIRES; PARTNER; PATHWAY	The cystic fibrosis transmembrane conductance regulator (CFTR)-interacting protein, CFTR-associated ligand (CAL) down-regulates total and cell surface CFTR by targeting CFTR for degradation in the lysosome. Here, we report that a Rho family small GTPase TC10 interacts with CAL. This interaction specifically up-regulates CFTR protein expression. Co-expression of the constitutively active form, TC10Q75L, increases total and cell surface CFTR in a dose-dependent fashion. Moreover, co-expression of the dominant-negative mutant TC10T31N causes a dose-dependent reduction in mature CFTR. The effect of TC10 is independent of the level of CFTR expression, because a similar effect was observed in a stable cell line that expresses one-tenth of CFTR. Co-expression of TC10Q75L did not have a similar effect on the expression of plasma membrane proteins such as Frizzled-3 and Pr-cadherin or cytosolic proteins such as tubulin and green fluorescent protein. TC10Q75L also did not have a similar effect on the vesicular stomatitis virus glycoprotein. Co-expression of constitutively active and dominant-negative forms of Cdc42 or RhoA did not affect CFTR expression in a manner similar to TC10, indicating that the effect of TC10 is unique within the Rho family. Metabolic pulse-chase experiments show that TC10 did not affect CFTR maturation, suggesting that it exerts its effects on the mature CFTR. Importantly, TC10Q75L reverses CAL-mediated CFTR degradation, suggesting that TC10Q75L inhibits CAL-mediated degradation of CFTR. TC10Q75L does not operate by reducing CAL protein expression or its ability to form dimers or interact with CFTR. Interestingly, the expression of TC10Q75L causes a dramatic redistribution of CAL from the juxtanuclear region to the plasma membrane where the two molecules overlap. These data suggest that TC10 regulates both total and plasma membrane CFTR expression by interacting with CAL. The GTP-bound form of TC10 directs the trafficking of CFTR from the juxtanuclear region to the secretory pathway toward the plasma membrane, away from CAL-mediated degradation of CFTR in the lysosome.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.	wguggino@bsjhmi.edu			NHLBI NIH HHS [HL-47122] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CHUNQIU HJ, 2003, MOL BIOL CELL, V14, P3578; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; He JQ, 2004, J BIOL CHEM, V279, P50190, DOI 10.1074/jbc.M404876200; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Lukacs GL, 1997, BIOCHEM J, V328, P353; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Neudauer CL, 2000, METHOD ENZYMOL, V325, P3; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; Rattner A, 2001, NEURON, V32, P775, DOI 10.1016/S0896-6273(01)00531-1; Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x; SHEN BQ, 1995, J BIOL CHEM, V270, P25102, DOI 10.1074/jbc.270.42.25102; Swiatecka-Urban A, 2004, J BIOL CHEM, V279, P38025, DOI 10.1074/jbc.M403141200; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9	37	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3731	3739		10.1074/jbc.M410026200	http://dx.doi.org/10.1074/jbc.M410026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15546864	hybrid			2022-12-25	WOS:000226983900073
J	Diaz, JF; Barasoain, I; Souto, AA; Amat-Guerri, F; Andreu, JM				Diaz, JF; Barasoain, I; Souto, AA; Amat-Guerri, F; Andreu, JM			Macromolecular accessibility of fluorescent taxoids bound at a paclitaxel binding site in the microtubule surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; BETA-TUBULIN; PROTOFILAMENT NUMBER; STABILIZES MICROTUBULES; PURIFIED TUBULIN; AMINO-ACIDS; GDP-TUBULIN; RESOLUTION; PROTEINS; AGENT	The macromolecular accessibility of the paclitaxel binding site in microtubules has been investigated using a fluorescent taxoid and antibodies against fluorescein, which cannot diffuse into the microtubule lumen. The formation of a specific ternary complex of microtubules, Hexaflutax (7-O-(N-[6(fluorescein-4'-carboxamido)-n-hexanoyl]-L-alanyl)paclitaxel) and 4-4-20 IgG (a monoclonal antibody against fluorescein) has been observed by means of sedimentation and electron microscopy methods. The kinetics of binding of the antibody to microtubule-bound Hexaflutax has been measured. The quenching of the observed fluorescence is fast; (k(+) 2.26 +/- 0.25 x 10(6) m(-1) s(-1) at 37degreesC), indicating that the fluorescein groups of Hexaflutax are exposed to the outer solvent. The velocity of the reaction is linearly dependent on the antibody concentration, indicating that a bimolecular reaction is being observed. Another fluorescent taxoid (Flutax-2) bound to microtubules has also been shown to be rapidly accessible to polyclonal antibodies directed against fluorescein. A reduced rate of Hexaflutax quenching by the antibody is observed in microtubule-associated proteins containing microtubules or in native cellular cytoskeletons. It can be concluded that the fluorescent taxoids bind to an outer site on the microtubules that is shared with paclitaxel. Paclitaxel would be internalized in a further step of binding to reach the known luminal site, this step being blocked in the case of the fluorescent taxoids. Because the fluorescent ligands are able to induce microtubule assembly, binding to the outer site should be enough to induce assembly by a preferential binding mechanism.	CSIC, Ctr Invest Biol, E-28040 Madrid, Spain; CSIC, Inst Quim Organ, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG)	Diaz, JF (corresponding author), CSIC, Ctr Invest Biol, Ramiro Maeztu 9, E-28040 Madrid, Spain.	fer@cib.csic.es	Díaz, J. Fernando/U-3532-2017; Díaz, J. Fernando/M-6853-2019; Souto, Andre A/E-6737-2011	Díaz, J. Fernando/0000-0003-2743-3319; Díaz, J. Fernando/0000-0003-2743-3319; Souto, Andre A/0000-0002-2437-8767; Andreu, Jose M/0000-0001-8064-6933				Abal M, 2001, CELL MOTIL CYTOSKEL, V49, P1, DOI 10.1002/cm.1016; Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; ANDREU JM, 1994, J BIOL CHEM, V269, P31785; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; Andrews LB, 2001, BIOFUTUR, V2001, P40; AREVALO MA, 1990, J MOL BIOL, V214, P105, DOI 10.1016/0022-2836(90)90150-K; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BOLLAG DM, 1995, CANCER RES, V55, P2325; Buey RM, 2004, CHEM BIOL, V11, P225, DOI 10.1016/j.chembiol.2004.01.014; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; CHAN MF, 1998, BIOCHEMISTRY-US, V37, P17692; Choy H, 2001, CRIT REV ONCOL HEMAT, V37, P237, DOI 10.1016/S1040-8428(00)00112-8; DEINES C, 1994, CANCER RES, V54, P75; DEINES C, 1995, THESIS U COMPLUTENSE, P59; DEPEREDA JM, 1995, CELL MOTIL CYTOSKEL, V30, P153, DOI 10.1002/cm.970300207; Diaz JF, 2000, J BIOL CHEM, V275, P26265, DOI 10.1074/jbc.M003120200; Diaz JF, 1996, BIOPHYS J, V70, P2408, DOI 10.1016/S0006-3495(96)79809-0; Diaz JF, 2003, J BIOL CHEM, V278, P8407, DOI 10.1074/jbc.M211163200; Diaz JF, 1998, J BIOL CHEM, V273, P33803, DOI 10.1074/jbc.273.50.33803; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Evangelio JA, 1998, CELL MOTIL CYTOSKEL, V39, P73, DOI 10.1002/(SICI)1097-0169(1998)39:1<73::AID-CM7>3.0.CO;2-H; Gaitanos TN, 2004, CANCER RES, V64, P5063, DOI 10.1158/0008-5472.CAN-04-0771; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gonzalez-Garay ML, 1999, J BIOL CHEM, V274, P23875, DOI 10.1074/jbc.274.34.23875; Hamel E, 1999, BIOCHEMISTRY-US, V38, P5490, DOI 10.1021/bi983023n; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; Hung DT, 1996, CHEM BIOL, V3, P287, DOI 10.1016/S1074-5521(96)90108-8; Jimenez-Barbero Jesus, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P91, DOI 10.2174/1568011023354416; KILAR F, 1985, EUR J BIOCHEM, V147, P17, DOI 10.1111/j.1432-1033.1985.tb08712.x; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; LACKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P291; LARSSON H, 1976, EXP CELL RES, V100, P104, DOI 10.1016/0014-4827(76)90332-3; Li HL, 2002, STRUCTURE, V10, P1317, DOI 10.1016/S0969-2126(02)00827-4; Long BH, 1998, CANCER RES, V58, P1111; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; Meurer-Grob P, 2001, BIOCHEMISTRY-US, V40, P8000, DOI 10.1021/bi010343p; Modig C, 1999, CELL MOTIL CYTOSKEL, V42, P315, DOI 10.1002/(SICI)1097-0169(1999)42:4<315::AID-CM5>3.0.CO;2-C; Moores CA, 2004, MOL CELL, V14, P833, DOI 10.1016/j.molcel.2004.06.009; Nicolaou KC, 2002, TETRAHEDRON, V58, P6413, DOI 10.1016/S0040-4020(02)00655-5; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; Pryor DE, 2002, BIOCHEMISTRY-US, V41, P9109, DOI 10.1021/bi020211b; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; Rao S, 1999, J BIOL CHEM, V274, P37990, DOI 10.1074/jbc.274.53.37990; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Snyder JP, 2001, P NATL ACAD SCI USA, V98, P5312, DOI 10.1073/pnas.051309398; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Souto AA, 1995, ANGEW CHEM INT EDIT, V34, P2710; terHaar E, 1996, BIOCHEMISTRY-US, V35, P243, DOI 10.1021/bi9515127; WADE RH, 1990, J MOL BIOL, V212, P775, DOI 10.1016/0022-2836(90)90236-F; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WHITLOW M, 1995, PROTEIN ENG, V8, P749, DOI 10.1093/protein/8.8.749	59	38	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3928	3937		10.1074/jbc.M407816200	http://dx.doi.org/10.1074/jbc.M407816200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550392	Green Published, hybrid			2022-12-25	WOS:000226983900095
J	Song, CY; Chen, WL; Yang, MC; Huang, JP; Mao, SJT				Song, CY; Chen, WL; Yang, MC; Huang, JP; Mao, SJT			Epitope mapping of a monoclonal antibody specific to bovine dry milk - Involvement of residues 66-76 of strand D in thermal denatured beta-lactoglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-A-II; PROTEIN-BINDING SITES; MOLTEN GLOBULE STATE; IMMUNOCHEMICAL PROPERTIES; ANTIGENIC STRUCTURES; SYNTHETIC MIMICKING; IMMUNE RECOGNITION; ALPHA-LACTALBUMIN; LIGAND-BINDING	beta-Lactoglobulin (beta-LG) is a bovine milk protein sensitive to thermal denaturation. Previously, we demonstrated that such structural change can be detected by a monoclonal antibody (mAb) specific to denatured beta-LG. In the present study, we show a dramatic increase in beta-LG immunoreactivity when heating raw milk between 70 and 80 degreesC. To map out the specific epitope of beta-LG recognized by this mAb, we used a combined strategy including tryptic and CNBr fragments, chemical modifications (acetylation and carboxymethylation), peptide array containing in situ synthesized peptides, and a synthetic soluble peptide for immunoassays. The antigenic determinant we defined was exactly located within the D strand (residues 66-76) of beta-LG. Circular dichroic spectral analysis shows that carboxymethylation on beta-LG not only resulted in a substantial loss of beta-configuration but also exerted a 10 times increase in immunoreactivity as compared with heated beta-LG. The result suggests that a further disordered structure occurred in beta-LG and thus rendered the mAb recognition. Mutations on each charged residue (three Lys and one Glu) revealed that Lys-69 and Glu-74 were extremely essential in maintaining the antigenic structure. We also show an inverse relationship between the immunoreactivity in heated beta-LG and its binding to retinol or palmitic acid. Most interestingly, pH 9-10, which neutralizes the Lys groups of beta-LG, not only reduced its immunoreactivity but also its binding to palmitic acid implicating a role of Lys-69. Taken together, we concluded that strand D of beta-LG participated in the thermal denaturation between 70 and 80 degreesC and the binding to retinol and palmitic acid. The antigenic and biochemical roles of mAb specific to D strand are discussed in detail.	Natl Chiao Tung Univ, Dept Biol Sci & Technol, Coll Biol Sci & Technol, Res Inst Biochem Engn, Hsinchu, Taiwan; Genesis Biotech Inc, Taipei, Taiwan	National Yang Ming Chiao Tung University	Mao, SJT (corresponding author), Natl Chiao Tung Univ, Dept Biol Sci & Technol, Coll Biol Sci & Technol, Res Inst Biochem Engn, 75 Po Ai St, Hsinchu, Taiwan.	mao1010@ms7.hinet.net						Abduragimov AR, 2000, CURR EYE RES, V21, P824, DOI 10.1076/ceyr.21.4.824.5551; ATASSI MZ, 1980, MOL CELL BIOCHEM, V32, P21; ATASSI MZ, 1984, EUR J BIOCHEM, V145, P1, DOI 10.1111/j.1432-1033.1984.tb08516.x; BHATNAGAR PK, 1983, PEPTIDES, V4, P343, DOI 10.1016/0196-9781(83)90145-6; CAILLARD I, 1994, AM J PHYSIOL, V266, pG1053, DOI 10.1152/ajpgi.1994.266.6.G1053; CASAL HL, 1988, BIOCHIM BIOPHYS ACTA, V957, P11, DOI 10.1016/0167-4838(88)90152-5; Chang JY, 2001, J BIOL CHEM, V276, P9705, DOI 10.1074/jbc.M010700200; CHEN L, 1994, J BIOL CHEM, V269, P28282; Chen WL, 2004, J DAIRY SCI, V87, P2720, DOI 10.3168/jds.S0022-0302(04)73399-8; Chevalier F, 2001, J AGR FOOD CHEM, V49, P5031, DOI 10.1021/jf010549x; CHO YJ, 1994, J BIOL CHEM, V269, P11102; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEWIT JN, 1980, BIOCHIM BIOPHYS ACTA, V624, P40, DOI 10.1016/0005-2795(80)90223-8; Fessas D, 2001, EUR J BIOCHEM, V268, P5439, DOI 10.1046/j.0014-2956.2001.02484.x; FRANCIS GL, 1995, J DAIRY SCI, V78, P1209, DOI 10.3168/jds.S0022-0302(95)76740-6; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Guo MR, 1995, J DAIRY SCI, V78, P2336, DOI 10.3168/jds.S0022-0302(95)76860-6; Hambling S. G., 1992, ADV DAIRY CHEM, V1, P141; Havea P, 2001, J DAIRY RES, V68, P483, DOI 10.1017/S0022029901004964; Kontopidis G, 2002, J MOL BIOL, V318, P1043, DOI 10.1016/S0022-2836(02)00017-7; Kushibiki S, 2001, J DAIRY RES, V68, P579, DOI 10.1017/S0022029901005040; Kuwata K, 1999, PROTEIN SCI, V8, P2541; MAO SJT, 1975, BIOCHEMISTRY-US, V14, P4127, DOI 10.1021/bi00689a033; MAO SJT, 1989, J IMMUNOL METHODS, V120, P45, DOI 10.1016/0022-1759(89)90287-1; MAO SJT, 1982, BIOCHIM BIOPHYS ACTA, V713, P365, DOI 10.1016/0005-2760(82)90255-7; MAO SJT, 1983, CLIN CHEM, V29, P1890; MAO SJT, 1988, J LIPID RES, V29, P1023; MAO SJT, 1990, THROMB HAEMOSTASIS, V63, P445; MAO SJT, 1980, BIOCHIM BIOPHYS ACTA, V617, P245, DOI 10.1016/0005-2760(80)90167-8; MAO SJT, 1977, BIOCHEMISTRY-US, V16, P4150, DOI 10.1021/bi00638a003; McCreath GE, 1997, J CHROMATOGR A, V773, P73, DOI 10.1016/S0021-9673(97)00191-X; MILLER EJ, 1991, AM J PHYSIOL, V260, P1; Nagaoka S, 2001, BIOCHEM BIOPH RES CO, V281, P11, DOI 10.1006/bbrc.2001.4298; Narayan M, 1997, BIOCHEMISTRY-US, V36, P1906, DOI 10.1021/bi9621526; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PATTON JG, 1983, CLIN CHEM, V29, P1898; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; QI XL, 1995, BBA-PROTEIN STRUCT M, V1248, P43, DOI 10.1016/0167-4838(94)00225-6; Qin BY, 1998, FEBS LETT, V438, P272, DOI 10.1016/S0014-5793(98)01199-5; Qin BY, 1999, PROTEIN SCI, V8, P75, DOI 10.1110/ps.8.1.75; Qin BY, 1998, BIOCHEMISTRY-US, V37, P14014, DOI 10.1021/bi981016t; Ragona L, 2003, J BIOL CHEM, V278, P38840, DOI 10.1074/jbc.M306269200; Sawyer L, 2000, BBA-PROTEIN STRUCT M, V1482, P136, DOI 10.1016/S0167-4838(00)00160-6; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; TANFORD C, 1959, J AM CHEM SOC, V81, P4032, DOI 10.1021/ja01524a054; Tseng CF, 2004, PROTEOMICS, V4, P2221, DOI 10.1002/pmic.200300787; Uhrinova S, 2000, BIOCHEMISTRY-US, V39, P3565, DOI 10.1021/bi992629o; Wu SY, 1999, J BIOL CHEM, V274, P170, DOI 10.1074/jbc.274.1.170; Yamauchi R, 2003, PEPTIDES, V24, P1955, DOI 10.1016/j.peptides.2003.10.003; Yang J, 2002, J AGR FOOD CHEM, V50, P5207, DOI 10.1021/jf020221j; Zommara M, 1998, BIOSCI BIOTECH BIOCH, V62, P710, DOI 10.1271/bbb.62.710	52	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3574	3582		10.1074/jbc.M407031200	http://dx.doi.org/10.1074/jbc.M407031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15536085	hybrid			2022-12-25	WOS:000226983900055
J	Takada, K; Takiguchi, M; Konno, A; Inaba, A				Takada, K; Takiguchi, M; Konno, A; Inaba, A			Autoimmunity against a tissue kallikrein in IQI/Jic mice - A model for Sjogren's syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SUBMANDIBULAR-GLAND; CARBONIC-ANHYDRASE-II; SJORGRENS SYNDROME; ANIMAL-MODEL; NOD MOUSE; AUTOANTIBODIES; EXPRESSION; IDENTIFICATION; EXOCRINOPATHY; ENZYMES	We have recently characterized IQI/Jic mice as a model for Sjogren's syndrome (SS), a chronic autoimmune disease in humans. In SS, local lymphocytic infiltrations into salivary and lacrimal glands frequently develop to the involvement of systemic exocrine and nonexocrine organs, and the mechanism for progression of this disease remains obscure. Herein, we report identification of an autoantigen shared by various target organs in IQI/Jic mice. Polypeptides identified based on immunorecognition by autoantibodies in sera from IQI/ Jic mice affected with autoimmune disease (> 12 weeks of age) were tissue kallikrein (Klk)-1 and -13 and were cross-reactive to the autoantibodies. Interestingly, Klk-13, but not Klk-1, caused a proliferative response of splenic T cells from IQI/Jic mice from the age of 4 weeks onward. In addition, remarkably enhanced expression of Klk-13 was observed in the salivary glands of the mice in accordance with the development of inflammatory lesions. These results indicate that Klk-13 acts as an autoantigen and may increase T cells responsive to organs commonly expressing Klk-13, playing a pivotal role in the etiology of progression of disease in IQI/Jic mice. Our findings provide insights into the contributions of autoantigens shared by multiple organs in the progress of SS from an organ-specific to a systemic disorder.	Hokkaido Univ, Grad Sch Vet Med, Dept Vet Clin Sci, Mol Med Lab, Sapporo, Hokkaido 0600818, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Dept Biomed Sci, Sapporo, Hokkaido 0600818, Japan	Hokkaido University; Hokkaido University	Inaba, A (corresponding author), Hokkaido Univ, Grad Sch Vet Med, Dept Vet Clin Sci, Mol Med Lab, Sapporo, Hokkaido 0600818, Japan.	inazo@vetmed.hokudai.ac.jp	Takiguchi, Mitsuyoshi/G-3662-2012					ATKINSON JC, 1995, J ORAL PATHOL MED, V24, P206, DOI 10.1111/j.1600-0714.1995.tb01168.x; Bhoola K, 2001, BIOL CHEM, V382, P77, DOI 10.1515/BC.2001.013; Billaut-Mulot O, 2001, J CLIN INVEST, V108, P861, DOI 10.1172/JCI13469; CARLSTEN H, 1990, SCAND J IMMUNOL, V32, P21, DOI 10.1111/j.1365-3083.1990.tb02887.x; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; EPSTEIN O, 1982, GASTROENTEROLOGY, V83, P1177; Esch TR, 1998, ANN NY ACAD SCI, V842, P221, DOI 10.1111/j.1749-6632.1998.tb09654.x; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FELTKAMP T. E. W., 1968, CLIN EXP IMMUNOL, V3, P1; Fox RI, 2000, CURR OPIN RHEUMATOL, V12, P391, DOI 10.1097/00002281-200009000-00007; FRIBERG B, 1988, CLIN EXP RHEUMATOL, V6, P135; HANEJI N, 1994, J IMMUNOL, V153, P2769; Haneji N, 1997, SCIENCE, V276, P604, DOI 10.1126/science.276.5312.604; Hernandez CC, 1998, J RHEUMATOL, V25, P2381; HOFFMAN RW, 1984, ARTHRITIS RHEUM, V27, P157, DOI 10.1002/art.1780270206; HOSOI K, 1994, J BIOCHEM-TOKYO, V115, P137, DOI 10.1093/oxfordjournals.jbchem.a124288; ISACKSON PJ, 1987, BIOCHEMISTRY-US, V26, P2082, DOI 10.1021/bi00382a003; KESSLER HS, 1968, AM J PATHOL, V52, P671; Kikkawa Y, 1998, BBA-PROTEIN STRUCT M, V1382, P55, DOI 10.1016/S0167-4838(97)00144-1; KIM WS, 1991, J BIOL CHEM, V266, P19283; Konno A, 2003, AUTOIMMUNITY, V36, P247, DOI 10.1080/0891693031000141077; Lindstrom J, 2002, J NEUROBIOL, V53, P656, DOI 10.1002/neu.10106; MACSWEEN RN, 1967, ANN RHEUM DIS, V26, P402, DOI 10.1136/ard.26.5.402; MIYAGAWA J, 1986, VIRCHOWS ARCH B, V51, P215, DOI 10.1007/BF02899031; MOUTSOPOULOS HM, 1994, CLIN IMMUNOL IMMUNOP, V72, P162, DOI 10.1006/clin.1994.1123; MURAKAMI K, 1989, FEBS LETT, V257, P400, DOI 10.1016/0014-5793(89)81581-9; NISHIMORI I, 1995, J IMMUNOL, V154, P4865; Okazaki T, 2003, NAT MED, V9, P1477, DOI 10.1038/nm955; Olsson AY, 2002, BIOCHEM BIOPH RES CO, V299, P305; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; Saegusa J, 1997, J VET MED SCI, V59, P897, DOI 10.1292/jvms.59.897; Saegusa K, 2002, J IMMUNOL, V169, P1050, DOI 10.4049/jimmunol.169.2.1050; Sakamoto M, 1999, J ORAL PATHOL MED, V28, P20; STRAND V, 1980, B RHEUM DIS, V30, P1046; Takada K, 2004, RHEUMATOLOGY, V43, P858, DOI 10.1093/rheumatology/keh209; Talal Norman, 1993, P1343; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Uchida K, 2002, LAB INVEST, V82, P411, DOI 10.1038/labinvest.3780435; Uddin M, 2003, BIOCHEM BIOPH RES CO, V304, P724, DOI 10.1016/S0006-291X(03)00645-4; van Blokland SCA, 2002, CLIN IMMUNOL, V103, P111, DOI 10.1006/clim.2002.5189; Vincent A, 2002, NAT REV IMMUNOL, V2, P797, DOI 10.1038/nri916; Waterman SA, 2000, ARTHRITIS RHEUM, V43, P1647; Winer S, 2003, NAT MED, V9, P198, DOI 10.1038/nm818; Winer S, 2002, LANCET, V360, P1063, DOI 10.1016/S0140-6736(02)11144-5; Zekzer D, 1998, J CLIN INVEST, V101, P68, DOI 10.1172/JCI119878	45	44	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3982	3988		10.1074/jbc.M410157200	http://dx.doi.org/10.1074/jbc.M410157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15545270	hybrid			2022-12-25	WOS:000226983900101
J	Battchikova, N; Zhang, PP; Rudd, S; Ogawa, T; Aro, EM				Battchikova, N; Zhang, PP; Rudd, S; Ogawa, T; Aro, EM			Identification of NdhL and Ssl1690 (NdhO) in NDH-1L, and NDH-1M complexes of Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDINE-NUCLEOTIDE DEHYDROGENASE; NADH-UBIQUINONE OXIDOREDUCTASE; PROTON-TRANSLOCATING NADH; RESPIRATORY COMPLEX; POLYACRYLAMIDE-GELS; PROTEIN COMPLEXES; ESCHERICHIA-COLI; CO2 UPTAKE; SUBUNITS; PCC6803	The subunit compositions of two types of NAD(P)H dehydrogenase complexes of Synechocystis sp. PCC 6803, NDH-1L and NDH-1M, were studied by two-dimensional blue-native/SDS-PAGE followed by electrospray tandem mass spectrometry. Fifteen proteins were observed in NDH-1L including hydrophilic subunits (NdhH, -K, -I, -J, -M, and -N) and hydrophobic subunits (NdhA, -B, -E, -G, -D1, and -F1). In addition, NdhL and a novel subunit, SsI1690 (designated NdhO), were shown to be components of this complex. All subunits mentioned above were present in the NDH-1M complex except NdhD1 and NdhF1. NdhL and SsI1690 (NdhO) were homologous to hypothetical proteins encoded by genomic DNA in higher plants, suggesting that chloroplast NDH-1 complexes contain related subunits. Diagnostic sequence motifs were found for both NdhL and NdhO homologous proteins. Analysis of ndhL deletion mutant (W revealed the presence of assembled NDH-1L and NDH-1M complexes, but these complexes appear to be functionally impaired in the absence of NdhL. Both NDH-1 complexes were absent in the ndhB deletion mutant (M55).	Univ Turku, Dept Biol Plant Physiol & Mol Biol, FI-20014 Turku, Finland; Turku Ctr Biotechnol, FIN-20521 Turku, Finland	University of Turku	Aro, EM (corresponding author), Univ Turku, Dept Biol Plant Physiol & Mol Biol, FI-20014 Turku, Finland.	evaaro@utu.fi	Aro, Eva-Mari/Q-8664-2017; Rudd, Stephen A/A-6434-2013	Aro, Eva-Mari/0000-0002-2922-1435; Rudd, Stephen A/0000-0002-0344-7487				BERGER S, 1993, FEBS LETT, V326, P246, DOI 10.1016/0014-5793(93)81800-F; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; GOMBOS Z, 1994, P NATL ACAD SCI USA, V91, P8787, DOI 10.1073/pnas.91.19.8787; Heazlewood JL, 2003, BBA-BIOENERGETICS, V1604, P159, DOI 10.1016/S0005-2728(03)00045-8; Herranen M, 2004, PLANT PHYSIOL, V134, P470, DOI 10.1104/pp.103.032326; JONASSEN I, 1995, PROTEIN SCI, V4, P1587, DOI 10.1002/pro.5560040817; Kaneko T, 1996, DNA Res, V3, P109; Klughammer B, 1999, MOL MICROBIOL, V32, P1305, DOI 10.1046/j.1365-2958.1999.01457.x; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Matsuo M, 1998, PLANT CELL PHYSIOL, V39, P263, DOI 10.1093/oxfordjournals.pcp.a029366; MI HL, 1992, PLANT CELL PHYSIOL, V33, P1233; MI HL, 1995, PLANT CELL PHYSIOL, V36, P661; Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373; Munekaga Y, 2004, NATURE, V429, P579, DOI 10.1038/nature02598; OGAWA T, 1992, PLANT PHYSIOL, V99, P1604, DOI 10.1104/pp.99.4.1604; OGAWA T, 1991, PLANT PHYSIOL, V96, P280, DOI 10.1104/pp.96.1.280; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; Ohkawa H, 2000, J BIOL CHEM, V275, P31630, DOI 10.1074/jbc.M003706200; Ohkawa H, 1998, CAN J BOT, V76, P1035, DOI 10.1139/b98-076; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Peltier G, 2002, ANNU REV PLANT BIOL, V53, P523, DOI 10.1146/annurev.arplant.53.100301.135242; Prommeenate P, 2004, J BIOL CHEM, V279, P28165, DOI 10.1074/jbc.M401107200; Rudd S, 2003, NUCLEIC ACIDS RES, V31, P128, DOI 10.1093/nar/gkg075; Schoof H, 2004, NUCLEIC ACIDS RES, V32, pD373, DOI 10.1093/nar/gkh068; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shibata M, 2001, P NATL ACAD SCI USA, V98, P11789, DOI 10.1073/pnas.191258298; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800; Wang YC, 2000, ELECTROPHORESIS, V21, P1746, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1746::AID-ELPS1746>3.3.CO;2-F; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yuan QP, 2003, NUCLEIC ACIDS RES, V31, P229, DOI 10.1093/nar/gkg059	41	78	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2587	2595		10.1074/jbc.M410914200	http://dx.doi.org/10.1074/jbc.M410914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548534	hybrid			2022-12-25	WOS:000226449100027
J	Egelhoff, TT; Croft, D; Steimle, PA				Egelhoff, TT; Croft, D; Steimle, PA			Actin activation of myosin heavy chain kinase A in Dictyostelium - A biochemical mechanism for the spatial regulation of myosin II filament disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL DOMAIN; PROTEIN-KINASE; CELL MOTILITY; THICK FILAMENTS; C-EPSILON; BINDING; LOCALIZATION; PHOSPHORYLATION; CYTOKINESIS; CHEMOTAXIS	Studies in Dictyostehum discoideum have established that the cycle of myosin 11 bipolar filament assembly and disassembly controls the temporal and spatial localization of myosin 11 during critical cellular processes, such as cytokinesis and cell locomotion. Myosin heavy chain kinase A (MHCK A) is a key enzyme regulating myosin 11 filament disassembly through myosin heavy chain phosphorylation in Dictyostehum. Under various cellular conditions, MHCK A is recruited to actin-rich cortical sites and is preferentially enriched at sites of pseudopod formation, and thus MHCK A is proposed to play a role in regulating localized disassembly of myosin 11 filaments in the cell. MHCK A possesses an aminoterminal coiled-coil domain that participates in the oligomerization, cellular localization, and actin binding activities of the kinase. In the current study, we show that the interaction between the coiled-coil domain of MHCK A and filamentous actin leads to an similar to40-fold increase in the initial rate of kinase catalytic activity. Actin-mediated activation of MHCK A involves increased rates of kinase autophosphorylation and requires the presence of the coiled-coil domain. Structure-function analyses revealed that the coiled-coil domain alone binds to actin filaments (apparent K-D = 0.9 muM) and thus mediates the direct interaction with F-actin required for MHCK A activation. Collectively, these results indicate that MHCK A recruitment to actin-rich sites could lead to localized activation of the kinase via direct interaction with actin filaments, and thus this mode of kinase regulation may represent an important mechanism by which the cell achieves localized disassembly of myosin 11 filaments required for specific changes in cell shape.	Univ N Carolina, Dept Biol, Greensboro, NC 27402 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	University of North Carolina; University of North Carolina Greensboro; Case Western Reserve University	Steimle, PA (corresponding author), Univ N Carolina, Dept Biol, 312 Eberhart Bldg, Greensboro, NC 27402 USA.	p_steiml@uncg.edu			NIGMS NIH HHS [GM50009, R15 GM066789, 1R15GM066789-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050009, R15GM066789, R01GM050009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cheng HY, 2001, MOL CELL BIOL, V21, P6170, DOI 10.1128/MCB.21.18.6170-6180.2001; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; COTE GP, 1987, J BIOL CHEM, V262, P1065; De la Roche MA, 2002, J MUSCLE RES CELL M, V23, P703, DOI 10.1023/A:1024467426244; de la Roche MA, 2001, BBA-GEN SUBJECTS, V1525, P245, DOI 10.1016/S0304-4165(01)00110-6; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; EGELHOFF TT, 1999, GUIDEBOOK CYTOSKELET, P460; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; Juris SJ, 2000, P NATL ACAD SCI USA, V97, P9431, DOI 10.1073/pnas.170281997; Kessin RH, 2003, NATURE, V422, P481, DOI 10.1038/422481a; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Kolman MF, 1996, J CELL BIOL, V132, P101, DOI 10.1083/jcb.132.1.101; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; KYTE J, 1995, STRUCTURE PROTEIN CH, P197; Laevsky G, 2003, J CELL SCI, V116, P3761, DOI 10.1242/jcs.00684; Liang WC, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-19; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; Luo X, 2001, J BIOL CHEM, V276, P17836, DOI 10.1074/jbc.M009366200; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; MEDLEY QG, 1992, BIOCHIM BIOPHYS ACTA, V1175, P7, DOI 10.1016/0167-4889(92)90003-T; MEDLEY QG, 1991, METHOD ENZYMOL, V196, P23; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; Murphy MB, 1999, FEBS LETT, V456, P7, DOI 10.1016/S0014-5793(99)00835-2; Murphy MB, 1999, EUR J BIOCHEM, V264, P582, DOI 10.1046/j.1432-1327.1999.00670.x; Nagasaki A, 2002, MOL BIOL CELL, V13, P4333, DOI 10.1091/mbc.E02-04-0228; Newell PC, 1995, BIOSCIENCE REP, V15, P445, DOI 10.1007/BF01204348; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1994, ANNU REV CELL BIOL, V10, P207, DOI 10.1146/annurev.cellbio.10.1.207; Postma M, 2004, EMBO REP, V5, P35, DOI 10.1038/sj.embor.7400051; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Rico M, 2003, J CELL BIOCHEM, V88, P521, DOI 10.1002/jcb.10361; Robinson DN, 2002, J MUSCLE RES CELL M, V23, P719, DOI 10.1023/A:1024419510314; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Steimle PA, 2002, FEBS LETT, V516, P58, DOI 10.1016/S0014-5793(02)02494-8; Steimle PA, 2001, CURR BIOL, V11, P708, DOI 10.1016/S0960-9822(01)00182-8; Steimle PA, 2001, J BIOL CHEM, V276, P6853, DOI 10.1074/jbc.M008992200; Stites J, 1998, CELL MOTIL CYTOSKEL, V39, P31, DOI 10.1002/(SICI)1097-0169(1998)39:1<31::AID-CM4>3.0.CO;2-J; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Uchida KSK, 2003, J CELL SCI, V116, P51, DOI 10.1242/jcs.00195; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1990, J CELL BIOL, V111, P1137, DOI 10.1083/jcb.111.3.1137; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; Yumura S, 2003, INT REV CYTOL, V224, P173, DOI 10.1016/S0074-7696(05)24005-6; YUMURA S, 1993, CELL STRUCT FUNCT, V18, P379, DOI 10.1247/csf.18.379; YUMURA S, 1994, CELL STRUCT FUNCT, V19, P143, DOI 10.1247/csf.19.143; Zang JH, 1997, MOL BIOL CELL, V8, P2617, DOI 10.1091/mbc.8.12.2617; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210	62	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2879	2887		10.1074/jbc.M410803200	http://dx.doi.org/10.1074/jbc.M410803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15545285	hybrid			2022-12-25	WOS:000226449100063
J	Hulsmeyer, M; Chames, P; Hillig, RC; Stanfield, RL; Held, G; Coulie, PG; Alings, C; Wille, G; Saenger, W; Uchanska-Ziegler, B; Hoogenboom, HR; Ziegler, A				Hulsmeyer, M; Chames, P; Hillig, RC; Stanfield, RL; Held, G; Coulie, PG; Alings, C; Wille, G; Saenger, W; Uchanska-Ziegler, B; Hoogenboom, HR; Ziegler, A			A major histocompatibility complex-peptide-restricted antibody and T cell receptor molecules recognize their target by distinct binding modes - Crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with Fab-Hyb3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; HUMAN RECOMBINANT ANTIBODIES; HIGH-AFFINITY; ESCHERICHIA-COLI; VITRO EVOLUTION; SELF-PEPTIDE; SPECIFICITY; FRAGMENT; CONFORMATION; QUANTITATION	Antibodies with T cell receptor-like specificity possess a considerable diagnostic and therapeutic potential, but the structural basis of the interaction between an antibody and an histocompatibility antigen has so far not been determined. We present here the crystal structure (at 2.15 Angstrom resolution) of the recombinant, affinity-matured human antibody fragment Fab-Hyb3 bound to the tumor-associated human leukocyte antigen (HIA)/peptide complex HIA-A1.MAGE-A1. Fab-Hyb3 employs a diagonal docking mode resembling that of T cell receptors. However, other than these natural ligands, the antibody uses only four of its six complementarity-determining regions for direct interactions with the target. It recognizes the C-terminal half of the MAGE-A1 peptide, the HIA-A1 alpha1-helix, and N-terminal residues of the alpha2-helix, accompanied by a large tilting angle between the two types of molecules within the complex. Interestingly, only a single hydrogen bond between a peptide side chain and Fab-Hyb3 contributes to the interaction, but large buried surface areas with pronounced shape complementarity assure high affinity and specificity for MAGE-A1. The HIA-A1.MAGE-A1.antibody structure is discussed in comparison with those of natural ligands recognizing HLA.peptide complexes.	Humboldt Univ, Charite Univ Med Berlin, Inst Immungenet, D-14050 Berlin, Germany; Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany; Cellectis, F-93235 Romainville, France; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Saarland, Dept Med 1, D-66421 Homburg, Germany; Catholic Univ Louvain, Inst Cellular Pathol, Cellular Genet Unit, B-1200 Brussels, Belgium; Merus BV, Utrecht, Netherlands	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Scripps Research Institute; Saarland University; Universite Catholique Louvain	Ziegler, A (corresponding author), Humboldt Univ, Charite Univ Med Berlin, Inst Immungenet, Campus Virchow Klinikum,Spandauer Damm 130, D-14050 Berlin, Germany.	andreas.ziegler@charite.de	Chames, Patrick/R-1800-2016; Stanfield, Robyn/AAH-3190-2019	Chames, Patrick/0000-0002-6104-6286; 				ABASTADO JP, 1989, RES IMMUNOL, V140, P581, DOI 10.1016/0923-2494(89)90121-1; AHARONI R, 1991, NATURE, V351, P147, DOI 10.1038/351147a0; Andersen PS, 1996, P NATL ACAD SCI USA, V93, P1820, DOI 10.1073/pnas.93.5.1820; Apostolopoulos V, 2002, J MOL BIOL, V318, P1307, DOI 10.1016/S0022-2836(02)00198-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biddison WE, 2003, J IMMUNOL, V171, P3064, DOI 10.4049/jimmunol.171.6.3064; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; Chames P, 2000, P NATL ACAD SCI USA, V97, P7969, DOI 10.1073/pnas.97.14.7969; Chames P, 2002, J IMMUNOL, V169, P1110, DOI 10.4049/jimmunol.169.2.1110; Cohen CJ, 2003, J MOL RECOGNIT, V16, P324, DOI 10.1002/jmr.640; Dadaglio G, 1997, IMMUNITY, V6, P727, DOI 10.1016/S1074-7613(00)80448-3; Denkberg G, 2002, P NATL ACAD SCI USA, V99, P9421, DOI 10.1073/pnas.132285699; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Eastman S, 1996, EUR J IMMUNOL, V26, P385, DOI 10.1002/eji.1830260218; Engberg J, 1999, IMMUNOTECHNOLOGY, V4, P273; Fan QR, 2001, NAT IMMUNOL, V2, P452, DOI 10.1038/87766; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Holler PD, 2000, P NATL ACAD SCI USA, V97, P5387, DOI 10.1073/pnas.080078297; Holler PD, 2003, NAT IMMUNOL, V4, P55, DOI 10.1038/ni863; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Housset D, 2003, TRENDS IMMUNOL, V24, P429, DOI 10.1016/S1471-4906(03)00180-7; Hulsmeyer M, 2004, J EXP MED, V199, P271, DOI 10.1084/jem.20031690; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lev A, 2002, CANCER RES, V62, P3184; Li YL, 2003, NAT STRUCT BIOL, V10, P482, DOI 10.1038/nsb930; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Maeurer MJ, 1996, MELANOMA RES, V6, P11, DOI 10.1097/00008390-199602000-00003; Malissen B, 2003, IMMUNITY, V19, P463, DOI 10.1016/S1074-7613(03)00271-1; Menssen R, 1999, J MOL BIOL, V285, P645, DOI 10.1006/jmbi.1998.2363; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Messaoudi I, 1999, J IMMUNOL, V163, P3286; MURPHY DB, 1992, J IMMUNOL, V148, P3483; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; Stryhn A, 1996, P NATL ACAD SCI USA, V93, P10338, DOI 10.1073/pnas.93.19.10338; Sundberg EJ, 2003, STRUCTURE, V11, P1151, DOI 10.1016/S0969-2126(03)00187-4; UCHANSKAZIEGLER B, 1993, EUR J IMMUNOL, V23, P734, DOI 10.1002/eji.1830230325; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VANLEEUWEN A, 1979, J EXP MED, V150, P1075, DOI 10.1084/jem.150.5.1075; Willemsen RA, 2001, GENE THER, V8, P1601, DOI 10.1038/sj.gt.3301570; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WULFING C, 1994, J MOL BIOL, V242, P655, DOI 10.1006/jmbi.1994.1615; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412; Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200	57	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2972	2980		10.1074/jbc.M411323200	http://dx.doi.org/10.1074/jbc.M411323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15537658	hybrid			2022-12-25	WOS:000226449100073
J	Postma, B; Kleibeuker, W; Poppelier, MJJG; Boonstra, M; Van Kessel, KPM; Van Strijp, JAG; de Haas, CJC				Postma, B; Kleibeuker, W; Poppelier, MJJG; Boonstra, M; Van Kessel, KPM; Van Strijp, JAG; de Haas, CJC			Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLATED PEPTIDE RECEPTOR; ANAPHYLATOXIN; REGION; SITE; COMPLEMENT; STEPS	Chemotaxis inhibitory protein of Staphylococcus aureus ( CHIPS) is excreted by the majority of S. aureus strains and is a potent inhibitor of C5a- and formylated peptide-mediated chemotaxis of neutrophils and monocytes. Recently, we reported that CHIPS binds to the C5a receptor (C5aR) and the formylated peptide receptor, thereby blocking activation by C5a and formylated peptides, respectively. The anaphylatoxin C5a plays an important role in host immunity and pathological inflammatory processes. For C5a a two-site binding model is proposed in which C5a initially binds the C5aR N terminus, followed by interaction of the C5a C-terminal tail with an effector domain on the receptor. We have shown here that CHIPS does not affect activation of the C5aR by a peptide mimic of the C5a C terminus. Moreover, CHIPS was found to bind human embryonic kidney 293 cells expressing only the C5aR N terminus. Deletion and mutation experiments within this C5aR N-terminal expression system revealed that the binding site of CHIPS is contained in a short stretch of 9 amino acids (amino acids 10-18), of which the aspartic acid residues at positions 10, 15, and 18 plus the glycine at position 12 are crucial. Binding studies with C5aR/C3aR and C5aR/IL8RA chimeras confirmed that CHIPS binds only to the C5aR N terminus without involvement of its extracellular loops. CHIPS may provide new strategies to block the C5aR, which may lead to the development of new C5aR antagonists.	Univ Med Ctr Utrecht, Eijkman Winkler Inst, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	de Haas, CJC (corresponding author), Univ Med Ctr Utrecht, Eijkman Winkler Inst, G04-614,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	c.j.c.dehaas@lab.azu.nl	van Strijp, Jos A.G./J-9549-2014	van Strijp, Jos A.G./0000-0001-6253-0830				Bieri O, 1999, BIOL CHEM, V380, P923, DOI 10.1515/BC.1999.114; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Finch AM, 1997, J MED CHEM, V40, P877, DOI 10.1021/jm960727r; Haas PJ, 2004, J IMMUNOL, V173, P5704, DOI 10.4049/jimmunol.173.9.5704; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAWAI M, 1991, J MED CHEM, V34, P2068, DOI 10.1021/jm00111a022; Kirschfink M, 2001, IMMUNOL REV, V180, P177, DOI 10.1034/j.1600-065X.2001.1800116.x; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MERY L, 1994, J BIOL CHEM, V269, P3457; MERY L, 1993, EUR J HAEMATOL, V51, P282; Ni F, 1996, BIOPOLYMERS, V38, P31, DOI 10.1002/(SICI)1097-0282(199601)38:1<31::AID-BIP3>3.0.CO;2-X; Pellas TC, 1999, CURR PHARM DESIGN, V5, P737; Postma B, 2004, J IMMUNOL, V172, P6994, DOI 10.4049/jimmunol.172.11.6994; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Sumichika Hiroshi, 2004, Curr Opin Investig Drugs, V5, P505; Veldkamp KE, 2000, INFECT IMMUN, V68, P5908, DOI 10.1128/IAI.68.10.5908-5913.2000; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; Yang D, 2001, CELL MOL LIFE SCI, V58, P978, DOI 10.1007/PL00000914; Zhang XL, 1997, PROTEIN SCI, V6, P65	23	58	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2020	2027		10.1074/jbc.M412230200	http://dx.doi.org/10.1074/jbc.M412230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542591	hybrid			2022-12-25	WOS:000226341700036
J	Tremper-Wells, B; Vallano, ML				Tremper-Wells, B; Vallano, ML			Nuclear calpain regulates Ca2+-dependent signaling via proteolysis of nuclear Ca2+/calmodulin-dependent protein kinase type IV in cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; DYSTROPHY TYPE 2A; ADULT-RAT BRAIN; MU-CALPAIN; CORTICAL-NEURONS; SKELETAL-MUSCLE; CROSS-TALK; IN-VIVO; INTRACELLULAR-DISTRIBUTION; SUBCELLULAR-LOCALIZATION	Accumulating evidence indicates that calpains can reside in or translocate to the cell nucleus, but their functions in this compartment remain poorly understood. Dissociated cultures of cerebellar granule cells (GCs) demonstrate improved long-term survival when their growth medium is supplemented with depolarizing agentsthatstimulate Ca2+ influx and activate calmodulin-dependent signaling cascades, notably 20 mM KCl. We previously observed Ca2+-dependent down-regulation of Ca2+/calmodulin-dependent protein kinase (CaMK) type IV, which was attenuated by calpain inhibitors, in GCs supplemented with 20 mM KCl (Tremper-Wells, B., Mathur, A., Beaman-Hall, C. M., and Vallano, M. L. ( 2002) J. Neurochem. 81, 314-324). CaMKIV is highly enriched in the nucleus and thought to be critical for improved survival. Here, we demonstrate by immunolocalization/confocal microscopy and subcellular fractionation that the regulatory and catalytic subunits of m-calpain are enriched in GC nuclei, including GCs grown in medium containing 5 mM KCl. Calpain-mediated proteolysis of CaMKIV is selective, as several other nuclear and nonnuclear calpain substrates were not degraded under chronic depolarizing culture conditions. Depolarization and Ca(2+)dependent down-regulation of CaMKIV were associated with significant alterations in other components of the Ca2+CaMKIV signaling cascade: the ratio of phosphorylated to total cAMP response element-binding protein ( a downstream CaMKIV substrate) was reduced by similar to10-fold, and the amount of CaMK kinase (an upstream activator of CaMKIV) protein and mRNA was significantly reduced. We hypothesize that calpain-mediated CaMKIV proteolysis is an autoregulatory feedback response to sustained activation of a Ca2+CaMKIV signaling pathway, resulting from growth of cultures in medium containing 25 mM KCl. This study establishes nuclear m-calpain as a regulator of CaMKIV and associated signaling molecules under conditions of sustained Ca2+ influx.	SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Vallano, ML (corresponding author), SUNY Upstate Med Univ, Dept Neurosci & Physiol, 750 E Adams St, Syracuse, NY 13210 USA.	VallanoM@upstate.edu			NINDS NIH HHS [NS40582] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040582] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Anderson KA, 2004, J BIOL CHEM, V279, P31708, DOI 10.1074/jbc.M404523200; Armstrong RC, 1997, J NEUROSCI, V17, P553; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Baghdiguian S, 2001, J MOL MED, V79, P254, DOI 10.1007/s001090100225; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; Barnoy S, 2003, FEBS LETT, V546, P213, DOI 10.1016/S0014-5793(03)00573-8; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bizat N, 2003, J BIOL CHEM, V278, P43245, DOI 10.1074/jbc.M305057200; Boutillier AL, 1999, EUR J NEUROSCI, V11, P441, DOI 10.1046/j.1460-9568.1999.00451.x; BUI CJ, 2004, SFN 2004 ABSTRACT VI; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Cheung NS, 2004, CELL MOL LIFE SCI, V61, P1926, DOI 10.1007/s00018-004-4127-7; Ciruela A, 2000, BIOCHEM J, V346, P587, DOI 10.1042/0264-6021:3460587; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Di Rosa G, 2002, J MOL NEUROSCI, V19, P135, DOI 10.1007/s12031-002-0024-4; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; Futai E, 2001, BBA-GENE STRUCT EXPR, V1517, P316, DOI 10.1016/S0167-4781(00)00256-6; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; GALLO V, 1987, J NEUROSCI, V7, P2203; Gil-Parrado S, 2003, J BIOL CHEM, V278, P16336, DOI 10.1074/jbc.M208657200; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Grynspan F, 1997, J NEUROSCI RES, V48, P181; GUROFF G, 1964, J BIOL CHEM, V239, P149; Guttmann RP, 2002, J PHARMACOL EXP THER, V302, P1023, DOI 10.1124/jpet.102.036962; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Honma T, 2001, J MED CHEM, V44, P4615, DOI 10.1021/jm0103256; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kimura Y, 2002, EMBO REP, V3, P962, DOI 10.1093/embo-reports/kvf191; Kitani T, 1997, J BIOCHEM-TOKYO, V121, P804; Kudo H, 2000, J NUTR, V130, P38; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; KUMAMOTO T, 1992, ANAT REC, V232, P60, DOI 10.1002/ar.1092320108; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200; Marks N, 1998, J NEUROSCI RES, V52, P334, DOI 10.1002/(SICI)1097-4547(19980501)52:3<334::AID-JNR9>3.0.CO;2-E; Marshall J, 2003, NEURON, V39, P625, DOI 10.1016/S0896-6273(03)00496-3; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; MELLGREN RL, 1994, BIOCHEM BIOPH RES CO, V204, P544, DOI 10.1006/bbrc.1994.2493; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; Mengual E, 1996, J NEUROSCI, V16, P6331; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Moraczewski J, 1996, CR ACAD SCI III-VIE, V319, P681; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Murray SS, 1997, EXP CELL RES, V233, P297, DOI 10.1006/excr.1997.3550; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1998, J NEUROCHEM, V71, P186; Neuberger T, 1997, J NEUROSCI RES, V47, P521, DOI 10.1002/(SICI)1097-4547(19970301)47:5<521::AID-JNR7>3.0.CO;2-J; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Okuno S, 1997, J BIOCHEM-TOKYO, V121, P155; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Piccioli P, 2001, J NEUROSCI RES, V66, P1064, DOI 10.1002/jnr.1251.abs; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Raynaud F, 2004, EXP CELL RES, V298, P48, DOI 10.1016/j.yexcr.2004.03.053; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; Rideout HJ, 2003, J NEUROSCI, V23, P1237, DOI 10.1523/JNEUROSCI.23-04-01237.2003; Sakagami H, 1998, MOL BRAIN RES, V54, P311, DOI 10.1016/S0169-328X(97)00362-8; Sakagami H, 2000, EUR J NEUROSCI, V12, P89, DOI 10.1046/j.1460-9568.2000.00883.x; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; Shields DC, 1999, J NEUROSCI RES, V55, P533, DOI 10.1002/(SICI)1097-4547(19990301)55:5<533::AID-JNR1>3.0.CO;2-8; Shields DC, 1998, J NEUROSCI RES, V53, P482, DOI 10.1002/(SICI)1097-4547(19980815)53:4<482::AID-JNR10>3.0.CO;2-4; Small GW, 2002, ARCH BIOCHEM BIOPHYS, V400, P151, DOI 10.1016/S0003-9861(02)00005-X; Snider BJ, 2002, EUR J NEUROSCI, V15, P419, DOI 10.1046/j.0953-816x.2001.01867.x; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; STURGES MR, 1994, J BIOL CHEM, V269, P5712; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Tremper-Wells B, 2002, J NEUROCHEM, V81, P314, DOI 10.1046/j.1471-4159.2002.00829.x; TREMPERWELLS B, 2003, RRD NEUROCHEMISTRY, V6, P1; Vallano ML, 1996, J NEUROSCI, V16, P631; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; Yajima Y, 2002, BIOL CHEM, V383, P757, DOI 10.1515/BC.2002.079	98	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2165	2175		10.1074/jbc.M410591200	http://dx.doi.org/10.1074/jbc.M410591200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537635	hybrid			2022-12-25	WOS:000226341700052
J	Perry, C; Sastry, R; Nasrallah, IM; Stover, PJ				Perry, C; Sastry, R; Nasrallah, IM; Stover, PJ			Mimosine attenuates serine hydroxymethyltransferase transcription by chelating zinc - Implications for inhibition of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; FOLATE METABOLISM; EXPRESSION; FINGER; IRON; DEOXYRIBONUCLEOTIDE; COMPETITION; INITIATION; APOPTOSIS; PROTEIN	L-Mimosine is a naturally occurring plant amino acid and iron chelator that arrests the cell cycle in the late G(1) phase, although its mechanism of action is not known. Some studies indicate that mimosine prevents the initiation of DNA replication, whereas other studies indicate that mimosine disrupts elongation of the replication fork by impairing deoxyribonucleotide synthesis by inhibiting the activity of the iron-dependent enzyme ribonucleotide reductase and the transcription of the cytoplasmic serine hydroxymethyltransferase gene (SHMT1). In this study, the mechanism for mimosine-induced inhibition of SHMT1 transcription was elucidated. A mimosine-responsive transcriptional element was localized within the first 50 base pairs of the human SHMT1 promoter by deletion analyses and gel mobility shift assays. The 50-base-pair sequence contains a consensus zinc-sensing metal regulatory element (MRE) at position -44 to -38, and mutation of the MRE attenuated mimosine-induced transcription repression. Mimosine treatment eliminated MRE- and Sp1-binding activity in nuclear extracts from MCF-7 cells but not in nuclear extracts from a mimosine-resistant cell line, MCF-7/2a. MCF-7 cells cultured in zinc-depleted medium for more than 16 days were viable and lacked cytoplasmic serine hydroxymethyltransferase protein, confirming that mimosine inhibits SHMT1 transcription by chelating zinc. The disruption of DNA-protein interactions by zinc chelation provides a general mechanism for the inhibitory effects of mimosine on nuclear processes, including replication and transcription. Furthermore, this study establishes that SHMT1 is a zinc-inducible gene, which provides the first mechanism for the regulation of folate-mediated one-carbon metabolism by zinc.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Grad Field Biochem Mol & Cellular Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 315 Savage Hall, Ithaca, NY 14853 USA.	PJS13@cornell.edu		Pandya, Renuka/0000-0002-7667-607X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058144] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58144] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; ALREFAIE FN, 1994, J CLIN PATHOL, V47, P657, DOI 10.1136/jcp.47.7.657; Ames BN, 2004, ANN NY ACAD SCI, V1019, P406, DOI 10.1196/annals.1297.073; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Chang HC, 2000, INT J ONCOL, V17, P659; Conti P, 2002, MOL CELL BIOCHEM, V229, P129, DOI 10.1023/A:1017989014906; Cook CR, 2003, J BIOL CHEM, V278, P36051, DOI 10.1074/jbc.M306049200; COUSINS RJ, 1994, ANNU REV NUTR, V14, P449, DOI 10.1146/annurev.nu.14.070194.002313; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; Giedroc DP, 2001, ANTIOXID REDOX SIGN, V3, P577, DOI 10.1089/15230860152542943; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Hider RC, 1999, BIOCHEM PHARMACOL, V57, P1031, DOI 10.1016/S0006-2952(99)00014-3; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Hong KH, 2000, J NUTR BIOCHEM, V11, P165, DOI 10.1016/S0955-2863(99)00089-3; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; KINGSTON RE, 2001, CURRENT PROTOCOLS MO, V2; Kulp KS, 1996, TOXICOL APPL PHARM, V139, P356, DOI 10.1006/taap.1996.0176; Lin HB, 1996, J BIOL CHEM, V271, P2548, DOI 10.1074/jbc.271.5.2548; Maclean KH, 2001, BLOOD, V98, P3831, DOI 10.1182/blood.V98.13.3831; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; Oppenheim EW, 2000, J BIOL CHEM, V275, P19268, DOI 10.1074/jbc.M001610200; Oppenheim EW, 2001, J BIOL CHEM, V276, P19855, DOI 10.1074/jbc.M100039200; Reno F, 1999, APOPTOSIS, V4, P469, DOI 10.1023/A:1009608628076; THOMPSON JF, 1969, ANNU REV BIOCHEM, V38, P137, DOI 10.1146/annurev.bi.38.070169.001033; Vitour D, 2004, J VIROL, V78, P3851, DOI 10.1128/JVI.78.8.3851-3862.2004; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; WANG Y, 1995, EXP CELL RES, V217, P84, DOI 10.1006/excr.1995.1066	29	35	35	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					396	400		10.1074/jbc.M410467200	http://dx.doi.org/10.1074/jbc.M410467200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15531579	hybrid			2022-12-25	WOS:000226025100048
J	Wu, Y; Qian, XG; He, YJ; Moya, IA; Luo, Y				Wu, Y; Qian, XG; He, YJ; Moya, IA; Luo, Y			Crystal structure of an ATPase-active form of rad51 homolog from Methanococcus voltae - Insights into potassium dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECA; DNA STRAND EXCHANGE; RECOMBINATION PROTEIN RAD51; MOLECULAR CHAPERONE HSC70; STALLED REPLICATION FORKS; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL-CHANGES; ALLOSTERIC REGULATION; TERMINAL DOMAIN; PAIRING DOMAIN	Homologous gene recombination is crucial for the repair of DNA. A superfamily of recombinases facilitate a central strand exchange reaction in the repair process. This reaction is initiated by coating single-stranded DNA (ssDNA) with recombinases in the presence of ATP and Mg2+ co-factors to form helical nucleoprotein filaments with elevated ATPase and strand invasion activities ( 1). At the amino acid sequence level, archaeal RadA and Rad51 and eukaryal Rad51 and meiosis-specific DMC1 form a closely related group of recombinases distinct from bacterial RecA ( 2). Unlike the extensively studied Escherichia coli RecA (EcRecA), increasing evidences on yeast and human recombinases imply that their optimal activities are dependent on the presence of a monovalent cation, particularly potassium (3-5). Here we present the finding that archaeal RadA from Methanococcusvoltae (MvRadA) is a stringent potassium-dependent ATPase, and the crystal structure of this protein in complex with the non-hydrolyzable ATP analog adenosine 5'-(beta,gamma-iminotriphosphate), Mg2+, and K+ at 2.4 Angstrom resolution. Potassium triggered an in situ conformational change in the ssDNA-binding L2 region concerted with incorporation of two potassium ions at the ATPase site in the RadA crystals preformed in K+-free medium. Both potassium ions were observed in contact with the gamma-phosphate of the ATP analog, implying a direct role by the monovalent cations in stimulating the ATPase activity. Cross-talk between the ATPase site and the ssDNA-binding L2 region visualized in the MvRadA structure provides an explanation to the co-factor-induced allosteric effect on RecA-like recombinases.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Luo, Y (corresponding author), Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Aihara H, 1997, J MOL BIOL, V274, P213, DOI 10.1006/jmbi.1997.1403; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Brendel V, 1997, J MOL EVOL, V44, P528, DOI 10.1007/PL00006177; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bugreev DV, 2004, P NATL ACAD SCI USA, V101, P9988, DOI 10.1073/pnas.0402105101; Campbell MJ, 1999, J MOL BIOL, V286, P437, DOI 10.1006/jmbi.1998.2457; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Courcelle J, 2001, BIOESSAYS, V23, P463, DOI 10.1002/bies.1065; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; De Zutter JK, 2001, STRUCTURE, V9, P47, DOI 10.1016/S0969-2126(00)00552-9; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; Kelley JA, 1997, J BIOL CHEM, V272, P25778, DOI 10.1074/jbc.272.41.25778; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu YL, 2004, J MOL BIOL, V337, P817, DOI 10.1016/j.jmb.2004.02.022; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Morrison C, 1999, MOL CELL BIOL, V19, P6891; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; Pattanayek R, 2004, MOL CELL, V15, P375, DOI 10.1016/j.molcel.2004.07.013; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; PUGH BF, 1988, J BIOL CHEM, V263, P76; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Reich CI, 2001, EXTREMOPHILES, V5, P265, DOI 10.1007/s007920100197; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Sandler SJ, 1996, NUCLEIC ACIDS RES, V24, P2125, DOI 10.1093/nar/24.11.2125; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; Seitz EM, 2000, MOL MICROBIOL, V37, P555, DOI 10.1046/j.1365-2958.2000.02009.x; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Sprang SR, 1997, SCIENCE, V277, P329, DOI 10.1126/science.277.5324.329; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; Voloshin ON, 2000, J MOL BIOL, V303, P709, DOI 10.1006/jmbi.2000.4163; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; Wang LJ, 1998, J MOL BIOL, V277, P1, DOI 10.1006/jmbi.1997.1591; Wilbanks SM, 1998, BIOCHEMISTRY-US, V37, P7456, DOI 10.1021/bi973046m; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Yang SX, 2001, J MOL BIOL, V312, P999, DOI 10.1006/jmbi.2001.5025; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	58	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					722	728		10.1074/jbc.M411093200	http://dx.doi.org/10.1074/jbc.M411093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15537659	hybrid			2022-12-25	WOS:000226025100085
J	Gerdin, MJ; Masana, MI; Rivera-Bermudez, MA; Hudson, RL; Earnest, DJ; Gillette, MU; Dubocovich, ML				Gerdin, MJ; Masana, MI; Rivera-Bermudez, MA; Hudson, RL; Earnest, DJ; Gillette, MU; Dubocovich, ML			Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin	FASEB JOURNAL			English	Article						desensitization; internalization; protein kinase C; SCN2.2 cells; circadian rhythms	PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; PHASE ADVANCES; C3H/HEN MOUSE; CELL-LINES; KINASE-C; EXPRESSION; RHYTHMS; TRAFFICKING; ENDOCYTOSIS	The hormone melatonin phase shifts circadian rhythms generated by the mammalian biological clock, the suprachiasmatic nucleus (SCN) of the hypothalamus, through activation of G protein-coupled MT2 melatonin receptors. This study demonstrated that pretreatment with physiological concentrations of melatonin (30-300 pM or 7-70 pg/mL) decreased the number of hMT(2) melatonin receptors heterologously expressed in mammalian cells in a time and concentration-dependent manner. Furthermore, hMT(2)-GFP melatonin receptors heterologously expressed in immortalized SCN2.2 cells or in non-neuronal mammalian cells were internalized upon pretreatment with both physiological (300 pM or 70 pg/mL) and supraphysiological (10 nM or 2.3 ng/mL) concentrations of melatonin. The decrease in MT2 melatonin receptor number induced by melatonin (300 pM for 1 h) was reversible and reached almost full recovery after 8 h; however, after treatment with 10 nM melatonin full recovery was not attained even after 24 h. This recovery process was partially protein synthesis dependent. Furthermore, exposure to physiological concentrations of melatonin (300 pM) for a time mimicking the nocturnal surge (8 h) desensitized functional responses mediated through melatonin activation of endogenous MT2 receptors, i.e., stimulation of protein kinase C (PKC) in immortalized SCN2.2 cells and phase shifts of circadian rhythms of neuronal firing in the rat SCN brain slice. We conclude that in vivo the nightly secretion of melatonin desensitizes endogenous MT2 melatonin receptors in the mammalian SCN thereby providing a temporally integrated profile of sensitivity of the mammalian biological clock to a melatonin signal.	Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60680 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Human Anat & Med Neurobiol, College Stn, TX USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Illinois System; University of Illinois Urbana-Champaign	Dubocovich, ML (corresponding author), Northwestern Univ, Dept Mol Pharmacol & Biol Chem S215, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	mdubo@northwestern.edu		Earnest, David/0000-0003-4433-6481	NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH067320, R01MH052685, R01MH042922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022155, P01NS039546] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 42922, F31 MH 67320-01, R01 MH052685-06, R01 MH042922-18, MH 52685, R01 MH042922, R01 MH052685] Funding Source: Medline; NINDS NIH HHS [P01 NS39546, NS22155, R01 NS022155] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi A, 2002, GLIA, V39, P268, DOI 10.1002/glia.10109; Al-Ghoul WM, 1998, NEUROREPORT, V9, P4063, DOI 10.1097/00001756-199812210-00011; Allen G, 2001, J NEUROSCI, V21, P7937, DOI 10.1523/JNEUROSCI.21-20-07937.2001; ARMSTRONG SM, 1991, ADV PINEAL, V5, P259; Benloucif S, 1996, J BIOL RHYTHM, V11, P113, DOI 10.1177/074873049601100204; Cajochen C, 2003, J NEUROENDOCRINOL, V15, P432, DOI 10.1046/j.1365-2826.2003.00989.x; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; Dubocovich ML, 2003, FRONT BIOSCI-LANDMRK, V8, pD1093, DOI 10.2741/1089; Dubocovich ML, 1998, FASEB J, V12, P1211, DOI 10.1096/fasebj.12.12.1211; Earnest DJ, 1999, SCIENCE, V283, P693, DOI 10.1126/science.283.5402.693; Earnest DJ, 1999, J NEUROBIOL, V39, P1, DOI 10.1002/(SICI)1097-4695(199904)39:1<1::AID-NEU1>3.0.CO;2-F; GAUER F, 1993, BRAIN RES, V602, P153, DOI 10.1016/0006-8993(93)90256-M; Gerdin MJ, 2004, BIOCHEM PHARMACOL, V67, P2023, DOI 10.1016/j.bcp.2004.01.027; Gerdin MJ, 2003, J PHARMACOL EXP THER, V304, P931, DOI 10.1124/jpet.102.044990; Hunt AE, 2001, AM J PHYSIOL-CELL PH, V280, pC110, DOI 10.1152/ajpcell.2001.280.1.C110; Hurst WJ, 2002, BIOCHEM BIOPH RES CO, V292, P20, DOI 10.1006/bbrc.2002.6589; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lewy AJ, 1998, PSYCHIAT RES, V77, P57, DOI 10.1016/S0165-1781(97)00128-5; Lewy AJ, 2002, CHRONOBIOL INT, V19, P649, DOI 10.1081/CBI-120004546; Lewy AJ, 1998, CHRONOBIOL INT, V15, P71, DOI 10.3109/07420529808998671; Liang FQ, 1998, NEUROSCI LETT, V242, P89, DOI 10.1016/S0304-3940(98)00062-7; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; MacKenzie RS, 2002, BIOCHEM PHARMACOL, V63, P587, DOI 10.1016/S0006-2952(01)00881-4; Masana MI, 2003, BIOCHEM PHARMACOL, V65, P731, DOI 10.1016/S0006-2952(02)01627-1; Masana MI, 2000, J PINEAL RES, V28, P185, DOI 10.1034/j.1600-079X.2001.280309.x; MCARTHUR AJ, 1991, BRAIN RES, V565, P158, DOI 10.1016/0006-8993(91)91748-P; McArthur AJ, 1997, ENDOCRINOLOGY, V138, P627, DOI 10.1210/en.138.2.627; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Poirel VJ, 2002, BRAIN RES, V946, P64, DOI 10.1016/S0006-8993(02)02824-X; River-Bermudez MA, 2004, BRAIN RES, V1002, P21, DOI 10.1016/j.brainres.2003.12.008; Rivera-Bermudez MA, 2003, NEUROSCI LETT, V346, P37, DOI 10.1016/S0304-3940(03)00590-1; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Roy D, 2001, ENDOCRINOLOGY, V142, P4711, DOI 10.1210/en.142.11.4711; TENN C, 1993, MOL CELL ENDOCRINOL, V98, P43, DOI 10.1016/0303-7207(93)90234-B; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Weaver DR, 1996, NEUROREPORT, V8, P109, DOI 10.1097/00001756-199612200-00022; Wirz-Justice A, 2002, J PINEAL RES, V32, P1, DOI 10.1034/j.1600-079x.2002.10808.x; WittEnderby PA, 1996, MOL PHARMACOL, V50, P166; Zeitzer JM, 1999, AM J MED, V107, P432, DOI 10.1016/S0002-9343(99)00266-1	41	114	118	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1646	1656		10.1096/fj.03-1339com	http://dx.doi.org/10.1096/fj.03-1339com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522910				2022-12-25	WOS:000225482100033
J	Hausmann, S; Altura, MA; Witmer, M; Singer, SM; Elmendorf, HG; Shuman, S				Hausmann, S; Altura, MA; Witmer, M; Singer, SM; Elmendorf, HG; Shuman, S			Yeast-like mRNA capping apparatus in Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CAP METHYLTRANSFERASES; TERMINAL DOMAIN; TRIPHOSPHATASE; MECHANISM; COMPONENT; SEQUENCE; POMBE	A scheme of eukaryotic phylogeny has been suggested based on the structure and physical linkage of the RNA triphosphatase and RNA guanylyltransferase enzymes that catalyze mRNA cap formation. Here we show that the unicellular pathogen Giardia lamblia encodes an mRNA capping apparatus consisting of separate triphosphatase and guanylyltransferase components, which we characterize biochemically. We also show that native Giardia mRNAs have blocked 5'-ends and that 7-methylguanosine caps promote translation of transfected mRNAs in Giardia in vivo. The Giardia triphosphatase belongs to the tunnel family of metal-dependent phosphohydrolases that includes the RNA triphosphatases of fungi, microsporidia, and protozoa such as Plasmodium and Trypanosoma. The tunnel enzymes adopt a unique active-site fold and are structurally and mechanistically unrelated to the cysteine-phosphatase-type RNA triphosphatases found in metazoans and plants, which comprise part of a bifunctional triphosphatase-guanylyltransferase fusion protein. All available evidence now points to the separate tunnel-type triphosphatase and guanylyltransferase as the aboriginal state of the capping apparatus. We identify a putative tunnel-type triphosphatase and a separate guanylyltransferase encoded by the red alga Cyanidioschyzon merolae. These findings place fungi, protozoa, and red algae in a common lineage distinct from that of metazoa and plants.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Georgetown Univ, Dept Biol, Washington, DC 20057 USA	Memorial Sloan Kettering Cancer Center; Georgetown University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Singer, Steven/V-7778-2019	Singer, Steven/0000-0001-5719-7535				Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; Bujnicki JM, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-2; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Elmendorf HG, 2001, NUCLEIC ACIDS RES, V29, P4674, DOI 10.1093/nar/29.22.4674; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gong CL, 2003, J BIOL CHEM, V278, P50843, DOI 10.1074/jbc.M309188200; Gong CL, 2003, VIROLOGY, V309, P125, DOI 10.1016/S0042-6822(03)00002-3; Gong CL, 2002, J BIOL CHEM, V277, P15317, DOI 10.1074/jbc.M200532200; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; Ho CK, 2001, J BIOL CHEM, V276, P46182, DOI 10.1074/jbc.M108706200; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Knodler LA, 1999, MOL MICROBIOL, V34, P327, DOI 10.1046/j.1365-2958.1999.01602.x; Li L, 2004, J BIOL CHEM, V279, P14656, DOI 10.1074/jbc.M309879200; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Martins A, 2003, NUCLEIC ACIDS RES, V31, P1455, DOI 10.1093/nar/gkg244; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; McFadden GI, 2004, CURR BIOL, V14, pR514, DOI 10.1016/j.cub.2004.06.041; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Mouaikel J, 2002, MOL CELL, V9, P891, DOI 10.1016/S1097-2765(02)00484-7; NIU XH, 1994, MOL BIOCHEM PARASIT, V66, P49, DOI 10.1016/0166-6851(94)90035-3; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Seshadri V, 2003, J BIOL CHEM, V278, P27804, DOI 10.1074/jbc.M303316200; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Singer SM, 1998, MOL BIOCHEM PARASIT, V92, P59, DOI 10.1016/S0166-6851(97)00225-9; Stiller JW, 2004, EUKARYOT CELL, V3, P735, DOI 10.1128/EC.3.3.735-740.2004; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1	36	27	27	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12077	12086		10.1074/jbc.M412063200	http://dx.doi.org/10.1074/jbc.M412063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15556935	hybrid			2022-12-25	WOS:000227922000004
J	Ozvegy-Laczka, C; Varady, G; Koblos, G; Ujhelly, O; Cervenak, J; Schuetz, JD; Sorrentino, BP; Koomen, GJ; Varadi, A; Nemet, K; Sarkadi, B				Ozvegy-Laczka, C; Varady, G; Koblos, G; Ujhelly, O; Cervenak, J; Schuetz, JD; Sorrentino, BP; Koomen, GJ; Varadi, A; Nemet, K; Sarkadi, B			Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER RESISTANCE; P-GLYCOPROTEIN; ATP-BINDING; HALF-TRANSPORTER; SUBCELLULAR-LOCALIZATION; EFFLUX PUMP; PROTEIN; NUCLEOTIDE; GENE; OVEREXPRESSION	The human ABCG2 protein is an important primary active transporter for hydrophobic compounds in several cell types, and its overexpression causes multidrug resistance in tumors. A monoclonal antibody (5D3) recognizes this protein on the cell surface. In ABCG2-expressing cells 5D3 antibody showed a saturable labeling and inhibited ABCG2 transport and ATPase function. However, at low antibody concentrations 5D3 binding to intact cells depended on the actual conformation of the ABCG2 protein. ATP depletion or the addition of the ABCG2 inhibitor Ko143 significantly increased, whereas the vanadate-induced arrest of ABCG2 strongly decreased 5D3 binding. The binding of the 5D3 antibody to a non-functional ABCG2 catalytic center mutant (K86M) in intact cells was not affected by the addition of vanadate but still increased with the addition of Ko143. In isolated membrane fragments the ligand modulation of 5D3 binding to ABCG2 could be analyzed in detail. In this case 5D3 binding was maximum in the presence of ATP, ADP, or Ko143, whereas the non-hydrolysable ATP analog, adenosine 5'-(beta,gamma-imido)triphosphate (AMP-PNP), and nucleotide trapping by vanadate decreased antibody binding. In membranes expressing the ABCG2-K86M mutant, ATP, ADP, and AMP-PNP decreased, whereas Ko143 increased 5D3 binding. Based on these data we suggest that the 5D3 antibody can be used as a sensitive tool to reveal intramolecular changes, reflecting ATP binding, the formation of a catalytic intermediate, or substrate inhibition within the transport cycle of the ABCG2 protein.	Natl Med Ctr, Inst Haematol & Immunol, Membrane Res Grp, H-1113 Budapest, Hungary; Hungarian Acad Sci, Inst Haematol & Immunol, H-1113 Budapest, Hungary; Natl Med Ctr, Inst Haematol & Immunol, Expt Gene Therapy Unit, H-1113 Budapest, Hungary; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA; Univ Amsterdam, Inst Mol Chem, Organ Chem Lab, NL-1100 DE Amsterdam, Netherlands	Hungarian Academy of Sciences; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Amsterdam	Sarkadi, B (corresponding author), Natl Med Ctr, Inst Haematol & Immunol, Membrane Res Grp, Dioszegi U64, H-1113 Budapest, Hungary.	sarkadi@biomembrane.hu	György, Várady/J-8118-2017; Sarkadi, Balazs/I-5024-2013; Varadi, Andras/A-2055-2012; Laczka, Csilla/AAE-5543-2021; Schuetz, John D/N-2692-2018					Abbott BL, 2002, BLOOD, V100, P4594, DOI 10.1182/blood-2002-01-0271; Allen JD, 2002, MOL CANCER THER, V1, P417; Allen JD, 1999, CANCER RES, V59, P4237; Allikmets R, 1998, CANCER RES, V58, P5337; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; Cooray HC, 2002, NEUROREPORT, V13, P2059, DOI 10.1097/00001756-200211150-00014; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Goda K, 2000, CANCER DETECT PREV, V24, P415; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kim M, 2002, CLIN CANCER RES, V8, P22; Knutsen T, 2000, GENE CHROMOSOME CANC, V27, P110, DOI 10.1002/(SICI)1098-2264(200001)27:1<110::AID-GCC14>3.0.CO;2-4; Lechner A, 2002, BIOCHEM BIOPH RES CO, V293, P670, DOI 10.1016/S0006-291X(02)00275-9; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2000, J CELL SCI, V113, P2011; Maliepaard M, 1999, CANCER RES, V59, P4559; Maliepaard M, 2001, CANCER RES, V61, P3458; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; Miyake K, 1999, CANCER RES, V59, P8; Nagy H, 2001, EUR J BIOCHEM, V268, P2416, DOI 10.1046/j.1432-1327.2001.02122.x; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Ozvegy-Laczka C, 2004, MOL PHARMACOL, V65, P1485, DOI 10.1124/mol.65.6.1485; Robey RW, 2001, CLIN CANCER RES, V7, P145; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Rocchi E, 2000, BIOCHEM BIOPH RES CO, V271, P42, DOI 10.1006/bbrc.2000.2590; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Scheffer GL, 2000, CANCER RES, V60, P2589; Sinko E, 2003, BIOCHEM BIOPH RES CO, V308, P263, DOI 10.1016/S0006-291X(03)01349-4; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; SZVEGY C, 2001, BOCH BIOPHYS RES COM, V285, P111; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Ujhelly O, 2003, HUM GENE THER, V14, P403, DOI 10.1089/104303403321209005; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Volk EL, 2002, CANCER RES, V62, P5035; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	44	77	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4219	4227		10.1074/jbc.M411338200	http://dx.doi.org/10.1074/jbc.M411338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557326	hybrid			2022-12-25	WOS:000227096600029
J	Inagaki, S; Masuda, C; Akaishi, T; Nakajima, H; Yoshioka, S; Ohta, T; Pal, B; Kitagawa, T; Aono, S				Inagaki, S; Masuda, C; Akaishi, T; Nakajima, H; Yoshioka, S; Ohta, T; Pal, B; Kitagawa, T; Aono, S			Spectroscopic and redox properties of a CooA homologue from Carboxydothermus hydrogenoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR COOA; RESONANCE RAMAN-SPECTROSCOPY; CARBON-MONOXIDE; GENE-EXPRESSION; OXYGEN SENSOR; HEME; BINDING; PROTEIN; LIGAND; MYOGLOBIN	CooA is a CO-sensing transcriptional activator that contains a b-type heme as the active site for sensing its physiological effector, CO. In this study, the spectroscopic and redox properties of a new CooA homologue from Carboxydothermus hydrogenoformans (Ch-CooA) were studied. Spectroscopic and mutagenesis studies revealed that His-82 and the N-terminal alpha-amino group were the axial ligands of the Fe(III) and Fe(II) hemes in Ch-CooA and that the N-terminal a-amino group was replaced by CO upon CO binding. Two neutral ligands, His-82 and the N-terminal alpha-amino group, are coordinated to the Fe(III) heme in Ch-CooA, whereas two negatively charged ligands, a thiolate from Cys-75 and the nitrogen atom of the N-terminal Pro, are the axial ligands of the Fe(III) heme in Rr-CooA. The difference in the coordination structure of the Fe(III) heme resulted in a large positive shift of redox potentials of Ch-CooA compared with Rr-CooA. Comparing the properties of Ch-CooA and Rr-CooA demonstrates that the essential elements for CooA function will be: (i) the heme is six-coordinate in the Fe(III), Fe(II), and Fe(II)-CO forms; (ii) the N-terminal is coordinated to the heme as an axial ligand, and (iii) CO replaces the N-terminal bound to the heme upon CO binding.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Grad Univ Adv Studies, Dept Struct Mol Sci, Okazaki, Aichi 4448787, Japan; Japan Adv Ins Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Japan Advanced Institute of Science & Technology (JAIST)	Aono, S (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan.	aono@ims.ac.jp	Aono, Shigetoshi/ABD-7618-2020	Aono, Shigetoshi/0000-0002-2870-3694				Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Aono S, 2000, PROG REACT KINET MEC, V25, P65, DOI 10.3184/007967400103165128; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Miyatake H, 1999, J BIOL CHEM, V274, P23176, DOI 10.1074/jbc.274.33.23176; Nakajima H, 2001, J BIOL CHEM, V276, P7055, DOI 10.1074/jbc.M003972200; OLDFIELD E, 1991, J AM CHEM SOC, V113, P7537, DOI 10.1021/ja00020a014; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pal B, 2004, J INORG BIOCHEM, V98, P824, DOI 10.1016/j.jinorgbio.2003.12.007; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; Roberts GP, 2001, PROG NUCLEIC ACID RE, V67, P35, DOI 10.1016/S0079-6603(01)67024-7; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SVETLICHNY VA, 1991, SYST APPL MICROBIOL, V14, P254, DOI 10.1016/S0723-2020(11)80377-2; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Voordouw G, 2002, J BACTERIOL, V184, P5903, DOI 10.1128/JB.184.21.5903-5911.2002; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Youn H, 2004, J BACTERIOL, V186, P1320, DOI 10.1128/JB.186.5.1320-1329.2004; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	28	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3269	3274		10.1074/jbc.M409884200	http://dx.doi.org/10.1074/jbc.M409884200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15537640	hybrid			2022-12-25	WOS:000226983900019
J	Li, SW; Zhang, J; He, ZQ; Gu, Y; Liu, RS; Lin, J; Chen, YX; Ng, MH; Xia, NS				Li, SW; Zhang, J; He, ZQ; Gu, Y; Liu, RS; Lin, J; Chen, YX; Ng, MH; Xia, NS			Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTALLOGRAPHIC STRUCTURE; NON-A; NON-B; PROTEIN; ANTIBODIES; INFECTION; PEPTIDE	The hepatitis E virus (HEV) capsid consists of a single structural protein, a portion of which is engaged in isosahedral contact to form a basal shell, and another portion in dimeric contact to form the homodimers protruding from the shell. Previous studies revealed that homodimers of the truncated HEV capsid proteins, E2 (amino acids 394-606) and p239 (amino acids 368-606), model dominant antigenic determinants of HEV. Immunization with these proteins protected rhesus monkeys against the virus, and three monoclonal antibodies against the homodimers could neutralize HEV infectivity and/or immune-capture of the virus. Furthermore, homodimers of p239 further interact to form particles of 23 nm diameter, rendering it an efficacious candidate vaccine. In light of this we postulate that the interactions involved in the formation of the homodimers and particles might be similar to those involved in assembly of the virus capsid. Presently, mutational analysis was carried out to identify these sites of interactions. The site of dimeric interactions was located to a cluster of six hydrophobic amino acids residues, Ala(597), Val(598), Ala(599), Leu(601), and Ala(602); furthermore, the site involved in particle formation was located at amino acids 368-394. The possibility that these sites are also involved in assembly of the virus capsid is supported by the fact that they are located at two major and highly conserved hydrophobic regions of the HEV structural protein.	Xiamen Univ, Sch Life Sci, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Peoples R China; Xiamen Univ, Res Ctr Med Mol Virol Fujian Prov, Xiamen 361005, Peoples R China	Xiamen University; Xiamen University	Xia, NS (corresponding author), Xiamen Univ, Sch Life Sci, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Peoples R China.	nsxia@jingxian.xmu.edu.cn	Gu, Y/G-4686-2010; Xia, NS/G-4647-2010; Chen, YX/G-3937-2010; Zhang, Jun/G-4598-2010	Zhang, Jun/0000-0002-6601-9180; Xia, Ningshao/0000-0003-0179-5266				Arankalle VA, 2001, J VIRAL HEPATITIS, V8, P223, DOI 10.1046/j.1365-2893.2001.00290.x; AYE TT, 1992, NUCLEIC ACIDS RES, V20, P3512, DOI 10.1093/nar/20.13.3512; Bertolotti-Ciarlet A, 2002, J VIROL, V76, P4044, DOI 10.1128/JVI.76.8.4044-4055.2002; BRADLEY D, 1988, J GEN VIROL, V69, P731, DOI 10.1099/0022-1317-69-3-731; Emerson SU, 2003, REV MED VIROL, V13, P145, DOI 10.1002/rmv.384; Harrison TJ, 1999, LIVER, V19, P171, DOI 10.1111/j.1478-3231.1999.tb00031.x; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; Im SWK, 2001, VACCINE, V19, P3726, DOI 10.1016/S0264-410X(01)00100-1; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KATZ BA, 1986, J BIOL CHEM, V261, P5480; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LI SW, 2005, IN PRESS VACCINE; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; Luo W X, 2000, Sheng Wu Gong Cheng Xue Bao, V16, P578; Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287; PRASAD BVV, 1994, J MOL BIOL, V240, P256, DOI 10.1006/jmbi.1994.1439; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; Taylor AM, 2001, BIOCHEM J, V359, P661, DOI 10.1042/0264-6021:3590661; Worm HC, 2002, MICROBES INFECT, V4, P657, DOI 10.1016/S1286-4579(02)01584-8; Xing L, 1999, VIROLOGY, V265, P35, DOI 10.1006/viro.1999.0005; Zhang J, 2003, J MED VIROL, V71, P518, DOI 10.1002/jmv.10523; ZHANG J, 2005, IN PRESS VACCINE; Zhang JZ, 2002, J MED VIROL, V66, P40, DOI 10.1002/jmv.2109; Zhang JZ, 2001, J MED VIROL, V64, P125, DOI 10.1002/jmv.1027	25	64	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3400	3406		10.1074/jbc.M410361200	http://dx.doi.org/10.1074/jbc.M410361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557331	hybrid			2022-12-25	WOS:000226983900034
J	Mizrahi, A; Molshanski-Mor, S; Weinbaum, C; Zheng, Y; Hirshberg, M; Pick, E				Mizrahi, A; Molshanski-Mor, S; Weinbaum, C; Zheng, Y; Hirshberg, M; Pick, E			Activation of the phagocyte NADPH oxidase by Rac guanine nucleotide exchange factors in conjunction with ATP and nucleoside diphosphate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; DEPENDENT SUPEROXIDE-PRODUCTION; RESPIRATORY BURST OXIDASE; GTP-BINDING PROTEINS; SODIUM DODECYL-SULFATE; HUMAN-NEUTROPHILS; CYTOSOLIC COMPONENT; SENSITIVE METHOD; PURIFICATION; GENERATION	Activation of the phagocyte NADPH oxidase is the consequence of the assembly of membranal cytochrome b(559) with the cytosolic components p47(phox), p67(phox), and the GTPase Rac and is mimicked by a cell-free system comprising these components and an activator. We designed a variant of this system, consisting of membranes, p67(phox), prenylated Rac1-GDP, and the Rac-specific guanine nucleotide exchange factor (GEF) Trio, in which oxidase activation is induced in the absence of an activator and p47(phox). We now show that: 1) Trio and another Rae GEF (Tiam1) act by inducing GDP to GTP exchange on prenylated Rac1-GDP and that our earlier assertion that activation is GTP-independent is explained by contamination of p67(phox) preparations with GTP and/or ATP. 2) Oxidase activation by Rae GEFs is supported not only by GTP but also by ATP. 3) Non-hydrolysable GTP analogs are active, whereas ATP analogs, incapable of gamma-phosphoryl transfer, are inactive. 4) The ability of ATP to support GEF-induced oxidase activation is explained by ATP serving as a gamma-phosphoryl donor for a membrane-localized nucleoside diphosphate kinase (NDPK), converting GDP to GTP. 5) The existence of a NDPK in macrophage membranes is proven by functional, enzymatic, and immunologic criteria. 6) NDPK acts on free GDP, and the newly formed GTP is bound again to Rac. 7) Free GDP is derived exclusively by dissociation from prenylated Rac1-GDP, mediated by GEF. NDPK and GEF appear to be functionally linked in the sense that the availability of GDP, serving as substrate for NDPK, is dependent on the level of activity of GEF.	Tel Aviv Univ, Julius Friedrich Cohnheim Minerva Ctr Phagocyte, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Ela Kodesz Inst Host Def Against Infect Dis, IL-69978 Tel Aviv, Israel; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Duke University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Cambridge	Pick, E (corresponding author), Tel Aviv Univ, Julius Friedrich Cohnheim Minerva Ctr Phagocyte, POB 39040, IL-69978 Tel Aviv, Israel.	epick@post.tau.ac.il	Zheng, Yi/J-7235-2015; Pick, Edgar/B-1795-2008	Zheng, Yi/0000-0001-7089-6074; Pick, Edgar/0000-0003-4625-3233	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523, R01GM046372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46372, GM60523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abell AN, 2004, J CELL SCI, V117, P243, DOI 10.1242/jcs.00853; ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Agarwal R P, 1978, Methods Enzymol, V51, P376; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Diebold BA, 2004, J BIOL CHEM, V279, P28136, DOI 10.1074/jbc.M313891200; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Gallagher BC, 2003, J CELL SCI, V116, P3239, DOI 10.1242/jcs.00630; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Guignard F, 1996, BIOCHEM J, V316, P233, DOI 10.1042/bj3160233; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HORECKER BL, 1948, J BIOL CHEM, V175, P385; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; LETO TL, 1991, J BIOL CHEM, V266, P19812; LUCAS DL, 1983, J CLIN INVEST, V72, P1889, DOI 10.1172/JCI111152; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PERRETT D, 1987, HPLC SMALL MOL PRACT, P221; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; Schaertl S, 1998, J BIOL CHEM, V273, P5662, DOI 10.1074/jbc.273.10.5662; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; Sigal N, 2003, J BIOL CHEM, V278, P4854, DOI 10.1074/jbc.M211011200; Sorota S, 1998, CIRC RES, V82, P971, DOI 10.1161/01.RES.82.9.971; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Williams DA, 2000, BLOOD, V96, P1646; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	68	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3802	3811		10.1074/jbc.M410257200	http://dx.doi.org/10.1074/jbc.M410257200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557278	hybrid			2022-12-25	WOS:000226983900082
J	Mizuhara, E; Nakatani, T; Minaki, Y; Sakamoto, Y; Ono, Y				Mizuhara, E; Nakatani, T; Minaki, Y; Sakamoto, Y; Ono, Y			Corl1, a novel neuronal lineage-specific transcriptional corepressor for the hameodomain transcription factor Lbx1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL SPINAL-CORD; PROGENITOR-CELL IDENTITY; VENTRAL NEURAL-TUBE; MOTOR-NEURON; SKI ONCOPROTEIN; HOMEODOMAIN PROTEIN; REPRESSOR ACTIVITY; ROOF PLATE; DIFFERENTIATION; INTERNEURONS	During development, neuronal identity is determined by a combination of numerous transcription factors. However, the mechanisms of synergistic action of these factors in transcriptional regulation and subsequent cell fate specification are largely unknown. In this study, we identified a novel gene, Corl1, encoding a nuclear protein with homology to the Ski oncoprotein. Corl1 was highly selectively expressed in the central nervous system (CNS). In the embryonic CNS, Corl1 was expressed in a certain subset of postmitotic neurons generated posterior to the midbrain-hindbrain border. In the developing spinal cord, Corl1 was selectively expressed in the dorsal horn interneurons where a homeodomain transcription factor, Lbx1, is required for proper specification. Corl1 was localized in a nuclear dot-like structure and interacted with general transcriptional corepressors. In addition, Corl1 showed transcriptional repression activity in the GAL4-fusion system, indicating its involvement in the regulation of transcriptional repression. Furthermore, Corl1 interacted with Lbx1 and cooperatively repressed transcription, suggesting that it acts as a transcriptional corepressor for Lbx1 in regulating cell fate determination in the dorsal spinal cord. Corl1 corepressor activity did not depend on Gro/TLE activity, and Gro/TLE also functioned as a corepressor for Lbx1. Thus, Lbx1 can select two independent partners, Corl1 and Gro/TLE, as corepressors. Identification of a novel transcriptional corepressor with neuronal subtype-restricted expression might provide insights into the mechanisms of cell fate determination in neurons.	KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	KAN Research Institute	Ono, Y (corresponding author), KAN Res Inst Inc, Shimogyo Ku, 93 Chudoji Awata Cho, Kyoto 6008815, Japan.	y-ono@kan.gr.jp		Minaki, Yasuko/0000-0001-5926-4746				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; CACCAMO D, 1989, LAB INVEST, V60, P390; Caspary T, 2003, NAT REV NEUROSCI, V4, P289, DOI 10.1038/nrn1073; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Cheng LP, 2004, NAT NEUROSCI, V7, P510, DOI 10.1038/nn1221; Cheng LP, 2003, J NEUROSCI, V23, P9961; Courey AJ, 2001, GENE DEV, V15, P2786; da Graca LS, 2004, DEVELOPMENT, V131, P435, DOI 10.1242/dev.00922; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Gowan K, 2001, NEURON, V31, P219, DOI 10.1016/S0896-6273(01)00367-1; Gross MK, 2002, NEURON, V34, P535, DOI 10.1016/S0896-6273(02)00690-6; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Helms AW, 2003, CURR OPIN NEUROBIOL, V13, P42, DOI 10.1016/S0959-4388(03)00010-2; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Lee KJ, 2000, NATURE, V403, P734, DOI 10.1038/35001507; Lee KJ, 1998, GENE DEV, V12, P3394, DOI 10.1101/gad.12.21.3394; Lee SK, 2003, NEURON, V38, P731, DOI 10.1016/S0896-6273(03)00296-4; Lee SK, 2004, DEVELOPMENT, V131, P3295, DOI 10.1242/dev.01179; Lee SK, 2001, NAT NEUROSCI, V4, P1183, DOI 10.1038/nn750; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Liu Y, 2004, DEVELOPMENT, V131, P1017, DOI 10.1242/dev.00994; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Matise M, 2002, NEURON, V34, P491, DOI 10.1016/S0896-6273(02)00710-9; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Muller T, 2002, NEURON, V34, P551, DOI 10.1016/S0896-6273(02)00689-X; Nakada Y, 2004, DEVELOPMENT, V131, P1319, DOI 10.1242/dev.01008; Nakatani T, 2004, J BIOL CHEM, V279, P16356, DOI 10.1074/jbc.M311740200; Nomura T, 2004, J BIOL CHEM, V279, P16715, DOI 10.1074/jbc.M313069200; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Novitch BG, 2003, NEURON, V40, P81, DOI 10.1016/j.neuron.2003.08.006; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Ono Y, 1998, MOL CELL BIOL, V18, P6939, DOI 10.1128/MCB.18.12.6939; Pierani A, 1999, CELL, V97, P903, DOI 10.1016/S0092-8674(00)80802-8; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Schafer K, 1999, NAT GENET, V23, P213, DOI 10.1038/13843; Schuurmans C, 2002, CURR OPIN NEUROBIOL, V12, P26, DOI 10.1016/S0959-4388(02)00286-6; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; Thaler J, 1999, NEURON, V23, P675, DOI 10.1016/S0896-6273(01)80027-1; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; Timmer JR, 2002, DEVELOPMENT, V129, P2459; Vallstedt A, 2001, NEURON, V31, P743, DOI 10.1016/S0896-6273(01)00412-3; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; William CM, 2003, DEVELOPMENT, V130, P1523, DOI 10.1242/dev.00358; Wu KM, 2003, J BIOL CHEM, V278, P51673, DOI 10.1074/jbc.M310021200; Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	56	49	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3645	3655		10.1074/jbc.M411652200	http://dx.doi.org/10.1074/jbc.M411652200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15528197	hybrid			2022-12-25	WOS:000226983900064
J	Prochazkova, K; Osicka, R; Linhartova, I; Halada, P; Sulc, M; Sebo, P				Prochazkova, K; Osicka, R; Linhartova, I; Halada, P; Sulc, M; Sebo, P			The Neisseria meningitidis outer membrane lipoprotein FrpD binds the RTX protein FrpC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS ADENYLATE-CYCLASE; ESCHERICHIA-COLI HEMOLYSIN; NUCLEOTIDE-SEQUENCE; FATTY-ACYLATION; EXTRACELLULAR PROTEASES; ERWINIA-CHRYSANTHEMI; CROSS-LINKING; GENE; TOXIN; CLONING	At conditions of low iron availability, Neisseria meningitidis produces a family of FrpC-like, type I-secreted RTX proteins of unknown role in meningococcal lifestyle. It is shown here that iron starvation also induces production of FrpD, the other protein expressed from a gene located immediately upstream of the frpC gene in a predicted iron-regulated frpDC operon. We found that FrpD is highly conserved in a set of meningococcal strains representative of all serogroups and does not exhibit any similarity to known sequences of other organisms. Subcellular localization and [H-3]palmitic acid labeling in Escherichia coli revealed that FrpD is synthesized with a type II signal peptide for export across the cytoplasmic membrane and is, upon processing to a lipoprotein, sorted to the outer bacterial membrane Furthermore, the biological function of FrpD appears to be linked to that of the RTX protein FrpC, because FrpD was found to bind the amino-proximal portion of FrpC (first 300 residues) with very high affinity (apparent K-d similar to0.2 nm). These results suggest that FrpD represents an rtx loci-encoded accessory lipoprotein that could be involved in anchoring of the secreted RTX protein to the outer bacterial membrane.	Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague 4, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Sebo, P (corresponding author), Acad Sci Czech Republ, Inst Microbiol, Videnska 1083, CR-14220 Prague 4, Czech Republic.	sebo@biomed.cas.cz	Osicka, Radim/H-6776-2014; SEBO, Peter/F-7423-2011; Linhartova, Irena/R-3683-2017; SEBO, Peter/N-2043-2019; Halada, Petr/H-3330-2014; Sulc, Miroslav/K-1029-2014; Linhartova, Irena/J-8413-2014	Osicka, Radim/0000-0003-2626-5456; SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; Halada, Petr/0000-0002-7229-3450; Sulc, Miroslav/0000-0002-2659-0489; 				Baneyx F, 1999, CURR OPIN BIOTECH, V10, P411, DOI 10.1016/S0958-1669(99)00003-8; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; Basar T, 2001, J BIOL CHEM, V276, P348, DOI 10.1074/jbc.M006463200; Booy Robert, 1998, Current Opinion in Pediatrics, V10, P13, DOI 10.1097/00008480-199802000-00004; CHUNG GH, 1991, AGR BIOL CHEM TOKYO, V55, P2359, DOI 10.1080/00021369.1991.10870954; Daefler S, 1997, MOL MICROBIOL, V24, P465, DOI 10.1046/j.1365-2958.1997.3531727.x; Davies RL, 2003, VET MICROBIOL, V92, P263, DOI 10.1016/S0378-1135(02)00408-X; DEMAAGD RA, 1989, J BACTERIOL, V171, P6764, DOI 10.1128/jb.171.12.6764-6770.1989; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; Forman S, 2003, INFECT IMMUN, V71, P2253, DOI 10.1128/IAI.71.4.2253-2257.2003; FREUDL R, 1986, J BIOL CHEM, V261, P1355; Fullner KJ, 2000, EMBO J, V19, P5315, DOI 10.1093/emboj/19.20.5315; GENTSCHEV I, 1992, MOL GEN GENET, V232, P40, DOI 10.1007/BF00299135; GILCHRIST A, 1992, CAN J MICROBIOL, V38, P193, DOI 10.1139/m92-033; GOEBEL W, 1982, J BACTERIOL, V151, P1290, DOI 10.1128/JB.151.3.1290-1298.1982; Gomez L, 2000, INFECT IMMUN, V68, P2323, DOI 10.1128/IAI.68.4.2323-2327.2000; Guibourdenche M, 1996, EPIDEMIOL INFECT, V116, P115, DOI 10.1017/S095026880005233X; Haesebrouck F, 1997, VET MICROBIOL, V58, P239, DOI 10.1016/S0378-1135(97)00162-4; Hardie KR, 1996, MOL MICROBIOL, V22, P967, DOI 10.1046/j.1365-2958.1996.01539.x; HART CA, 1993, J MED MICROBIOL, V39, P3, DOI 10.1099/00222615-39-1-3; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; KADOKURA H, 1995, J BACTERIOL, V177, P3596, DOI 10.1128/jb.177.12.3596-3600.1995; KLEIN P, 1988, PROTEIN ENG, V2, P15, DOI 10.1093/protein/2.1.15; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LETOFFE S, 1989, MOL MICROBIOL, V3, P79, DOI 10.1111/j.1365-2958.1989.tb00106.x; LEWIS LA, 1995, J BACTERIOL, V177, P1299, DOI 10.1128/jb.177.5.1299-1306.1995; Liao CH, 1998, APPL ENVIRON MICROB, V64, P914; Lin W, 1999, P NATL ACAD SCI USA, V96, P1071, DOI 10.1073/pnas.96.3.1071; NAKAHAMA K, 1986, NUCLEIC ACIDS RES, V14, P5843, DOI 10.1093/nar/14.14.5843; Oresnik IJ, 1999, APPL ENVIRON MICROB, V65, P2833; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Osicka R, 2004, J BIOL CHEM, V279, P24944, DOI 10.1074/jbc.M314013200; Osicka R, 2001, INFECT IMMUN, V69, P5509; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; PETTERSSON A, 1995, INFECT IMMUN, V63, P4181, DOI 10.1128/IAI.63.10.4181-4184.1995; Pollard AJ, 1998, J ROY COLL PHYS LOND, V32, P319; Sambrook J, 2001, MOL CLONING LAB MANU; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; SCHULEIN R, 1992, MOL GEN GENET, V234, P155; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; THOMPSON SA, 1993, MOL MICROBIOL, V9, P85, DOI 10.1111/j.1365-2958.1993.tb01671.x; THOMPSON SA, 1993, INFECT IMMUN, V61, P2906, DOI 10.1128/IAI.61.7.2906-2911.1993; THOMPSON SA, 1993, J BACTERIOL, V175, P811, DOI 10.1128/JB.175.3.811-818.1993; Tzeng YL, 2000, MICROBES INFECT, V2, P687, DOI 10.1016/S1286-4579(00)00356-7; WANDERSMAN C, 1987, J BACTERIOL, V169, P5046, DOI 10.1128/jb.169.11.5046-5053.1987; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; WELCH RA, 1988, J BACTERIOL, V170, P1622, DOI 10.1128/jb.170.4.1622-1630.1988; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; Woods RG, 2001, MICROBIOL-SGM, V147, P345, DOI 10.1099/00221287-147-2-345	57	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3251	3258		10.1074/jbc.M411232200	http://dx.doi.org/10.1074/jbc.M411232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15525636	hybrid			2022-12-25	WOS:000226983900017
J	Tintignac, LA; Lagirand, J; Batonnet, S; Sirri, V; Leibovitch, MP; Leibovitch, SA				Tintignac, LA; Lagirand, J; Batonnet, S; Sirri, V; Leibovitch, MP; Leibovitch, SA			Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEASOME PATHWAY; KINASE-ACTIVITY; DIRECT BINDING; NUCLEAR; PHOSPHORYLATION; PROTEIN; IDENTIFICATION; RECEPTOR; MOTIF	MyoD controls myoblast identity and differentiation and is required for myogenic stem cell function in adult skeletal muscle. MyoD is degraded by the ubiquitin-proteasome pathway mediated by different E3 ubiquitin ligases not identified as yet. Here we report that MyoD interacts with Atrogin-1/MAFbx (MAFbx), a striated muscle-specific E3 ubiquitin ligase dramatically up-regulated in atrophying muscle. A core LXXLL motif sequence in MyoD is necessary for binding to MAFbx. MAFbx associates with MyoD through an inverted LXXLL motif located in a series of helical leucine-charged residue-rich domains. Mutation in the LXXLL core motif represses ubiquitination and degradation of MyoD induced by MAFbx. Overexpression of MAFbx suppresses MyoD-induced differentiation and inhibits myotube formation. Finally the purified recombinant SCFMAFbx complex (SCF, Skp1, Cdc53/Cullin 1, F-box protein) mediated MyoD ubiquitination in vitro in a lysine-dependent pathway. Mutation of the lysine 133 in MyoD prevented its ubiquitination by the recombinant SCFMAFbx complex. These observations thus demonstrated that MAFbx functions in ubiquitinating MyoD via a sequence found in transcriptional coactivators. These transcriptional coactivators mediate the binding to liganded nuclear receptors. We also identified a novel protein-protein interaction module not yet identified in F-box proteins. MAFbx may play an important role in the course of muscle differentiation by determining the abundance of MyoD.	Univ Montpellier 2, INRA, Lab Genom Fonct & Myogenese, Differenciat Cellulaire & Croissance UMR 866, F-34060 Montpellier 1, France; Inst Jacques Monod, CNRS, UMR 7592, F-75251 Paris, France	INRAE; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Leibovitch, SA (corresponding author), Univ Montpellier 2, INRA, Lab Genom Fonct & Myogenese, Differenciat Cellulaire & Croissance UMR 866, Campus INRA-ENSA,2 Pl Pierre Viala, F-34060 Montpellier 1, France.	serge.leibovitch@ensam.inra.fr		Tintignac, Lionel/0000-0001-5902-1138				Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Batonnet S, 2004, J BIOL CHEM, V279, P5413, DOI 10.1074/jbc.M310315200; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cornelison DDW, 2000, DEV BIOL, V224, P122, DOI 10.1006/dbio.2000.9682; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Schultz E, 1996, DEV BIOL, V175, P84, DOI 10.1006/dbio.1996.0097; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; Tintignac LAJ, 2004, MOL CELL BIOL, V24, P1809, DOI 10.1128/MCB.24.4.1809-1821.2004; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILSON JT, 1999, CURR BIOL, V9, P1180; Wyzykowski JC, 2002, MOL CELL BIOL, V22, P6199, DOI 10.1128/MCB.22.17.6199-6208.2002; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	45	276	289	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2847	2856		10.1074/jbc.M411346200	http://dx.doi.org/10.1074/jbc.M411346200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15531760	hybrid, Green Published			2022-12-25	WOS:000226449100059
J	Larsson, KP; Peltonen, HM; Bart, G; Louhivouri, LM; Penttonen, A; Antikainen, M; Kukkonen, JP; Akerman, KEO				Larsson, KP; Peltonen, HM; Bart, G; Louhivouri, LM; Penttonen, A; Antikainen, M; Kukkonen, JP; Akerman, KEO			Orexin-A-induced Ca2+ entry - Evidence for involvement of TRPC channels and protein kinase C regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNELS; TRANSIENT RECEPTOR; INTRACELLULAR CALCIUM; COUPLED RECEPTORS; STORE DEPLETION; INFLUX; CELLS; DIACYLGLYCEROL; ACTIVATION; NEUROENDOCRINE	The orexins are peptide transmitters/hormones, which exert stimulatory actions in many types of cells via the G-protein-coupled OX1 and OX2 receptors. Our previous results have suggested that low (subnanomolar) concentrations of orexin-A activate Ca2+ entry, whereas higher concentrations activate phospholipase C, Ca2+ release, and capacitative Ca2+ entry. As shown here, the Ca2+ response to subnanomolar orexin-A concentrations was blocked by activation of protein kinase C by using different approaches (12-O-tetradecanoylphorbol acetate, dioctanoylglycerol, and diacylglycerol kinase inhibition) and protein phosphatase inhibition by calyculin A. The Ca2+ response to subnanomolar orexin-A concentrations was also blocked by Mg2+, dextromethorphan, and tetraethylammonium. These treatments neither affected the response to high concentrations of orexin-A nor the thapsigargin-stimulated capacitative entry. The capacitative entry was instead strongly suppressed by SKF96365. An inward membrane current activated by subnanomolar concentrations of orexin-A and the currents activated upon transient expression of trpc3 channels were also sensitive to Mg2+, dextromethorphan, and tetraethylammonium. Responses to subnanomolar concentrations of orexin-A (Ca2+ elevation, inward current, and membrane depolarization) were voltage-dependent with a loss of the response around -15 mV. By using reverse transcription-PCR, mRNA for the trpc1-4 channel isoforms were detected in the CHO-hOX1-C1 cells. The expression of truncated TRPC channel isoforms, in particular trpc1 and trpc3, reduced the response to subnanomolar concentrations of orexin-A but did not affect the response to higher concentrations of orexin-A. The results suggest that activation of the OX1 receptor leads to opening of a Ca2+-permeable channel, involving trpc1 and -3, which is controlled by protein kinase C.	Univ Kuopio, Dept Neurobiol, AI Virtanen Inst Mol Sci, Cell Biol Lab, FIN-70211 Kuopio, Finland; Uppsala Univ, Dept Neurosci, Div Physiol, BMC, S-75123 Uppsala, Sweden	University of Eastern Finland; Uppsala University	Akerman, KEO (corresponding author), Univ Kuopio, Dept Neurobiol, AI Virtanen Inst Mol Sci, Cell Biol Lab, POB 1627, FIN-70211 Kuopio, Finland.	karl.okerman@uku.fi		Bart, Genevieve/0000-0001-9809-150X; Louhivuori, Lauri/0000-0001-8649-781X; Kukkonen, Jyrki/0000-0002-6989-1564				Agam K, 2004, CELL CALCIUM, V35, P87, DOI 10.1016/j.ceca.2003.08.001; ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambudkar Indu S, 2004, Novartis Found Symp, V258, P63; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Beech DJ, 2003, CELL CALCIUM, V33, P433, DOI 10.1016/S0143-4160(03)00054-X; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; CHURCH J, 1995, BRIT J PHARMACOL, V116, P2801, DOI 10.1111/j.1476-5381.1995.tb15929.x; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; Ferguson AV, 2003, FRONT NEUROENDOCRIN, V24, P141, DOI 10.1016/S0091-3022(03)00028-1; Gailly P, 2001, CELL CALCIUM, V30, P157, DOI 10.1054/ceca.2001.0221; Gamberucci A, 2002, BIOCHEM J, V364, P245, DOI 10.1042/bj3640245; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hardie RC, 1997, CELL CALCIUM, V21, P431, DOI 10.1016/S0143-4160(97)90054-3; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Holmqvist T, 2002, FEBS LETT, V526, P11, DOI 10.1016/S0014-5793(02)03101-0; Itagaki K, 2003, J BIOL CHEM, V278, P27540, DOI 10.1074/jbc.M301763200; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; Kim SJ, 2003, NATURE, V426, P285, DOI 10.1038/nature02162; Kohlmeier KA, 2004, J NEUROPHYSIOL, V92, P221, DOI 10.1152/jn.00076.2004; Kukkonen JP, 2002, AM J PHYSIOL-CELL PH, V283, pC1567, DOI 10.1152/ajpcell.00055.2002; Kukkonen JP, 2001, TRENDS PHARMACOL SCI, V22, P616, DOI 10.1016/S0165-6147(00)01864-2; Kukkonen JP, 2001, NEUROREPORT, V12, P2017, DOI 10.1097/00001756-200107030-00046; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lund PE, 2000, J BIOL CHEM, V275, P30806, DOI 10.1074/jbc.M002603200; Michel AD, 1998, BRIT J PHARMACOL, V125, P1194, DOI 10.1038/sj.bjp.0702205; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Miyakawa T, 1998, BIOCHEM J, V329, P107, DOI 10.1042/bj3290107; Obukhov AG, 2002, J BIOL CHEM, V277, P16172, DOI 10.1074/jbc.M111664200; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Sergeeva OA, 2003, J NEUROCHEM, V85, P1547, DOI 10.1046/j.1471-4159.2003.01806.x; Shariatmadari R, 2001, PFLUG ARCH EUR J PHY, V442, P312, DOI 10.1007/s004240000513; Shuttleworth TJ, 2003, BIOCHEM SOC T, V31, P916; Smart D, 1999, BRIT J PHARMACOL, V128, P1, DOI 10.1038/sj.bjp.0702780; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; TORNQUIST K, 1993, MOL CELL ENDOCRINOL, V93, P17, DOI 10.1016/0303-7207(93)90134-6; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Uramura K, 2001, NEUROREPORT, V12, P1885, DOI 10.1097/00001756-200107030-00024; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; van den Pol AN, 1998, J NEUROSCI, V18, P7962; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	59	60	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1771	1781		10.1074/jbc.M406073200	http://dx.doi.org/10.1074/jbc.M406073200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537648	hybrid			2022-12-25	WOS:000226341700010
J	Kamaraju, SK; Roberts, AB				Kamaraju, SK; Roberts, AB			Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; MESENCHYMAL TRANSDIFFERENTIATION; SIGNALING PATHWAY; DIRECT BINDING; CROSS-TALK; C-MYC; CANCER; EXPRESSION; PROTEIN; ACTIVATION	TGF-beta is a multifunctional cytokine known to exert its biological effects through a variety of signaling pathways of which Smad signaling is considered to be the main mediator. At present, the Smad-independent pathways, their interactions with each other, and their roles in TGF-beta-mediated growth inhibitory effects are not well understood. To address these questions, we have utilized a human breast cancer cell line MCF10CA1h and demonstrate that p38 MAP kinase and Rho/ROCK pathways together with Smad2 and Smad3 are necessary for TGF-beta-mediated growth inhibition of this cell line. We show that Smad2/3 are indispensable for TGF-beta- mediated growth inhibition, and that both p38 and Rho/ROCK pathways affect the linker region phosphorylation of Smad2/3. Further, by using Smad3 mutated at the putative phosphorylation sites in the linker region, we demonstrate that phosphorylation at Ser(203) and Ser(207) residues is required for the full transactivation potential of Smad3, and that these residues are targets of the p38 and Rho/ROCK pathways. We demonstrate that activation of the p38 MAP kinase pathway is necessary for the full transcriptional activation potential of Smad2/Smad3 by TGF-beta, whereas activity of Rho/ROCK is necessary for both down-regulation of c-Myc protein and up-regulation of p21(waf1) protein, directly interfering with p21(waf1) transcription. Our results not only implicate Rho/ROCK and p38 MAPK pathways as necessary for TGF-beta-\mediated growth inhibition, but also demonstrate their individual contributions and the basis for their cooperation with each other.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Rm C629,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.	robertsa@dce41.nci.nih.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC005051] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrow MG, 1997, J CELL BIOCHEM, V66, P427, DOI 10.1002/(SICI)1097-4644(19970915)66:4<427::AID-JCB1>3.3.CO;2-Y; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Dawson PJ, 1996, AM J PATHOL, V148, P313; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; HOROWITZ JC, 2003, J BIOL CHEM, V23, P23; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Johansson N, 2000, J CELL SCI, V113, P227; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LEE S, 2003, J BIOL CHEM, V14, P14; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; OHSHIMA T, 2003, J BIOL CHEM, V26, P26; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Park BJ, 2000, CANCER RES, V60, P3031; Piek E, 1999, J CELL SCI, V112, P4557; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SOULE HD, 1990, CANCER RES, V50, P6075; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tian F, 2003, CANCER RES, V63, P8284; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; WRANA JL, 2000, SCI STKE, pRE1; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yan ZF, 2001, J BIOL CHEM, V276, P1555, DOI 10.1074/jbc.M004553200; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	63	189	207	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1024	1036		10.1074/jbc.M403960200	http://dx.doi.org/10.1074/jbc.M403960200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15520018	hybrid			2022-12-25	WOS:000226195200022
J	Kusaba, H; Ghosh, P; Derin, R; Buchholz, M; Sasaki, C; Madara, K; Longo, DL				Kusaba, H; Ghosh, P; Derin, R; Buchholz, M; Sasaki, C; Madara, K; Longo, DL			Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; SERINE PHOSPHORYLATION; NATURAL-KILLER; TRANSCRIPTIONAL ACTIVITY; MOLECULAR-MECHANISMS; PROMOTER ACTIVATION; MAXIMAL ACTIVATION; STIMULATORY FACTOR; GENE-EXPRESSION; CYCLOSPORINE-A	Depending on the type of external signals, T cells can initiate multiple intracellular signaling pathways that can be broadly classified into two groups based on their sensitivity to the immunosuppressive drug cyclosporin A (CsA). Interleukin (IL)-12-mediated interferon (IFN)-gamma production by activated T cells has been shown to be CsA-insensitive. In this report, we demonstrate that the IL-12-induced CsA-resistant pathway of IFN-gamma production is sensitive to rapamycin. Rapamycin treatment resulted in the aberrant recruitment of Stat3, Stat4, and phospho-c-Jun to the genomic promoter region resulting in decreased IFN-gamma transcription. IL-12-induced phosphorylation of Stat3 on Ser-727 was affected by rapamycin, which may be due to the effect of rapamycin on the IL-12-induced interaction between mammalian target of rapamycin ( mTOR) and Stat3. In accordance with this, reduction in the mTOR protein level by small interfering RNA resulted in suppression of Stat3 phosphorylation and decreased production of IFN-gamma after IL-12 stimulation. These results suggest that mTOR may play a major role in IL-12-induced IFN-gamma production by activated T cells.	NIA, Lymphocyte Cell Biol Unit, Immunol Lab, Gerontol Res Ctr,NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Ghosh, P (corresponding author), NIA, Lymphocyte Cell Biol Unit, Immunol Lab, Gerontol Res Ctr,NIH, 5600 Nathan Schock Dr, Baltimore, MD 21224 USA.	ghoshp@grc.nia.nih.gov	Longo, Dan L./F-6022-2011		NATIONAL INSTITUTE ON AGING [Z01AG000115, ZICAG000912, Z01AG000912, ZIAAG000115] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barbulescu K, 1998, J IMMUNOL, V160, P3642; BERTAGNOLLI MM, 1994, TRANSPLANTATION, V58, P1091, DOI 10.1097/00007890-199411270-00006; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Brazelton TR, 1996, CURR OPIN IMMUNOL, V8, P710, DOI 10.1016/S0952-7915(96)80090-2; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHAN SH, 1992, J IMMUNOL, V148, P92; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Ghosh P, 2002, BLOOD, V99, P4517, DOI 10.1182/blood-2001-11-0062; Gollob JA, 1999, J IMMUNOL, V162, P4472; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hodge DL, 2002, MOL CELL BIOL, V22, P1742, DOI 10.1128/MCB.22.6.1742-1753.2002; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; KUBIN M, 1994, J EXP MED, V180, P211, DOI 10.1084/jem.180.1.211; Kwon TK, 1997, J IMMUNOL, V158, P5642; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Nakahira M, 2002, J IMMUNOL, V168, P1146, DOI 10.4049/jimmunol.168.3.1146; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PAI SY, 1994, BLOOD, V84, P3974, DOI 10.1182/blood.V84.11.3974.bloodjournal84113974; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Walker W, 1999, J IMMUNOL, V162, P5894; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wu CY, 1997, EUR J IMMUNOL, V27, P147, DOI 10.1002/eji.1830270122; Yang JF, 1999, EUR J IMMUNOL, V29, P548, DOI 10.1002/(SICI)1521-4141(199902)29:02<548::AID-IMMU548>3.0.CO;2-Z; Yano S, 2003, J IMMUNOL, V171, P2510, DOI 10.4049/jimmunol.171.5.2510; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yoshimoto T, 1998, J IMMUNOL, V161, P3400	37	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1037	1043		10.1074/jbc.M405204200	http://dx.doi.org/10.1074/jbc.M405204200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522880	hybrid			2022-12-25	WOS:000226195200023
J	Richman, RW; Strock, J; Hains, MD; Cabanilla, NJ; Lau, KK; Siderovski, DP; Diverse-Pierluissi, M				Richman, RW; Strock, J; Hains, MD; Cabanilla, NJ; Lau, KK; Siderovski, DP; Diverse-Pierluissi, M			RGS12 interacts with the SNARE-binding region of the Ca(v)2.2 calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; MODULATION; DOMAIN; SHC; REGULATORS; PROTEINS; DISTINCT; MOTIFS; SYSTEM; SITE	Activation of GABA(B) receptors in chick dorsal root ganglion (DRG) neurons inhibits the Ca(v)2.2 calcium channel in both a voltage-dependent and voltage-independent manner. The voltage-independent inhibition requires activation of a tyrosine kinase that phosphorylates the alpha(1) subunit of the channel and thereby recruits RGS12, a member of the "regulator of G protein signaling" (RGS) proteins. Here we report that RGS12 binds to the SNARE-binding or "synprint" region ( amino acids 726-985) in loop II-III of the calcium channel alpha(1) subunit. A recombinant protein encompassing the N-terminal PTB domain of RGS12 binds to the synprint region in protein overlay and surface plasmon resonance binding assays; this interaction is dependent on tyrosine phosphorylation and yet is within a sequence that differs from the canonical NPXY motif targeted by other PTB domains. In electrophysiological experiments, microinjection of DRG neurons with synprint-derived peptides containing the tyrosine residue Tyr-804 altered the rate of desensitization of neurotransmitter-mediated inhibition of the Ca(v)2.2 calcium channel, whereas peptides centered about a second tyrosine residue, Tyr-815, were without effect. RGS12 from a DRG neuron lysate was precipitated using synprint peptides containing phosphorylated Tyr-804. The high degree of conservation of Tyr-804 in the SNARE-binding region of Ca(v)2.1 and Ca(v)2.2 calcium channels suggests that this region, in addition to the binding of SNARE proteins, is also important for determining the time course of the modulation of calcium current via tyrosine phosphorylation.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA	Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Diverse-Pierluissi, M (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 1 Gustave L Levy Pl,Box 1603, New York, NY 10029 USA.	Maria.Diverse@mssm.edu	Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM062338] Funding Source: Medline; NINDS NIH HHS [NS 37443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Ikeda SR, 1999, ADV SEC MESS PHOSPH, V33, P131; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Lu Q, 1999, J BIOL CHEM, V274, P34566, DOI 10.1074/jbc.274.49.34566; LUEBKE JI, 1994, PFLUG ARCH EUR J PHY, V428, P499, DOI 10.1007/BF00374571; Malmqvist M, 1999, BIOCHEM SOC T, V27, P335, DOI 10.1042/bst0270335; MARK T, 2004, J MOL BIOL, V345, P1; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Richman RW, 2004, J BIOL CHEM, V279, P24649, DOI 10.1074/jbc.M312182200; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Spafford JD, 2003, CURR OPIN NEUROBIOL, V13, P308, DOI 10.1016/S0959-4388(03)00061-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WILSON LK, 1995, J BIOL CHEM, V270, P25185, DOI 10.1074/jbc.270.42.25185; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	31	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1521	1528		10.1074/jbc.M406607200	http://dx.doi.org/10.1074/jbc.M406607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536086	Green Published, hybrid			2022-12-25	WOS:000226195200082
J	Yamakoshi, Y; Hu, JCC; Fukae, M; Iwata, T; Kim, JW; Zhang, HM; Simmer, JP				Yamakoshi, Y; Hu, JCC; Fukae, M; Iwata, T; Kim, JW; Zhang, HM; Simmer, JP			Porcine dentin sialoprotein is a proteoglycan with glycosaminoglycan chains containing chondroitin 6-sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; IMPERFECTA TYPE-II; SIALOPHOSPHOPROTEIN GENE; SEQUENCE DETERMINATION; ACID-RICH; DENTINOGENESIS; DSPP; BONE; PHOSPHOPROTEIN; MUTATION	Dentin sialoprotein (DSP) is a glycoprotein that is critical for proper tooth dentin formation, but little is known about the nature of its carbohydrate attachments and other post-translational modifications. We have isolated DSP from pig dentin and demonstrate that it is a proteoglycan. Polyclonal antibodies were raised in chicken against recombinant pig DSP, and used to identify native DSP in fractions of tooth dentin proteins extracted from developing pig molars. Amino acid analyses and characterization of lysylendopeptidase cleavage products confirmed that the purified protein was DSP, and that Arg(391) is at the DSP C terminus. On SDS-PAGE and on urea gels, DSP appeared as a smear extending from 280 to 100 kDa, but in the presence of beta-mercaptoethanol the top of the DSP smear disappeared. The high molecular weight material was likely comprised of covalent DSP dimers connected by a disulfide bridge at Cys(205). Oligosaccharides were released from DSP following N- and O-linked glycosidase digestions, but these digestions had little effect on the apparent molecular weight of DSP on SDS-PAGE, when compared with the significant reduction following chondroitinase ABC digestion. Glycosaminoglycanases with assorted glycosaminoglycan ( GAG) cleavage specificities coupled with Western analyses of the cleaved GAG "stubs" demonstrated that the DSP GAG attachments contain chondroitin 6-sulfate, but not keratan sulfate, heparan sulfate, chondroitin, or chondroitin 4-sulfate. DSP binds biotin-labeled hyaluronic acid, and such binding is inhibited by the addition of unlabeled hyaluronic acid. We conclude that DSP is a proteoglycan and that GAG attachments are the predominant structural feature of porcine DSP.	Univ Michigan, Dent Res Lab, Ann Arbor, MI 48108 USA; Tsurumi Univ, Sch Dent Med, Dept Biochem, Tsurumi Ku, Yokohama, Kanagawa 230, Japan; Seoul Natl Univ, Coll Dent, Dept Pediat Dent, Seoul 110768, South Korea; Seoul Natl Univ, Coll Dent, Dent Res Inst, Seoul 110768, South Korea	University of Michigan System; University of Michigan; Tsurumi University; Seoul National University (SNU); Seoul National University (SNU)	Simmer, JP (corresponding author), Univ Michigan, Dent Res Lab, 1210 Eisenhower Pl, Ann Arbor, MI 48108 USA.	jsimmer@umich.edu	Hu, Jan C-C./F-5679-2015; KIM, JUNG-WOOK/G-8992-2012	Hu, Jan C-C./0000-0002-9294-0248; Simmer, James/0000-0002-7192-6105	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011301, R29DE011301, R01DE012769, R56DE011301] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE15846, DE11301, DE12769] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Boskey A, 2000, CALCIFIED TISSUE INT, V67, P472, DOI 10.1007/s002230001169; Butler WT, 2002, CONNECT TISSUE RES, V43, P301, DOI 10.1080/03008200290000682; BUTLER WT, 1981, COLLAGEN REL RES, V1, P187; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; Butler WT, 1997, CIBA F SYMP, V205, P107; Butler WT, 2003, CONNECT TISSUE RES, V44, P171, DOI 10.1080/03008200390152287; BUTLER WT, 1992, OPER DENT, P18; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; Embery G, 1998, EUR J ORAL SCI, V106, P267, DOI 10.1111/j.1600-0722.1998.tb02186.x; Embery G, 2001, CRIT REV ORAL BIOL M, V12, P331, DOI 10.1177/10454411010120040401; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106; Kim JW, 2004, HUM GENET, V115, P248, DOI 10.1007/s00439-004-1143-5; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Malmgren B, 2004, HUM GENET, V114, P491, DOI 10.1007/s00439-004-1084-z; Neame P J, 1994, EXS, V70, P53; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Qin CL, 2003, CONNECT TISSUE RES, V44, P179, DOI 10.1080/03008200390152296; Qin CL, 2003, EUR J ORAL SCI, V111, P235, DOI 10.1034/j.1600-0722.2003.00043.x; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; Ritchie HH, 2001, EUR J ORAL SCI, V109, P342, DOI 10.1034/j.1600-0722.2001.00093.x; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Takano Y, 2003, J ELECTRON MICROSC, V52, P573, DOI 10.1093/jmicro/52.6.573; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; Waddington RJ, 2003, MATRIX BIOL, V22, P153, DOI 10.1016/S0945-053X(03)00019-2; Winzen U, 2003, J BIOL CHEM, V278, P30106, DOI 10.1074/jbc.M212676200; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; YAMAKOSHI Y, 1995, CALCIFIED TISSUE INT, V56, P323, DOI 10.1007/BF00318054; Yamakoshi Y, 2003, EUR J ORAL SCI, V111, P60, DOI 10.1034/j.1600-0722.2003.00009.x; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Young MF, 2002, GLYCOCONJUGATE J, V19, P257, DOI 10.1023/A:1025336114352; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	40	58	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1552	1560		10.1074/jbc.M409606200	http://dx.doi.org/10.1074/jbc.M409606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15537641	hybrid			2022-12-25	WOS:000226195200086
J	Venkataraman, S; Jiang, XH; Weydert, C; Zhang, YP; Zhang, HJ; Goswami, PC; Ritchie, JM; Oberley, LW; Buettner, GR				Venkataraman, S; Jiang, XH; Weydert, C; Zhang, YP; Zhang, HJ; Goswami, PC; Ritchie, JM; Oberley, LW; Buettner, GR			Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells	ONCOGENE			English	Article						superoxide dismutase; prostate cancer; reactive oxygen species; cell cycle; overexpression; hydrogen peroxide	NORMAL HUMAN FIBROBLASTS; NF-KAPPA-B; ANTIOXIDANT ENZYMES; CARCINOMA-CELLS; TYROSINE PHOSPHORYLATION; MALIGNANT PHENOTYPE; OXIDATIVE STRESS; FREE-RADICALS; GENE-TRANSFER; H2O2 RELEASE	This study investigates the role of the antioxidant enzyme manganese superoxide dismutase (MnSOD) in androgen-independent human prostate cancer (PC-3) cells' growth rate in vitro and in vivo. MnSOD levels were found to be lower in parental PC-3 cells compared to nonmalignant, immortalized human prostate epithelial cells (P69SV40T). To unravel the role of MnSOD in the prostate cancer phenotype, PC-3 cells were stably transfected with MnSOD cDNA plasmid. The MnSOD protein and activity levels in clones overexpressing MnSOD were increased seven- to eightfold. These cell lines showed elongated cell doubling time, reduced anchorage-independent growth in soft agar compared to parental PC-3 (Wt) cells, and reduced growth rate of PC-3 tumor xenografts in athymic nude mice. Flow cytometric studies showed an increase in membrane potential in the MnSOD-overexpressing clone (Mn32) compared to Wt and Neo cells. Also, production of extracellular H2O2 was increased in the MnSOD-overexpressing clones. As determined by DNA cell cycle analysis, the proportion of cells in G(1) phase was enhanced by MnSOD overexpression. Therefore, MnSOD not only regulates cell survival but also affects PC-3 cell proliferation by retarding G(1) to S transition. Our results are consistent with MnSOD being a tumor suppressor gene in human prostate cancer.	Univ Iowa, Free Rad & Radiat Biol Program, ESR Facil, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Buettner, GR (corresponding author), Univ Iowa, Free Rad & Radiat Biol Program, ESR Facil, EMRB 68, Iowa City, IA 52242 USA.	garry-buettner@uiowa.edu		Buettner, Garry/0000-0002-5594-1903; Goswami, Prabhat/0000-0002-5700-2096	NCI NIH HHS [CA 66081, CA 81090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066081, R01CA081090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RG, 1989, FREE RADICAL BIO MED, V6, P631, DOI 10.1016/0891-5849(89)90071-3; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BEERS RF, 1952, J BIOL CHEM, V195, P133; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chin CWS, 2003, J PATHOL, V200, P308, DOI 10.1002/path.1363; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; da Silva MM, 2003, AM J PHYSIOL-HEART C, V285, pH154, DOI 10.1152/ajpheart.00955.2002; Foster CS, 1999, BJU INT, V83, P171; Fu WM, 1998, NEUROBIOL DIS, V5, P229, DOI 10.1006/nbdi.1998.0192; Jung K, 1997, FREE RADICAL BIO MED, V23, P127, DOI 10.1016/S0891-5849(96)00613-2; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Lam EWN, 1997, CANCER RES, V57, P5550; Lam EWN, 2000, J DENT RES, V79, P1410, DOI 10.1177/00220345000790061001; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li SJ, 2000, CANCER RES, V60, P3927; Liochev SI, 1997, FREE RADICAL BIO MED, V23, P668, DOI 10.1016/S0891-5849(97)00060-9; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Menon SG, 2003, CANCER RES, V63, P2109; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1985, CRC HDB METHODS OXYG, P217; OBERLEY LW, 1986, MODERN AGING RES, V8, P352; OBERLEY TD, 1991, FREE RADICAL BIO MED, V10, P79, DOI 10.1016/0891-5849(91)90024-W; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Palazzotti B, 1999, INT J CANCER, V82, P145, DOI 10.1002/(SICI)1097-0215(19990702)82:1<145::AID-IJC24>3.3.CO;2-2; Palmeira CM, 1996, J PHARMACOL TOX MET, V35, P35, DOI 10.1016/1056-8719(95)00131-X; PANUS PC, 1993, FREE RADICAL BIO MED, V14, P217, DOI 10.1016/0891-5849(93)90013-K; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; SAS Institute, 2001, SAS SYST WIND VERS 8; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Wang D, 1997, Chin Med Sci J, V12, P76; Weydert C, 2003, MOL CANCER THER, V2, P361; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang HJ, 1999, CANCER RES, V59, P6276; Zhang Y, 2002, CANCER RES, V62, P1205; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	56	127	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					77	89		10.1038/sj.onc.1208145	http://dx.doi.org/10.1038/sj.onc.1208145			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15543233				2022-12-25	WOS:000226125800010
J	Pitkanen, JP; Torma, A; Alff, S; Huopaniemi, L; Mattila, P; Renkonen, R				Pitkanen, JP; Torma, A; Alff, S; Huopaniemi, L; Mattila, P; Renkonen, R			Excess mannose limits the growth of phosphomannose isomerase PMI40 deletion strain of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI; MASS-SPECTROMETRY; PROTEIN COMPLEXES; YEAST; EXPRESSION; MUTANT; TRANSPORTER; IDENTIFICATION; EXTRACTION; BINDING	Phosphomannose isomerase (PMI40) catalyzes the conversion between fructose 6-phosphate and mannose 6-phosphate and thus connects glycolysis, i.e. energy production and GDP-mannose biosynthesis or cell wall synthesis in Saccharomyces cerevisiae. After PMI40 deletion (pmi(-)) the cells were viable only if fed with extracellular mannose and glucose. In an attempt to force the GDP-mannose synthesis in the pmi(-) strain by increasing the extracellular mannose concentrations, the cells showed significantly reduced growth rates without any alterations in the intracellular GDPmannose levels. To reveal the mechanisms resulting in reduced growth rates, we measured genome-wide gene expression levels, several metabolite concentrations, and selected in vitro enzyme activities in central metabolic pathways. The increasing of the initial mannose concentration led to an increase in the mannose 6-phosphate concentration, which inhibited the activity of the second enzyme in glycolysis, i.e. phosphoglucose isomerase converting glucose 6-phosphate to fructose 6-phosphate. As a result of this limitation, the flux through glycolysis was decreased as was the median expression of the genes involved in glycolysis. The expression levels of RAP1, a transcription factor involved in the regulation of the mRNA levels of several enzymes in glycolysis, as well as those of cell cycle regulators CDC28 and CLN3, decreased concomitantly with the growth rates and expression of many genes encoding for enzymes in glycolysis.	Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Rat Drug Design Program, FIN-00014 Helsinki, Finland; MediCel Ltd, FIN-00290 Helsinki, Finland; Univ Helsinki, Biomedicum, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Renkonen, R (corresponding author), Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Rat Drug Design Program, POB 63, FIN-00014 Helsinki, Finland.	Risto.Renkonen@helsinki.fi	Pitkänen, Juha-Pekka/K-4658-2013	Pitkänen, Juha-Pekka/0000-0002-4006-0302				Berg JM, 2002, BIOCHEMISTRY-US, V5th; Bergmeyer H. U., 1983, METHODS ENZYMATIC AN; Boles E, 1996, MOL MICROBIOL, V20, P65, DOI 10.1111/j.1365-2958.1996.tb02489.x; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buziol S, 2002, FEMS YEAST RES, V2, P283, DOI 10.1016/S1567-1356(02)00113-7; COROMINAS J, 1992, FEBS LETT, V210, P182; DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2; Diderich JA, 2001, YEAST, V18, P1515, DOI 10.1002/yea.779; Entian KD, 1998, METHOD MICROBIOL, V26, P431; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Gao XD, 2001, J BIOL CHEM, V276, P4424, DOI 10.1074/jbc.M009114200; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Jarvinen N, 2001, EUR J BIOCHEM, V268, P6458, DOI 10.1046/j.0014-2956.2001.02601.x; Klinder A, 1998, YEAST, V14, P323, DOI 10.1002/(SICI)1097-0061(19980315)14:4<323::AID-YEA223>3.0.CO;2-W; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Maki M, 2002, EUR J BIOCHEM, V269, P593, DOI 10.1046/j.0014-2956.2001.02688.x; MANHART A, 1988, YEAST, V4, P227, DOI 10.1002/yea.320040308; Newcomb LL, 2003, EUKARYOT CELL, V2, P143, DOI 10.1128/EC.2.1.143-149.2003; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; NOLTMANN EA, 1972, ENZYMES, V6, P271; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Parks R.E.E., 1973, ENZYMES, V8, P307, DOI [DOI 10.1016/S1874-6047(08)60067-0, 10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rider MH, 2004, BIOCHEM J, V381, P561, DOI 10.1042/BJ20040752; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; UEMURA H, 1992, MOL CELL BIOL, V12, P3834, DOI 10.1128/MCB.12.9.3834; van Dam JC, 2002, ANAL CHIM ACTA, V460, P209, DOI 10.1016/S0003-2670(02)00240-4; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; Wu BY, 2002, FEBS LETT, V519, P87, DOI 10.1016/S0014-5793(02)02717-5; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777	37	27	28	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55737	55743		10.1074/jbc.M410619200	http://dx.doi.org/10.1074/jbc.M410619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15520001	hybrid			2022-12-25	WOS:000225960800095
J	Li, J; Sahagian, GG				Li, J; Sahagian, GG			Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor	ONCOGENE			English	Article						breast cancer; apoptosis; lysosomal trafficking; TGF-beta; uPAR; retinoic acid	GROWTH-FACTOR-II; SQUAMOUS-CELL CARCINOMA; LYSINE-BASED STRUCTURE; MOUSE MAMMARY-TUMOR; BREAST-CANCER CELLS; TGF-BETA-RII; 6-PHOSPHATE RECEPTOR; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROSATELLITE INSTABILITY	The mannose 6-phosphate/IGF-2 receptor has been proposed to be a tumor suppressor gene on the basis of loss of heterozygosity and mutations in tumors from cancer patients. To test this hypothesis, the receptor was expressed in 66cl4, a mouse mammary tumor cell line deficient in the receptor. Expression of the receptor corrected the abnormal lysosomal trafficking phenotype displayed by these cells. Receptor expression had no apparent effect on growth or invasiveness of the cells in vitro but effectively inhibited formation of mammary tumors in BALB/c mice. Analysis of cell proliferation and apoptosis in tumors indicated that the primary effect of the receptor was to inhibit cell proliferation. Proliferation indices for receptor-deficient and receptor-expressing tumors, as determined by BrdU incorporation, were 24.6 and 7.6%, respectively. No significant effect of receptor expression on apoptosis was observed. Receptor expression similarly inhibited tumor growth in BALB/c scid mice indicating that cytotoxic T cells and other components of the immune system missing in scid mice are not involved in the receptor's tumor suppressing effect. These findings establish a role for the receptor as a bona. de tumor suppressor gene and together with previous studies, suggest an important role for the receptor in human and rodent cancers.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Sahagian, GG (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	gary.sahagian@tufts.edu			NCI NIH HHS [R01-CA66575] Funding Source: Medline; NIDDK NIH HHS [P30DK34928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Beck S, 2002, PROTEOMICS, V2, P247, DOI 10.1002/1615-9861(200203)2:3<247::AID-PROT247>3.0.CO;2-K; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; Caligo MA, 2000, ONCOL REP, V7, P1371; Calin GA, 2000, INT J CANCER, V89, P230, DOI 10.1002/1097-0215(20000520)89:3<230::AID-IJC4>3.3.CO;2-A; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; Chen ZH, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-18; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DOLE M, 1994, CANCER RES, V54, P3253; FILSON AJ, 1993, DEVELOPMENT, V118, P731; Gamma A, 2000, LUNG CANCER-J IASLC, V30, P91, DOI 10.1016/S0169-5002(00)00130-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ghahary A, 1999, J CELL PHYSIOL, V180, P61, DOI 10.1002/(SICI)1097-4652(199907)180:1<61::AID-JCP7>3.0.CO;2-R; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Hale AJ, 1996, EUR J BIOCHEM, V237, P884; Hankins GR, 1996, ONCOGENE, V12, P2003; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; KIESS W, 1988, J BIOL CHEM, V263, P9339; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Leboulleux S, 2001, EUR J ENDOCRINOL, V144, P163, DOI 10.1530/eje.0.1440163; Lee JS, 2003, INT J CANCER, V107, P564, DOI 10.1002/ijc.11453; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P7523; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; McKinnon T, 2001, J CLIN ENDOCR METAB, V86, P3665, DOI 10.1210/jc.86.8.3665; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; O'Gorman DB, 1999, CANCER RES, V59, P5692; O'Gorman DB, 2002, ENDOCRINOLOGY, V143, P4287, DOI 10.1210/en.2002-220548; Oka Y, 2002, HEPATOLOGY, V35, P1153, DOI 10.1053/jhep.2002.32669; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; SAHAGIAN GG, 1981, P NATL ACAD SCI-BIOL, V78, P4289, DOI 10.1073/pnas.78.7.4289; Seitz S, 2003, GENE CHROMOSOME CANC, V37, P29, DOI 10.1002/gcc.10196; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Tao K, 2001, INT J ONCOL, V19, P1333; TONG PY, 1988, J BIOL CHEM, V263, P2585; Wang SN, 1997, CANCER RES, V57, P2543; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; Zavras AI, 2003, CANCER RES, V63, P296	47	28	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9359	9368		10.1038/sj.onc.1208039	http://dx.doi.org/10.1038/sj.onc.1208039			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543235				2022-12-25	WOS:000225764100007
J	Murashov, AK; Pak, ES; Hendricks, WA; Owensby, JP; Sierpinski, PL; Tatko, LM; Fletcher, PL				Murashov, AK; Pak, ES; Hendricks, WA; Owensby, JP; Sierpinski, PL; Tatko, LM; Fletcher, PL			Directed differentiation of embryonic stem cells into dorsal interneurons	FASEB JOURNAL			English	Article						Wnt; spinal cord	SPINAL-CORD; MOTOR-NEURONS; SONIC HEDGEHOG; AXON GROWTH; TRANSPLANTATION; SPECIFICATION; IDENTITY; CULTURE; OLIGODENDROCYTES; EXPRESSION	During neural development caudalization and dorsoventral patterning of the neural tube is directed by several inductive factors including retinoic acid, sonic hedgehog (Shh), bone morphogenetic proteins (BMPs), and Wnt signaling. The purpose of the current study was to investigate whether dorsal interneurons specific for the spinal cord can be generated from mouse embryonic stem (ES) cells using known inductive signals. Here we show that specific combination of developmental signaling molecules including all trans-retinoic acid, Shh, bone morphogenetic protein 2 (BMP2), and Wnt3A can direct differentiation of ES cells into dorsal interneurons possessing appropriate neuronal markers, synaptic proteins and functional neurotransmitter machineries. We introduce a concept that Wnt3A morphogenic action relies on crosstalk with both Shh and BMP2 signaling pathways.	E Carolina Univ, Sch Med, Dept Physiol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Murashov, AK (corresponding author), E Carolina Univ, Sch Med, Dept Physiol, Brody Bldg 6N-98,600 Moye Blvd, Greenville, NC 27858 USA.	murashoval@mail.ecu.edu	Murashov, Alexander K/F-2241-2011	Murashov, Alexander K/0000-0002-8912-5891; Fletcher, Paul/0000-0002-3200-4693				Appel B, 2003, NEURON, V40, P461, DOI 10.1016/S0896-6273(03)00688-3; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Bain G, 1996, BIOCHEM BIOPH RES CO, V223, P691, DOI 10.1006/bbrc.1996.0957; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Butler SJ, 2003, NEURON, V38, P389, DOI 10.1016/S0896-6273(03)00254-X; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gulacsi A, 2003, J NEUROSCI, V23, P9862; Gunhaga L, 2003, NAT NEUROSCI, V6, P701, DOI 10.1038/nn1068; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Lee SK, 2001, NAT NEUROSCI, V4, P1183, DOI 10.1038/nn750; Liu RY, 2002, MOL CELL NEUROSCI, V20, P2, DOI 10.1006/mcne.2002.1107; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Lovell-Badge R, 2001, NATURE, V414, P88, DOI 10.1038/35102150; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Megason SG, 2002, DEVELOPMENT, V129, P2087; Muller T, 2002, NEURON, V34, P551, DOI 10.1016/S0896-6273(02)00689-X; Muroyama Y, 2004, BIOCHEM BIOPH RES CO, V313, P915, DOI 10.1016/j.bbrc.2003.12.023; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Panchision DM, 2002, CURR OPIN GENET DEV, V12, P478, DOI 10.1016/S0959-437X(02)00329-5; Price SR, 2002, CELL, V109, P205, DOI 10.1016/S0092-8674(02)00695-5; Schnorrer F, 2004, CURR BIOL, V14, pR19, DOI 10.1016/j.cub.2003.12.016; Sockanathan S, 2003, NEURON, V40, P97, DOI 10.1016/S0896-6273(03)00532-4; Thaler J, 1999, NEURON, V23, P675, DOI 10.1016/S0896-6273(01)80027-1; Trousse F, 2001, DEVELOPMENT, V128, P3927; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Yabe T, 2002, J NEUROSCI RES, V68, P161, DOI 10.1002/jnr.10210; Yu X, 2003, NAT NEUROSCI, V6, P1169, DOI 10.1038/nn1132; Yung SY, 2002, P NATL ACAD SCI USA, V99, P16273, DOI 10.1073/pnas.232586699	32	41	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					252	+		10.1096/fj.04-2251fje	http://dx.doi.org/10.1096/fj.04-2251fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545303				2022-12-25	WOS:000225482100017
J	Volonte, D; Liu, YH; Galbiati, F				Volonte, D; Liu, YH; Galbiati, F			The modulation of caveolin-1 expression controls satellite cell activation during muscle repair	FASEB JOURNAL			English	Article						caveolae; hepatocyte growth factor; muscle regeneration	HEPATOCYTE GROWTH-FACTOR; P42/44 MAP KINASE; ADULT SKELETAL-MUSCLE; ONCOGENICALLY TRANSFORMED-CELLS; GENE-EXPRESSION; TRANSGENIC MICE; MUSCULAR-DYSTROPHY; SIGNALING PATHWAYS; NITRIC-OXIDE; IN-VITRO	We have previously shown that caveolin-1, the principal structural protein component of caveolar membrane domains, inhibits cellular proliferation and induces cell cycle arrest. We demonstrate here for the first time that caveolin-1 is expressed in satellite cells but not in mature muscle fibers. Satellite cells are quiescent myogenic precursors that, after muscle injury, become mitotically active, proliferate, and fuse together or, to existing myofibers, to form new muscle fibers. We show that down-regulation of caveolin-1 expression occurs in satellite cells/myogenic precursor cells (MPCs) during muscle regeneration and that hepatocyte growth factor, which is produced after muscle injury, down-regulates caveolin-1. We also demonstrate that down-regulation of endogenous caveolin-1 expression activates ERK and that activation of the p42/44 MAP kinase pathway is necessary to promote muscle regeneration. Finally, we show that overexpression of caveolin-1 inhibits muscle repair mechanisms both in vitro and in vivo. Taken together, these results propose caveolin-1 as a novel regulator of satellite cell functions and suggest that the following signaling pathway modulates satellite cell activation during muscle repair: injured fibers release HGF --> HGF down-regulates caveolin-1 protein expression --> down-regulation of caveolin-1 activates ERK --> activation of ERK promotes muscle repair by stimulating the proliferation and migration of MPCs toward the wounded area.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Galbiati, F (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.	feg5@pitt.edu	Wilson, Matthew H/K-3193-2013; Galbiati, Ferruccio/AAF-3527-2020	Liu, Youhua/0000-0002-4740-805X				ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859; Andree B, 2002, MOL CELL BIOL, V22, P1504, DOI 10.1128/MCB.22.5.1504-1512.2002; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; BISCHOFF R, 1989, MED SCI SPORTS EXERC, V21, P164; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cooper RN, 1999, J CELL SCI, V112, P2895; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; COUTEAUX R, 1988, BIOL CELL, V62, P171, DOI 10.1016/0248-4900(88)90034-2; Dai CS, 2002, J AM SOC NEPHROL, V13, P411, DOI 10.1681/ASN.V132411; DALBIS A, 1989, DEV BIOL, V135, P320, DOI 10.1016/0012-1606(89)90182-6; EHLER E, 1995, CIRCULATION, V92, P3289, DOI 10.1161/01.CIR.92.11.3289; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Galbiati F, 2000, P NATL ACAD SCI USA, V97, P9689, DOI 10.1073/pnas.160249097; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Garry DJ, 2000, P NATL ACAD SCI USA, V97, P5416, DOI 10.1073/pnas.100501197; Garry DJ, 1997, DEV BIOL, V188, P280, DOI 10.1006/dbio.1997.8657; Haxhinasto K, 2004, AM J PHYSIOL-CELL PH, V287, pC1125, DOI 10.1152/ajpcell.00530.2003; IRINTCHEV A, 1994, DEV DYNAM, V199, P326, DOI 10.1002/aja.1001990407; Ishii A, 2001, BIOCHEM J, V356, P737, DOI 10.1042/0264-6021:3560737; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KANDA S, 1996, CELL GROWTH DIFFER, V92, P3289; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Launay T, 2001, J HISTOCHEM CYTOCHEM, V49, P887, DOI 10.1177/002215540104900709; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; MOSS FP, 1971, ANAT REC, V170, P421, DOI 10.1002/ar.1091700405; NOBLE M, 1995, TRANSGENIC RES, V4, P215, DOI 10.1007/BF01969114; Pirskanen A, 2000, DEV BIOL, V224, P189, DOI 10.1006/dbio.2000.9784; SCHULTZ E, 1978, J EXP ZOOL, V206, P451, DOI 10.1002/jez.1402060314; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; SMITH TH, 1993, DEVELOPMENT, V117, P1125; SNOW MH, 1990, ANAT REC, V227, P437, DOI 10.1002/ar.1092270407; Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Volonte D, 2003, MOL BIOL CELL, V14, P4075, DOI 10.1091/mbc.E03-03-0161; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; WINCHESTER PK, 1991, AM J PHYSIOL, V260, pC206, DOI 10.1152/ajpcell.1991.260.2.C206; YABLONKAREUVENI Z, 1995, MICROSC RES TECHNIQ, V30, P366, DOI 10.1002/jemt.1070300504; YABLONKAREUVENI Z, 1994, DEV BIOL, V164, P588, DOI 10.1006/dbio.1994.1226; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199	53	86	91	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					237	+		10.1096/fj.04-2215fje	http://dx.doi.org/10.1096/fj.04-2215fje			36	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545301				2022-12-25	WOS:000225482100021
J	Klein, FAC; Atkinson, RA; Potier, N; Moras, D; Cavarelli, J				Klein, FAC; Atkinson, RA; Potier, N; Moras, D; Cavarelli, J			Biochemical and NMR mapping of the interface between CREB-binding protein and ligand binding domains of nuclear receptor - Beyond the LXXLL motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; TRANSCRIPTIONAL ACTIVATION; HORMONE-RECEPTORS; ANDROGEN RECEPTOR; HISTONE ACETYLTRANSFERASE; COACTIVATOR RECRUITMENT; ALPHA; GAMMA; P300; SPECTROSCOPY	CBP, cAMP-response element-binding protein (CREB)binding protein, plays an important role as a general cointegrator of various signaling pathways and interacts with a large number of transcription factors. Interactions of CBP with ligand binding domains (LBDs) of nuclear receptors are mediated by LXXLL motifs, as are those of p160 proteins, although the number, distribution, and precise sequences of the motifs differ. We used a large N-terminal fragment of murine CBP to map by biochemical methods and NMR spectroscopy the interaction domain of CBP with the LBDs of several nuclear receptors. We show that distinct zones of that fragment are involved in the interactions: a 20-residue segment containing the LXXLL motif (residues 61-80) is implicated in the interaction with all three domains tested (peroxisome proliferator-activated receptor gamma-LBD, retinoid X receptor alpha-LBD, and estrogen-related receptor gamma-LBD), whereas a second N-terminal well conserved block of around 25 residues centered on a consensus (LPDEV44)-P-40 motif constitutes a secondary motif of interaction with peroidsome proliferator-activated receptor rLBD. Sequence analysis reveals that both zones are well conserved in all vertebrate p300/CBP proteins, suggesting their functional importance. Interactions of p300/CBP coactivators with the LBDs of nuclear receptors are not limited to the canonical LXXLL motifs, involving both a longer contiguous segment around the motif and, for certain domains, an additional zone.	ULP, INSERM, CNRS,Dept Biol & Genom Struct, Inst Genet & Biol Mol & Cellulaire,UMR 7104, F-67404 Illkirch Graffenstaden, France; Ecole Europeenne Chim Polymeres & Mat, CNRS, UMR 7509, Lab Spectrometrie Masse Bioorgan, F-67087 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Cavarelli, J (corresponding author), ULP, INSERM, CNRS,Dept Biol & Genom Struct, Inst Genet & Biol Mol & Cellulaire,UMR 7104, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.	cava@igbmc.u-strasbg.fr	Atkinson, Robert Andrew/ABE-8068-2020; Cavarelli, Jean/P-3566-2016; Noelle, POTIER/AAX-7633-2021	Atkinson, Robert Andrew/0000-0002-3645-9492; Cavarelli, Jean/0000-0001-8620-8723; Klein, Fabrice/0000-0002-9845-8735; POTIER, Noelle/0000-0002-6381-4365				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chan HM, 2001, J CELL SCI, V114, P2363; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Cheskis BJ, 2003, J BIOL CHEM, V278, P13271, DOI 10.1074/jbc.M211031200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Greschik H, 2004, J BIOL CHEM, V279, P33639, DOI 10.1074/jbc.M402195200; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henke BR, 1998, J MED CHEM, V41, P5020, DOI 10.1021/jm9804127; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Johnson BA, 2000, J MOL BIOL, V298, P187, DOI 10.1006/jmbi.2000.3636; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Matsuda S, 2004, J BIOL CHEM, V279, P14055, DOI 10.1074/jbc.M310188200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mi LZ, 2003, MOL CELL, V11, P1093, DOI 10.1016/S1097-2765(03)00112-6; Mukherjee R, 2002, J STEROID BIOCHEM, V81, P217, DOI 10.1016/S0960-0760(02)00066-3; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Shao G, 2000, MOL ENDOCRINOL, V14, P1198, DOI 10.1210/me.14.8.1198; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	52	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5682	5692		10.1074/jbc.M411697200	http://dx.doi.org/10.1074/jbc.M411697200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15542861	hybrid			2022-12-25	WOS:000227217100070
J	Robenek, H; Lorkowski, S; Schnoor, M; Troyer, D				Robenek, H; Lorkowski, S; Schnoor, M; Troyer, D			Spatial integration of TIP47 and adipophilin in macrophage lipid bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; GENE-EXPRESSION; CHOLESTEROL; DROPLETS; DROSOPHILA; RECEPTOR; STORAGE; LOCALIZATION; ASSOCIATION; PERILIPINS	We studied the distribution of the PAT family proteins TIP47 and adipophilin in lipid bodies of THP-1 cell-derived macrophages using fireeze-fracture immunolabeling and other techniques. Lipid bodies in macrophages comprise lipid droplets and extensive, previously scantily characterized sheet-like organelles, which we descriptively call "lipid sails." TIP47 and adipophilin are components of many, but not all, the lipid droplets. Both proteins are not confined to the surface of lipid droplets, as supposed, but are also inside lipid droplet cores. They are not codistributed stoichiometrically in lipid droplets. How TIP47 and adipophilin, which are polar proteins, enter the lipid droplets and are packaged among the hydrophobic neutral lipids of the core is unclear. However, in the lipid layers of the core, these proteins are directed sometimes inward and sometimes outward. Because TIP47 and adipophilin also localize to lipid sails, lipid sails are intimately involved in intracellular lipid metabolism.	Univ Munster, Dept Cell Biol & Utrastruct Res, Inst Arteriosclerosis Res, D-48149 Munster, Germany	University of Munster	Robenek, H (corresponding author), Univ Munster, Dept Cell Biol & Utrastruct Res, Inst Arteriosclerosis Res, Domagkstr 3, D-48149 Munster, Germany.	robenek@uni-muenster.de	Lorkowski, Stefan/B-9689-2008; Schnoor, Michael/H-1863-2016	Lorkowski, Stefan/0000-0002-9649-840X; Schnoor, Michael/0000-0002-0269-5884				Barbero P, 2001, J BIOL CHEM, V276, P24348, DOI 10.1074/jbc.M102468200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245; Fujimoto K, 1997, HISTOCHEM CELL BIOL, V107, P87, DOI 10.1007/s004180050092; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; Gronke S, 2003, CURR BIOL, V13, P603, DOI 10.1016/S0960-9822(03)00175-1; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; Iwashima Y, 2000, BIOCHEM BIOPH RES CO, V277, P368, DOI 10.1006/bbrc.2000.3685; Krise JP, 2000, J BIOL CHEM, V275, P25188, DOI 10.1074/jbc.M001138200; Larigauderie G, 2004, ARTERIOSCL THROM VAS, V24, P504, DOI 10.1161/01.ATV.0000115638.27381.97; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Mishra R, 2004, AM J PHYSIOL-RENAL, V286, pF913, DOI 10.1152/ajprenal.00323.2003; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy D. J., 2005, PLANT LIPIDS BIOL UT; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Reuter A, 2004, CELL MOL LIFE SCI, V61, P2092, DOI 10.1007/s00018-004-4193-x; Robenek MJ, 2004, FASEB J, V18, P866, DOI 10.1096/fj.03-0782fje; Robenek MJ, 2003, FASEB J, V17, P1940, DOI 10.1096/fj.03-0008fje; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; Sincock PM, 2003, TRAFFIC, V4, P18, DOI 10.1034/j.1600-0854.2003.40104.x; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Teixeira L, 2003, MECH DEVELOP, V120, P1071, DOI 10.1016/S0925-4773(03)00158-8; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200	31	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5789	5794		10.1074/jbc.M407194200	http://dx.doi.org/10.1074/jbc.M407194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15545278	hybrid			2022-12-25	WOS:000227217100081
J	Buck, E; Bourne, H; Wells, JA				Buck, E; Bourne, H; Wells, JA			Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DIRECTED MUTAGENESIS; BINDING; ACTIVATION; RESIDUES; ANAPHYLATOXIN; IDENTIFICATION; COMPLEMENT; RHODOPSIN; SWITCH	The manner by which peptidic ligands bind and activate their corresponding G-protein-coupled receptors is not well understood. One of the better characterized peptidic ligands is the chemotactic cytokine complement factor 5a (C5a), a 74-amino acid helical bundle. Previous studies showed 6-mer peptide analogs derived from the C terminus of the C5a ligand can bind to C5aR (K-d values similar to0.1-1 muM) and either agonize or antagonize the receptor (Gerber, B. O., Meng, E. C., Dotsch, V., Baranski, T. J., and Bourne, H. R. (2001) J. Biol. Chem. 276, 3394-3400). Here, we provide direct biochemical data using disulfide trapping to support a model that these peptides bind within a transmembrane helical triad formed by a-helices III, VI, and VII. We show that the three amino acids on the C terminus of the peptide analogs bind too weakly to exert a functional effect themselves. However, when a cysteine residue is placed on their N terminus they can be trapped by disulfide interchange to specific cysteines in helix III and VI and not to other cysteines, engineered into the C5aR. The trapped peptides function as agonists or partial antagonists, similar to the non-covalent parents from which they were derived. These data help to further refine the binding mode for C5a to the C5aR and suggest an approach and a binding site that may be applicable to studying other peptide binding receptors.	Sunesis Pharmaceut Inc, San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wells, JA (corresponding author), Sunesis Pharmaceut Inc, San Francisco, CA 94080 USA.	jaw@sunesis.com	Wells, Jim A/O-9854-2016					Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BUBECK P, 1994, EUR J BIOCHEM, V219, P897, DOI 10.1111/j.1432-1033.1994.tb18571.x; Cain SA, 2001, BIOCHEMISTRY-US, V40, P14047, DOI 10.1021/bi011055w; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Erlanson DA, 2004, ANNU REV BIOPH BIOM, V33, P199, DOI 10.1146/annurev.biophys.33.110502.140409; Erlanson DA, 2000, P NATL ACAD SCI USA, V97, P9367, DOI 10.1073/pnas.97.17.9367; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; Gurrath M, 2001, CURR MED CHEM, V8, P1605, DOI 10.2174/0929867013371798; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; Holst B, 2003, ANN NY ACAD SCI, V994, P1, DOI 10.1111/j.1749-6632.2003.tb03156.x; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Kirschfink M, 2001, IMMUNOL REV, V180, P177, DOI 10.1034/j.1600-065X.2001.1800116.x; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; Rao VR, 1996, ANNU REV BIOPH BIOM, V25, P287; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Taylor SM, 2001, CURR MED CHEM, V8, P675, DOI 10.2174/0929867013373156; Thanos CD, 2003, J AM CHEM SOC, V125, P15280, DOI 10.1021/ja0382617; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803	33	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4009	4012		10.1074/jbc.C400500200	http://dx.doi.org/10.1074/jbc.C400500200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15550394	hybrid			2022-12-25	WOS:000227096600002
J	Koldamova, T; Lefterov, IM; Staufenbiel, M; Wolfe, D; Huang, SH; Glorioso, JC; Walter, M; Roth, MG; Lazo, JS				Koldamova, T; Lefterov, IM; Staufenbiel, M; Wolfe, D; Huang, SH; Glorioso, JC; Walter, M; Roth, MG; Lazo, JS			The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CENTRAL-NERVOUS-SYSTEM; DIET-INDUCED HYPERCHOLESTEROLEMIA; CASSETTE TRANSPORTER 1; VASCULAR RISK-FACTORS; E EPSILON-4 ALLELE; APOLIPOPROTEIN-E; TANGIER-DISEASE; PRECURSOR PROTEIN; A-BETA	Recent studies indicate that oxysterols, which are ligands for the nuclear hormone liver X receptors (LXR), decrease amyloid 13 (Abeta) secretion in vitro. The effect was attributed primarily to the ATP-binding cassette transporter A1 (ABCA1) transcriptionally up-regulated by ligand-activated LXRs. We now examined the effect of the synthetic LXR ligand T0901317, which can be used in vivo, on Abeta production in vitro and in APP23 transgenic mice. T0901317 applied to a variety of in vitro models, including immortalized fibroblasts from Tangier patients, and primary embryonic mouse neurons caused a concentration-dependent decrease in Abeta secretion, and this effect was increased by the addition of apolipoprotein A-I. The inhibition of Abeta production by T0901317 was cell-type specific, being more prominent in primary neurons than in non-neuronal cells. Tangier fibroblasts lacking a functional ABCA1 secreted more Abeta than control fibroblasts, thus demonstrating the role of ABCA1 in amyloid precursor protein (APP) processing and Abeta generation. T0901317 treatment of 11-week-old APP23 mice for 6 days showed a significant increase in ABCA1 expression and a decrease in the ratio of soluble APP (sAPP)beta- to sAPPalpha-cleavage products. Most importantly, the treatment caused a statistically significant reduction in the levels of soluble Abeta(40) and Abeta(42) in the brain of these mice. Our experiments demonstrate that T0901317 decreases amyloidogenic processing of APP in vitro and in vivo, thus supporting the search for potent and specific LXR ligands with properties allowing therapeutic application.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Novartis Inst BioMed Res, CH-4002 Basel, Switzerland; Univ Munster, Inst Clin Chem, D-48149 Munster, Germany; Univ Munster, Lab Med, D-48149 Munster, Germany; Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Novartis; University of Munster; University of Munster; University of Munster; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Koldamova, T (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E-1358 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	radak@pitt.edu; iliyal@pitt.edu	Lefterov, Iliya/B-4767-2008	Lefterov, Iliya/0000-0002-0249-0280; Koldamova, Radosveta/0000-0002-6761-0984; Roth, Michael/0000-0002-9056-332X	NATIONAL INSTITUTE ON AGING [R03AG023304] Funding Source: NIH RePORTER; NIA NIH HHS [AG 23304, AG 18558] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bonarek M, 2000, NEUROEPIDEMIOLOGY, V19, P141, DOI 10.1159/000026249; Breteler MMB, 2000, NEUROBIOL AGING, V21, P153, DOI 10.1016/S0197-4580(99)00110-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Clee SM, 2001, CIRCULATION, V103, P1198; Cole GM, 1999, J NEUROSCI RES, V57, P504, DOI 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H; Farhangrazi ZS, 1997, NEUROREPORT, V8, P1127, DOI 10.1097/00001756-199703240-00013; George AJ, 2004, NEUROBIOL DIS, V16, P124, DOI 10.1016/j.nbd.2004.01.009; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Katzov H, 2004, HUM MUTAT, V23, P358, DOI 10.1002/humu.20012; Kawashiri M A, 2000, Curr Atheroscler Rep, V2, P363, DOI 10.1007/s11883-000-0074-4; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Kivipelto M, 2002, ANN INTERN MED, V137, P149, DOI 10.7326/0003-4819-137-3-200208060-00006; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Koldamova RP, 2001, BIOCHEMISTRY-US, V40, P3553, DOI 10.1021/bi002186k; Koudinov AR, 1998, CLIN CHIM ACTA, V270, P75, DOI 10.1016/S0009-8981(97)00207-6; Kuo YM, 1998, BIOCHEM BIOPH RES CO, V252, P711, DOI 10.1006/bbrc.1998.9652; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Laffitte BA, 2003, MOL CELL BIOL, V23, P2182, DOI 10.1128/MCB.23.6.2182-2191.2003; Lefterov IM, 2001, BIOCHEM BIOPH RES CO, V283, P994, DOI 10.1006/bbrc.2001.4860; Lefterov IM, 2000, FASEB J, V14, P1837, DOI 10.1096/fj.99-0938com; Lesser G, 2001, DEMENT GERIATR COGN, V12, P138, DOI 10.1159/000051248; Li YH, 2004, NEUROSCI LETT, V366, P268, DOI 10.1016/j.neulet.2004.05.047; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Merched A, 2000, NEUROBIOL AGING, V21, P27, DOI 10.1016/S0197-4580(99)00103-7; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; Olesen OF, 2000, BIOCHEM BIOPH RES CO, V270, P62, DOI 10.1006/bbrc.2000.2372; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Puskovic V, 2004, MOL THER, V10, P67, DOI 10.1016/j.ymthe.2004.04.004; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Utech M, 2001, BIOCHEM BIOPH RES CO, V280, P229, DOI 10.1006/bbrc.2000.4061; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Walter M, 2004, J BIOL CHEM, V279, P20866, DOI 10.1074/jbc.M401714200; WALTER M, 1994, ATHEROSCLEROSIS, V110, P203, DOI 10.1016/0021-9150(94)90205-4; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Wollmer MA, 2003, NEUROBIOL AGING, V24, P421, DOI 10.1016/S0197-4580(02)00094-5; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825	55	222	231	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4079	4088		10.1074/jbc.M411420200	http://dx.doi.org/10.1074/jbc.M411420200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557325	hybrid			2022-12-25	WOS:000227096600012
J	Wilson, CM; Kraft, C; Duggan, C; Ismail, N; Crawshaw, SG; High, S				Wilson, CM; Kraft, C; Duggan, C; Ismail, N; Crawshaw, SG; High, S			Ribophorin I associates with a subset of membrane proteins after their integration at the Sec61 translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; OLIGOSACCHARYLTRANSFERASE COMPLEX; ALZHEIMERS-DISEASE; QUALITY-CONTROL; ER MEMBRANE; FRAGMENTS; GLYCOSYLATION; BETA-A4; BIOGENESIS; SEQUENCES	The biosynthesis of membrane proteins at the endoplasmic reticulum (ER) involves the integration of the polypeptide at the Sec61. translocon together with a number of maturation events, such as N-glycosylation and signal sequence cleavage, that can occur both during and after synthesis. To better understand the events occurring after the release of the nascent chain from the ER translocon, we investigated the ER components adjacent to the transmembrane-spanning domain of a well characterized fragment of the amyloid precursor protein. Using individual cysteine residues as site-specific cross-linking targets, we found that several ER components can be cross-linked to the fully integrated polypeptide. We identified strong adducts with both the ribophorin I subunit of the oligosaccharyltransferase complex and the 25-kDa subunit of the signal peptidase complex. Focusing on the association with ribophorin I, we found that adduct formation occurred exclusively after the exit of the nascent chain from the Sec61. trans-Iocon and was unaffected by the N-glycosylation status of the associated precursor. Only a subset of newly made membrane proteins associated with ribophorin I in vitro, and we could recapitulate a specific association between the amyloid precursor protein fragment and ribophorin I in vivo. Taken together, our data suggest a model where ribophorin I may function to retain potential substrates in close proximity to the catalytic subunit of the oligosaccharyltransferase and thereby stochastically improve the efficiency of the N-glycosylation reaction in vivo. Alternatively ribophorin I may be multifunctional and facilitate additional processes, for example, ER quality control.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	High, S (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	stephen.high@manchester.ac.uk		Wilson, Cornelia/0000-0001-6584-6179; High, Stephen/0000-0002-4532-8152	Biotechnology and Biological Sciences Research Council [BB/C500152/1, BBS/B/02398, SF16973] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abell BM, 2003, J BIOL CHEM, V278, P5669, DOI 10.1074/jbc.M209968200; Abell BM, 2004, EMBO J, V23, P2755, DOI 10.1038/sj.emboj.7600281; Alder NN, 2004, J BIOL CHEM, V279, P22787, DOI 10.1074/jbc.R400002200; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; Bause E, 1997, BIOCHEM J, V322, P95, DOI 10.1042/bj3220095; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; DYRKS T, 1992, FEBS LETT, V309, P20, DOI 10.1016/0014-5793(92)80730-5; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; Lecomte FJL, 2003, BIOCHEM SOC T, V31, P1248; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Meacock SL, 2002, MOL BIOL CELL, V13, P4114, DOI 10.1091/mbc.E02-04-0198; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Nikonov AV, 2002, J CELL BIOL, V158, P497, DOI 10.1083/jcb.200201116; Nilsson I, 2003, J CELL BIOL, V161, P715, DOI 10.1083/jcb.200301043; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; Santhamma KR, 2000, J BIOL CHEM, V275, P23253, DOI 10.1074/jbc.M000593200; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Yan G, 2002, J BIOL CHEM, V277, P47692, DOI 10.1074/jbc.M208136200; Yan Q, 1999, J BIOL CHEM, V274, P5021, DOI 10.1074/jbc.274.8.5021	38	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4195	4206		10.1074/jbc.M410329200	http://dx.doi.org/10.1074/jbc.M410329200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15556939	hybrid			2022-12-25	WOS:000227096600026
J	Sugatani, T; Hruska, KA				Sugatani, T; Hruska, KA			Akt1/Akt2 and mammalian target of rapamycin/bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE; HEMATOPOIETIC-CELLS; BAD PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FAMILY-MEMBER; APOPTOSIS; ACTIVATION; MICE; INHIBITION	Akt, also known as protein kinase B, is a serine/threonine protein kinase with antiapoptotic activities; also, it is a downstream target of phosphatidylinositol 3-kinase. Here we show that Akt1/Akt2 play a critical role in osteoclast differentiation but not cell survival and that mammalian target of rapamycin (mTOR) and Bim, a proapoptotic Bcl-2 family member, are required for cell survival in isolated osteoclast precursors. To investigate the function of Akt1, Akt2, mTOR, and Bim, we employed a retroviral system for delivery of small interfering RNA into cells. Loss of Akt1 and/or Akt2 protein inhibited osteoclast differentiation due to down-regulation of IkappaB-kinase (IKK) alpha/beta activity, phosphorylation of IkappaB-alpha, nuclear translocation of nuclear factor-kappaB (NFkappaB) p50, and NFkappaB p50 DNA-binding activity. Surprisingly, deletion of Akt1 and/or Akt2 protein did not stimulate cleaved caspase-3 activity and failed to promote apoptosis. Conversely, loss of mTOR protein induced apoptosis due to up-regulation of cleaved caspase-3 activity. In addition, we found that mTOR is downstream of phosphatidylinositol 3-kinase (but not Akt) and that macrophage colony-stimulating factor regulates Bim expression through mTOR activation for cell survival. These results demonstrate that Akt1/Akt2 are key elements in osteoclast differentiation and that the macrophage colony-stimulating factor stimulation of mTOR leading to Bim inhibition is essential for cell survival in isolated osteoclast precursors.	Washington Univ, Sch Med, Dept Pediat, Cell & Mol Biol Unit, St Louis, MO 63110 USA	Washington University (WUSTL)	Hruska, KA (corresponding author), Washington Univ, Sch Med, Dept Pediat, Cell & Mol Biol Unit, 5th Fl,McDonnell Pediat Res Bldg,Campus Box 8208, St Louis, MO 63110 USA.	hruska_k@kids.wustl.edu			NIAMS NIH HHS [AR41677] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041677] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285; Hinton HJ, 1999, J IMMUNOL, V162, P7002; HOSOI H, 1991, CANCER RES, V59, P886; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Ozaki K, 1997, FEBS LETT, V410, P297, DOI 10.1016/S0014-5793(97)00653-4; Ozes ON, 1999, NATURE, V401, P82; Panwalkar A, 2004, CANCER-AM CANCER SOC, V100, P657, DOI 10.1002/cncr.20026; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Sugatani T, 2003, J CELL BIOCHEM, V90, P59, DOI 10.1002/jcb.10613; Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	29	170	187	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3583	3589		10.1074/jbc.M410480200	http://dx.doi.org/10.1074/jbc.M410480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15545269	hybrid			2022-12-25	WOS:000226983900056
J	Esue, O; Cordero, M; Wirtz, D; Tseng, Y				Esue, O; Cordero, M; Wirtz, D; Tseng, Y			The assembly of MreB, a prokaryotic homolog of actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUBACTERIUM THERMOTOGA-MARITIMA; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; F-ACTIN; BACTERIAL CYTOSKELETON; LACTATE-DEHYDROGENASE; FILAMENT NETWORKS; DNA SEGREGATION; CELL-DIVISION; PROTEIN	MreB, a major component of the bacterial cytoskeleton, exhibits high structural homology to its eukaryotic counterpart actin. Live cell microscopy studies suggest that MreB molecules organize into large filamentous spirals that support the cell membrane and play a key shape-determining function. However, the basic properties of MreB filament assembly remain unknown. Here, we studied the assembly of Thermotoga maritima MreB triggered by ATP in vitro and compared it to the well-studied assembly of actin. These studies show that MreB filament ultrastructure and polymerization depend crucially on temperature as well as the ions present on solution. At the optimal growth temperature of T. maritima, MreB assembly proceeded much faster than that of actin, without nucleation (or nucleation is highly favorable and fast) and with little or no contribution from filament end-to-end annealing. MreB exhibited rates of ATP hydrolysis and phosphate release similar to that of F-actin, however, with a critical concentration of similar to3 nM, which is similar to100-fold lower than that of actin. Furthermore, MreB assembled into filamentous bundles that have the ability to spontaneously form ring-like structures without auxiliary proteins. These findings suggest that despite high structural homology, MreB and actin display significantly different assembly properties.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA	Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	wirtz@jhu.edu; yiider@jhu.edu	Wirtz, Denis/A-3257-2010	Cordero-Ricardo, Maria/0000-0002-8913-2370				Andrianantoandro E, 2001, J MOL BIOL, V312, P721, DOI 10.1006/jmbi.2001.5005; Ausmees N, 2003, CELL, V115, P705, DOI 10.1016/S0092-8674(03)00935-8; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Blanchoin L, 2002, BIOCHEMISTRY-US, V41, P597, DOI 10.1021/bi011214b; Carballido-Lopez R, 2003, DEV CELL, V4, P19, DOI 10.1016/S1534-5807(02)00403-3; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; Daniel RA, 2003, CELL, V113, P767, DOI 10.1016/S0092-8674(03)00421-5; Figge RM, 2004, MOL MICROBIOL, V51, P1321, DOI 10.1111/j.1365-2958.2003.03936.x; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HECHT K, 1989, EUR J BIOCHEM, V183, P69, DOI 10.1111/j.1432-1033.1989.tb14897.x; HECHT K, 1990, BIOL CHEM H-S, V371, P515, DOI 10.1515/bchm3.1990.371.1.515; Heidemann SR, 2004, TRENDS CELL BIOL, V14, P160, DOI 10.1016/j.tcb.2004.02.003; HIGGINS JS, 1994, POLYM NEUTRON SCATTE, P141; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; Itoh T, 1999, DNA Res, V6, P299, DOI 10.1093/dnares/6.5.299; Jensen RB, 1997, J MOL BIOL, V269, P505, DOI 10.1006/jmbi.1997.1061; Jensen RB, 1999, EMBO J, V18, P4076, DOI 10.1093/emboj/18.14.4076; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; Kole TP, 2004, MOL BIOL CELL, V15, P3475, DOI 10.1091/mbc.E04-03-0218; KOLE TP, 2004, IN PRESS MOL BIOL CE; Kruse T, 2003, EMBO J, V22, P5283, DOI 10.1093/emboj/cdg504; Lee DW, 2004, APPL ENVIRON MICROB, V70, P1397, DOI 10.1128/AEM.70.3.1397-1404.2004; Li FQ, 1997, J MOL CELL CARDIOL, V29, P1541, DOI 10.1006/jmcc.1997.0381; LONDEI P, 1988, J BACTERIOL, V170, P4353, DOI 10.1128/jb.170.9.4353-4360.1988; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; Moller-Jensen J, 2002, EMBO J, V21, P3119, DOI 10.1093/emboj/cdf320; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MURPHY DB, 1988, J CELL BIOL, V106, P1947, DOI 10.1083/jcb.106.6.1947; NISHIDA E, 1983, J BIOCHEM-TOKYO, V93, P1011, DOI 10.1093/oxfordjournals.jbchem.a134224; POLALRD TD, 2000, ANNU REV BIOPH BIOM, V29, P545; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Soufo HJD, 2003, CURR BIOL, V13, P1916, DOI 10.1016/j.cub.2003.10.024; Tseng Y, 2004, J BIOL CHEM, V279, P1819, DOI 10.1074/jbc.M306090200; Tseng Y, 2002, J BIOL CHEM, V277, P18143, DOI 10.1074/jbc.M110868200; Tseng Y, 2002, J BIOL CHEM, V277, P25609, DOI 10.1074/jbc.M202609200; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; van den Ent F, 2002, EMBO J, V21, P6935, DOI 10.1093/emboj/cdf672; van den Ent F, 2000, EMBO J, V19, P5300, DOI 10.1093/emboj/19.20.5300; WACHI M, 1989, J BACTERIOL, V171, P3123, DOI 10.1128/jb.171.6.3123-3127.1989; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7	45	96	98	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2628	2635		10.1074/jbc.M410298200	http://dx.doi.org/10.1074/jbc.M410298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548516	hybrid			2022-12-25	WOS:000226449100032
J	Humphries, KM; Deal, MS; Taylor, SS				Humphries, KM; Deal, MS; Taylor, SS			Enhanced dephosphorylation of cAMP-dependent protein kinase by oxidation and thiol modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; CATALYTIC SUBUNIT; HYDROGEN-PEROXIDE; C-ALPHA; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; PHOSPHATASE-2A; AUTOPHOSPHORYLATION; GLUTATHIONYLATION; IDENTIFICATION	The catalytic subunit of cAMP-dependent protein kinase (PKA) is phosphorylated at threonine 197 and serine 338. Phosphorylation of threonine 197, located in the activation loop, is required for coordinating the active site conformation and optimal enzymatic activity. However, this phosphorylation has not been widely appreciated as a regulatory site because of the apparent constitutive nature of the phosphorylation and the general resistance of the kinase to phosphatase treatment. We demonstrate here that the observed resistance of the catalytic subunit to dephosphorylation is due, in part, to the presence of the highly nucleophilic cysteine 199 located proximal to the phosphate on threonine 197. Experiments performed in vitro demonstrated that mutation (cysteine 199 to alanine), oxidation, such as by glutathionylation or internal disulfide bond formation, or alkylation of the C-subunit enhanced its ability to be dephosphorylated. Furthermore, rephosphorylation of reduced C-subunit by PDK1 created a cycle whereby the inactive kinase could be reactivated. To demonstrate that thiol modification of PKA can lead to enhanced dephosphorylation in vivo, PC12 cells were treated with N-ethylmaleimide (NEM). Such treatment resulted in complete PKA inactivation and dephosphorylation of threonine 197. This effect of NEM was contingent upon prior treatment of the cells with PKA activators, demonstrating the resistance of the holoenzyme to thiol alkylation-mediated dephosphorylation. Our results also demonstrated that NEM treatment of PC12 cells enhanced the dephosphorylation of the protein kinase Calpha activation loop, suggesting a common mechanism of regulation among members of the AGC family of kinases.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, CMM-W 125,9500 Gilman Dr, La Jolla, CA 92093 USA.	staylor@ucsd.edu		Humphries, Kenneth/0000-0002-6167-3175	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064991, R01GM019301, R37GM019301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64991, GM19301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; Brennan JP, 2004, J BIOL CHEM, V279, P41352, DOI 10.1074/jbc.M403827200; Cauthron RD, 1998, MOL CELL BIOL, V18, P1416, DOI 10.1128/MCB.18.3.1416; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Cho YS, 2000, P NATL ACAD SCI USA, V97, P835, DOI 10.1073/pnas.97.2.835; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Cvijic ME, 2000, CLIN CANCER RES, V6, P2309; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FIRST EA, 1989, BIOCHEMISTRY-US, V28, P3606, DOI 10.1021/bi00434a068; FIRST EA, 1989, BIOCHEMISTRY-US, V28, P3598, DOI 10.1021/bi00434a067; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; GAUDEMER Y, 1975, FEBS LETT, V54, P30, DOI 10.1016/0014-5793(75)81061-1; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Liauw S, 1996, J BIOL CHEM, V271, P258, DOI 10.1074/jbc.271.1.258; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; Macala LJ, 1998, KIDNEY INT, V54, P1746, DOI 10.1046/j.1523-1755.1998.00140.x; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Moore MJ, 2002, J BIOL CHEM, V277, P47878, DOI 10.1074/jbc.M204970200; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; NELSON NC, 1983, J BIOL CHEM, V258, P981; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; SHOJI S, 1979, J BIOL CHEM, V254, P6211; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; TONERWEBB J, 1992, J BIOL CHEM, V267, P25174; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; WEN W, 1994, J BIOL CHEM, V269, P32214; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; Zakany R, 2002, EXP CELL RES, V275, P1, DOI 10.1006/excr.2002.5487	46	108	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2750	2758		10.1074/jbc.M410242200	http://dx.doi.org/10.1074/jbc.M410242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15533936	hybrid			2022-12-25	WOS:000226449100048
J	Wilmann, PG; Petersen, J; Devenish, RJ; Prescott, M; Rossjohn, J				Wilmann, PG; Petersen, J; Devenish, RJ; Prescott, M; Rossjohn, J			Variations on the GFP chromophore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; ENTACMAEA-QUADRICOLOR; POCILLOPORIN PIGMENT; PURPLE CHROMOPROTEIN; CRYSTAL-STRUCTURE; ANEMONIA-SULCATA; FAMILY; CORAL; FRAGMENTATION; CYCLIZATION	We have determined to 2.1 Angstrom resolution the crystal structure of a dark state, kindling fluorescent protein isolated from the sea anemone, Anemonia sulcata. The chromophore sequence Met(63)-Tyr(64)-Gly(65) of the A. sulcata chromoprotein was previously proposed to comprise a 6-membered pyrazine-type heterocycle (Martynov, V. I., Savitsky, A. P., Martynova, N. Y., Savitsky, P. A., Lukyanov, K. A., and Lukyanov, S. A. (2001) J. Biol. Chem. 2 76, 21012-21016). However, our crystallographic data revealed the chromophore to comprise a 5-membered p-hydroxybenzylideneimidazolinone moiety that adopts a non-coplanar trans conformation within the interior of the GFP beta-can fold. Unexpectedly, fragmentation of the polypeptide was found to occur within the chromophore moiety, at the bond between Cys(62C) and Met(63N1) Our structural data reveal that fragmentation of the chromophore represents an intrinsic, autocatalytic step toward the formation of the mature chromophore within the specific GFP-like proteins.	Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Monash Ctr Synchrotron Sci, Prot Crystallog Unit, Clayton, Vic 3800, Australia	Monash University; Monash University	Prescott, M (corresponding author), Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.	Mark.Prescott@med.monash.edu.au; Jamie.rossjohn@med.monash.edu.au	Rossjohn, Jamie/F-9032-2013	Rossjohn, Jamie/0000-0002-2020-7522; Wilmann, Pascal/0000-0002-8376-5150				Beddoe T, 2003, ACTA CRYSTALLOGR D, V59, P597, DOI 10.1107/S0907444902023466; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chudakov DM, 2003, NAT BIOTECHNOL, V21, P191, DOI 10.1038/nbt778; Chudakov DM, 2003, J BIOL CHEM, V278, P7215, DOI 10.1074/jbc.M211988200; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; Lukyanov KA, 2000, J BIOL CHEM, V275, P25879, DOI 10.1074/jbc.C000338200; Martynov VI, 2001, J BIOL CHEM, V276, P21012, DOI 10.1074/jbc.M100500200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Matz MV, 2002, BIOESSAYS, V24, P953, DOI 10.1002/bies.10154; Mizuno H, 2003, MOL CELL, V12, P1051, DOI 10.1016/S1097-2765(03)00393-9; Petersen J, 2003, J BIOL CHEM, V278, P44626, DOI 10.1074/jbc.M307896200; Prescott M, 2003, STRUCTURE, V11, P275, DOI 10.1016/S0969-2126(03)00028-5; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; van Thor JJ, 2002, NAT STRUCT BIOL, V9, P37, DOI 10.1038/nsb739; Verkhusha VV, 2004, NAT BIOTECHNOL, V22, P289, DOI 10.1038/nbt943; Wall MA, 2000, NAT STRUCT BIOL, V7, P1133; Wiedenmann J, 2002, P NATL ACAD SCI USA, V99, P11646, DOI 10.1073/pnas.182157199; Zagranichny VE, 2004, BIOCHEMISTRY-US, V43, P13598, DOI 10.1021/bi0488247; Zagranichny VE, 2004, BIOCHEMISTRY-US, V43, P4764, DOI 10.1021/bi036059a	21	73	76	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2401	2404		10.1074/jbc.C400484200	http://dx.doi.org/10.1074/jbc.C400484200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15542608	hybrid			2022-12-25	WOS:000226449100003
J	Winkler, DG; Sutherland, MSK; Ojala, E; Turcott, E; Geoghegan, JC; Shpektor, D; Skonier, JE; Yu, CP; Latham, JA				Winkler, DG; Sutherland, MSK; Ojala, E; Turcott, E; Geoghegan, JC; Shpektor, D; Skonier, JE; Yu, CP; Latham, JA			Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; WNT; BMP; ANTAGONIST; CHONDROGENESIS; NOGGIN	High bone mass diseases are caused both by activating mutations in the Wnt pathway and by loss of SOST, a bone morphogenetic protein (BMP) antagonist, leading to the activation of BMP signaling. Given the phenotypic similarity between mutations that activate these signaling pathways, it seems likely that BMPs and Wnts operate in parallel or represent components of the same pathway, modulating osteoblast differentiation. In this study, we show that in C3H10T1/2 cells, Wnt-3A and BMP-6 proteins were inducers of osteoblast differentiation, as measured by alkaline phosphatase (ALP) induction. Surprisingly, sclerostin, noggin, and human BMP receptor 1A (BMPR1A)-FC fusion proteins blocked Wnt-3A-induced ALP as well as BMP-6-induced ALP activity. Dkk-1, a Wnt inhibitor, blocked Wnt-induced ALP activity but not BMP-induced ALP activity. Early Wnt-3A signaling as measured by beta-catenin accumulation was not affected by the BMP antagonists but was blocked by Dkk-1. Wnt-3A induced the appearance of BMP-4 mRNA 12 h prior to that of ALP in C3H10T1/2 cells. We propose that sclerostin and other BMP antagonists do not block Wnt signaling directly. Sclerostin blocks Wnt-induced ALP activity by blocking the activity of BMP proteins produced by Wnt treatment. The expression of BMP proteins in this autocrine loop is essential for Wnt-3A-induced osteoblast differentiation.	Celltech R&D Inc, Dept Gene Funct & Target Validat, Bothell, WA 98119 USA		Latham, JA (corresponding author), 2409 10th Ave W, Seattle, WA 98119 USA.	latham@alderbio.com						Agathon A, 2003, NATURE, V424, P448, DOI 10.1038/nature01822; AYSIANKRETCHMER O, 2003, MOL ENDOCRINOL, V2, P1; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; Barrantes ID, 2003, GENE DEV, V17, P2239, DOI 10.1101/gad.269103; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Merino R, 1999, DEVELOPMENT, V126, P5515; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shibamoto S, 1998, GENES CELLS, V3, P659; Soshnikova N, 2003, GENE DEV, V17, P1963, DOI 10.1101/gad.263003; Tsumaki N, 2002, J BONE MINER RES, V17, P898, DOI 10.1359/jbmr.2002.17.5.898; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Winkler DG, 2004, J BIOL CHEM, V279, P36293, DOI 10.1074/jbc.M400521200; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zhang DH, 2002, J BONE MINER RES, V17, P293, DOI 10.1359/jbmr.2002.17.2.293	23	135	167	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2498	2502		10.1074/jbc.M400524200	http://dx.doi.org/10.1074/jbc.M400524200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15545262	hybrid			2022-12-25	WOS:000226449100016
J	Bryan, KE; Rubenstein, PA				Bryan, KE; Rubenstein, PA			An intermediate form of ADP-F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-I RELEASE; DIVALENT-CATION; INORGANIC-PHOSPHATE; FILAMENT DYNAMICS; ARP2/3 COMPLEX; ATP HYDROLYSIS; TRYPTOPHAN FLUORESCENCE; CONFORMATIONAL-CHANGES; BERYLLIUM FLUORIDE; STRUCTURAL-CHANGES	With yeast actin, contrary to other actins, filament formation, ATP hydrolysis, and P-i release are concurrent at low actin concentrations, the condition usually employed to assess actin polymerization. This observation leads to a question concerning the conformation of the filament barbed end that might be recognized by specific actin-binding proteins. To try to detect possible new actin polymer conformations that might be intermediate in the pathway leading to mature F-actin, we monitored the change in intrinsic tryptophan fluorescence of yeast and muscle actins polymerized at pH 6 to accelerate the rate of filament formation. This allowed temporal resolution of the P-i release process from the slower process of polymerization. With both actins, we detected a biphasic instead of the usual monophasic fluorescence change, a rapid decrease that tracks with filament formation followed by a slower rebound ( the second phase). This second phase postpolymerization conformational change requires P-i release and occurs nearly coincident with its release. The addition of P-i causes this second phase response to disappear, and the inclusion of P-i during polymerization prevents its appearance. At pH 7.5, with higher yeast actin concentrations to accelerate polymerization, a two-phase fluorescence change is also observed. In this case, the second phase change lags substantially behind P-i release. P-i release could also be resolved from polymer formation. V159N yeast actin, hypothesized previously as remaining in a postpolymerization ATP-like state, exhibits the same two-phase intrinsic tryptophan fluorescence behavior as wild-type yeast actin. Together, these observations demonstrate the presence of an intermediate filament state between ADP-P-i and mature ADP-F-actin.	Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NIGMS NIH HHS [GM33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Belmont LD, 1998, J CELL BIOL, V142, P1289, DOI 10.1083/jcb.142.5.1289; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; Bobkov AA, 2004, J MOL BIOL, V337, P93, DOI 10.1016/j.jmb.2004.01.014; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Carlier MF, 1991, CURR OPIN CELL BIOL, V3, P12, DOI 10.1016/0955-0674(91)90160-Z; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; Cheng DM, 1999, J BIOL CHEM, V274, P35873, DOI 10.1074/jbc.274.50.35873; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; COOK RK, 1991, J BIOL CHEM, V266, P16825; Doyle TC, 2001, BIOPHYS J, V80, P427, DOI 10.1016/S0006-3495(01)76025-0; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; Frieden C, 2000, BIOCHEM BIOPH RES CO, V271, P464, DOI 10.1006/bbrc.2000.2650; Galkin VE, 2003, J CELL BIOL, V163, P1057, DOI 10.1083/jcb.200308144; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Gaszner B, 1999, BIOCHEMISTRY-US, V38, P12885, DOI 10.1021/bi990748y; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kim E, 1995, BIOPHYS J, V69, P2024, DOI 10.1016/S0006-3495(95)80072-X; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; Moraczewska J, 1996, BIOCHEM J, V317, P605, DOI 10.1042/bj3170605; Moraczewska J, 1999, BIOPHYS J, V77, P373, DOI 10.1016/S0006-3495(99)76896-7; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; POLLARD TD, 2002, CELL BIOL, P557; RICKARD JE, 1986, J MOL BIOL, V191, P273, DOI 10.1016/0022-2836(86)90264-0; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; Schuler H, 2001, BBA-PROTEIN STRUCT M, V1549, P137, DOI 10.1016/S0167-4838(01)00255-2; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SELDEN LA, 1994, ADV EXP MED BIOL, V358, P51; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; StrzeleckaGolaszewska H, 1996, BIOCHEM J, V316, P713, DOI 10.1042/bj3160713; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; Yao XY, 2001, J BIOL CHEM, V276, P25598, DOI 10.1074/jbc.M011797200; ZIMMERLE CT, 1988, BIOCHEMISTRY-US, V27, P7766, DOI 10.1021/bi00420a027	54	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1696	1703		10.1074/jbc.M410180200	http://dx.doi.org/10.1074/jbc.M410180200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536092	hybrid			2022-12-25	WOS:000226195200101
J	Raymond, JB; Mahapatra, S; Crick, DC; Pavelka, MS				Raymond, JB; Mahapatra, S; Crick, DC; Pavelka, MS			Identification of the namH gene, encoding the hydroxylase responsible for the N-glycolylation of the mycobacterial peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLYLMURAMIC ACID; ACETYLGLUCOSAMINE DEACETYLASE; TUBERCULOSIS; ARABINOGALACTAN; BIOSYNTHESIS; PRECURSOR; ALIGNMENT; PROTEIN; DAMAGE	The peptidoglycan of most bacteria consists of a repeating disaccharide unit of beta-1,4-linked N-acetylmuramic acid and N-acetylglucosamine. However, the muramic acid moieties of the mycobacterial peptidoglycan are N-glycolylated, not N-acetylated. This is a rare modification seen only in the peptidoglycan of mycobacteria and five other closely related genera of bacteria. The N-glycolylation of sialic acids is a unique carbohydrate modification that has been studied extensively in eukaryotes. However, the significance of the N-glycolylation of bacterial peptidoglycan is unknown. The goal of this project was to identify the gene encoding the hydroxylase responsible for the N-glycolylation of the mycobacterial peptidoglycan. We developed a novel assay for the mycobacterial UDP-N-acetylmuramic acid hydroxylation reaction and demonstrated that Mycobacterium smegmatis has an enzyme activity that can convert UDP-N-acetylmuramic acid to UDP-N-glycolylmuramic acid. We identified the gene namH encoding the mycobacterial UDP-N-acetylmuramic acid hydroxylase by computer data base searching and motif comparisons with the eukaryotic enzymes responsible for the N-glycolyation of sialic acids. The namH gene is not essential for in vitro growth as we were successful in deleting the gene in M. smegmatis. The M. smegmatis mutant is devoid of UDP-N-acetylmuramic acid hydroxylase activity and synthesizes only N-acetylated muropeptide precursors. Furthermore, the mutant exhibits increased susceptibility to beta-lactam antibiotics and lysozyme. Our studies suggest that the N-glycolylation of mycobacterial peptidoglycan may play a role in lysozyme resistance or may contribute to the structural stability of the cell wall architecture.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	University of Rochester; Colorado State University	Pavelka, MS (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	martin_pavelka@urmc.rochester.edu	Crick, Dean/H-8251-2017; Mahapatra, Sebabrata/D-6033-2017	Crick, Dean/0000-0001-9281-7058; 	NIAID NIH HHS [AI049151, T32 AI07362, AI47311] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047311, R56AI049151, T32AI007362, R01AI049151] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; AZUMA I, 1970, BIOCHIM BIOPHYS ACTA, V208, P444, DOI 10.1016/0304-4165(70)90217-5; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BURROUGHS M, 1993, J CLIN INVEST, V92, P297, DOI 10.1172/JCI116565; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Crick DC, 2001, GLYCOBIOLOGY, V11, p107R, DOI 10.1093/glycob/11.9.107R; DRAPER P, 1987, J GEN MICROBIOL, V133, P1187; ESSERS L, 1978, BIOCHIM BIOPHYS ACTA, V544, P180, DOI 10.1016/0304-4165(78)90221-0; FLOES AR, 2004, IN PRESS MICROBIOLOG; Fortune SM, 2004, J IMMUNOL, V172, P6272, DOI 10.4049/jimmunol.172.10.6272; GATEAU O, 1976, BIOCHIM BIOPHYS ACTA, V421, P395, DOI 10.1016/0304-4165(76)90305-6; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; HECKELS JE, 1988, BACTERIAL CELL SURFA, P82; HOLT J. G., 1994, BERGEYS MANUAL DETER, P597; LUKER KE, 1995, MOL MICROBIOL, V16, P733, DOI 10.1111/j.1365-2958.1995.tb02434.x; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MELLY MA, 1984, J INFECT DIS, V149, P378, DOI 10.1093/infdis/149.3.378; Miesel L, 1998, J BACTERIOL, V180, P2459, DOI 10.1128/JB.180.9.2459-2467.1998; Pavelka MS, 1996, J BACTERIOL, V178, P6496, DOI 10.1128/jb.178.22.6496-6507.1996; Pavelka MS, 1999, J BACTERIOL, V181, P4780, DOI 10.1128/JB.181.16.4780-4789.1999; PETIT JF, 1970, FEBS LETT, V6, P55, DOI 10.1016/0014-5793(70)80042-4; Raymond JB, 2003, FEMS MICROBIOL LETT, V229, P83, DOI 10.1016/S0378-1097(03)00793-6; Royet J, 2003, TRENDS CELL BIOL, V13, P610, DOI 10.1016/j.tcb.2003.10.003; Schlenzka W, 1996, FEBS LETT, V385, P197, DOI 10.1016/0014-5793(96)00384-5; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vollmer W, 2000, J BIOL CHEM, V275, P20496, DOI 10.1074/jbc.M910189199; Vollmer W, 2002, INFECT IMMUN, V70, P7176, DOI 10.1128/IAI.70.12.7176-7178.2002; Yagi T, 2003, J BIOL CHEM, V278, P26497, DOI 10.1074/jbc.M302216200	32	133	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					326	333		10.1074/jbc.M411006200	http://dx.doi.org/10.1074/jbc.M411006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15522883	hybrid			2022-12-25	WOS:000226025100040
J	Lim, JH; Lee, ES; You, HJ; Lee, JW; Park, JW; Chun, YS				Lim, JH; Lee, ES; You, HJ; Lee, JW; Park, JW; Chun, YS			Ras-dependent induction of HIF-1a(785) via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion	ONCOGENE			English	Article						HIF-1 alpha isoform; Ras signaling; phobol ester; EGF	INDUCIBLE FACTOR 1-ALPHA; OVEREXPRESSION; STABILIZATION; HIF-1-ALPHA; EXPRESSION; PROTEIN; TARGET; CELLS	Hypoxia-inducible factor-1alpha (HIF-1alpha) plays crucial roles in tumor promotion by transactivating approximately 60 kinds of its target genes. Recently, we reported a novel splice variant HIF-1alpha(785), which is regulated primarily by phorbol ester. This variant can be stabilized under normoxic conditions because it loses an acetylation site Lys532. Its expression was found to promote xenografted tumor growth in nude mice. We here found that the Ras oncogene regulates HIF-1alpha(785) expression via the Raf/MEK/ERK pathway, and that both phorbol ester and epidermal growth factor also induced HIF-1alpha(785) via the same pathway. We also identified the nonhypoxic regulatory domain responsible for phorbol ester-induced HIF-1alpha(785) expression. These results imply that HIF-1alpha(785) may play an important role in tumor promotion mediated by the Ras oncogene, phorbol ester or tumor growth factors.	Seoul Natl Univ, Coll Med, Human Genome Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; Chosun Univ, Coll Med, Dept Pharmacol, Kwangju 501759, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chosun University; Seoul National University (SNU)	Chun, YS (corresponding author), Seoul Natl Univ, Coll Med, Human Genome Res Inst, 28 Yongon Dong, Seoul 110799, South Korea.	chunys@snu.ac.kr	Park, Jong-Wan/J-2758-2012; Lee, Jung Weon/F-9149-2012; Lee, Jung Weon/AAC-1146-2020; Chun, Yang Sook/J-2789-2012	Lee, Jung Weon/0000-0003-2722-8200; 				Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Birner P, 2000, CANCER RES, V60, P4693; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Chun YS, 2003, CANCER RES, V63, P8700; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Chun YS, 2001, J CELL SCI, V114, P4051; Feldser D, 1999, CANCER RES, V59, P3915; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541	20	85	91	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9427	9431		10.1038/sj.onc.1208003	http://dx.doi.org/10.1038/sj.onc.1208003			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543236				2022-12-25	WOS:000225764100014
J	Chernova, MN; Jiang, LW; Friedman, DJ; Darman, RB; Lohi, H; Kere, J; Vandorpe, DH; Alper, SL				Chernova, MN; Jiang, LW; Friedman, DJ; Darman, RB; Lohi, H; Kere, J; Vandorpe, DH; Alper, SL			Functional comparison of mouse slc26a6 anion exchanger with human SLC26A6 polypeptide variants - Differences in anion selectivity, regulation, and electrogenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL CHLORIDE DIARRHEA; GUINEA-PIG PANCREAS; OUTER HAIR CELL; SENSITIVE FLUORESCENT INDICATORS; DEPENDENT HCO3-TRANSPORT; PENDRED-SYNDROME GENE; CYSTIC-FIBROSIS; XENOPUS OOCYTES; SULFATE TRANSPORTER; INTERLOBULAR DUCTS	The unusually low 78% amino acid identity between the orthologous human SLC26A6 and mouse slc26a6 polypeptides prompted systematic comparison of their anion transport functions in Xenopus oocytes. Multiple human SLC26A6 variant polypeptides were also functionally compared. Transport was studied as unidirectional fluxes of Cl-36(-), [C-14] oxalate, and [S-35] sulfate; as net fluxes of HCO3- by fluorescence ratio measurement of intracellular pH; as current by two-electrode voltage clamp; and as net Cl- flux by fluorescence intensity measurement of relative changes in extracellular and intracellular [Cl-]. Four human SLC26A6 polypeptide variants each exhibited rates of bidirectional [C-14] oxalate flux, Cl-/HCO3- exchange, and Cl-/OH- exchange nearly equivalent to those of mouse slc26a6. Cl-/HCO3- exchange by both orthologs was cAMP-sensitive, further enhanced by coexpressed wild type cystic fibrosis transmembrane regulator but inhibited by cystic fibrosis transmembrane regulator DeltaF508. However, the very low rates of Cl-36(-) and [S-35] sulfate transport by all active human SLC26A6 isoforms contrasted with the high rates of the mouse ortholog. Human and mouse orthologs also differed in patterns of acute regulation. Studies of human-mouse chimeras revealed cosegregation of the high Cl-36(-) transport phenotype with the transmembrane domain of mouse slc26a6. Mouse slc26a6 and human SLC26A6 each mediated electroneutral Cl-/HCO3- and Cl-/OH- exchange. In contrast, whereas Cl-/oxalate exchange by mouse slc26a6 was electrogenic, that mediated by human SLC26A6 appeared electroneutral. The increased currents observed in oocytes expressing either mouse or human ortholog were pharmacologically distinct from the accompanying monovalent anion exchange activities. The human SLC26A6 polypeptide variants SLC26A6c and SLC26A6d were inactive as transporters of oxalate, sulfate, and chloride. Thus, the orthologous mouse and human SLC26A6 proteins differ in anion selectivity, transport mechanism, and acute regulation, but both mediate electroneutral Cl-/HCO3- exchange.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Mol & Vasc Med Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Univ Helsinki, Dept Genet, FIN-00014 Helsinki, Finland; Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; University of Helsinki; Karolinska Institutet	Alper, SL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Mol & Vasc Med Unit, E-RW-763,330 Brookline Ave, Boston, MA 02215 USA.	salper@bidmc.harvard.edu	Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008; Lohi, Hannes/F-4596-2011	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Lohi, Hannes/0000-0003-1087-5532; Friedman, David/0000-0002-0301-9298	NHLBI NIH HHS [HL73112] Funding Source: Medline; NIDDK NIH HHS [DK43495] Funding Source: Medline; PHS HHS [34854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043495, R37DK043495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; Bennekou F, 2001, BLOOD, V97, P1451, DOI 10.1182/blood.V97.5.1451; BIWERSI J, 1994, ANAL BIOCHEM, V219, P139, DOI 10.1006/abio.1994.1242; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; Byeon MK, 1996, ONCOGENE, V12, P387; Casula S, 2001, J BIOL CHEM, V276, P41870, DOI 10.1074/jbc.M107155200; Chapman Jeannie M., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P990; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Chernova MN, 2003, AM J PHYSIOL-CELL PH, V284, pC1235, DOI 10.1152/ajpcell.00522.2002; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EVERETT LA, 2003, NAT GENET, V17, P215; Goss GG, 2001, AM J PHYSIOL-CELL PH, V281, pC1978, DOI 10.1152/ajpcell.2001.281.6.C1978; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; Humphreys BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1232, DOI 10.1152/ajpcell.1997.272.4.C1232; Ishiguro H, 2000, J PHYSIOL-LONDON, V528, P305, DOI 10.1111/j.1469-7793.2000.00305.x; Ishiguro H, 2004, J GEN PHYSIOL, V124, p28A; Ishiguro H, 2001, JOP, V2, P192; Ishiguro H, 2002, J GEN PHYSIOL, V120, P617, DOI 10.1085/jgp.20028631; Ishiguro H, 2002, J PHYSIOL-LONDON, V539, P175, DOI 10.1113/jphysiol.2001.012490; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; Jiang JJ, 2003, J APPL PHYSIOL, V94, P343, DOI 10.1152/japplphysiol.00562.2002; Jiang Z, 2002, J BIOL CHEM, V277, P33963, DOI 10.1074/jbc.M202660200; Knauf F, 2001, P NATL ACAD SCI USA, V98, P9425, DOI 10.1073/pnas.141241098; Ko SBH, 2004, NAT CELL BIOL, V6, P343, DOI 10.1038/ncb1115; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Kohn LD, 2001, TRENDS ENDOCRIN MET, V12, P10, DOI 10.1016/S1043-2760(00)00337-4; Liberman MC, 2002, NATURE, V419, P300, DOI 10.1038/nature01059; Liu XZ, 2003, HUM MOL GENET, V12, P1155, DOI 10.1093/hmg/ddg127; Loh SH, 2001, J BIOMED SCI, V8, P395, DOI 10.1007/BF02255948; Lohi H, 2003, AM J PHYSIOL-CELL PH, V284, pC769, DOI 10.1152/ajpcell.00270.2002; Lohi H, 2002, J BIOL CHEM, V277, P14246, DOI 10.1074/jbc.M111802200; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; Makela S, 2002, HUM MUTAT, V20, P425, DOI 10.1002/humu.10139; MANGOS JA, 1973, AM J PHYSIOL, V225, P18, DOI 10.1152/ajplegacy.1973.225.1.18; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Petrovic S, 2003, AM J PHYSIOL-CELL PH, V285, pC608, DOI 10.1152/ajpcell.00084.2003; Petrovic S, 2003, AM J PHYSIOL-GASTR L, V284, pG1093, DOI 10.1152/ajpgi.00454.2002; Reddy CM, 2002, J AM CHEM SOC, V124, P14526, DOI 10.1021/ja0284097; Royaux IE, 2001, P NATL ACAD SCI USA, V98, P4221, DOI 10.1073/pnas.071516798; Santos-Sacchi J, 2003, CURR OPIN NEUROBIOL, V13, P459, DOI 10.1016/S0959-4388(03)00100-4; Satoh H, 1998, J BIOL CHEM, V273, P12307, DOI 10.1074/jbc.273.20.12307; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; Shcheynikov N, 2004, J BIOL CHEM, V279, P21857, DOI 10.1074/jbc.M313323200; Sohma Y, 2001, JOP, V2, P198; Soleimani M, 2001, AM J PHYSIOL-RENAL, V280, pF356, DOI 10.1152/ajprenal.2001.280.2.F356; STEWARD MC, 2005, IN PRESS ANN REV PHY; Stewart AK, 2002, J GEN PHYSIOL, V120, P707, DOI 10.1085/jgp.20028641; Stewart AK, 2001, AM J PHYSIOL-CELL PH, V281, pC1344, DOI 10.1152/ajpcell.2001.281.4.C1344; Toure A, 2001, J BIOL CHEM, V276, P20309, DOI 10.1074/jbc.M011740200; VERKMAN AS, 1989, ANAL BIOCHEM, V178, P355, DOI 10.1016/0003-2697(89)90652-0; Verlander JW, 2003, HYPERTENSION, V42, P356, DOI 10.1161/01.HYP.0000088321.67254.B7; Vincourt JB, 2003, FASEB J, V17, P890, DOI 10.1096/fj.02-0787fje; Vincourt JB, 2002, GENOMICS, V79, P249, DOI 10.1006/geno.2002.6689; Waldegger S, 2001, GENOMICS, V72, P43, DOI 10.1006/geno.2000.6445; WANG Z, 2005, IN PRESS AM J PHYSL; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; Wangemann P, 2003, FASEB J, V17, pA465; Wright AM, 2004, J BIOL CHEM, V279, P41658, DOI 10.1074/jbc.M405517200; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002; Zhang Y, 1996, J BIOL CHEM, V271, P5741, DOI 10.1074/jbc.271.10.5741; Zhu BZ, 2002, FEBS LETT, V532, P80, DOI 10.1016/S0014-5793(02)03637-2	66	117	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8564	8580		10.1074/jbc.M411703200	http://dx.doi.org/10.1074/jbc.M411703200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15548529	hybrid			2022-12-25	WOS:000227395700133
J	Moreland, RJ; Jin, XY; Zhang, XK; Decker, RW; Albee, KL; Lee, KL; Cauthron, RD; Brewer, K; Edmunds, T; Canfield, WM				Moreland, RJ; Jin, XY; Zhang, XK; Decker, RW; Albee, KL; Lee, KL; Cauthron, RD; Brewer, K; Edmunds, T; Canfield, WM			Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE TYPE-II; HIGH-LEVEL PRODUCTION; GLYCOGENOSIS TYPE-II; POMPE-DISEASE; STORAGE; PURIFICATION; FIBROBLASTS; MUSCLE; ENZYME; LIVER	Pompe's disease is caused by a deficiency of the lysosomal enzyme acid a-glucosidase (GAA). GAA is synthesized as a 110-kDa precursor containing N-linked carbohydrates modified with mannose 6-phosphate groups. Following trafficking to the lysosome, presumably via the mannose 6-phosphate receptor, the 110-kDa precursor undergoes a series of complex proteolytic and N-glycan processing events, yielding major species of 76 and 70 kDa. During a detailed characterization of human placental and recombinant human GAA, we found that the peptides released during proteolytic processing remained tightly associated with the major species. The 76-kDa form (amino acids (aa) 122-782) of GAA is associated with peptides of 3.9 kDa (aa 78-113) and 19.4 kDa (aa 792-952). The 70-kDa form (aa 204-782) contains the 3.9- and 19.4-kDa peptide species as well as a 10.3-kDa species (aa 122-199). A similar set of proteolytic fragments has been identified in hamster GAA, suggesting that the multicomponent character is a general phenomenon. Rabbit anti-peptide antibodies have been generated against sequences in the proteolytic fragments and used to demonstrate the time course of uptake and processing of the recombinant GAA precursor in Pompe's disease fibroblasts. The results indicate that the observed fragments are produced intracellularly in the lysosome and not as a result of nonspecific proteolysis during purification. These data demonstrate that the mature forms of GAA characterized by polypeptides of 76 or 70 kDa are in fact larger molecular mass multicomponent enzyme complexes.	Genzyme Corp, Oklahoma City, OK 73104 USA; Genzyme Corp, Framingham, MA 01701 USA	Sanofi-Aventis; Genzyme Corporation; Sanofi-Aventis; Genzyme Corporation	Canfield, WM (corresponding author), Genzyme Corp, 800 Res Pkwy,Suite 200, Oklahoma City, OK 73104 USA.	william.canfield@genzyme.com						Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Bijvoet AGA, 1999, HUM MOL GENET, V8, P2145, DOI 10.1093/hmg/8.12.2145; Bijvoet AGA, 1998, HUM MOL GENET, V7, P1815, DOI 10.1093/hmg/7.11.1815; Bijvoet AGA, 1998, HUM MOL GENET, V7, P53, DOI 10.1093/hmg/7.1.53; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOERKOEL CF, 1995, AM J HUM GENET, V56, P887; CANFIELD WM, 2003, Patent No. 6642038; CHAMBERS JP, 1983, ENZYME, V29, P109, DOI 10.1159/000469615; ELFERINK RPJO, 1984, EUR J BIOCHEM, V139, P489, DOI 10.1111/j.1432-1033.1984.tb08032.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HERMANS MMP, 1993, BIOCHEM J, V289, P687, DOI 10.1042/bj2890687; Hirschhorn R, 2002, P NATL ACAD SCI USA, V99, P13642, DOI 10.1073/pnas.202383599; HIRSCHORN R, METABOLIC MOL BASES, P3389; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MARTINIUK F, 1984, ARCH BIOCHEM BIOPHYS, V231, P454, DOI 10.1016/0003-9861(84)90408-9; Martiniuk F, 2000, BIOCHEM BIOPH RES CO, V276, P917, DOI 10.1006/bbrc.2000.3555; MATSUI H, 1984, J BIOCHEM, V96, P993, DOI 10.1093/oxfordjournals.jbchem.a134958; MURRAY AK, 1978, ARCH BIOCHEM BIOPHYS, V185, P511, DOI 10.1016/0003-9861(78)90196-0; MUTSAERS JHGM, 1987, BIOCHIM BIOPHYS ACTA, V911, P244, DOI 10.1016/0167-4838(87)90014-8; Nilssen O, 1997, HUM MOL GENET, V6, P717, DOI 10.1093/hmg/6.5.717; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Raben N, 1998, J BIOL CHEM, V273, P19086, DOI 10.1074/jbc.273.30.19086; RADIN NS, 1989, BIOCHEM J, V264, P845, DOI 10.1042/bj2640845; REUSER AJJ, 1984, EXP CELL RES, V155, P178, DOI 10.1016/0014-4827(84)90779-1; SCHEIBE R, 1985, BIOMED BIOCHIM ACTA, V44, P1279; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWALLOW DM, 1975, ANN HUM GENET, V38, P391, DOI 10.1111/j.1469-1809.1975.tb00629.x; TASHIRO K, 1986, J BIOCHEM, V99, P693, DOI 10.1093/oxfordjournals.jbchem.a135528; Van Hove JLK, 1997, BIOCHEM MOL BIOL INT, V43, P613; VanHove JLK, 1996, P NATL ACAD SCI USA, V93, P65, DOI 10.1073/pnas.93.1.65; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223	32	93	119	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6780	6791		10.1074/jbc.M404008200	http://dx.doi.org/10.1074/jbc.M404008200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15520017	hybrid			2022-12-25	WOS:000227332700067
J	Kim, JE; Billadeau, DD; Chen, JJ				Kim, JE; Billadeau, DD; Chen, JJ			The tandem BRCT domains of Ect2 are required for both negative and positive regulation of Ect2 in cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE ACTIVITY; DBL HOMOLOGY DOMAIN; RHO-GTPASES; FAMILY; OLIGOMERIZATION; AUTOINHIBITION; MECHANISM; VAV	Epithelial cell transforming protein 2 (Ect2) is a guanine nucleotide exchange factor (GEF) for Rho GTPases, molecular switches essential for the control of cytokinesis in mammalian cells. Aside from the canonical Dbl homology/pleckstrin homology cassette found in virtually all Dbl family members, Ect2 contains N-terminal tandem BRCT domains. In this study, we address the role of the Ect2 BRCT domains in the regulation of Ect2 activity and cytokinesis. First, we show that the depletion of endogenous Ect2 by small interfering RNA induces multinucleation, suggesting that Ect2 is required for cytokinesis. In addition, we provide evidence that Ect2 normally exists in an inactive conformation, which is at least partially due to an intramolecular interaction between the BRCT domains and the C-terminal domain of Ect2. This intramolecular interaction masks the catalytic domain responsible for guanine nucleotide exchange toward RhoA. Consistent with a role in regulating Ect2 GEF activity, overexpression of an N-terminal Ect2 containing the tandem BRCT domains, but not single BRCT domain or BRCT domain mutant, leads to a failure in cytokinesis. Surprisingly, although ectopically expressed wild-type Ect2 rescues the multinucleation resulting from the depletion of endogenous Ect2, expression of a BRCT mutant of Ect2 failed to restore proper cytokinesis in these cells. Taken together, the results of our study indicate that the tandem BRCT domains of Ect2 play dual roles in the regulation of Ect2. Whereas these domains negatively regulate Ect2 GEF activity in interphase cells, they are also required for the proper function of Ect2 during cytokinesis.	Mayo Clin, Coll Med, Dept Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin, Coll Med, Dept Oncol Res, 200 1st St SW, Rochester, MN 55905 USA.	Chen.Junjie@mayo.edu	Kim, Ja-Eun/AAI-1896-2020	Kim, Ja-Eun/0000-0002-9132-1277				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Eisenhaure TM, 2003, J BIOL CHEM, V278, P30975, DOI 10.1074/jbc.M303277200; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Maddox AS, 2003, MOL CELL, V11, P846, DOI 10.1016/S1097-2765(03)00151-5; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Solski PA, 2004, J BIOL CHEM, V279, P25226, DOI 10.1074/jbc.M313792200; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001	31	82	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5733	5739		10.1074/jbc.M409298200	http://dx.doi.org/10.1074/jbc.M409298200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15545273	hybrid			2022-12-25	WOS:000227217100075
J	Beerens, N; Hoeijmakers, JHJ; Kanaar, R; Vermeulen, W; Wyman, C				Beerens, N; Hoeijmakers, JHJ; Kanaar, R; Vermeulen, W; Wyman, C			The CSB protein actively wraps DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR COUPLING FACTOR; RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; COCKAYNE-SYNDROME; FACTOR CSB/ERCC6; TRANSCRIPTION; COMPLEX; NUCLEOSOME; TRANSLOCATION; ELONGATION	The CSB protein is a member of the SWI2/SNF2 family of ATP-dependent chromatin remodeling factors and is essential for transcription-coupled DNA repair. The role of CSB in this DNA repair process is unclear, but the protein was found to remodel nucleosomes and alter DNA double helix conformation upon binding. Elucidating the nature of the change in DNA structure induced by CSB is of great interest for understanding the CSB mechanism of action. We analyzed the CSB.DNA complex by scanning force microscopy and measured a shortening of DNA contour length upon CSB binding in the presence of ATP. This DNA length reduction most likely results from DNA wrapping around the protein. Shorter DNA molecules were observed more frequently in the presence of non-hydrolyzable ATP analogues. These results suggest that DNA wrapping depends on ATP binding, whereas ATP hydrolysis results in unwrapping. We also provide evidence suggesting that CSB binds DNA as a dimer. DNA wrapping and unwrapping allows CSB to actively alter the DNA double helix conformation, which could influence nucleosomes and other protein-DNA interactions.	Erasmus MC, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Radiat Oncol, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Vermeulen, W (corresponding author), Erasmus MC, Dept Cell Biol & Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.	W.Vermeulen@erasmusMC.nl	Vermeulen, Wim/W-8708-2019; Hoeijmakers, Jan/AAX-6972-2021	Vermeulen, Wim/0000-0003-3616-734X; 				Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Becker PB, 2002, EMBO J, V21, P4749, DOI 10.1093/emboj/cdf486; Bradsher J, 2002, MOL CELL, V10, P819, DOI 10.1016/S1097-2765(02)00678-0; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Heddle JG, 2004, J MOL BIOL, V337, P597, DOI 10.1016/j.jmb.2004.01.049; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; Kosikov KM, 1999, J MOL BIOL, V289, P1301, DOI 10.1006/jmbi.1999.2798; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; Peterson CL, 2000, FEBS LETT, V476, P68, DOI 10.1016/S0014-5793(00)01673-2; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Rivetti C, 1998, J MOL BIOL, V280, P41, DOI 10.1006/jmbi.1998.1830; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; Svejstrup JQ, 2002, MOL CELL, V9, P1151, DOI 10.1016/S1097-2765(02)00553-1; Szczelkun M D, 2000, Essays Biochem, V35, P131; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; Tremeau-Bravard A, 2004, J BIOL CHEM, V279, P7751, DOI 10.1074/jbc.M309853200; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; van den Boom V, 2004, J CELL BIOL, V166, P27, DOI 10.1083/jcb.200401056; van den Boom V, 2002, BIOESSAYS, V24, P780, DOI 10.1002/bies.10150; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Verhoeven EEA, 2002, EMBO J, V21, P4196, DOI 10.1093/emboj/cdf396; Verhoeven EEA, 2001, EMBO J, V20, P601, DOI 10.1093/emboj/20.3.601; WHITE JH, 1988, SCIENCE, V241, P323, DOI 10.1126/science.3388041; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658	46	85	90	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4722	4729		10.1074/jbc.M409147200	http://dx.doi.org/10.1074/jbc.M409147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15548521	hybrid			2022-12-25	WOS:000227096600088
J	White, P; Brestelli, JE; Kaestner, KH; Greenbaum, LE				White, P; Brestelli, JE; Kaestner, KH; Greenbaum, LE			Identification of transcriptional networks during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; GENE-EXPRESSION; PARTIAL-HEPATECTOMY; ENDOCRINE PANCREAS; DNA-REPLICATION; MICE; RECEPTOR; GROWTH; AMINOPEPTIDASE; ORGANIZATION	The molecular analysis of mammalian cellular proliferation in vivo is limited in most organ systems by the low turnover and/or the asynchronous nature of cell cycle progression. A notable exception is the partial hepatectomy model, in which quiescent hepatocytes re-enter the cell cycle and progress in a synchronous fashion. Here we have exploited this model to identify regulatory networks operative in the mammalian cell cycle. We performed microarray-based expression profiling on livers 0-40 h post-hepatectomy corresponding to G(0), G(1), and S phases. Differentially expressed genes were identified using the statistical analysis program PaGE ((P) under bar(a) under bar tterns from (G) under bar ene (E) under bar xpression), which was highly accurate as confirmed by quantitative reverse transcription-PCR of randomly selected targets. A shift in the transcriptional program from genes involved in lipid and hormone biosynthesis in the quiescent liver to those contributing to cytoskeleton assembly and DNA synthesis in the proliferating liver was demonstrated by biological theme analysis. In a novel approach, we employed computational pathway analysis tools to identify specific regulatory networks operative at various stages of the cell cycle. This allowed us to identify a large cluster of genes controlling mitotic spindle assembly and checkpoint control at the 40-h time point as regulated at the mRNA level in vivo.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Greenbaum, LE (corresponding author), Univ Penn, Sch Med, Dept Med, 415 Curie Bldg,Clin Res Bldg 675A, Philadelphia, PA 19104 USA.	greenbal@rnail.med.upenn.edu	White, Peter/E-4301-2011	White, Peter/0000-0002-5218-5903	PHS HHS [R01-56669, U01-56947] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Arai M, 2003, J BIOL CHEM, V278, P29813, DOI 10.1074/jbc.M212648200; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; *COMP BIOL INF LAB, 2004, ALL GEN; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Cui XL, 2003, J BIOL CHEM, V278, P28677, DOI 10.1074/jbc.M300456200; Cui XL, 2003, J IMMUNOL, V171, P6814, DOI 10.4049/jimmunol.171.12.6814; Deguchi M, 2002, BIOCHEM BIOPH RES CO, V297, P59, DOI 10.1016/S0006-291X(02)02128-9; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Dudoit S, 2002, GENOME BIOL, V3; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fukuhara Y, 2003, J HEPATOL, V38, P784, DOI 10.1016/S0168-8278(03)00077-1; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Kaestner KH, 2003, DIABETES, V52, P1604, DOI 10.2337/diabetes.52.7.1604; Kitamura T, 2001, CELL STRUCT FUNCT, V26, P645, DOI 10.1247/csf.26.645; Koniaris LG, 2003, J AM COLL SURGEONS, V197, P634, DOI 10.1016/S1072-7515(03)00374-0; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; Liao YJ, 2004, J BIOL CHEM, V279, P43107, DOI 10.1074/jbc.M407969200; Locker J, 2003, HEPATOLOGY, V38, P314, DOI 10.1053/jhep.2003.50299; LOYER P, 1994, J BIOL CHEM, V269, P2491; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Manduchi E, 2000, BIOINFORMATICS, V16, P685, DOI 10.1093/bioinformatics/16.8.685; Manduchi E, 2004, BIOINFORMATICS, V20, P452, DOI 10.1093/bioinformatics/btg428; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; Piehl M, 2003, MOL BIOL CELL, V14, P916, DOI 10.1091/mbc.E02-09-0607; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Porter ACG, 2004, CHROMOSOME RES, V12, P569, DOI 10.1023/B:CHRO.0000036608.91085.d1; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; Scearce LM, 2002, DIABETES, V51, P1997, DOI 10.2337/diabetes.51.7.1997; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; Su AI, 2002, P NATL ACAD SCI USA, V99, P11181, DOI 10.1073/pnas.122359899; Su LK, 2001, GENOMICS, V71, P142, DOI 10.1006/geno.2000.6428; Taub R, 1999, SEMIN LIVER DIS, V19, P117, DOI 10.1055/s-2007-1007104; Tunquist BJ, 2003, J CELL BIOL, V163, P1231, DOI 10.1083/jcb.200306153; Van de Putte T, 2001, MECH DEVELOP, V102, P33, DOI 10.1016/S0925-4773(01)00279-9; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Weglarz TC, 2000, P NATL ACAD SCI USA, V97, P12595, DOI 10.1073/pnas.220430497; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	54	97	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3715	3722		10.1074/jbc.M410844200	http://dx.doi.org/10.1074/jbc.M410844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15546871	hybrid			2022-12-25	WOS:000226983900071
J	Gin, P; Clarke, CF				Gin, P; Clarke, CF			Genetic evidence for a multi-subunit complex in coenzyme Q biosynthesis in yeast and the role of the Coq1 hexaprenyl diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-METHYLTRANSFERASE STEPS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; UBIQUINONE BIOSYNTHESIS; STRUCTURAL GENE; CAENORHABDITIS-ELEGANS; FUNCTIONAL EXPRESSION; C-METHYLTRANSFERASE; CHAIN-LENGTH; SIDE-CHAIN	Coenzyme Q (Q) is a lipid that functions as an electron carrier in the mitochondrial respiratory chain in eukaryotes. There are eight complementation groups of Q-deficient Saccharomyces cerevisiae mutants designated coq1-coq8. Here we provide genetic evidence that several of the Coq polypeptides interact with one another. Deletions in any of the COQ genes affect the steady-state expression of Coq3p, Coq4p, and Coq6p. Antibodies that recognize Coq1p, a hexaprenyl diphosphate synthase, were generated and used to determine that Coq1p is peripherally associated with the inner membrane on the matrix side. Yeast Deltacoq1 mutants harboring diverse Coq1 orthologs from prokaryotic species produce distinct sizes of polyprenyl diphosphate and hence distinct isoforms of Q including Q(7), Q(8), Q(9), or Q(10) (Okada, K., Kainou, T., Matsuda, H., and Kawamukai, M. (1998) FEBS Lett. 431, 241-244). We find that steady-state levels of Coq3p, Coq4p, and Coq6p are rescued in some cases to near wild-type levels by the presence of these diverse Coq1 orthologs in the Deltacoq1 mutant. These data suggest that the lipid product of Coq1p or a Q-intermediate derived from polyprenyl diphosphate is involved in stabilizing the Coq3, Coq4, and Coq6 polypeptides.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr, Los Angeles, CA 90095 USA.	cathy@chem.ucla.edu			NIGMS NIH HHS [GM45952] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; Baba SW, 2004, J BIOL CHEM, V279, P10052, DOI 10.1074/jbc.M313712200; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; Belogrudov GI, 2001, ARCH BIOCHEM BIOPHYS, V392, P48, DOI 10.1006/abbi.2001.2448; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Burke D., 2000, METHODS YEAST GENETI; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; Forsgren M, 2004, BIOCHEM J, V382, P519, DOI 10.1042/BJ20040261; Geromel V, 2002, MOL GENET METAB, V77, P21, DOI 10.1016/S1096-7192(02)00145-2; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gille L, 2000, ARCH BIOCHEM BIOPHYS, V375, P347, DOI 10.1006/abbi.1999.1649; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; HOLLANDER R, 1975, INT J SYST BACTERIOL, V25, P102, DOI 10.1099/00207713-25-2-102; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jonassen T, 2003, J BIOL CHEM, V278, P51735, DOI 10.1074/jbc.M308760200; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; MELZER M, 1994, BBA-LIPID LIPID MET, V1212, P93, DOI 10.1016/0005-2760(94)90193-7; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Okada K, 1996, BBA-LIPID LIPID MET, V1302, P217, DOI 10.1016/0005-2760(96)00064-1; Okada K, 1998, FEBS LETT, V431, P241, DOI 10.1016/S0014-5793(98)00753-4; Okada K, 1997, J BACTERIOL, V179, P5992, DOI 10.1128/jb.179.19.5992-5998.1997; Padilla S, 2004, J BIOL CHEM, V279, P25995, DOI 10.1074/jbc.M400001200; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; POON WW, 1997, MOL ASPECTS MED, V18, P121; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; SIKORSKI RS, 1989, GENETICS, V122, P19; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; THURL S, 1986, BIOL CHEM H-S, V367, P191, DOI 10.1515/bchm3.1986.367.1.191; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	41	62	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2676	2681		10.1074/jbc.M411527200	http://dx.doi.org/10.1074/jbc.M411527200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548532	hybrid			2022-12-25	WOS:000226449100038
J	Nie, M; Corbett, L; Knox, AJ; Pang, LH				Nie, M; Corbett, L; Knox, AJ; Pang, LH			Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists - Interactions with glucocorticoids and beta(2)-agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CHEMOATTRACTANT PROTEIN-1 GENE; STEROID-HORMONE RECEPTORS; HISTONE H4 ACETYLATION; PPAR-GAMMA; TRANSCRIPTION FACTORS; ACETYLTRANSFERASE ACTIVITY; CHROMATIN-STRUCTURE	Chemokine-mediated inflammatory cell infiltration is a hallmark of asthma. We recently demonstrated that glucocorticoids and beta(2)-agonists additively or synergistically suppress tumor necrosis factor-alpha (TNFalpha)-induced production of chemokines eotaxin and interleukin-8 (IL-8), respectively, in human airway smooth muscle (HASM) cells, which may partly explain their combined benefits in asthma. Peroxisome proliferator-activated receptors (PPARs) also modulate inflammatory gene expression. We reported here that the PPARgamma agonists 15-deoxy-Delta(12,14)- PGJ(2) (15d-PGJ(2)) and troglitazone, but not PPARalpha agonist VVY-14643, inhibited TNFalpha-induced production of eotaxiin and monocyte chemotactic protein-1 (MCP-1) but not IL-8. Eotaxin inhibition was transcriptional and additively enhanced by the glucocorticoid fluticasone and the beta(2)-agonist salmeterol, whereas MCP-1 inhibition was post-transcriptional and additively and synergistically enhanced by fluticasone and salmeterol, respectively. Coinununoprecipitation revealed that 15d-PGJ2 induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol. 15d-PGJ2, fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay. Our data suggest that chemokine expression in HASM cells is differentially regulated by PPARgamma agonists and that the interaction between PPARgamma and GR may be responsible for the additive and synergistic inhibition of chemokine expression by PPARgamma agonists, glucocorticoids, and beta(2)-agonists, particularly the chromatin-dependent suppression of eotaxin gene transcription. The interaction may have wide applications and may provide a potential target for pharmacological and molecular intervention.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Pang, LH (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	linhua.pang@nottingham.ac.uk		Knox, Alan/0000-0002-5906-4143				BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Beato M, 1996, J MOL MED, V74, P711, DOI 10.1007/s001090050076; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P550, DOI 10.1046/j.1365-2222.2003.01636.x; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen F, 2003, J CELL BIOCHEM, V90, P732, DOI 10.1002/jcb.10668; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2004, MOL CELL, V13, P459, DOI 10.1016/S1097-2765(04)00093-0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hallsworth MP, 2001, BRIT J PHARMACOL, V132, P729, DOI 10.1038/sj.bjp.0703866; Harris SG, 2002, J IMMUNOL, V168, P1372, DOI 10.4049/jimmunol.168.3.1372; Imaizumi T, 2003, PROSTAG OTH LIPID M, V71, P293, DOI 10.1016/S1098-8823(03)00051-0; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Johnson TE, 1999, ENDOCRINOLOGY, V140, P3245, DOI 10.1210/en.140.7.3245; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kardassis D, 2002, BIOCHEMISTRY-US, V41, P1217, DOI 10.1021/bi015618f; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Matsukura S, 1999, J IMMUNOL, V163, P6876; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Nie M, 2003, MOL CELL BIOL, V23, P9233, DOI 10.1128/MCB.23.24.9233-9244.2003; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 2003, J IMMUNOL, V170, P1043, DOI 10.4049/jimmunol.170.2.1043; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Patel HJ, 2003, J IMMUNOL, V170, P2663, DOI 10.4049/jimmunol.170.5.2663; Pinkenburg O, 2004, J VIROL METHODS, V120, P119, DOI 10.1016/j.jviromet.2004.04.007; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Wuyts WA, 2003, EUR RESPIR J, V22, P220, DOI 10.1183/09031936.03.00112002; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104	53	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2550	2561		10.1074/jbc.M410616200	http://dx.doi.org/10.1074/jbc.M410616200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15531761	hybrid			2022-12-25	WOS:000226449100023
J	Chamot, D; Colvin, KR; Kujat-Choy, SL; Owttrim, GW				Chamot, D; Colvin, KR; Kujat-Choy, SL; Owttrim, GW			RNA structural rearrangement via unwinding and annealing by the cyanobacterial RNA helicase, CrhR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAD-BOX PROTEINS; SACCHAROMYCES-CEREVISIAE; TRANSLATION INITIATION; MACROMOLECULAR MACHINES; BRANCH MIGRATION; ATP HYDROLYSIS; IN-VIVO; P68; REDUCTION; DBPA	Rearrangement of RNA secondary structure is crucial for numerous biological processes. RNA helicases participate in these rearrangements through the unwinding of duplex RNA. We report here that the redox-regulated cyanobacterial RNA helicase, CrhR, is a bona fide RNA helicase possessing both RNA-stimulated ATPase and bidirectional ATP-stimulated RNA helicase activity. The processivity of the unwinding reaction appears to be low, because RNA substrates containing duplex regions of 41 bp are not unwound. CrhR also catalyzes the annealing of complementary RNA into intermolecular duplexes. Uniquely and in contrast to other proteins that perform annealing, the CrhR-catalyzed reactions require ATP hydrolysis. Through a combination of the unwinding and annealing activities, CrhR also catalyzes RNA strand exchange resulting in the formation of RNA secondary structures that are too stable to be resolved by helicase activity. RNA strand exchange most probably occurs through the CrhR-dependent formation and resolution of an RNA branch migration structure. Demonstration that another cyanobacterial RNA helicase, CrhC, does not catalyze annealing indicates that this activity is not a general biochemical characteristic of RNA helicases. Biochemically, CrhR resembles RecA and related proteins that catalyze strand exchange and branch migration on DNA substrates, a characteristic that is reflected in the recently reported structural similarities between these proteins. The data indicate the potential for CrhR to catalyze dynamic RNA secondary structure rearrangements through a combination of RNA helicase and annealing activities.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Owttrim, GW (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.	g.owttrim@ualberta.ca	Owttrim, George/L-4605-2013	Owttrim, George/0000-0002-4709-2091				Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; BELKIN S, 1987, PLANT PHYSIOL, V84, P25, DOI 10.1104/pp.84.1.25; BLUM S, 1992, P NATL ACAD SCI USA, V89, P7664, DOI 10.1073/pnas.89.16.7664; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; El-Fahmawi B, 2003, MOL MICROBIOL, V50, P1439, DOI 10.1046/j.1365-2958.2003.03783.x; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Forti G, 2003, PLANT PHYSIOL, V132, P1464, DOI 10.1104/pp.102.018861; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Huang YL, 2002, J BIOL CHEM, V277, P12810, DOI 10.1074/jbc.M200182200; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Kaneko T, 1996, DNA Res, V3, P109; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kujat SL, 2000, PLANT PHYSIOL, V124, P703, DOI 10.1104/pp.124.2.703; Lamm GM, 1996, NUCLEIC ACIDS RES, V24, P3739, DOI 10.1093/nar/24.19.3739; NICOL SM, 1995, P NATL ACAD SCI USA, V92, P11681, DOI 10.1073/pnas.92.25.11681; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; Raghunathan PL, 1998, SCIENCE, V279, P857, DOI 10.1126/science.279.5352.857; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rossler OG, 2001, NUCLEIC ACIDS RES, V29, P2088, DOI 10.1093/nar/29.10.2088; Savitch LV, 2001, PLANTA, V214, P295, DOI 10.1007/s004250100622; Schroeder R, 2002, CURR OPIN STRUC BIOL, V12, P296, DOI 10.1016/S0959-440X(02)00325-1; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tsu CA, 1998, BIOCHEMISTRY-US, V37, P16989, DOI 10.1021/bi981837y; Valdez BC, 1997, EUR J BIOCHEM, V250, P800, DOI 10.1111/j.1432-1033.1997.00800.x; Vinnemeier J, 1999, ARCH MICROBIOL, V172, P377, DOI 10.1007/s002030050774; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Yu E, 2000, NUCLEIC ACIDS RES, V28, P3926, DOI 10.1093/nar/28.20.3926	33	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2036	2044		10.1074/jbc.M409700200	http://dx.doi.org/10.1074/jbc.M409700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542859	hybrid			2022-12-25	WOS:000226341700038
J	Maga, G; Ramadan, K; Locatelli, GA; Shevelev, I; Spadari, S; Hubscher, U				Maga, G; Ramadan, K; Locatelli, GA; Shevelev, I; Spadari, S; Hubscher, U			DNA elongation by the human DNA polymerase lambda polymerase and terminal transferase activities are differentially coordinated by proliferating cell nuclear antigen and replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYNUCLEOTIDYL TRANSFERASE; HOMOPOLYMER TRACTS; REPAIR; IDENTIFICATION; BIOCHEMISTRY; BINDING; MU; FRAGMENTS; MECHANISM; COMPLEX	DNA polymerase lambda contains template-dependent (DNA polymerase) and template-independent ( terminal transferase) activities. In this study we enzymologically characterized the terminal transferase activity of polymerase lambda (pol lambda-tdt). Pol lambda-tdt activity was strongly influenced by the nature of the 3'-terminal sequence of the DNA substrate, and it required a single-stranded (ss) DNA 3'-overhang of about 9-12 nucleotides for optimal activity. The strong preference observed for pyrimidine versus purine nucleotide incorporation was found to be due, at least partially, to a steric block imposed by the residue Tyr-505 in the active site of pol lambda. Pol lambda-tdt was found to be able to elongate a 3'-ssDNA end by two alternative mechanisms: first, a template-independent one resulting in addition of 1 or 2 nucleotides, and second, a template-dependent one where a homopolymeric tract as short as 3 nucleotides at the 3'-end could be used as a template to direct DNA polymerization by a looping back mechanism. Furthermore repetitive cycles of DNA synthesis resulted in the expansion of such a short homopolymeric terminal sequence. Most importantly we found that the proliferating cell nuclear antigen was able to selectively block the looping back mechanism while stimulating the single terminal nucleotide addition. Finally replication protein A completely suppressed the transferase activity of pol lambda while stimulating the polymerase activity, suggesting that proliferating cell nuclear antigen and replication protein A can coordinate the polymerase and the terminal transferase activities of pol lambda.	CNR, Ist Genet Mol, I-27100 Pavia, Italy; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Zurich	Maga, G (corresponding author), CNR, Ist Genet Mol, Via Abbiategrasso 207, I-27100 Pavia, Italy.	maga@igm.cnr.it	Maga, Giovanni/C-5409-2009	Maga, Giovanni/0000-0001-8092-1552				Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Blanca G, 2004, BIOCHEMISTRY-US, V43, P11605, DOI 10.1021/bi049050x; Blanca G, 2003, BIOCHEMISTRY-US, V42, P7467, DOI 10.1021/bi034198m; Covo S, 2004, J BIOL CHEM, V279, P859, DOI 10.1074/jbc.M310447200; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; DIXON M, 1979, ENZYMES, P182; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Fan W, 2004, BIOCHEM BIOPH RES CO, V323, P1328, DOI 10.1016/j.bbrc.2004.09.002; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Maga G, 2004, FASEB J, V18, P1743, DOI 10.1096/fj.04-2268fje; Maga G, 2002, J BIOL CHEM, V277, P48434, DOI 10.1074/jbc.M206889200; PANDEY V, 1987, BIOCHEMISTRY-US, V26, P2033, DOI 10.1021/bi00381a036; PANDEY V, 1988, J BIOL CHEM, V263, P3744; PANDEY VN, 1989, J BIOL CHEM, V264, P867; Ramadan K, 2004, J MOL BIOL, V339, P395, DOI 10.1016/j.jmb.2004.03.056; ROYCHOUDHURY R, 1976, NUCLEIC ACIDS RES, V3, P863, DOI 10.1093/nar/3.4.863; ROYCHOUDHURY R, 1976, NUCLEIC ACIDS RES, V3, P101, DOI 10.1093/nar/3.1.101; Shevelev I, 2003, NUCLEIC ACIDS RES, V31, P6916, DOI 10.1093/nar/gkg896; Vo NV, 2004, BIOCHEMISTRY-US, V43, P10579, DOI 10.1021/bi049773g; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003	28	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1971	1981		10.1074/jbc.M411650200	http://dx.doi.org/10.1074/jbc.M411650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537631	Green Published, hybrid			2022-12-25	WOS:000226341700031
J	Marella, M; Gaggioli, C; Batoz, M; Deckert, M; Tartare-Deckert, S; Chabry, J				Marella, M; Gaggioli, C; Batoz, M; Deckert, M; Tartare-Deckert, S; Chabry, J			Pathological prion protein exposure switches on neuronal mitogen-activated protein kinase pathway resulting in microglia recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; MAP KINASE; LAMININ RECEPTOR; SPONGIFORM ENCEPHALOPATHIES; SCRAPIE; EGR-1; TRANSCRIPTION; INHIBITION; STRESS; CELLS	Transmissible spongiform encephalopathies are accompanied by the recruitment of microglial cells in the vicinity of amyloid aggregates of the pathological prion protein (PrPres). We previously showed that PrPres itself triggered the recruitment of microglia by interacting with neurons leading to the up-regulation of the expression level of chemokines, mainly RANTES (regulated on activation normal T cell expressed and secreted). The intracellular mechanisms underlying the PrPres-inducible expression of chemokines in this setting are not clear. Here we demonstrate that the mitogen-activated protein kinase pathway is switched on shortly after PrPres exposure to neurons leading to the expression of early growth response factor-1 (Egr-1), a transcription factor initially linked to differentiation and growth and to up-regulation of RANTES mRNA expression. PD98059, a selective inhibitor of extracellular signal-regulated kinase1/2 activation, resulted in a decrease of RANTES mRNA expression and as a consequence to the lowering of microglial cell migration. Neuronal overexpression of Nab2, a corepressor of Egr-1, produced similar effects. PrPres-induced chemoattraction is independent of the presence of PrPc and the laminin receptor on the neuronal cell surface. Our report is the first demonstration that PrPres exposure on neurons results in the activation of the MAP kinase signaling pathway that acts as a master switch to trigger neuronal expression of regulators of chemoattraction.	CNRS, Inst Pharmacol Mol & Cellulaire, Unite Mixte Rech 6097, F-06560 Valbonne, France; Fac Med, INSERM, U597, F-06107 Nice 02, France; Hop Archet, INSERM, U576, F-06202 Nice 03, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Chabry, J (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, Unite Mixte Rech 6097, 660 Route Lucioles, F-06560 Valbonne, France.	chabry@ipmc.cnrs.fr	Gaggioli, Cedric/Q-2642-2019; Gaggioli, Cedric/F-3658-2011; Deckert, Marcel/M-4998-2016; Chabry, Joelle/O-2101-2016; TARTARE-DECKERT, Sophie/P-6057-2015; Deckert, Marcel/T-3566-2019; gaggioli, cedric/L-5363-2019	Gaggioli, Cedric/0000-0002-4710-1605; Gaggioli, Cedric/0000-0002-4710-1605; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Deckert, Marcel/0000-0003-2094-559X; 				Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; Baker CA, 1999, J VIROL, V73, P5089, DOI 10.1128/JVI.73.6.5089-5097.1999; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Baker CA, 2002, J VIROL, V76, P10905, DOI 10.1128/JVI.76.21.10905-10913.2002; Brown DR, 1997, HISTOL HISTOPATHOL, V12, P883; Brown DR, 2001, MICROSC RES TECHNIQ, V54, P71, DOI 10.1002/jemt.1122; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Chesebro B, 2003, BRIT MED BULL, V66, P1, DOI 10.1093/bmb/66.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen DM, 1996, P NATL ACAD SCI USA, V93, P11242, DOI 10.1073/pnas.93.20.11242; Combs CK, 1999, J NEUROSCI, V19, P928; Ehrengruber MU, 2000, GENE, V258, P63, DOI 10.1016/S0378-1119(00)00445-5; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GUIROY DC, 1994, ACTA NEUROPATHOL, V87, P526; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Hughes PM, 2002, GLIA, V37, P314, DOI 10.1002/glia.10037; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; Leucht C, 2003, EMBO REP, V4, P290, DOI 10.1038/sj.embor.embor768; Marella M, 2004, J NEUROSCI, V24, P620, DOI 10.1523/JNEUROSCI.4303-03.2004; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MIYAZONO M, 1991, AM J PATHOL, V139, P589; Muhleisen H, 1995, NEUROPATH APPL NEURO, V21, P505, DOI 10.1111/j.1365-2990.1995.tb01097.x; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Ostlund P, 2001, MOL BRAIN RES, V97, P161, DOI 10.1016/S0169-328X(01)00316-3; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; PORTER DD, 1973, J IMMUNOL, V111, P1407; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Rezaie P, 2001, BRAIN RES REV, V35, P55, DOI 10.1016/S0165-0173(01)00042-X; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Williams A, 1997, EXP NEUROL, V144, P433, DOI 10.1006/exnr.1997.6424; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426; Zielasek J, 1996, ADV NEUROIMMUNOL, V6, P191, DOI 10.1016/0960-5428(96)00017-4	46	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1529	1534		10.1074/jbc.M410966200	http://dx.doi.org/10.1074/jbc.M410966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528202	hybrid			2022-12-25	WOS:000226195200083
J	Yi, FH; Brubaker, PL; Jin, TR				Yi, FH; Brubaker, PL; Jin, TR			TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; GLYCOGEN-SYNTHASE KINASE-3; PANCREATIC-ISLET CELLS; AMP-RESPONSIVE ELEMENT; TRANSCRIPTIONAL ACTIVATION; LITHIUM-CHLORIDE; PROMOTER ELEMENT; PROTEIN CDX-2/3; MOUSE PANCREAS; 7-36 AMIDE	The proglucagon gene (glu) encodes glucagon, expressed in pancreatic islets, and the insulinotropic hormone GLP-1, expressed in the intestines. These two hormones exert critical and opposite effects on blood glucose homeostasis. An intriguing question that remains to be answered is whether and how glu gene expression is regulated in a cell type-specific manner. We reported previously that the glu gene promoter in gut endocrine cell lines was stimulated by beta-catenin, the major effector of the Wnt signaling pathway, whereas glu mRNA expression and GLP-1 synthesis were activated via inhibition of glycogen synthase kinase-3beta, the major negative modulator of the Wnt pathway (Ni, Z., Anini, Y., Fang, X., Mills, G. B., Brubaker, P. L., & Jin, T. (2003) J. Biol. Chem. 278, 1380-1387). We now show that beta-catenin and the glycogen synthase kinase-3beta inhibitor lithium do not activate glu mRNA or glu promoter expression in pancreatic cell lines. In the intestinal GLUTag cell line, but not in the pancreatic InR1-G9 cell line, the glu promoter G2 enhancer-element was activated by lithium treatment via a TCF-binding motif. TCF-4 is abundantly expressed in the gut but not in pancreatic islets. Furthermore, both TCF-4 and beta-catenin bind to the glu gene promoter, as detected by chromatin immunoprecipitation. Finally, stable introduction of dominant-negative TCF-4 into the GLUTag cell line repressed basal glu mRNA expression and abolished the effect of lithium on glu mRNA expression and GLP-1 synthesis. We have therefore identified a unique mechanism that regulates glu expression in gut endocrine cells only. Tissue-specific expression of TCF factors thus may play a role in the diversity of the Wnt pathway.	Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Jin, TR (corresponding author), Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Rm 421,67 Coll St, Toronto, ON M5G 2M1, Canada.	tianru.jin@utoronto.ca						Anini Y, 2002, ENDOCRINOLOGY, V143, P2420, DOI 10.1210/en.143.6.2420; Bertrand JA, 2003, J MOL BIOL, V333, P393, DOI 10.1016/j.jmb.2003.08.031; Bode HP, 1999, PFLUG ARCH EUR J PHY, V437, P324, DOI 10.1007/s004240050786; Brubaker PL, 1998, ENDOCRINOLOGY, V139, P4108, DOI 10.1210/en.139.10.4108; Chertow BS, 1996, METABOLISM, V45, P300, DOI 10.1016/S0026-0495(96)90282-6; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; Drucker DJ, 2002, GASTROENTEROLOGY, V122, P531, DOI 10.1053/gast.2002.31068; DRUCKER DJ, 1994, MOL ENDOCRINOL, V8, P1646, DOI 10.1210/me.8.12.1646; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; FLOCK G, 2005, IN PRESS ENDOCRINOLO; GAJIC D, 1993, ENDOCRINOLOGY, V132, P1055, DOI 10.1210/en.132.3.1055; Gevrey JC, 2004, DIABETOLOGIA, V47, P926, DOI 10.1007/s00125-004-1380-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Hussain MA, 2002, J BIOL CHEM, V277, P16028, DOI 10.1074/jbc.M107124200; JIN T, 1995, MOL ENDOCRINOL, V9, P1306, DOI 10.1210/me.9.10.1306; Jin TR, 1996, MOL CELL BIOL, V16, P19; Jin TR, 1997, MOL ENDOCRINOL, V11, P203, DOI 10.1210/me.11.2.203; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lu F, 1996, ENDOCRINOLOGY, V137, P3710, DOI 10.1210/en.137.9.3710; MCCANN MJ, 1989, AM J PHYSIOL, V256, pR463, DOI 10.1152/ajpregu.1989.256.2.R463; Meeran K, 1999, ENDOCRINOLOGY, V140, P244, DOI 10.1210/en.140.1.244; MontroseRafizadeh C, 1997, J BIOL CHEM, V272, P21201, DOI 10.1074/jbc.272.34.21201; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Ni ZY, 2003, J BIOL CHEM, V278, P1380, DOI 10.1074/jbc.M206006200; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; ONE J, 1986, DIABETES RES CLIN PR, V2, P29; Peters CT, 2001, J NUTR, V131, P2164, DOI 10.1093/jn/131.8.2164; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Rinaman L, 1999, AM J PHYSIOL-REG I, V277, pR1537, DOI 10.1152/ajpregu.1999.277.5.R1537; RITTER S, 1980, BRAIN RES, V201, P501, DOI 10.1016/0006-8993(80)91061-6; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; Seeley RJ, 2000, J NEUROSCI, V20, P1616; Shih DQ, 1999, P NATL ACAD SCI USA, V96, P10152, DOI 10.1073/pnas.96.18.10152; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Steiner DF, 1996, DIABETES METAB, V22, P94; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Thiele TE, 1998, BRAIN RES, V801, P164, DOI 10.1016/S0006-8993(98)00584-8; Trinh DKY, 2003, DIABETES, V52, P425, DOI 10.2337/diabetes.52.2.425; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; van Dijk G, 1999, NEUROPEPTIDES, V33, P406; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Wang J, 2003, J BIOL CHEM, V278, P32899, DOI 10.1074/jbc.M305456200; WANG M, 1994, ENDOCRINOLOGY, V134, P1416, DOI 10.1210/en.134.3.1416; Webb GC, 2004, J BIOL CHEM, V279, P31068, DOI 10.1074/jbc.M404110200; Wojdemann M, 1998, SCAND J GASTROENTERO, V33, P828; YI F, 2003, CANCER RES, V63, P2823	62	328	350	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1457	1464		10.1074/jbc.M411487200	http://dx.doi.org/10.1074/jbc.M411487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15525634	hybrid			2022-12-25	WOS:000226195200074
J	Maeta, K; Izawa, S; Inoue, Y				Maeta, K; Izawa, S; Inoue, Y			Methylglyoxal, a metabolite derived from glycolysis, functions as a signal initiator of the high osmolarity glycerol-mitogen-activated protein kinase cascade and Calcineurin/Crz1-mediated pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYOXALASE-I; OXIDATIVE STRESS; TRIOSEPHOSPHATE ISOMERASE; NUCLEAR-LOCALIZATION; 2-COMPONENT SYSTEM; GENE-EXPRESSION; OSMOTIC-STRESS; YEAST; IDENTIFICATION; GROWTH	Methylglyoxal (MG) is a typical 2-oxoaldehyde derived from glycolysis, although it inhibits the growth of cells in all types of organism. Hence, it has been questioned why such a toxic metabolite is synthesized via the ubiquitous energy-generating pathway. We have previously reported that expression of GLO1, coding for the major enzyme detoxifying MG, was induced by osmotic stress in a high osmolarity glycerol (HOG)-mitogen-activated protein ( MAP) kinase-dependent manner in Saccharomyces cerevisiae. Here we show that MG activates the HOG-MAP kinase cascade. Two osmosensors, Sln1 and Sho1, have been identified to function upstream of the HOG-MAP kinase cascade, and we reveal that MG initiates the signal transduction to this MAP kinase cascade through the Sln1 branch. We also demonstrate that MG activates the Msn2 transcription factor. Moreover, MG activated the uptake of Ca2+ in yeast cells, thereby stimulating the calcineurin/Crz1-mediated Ca2+ signaling pathway. We propose that MG functions as a signal initiator in yeast.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Mol Microbiol Lab, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Mol Microbiol Lab, Kyoto 6110011, Japan.	y_inoue@kais.kyoto-u.ac.jp		Izawa, Shingo/0000-0002-4920-2450				Aguilera J, 2001, CURR GENET, V39, P273, DOI 10.1007/s002940100213; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Beisswenger PJ, 1999, DIABETES, V48, P198, DOI 10.2337/diabetes.48.1.198; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Bito A, 1997, J BIOL CHEM, V272, P21509, DOI 10.1074/jbc.272.34.21509; Boustany LM, 2002, GENE DEV, V16, P608, DOI 10.1101/gad.967602; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Chen CN, 2003, YEAST, V20, P545, DOI 10.1002/yea.979; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IIDA H, 1990, J BIOL CHEM, V265, P13391; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Inoue Y, 1999, P JPN ACAD B-PHYS, V75, P127, DOI 10.2183/pjab.75.127; IYENGAR R, 1981, BIOCHEMISTRY-US, V20, P1229, DOI 10.1021/bi00508a027; Kaida D, 2002, GENES CELLS, V7, P543, DOI 10.1046/j.1365-2443.2002.00538.x; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Maeta K, 2004, MOL CELL BIOL, V24, P8753, DOI 10.1128/MCB.24.19.8753-8764.2004; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; O'Rourke SM, 2004, MOL BIOL CELL, V15, P532, DOI 10.1091/mbc.E03-07-0521; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Reiser V, 2003, J CELL BIOL, V161, P1035, DOI 10.1083/jcb.200301099; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shitamukai A, 2004, J BIOL CHEM, V279, P3651, DOI 10.1074/jbc.M306098200; Singh KK, 2000, FREE RADICAL BIO MED, V29, P1043, DOI 10.1016/S0891-5849(00)00432-9; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Takatsume Y, 2004, ARCH MICROBIOL, V181, P371, DOI 10.1007/s00203-004-0666-4; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Tsuzi D, 2004, FEBS LETT, V569, P301, DOI 10.1016/j.febslet.2004.05.077; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	54	92	99	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					253	260		10.1074/jbc.M408061200	http://dx.doi.org/10.1074/jbc.M408061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15520007	hybrid			2022-12-25	WOS:000226025100031
J	Muller, I; Stuckl, C; Wakely, J; Kertesz, M; Uson, I				Muller, I; Stuckl, C; Wakely, J; Kertesz, M; Uson, I			Succinate complex crystal structures of the alpha-ketoglutarate-dependent dioxygenase AtsK - Steric aspects of enzyme self-hydroxlation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL HYDROXYLASE; IRON; DECARBOXYLATION; ALKYLSULFATASE; MECHANISM; OXYGENASE; MOLSCRIPT; PROGRAM; TAURINE	The alkylsulfatase AtsK from Pseudomonas putida S-313 is a member of the non-heme iron(II)-alpha-ketoglutarate-dependent dioxygenase superfamily. In the initial step of their catalytic cycle, enzymes belonging to this widespread and versatile family coordinate molecular oxygen to the iron center in the active site. The subsequent decarboxylation of the cosubstrate alpha-ketoglutarate yields carbon dioxide, succinate, and a highly reactive ferryl (IV) species, which is required for substrate oxidation via a complex mechanism involving the transfer of radical species. Non-productive activation of oxygen may lead to harmful side reactions; therefore, such enzymes need an effective built-in protection mechanism. One of the ways of controlling undesired side reactions is the self-hydroxylation of an aromatic side chain, which leads to an irreversibly inactivated species. Here we describe the crystal structure of the alkylsulfatase AtsK in complexes with succinate and with Fe(II)/succinate. In the crystal structure of the AtsKFe(II)-succinate complex, the side chain of Tyr(168) is coordinated to the iron, suggesting that Tyr(168) is the target of enzyme self-hydroxylation. This is the first structural study of an Fe(II)-alpha-ketoglutarate-dependent dioxygenase that presents an aromatic side chain coordinated to the metal center, thus allowing structural insight into this protective mechanism of enzyme self-inactivation.	Inst Biol Mol Barcelona, Inst Catalana Recera Estudis Auancats, CSIC, Barcelona 08034, Spain; Univ Gottingen, Lehrstuhl Strukturchem, D-37077 Gottingen, Germany; Univ Gottingen, Inst Anorgan Chem, D-37077 Gottingen, Germany; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); ICREA; University of Gottingen; University of Gottingen; University of Manchester	Uson, I (corresponding author), Inst Biol Mol Barcelona, Inst Catalana Recera Estudis Auancats, CSIC, Jordi Girona 18-26, Barcelona 08034, Spain.	uson@ibmb.csic.es	KERTESZ, Michael/A-6720-2011	KERTESZ, Michael/0000-0003-2112-4451	ICREA Funding Source: Custom	ICREA(ICREA)		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COUNTS DF, 1978, P NATL ACAD SCI USA, V75, P2145, DOI 10.1073/pnas.75.5.2145; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Elkins JM, 2002, BIOCHEMISTRY-US, V41, P5185, DOI 10.1021/bi016014e; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Henshaw TF, 2004, J INORG BIOCHEM, V98, P856, DOI 10.1016/j.jinorgbio.2003.10.021; Kahnert A, 2000, J BIOL CHEM, V275, P31661, DOI 10.1074/jbc.M005820200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu A, 2001, J AM CHEM SOC, V123, P5126, DOI 10.1021/ja005879x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Muller I, 2004, BIOCHEMISTRY-US, V43, P3075, DOI 10.1021/bi035752v; Munro OQ, 1998, J CHEM SOC FARADAY T, V94, P1743, DOI 10.1039/a800998h; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; O'Brien JR, 2003, BIOCHEMISTRY-US, V42, P5547, DOI 10.1021/bi0341096; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Price JC, 2003, J AM CHEM SOC, V125, P13008, DOI 10.1021/ja037400h; RAO NV, 1978, J BIOL CHEM, V253, P6327; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; Ryle MJ, 1999, BIOCHEMISTRY-US, V38, P15278, DOI 10.1021/bi9912746; Ryle MJ, 2003, P NATL ACAD SCI USA, V100, P3790, DOI 10.1073/pnas.0636740100; Ryle MJ, 2003, BIOCHEMISTRY-US, V42, P1854, DOI 10.1021/bi026832m; TUDERMAN L, 1977, EUR J BIOCHEM, V80, P341, DOI 10.1111/j.1432-1033.1977.tb11888.x; Valegard K, 2004, NAT STRUCT MOL BIOL, V11, P95, DOI 10.1038/nsmb712; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	29	30	31	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5716	5723		10.1074/jbc.M410840200	http://dx.doi.org/10.1074/jbc.M410840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15542595	hybrid			2022-12-25	WOS:000227217100073
J	Lin, Y; Berg, AH; Iyengar, P; Lam, TKT; Giacca, A; Combs, TP; Rajala, MW; Du, XL; Rollman, B; Li, WJ; Hawkins, M; Barzilai, N; Rhodes, CJ; Fantus, IG; Brownlee, M; Scherer, PE				Lin, Y; Berg, AH; Iyengar, P; Lam, TKT; Giacca, A; Combs, TP; Rajala, MW; Du, XL; Rollman, B; Li, WJ; Hawkins, M; Barzilai, N; Rhodes, CJ; Fantus, IG; Brownlee, M; Scherer, PE			The hyperglycemia-induced inflammatory response in adipocytes - The role of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; OXIDATIVE STRESS; N-ACETYLCYSTEINE; GENE-EXPRESSION; IN-VIVO; ACTIVATION; RESISTANCE; OBESITY; KINASE; GLUCOSE	Hyperglycemia is a major independent risk factor for diabetic macrovascular disease. The consequences of exposure of endothelial cells to hyperglycemia are well established. However, little is known about how adipocytes respond to both acute as well as chronic exposure to physiological levels of hyperglycemia. Here, we analyze adipocytes exposed to hyperglycemia both in vitro as well as in vivo. Comparing cells differentiated at 4 mm to cells differentiated at 25 mm glucose (the standard differentiation protocol) reveals severe insulin resistance in cells exposed to 25 mm glucose. A global assessment of transcriptional changes shows an up-regulafion of a number of mitochondrial proteins. Exposure to hyperglycemia is associated with a significant induction of reactive oxygen species (ROS), both in vitro as well as in vivo in adipocytes isolated from streptozotocin-treated hyperglycemic mice. Furthermore, hyperglycemia for a few hours in a clamped setting will trigger the induction of a pro-inflammatory response in adipose tissue from rats that can effectively be reduced by co-infusion of N-acetylcysteine (NAC). ROS levels in 3T3-L1 adipocytes can be reduced significantly with pharmacological agents that lower the mitochondrial membrane potential, or by overexpression of uncoupling protein 1 or superoxide dismutase. In parallel with ROS, interleukin-6 secretion from adipocytes is significantly reduced. On the other hand, treatments that lead to a hyperpolarization of the mitochondrial membrane, such as overexpression of the mitochondrial dicarboxylate carrier result in increased ROS formation and decreased insulin sensitivity, even under normoglycemic conditions. Combined, these results highlight the importance ROS production in adipocytes and the associated insulin resistance and inflammatory response.	Albert Einstein Coll Med, Diabet Res & Training Ctr, Bronx, NY 10461 USA; Univ Toronto, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5G 1X5, Canada; ABR Affin BioReagents, Golden, CO 80403 USA; Univ Washington, Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	Yeshiva University; Albert Einstein College of Medicine; University of Toronto; University of Toronto; University of Toronto; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Scherer, PE (corresponding author), Albert Einstein Coll Med, Diabet Res & Training Ctr, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050610, R01DK055758, F32DK061228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021654] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-073163-01] Funding Source: Medline; NIA NIH HHS [P01-AG021654] Funding Source: Medline; NIDDK NIH HHS [1R01-DK55758, R01 DK050610, DK61228] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abderrahim-Ferkoune A, 2003, J LIPID RES, V44, P994, DOI 10.1194/jlr.M200382-JLR200; Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Berg AH, 2004, AM J PHYSIOL-ENDOC M, V287, pE1178, DOI 10.1152/ajpendo.00002.2004; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Das K, 1999, BIOCHEM J, V344, P313, DOI 10.1042/0264-6021:3440313; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; Gagnon AM, 1998, OBES RES, V6, P157, DOI 10.1002/j.1550-8528.1998.tb00330.x; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Gottschling-Zeller H, 2000, DIABETOLOGIA, V43, P377, DOI 10.1007/s001250050057; Granowitz EV, 1997, BIOCHEM BIOPH RES CO, V240, P382, DOI 10.1006/bbrc.1997.7663; Haber CA, 2003, AM J PHYSIOL-ENDOC M, V285, pE744, DOI 10.1152/ajpendo.00355.2002; Haegele AD, 1998, CARCINOGENESIS, V19, P1319, DOI 10.1093/carcin/19.7.1319; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Lu B, 2001, J BIOL CHEM, V276, P35589, DOI 10.1074/jbc.M106783200; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Orlicky DJ, 2001, J LIPID RES, V42, P460; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; Rajala MW, 2002, MOL ENDOCRINOL, V16, P1920, DOI 10.1210/me.2002-0048; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Talior I, 2003, AM J PHYSIOL-ENDOC M, V285, pE295, DOI 10.1152/ajpendo.00044.2003; Tang SG, 2001, DIABETES, V50, P83, DOI 10.2337/diabetes.50.1.83; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001	40	388	405	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4617	4626		10.1074/jbc.M411863200	http://dx.doi.org/10.1074/jbc.M411863200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15536073	hybrid			2022-12-25	WOS:000227096600076
J	Davies, JD; Carpenter, KLH; Challis, IR; Figg, NL; McNair, R; Proudfoot, D; Weissberg, PL; Shanahan, CM				Davies, JD; Carpenter, KLH; Challis, IR; Figg, NL; McNair, R; Proudfoot, D; Weissberg, PL; Shanahan, CM			Adipocytic differentiation and liver X receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; ELEMENT-BINDING PROTEIN-1C; HUMAN PREADIPOCYTE DIFFERENTIATION; NONESTERIFIED FATTY-ACIDS; SYNTHASE GENE-EXPRESSION; ADIPOSE-TISSUE; STEROL 27-HYDROXYLASE; LXR-ALPHA; SCAVENGER RECEPTORS	Lipid accumulation by vascular smooth muscle cells (VSMC) is a feature of atherosclerotic plaques. In this study we describe two mechanisms whereby human VSMC foam cell formation is driven by de novo synthesis of fatty acids leading to triacylglycerol accumulation in intracellular vacuoles, a process distinct from serum lipoprotein uptake. VSMC cultured in adipogenic differentiation medium accumulated lipids and were induced to express the adipocyte marker genes adipsin, adipocyte fatty acid-binding protein, CIEBPalpha, PPARgamma, and leptin. However, complete adipocyte differentiation was not observed as numerous genes present in mature adipocytes were not detected, and the phenotype was reversible. The rate of lipid accumulation was not affected by PPARgamma agonists, but screening for the effects of other nuclear receptor agonists showed that activation of the liver X receptors (LXR) dramatically promoted lipid accumulation in VSMC. Both LXRalpha and LXRbeta were present in VSMC, and their activation with TO901317 resulted in induction of the lipogenic genes fatty acid synthetase, sterol regulatory element binding protein (SREBP1c), and stearoyl-CoA desaturase. 27-Hydroxy-cholesterol, an abundant oxysterol synthesized by VSMC acted as an LXR antagonist and, therefore, may have a protective role in preventing foam cell formation. Immunohistochemistry showed that VSMC within atherosclerotic plaques express adipogenic and lipogenic markers, suggesting these pathways are present in vivo. Moreover, the development of an adipogenic phenotype in VSMC is consistent with their known phenotypic plasticity and may contribute to their dysfunction in atherosclerotic plaques and, thus, impinge on plaque growth and stability.	Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Davies, JD (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Dept Med, ACCI Bldg,Level 6,Box 110,Hills Rd, Cambridge CB2 2QQ, England.	jdd24@cam.ac.uk		Carpenter, Keri/0000-0001-8236-7727; Shanahan, Catherine/0000-0002-8352-8171				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Argmann CA, 2004, ARTERIOSCL THROM VAS, V24, P1290, DOI 10.1161/01.ATV.0000131260.80316.37; Babiker A, 1999, J LIPID RES, V40, P1417; BALIS JOHN U., 1964, EXP MOL PATHOL, V3-(5), P511; Bjorkhem I, 1999, CURR OPIN LIPIDOL, V10, P161, DOI 10.1097/00041433-199904000-00010; Bornstein SR, 2000, DIABETES, V49, P532, DOI 10.2337/diabetes.49.4.532; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Brown AJ, 2000, J BIOL CHEM, V275, P27627; CARPENTER KLH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P121, DOI 10.1016/0005-2760(93)90151-X; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; Carpenter KLH, 2003, FREE RADICAL RES, V37, P1235, DOI 10.1080/10715760310001604143; CHERNICK S, 1949, J BIOL CHEM, V179, P113; Crisby M, 1997, BBA-LIPID LIPID MET, V1344, P278, DOI 10.1016/S0005-2760(96)00152-X; Diascro DD, 1998, J BONE MINER RES, V13, P96, DOI 10.1359/jbmr.1998.13.1.96; DUSSERRE E, 1993, LIPIDS, V28, P589, DOI 10.1007/BF02536051; Frape DL, 2000, BRIT J NUTR, V84, P737; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Garcia-Cruset S, 2001, FREE RADICAL RES, V35, P31, DOI 10.1080/10715760100300571; Gough PJ, 1999, ARTERIOSCL THROM VAS, V19, P461, DOI 10.1161/01.ATV.19.3.461; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Guillet-Deniau I, 2004, J CELL SCI, V117, P1937, DOI 10.1242/jcs.01069; HOFF HF, 1991, J LIPID RES, V32, P115; Horton JD, 2003, J BIOL CHEM, V278, P36652, DOI 10.1074/jbc.M306540200; Hummasti S, 2004, J LIPID RES, V45, P616, DOI 10.1194/jlr.M300312-JLR200; Hutley LJ, 2003, EUR J CLIN INVEST, V33, P574, DOI 10.1046/j.1365-2362.2003.01178.x; Ishii I, 2002, BBA-MOL CELL BIOL L, V1585, P30, DOI 10.1016/S1388-1981(02)00305-0; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; KASTURI R, 1982, J BIOL CHEM, V257, P2224; KATSUDA S, 1992, AM J PATHOL, V140, P907; Kim YC, 1999, BIOCHEM BIOPH RES CO, V266, P1, DOI 10.1006/bbrc.1999.1704; Kohro T, 2000, J Atheroscler Thromb, V7, P145; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; LAUGHTON CW, 1988, ATHEROSCLEROSIS, V70, P233, DOI 10.1016/0021-9150(88)90174-8; Lecka-Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Llorente-Cortes V, 2000, ARTERIOSCL THROM VAS, V20, P1572, DOI 10.1161/01.ATV.20.6.1572; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Miao B, 2004, J LIPID RES, V45, P1410, DOI 10.1194/jlr.M300450-JLR200; MietusSnyder M, 1997, ARTERIOSCL THROM VAS, V17, P969, DOI 10.1161/01.ATV.17.5.969; NAITO M, 1992, AM J PATHOL, V141, P591; Nuttall ME, 1998, J BONE MINER RES, V13, P371, DOI 10.1359/jbmr.1998.13.3.371; Palmer DG, 2002, BIOCHEM BIOPH RES CO, V291, P439, DOI 10.1006/bbrc.2002.6467; Parhami F, 1999, J BONE MINER RES, V14, P2067, DOI 10.1359/jbmr.1999.14.12.2067; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Portman O W, 1970, Adv Lipid Res, V8, P41; Proudfoot D, 2002, CIRCULATION, V106, P3044, DOI 10.1161/01.CIR.0000041429.83465.41; Proudfoot D, 1998, ARTERIOSCL THROM VAS, V18, P379, DOI 10.1161/01.ATV.18.3.379; Quinet EM, 2004, J LIPID RES, V45, P1929, DOI 10.1194/jlr.M400257-JLR200; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; RIEMERSMA RA, 1986, BMJ-BRIT MED J, V292, P1423, DOI 10.1136/bmj.292.6533.1423; Rosen ED, 2000, GENE DEV, V14, P1293; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SEILLAN C, 1990, LIPIDS, V25, P172, DOI 10.1007/BF02544334; Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430-3444.2004; Sewter CP, 2002, DIABETES, V51, P718, DOI 10.2337/diabetes.51.3.718; Shanahan CM, 1999, CURR OPIN LIPIDOL, V10, P507, DOI 10.1097/00041433-199912000-00005; Shanahan CM, 2001, ATHEROSCLEROSIS, V154, P269, DOI 10.1016/S0021-9150(00)00473-1; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SMITH EB, 1967, J ATHEROSCLER RES, V7, P171, DOI 10.1016/S0368-1319(67)80079-6; SMITH EB, 1972, ATHEROSCLEROSIS, V15, P37, DOI 10.1016/0021-9150(72)90036-6; SMITH EB, 1965, J ATHEROSCLER RES, V5, P224, DOI 10.1016/S0368-1319(65)80064-3; Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; Steffensen KR, 2003, BIOCHEM BIOPH RES CO, V310, P589, DOI 10.1016/j.bbrc.2003.08.139; STEIN O, 1991, BIOCHIM BIOPHYS ACTA, V1082, P33, DOI 10.1016/0005-2760(91)90296-T; Stein O, 1977, Adv Exp Med Biol, V82, P903; STEIN O, 1977, ATHEROSCLEROSIS, V26, P465, DOI 10.1016/0021-9150(77)90115-0; Sun LJ, 2002, J BIOL CHEM, V277, P18919, DOI 10.1074/jbc.M110650200; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31; Wang HY, 2003, J BIOL CHEM, V278, P16622, DOI 10.1074/jbc.M212488200; Weissberg PL, 2000, HEART, V83, P247, DOI 10.1136/heart.83.2.247; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; You M, 2002, J BIOL CHEM, V277, P29342, DOI 10.1074/jbc.M202411200; Zhang Z, 2001, J LIPID RES, V42, P649	89	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3911	3919		10.1074/jbc.M410075200	http://dx.doi.org/10.1074/jbc.M410075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548517	hybrid			2022-12-25	WOS:000226983900093
J	Lin, RT; Yang, L; Arguello, M; Penafuerte, C; Hiscott, J				Lin, RT; Yang, L; Arguello, M; Penafuerte, C; Hiscott, J			A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; POSITIVE FEEDBACK; VIRUS-INFECTION; INTERFERON-ALPHA; IFN INDUCTION; IKK-EPSILON; IN-VIVO; ACTIVATION; FACTOR-3; KINASE	Interferon regulatory factors (IRFs) are involved in gene regulation in many biological processes including the antiviral, growth regulatory, and immune modulatory functions of the interferon system. Several studies have demonstrated that IRF-3, IRF-5, and IRF-7 specifically contribute to the innate antiviral response to virus infection. It has been reported that virus-specific phosphorylation leads to IRF-5 nuclear localization and up-regulation of interferon, cytokine, and chemokine gene expression. Two nuclear localization signals have been identified in IRF-5, both of which are sufficient for nuclear translocation and retention in virus-infected cells. In the present study, we demonstrate that a CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization. IRF-5 possesses a functional nuclear export signal (NES) that controls dynamic shuttling between the cytoplasm and the nucleus. The NES element is dominant in unstimulated cells and results in the predominant cytoplasmic localization of IRF-5. Mutation of two leucine residues in the NES motif to alanine, or three adjacent Ser/Thr residues to the phosphomimetic Asp, results in constitutively nuclear IRF-5 and suggests that phosphorylation of adjacent Ser/Thr residues may contribute to IRF-5 nuclear accumulation in virus-induced cells. IKK-related kinases TBK1 and IKKepsilon have been shown to phosphorylate and activate IRF-3 and IRF-7, leading to the production of type 1 interferons and the development of a cellular antiviral state. We examined the phosphorylation and activation of IRF-5 by TBK1 and IKKepsilon kinases. Although IRF-5 is phosphorylated by IKKepsilon and TBK1 in co-transfected cells, the phosphorylation of IRF-5 did not lead to IRF-5 nuclear localization or activation.	Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Lin, RT (corresponding author), Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	rongtuan.lin@mcgill.ca	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Barnes BJ, 2003, CANCER RES, V63, P6424; Barnes BJ, 2003, J BIOL CHEM, V278, P16630, DOI 10.1074/jbc.M212609200; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; BARNES BJ, 2001, J BIOL CHEM, V12, P12; Biron CA, 1997, CURR OPIN IMMUNOL, V9, P24, DOI 10.1016/S0952-7915(97)80155-0; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; OLIN R, 2000, MOL CELL BIOL, V20, P6342; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Servant MJ, 2002, BIOCHEM PHARMACOL, V64, P985, DOI 10.1016/S0006-2952(02)01165-6; Servant MJ, 2002, J INTERF CYTOK RES, V22, P49, DOI 10.1089/107999002753452656; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; ULMAN K, 1997, CELL, V90, P967; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	48	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3088	3095		10.1074/jbc.M408452200	http://dx.doi.org/10.1074/jbc.M408452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15556946	hybrid			2022-12-25	WOS:000226449100085
J	Mills, KV; Dorval, DM; Lewandowski, KT				Mills, KV; Dorval, DM; Lewandowski, KT			Kinetic analysis of the individual steps of protein splicing for the Pyrococcus abyssi PolII intein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SSP DNAE INTEIN; DELTA-5-3-KETOSTEROID ISOMERASE; BRANCHED INTERMEDIATE; CRYSTAL-STRUCTURE; ACTIVE-SITE; MINI-INTEIN; ZINC ION; CLEAVAGE; IDENTIFICATION; TETRAPEPTIDE	Protein splicing involves the excision of an intervening polypeptide, the intein, from flanking polypeptides, the exteins, concomitant with the specific ligation of the exteins. The intein that interrupts the DNA polymerase II DP2 subunit in Pyrococcus abyssi can be overexpressed and purified as an unspliced precursor, which allows for a detailed in vitro kinetic analysis of the individual steps of protein splicing. The first order rate constant for splicing of this intein, which has a non-canonical Gln at its C terminus, is 9.3 x 10(-6) s(-1) at 60degreesC. The rate constant for splicing increases 3-fold with substitution of Asn for the C-terminal Gln. The pseudo first order rate constant of dithiothreitol-dependent N-terminal cleavage is 1 x 10(-4) s(-1). The first order rate constant of C-terminal cleavage is 1.2 x 10(-5) s(-1) with Gln at the C-terminal position, 2.8 x 10(-4) s(-1) with Asn, and decreases significantly with mutation of the penultimate His of the intein to Ala. N-terminal cleavage is most efficient between pH 7 and 7.5 and decreases at both more acidic and alkaline pH values, whereas C-terminal cleavage and splicing are both efficient over a broader range of pH values.	Coll Holy Cross, Dept Chem, Worcester, MA 01610 USA	College of the Holy Cross	Mills, KV (corresponding author), Coll Holy Cross, Dept Chem, 1 Coll St, Worcester, MA 01610 USA.	kmills@holycross.edu						Amitai G, 2004, J BIOL CHEM, V279, P3121, DOI 10.1074/jbc.M311343200; BROWN HC, 1954, J AM CHEM SOC, V76, P467, DOI 10.1021/ja01631a041; Cambon-Bonavita MA, 2000, EXTREMOPHILES, V4, P215, DOI 10.1007/PL00010714; Chen LX, 2000, J BIOL CHEM, V275, P20431, DOI 10.1074/jbc.M000178200; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; CLARKE ND, 1994, P NATL ACAD SCI USA, V91, P11084, DOI 10.1073/pnas.91.23.11084; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; Ding Y, 2003, J BIOL CHEM, V278, P39133, DOI 10.1074/jbc.M306197200; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Giriat I, 2001, GENET ENG P, V23, P171; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Martin DD, 2001, BIOCHEMISTRY-US, V40, P1393, DOI 10.1021/bi001786g; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; Mills KV, 2004, J BIOL CHEM, V279, P20685, DOI 10.1074/jbc.M400887200; Mills KV, 2001, J BIOL CHEM, V276, P10832, DOI 10.1074/jbc.M011149200; Nichols NM, 2004, BIOCHEMISTRY-US, V43, P10265, DOI 10.1021/bi0494065; Nichols NM, 2003, BIOCHEMISTRY-US, V42, P5301, DOI 10.1021/bi020679e; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; PENNING TM, 1981, J BIOL CHEM, V256, P6851; PENNING TM, 1982, J BIOL CHEM, V257, P2589; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; Sircar SSG, 1927, J CHEM SOC, P1252, DOI 10.1039/jr9270001252; Sircar SSG, 1927, J CHEM SOC, P600, DOI 10.1039/jr9270000600; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; Wang SL, 1997, J BIOL CHEM, V272, P11869, DOI 10.1074/jbc.272.18.11869; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	32	28	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2714	2720		10.1074/jbc.M412313200	http://dx.doi.org/10.1074/jbc.M412313200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15557319	hybrid			2022-12-25	WOS:000226449100043
J	Nichols, MR; Moss, MA; Reed, DK; Cratic-McDaniei, S; Hoh, JH; Rosenberry, TL				Nichols, MR; Moss, MA; Reed, DK; Cratic-McDaniei, S; Hoh, JH; Rosenberry, TL			Amyloid-beta protofibrils differ from Amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; CIRCULAR-DICHROISM SPECTRA; SURFACE-PLASMON RESONANCE; TG2576 MOUSE MODEL; X-RAY-DIFFRACTION; ALZHEIMERS-DISEASE; A-BETA; IN-VITRO; FIBRIL FORMATION; PROTEIN FIBRILLOGENESIS	The brains of Alzheimer's disease (AD) patients contain large numbers of amyloid plaques that are rich in fibrils composed of 40- and 42-residue amyloid-beta (Abeta) peptides. Several lines of evidence indicate that fibrillar Abeta and especially soluble Abeta aggregates are important in the etiology of AD. Recent reports also stress that amyloid aggregates are polymorphic and that a single polypeptide can fold into multiple amyloid conformations. Here we demonstrate that Abeta-(1-40) can form soluble aggregates with predominant beta-structures that differ in stability and morphology. One class of aggregates involved soluble Abeta protofibrils, prepared by vigorous overnight agitation of monomeric Abeta-(1-40) at low ionic strength. Dilution of these aggregation reactions induced disaggregation to monomers as measured by size exclusion chromatography. Protofibril concentrations monitored by thioflavin T fluorescence decreased in at least two kinetic phases, with initial disaggregation (rate constant similar to1 h(-1)) followed by a much slower secondary phase. Incubation of the reactions without agitation resulted in less disaggregation at slower rates, indicating that the protofibrils became progressively more stable over time. In fact, protofibrils isolated by size exclusion chromatography were completely stable and gave no disaggregation. A second class of soluble Abeta aggregates was generated rapidly (< 10 min) in buffered 2% hexafluoroisopropanol (HFIP). These aggregates showed increased thioflavin T fluorescence and were rich in beta-structure by circular dichroism. Electron microscopy and atomic force microscopy revealed initial globular clusters that progressed over several days to soluble fibrous aggregates. When diluted out of HFIP, these aggregates initially were very unstable and disaggregated completely within 2 min. However, their stability increased as they progressed to fibers. Relative to A beta protofibrils, the HFIP-induced aggregates seeded elongation by A beta monomer deposition very poorly. The techniques used to distinguish these two classes of soluble A beta aggregates may be useful in characterizing A beta aggregates formed in vivo.	Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Mayo Clinic; Johns Hopkins University	Rosenberry, TL (corresponding author), Mayo Clin, Coll Med, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	rosenberry@mayo.edu	Hoh, Jan H./P-8695-2019	Hoh, Jan/0000-0003-3842-9454	NIGMS NIH HHS [5 R25 GM64124] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM064124] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Burkoth TS, 2000, J AM CHEM SOC, V122, P7883, DOI 10.1021/ja000645z; Chan W, 1996, BIOCHEMISTRY-US, V35, P7123, DOI 10.1021/bi952852v; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; COHEN AS, 1959, NATURE, V183, P1202, DOI 10.1038/1831202a0; DEBYE P, 1947, J PHYS COLLOID CHEM, V51, P18, DOI 10.1021/j150451a002; Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Goldsbury CS, 2000, J STRUCT BIOL, V130, P217, DOI 10.1006/jsbi.2000.4259; Gursky O, 2000, BBA-PROTEIN STRUCT M, V1476, P93, DOI 10.1016/S0167-4838(99)00228-9; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hasegawa K, 2002, BIOCHEMISTRY-US, V41, P13489, DOI 10.1021/bi020369w; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kakio A, 2002, BIOCHEMISTRY-US, V41, P7385, DOI 10.1021/bi0255874; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; Li HT, 2002, BIOPOLYMERS, V64, P221, DOI 10.1002/bip.10179; Means G E, 1977, Methods Enzymol, V47, P469; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; Myszka DG, 1999, METHOD ENZYMOL, V309, P386; Naiki H, 1996, LAB INVEST, V74, P374; Nichols MR, 2005, BIOCHEMISTRY-US, V44, P165, DOI 10.1021/bi048846t; Nichols MR, 2002, BIOCHEMISTRY-US, V41, P6115, DOI 10.1021/bi015985r; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; O'Nuallain B, 2004, J BIOL CHEM, V279, P17490, DOI 10.1074/jbc.M311300200; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Padrick SB, 2002, BIOCHEMISTRY-US, V41, P4694, DOI 10.1021/bi0160462; Petkova AT, 2004, J MOL BIOL, V335, P247, DOI 10.1016/j.jmb.2003.10.044; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Sengupta P, 2003, BIOCHEMISTRY-US, V42, P10506, DOI 10.1021/bi0341410; Serpell LC, 2000, J MOL BIOL, V300, P1033, DOI 10.1006/jmbi.2000.3908; Sikorski P, 2003, STRUCTURE, V11, P915, DOI 10.1016/S0969-2126(03)00149-7; SOTO C, 1995, NEUROSCI LETT, V186, P115, DOI 10.1016/0304-3940(95)11299-C; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; Tycko R, 2003, BIOCHEMISTRY-US, V42, P3151, DOI 10.1021/bi027378p; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; Yoshida K, 2003, J CHEM PHYS, V119, P6132, DOI 10.1063/1.1602070; Zagorski MG, 1999, METHOD ENZYMOL, V309, P189; ZIMM BH, 1948, J CHEM PHYS, V16, P1093, DOI 10.1063/1.1746738	70	93	97	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2471	2480		10.1074/jbc.M410553200	http://dx.doi.org/10.1074/jbc.M410553200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15528204	Green Published, hybrid			2022-12-25	WOS:000226449100013
J	Park, JI; Collinson, EJ; Grant, CM; Dawes, IW				Park, JI; Collinson, EJ; Grant, CM; Dawes, IW			Rom2p, the Rho1 GTP/GDP exchange factor of Saccharomyces cerevisiae, can mediate stress responses via the Ras-cAMP pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GTP-BINDING PROTEIN; AMP PATHWAY; STATIONARY-PHASE; GENE-EXPRESSION; HEAT-SHOCK; YEAST; GROWTH; MECHANISMS; TRANSCRIPTION	The Ras-cyclic AMP pathway is connected to other nutrient-regulated signaling pathways and mediates the global stress responses of Saccharomyces cerevisiae. Here, we show that Rom2p, the Rhol GTP/GDP exchange factor, can mediate stress responses and cell growth via the Ras-cAMP pathways. ROM2 was isolated as a suppresser of heat and NaCl sensitivity caused by the lack of the Ras-GTPase activator Ira2p or of cAMP phosphodiesterases. Subsequent analysis of strains with a rom2 deletion showed that Rom2p is essential for resistance to a variety of stresses caused by freeze-thawing, oxidants, cycloheximide, NaCl, or cobalt ions. Stress sensitivity and the growth defect caused by the rom2 deletion could be suppressed by depleting Ras or protein kinase A (PKA) activity or by overexpressing the high affinity cAMP phosphodiesterase Pde2p. In addition, overexpression of ROM2 could not rescue cells lacking the regulatory subunit of PKA, indicating that the Ras-adenylate, cyclase-PKA cascade is essential for Rom2p-mediated stress responses and cell growth. Deletion of IRA2 exacerbated the freeze-thaw sensitivity and growth defect of the rom2 mutant, indicating that Rom2p signaling may control Ras independently of IRA2. Increases in cAMP levels were detected in the rom2 deletion mutants, and these were comparable with the effects of an ira2 mutation. The effects of the deletion of ROM2 on sensitivity to hydrogen peroxide, paraquat, and cobalt ions, but not to caffeine, were reduced when a constitutive allele of RHO1 was introduced on a single copy plasmid. However, the effects of the deletion of ROM2 on sensitivity to diamide and NaCl were exacerbated. Taken together, our data indicate that Rom2p can regulate PKA activity by controlling cAMP levels via the Ras-cAMP pathway and that for those stresses related to oxidative stress, this cross-talk is probably mediated via the Rho1p-activated MAPK pathway.	Univ New S Wales, Sch Biotechnol & Biomol Sci, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Dawes, IW (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia.	I.Dawes@unsw.edu.au		Grant, Chris/0000-0002-0616-6576; Park, Jong-In/0000-0001-7248-4735				Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Alic N, 2003, J BIOL CHEM, V278, P41849, DOI 10.1074/jbc.M307760200; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BELAZZI T, 1991, EMBO J, V10, P585, DOI 10.1002/j.1460-2075.1991.tb07985.x; Bolte M, 2003, MICROBIOL-SGM, V149, P1205, DOI 10.1099/mic.0.26062-0; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; Charizanis C, 1999, MOL GEN GENET, V262, P437, DOI 10.1007/s004380051103; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; Dejean L, 2002, BBA-BIOENERGETICS, V1554, P159, DOI 10.1016/S0005-2728(02)00240-2; Dihazi H, 2004, J BIOL CHEM, V279, P23961, DOI 10.1074/jbc.M312974200; Dihazi H, 2003, BIOCHEMISTRY-US, V42, P6275, DOI 10.1021/bi034167r; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fortuniak A, 1996, BIOCHEM MOL BIOL INT, V38, P901; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1111/j.1574-6976.2001.tb00574.x; Garreau H, 2000, MICROBIOL-UK, V146, P2113, DOI 10.1099/00221287-146-9-2113; Geymonat M, 1998, MOL MICROBIOL, V30, P855, DOI 10.1046/j.1365-2958.1998.01118.x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; Harrison JC, 2004, J BIOL CHEM, V279, P2616, DOI 10.1074/jbc.M306110200; Hasan R, 2002, MOL MICROBIOL, V45, P233, DOI 10.1046/j.1365-2958.2002.03011.x; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HIRATA D, 1995, MOL GEN GENET, V249, P257, DOI 10.1007/BF00290525; Howard SC, 2003, GENETICS, V165, P1059; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Lorberg A, 2003, CURR TOP MICROBIOL, V279, P1; MAZON MJ, 1993, EUR J BIOCHEM, V213, P501, DOI 10.1111/j.1432-1033.1993.tb17787.x; Muller D, 2003, YEAST, V20, P351, DOI 10.1002/yea.967; Ng DTW, 2001, DEV CELL, V1, P319, DOI 10.1016/S1534-5807(01)00052-1; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; Ohkuni K, 2003, GENETICS, V165, P517; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; Paravicini G, 1996, MOL GEN GENET, V251, P682, DOI 10.1007/s004380050217; Park JI, 1997, APPL ENVIRON MICROB, V63, P3818, DOI 10.1128/AEM.63.10.3818-3824.1997; Reinders A, 1998, GENE DEV, V12, P2943, DOI 10.1101/gad.12.18.2943; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Sekiya-Kawasaki M, 2002, GENETICS, V162, P663; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; Stark M. J., 2004, METABOLISM MOL PHYSL, P284; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Thorpe GW, 2004, P NATL ACAD SCI USA, V101, P6564, DOI 10.1073/pnas.0305888101; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; Van Dijck P, 2000, INT J FOOD MICROBIOL, V55, P187, DOI 10.1016/S0168-1605(00)00162-8; Verstrepen KJ, 2003, FEMS YEAST RES, V4, P285, DOI 10.1016/S1567-1356(03)00166-1; Wojda I, 2003, MICROBIOL-SGM, V149, P1193, DOI 10.1099/mic.0.26110-0	61	37	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2529	2535		10.1074/jbc.M407900200	http://dx.doi.org/10.1074/jbc.M407900200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15545276	hybrid			2022-12-25	WOS:000226449100020
J	Cal, S; Quesada, V; Llamazares, M; Diaz-Perales, A; Garabaya, C; Lopez-Otin, C				Cal, S; Quesada, V; Llamazares, M; Diaz-Perales, A; Garabaya, C; Lopez-Otin, C			Human polyserase-2, a novel enzyme with three tandem serine protease domains in a single polypeptide chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MATRIX METALLOPROTEINASES; CONVERTING-ENZYME; OVIDUCTAL PROTEASE; MESSENGER-RNA; EXPRESSION; CANCER; EVOLUTION; SEQUENCE; GENOME	We have cloned a human cDNA encoding a new serine protease that has been called polyserase-2 ( polyserine protease-2) because it is the second identified human enzyme with several tandem serine protease domains in its amino acid sequence. The first serine protease domain contains all characteristic features of these enzymes, whereas the second and third domains lack one residue of the catalytic triad of serine proteases and are predicted to be catalytically inactive. This complex domain organization is also present in the sequences of mouse and rat polyserase-2 and resembles that of polyserase-1, which also contains three serine protease domains in its amino acid sequence. However, polyserase-2 lacks additional domains present in polyserase-1, including a type II transmembrane motif and a low-density lipoprotein receptor A module. Enzymatic analysis demonstrated that both full-length polyserase-2 and its first serine protease domain hydrolyzed synthetic peptides used for assaying serine proteases. Nevertheless, the activity of the isolated domain was greater than that of the entire protein, suggesting that the two catalytically inactive serine protease domains of polyserase-2 may modulate the activity of the first domain. Northern blot analysis showed that polyserase-2 is expressed in fetal kidney; adult skeletal muscle, liver, placenta, prostate, and heart; and tumor cell lines derived from lung and colon adenocarcinomas. Finally, analysis of post-translational processing mechanisms of polyserase-2 revealed that, contrary to those affecting to the membrane-bound polyserase-1, this novel polyprotein is a secreted enzyme whose three protease domains remain as an integral part of a single polypeptide chain.	Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias	Cal, S (corresponding author), Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	santical@uniovi.es	López-Otín, Carlos/AAB-2106-2020; Quesada, Víctor/B-6557-2014; Díaz-Perales, Araceli/D-8433-2016	López-Otín, Carlos/0000-0001-6964-1904; Quesada, Víctor/0000-0002-8398-3457; Díaz-Perales, Araceli/0000-0002-1093-3627; Llamazares Prada, Maria/0000-0001-6559-9374				Bhagwandin VJ, 2003, J BIOL CHEM, V278, P3363, DOI 10.1074/jbc.M209353200; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Cal S, 2003, P NATL ACAD SCI USA, V100, P9185, DOI 10.1073/pnas.1633392100; Disse S, 1999, AM J HUM GENET, V65, P1242, DOI 10.1086/302624; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Hiyoshi M, 2002, DEV BIOL, V243, P176, DOI 10.1006/dbio.2001.0558; Hooper JD, 2003, BIOCHEM J, V373, P689, DOI 10.1042/BJ20030390; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Krem MM, 2000, TRENDS CARDIOVAS MED, V10, P171, DOI 10.1016/S1050-1738(00)00068-2; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lindsay LL, 1999, P NATL ACAD SCI USA, V96, P11253, DOI 10.1073/pnas.96.20.11253; Lindsay LL, 1999, BIOL REPROD, V60, P989, DOI 10.1095/biolreprod60.4.989; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Novikova EG, 1999, J BIOL CHEM, V274, P28887, DOI 10.1074/jbc.274.41.28887; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Puente XS, 2004, GENOME RES, V14, P609, DOI 10.1101/gr.1946304; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stiburkova B, 2003, EUR J HUM GENET, V11, P145, DOI 10.1038/sj.ejhg.5200937; Tomita H, 1999, AM J HUM GENET, V65, P1688, DOI 10.1086/302682; Velasco G, 2002, J BIOL CHEM, V277, P37637, DOI 10.1074/jbc.M203007200; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WEI L, 1992, J BIOL CHEM, V267, P13398; Wong GW, 2004, J BIOL CHEM, V279, P2438, DOI 10.1074/jbc.M308209200; Wong GW, 2001, J BIOL CHEM, V276, P49169, DOI 10.1074/jbc.M108677200; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483	39	17	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1953	1961		10.1074/jbc.M409139200	http://dx.doi.org/10.1074/jbc.M409139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15536082	hybrid, Green Published			2022-12-25	WOS:000226341700029
J	Downward, J				Downward, J			RNA interference-based functional genomics in cancer research - an introduction	ONCOGENE			English	Editorial Material									Canc Res UK London Res Inst, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Baum B, 2004, ONCOGENE, V23, P8336, DOI 10.1038/sj.onc.1208009; Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Fraser A, 2004, ONCOGENE, V23, P8346, DOI 10.1038/sj.onc.1208044; Poulin G, 2004, ONCOGENE, V23, P8340, DOI 10.1038/sj.onc.1208010; Sachse C, 2004, ONCOGENE, V23, P8384, DOI 10.1038/sj.onc.1208072; Silva J, 2004, ONCOGENE, V23, P8401, DOI 10.1038/sj.onc.1208176; van Haaften G, 2004, ONCOGENE, V23, P8366, DOI 10.1038/sj.onc.1208011; Vanhecke D, 2004, ONCOGENE, V23, P8353, DOI 10.1038/sj.onc.1208027; Willingham AT, 2004, ONCOGENE, V23, P8392, DOI 10.1038/sj.onc.1208217	10	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2004	23	51					8334	8335		10.1038/sj.onc.1208121	http://dx.doi.org/10.1038/sj.onc.1208121			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517012				2022-12-25	WOS:000224815900001
J	Roato, I; Grano, M; Brunetti, G; Colucci, S; Mussa, A; Bertetto, O; Ferracini, R				Roato, I; Grano, M; Brunetti, G; Colucci, S; Mussa, A; Bertetto, O; Ferracini, R			Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement	FASEB JOURNAL			English	Article						bone metastases; osteoclast; osteolysis; T lymphocytes	KAPPA-B LIGAND; REGULATORY T-CELLS; BLOOD MONONUCLEAR-CELLS; RECEPTOR ACTIVATOR; PERIPHERAL-BLOOD; MULTIPLE-MYELOMA; DIFFERENTIATION FACTOR; LUNG-CANCER; RESORPTION; DISEASE	Bone metastases represents a common cause of morbidity in patients suffering many types of cancer: breast, lung, kidney, prostate, and multiple myeloma. Osteolytic metastases often cause severe pain, pathologic fractures, hypercalcemia, spinal cord compression, and other nerve-compression syndromes. Osteoclasts (OCs), cells deriving from granulocitic-macrophagic lineage, are responsible for osteolysis, which may be reduced by inhibiting both OCs formation and activity. By studying bone osteolytic metastases mechanism in solid tumors, we report here our findings that cancer patients with bone involvement display an increase in osteoclasts precursors, compared with both healthy controls and cancer patients without bone metastases. Peripheral blood mononuclear cells (PBMCs) from patients with osteolytic lesions show osteoclastogenesis without adding M-CSF, RANKL, or TNF-alpha. However, these factors are necessary to generate OCs from healthy donors, non-osteolytic patient PBMCs and T-cell depleted PBMCs. OCs derived from cancer patients show more resorption pits than OCs from healthy donors and express genes involved in osteoclastogenesis. Our data show that a spontaneous osteoclastogenesis occurs in patients affected by osteolytic lesions and may be supported by factors released by T lymphocytes. These factors could give a priming to osteoclast precursors and promote osteoclastogenesis. In fact, T-cell depleted PBMCs do not differentiate into OCs without adding M-CSF and RANKL. Moreover, we do not obtain a higher number of OCs by increasing RANKL doses in cultures, and OCs and T lymphocytes mRNA level are detected for TNF-alpha but not for RANKL. The addition of OPG to PBMCs cultures do not modify spontaneous osteoclastogenesis. A neutralizing anti-TNF-alpha antibody in unstimulated PBMC cultures of osteolytic cancer patients induces an inhibition of osteoclastogenesis.	Univ & ASO San Giovanni Battista, CeRMS, I-10126 Turin, Italy; Univ Bari, Dept Human Anat & Histol, I-70121 Bari, Italy; Univ & ASO San Giovanni Battista, Dept Med Oncol, I-10126 Turin, Italy; ASO San Giovanni Battista, Dept Orthopaed, Turin, Italy	A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Universita degli Studi di Bari Aldo Moro; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Roato, I (corresponding author), Univ & ASO San Giovanni Battista, CeRMS, I-10126 Turin, Italy.	roato78@libero.it	Ferracini, Riccardo/AAL-4622-2020; Giacomina, Brunetti/J-7692-2016	Giacomina, Brunetti/0000-0002-0681-1432; bertetto, oscar/0000-0001-5133-2724; Roato, Ilaria/0000-0003-3029-4743; Colucci, Silvia/0000-0001-9970-3539; Grano, Maria/0000-0002-7121-5899				Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Assuma R, 1998, J IMMUNOL, V160, P403; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Berenson JR, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34071; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688; Capanna R, 2001, J BONE JOINT SURG BR, V83B, P471, DOI 10.1302/0301-620X.83B4.12202; COLUCCI S, 2004, BLOOD; DEMULDER A, 1993, ENDOCRINOLOGY, V133, P1978, DOI 10.1210/en.133.5.1978; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood-2002-04-1121; GREGORETTI MG, 1995, LEUKEMIA, V9, P1392; Hofbauer LC, 2001, CANCER-AM CANCER SOC, V92, P460, DOI 10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D; HORTON MA, 1985, CANCER RES, V45, P5663; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Massey HM, 1999, BRIT J HAEMATOL, V106, P167; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355; Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634; Onizuka S, 1999, CANCER RES, V59, P3128; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sabokbar A, 2003, J ORTHOP RES, V21, P73, DOI 10.1016/S0736-0266(02)00106-7; Shimizu J, 1999, J IMMUNOL, V163, P5211; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sprent J, 2001, CURR OPIN IMMUNOL, V13, P248, DOI 10.1016/S0952-7915(00)00211-9; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Wolf AM, 2003, CLIN CANCER RES, V9, P606; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272; Woo EY, 2001, CANCER RES, V61, P4766; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yee C, 2002, NAT REV CANCER, V2, P409, DOI 10.1038/nrc820	44	79	82	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					228	+		10.1096/fj.04-1823fje	http://dx.doi.org/10.1096/fj.04-1823fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15550550				2022-12-25	WOS:000225482100008
J	Unnikrishnan, M; Burleigh, BA				Unnikrishnan, M; Burleigh, BA			Inhibition of host connective tissue growth factor expression: a novel Trypanosoma cruzi-mediated response	FASEB JOURNAL			English	Article						parasite; extracellular matrix; infection; mitogen-activated kinases	INTESTINAL EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; TGF-BETA; GENE-EXPRESSION; MAMMALIAN-CELLS; BACTERIAL PROTEINASES; EXTRACELLULAR-MATRIX; CTGF EXPRESSION; INVASION; FIBROBLASTS	Connective tissue growth factor ( CTGF) is a secreted cytokine that plays a fundamental role in the development of tissue fibrosis by mediating many of the profibrotic effects of TGF-beta. We present the novel finding that the intracellular pathogen Trypanosoma cruzi elicits immediate and sustained repression of basal CTGF expression in dermal fibroblasts, followed by down-regulation of the extracellular matrix proteins, fibronectin, and collagen I alpha1. To address mechanisms underlying this response, the major CTGF-regulating pathways were investigated. We report that both T. cruzi trypomastigotes and secreted parasite factor(s) antagonize TGF-beta-dependent induction of CTGF in fibroblasts. Of the TGF-beta-dependent signaling pathways required for CTGF expression, we demonstrate that T. cruzi interferes with cellular Erk1/2 phosphorylation but not Smad3 signaling. While increased stimulation of Erk phosphorylation alone was insufficient to override the parasite-mediated repression of CTGF, stimulation of fibroblasts with increased concentrations of TGF-beta, which activates both Smad3 and Erk1/2, completely abrogated this inhibition. Together with the finding that T. cruzi-mediated down-regulation of CTGF expression requires de novo host cell protein synthesis, our data indicate that the unique ability of T. cruzi to interfere with the host fibrogenic response is a complex process requiring input from multiple host cell signaling pathways.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Burleigh, BA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bburleig@hsph.harvard.edu		Unnikrishnan, Meera/0000-0001-5417-9331	NHLBI NIH HHS [HL073227] Funding Source: Medline; NIAID NIH HHS [AI47960] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047960] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Baldwin DN, 2003, GENOME BIOL, V4; Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Burleigh BA, 2002, CELL MICROBIOL, V4, P701, DOI 10.1046/j.1462-5822.2002.00226.x; BURLEIGH BA, 1995, J BIOL CHEM, V270, P5172, DOI 10.1074/jbc.270.10.5172; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; Caler EV, 2000, INFECT IMMUN, V68, P6602, DOI 10.1128/IAI.68.12.6602-6610.2000; Chen MM, 2000, J MOL CELL CARDIOL, V32, P1805, DOI 10.1006/jmcc.2000.1215; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Chuenkova MV, 2001, P NATL ACAD SCI USA, V98, P9936, DOI 10.1073/pnas.161298398; de Avalos SV, 2002, J BIOL CHEM, V277, P639, DOI 10.1074/jbc.M109037200; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Eckmann L, 2000, J BIOL CHEM, V275, P14084, DOI 10.1074/jbc.275.19.14084; Fan WH, 2000, BIOCHEM BIOPH RES CO, V275, P312, DOI 10.1006/bbrc.2000.3314; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gebbia JA, 2001, INFECT IMMUN, V69, P456, DOI 10.1128/IAI.69.1.456-462.2001; Grellier P, 2001, J BIOL CHEM, V276, P47078, DOI 10.1074/jbc.M106017200; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Gull K, 2001, INT J PARASITOL, V31, P443, DOI 10.1016/S0020-7519(01)00154-0; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; Hishikawa K, 2000, EUR J PHARMACOL, V392, P19, DOI 10.1016/S0014-2999(00)00115-1; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Igarashi A, 1998, J CUTAN PATHOL, V25, P143, DOI 10.1111/j.1600-0560.1998.tb01706.x; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; Kirchhoff LV, 1996, GASTROENTEROL CLIN N, V25, P517, DOI 10.1016/S0889-8553(05)70261-2; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nowinski D, 2002, J INVEST DERMATOL, V119, P449, DOI 10.1046/j.1523-1747.2002.01841.x; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Okamoto T, 1997, J BIOL CHEM, V272, P6059, DOI 10.1074/jbc.272.9.6059; Potempa J, 2000, PERIODONTOL 2000, V24, P153, DOI 10.1034/j.1600-0757.2000.2240108.x; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rishikof DC, 2002, J CELL BIOCHEM, V85, P496, DOI 10.1002/jcb.10144; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; Rodriguez A, 1999, J BIOL CHEM, V274, P16754, DOI 10.1074/jbc.274.24.16754; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; Santana JM, 1997, BIOCHEM J, V325, P129, DOI 10.1042/bj3250129; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; Tabibzadeh S, 2002, FRONT BIOSCI-LANDMRK, V7, pD1231; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Williams EJ, 2000, J HEPATOL, V32, P754, DOI 10.1016/S0168-8278(00)80244-5; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	53	15	16	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					1625	1635		10.1096/fj.04-1554com	http://dx.doi.org/10.1096/fj.04-1554com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522908				2022-12-25	WOS:000225482100031
J	Matarrese, P; Tinari, A; Mormone, E; Bianco, GA; Toscano, MA; Ascione, B; Rabinovich, GA; Malorni, W				Matarrese, P; Tinari, A; Mormone, E; Bianco, GA; Toscano, MA; Ascione, B; Rabinovich, GA; Malorni, W			Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; RECOMBINANT GALECTIN-1; SURFACE GLYCOSYLATION; EXTRACELLULAR-MATRIX; CASPASE ACTIVATION; EXPRESSION; PROTEINS; CD95; MACROPHAGES; HOMEOSTASIS	Galectins have emerged as a novel family of immunoregulatory proteins implicated in T cell homeostasis. Recent studies showed that galectin-1 (Gal-1) plays a key role in tumor-immune escape by killing antitumor effector T cells. Here we found that Gal-1 sensitizes human resting T cells to Fas (CD95)/caspase-8-mediated cell death. Furthermore, this protein triggers an apoptotic program involving an increase of mitochondrial membrane potential and participation of the ceramide pathway. In addition, Gal-1 induces mitochondrial coalescence, budding, and fission accompanied by an increase and/or redistribution of fission-associated molecules h-Fis and DRP-1. Importantly, these changes are detected in both resting and activated human T cells, suggesting that Gal-1-induced cell death might become an excellent model to analyze the morphogenetic changes of mitochondria during the execution of cell death. This is the first association among Gal-1, Fas/Fas ligand-mediated cell death, and the mitochondrial pathway, providing a rational basis for the immunoregulatory properties of Gal-1 in experimental models of chronic inflammation and cancer.	Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, I-00161 Rome, Italy; Ist Super Sanita, Dept Technol & Hlth, I-00161 Rome, Italy; Univ Buenos Aires, Hosp Clin Jose San Martin, Fac Med, Immunogenet Lab, Buenos Aires C1120, DF, Argentina	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); University of Buenos Aires; Hospital de Clinicas Jose de San Martin	Malorni, W (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, Viale Regina Elena 299, I-00161 Rome, Italy.	malorni@iss.it	Mormone, Elisabetta/AAB-1736-2021; TINARI, ANTONELLA/F-2109-2015; Malorni, Walter/G-5874-2016; Toscano, Marta/HGU-4103-2022; Matarrese, Paola/A-4369-2014	malorni, walter/0000-0002-1223-7000; Toscano, Marta/0000-0003-0502-8929				Amano M, 2003, J BIOL CHEM, V278, P7469, DOI 10.1074/jbc.M209595200; Banki K, 1999, J IMMUNOL, V162, P1466; Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chung CD, 2000, J IMMUNOL, V165, P3722, DOI 10.4049/jimmunol.165.7.3722; Conti L, 1998, J EXP MED, V187, P403, DOI 10.1084/jem.187.3.403; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Fukumori T, 2004, CANCER RES, V64, P3376, DOI 10.1158/0008-5472.CAN-04-0336; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; Giovannini C, 2002, FEBS LETT, V523, P200, DOI 10.1016/S0014-5793(02)02972-1; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hahn HP, 2004, CELL DEATH DIFFER, V11, P1277, DOI 10.1038/sj.cdd.4401485; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; Hildeman DA, 2004, FREE RADICAL BIO MED, V36, P1496, DOI 10.1016/j.freeradbiomed.2004.03.023; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kashio Y, 2003, J IMMUNOL, V170, P3631, DOI 10.4049/jimmunol.170.7.3631; Krueger A, 2003, IMMUNOL REV, V193, P58, DOI 10.1034/j.1600-065X.2003.00047.x; Lanteri M, 2003, GLYCOBIOLOGY, V13, P909, DOI 10.1093/glycob/cwg110; Lenardo MJ, 2003, IMMUNOL RES, V27, P387, DOI 10.1385/IR:27:2-3:387; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Matarrese P, 2000, FEBS LETT, V473, P311, DOI 10.1016/S0014-5793(00)01547-7; Matarrese P, 2003, CELL DEATH DIFFER, V10, P609, DOI 10.1038/sj.cdd.4401212; Matarrese P, 2003, J IMMUNOL, V170, P6006, DOI 10.4049/jimmunol.170.12.6006; Mattson MP, 2003, BIOCHEM BIOPH RES CO, V304, P539, DOI 10.1016/S0006-291X(03)00627-2; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Nagy G, 2003, J IMMUNOL, V171, P5188, DOI 10.4049/jimmunol.171.10.5188; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Rabinovich GA, 2002, CELL DEATH DIFFER, V9, P661, DOI 10.1038/sj.cdd.4401009; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; Rabinovich GA, 1998, J IMMUNOL, V160, P4831; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Rabinovich GA, 1999, IMMUNOLOGY, V97, P100; Rappl G, 2002, LEUKEMIA, V16, P840, DOI 10.1038/sj.leu.2402438; Roberts AA, 2003, MODERN PATHOL, V16, P543, DOI 10.1097/01.MP.0000071840.84469.06; Roberts AI, 2003, IMMUNOL RES, V28, P285, DOI 10.1385/IR:28:3:285; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Santucci L, 2003, GASTROENTEROLOGY, V124, P1381, DOI 10.1016/S0016-5085(03)00267-1; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Sturm A, 2004, J IMMUNOL, V173, P3825, DOI 10.4049/jimmunol.173.6.3825; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Zuniga E, 2001, INFECT IMMUN, V69, P6804, DOI 10.1128/IAI.69.11.6804-6812.2001	52	135	140	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6969	6985		10.1074/jbc.M409752200	http://dx.doi.org/10.1074/jbc.M409752200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15556941	Green Published, hybrid			2022-12-25	WOS:000227332700087
J	de Leon, MB; Montanez, C; Gomez, P; Morales-Lazaro, SL; Tapia-Ramirez, V; Valadez-Graham, V; Recillas-Targa, F; Yaffe, D; Nudel, U; Cisneros, B				de Leon, MB; Montanez, C; Gomez, P; Morales-Lazaro, SL; Tapia-Ramirez, V; Valadez-Graham, V; Recillas-Targa, F; Yaffe, D; Nudel, U; Cisneros, B			Dystrophin Dp71 expression is down-regulated during myogenesis - Role of Sp1 and Sp3 on the Dp71 promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCULAR-DYSTROPHY; TRANSCRIPTIONAL REGULATION; MUSCLE-CELLS; SP-FAMILY; FUNCTIONAL-ANALYSIS; NONMUSCLE TISSUES; BRAIN DYSTROPHIN; SKELETAL-MUSCLE; EXOGENOUS DP71; RETINOIC ACID	Dp71 expression is present in myoblasts but declines during myogenesis to avoid interfering with the function of dystrophin, the predominant Duchenne muscular dystrophy gene product in differentiated muscle fibers. To elucidate the transcriptional regulatory mechanisms operating on the developmentally regulated expression of Dp71, we analyzed the Dp71 expression and promoter activity during myogenesis of the C2C12 cells. We demonstrated that the cellular content of Dp71 transcript and protein decrease in myotubes as a consequence of the negative regulation that the differentiation stimulus exerts on the Dp71 promoter. Promoter deletion analysis showed that the 224-bp 5'-flanking region, which contains several Sp-binding sites (Sp-A to Sp-D), is responsible for the Dp71. promoter basal activity in myoblasts as well as for down-regulation of the promoter in differentiated cells. Electrophoretic mobility shift and chromatin immunoprecipitation assays indicated that Sp1 and Sp3 transcription factors specifically bind to the Sp-binding sites in the minimal Dp71 promoter region. Site-directed mutagenesis assay revealed that Sp-A is the most important binding site for the proximal Dp71 promoter activity. Additionally, cotransfection of the promoter construct with Sp1- and Sp3-expressing vectors into Drosophila SL2 cells, which lack endogenous Sp family, confirmed that these proteins activate specifically the minimal Dp71. promoter. Endogenous Sp1 and Sp3 proteins were detected only in myoblasts and not in myotubes, which indicates that the lack of these factors causes downregulation of the Dp71. promoter activity in differentiated cells. In corroboration, efficient promoter activity was restored in differentiated muscle cells by exogenous expression of Sp1 and Sp3.	Ctr Invest & Estudios Avanzados, IPN, Dept Genet & Mol Biol, Mexico City 07360, DF, Mexico; Univ Nacl Autonoma Mexico, Dept Mol Genet, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Universidad Nacional Autonoma de Mexico; Weizmann Institute of Science	Cisneros, B (corresponding author), Av IPN 2508, Mexico City 07360, DF, Mexico.	bcisnero@mail.einvestav.mx	de Leon, Mario Bermudez/AAF-9125-2020; Morales-Lázaro, Sara Luz/B-7333-2016	Valadez, Viviana/0000-0002-2556-7375; Bermudez de Leon, Mario/0000-0002-0993-2969				Acosta R, 2004, EXP CELL RES, V296, P265, DOI 10.1016/j.yexcr.2004.01.015; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BAR S, 1990, BIOCHEM J, V272, P557, DOI 10.1042/bj2720557; BARNEA E, 1990, NEURON, V5, P881, DOI 10.1016/0896-6273(90)90348-J; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; BYERS TJ, 1993, NAT GENET, V4, P77, DOI 10.1038/ng0593-77; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Dennis CL, 1996, NUCLEIC ACIDS RES, V24, P1646, DOI 10.1093/nar/24.9.1646; Drab M, 1997, FASEB J, V11, P905, DOI 10.1096/fasebj.11.11.9285489; DSOUZA VN, 1995, HUM MOL GENET, V4, P837, DOI 10.1093/hmg/4.5.837; Fandos C, 1999, J MOL BIOL, V294, P103, DOI 10.1006/jmbi.1999.3216; Galvagni F, 1998, J BIOL CHEM, V273, P33708, DOI 10.1074/jbc.273.50.33708; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; GREENBERG DS, 1994, NAT GENET, V8, P340, DOI 10.1038/ng1294-340; Howard PL, 1999, MUSCLE NERVE, V22, P16, DOI 10.1002/(SICI)1097-4598(199901)22:1<16::AID-MUS5>3.0.CO;2-R; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAMBERT M, 1993, NEUROMUSCULAR DISORD, V3, P519, DOI 10.1016/0960-8966(93)90108-V; LEDERFEIN D, 1993, HUM MOL GENET, V2, P1883, DOI 10.1093/hmg/2.11.1883; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; Leibovitz S, 2002, NEUROMUSCULAR DISORD, V12, P836, DOI 10.1016/S0960-8966(02)00141-4; LEV AA, 1987, J BIOL CHEM, V262, P15817; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LIDOV HGW, 1995, HUM MOL GENET, V4, P329, DOI 10.1093/hmg/4.3.329; Liu AG, 2004, J BIOL CHEM, V279, P17449, DOI 10.1074/jbc.M311267200; Loh NY, 2000, J CELL SCI, V113, P2715; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; Mehler MF, 2000, BRAIN RES REV, V32, P277, DOI 10.1016/S0165-0173(99)00090-9; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; RAPAPORT D, 1992, DIFFERENTIATION, V49, P187, DOI 10.1111/j.1432-0436.1992.tb00666.x; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Saito T, 2001, J BIOL CHEM, V276, P38010; SCHOFIELD JN, 1994, HUM MOL GENET, V3, P1309; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tennyson CN, 1996, HUM MOL GENET, V5, P1559, DOI 10.1093/hmg/5.10.1559; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; USUKI F, 1995, BIOCHEM BIOPH RES CO, V210, P654, DOI 10.1006/bbrc.1995.1710; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zhao JQ, 2003, FEBS LETT, V536, P111, DOI 10.1016/S0014-5793(03)00038-3	52	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5290	5299		10.1074/jbc.M411571200	http://dx.doi.org/10.1074/jbc.M411571200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15550398	hybrid			2022-12-25	WOS:000227217100024
J	Lee, I; Salomon, AR; Ficarro, S; Mathes, I; Lottspeich, F; Grossman, LI; Huttemann, M				Lee, I; Salomon, AR; Ficarro, S; Mathes, I; Lottspeich, F; Grossman, LI; Huttemann, M			cAMP-dependent tyrosine phosphorylation of subunit I inhibits cytochrome c oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ROS FORMATION; BOVINE HEART; RAT-LIVER; MITOCHONDRIA; LOCALIZATION; BINDING; ATP; RESPIRATION; DEFINITION	Signaling pathways targeting mitochondria are poorly understood. We here examine phosphorylation by the cAMP-dependent pathway of subunits of cytochrome c oxidase (COX), the terminal enzyme of the electron transport chain. Using anti-phospho antibodies, we show that cow liver COX subunit I is tyrosine-phosphorylated in the presence of theophylline, a phosphodiesterase inhibitor that creates high cAMP levels, but not in its absence. The site of phosphorylation, identified by mass spectrometry, is tyrosine 304 of COX catalytic subunit I. Subunit I phosphorylation leads to a decrease of V-max and an increase of K-m for cytochrome c and shifts the reaction kinetics from hyperbolic to sigmoidal such that COX is fully or strongly inhibited up to 10 muM cytochrome c substrate concentrations, even in the presence of allosteric activator ADP. To assess our findings with the isolated enzyme in a physiological context, we tested the starvation signal glucagon on human HepG2 cells and cow liver tissue. Glucagon leads to COX inactivation, an effect also observed after incubation with adenylyl cyclase activator forskolin. Thus, the glucagon receptor/G-protein/cAMP pathway regulates COX activity. At therapeutic concentrations used for asthma relief, theophylline causes lung COX inhibition and decreases cellular ATP levels, suggesting a mechanism for its clinical action.	Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Wayne State University; Novartis; Max Planck Society	Huttemann, M (corresponding author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, 540 E Canfield Ave, Detroit, MI 48201 USA.	mhuttema@med.wayne.edu		Huttemann, Maik/0000-0001-6310-7081				Acin-Perez R, 2003, HUM MOL GENET, V12, P329, DOI 10.1093/hmg/ddg021; Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Arnold S, 1998, EUR J BIOCHEM, V252, P325, DOI 10.1046/j.1432-1327.1998.2520325.x; Arnold S, 1999, FEBS LETT, V443, P105, DOI 10.1016/S0014-5793(98)01694-9; Arnold S, 1997, EUR J BIOCHEM, V249, P350, DOI 10.1111/j.1432-1033.1997.t01-1-00350.x; Bender E, 2000, FEBS LETT, V466, P130, DOI 10.1016/S0014-5793(99)01773-1; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BRAND MD, 1990, ARCH BIOCHEM BIOPHYS, V283, P278, DOI 10.1016/0003-9861(90)90643-D; BURGESS JW, 1987, BIOCHEM CELL BIOL, V65, P137, DOI 10.1139/o87-019; Cardone L, 2004, MOL CELL BIOL, V24, P4613, DOI 10.1128/MCB.24.11.4613-4626.2004; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Chen RM, 2004, J BIOL CHEM, V279, P26036, DOI 10.1074/jbc.M402710200; Corso M, 2001, PLACENTA, V22, P432, DOI 10.1053/plac.2001.0672; Dal Piaz V, 2000, EUR J MED CHEM, V35, P463, DOI 10.1016/S0223-5234(00)00179-3; DIMINO MJ, 1981, J BIOL CHEM, V256, P876; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; Frank V, 1996, FEBS LETT, V382, P121, DOI 10.1016/0014-5793(96)00096-8; GARBER EAE, 1990, BIOCHIM BIOPHYS ACTA, V1015, P279, DOI 10.1016/0005-2728(90)90032-Y; GOMPERTS BD, 2003, SIGNAL TRANSDUCTION; Griffioen G, 2002, CURR GENET, V41, P199, DOI 10.1007/s00294-002-0308-9; Grossman LI, 1997, BBA-GENE STRUCT EXPR, V1352, P174, DOI 10.1016/S0167-4781(97)00025-0; Huttemann M, 2003, MOL REPROD DEV, V66, P8, DOI 10.1002/mrd.10327; Huttemann M, 2003, GENE, V312, P95, DOI 10.1016/S0378-1119(03)00604-8; Huttemann M, 2001, GENE, V267, P111, DOI 10.1016/S0378-1119(01)00385-7; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kadenbach B, 2004, BBA-BIOENERGETICS, V1655, P400, DOI 10.1016/j.bbabio.2003.06.005; KADENBACH B, 1986, METHOD ENZYMOL, V126, P32; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KLEITKE B, 1976, ACTA BIOL MED GER, V35, pK9; Kondrashin AA, 1998, BIOCHEM MOL BIOL INT, V45, P237; Lee I, 2001, BIOL CHEM, V382, P1629, DOI 10.1515/BC.2001.198; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; Lee I, 2001, EUR J BIOCHEM, V268, P6329, DOI 10.1046/j.0014-2956.2001.02602.x; Licklider LJ, 2002, ANAL CHEM, V74, P3076, DOI 10.1021/ac025529o; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098; MULLER G, 1987, YEAST, V3, P161, DOI 10.1002/yea.320030304; Napiwotzki J, 1997, BIOL CHEM, V378, P1013, DOI 10.1515/bchm.1997.378.9.1013; OSHEROFF N, 1983, J BIOL CHEM, V258, P5731; PARISET C, 1994, MOL REPROD DEV, V39, P415, DOI 10.1002/mrd.1080390410; POHL SL, 1971, J BIOL CHEM, V246, P1849; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SPECK SH, 1984, P NATL ACAD SCI-BIOL, V81, P347, DOI 10.1073/pnas.81.2.347; Steenaart NAE, 1997, FEBS LETT, V415, P294, DOI 10.1016/S0014-5793(97)01145-9; SUAREZ MD, 1984, J BIOL CHEM, V259, P3791; Technikova-Dobrova Z, 2001, BIOCHEMISTRY-US, V40, P13941, DOI 10.1021/bi011066p; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Tsukihara T, 2003, P NATL ACAD SCI USA, V100, P15304, DOI 10.1073/pnas.2635097100; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; VONJAGOW G, 1972, FEBS LETT, V24, P278, DOI 10.1016/0014-5793(72)80372-7; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200	55	175	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6094	6100		10.1074/jbc.M411335200	http://dx.doi.org/10.1074/jbc.M411335200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15557277	hybrid			2022-12-25	WOS:000227217100116
J	Emerson, DK; McCormick, ML; Schmidt, JA; Knudson, CM				Emerson, DK; McCormick, ML; Schmidt, JA; Knudson, CM			Taurine monochloramine activates a cell death pathway involving Bax and caspase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORAMINE INHIBITS PRODUCTION; BCL-2 FAMILY-MEMBERS; HYPOCHLOROUS ACID; GENE-EXPRESSION; ALVEOLAR MACROPHAGES; BH3-ONLY PROTEINS; INDUCED APOPTOSIS; NITRIC-OXIDE; TNF-ALPHA; X-L	Taurine is an abundant free amino acid that interacts with the potent oxidant hypochlorous acid to form the less toxic and more stable oxidant taurine monochloramine (TauNHCl). TauNHCl has diverse cellular effects ranging from inhibiting the production of proinflammatory mediators to inhibiting cell proliferation and inducing cell death. We hypothesized that TauNHCl could activate a cell death pathway involving Bcl-2 members and the activation of caspase proteases. FL5.12 cells are lymphocytic cells that undergo apoptosis following interleukin-3 (IL-3) withdrawal. Therefore, cell death following TauNHCl treatment of FL5.12 cells was compared and contrasted with IL-3 withdrawal. We found that TauNHCI treatment activates a cell death pathway with kinetics very similar to IL-3 withdrawal. TauNHCl-treated cells undergo an annexin V-positive/propidium iodide-negative phase of death consistent with apoptosis. TauNHCl treatment results in a conformational change in BAX that is associated with its activation. Both Bcl-2 and, to a lesser degree, the dominant negative form of caspase-9 inhibit cell death following TauNHCI treatment. In contrast with IL-3 withdrawal, TauNHCI treatment of FL5.12 cells results in a rapid cell cycle arrest that is cell cycle phase-independent. These results demonstrate that TauNHCI treatment induces a rapid, cell cycle-independent proliferative arrest followed by the activation of a cell death pathway involving Bcl-2 family members and caspase activation.	Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Med Interne, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille P Carver Coll Med, Mol Biol Grad Program, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille P Carver Coll Med, Grad Program Immunol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa	Knudson, CM (corresponding author), Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, 200 Hawkins Dr,1169 ML, Iowa City, IA 52242 USA.	c-knudson@uiowa.edu		Knudson, Charles Michael/0000-0003-3964-5466				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Barua M, 2001, J IMMUNOL, V167, P2275, DOI 10.4049/jimmunol.167.4.2275; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cheng NL, 2004, ONCOGENE, V23, P3770, DOI 10.1038/sj.onc.1207478; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; Englert RP, 2002, J BIOL CHEM, V277, P20518, DOI 10.1074/jbc.M200212200; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; FUKUDA K, 1982, CLIN CHEM, V28, P1758; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kanayama A, 2002, J BIOL CHEM, V277, P24049, DOI 10.1074/jbc.M110832200; Knudson CM, 2001, CANCER RES, V61, P659; Krishan A, 1990, Methods Cell Biol, V33, P121; Luke JJ, 2003, CELL DEATH DIFFER, V10, P740, DOI 10.1038/sj.cdd.4401233; MacCarthy-Morrogh L, 1999, BIOCHEM SOC T, V27, P785, DOI 10.1042/bst0270785; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; PARK E, 1995, J IMMUNOL, V154, P4778; Park E, 2002, CLIN IMMUNOL, V102, P179, DOI 10.1006/clim.2001.5160; Park E, 1998, ADV EXP MED BIOL, V442, P177; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Quinn MR, 2003, ADV EXP MED BIOL, V526, P341; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Schmitt CA, 2002, J MOL MED-JMM, V80, P137, DOI 10.1007/s00109-001-0293-3; Schuller-Levis GB, 2004, NEUROCHEM RES, V29, P117, DOI 10.1023/B:NERE.0000010440.37629.17; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Wagner BA, 2002, ARCH BIOCHEM BIOPHYS, V401, P223, DOI 10.1016/S0003-9861(02)00053-X; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	47	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3233	3241		10.1074/jbc.M411672200	http://dx.doi.org/10.1074/jbc.M411672200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15545281	hybrid			2022-12-25	WOS:000226983900015
J	Mitchell, C; Nivison, M; Jackson, LF; Fox, R; Lee, DC; Campbell, JS; Fausto, N				Mitchell, C; Nivison, M; Jackson, LF; Fox, R; Lee, DC; Campbell, JS; Fausto, N			Heparin-binding epidermal growth factor-like growth factor links hepatocyte priming with cell cycle progression during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PARTIAL-HEPATECTOMY; FACTOR-ALPHA; DEOXYRIBONUCLEIC ACID; DNA-REPLICATION; TRANSGENIC MICE; MESSENGER-RNA; IN-VIVO; C-JUN; EXPRESSION	The mechanisms that regulate the transition between the initial priming phase and DNA replication in liver regeneration are poorly understood. To study this transition, we compared events occurring after standard two-thirds partial hepatectomy, which elicits full regeneration, with response to a reduced hepatectomy, one-third partial hepatectomy (1/3PH), which leads to little DNA replication. Although the initial response to partial hepatectomy at the priming phase appeared to be similar between the two procedures, cell cycle progression was significantly blunted in 1/3PH mice. Among the main defects observed in 1/3PH mice were an almost complete deficiency in retinoblastoma phosphorylation and the lack of increase in kinase activity associated with cyclin E. We report that, in two-thirds partial hepatectomy mice, the expression of heparin-binding epidermal growth factor-like growth factor (HB-EGF) preceded the start of DNA replication and was not detectable in 1/3PH animals. Injection of HB-EGF into 1/3PH mice resulted in a >15-fold increase in DNA replication. Moreover, we show that hepatocyte DNA replication was delayed in HB-EGF knock-out mice. In summary, we show that HB-EGF is a key factor for hepatocyte progression through G(1)/S transition during liver regeneration.	Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Fausto, N (corresponding author), Univ Washington, Sch Med, Dept Pathol, K-078 HSB,Box 357705, Seattle, WA 98195 USA.	nfausto@u.washington.edu		Campbell, Jean/0000-0002-9187-2204	NATIONAL CANCER INSTITUTE [R01CA043793, R01CA023226, R37CA023226] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23226, CA-43793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCORN JA, 1990, HEPATOLOGY, V11, P909, DOI 10.1002/hep.1840110602; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; BUCHER NLR, 1964, CANCER RES, V24, P1611; Costa RH, 2003, HEPATOLOGY, V38, P1331, DOI 10.1016/j.hep.2003.09.034; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; GRISHAM JW, 1962, CANCER RES, V22, P842; Higgins GM, 1931, ARCH PATHOL, V12, P186; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; Kiso S, 2003, GASTROENTEROLOGY, V124, P701, DOI 10.1053/gast.2003.50097; KISO S, 1995, HEPATOLOGY, V22, P1584, DOI 10.1016/0270-9139(95)90168-X; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; Nelsen CJ, 2001, CANCER RES, V61, P8564; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; Russell WE, 1996, MOL CARCINOGEN, V15, P183; Scotte M, 1997, LIVER, V17, P171; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; THOMPSON NL, 1986, CANCER RES, V46, P3111; Vail ME, 2002, ONCOGENE, V21, P1548, DOI 10.1038/sj.onc.1205212; WEBBER EM, 1994, HEPATOLOGY, V19, P489; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Yamada A, 1998, BIOCHEM BIOPH RES CO, V246, P783, DOI 10.1006/bbrc.1998.8703; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yusuf A, 1999, CARCINOGENESIS, V20, P1143, DOI 10.1093/carcin/20.6.1143; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K	28	110	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2562	2568		10.1074/jbc.M412372200	http://dx.doi.org/10.1074/jbc.M412372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15536070	Green Published, hybrid			2022-12-25	WOS:000226449100024
J	Kruth, HS; Jones, NL; Huang, W; Zhao, B; Ishii, I; Chang, J; Combs, CA; Malide, D; Zhang, WY				Kruth, HS; Jones, NL; Huang, W; Zhao, B; Ishii, I; Chang, J; Combs, CA; Malide, D; Zhang, WY			Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOGENOUS SOLUBLE-ANTIGEN; DENDRITIC CELLS; GROWTH-FACTOR; CONSTITUTIVE MACROPINOCYTOSIS; MANNOSE RECEPTOR; MEMBRANE RUFFLES; CHOLESTEROL; ATHEROSCLEROSIS; LYSOSOMES; TRANSPORT	Previously, we reported that fluid-phase endocytosis of native LDL by PMA-activated human monocyte-derived macrophages converted these macrophages into cholesterol-enriched foam cells (Kruth, H. S., Huang, W., Ishii, I., and Zhang, W. Y. ( 2002) J. Biol. Chem. 277, 34573 - 34580). Uptake of fluid by cells can occur either by micropinocytosis within vesicles (<0.1 mu m diameter) or by macropinocytosis within vacuoles (similar to 0.5 - 5.0 mu m) named macropinosomes. The current investigation has identified macropinocytosis as the pathway for fluid-phase LDL endocytosis and determined signaling and cytoskeletal components involved in this LDL endocytosis. The phosphatidylinositol 3-kinase inhibitor, LY294002, which inhibits macropinocytosis but does not inhibit micropinocytosis, completely blocked PMA- activated macrophage uptake of fluid and LDL. Also, nystatin and filipin, inhibitors of micropinocytosis from lipid-raft plasma membrane domains, both failed to inhibit PMA- stimulated macrophage cholesterol accumulation. Time-lapse video phase-contrast microscopy and time-lapse digital confocal-fluorescence microscopy with fluorescent DiI-LDL showed that PMA- activated macrophages took up LDL in the fluid phase by macropinocytosis. Macropinocytosis of LDL depended on Rho GTPase signaling, actin, and microtubules. Bafilomycin A1, the vacuolar H+-ATPase inhibitor, inhibited degradation of LDL and caused accumulation of undegraded LDL within macropinosomes and multivesicular body endosomes. LDL in multivesicular body endosomes was concentrated > 40-fold over its concentration in the culture medium consistent with macropinosome shrinkage by maturation into multivesicular body endosomes. Macropinocytosis of LDL taken up in the fluid phase without receptor-mediated binding of LDL is a novel endocytic pathway that generates macrophage foam cells. Macropinocytosis in macrophages and possibly other vascular cells is a new pathway to target for modulating foam cell formation in atherosclerosis.	NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; NHLBI, Light Microscopy Core Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kruth, HS (corresponding author), NHLBI, Sect Expt Atherosclerosis, NIH, Bldg 10,Rm 5N-113,10 Ctr Dr MSC 1422, Bethesda, MD 20892 USA.	kruthh@nhlbi.nih.gov	Huang, Wei/E-3270-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002832, R01HL041990] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41990] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; Amyere M, 2002, INT J MED MICROBIOL, V291, P487; Araki N, 2003, J CELL SCI, V116, P247, DOI 10.1242/jcs.00235; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bayer N, 1998, J VIROL, V72, P9645, DOI 10.1128/JVI.72.12.9645-9655.1998; Bobryshev YV, 2000, CURR OPIN LIPIDOL, V11, P511, DOI 10.1097/00041433-200010000-00009; DOWRICK P, 1993, EUR J CELL BIOL, V61, P44; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Fiorentini C, 2001, MOL BIOL CELL, V12, P2061, DOI 10.1091/mbc.12.7.2061; FOLCH J, 1957, J BIOL CHEM, V226, P497; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GAMBLE W, 1978, J LIPID RES, V19, P1068; Garcia-Perez BE, 2003, MICROB PATHOGENESIS, V35, P49, DOI 10.1016/S0882-4010(03)00089-5; Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; HASEGAWA T, 1993, J CELL BIOL, V120, P1439, DOI 10.1083/jcb.120.6.1439; HEWLETT LJ, 1994, J CELL BIOL, V124, P689, DOI 10.1083/jcb.124.5.689; HOFF HF, 1978, BIOCHEM BIOPH RES CO, V85, P1424, DOI 10.1016/0006-291X(78)91162-2; INOUE I, 1992, ATHEROSCLEROSIS, V93, P245, DOI 10.1016/0021-9150(92)90261-E; Jones NL, 1999, ANAT REC, V255, P57; Jones NL, 2000, ARTERIOSCL THROM VAS, V20, P773, DOI 10.1161/01.ATV.20.3.773; Kruth Howard S., 2001, Current Molecular Medicine (Hilversum), V1, P633, DOI 10.2174/1566524013363212; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; Kruth HS, 2002, J BIOL CHEM, V277, P34573, DOI 10.1074/jbc.M205059200; Kruth HS, 2001, FRONT BIOSCI-LANDMRK, V6, pD429, DOI 10.2741/Kruth; Kruth HS, 2001, J LIPID RES, V42, P1492; LANG T, 1985, BIOL CELL, V53, P149, DOI 10.1111/j.1768-322X.1985.tb00362.x; LESNIK P, 1992, P NATL ACAD SCI USA, V89, P10370, DOI 10.1073/pnas.89.21.10370; Libby P, 1997, CIRCULATION, V96, P4095; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMGREN L, 1977, J HISTOCHEM CYTOCHEM, V25, P1280, DOI 10.1177/25.11.915248; Maniak M, 2002, INT REV CYTOL, V221, P257; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Muhlestein Joseph B., 2003, Cardiology Clinics, V21, P333, DOI 10.1016/S0733-8651(03)00054-7; Murayama T, 1999, CIRCULATION, V99, P1740, DOI 10.1161/01.CIR.99.13.1740; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; Ory S, 2002, EUR J CELL BIOL, V81, P351, DOI 10.1078/0171-9335-00255; Ostap EM, 2003, CELL MOTIL CYTOSKEL, V54, P29, DOI 10.1002/cm.10081; Qualmann B, 2003, BIOCHEM J, V371, P233, DOI 10.1042/bj20030139; RACOOSIN EL, 1993, J CELL BIOL, V121, P1011, DOI 10.1083/jcb.121.5.1011; RACOOSIN EL, 1992, J CELL SCI, V102, P867; RACOOSIN EL, 1989, J EXP MED, V170, P1635, DOI 10.1084/jem.170.5.1635; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROUIS M, 1990, ARTERIOSCLEROSIS, V10, P246, DOI 10.1161/01.ATV.10.2.246; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sansonetti PJ, 2001, AM J PHYSIOL-GASTR L, V280, pG319, DOI 10.1152/ajpgi.2001.280.3.G319; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; SMITH EB, 1983, BIOCHIM BIOPHYS ACTA, V754, P249, DOI 10.1016/0005-2760(83)90139-X; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STAHL PD, 2002, SCI STKE 2002; Sun P, 2003, J BIOL CHEM, V278, P4063, DOI 10.1074/jbc.M208699200; SWANSON JA, 1989, J CELL SCI, V94, P135; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Titus MA, 2000, J EUKARYOT MICROBIOL, V47, P191, DOI 10.1111/j.1550-7408.2000.tb00038.x; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Watarai M, 2002, CELL MICROBIOL, V4, P341, DOI 10.1046/j.1462-5822.2002.00195.x; Watarai M, 2001, J EXP MED, V194, P1081, DOI 10.1084/jem.194.8.1081; West MA, 2000, CURR BIOL, V10, P839, DOI 10.1016/S0960-9822(00)00595-9; WILLS EJ, 1972, NATURE-NEW BIOL, V240, P58, DOI 10.1038/newbio240058a0; Zhang Q, 1999, MOL CELL BIOL, V19, P8158	72	202	210	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2352	2360		10.1074/jbc.M407167200	http://dx.doi.org/10.1074/jbc.M407167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15533943	hybrid			2022-12-25	WOS:000226341700072
J	Zamora-Leon, SP; Bresnick, A; Backer, JM; Shafit-Zagardo, B				Zamora-Leon, SP; Bresnick, A; Backer, JM; Shafit-Zagardo, B			Fyn phosphorylates human MAP-2c on tyrosine 67	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; HIGH-MOLECULAR-WEIGHT; RECEPTOR KINASE; SH2 DOMAIN; SUBCELLULAR-LOCALIZATION; BRAIN-DEVELOPMENT; RAS ACTIVATION; GRB2; MAP2; BINDING	The Src homology 3 (SH3) domain of Fyn binds to a conserved PXXP motif on microtubule-associated protein-2. Co-transfections into COS7 cells and in vitro kinase assays performed with Fyn and wild-type, or mutant MAP-2c, determined that Fyn phosphorylated MAP-2c on tyrosine 67. The phosphorylation generated a consensus sequence for the binding of the SH2 domain of Grb2 (pYSN). Pull-down assays with SH2-Grb2 from human fetal brain homogenates, and co-immunoprecipitation of Grb2 and MAP-2 confirmed the interaction in vivo, and demonstrated that MAP-2c is tyrosine-phosphorylated in human fetal brain. Filter overlay assays confirmed that the SH2 domain of Grb2 binds to human MAP-2c following incubation with active Fyn. Enzyme-linked immunosorbent assays confirmed the interaction between the SH2 domain of Grb2 and a tyrosine-phosphorylated MAP-2 peptide spanning the pY(67)SN motif. Thus, MAP-2c can directly recruit multiple signaling proteins important for central nervous system development.	Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Shafit-Zagardo, B (corresponding author), Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA.	zagardo@aecom.yu.edu	-León, S. Pilar Zamora/AAL-8512-2020	-León, S. Pilar Zamora/0000-0002-4738-9768	NIGMS NIH HHS [GM55692] Funding Source: Medline; NINDS NIH HHS [NS38102] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038102] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBALA JS, 1995, J NEUROCHEM, V64, P2480; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARE DJ, 1993, ONCOGENE, V8, P1429; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; Chung WJ, 1996, J NEUROCHEM, V66, P1273; DOLL T, 1993, J CELL SCI, V106, P633; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; GREER K, 1989, CELL MOVEMENT, V2, P47; GUILLEMINOT J, 1995, CR ACAD SCI III-VIE, V318, P959; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; KADOWAKI T, 1985, J BIOL CHEM, V260, P4016; KALCHEVA N, 1995, P NATL ACAD SCI USA, V92, P10894, DOI 10.1073/pnas.92.24.10894; Kalcheva N, 1998, CELL MOTIL CYTOSKEL, V40, P272, DOI 10.1002/(SICI)1097-0169(1998)40:3<272::AID-CM6>3.0.CO;2-F; KALCHEVA N, 1995, J NEUROCHEM, V65, P1472; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee G, 1998, J CELL SCI, V111, P3167; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; Lim RWL, 2000, J BIOL CHEM, V275, P20578, DOI 10.1074/jbc.M001887200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MarieCardine A, 1995, EUR J IMMUNOL, V25, P3290, DOI 10.1002/eji.1830251214; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; NISHIDA E, 1987, J BIOL CHEM, V262, P16200; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; Ogura K, 1999, J MOL BIOL, V289, P439, DOI 10.1006/jmbi.1999.2792; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; SCHULZE E, 1987, J CELL BIOL, V104, P277, DOI 10.1083/jcb.104.2.277; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shafit-Zagardo B, 2000, GLIA, V29, P233, DOI 10.1002/(SICI)1098-1136(20000201)29:3<233::AID-GLIA5>3.0.CO;2-U; Shafit-Zagardo B, 1998, MOL NEUROBIOL, V16, P149, DOI 10.1007/BF02740642; ShafitZagardo B, 1997, J NEUROCHEM, V68, P862; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SU J, 1994, J BIOL CHEM, V269, P18731; TOBE K, 1993, J BIOL CHEM, V268, P11167; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; TUCKER RP, 1988, J NEUROSCI, V8, P4503; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VIERECK C, 1989, J NEUROSCI, V9, P3547; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Wolf RM, 2001, J NEUROBIOL, V49, P62, DOI 10.1002/neu.1066; Zamora-Leon SP, 2001, J BIOL CHEM, V276, P39950, DOI 10.1074/jbc.M107807200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1962	1970		10.1074/jbc.M411380200	http://dx.doi.org/10.1074/jbc.M411380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15536091	hybrid			2022-12-25	WOS:000226341700030
J	Zhang, P; Ostrander, JH; Faivre, EJ; Olsen, A; Fitzsimmons, D; Lange, CA				Zhang, P; Ostrander, JH; Faivre, EJ; Olsen, A; Fitzsimmons, D; Lange, CA			Regulated association of protein kinase B/Akt with breast tumor kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; EPIDERMAL-GROWTH-FACTOR; GASTROINTESTINAL-TRACT; THERAPEUTIC TARGET; DISTINCT FAMILY; AKT ACTIVATION; CANCER-CELLS; BRK; PHOSPHORYLATION	Increased protein-tyrosine kinase activity is a prognostic indicator of decreased disease-free survival in patients with advanced breast tumors. Breast tumor kinase (Brk) is a soluble protein-tyrosine kinase overexpressed in the majority of breast cancers and also in normal skin and gut epithelium, but not in normal breast epithelial cells. Herein, we show that Brk interacts with protein kinase B/Akt, a serine/threonine kinase involved in cell growth and survival. Epidermal growth factor (EGF) treatment of human keratinocytes or Brk-transfected COS-1 cells leads to the dissociation of the Brk.Akt complex, whereas a constitutively active Brk mutant containing a point mutation at Tyr-447 (YF-Brk) failed to dissociate from Akt upon EGF treatment. In addition, Brk.Akt dissociation was blocked by the inhibition of phosphatidylinositol 3-kinase. Similar to ectopic Brk, endogenous Brk in T47D breast cancer cells was less phosphorylated upon EGF treatment, but it remained constitutively associated with Akt in the presence of EGF. Overexpression of wild-type (wt)-Brk, kinase-inactive (KM)-Brk, or YF-Brk increased the Tyr phosphorylation of multiple signaling molecules including EGF receptor. However, only wt- and YF-Brk, but not KM-Brk, induced phosphorylation of Akt and inhibited the kinase activity of Akt in unstimulated cells. Similarly, overexpression of wt- or YF-, but not KM-Brk, blocked the phosphorylation of the forkhead transcription factor, a downstream Akt target. These results suggest that Brk may function as a signaling molecule whose kinase activity normally limits the activity of Akt in unstimulated cells. Additionally, these results suggest that in breast cancer cells Brk behaves similarly to a constitutively active Brk mutant ( YF- Brk) and associates with tyrosine-phosphorylated proteins in deregulated signaling complexes. Together these data provide clues to the possible proto-oncogenic and oncogenic functions of Brk.	Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Lange, CA (corresponding author), Univ Minnesota, Ctr Canc, 420 Delaware St SE,MMC 806, Minneapolis, MN 55455 USA.	Lange047@tc.umn.edu	Olsen, Abby/AAJ-7345-2021	Olsen, Abby L./0000-0002-7680-1758; Lange, Carol/0000-0003-2751-3976	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK058347] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21DK058347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bjorge JD, 1996, BIOCHEM CELL BIOL, V74, P477, DOI 10.1139/o96-052; Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Harvey AJ, 2004, ANTI-CANCER DRUG, V15, P107, DOI 10.1097/01.cad.0000113339.62364.b5; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; Hong EM, 2004, J BIOL CHEM, V279, P29700, DOI 10.1074/jbc.M313185200; HORWITZ KB, 1982, CELL, V28, P633, DOI 10.1016/0092-8674(82)90218-5; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee HY, 1998, MOL CELLS, V8, P401; Lin HS, 2004, ARCH OTOLARYNGOL, V130, P311, DOI 10.1001/archotol.130.3.311; Llor X, 1999, CLIN CANCER RES, V5, P1767; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mao ML, 2000, BIOCHEM J, V352, P475, DOI 10.1042/0264-6021:3520475; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Reddy TR, 2000, ONCOGENE, V19, P4071, DOI 10.1038/sj.onc.1203749; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schenborn E T, 2000, Methods Mol Biol, V130, P147; Serfas MS, 2003, ONCOL RES, V13, P409; TRAN H, 2003, SCI STKE; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Zhang Q, 1999, GENETICS, V151, P697	43	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1982	1991		10.1074/jbc.M412038200	http://dx.doi.org/10.1074/jbc.M412038200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15539407	hybrid			2022-12-25	WOS:000226341700032
J	Jobby, MK; Sharma, Y				Jobby, MK; Sharma, Y			Calcium-binding crystallins from Yersinia pestis - Characterization of two single beta gamma-crystallin domains of a putative exported protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; MYXOCOCCUS-XANTHUS; LENS CRYSTALLINS; GENOME SEQUENCE; PRECURSOR STRUCTURE; NMR STRUCTURE; SPHERULIN 3A; KILLER TOXIN; SUPERFAMILY; STABILITY	betagamma-Crystallin is a superfamily with diverse members from vertebrate lens to microbes. However, not many members have been identified and studied. Here, we report the identification of a putative exported protein from Yersinia pestis as a member of the betagamma-crystallin superfamily. Even though calcium has been known to play an important role in the physiology and virulence of the Yersinia genus, calcium-binding proteins have not yet been identified. We have studied the calcium-binding properties of two of the three crystallin domains present in this putative exported protein designated "Yersinia crystallin." These two domains (D1 and D2) have unique AA and BB types of arrangement of their Greek key motifs unlike the domains of other members of the betagamma-crystallin superfamily, which are either AB or BA types. These domains bind two calcium ions with low and high affinity-binding sites. We showed their calcium-binding properties using various probes for calcium and the effect of calcium on their secondary and tertiary structures. Although both domains bind calcium, D1 underwent drastic changes in secondary and tertiary structure and hydrodynamic volume upon calcium binding. Domain D1, which is intrinsically unstructured in the apo form, requires calcium for the typical betagamma-crystallin fold. Calcium exerted an extrinsic stabilization effect on domain D1 but not on D2, which is also largely unstructured. We suggest that this protein might be involved in calcium-dependent processes, such as stress response or physiology in the Yersinia genus, similar to its microbial relatives and mammalian lens crystallins.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Sharma, Y (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	yogendra@ccmb.res.in						Achtman M, 1999, P NATL ACAD SCI USA, V96, P14043, DOI 10.1073/pnas.96.24.14043; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; Antuch W, 1996, NAT STRUCT BIOL, V3, P662, DOI 10.1038/nsb0896-662; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BERNIER F, 1987, GENE, V59, P265, DOI 10.1016/0378-1119(87)90334-9; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Brzostek K, 2003, FEMS MICROBIOL LETT, V228, P265, DOI 10.1016/S0378-1097(03)00779-1; Clout NJ, 2001, STRUCTURE, V9, P115, DOI 10.1016/S0969-2126(01)00573-1; Deng W, 2002, J BACTERIOL, V184, P4601, DOI 10.1128/JB.184.16.4601-4611.2002; Drake SK, 1996, BIOCHEMISTRY-US, V35, P1753, DOI 10.1021/bi952335c; FOWLER JM, 1994, INFECT IMMUN, V62, P5234, DOI 10.1128/IAI.62.12.5234-5241.1994; Golubov A, 2003, FEMS IMMUNOL MED MIC, V38, P107, DOI 10.1016/S0928-8244(03)00182-2; Haddad A, 2002, EUKARYOT CELL, V1, P583, DOI 10.1128/EC.1.4.583-593.2002; HIGUCHI K, 1961, J BACTERIOL, V81, P605, DOI 10.1128/JB.81.4.605-608.1961; INOUYE M, 1979, P NATL ACAD SCI USA, V76, P209, DOI 10.1073/pnas.76.1.209; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kretschmar W, 1999, J MOL BIOL, V289, P701, DOI 10.1006/jmbi.1999.2833; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINSE S, 1991, J BIOL CHEM, V266, P8050; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEHIGH RJ, 1993, INFECT IMMUN, V61, P13, DOI 10.1128/IAI.61.1.13-22.1993; Ogawa M, 1998, DEV GROWTH DIFFER, V40, P465; Ohki S, 2001, J MOL BIOL, V305, P109, DOI 10.1006/jmbi.2000.4244; Ohno A, 1998, J MOL BIOL, V282, P421, DOI 10.1006/jmbi.1998.2022; Oyston PCF, 2000, INFECT IMMUN, V68, P3419, DOI 10.1128/IAI.68.6.3419-3425.2000; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; PEPE JC, 1994, MOL MICROBIOL, V11, P123, DOI 10.1111/j.1365-2958.1994.tb00295.x; PERROW C, 1997, ORG ENV, V10, P66, DOI DOI 10.1177/0921810697101009; PERRY RD, 1987, J BACTERIOL, V169, P4861, DOI 10.1128/jb.169.10.4861-4864.1987; Rajini B, 2003, BIOCHEMISTRY-US, V42, P4552, DOI 10.1021/bi027384l; Rajini B, 2001, J BIOL CHEM, V276, P38464, DOI 10.1074/jbc.M102164200; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Rosinke B, 1997, J MOL BIOL, V271, P645, DOI 10.1006/jmbi.1997.1184; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shivaji S, 2000, FEMS MICROBIOL LETT, V189, P247, DOI 10.1111/j.1574-6968.2000.tb09238.x; Song YJ, 2004, DNA RES, V11, P179, DOI 10.1093/dnares/11.3.179; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; TEINTZE M, 1988, J BIOL CHEM, V263, P1199; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; VENYAMINOV SY, 1994, ANAL BIOCHEM, V222, P176, DOI 10.1006/abio.1994.1470; Wenk M, 1999, J MOL BIOL, V286, P1533, DOI 10.1006/jmbi.1999.2582; Wenk M, 1998, EUR J BIOCHEM, V255, P604, DOI 10.1046/j.1432-1327.1998.2550604.x; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1985, NATURE, V315, P771, DOI 10.1038/315771a0; WISTOW G, 1995, EXP EYE RES, V61, P637, DOI 10.1016/S0014-4835(05)80058-2; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Yamamoto K, 1977, Nippon Ganka Gakkai Zasshi, V81, P472; ZAHORCHAK RJ, 1979, J BACTERIOL, V139, P792, DOI 10.1128/JB.139.3.792-799.1979	52	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1209	1216		10.1074/jbc.M409253200	http://dx.doi.org/10.1074/jbc.M409253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536081	hybrid			2022-12-25	WOS:000226195200043
J	Moon, KD; Post, CB; Dirdem, DL; Zhou, Q; De, P; Harrison, ML; Geahlen, RL				Moon, KD; Post, CB; Dirdem, DL; Zhou, Q; De, P; Harrison, ML; Geahlen, RL			Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; FC-GAMMA RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; LINKER REGION; B-CELLS; PROTOONCOGENE PRODUCT; PLATELET ACTIVATION; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT	After engagement of the B cell receptor for antigen, the Syk protein-tyrosine kinase becomes phosphorylated on multiple tyrosines, some of which serve as docking sites for downstream effectors with SH2 or other phosphotyrosine binding domains. The most frequently identified binding partner for catalytically active Syk identified in a yeast two-hybrid screen was the p85 regulatory subunit of phosphoinositide 3-kinase. The C-terminal SH2 domain of p85 was sufficient for mediating an interaction with tyrosine-phosphorylated Syk. Interestingly, this domain interacted with Syk at phosphotyrosine 317, a site phosphorylated in trans by the Src family kinase, Lyn, and identified previously as a binding site for c-Cbl. This site interacted preferentially with the p85 C-terminal SH2 domain compared with the c-Cbl tyrosine kinase binding domain. Molecular modeling studies showed a good fit between the p85 SH2 domain and a peptide containing phosphotyrosine 317. Tyr-317 was found to be essential for Syk to support phagocytosis mediated by FcgammaRIIA receptors expressed in a heterologous system. These studies establish a new type of p85 binding site that can exist on proteins that serve as substrates for Src family kinases and provide a molecular explanation for observations on direct interactions between Syk and phosphoinositide 3-kinase.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA; Emory Univ, Sch Med, AFLAC Canc Ctr, Dept Pediat, Atlanta, GA 30322 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Emory University	Geahlen, RL (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Hansen Life Sci Res Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	geahlen@purdue.edu	Post, Carol/AAD-7910-2021	Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [CA94233, CA37372] Funding Source: Medline; NIGMS NIH HHS [GM39478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA094233, R01CA037372, R01CA094233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039478, R29GM039478] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Buhl AM, 1999, J IMMUNOL, V162, P4438; Campbell SJ, 2003, PROTEIN ENG, V16, P217, DOI 10.1093/proeng/gzg025; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; Cooney DS, 2001, J IMMUNOL, V167, P844, DOI 10.4049/jimmunol.167.2.844; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Ding JY, 2000, J BIOL CHEM, V275, P30873, DOI 10.1074/jbc.M004813200; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; HE TC, 1993, BLOOD, V82, P3530; Hong JJ, 2002, J BIOL CHEM, V277, P31703, DOI 10.1074/jbc.M201362200; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Jiang K, 2003, BLOOD, V101, P236, DOI 10.1182/blood-2002-04-1251; Jiang K, 2002, J IMMUNOL, V168, P3155, DOI 10.4049/jimmunol.168.7.3155; Kanie T, 2004, LEUKEMIA, V18, P548, DOI 10.1038/sj.leu.2403266; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kim JS, 2002, BLOOD, V99, P694, DOI 10.1182/blood.V99.2.694; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Law CL, 1996, MOL CELL BIOL, V16, P1305; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; Oda A, 2001, BLOOD, V97, P2633, DOI 10.1182/blood.V97.9.2633; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; Paolini R, 2002, J BIOL CHEM, V277, P36940, DOI 10.1074/jbc.M204948200; Peters JD, 1996, J BIOL CHEM, V271, P4755; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Raeder EMB, 1999, J IMMUNOL, V163, P6785; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Saci A, 2002, BIOCHEM J, V363, P717, DOI 10.1042/0264-6021:3630717; Sada K, 2000, J IMMUNOL, V164, P338, DOI 10.4049/jimmunol.164.1.338; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; Sohn HW, 2003, J EXP MED, V197, P1511, DOI 10.1084/jem.20021686; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Vines CM, 2001, IMMUNITY, V15, P507, DOI 10.1016/S1074-7613(01)00221-7; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; Yankee TM, 1999, J IMMUNOL, V163, P5827; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Zhang J, 2002, MOL CELL BIOL, V22, P8144, DOI 10.1128/MCB.22.23.8144-8154.2002; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	82	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1543	1551		10.1074/jbc.M407805200	http://dx.doi.org/10.1074/jbc.M407805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536084	hybrid			2022-12-25	WOS:000226195200085
J	Soderberg, L; Kakuyama, H; Moller, A; Ito, A; Winblad, B; Tjernberg, LO; Naslund, J				Soderberg, L; Kakuyama, H; Moller, A; Ito, A; Winblad, B; Tjernberg, LO; Naslund, J			Characterization of the Alzheimer's disease-associated CLAC protein and identification of an amyloid beta-peptide-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XIII COLLAGEN; A-BETA; OLIGOMERIZATION DOMAINS; NEURITIC PLAQUES; TRIPLE-HELIX; COMPONENT; SULFATE; CHAIN; BRAIN; C1Q	Amyloid beta-peptide (Abeta) deposition into amyloid plaques is one of the invariant neuropathological features of Alzheimer's disease. Other proteins co-deposit with Abeta in plaques, and one recently identified amyloid-associated protein is the collagen-like Alzheimer amyloid plaque component CLAC. It is not known how CLAC deposition affects Abeta plaque genesis and the progress of the disease. Here, we studied the in vitro properties of CLAC purified from a mammalian expression system. CLAC displays features characteristic of a collagen protein, e. g. it forms a partly protease-resistant triple-helical structure, exhibits an intermediate affinity for heparin, and is glycosylated. Purified CLAC was also used to investigate the interaction between CLAC and Abeta. Using a solid-phase binding assay, we show that CLAC bound with a similar affinity to aggregates formed by Abeta- ( 1 - 40) and Abeta- ( 1 - 42) and that the interaction was impaired by increasing salt concentrations. An 8-residue-long sequence located in non-collagenous domain 2 of CLAC was found to be crucial for the interaction with Abeta. These findings may be useful for future therapeutic interventions aimed at finding compounds that modulate the binding of CLAC to Abeta deposits.	Karolinska Inst, Novum, Neurotec, SE-14157 Huddinge, Sweden; Novum, Neurotec, Sumitomo Pharmaceut Alzheimer Ctr, SE-14157 Huddinge, Sweden; Sumitomo Pharmaceut Res Ctr, Osaka 5540022, Japan	Karolinska Institutet; Karolinska Institutet	Soderberg, L (corresponding author), Karolinska Inst, Novum, Neurotec, Kaspac Plan 5, SE-14157 Huddinge, Sweden.	linda.soderberg@neurotec.ki.se		Kakuyama, Hiroyoshi/0000-0003-0176-7775				ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Bronfman FC, 1998, AMYLOID, V5, P16, DOI 10.3109/13506129809007285; Bronfman FC, 1996, NEUROSCI LETT, V218, P201, DOI 10.1016/S0304-3940(96)13147-5; BROWN FR, 1972, J MOL BIOL, V63, P101, DOI 10.1016/0022-2836(72)90524-4; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; Calero M, 2000, MICROSC RES TECHNIQ, V50, P305, DOI 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; FURTHMAY.H, 1972, FEBS LETT, V28, P247, DOI 10.1016/0014-5793(72)80723-3; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kiuchi Y, 2002, LIFE SCI, V70, P1555, DOI 10.1016/S0024-3205(01)01528-4; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Latvanlehto A, 2003, J BIOL CHEM, V278, P37590, DOI 10.1074/jbc.M305974200; Lemere CA, 1999, AM J PATHOL, V155, P29, DOI 10.1016/S0002-9440(10)65095-X; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; Naiki H, 1996, LAB INVEST, V74, P374; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; OSADA Y, 2003, 33 ANN M SOC NEUR NE; Peltonen S, 1999, J INVEST DERMATOL, V113, P635, DOI 10.1046/j.1523-1747.1999.00736.x; PERLMUTTER LS, 1990, BRAIN RES, V508, P13, DOI 10.1016/0006-8993(90)91111-S; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; SCMIDT ML, 1997, AM J PATHOL, V151, P69; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; SNOW AD, 1988, AM J PATHOL, V133, P456; Soderberg L, 2003, J NEUROPATH EXP NEUR, V62, P1108; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; TILLET E, 1995, EUR J BIOCHEM, V228, P160, DOI 10.1111/j.1432-1033.1995.tb20245.x; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; Webster S, 1995, BIOCHEM BIOPH RES CO, V217, P869, DOI 10.1006/bbrc.1995.2852; Webster S, 1997, AM J PATHOL, V150, P1531	46	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1007	1015		10.1074/jbc.M403628200	http://dx.doi.org/10.1074/jbc.M403628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522881	hybrid			2022-12-25	WOS:000226195200020
J	Chan, EL; Peace, BE; Collins, MH; Toney-Earley, K; Waltz, SE				Chan, EL; Peace, BE; Collins, MH; Toney-Earley, K; Waltz, SE			Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis	ONCOGENE			English	Article						tyrosine kinase; Ras; hepatocyte growth factor-like protein (HGFL); macrophage-stimulating protein (MSP); Met; stem cell-derived tyrosine kinase (stk)	MACROPHAGE-STIMULATING PROTEIN; RAS GENE MUTATION; TRANSGENIC MOUSE; SPLICING VARIANT; POINT MUTATIONS; RETINOIC ACID; ACTIVATED RAS; MET; TRANSFORMATION; CARCINOMA	Recent studies demonstrate that the receptor tyrosine kinase (TK) Ron is tumorigenic when overexpressed and plays a role in regulating skin homeostasis. We hypothesized that Ron signaling promotes skin carcinogenesis. To test this hypothesis, mice deficient in the TK domain of Ron (TK-/- mice) were crossed with v-Ha-ras (Tg.AC) transgenic mice; the resulting TK-/- Tg.AC(+/-) mice, and their controls, we re utilized in a model of chemically induced Ras-mediated skin carcinogenesis. The mice were treated with 2.5 mug of 12-O-tetradecanoylphorbol-13-acetate applied weekly to the shaved back of 36 control (TK+/+ Tg.AC(+/-)) and 35 experimental (TK-/- Tg.AC(+/-)) mice. In an analysis of the resulting papillomas, a reduction in cellular proliferation and papilloma volume was found in the TK-/- Tg.AC(+/-) mice compared to controls. Further, Ron protein expression was upregulated during papilloma formation. Ablation of Ron signaling resulted in partial defects in MAPK and Akt signaling that may account for the decreased papilloma growth in the TK-/- Tg.AC(+/-) mice. The papilloma-bearing mice were monitored for the occurrence of malignant skin tumors and other malignant tumor types for a period of 48 weeks. Loss of Ron receptor signaling significantly reduced the percent of papillomas that underwent malignant conversion as well as the number of mice developing other malignant tumor types. In conclusion, these studies demonstrate that Ron signaling augments papilloma growth and malignant conversion in vivo.	Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Waltz, SE (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, SRU-MSB G482,ML 0558,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu		Waltz, Susan/0000-0003-3572-4642	NCI NIH HHS [R01 CA100002-02, R01 CA100002-01A1, R01 CA100002, R01 CA100002-03] Funding Source: Medline; NICHD NIH HHS [T32 HD43005-01, HD-36888, T32 HD043005, R01 HD036888-04, R01 HD036888, R01 HD036888-05] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036888, T32HD043005] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA100002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Bohle RM, 1996, AM J PATHOL, V148, P731; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; Chen QY, 1997, HEPATOLOGY, V26, P59; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HENNINGS H, 1990, CANCER RES, V50, P653; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; KULESZMARTIN MF, 1991, CANCER RES, V51, P4701; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Leonis NA, 2002, HEPATOLOGY, V36, P1053, DOI 10.1053/jhep.2002.36822; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McDowell SA, 2002, AM J RESP CELL MOL, V26, P99, DOI 10.1165/ajrcmb.26.1.4621; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; Okino T, 1999, INT J ONCOL, V15, P709; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakamoto A, 2001, HUM PATHOL, V32, P1225, DOI 10.1053/hupa.2001.28953; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Spalding JW, 1999, TOXICOL SCI, V49, P241, DOI 10.1093/toxsci/49.2.241; SPENCER JM, 1995, ARCH DERMATOL, V131, P796, DOI 10.1001/archderm.131.7.796; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; Webb CP, 1998, ONCOGENE, V17, P2019, DOI 10.1038/sj.onc.1202135; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	36	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					479	488		10.1038/sj.onc.1208231	http://dx.doi.org/10.1038/sj.onc.1208231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531916				2022-12-25	WOS:000226279700018
J	Du, LH; Lyle, CS; Chambers, TC				Du, LH; Lyle, CS; Chambers, TC			Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction	ONCOGENE			English	Article						vinblastine; Bcl-xL; Bcl-2; phosphorylation; apoptosis; protein kinase	N-TERMINAL KINASE; CELL-DEATH; SIGNALING PATHWAYS; CYTOCHROME-C; LOOP DOMAIN; MITOCHONDRIA; BCL-X(L); FAMILY; JNK; IDENTIFICATION	Bcl-xL and Bcl-2 are phosphorylated in response to microtubule inhibitors, but the kinase(s) responsible and the functional significance have remained unclear. In this study, we investigated the characteristics of Bcl-xL and Bcl-2 phosphorylation in KB-3 carcinoma cells treated with vinblastine. In both asynchronous and synchronous cell cultures, Bcl-xL and Bcl-2 underwent a well-defined and coordinated cycle of phosphorylation and dephosphorylation, with a lengthy period of phosphorylation preceding apoptosis induction, and with dephosphorylation closely correlated with initiation of apoptosis. Internally, validated inhibitors of JNK, ERK, p38(MAPK), or CDK1 failed to inhibit vinblastine-induced phosphorylation of Bcl-xL or Bcl-2. In vitro, Bcl-xL and Bcl-2 were poor substrates relative to c-Jun and ATF2 for active recombinant JNK1. Both Bcl-xL and Bcl-2 were localized primarily to the mitochondrial fraction in both control and vinblastine-treated cells, indicating that phosphorylation did not promote subcellular redistribution. Bcl-xL kinase activity was demonstrated in mitochondrial extracts from vinblastine-treated, but not control, cells. These findings suggest that phosphorylation of these key antiapoptotic proteins may be catalysed by a novel or unsuspected kinase that is activated or induced in response to microtubule damage. Furthermore, the same kinase and phosphatase system may be operating in tandem on both proteins, and phosphorylation appears to maintain their antiapoptotic function, whereas dephosphorylation may trigger apoptosis. These results provide evidence for a novel signaling pathway connecting microtubule damage to apoptosis induction, and help to clarify some of the controversy concerning the role of Bcl-2 phosphorylation in microtubule inhibitor-induced apoptosis.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	chamberstimothyc@.uams.edu			NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER; NCI NIH HHS [CA10982, CA75577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Amundson SA, 2000, CANCER RES, V60, P6101; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blagosklonny MV, 1997, CANCER RES, V57, P130; Brichese L, 2002, EXP CELL RES, V278, P101, DOI 10.1006/excr.2002.5563; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fan MY, 2000, CANCER RES, V60, P6403; Fang GF, 1998, CANCER RES, V58, P3202; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Osborn MT, 1999, ONCOGENE, V18, P5756, DOI 10.1038/sj.onc.1202943; Pathan N, 2001, NEOPLASIA, V3, P550, DOI 10.1038/sj.neo.7900213; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang SJ, 1999, BIOCHEM BIOPH RES CO, V259, P67, DOI 10.1006/bbrc.1999.0669; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	33	68	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					107	117		10.1038/sj.onc.1208189	http://dx.doi.org/10.1038/sj.onc.1208189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531923				2022-12-25	WOS:000226125800013
J	Lim, MA; Yang, L; Zheng, Y; Wu, H; Dong, LQ; Liu, F				Lim, MA; Yang, L; Zheng, Y; Wu, H; Dong, LQ; Liu, F			Roles of PDK-1 and PKN in regulating cell migration and cortical actin formation of PTEN-knockout cells	ONCOGENE			English	Article						PTEN; cortical actin; Rho; Rac; PKN; PDK-1; cell migration	TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE-C; ZIPPER-LIKE SEQUENCES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CATALYTIC DOMAIN; PUTATIVE TARGET; PROSTATE-CANCER; HUMAN BRAIN; ACTIVATION	Mutations in the tumor suppressor protein PTEN (phosphatase and tensin homologue deleted on chromosome 10) enhance cell migration, yet the underlying molecular mechanisms remain largely uncharacterized. Loss of PTEN in mouse embryonic fibroblasts (MEFs) correlates with striking cortical actin accumulation. However, how loss of PTEN leads to cortical actin formation and whether the presence of cortical actin contributes to the increased cell migration are unclear. Here we show that overexpression of dominant-negative forms of (DN) PTEN, RhoA or its kinase-dead (KD) effector, PKN, inhibited cortical actin formation, indicating that cortical actin of Pten(-/-) MEFs is mediated by the PTEN/Rho/PKN pathway. However, neither DN RhoA nor KD PKN inhibited the enhanced migration of Pten(-/-) cells, in contrast to the inhibitory effect of DN Rac. In agreement with the previous observation that DN Akt inhibits migration of Pten(-/-) cells, we demonstrate here that overexpression of KD PDK-1, the Akt kinase, reduces Pten(-/-) cell migration. Furthermore, overexpression of DN forms of Akt, Rac, or PDK-1, all of which inhibit migration of Pten(-/-) cells, had no effect on cortical actin accumulation. Our findings suggest that PDK-1/Akt signaling pathway plays a major role in regulating cell migration induced by PTEN deficiency.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56166] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Celebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Davies MA, 2002, CLIN CANCER RES, V8, P1904; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hahn M, 1999, CLIN CANCER RES, V5, P2431; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; Mertens F, 1997, CANCER RES, V57, P2765; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nakanishi K, 1999, CLIN EXP METASTAS, V17, P507, DOI 10.1023/A:1006685218766; NOBES CD, 1995, J CELL SCI, V108, P225; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; RIJKEN PJ, 1991, J CELL SCI, V100, P491; Risinger JI, 1997, CANCER RES, V57, P4736; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang SI, 1997, CANCER RES, V57, P4183; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Zeng X, 2002, CANCER RES, V62, P3538; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	60	31	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9348	9358		10.1038/sj.onc.1208147	http://dx.doi.org/10.1038/sj.onc.1208147			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531926				2022-12-25	WOS:000225764100006
J	Chattopadhyay, A; Jones, NG; Nietlispach, D; Nielsen, PR; Voorheis, HP; Mott, HR; Carrington, M				Chattopadhyay, A; Jones, NG; Nietlispach, D; Nielsen, PR; Voorheis, HP; Mott, HR; Carrington, M			Structure of the C-terminal domain from Trypanosoma brucei variant surface glycoprotein MITat1.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BONDS; COAT; PROTEINS; DYNAMICS; ANTIGENS; DATABASE; PATTERN; SYSTEM	The variant surface glycoprotein (VSG) of African trypanosomes has a structural role in protecting cell surface proteins from effector molecules of the mammalian immune system and also undergoes antigenic variation necessary for a persistent infection in a host. Here we have reported the solution structure of a VSG type 2 C-terminal domain from MITat1.2, completing the first structure of both domains of a VSG. The isolated C-terminal domain is a monomer in solution and forms a novel fold, which commences with a short alpha-helix followed by a single turn of 3(10)-helix and connected by a short loop to a small anti-parallel beta-sheet and then a longer alpha-helix at the C terminus. This compact domain is flanked by two unstructured regions. The structured part of the domain contains 42 residues, and the core comprises 2 disulfide bonds and 2 hydrophobic residues. These cysteines and hydrophobic residues are conserved in other VSGs, and we have modeled the structures of two further VSG C-terminal domains using the structure of MITat1.2. The models suggest that the overall structure of the core is conserved in the different VSGs but that the C-terminal alpha-helix is of variable length and depends on the presence of charged residues. The results provided evidence for a conserved tertiary structure for all the type 2 VSG C-terminal domains, indicated that VSG dimers form through interactions between N-terminal domains, and showed that the selection pressure for sequence variation within a conserved tertiary structure acts on the whole of the VSG molecule.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Trinity Coll Dublin, Dept Biochem, Dublin 2, Ireland	University of Cambridge; Trinity College Dublin	Carrington, M (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	h.r.mott@bioc.cam.ac.uk; mc115@cam.ac.uk	Carrington, Mark/N-3653-2019; Mott, Helen/AAV-3873-2020; Carrington, Mark/N-4892-2018; Jones, Nicola/AAP-5835-2021	Carrington, Mark/0000-0002-6435-7266; Mott, Helen/0000-0002-7890-7097; Carrington, Mark/0000-0002-6435-7266; Jones, Nicola/0000-0003-3384-0156; Nietlispach, Daniel/0000-0003-4364-9291				ALLEN G, 1983, BIOCHEM J, V209, P481, DOI 10.1042/bj2090481; AUFFRET CA, 1981, BIOCHEM J, V193, P647, DOI 10.1042/bj1930647; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bussler H, 1998, J BIOL CHEM, V273, P32582, DOI 10.1074/jbc.273.49.32582; Campillo N, 2003, MOL BIOCHEM PARASIT, V127, P79, DOI 10.1016/S0166-6851(02)00306-7; Carrington M, 1996, MOL BIOCHEM PARASIT, V81, P119, DOI 10.1016/0166-6851(96)02706-5; CARRINGTON M, 1991, J MOL BIOL, V221, P823, DOI 10.1016/0022-2836(91)80178-W; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DOWN JA, 1991, J MOL BIOL, V218, P679, DOI 10.1016/0022-2836(91)90254-4; FARROW NA, 1995, BIOCHEMISTRY-US, V34, P868, DOI 10.1021/bi00003a021; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; GARMAN SC, 1994, THESIS HARVARD U CAM; Gelly JC, 2004, NUCLEIC ACIDS RES, V32, pD156, DOI 10.1093/nar/gkh015; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Hwang TL, 1998, J BIOMOL NMR, V11, P221, DOI 10.1023/A:1008276004875; JOHNSON JG, 1979, BIOCHEM J, V178, P689, DOI 10.1042/bj1780689; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P627; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LYU PCC, 1992, J MOL BIOL, V223, P343, DOI 10.1016/0022-2836(92)90735-3; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; McCulloch R, 2004, TRENDS PARASITOL, V20, P117, DOI 10.1016/j.pt.2003.12.004; Mehlert A, 2002, GLYCOBIOLOGY, V12, P607, DOI 10.1093/glycob/cwf079; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moont G, 1999, PROTEINS, V35, P364, DOI 10.1002/(SICI)1097-0134(19990515)35:3<364::AID-PROT11>3.0.CO;2-4; Salmon D, 1997, EMBO J, V16, P7272, DOI 10.1093/emboj/16.24.7272; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; STRICKLER JE, 1982, EXP PARASITOL, V53, P117, DOI 10.1016/0014-4894(82)90098-4; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244; ZIEGELBAUER K, 1993, INFECT IMMUN, V61, P4540, DOI 10.1128/IAI.61.11.4540-4545.1993	37	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7228	7235		10.1074/jbc.M410787200	http://dx.doi.org/10.1074/jbc.M410787200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15557330	hybrid			2022-12-25	WOS:000227332700114
J	Fu, XM; Zhang, H; Zhang, XF; Cao, Y; Jiao, WW; Liu, C; Song, Y; Abulimiti, A; Chang, ZY				Fu, XM; Zhang, H; Zhang, XF; Cao, Y; Jiao, WW; Liu, C; Song, Y; Abulimiti, A; Chang, ZY			A dual role for the N-terminal region of Mycobacterium tuberculosis Hsp16.3 in self-oligomerization and binding denaturing substrate proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-A-CRYSTALLIN; CHAPERONE-LIKE ACTIVITY; BLUE NATIVE ELECTROPHORESIS; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; SUBUNIT EXCHANGE; MEMBRANE-PROTEIN; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; METHANOCOCCUS-JANNASCHII	The N-terminal regions, which are highly variable in small heat-shock proteins, were found to be structurally disordered in all the 24 subunits of Methanococcus jannaschii Hsp16.5 oligomer and half of the 12 subunits of wheat Hsp16.9 oligomer. The structural and functional roles of the corresponding region (potentially disordered) in Mycobacterium tuberculosis Hsp16.3, existing as nonamers, were investigated in this work. The data demonstrate that the mutant Hsp16.3 protein with 35 N-terminal residues removed (DeltaN35) existed as trimers/dimers rather than as nonamers, failing to bind the hydrophobic probe (1,1'-bi(4-anilino)naphthalene-5,5'-disulfonic acid) and exhibiting no chaperone-like activity. Nevertheless, another mutant protein with the C-terminal extension (of nine residues) removed, although existing predominantly as dimers, exhibited efficient chaperone-like activity even at room temperatures, indicating that pre-existence as nonamers is not a prerequisite for its chaperone-like activity. Meanwhile, the mutant protein with both the N- and C-terminal ends removed fully exists as a dimer lacking any chaperone-like activity. Furthermore, the N-terminal region alone, either as a synthesized peptide or in fusion protein with glutathione S-transferase, was capable of interacting with denaturing proteins. These observations strongly suggest that the N-terminal region of Hsp16.3 is not only involved in self-oligomerization but also contains the critical site for substrate binding. Such a dual role for the N-terminal region would provide an effective mechanism for the small heat-shock protein to modulate its chaperone-like activity through oligomeric dissociation/reassociation. In addition, this study demonstrated that the wild-type protein was able to form heterononamers with DeltaN35 via subunit exchange at a subunit ratio of 2:1. This implies that the 35 N-terminal residues in three of the nine subunits in the wild-type nonamer are not needed for the assembly of nonamers from trimers and are thus probably structurally disordered.	Peking Univ, State Key Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Tsing Hua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China	Peking University; Peking University; Tsinghua University	Chang, ZY (corresponding author), Peking Univ, State Key Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China.	changzy@pku.edu.cn	Song, Yang/D-3319-2015; Liu, Chong/G-3514-2011; Fu, Xinmiao/ABE-9050-2020	Song, Yang/0000-0002-9993-9258; Fu, Xinmiao/0000-0003-3361-6904				Abulimiti A, 2003, J MOL BIOL, V326, P1013, DOI 10.1016/S0022-2836(03)00018-4; ARRIGO AP, 1994, BIOL HEAT SHOCK PROT; Berengian AR, 1999, J BIOL CHEM, V274, P6305, DOI 10.1074/jbc.274.10.6305; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Buchner J, 1998, METHOD ENZYMOL, V290, P339, DOI 10.1016/S0076-6879(98)90030-1; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; Chen Y, 2001, PROTEIN PEPTIDE LETT, V8, P499, DOI 10.2174/0929866013409111; COATES ARM, 1981, LANCET, V2, P167; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Fu XM, 2004, BIOCHEM BIOPH RES CO, V316, P291, DOI 10.1016/j.bbrc.2004.02.053; Fu XM, 2003, BIOCHEM BIOPH RES CO, V310, P412, DOI 10.1016/j.bbrc.2003.09.027; Fu XM, 2003, BIOCHEM BIOPH RES CO, V308, P627, DOI 10.1016/S0006-291X(03)01450-5; Giese KC, 2004, J BIOL CHEM, V279, P32674, DOI 10.1074/jbc.M404455200; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2004, J MOL BIOL, V343, P445, DOI 10.1016/j.jmb.2004.08.048; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KAPPE G, 2000, PROG MOL SUBCELL BIO, V28, P1; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 2003, P NATL ACAD SCI USA, V100, P8151, DOI 10.1073/pnas.1032940100; Kokke BPA, 1998, FEBS LETT, V433, P228, DOI 10.1016/S0014-5793(98)00917-X; Koteiche HA, 2002, FEBS LETT, V519, P16, DOI 10.1016/S0014-5793(02)02688-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE BY, 1992, INFECT IMMUN, V60, P2066, DOI 10.1128/IAI.60.5.2066-2074.1992; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Liao DI, 2001, STRUCTURE, V9, P399, DOI 10.1016/S0969-2126(01)00600-1; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; PLESOFSKYVIG N, 1992, J MOL EVOL, V35, P537, DOI 10.1007/BF00160214; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; Stromer T, 2004, J BIOL CHEM, V279, P11222, DOI 10.1074/jbc.M310149200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Studer S, 2002, EUR J BIOCHEM, V269, P3578, DOI 10.1046/j.1432-1033.2002.03049.x; van de Klundert FAJM, 1998, EUR J BIOCHEM, V258, P1014, DOI 10.1046/j.1432-1327.1998.2581014.x; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; WATERS ER, 1995, GENETICS, V141, P785; Yamaoka T, 1998, ANAL CHIM ACTA, V372, P91, DOI 10.1016/S0003-2670(98)00343-2	52	64	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6337	6348		10.1074/jbc.M406319200	http://dx.doi.org/10.1074/jbc.M406319200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15545279	hybrid			2022-12-25	WOS:000227332700014
J	Jin, L; Pandey, P; Babine, RE; Gorga, JC; Seidl, KJ; Gelfand, E; Weaver, DT; Abdel-Meguid, SS; Strickler, JE				Jin, L; Pandey, P; Babine, RE; Gorga, JC; Seidl, KJ; Gelfand, E; Weaver, DT; Abdel-Meguid, SS; Strickler, JE			Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XI; BLOOD-COAGULATION; BINDING-SITE; SERINE PROTEASES; FACTOR-XA; ESCHERICHIA-COLI; PLATELET SURFACE; APPLE-3 DOMAIN; DRUG DESIGN; IN-VIVO	Thrombosis can lead to life-threatening conditions such as acute myocardial infarction, pulmonary embolism, and stroke. Although commonly used anti-coagulant drugs, such as low molecular weight heparin and warfarin, are effective, they carry a significant risk of inducing severe bleeding complications, and there is a need for safer drugs. Activated Factor XI (FXIa) is a key enzyme in the amplification phase of the coagulation cascade. Anti-human FXI antibody significantly reduces thrombus growth in a baboon thrombosis model without bleeding problems (Gruber, A., and Hanson, S. R. (2003) Blood 102, 953-955). Therefore, FXIa is a potential target for anti-thrombosis therapy. To determine the structure of FXIa, we derived a recombinant catalytic domain of FXI, consisting of residues 370-607 (rhFXI(370-607)). Here we report the first crystal structure of rhFXI(370-607) in complex with a substitution mutant of ecotin, a panserine protease protein inhibitor secreted by Escherichia coli, to 2.2 Angstrom resolution. The presence of ecotin not only assisted in the crystallization of the enzyme but also revealed unique structural features in the active site of FXIa. Subsequently, the sequence from P5 to P2' in ecotin was mutated to the FXIa substrate sequence, and the structures of the rhFXI(370-607)-ecotin mutant complexes were determined. These structures provide us with an understanding of substrate binding interactions of FXIa, the structural information essential for the structure-based design of FXIa-selective inhibitors.	Daiichi Asubio Med Res Labs LLC, Cambridge, MA 02139 USA		Jin, L (corresponding author), Daiichi Asubio Med Res Labs LLC, Cambridge, MA 02139 USA.	lei.jin@daiamed.com						Adler M, 2000, BIOCHEMISTRY-US, V39, P12534, DOI 10.1021/bi001477q; Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z; Badellino KO, 2001, BIOCHEMISTRY-US, V40, P7569, DOI 10.1021/bi0027433; Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2004, J BIOL CHEM, V279, P45470, DOI 10.1074/jbc.M406727200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; Bouma BN, 2000, CURR OPIN HEMATOL, V7, P266, DOI 10.1097/00062752-200009000-00002; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CHUNG CH, 1983, J BIOL CHEM, V258, P1032; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; Eggers CT, 2001, J MOL BIOL, V308, P975, DOI 10.1006/jmbi.2001.4754; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gillmor SA, 2000, J MOL BIOL, V299, P993, DOI 10.1006/jmbi.2000.3812; Gruber A, 2003, BLOOD, V102, P953, DOI 10.1182/blood-2003-01-0324; HIRSH J, 2004, BLOOD; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; Katz BA, 2001, CHEM BIOL, V8, P1107, DOI 10.1016/S1074-5521(01)00084-9; Katz BA, 2000, CHEM BIOL, V7, P299, DOI 10.1016/S1074-5521(00)00104-6; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; LEIBA H, 1965, BRIT J HAEMATOL, V11, P654, DOI 10.1111/j.1365-2141.1965.tb00114.x; Mackman RL, 2001, J MED CHEM, V44, P3856, DOI 10.1021/jm010244+; MCGRATH ME, 1991, J BIOL CHEM, V266, P6620; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; MCGRATH ME, 1991, J MOL BIOL, V222, P139, DOI 10.1016/0022-2836(91)90199-G; Minnema MC, 1998, J CLIN INVEST, V101, P10, DOI 10.1172/JCI781; NAITO K, 1991, J BIOL CHEM, V266, P7353; Narasimhan LS, 2000, J MED CHEM, V43, P361, DOI 10.1021/jm990216f; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nienaber V, 2000, J BIOL CHEM, V275, P7239, DOI 10.1074/jbc.275.10.7239; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Perona JJ, 1997, BIOCHEMISTRY-US, V36, P5381, DOI 10.1021/bi9617522; Radisky ES, 2002, P NATL ACAD SCI USA, V99, P10316, DOI 10.1073/pnas.112332899; RAGNI MV, 1985, BLOOD, V65, P719; Sandler B, 1998, J AM CHEM SOC, V120, P595, DOI 10.1021/ja972991v; Scandura JM, 1997, BIOCHEMISTRY-US, V36, P412, DOI 10.1021/bi9612576; Sinha D, 2004, BIOCHEMISTRY-US, V43, P7593, DOI 10.1021/bi049808c; Skordalakes E, 2001, J MOL BIOL, V311, P549, DOI 10.1006/jmbi.2001.4872; Wang SX, 2003, BIOCHEMISTRY-US, V42, P7959, DOI 10.1021/bi027320a; Wang SX, 2001, BIOCHEMISTRY-US, V40, P10038, DOI 10.1021/bi010712h; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992; Wuillemin WA, 1996, THROMB HAEMOSTASIS, V76, P549; Yang SQ, 1998, J MOL BIOL, V279, P945, DOI 10.1006/jmbi.1998.1748	48	46	52	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4704	4712		10.1074/jbc.M411309200	http://dx.doi.org/10.1074/jbc.M411309200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15545266	hybrid			2022-12-25	WOS:000227096600086
J	Nandini, CD; Itoh, N; Sugahara, K				Nandini, CD; Itoh, N; Sugahara, K			Novel 70-kDa chondroitin sulfate/dermatan sulfate hybrid chains with a unique heterogenous sulfation pattern from shark skin, which exhibit neuritogenic activity and binding activities for growth factors and neurotrophic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; OVERSULFATED DERMATAN SULFATE; PROTEIN LINKAGE REGION; HEXASACCHARIDE SEQUENCES; MOLECULAR-INTERACTIONS; HIGH-AFFINITY; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; HAGFISH	Chondroitin sulfate (CS) and dermatan sulfate (DS) hybrid chains of proteoglycans are critical in growth factor binding, neuritogenesis, and brain development. Here we isolated CS/DS hybrid chains from shark skin aiming to develop therapeutic agents. Digestion with various chondroitinases showed that both G1cUA- and IdoUA-containing disaccharides are scattered along the polysaccharide chains with an unusually large average molecular mass of 70 kDa. The CS/DS chains were separated into major (80%) and minor (20% fractions by anion-exchange chromatography. Both fractions had relatively low degrees of sulfation (sulfate/disaccharide molar ratio = 1.17 versus 0.87), showing a unique feature compared with the marine CS and DS isolated to date, most of which are oversulfated. They were highly heterogeneous and characterized by multiple disaccharides including G1cUA-Ga1NAc, G1cUA-Ga1NAc(6S), GlcUA-Ga1NAc(4S), IdoUA-Ga1NAc(4S), G1cUA-Ga1NAc(4S,6S), IdoUA-Ga1NAc(4S,6S), G1cUA(2S)-Ga1NAc(6S), and/or IdoUA(2S)-Ga1NAc(6S), IdoUA(2S)-Ga1NAc(4S) and novel GlcUA(2S)-Ga1NAc(4S), where 2S, 4S, and 6S represent 2-O-, 4-O- and 6-O-sulfate, respectively. The CS/DS chains bound two neurotrophic factors and various growth factors expressed in the brain with high affinity as evaluated for the major fraction by kinetic analysis using a surface plasmon resonance detector, and also promoted the outgrowth of neurites of both an axonic and a dendritic nature. The neuritogenic activity was abolished completely by digestion with chondroitinase ABC, AC-I, or B, suggesting the importance of both G1cUA- and IdoUA-containing moieties. It also showed anti-heparin cofactor II activity comparable to that exhibited by DS from porcine skin. Thus, by virtue of its unique structure and biological activities, DS will find a potential use in therapeutics.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan	Kobe Pharmaceutical University; Kyoto University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp						ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRUCKNER J, 1955, BIOCHEM J, V60, P200; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Danilenko DM, 1999, ARCH BIOCHEM BIOPHYS, V361, P34, DOI 10.1006/abbi.1998.0967; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FERRO DR, 1986, J AM CHEM SOC, V108, P6773, DOI 10.1021/ja00281a052; Gorio A, 2002, J NEUROCHEM, V81, P194, DOI 10.1046/j.1471-4159.2002.00830.x; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; ICHIJO H, 2003, CONNECT TISSUE, V35, P11; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; LAFONT F, 1992, DEVELOPMENT, V114, P17; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; LINHARDT RJ, 1991, BIOCHEM PHARMACOL, V42, P1609, DOI 10.1016/0006-2952(91)90431-4; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; Mascellani G, 1996, THROMB RES, V84, P21, DOI 10.1016/0049-3848(96)00158-2; MATHEWS MB, 1971, BIOCHIM BIOPHYS ACTA, V244, P30; MIWA H, 1994, J VASC SURG, V19, P658, DOI 10.1016/S0741-5214(94)70039-7; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Muramatsu T, 2001, TRENDS GLYCOSCI GLYC, V13, P563, DOI 10.4052/tigg.13.563; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Park Y, 1997, BBA-PROTEIN STRUCT M, V1337, P217, DOI 10.1016/S0167-4838(96)00167-7; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; Rickard SM, 2003, GLYCOBIOLOGY, V13, P419, DOI 10.1093/glycob/cwg046; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; SAITO H, 1968, J BIOL CHEM, V243, P1536; Sakai S, 2003, CARBOHYD RES, V338, P263, DOI 10.1016/S0008-6215(02)00442-1; SCOTT J. E., 1960, METHODS BIOCHEM ANAL, V8, P145; SCOTT JE, 1995, BIOCHEMISTRY-US, V34, P15467, DOI 10.1021/bi00047a011; SCULLY MF, 1988, BIOCHEM J, V254, P547, DOI 10.1042/bj2540547; SENO N, 1963, BIOCHIM BIOPHYS ACTA, V78, P258, DOI 10.1016/0006-3002(63)91636-6; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; Vilela-Silva ACES, 2001, GLYCOBIOLOGY, V11, P433, DOI 10.1093/glycob/11.6.433; WESTERGRENTHORSSON G, 1991, J CELL PHYSIOL, V147, P523, DOI 10.1002/jcp.1041470319; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yamada Shuhei, 2003, Methods Mol Biol, V213, P71; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	68	82	88	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4058	4069		10.1074/jbc.M412074200	http://dx.doi.org/10.1074/jbc.M412074200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557276	hybrid			2022-12-25	WOS:000227096600010
J	Ling, Y; Maile, LA; Badley-Clarke, J; Clemmons, DR				Ling, Y; Maile, LA; Badley-Clarke, J; Clemmons, DR			DOK1 mediates SHP-2 binding to the alpha V beta 3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; LIGAND OCCUPANCY; FACTOR RECEPTOR; PROTEIN; ASSOCIATION; DOMAIN; KINASE; TRANSDUCTION; STIMULATION; RECRUITMENT	Recruitment of the Src homology 2 domain tyrosine phosphatase (SHP-2) to the phosphorylated beta3 subunit of the alphaVbeta3 integrin is required for insulin-like growth factor I (IGF-I)-stimulated cell migration and proliferation in vascular smooth muscle cells. Because SHP-2 does not bind directly to 133, we attempted to identify a linker protein that could mediate SHP-2/beta3 association. DOK1 is a member of insulin receptor substrate protein family that binds 133 and contains YXXL/I motifs that are potential binding sites for SHP-2. Our results show that IGF-I induces DOK1 binding to beta3 and to SHP-2. Preincubation of cells with synthetic peptides that blocked either DOK1/beta3 or DOK1/SHP-2 association inhibited SHP-2 recruitment to beta3. Expression of a DOK1 mutant that does not bind to 133 also disrupts SHP-2/beta3 association. As a result of SHP-2/beta3 disruption, IGF-I dependent phosphorylation of Akt and p44/p42 mitogen-activated protein kinase and its ability to stimulate cell migration and proliferation were significantly impaired. These results demonstrate that DOK1 mediates SHP-2/beta3 association in response to IGF-I thereby mediating the effect of integrin ligand occupancy on IGF-IR-linked signaling in smooth muscle cells.	Univ N Carolina, Div Endocrinol, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Clemmons, DR (corresponding author), Univ N Carolina, Div Endocrinol, Sch Med, CB 7170,6111 Thurston Bowles, Chapel Hill, NC 27599 USA.	endo@med.unc.edu			NHLBI NIH HHS [HL56850] Funding Source: Medline; NIA NIH HHS [AG02331] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG002331, R01AG002331] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; CASE RD, 1994, J BIOL CHEM, V269, P10467; ELLIS C, 1991, ONCOGENE, V6, P895; Goel HL, 2004, J CELL BIOL, V166, P407, DOI 10.1083/jcb.200403003; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Ho A, 2001, CANCER RES, V61, P474; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Lee S, 2004, ONCOGENE, V23, P2287, DOI 10.1038/sj.onc.1207385; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Maile LA, 2003, MOL BIOL CELL, V14, P3519, DOI 10.1091/mbc.E03-04-0239; Maile LA, 2002, ENDOCRINOLOGY, V143, P4259, DOI 10.1210/en.2002-220395; Maile LA, 2001, J CELL SCI, V114, P1417; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANCHEZMARGALET V, 1995, ENDOCRINOLOGY, V136, P316, DOI 10.1210/en.136.1.316; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Woodring PJ, 2004, J CELL BIOL, V165, P493, DOI 10.1083/jcb.200312171; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	30	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3151	3158		10.1074/jbc.M411035200	http://dx.doi.org/10.1074/jbc.M411035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15546884	hybrid			2022-12-25	WOS:000226983900006
J	Muller, SL; Portwich, M; Schmidt, A; Utepbergenov, DI; Huber, O; Blasig, IE; Krause, G				Muller, SL; Portwich, M; Schmidt, A; Utepbergenov, DI; Huber, O; Blasig, IE; Krause, G			The tight junction protein occludin and the adherens junction protein alpha-catenin share a common interaction mechanism with ZO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; BINDING REGION; COILED COILS; BETA-CATENIN; SH3 DOMAIN; KINASE; CADHERIN; IDENTIFICATION; ARCHITECTURE; EXPRESSION	The exact sites, structures, and molecular mechanisms of interaction between junction organizing zona occludence protein 1 (ZO-1) and the tight junction protein occludin or the adherens junction protein alpha-catenin are unknown. Binding studies by surface plasmon resonance spectroscopy and peptide mapping combined with comparative modeling utilizing crystal structures led for the first time to a molecular model revealing the binding of both occludin and alpha-catenin to the same binding site in ZO-1. Our data support a concept that ZO-1 successively associates with alpha-catenin at the adherens junction and occludin at the tight junction. Strong spatial evidence indicates that, the occludin C-terminal coiled-coil domain dimerizes and interacts finally as a four-helix bundle with the identified structural motifs in ZO-1. The helix bundle of occludin(406-521) and alpha-catenin(509-906) interacts with the hinge region (ZO-1(591-632) and ZO-1(591-622), respectively) and with (ZO-1(726-754) and ZO-1(756-781)) in the GuK domain of ZO-1 containing coiled-coil and alpha-helical structures, respectively. The selectivity of both protein-protein interactions is defined by complementary shapes and charges between the participating epitopes. In conclusion, a common molecular mechanism of forming an intermolecular helical bundle between the hinge region/GuK domain of ZO-1 and alpha-catenin and occludin is identified as a general molecular principle organizing the association of ZO-1 at adherens and tight junctions.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany		Krause, G (corresponding author), Forschungsinst Mol Pharmakol, Robert Rossle Str 10, D-13125 Berlin, Germany.	gkrause@fmp-berlin.de	Utepbergenov, Darkhan/N-9881-2014; Huber, Otmar/AAA-4548-2021; Utepbergenov, Darkhan/AAA-1249-2021	Utepbergenov, Darkhan/0000-0002-9005-4103; Huber, Otmar/0000-0003-4359-1747; Utepbergenov, Darkhan/0000-0002-9005-4103				Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Andreeva AY, 2001, J BIOL CHEM, V276, P38480, DOI 10.1074/jbc.M104923200; Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; Fanning AS, 2002, FASEB J, V16, P1835, DOI 10.1096/fj.02-0121fje; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FISCHETTI VA, 1993, INFORM PROCESS LETT, V45, P11, DOI 10.1016/0020-0190(93)90245-5; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Huber O, 1997, J CELL SCI, V110, P1759; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Kausalya PJ, 2001, FEBS LETT, V505, P92, DOI 10.1016/S0014-5793(01)02786-7; Kramer A, 1998, METH MOL B, V87, P25; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mankertz J, 2002, BIOCHEM BIOPH RES CO, V298, P657, DOI 10.1016/S0006-291X(02)02487-7; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Paarmann I, 2002, J BIOL CHEM, V277, P40832, DOI 10.1074/jbc.M205618200; Peng BH, 2003, J BIOL CHEM, V278, P49644, DOI 10.1074/jbc.M302782200; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Ryeom SW, 2000, MOL BIOL CELL, V11, P1687, DOI 10.1091/mbc.11.5.1687; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Schmidt A, 2001, BIOCHEM BIOPH RES CO, V288, P1194, DOI 10.1006/bbrc.2001.5914; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Simons KT, 1999, PROTEINS, P171; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Toepert F, 2003, ANGEW CHEM INT EDIT, V42, P1136, DOI 10.1002/anie.200390298; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Yang J, 2001, EMBO J, V20, P3645, DOI 10.1093/emboj/20.14.3645	40	57	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3747	3756		10.1074/jbc.M411365200	http://dx.doi.org/10.1074/jbc.M411365200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548514	hybrid			2022-12-25	WOS:000226983900075
J	Pickhardt, M; Gazova, Z; von Bergen, M; Khlistunova, I; Wang, YP; Hascher, A; Mandelkow, EM; Biernat, J; Mandelkow, E				Pickhardt, M; Gazova, Z; von Bergen, M; Khlistunova, I; Wang, YP; Hascher, A; Mandelkow, EM; Biernat, J; Mandelkow, E			Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRILS; BETA-STRUCTURE; NEURODEGENERATIVE DISORDERS; FRONTOTEMPORAL DEMENTIA; HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; PROTEIN-TAU; CONGO RED; PHOSPHORYLATION	The abnormal aggregation of tau protein into paired helical filaments (PHFS) is one of the hallmarks of Alzheimer's disease. Aggregation takes place in the cytoplasm and could therefore be cytotoxic for neurons. To find inhibitors of PHF aggregation we screened a library of 200,000 compounds. The hits found in the PHF inhibition assay were also tested for their ability to dissolve preformed PHFs. The results were obtained using a thioflavin S fluorescence assay for the detection and quantification of tau aggregation in solution, a tryptophan fluorescence assay using tryptophan-containing mutants of tau, and confirmed by a pelleting assay and electron microscopy of the products. Here we demonstrate the feasibility of the approach with several compounds from the family of anthraquinones including emodin, daunorubicin, adriamycin, and others. They were able to inhibit PHF formation with IC50 values of 1-5 muM and to disassemble preformed PHFs at DC50 values of 2-4 muM. The compounds had a similar activity for PHFs made from different tau isoforms and constructs. The compounds did not interfere with the stabilization of microtubules by tau. Tau-inducible neuroblastoma cells showed the formation of tau aggregates and concomitant cytotoxicity, which could be prevented by inhibitors. Thus, small molecule inhibitors could provide a basis for the development of tools for the treatment of tau pathology in AD and other tauopathies.	Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Max Planck Society	Mandelkow, E (corresponding author), Max Planck Unit Struct Mol Biol, Notkestr 85, D-22607 Hamburg, Germany.	mandelkow@mpasmb.desy.de	Gazova, Zuzana/L-6685-2019; von Bergen, Martin/D-7960-2011; Gazova, Zuzana/T-4146-2019	Gazova, Zuzana/0000-0002-0670-3431; von Bergen, Martin/0000-0003-2732-2977; 				Abraha A, 2000, J CELL SCI, V113, P3737; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BURDICK D, 1992, J BIOL CHEM, V267, P546; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Fernandez CO, 2004, EMBO J, V23, P2039, DOI 10.1038/sj.emboj.7600211; Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; GLENNER GG, 1972, J HISTOCHEM CYTOCHEM, V20, P821, DOI 10.1177/20.10.821; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; Gossen M, 2002, ANNU REV GENET, V36, P153, DOI 10.1146/annurev.genet.36.041002.120114; Gotz J, 2004, MOL PSYCHIATR, V9, P664, DOI 10.1038/sj.mp.4001508; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Howlett DR, 1999, BIOCHEM J, V343, P419, DOI 10.1042/0264-6021:3430419; Hutton M, 2001, TRENDS MOL MED, V7, P467, DOI 10.1016/S1471-4914(01)02123-2; Iqbal K, 2003, J MOL NEUROSCI, V20, P425, DOI 10.1385/JMN:20:3:425; Johnson GVW, 2002, J ALZHEIMERS DIS, V4, P375, DOI 10.3233/JAD-2002-4505; Kammerer RA, 2004, P NATL ACAD SCI USA, V101, P4435, DOI 10.1073/pnas.0306786101; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Kosik KS, 2002, J MOL NEUROSCI, V19, P261, DOI 10.1385/JMN:19:3:261; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Perez M, 1996, J NEUROCHEM, V67, P1183; Petersen A, 2002, INT REV NEUROBIOL, V53, P315; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; Sikorski P, 2003, STRUCTURE, V11, P915, DOI 10.1016/S0969-2126(03)00149-7; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; van Swieten JC, 1999, ANN NEUROL, V46, P617, DOI 10.1002/1531-8249(199910)46:4<617::AID-ANA10>3.0.CO;2-I; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wischik CM, 1996, P NATL ACAD SCI USA, V93, P11213, DOI 10.1073/pnas.93.20.11213	56	271	296	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3628	3635		10.1074/jbc.M410984200	http://dx.doi.org/10.1074/jbc.M410984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15525637	hybrid			2022-12-25	WOS:000226983900062
J	Plank, JL; Chu, SH; Pohlhaus, JR; Wilson-Sali, T; Hsieh, TS				Plank, JL; Chu, SH; Pohlhaus, JR; Wilson-Sali, T; Hsieh, TS			Drosophila melanogaster topoisomerase III alpha preferentially relaxes a positively or negatively supercoiled bubble substrate and is essential during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA TOPOISOMERASE; SINGLE-STRANDED-DNA; SYNDROME GENE-PRODUCT; ESCHERICHIA-COLI; BLOOMS-SYNDROME; BINDING DOMAIN; HYPER-RECOMBINATION; TERMINAL DOMAIN; REVERSE GYRASE; MICE LACKING	Eukaryotic type IA topoisomerases are important for the normal function of the cell, and in some cases essential for the organism, although their role in DNA metabolism remains to be elucidated. In this study, we cloned Drosophila melanogaster topoisomerase (topo) IIIalpha from an embryonic cDNA library and expressed and purified the protein to >95% homogeneity. This enzyme partially relaxes a hypernegatively supercoiled plasmid substrate consistent with other purified topo IIIs. A novel, covalently closed bubble substrate was prepared for this study, which topo IIIalpha fully relaxed, regardless of the handedness of the supercoils. Experiments with the bubble substrate demonstrate that topo IIIalpha has much different reaction preferences from those obtained by plasmid substrate-based assays. This is presumably due to the fact that solution conditions can affect the structure of plasmid based substrates and therefore their suitability as a substrate. A mutant allele of the Top3alpha gene, Top3alpha(191), was isolated through imprecise excision mutagenesis of an existing P-element inserted in the first intron of the gene. Top3alpha(191) is recessive lethal, with most of the homozygous individuals surviving to pupation but never emerging to adulthood. Whereas this mutation can be rescued by a Top3alpha transgene, ubiquitous overexpression of D. melanogaster topo IIIbeta cannot rescue this allele.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, 134 Nanaline Duke Bldg,Res Dr, Durham, NC 27710 USA.	hsieh@biochem.due.edu	Plank, Jody/B-4827-2009; Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NIGMS NIH HHS [GM29006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 1998, BIOCHEM BIOPH RES CO, V251, P509, DOI 10.1006/bbrc.1998.9500; Bennett RJ, 2000, J BIOL CHEM, V275, P26898; Bennett RJ, 2001, P NATL ACAD SCI USA, V98, P11108, DOI 10.1073/pnas.201387098; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Changela A, 2001, NATURE, V411, P1077, DOI 10.1038/35082615; Cheng BK, 2003, J BIOL CHEM, V278, P30705, DOI 10.1074/jbc.M303403200; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; Fricke WM, 2001, J BIOL CHEM, V276, P8848, DOI 10.1074/jbc.M009719200; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Goulaouic H, 1999, NUCLEIC ACIDS RES, V27, P2443, DOI 10.1093/nar/27.12.2443; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Hotoda N, 2000, J BIOCHEM, V127, P1109, DOI 10.1093/oxfordjournals.jbchem.a022705; Johnson FB, 2000, CANCER RES, V60, P1162; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kwan KY, 2003, P NATL ACAD SCI USA, V100, P2526, DOI 10.1073/pnas.0437998100; Kwan KY, 2001, P NATL ACAD SCI USA, V98, P5717, DOI 10.1073/pnas.101132498; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIN TC, 1980, J BIOL CHEM, V255, P331; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; Nurse P, 2003, J BIOL CHEM, V278, P8653, DOI 10.1074/jbc.M211211200; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rodriguez AC, 2002, J BIOL CHEM, V277, P29865, DOI 10.1074/jbc.M202853200; Rothstein R, 1995, GENOME RES, V5, P421, DOI 10.1101/gr.5.5.421; Seki T, 1998, J BIOL CHEM, V273, P28553, DOI 10.1074/jbc.273.44.28553; Seki T, 1998, BBA-GENE STRUCT EXPR, V1396, P127, DOI 10.1016/S0167-4781(97)00192-9; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499; Wilson TM, 2000, J BIOL CHEM, V275, P1533, DOI 10.1074/jbc.275.3.1533; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Yu LP, 1996, BIOCHEMISTRY-US, V35, P9661, DOI 10.1021/bi960507f; YU LP, 1995, BIOCHEMISTRY-US, V34, P7622, DOI 10.1021/bi00023a008; ZHU CX, 1994, BIOCHEM MOL BIOL INT, V33, P195	51	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3564	3573		10.1074/jbc.M411337200	http://dx.doi.org/10.1074/jbc.M411337200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15537633	hybrid			2022-12-25	WOS:000226983900054
J	Roccato, E; Miranda, C; Raho, G; Pagliardini, S; Pierotti, MA; Greco, A				Roccato, E; Miranda, C; Raho, G; Pagliardini, S; Pierotti, MA; Greco, A			Analysis of SHP-1-mediated down-regulation of the TRK-T3 oncoprotein identifies Trk-fused gene (TFG) as a novel SHP-1-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; COILED-COIL DOMAIN; GROWTH-FACTOR RECEPTOR; TRANSFORMING ACTIVITY; NEGATIVE REGULATION; ALK TRANSLOCATIONS; ONCOGENE; PHOSPHORYLATION; SPECIFICITY; TERMINUS	SHP-1 is a cytoplasmic SH2 domain containing protein-tyrosine phosphatase (PTP) involved in the negative regulation of multiple signaling pathways in hematopoietic, nervous, and epithelial cells. The thyroid TRK-T3 oncogene consists of the NTRK1 tyrosine kinase domain fused in-frame with sequences of the TFG (TRK-fused gene), encoding a protein of unknown function. TFG contains a coiled-coil domain responsible for TRK-T3 oligomerization. In addition, recent analysis of the sequences outside of the coiled-coil domain suggested possible interactions with other proteins. Based on the presence of a putative SHP-1 SH2-binding site within the TFG sequences, we have investigated the role of the SHP-1 phosphatase in TRK-T3 oncoprotein signaling. In this study we show that SHP-1 interacts with and down-regulates TRK-T3. We provide evidence that SHP-1 SH2 and catalytic domains, respectively, associate with the TFG- and NTRK1-derived portions of TRK-T3. Our data contribute to the definition of cellular mechanisms involved in thyroid tumorigenesis. Moreover, it reveals TFG as a novel protein able to modulate SHP-1 activity.	Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, I-20133 Milan, Italy; IFOM Fdn, I-20139 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Greco, A (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, Via Venezian 1, I-20133 Milan, Italy.	angela.greco@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349				Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Duchesne C, 2003, J BIOL CHEM, V278, P14274, DOI 10.1074/jbc.M300425200; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Hennige AM, 2001, ENDOCRINOLOGY, V142, P4441, DOI 10.1210/en.142.10.4441; Hernandez L, 1999, BLOOD, V94, P3265; Hernandez L, 2002, AM J PATHOL, V160, P1487, DOI 10.1016/S0002-9440(10)62574-6; Hisaoka M, 2004, GENE CHROMOSOME CANC, V40, P325, DOI 10.1002/gcc.20044; Jones ML, 2004, J BIOL CHEM, V279, P40475, DOI 10.1074/jbc.M402970200; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lyons BL, 2003, EXP HEMATOL, V31, P234, DOI 10.1016/S0301-472X(02)01031-7; Marsh HN, 2003, J CELL BIOL, V163, P999, DOI 10.1083/jcb.200309036; Mencinger M, 1999, BIOCHEM BIOPH RES CO, V257, P67, DOI 10.1006/bbrc.1999.0417; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Ranzi V, 2003, ENDOCRINOLOGY, V144, P922, DOI 10.1210/en.2002-221002; Roccato E, 2003, ONCOGENE, V22, P807, DOI 10.1038/sj.onc.1206189; Roccato E, 2002, BRIT J CANCER, V87, P645, DOI 10.1038/sj.bjc.6600544; Sozio MS, 2004, J BIOL CHEM, V279, P7760, DOI 10.1074/jbc.M309994200; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Wheadon H, 2002, CELL SIGNAL, V14, P219, DOI 10.1016/S0898-6568(01)00241-8; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066	29	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3382	3389		10.1074/jbc.M407522200	http://dx.doi.org/10.1074/jbc.M407522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557341	hybrid			2022-12-25	WOS:000226983900032
J	Kippenberger, S; Loitsch, S; Guschel, M; Muller, J; Knies, Y; Kaufmann, R; Bernd, A				Kippenberger, S; Loitsch, S; Guschel, M; Muller, J; Knies, Y; Kaufmann, R; Bernd, A			Mechanical stretch stimulates protein kinase B/Akt phosphorylation in epidermal cells via angiotensin II type 1 receptor and epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; HUMAN KERATINOCYTES; ENDOTHELIAL-CELLS; AKT PROTOONCOGENE; ACTIVATION; TRANSACTIVATION; ADHESION; INVOLVEMENT; INTEGRINS; APOPTOSIS	Mechanical stress is known to modulate fundamental events such as cell life and death. Mechanical stretch in particular has been identified as a positive regulator of proliferation in skin keratinocytes and other cell systems. In the present study it was investigated whether antiapoptotic signaling is also stimulated by mechanical stretch. It was demonstrated that mechanical stretch rapidly induced the phosphorylation of the proto-oncogene protein kinase B (PKB)/Akt at both phosphorylation sites (serine 473/threonine 308) in different epithelial cells (HaCaT, A-431, and human embryonic kidney-293). Blocking of phosphoinositide 3-OH kinase by selective inhibitors (LY-294002 and wortmannin) abrogated the stretch-induced PKB/Akt phosphorylation. Furthermore mechanical stretch stimulated phosphorylation of epidermal growth factor receptor (EGFR) and the formation of EGFR membrane clusters. Functional blocking of EGFR phosphorylation by either selective inhibitors (AG1478 and PD168393) or dominant-negative expression suppressed stretch-induced PKB/ Akt phosphorylation. Finally, the angiotensin 11 type 1 receptor (AT1-R) was shown to induce positive transactivation of EGFR in response to cell stretch. These findings define a novel signaling pathway of mechanical stretch, namely the activation of PKB/Akt by transactivation of EGFR via angiotensin 11 type 1 receptor. Evidence is provided that stretch-induced activation of PKB/Akt protects cells against induced apoptosis.	Goethe Univ Frankfurt, Sch Med, Dept Internal Med, Div Pneumol, D-60596 Frankfurt, Germany; Goethe Univ Frankfurt, Sch Med, Dept Dermatol, D-60596 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Kippenberger, S (corresponding author), Univ Frankfurt Klinikum, Zentrum Dermatol & Venerol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	kippenberger@em.uni-frankfurt.de						Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Bernd A, 1992, EUR J DERMATOL, V2, P450; BOUCHER Y, 1992, CANCER RES, V52, P5110; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Durvasula RV, 2004, KIDNEY INT, V65, P30, DOI 10.1111/j.1523-1755.2004.00362.x; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Fisslthaler B, 2001, HYPERTENSION, V38, P1427, DOI 10.1161/hy1201.096532; Fornaro M, 2000, MOL BIOL CELL, V11, P2235, DOI 10.1091/mbc.11.7.2235; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GORMAR FE, 1993, CELL TISSUE CULTURE, P87; Hosokawa H, 2002, BIOL PHARM BULL, V25, P1588, DOI 10.1248/bpb.25.1588; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; Karasek M A, 1980, Curr Probl Dermatol, V10, P143; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kippenberger S, 2000, PIGM CELL RES, V13, P278, DOI 10.1034/j.1600-0749.2000.130410.x; Kippenberger S, 2000, J INVEST DERMATOL, V114, P408, DOI 10.1046/j.1523-1747.2000.00915.x; KOHN AD, 1995, EMBO J, V4288, P4295; Liu XM, 2003, FEBS LETT, V541, P52, DOI 10.1016/S0014-5793(03)00285-0; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Pearl LH, 2002, CURR OPIN STRUC BIOL, V12, P761, DOI 10.1016/S0959-440X(02)00386-X; Piiper A, 2003, J BIOL CHEM, V278, P7065, DOI 10.1074/jbc.M211234200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rubio I, 2003, BIOCHEM J, V376, P571, DOI 10.1042/BJ20031410; Sedding DG, 2003, CIRCULATION, V108, P616, DOI 10.1161/01.CIR.0000079102.08464.E2; Takei T, 1997, J CELL PHYSIOL, V173, P64, DOI 10.1002/(SICI)1097-4652(199710)173:1<64::AID-JCP8>3.0.CO;2-H; Tang KQ, 1999, BIOCHEM BIOPH RES CO, V264, P127, DOI 10.1006/bbrc.1999.1496; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Zeng YJ, 2003, BRIT J PLAST SURG, V56, P660, DOI 10.1016/S0007-1226(03)00217-0; Zhou RH, 2003, ARTERIOSCL THROM VAS, V23, P2015, DOI 10.1161/01.ATV.0000095161.06906.ED; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	43	78	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3060	3067		10.1074/jbc.M409590200	http://dx.doi.org/10.1074/jbc.M409590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15545271	hybrid			2022-12-25	WOS:000226449100082
J	Latres, E; Amini, AR; Amini, AA; Griffiths, J; Martin, FJ; Wei, Y; Lin, HC; Yancopoulos, GD; Glass, DJ				Latres, E; Amini, AR; Amini, AA; Griffiths, J; Martin, FJ; Wei, Y; Lin, HC; Yancopoulos, GD; Glass, DJ			Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SKELETAL-MUSCLE ATROPHY; UBIQUITIN-PROTEASOME PATHWAY; FOXO TRANSCRIPTION FACTORS; P70 S6 KINASE; MAMMALIAN TARGET; 4E-BP1 PHOSPHORYLATION; EXPRESSION; HYPERTROPHY; ACTIVATION	Skeletal muscle size is regulated by anabolic (hypertrophic) and catabolic (atrophic) processes. We first characterized molecular markers of both hypertrophy and atrophy and identified a small subset of genes that are inversely regulated in these two settings (e.g. up-regulated by an inducer of hypertrophy, insulin-like growth factor-1 (IGF-1), and down-regulated by a mediator of atrophy, dexamethasone). The genes identified as being inversely regulated by atrophy, as opposed to hypertrophy, include the E3 ubiquitin ligase MAFbx (also known as atrogin-1). We next sought to investigate the mechanism by which IGF-1 inversely regulates these markers, and found that the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway, which we had previously characterized as being critical for hypertrophy, is also required to be active in order for IGF-1-mediated transcriptional changes to occur. We had recently demonstrated that the IGF1/PI3K/Akt pathway can block dexamethasone-induced up-regulation of the atrophy-induced ubiquitin ligases MuRF1 and MAFbx by blocking nuclear translocation of a FOXO transcription factor. In the current study we demonstrate that an additional step of IGF1 transcriptional regulation occurs downstream of mTOR, which is independent of FOXO. Thus both the Akt/FOXO and the Akt/mTOR pathways are required for the transcriptional changes induced by IGF-1.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Regeneron	Glass, DJ (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	david.glass@regeneron.com	Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DeVol DL, 1990, AM J PHYSIOL, V259, P89; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Glass DJ, 2003, TRENDS MOL MED, V9, P344, DOI 10.1016/S1471-4914(03)00138-2; GOLDSPINK DF, 1983, BIOCHEM J, V210, P89, DOI 10.1042/bj2100089; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hasselgren P O, 1999, Curr Opin Clin Nutr Metab Care, V2, P201, DOI 10.1097/00075197-199905000-00002; HONG DH, 1995, MOL CELL ENDOCRINOL, V108, P199, DOI 10.1016/0303-7207(95)03476-N; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Matsui T, 2003, CELL CYCLE, V2, P220, DOI 10.4161/cc.2.3.381; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WING SS, 1993, AM J PHYSIOL, V264, P668; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2	45	376	401	3	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2737	2744		10.1074/jbc.M407517200	http://dx.doi.org/10.1074/jbc.M407517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15550386	hybrid			2022-12-25	WOS:000226449100046
J	Lucet, IS; Tynan, FE; Adams, V; Rossjohn, J; Lyras, D; Rood, J				Lucet, IS; Tynan, FE; Adams, V; Rossjohn, J; Lyras, D; Rood, J			Identification of the structural and functional domains of the large serine recombinase TnpX from Clostridium perfringens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-DELTA RESOLVASE; CHLORAMPHENICOL-RESISTANCE; TN4451; TRANSPOSITION; INTEGRATION; EXCISION; CLEAVAGE; ELEMENT; BINDING; FORMS	Members of the large serine resolvase family of site-specific recombinases are responsible for the movement of several mobile genetic elements; however, little is known regarding the structure or function of these proteins. TnpX is a serine recombinase that is responsible for the movement of the chloramphenicol resistance elements of the Tn4451/3 family. We have shown that TnpX binds differentially to its transposon and target sites, suggesting that resolvase-like excision and insertion were two distinct processes. To analyze the structural and functional domains of TnpX and, more specifically, to define the domains involved in protein-DNA and protein-protein interactions, we conducted limited proteolysis studies on the wild-type dimeric TnpX(1-707) protein and its functional truncation mutant, TnpX(1-597). The results showed that TnpX was organized into three major domains: domain I (amino acids (aa) 1-170), which included the resolvase catalytic domain; domain 11 (aa 170-266); and domain III (aa 267-707), which contained the dimerization region and two separate regions involved in binding to the DNA target. A small polypeptide (aa 533-587) was shown to bind specifically to the TnpX binding sites providing further evidence that it was the primary DNA binding region. In addition, a previously unidentified DNA binding site was shown to be located between residues 583 and 707. Finally, the DNA binding and multerimization but not the catalytic functions of TnpX could be reconstituted by recombining separate polypeptides that contain the N- and C-terminal regions of the protein. These data provide evidence that TnpX has separate catalytic, DNA binding, and multimerization domains.	Monash Univ, Dept Microbiol, Australian Bacterial Pathogenesis Program, Clayton, Vic 3800, Australia; Monash Univ, Dept Biochem & Mol Biol, Prot Crystallog Unit, Clayton, Vic 3800, Australia; Monash Univ, Australian Res Council Ctr Struct & Funct Microbi, Clayton, Vic 3800, Australia	Monash University; Monash University; Monash University	Rood, J (corresponding author), Monash Univ, Dept Microbiol, Australian Bacterial Pathogenesis Program, Clayton, Vic 3800, Australia.	julian.rood@med.monash.edu.au	Rossjohn, Jamie/F-9032-2013; Adams, Vicki/V-7077-2019; Rood, Julian I/A-4858-2008	Rossjohn, Jamie/0000-0002-2020-7522; Adams, Vicki/0000-0002-1506-1864; Rood, Julian I/0000-0003-2126-7209; Lyras, Dena/0000-0003-2345-9271				ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; Adams V, 2004, MOL MICROBIOL, V53, P1195, DOI 10.1111/j.1365-2958.2004.04198.x; Adams V, 2002, CELL MOL LIFE SCI, V59, P2033, DOI 10.1007/s000180200003; BANNAM TL, 1995, MOL MICROBIOL, V16, P535, DOI 10.1111/j.1365-2958.1995.tb02417.x; Bibb LA, 2002, MOL MICROBIOL, V45, P1515, DOI 10.1046/j.1365-2958.2002.03130.x; Breuner A, 1999, J BACTERIOL, V181, P7291; Crellin PK, 1997, J BACTERIOL, V179, P5148, DOI 10.1128/jb.179.16.5148-5156.1997; Hall Randy A, 2004, Methods Mol Biol, V261, P167; Hallet B, 1997, FEMS MICROBIOL REV, V21, P157, DOI 10.1016/S0168-6445(97)00055-7; Iyer LM, 2001, J VIROL, V75, P11720, DOI 10.1128/JVI.75.23.11720-11734.2001; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kim AI, 2003, MOL MICROBIOL, V50, P463, DOI 10.1046/j.1365-2958.2003.03723.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lyras D, 1998, ANTIMICROB AGENTS CH, V42, P1563, DOI 10.1128/AAC.42.7.1563; Lyras D, 2000, MOL MICROBIOL, V38, P588, DOI 10.1046/j.1365-2958.2000.02154.x; Lyras D, 2004, MOL MICROBIOL, V51, P1787, DOI 10.1111/j.1365-2958.2003.03950.x; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Matsuura T, 1996, J BACTERIOL, V178, P3374, DOI 10.1128/jb.178.11.3374-3376.1996; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; POPHAM DL, 1992, P NATL ACAD SCI USA, V89, P5991, DOI 10.1073/pnas.89.13.5991; Rood JI, 2004, PLASMID BIOLOGY, P413; Smith MCM, 2002, MOL MICROBIOL, V44, P299, DOI 10.1046/j.1365-2958.2002.02891.x; Thorpe HM, 1998, P NATL ACAD SCI USA, V95, P5505, DOI 10.1073/pnas.95.10.5505; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0	25	17	18	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2503	2511		10.1074/jbc.M409702200	http://dx.doi.org/10.1074/jbc.M409702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15542858	hybrid			2022-12-25	WOS:000226449100017
J	Neculai, AM; Neculai, D; Griesinger, C; Vorholt, JA; Becker, S				Neculai, AM; Neculai, D; Griesinger, C; Vorholt, JA; Becker, S			A dynamic zinc redox switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMALDEHYDE DEHYDROGENASE; PARACOCCUS-DENITRIFICANS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NMR-SPECTROSCOPY; TERNARY COMPLEX; CHAPERONE HSP33; METALLOTHIONEIN; MECHANISM; ACTIVATION	The crystal structures of glutathione-dependent formaldehyde-activating enzyme (Gfa) from Paracoccus denitrificans, which catalyzes the formation of S-hydroxymethylglutathione from formaldehyde and glutathione, and its complex with glutathione (Gfa-GTT) have been determined. Gfa has a new fold with two zinc-sulfur centers, one that is structural (zinc tetracoordinated) and one catalytic (zinc apparently tricoordinated). In Gfa-GTT, the catalytic zinc is displaced due to disulfide bond formation of glutathione with one of the zinc-coordinating cysteines. Soaking crystals of Gfa-GTT with formaldehyde restores the holoenzyme. Accordingly, the displaced zinc forms a complex by scavenging formaldehyde and glutathione. The activation of formaldehyde and of glutathione in this zinc complex favors the final nucleophilic addition, followed by relocation of zinc in the catalytic site. Therefore, the structures of Gfa and Gfa-GTT draw the critical association between a dynamic zinc redox switch and a nucleophilic addition as a new facet of the redox activity of zinc-sulfur sites.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; INRA, CNRS, Lab Interact Plantes Microorganisms, F-31326 Castanet Tolosan, France	Max Planck Society; INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS)	Becker, S (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany.	sabe@nmr.mpibpc.mpg.de	Neculai, Dante/A-9923-2011; Vorholt, Julia/K-3514-2016	Neculai, Dante/0000-0001-8887-9168; Vorholt, Julia/0000-0002-6011-4910				Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; Dauter Z, 2002, ACTA CRYSTALLOGR D, V58, P494, DOI 10.1107/S090744490200118X; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Goenrich M, 2002, J BIOL CHEM, V277, P3069, DOI 10.1074/jbc.C100579200; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; Gutheil WG, 1997, BIOCHEM BIOPH RES CO, V238, P693, DOI 10.1016/S0006-291X(00)90000-7; Harding MM, 2004, ACTA CRYSTALLOGR D, V60, P849, DOI 10.1107/S0907444904004081; Harms N, 1996, J BACTERIOL, V178, P6296, DOI 10.1128/jb.178.21.6296-6299.1996; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Janda I, 2004, STRUCTURE, V12, P1901, DOI 10.1016/j.str.2004.08.003; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Krezel A, 2003, CHEM COMMUN, P704, DOI 10.1039/b300632h; Kruer M, 2002, EUR J BIOCHEM, V269, P2117, DOI 10.1046/j.1432-1033.2002.02860.x; Kurek I, 2002, P NATL ACAD SCI USA, V99, P11109, DOI 10.1073/pnas.162077099; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARET W, 1995, NEUROCHEM INT, V27, P111, DOI 10.1016/0197-0186(94)00173-R; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; Maret W, 2004, BIOCHEMISTRY-US, V43, P3301, DOI 10.1021/bi036340p; MASON RP, 1986, BIOCHEMISTRY-US, V25, P4504, DOI 10.1021/bi00364a008; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Sanghani PC, 2002, BIOCHEMISTRY-US, V41, P15189, DOI 10.1021/bi026705q; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Won HS, 2004, J MOL BIOL, V341, P893, DOI 10.1016/j.jmb.2004.06.046; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	33	12	13	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2826	2830		10.1074/jbc.C400517200	http://dx.doi.org/10.1074/jbc.C400517200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548539	Green Published, hybrid			2022-12-25	WOS:000226449100056
J	Jiang, GL; Zhuang, LN; Miyauchi, S; Miyake, K; Fei, YJ; Ganapathy, V				Jiang, GL; Zhuang, LN; Miyauchi, S; Miyake, K; Fei, YJ; Ganapathy, V			A Na+/Cl--coupled GABA transporter, GAT-1, from Caenorhabditis elegans - Structural and functional features, specific expression in GABA-ergic neurons, and involvement in muscle function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE TRANSPORTER; MOLECULAR-CLONING; CALCIUM-CHANNEL; NERVOUS-SYSTEM; ACID; PHYSIOLOGY; RECEPTORS; SEROTONIN; RELEVANCE; DOPAMINE	GABA functions as an inhibitory neurotransmitter in body muscles and as an excitatory neurotransmitter in enteric muscles in Caenorhabditis elegans. Whereas many of the components of the GABA-ergic neurotransmission in this organism have been identified at the molecular and functional levels, no transporter specific for this neurotransmitter has been identified to date. Here we report on the cloning and functional characterization of a GABA transporter from C. elegans (ceGAT-1) and on the functional relevance of the transporter to the biology of body muscles and enteric muscles. ceGAT-1 is coded by snf-11 gene, a member of the sodium-dependent neurotransmitter symporter gene family in C. elegans. The cloned ceGAT-1 functions as a Na+/Cl--coupled high-affinity transporter selective for GABA with a K-t of similar to15 muM. The Na+:Cl-:GABA stoichiometry for ce-GAT-1-mediated transport process is 2:1:1. The transport process is electrogenic as evidenced from GABA-induced inward currents in Xenopus laevis oocytes that express ceGAT-1 heterologously. The transporter is expressed exclusively in GABA-ergic neurons and in two other additional neurons. We also investigated the functional relevance of ceGAT-1 to the biology of body muscles and enteric muscles by ceGAT-1-specific RNA interference (RNAi) in rrf-3 mutant, a strain of C. elegans in which neurons are not refractory to RNAi as in the wild type strain. The down-regulation of ceGAT-1 by RNAi leads to an interesting phenotype associated with altered function of body muscles ( as evident from changes in thrashing frequency) and enteric muscles ( as evident from the rates of defecation failure) and also with altered sensitivity to aldicarb-induced paralysis. These findings provide unequivocal evidence for a modulatory role of GABA and ceGAT-1 in the biology of cholinergic neurons and in the function of body muscles and enteric muscles in this organism.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	vganapat@mail.mcg.edu			NHLBI NIH HHS [HL64196] Funding Source: Medline; NIAID NIH HHS [AI49849] Funding Source: Medline; NIA NIH HHS [AG22468] Funding Source: Medline; NICHD NIH HHS [HD44404] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD044404] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022468] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashton H, 2003, J PSYCHOPHARMACOL, V17, P174, DOI 10.1177/0269881103017002004; Bamber BA, 1999, J NEUROSCI, V19, P5348; Bamber BA, 2003, BRIT J PHARMACOL, V138, P883, DOI 10.1038/sj.bjp.0705119; Beg AA, 2003, NAT NEUROSCI, V6, P1145, DOI 10.1038/nn1136; BOWERY NG, 1989, GABA BASIC RES CLIN, P1; Brambilla P, 2003, MOL PSYCHIATR, V8, P721, DOI 10.1038/sj.mp.4001362; Bridges CC, 2004, INVEST OPHTH VIS SCI, V45, P2906, DOI 10.1167/iovs.03-1355; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Dalby NO, 2003, EUR J PHARMACOL, V479, P127, DOI 10.1016/j.ejphar.2003.08.063; De Biasi S, 1998, NEUROSCIENCE, V83, P815, DOI 10.1016/S0306-4522(97)00414-4; Fei YJ, 2004, BIOCHEM J, V379, P191, DOI 10.1042/BJ20031807; Fei YJ, 1998, BIOCHEM J, V332, P565, DOI 10.1042/bj3320565; Fei YJ, 2000, J BIOL CHEM, V275, P9563, DOI 10.1074/jbc.275.13.9563; Fei YJ, 2003, J BIOL CHEM, V278, P6136, DOI 10.1074/jbc.M208763200; Feinberg EH, 2003, SCIENCE, V301, P1545, DOI 10.1126/science.1087117; George RL, 1999, J PHARMACOL EXP THER, V291, P596; Gupta M, 2003, ANN NEUROL, V54, pS81, DOI 10.1002/ana.10625; Hebert SC, 2004, PFLUG ARCH EUR J PHY, V447, P580, DOI 10.1007/s00424-003-1066-3; IKEGAKI N, 1994, MOL BRAIN RES, V26, P47, DOI 10.1016/0169-328X(94)90072-8; Jayanthi LD, 1998, MOL PHARMACOL, V54, P601; Jin YS, 1999, J NEUROSCI, V19, P539; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; LIU DWC, 1994, J NEUROSCI, V14, P1953; Lydiard RB, 2003, J CLIN PSYCHIAT, V64, P21; Mathews EA, 2003, J NEUROSCI, V23, P6537; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; Mello C, 1995, METHOD CELL BIOL, V48, P451; MINELLI A, 1995, J NEUROSCI, V15, P7734, DOI 10.1523/jneurosci.15-11-07734.1995; Minelli A, 1996, J NEUROSCI, V16, P6255, DOI 10.1523/jneurosci.16-19-06255.1996; RADIAN R, 1990, J NEUROSCI, V10, P1319; Ranganathan R, 2001, J NEUROSCI, V21, P5871, DOI 10.1523/JNEUROSCI.21-16-05871.2001; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; Sarup A, 2003, CNS NEUROL DISORD-DR, V2, P269, DOI 10.2174/1568007033482788; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Scheffer IE, 2003, TRENDS PHARMACOL SCI, V24, P428, DOI 10.1016/S0165-6147(03)00194-9; Schuske K, 2004, TRENDS NEUROSCI, V27, P407, DOI 10.1016/j.tins.2004.05.005; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Sulston J., 1988, NEMATODE CAENORHABDI, P587; THOMAS JH, 1990, GENETICS, V124, P855; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Wong CGT, 2003, ANN NEUROL, V54, pS3, DOI 10.1002/ana.10696; Wu X, 1999, BBA-BIOMEMBRANES, V1418, P239, DOI 10.1016/S0005-2736(99)00020-6	45	25	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2065	2077		10.1074/jbc.M408470200	http://dx.doi.org/10.1074/jbc.M408470200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542610	hybrid			2022-12-25	WOS:000226341700041
J	Kelley, RF; Totpal, K; Lindstrom, SH; Mathieu, M; Billeci, K; DeForge, L; Pai, R; Hymowitz, SG; Ashkenazi, A				Kelley, RF; Totpal, K; Lindstrom, SH; Mathieu, M; Billeci, K; DeForge, L; Pai, R; Hymowitz, SG; Ashkenazi, A			Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMORICIDAL ACTIVITY; CRYSTAL-STRUCTURE; DEATH RECEPTORS; DECOY RECEPTORS; PHAGE DISPLAY; FACTOR VIIA; HUMAN TRAF2; IN-VIVO; APO2L/TRAIL; INITIATION	Apoptosis-inducing ligand 2 (Apo2L), also called tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), triggers programmed cell death in various types of cancer cells but not in most normal cells. Apo2L/TRAIL is a homotrimeric protein that interacts with five receptors: death receptor 4 (DR4) and DR5 mediate apoptosis activation, whereas decoy receptor 1 (DcR1), DcR2, and osteoprotegerin counteract this function. Many cancer cell lines express both DR4 and DR5, and each of these receptors can initiate apoptosis independently of the other. However, the relative contribution of DR4 and DR5 to ligand-induced apoptosis is unknown. To investigate this question, we generated death receptor-selective Apo2L/TRAIL variants using a novel approach that enables phage display of mutated trimeric proteins. Selective binding to DR4 or DR5 was achieved with three to six-ligand amino acid substitutions. The DR4-selective Apo2L/TRAIL variants examined in this study showed a markedly reduced ability to trigger apoptosis, whereas the DR5-selective variants had minimally decreased or slightly increased apoptosis-inducing activity. These results suggest that DR5 may contribute more than DR4 to Apo2L/TRAIL-induced apoptosis in cancer cells that express both death receptors.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Proc Sci, San Francisco, CA 94080 USA; Genentech Inc, Dept Assay & Automat Technol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Kelley, RF (corresponding author), Genentech Inc, Dept Prot Engn MS 27, 1 DNA Way, San Francisco, CA 94080 USA.	rk@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee GF, 1998, J BIOL CHEM, V273, P4149, DOI 10.1074/jbc.273.7.4149; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Sidhu SS, 2004, J MOL BIOL, V338, P299, DOI 10.1016/j.jmb.2004.02.050; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	28	231	241	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2205	2212		10.1074/jbc.M410660200	http://dx.doi.org/10.1074/jbc.M410660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15520016	hybrid			2022-12-25	WOS:000226341700056
J	Gulberti, S; Lattard, V; Fondeur, M; Jacquinet, JC; Mullier, G; Netter, P; Magdalou, J; Ouzzine, M; Fournel-Gigleux, S				Gulberti, S; Lattard, V; Fondeur, M; Jacquinet, JC; Mullier, G; Netter, P; Magdalou, J; Ouzzine, M; Fournel-Gigleux, S			Phosphorylation and sulfation of oligosaccharide substrates critically influence the activity of human beta 1,4-galactosyltransferase 7 (GalT-I) and beta 1,3-glucuronosyltransferase I (GlcAT-I) involved in the biosynthesis of the glycosaminoglycan-protein linkage region of Proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE; HEPARAN-SULFATE; HUMAN GLUCURONOSYLTRANSFERASE; MOLECULAR-CLONING; IDENTIFICATION; EXPRESSION; GALACTOSE; XYLOSE; GLYCOPEPTIDES; SULFOFORMS	We determined whether the two major structural modifications, i.e. phosphorylation and sulfation of the glycosaminoglycan-protein linkage region (GlcAbeta1-3Galbeta1-3Galbeta1-4Xylbeta1), govern the specificity of the glycosyltransferases responsible for the biosynthesis of the tetrasaccharide primer. We analyzed the influence of C-2 phosphorylation of Xyl residue on human beta1,4-galactosyltransferase 7 (GalT-I), which catalyzes the transfer of Gal onto Xyl, and we evaluated the consequences of C-4/C-6 sulfation of Galbeta1-3Gal (Gal2-Gal1) on the activity and specificity of beta1,3-glucuronosyltransferase I (GlcAT-I) responsible for the completion of the glycosaminoglycan primer sequence. For this purpose, a series of phosphorylated xylosides and sulfated C-4 and C-6 analogs of Galbeta1-3Gal was synthesized and tested as potential substrates for the recombinant enzymes. Our results revealed that the phosphorylation of Xyl on the C-2 position prevents GalT-I activity, suggesting that this modification may occur once Gal is attached to the Xyl residue of the nascent oligosaccharide linkage. On the other hand, we showed that sulfation on C-6 position of Gal1 of the Galbeta1-3Gal analog markedly enhanced GlcAT-I catalytic efficiency and we demonstrated the importance of Trp(243) and Lys(317) residues of Gal1 binding site for enzyme activity. In contrast, we found that GlcAT-I was unable to use digalactosides as acceptor substrates when Gal1 was sulfated on C-4 position or when Gal2 was sulfated on both C-4 and C-6 positions. Altogether, we demonstrated that oligosaccharide modifications of the linkage region control the specificity of the glycosyltransferases, a process that may regulate maturation and processing of glycosaminoglycan chains.	Univ Nancy 1, Fac Med, CNRS, UMR 7561, F-54505 Vandoeuvre Les Nancy, France; UFR Sci, CNRS, UMR 6005, F-45067 Orleans 02, France; Univ Nancy 1, Fac Sci, CNRS, UMR 7036, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; CEA; Centre National de la Recherche Scientifique (CNRS); Universite de Orleans; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Universite de Lorraine	Fournel-Gigleux, S (corresponding author), Univ Nancy 1, Fac Med, CNRS, UMR 7561, BP 184, F-54505 Vandoeuvre Les Nancy, France.	sfg@medecine.uhp-nancy.fr	Wahhed, Abdul/AAA-3099-2020; Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950; GULBERTI, Sandrine/0000-0002-9378-4697				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng F, 1996, J BIOL CHEM, V271, P28572, DOI 10.1074/jbc.271.45.28572; Crossman A, 2002, CARBOHYD RES, V337, P2049, DOI 10.1016/S0008-6215(02)00187-8; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gulberti S, 2003, J BIOL CHEM, V278, P32219, DOI 10.1074/jbc.M207899200; Jacquinet JC, 2004, CARBOHYD RES, V339, P349, DOI 10.1016/j.carres.2003.10.012; Kakuda S, 2004, J BIOL CHEM, V279, P22693, DOI 10.1074/jbc.M400622200; Kisilevsky R, 2004, J MOL NEUROSCI, V24, P167, DOI 10.1385/JMN:24:1:167; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Krishna NR, 2001, ADV CARBOHYD CHEM BI, V56, P201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauder RM, 2001, BIOCHEM J, V358, P523, DOI 10.1042/0264-6021:3580523; Lauder RM, 2000, BIOCHEM J, V347, P339, DOI 10.1042/0264-6021:3470339; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Martin NB, 1996, SEMIN THROMB HEMOST, V22, P247, DOI 10.1055/s-2007-999015; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Moses J, 1997, EUR J BIOCHEM, V248, P767, DOI 10.1111/j.1432-1033.1997.t01-1-00767.x; Ouzzine M, 2002, J BIOL CHEM, V277, P25439, DOI 10.1074/jbc.M201912200; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; RIO S, 1991, CARBOHYD RES, V219, P71, DOI 10.1016/0008-6215(91)89043-F; RIO S, 1994, CARBOHYD RES, V255, P103, DOI 10.1016/S0008-6215(00)90973-X; SALIMATH PV, 1995, J BIOL CHEM, V270, P9164, DOI 10.1074/jbc.270.16.9164; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Seko A, 2003, J BIOL CHEM, V278, P9150, DOI 10.1074/jbc.M211480200; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; Thollas B, 2004, ORG BIOMOL CHEM, V2, P434, DOI 10.1039/b314244b; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; van der Veen BA, 2001, J BIOL CHEM, V276, P44557, DOI 10.1074/jbc.M107533200; YAMADA S, 1995, GLYCOBIOLOGY, V5, P335, DOI 10.1093/glycob/5.3.335; YAMADA S, 1995, EUR J BIOCHEM, V233, P687, DOI 10.1111/j.1432-1033.1995.687_2.x	44	66	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1417	1425		10.1074/jbc.M411552200	http://dx.doi.org/10.1074/jbc.M411552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522873	hybrid			2022-12-25	WOS:000226195200069
J	Pickett, JA; Thorn, P; Edwardson, JM				Pickett, JA; Thorn, P; Edwardson, JM			The plasma membrane Q-SNARE syntaxin 2 enters the zymogen granule membrane during exocytosis in the pancreatic acinar cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EXOCYTOSIS; FUSION PORE; IDENTIFICATION; STIMULATION; SECRETION; SNAP-23	During exocytosis in the pancreatic acinar cell, zymogen granules fuse directly with the apical plasma membrane and also with granules that have themselves fused with the plasma membrane. Together, these primary and secondary fusion events constitute the process of compound exocytosis. It has been suggested that the sequential nature of primary and secondary fusion is a consequence of the requirement for plasma membrane soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptors, such as syntaxin 2, to enter the membrane of the primary fused granule. We have tested this possibility by determining the location of syntaxin 2 in unstimulated and stimulated pancreatic acini. Syntaxin 2 was imaged by confocal immunofluorescence microscopy. Fused granules were detected both through their filling with the aqueous dye lysine-fixable Texas Red-dextran and through the decoration of their cytoplasmic surfaces with filamentous actin. In unstimulated cells, syntaxin 2 was exclusively present on the apical plasma membrane. In contrast, after stimulation, syntaxin 2 had moved into the membranes of fused granules, as judged by its location around dye-filled structures of 1-mum diameter that were coated with filamentous actin. At long times of stimulation (5 min), the majority (85%) of dye-filled granules were also positive for syntaxin 2. In contrast, at shorter times (1 min), more dye-filled granules (29%) were syntaxin 2-negative. We conclude that syntaxin 2 enters the membrane of a fused zymogen granule after the opening of the fusion pore, and we suggest that this movement might permit the onset of secondary fusion.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Edwardson, JM (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	jme1000@cam.ac.uk	Thorn, Peter/F-7030-2010	Thorn, Peter/0000-0002-3228-770X; Pickett, James/0000-0002-2657-0795				Campos-Toimil M, 2000, J PHYSIOL-LONDON, V528, P317, DOI 10.1111/j.1469-7793.2000.00317.x; DECAMILLI P, 1976, J CELL BIOL, V70, P59, DOI 10.1083/jcb.70.1.59; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; ICHIKAWA A, 1965, J CELL BIOL, V24, P369, DOI 10.1083/jcb.24.3.369; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; NADIN CY, 1989, J CELL BIOL, V109, P2801, DOI 10.1083/jcb.109.6.2801; Nemoto T, 2004, J BIOL CHEM, V279, P37544, DOI 10.1074/jbc.M403976200; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Padfield PJ, 1998, PFLUG ARCH EUR J PHY, V436, P782, DOI 10.1007/s004240050702; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Schmidt K, 2001, J BIOL CHEM, V276, P14315, DOI 10.1074/jbc.M006221200; Schneider SW, 1997, P NATL ACAD SCI USA, V94, P316, DOI 10.1073/pnas.94.1.316; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takahashi N, 2004, J CELL BIOL, V165, P255, DOI 10.1083/jcb.200312033; TANAKA Y, 1980, J CELL BIOL, V84, P438, DOI 10.1083/jcb.84.2.438; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; Thorn P, 2004, P NATL ACAD SCI USA, V101, P6774, DOI 10.1073/pnas.0400336101; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Turvey MR, 2004, PFLUG ARCH EUR J PHY, V448, P552, DOI 10.1007/s00424-004-1288-z; Valentijn JA, 2000, P NATL ACAD SCI USA, V97, P1091, DOI 10.1073/pnas.97.3.1091; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002	27	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1506	1511		10.1074/jbc.M411967200	http://dx.doi.org/10.1074/jbc.M411967200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536072	hybrid			2022-12-25	WOS:000226195200080
J	Yamamoto, K; Hirao, K; Oshima, T; Aiba, H; Utsumi, R; Ishihama, A				Yamamoto, K; Hirao, K; Oshima, T; Aiba, H; Utsumi, R; Ishihama, A			Functional characterization in vitro of all two-component signal transduction systems from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SYSTEM; RESPONSE REGULATOR; RNA-POLYMERASE; ENVELOPE STRESS; SENSOR KINASE; OMPC GENES; PHOP-PHOQ; IDENTIFICATION; PHOSPHORELAY; K-12	Bacteria possess a signal transduction system, referred to as a two-component system, for adaptation to external stimuli. Each two-component system consists of a sensor protein-histidine kinase (HK) and a response regulator (RR), together forming a signal transduction pathway via histidyl-aspartyl phospho-relay. A total of 30 sensor HKs, including as yet uncharacterized putative HKs (BaeS, BasS, CreC, CusS, HydH, RstB, YedV, and YfhK), and a total of 34 RRs, including putative RRs (BaeR, BasR, CreB, CusR, HydG, RstA, YedW, YfhA, YgeK, and YhjB), have been suggested to exist in Escherichia coli. We have purified the carboxyl-terminal catalytic domain of 27 sensor HKs and the full-length protein of all 34 RRs to apparent homogeneity. Self-phosphorylation in vitro was detected for 25 HKs. The rate of self-phosphorylation differed among HKs, whereas the level of phosphorylation was generally co-related with the phosphorylation rate. However, the phosphorylation level was low for ArcB, HydH, NarQ, and NtrB even though the reaction rate was fast, whereas the level was high for the slow phosphorylation species BasS, CheA, and CreC. By using the phosphorylated HKs, we examined trans-phosphorylation in vitro of RRs for all possible combinations. Trans-phosphorylation of presumed cognate RRs by HKs was detected, for the first time, for eight pairs, BaeS-BaeR, BasS-BasR, CreC-CreB, CusS-CusR, HydH-HydG, RstB-RstA, YedV-YedW, and YfhK-YfhA. All trans-phosphorylation took place within less than 1/2 min, but the stability of phosphorylated RRs differed, indicating the involvement of de-phosphorylation control. In addition to the trans-phosphorylation between the cognate pairs, we detected trans-phosphorylation between about 3% of non-cognate HK-RR pairs, raising the possibility that the cross-talk in signal transduction takes place between two-component systems.	Kinki Univ, Dept Agr Chem, Nara 6318505, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; Nagoya Univ, Sch Agr, Mol Microbiol Lab, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nippon Inst Biol Sci, Div Mol Biol, Tokyo 1980024, Japan	Kindai University (Kinki University); Nara Institute of Science & Technology; Nagoya University	Yamamoto, K (corresponding author), Kinki Univ, Dept Agr Chem, Nakamachi 3327, Nara 6318505, Japan.	kyamam@nara.kindai.ac.jp						Abo-Amer AE, 2004, J BACTERIOL, V186, P1879, DOI 10.1128/JB.186.6.1879-1889.2004; AIBA H, 1989, J BIOL CHEM, V264, P8563; Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; Bordi C, 2003, MOL MICROBIOL, V48, P211, DOI 10.1046/j.1365-2958.2003.03428.x; COMPAN I, 1994, MOL MICROBIOL, V11, P955, DOI 10.1111/j.1365-2958.1994.tb00374.x; De Wulf P, 1999, J BACTERIOL, V181, P6772, DOI 10.1128/JB.181.21.6772-6778.1999; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Hagiwara D, 2004, BIOSCI BIOTECH BIOCH, V68, P1758, DOI 10.1271/bbb.68.1758; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; IUCHI S, 1995, 2 COMPONENT SIGNAL T, P223; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; Jung K, 2002, J MOL MICROB BIOTECH, V4, P223; Kadner R., 1995, TWOCOMPONENT SIGNAL, P263; Kato A, 1999, J BACTERIOL, V181, P5516, DOI 10.1128/JB.181.17.5516-5520.1999; Leonhartsberger S, 2001, J MOL BIOL, V307, P93, DOI 10.1006/jmbi.2000.4451; Levit MN, 1998, MOL MICROBIOL, V30, P459, DOI 10.1046/j.1365-2958.1998.01066.x; Maeda H, 2000, NUCLEIC ACIDS RES, V28, P3497, DOI 10.1093/nar/28.18.3497; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; Makinoshima H, 2003, J BACTERIOL, V185, P1338, DOI 10.1128/JB.185.4.1338-1345.2003; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; Mori H, 2000, RES MICROBIOL, V151, P121, DOI 10.1016/S0923-2508(00)00119-4; Munson GP, 2000, J BACTERIOL, V182, P5864, DOI 10.1128/JB.182.20.5864-5871.2000; Oshima T, 2002, MOL MICROBIOL, V46, P281, DOI 10.1046/j.1365-2958.2002.03170.x; Pernestig AK, 2001, J BIOL CHEM, V276, P225, DOI 10.1074/jbc.M001550200; Pratt LA, 1996, P NATL ACAD SCI USA, V93, P2488, DOI 10.1073/pnas.93.6.2488; Puppe W, 1996, J BIOL CHEM, V271, P25027, DOI 10.1074/jbc.271.40.25027; Raffa RG, 2002, MOL MICROBIOL, V45, P1599, DOI 10.1046/j.1365-2958.2002.03112.x; Raivio TL, 1997, J BACTERIOL, V179, P7724, DOI 10.1128/jb.179.24.7724-7733.1997; Raivio TL, 2001, ANNU REV MICROBIOL, V55, P591, DOI 10.1146/annurev.micro.55.1.591; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; Stewart V., 1995, 2 COMPONENT SIGNAL T, P233; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Sugiura M, 2003, BIOSCI BIOTECH BIOCH, V67, P1612, DOI 10.1271/bbb.67.1612; Takeda S, 2001, MOL MICROBIOL, V40, P440, DOI 10.1046/j.1365-2958.2001.02393.x; WANNER BL, 1995, 2 COMPONENT SIGNAL T, P203; Wright JS, 2000, J BACTERIOL, V182, P6279, DOI 10.1128/JB.182.22.6279-6286.2000; Yamamoto K, 2002, MOL MICROBIOL, V45, P423, DOI 10.1046/j.1365-2958.2002.03017.x; YZENG YL, 1997, J MOL BIOL, V272, P200; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	45	336	363	3	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1448	1456		10.1074/jbc.M410104200	http://dx.doi.org/10.1074/jbc.M410104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522865	hybrid			2022-12-25	WOS:000226195200073
J	Buonamici, S; Li, DL; Mikhail, FM; Sassano, A; Platanias, LC; Colamonici, O; Anastasi, J; Nucifora, G				Buonamici, S; Li, DL; Mikhail, FM; Sassano, A; Platanias, LC; Colamonici, O; Anastasi, J; Nucifora, G			EVI1 abrogates interferon-alpha response by selectively blocking PML induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-TRANSFORMING GENE; LEUKEMIA PROTEIN PML; PR-DOMAIN FAMILY; TRANSCRIPTIONAL ACTIVATOR; ZINC FINGERS; EXPRESSION; SEQUENCE; CELLS; PATHWAY; BINDING	EVI1 is an oncogene frequently associated with chronic and acute myeloid leukemia. In hematopoietic cells, EVI1 impairs several pathways including proliferation, differentiation, and apoptosis. Interferon-alpha (IFN-alpha) is a powerful cytokine that controls the immune response and limits the expansion of several tissues including bone marrow. These properties contribute to the effectiveness of IFN-alpha in the treatment of many neoplastic disorders especially chronic myeloid leukemia. We report here that in murine hematopoietic progenitors the expression of EVI1 completely abrogates the antiproliferative and apoptotic effects of IFN-alpha. EVI1 does not repress the JAK/STAT signaling pathway or the activation of many IFN-responsive genes. On the contrary, EVI1 prolongs the phosphorylation of STAT1 and the activation of an IFN-dependent reporter gene. However, EVI1 specifically represses the IFN-dependent induction of the tumor suppressor PML and blocks the apoptotic pathways activated by PML. We show that the position of the ISRE, which is located within the first exon of PML, is critical to block PML induction by IFN-alpha. The relocation of the ISRE to a position upstream of the transcription start site is sufficient to re-establish the response to IFN in the presence of EVI1. Our data suggest that stabilized STAT1 phosphorylation and prolonged binding of the STAT1 complex to the first exon could impair PML transcription and inhibit the activation of PML-dependent apoptotic pathways resulting in loss of IFN response. These results point to a novel mechanism utilized by an oncogene to escape normal cell response to growth-controlling cytokines.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Univ Alexandria, Fac Med, Dept Clin Pathol, Alexandria, Egypt; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Hematol Oncol Sect, Chicago, IL 60611 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60607 USA; Univ Chicago, Dept Pathol, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Egyptian Knowledge Bank (EKB); Alexandria University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, M-C 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu						BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Bohlander SK, 2000, CYTOGENET CELL GENET, V91, P52, DOI 10.1159/000056818; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Bounamici S, 2002, BLOOD, V99, P443, DOI 10.1182/blood.V99.2.443; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Buonamici S, 2003, BLOOD CELL MOL DIS, V31, P206, DOI 10.1016/S1079-9796(03)00159-1; Buyse IM, 1996, GENOMICS, V34, P119, DOI 10.1006/geno.1996.0249; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chi YQ, 2003, J BIOL CHEM, V278, P49806, DOI 10.1074/jbc.M309645200; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUNABIKI T, 1994, ONCOGENE, V9, P1575; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LAVAU C, 1995, ONCOGENE, V11, P871; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Manzella L, 2000, EXP CELL RES, V256, P248, DOI 10.1006/excr.1999.4794; Massion PP, 2002, CANCER RES, V62, P3636; Melo JV, 1996, LEUKEMIA, V10, P751; Mock BA, 1996, GENOMICS, V37, P24, DOI 10.1006/geno.1996.0516; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nishikata I, 2003, BLOOD, V102, P3323, DOI 10.1182/blood-2002-12-3944; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Senyuk V, 2002, ONCOGENE, V21, P3232, DOI 10.1038/sj.onc.1205436; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Sitailo S, 1999, LEUKEMIA, V13, P1639, DOI 10.1038/sj.leu.2401585; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; van Doorn-Khosrovani SBV, 2003, EXP HEMATOL, V31, P1066, DOI 10.1016/j.exphem.2003.08.003; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Yokoi S, 2003, CLIN CANCER RES, V9, P4705	49	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					428	436		10.1074/jbc.M410836200	http://dx.doi.org/10.1074/jbc.M410836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15519999	hybrid			2022-12-25	WOS:000226025100052
J	Galani, K; Nissan, TA; Petfalski, E; Tollervey, D; Hurt, E				Galani, K; Nissan, TA; Petfalski, E; Tollervey, D; Hurt, E			Rea1, a dynein-related nuclear AAA-ATPase, is involved in late rRNA processing and nuclear export of 60 S subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-RIBOSOME; PROTEIN; IDENTIFICATION; BIOGENESIS; NUCLEOLUS; MATURATION; GTPASE; 90S	Rea1, the largest predicted protein in the yeast genome, is a member of the AAA(+) family of ATPases and is associated with pre-60 S ribosomes. Here we report that Rea1 is required for maturation and nuclear export of the pre-60 S subunit. Rea1 exhibits a predominantly nucleoplasmic localization and is present in a late pre-60 S particle together with members of the Rix1 complex. To study the role of Rea1 in ribosome biogenesis, we generated a repressible GAL::REA1 strain and temperature-sensitive rea1 alleles. In vivo depletion of Rea1 results in the significant reduction of mature 60 S subunits concomitant with defects in pre-rRNA processing and late pre-60 S ribosome stability following ITS2 cleavage and prior to the generation of mature 5.8 S rRNA. Strains depleted of the components of the Rix1 complex (Rix1, Ipi1, and Ipi3) showed similar defects. Using an in vivo 60 S subunit export assay, a strong accumulation of the large subunit reporter Rpl25-GFP (green fluorescent protein) in the nucleus and at the nuclear periphery was seen in rea1 mutants at restrictive conditions.	Univ Heidelberg BZH, Zentrum Biochem, D-69120 Heidelberg, Germany; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Ruprecht Karls University Heidelberg; University of Edinburgh	Hurt, E (corresponding author), Univ Heidelberg BZH, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uniheidelberg.de	Nissan, Tracy/D-5223-2012; Tollervey, David/AAR-6662-2020; Ed Hurt, Dr./AAE-8874-2019	Nissan, Tracy/0000-0003-0482-0543; Tollervey, David/0000-0003-2894-2772; Ed Hurt, Dr./0000-0002-4535-8255				AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; Cote CA, 2002, RNA, V8, P786, DOI 10.1017/S1355838202023063; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; Gadal O, 2001, EMBO J, V20, P3695, DOI 10.1093/emboj/20.14.3695; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Gadal O, 2002, J CELL BIOL, V157, P941, DOI 10.1083/jcb.200111039; Garbarino JE, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-18; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Ho JHN, 1999, MOL CELL BIOL, V19, P2389; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; Jensen BC, 2003, J BIOL CHEM, V278, P32204, DOI 10.1074/jbc.M304198200; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Milkereit P, 2003, J BIOL CHEM, V278, P4072, DOI 10.1074/jbc.M208898200; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Neuwald AF, 1999, GENOME RES, V9, P27; Nissan TA, 2004, MOL CELL, V15, P295, DOI 10.1016/j.molcel.2004.06.033; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Oeffinger M, 2004, GENE DEV, V18, P196, DOI 10.1101/gad.285604; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Suzuki N, 2001, GENETICS, V158, P613; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	40	57	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55411	55418		10.1074/jbc.M406876200	http://dx.doi.org/10.1074/jbc.M406876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15528184	hybrid			2022-12-25	WOS:000225960800055
J	Mourtada-Maarabouni, M; Kirkham, L; Farzaneh, F; Williams, GT				Mourtada-Maarabouni, M; Kirkham, L; Farzaneh, F; Williams, GT			Regulation of apoptosis by fau revealed by functional expression cloning and antisense expression	ONCOGENE			English	Article						fau; functional expression cloning; Finkel-Biskis-Reilly osteosarcoma virus; apoptosis	CHROMOSOMAL LOCALIZATION; DEPENDENT DEGRADATION; GENOMIC STRUCTURE; GENE-EXPRESSION; UBIQUITIN; PROTEIN; CDNA; SUPPRESSOR; CANCER; INVOLVEMENT	Functional expression cloning is a powerful strategy for identifying critical steps in biological pathways independently of prior assumptions. It is particularly suitable for the identification of molecules crucial to the control of apoptosis. Our screen for sequences suppressing T-cell apoptosis isolated a sequence antisense to fau (Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)-associated ubiquitously expressed gene). The fox gene in FBR murine osteosarcoma virus is also antisense to fau and several reports have indicated that fau displays tumour suppressor and oncogenic properties in different contexts. Our observations indicate that the fau antisense sequence suppresses expression of endogenous fau mRNA and produces resistance to apoptosis induced both by the glucocorticoid analogue dexamethasone' by ultraviolet radiation, and by the anticancer drug cisplatin. In all cases, colony-forming ability is protected, indicating that fau affects the critical events prior to commitment to cell death. Overexpression of fau in the sense orientation induces cell death, which is inhibited both by Bcl-2 and by inhibition of caspases, in line with its proposed role in apoptosis.	Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England; GKT Sch Med, Rayne Inst, London SE21 7AN, England	Keele University; University of London; King's College London	Williams, GT (corresponding author), Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England.	bia19@biol.keele.ac.uk; g.t.williams@keele.ac.uk	Farzaneh, Farzin/B-4902-2009; Williams, Gwyn/GQY-7555-2022	Farzaneh, Farzin/0000-0002-9275-2415; /0000-0001-8324-1325; Williams, Gwyn/0000-0003-4556-9930				Anderson Claire L, 2003, ScientificWorldJournal, V3, P51; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; CASTEELS D, 1995, GENOMICS, V25, P291, DOI 10.1016/0888-7543(95)80140-H; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; DANIELSEN M, 1983, MOL CELL BIOL, V3, P1310, DOI 10.1128/MCB.3.7.1310; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; DENHARDT DT, 1992, NEW BIOL, V4, P473; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Finkel M P, 1976, Recent Results Cancer Res, P92; Gabig TG, 1998, MAMM GENOME, V9, P660, DOI 10.1007/s003359900840; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; KAS K, 1993, HUM MOL GENET, V2, P349, DOI 10.1093/hmg/2.4.349; Katoh M, 2003, INT J ONCOL, V22, P1375; Knee R, 1997, NEUROCHEM INT, V31, P379, DOI 10.1016/S0197-0186(96)00108-8; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Lock RB, 1996, INT J ONCOL, V8, P305; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; MICHIELS L, 1993, ONCOGENE, V8, P2537; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; MONIA BP, 1990, J BIOL CHEM, V265, P19356; Mourtada-Maarabouni M, 2003, CELL DEATH DIFFER, V10, P1016, DOI 10.1038/sj.cdd.4401274; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Nakamura M, 2003, EUR J BIOCHEM, V270, P4052, DOI 10.1046/j.1432-1033.2003.03790.x; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; RATHMELL JC, 2002, CELL S, V109, P97; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Rossman TG, 2003, ONCOGENE, V22, P1817, DOI 10.1038/sj.onc.1206283; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; Seraj MJ, 2000, CANCER RES, V60, P2764; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WLODARSKA I, 1993, GENE CHROMOSOME CANC, V8, P224, DOI 10.1002/gcc.2870080404; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zannettino ACW, 1996, J IMMUNOL, V156, P611	58	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9419	9426		10.1038/sj.onc.1208048	http://dx.doi.org/10.1038/sj.onc.1208048			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543234				2022-12-25	WOS:000225764100013
J	Raafat, A; Bargo, S; Anver, MR; Callahan, R				Raafat, A; Bargo, S; Anver, MR; Callahan, R			Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh)	ONCOGENE			English	Article						Notch4/Int3 signaling; mammary tumorigenesis; mammary gland development	NEOPLASTIC TRANSFORMATION; GLAND TUMORIGENESIS; EPITHELIAL-CELLS; FVB/N MICE; INT3 GENE; NOTCH; DIFFERENTIATION; HYPERPLASIA; INTEGRATION; MEMBER	Recently, we have identified a novel 1.8 kb human Notch4/Int3 RNA species (designated h-Int3sh). The h-Int3sh RNA encodes a protein that is missing the CBF1-binding region (RAM23) of the Notch 4/Int3 intracellular domain (ICD). Expression of h-Int3sh in the MCF10A 'normal' human mammary epithelial cell line has been previously shown to induce changes characteristic of oncogenic transformation, including anchorage-independent growth in soft agar. To study the consequences of h-Int3sh expression in vivo on mammary gland development and tumorigenesis, three transgenic mouse lines were established, in which the transgene is the Whey acidic protein (WAP) promoter linked to h-Int3sh. Expression of WAP-Int3sh was detectable in the mammary gland at day 15 of pregnancy in each transgenic line. Mammary gland development in all founder lines is normal and the females can lactate. WAP-h-Int3sh females from each of the founder lines develop mammary tumors, but with a long latency (average age of 18 months). Tumor development was associated with activation of Notch pathway, as evidenced by upregulation of Hes-1. The long latency of mammary tumors in WAP-h-Int3sh mice could be due in part to the subcellular localization of h-Int3sh. Immuno. fluorescence analysis of transfected COS-1 cells showed that h-Int3sh is localized in the cytoplasm and nucleus, while Int3-ICD is detected only in the nucleus. We speculate that the Notch4/Int3 ICD-induced block to mammary gland development and tumorigenesis are consequences of an increasing gradient of CBF1-dependent Notch4/Int3 signaling.	NCI, Mammary Biol & Tumorignesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Pathol & Histotechnol Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Callahan, R (corresponding author), NCI, Mammary Biol & Tumorignesis Lab, NIH, Bldg 10 Room 5B50, Bethesda, MD 20892 USA.	rc54d@nih.gov			PHS HHS [N01-C0-12400] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Nieto AI, 2003, COMPARATIVE MED, V53, P433; Pirkmaier A, 2003, ONCOGENE, V22, P4425, DOI 10.1038/sj.onc.1206488; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910	22	43	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9401	9407		10.1038/sj.onc.1208187	http://dx.doi.org/10.1038/sj.onc.1208187			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531924				2022-12-25	WOS:000225764100011
J	Oshio, K; Watanabe, H; Song, Y; Verkman, AS; Manley, GT				Oshio, K; Watanabe, H; Song, Y; Verkman, AS; Manley, GT			Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1	FASEB JOURNAL			English	Article						water transport; brain injury	BRAIN EDEMA; SECRETION; PERMEABILITY; TRANSPORT; EPITHELIA; DELETION	Aquaporin-1 (AQP1) is a water channel expressed strongly at the ventricular-facing surface of choroid plexus epithelium. We developed novel methods to compare water permeability in isolated choroid plexus of wild-type vs. AQP1 null mice, as well as intracranial pressure (ICP) and cerebrospinal fluid (CSF) production and absorption. Osmotically induced water transport was rapid in choroid plexus from wild-type mice and reduced by fivefold by AQP1 deletion. AQP1 deletion did not affect choroid plexus size or structure. By stereotaxic puncture of the lateral ventricle with a microneedle, ICP was 9.5 +/- 1.4 cm H2O in wild-type mice and 4.2 +/- 0.4 cm H2O in AQP1 null mice. CSF production, an isosmolar fluid secretion process, was measured by a dye dilution method involving fluid collections using a second microneedle introduced into the cisterna magna. CSF production in wild-type mice was (in mul min(-1)) 0.37 +/- 0.04 (control), 0.16 +/- 0.03 (acetazolamide-treated), and 1.14 +/- 0.15 (forskolin-treated), and reduced by similar to25% in AQP1 null mice. Pressure-dependent CSF outflow, measured from steady-state ICP at different ventricular infusion rates, was not affected by AQP1 deletion. In a model of focal brain injury, AQP1 null mice had remarkably reduced ICP and improved survival compared with wild-type mice. The reduced ICP and CSF production in AQP1 null mice provides direct functional evidence for the involvement of AQP1 in CSF dynamics, suggesting AQP1 inhibition as a novel option for therapy of elevated ICP.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; BERING EA, 1963, J NEUROSURG, V20, P1050, DOI 10.3171/jns.1963.20.12.1050; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; DAVSON H, 1970, Brain Behavior and Evolution, V93, P665, DOI 10.1093/brain/93.4.665; DENG QS, 1992, NEUROSCI LETT, V143, P146, DOI 10.1016/0304-3940(92)90253-4; Farinas J, 1997, J GEN PHYSIOL, V110, P283, DOI 10.1085/jgp.110.3.283; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2001, AM J PHYSIOL-CELL PH, V280, pC126; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MCCOMB JG, 1983, J NEUROSURG, V59, P369, DOI 10.3171/jns.1983.59.3.0369; MILHORAT TH, 1971, SCIENCE, V173, P330, DOI 10.1126/science.173.3994.330; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Oshio K, 2003, ACT NEUR S, V86, P525; Pallone TL, 2000, J CLIN INVEST, V105, P215, DOI 10.1172/JCI8214; PAPPENHEIMER JR, 1962, AM J PHYSIOL, V203, P763, DOI 10.1152/ajplegacy.1962.203.5.763; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RUBIN RC, 1966, J NEUROSURG, V25, P430, DOI 10.3171/jns.1966.25.4.0430; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SEGAL MB, 1977, EXP EYE RES, V25, P127, DOI 10.1016/S0014-4835(77)80012-2; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; Speake T, 2001, MICROSC RES TECHNIQ, V52, P49, DOI 10.1002/1097-0029(20010101)52:1<49::AID-JEMT7>3.0.CO;2-C; URSINO M, 1988, ANN BIOMED ENG, V16, P379, DOI 10.1007/BF02364625; Verkman AS, 2002, ANN MED, V34, P192, DOI 10.1080/713782138; WELCH K, 1963, AM J PHYSIOL, V205, P617, DOI 10.1152/ajplegacy.1963.205.3.617; WRIGHT EM, 1977, EXP EYE RES, V25, P149, DOI 10.1016/S0014-4835(77)80013-4; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; [No title captured]	37	312	322	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					76	+		10.1096/fj.04-1711fje	http://dx.doi.org/10.1096/fj.04-1711fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15533949				2022-12-25	WOS:000225482100025
J	Arai, T; Guo, JP; McGeer, PL				Arai, T; Guo, JP; McGeer, PL			Proteolysis of non-phosphorylated and phosphorylated tau by thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROGRESSIVE SUPRANUCLEAR PALSY; ALZHEIMERS-DISEASE; PROTEIN-TAU; NEUROFIBRILLARY TANGLES; ANTITHROMBIN-III; MESSENGER-RNA; RAT-BRAIN; LOCALIZATION; PROTHROMBIN	The microtubule-associated protein tau aggregates intracellularly by unknown mechanisms in Alzheimer's disease and other tauopathies. A contributing factor may be a failure to break down free cytosolic tau, thus creating a surplus for aggregation, although the proteases that degrade tau in brain remain unknown. To address this issue, we prepared cytosolic fractions from five normal human brains and from perfused rat brains and incubated them with or without protease inhibitors. D-Phenylalanyl-L-prolylarginyl chloromethyl ketone, a thrombin-specific inhibitor, prevented tau breakdown in these fractions, suggesting that thrombin is a brain protease that processes tau. We next exposed human recombinant tau to purified human thrombin and analyzed the fragments by N-terminal sequencing. We found that thrombin proteolyzed tau at multiple arginine and lysine sites. These include Arg(155)-Gly(156), Arg(209)-Ser(210), Arg(230)-Thr(231), Lys(257)-Ser(258), and Lys(340)-Ser(341) (numbering according to the longest human tau isoform). Temporally, the initial cleavage occurred at the Arg(155)-Gly(156) bond. Proteolysis of the resultant C-terminal tau fragment then proceeded bidirectionally. When tau was phosphorylated by glycogen synthase kinase-33, most of these proteolytic processes were inhibited, except for the first cleavage at the Arg(155)-Gly(156) bond. Furthermore, paired helical filament tau prepared from Alzheimer's disease brain was more resistant to thrombin proteolysis than following dephosphorylation by alkaline phosphatase. The results suggest a possible role for thrombin in proteolysis of tau under physiological and/or pathological conditions in human brains. They are consistent with the hypothesis that phosphorylation of tau inhibits proteolysis by thrombin or other endogenous proteases, leading to aggregation of tau into insoluble fibrils.	Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	McGeer, PL (corresponding author), Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	mcgeerpl@interchange.ubc.ca						AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Arai T, 2004, ANN NEUROL, V55, P72, DOI 10.1002/ana.10793; Arai T, 2003, ACTA NEUROPATHOL, V105, P489, DOI 10.1007/s00401-003-0671-8; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BAUER RS, 1980, J BIOL CHEM, V255, P5900; BLOMBACK B, 1977, SUBSTRATE SPECIFICIT, P275; BRASS LF, 1988, J BIOL CHEM, V263, P5210; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FENTON JW, 1977, HUMAN THROMBINS, P43; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Ikeda K, 1998, NEUROSCI LETT, V258, P113, DOI 10.1016/S0304-3940(98)00867-2; Imamura T, 2001, J BIOL CHEM, V276, P18984, DOI 10.1074/jbc.M006760200; Ishiguro K, 1999, NEUROSCI LETT, V270, P91, DOI 10.1016/S0304-3940(99)00476-0; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JOHSON GVW, 1997, J NEUROCHEM, V68, P430; Kenessey A, 1997, J NEUROCHEM, V69, P2026; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERCKEN M, 1995, FEBS LETT, V368, P10, DOI 10.1016/0014-5793(95)00590-6; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; OLESEN OF, 1994, BIOCHEM BIOPH RES CO, V201, P716, DOI 10.1006/bbrc.1994.1759; SCHERAGA HA, 1977, ACTIVE SITE MAPPING, P145; Shikamoto Y, 1999, FEBS LETT, V463, P387, DOI 10.1016/S0014-5793(99)01657-9; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; Wang XH, 1996, BIOCHEM BIOPH RES CO, V219, P591, DOI 10.1006/bbrc.1996.0278; Watanabe A, 1999, J BIOL CHEM, V274, P7368, DOI 10.1074/jbc.274.11.7368; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x	50	61	65	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5145	5153		10.1074/jbc.M409234200	http://dx.doi.org/10.1074/jbc.M409234200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15542598	hybrid			2022-12-25	WOS:000227217100006
J	Berg, S; Starbuck, J; Torrelles, JB; Vissa, VD; Crick, DC; Chatterjee, D; Brennan, PJ				Berg, S; Starbuck, J; Torrelles, JB; Vissa, VD; Crick, DC; Chatterjee, D; Brennan, PJ			Roles of conserved proline and glycosyltransferase motifs of embC in biosynthesis of lipoarabinomannan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL HEXAARABINOFURANOSYL MOTIF; MYCOBACTERIAL CELL-WALLS; ARABINAN BIOSYNTHESIS; ETHAMBUTOL RESISTANCE; SHIGELLA-FLEXNERI; MEMBRANE-PROTEIN; CHAIN-LENGTH; TUBERCULOSIS; ARABINOGALACTAN; MACROPHAGES	D-Arabinans, composed Of D-arabinofuranose (D-Araf), dominate the structure of mycobacterial cell walls in two settings, as part of lipoarabinomannan (LAM) and arabinogalactan, each with markedly different structures and functions. Little is known of the complexity of their biosynthesis. beta-D-Arabinofuranosyl-1-monophosphoryldecaprenol is the only known sugar donor. EmbA, EmbB, and EmbC, products of the paralogous genes embA, embB, and embC, the sites of resistance to the anti-tuberculosis drug ethambutol (EMB), are the only known implicated enzymes. EmbA and -B apparently contribute to the synthesis of arabinogalactan, whereas EmbC is reserved for the synthesis of LAM. The Emb proteins show no overall similarity to any known proteins beyond Mycobacterium and related genera. However, functional motifs, equivalent to a proline-rich motif of several bacterial polysaccharide co-polymerases and a superfamily of glycosyltransferases, were found. Site-directed mutagenesis in glycosyltransferase superfamily C resulted in complete ablation of LAM synthesis. Point mutations in three amino acids of the proline motif of EmbC resulted in marked reduction of LAM-arabinan synthesis and accumulation of an unknown intermediate and of the known precursor lipomannan. Yet the pattern of the differently linked D-Araf units observed in wild type LAM-arabinan was largely retained in the proline motif mutants. The results allow for the presentation of a unique model of arabinan synthesis.	Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	Colorado State University	Brennan, PJ (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	Patrick.Brennan@colostate.edu	Berg, Stefan/AAU-6463-2020; Torrelles, Jordi/E-4204-2011; Berg, Stefan O/D-3847-2011; Crick, Dean/H-8251-2017	Berg, Stefan/0000-0002-3470-7579; Crick, Dean/0000-0001-9281-7058	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI049151, R01AI037139, R01AI018357, R01AI049151, R22AI018357, R37AI018357, R21AI037139] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18357, AI49151, AI37139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATLAS RM, 1997, HDB MICROBIOL MEDIA, P1225; BASTIN DA, 1993, MOL MICROBIOL, V7, P725, DOI 10.1111/j.1365-2958.1993.tb01163.x; Becker A, 1998, J BACTERIOL, V180, P395, DOI 10.1128/JB.180.2.395-399.1998; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Daniels C, 1999, MOL MICROBIOL, V34, P181, DOI 10.1046/j.1365-2958.1999.01591.x; DELL A, 1994, METHOD ENZYMOL, V230, P108; Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001; Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Kaur D, 2002, MICROBIOL-SGM, V148, P3049, DOI 10.1099/00221287-148-10-3049; Khoo KH, 1996, J BIOL CHEM, V271, P28682, DOI 10.1074/jbc.271.45.28682; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL MR, 1994, GLYCOBIOLOGY, V4, P165, DOI 10.1093/glycob/4.2.165; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; MORONA R, 1995, J BACTERIOL, V177, P1059, DOI 10.1128/jb.177.4.1059-1068.1995; Morona R, 2000, MICROBIOL-UK, V146, P1, DOI 10.1099/00221287-146-1-1; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ramaswamy SV, 2000, ANTIMICROB AGENTS CH, V44, P326, DOI 10.1128/AAC.44.2.326-336.2000; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P1677, DOI 10.1128/AAC.41.8.1677; STOKES RW, 1995, J IMMUNOL, V155, P1361; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; SWEET DP, 1975, CARBOHYD RES, V40, P217, DOI 10.1016/S0008-6215(00)82604-X; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; Tuncer T, 2003, FOLIA MICROBIOL, V48, P168, DOI 10.1007/BF02930950; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; Xin Y, 1997, BBA-GEN SUBJECTS, V1335, P231, DOI 10.1016/S0304-4165(97)00002-0; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	48	68	74	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5651	5663		10.1074/jbc.M411418200	http://dx.doi.org/10.1074/jbc.M411418200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15546869	hybrid			2022-12-25	WOS:000227217100067
J	Johnson, BJ; Le, TTT; Dobbin, CA; Banovic, T; Howard, CB; Flores, FDL; Vanags, D; Naylor, DJ; Hill, GR; Suhrbier, A				Johnson, BJ; Le, TTT; Dobbin, CA; Banovic, T; Howard, CB; Flores, FDL; Vanags, D; Naylor, DJ; Hill, GR; Suhrbier, A			Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY-PREGNANCY FACTOR; HEAT-SHOCK PROTEINS; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; TUMOR-NECROSIS-FACTOR; IDIOPATHIC PNEUMONIA SYNDROME; TOLL-LIKE RECEPTORS; MONOCLONAL-ANTIBODIES; TNF-ALPHA; MACROPHAGE ACTIVATION	Heat shock protein 10 (Hsp10) and heat shock protein 160 (Hsp60) were originally described as essential mitochondrial proteins involved in protein folding. How,ever, both proteins have also been shown to have a number of extracellular immunomodulatory activities. Here we show that purified recombinant human Hsp10 incubated with cells in vitro reduced lipopolysaccharide (LPS)-induced nuclear factor-kappaB activation and secretion of several inflammatory mediators from RAW264.7 cells, murine macrophages, and human peripheral blood mononuclear cells. Induction of tolerance by contaminating LPS was formally excluded as being responsible for Hsp10 activity. Treatment of mice with Hsp10 before,endotoxin challenge resulted in the reduction of serum tumor necrosis factor-a and RANTES (regulated upon activation, normal T cell expressed and secreted) levels and an elevation of serum interleukin-10 levels. Hsp10 treatment also delayed mortality in a murine graft-ver-sus-host disease model, where gut-derived LPS contributes to pathology. We were unable to confirm previous reports that Hsp10 has tumor growth factor properties and suggest that Hsp10 exerts anti-inflammatory activity by inhibiting Toll-like receptor signaling possibly by interacting with extracellular Hsp60.	CBio Ltd, Alderley, Qld 4051, Australia; Australian Natl Ctr Int & Trop Hlth & Nutr, Queensland Inst Med Res, Herston, Qld 4029, Australia; Univ Queensland, Dept Pathol, Herston, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; University of Queensland	Johnson, BJ (corresponding author), CBio Ltd, 17 Wakefield St, Alderley, Qld 4051, Australia.	barbara.johnson@cbio.com.au	Hill, Geoffrey/O-2630-2016; Howard, Christopher/D-3859-2017	Hill, Geoffrey/0000-0003-2994-0429; Howard, Christopher/0000-0001-9797-8686; Suhrbier, Andreas/0000-0001-8986-9025				Anraku I, 2002, J VIROL, V76, P3791, DOI 10.1128/JVI.76.8.3791-3799.2002; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Athanasas-Platsis S, 2004, IMMUNOL CELL BIOL, V82, P361, DOI 10.1111/j.0818-9641.2004.01260.x; Barazi HO, 2002, CANCER RES, V62, P1541; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Beigi RD, 2000, J IMMUNOL, V165, P7189, DOI 10.4049/jimmunol.165.12.7189; Belles C, 1999, INFECT IMMUN, V67, P4191, DOI 10.1128/IAI.67.8.4191-4200.1999; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; Brinker A, 2001, CELL, V107, P223, DOI 10.1016/S0092-8674(01)00517-7; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Cavanagh A C, 1996, Rev Reprod, V1, P28; Cooke KR, 2000, J IMMUNOL, V165, P6612, DOI 10.4049/jimmunol.165.11.6612; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Cooke KR, 2001, J CLIN INVEST, V107, P1581, DOI 10.1172/JCI12156; Derksen R H W M, 2002, Ned Tijdschr Geneeskd, V146, P1165; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Elenkov IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/j.1749-6632.2002.tb04229.x; Feng HP, 2001, BLOOD, V97, P3505, DOI 10.1182/blood.V97.11.3505; Fiaux J, 2002, NATURE, V418, P207, DOI 10.1038/nature00860; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Gao BC, 2004, BIOCHEM BIOPH RES CO, V317, P1149, DOI 10.1016/j.bbrc.2004.03.160; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; GEARING AJH, 1989, HYBRIDOMA, V8, P361, DOI 10.1089/hyb.1989.8.361; GRANOWITZ EV, 1993, J IMMUNOL, V151, P1637; Habich C, 2003, FEBS LETT, V533, P105, DOI 10.1016/S0014-5793(02)03772-9; Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896; Hill GR, 1998, J CLIN INVEST, V102, P115, DOI 10.1172/JCI3132; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Iwamoto GK, 1999, AM J PHYSIOL-LUNG C, V277, pL1051, DOI 10.1152/ajplung.1999.277.5.L1051; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kanda T, 2004, JPN HEART J, V45, P183, DOI 10.1536/jhj.45.183; KAUR I, 1993, J IMMUNOL, V150, P2046; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Kligman I, 1998, AM J REPROD IMMUNOL, V40, P32; Kligman I, 1996, HUM REPROD, V11, P2736; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Laad AD, 1999, INT J CANCER, V80, P709, DOI 10.1002/(SICI)1097-0215(19990301)80:5<709::AID-IJC14>3.3.CO;2-I; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Lewthwaite J, 2002, CIRCULATION, V106, P196, DOI 10.1161/01.CIR.0000021121.26290.2C; LINN ML, 1995, J VIROL METHODS, V52, P51; Lynn M, 2003, J INFECT DIS, V187, P631, DOI 10.1086/367990; MacDonald KPA, 2003, BLOOD, V101, P2033, DOI 10.1182/blood-2002-05-1529; Mateo L, 2000, INTERVIROLOGY, V43, P55, DOI 10.1159/000025023; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; MORSE HC, 1987, IMMUNOGENETICS, V25, P71, DOI 10.1007/BF00364270; Morton H, 2000, IMMUNOL CELL BIOL, V78, P603, DOI 10.1046/j.1440-1711.2000.00951.x; Morton H, 1998, IMMUNOL CELL BIOL, V76, P483, DOI 10.1046/j.1440-1711.1998.00782.x; MORTON H, 1992, REPROD FERT DEVELOP, V4, P411, DOI 10.1071/RD9920411; Moseley P, 2000, IMMUNOPHARMACOLOGY, V48, P299, DOI 10.1016/S0162-3109(00)00227-7; QUINN KA, 1992, CANCER IMMUNOL IMMUN, V34, P265, DOI 10.1007/BF01741795; QUINN KA, 1990, CLIN EXP IMMUNOL, V80, P100; RETZLAFF C, 1994, INFECT IMMUN, V62, P5689, DOI 10.1128/IAI.62.12.5689-5693.1994; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; RYAN MT, 1995, J BIOL CHEM, V270, P22037, DOI 10.1074/jbc.270.37.22037; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Soltys BJ, 1997, CELL BIOL INT, V21, P315, DOI 10.1006/cbir.1997.0144; Suhrbier A, 2003, TRENDS IMMUNOL, V24, P165, DOI 10.1016/S1471-4906(03)00065-6; SWEET MJ, 1995, J INFLAMM, V45, P126; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Triantafilou M, 2004, BIOCHEM SOC T, V32, P636, DOI 10.1042/BST0320636; Triantafilou Martha, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007654; Tsan MF, 2004, AM J PHYSIOL-CELL PH, V286, pC739, DOI 10.1152/ajpcell.00364.2003; Ueki K, 2002, CLIN EXP IMMUNOL, V127, P72, DOI 10.1046/j.1365-2249.2002.01723.x; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Westby DL, 2002, J POLIT MIL SOCIOL, V30, P1; Wiendl H, 2002, BIODRUGS, V16, P183, DOI 10.2165/00063030-200216030-00003; Xu QB, 2003, CURR OPIN CARDIOL, V18, P245, DOI 10.1097/00001573-200307000-00001; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yamamoto A, 2002, BIOLOGICALS, V30, P85, DOI 10.1006/biol.2002.0323; Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje; Zhang B, 2003, J NEUROL SCI, V212, P37, DOI 10.1016/S0022-510X(03)00103-5; Ziegert M, 1999, Infect Dis Obstet Gynecol, V7, P180; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015	77	117	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4037	4047		10.1074/jbc.M411569200	http://dx.doi.org/10.1074/jbc.M411569200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15546885	hybrid			2022-12-25	WOS:000227096600008
J	Koga, Y; Ikebe, M				Koga, Y; Ikebe, M			p116(Rip) decreases myosin II phosphorylation by activating myosin light chain phosphatase and by inactivating RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; BINDING PROTEIN-RHO; ACTIN MICROFILAMENT INTEGRITY; LIVING NONMUSCLE CELLS; INTERACTING PROTEIN; SIGNAL-TRANSDUCTION; ZIP KINASE; SUBUNIT; IDENTIFICATION; TYPE-1	p116(Rip) was originally found to be a RhoA-binding protein, but its function has been unknown. Here, we clarify the function of p116(Rip). Two critical findings were made. First, we found that p116(Rip) activated the GTPase activity of RhoA in vitro and that p116(Rip) overexpression in cells consistently diminished the epidermal growth factor-induced increase in GTP-bound RhoA. Second, p116(Rip) activated the myosin light chain phosphatase (MLCP) activity of the holoenzyme. p116(Rip) did not activate the catalytic subunit alone, indicating that the activation is due to the binding of p116(Rip) to the myosin phosphatase targeting subunit MYPT1. Interestingly, the activation of phosphatase was specific to my-osin as substrate, and P116(Rip) directly bound to myosin, thus facilitating myosin/MLCP interaction. The gene silencing of p1161(Rip) consistently and significantly increased myosin phosphorylation as well as stress fiber formation in cells. Based upon these findings, we propose that P116(Rip) is an important regulatory component that controls the RhoA signaling pathway, thus regulating MLCP activity and myosin phosphorylation in cells.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gumma 3718511, Japan	University of Massachusetts System; University of Massachusetts Worcester; Gunma University	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu	古賀, 康彦/V-3913-2019; KOGA, YASUHIKO/GQG-9830-2022	KOGA, YASUHIKO/0000-0002-4974-9026	NHLBI NIH HHS [HL073050] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GONG MC, 1992, J BIOL CHEM, V267, P21492; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; Komatsu S, 2004, J CELL BIOL, V165, P243, DOI 10.1083/jcb.200309056; Komatsu S, 2002, AM J PHYSIOL-CELL PH, V283, pC752, DOI 10.1152/ajpcell.00501.2001; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LYNCH RM, 1991, J CELL BIOL, V112, P385, DOI 10.1083/jcb.112.3.385; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MITSUI T, 1992, J BIOL CHEM, V267, P16727; Mulder J, 2003, J BIOL CHEM, V278, P27216, DOI 10.1074/jbc.M302399200; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Niiro N, 2003, BIOCHEM J, V369, P117, DOI 10.1042/BJ20021040; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; ONISHI H, 1979, J BIOCHEM, V85, P457, DOI 10.1093/oxfordjournals.jbchem.a132352; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTSON D, 1995, J HISTOCHEM CYTOCHEM, V43, P471, DOI 10.1177/43.5.7537292; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Takizawa N, 2002, BIOCHEM BIOPH RES CO, V297, P773, DOI 10.1016/S0006-291X(02)02302-1; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; WADZINSKI BE, 1990, J BIOL CHEM, V265, P21504	50	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4983	4991		10.1074/jbc.M410909200	http://dx.doi.org/10.1074/jbc.M410909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15545284	hybrid			2022-12-25	WOS:000227096600120
J	Kolachala, V; Asamoah, V; Wang, LX; Srinivasan, S; Merlin, D; Sitaraman, SV				Kolachala, V; Asamoah, V; Wang, LX; Srinivasan, S; Merlin, D; Sitaraman, SV			Interferon-gamma down-regulates adenosine 2b receptor-mediated signaling and short circuit current in the intestinal epithelia by inhibiting the expression of adenylate cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-C; CHLORIDE SECRETION; T84 CELLS; PLASMA-MEMBRANE; MAMMALIAN COLON; GENE-EXPRESSION; 2B RECEPTOR; IN-VITRO; ISOFORMS	Adenosine is an endogenous signaling molecule that is highly up-regulated in inflammatory states. Adenosine acts through the A2b receptor, a G protein-coupled receptor that couples positively to Galpha(s) and activates adenylate cyclase. This leads to cAMP-mediated electrogenic chloride secretion in intestinal epithelia. To better understand the regulation of the A2b receptor in intestinal epithelia, we studied the effects of interferon-gamma (IFN-gamma), a potent immunomodulatory cytokine, in the T84 cell line. Pretreatment of cells with 500 units/ml IFN-gamma for 12 h inhibited an adenosine-induced short circuit current (I-sc) without affecting the transepithelial resistance. Under these conditions, IFN-gamma did not inhibit the protein expression or membrane recruitment of the A2b receptor, shown to be essential for its function. Interestingly, IFN-gamma inhibited cAMP levels as well as its downstream signaling pathway as shown by the inhibition of adenosine-induced phosphorylation of cAMP response element-binding protein and protein kinase A activity. Similar studies with forskolin, a direct activator of adenylate cyclase, also demonstrated inhibition of cAMP and its downstream response by IFN-gamma. However, IFN-gamma did not affect secretory responses to the calcium-dependent secretagogue carbachol or cAMP analog 8-bromo-cAMP, indicating that normal secretory responses to adequate second messengers in IFN-gamma-treated cells are achievable. Moreover, IFN-gamma inhibited the expression of adenylate cyclase isoforms 5 and 7. In conclusion, we demonstrate that IFN-gamma down-regulates adenosine-mediated signaling possibly through the direct inhibition of adenylate cyclase expression. We propose that IFN-gamma may acutely affect global cAMP-mediated responses in the intestinal epithelia, thereby decreasing secretory responses, which may consequently aggravate inflammatory processes.	Emory Univ, Sch Med, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA	Emory University	Sitaraman, SV (corresponding author), Emory Univ, Sch Med, Div Digest Dis, Dept Med, Whitehead Res Bldg,Rm 201-F,615 Michael St, Atlanta, GA 30322 USA.	ssitar2@emory.edu	Srinivasan, Shanthi/A-6133-2013		NIDDK NIH HHS [5R24DK064399-02, DK 02831, DK 02802, DK06411, DK 064644] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, K01DK002831, R03DK064644, K08DK002802] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asfaha S, 2001, AM J PHYSIOL-GASTR L, V281, pG635, DOI 10.1152/ajpgi.2001.281.3.G635; BAIRD AW, 1994, IRISH J MED SCI, V163, P277, DOI 10.1007/BF02942126; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; BARRETT KE, 1990, AM J PHYSIOL, V258, pC902, DOI 10.1152/ajpcell.1990.258.5.C902; Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; BELL CL, 1992, AM J PHYSIOL, V262, pC555, DOI 10.1152/ajpcell.1992.262.3.C555; BESANCON F, 1994, AM J PHYSIOL-CELL PH, V267, pC1398, DOI 10.1152/ajpcell.1994.267.5.C1398; BOLTON JE, 1977, J MEMBRANE BIOL, V35, P159, DOI 10.1007/BF01869947; BREESE E, 1993, IMMUNOLOGY, V78, P127; Bucheimer RE, 2004, J PHYSIOL-LONDON, V555, P311, DOI 10.1113/jphysiol.2003.056697; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; CHEN FH, 1995, BIOCHEM BIOPH RES CO, V216, P190, DOI 10.1006/bbrc.1995.2609; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; Christofi FL, 2001, J COMP NEUROL, V439, P46, DOI 10.1002/cne.1334; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Emala CW, 1998, BIOL REPROD, V59, P169, DOI 10.1095/biolreprod59.1.169; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Feoktistov I, 1999, MOL PHARMACOL, V55, P726; Fish SM, 1999, GUT, V45, P191, DOI 10.1136/gut.45.2.191; Freeman SL, 2004, GUT, V53, P214, DOI 10.1136/gut.2003.023895; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gouraud S, 2002, J CELL SCI, V115, P3667, DOI 10.1242/jcs.00053; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Hanoune J, 1997, MOL CELL ENDOCRINOL, V128, P179, DOI 10.1016/S0303-7207(97)04013-6; HELLEVUO K, 1995, HUM GENET, V95, P197; Hill J, 2000, CELL SIGNAL, V12, P233, DOI 10.1016/S0898-6568(99)00082-0; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KAWABE J, 1994, J BIOL CHEM, V269, P16554; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; MacNaughton WK, 1998, AM J PHYSIOL-GASTR L, V275, pG1353, DOI 10.1152/ajpgi.1998.275.6.G1353; MacNaughton WK, 2000, J PHARMACOL EXP THER, V293, P539; MANOLOPOULOS VG, 1995, J CELL BIOCHEM, V57, P590, DOI 10.1002/jcb.240570403; MCCABE RD, 1985, AM J PHYSIOL, V248, pG103, DOI 10.1152/ajpgi.1985.248.1.G103; Merlin D, 1998, AM J PHYSIOL-CELL PH, V275, pC484, DOI 10.1152/ajpcell.1998.275.2.C484; NIESSNER M, 1995, CLIN EXP IMMUNOL, V101, P428; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; RIVKEES SA, 1992, MOL ENDOCRINOL, V6, P1598, DOI 10.1210/me.6.10.1598; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; SCOTT P, 1991, J IMMUNOL, V147, P3149; SILVA P, 1977, AM J PHYSIOL, V233, P298; Singh AE, 1998, AM J PHYSIOL-CELL PH, V275, pC562, DOI 10.1152/ajpcell.1998.275.2.C562; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Sitaraman SV, 2000, AM J PHYSIOL-CELL PH, V278, pC1230, DOI 10.1152/ajpcell.2000.278.6.C1230; Stockmann M, 2000, ANN NY ACAD SCI, V915, P293, DOI 10.1111/j.1749-6632.2000.tb05257.x; STROHMEIER GR, 1995, J BIOL CHEM, V270, P2387, DOI 10.1074/jbc.270.5.2387; Sugi K, 2001, GASTROENTEROLOGY, V120, P1393, DOI 10.1053/gast.2001.24045; TANG WJ, 1991, J BIOL CHEM, V266, P8595; Vancott JL, 2003, J INTERF CYTOK RES, V23, P163, DOI 10.1089/107999003321532501; Walia B, 2004, BIOCHEM J, V382, P589, DOI 10.1042/BJ20040021; Wang LX, 2004, AM J PHYSIOL-GASTR L, V287, pG1100, DOI 10.1152/ajpgi.00164.2004; Xu DB, 2001, AM J PHYSIOL-LUNG C, V281, pL832, DOI 10.1152/ajplung.2001.281.4.L832; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	63	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4048	4057		10.1074/jbc.M409577200	http://dx.doi.org/10.1074/jbc.M409577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15550390	hybrid			2022-12-25	WOS:000227096600009
J	Bunoust, O; Devin, A; Averet, N; Camougrand, N; Rigoulet, M				Bunoust, O; Devin, A; Averet, N; Camougrand, N; Rigoulet, M			Competition of electrons to enter the respiratory chain - A new regulatory mechanism of oxidative metabolism in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH DEHYDROGENASE; REDOX BALANCES; GROWTH; YEAST; SUPERCOMPLEXES; IDENTIFICATION; MITOCHONDRIA; PRODUCT	In the yeast Saccharomyces cerevisiae, the most important systems for conveying excess cytosolic NADH to the mitochondrial respiratory chain are the external NADH dehydrogenases (Nde1p and Nde2p) and the glycerol-3-phosphate dehydrogenase shuttle. In the latter system, NADH is oxidized to NAD(+) and dihydroxyacetone phosphate is reduced to glycerol 3-phosphate by the cytosolic Gpd1p. Subsequently, glycerol 3-phosphate donates electrons to the respiratory chain via mitochondrial glycerol-3-phosphate dehydrogenase (Gut2p). At saturating concentrations of NADH, the activation of external NADH dehydrogenases completely inhibits glycerol 3-phosphate oxidation. Studies on the functionally isolated enzymes demonstrated that neither Nde1p nor Nde2p directly inhibits Gut2p. Thus, the inhibition of glycerol 3-phosphate oxidation may be caused by competition for the entrance of electrons into the respiratory chain. Using single deletion mutants of Nde1p or Nde2p, we have shown that glycerol 3-phosphate oxidation via Gut2p is inhibited fully when NADH is oxidized via Nde1p, whereas only 50% of glycerol 3-phosphate oxidation is inhibited when Nde2p is functioning. By comparing respiratory rates with different respiratory substrates, we show that electrons from Nde1p are favored over electrons coming from Ndip (internal NADH dehydrogenase) and that when electrons come from either Nde1p or Nde2p and succinodehydrogenase, their use by the respiratory chain is shared to a comparable extent. This suggests a very specific competition for electron entrance into the respiratory chain, which may be caused by the supramolecular organization of the respiratory chain. The physiological consequences of such regulation are discussed.	Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, CNRS, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Rigoulet, M (corresponding author), Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, CNRS, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	michel.rigoulet@ibgc.u-bordeaux2.fr						Albers E, 1996, APPL ENVIRON MICROB, V62, P3187, DOI 10.1128/AEM.62.9.3187-3195.1996; Averet N, 2002, J BIOENERG BIOMEMBR, V34, P499, DOI 10.1023/A:1022526411188; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; BERGMEYER HU, 1988, METHOD ENZYMAT AN, V6, P342; BRUINENBERG PM, 1985, ARCH MICROBIOL, V142, P302, DOI 10.1007/BF00693408; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Gombert AK, 2001, J BACTERIOL, V183, P1441, DOI 10.1128/JB.183.4.1441-1451.2001; Grandier-Vazeille X, 2001, BIOCHEMISTRY-US, V40, P9758, DOI 10.1021/bi010277r; Guerin B, 1979, Methods Enzymol, V55, P149; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; NORDSTROM K, 1968, J I BREWING, V74, P429, DOI 10.1002/j.2050-0416.1968.tb03154.x; Pahlman IL, 2002, J BIOL CHEM, V277, P27991, DOI 10.1074/jbc.M204079200; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; Small WC, 1998, J BACTERIOL, V180, P4051, DOI 10.1128/JB.180.16.4051-4055.1998; VANDIJKEN JP, 1986, FEMS MICROBIOL LETT, V32, P199, DOI 10.1016/0378-1097(86)90291-0; [No title captured]	20	35	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3407	3413		10.1074/jbc.M407746200	http://dx.doi.org/10.1074/jbc.M407746200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557339	hybrid			2022-12-25	WOS:000226983900035
J	Choi, WY; Gerner, EW; Ramdas, L; Dupart, J; Carew, J; Proctor, L; Huang, P; Zhang, W; Hamilton, SR				Choi, WY; Gerner, EW; Ramdas, L; Dupart, J; Carew, J; Proctor, L; Huang, P; Zhang, W; Hamilton, SR			Combination of 5-fluorouracil and N-1,N-11-diethylnorspermine markedly activates spermidine/spermine N-1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-II TRIAL; ALPHA-DIFLUOROMETHYLORNITHINE; ORNITHINE-DECARBOXYLASE; GLIOBLASTOMA-MULTIFORME; BREAST-CANCER; DNA-DAMAGE; CELLS; GENE; INDUCTION; CHEMOPREVENTION	The thymidylate synthase inhibitor 5-fluorouracil (5-FU) is used widely for chemotherapy of colorectal carcinoma. Recent studies showed that 5-FU affects polyamine metabolism in colon carcinoma cells. We therefore examined whether combinations of 5-FU with drugs that specifically target polyamine metabolism, i.e. N-1, N-11-diethylnorspermine (DENSPM) or alpha-difluoromethylornithine (DFMO), have synergistic effects in killing HCT116 colon carcinoma cells with wild-type or absent p53. Our results showed that simultaneous 5-FU and DENSPM, a spermine analogue, synergistically increased transcript levels of the polyamine catabolism enzyme spermidine/spermine N-1-acetyltransferase, depleted spermine and spermidine, increased acetylated spermidine, and produced synergistic tumor cell apoptosis in both p53 wild-type and p53-null variants. By contrast, simultaneous combination of 5-FU with DFMO, an inhibitor of the polyamine biosynthetic enzyme ornithine decarboxylase, depleted putrescine but did not produce synergistic cell killing. Some pre-treatment and post-treatment regimens of DENSPM and DFMO were antagonistic to 5-FU depending on cellular p53 status. Protein and transcriptome expression analysis showed that combined 5-FU and DENSPM treatment activated caspase 9, but not caspase 3, and significantly suppressed NADH dehydrogenases and cytochrome c oxidases, consistent with the observed increase in hydrogen peroxide, loss of mitochondrial membrane potential, and release of cytochrome c. Our findings demonstrate the importance of the polyamine pathway in 5-FU effects and suggest that the combination of 5-FU with DENSPM has potential for development as therapy for colorectal carcinoma.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85,Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Arizona, Arizona Canc Ctr, Dept Biochem & Biophys, Tucson, AZ 85724 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Arizona Center Cancer Care; University of Arizona	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85,Div Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, 5P30 CA016672-28] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSFIELD F, 1977, CANCER-AM CANCER SOC, V39, P34, DOI 10.1002/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO;2-2; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; Baggerly KA, 2001, J COMPUT BIOL, V8, P639, DOI 10.1089/106652701753307539; BASU HS, 1990, BIOCHEM J, V269, P329, DOI 10.1042/bj2690329; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Calvo Emiliano, 2002, Clin Colorectal Cancer, V2, P104, DOI 10.3816/CCC.2002.n.016; CANMAN CE, 1994, CANCER RES, V54, P2296; Chen Y, 2001, CANCER RES, V61, P6437; Chinnery PF, 1999, J MED GENET, V36, P425; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; EDWARDS ML, 1991, J MED CHEM, V34, P2414, DOI 10.1021/jm00112a016; Einspahr JG, 2002, CLIN CANCER RES, V8, P149; Elmore E, 2001, ANTICANCER RES, V21, P1163; Fabian CJ, 2002, CLIN CANCER RES, V8, P3105; FINE S, 1994, BREAST CANCER RES TR, V30, P205, DOI 10.1007/BF00666065; FogelPetrovic M, 1997, MOL PHARMACOL, V52, P69, DOI 10.1124/mol.52.1.69; Fuller GN, 1999, CANCER RES, V59, P4228; GERHARD M, 1998, BIOCH PATHWAYS ATLAS; Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3; Gil-Delgado MA, 2001, AM J CLIN ONCOL-CANC, V24, P101, DOI 10.1097/00000421-200102000-00021; Goldberg RM, 2002, ANN ONCOL, V13, P1674, DOI 10.1093/annonc/mdf260; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HILL BC, 1993, J BIOENERG BIOMEMBR, V25, P115, DOI 10.1007/BF00762853; Hu LM, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-16; Levin VA, 2000, CLIN CANCER RES, V6, P3878; Marverti G, 1998, INT J CANCER, V78, P33, DOI 10.1002/(SICI)1097-0215(19980925)78:1<33::AID-IJC7>3.0.CO;2-Y; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; MOERTEL CG, 1972, CANCER RES, V32, P2717; Park JH, 2003, J BIOL CHEM, V278, P32683, DOI 10.1074/jbc.M304247200; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; RUSSELL DH, 1974, CANCER RES, V34, P2382; SARHAN S, 1992, ANTICANCER RES, V12, P457; SNYDER RD, 1989, BIOCHEM J, V260, P697, DOI 10.1042/bj2600697; SNYDER RD, 1994, ANTICANCER RES, V14, P347; Subhi AL, 2003, J BIOL CHEM, V278, P49868, DOI 10.1074/jbc.M308451200; Tome ME, 1997, BIOCHEM J, V328, P847; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang YL, 1999, J BIOL CHEM, V274, P22095, DOI 10.1074/jbc.274.31.22095; Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623; Xie XZ, 1997, J BIOL CHEM, V272, P20484, DOI 10.1074/jbc.272.33.20484; Zhang W, 2003, CANCER BIOL THER, V2, P572, DOI 10.4161/cbt.2.5.532	46	47	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3295	3304		10.1074/jbc.M409930200	http://dx.doi.org/10.1074/jbc.M409930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15546879	hybrid, Green Accepted			2022-12-25	WOS:000226983900022
J	Johansson, E; Fano, M; Bynck, JH; Neuhard, J; Larsen, S; Sigurskjold, BW; Christensen, U; Willemoes, M				Johansson, E; Fano, M; Bynck, JH; Neuhard, J; Larsen, S; Sigurskjold, BW; Christensen, U; Willemoes, M			Structures of dCTP deaminase from Escherichia coli with bound substrate and product - Reaction mechanism and determinants of mono- and bifunctionality for a family of enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DUTP PYROPHOSPHATASE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; C-TERMINUS; PROTEIN; INSIGHTS; CRYSTALLIZATION; RECOGNITION; JANNASCHII	dCTP deaminase (EC 3.5.4.13) catalyzes the deamination of dCTP forming dUTP that via dUTPase is the main pathway providing substrate for thymidylate synthase in Escherichia coli and Salmonella typhimurium. dCTP deaminase is unique among nucleoside and nucleotide deaminases as it functions without aid from a catalytic metal ion that facilitates preparation of a water molecule for nucleophilic attack on the substrate. Two active site amino acid residues, Arg(115) and Glu(138), were identified by mutational analysis as important for activity in E. coli dCTP deaminase. None of the mutant enzymes R115A, E138A, or E138Q had any detectable activity but circular dichroism spectra for all mutant enzymes were similar to wild type suggesting that the overall structure was not changed. The crystal structures of wildtype E. coli dCTP deaminase and the E138A mutant enzyme have been determined in complex with dUTP and Mg2+ and the mutant enzyme also with the substrate dCTP and Mg2+. The enzyme is a third member of the family of the structurally related trimeric dUTPases and the bifunctional dCTP deaminase-dUTPase from Methanocaldococcus jannaschii. However, the C-terminal fold is completely different from dUTPases resulting in an active site built from residues from two of the trimer subunits, and not from three subunits as in dUTPases. The nucleotides are well defined as well as Mg2+ that is tridentately coordinated to the nucleotide phosphate chains. We suggest a catalytic mechanism for the dCTP deaminase and identify structural differences to dUTPases that prevent hydrolysis of the dCTP triphosphate.	Univ Copenhagen, Dept Chem, Ctr Crystalog Studies, DK-2100 Copenhagen, Denmark; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Copenhagen, August Krogh Inst, Dept Biochem, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, DK-1307 Copenhagen, Denmark; Univ Copenhagen, Dept Chem, Phys Chem Lab, DK-2100 Copenhagen, Denmark	University of Copenhagen; European Synchrotron Radiation Facility (ESRF); University of Copenhagen; University of Copenhagen; University of Copenhagen	Willemoes, M (corresponding author), Univ Copenhagen, Dept Chem, Ctr Crystalog Studies, Univ Pk 5, DK-2100 Copenhagen, Denmark.	martin@ccs.ki.ku.dk	Larsen, Sine/A-4487-2017; Johansson, Eva/AAB-9003-2021; Willemoës, Martin/K-4359-2014	Larsen, Sine/0000-0003-3848-1789; Johansson, Eva/0000-0001-9330-5169; Willemoës, Martin/0000-0003-1689-2712				Barabas O, 2004, J BIOL CHEM, V279, P42907, DOI 10.1074/jbc.M406135200; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Bjornberg O, 2003, J BIOL CHEM, V278, P20667, DOI 10.1074/jbc.M213010200; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Cerenius Y, 2000, J SYNCHROTRON RADIAT, V7, P203, DOI 10.1107/S0909049500005331; Chan S, 2004, J MOL BIOL, V341, P503, DOI 10.1016/j.jmb.2004.06.028; Cooper BF, 1997, PROTEIN SCI, V6, P1031, DOI 10.1002/pro.5560060509; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Huffman JL, 2003, J MOL BIOL, V331, P885, DOI 10.1016/S0022-2836(03)00789-7; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Johansson E, 2003, J BIOL CHEM, V278, P27916, DOI 10.1074/jbc.M304361200; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Ko TP, 2003, J BIOL CHEM, V278, P19111, DOI 10.1074/jbc.M300874200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 2003, J BIOL CHEM, V278, P11100, DOI 10.1074/jbc.M212460200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1995, ACTA CRYSTALLOGR A, V51, P445, DOI 10.1107/S0108767394011335; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuhard, 1987, ESCHERICHIA COLI SAL, V1, P445; Neuhard J, 1978, Methods Enzymol, V51, P418; Nord J, 2001, FEBS LETT, V492, P228, DOI 10.1016/S0014-5793(01)02257-8; Nord J, 2000, FEBS LETT, V472, P312, DOI 10.1016/S0014-5793(00)01453-8; Nygaard P, 1996, J BACTERIOL, V178, P846, DOI 10.1128/jb.178.3.846-853.1996; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PORTER DJT, 1993, J BIOL CHEM, V268, P24005; Prasad GS, 2000, ACTA CRYSTALLOGR D, V56, P1100, DOI 10.1107/S0907444900009197; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheldrick G.M., 2015, ACTA CRYSTALLOGR C, V71, P3; STURA EA, 1992, J CRYST GROWTH, V122, P273, DOI 10.1016/0022-0248(92)90256-I; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P45, DOI 10.1107/S0907444902018048; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WANG LH, 1992, J BACTERIOL, V174, P5647, DOI 10.1128/JB.174.17.5647-5653.1992; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003	43	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3051	3059		10.1074/jbc.M409534200	http://dx.doi.org/10.1074/jbc.M409534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15539408	hybrid			2022-12-25	WOS:000226449100081
J	Fontanini, A; Chies, R; Snapp, EL; Ferrarini, M; Fabrizi, GM; Brancolini, C				Fontanini, A; Chies, R; Snapp, EL; Ferrarini, M; Fabrizi, GM; Brancolini, C			Glycan-independent role of calnexin in the intracellular retention of Charcot-Marie-Tooth 1A Gas3/PMP22 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL MYELIN PROTEIN-22; ARREST-SPECIFIC GENE; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; MOLECULAR CHAPERONE; MEMBRANE-PROTEINS; CELL-SURFACE; IN-VITRO; PMP22; MUTATIONS	Missense point mutations in Gas3/PMP22 are responsible for the peripheral neuropathies Charcot-Marie-Tooth 1A and Dejerine Sottas syndrome. These mutations induce protein misfolding with the consequent accumulation of the proteins in the endoplasmic reticulum and the formation of aggresomes. During folding, Gas3/PMP22 associates with the lectin chaperone calnexin. Here, we show that calnexin interacts with the misfolded transmembrane domains of Gas3/PMP22, fused to green fluorescent protein, in a glycan-independent manner. In addition, photobleaching experiments in living cells revealed that Gas3/PMP22-green fluorescent protein mutants are mobile but diffuse at almost half the diffusion coefficient of wild type protein. Our results support emerging models for a glycan-independent chaperone role for calnexin and for the mechanism of retention of misfolded membrane proteins in the endoplasmic reticulum.	Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, I-33100 Udine, Italy; Univ Udine, MATI Ctr Excellence, I-33100 Udine, Italy; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Policlin GB Rossi, Dept Neurol & Visual Sci, Sect Clin Neurol, I-37134 Verona, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Udine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Brancolini, C (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, Piazza Kolbe 4, I-33100 Udine, Italy.	cbrancolini@makek.dstb.uniud.it	Snapp, Erik Lee/H-7152-2019	Snapp, Erik Lee/0000-0001-9482-2272; BRANCOLINI, Claudio/0000-0002-6597-5373				Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Brancolini C, 2000, MOL BIOL CELL, V11, P2901, DOI 10.1091/mbc.11.9.2901; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; Chies R, 2003, J CELL SCI, V116, P987, DOI 10.1242/jcs.00326; D'Urso D, 1998, J NEUROSCI, V18, P731; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; DEJONGHE P, 1997, J PERIPHER NERV SYST, V2, P370; Dickson KM, 2002, P NATL ACAD SCI USA, V99, P9852, DOI 10.1073/pnas.152621799; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Erne B, 2002, J NEUROCHEM, V82, P550, DOI 10.1046/j.1471-4159.2002.00987.x; FABBRETTI E, 1995, GENE DEV, V9, P1846, DOI 10.1101/gad.9.15.1846; Haggie PM, 2002, J BIOL CHEM, V277, P16419, DOI 10.1074/jbc.M112361200; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hasse B, 2002, J NEUROSCI RES, V69, P227, DOI 10.1002/jnr.10287; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HUGHES BD, 1982, BIOPHYS J, V37, P673; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Isaacs AM, 2002, MOL CELL NEUROSCI, V21, P114, DOI 10.1006/mcne.2002.1158; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Meuleman J, 2001, NEUROMUSCULAR DISORD, V11, P400, DOI 10.1016/S0960-8966(00)00214-5; Muller HW, 2000, GLIA, V29, P182; Naef R, 1999, NEUROBIOL DIS, V6, P1, DOI 10.1006/nbdi.1998.0227; Naef R, 1998, MICROSC RES TECHNIQ, V41, P359, DOI 10.1002/(SICI)1097-0029(19980601)41:5<359::AID-JEMT3>3.0.CO;2-L; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A; Notterpek L, 1999, NEUROBIOL DIS, V6, P450, DOI 10.1006/nbdi.1999.0274; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; PATEL PI, 1994, TRENDS GENET, V10, P128, DOI 10.1016/0168-9525(94)90214-3; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; Ryan MC, 2002, NEUROBIOL DIS, V10, P109, DOI 10.1006/nbdi.2002.0500; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Sanders CR, 2001, BIOCHEMISTRY-US, V40, P9453, DOI 10.1021/bi010894f; Sato K, 2001, J CELL BIOL, V152, P935, DOI 10.1083/jcb.152.5.935; Shames I, 2003, J NEUROPATH EXP NEUR, V62, P751, DOI 10.1093/jnen/62.7.751; Siggia ED, 2000, BIOPHYS J, V79, P1761, DOI 10.1016/S0006-3495(00)76428-9; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Snapp E.L., 2003, CURRENT PROTOCOLS CE; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; SUTER U, 1995, ANNU REV NEUROSCI, V18, P45, DOI 10.1146/annurev.ne.18.030195.000401; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Taylor V, 2000, J NEUROSCI RES, V62, P15, DOI 10.1002/1097-4547(20001001)62:1<15::AID-JNR3>3.3.CO;2-6; Tobler AR, 2002, P NATL ACAD SCI USA, V99, P483, DOI 10.1073/pnas.012593399; Tobler AR, 1999, J NEUROSCI, V19, P2027; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195	59	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2378	2387		10.1074/jbc.M405104200	http://dx.doi.org/10.1074/jbc.M405104200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537650	hybrid			2022-12-25	WOS:000226341700075
J	Obermair, GJ; Kugler, G; Baumgartner, S; Tuluc, P; Grabner, M; Flucher, BE				Obermair, GJ; Kugler, G; Baumgartner, S; Tuluc, P; Grabner, M; Flucher, BE			The Ca2+ channel alpha(2)delta-1 subunit determines Ca2+ current kinetics in skeletal muscle but not targeting of alpha(1S) or excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; DIHYDROPYRIDINE RECEPTORS; MONOCLONAL-ANTIBODY; RYANODINE RECEPTOR; CHARGE MOVEMENT; DYSGENIC MUSCLE; BETA-SUBUNIT; EXPRESSION; CELLS; MYOTUBES	Auxiliary channel subunits regulate membrane expression and modulate current properties of voltage-activated Ca2+ channels and thus are involved in numerous important cell functions, including muscle contraction. Whereas the importance of the alpha(1S), beta(1a), and gamma Ca2+ channel subunits in skeletal muscle has been determined by using null-mutant mice, the role of the alpha(2)delta-1 subunit in skeletal muscle is still elusive. We addressed this question by small interfering RNA silencing of alpha(2)delta-1 in reconstituted dysgenic (alpha(1S)-null) myotubes and in BC3H1 skeletal muscle cells. Immunofluorescence labeling of the alpha(1S) and alpha(2)delta-1 subunits and whole cell patch clamp recordings demonstrated that triad targeting and functional expression of the skeletal muscle Ca2+ channel were not compromised by the depletion of the alpha(2)delta-1 subunit. The amplitudes and voltage dependences of L-type Ca2+ currents and of the depolarization-induced Ca2+ transients were identical in control and in alpha(2)delta-1-depleted muscle cells. However, alpha(2)delta-1 depletion significantly accelerated the current kinetics, most likely by the conversion of slowly activating into fast activating Ca2+ channels. Reverse transcription-PCR analysis indicated that alpha(2)delta-1 is the exclusive isoform expressed in differentiated BC3H1 cells and that depletion of alpha(2)delta-1 was not compensated by the up-regulation of any other alpha(2)delta-1 isoform. Thus, in skeletal muscle the Ca2+ channel alpha(2)delta-1 subunit functions as a major determinant of the characteristic slow L-type Ca2+ current kinetics. However, this subunit is not essential for targeting of Ca2+ channels or for their primary physiological role in activating skeletal muscle excitation-contraction coupling.	Innsbruck Med Univ, Dept Physiol & Med Phys, A-6020 Innsbruck, Austria; Innsbruck Med Univ, Dept Med Genet Mol & Clin Pharmacol, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Flucher, BE (corresponding author), Innsbruck Med Univ, Dept Physiol & Med Phys, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	bernhard.e.flucher@uibk.ac.at	, Gerald/AAD-3183-2020; Tuluc, Petronel/C-2527-2011	Tuluc, Petronel/0000-0003-3660-6138; Flucher, Bernhard/0000-0002-5255-4705				ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; Alden KJ, 2002, AM J PHYSIOL-CELL PH, V283, pC941, DOI 10.1152/ajpcell.00004.2002; Angelotti T, 1996, FEBS LETT, V397, P331, DOI 10.1016/S0014-5793(96)01205-7; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Avila G, 2000, J GEN PHYSIOL, V115, P467, DOI 10.1085/jgp.115.4.467; Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; Bryans JS, 1999, MED RES REV, V19, P149, DOI 10.1002/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B; CAFFREY JM, 1994, PFLUG ARCH EUR J PHY, V427, P277, DOI 10.1007/BF00374535; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Dworkin RH, 2003, NEUROLOGY, V60, P1274, DOI 10.1212/01.WNL.0000055433.55136.55; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Felix R, 1997, J NEUROSCI, V17, P6884; FLUCHER BE, 1991, J CELL BIOL, V115, P1345, DOI 10.1083/jcb.115.5.1345; Flucher BE, 2000, J CELL BIOL, V151, P467, DOI 10.1083/jcb.151.2.467; FLUCHER BE, 1994, MOL BIOL CELL, V5, P1105, DOI 10.1091/mbc.5.10.1105; Freise D, 2000, J BIOL CHEM, V275, P14476, DOI 10.1074/jbc.275.19.14476; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; Morrill JA, 2000, J GEN PHYSIOL, V116, P341, DOI 10.1085/jgp.116.3.341; MORTON ME, 1987, J BIOL CHEM, V262, P11904; MORTON ME, 1988, J BIOL CHEM, V263, P613; Neuhuber B, 1998, J BIOL CHEM, V273, P9110, DOI 10.1074/jbc.273.15.9110; Obermair GJ, 2004, EUR J NEUROSCI, V19, P2109, DOI 10.1111/j.0953-816X.2004.03272.x; Powell JA, 1996, J CELL BIOL, V134, P375, DOI 10.1083/jcb.134.2.375; Protasi F, 1997, J CELL BIOL, V137, P859, DOI 10.1083/jcb.137.4.859; Ren DJ, 1997, J BIOL CHEM, V272, P22393, DOI 10.1074/jbc.272.36.22393; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Sipos I, 2000, PFLUG ARCH EUR J PHY, V439, P691, DOI 10.1007/s004240050994; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9	37	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2229	2237		10.1074/jbc.M411501200	http://dx.doi.org/10.1074/jbc.M411501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15536090	hybrid			2022-12-25	WOS:000226341700059
J	Pogenberg, V; Guichou, JF; Vivat-Hannah, V; Kammerer, S; Perez, E; Germain, P; de Lera, AR; Gronemeyer, H; Royer, CA; Bourguet, W				Pogenberg, V; Guichou, JF; Vivat-Hannah, V; Kammerer, S; Perez, E; Germain, P; de Lera, AR; Gronemeyer, H; Royer, CA; Bourguet, W			Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAINS; NUCLEAR HORMONE-RECEPTORS; HUMAN ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; RXR-ALPHA; PEPTIDE ANTAGONISTS; CO-REPRESSOR; RAR-BETA; ACTIVATION; DETERMINANTS	Retinoid receptors (RARs and RXRs) are ligand-activated transcription factors that regulate the transcription of target genes by recruiting coregulator complexes at cognate promoters. To understand the effects of heterodimerization and ligand binding on coactivator recruitment, we solved the crystal structure of the complex between the RARbeta/RXRalpha ligand-binding domain heterodimer, its 9-cis retinoic acid ligand, and an LXXLL-containing peptide (termed NR box 2) derived from the nuclear receptor interaction domain (NID) of the TRAP220 coactivator. In parallel, we measured the binding affinities of the isolated NR box 2 peptide or the full-length NID of the coactivator SRC-1 for retinoid receptors in the presence of various types of ligands. Our correlative analysis of three-dimensional structures and fluorescence data reveals that heterodimerization does not significantly alter the structure of individual subunits or their intrinsic capacity to interact with NR box 2. Similarly, we show that the ability of a protomer to recruit NR box 2 does not vary as a function of the ligand binding status of the partner receptor. In contrast, the strength of the overall association between the heterodimer and the full-length SRC-1 NID is dictated by the combinatorial action of RAR and RXR ligands, the simultaneous presence of the two receptor agonists being required for highest binding affinity. We identified an LXXLL peptide-driven mechanism by which the concerted reorientation of three phenylalanine side chains generates an "aromatic clamp" that locks the RXR activation helix H12 in the transcriptionally active conformation. Finally, we show how variations of helix H11-ligand interactions can alter the communication pathway linking helices H11, H12, and the connecting loop L11-12 to the coactivator-binding site. Together, our results reveal molecular and structural features that impact on the ligand-dependent interaction of the RAR/RXR heterodimer with nuclear receptor coactivators.	UM1, Fac Pharm, Ctr Biochim Struct, CNRS,U5048,INSERM,U554, F-34093 Montpellier, France; Inst Genet & Biol Mol & Cellulaire, Dept Cell Biol & Signal Transduct, F-67404 Illkirch Graffenstaden, France; Inst Genet & Biol Mol & Cellulaire, Dept Struct Biol & Genom, F-67404 Illkirch Graffenstaden, France; Univ Vigo, Fac Quim, Dept Quim Organ, Vigo 36200, Spain	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universidade de Vigo	Bourguet, W (corresponding author), UM1, Fac Pharm, Ctr Biochim Struct, CNRS,U5048,INSERM,U554, 15 Ave Charles Flahault, F-34093 Montpellier, France.	bourguet@cbs.cnrs.fr	Pérez Santín, Efrén/F-6323-2016; Gronemeyer, Hinrich/AAH-5575-2019; Pogenberg, Vivian/A-3463-2012; Bourguet, William/Y-6600-2019; Gronemeyer, Hinrich/G-6240-2011; Royer, Catherine A/E-5266-2016; Bourguet, William/I-5569-2013; Gronemeyer, Hinrich/H-7002-2016	Pérez Santín, Efrén/0000-0002-1484-3127; Gronemeyer, Hinrich/0000-0001-9454-2449; Pogenberg, Vivian/0000-0002-1021-6804; Bourguet, William/0000-0002-0643-7719; Gronemeyer, Hinrich/0000-0001-9454-2449; Royer, Catherine A/0000-0002-2670-3391; Bourguet, William/0000-0002-0643-7719; Gronemeyer, Hinrich/0000-0001-9454-2449; guichou, jean-francois/0000-0002-7699-3235; Rodriguez de Lera, Angel/0000-0001-6896-9078; Germain, Pierre/0000-0003-2962-9593				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang CY, 1999, MOL CELL BIOL, V19, P8226; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JD, 2000, VITAM HORM, V58, P391, DOI 10.1016/S0083-6729(00)58032-7; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; *COMM COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DeLano WL, 2004, PYMOL VERSION 0 95; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Egea PF, 2000, FEBS LETT, V476, P62, DOI 10.1016/S0014-5793(00)01672-0; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Germain P, 2004, EMBO REP, V5, P877, DOI 10.1038/sj.embor.7400235; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Glass CK, 2000, GENE DEV, V14, P121; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Klaholz BP, 1998, NAT STRUCT BIOL, V5, P199, DOI 10.1038/nsb0398-199; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, NEWSL PROTEIN CRYSTA, V26; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Margeat E, 2001, J MOL BIOL, V306, P433, DOI 10.1006/jmbi.2000.4418; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nettles KW, 2004, MOL CELL, V13, P317, DOI 10.1016/S1097-2765(04)00054-1; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Pogenberg V, 2004, ACTA CRYSTALLOGR D, V60, P1170, DOI 10.1107/S0907444904009928; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; ROYER CA, 1990, ANAL BIOCHEM, V191, P287, DOI 10.1016/0003-2697(90)90221-T; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359-6446(02)02526-6	58	104	112	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1625	1633		10.1074/jbc.M409302200	http://dx.doi.org/10.1074/jbc.M409302200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528208	hybrid			2022-12-25	WOS:000226195200093
J	Pankonin, MS; Gallagher, JT; Loeb, JA				Pankonin, MS; Gallagher, JT; Loeb, JA			Specific structural features of heparan sulfate proteoglycans potentiate neuregulin-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; EXPRESSION PATTERNS; BINDING; MUSCLE; MICE; SULFOTRANSFERASES; OLIGOSACCHARIDES; BIOSYNTHESIS; SACCHARIDES; AFFINITIES	Neuregulins are a family of growth and differentiation factors that act through activation of cell-surface erbB receptor tyrosine kinases and have essential functions both during development and on the growth of cancer cells. One alternatively spliced neuregulin-1 form has a distinct heparin-binding immunoglobulin-like domain that enables it to adhere to heparan sulfate proteoglycans at key locations during development and substantially potentiates its activity. We examined the structural specificity needed for neuregulin-1-heparin interactions using a gel mobility shift assay together with an assay that measures the ability of specific oligosaccharides to block erbB receptor phosphorylation in L6 muscle cells. Whereas the N-sulfate group of heparin was most important, the 2-O-sulfate and 6-O-sulfate groups also contributed to neuregulin-1 binding in these two assays. Optimal binding to neuregulin-1 required eight or more heparin disaccharides; however, as few as two disaccharides were still able to bind neuregulin-1 to a lesser extent. The physiological importance of this specificity was shown both by chemical and siRNA treatment of cultured muscle cells. Pretreatment of muscle cells with chlorate that blocks all sulfation or with an siRNA that selectively blocks N-sulfation significantly reduced erbB receptor activation by neuregulin-1 but had no effect on the activity of neuregulin-1 that lacks the heparin-binding domain. These results suggest that the regulation of glycosaminoglycan sulfation is an important biological mechanism that can modulate both the localization and potentiation of neuregulin-1 signaling.	Wayne State Univ, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA; Univ Manchester, Canc Res UK, Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England	Wayne State University; Wayne State University; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Loeb, JA (corresponding author), Wayne State Univ, Dept Neurol, Elliman 3122,421 E Canfield Ave, Detroit, MI 48201 USA.	jloeb@med.wayne.edu			NINDS NIH HHS [NS 43943] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS043943] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; BAI XM, 1994, J HISTOCHEM CYTOCHEM, V42, P1043, DOI 10.1177/42.8.8027524; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Deguchi Y, 2002, J NEUROCHEM, V83, P381, DOI 10.1046/j.1471-4159.2002.01129.x; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esper RM, 2004, J NEUROSCI, V24, P6218, DOI 10.1523/JNEUROSCI.1692-04.2004; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Gabius HJ, 2000, NATURWISSENSCHAFTEN, V87, P108, DOI 10.1007/s001140050687; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Garcia-Olivas R, 2003, HISTOCHEM CELL BIOL, V120, P371, DOI 10.1007/s00418-003-0576-6; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Honke K, 2002, MED RES REV, V22, P637, DOI 10.1002/med.10020; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; IZVOLSKY KI, 2003, AM J PHYSIOL, V285, pL338; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; Kaneider NC, 2004, BIOCHEMISTRY-US, V43, P237, DOI 10.1021/bi035295i; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Li QF, 2004, MOL CELL NEUROSCI, V26, P558, DOI 10.1016/j.mcn.2004.04.009; Li QF, 2001, J BIOL CHEM, V276, P38068; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Loeb JA, 2003, J NEUROCYTOL, V32, P649, DOI 10.1023/B:NEUR.0000020640.84708.35; Loeb JA, 1999, DEVELOPMENT, V126, P781; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; Meier T, 1998, J CELL BIOL, V141, P715, DOI 10.1083/jcb.141.3.715; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PETITOU M, 1988, CARBOHYD RES, V179, P163, DOI 10.1016/0008-6215(88)84116-8; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Sudhalter J, 1996, GLIA, V17, P28, DOI 10.1002/(SICI)1098-1136(199605)17:1<28::AID-GLIA3>3.0.CO;2-3; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Turnbull J, 2003, BIOCHEM SOC T, V31, P343, DOI 10.1042/BST0310343; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Wu ZLL, 2002, FASEB J, V16, P539, DOI 10.1096/fj.01-0807com	45	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					383	388		10.1074/jbc.M402645200	http://dx.doi.org/10.1074/jbc.M402645200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15528194	hybrid			2022-12-25	WOS:000226025100046
J	Wang, XH; Wang, F; Sy, MS; Ma, JY				Wang, XH; Wang, F; Sy, MS; Ma, JY			Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRPSC-LIKE CONFORMATION; HEAT-SHOCK; ENDOPLASMIC-RETICULUM; SCRAPIE PRION; INDUCED NEUROTOXICITY; DISEASES; CELLS; EXPRESSION; CONVERSION; REVEALS	PrP, a cell surface-localized N-linked glycoprotein, is required for the pathogenesis of prion diseases. Recent studies have revealed that prion protein ( PrP) becomes neurotoxic and prone to aggregation when it is in the cytosol, suggesting that cytosolic PrP may play a role in the pathogenesis of prion disease. Retro-translocation of PrP from the endoplasmic reticulum to the cytosol for proteasome degradation offers a natural route for PrP to enter the cytosol, but whether PrP is subject to retro-translocation is controversial. In this study, we investigated the metabolism of endogenous wild-type PrP in several cell lines and in primary mouse cortical neurons. Our results suggest that a portion of the endogenous wild-type PrP is retro-translocated to the cytosol and degraded by the proteasome. Moreover, we also found that calpain and other cytosolic proteases could degrade PrP in the cytosol when the proteasome activity is compromised. These results provide the foundation for the hypothesis that cytosolic PrP may be involved in the pathogenesis of prion disease.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Ohio State University; Case Western Reserve University	Ma, JY (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	ma.131@osu.edu	Wang, Fei/D-9550-2013	Ma, Jiyan/0000-0001-7150-1898				Aguzzi A, 2004, CURR OPIN NEUROL, V17, P337, DOI 10.1097/00019052-200406000-00015; Aguzzi A, 2003, NATURE, V423, P127, DOI 10.1038/423127a; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kang SC, 2004, J PATHOL, V203, P603, DOI 10.1002/path.1555; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kikuchi S, 2003, J NEUROSCI RES, V71, P591, DOI 10.1002/jnr.10479; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Ochel HJ, 2003, GLYCOBIOLOGY, V13, P655, DOI 10.1093/glycob/cwg081; Pan T, 2004, J NEUROCHEM, V90, P1205, DOI 10.1111/j.1471-4159.2004.02582.x; Pan T, 2002, J NEUROCHEM, V81, P1092, DOI 10.1046/j.1471-4159.2002.00909.x; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Priola SA, 2003, SCIENCE, V300, P917, DOI 10.1126/science.1085920; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Shyu WC, 2000, NEUROREPORT, V11, P771, DOI 10.1097/00001756-200003200-00023; Shyu WC, 2002, MOL NEUROBIOL, V26, P1, DOI 10.1385/MN:26:1:001; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Wang L, 2001, PROSTATE, V47, P21; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yadavalli R, 2004, J BIOL CHEM, V279, P21948, DOI 10.1074/jbc.M400793200; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	53	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					317	325		10.1074/jbc.M410649200	http://dx.doi.org/10.1074/jbc.M410649200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15525638	hybrid			2022-12-25	WOS:000226025100039
J	Wichroski, MJ; Ichiyama, K; Rana, TM				Wichroski, MJ; Ichiyama, K; Rana, TM			Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIF PROTEIN; ANTIVIRAL ACTIVITY; VIRION INCORPORATION; ENZYME APOBEC3G; GAG PROTEINS; DNA; DEGRADATION; EXPRESSION; HYPERMUTATION	To study how HIV- 1 viral infectivity factor ( Vif) mediates proteasome- dependent depletion of host factor APOBEC3G, functional and non- functional VifAPOBEC3G interactions were correlated with subcellular localization. APOBEC3G localized throughout the cytoplasm and co- localized with gamma-tubulin, 20 S proteasome subunit, and ubiquitin at punctate cytoplasmic bodies that can be used to monitor the Vif- APOBEC3G interaction in the cell. Through immunostaining and live imaging, we showed that a substantial fraction of Vif localized to the nucleus, and this localization was impaired by deletion of amino acids 12 - 23. When coexpressed, Vif exhibited more pronounced localization to the cytoplasm and reduced the total cellular levels of APOBEC3G but rarely co- localized with APOBEC3G at cytoplasmic bodies. On the contrary, Vif(C114S), which is inactive but continues to interact with APOBEC3G, stably associated with APOBEC3G in the cytoplasm, resulting in complete co- localization at cytoplasmic bodies and a dose- dependent exclusion of VifC114S from the nucleus. Following proteasome inhibition, cytoplasmic APOBEC3G levels increased, and both proteins co- accumulated nonspecifically into a vimentin- encaged aggresome. Furthermore in the presence or absence of APOBEC3G, Vif localization was significantly altered by proteasome inhibition, suggesting that aberrant localization may also contribute to the loss of Vif function. Finally mutations at Vif Ile(9) disrupted the ability of Vif or Vif(C114S) to coimmunoprecipitate and to co- localize with APOBEC3G, suggesting that the N terminus of Vif mediates interactions with APOBEC3G. Taken together, these results demonstrate that cytoplasmic VifAPOBEC3G interactions are required but are not sufficient for Vif to modulate APOBEC3G and can be monitored by co- localization in vivo.	Univ Massachusetts, Sch Med, Chem Biol Program, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Rana, TM (corresponding author), Univ Massachusetts, Sch Med, Chem Biol Program, Dept Biochem & Mol Pharmacol, 364 Plantat St, Worcester, MA 01605 USA.	tariq.rana@umassmed.edu			NIAID NIH HHS [AI 43198, AI 41404] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043198, R01AI041404, R56AI041404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akari H, 2004, J BIOL CHEM, V279, P12355, DOI 10.1074/jbc.M312426200; Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Chatterji U, 2000, J VIROL, V74, P2533, DOI 10.1128/JVI.74.6.2533-2540.2000; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Douaisi M, 2004, BIOCHEM BIOPH RES CO, V321, P566, DOI 10.1016/j.bbrc.2004.07.005; Feng F, 2004, J VIROL, V78, P10574, DOI 10.1128/JVI.78.19.10574-10581.2004; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goff SP, 2003, CELL, V114, P281, DOI 10.1016/S0092-8674(03)00602-0; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; Gu YP, 2003, NATURE, V424, P21, DOI 10.1038/424021a; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kao S, 2003, J VIROL, V77, P1131, DOI 10.1128/JVI.77.2.1131-1140.2003; Karczewski MK, 1996, J VIROL, V70, P494, DOI 10.1128/JVI.70.1.494-507.1996; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004; Madani N, 2002, J VIROL, V76, P11133, DOI 10.1128/JVI.76.21.11133-11138.2002; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Rose KM, 2004, TRENDS MOL MED, V10, P291, DOI 10.1016/j.molmed.2004.04.008; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	45	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8387	8396		10.1074/jbc.M408048200	http://dx.doi.org/10.1074/jbc.M408048200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15537645	hybrid			2022-12-25	WOS:000227395700115
J	Okumura-Nakanishi, S; Saito, M; Niwa, H; Ishikawa, F				Okumura-Nakanishi, S; Saito, M; Niwa, H; Ishikawa, F			Oct-3/4 and Sox2 regulate Oct-3/4 gene in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR-4 ENHANCER; BINDING TRANSCRIPTION FACTOR; PUTATIVE DOWNSTREAM GENES; POU-DOMAIN; MOUSE DEVELOPMENT; CRYSTAL-STRUCTURE; MAMMALIAN EMBRYO; SELF-RENEWAL; OCTAMER SITE; ES CELLS	Oct-3/4 is a key transcriptional factor whose expression level governs the fate of primitive inner cell mass and embryonic stem (ES) cells. Previously, an upstream 3.3-kb distal enhancer (DE) fragment was identified to be responsible for the specific expression of mouse Oct-3/4 in the inner cell mass and ES cells. However, little is known about the cis-elements and trans-factors required for DE activity. In this study, we identified a novel cis-element, called Site 2B here, located similar to30 bp downstream from Site 2A, which was previously revealed in DE by an in vivo chemical modification experiment. Using the luciferase reporter assay, we demonstrated that both Site 2A and Site 2B are necessary and sufficient for activating DE in the contexts of both the native Oct-3/4 promoter and the heterologous thymidine kinase minimal promoter. In an electrophoretic mobility shift assay we showed that Site 2B specifically binds to Oct-3/4 and Sox2 when ES-derived cell extracts were used, whereas Site 2A binds to a factor(s) present in both ES and NIH 3T3 cells. Furthermore, we showed that the physiological level of Oct-3/4 in ES cells is required for Site 2B-mediated DE activity using the inducible knockout system of Oct-3/4 in ES cells. These results indicate that Oct-3/4 is a member of the gene family regulated by Oct-3/4 and Sox2, as reported before for the FGF-4, UTF1, Sox2, and Fbx15 genes. Thus, Oct-3/4 and Sox2 comprise a regulatory complex that controls the expression of genes important for the maintenance of the primitive state, including themselves. This autoregulatory circuit of the Sox2.Oct-3/4 complex may contribute to maintaining robustly the precise expression level of Oct-3/4 in primitive cells.	Tokyo Inst Technol, Lab Mol & Cellular Assembly, Dept Biol Informat, Grad Sch Biosci & Biotechnol,Midori Ku, Yokohama, Kanagawa 2268501, Japan; RIKEN, Ctr Dev Biol, Lab Pluripotent Cell Studies, Chuo Ku, Kobe, Hyogo 6500047, Japan; Kyoto Univ, Lab Cell Cycle Regulat, Dept Gene Mech, Grad Sch Biostudies, Kitashirakawa Oiwake, Kyoto 6068502, Japan	Tokyo Institute of Technology; RIKEN; Kyoto University	Ishikawa, F (corresponding author), Tokyo Inst Technol, Lab Mol & Cellular Assembly, Dept Biol Informat, Grad Sch Biosci & Biotechnol,Midori Ku, 4259 Nagatuda, Yokohama, Kanagawa 2268501, Japan.	fishikaw@lif.kyoto-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				Ambrosetti DC, 2000, J BIOL CHEM, V275, P23387, DOI 10.1074/jbc.M000932200; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; Du ZW, 2001, BIOCHEM BIOPH RES CO, V282, P701, DOI 10.1006/bbrc.2001.4636; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kim MH, 2002, BIOCHEM BIOPH RES CO, V296, P1372, DOI 10.1016/S0006-291X(02)02070-3; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Minucci S, 1996, EMBO J, V15, P888, DOI 10.1002/j.1460-2075.1996.tb00423.x; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 2003, BIOCHEM BIOPH RES CO, V302, P581, DOI 10.1016/S0006-291X(03)00218-3; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; Nordhoff V, 2001, MAMM GENOME, V12, P309, DOI 10.1007/s003350010279; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; POGULIS RJ, 1995, GENE, V158, P231, DOI 10.1016/0378-1119(95)00157-2; Remenyi A, 2003, GENE DEV, V17, P2048, DOI 10.1101/gad.269303; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Yeom YI, 1996, DEVELOPMENT, V122, P881; Yuan H., 1996, GENE DEV, V9, P2635	39	286	309	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5307	5317		10.1074/jbc.m410015200	http://dx.doi.org/10.1074/jbc.m410015200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15557334	hybrid			2022-12-25	WOS:000227217100026
J	Baggio, R; Carven, GJ; Chiulli, A; Palmer, M; Stern, LJ; Arenas, JE				Baggio, R; Carven, GJ; Chiulli, A; Palmer, M; Stern, LJ; Arenas, JE			Induced fit of an epitope peptide to a monoclonal antibody probed with a novel parallel surface plasmon resonance assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURAL CONTENT; AMINO-ACID-COMPOSITION; ALPHA-HELIX; T4 LYSOZYME; FOLDING PROBLEM; BINDING; PROTEIN; PREDICTION; CONSTANTS	Class II major histocompatibility complex proteins bind peptides for presentation to T-cells as part of the immune response process. Monoclonal antibody MEM-265 recognizes the peptide-free conformation of the major histocompatibility complex class II protein HIA-DR1 through specific binding to an epitope contained between residues 50-67 of the beta-chain. In previous work using alanine scanning (1), we identified residues Leu-53, Asp-57, Tyr-60, Trp-61, Ser-63, and Leu-67 as essential for specific recognition by MEM-265. The spacing of these residues approximates a 3.5-residue repeat, suggesting that MEM-265 may recognize the epitope in an a-helical conformation. In the folded, peptide-loaded DR1 structure, the beta-chain residues 50-67 contain a kinked a-helical segment spanning Glu-52-Ser-63 (2). However, the conformation of this segment in the peptide-free form is unknown. We have used a new surface plasmon resonance approach in a SpotMatrix format to compare the kinetic rates and affinities for 18 alanine scanning mutants comprising epitope residues 50-67. In addition to the six essential residues described previously, we found two additional residues, Glu-52 and Gln-64, that contribute by enhancing NMM-265 binding. By contrast, mutation of either Gly-54 or Pro-56 to an alanine actually improved binding to MEM-265. In essentially all cases peptide substitutions that either improve or reduce MEM-265 recognition could be traced to differences in the dissociation rate (k(off)). The kinetic details of the present study support the presence of a structural component in the antigenic epitope recognized by MEM-265 in the peptide-free form of major histocompatibility complex II DR1 beta-chain.	HTS Biosyst, E Hartford, CT 06108 USA; Appl Biosyst Inc, Cell Biol & Funct Proteom, Bedford, MA 01730 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Thermo Fisher Scientific; Applied Biosystems; University of Massachusetts System; University of Massachusetts Worcester; Massachusetts Institute of Technology (MIT)	Arenas, JE (corresponding author), 104 Bertwell Rd, Lexington, MA 02420 USA.	Jarenas@rcn.com		Carven, Gregory/0000-0002-8468-6323	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI038996, R37AI038996, R01AI038996] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38996] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; Calvo JC, 2003, J MED CHEM, V46, P5389, DOI 10.1021/jm030210x; Carven GJ, 2004, J BIOL CHEM, V279, P16561, DOI 10.1074/jbc.M314315200; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; Chen JF, 2001, BIOCHEMISTRY-US, V40, P1144, DOI 10.1021/bi0017226; Choulier L, 1999, BIOCHEMISTRY-US, V38, P3530, DOI 10.1021/bi982011z; CULLEN DC, 1990, SENSOR ACTUAT B-CHEM, V1, P576, DOI 10.1016/0925-4005(90)80276-6; CULLEN DC, 1987, BIOSENSORS, V3, P211; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; DELANO WL, 2002, PYMOL MOL GRAPHICS D; DEMPSEY CE, 1992, BIOCHEMISTRY-US, V31, P4705, DOI 10.1021/bi00134a025; Eisenhaber F, 1996, PROTEINS, V25, P157, DOI 10.1002/(SICI)1097-0134(199606)25:2<157::AID-PROT2>3.0.CO;2-F; Eisenhaber F, 1996, PROTEINS, V25, P169, DOI 10.1002/(SICI)1097-0134(199606)25:2<169::AID-PROT3>3.3.CO;2-5; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; Homola J, 1999, SENSOR ACTUAT B-CHEM, V54, P3, DOI 10.1016/S0925-4005(98)00321-9; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Shinohara Y, 1997, GLYCOBIOLOGY, V7, P1201, DOI 10.1093/glycob/7.8.1201; Sigmundsson K, 2002, BIOCHEMISTRY-US, V41, P8263, DOI 10.1021/bi020099h; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Wegner GJ, 2002, ANAL CHEM, V74, P5161, DOI 10.1021/ac025922u; Wood RW, 1902, PHILOS MAG, V4, P396, DOI 10.1080/14786440209462857; Yang JX, 1997, PROTEIN SCI, V6, P1264, DOI 10.1002/pro.5560060614; ZHANG XJ, 1992, PROTEIN SCI, V1, P761, DOI 10.1002/pro.5560010608; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001	27	21	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4188	4194		10.1074/jbc.M410687200	http://dx.doi.org/10.1074/jbc.M410687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15556932	hybrid			2022-12-25	WOS:000227096600025
J	Song, MS; Chang, JS; Song, SJ; Yang, TH; Lee, H; Lim, DS				Song, MS; Chang, JS; Song, SJ; Yang, TH; Lee, H; Lim, DS			The centrosomal protein RAS association domain family protein 1A (RASSF1A)-binding protein 1 regulates mitotic progression by recruiting RASSF1A to spindle poles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; TUMOR-SUPPRESSOR RASSF1A; EPIGENETIC INACTIVATION; MICROTUBULE DYNAMICS; CELL-CYCLE; MITOSIS; PROTEOLYSIS; MAD2; DESTRUCTION; CDC20	The protein RAS association domain family protein 1A (RASSF1A), which is encoded by a gene that is frequently silenced in many types of sporadic tumor, functions in mitosis as a regulator of the anaphase-promoting complex (APC). With the use of a yeast two-hybrid screen, we identified a human protein, previously designated C19ORF5, that interacts with RASSF1A. This protein, here redesignated RASSF1A-binding protein 1 (RABP1), contains two microtubule-associated protein domains, and its association with RASSF1A was confirmed in mammalian cells by immunoprecipitation and immunofluorescence analyses. RABP1 was found to be localized to the centrosome throughout the cell cycle in a manner dependent on its microtubule-associated protein domains. Ectopic expression of RABP1 induced both stabilization of mitotic cyclins and mitotic arrest at prometaphase in a RASSF1A-dependent manner. It also increased the extent of association between RASSF1A and Cdc20. Conversely depletion of RABP1 by RNA interference prevented both the localization of RASSF1A to the spindle poles as well as its binding to Cdc20, resulting in premature destruction of mitotic cyclins and acceleration of mitotic progression. These findings indicate that RABP1 is required for the recruitment of RASSF1A to the spindle poles and for its inhibition of APC-Cdc20 activity during mitosis.	Korea Adv Inst Sci & Technol, Biomed Res Ctr, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Lim, DS (corresponding author), Korea Adv Inst Sci & Technol, Biomed Res Ctr, Dept Biol Sci, 373-1 Guseoung D, Taejon 305701, South Korea.	daesiklim@kaist.ae.kr	Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555				Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Feig LA, 2002, CURR BIOL, V12, pR259, DOI 10.1016/S0960-9822(02)00787-X; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jackson PK, 2004, TRENDS CELL BIOL, V14, P331, DOI 10.1016/j.tcb.2004.05.005; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kuzmin I, 2002, CANCER RES, V62, P3498; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Lo KW, 2001, CANCER RES, V61, P3877; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Mathe E, 2004, NAT GENET, V36, P117, DOI 10.1038/ng0204-117; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Song MS, 2004, CELL CYCLE, V3, P574; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	38	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3920	3927		10.1074/jbc.M409115200	http://dx.doi.org/10.1074/jbc.M409115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15546880	hybrid			2022-12-25	WOS:000226983900094
J	Adler, J; Bibi, E				Adler, J; Bibi, E			Promiscuity in the geometry of electrostatic interactions between the Escherichia coli multidrug resistance transporter MdfA and cationic substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DRUG-RESISTANCE; AMINO-ACID-RESIDUES; GENOME SEQUENCE; FUNCTIONAL EXPRESSION; SIMULTANEOUS BINDING; MEMBRANE TOPOLOGY; STRUCTURAL BASIS; LIGAND-BINDING; CROSS-LINKING; MOUSE MDR1	The Escherichia coli multidrug transporter MdfA contains a single membrane-embedded charged residue (Glu-26) that plays a critical role in the recognition of cationic substrates (Edgar, M, and Bibi, E. (1999) EMBO J. 18, 822-832). Using an inactive mutant (MdfA-E26T), we isolated a spontaneous second-site mutation (MdfA-E26T/V335E) that re-established the recognition of cationic drugs by the transporter. Only a negative charge at position 335 was able to restore the functioning of the inactive mutant MdfA-E26T. Intriguingly, the two genetically interacting residues are located at remote and distinct regions along the secondary structure of MdfA. Glu-26 is located in the periplasmic half of transmembrane helix 1, and as shown here, the complementing charge at position 335 resides within the cytoplasmic loop connecting transmembrane helices 10 and 11. The spatial relation between the two residues was investigated by cross-linking. A functional split version of MdfA devoid of cysteines was constructed and introduced with a cysteine pair at positions 26 and 335. Strikingly, the results indicate that residues 26 and 335 are spatially adjacent, suggesting that they both constitute parts of the multidrug recognition pocket of MdfA. The fact that electrostatic interactions are preserved with cationic substrates even if the critical acidic residue is placed on another face of the pocket reveals an additional dimension of promiscuity in multidrug recognition and transport.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Bibi, E (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	e.bibi@weizmann.ac.il		Bibi, Eitan/0000-0003-3700-2707				Adler J, 2004, J BIOL CHEM, V279, P8957, DOI 10.1074/jbc.M313422200; Adler J, 2004, BIOCHEMISTRY-US, V43, P518, DOI 10.1021/bi035485t; Adler J, 2002, J BACTERIOL, V184, P3313, DOI 10.1128/JB.184.12.3313-3320.2002; Beja O, 1996, P NATL ACAD SCI USA, V93, P5969, DOI 10.1073/pnas.93.12.5969; BIBI E, 1993, P NATL ACAD SCI USA, V90, P9209, DOI 10.1073/pnas.90.19.9209; Bibi E, 2001, J MOL MICROB BIOTECH, V3, P171; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Bohn C, 1998, J BACTERIOL, V180, P6072, DOI 10.1128/JB.180.22.6072-6075.1998; Edgar R, 1997, J BACTERIOL, V179, P2274, DOI 10.1128/jb.179.7.2274-2280.1997; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Gutman N, 2003, J BIOL CHEM, V278, P16082, DOI 10.1074/jbc.M213120200; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Jin Q, 2002, NUCLEIC ACIDS RES, V30, P4432, DOI 10.1093/nar/gkf566; Kimura-Someya T, 2000, J BIOL CHEM, V275, P18692, DOI 10.1074/jbc.M000354200; Krom BP, 2003, BIOCHEMISTRY-US, V42, P467, DOI 10.1021/bi026874a; Levy SB, 2002, J APPL MICROBIOL, V92, p65S, DOI 10.1046/j.1365-2672.92.5s1.4.x; Lewinson O, 2004, P NATL ACAD SCI USA, V101, P14073, DOI 10.1073/pnas.0405375101; Lewinson O, 2003, P NATL ACAD SCI USA, V100, P1667, DOI 10.1073/pnas.0435544100; Lewinson O, 2001, BIOCHEMISTRY-US, V40, P12612, DOI 10.1021/bi011040y; Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004; Lu JL, 2001, BIOCHEMISTRY-US, V40, P13288, DOI 10.1021/bi0107647; Ma C, 2004, P NATL ACAD SCI USA, V101, P2852, DOI 10.1073/pnas.0400137101; Markham PN, 2001, CURR OPIN MICROBIOL, V4, P509, DOI 10.1016/S1369-5274(00)00243-5; Mazurkiewicz P, 2002, J BIOL CHEM, V277, P26081, DOI 10.1074/jbc.M203141200; Mine T, 1998, J BIOCHEM-TOKYO, V124, P187, DOI 10.1093/oxfordjournals.jbchem.a022078; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; SOMEYA Y, 1995, BIOCHEMISTRY-US, V34, P7, DOI 10.1021/bi00001a002; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; Wang QD, 1999, BIOCHEMISTRY-US, V38, P3120, DOI 10.1021/bi982507g; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; WILSON DM, 1995, BIOCHEM BIOPH RES CO, V209, P242, DOI 10.1006/bbrc.1995.1495; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P26990; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; Zgurskaya HI, 2003, FRONT BIOSCI, V8, pS862, DOI 10.2741/1134; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	53	41	44	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2721	2729		10.1074/jbc.M412332200	http://dx.doi.org/10.1074/jbc.M412332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15557318	hybrid			2022-12-25	WOS:000226449100044
J	Fiorillo, MT; Ruckert, C; Hulsmeyer, M; Sorrentino, R; Saenger, W; Ziegler, A; Uchanska-Ziegler, B				Fiorillo, MT; Ruckert, C; Hulsmeyer, M; Sorrentino, R; Saenger, W; Ziegler, A; Uchanska-Ziegler, B			Allele-dependent similarity between viral and self-peptide presentation by HLA-B27 subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; MOLECULAR MIMICRY; STRUCTURAL BASIS; ANKYLOSING-SPONDYLITIS; KLEBSIELLA-PNEUMONIAE; ANTIGEN PRESENTATION; CRYSTAL-STRUCTURES; PROTEIN-STRUCTURE; POLYMORPHISM; ASSOCIATION	Molecular mimicry is discussed as a possible mechanism that may contribute to the development of autoimmune diseases. It could also be involved in the differential association of the human major histocompatibility subtypes HLA-B*2705 and HLA-B*2709 with ankylosing spondylitis. These two subtypes differ only in residue 116 of the heavy chain (Asp in B*2705 and His in B*2709), but the reason for the differential disease association is not understood. Using x-ray crystallography, we show here that the viral peptide pLMP2 (RRRWRRLTV, derived from latent membrane protein 2 (residues 236244) of Epstein-Barr virus) is presented by the B*2705 and B*2709 molecules in two drastically deviating conformations. Extensive structural similarity between pLMP2 and the self-peptide pVIPR (RRKWRRWHL, derived from vasoactive intestinal peptide type 1 receptor (residues 400-408)) is observed only when the peptides are presented by B*2705 because of a salt bridge between Arg(5) of both peptides and the subtype-specific heavy chain residue Asp(116). Combined with functional studies using pLMP2/pVIPR-cross-reactive cytotoxic T cell lines and clones, together with target cells presenting these peptides or a modified peptide analogue, our results reveal that a pathogen-derived peptide can exhibit major histocompatibility complex class I subtype-dependent, drastically distinct binding modes. Furthermore, the results demonstrate that molecular mimicry between pLMP2 and pVIPR in the HLA-B27 context is an allele-dependent property.	Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany; Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Humboldt Univ, Charite Univ Med Berlin, Inst Immungenet, D-14050 Berlin, Germany; Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany	Free University of Berlin; Sapienza University Rome; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Saenger, W (corresponding author), Free Univ Berlin, Inst Chem Kristallog, Takustr 6, D-14195 Berlin, Germany.	saenger@chemie.fu-berlin.de; barbara.uchanska-ziegler@charite.de	Sorrentino, Rosa/G-5472-2012	Sorrentino, Rosa/0000-0002-9632-2383; FIORILLO, Maria Teresa/0000-0002-6859-5851				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BROOKS JM, 1993, J EXP MED, V178, P879, DOI 10.1084/jem.178.3.879; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CONTU L, 1992, TISSUE ANTIGENS, V40, P165, DOI 10.1111/j.1399-0039.1992.tb02041.x; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; Doxiadis IIN, 1996, LANCET, V348, P850, DOI 10.1016/S0140-6736(96)02296-9; EARNEST T, 1991, PROTEINS, V10, P171, DOI 10.1002/prot.340100303; Ferrara GB, 2001, BLOOD, V98, P3150, DOI 10.1182/blood.V98.10.3150; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GECZY AF, 1982, J RHEUMATOL, V9, P97; Hildebrand WH, 2002, HUM IMMUNOL, V63, P248, DOI 10.1016/S0198-8859(02)00364-6; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Housset D, 2003, TRENDS IMMUNOL, V24, P429, DOI 10.1016/S1471-4906(03)00180-7; Hulsmeyer M, 2004, J EXP MED, V199, P271, DOI 10.1084/jem.20031690; Hulsmeyer M, 2002, J BIOL CHEM, V277, P47844, DOI 10.1074/jbc.M206392200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Liu YZ, 2004, BIOCHEMISTRY-US, V43, P10112, DOI 10.1021/bi049438s; Lombardi G, 2001, J IMMUNOL, V166, P3549, DOI 10.4049/jimmunol.166.5.3549; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Massa M, 2002, ARTHRITIS RHEUM, V46, P2721, DOI 10.1002/art.10564; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; Misko IS, 1999, P NATL ACAD SCI USA, V96, P2279, DOI 10.1073/pnas.96.5.2279; Moss DJ, 2001, PHILOS T ROY SOC B, V356, P475, DOI 10.1098/rstb.2000.0784; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park BY, 2004, IMMUNITY, V20, P71, DOI 10.1016/S1074-7613(03)00355-8; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pohlmann T, 2004, J BIOL CHEM, V279, P28197, DOI 10.1074/jbc.C400128200; Ramos M, 2002, J BIOL CHEM, V277, P28749, DOI 10.1074/jbc.M204155200; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; Ramos M, 2002, J BIOL CHEM, V277, P37573, DOI 10.1074/jbc.M205470200; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHWIMMBECK PL, 1987, J EXP MED, V166, P173, DOI 10.1084/jem.166.1.173; Selin LK, 2004, IMMUNITY, V20, P5, DOI 10.1016/S1074-7613(03)00356-X; Stollar EJ, 2003, J BIOL CHEM, V278, P43699, DOI 10.1074/jbc.M308029200; Stone MA, 2004, RHEUMATOLOGY, V43, P148, DOI 10.1093/rheumatology/keg482; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006; Tiwana H, 1998, BRIT J RHEUMATOL, V37, P525; Turnquist HR, 2000, EUR J IMMUNOL, V30, P3021, DOI 10.1002/1521-4141(200010)30:10<3021::AID-IMMU3021>3.0.CO;2-U; Turnquist HR, 2002, IMMUNOGENETICS, V53, P830, DOI 10.1007/s00251-001-0404-x; UCHANSKAZIEGLER B, 2004, IN PRESS P 13 INT HI; WAGNER G, 1992, ANNU REV BIOPH BIOM, V21, P167, DOI 10.1146/annurev.biophys.21.1.167; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wucherpfennig KW, 2001, J AUTOIMMUN, V16, P293, DOI 10.1006/jaut.2000.0499; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Zernich D, 2004, J EXP MED, V200, P13, DOI 10.1084/jem.20031680	60	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2962	2971		10.1074/jbc.M410807200	http://dx.doi.org/10.1074/jbc.M410807200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15537660	hybrid			2022-12-25	WOS:000226449100072
J	Tamburro, AM; Pepe, A; Bochicchio, B; Quaglino, D; Ronchetti, IP				Tamburro, AM; Pepe, A; Bochicchio, B; Quaglino, D; Ronchetti, IP			Supramolecular amyloid-like assembly of the polypeptide sequence coded by exon 30 of human tropoelastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPROLINE-II STRUCTURE; PROTEIN SECONDARY STRUCTURE; INFRARED-SPECTROSCOPY; ELASTIC FIBERS; WATER SOLUTION; HUMAN-SKIN; AGGREGATION; IDENTIFICATION; CONFORMATIONS; REQUIREMENTS	Elastin is known to self-aggregate in twisted-rope filaments. However, an ultrastructural organization different from the fibrils typical of elastin, but rather similar to those shown by amyloid networks, is shown by the polypeptide sequence encoded by exon 30 of human tropoelastin. To better understand the molecular properties of this sequence to give amyloid fibers, we used CD, NMR, and FTIR (Fourier transform infrared spectroscopy) to identify the structural characteristics of the peptide. In this study, we have demonstrated, by FTIR, that antiparallel beta-sheet conformation is predominant in the exon 30 fibers. These physical-chemical studies were combined with transmission electron microscopy and atomic force microscopy to analyze the supramolecular structure of the self-assembled aggregate. These studies show the presence of fibrils that interact side-by-side probably originating from an extensive self-interaction of elemental cross beta-structures. Similar sequences, of the general type XGGZG (X, Z = V, L, A, 1), are widely found in many proteins such as collagens IV and XVII, major prion protein precursor, amyloid beta A4 precursor protein-binding family, etc., thus suggesting that this sequence could be involved in contributing to the self-assembly of amyloid fibers even in other proteins.	Univ Basilicata, Dept Chem, I-85100 Potenza, Italy; Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy	University of Basilicata; Universita di Modena e Reggio Emilia	Tamburro, AM (corresponding author), Univ Basilicata, Dept Chem, Via N Sauro 85, I-85100 Potenza, Italy.	tamburro@unibas.it	Quaglino, Daniela/A-9381-2010; Pepe, Antonietta/J-2489-2012; Bochicchio, Brigida/P-2912-2015	Quaglino, Daniela/0000-0002-4302-5078; Pepe, Antonietta/0000-0002-1285-2273; Bochicchio, Brigida/0000-0002-0700-9257				ANDRIES JC, 1971, BIOPOLYMERS, V10, P1049, DOI 10.1002/bip.360100611; Balbach JJ, 2002, BIOPHYS J, V83, P1205, DOI 10.1016/S0006-3495(02)75244-2; BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; Bellingham CM, 2003, BIOPOLYMERS, V70, P445, DOI 10.1002/bip.10512; Bochicchio B, 2004, CHEM-EUR J, V10, P3166, DOI 10.1002/chem.200305661; Bochicchio B, 2004, BIOPOLYMERS, V73, P484, DOI 10.1002/bip.10552; Bochicchio B, 2002, CHIRALITY, V14, P782, DOI 10.1002/chir.10153; Bochicchio B, 2001, MATRIX BIOL, V20, P243, DOI 10.1016/S0945-053X(01)00139-1; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRESSAN GM, 1983, J ULTRA MOL STRUCT R, V82, P335, DOI 10.1016/S0022-5320(83)80021-5; Burgi R, 2001, J BIOMOL NMR, V19, P305, DOI 10.1023/A:1011295422203; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; CLARK AH, 1981, INT J PEPT PROT RES, V17, P353; Debelle L, 1998, EUR J BIOCHEM, V258, P533, DOI 10.1046/j.1432-1327.1998.2580533.x; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; Debelle L, 1999, BIOCHIMIE, V81, P981, DOI 10.1016/S0300-9084(99)00221-7; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dubay KF, 2004, J MOL BIOL, V341, P1317, DOI 10.1016/j.jmb.2004.06.043; Dyson HJ, 1998, EUR J BIOCHEM, V255, P462, DOI 10.1046/j.1432-1327.1998.2550462.x; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Fan Kang, 2002, BMC Pulm Med, V2, P5, DOI 10.1186/1471-2466-2-5; Fiebig KM, 1996, J PHYS CHEM-US, V100, P2661, DOI 10.1021/jp952747v; Flamia R, 2004, BIOMACROMOLECULES, V5, P1511, DOI 10.1021/bm049930r; Getie M, 2004, MATRIX BIOL, V23, P402; GUANTIERI V, 1983, CONNECT TISSUE RES, V12, P79, DOI 10.3109/03008208309005614; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; JACKSON M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P231, DOI 10.1016/0167-4838(91)90563-F; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KARPLUS M, 1959, J CHEM PHYS, V30, P11, DOI 10.1063/1.1729860; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kozel BA, 2003, J BIOL CHEM, V278, P18491, DOI 10.1074/jbc.M212715200; Lefevre T, 2004, BIOPOLYMERS, V73, P705, DOI 10.1002/bip.20010; Martino M, 2000, J MOL STRUCT, V519, P173, DOI 10.1016/S0022-2860(99)00299-9; Miao M, 2003, J BIOL CHEM, V278, P48553, DOI 10.1074/jbc.M308465200; MORELLI MAC, 1993, J BIOMOL STRUCT DYN, V11, P181; Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012; PEPE A, 2004, IN PRESS MATRIX BIOL; Petsko G., 2004, PROTEIN STRUCTURE FU; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; ROBSON P, 1993, J BIOL CHEM, V268, P1440; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; SUSI H, 1967, J BIOL CHEM, V242, P5460; TAMBURRO AM, 1991, CHIRALITY, V3, P318, DOI 10.1002/chir.530030417; TAMBURRO AM, 1990, BIOPOLYMERS, V29, P855, DOI 10.1002/bip.360290419; Tamburro AM, 2003, BIOCHEMISTRY-US, V42, P13347, DOI 10.1021/bi034837t; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; UITTO J, 1983, LAB INVEST, V49, P499; URRY DW, 1988, J PROTEIN CHEM, V7, P1, DOI 10.1007/BF01025411; VARADI DP, 1972, J INVEST DERMATOL, V59, P238, DOI 10.1111/1523-1747.ep12627261; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WEINSTEIN GD, 1960, J INVEST DERMATOL, V35, P227, DOI 10.1038/jid.1960.109; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858	62	80	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2682	2690		10.1074/jbc.M411617200	http://dx.doi.org/10.1074/jbc.M411617200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15550396	Green Published, hybrid			2022-12-25	WOS:000226449100039
J	Gerasimovskaya, EV; Tucker, DA; Weiser-Evans, M; Wenzlau, JM; Klemm, DJ; Banks, M; Stenmark, KR				Gerasimovskaya, EV; Tucker, DA; Weiser-Evans, M; Wenzlau, JM; Klemm, DJ; Banks, M; Stenmark, KR			Extracellular ATP-induced proliferation of adventitial fibroblasts requires phosphoinositide 3-kinase, Akt, mammalian target of rapamycin, and p70 S6 kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE BETA; PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE-CELLS; IN-VIVO; DNA-SYNTHESIS; PI 3-KINASE; MAP KINASE; C-ZETA; ACTIVATION; INSULIN	Extracellular nucleotides are increasingly recognized as important regulators of growth in a variety of cell types. Recent studies have demonstrated that extracellular ATP is a potent inducer of fibroblast growth acting, at least in part, through an ERK1/2-dependent signaling pathway. However, the contributions of additional signaling pathways to extracellular ATP-mediated cell proliferation have not been defined. By using both pharmacologic and genetic approaches, we found that in addition to ERK1/2, phosphatidylinositol 3-kinase (PI3K), Akt, mammalian target of rapamycin ( mTOR), and p70 S6K-dependent signaling pathways are required for ATP-induced proliferation of adventitial fibroblasts. We found that extracellular ATP acting in part through G(i) proteins increased PI3K activity in a time-dependent manner and transient phosphorylation of Akt. This PI3K pathway is not involved in ATP-induced activation of ERK1/2, implying activation of independent parallel signaling pathways by ATP. Extracellular ATP induced dramatic increases in mTOR and p70 S6K phosphorylation. This activation of the mTOR/p70 S6 kinase (p70 S6K) pathway in response to ATP is because of independent contributions of PI3K/Akt and ERK1/2 pathways, which converge on the level of p70 S6K. ATP-dependent activation of mTOR and p70 S6K also requires additional signaling inputs perhaps from pathways operating through Galpha or Gbetagamma subunits. Collectively, our data demonstrate that ATP-induced adventitial fibroblast proliferation requires activation and interaction of multiple signaling pathways such as PI3K, Akt, mTOR, p70 S6K, and ERK1/2 and provide evidence for purinergic regulation of the protein translational pathways related to cell proliferation.	Univ Colorado, Hlth Sci Ctr, Dev Lung Biol Lab, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Cardiovasc Pulm Res Lab, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gerasimovskaya, EV (corresponding author), Univ Colorado, Hlth Sci Ctr, Dev Lung Biol Lab, 4200 E 9th Ave,Res Bridge,B131, Denver, CO 80262 USA.	Evgenia.Gerasimovskaya@UCHSC.edu	stenmark, kurt/AAH-3124-2022; stenmark, kurt/AFI-6776-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL057144] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-57144, HL-14985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrams CS, 1996, BBA-MOL CELL RES, V1314, P233, DOI 10.1016/S0167-4889(96)00109-7; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; Belham CM, 1997, CELL SIGNAL, V9, P109, DOI 10.1016/S0898-6568(96)00120-9; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; Dugourd C, 2003, HYPERTENSION, V41, P882, DOI 10.1161/01.HYP.0000060821.62417.35; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Goel R, 2002, ANN NY ACAD SCI, V973, P138, DOI 10.1111/j.1749-6632.2002.tb04622.x; GONCHAROVA EA, 2002, AM J PHYSIOL, V83, pL354; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Guizzetti M, 2002, J NEUROCHEM, V82, P38, DOI 10.1046/j.1471-4159.2002.00942.x; HARA K, 1995, BIOCHEM BIOPH RES CO, V208, P735, DOI 10.1006/bbrc.1995.1399; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Huwiler A, 2002, BRIT J PHARMACOL, V136, P520, DOI 10.1038/sj.bjp.0704748; HUWILER A, 1994, BRIT J PHARMACOL, V113, P1455, DOI 10.1111/j.1476-5381.1994.tb17160.x; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Kuemmerle JF, 1998, AM J PHYSIOL-GASTR L, V275, pG151, DOI 10.1152/ajpgi.1998.275.1.G151; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Novak I, 2003, NEWS PHYSIOL SCI, V18, P12, DOI 10.1152/nips.01409.2002; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ralevic V, 1998, PHARMACOL REV, V50, P413; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Stabile E, 2003, CIRC RES, V93, P1059, DOI 10.1161/01.RES.0000105086.31909.1B; Stenmark KR, 2002, CHEST, V122, p326S, DOI 10.1378/chest.122.6_suppl.326S; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Van Brocklyn JR, 2002, CANCER LETT, V181, P195, DOI 10.1016/S0304-3835(02)00050-2; VANDAELE P, 1992, CIRC RES, V70, P82, DOI 10.1161/01.RES.70.1.82; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; WANG T, 2002, J BIOL CHEM, V275, P7466; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; WILLIAMS CA, 1983, CARDIOVASC RES, V17, P301, DOI 10.1093/cvr/17.5.301; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	65	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1838	1848		10.1074/jbc.M409466200	http://dx.doi.org/10.1074/jbc.M409466200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15522879	hybrid			2022-12-25	WOS:000226341700017
J	Harikumar, KG; Puri, V; Singh, RD; Hanada, K; Pagano, RE; Miller, LJ				Harikumar, KG; Puri, V; Singh, RD; Hanada, K; Pagano, RE; Miller, LJ			Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-BETA-CYCLODEXTRIN; ACETYLCHOLINE-RECEPTOR; HUMAN GALLBLADDER; STORAGE DISEASES; PLASMA-MEMBRANE; LIPID RAFTS; CELLS; ACTIVATION; DOMAINS; INTERNALIZATION	The lipid microenvironment of receptors can influence their conformation, function, and regulation. Cholecystokinin (CCK)-stimulated signaling is abnormal in some forms of hyperlipidemia, suggesting the possibility of unique sensitivity to its lipid environment. Here we examined the influence of cholesterol and sphingolipids on CCK receptors in model Chinese hamster ovary cell systems having lipid levels modified. Cholesterol was modulated chemically or metabolically, and sphingolipids were modulated using a temperature-sensitive cell line (SPB-1). Receptor conformation was probed with a fluorescent full agonist ligand, Alexa 488-conjugated Gly-[Nle(28,31)]CCK-(26-33), shown previously to decrease in anisotropy and lifetime when occupying a receptor in the active conformation (Harikumar, K. G., Pinon, D. L., Wessels, W. S., Prendergast, F. G., and Miller, L. J. (2002) J. Biol. Chem. 277, 18552-18560). Anisotropy and lifetime of this probe were increased and prolonged with cholesterol enrichment, and decreased and shortened with depletion of cholesterol or sphingolipids. The increase in these parameters with cholesterol enrichment may reflect change in CCK receptor conformation toward its inactive, uncoupled state. Indeed, cholesterol enrichment resulted in nonproductive agonist ligand binding, with affinity of binding higher than normal and calcium signaling in response to this reduced. In cholesterol- and sphingolipid-depleted states, the receptor moved into conformations that were less than optimal. With cholesterol depletion, both ligand binding and signaling were decreased, yet internalization and trafficking were unperturbed. With sphingolipid depletion, ligand binding and signaling were normal, but internalization and trafficking were markedly inhibited. Of note, normal transferrin receptor trafficking through the same clathrin-dependent pathway was maintained under these conditions. Thus, lipid microenvironment of the CCK receptor is particularly important, with different lipids having distinct effects.	Mayo Clin Scottsdale, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin Scottsdale, Ctr Canc, 13400 Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu	Takhter, Ramandeep/AAG-8977-2019	Harikumar, Kaleeckal/0000-0003-0411-5334; Takhter, Ramandeep/0000-0002-1441-2722; Hanada, Kentaro/0000-0003-1383-2781	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032878, R37DK032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942, R01GM022942] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32878] Funding Source: Medline; NIGMS NIH HHS [GM22942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BLIGH ED, 1959, CAN J BIOCHEM, V37, P333; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; Chen Q, 1999, GASTROENTEROLOGY, V116, P678, DOI 10.1016/S0016-5085(99)70190-3; CRIADO M, 1982, BIOCHEMISTRY-US, V21, P3622, DOI 10.1021/bi00258a015; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Franco R, 2003, TRENDS BIOCHEM SCI, V28, P238, DOI 10.1016/S0968-0004(03)00065-3; Geary N, 2001, PEPTIDES, V22, P1251, DOI 10.1016/S0196-9781(01)00449-1; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Gouldson PR, 2001, PROTEIN ENG, V14, P759, DOI 10.1093/protein/14.10.759; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HANADA K, 1992, J BIOL CHEM, V267, P23527; Harikumar KG, 2002, J BIOL CHEM, V277, P18552, DOI 10.1074/jbc.M201164200; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Le Melledo JM, 2001, PEPTIDES, V22, P1349, DOI 10.1016/S0196-9781(01)00462-4; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; MILLER LJ, 1995, GASTROENTEROLOGY, V109, P1375, DOI 10.1016/0016-5085(95)90601-0; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nardone G, 1995, HEPATOLOGY, V22, P1751, DOI 10.1002/hep.1840220621; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Niu SL, 2002, J BIOL CHEM, V277, P20139, DOI 10.1074/jbc.M200594200; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; Pang L, 1999, BIOCHEMISTRY-US, V38, P12003, DOI 10.1021/bi990227a; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rao RV, 1997, MOL PHARMACOL, V51, P185, DOI 10.1124/mol.51.2.185; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Roccamo AM, 1999, EUR J NEUROSCI, V11, P1615, DOI 10.1046/j.1460-9568.1999.00574.x; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; SPIRT BA, 1995, INT J OBESITY, V19, P593; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Tate CG, 1996, TRENDS BIOTECHNOL, V14, P426, DOI 10.1016/0167-7799(96)10059-7; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Wu G, 1998, ANN NY ACAD SCI, V845, P126, DOI 10.1111/j.1749-6632.1998.tb09666.x; Xiao ZL, 2000, AM J PHYSIOL-GASTR L, V278, pG251, DOI 10.1152/ajpgi.2000.278.2.G251; YU PR, 1995, AM J PHYSIOL-GASTR L, V269, pG659, DOI 10.1152/ajpgi.1995.269.5.G659; Yu PR, 1996, AM J PHYSIOL-GASTR L, V271, pG56, DOI 10.1152/ajpgi.1996.271.1.G56	51	63	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2176	2185		10.1074/jbc.M410385200	http://dx.doi.org/10.1074/jbc.M410385200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537636	hybrid			2022-12-25	WOS:000226341700053
J	Hashimoto, T; Nakamura, T; Maegawa, H; Nishio, Y; Egawa, K; Kashiwagi, A				Hashimoto, T; Nakamura, T; Maegawa, H; Nishio, Y; Egawa, K; Kashiwagi, A			Regulation of ATP-sensitive potassium channel subunit Kir6.2 expression in rat intestinal insulin-producing progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR 3-BETA; GENE-EXPRESSION; GLUCOSE-HOMEOSTASIS; SULFONYLUREA RECEPTOR; IMMATURE ENTEROCYTES; IN-VIVO; TRANSCRIPTION; FOXA2; MICE; DIFFERENTIATION	We have reported that the combined expression of Pdx-1 (pancreatic duodenal homeobox 1) and Isl-1 (islet 1) enables immature rat enterocytes (IEC-6) to produce and release insulin. A key component regulating the release of insulin is the ATP-sensitive potassium channel subunit Kir6.2. To investigate the regulation of Kir6.2 gene expression, we assessed Kir6.2 expression in IEC-6 cells expressing Pdx-1 and/or Isl-1. We observed that Kir6.2 protein was expressed de novo in IEC-6 cells expressing both Pdx-1 and Isl-1 but not in cells expressing Pdx-1 alone. Next, we analyzed the regions of the Kir6.2 promoter (-1677/-45) by performing a luciferase assay and electrophoretic mobility shift assay. The results have demonstrated that Kir6.2 promoter possesses two regions regulating the promoter activity: a Foxa2-binding site (-1364 to -1210) and an Sp1/Sp3-binding site (-1035 to -939). The additional expression of Isl-1 in IEC-6 cells expressing Pdx-1 attenuated overexpression of Foxa2 protein and enhanced Kir6.2 expression. Finally, knockdown of Isl-1 using the iRNA technique resulted in decreased expression of Kir6.2 protein in a rat pancreatic beta-cell line (RIN-5F cells). These results indicate that expression of Kir6.2 in the rat intestine is moderated by Isl-1.	Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Anat, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science	Kashiwagi, A (corresponding author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan.	kasiwagi@belle.shiga-med.ac.jp	Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ashfield R, 1998, DIABETES, V47, P1274, DOI 10.2337/diabetes.47.8.1274; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; Dohrmann C, 2000, MECH DEVELOP, V92, P47, DOI 10.1016/S0925-4773(99)00324-X; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Edlund H, 1999, CURR OPIN CELL BIOL, V11, P663, DOI 10.1016/S0955-0674(99)00033-2; Hernandez-Sanchez C, 1999, J BIOL CHEM, V274, P18261, DOI 10.1074/jbc.274.26.18261; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kishi A, 2003, AM J PHYSIOL-ENDOC M, V284, pE830, DOI 10.1152/ajpendo.00390.2002; Kojima H, 2002, DIABETES, V51, P1398, DOI 10.2337/diabetes.51.5.1398; Kojima H, 2003, NAT MED, V9, P596, DOI 10.1038/nm867; Lantz KA, 2004, J CLIN INVEST, V114, P512, DOI 10.1172/JCI200421149; Lee CS, 2002, DIABETES, V51, P2546, DOI 10.2337/diabetes.51.8.2546; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Nakamura T, 2001, J CLIN ENDOCR METAB, V86, P1795, DOI 10.1210/jc.86.4.1795; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Sander M, 2000, DEVELOPMENT, V127, P5533; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sekine O, 2002, J BIOL CHEM, V277, P36631, DOI 10.1074/jbc.M206266200; Shih DQ, 1999, P NATL ACAD SCI USA, V96, P10152, DOI 10.1073/pnas.96.18.10152; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Trinh DKY, 2003, DIABETES, V52, P425, DOI 10.2337/diabetes.52.2.425; Wang HY, 2002, J BIOL CHEM, V277, P17564, DOI 10.1074/jbc.M111037200; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Yamada S, 2001, AM J PHYSIOL-GASTR L, V281, pG229, DOI 10.1152/ajpgi.2001.281.1.G229	40	14	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1893	1900		10.1074/jbc.M410759200	http://dx.doi.org/10.1074/jbc.M410759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15528203	hybrid			2022-12-25	WOS:000226341700023
J	Korneeva, NL; First, EA; Benoit, CA; Rhoads, RE				Korneeva, NL; First, EA; Benoit, CA; Rhoads, RE			Interaction between the NH2-terminal domain of eIF4A and the central domain of eIF4G modulates RNA-stimulated ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4A; FACTOR 4G EIF4G; BOX PROTEIN EIF4A; TRANSLATION-INITIATION; EUKARYOTIC TRANSLATION; CRYSTAL-STRUCTURE; HEPATITIS-C; HELICASE ACTIVITY; BINDING-PROTEIN; KINETIC CHARACTERIZATION	The eukaryotic translation factor 4A (eIF4A) is a member of DEA(D/H)-box RNA helicase family, a diverse group of proteins that couples ATP hydrolysis to RNA binding and duplex separation. eIF4A participates in the initiation of translation by unwinding secondary structure in the 5'-untranslated region of mRNAs and facilitating scanning by the 40 S ribosomal subunit for the initiation codon. eIF4A alone has only weak ATPase and helicase activities, but these are stimulated by eIF4G, eIF4B, and eIF4H. eIF4G has two eIF4A-binding sites, one in the central domain (cp(C3)) and one in the COOH-terminal domain (cp(C2)). In the current work, we demonstrate that these two eIF4G domains have different effects on the RNA-stimulated ATPase activity of eIF4A. cp(C3) stimulates ATP-hydrolytic efficiency by about 40-fold through two mechanisms: lowering K-m RNA by 10-fold and raising k(cat) by 4-fold. cp(C3) also stimulates RNA cross-linking to eIF4A in an ATP-independent manner. Studies with eIF4G and eIF4A variants suggest a model by which cp(C3) alters the conformation of the catalytic site to favor RNA binding. cp(C2) does not stimulate ATPase activity and furthermore increases both K-m (ATP) (at saturating RNA concentrations) and K-m (RNA) ( at subsaturating ATP concentrations). Both cp(C3) and cp(C2) directly interact with the NH2-terminal domain of eIF4A, which possesses conserved ATP- and oligonucleotide-binding motifs, but not with the COOH-terminal domain.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu			NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; CLARK BFC, 1996, BIOCHIMIE PARIS, V78, P11; De Gregorio E, 1998, RNA, V4, P828, DOI 10.1017/S1355838298980372; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; Du MX, 2002, BIOCHEM J, V363, P147, DOI 10.1042/0264-6021:3630147; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lomakin IB, 2000, MOL CELL BIOL, V20, P6019, DOI 10.1128/MCB.20.16.6019-6029.2000; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Richter NJ, 1999, J BIOL CHEM, V274, P35415, DOI 10.1074/jbc.274.50.35415; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WELLS TNC, 1991, BIOCHEMISTRY-US, V30, P5151, DOI 10.1021/bi00235a006; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8	59	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1872	1881		10.1074/jbc.M406168200	http://dx.doi.org/10.1074/jbc.M406168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15528191	hybrid			2022-12-25	WOS:000226341700021
J	Nakamura, N; Tanaka, S; Teko, Y; Mitsui, K; Kanazawa, H				Nakamura, N; Tanaka, S; Teko, Y; Mitsui, K; Kanazawa, H			Four Na+/H+ exchanger isoforms are distributed to Golgi and post-Golgi compartments and are involved in organelle pH regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; LIVING CELLS; ACIDIFICATION; TRANSPORT; YEAST; PROTEIN; PROTON	Four isoforms of the Na+/H+ exchanger (NHE6-NHE9) are distributed to intracellular compartments in human cells. They are localized to Golgi and post-Golgi endocytic compartments as follows: mid- to trans-Golgi, NHE8; trans-Golgi network, NHE7; early recycling endosomes, NHE6; and late recycling endosomes, NHE9. No significant localization of these NHEs was observed in lysosomes. The distribution of these NHEs is not discrete in the cells, and there is partial overlap with other isoforms, suggesting that the intracellular localization of the NHEs is established by the balance of transport in and out of the post-Golgi compartments as the dynamic membrane trafficking. The overexpression of NHE isoforms increased the luminal pH of the compartments in which the protein resided from the mildly acidic pH to the cytosolic pH, suggesting that their in vivo function is to regulate the pH and monovalent cation concentration in these organelles. We propose that the specific NHE isoforms contribute to the maintenance of the unique acidic pH values of the Golgi and post-Golgi compartments in the cell.	Osaka Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5600043, Japan	Osaka University	Nakamura, N (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5600043, Japan.	nnakamur@bio.sci.osaka-u.ac.jp						Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Attaphitaya S, 1999, J BIOL CHEM, V274, P4383, DOI 10.1074/jbc.274.7.4383; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; Barrett AJ, 1977, LYSOSOMES LABORATORY, P19; BIANCHINI L, 1994, J EXP BIOL, V196, P337; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; BORDEN LA, 1990, J BIOL CHEM, V265, P8497; Brett CL, 2002, AM J PHYSIOL-CELL PH, V282, pC1031, DOI 10.1152/ajpcell.00420.2001; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; Farinas J, 1999, J BIOL CHEM, V274, P7603, DOI 10.1074/jbc.274.12.7603; FUCHS R, 1989, J BIOL CHEM, V264, P2212; Futai M, 2000, J EXP BIOL, V203, P107; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; Goyal S, 2003, AM J PHYSIOL-RENAL, V284, pF467, DOI 10.1152/ajprenal.00352.2002; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kamauchi S, 2002, J BIOCHEM, V131, P821, DOI 10.1093/oxfordjournals.jbchem.a003171; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kokke FTM, 1996, MAMM GENOME, V7, P235, DOI 10.1007/s003359900066; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Murtazina R, 2001, EUR J BIOCHEM, V268, P4674, DOI 10.1046/j.1432-1327.2001.02391.x; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Nakamura N, 1997, J BIOL CHEM, V272, P11344; NAKAMURA T, 1986, J BIOL CHEM, V261, P678; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; Pizzonia JH, 1998, AM J PHYSIOL-RENAL, V275, pF510, DOI 10.1152/ajprenal.1998.275.4.F510; Rose MD., 1990, METHODS YEAST GENETI; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; Saier MH, 1999, INT REV CYTOL, V190, P61, DOI 10.1016/S0074-7696(08)62146-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271, DOI 10.1091/mbc.6.10.1271; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; TSE CM, 1993, J BIOL CHEM, V268, P11917; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; VANDYKE RW, 1985, J BIOL CHEM, V260, P1021; Venema K, 2002, J BIOL CHEM, V277, P2413, DOI 10.1074/jbc.M105043200; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG Z, 1993, J BIOL CHEM, V268, P11925; Wells KM, 2001, J BIOL CHEM, V276, P3401, DOI 10.1074/jbc.M001688200; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Wu MM, 2000, CHEM BIOL, V7, P197, DOI 10.1016/S1074-5521(00)00088-0; XU HX, 1994, J BIOL CHEM, V269, P22875; Yamaguchi T, 2003, P NATL ACAD SCI USA, V100, P12510, DOI 10.1073/pnas.2034966100; Yamaguchi T, 2001, PLANT CELL PHYSIOL, V42, P451, DOI 10.1093/pcp/pce080	73	254	265	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1561	1572		10.1074/jbc.M410041200	http://dx.doi.org/10.1074/jbc.M410041200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522866	hybrid			2022-12-25	WOS:000226195200087
J	Kim, Y; McBride, J; Zhang, R; Zhou, XF; Wong, DT				Kim, Y; McBride, J; Zhang, R; Zhou, XF; Wong, DT			p12(CDK2-AP1) mediates DNA damage responses induced by cisplatin	ONCOGENE			English	Article						p12(CDK2-AP1); DNA-damaging agent; cisplatin; cell cycle; human oral cancer	HUMAN OVARIAN-CANCER; SQUAMOUS-CELL CARCINOMA; NUCLEOTIDE EXCISION-REPAIR; TUMOR-SUPPRESSOR GENE; MISMATCH REPAIR; ACQUIRED-RESISTANCE; DRUG ACCUMULATION; GROWTH SUPPRESSOR; CYCLE ARREST; NECK-CANCER	We examined the biological role of p12(CDK2-AP1) in cisplatin-mediated responses by using murine ES p12(CDK2-AP1) knockout clones generated by a targeted disruption of murine p12(CDK2-AP1). Homozygous knockout clones showed an increased cellular proliferation along with an increase in Sand a decrease in G2/M phase populations. Interestingly, ES p12(CDK2-AP1) knockout clones showed a resistance to cisplatin treatment along with an increased DNA repair activity assessed by host cell reactivation assay using a cisplatin-damaged reporter DNA and a significant reduction of apoptosis upon cisplatin treatment. By using stable p12(CDK2-AP1) short interfering RNA ( siRNA) clones from human normal oral keratinocytes, we confirmed that downregulation of p12(CDK2-AP1) resulted in a resistance to cisplatin. More interestingly, cisplatin treatment resulted in a reduction of CDK2 kinase activity in control clones, but p12(CDK2-AP1) knockout clones showed a sustained CDK2 kinase activity. These data suggest that p12(CDK2-AP1) plays a role in cisplatin-mediated cellular responses by modulating CDK2 activity. These data further suggest p12(CDK2-AP1) is a potential gene therapeutic agent for oral/head and neck cancer in conjunction with DNA-damaging agents such as cisplatin.	Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Wong, DT (corresponding author), Univ Calif Los Angeles, Sch Dent, Dent Res Inst, 10833 Le Conte Ave,73-017 CHS, Los Angeles, CA 90095 USA.	dtww@ucla.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014857, T32DE007296] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 14857, T32 DE 007296-08] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aebi S, 1996, CANCER RES, V56, P3087; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AHN HJ, 1994, J UROLOGY, V151, P263, DOI 10.1016/S0022-5347(17)34929-7; Andreadis C, 2003, ORAL ONCOL, V39, P380, DOI 10.1016/S1368-8375(02)00141-0; ANDREWS PA, 1990, CANCER COMMUN-US, V2, P93, DOI 10.3727/095535490820874641; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; Anthoney DA, 1996, CANCER RES, V56, P1374; Bergoglio V, 2001, ONCOGENE, V20, P6181, DOI 10.1038/sj.onc.1204743; Boulikas T, 2004, ONCOL REP, V11, P559; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Cwikla SJ, 2000, J ORAL MAXIL SURG, V58, P406, DOI 10.1016/S0278-2391(00)90924-8; DEDON PC, 1987, BIOCHEM PHARMACOL, V36, P1955, DOI 10.1016/0006-2952(87)90494-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Fink D, 1998, CLIN CANCER RES, V4, P1; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FOSSA SD, 1995, ONCOLOGY-BASEL, V52, P300; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Higuchi E, 2003, HEAD NECK-J SCI SPEC, V25, P187, DOI 10.1002/hed.10204; Hoffmann TK, 2002, ANTI-CANCER DRUG, V13, P93, DOI 10.1097/00001813-200201000-00011; Hu MG, 2004, CANCER RES, V64, P490, DOI 10.1158/0008-5472.CAN-03-2284; Johnson SW, 1997, CANCER RES, V57, P850; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KASTAN MB, 1991, CANCER RES, V51, P6304; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Khuri FR, 2000, SEMIN ONCOL, V27, P25; Kim ES, 2003, CANC TREAT, V114, P295; Kim Y, 2001, INT J ORAL BIOL  DEC, V2001, P87; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kohno Y, 2002, ORAL ONCOL, V38, P274, DOI 10.1016/S1368-8375(01)00055-0; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Leirdal M, 2002, BIOCHEM BIOPH RES CO, V295, P744, DOI 10.1016/S0006-291X(02)00736-2; Li QD, 2000, ANTICANCER RES, V20, P645; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MASUDA H, 1988, CANCER RES, V48, P5713; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Milas L, 2003, HEAD NECK-J SCI SPEC, V25, P152, DOI 10.1002/hed.10232; MISTRY P, 1993, INT J CANCER, V55, P848, DOI 10.1002/ijc.2910550526; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Mukai M, 2002, ONCOL REP, V9, P839; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; OZOLS RF, 1989, CURR PROB CANCER, V13, P287; OZOLS RF, 1992, CURR PROB CANCER, V16, pU63; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Pendyala L, 1997, CLIN CANCER RES, V3, P793; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; RUBIN E, 1992, CANCER RES, V52, P878; Runger TM, 2000, J INVEST DERMATOL, V114, P34, DOI 10.1046/j.1523-1747.2000.00844.x; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; Song H, 2004, INT J ONCOL, V24, P1017; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Tsutsumi T, 1991, Gan To Kagaku Ryoho, V18, P1003; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; Yuan ZQ, 2003, ONCOGENE, V22, P6304, DOI 10.1038/sj.onc.1206609; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang X, 1999, BIOCHEM BIOPH RES CO, V255, P59, DOI 10.1006/bbrc.1999.0148	69	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					407	418		10.1038/sj.onc.1208222	http://dx.doi.org/10.1038/sj.onc.1208222			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543230				2022-12-25	WOS:000226279700012
J	Nasr, R; El-Sabban, ME; Karam, JA; Dbaibo, G; Kfoury, Y; Arnulf, B; Lepelletier, Y; Bex, F; de The, H; Hermine, O; Bazarbachi, A				Nasr, R; El-Sabban, ME; Karam, JA; Dbaibo, G; Kfoury, Y; Arnulf, B; Lepelletier, Y; Bex, F; de The, H; Hermine, O; Bazarbachi, A			Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma	ONCOGENE			English	Article						HTLV-I; leukemia; lymphoma; treatment; proteasome inhibitors; PS-341	VIRUS TYPE-I; NF-KAPPA-B; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA; INDUCED APOPTOSIS; CYCLE ARREST; TAX PROTEIN; ACTIVATION; GROWTH; INDUCTION	HTLV-I associated adult T-cell leukemia (ATL) and HTLV-I-negative peripheral T-cell lymphomas are associated with poor prognosis. Using pharmacological concentrations of the proteasome inhibitor PS-341, we demonstrate inhibition of cell proliferation and induction of apoptosis in fresh ATL cells, HTLV-I transformed and HTLV-I-negative malignant T cells, while normal resting or activated T lymphocytes were resistant. Combination of PS-341 and doxorubicin or etoposide resulted in an additive growth inhibition. In HTLV-I-negative malignant cells, PS-341 treatment significantly downregulated the antiapoptotic protein X-IAP and to a lesser extent c-IAP-1 and bcl-XL and resulted in caspase-dependent apoptosis. In HTLV-I transformed cells, the inhibition of the proteasomal degradation of Tax by PS-341 likely explains the relative protection of HTLV-I infected cells against caspase-dependent apoptosis. PS-341 treatment of these cells stabilized IkappaBalpha, IkappaBbeta, IkappaBepsilon, p21, p27 and p53 proteins and selectively inhibited Rel-A DNA binding NF-kappaB complexes. In both HTLV-I-positive and -negative cells, PS-341 treatment induced ceramide accumulation that correlated with apoptosis. We conclude that PS-341 affects multiple pathways critical for the survival of HTLV-I-positive and -negative malignant T cells supporting a potential therapeutic role for PS-341 in both ATL and HTLV-I-negative T-cell lymphomas, whether alone or in combination with chemotherapy.	Amer Univ Beirut, Fac Med, Dept Internal Med, Beirut, Lebanon; Amer Univ Beirut, Fac Med, Dept Human Morphol, Beirut, Lebanon; Amer Univ Beirut, Fac Med, Dept Pediat, Beirut, Lebanon; Hop Necker Enfants Malad, CNRS, UMR 8603, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Hematol, F-75743 Paris 15, France; Free Univ Brussels, Dept Mol Biol, Brussels, Belgium; Com Paris Ligue Canc, Lab Associe, CNRS, UPR 9051, Paris, France	American University of Beirut; American University of Beirut; American University of Beirut; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS)	Hermine, O (corresponding author), Amer Univ Beirut, Fac Med, Dept Internal Med, POB 113-6044, Beirut, Lebanon.	hermine@necker.fr; bazarbac@aub.edu.lb	Karam, Jose A/A-9006-2009; Dbaibo, Ghassan S./X-2978-2019; Nasr, Rihab/AAF-1606-2020; Hermine, Olivier/Q-7072-2018; lepelletier, yves/AAF-1546-2020	lepelletier, yves/0000-0001-7746-5170; Hermine, Olivier/0000-0003-2574-3874; Bazarbachi, Ali/0000-0002-7171-4997; Nasr, Rihab/0000-0003-1166-4999				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016/S0952-7915(00)00107-2; Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, pS186, DOI 10.1097/00042560-199600001-00028; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016/S0168-1702(01)00286-6; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; El-Sabban ME, 2000, BLOOD, V96, P2849; Gatto S, 2003, HAEMATOLOGICA, V88, P853; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Gisselbrecht C, 1998, BLOOD, V92, P76; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038/sj.thj.6200195; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Huang Y, 2000, CANCER RES, V60, P4426; Ikeda K, 1999, INT J CANCER, V82, P599, DOI 10.1002/(SICI)1097-0215(19990812)82:4<599::AID-IJC21>3.0.CO;2-R; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Kawata S, 2003, J VIROL, V77, P7291, DOI 10.1128/JVI.77.13.7291-7299.2003; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lau A, 1998, BLOOD, V91, P2467, DOI 10.1182/blood.V91.7.2467.2467_2467_2474; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Lomas M, 2002, J GEN VIROL, V83, P641, DOI 10.1099/0022-1317-83-3-641; Ma MH, 2003, CLIN CANCER RES, V9, P1136; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Mitra-Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182/blood-2003-11-3967; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182/blood-2002-09-2986; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Pham LV, 2003, J IMMUNOL, V171, P88, DOI 10.4049/jimmunol.171.1.88; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Tamiya S, 1998, BLOOD, V91, P3935; Tan C, 2002, CANCER RES, V62, P1083; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zar JH, 1999, BIOSTATISTICAL ANAL	51	70	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					419	430		10.1038/sj.onc.1208212	http://dx.doi.org/10.1038/sj.onc.1208212			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543232				2022-12-25	WOS:000226279700013
J	Liu, CL; Kuei, C; Sutton, S; Chen, JC; Bonaventure, P; Wu, JJ; Nepomuceno, D; Kamme, F; Tran, DT; Zhu, J; Wilkinson, T; Bathgate, R; Eriste, E; Sillard, R; Lovenberg, TW				Liu, CL; Kuei, C; Sutton, S; Chen, JC; Bonaventure, P; Wu, JJ; Nepomuceno, D; Kamme, F; Tran, DT; Zhu, J; Wilkinson, T; Bathgate, R; Eriste, E; Sillard, R; Lovenberg, TW			INSL5 is a high affinity specific agonist for GPCR142 (GPR100)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING SITE; INSULIN-LIKE PEPTIDE; GROWTH FACTOR-I; HUMAN RELAXIN; RAT ATRIA; IDENTIFICATION; FAMILY; GENE; EXPRESSION; SEQUENCE	Insulin-like peptide 5 (INSL5) is a peptide that belongs to the relaxin/insulin family, and its receptor has not been identified. In this report, we demonstrate that INSL5 is a specific agonist for GPCR142. Human INSL5 displaces the binding of I-125-relaxin-3 to GPCR142 with a high affinity (K-i = 1.5 nM). In a saturation binding assay, I-125-INSL5 binds GPCR142 with a K-d value of 2.5 nM. In functional guanosine (gamma-thio)-triphosphate binding and cAMP accumulation assays, INSL5 potently activates GPCR142 with EC50 values of 1.3 and 1.2 nM, respectively. In addition, INSL5 stimulates Ca2+ mobilization in HEK293 cells expressing GPCR142 and Galpha(16). Overall, INSL5 behaves as an agonist for GPCR142 similar to relaxin-3. However, unlike relaxin-3, which is also a potent agonist for GPCR135 and LGR7, INSL5 does not activate either GPCR135 or LGR7. INSL5 inhibits I-125-relaxin-3 binding to GPCR135 with a low potency (K-i = 500 nM). A functional assay shows that INSL5 (1 muM) is a weak antagonist for GPCR135. In addition, INSL5 ( up to 1 muM) shows no affinity or activity at LGR7 or LGR8 either in a binding assay or a bio-functional assay. Previously, we have demonstrated that GPCR142 mRNA is expressed in peripheral tissues, particularly in the colon. Here we show that INSL5 mRNA is expressed in many peripheral tissues, similar to GPCR142. The high affinity interaction between INSL5 and GPCR142 coupled with their co-evolution and partially overlapping tissue expression patterns strongly suggest that INSL5 is an endogenous ligand for GPCR142.	Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA; Univ Melbourne, Howard Florey Inst, Melbourne, Vic, Australia; Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden	Johnson & Johnson; Johnson & Johnson USA; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Karolinska Institutet	Liu, CL (corresponding author), Johnson & Johnson Pharmaceut Res & Dev LLC, 3210 Merryfield Row, San Diego, CA 92121 USA.	cliu9@prdus.jnj.com	Bonaventure, Pascal/K-3052-2015; Bathgate, Ross/ABE-6471-2020	Bonaventure, Pascal/0000-0003-2971-6152; Bathgate, Ross/0000-0001-6301-861X				ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; Burazin TCD, 2002, J NEUROCHEM, V82, P1553, DOI 10.1046/j.1471-4159.2002.01114.x; CHEN J, 2005, IN PRESS J PHARM EXP, V312; Claasz AA, 2002, EUR J BIOCHEM, V269, P6287, DOI 10.1046/j.1432-1033.2002.03348.x; Conklin D, 1999, GENOMICS, V60, P50, DOI 10.1006/geno.1999.5899; Goh CS, 2000, J MOL BIOL, V299, P283, DOI 10.1006/jmbi.2000.3732; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SYT, 2003, TRENDS ENDOCRIN MET, V14, P303, DOI 10.1016/S1043-2760(03)00106-1; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; Koman A, 1996, J BIOL CHEM, V271, P20238, DOI 10.1074/jbc.271.34.20238; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; LIU C, 2005, IN PRESS MOL PHARM, V67; Liu CL, 2001, J PHARMACOL EXP THER, V299, P121; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Liu CL, 2003, J BIOL CHEM, V278, P50754, DOI 10.1074/jbc.M308995200; Lok S, 2000, BIOL REPROD, V62, P1593, DOI 10.1095/biolreprod62.6.1593; OSHEROFF PL, 1993, J BIOL CHEM, V268, P15193; OSHEROFF PL, 1991, P NATL ACAD SCI USA, V88, P6413, DOI 10.1073/pnas.88.15.6413; RASCHDORF F, 1988, BIOMED ENVIRON MASS, V16, P3, DOI 10.1002/bms.1200160102; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; RYLE AP, 1955, BIOCHEM J, V60, P541, DOI 10.1042/bj0600541; SCHWABE C, 1977, SCIENCE, V197, P914, DOI 10.1126/science.887933; Sherwood O. David, 1994, P861; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; TAGER H, 1979, NATURE, V281, P122, DOI 10.1038/281122a0; Tan YY, 2002, EUR J PHARMACOL, V457, P153, DOI 10.1016/S0014-2999(02)02662-6; Tan YY, 1999, BRIT J PHARMACOL, V127, P91, DOI 10.1038/sj.bjp.0702517; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0	38	145	156	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					292	300		10.1074/jbc.M409916200	http://dx.doi.org/10.1074/jbc.M409916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15525639	hybrid			2022-12-25	WOS:000226025100036
J	Jimenez, D; Roda-Navarro, P; Springer, TA; Casasnovas, JM				Jimenez, D; Roda-Navarro, P; Springer, TA; Casasnovas, JM			Contribution of N-linked glycans to the conformation and function of intercellular adhesion molecules (ICAMs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DC-SIGN; CELLULAR RECEPTOR; STRUCTURAL BASIS; LIGAND-BINDING; RHINOVIRUS; OLIGOSACCHARIDES; GLYCOSYLATION; DOMAINS; LFA-1; CELLS	The crystal structures of the glycosylated N-terminal two domains of ICAM-1 and ICAM-2 provided a framework for understanding the role of glycosylation in the structure and function of intercellular adhesion molecules (ICAMs). The most conserved glycans were less flexible in the structures, interacting with protein residues and contributing to receptor folding and expression. The first N-linked glycan in ICAM-2 contacts an exposed tryptophan residue, defining a conserved glycan-W motif critical for the conformation of the integrin binding domain. The absence of this motif in human ICAM-1 exposes regions used in receptor dimerization and rhinovirus recognition. Experiments with soluble molecules having the N-terminal two domains of human ICAMs identified glycans of the high mannose type N-linked to the second domain of the dendritic cell-specific ICAM-grabbing nonintegrin lectin-ligands ICAM-2 and ICAM-3. About 40% of those receptor molecules bear endoglycosidase H sensitive glycans responsible of the lectin binding activity. High mannose glycans were absent in ICAM-1, which did not bind to the lectin, but they appeared in ICAM-1 mutants with additional N-linked glycosylation and lectin binding activity. N-Linked glycosylation regulate both conformation and immune related functions of ICAM receptors.	CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Autonoma Madrid, Hosp Univ Princesa, Unidad Biol Mol, Madrid 28006, Spain; CBR Inst Biomed Res, Dept Pathol, Boston, MA 02115 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Hospital de La Princesa; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Casasnovas, JM (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma, E-28049 Madrid, Spain.	jcasasnovas@cnb.uam.es	Casasnovas, Jose M/L-6299-2014	Casasnovas, Jose M/0000-0002-2873-6410				ASHFORD DA, 1993, J BIOL CHEM, V268, P3260; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Casasnovas JM, 1999, P NATL ACAD SCI USA, V96, P3017, DOI 10.1073/pnas.96.6.3017; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Casasnovas JM, 1998, J VIROL, V72, P6244, DOI 10.1128/JVI.72.7.6244-6246.1998; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Funatsu O, 2001, EUR J BIOCHEM, V268, P1020, DOI 10.1046/j.1432-1327.2001.01960.x; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Sanchez R, 2000, METH MOL B, V143, P97; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Thompson P, 1998, J VIROL, V72, P3751, DOI 10.1128/JVI.72.5.3751-3761.1998; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493	30	58	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5854	5861		10.1074/jbc.M412104200	http://dx.doi.org/10.1074/jbc.M412104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15545280	hybrid			2022-12-25	WOS:000227217100089
J	Fujiwara, N; Miyamoto, Y; Ogasahara, K; Takahashi, M; Ikegami, T; Takamiya, R; Suzuki, K; Taniguchi, N				Fujiwara, N; Miyamoto, Y; Ogasahara, K; Takahashi, M; Ikegami, T; Takamiya, R; Suzuki, K; Taniguchi, N			Different immunoreactivity against monoclonal antibodies between wild-type and mutant copper/zinc superoxide dismutase linked to amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL TRANSITION; RECOMBINANT HUMAN; MUTATIONS; STABILITY; SOD1; MICE; AGGREGATION; ALZHEIMER; TOXICITY; FEATURES	Although more than 100 mutations have been identified in the copper/zinc superoxide dismutase (Cu/Zn-SOD) in familial amyotrophic lateral sclerosis (FAILS), the mechanism responsible for FAILS remains unclear. The finding of the present study shows that FALS-causiing mutant Cu/Zn-SOD proteins (FALS mutant SODs), but not wild-type SOD, are barely detected by three monoclonal antibodies (mAbs) in Western blot analyses. The enzyme-linked immunosorbent assay for denatured FALS mutant SODs by dithiothreitol, SDS, or heat treatment also showed a lowered immunoreactivity against the mAbs compared with wild-type SOD. Because all the epitopes of these mAbs are mapped within the Greek key loop (residues 102-115 in human Cu/Zn-SOD), these data suggest that different conformational changes occur in the loop between wild-type and FAILS mutant SODs during the unfolding process. Circular dichroism measurements revealed that the FALS mutant SODs are sensitive to denaturation by dithiothreitol, SDS, or heat treatment, but these results do not completely explain the different recognition by the mAbs between wild-type and FAILS mutant SODs under the denatured conditions. The study on the conformational changes in local areas monitoring with mAbs may provide a new insight into the etiology of FALS.	Osaka Univ, Dept Biochem, Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; Hyogo Med Univ, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Hyogo College of Medicine; University of Hyogo; Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Dept Biochem, Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014; Ikegami, Takahisa/I-9626-2017; Takahashi, Motoko/I-3154-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Ikegami, Takahisa/0000-0002-1429-1844; Takahashi, Motoko/0000-0002-2112-6142				BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bozzi M, 2001, INT J BIOL MACROMOL, V29, P99, DOI 10.1016/S0141-8130(01)00146-5; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Cardoso RMF, 2002, J MOL BIOL, V324, P247, DOI 10.1016/S0022-2836(02)01090-2; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HALLEWELL RA, 1991, BIOCHEM BIOPH RES CO, V181, P474, DOI 10.1016/S0006-291X(05)81443-3; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Leclerc E, 2003, J MOL BIOL, V326, P475, DOI 10.1016/S0022-2836(02)01365-7; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; LITTLE JR, 1967, METHODS IMMUNOLOGY I, V1, P128; Matsunaga Y, 2002, BIOCHEM J, V361, P547, DOI 10.1042/0264-6021:3610547; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; OGASAWARA M, 1993, NAT GENET, V5, P323, DOI 10.1038/ng1293-323; OKADOMATSUMOTO A, 2002, FREE RADICAL RES, V33, P65; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; PIWNICAWORMS H, 1987, CURRENT PROTOCOLS MO; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Shipp EL, 2003, BIOCHEMISTRY-US, V42, P1890, DOI 10.1021/bi026704y; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Takamiya R, 2003, FASEB J, V17, P938, DOI 10.1096/fj.02-0768fje; Temussi PA, 2003, EMBO J, V22, P355, DOI 10.1093/emboj/cdg044; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100	47	9	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5061	5070		10.1074/jbc.M406106200	http://dx.doi.org/10.1074/jbc.M406106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15522870	hybrid			2022-12-25	WOS:000227096600128
J	Ismail, IH; Nystrom, S; Nygren, J; Hammarsten, O				Ismail, IH; Nystrom, S; Nygren, J; Hammarsten, O			Activation of ataxia telangiectasia mutated by DNA strand break-inducing agents correlates closely with the number of DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; IONIZING-RADIATION; HYDROGEN-PEROXIDE; HUMAN-CELLS; ATM KINASE; TORSIONAL TENSION; MAMMALIAN-CELLS; IN-VIVO; DAMAGE; PHOSPHORYLATION	The protein kinase ataxia telangiectasia mutated (ATM) is activated when cells are exposed to ionizing radiation (IR). It has been assumed that ATM is specifically activated by the few induced DNA double strand breaks (DSBs), although little direct evidence for this assumption has been presented. DSBs constitute only a few percent of the IR-induced DNA damage, whereas the more frequent single strand DNA breaks (SSBs) and base damage account for over 98% of the overall DNA damage. It is therefore unclear whether DSBs are the only IR-induced DNA lesions that activate ATM. To test directly whether or not DSBs are responsible for ATM activation, we exposed cells to drugs and radiation that produce different numbers of DSBs and SSBs. We determined the resulting ATM activation by measuring the amount of phosphorylated Chk2 and the numbers of SSBs and DSBs in the same cells after short incubation periods. We found a strong correlation between the number of DSBs and ATM activation but no correlation with the number of SSBs. In fact, hydrogen peroxide, which, similar to IR, induces DNA damage through hydroxyl radicals but fails to induce DSBs, did not activate ATM. In contrast, we found that calicheamicin-induced strand breaks activated ATM more efficiently than IR and that ATM activation correlated with the relative DSB induction by these agents. Our data indicate that ATM is specifically activated by IR-induced DSBs, with little or no contribution from SSBs and other types of DNA damage. These findings have implications for how ATM might recognize DSBs in cells.	Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, SE-41345 Gothenburg, Sweden; Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, Lab Mol & Cellular Toxicol, FIN-00250 Helsinki, Finland	Sahlgrenska University Hospital; University of Gothenburg; Finnish Institute of Occupational Health	Hammarsten, O (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, SE-41345 Gothenburg, Sweden.	ola.hammarsten@clinchem.gu.se	Hammarsten, Ola/A-2791-2012	Ismail, Ismail Hassan/0000-0002-5526-6063				Ahn JY, 2000, CANCER RES, V60, P5934; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BRADLEY MO, 1981, BIOCHIM BIOPHYS ACTA, V654, P135, DOI 10.1016/0005-2787(81)90146-5; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CANTONI O, 1988, XENOBIOTICA, V18, P1481, DOI 10.3109/00498258809042270; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Dahm-Daphi J, 2000, INT J RADIAT BIOL, V76, P67, DOI 10.1080/095530000139023; Elmroth K, 2003, DNA REPAIR, V2, P363, DOI 10.1016/S1568-7864(02)00235-5; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Goodarzi AA, 2004, DNA REPAIR, V3, P753, DOI 10.1016/j.dnarep.2004.03.041; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Ha N, 2003, J BIOL CHEM, V278, P17885, DOI 10.1074/jbc.M210560200; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; LEE MD, 1991, ACCOUNTS CHEM RES, V24, P235, DOI 10.1021/ar00008a003; LESKO SA, 1982, BIOCHEMISTRY-US, V21, P5010, DOI 10.1021/bi00263a026; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; Llorca O, 2003, ONCOGENE, V22, P3867, DOI 10.1038/sj.onc.1206649; MASSIE HR, 1972, BIOCHIM BIOPHYS ACTA, V272, P539, DOI 10.1016/0005-2787(72)90509-6; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nur-E-Kamal A, 2003, J BIOL CHEM, V278, P12475, DOI 10.1074/jbc.M212915200; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; PRISE KM, 1989, INT J RADIAT BIOL, V55, P583, DOI 10.1080/09553008914550631; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tounekti O, 2001, BRIT J CANCER, V84, P1272, DOI 10.1054/bjoc.2001.1786; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	50	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4649	4655		10.1074/jbc.M411588200	http://dx.doi.org/10.1074/jbc.M411588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15546858	hybrid			2022-12-25	WOS:000227096600080
J	Viniegra, JG; Martinez, N; Modirassari, P; Losa, JH; Cobo, CP; Lobo, VJSA; Luquero, CIA; Alvarez-Vallina, L; Cajal, SRY; Rojas, JM; Sanchez-Prieto, R				Viniegra, JG; Martinez, N; Modirassari, P; Losa, JH; Cobo, CP; Lobo, VJSA; Luquero, CIA; Alvarez-Vallina, L; Cajal, SRY; Rojas, JM; Sanchez-Prieto, R			Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; CELL-SURVIVAL; PDK2 ACTIVITY; PHOSPHORYLATION; P53; RESISTANCE; MICE; IDENTIFICATION; MECHANISM; APOPTOSIS	The gene mutated in ataxia telangiectasia, ATM, has been implicated in several cell functions such as cell cycle control and response to DNA damage and insulin. PKB/Akt has also been implicated in the cellular response to insulin, gamma-radiation, and cell cycle control. Interestingly, lack of PKB/Akt function in vivo is able to mimic some phenotypic abnormalities associated with ataxia telangiectasia (AT). Here we show that ATM is a major determinant of full PKB/Akt activation in response to insulin or gamma-radiation. This effect is mediated through the phosphatidylinositol 3-kinase domain of ATM that specifically affects Akt serine 473 phosphorylation. This conclusion was inferred from the results obtained in transient transfection assays using exogenous PKB/Akt and ATM in Cos cells. Moreover, the use of ATM inhibitors or small interfering RNA confirmed our observation. Further supporting these results, we also observed that biological responses tightly regulated by Akt, such as transcription factor of the forkhead family activity after insulin treatment or gamma-radiation response, were altered in cell lines derived from AT patients and knockout mice for ATM in which phosphorylation in serine 473 was almost abolished. This study proposes new clues in the search of the unknown PDK2 and new explanations for the radiosensitivity or insulin intolerance described more than 30 years ago in AT patients.	Univ Castilla La Mancha, Mol Oncol Lab, CRIB, Fac Med, Albacete 02071, Spain; Ctr Nacl Microbiol Virol & Inmunol Sanitarias Maja, Inst Salud Carlos III, Unidad Biol Celular, Madrid 28220, Spain; Hosp Univ Vall Hebron, Serv Anat Patol, Barcelona 08035, Spain; Hosp Univ Puerta Hierro, Serv Inmunol, Madrid 28035, Spain	Universidad de Castilla-La Mancha; Instituto de Salud Carlos III; Hospital Universitari Vall d'Hebron; Hospital Puerta de Hierro-Majadahonda	Sanchez-Prieto, R (corresponding author), Univ Castilla La Mancha, Mol Oncol Lab, CRIB, Fac Med, Avenida Almansa S-N, Albacete 02071, Spain.	rsprieto@med-ab.uclm.es	Sanchez-Prieto, Ricardo/AAY-4271-2021; Prieto, Ricardo/AAZ-7221-2021; Alvarez-Vallina, Luis/A-2033-2010; Alvarez-Vallina, Luis/ABD-2431-2020; Ramon y Cajal, Santiago/H-4955-2016; Álvarez-Vallina, Luis/A-2032-2010; Rojas, José M/D-3718-2018; Sanchez-Prieto, Ricardo/B-6877-2008; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Rojas, José M./AAA-3354-2021; Javier, Hernandez Losa/C-1173-2008; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Alvarez-Vallina, Luis/0000-0003-3053-6757; Ramon y Cajal, Santiago/0000-0002-3867-1390; Rojas, José M/0000-0002-5383-3482; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Rojas, José M./0000-0002-7547-2825; Javier, Hernandez Losa/0000-0003-1526-3201; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505				Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Brognard J, 2001, CANCER RES, V61, P3986; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHAN TO, 2001, SCI STKE; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P10351, DOI 10.1021/bi026065r; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Spacey SD, 2000, CAN J NEUROL SCI, V27, P184, DOI 10.1017/S0317167100000822; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Suzuki N, 2002, J BIOL CHEM, V277, P47, DOI 10.1074/jbc.M108195200; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542	40	214	225	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4029	4036		10.1074/jbc.M410344200	http://dx.doi.org/10.1074/jbc.M410344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15546863	hybrid			2022-12-25	WOS:000227096600007
J	Wong-Riley, MTT; Liang, HL; Eells, JT; Chance, B; Henry, MM; Buchmann, E; Kane, M; Whelan, HT				Wong-Riley, MTT; Liang, HL; Eells, JT; Chance, B; Henry, MM; Buchmann, E; Kane, M; Whelan, HT			Photobiomodulation directly benefits primary neurons functionally inactivated by toxins - Role of cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMITTING DIODE IRRADIATION; PLANTS; STATE	Far red and near infrared (NIR) light promotes wound healing, but the mechanism is poorly understood. Our previous studies using 670 nm light-emitting diode (LED) arrays suggest that cytochrome c oxidase, a photoacceptor in the NIR range, plays an important role in therapeutic photobiomodulation. If this is true, then an irreversible inhibitor of cytochrome c oxidase, potassium cyanide (KCN), should compete with LED and reduce its beneficial effects. This hypothesis was tested on primary cultured neurons. LED treatment partially restored enzyme activity blocked by 10-100 mum KCN. It significantly reduced neuronal cell death induced by 300 mum KCN from 83.6 to 43.5%. However, at 1-100 mm KCN, the protective effects of LED decreased, and neuronal deaths increased. LED significantly restored neuronal ATP content only at 10 mum KCN but not at higher concentrations of KCN tested. Pretreatment with LED enhanced efficacy of LED during exposure to 10 or 100 pm KCN but did not restore enzyme activity to control levels. In contrast, LED was able to completely reverse the detrimental effect of tetrodotoxin, which only indirectly down-regulated enzyme levels. Among the wavelengths tested (670, 728, 770, 830, and 880 nm), the most effective ones (830 nm, 670 nm) paralleled the NIR absorption spectrum of oxidized cytochrome c oxidase, whereas the least effective wavelength, 728 nm, did not. The results are consistent with our hypothesis that the mechanism of photobiomodulation involves the up-regulation of cytochrome c oxidase, leading to increased energy metabolism in neurons functionally inactivated by toxins.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA; Univ Wisconsin, Dept Hlth Sci, Milwaukee, WI 53201 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Milwaukee; University of Pennsylvania	Wong-Riley, MTT (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mwr@mcw.edu	Wong-Riley, Margaret/AGM-6202-2022		NATIONAL EYE INSTITUTE [R01EY011396, P30EY001931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006648] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAUVOIT B, 1994, BIOPHYS J, V67, P2501, DOI 10.1016/S0006-3495(94)80740-4; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Cebers G, 1997, BRAIN RES BULL, V43, P393, DOI 10.1016/S0361-9230(97)00025-7; CHANCE B, 1988, P NATL ACAD SCI USA, V85, P4971, DOI 10.1073/pnas.85.14.4971; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; Cooper CE, 1997, ADV EXP MED BIOL, V413, P63; Cooper CE, 1997, PHILOS T R SOC B, V352, P669, DOI 10.1098/rstb.1997.0048; DEYOE EA, 1995, VISUAL NEUROSCI, V12, P629, DOI 10.1017/S0952523800008920; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; EINARSDOTTIR O, 1992, P NATL ACAD SCI USA, V89, P6934, DOI 10.1073/pnas.89.15.6934; FERRARI M, 1990, ADV EXP MED BIOL, V277, P85; Goslin K., 1991, CULTURING NERVE CELL, P251; HEVNER RF, 1990, J NEUROSCI, V10, P1331; HEVNER RF, 1995, NEUROSCIENCE, V65, P313, DOI 10.1016/0306-4522(94)00514-6; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Prabhakaran K, 2002, J PHARMACOL EXP THER, V303, P510, DOI 10.1124/jpet.102.039453; RICH PR, 1992, FEBS LETT, V305, P171, DOI 10.1016/0014-5793(92)80659-5; Smith H, 2000, NATURE, V407, P585, DOI 10.1038/35036500; Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910; Strehler B L, 1968, Methods Biochem Anal, V16, P99, DOI 10.1002/9780470110348.ch2; Whelan HT, 2003, J CLIN LASER MED SUR, V21, P67, DOI 10.1089/104454703765035484; Whelan HT, 2002, J CLIN LASER MED SUR, V20, P319, DOI 10.1089/104454702320901107; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; WIKSTROM M, 1981, CYTOCHROME OXIDASE S, P61; WILSON DF, 1967, BIOCHIM BIOPHYS ACTA, V131, P421, DOI 10.1016/0005-2728(67)90002-3; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WONGRILEY MTT, 2002, SOC NEUR ABSTR; YAMANAKA T, 1988, ANN NY ACAD SCI, V550, P39; Yu W, 1997, LASER SURG MED, V20, P56, DOI 10.1002/(SICI)1096-9101(1997)20:1<56::AID-LSM9>3.0.CO;2-Y; Zhang CY, 1999, J NEUROCYTOL, V28, P525, DOI 10.1023/A:1007053204929	32	389	450	3	45	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4761	4771		10.1074/jbc.M409650200	http://dx.doi.org/10.1074/jbc.M409650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557336	hybrid			2022-12-25	WOS:000227096600093
J	Li, Y; Xiang, JH; Duan, CM				Li, Y; Xiang, JH; Duan, CM			Insulin-like growth factor-binding protein-3 plays an important role in regulating pharyngeal skeleton and inner ear formation and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; FACTOR-I; MESSENGER-RNAS; DEVELOPMENTAL EXPRESSION; CELLULAR-LOCALIZATION; TARGETED DISRUPTION; NUCLEAR TRANSPORT; CANCER CELLS; ZEBRAFISH; RECEPTOR	Insulin-like growth factor-binding protein (IGFBP)-3 is the major insulin-like growth factor (IGF) carrier protein in the bloodstream. IGFBP-3 prolongs the half-life of circulating IGFs and prevents their potential hypo-glycemic effect. IGFBP-3 is also expressed in many peripheral tissues in fetal and adult stages. In vitro, IGFBP-3 can inhibit or potentiate IGF actions and even possesses IGF-independent activities, suggesting that local IGFBP-3 may also have paracrine/autocrine function(s). The in vivo function of IGFBP-3, however, is unclear. In this study, we elucidate the developmental role of IGFBP-3 using the zebrafish model. IGFBP-3 mRNA expression is first detected in the migrating cranial neural crest cells and subsequently in pharyngeal arches in zebrafish embryos. IGFBP-3 mRNA is also persistently expressed in the developing inner ears. To determine the role of IGFBP-3 in these tissues, we ablated the IGFBP-3 gene product using morpholino-modified antisense oligonucleotides (MOs). The IGFBP-3 knocked down embryos had delayed pharyngeal skeleton morphogenesis and greatly reduced pharyngeal cartilage differentiation. Knockdown of IGFBP-3 also significantly decreased inner ear size and disrupted hair cell differentiation and semicircular canal formation. Furthermore, reintroduction of a MO-resistant form of IGFBP-3 "rescued" the MO-induced defects. These findings suggest that IGFBP-3 plays an important role in regulating pharyngeal cartilage and inner car development and growth in zebrafish.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Chinese Acad Sci, Grad Sch, Beijing 10039, Peoples R China; Chinese Acad Sci, Inst Oceanol, Qingdao 266071, Peoples R China	University of Michigan System; University of Michigan; Chinese Academy of Sciences; Chinese Academy of Sciences; Institute of Oceanology, CAS	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Kraus Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu	xiang, jianhai/A-4767-2012	xiang, jianhai/0000-0001-5395-7787				BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Braulke T, 1996, GROWTH REGULAT, V6, P55; Butt AJ, 2001, APOPTOSIS, V6, P199, DOI 10.1023/A:1011388710719; CERRO JA, 1993, REGUL PEPTIDES, V48, P189, DOI 10.1016/0167-0115(93)90347-B; Chen JY, 2004, MAR BIOTECHNOL, V6, P1, DOI 10.1007/s10126-002-0115-9; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; CONOVER CA, 1991, J CLIN INVEST, V88, P1354, DOI 10.1172/JCI115441; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; de los Rios P, 1999, CAN J PHYSIOL PHARM, V77, P235, DOI 10.1139/cjpp-77-4-235; Duan CM, 1999, P NATL ACAD SCI USA, V96, P15274, DOI 10.1073/pnas.96.26.15274; Duan CM, 1998, J NUTR, V128, p306S, DOI 10.1093/jn/128.2.306S; Duan Cunming, 2003, Acta Zoologica Sinica, V49, P421; Fanayan S, 2002, J BIOL CHEM, V277, P7255, DOI 10.1074/jbc.M108038200; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Haddon C, 1996, J COMP NEUROL, V365, P113, DOI 10.1002/(SICI)1096-9861(19960129)365:1<113::AID-CNE9>3.0.CO;2-6; Han VKM, 2000, PLACENTA, V21, P289, DOI 10.1053/plac.1999.0498; Han VKM, 1996, HORM RES, V45, P160, DOI 10.1159/000184780; HODGKINSON SC, 1989, J ENDOCRINOL, V123, P461, DOI 10.1677/joe.0.1230461; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Kimmel CB, 1998, DEV BIOL, V203, P245, DOI 10.1006/dbio.1998.9016; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kollmar R, 2001, P NATL ACAD SCI USA, V98, P10196, DOI 10.1073/pnas.171325898; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Lee CI, 2001, PEDIATR RES, V49, P379, DOI 10.1203/00006450-200103000-00012; Lee CY, 1996, ENDOCRINOLOGY, V137, P2051, DOI 10.1210/en.137.5.2051; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; LindenberghKortleve DJ, 1997, MOL CELL ENDOCRINOL, V132, P81, DOI 10.1016/S0303-7207(97)00123-8; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Maures T, 2002, ENDOCRINOLOGY, V143, P1858, DOI 10.1210/en.143.5.1858; Maures TJ, 2002, ENDOCRINOLOGY, V143, P2722, DOI 10.1210/en.143.7.2722; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; Nissen RM, 2003, DEVELOPMENT, V130, P2543, DOI 10.1242/dev.00455; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PINTAR JE, 2001, 83 ANN M END SOC DEN, pS33; Pozios KC, 2001, AM J PHYSIOL-REG I, V280, pR1230, DOI 10.1152/ajpregu.2001.280.4.R1230; RetschBogart GZ, 1996, AM J RESP CELL MOL, V14, P61, DOI 10.1165/ajrcmb.14.1.8534487; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; SCHLUETER PJ, 2003, END SOC 85 ANN M PHI, pP3; Scholpp S, 2001, GENESIS, V30, P129, DOI 10.1002/gene.1047; Serbedzija GN, 1998, DEVELOPMENT, V125, P1095; Shimizu M, 2000, GEN COMP ENDOCR, V119, P26, DOI 10.1006/gcen.2000.7498; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; van Kleffens M, 1999, ENDOCRINOLOGY, V140, P5944, DOI 10.1210/en.140.12.5944; WESTERFIELD M, 1995, ZEBRAFISH BOOK; WOOD AW, 2004, END SOC 86 ANN M NEW, pOR35; Wood TL, 2000, MOL ENDOCRINOL, V14, P1472, DOI 10.1210/me.14.9.1472; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	53	60	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3613	3620		10.1074/jbc.M411479200	http://dx.doi.org/10.1074/jbc.M411479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550380	hybrid			2022-12-25	WOS:000226983900060
J	Wong, LH; Saffery, R; Anderson, MA; Earle, E; Quach, JM; Stafford, AJ; Fowler, KJ; Choo, KHA				Wong, LH; Saffery, R; Anderson, MA; Earle, E; Quach, JM; Stafford, AJ; Fowler, KJ; Choo, KHA			Analysis of mitotic and expression properties of human neocentromere-based transchromosomes in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTIFICIAL CHROMOSOMES; POLYMERASE CHAIN-REACTION; DE-NOVO CENTROMERES; HUMAN MINICHROMOSOMES; ALPHA-SATELLITE; GERMLINE TRANSMISSION; CELL-LINES; CHIMERIC MICE; DNA; GENERATION	Human neocentromeres are functional centromeres that are devoid of the typical human centromeric a-satellite DNA. We have transferred a 60-Mb chromosome 10-derived neocentric marker chromosome, mardel(10), and its truncated 3.5-Mb derivative, NC-MiC1, into mouse embryonic stem cell and have demonstrated a relatively high structural and mitotic stability of the transchromosomes in a heterologous genetic background. We have also produced chimeric mice carrying mardel(10) or NC-MiC1. Both transchromosomes were detected as intact episomal entities in a variety of adult chimeric mouse tissues including hemopoietic stem cells. Genes residing on these transchromosomes were expressed in the different tissues tested. Meiotic transmission of both transchromosomes in the chimeric mice was evident from the detection of DNA from these chromosomes in sperm samples. In particular, germ line transmission of NC-MiC1 was demonstrated in the F1 embryos of the chimeric mice. Variable (low in mardel(10)- or NC-MiC1-containing embryonic stem cells and chimeric mouse tissues and relatively high in NC-MiC1-containing F1 embryos) levels of missegregation of these transchromosomes were detected, suggesting that they are not optimally predisposed to full mitotic regulation in the mouse background, particularly during early embryogenesis. These results provide promising data in support of the potential use of neocentromere-based human marker chromosomes and minichromosomes as a tool for the study of centromere, neocentromere, and chromosome biology and for gene therapy studies. in a mouse model system. They also highlight the need to further understand and overcome the factors that are responsible for the definable rates of instability of these transchromosomes in a mouse model.	Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Dept Pediat, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Choo, KHA (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	andy.choo@mcri.edu.au	Wong, Lee H/H-9757-2012; Saffery, Richard/GLS-1976-2022	Wong, Lee H/0000-0002-4005-7330; Saffery, Richard/0000-0002-9510-4181				Alazami AM, 2004, GENOMICS, V83, P844, DOI 10.1016/j.ygeno.2003.11.011; Amor DJ, 2002, AM J HUM GENET, V71, P695, DOI 10.1086/342730; BRADLEY A, 1992, CIBA F SYMP, V165, P256; Co DO, 2000, CHROMOSOME RES, V8, P183, DOI 10.1023/A:1009206926548; Craig JM, 2003, EMBO J, V22, P2495, DOI 10.1093/emboj/cdg232; Csonka E, 2000, J CELL SCI, V113, P3207; duSart D, 1997, NAT GENET, V16, P144; Ebersole TA, 2000, HUM MOL GENET, V9, P1623, DOI 10.1093/hmg/9.11.1623; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; Henning KA, 1999, P NATL ACAD SCI USA, V96, P592, DOI 10.1073/pnas.96.2.592; Hernandez D, 1999, HUM MOL GENET, V8, P923, DOI 10.1093/hmg/8.5.923; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; Kereso J, 1996, CHROMOSOME RES, V4, P226, DOI 10.1007/BF02254964; LIU P, 1993, CANCER GENET CYTOGEN, V65, P93, DOI 10.1016/0165-4608(93)90213-6; Loupart ML, 1998, CHROMOSOMA, V107, P255, DOI 10.1007/s004120050305; MANN GB, 1993, J REPROD FERTIL, V99, P505, DOI 10.1530/jrf.0.0990505; Masumoto H, 1998, CHROMOSOMA, V107, P406, DOI 10.1007/s004120050324; Mejia JE, 2002, GENOMICS, V79, P297, DOI 10.1006/geno.2002.6704; Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112; PONTECORVO G, 1971, NATURE, V230, P367, DOI 10.1038/230367a0; Rudd MK, 2003, MOL CELL BIOL, V23, P7689, DOI 10.1128/MCB.23.21.7689-7697.2003; Saffery R, 2000, HUM MOL GENET, V9, P175, DOI 10.1093/hmg/9.2.175; Saffery R, 2003, MOL CELL, V12, P509, DOI 10.1016/S1097-2765(03)00279-X; Saffery R, 2001, P NATL ACAD SCI USA, V98, P5705, DOI 10.1073/pnas.091468498; Shen MH, 2000, CURR BIOL, V10, P31, DOI 10.1016/S0960-9822(99)00261-4; Shen MH, 1997, HUM MOL GENET, V6, P1375, DOI 10.1093/hmg/6.8.1375; Shen MH, 2001, CHROMOSOMA, V109, P524, DOI 10.1007/s004120000110; Shinohara T, 2000, CHROMOSOME RES, V8, P713, DOI 10.1023/A:1026741321193; Slijepcevic P, 1999, CYTOGENET CELL GENET, V85, P196, DOI 10.1159/000015292; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; Tomizuka K, 2000, P NATL ACAD SCI USA, V97, P722, DOI 10.1073/pnas.97.2.722; Voet T, 2001, GENOME RES, V11, P124, DOI 10.1101/gr.159901; VOULLAIRE LE, 1993, AM J HUM GENET, V52, P1153; Yang JW, 2000, HUM MOL GENET, V9, P1891, DOI 10.1093/hmg/9.12.1891; Yoshimi K, 2000, NAT BIOTECHNOL, V18, P1086, DOI 10.1038/80287	37	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3954	3962		10.1074/jbc.M410047200	http://dx.doi.org/10.1074/jbc.M410047200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557333	hybrid			2022-12-25	WOS:000226983900098
J	Yang, WD; Wang, QD; Howell, KL; Lee, JT; Cho, DSC; Murray, JM; Nishikura, K				Yang, WD; Wang, QD; Howell, KL; Lee, JT; Cho, DSC; Murray, JM; Nishikura, K			ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DNA BINDING DOMAIN; ADENOSINE-DEAMINASE; EDITING ENZYME; CAENORHABDITIS-ELEGANS; MODIFYING ACTIVITY; PROTEIN-KINASE; 2 FORMS; GENE; RECOGNITION	Double-stranded RNA induces the homology-dependent degradation of cognate mRNA in the cytoplasm via RNA interference (RNAi) but also is a target for adenosine-to-inosine (A-to-I) RNA editing by adenosine deaminases acting on RNA (ADARs). An interaction between the RNAi and the RNA editing pathways in Caenorhabditis elegans has been suggested recently, but the precise mode of interaction remains to be established. In addition, it is unclear whether this interaction is possible in mammalian cells with their somewhat different RNAi pathways. Here we show that ADAR1 and ADAR2, but not ADAR3, avidly bind short interfering RNA (siRNA) without RNA editing. In particular, the cytoplasmic full-length isoform of ADAR1 has the highest affinity among known ADARs, with a subnanomolar dissociation constant. Gene silencing by siRNA is significantly more effective in mouse fibroblasts homozygous for an ADAR1 null mutation than in wild-type cells. In addition, suppression of RNAi effects are detected in fibroblast cells overexpressing functional ADAR1 but not when overexpressing mutant ADAR1 lacking double-stranded RNA-binding domains. These results identify ADAR1 as a cellular factor that limits the efficacy of siRNA in mammalian cells.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Nishikura, K (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	kazuko@wistar.upenn.edu			NCI NIH HHS [P01 CA072765, P01 CA072765-05S20002] Funding Source: Medline; NHLBI NIH HHS [R01 HL070045, R01 HL070045-02] Funding Source: Medline; NIGMS NIH HHS [R01 GM040536, R01 GM040536-15] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Desterro JMP, 2003, J CELL SCI, V116, P1805, DOI 10.1242/jcs.00371; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gerber A, 1997, RNA, V3, P453; Hartner JC, 2004, J BIOL CHEM, V279, P4894, DOI 10.1074/jbc.M311347200; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504; KIM U, 1994, J BIOL CHEM, V269, P13480; Knight SW, 2002, MOL CELL, V10, P809, DOI 10.1016/S1097-2765(02)00649-4; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Maas S, 2003, J BIOL CHEM, V278, P1391, DOI 10.1074/jbc.R200025200; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; Nishikura K, 2004, NAT BIOTECHNOL, V22, P962, DOI 10.1038/nbt0804-962; Nishikura K, 2001, CELL, V107, P415, DOI 10.1016/S0092-8674(01)00581-5; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Poulsen H, 2001, MOL CELL BIOL, V21, P7862, DOI 10.1128/MCB.21.22.7862-7871.2001; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sansam CL, 2003, P NATL ACAD SCI USA, V100, P14018, DOI 10.1073/pnas.2336131100; Scadden ADJ, 2001, EMBO REP, V2, P1107, DOI 10.1093/embo-reports/kve244; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Seeburg PH, 2002, NEURON, V35, P17, DOI 10.1016/S0896-6273(02)00760-2; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Tonkin LA, 2003, SCIENCE, V302, P1725, DOI 10.1126/science.1091340; Vargason JM, 2003, CELL, V115, P799, DOI 10.1016/S0092-8674(03)00984-X; VASQUEZ B, 1982, IN VITRO CELL DEV B, V18, P643; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Ye KQ, 2003, NATURE, V426, P874, DOI 10.1038/nature02213; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457	55	119	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3946	3953		10.1074/jbc.M407876200	http://dx.doi.org/10.1074/jbc.M407876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15556947	Green Accepted, hybrid			2022-12-25	WOS:000226983900097
J	Hochleitner, EO; Kastner, B; Frohlich, T; Schmidt, A; Luhrmann, R; Arnold, G; Lottspeich, F				Hochleitner, EO; Kastner, B; Frohlich, T; Schmidt, A; Luhrmann, R; Arnold, G; Lottspeich, F			Protein stoichiometry of a multiprotein complex, the human spliceosomal U1 small nuclear ribonucleoprotein - Absolute quantification using isotope-coded tags and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOMICS; PEPTIDES; RNA; QUANTITATION; CHROMATOGRAPHY; ARGININE; DOMAIN	The human U1 snRNP (small nuclear ribonucleoprotein), which is a part of the spliceosome, consists of U1 snRNA and ten different proteins: seven Sm proteins 13/1399 D1, D2, D3, Eq F, and G and the three U1-specific proteins U1-70 K, U1-A, U1-C. To determine the stoichiometry of all ten proteins, the complex was denatured, digested completely with an endoproteinase and labeled with an amine-specific tag. Corresponding peptides were synthesized and labeled with the same tag containing heavier isotopes. The digest was then spiked with defined amounts of the synthetic peptides, and the resulting isotopic peptide pairs were analyzed quantitatively by mass spectrometry. The mass spectra provided information about the absolute amount of each component in the starting protein mixture. The use of the isotope-coded, amine-specific reagents propionyl-N-oxysuceinimide and nicotinoyl-N-oxysuceinimide was evaluated for stoichiometry determination; the nicotinoyl reagent was found to be advantageous because of its greater mass spectrometric sensitivity. Absolute quantities of all ten proteins were measured, showing equal numbers of all ten proteins in the U1 spliceosomal snRNP. These data demonstrate that quantitative mass spectrometry has great potential for the determination of the stoichiometry of multiprotein complexes.	Max Planck Inst Biochem, Analyt Prot Chem Grp, D-82152 Martinsried, Germany; Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37070 Gottingen, Germany; Univ Munich, Gene Ctr, Lab Funct Genome Anal, D-81377 Munich, Germany	Max Planck Society; Max Planck Society; University of Munich	Hochleitner, EO (corresponding author), Max Planck Inst Biochem, Analyt Prot Chem Grp, Klopferspitz 18A, D-82152 Martinsried, Germany.		Schmidt, Alexander/C-5122-2009; Schmidt, Alexander/D-6426-2011; Fröhlich, Thomas/C-6735-2011	Schmidt, Alexander/0000-0002-3149-2381; Fröhlich, Thomas/0000-0002-4709-3211				Aebersold R, 2003, J AM SOC MASS SPECTR, V14, P685, DOI 10.1016/S1044-0305(03)00289-7; BACH M, 1990, METHOD ENZYMOL, V181, P232; Barnidge DR, 2003, ANAL CHEM, V75, P445, DOI 10.1021/ac026154+; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Chakraborty A, 2002, J CHROMATOGR A, V949, P173, DOI 10.1016/S0021-9673(02)00047-X; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Gunnewiek JMTK, 1995, NUCLEIC ACIDS RES, V23, P4864; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hochleitner EO, 2004, PROTEOMICS, V4, P669, DOI 10.1002/pmic.200300668; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Munchbach M, 2000, ANAL CHEM, V72, P4047, DOI 10.1021/ac000265w; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Ong SE, 2003, J PROTEOME RES, V2, P173, DOI 10.1021/pr0255708; ONG SE, 2002, MOL CELL PROTEOMICS, V74, P5774; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; VANDAM A, 1989, EMBO J, V8, P3853, DOI 10.1002/j.1460-2075.1989.tb08563.x; Walke S, 2001, J MOL BIOL, V308, P49, DOI 10.1006/jmbi.2001.4549; Wang SH, 2001, J CHROMATOGR A, V924, P345, DOI 10.1016/S0021-9673(01)00961-X; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8	23	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2536	2542		10.1074/jbc.M409587200	http://dx.doi.org/10.1074/jbc.M409587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15525645	hybrid			2022-12-25	WOS:000226449100021
J	Zhang, XT; Kolaczkowska, A; Devaux, F; Panwar, SL; Hallstrom, TC; Jacq, C; Moye-Rowley, WS				Zhang, XT; Kolaczkowska, A; Devaux, F; Panwar, SL; Hallstrom, TC; Jacq, C; Moye-Rowley, WS			Transcriptional regulation by Lge1p requires a function independent of its role in histone H2B ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; YEAST MULTIDRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; GENOME-WIDE; GENE-EXPRESSION; MITOCHONDRIAL DYSFUNCTION; IN-VIVO; PROTEIN; H3; METHYLATION	Saccharomyces cerevisiae cells that have lost their mitochondrial genome (rho(0)) strongly induce transcription of multidrug resistance genes, including the ATP-binding cassette transporter gene PDR5. PDR5 induction in rho(0) cells requires the presence of the zinc cluster transcription factor Pdr3p. The PDR3 gene is positively autoregulated in rho(0) cells by virtue of the presence of two binding sites for Pdr3p in its promoter. We identify the novel protein Lge1p as a required participant in the rho(0) activation of PDR3 and PDR5 expression. Lge1p is a nuclear protein that has been found to play a role in ubiquitination of histone 11213 at Lys(123). This ubiquitination requires the presence of the ubiquitin-conjugating enzyme Rad6p and the ubiquitin ligase Bre1p. Interestingly, rho(0) strains lacking Lge1p failed to induce PDR3 transcription, but induction was still seen in Deltarad6, Deltabre1, and H2B-K123R mutant strains. Microarray experiments also confirmed that the pattern of gene expression changes seen in cells lacking Lge1p, Bre1p, or Rad6p or containing the H2B-K123R mutant as the only form of 11213 share some overlap but are distinct. These findings provide a strong argument that Lge1p has roles in gene regulation independent of its participation in the Rad6p-dependent ubiquitination of H2B.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Mol Biol Grad Program, Iowa City, IA 52242 USA; Ecole Normale Super, CNRS, Genet Mol Lab, F-75230 Paris 05, France	University of Iowa; University of Iowa; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 6-530 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.	scott-moye-rowley@uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022; DEVAUX, Frédéric/N-2288-2019	Moye-Rowley, Scott/0000-0002-7163-1120; DEVAUX, Frédéric/0000-0002-0039-9096	NIGMS NIH HHS [GM49825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Chelstowska A, 1999, YEAST, V15, P1377, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1377::AID-YEA473>3.0.CO;2-0; Delahodde A, 2001, MOL MICROBIOL, V39, P304, DOI 10.1046/j.1365-2958.2001.02182.x; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; HEREFORD L, 1979, CELL, V18, P1261, DOI 10.1016/0092-8674(79)90237-X; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; Turner SD, 2002, MOL CELL BIOL, V22, P4011, DOI 10.1128/MCB.22.12.4011-4019.2002; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; van Leeuwen F, 2002, CURR OPIN CELL BIOL, V14, P756, DOI 10.1016/S0955-0674(02)00393-9; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang XT, 2001, J BIOL CHEM, V276, P47844, DOI 10.1074/jbc.M106285200	60	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2759	2770		10.1074/jbc.M408333200	http://dx.doi.org/10.1074/jbc.M408333200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15528187	hybrid			2022-12-25	WOS:000226449100049
J	Chen-Goodspeed, M; Lukan, AN; Dessauer, CW				Chen-Goodspeed, M; Lukan, AN; Dessauer, CW			Modeling of G alpha(s) and G alpha(i) regulation of human type V and VI adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINUS DOMAIN; PROTEIN-KINASE-C; G(S ALPHA); CYTOSOLIC DOMAINS; SITE; INHIBITION; IDENTIFICATION; ACTIVATION; EXPRESSION; CELLS	We examined the kinetics of Galpha(s) and Galpha(i) regulation of human type V and type VI adenylyl cyclase (AC V and AC VI) in order to better model interactions between AC and its regulators. Activation of AC VI by Galpha(s) displayed classical Michaelis-Menten kinetics, whereas AC V activation by Galpha(s) was cooperative with a Hill coefficient of 1.4. The basal activity of human AC V, but not that of AC VI, was inhibited by Galpha(i). Both enzymes showed greater inhibition by Galpha(i) at low Galpha(s) concentrations; however, human AC V was activated by Galpha(i) at high Galpha(s) concentrations. Neither regulator had an effect on the K-m for Mg-ATP. Mutations made within the Galpha(s) binding pocket of AC V (N1090D) and VI (F1078S) displayed 6- and 14-fold greater EC50 values for Galpha(s) activation but had no effect on Galpha(i) inhibition of basal activity or K-m for Mg-ATP. Galpha(s)-stimulated AC VI-F1078S was not significantly inhibited by Galpha(i), despite normal inhibition by Galpha(i) upon forskolin stimulation. Mechanistic models for Galpha(s) and Galpha(i) regulation of AC V and VI were derived to describe these results. Our models are consistent with previous studies, predicting a decrease in affinity of Galpha(i) in the presence of Galpha(s). For AC VI, Galpha(s) is required for inhibition but not binding by Galpha(i). For AC V, binding of two molecules of Galpha(s) and Galpha(i) to an AC dimer are required to fully describe the data. These models highlight the differences between AC V and VI and the complex interactions with two important regulators.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Dessauer, CW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	Carmen.W.Dessauer@uth.tmc.edu	Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NIGMS NIH HHS [R01 GM060419, R01 GM060419-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 2002, J BIOL CHEM, V277, P28823, DOI 10.1074/jbc.M203962200; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 2002, METHOD ENZYMOL, V345, P112; GILMAN AG, 1995, ANGEW CHEM INT EDIT, V34, P1406, DOI 10.1002/anie.199514061; Gu C, 2002, EUR J BIOCHEM, V269, P413, DOI 10.1046/j.0014-2956.2001.02708.x; Harry A, 1997, J BIOL CHEM, V272, P19017, DOI 10.1074/jbc.272.30.19017; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IWAMI G, 1995, MOL CELL ENDOCRINOL, V110, P43, DOI 10.1016/0303-7207(95)03514-8; Kao YY, 2004, J BIOL CHEM, V279, P34440, DOI 10.1074/jbc.M401952200; KAWABE J, 1994, J BIOL CHEM, V269, P16554; Kleuss C, 2003, EMBO J, V22, P826, DOI 10.1093/emboj/cdg095; Lai HL, 1999, MOL PHARMACOL, V56, P644, DOI 10.1124/mol.56.3.644; LEE E, 1994, METHOD ENZYMOL, V237, P146; LIN TH, 2002, J BIOL CHEM, V277; LINDER ME, 1991, J BIOL CHEM, V266, P4654; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Wu GC, 2001, J BIOL CHEM, V276, P35450, DOI 10.1074/jbc.M009704200; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968	35	45	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1808	1816		10.1074/jbc.M409172200	http://dx.doi.org/10.1074/jbc.M409172200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15545274	hybrid			2022-12-25	WOS:000226341700014
J	Di Giovanni, S; De Biase, A; Yakovlev, A; Finn, T; Beers, J; Hoffman, EP; Faden, AI				Di Giovanni, S; De Biase, A; Yakovlev, A; Finn, T; Beers, J; Hoffman, EP; Faden, AI			In vivo and in vitro characterization of novel neuronal plasticity factors identified following spinal cord injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH; GENE-EXPRESSION; PC12 CELLS; CORONIN FAMILY; ACTIN-BINDING; PROTEIN; GROWTH; REGENERATION; ACTIVATION; PI(4,5)P-2	Following spinal cord injury, there are numerous changes in gene expression that appear to contribute to either neurodegeneration or reparative processes. We utilized high density oligonucleotide microarrays to examine temporal gene profile changes after spinal cord injury in rats with the goal of identifying novel factors involved in neural plasticity. By comparing mRNA changes that were coordinately regulated over time with genes previously implicated in nerve regeneration or plasticity, we found a gene cluster whose members are involved in cell adhesion processes, synaptic plasticity, and/or cytoskeleton remodeling. This group, which included the small GTPase Rab13 and actin-binding protein Coronin 1b, showed significantly increased mRNA expression from 7-28 days after trauma. Overexpression in vitro using PC-12, neuroblastoma, and DRG neurons demonstrated that these genes enhance neurite outgrowth. Moreover, RNAi gene silencing for Coronin 1b or Rab13 in NGF-treated PC-12 cells markedly reduced neurite outgrowth. Coronin 1b and Rab13 proteins were expressed in cultured DRG neurons at the cortical cytoskeleton, and at growth cones along with the pro-plasticity/regeneration protein GAP-43. Finally, Coronin 1b and Rab13 were induced in the injured spinal cord, where they were also co-expressed with GAP-43 in neurons and axons. Modulation of these proteins may provide novel targets for facilitating restorative processes after spinal cord injury.	Georgetown Univ, Med Ctr, Sch Med, Dept Neurosci, Washington, DC 20057 USA; Childrens Natl Med Ctr, Ctr Genet Med, Washington, DC 20010 USA	Georgetown University; Children's National Health System	Di Giovanni, S (corresponding author), Georgetown Univ, Med Ctr, Sch Med, Dept Neurosci, 3900 Reservoir Rd NW, Washington, DC 20057 USA.	sd69@georgetown.edu; fadena@georgetown.edu		Hoffman, Eric/0000-0001-6470-5139	NHLBI NIH HHS [U01 HL66614] Funding Source: Medline; NINDS NIH HHS [NS-1-2339] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066614] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Anneren C, 2000, J BIOL CHEM, V275, P29153, DOI 10.1074/jbc.M003926200; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Detrait ER, 2000, J NEUROSCI RES, V62, P566, DOI 10.1002/1097-4547(20001115)62:4<566::AID-JNR11>3.3.CO;2-W; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Di Giovanni S, 2004, ANN NEUROL, V55, P195, DOI 10.1002/ana.10811; Diaz E, 2002, NEURON, V36, P417, DOI 10.1016/S0896-6273(02)01016-4; ERNFORS P, 1993, MOL BRAIN RES, V17, P217, DOI 10.1016/0169-328X(93)90005-A; FEDOROFF S, 2001, PROTOCOLS NEURAL CEL, P95; Fukuda M, 2000, NEUROSCI LETT, V295, P33, DOI 10.1016/S0304-3940(00)01585-8; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Hattula K, 2002, MOL BIOL CELL, V13, P3268, DOI 10.1091/mbc.E02-03-0143; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; Jung M, 1997, MOL CELL NEUROSCI, V9, P116, DOI 10.1006/mcne.1997.0611; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Li SX, 2003, J NEUROSCI, V23, P4219; Long KE, 2000, J NEUROBIOL, V44, P230, DOI 10.1002/1097-4695(200008)44:2<230::AID-NEU12>3.0.CO;2-W; Lu LG, 2000, EXP CELL RES, V259, P370, DOI 10.1006/excr.2000.4984; Mishima M, 1999, J CELL SCI, V112, P2833; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; MURPHY PG, 1995, J NEUROSCI, V15, P5130; Nakamura T, 1999, J BIOL CHEM, V274, P13322, DOI 10.1074/jbc.274.19.13322; Oku T, 2003, BIOL PHARM BULL, V26, P409; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Seo J, 2004, BIOINFORMATICS, V20, P2534, DOI 10.1093/bioinformatics/bth280; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Tang BL, 2001, J NEUROCHEM, V79, P923, DOI 10.1046/j.1471-4159.2001.00674.x	40	74	76	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2084	2091		10.1074/jbc.M411975200	http://dx.doi.org/10.1074/jbc.M411975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15522871	hybrid			2022-12-25	WOS:000226341700043
J	Grigoriou, V; Shapiro, IM; Cavalcanti-Adam, EA; Composto, RJ; Ducheyne, P; Adams, CS				Grigoriou, V; Shapiro, IM; Cavalcanti-Adam, EA; Composto, RJ; Ducheyne, P; Adams, CS			Apoptosis and survival of osteoblast-like cells are regulated by surface attachment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION; NF-KAPPA-B; BONE-CELLS; IN-VITRO; MATRIX REGULATION; PHOSPHATE IONS; NITRIC-OXIDE; PEPTIDES; AKT	We tested the hypothesis that RGDS peptides regulate osteoblast survival in culture. Osteoblast-like MC3T3-E1 cells were allowed to attach to RGDS peptides that had been tethered to a silicone surface utilizing a previously described grafting technique. The RGDS-modified surface caused up-regulation of alpha(v)beta(3) integrin. We noted that there was an increase in expression of activated focal adhesion kinase and activated Akt. There was no change in the expression level of the anti-apoptotic protein Bcl-2, the pro-apoptotic protein Bad, or the inactivated form of Bad, pBad. Attachment to the RGDS-treated membrane completely abolished apoptosis induced by staurosporine, the Ca2+ P-i ion pair, and sodium nitroprusside. However, the surface modification did not interfere with apoptosis mediated by the free RGDS peptide or serum-free medium. When the activity of the phosphatidylinositol 3-kinase pathway was inhibited, RGDS- dependent resistance to apoptosis was eliminated. These results indicated that the binding of cells to RGDS abrogated apoptosis via the mitochondrial pathway and that the suppression of apoptosis was dependent on the activity of phosphatidylinositol 3-kinase.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; Univ Penn, Sch Dent Med, Dept Orthodont, Philadelphia, PA 19104 USA; Univ Heidelberg, Inst Phys Chem, D-69120 Heidelberg, Germany; Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioact Mat & Tissue Engn, Philadelphia, PA 19104 USA	Jefferson University; University of Pennsylvania; Ruprecht Karls University Heidelberg; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Adams, CS (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Orthopaed Surg, 501 Curtis Bldg,1015 Walnut St, Philadelphia, PA 19107 USA.	Christopher.Adams@jefferson.edu	Cavalcanti-Adam, Elisabetta Ada/ABA-8495-2021; Adams, Christopher/Z-2537-2019	Adams, Christopher/0000-0003-2100-4417; Cavalcanti-Adam, Elisabetta/0000-0003-0243-1552	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013319, R01DE010875] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60426] Funding Source: Medline; NIDCR NIH HHS [DE-05748, DE-10875, DE-13319] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams CS, 2001, J BIOL CHEM, V276, P20316, DOI 10.1074/jbc.M006492200; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Alsberg E, 2001, J DENT RES, V80, P2025, DOI 10.1177/00220345010800111501; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cavalcanti-Adam EA, 2002, J BONE MINER RES, V17, P2130, DOI 10.1359/jbmr.2002.17.12.2130; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen RM, 2002, J ORTHOP RES, V20, P295, DOI 10.1016/S0736-0266(01)00086-9; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dee K C, 1995, Tissue Eng, V1, P135, DOI 10.1089/ten.1995.1.135; Dee KC, 1996, BIOMATERIALS, V17, P209, DOI 10.1016/0142-9612(96)85765-6; Dee KC, 1999, BIOMATERIALS, V20, P221, DOI 10.1016/S0142-9612(98)00161-6; DEL PL, 1997, SCIENCE, V278, P687; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; El-Ghannam AR, 2004, J BIOMED MATER RES A, V68A, P615, DOI 10.1002/jbm.a.20051; Ferris DM, 1999, BIOMATERIALS, V20, P2323, DOI 10.1016/S0142-9612(99)00161-1; Globus RK, 1998, J CELL SCI, V111, P1385; Grzesik WJ, 1998, J DENT RES, V77, P1606, DOI 10.1177/00220345980770080801; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; Mansfield K, 1999, J CELL PHYSIOL, V179, P276, DOI 10.1002/(SICI)1097-4652(199906)179:3<276::AID-JCP5>3.0.CO;2-#; McFarland CD, 1999, J BIOMED MATER RES, V44, P1; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756-3282(00)00346-X; Ozes ON, 1999, NATURE, V401, P82; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Perlot RL, 2002, J BONE MINER RES, V17, P66, DOI 10.1359/jbmr.2002.17.1.66; Piantadosi CA, 2002, NITRIC OXIDE-BIOL CH, V6, P45, DOI 10.1006/niox.2001.0368; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; PULEO DA, 1991, BONE, V12, P271, DOI 10.1016/8756-3282(91)90075-T; Rezania A, 1997, J BIOMED MATER RES, V37, P9, DOI 10.1002/(SICI)1097-4636(199710)37:1<9::AID-JBM2>3.0.CO;2-W; Rezania A, 2000, J BIOMED MATER RES, V52, P595, DOI 10.1002/1097-4636(20001215)52:4<595::AID-JBM3>3.0.CO;2-3; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; Squires MS, 2003, BIOCHEM PHARMACOL, V65, P361, DOI 10.1016/S0006-2952(02)01517-4; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Szymczyk KH, 2004, BONE, V34, P148, DOI 10.1016/j.bone.2003.09.003; Tafani M, 2001, CANCER RES, V61, P2459; Yang XB, 2001, BONE, V29, P523, DOI 10.1016/S8756-3282(01)00617-2; Yano S, 2003, BIOCHEM BIOPH RES CO, V301, P841, DOI 10.1016/S0006-291X(03)00060-3; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	47	71	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1733	1739		10.1074/jbc.M402550200	http://dx.doi.org/10.1074/jbc.M402550200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15522882	hybrid			2022-12-25	WOS:000226341700005
J	Smith, E; Frenkel, B				Smith, E; Frenkel, B			Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3 beta-dependent and -independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3-BETA; RECEPTOR-RELATED PROTEIN-5; BETA-CATENIN; INDUCED OSTEOPOROSIS; GENE-EXPRESSION; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC DOMAIN; BONE-DENSITY	Glucocorticoids, widely used as immune suppressors, cause osteoporosis by inhibiting bone formation. In MC3T3-E1 osteoblast-like cultures, dexamethasone (DEX) activates glycogen synthase kinase-3beta (GSK3beta) and inhibits a differentiation-related cell cycle that occurs at a commitment stage immediately after confluence. Here we show that DEX inhibition of the differentiation-related cell cycle is associated with a decrease in beta-catenin levels and inhibition of LEF/TCF-mediated transcription. These inhibitory activities are no longer observed in the presence of lithium, a GSK3beta inhibitor. DEX decreased the serum-responsive phosphorylation of protein kinase B/Akt-Ser(473) within minutes, and this inhibition was also observed after 12 h. When the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was inhibited by wortmannin, DEX no longer inhibited beta-catenin levels. Furthermore, DEX-mediated inhibition of LEF/ TCF transcriptional activity was attenuated in the presence of dominant negative forms of either PI3K or protein kinase B/Akt. These results suggest cross-talk between the PI3K/Akt and Wnt signaling pathways. Consistent with a role for Wnt signaling in the osteoblast differentiation-related cell cycle, wortmannin partially negated the DEX inhibition of this cell cycle. DEX also induced histone deacetylase ( HDAC) 1, which is known to inhibit LEF/ TCF transcriptional activity. Overexpression of HDAC1 negated the inhibitory effect of DEX on LEF/ TCF transcriptional activity. In the presence of trichostatin A, a deacetylase inhibitor, DEX-mediated inhibition of the differentiation-related cell cycle was partially negated. When administered together, wortmannin and trichostatin A completely negated the inhibitory effect of DEX on the differentiation-related cell cycle. These results suggest that inhibition of a PI3K/Akt/GSK3beta/beta-catenin/ LEF axis and stimulation of HDAC1 cooperate to mediate the inhibitory effect of DEX on Wnt signaling and the osteoblast differentiation-related cell cycle.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Orthoped Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Frenkel, B (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, 2250 Alcazar St, Los Angeles, CA 90033 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047052, R03AR049412] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47052, AR049412] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; LINKHART TA, 1991, J BONE MINER RES, V6, P1285; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; LUKERT B, 1997, OSTEOPOROSIS, P801; Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubin MR, 2002, J CLIN ENDOCR METAB, V87, P4033, DOI 10.1210/jc.2002-012101; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	55	121	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2388	2394		10.1074/jbc.M406294200	http://dx.doi.org/10.1074/jbc.M406294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537647	hybrid			2022-12-25	WOS:000226341700076
J	Narayanan, A; Nogueira, ML; Ruyechan, WT; Kristie, TM				Narayanan, A; Nogueira, ML; Ruyechan, WT; Kristie, TM			Combinatorial transcription of herpes simplex virus and varicella zoster virus immediate early genes is strictly determined by the cellular coactivator HCF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY PROTEIN IE62; MAMMALIAN-CELLS; HOMEO DOMAIN; FACTOR SP1; C1 FACTOR; VP16; ACTIVATION; RECOGNITION; EXPRESSION; SEQUENCES	The mammalian transcriptional coactivator host cell factor-1 (HCF-1) functions in concert with Oct-1 and VP16 to assemble the herpes simplex virus (HSV) immediate early (IE) transcription enhancer core complexes that mediate the high level transcription of these genes upon infection. Although this transcriptional model has been well characterized in vitro, the requirements and significance of the components have not been addressed. Oct-1 was previously determined to be critical but not essential for HSV IE gene expression. In contrast, RNA interference-mediated depletion of HCF-1 resulted in abrogation of HSV IE gene expression. The HSV IE gene enhancer domain is a model of combinatorial transcription and consists of the core enhancer and multiple binding sites for factors such as Sp1 and GA-binding protein. It was striking that HCF-1 was strictly required for VP16-mediated transcriptional induction via the core enhancer as well as for basal level transcription mediated by GA-binding protein and Sp1. HCF-1 was also found to be essential for the induction of varicella zoster virus IE gene expression by ORF10, the VZV ortholog of the HSV IE transactivator VP16, and the autostimulatory IE62 protein. The critical dependence upon HCF-1 demonstrates that this cellular component is a key factor for control of HSV and VZV IE gene expression by functioning as the common element for distinct factors cooperating at the IE gene enhancers. The requirements for this protein supports the model whereby the regulated transport of HCF-1 from the cytoplasm to the nucleus in sensory neurons may control IE gene expression and reactivation of these viruses from the latent state.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14214 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kristie, TM (corresponding author), Bldg 4,Rm 131,4 Ctr Dr, Bethesda, MD 20892 USA.	thomas_kristie@nih.gov	Nogueira, Mauricio L/B-7599-2012	Nogueira, Mauricio L/0000-0003-1102-2419	NIAID NIH HHS [AI18449] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000711, R21AI018449, R56AI018449, R01AI018449] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arvin AM, 2002, VIRAL IMMUNOL, V15, P507, DOI 10.1089/088282402760312377; BAUDOUX L, 1995, NUCLEIC ACIDS RES, V23, P1341, DOI 10.1093/nar/23.8.1341; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Julien E, 2003, EMBO J, V22, P2360, DOI 10.1093/emboj/cdg242; Khurana B, 2004, J BIOL CHEM, V279, P33673, DOI 10.1074/jbc.M401255200; KINCHINGTON PR, 1992, J VIROL, V66, P359, DOI 10.1128/JVI.66.1.359-366.1992; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Liu Y, 1999, GENE DEV, V13, P1692, DOI 10.1101/gad.13.13.1692; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Luciano RL, 2003, J BIOL CHEM, V278, P51116, DOI 10.1074/jbc.M303470200; Luciano RL, 2002, P NATL ACAD SCI USA, V99, P13403, DOI 10.1073/pnas.202200399; Lungu O, 1998, P NATL ACAD SCI USA, V95, P7080, DOI 10.1073/pnas.95.12.7080; MORIUCHI H, 1995, J VIROL, V69, P4693, DOI 10.1128/JVI.69.8.4693-4701.1995; Nogueira ML, 2004, P NATL ACAD SCI USA, V101, P1473, DOI 10.1073/pnas.0307300101; Peng H, 2003, J BIOL CHEM, V278, P38068, DOI 10.1074/jbc.M302259200; PERERA LP, 1992, VIROLOGY, V191, P346, DOI 10.1016/0042-6822(92)90197-W; Perera LP, 2000, J BIOL CHEM, V275, P487, DOI 10.1074/jbc.275.1.487; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; Roizman Bernard, 1996, P1043; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; VOGEL JL, 2001, ENCY MOL MED, V1, P732; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001	42	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1369	1375		10.1074/jbc.M410178200	http://dx.doi.org/10.1074/jbc.M410178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522876	hybrid			2022-12-25	WOS:000226195200063
J	Slice, LW; Chiu, T; Rozengurt, E				Slice, LW; Chiu, T; Rozengurt, E			Angiotensin II and epidermal growth factor induce cyclooxygenase-2 expression in intestinal epithelial cells through small GTPases using distinct signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; MESSENGER-RNA STABILITY; GENE-EXPRESSION; TRANSCRIPTION FACTOR; COLON-CANCER; POSTTRANSCRIPTIONAL REGULATION; TRANSDUCTION PATHWAYS; MITOGENIC RESPONSE; ERK ACTIVATION	Colorectal carcinogenesis is a multistep process involving genetic mutations and alterations in rigorously controlled signaling pathways and gene expression that control intestinal epithelial cell proliferation, differentiation, and apoptosis. Cyclooxygenase-2 (COX-2) is aberrantly expressed in premalignant adenomatous polyps and colorectal carcinomas and is associated with increased epithelial cell proliferation, decreased apoptosis, and increased cell invasiveness. Currently, knowledge of the regulation of expression of COX-2 by endogenous cell-surface receptors is inadequate. Recently, in a non-transformed rat intestinal epithelial cell line (IEC-18), we showed induction of cell proliferation and DNA synthesis by angiotensin II (Ang II) via the endogenous Ang II type 1 receptor (Chiu, T., Santiskulvong, C., and Rozengurt, E. ( 2003) Am. J. Physiol. 285, G1-G11). We report that Ang II potently stimulated expression of COX-2 mRNA and protein as an immediate-early gene response through the Ang II type 1 receptor, correlating with an increase in prostaglandin I-2 production. Ang II induced Cdc42 activation and filopodial formation. COX-2 expression was induced by epidermal growth factor (EGF), which activated Rac with lamellipodial formation. Inhibition of small GTPases by Clostridium difficile toxin B blocked COX-2 expression by Ang II and EGF. Inhibition of ERK activation by U0126 or PD98059 significantly decreased EGF-dependent COX-2 expression, but did not affect Ang II-dependent COX-2 expression. Conversely, inhibition of p38(MAPK) by SB202190 or PD169316 inhibited COX-2 expression by Ang II, but did not block COX-2 induction by EGF. Ang II caused Ca2+ mobilization. Inhibition of Ca2+ signaling by 2-aminobiphenyl borate blocked Ang II-dependent COX-2 expression. EGF did not induce Ca2+ mobilization, and 2-aminobiphenyl borate did not inhibit EGF-dependent COX-2 expression. Inhibition of COX-2 expression correlated with inhibition of prostaglandin I2 production. Luciferase promoter assays showed that Ang II-dependent transcriptional activation of the COX-2 promoter was dependent on activation of small GTPases and p38(MAPK) and on Ca2+ signaling via the cAMP-responsive element/activating transcription factor cis-acting element.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Slice, LW (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Warren Hall,14-109A,900 Vet Ave, Los Angeles, CA 90095 USA.	lslice@mednet.ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, R01DK017294, K08DK063983, R01DK061485, R37DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK017294, DK056930, DK055003, DK063983, DK061485] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; Ardaillou R, 1999, J AM SOC NEPHROL, V10, pS30; BARNARD JA, 1995, GASTROENTEROLOGY, V108, P564, DOI 10.1016/0016-5085(95)90087-X; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN JJ, 1979, HYPERTENSION, V1, P159, DOI 10.1161/01.HYP.1.3.159; Brown JR, 2004, CLIN CANCER RES, V10, p4266S, DOI 10.1158/1078-0432.CCR-040014; Burgess AW, 1998, PHILOS T ROY SOC B, V353, P903, DOI 10.1098/rstb.1998.0254; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng HF, 2000, J CLIN INVEST, V106, P681, DOI 10.1172/JCI10318; Chiu T, 2003, AM J PHYSIOL-GASTR L, V285, pG1, DOI 10.1152/ajpgi.00419.2002; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Ciesla WP, 1998, J BIOL CHEM, V273, P16021, DOI 10.1074/jbc.273.26.16021; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dechert MA, 2001, AM J PHYSIOL-CELL PH, V281, pC123, DOI 10.1152/ajpcell.2001.281.1.C123; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; DZAU VJ, 1991, HYPERTENSION, V18, P100, DOI 10.1161/01.HYP.18.4_Suppl.II100; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Gordon PV, 2004, PEDIATR RES, V55, P34, DOI 10.1203/01.PDR.0000100461.00878.75; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hatch M, 1998, PFLUG ARCH EUR J PHY, V436, P717; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hirasawa K, 2002, J HISTOCHEM CYTOCHEM, V50, P275, DOI 10.1177/002215540205000215; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Jin XH, 1998, AM J PHYSIOL-REG I, V275, pR515, DOI 10.1152/ajpregu.1998.275.2.R515; Kanai M, 1998, P NATL ACAD SCI USA, V95, P178, DOI 10.1073/pnas.95.1.178; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawai N, 2002, PROSTAG OTH LIPID M, V68-9, P187, DOI 10.1016/S0090-6980(02)00030-8; Kazanov D, 2004, CLIN CANCER RES, V10, P267, DOI 10.1158/1078-0432.CCR-0412-3; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; Lever AF, 1998, LANCET, V352, P179, DOI 10.1016/S0140-6736(98)03228-0; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; Masferrer JL, 2000, CANCER RES, V60, P1306; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Preston SL, 2003, CANCER RES, V63, P3819; PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rebsamen MC, 2003, J MOL CELL CARDIOL, V35, P81, DOI 10.1016/S0022-2828(02)00281-X; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ristimaki A, 1997, CANCER RES, V57, P1276; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Sasaki E, 2003, DIGEST DIS SCI, V48, P2257, DOI 10.1023/B:DDAS.0000007860.87503.09; SECHI LA, 1993, AM J PHYSIOL, V265, pG21, DOI 10.1152/ajpgi.1993.265.1.G21; Seo MR, 2004, J BIOL CHEM, V279, P17366, DOI 10.1074/jbc.M312442200; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; Sheng HM, 2001, CANCER RES, V61, P2670; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Slice LW, 2003, J CELL PHYSIOL, V196, P454, DOI 10.1002/jcp.10304; Slice LW, 2003, J CELL PHYSIOL, V194, P127, DOI 10.1002/jcp.10195; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Svensson CI, 2002, ANNU REV PHARMACOL, V42, P553, DOI 10.1146/annurev.pharmtox.42.092401.143905; TAYLOR GM, 1988, AM J PATHOL, V130, P543; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; van Haasteren G, 1999, J RECEPT SIGNAL TR R, V19, P481, DOI 10.3109/10799899909036666; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WIDDOP RE, 1993, AM J PHYSIOL, V265, pH226, DOI 10.1152/ajpheart.1993.265.1.H226; Wright DC, 2002, METABOLISM, V51, P271, DOI 10.1053/meta.2002.30500; Wu SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1432, DOI 10.1152/ajpcell.00323.2001; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; Yasumaru M, 2003, CANCER RES, V63, P6726; Yoshiji H, 2001, CLIN CANCER RES, V7, P1073; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117	96	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1582	1593		10.1074/jbc.M408172200	http://dx.doi.org/10.1074/jbc.M408172200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15525649	hybrid			2022-12-25	WOS:000226195200089
J	Rajabi, HN; Baluchamy, S; Kolli, S; Nag, A; Srinivas, R; Raychaudhuri, P; Thimmapaya, B				Rajabi, HN; Baluchamy, S; Kolli, S; Nag, A; Srinivas, R; Raychaudhuri, P; Thimmapaya, B			Effects of depletion of CREB-binding protein on c-Myc regulation and cell cycle G(1)-S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; E1A-ASSOCIATED P300; TUMOR-SUPPRESSOR; DISTINCT ROLES; CDK INHIBITOR; DNA-SYNTHESIS; APOPTOSIS; GROWTH; CBP	We recently reported that the transcriptional coactivator and histone acetyltransferase p300 plays an important role in the G(1) phase of the cell cycle by negatively regulating c-myc and thereby preventing premature G(1) exit (Kolli, et al. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 4646-4651; Baluchamy, et al. ( 2003) Proc. Natl. Acad. Sci. U. S. A. 100, 9524-9529). Because p300 does not substitute for all CREB-binding protein (CBP) functions, we investigated whether CBP also negatively regulates c-myc and prevents premature DNA synthesis. Here, we show that antisense-mediated depletion of CBP in serum-deprived human cells leads to induction of c-myc and that such cells emerge from quiescence without growth factors at a rate comparable with that of p300-depleted cells. The CBP-depleted cells contained significantly reduced levels of the cyclin-dependent kinase inhibitor p21 and low levels of p107 and p130 ( but not pRb) phosphorylation, suggesting that these factors, along with elevated levels of c-Myc, contribute to induction of DNA synthesis. Antisense c-Myc reversed the phosphorylation of p107 and p130 and the induction of S phase in CBP-depleted cells, indicating that up-regulation of c-myc is directly responsible for the induction of S phase. Furthermore, the serum-stimulated p300/CBP-depleted cells did not traverse beyond S phase, and a significant number of these cells died of apoptosis, which was not related to p53 levels. These cells also contained significantly higher levels of c-Myc compared with normal cells. When c-myc expression was blocked by antisense c-Myc, the apoptosis of the serum-stimulated CBP-depleted cells was reversed, indicating that high levels of c-Myc contribute to apoptosis. Thus, despite their high degree of structural and functional similarities, normal levels of both p300 and CBP are essential for keeping c-myc in a repressed state in G(1) and thereby preventing inappropriate entry of cells into S phase. In addition, both these proteins also provide important functions in coordinated cell cycle progression.	Northwestern Univ, Feinberg Sch Med, Lurie Canc Ctr, Dept Microbiol Immunol, Chicago, IL 60611 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Thimmapaya, B (corresponding author), Northwestern Univ, Feinberg Sch Med, Lurie Canc Ctr, Dept Microbiol Immunol, Olson 8452,303 E Chicago Ave, Chicago, IL 60611 USA.	b-thimmapaya@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA088863, R01CA074403] Funding Source: NIH RePORTER; NCI NIH HHS [CA 88863, CA 74403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Amanullah A, 2002, ONCOGENE, V21, P1600, DOI 10.1038/sj.onc.1205231; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ASKEW DS, 1991, ONCOGENE, V6, P1915; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Billon N, 1996, ONCOGENE, V13, P2047; Buchmann AM, 1998, MOL CELL BIOL, V18, P4565, DOI 10.1128/MCB.18.8.4565; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Goodman RH, 2000, GENE DEV, V14, P1553; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kung AL, 2000, GENE DEV, V14, P272; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin JY, 2003, J BIOL CHEM, V278, P46482, DOI 10.1074/jbc.M307044200; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MAYOL X, 1995, ONCOGENE, V11, P801; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Mitchell KO, 2000, CANCER RES, V60, P6318; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PENDERGAST GC, 1999, ONCOGENE, V18, P2967; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Rasola A, 2001, CYTOMETRY, V45, P151, DOI 10.1002/1097-0320(20011001)45:2<151::AID-CYTO1157>3.0.CO;2-I; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Sakamuro D, 1995, ONCOGENE, V11, P2411; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sasaguri T, 1996, J BIOL CHEM, V271, P8345, DOI 10.1074/jbc.271.14.8345; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; SOULE HD, 1990, CANCER RES, V50, P6075; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; Swaminathan S, 1996, J MOL BIOL, V258, P736, DOI 10.1006/jmbi.1996.0283; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	73	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					361	374		10.1074/jbc.M408633200	http://dx.doi.org/10.1074/jbc.M408633200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15522869	hybrid			2022-12-25	WOS:000226025100044
J	Takeuchi, H; Kao, S; Miyagi, E; Khan, MA; Buckler-White, A; Plishka, R; Strebel, K				Takeuchi, H; Kao, S; Miyagi, E; Khan, MA; Buckler-White, A; Plishka, R; Strebel, K			Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; CROSS-SPECIES TRANSMISSION; VIF PROTEIN; HIV-1 VIF; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; DEGRADATION; DNA; REPLICATION; PROTEASOME	The virus infectivity factor (Vif) is a protein encoded by most primate lentiviruses. Recent evidence suggests that HIV-1 Vif reduces the intracellular levels of the host cytidine deaminase APOBEC3G (Apo3G) and inhibits its packaging into virions. These functions of Vif are thought to be species-specific. Accordingly, HIV-1 Vif can target only human Apo3G (hApo3G), whereas, African green monkey simian immunodeficiency virus ( SIVagm) Vif can inhibit African green monkey but not human Apo3G. Consistent with this, we found that SIVagm Vif does not affect the stability of exogenously and endogenously expressed hApo3G and does not prevent packaging of exogenous and endogenous hApo3G into SIVagm virions. Nevertheless, SIVagm Vif supported spreading infection of SIVagm virus in the hApo3G-positive human A3.01 T cell line and rescued infectivity of viruses produced from Apo3G-expressing HeLa cells. Sequence analysis verified that SIVagm Vif inhibited the accumulation of hApo3G-induced mutations, suggesting that SIVagm Vif is indeed active in human cells. Our data suggest that SIVagm Vif can inhibit hApo3G activity without inducing its intracellular degradation or preventing its packaging into virions.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Strebel, K (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Rm 310,4 Ctr Dr,MSC 0460, Bethesda, MD 20892 USA.	kstrebel@nih.gov	Takeuchi, Hiroaki/F-9728-2012	Takeuchi, Hiroaki/0000-0002-5689-9858	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000669, ZIAAI000669] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Campbell BJ, 1997, J VIROL, V71, P5593, DOI 10.1128/JVI.71.7.5593-5602.1997; Chen ZW, 1997, J VIROL, V71, P3953, DOI 10.1128/JVI.71.5.3953-3960.1997; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Grimm TA, 2003, JAIDS-J ACQ IMM DEF, V32, P362, DOI 10.1097/00126334-200304010-00003; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; HIRSCH VM, 1995, J VIROL, V69, P955, DOI 10.1128/JVI.69.2.955-967.1995; Hirsch VM, 1999, J VIROL, V73, P1036, DOI 10.1128/JVI.73.2.1036-1045.1999; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Owen SM, 2000, J VIROL, V74, P5702, DOI 10.1128/JVI.74.12.5702-5708.2000; Roos JW, 2000, VIROLOGY, V273, P307, DOI 10.1006/viro.2000.0431; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	36	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					375	382		10.1074/jbc.M408987200	http://dx.doi.org/10.1074/jbc.M408987200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15528183	hybrid			2022-12-25	WOS:000226025100045
J	Li, C; Lin, MH; Liu, JW				Li, C; Lin, MH; Liu, JW			Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis	ONCOGENE			English	Article						p53; PRC1; ptsp53; cell cycle; cytokinesis; transcriptional regulation	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; CELL-CYCLE ARREST; TRANSCRIPTIONAL REGULATION; GROWTH ARREST; BINDING; PROTEIN; INHIBITION; MECHANISMS; SENESCENCE	Our previous studies conducted in MCF7-ptsp53 cells have demonstrated that overexpression of the wild-type (wt) p53 at permissive temperature 32degreesC leads to growth arrest at the G2/M phase of the cell cycle. To identify novel p53-regulated genes that are responsible for the p53-induced G2/M arrest, we conducted cDNA microarray analyses. The array results indicated that the mRNA level of protein regulator of cytokinesis (PRC1) was significantly decreased when the p53 transactivation activity was turned on, suggesting that PRC1 transcription could be downregulated by p53. In this study, we have extensively examined the functional role of p53 in the regulation of PRC1, a cell cycle protein that plays important roles during cytokinesis. We demonstrate that increased expression of the wt p53 either by exogenous transfection or chemical induction results in reduced mRNA and protein expression of PRC1 in HCT116 p53(+/+), HCT116 p53(-/-), MCF-7, T47D, and HeLa cells. Importantly, we show that the decreased PRC1 expression is accompanied by the appearance of binucleated cells, indicating the process of cell division after mitosis being inhibited. By isolation and characterization of a 3 kb genomic fragment containing the 5'-flanking region and part of exon 1 of PRC1 gene, we demonstrate that p53 directly suppresses PRC1 gene transcription. We further locate the p53-responsive sequence to the proximal promoter region -214 to -163, relative to the transcriptional start site. The in vivo interaction of p53 with PRC1 gene promoter is further demonstrated by chromatin immunoprecipitation assay. Taken together, these new findings suggest that p53 may have important roles in the regulation of cytokinesis through controlling the transcription of PRC1.	Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Liu, JW (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	jingwen.liu@med.va.gov			NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; CHENG KC, 1993, ADV CANCER RES, V60, P121; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Dubrez L, 2001, GENE THER, V8, P1705, DOI 10.1038/sj.gt.3301592; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Harris LC, 1996, CANCER RES, V56, P2029; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li C, 2003, BREAST CANCER RES TR, V80, P23, DOI 10.1023/A:1024483017549; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Nakamura S, 2002, ONCOGENE, V21, P2102, DOI 10.1038/sj.onc.1205251; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wesierska-Gadek J, 2000, J CELL BIOCHEM, V80, P85; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; YIN XY, 2001, CANCER RES, V61, P6493	35	48	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9336	9347		10.1038/sj.onc.1208114	http://dx.doi.org/10.1038/sj.onc.1208114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531928				2022-12-25	WOS:000225764100005
J	Sbrissa, D; Shisheva, A				Sbrissa, D; Shisheva, A			Acquisition of unprecedented phosphatidylinositol 3,5-bisphosphate rise in hyperosmotically stressed 3T3-L1 adipocytes, mediated by ArPIKfyve-PIKfyve pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSMOTIC-STRESS; LIPID KINASE; GRAM DOMAIN; 3-KINASE; IDENTIFICATION; ENDOSOME; DYNAMICS; PROTEIN; PHOSPHOINOSITIDES; ASSOCIATION	Unlike yeast, where hyperosmotic stress induces a dramatic increase in phosphatidylinositol 3,5-bisphosphate (PtdIns 3,5-P-2) synthesis, in mammalian cells, although activating a complex array of signaling events, hyperosmotic stress fails to up-regulate PtdIns 3,5-P-2, indicating the PtdIns 3,5-P-2 pathway is not involved in mammalian osmo-protective responses. Here we report an unexpected and marked PtdIns 3,5-P-2 increase in response to hyperosmotic stress in differentiated 3T3-L1 adipocytes. Because this effect was not observed in the precursor preadipocytes, a specific role during acquisition of the adipocyte phenotype and transition into insulin-responsive cells could be suggested. However, acute insulin action did not result in a measurable PtdIns 3,5-P-2 rise, indicating the PtdIns 3,5-P-2 pathway is a specific hyperosmotically activated signaling cascade selectively operating in differentiated 3T3-L1 adipocytes. Hyperosmolarity activates different components of several kinase cascades, including p38 mitogen-activated protein and tyrosine kinases, but these appear to be separate from the activated PtdIns 3,5-P-2 pathway. Because PtdIns 3,5-P-2 is primarily produced by PIKfyve-catalyzed synthesis and requires the upstream activator hVac14 ( called herein ArPIKfyve) that physically associates with and activates PIKfyve, we examined the contribution of ArPIKfyve-PIKfyve for the hyperosmotic stress-induced rise in PtdIns 3,5-P-2. Small interfering RNA-directed gene silencing to selectively deplete ArPIKfyve or PIKfyve in 3T3-L1 adipocytes determined the ArPIKfyve-PIKfyve axis fully accountable for the hyperosmotically activated PtdIns 3,5-P-2. Together these results reveal a previously uncharacterized PtdIns 3,5-P-2 pathway activated selectively in hyperosmotically stressed 3T3-L1 adipocytes and suggest a plausible role for PtdIns 3,5-P-2 in the osmo-protective response mechanism in this cell type.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.	ashishev@med.wayne.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58058] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Berger P, 2003, P NATL ACAD SCI USA, V100, P12177, DOI 10.1073/pnas.2132732100; Bonangelino CJ, 2002, J CELL BIOL, V156, P1015, DOI 10.1083/jcb.200201002; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; Czech MP, 2003, ANNU REV PHYSIOL, V65, P791, DOI 10.1146/annurev.physiol.65.092101.142522; DIGIROLAMO M, 1976, AM J PHYSIOL, V231, P1568, DOI 10.1152/ajplegacy.1976.231.5.1568; Dove SK, 2004, EMBO J, V23, P1922, DOI 10.1038/sj.emboj.7600203; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Friant S, 2003, DEV CELL, V5, P499, DOI 10.1016/S1534-5807(03)00238-7; GOZIER GE, 2002, J BIOL CHEM, V277, P48730; Gual P, 2003, DIABETES METAB, V29, P566, DOI 10.1016/S1262-3636(07)70071-X; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Ikonomov OC, 2003, MOL BIOL CELL, V14, P4581, DOI 10.1091/mbc.E03-04-0222; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Janez A, 2000, J BIOL CHEM, V275, P26870; Jeffries TR, 2004, MOL BIOL CELL, V15, P2652, DOI 10.1091/mbc.E03-10-0732; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Meijer HJG, 1999, PLANTA, V208, P294; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Rudge SA, 2004, MOL BIOL CELL, V15, P24, DOI 10.1091/mbc.E03-05-0297; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2004, MOL CELL BIOL, V24, P10437, DOI 10.1128/MCB.24.23.10437-10447.2004; Sbrissa D, 2002, J BIOL CHEM, V277, P47276, DOI 10.1074/jbc.M207576200; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Shisheva A, 2003, FRONT BIOSCI-LANDMRK, V8, pS945, DOI 10.2741/1101; SHISHEVA A, 2002, FRONT ANIM DIAB RES, V3, P189; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Weisman LS, 2003, ANNU REV GENET, V37, P435, DOI 10.1146/annurev.genet.37.050203.103207; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Whitley P, 2003, J BIOL CHEM, V278, P38786, DOI 10.1074/jbc.M306864200; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Zonia L, 2004, PLANT PHYSIOL, V134, P813, DOI 10.1104/pp.103.029454	47	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7883	7889		10.1074/jbc.M412729200	http://dx.doi.org/10.1074/jbc.M412729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15546865	hybrid			2022-12-25	WOS:000227395700056
J	Jeppesen, MG; Navratil, T; Spremulli, LL; Nyborg, J				Jeppesen, MG; Navratil, T; Spremulli, LL; Nyborg, J			Crystal structure of the bovine mitochondrial elongation factor Tu(.)Ts complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EF-TU; GUANINE-NUCLEOTIDE EXCHANGE; COILED-COIL MOTIF; FACTOR-TS; ESCHERICHIA-COLI; PROTEIN-BIOSYNTHESIS; QBETA REPLICASE; THERMUS-THERMOPHILUS; ANGSTROM RESOLUTION; KINETIC MECHANISM	The three-dimensional structure of the bovine mitochondrial elongation factor (EF)-Tu-Ts complex (EF-Tu(mt).Ts-mt) has been determined to 2.2-Angstrom resolution using the multi-wavelength anomalous dispersion experimental method. This complex provides the first insight into the structure of EF-Ts-mt.. EF-Ts-mt is similar to Escherichia coli and Thermus thermophilus EF-Ts in the amino-terminal domain. However, the structure of EF-Ts-mt deviates considerably in the core domain with a five-stranded beta-sheet forming a portion of subdomain N of the core. In E. coli EF-Ts, this region is composed of a three-stranded sheet. The coiled-coil domain of the E. coli EF-Ts is largely eroded in EF-Ts-mt, in which it consists of a large loop packed against subdomain C of the core. The conformation of bovine EF-Tu(mt) in complex with EF-Ts-mt is distinct from its conformation in the EF-Tu(mt)-GDP complex. When domain III of bovine EF-Tu(mt).GDP is superimposed on domain III of EF-Tu(mt) in the EF-Tu(mt).Ts-mt complex, helix B from domain I is also almost superimposed. However, the rest of domain I is rotated relative to this helix toward domain 11, which itself is rotated toward domain I relative to domain III. Extensive contacts are observed between the amino-terminal domain of EF-Tsmt and domain I of EF-Tu(mt). Furthermore, the conserved TDFV sequence of EF-Tsmt also contacts domain I with the side chain of Asp (139) contacting helix B of EF-Tu(mt) and inserting the side chain of Phe(140) between helices B and C. The structure of the EF-Tu(mt).Ts-mt complex provides new insights into the nucleotide exchange mechanism and provides a framework for explaining much of the mutational data obtained for this complex.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	Aarhus University; University of North Carolina; University of North Carolina Chapel Hill	Nyborg, J (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10 C, DK-8000 Aarhus C, Denmark.	jnb@imsb.au.dk			NIGMS NIH HHS [GM32734-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2000, J MOL BIOL, V297, P421, DOI 10.1006/jmbi.2000.3564; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clark BFC, 1997, CURR OPIN STRUC BIOL, V7, P110, DOI 10.1016/S0959-440X(97)80014-0; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; DeLano WL, 2002, PYMOL USERS MANUAL; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ECCLESTON JF, 1988, J BIOL CHEM, V263, P4668; FOX TD, 1987, ANNU REV GENET, V21, P67, DOI 10.1146/annurev.ge.21.120187.000435; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Gromadski KB, 2002, BIOCHEMISTRY-US, V41, P162, DOI 10.1021/bi015712w; Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047; Jiang YX, 1996, BIOCHEMISTRY-US, V35, P10269, DOI 10.1021/bi960918w; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMEN R, 1970, NATURE, V228, P527, DOI 10.1038/228527a0; Karring H, 2004, J BIOL CHEM, V279, P1878, DOI 10.1074/jbc.M306605200; Karring H, 2003, EUR J BIOCHEM, V270, P4294, DOI 10.1046/j.1432-1033.2003.03822.x; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; O'Brien TW, 2002, GENE, V286, P73, DOI 10.1016/S0378-1119(01)00808-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Scheffler IE, 1999, MITOCHONDRIA; Song HW, 1999, J MOL BIOL, V285, P1245, DOI 10.1006/jmbi.1998.2387; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Spremulli LL, 2004, PROG NUCLEIC ACID RE, V77, P211, DOI 10.1016/S0079-6603(04)77006-3; WAHBA AJ, 1974, J BIOL CHEM, V249, P3314; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243; Zhang YL, 1998, J BIOL CHEM, V273, P28142, DOI 10.1074/jbc.273.43.28142; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2; Zhang YL, 1998, J BIOL CHEM, V273, P4556, DOI 10.1074/jbc.273.8.4556	40	39	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5071	5081		10.1074/jbc.M411782200	http://dx.doi.org/10.1074/jbc.M411782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557323	Green Published, hybrid			2022-12-25	WOS:000227096600129
J	Mould, AP; Travis, MA; Barton, SJ; Hamilton, JA; Askari, JA; Craig, SE; MacDonald, PR; Kammerer, RA; Buckley, PA; Humphries, MJ				Mould, AP; Travis, MA; Barton, SJ; Hamilton, JA; Askari, JA; Craig, SE; MacDonald, PR; Kammerer, RA; Buckley, PA; Humphries, MJ			Evidence that monoclonal antibodies directed against the integrin beta subunit plexin/semaphorin/integrin domain stimulate function by inducing receptor extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-LIKE DOMAIN; BINDING-SITES; CONFORMATIONAL REGULATION; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; LIGAND-BINDING; ALPHA-SUBUNIT; PSI DOMAIN; ACTIVATION	The overall structure of integrins is that of a ligand-binding head connected to two long legs. The legs can exhibit a pronounced bend at the "knees," and it has been proposed that the legs undergo a dramatic straightening when integrins transit from a low affinity to a high affinity state. The knee region contains domains from both a and beta subunits, including the N-terminal plexin/semaphorin/integrin (PSI) domain of the beta subunit. The role played by the knee domains in the regulation of integrinligand binding is uncertain. Here we show that: (i) monoclonal antibodies (mAbs) N29 and SE3 have epitopes in the beta(1) subunit PSI domain and stimulate ligand binding to alpha(5)beta(1); (ii) N29 and SE3 cause long range conformational changes that alter the ligand binding activity of the head region; (iii) the stimulatory action of these mAbs is dependent on the calf-1 domain, which forms part of the a subunit knee; and (iv) the epitopes of 8E3 and N29 map close to the extreme N terminus of the PSI and are likely to lie on the side of this domain that faces the a subunit. Taken together, our data suggest that the binding of these mAbs results in a levering apart of the PSI and calf-1 domains, and thereby causes the a and beta subunit knees to separate. Several major inferences can be drawn from our findings. First, the PSI domain appears to form part of an interface with the a subunit that normally restrains the integrin in a bent state. Second, the PSI domain is important for the transduction of conformational changes from the knee to head. Third, unbending is likely to provide a general mechanism for control of integrin-ligand recognition.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	paul.mould@manchester.ac.uk	Travis, Mark/E-9643-2015	Travis, Mark/0000-0002-8485-2272; Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967; Kammerer, Richard/0000-0003-4570-5197	Wellcome Trust [074941] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Antipenko A, 2003, NEURON, V39, P589, DOI 10.1016/S0896-6273(03)00502-6; Aster RH, 2004, SEMIN THROMB HEMOST, V30, P569, DOI 10.1055/s-2004-835677; Barton SJ, 2004, BIOCHEM J, V380, P401, DOI 10.1042/BJ20031973; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Chigaev A, 2003, BIOPHYS J, V85, P3951, DOI 10.1016/S0006-3495(03)74809-7; Chigaev A, 2004, J BIOL CHEM, V279, P32435, DOI 10.1074/jbc.M404387200; CLARK K, 2005, IN PRESS J CELL SCI; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Humphries MJ, 2003, CURR OPIN STRUC BIOL, V13, P236, DOI 10.1016/S0959-440X(03)00035-6; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kozlov G, 2004, BIOCHEM BIOPH RES CO, V321, P234, DOI 10.1016/j.bbrc.2004.06.132; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 2003, J BIOL CHEM, V278, P51622, DOI 10.1074/jbc.M306655200; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; Ni HY, 1998, CELL ADHES COMMUN, V5, P257, DOI 10.3109/15419069809040296; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Travis MA, 2004, FEBS LETT, V569, P185, DOI 10.1016/j.febslet.2004.04.099; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Tsuchida J, 1998, J CELL SCI, V111, P1759; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wilkins JA, 1996, J BIOL CHEM, V271, P3046, DOI 10.1074/jbc.271.6.3046; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xie C, 2004, P NATL ACAD SCI USA, V101, P15422, DOI 10.1073/pnas.0406680101; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; Yang W, 2004, P NATL ACAD SCI USA, V101, P2333, DOI 10.1073/pnas.0307291101; Zang Q, 2001, J BIOL CHEM, V276, P6922, DOI 10.1074/jbc.M005868200	50	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4238	4246		10.1074/jbc.M412240200	http://dx.doi.org/10.1074/jbc.M412240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557320	Green Accepted, hybrid			2022-12-25	WOS:000227096600031
J	Blaudeck, N; Kreutzenbeck, P; Muller, M; Sprenger, GA; Freudl, R				Blaudeck, N; Kreutzenbeck, P; Muller, M; Sprenger, GA; Freudl, R			Isolation and characterization of bifunctional Escherichia coli TatA mutant proteins that allow efficient Tat-dependent protein translocation in the absence of TatB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE SIGNAL PEPTIDE; SEC-INDEPENDENT PROTEIN; MALTOSE-BINDING PROTEIN; BACILLUS-SUBTILIS; PATHWAY; MEMBRANE; EXPORT; SECRETION; SYSTEM; COMPONENTS	In Escherichia coli, the Tat system promotes the membrane translocation of a subset of exported proteins across the cytoplasmic membrane. Four genes (tatA, tatB, tatC, and tatE) have been identified that encode the components of the E. coli Tat translocation apparatus. Whereas TatA and TatE can functionally substitute for each other, the TatB and the TatC proteins have been shown to perform distinct functions. In contrast to Tat systems of the ABC (E) type found in E. coli and many other bacteria, some microorganisms possess a TatAC-type translocase that consists of TatA and TatC only, suggesting that, in these systems, TatB is not required or that one of the remaining components (TatA or TatC) additionally takes over the TatB function. We have addressed the molecular basis for the difference in subunit composition between TatABC(E) and TatAC-type systems by using a genetic approach. A plasmid-encoded E. coli minimal Tat translocase consisting solely of TatA and TatC was shown to mediate a low level translocation of a sensitive Tat-dependent reporter protein. Suppressor mutations in the minimal Tat translocase were isolated that compensate for the absence of TatB and that showed substantial increases in translocation activities. All of the mutations mapped to the extreme amino-terminal domain of TatA. No mutations affecting TatC were identified. These results suggest that in TatAC-type systems, the TatA protein represents a bifunctional component fulfilling both the TatA and TatB functions. Furthermore, our results indicate that the structure of the amino-terminal domain of TatA is decisive for whether or not TatB is required.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	Helmholtz Association; Research Center Julich; University of Freiburg	Freudl, R (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	r.freudl@fz-juelich.de	Freudl, Roland/N-4179-2017; Sprenger, Georg A./E-2384-2011	Freudl, Roland/0000-0003-0743-1279; Sprenger, Georg A./0000-0002-7879-8978				Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Blaudeck N, 2003, J BACTERIOL, V185, P2811, DOI 10.1128/JB.185.9.2811-2819.2003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; Dassa E, 1997, RES MICROBIOL, V148, P389, DOI 10.1016/S0923-2508(97)83869-7; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; de Leeuw E, 2002, J MOL BIOL, V322, P1135, DOI 10.1016/S0022-2836(02)00820-3; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; DUPLAY P, 1984, J BIOL CHEM, V259, P606; Halbig D, 1999, EUR J BIOCHEM, V263, P543, DOI 10.1046/j.1432-1327.1999.00536.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hicks MG, 2003, FEBS LETT, V539, P61, DOI 10.1016/S0014-5793(03)00198-4; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; Ize B, 2002, J MOL BIOL, V317, P327, DOI 10.1006/jmbi.2002.5431; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Jongbloed JDH, 2002, J BIOL CHEM, V277, P44068, DOI 10.1074/jbc.M203191200; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Lee PA, 2002, J BACTERIOL, V184, P5871, DOI 10.1128/JB.184.21.5871-5879.2002; Miller J.H., 1972, EXPT MOL GENETICS; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; Palmer T, 2003, MICROBIOL-SGM, V149, P547, DOI 10.1099/mic.0.25900-0; Pop O, 2002, J BIOL CHEM, V277, P3268, DOI 10.1074/jbc.M110829200; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Schaerlaekens K, 2004, MICROBIOL-SGM, V150, P21, DOI 10.1099/mic.0.26684-0; SPRENGER GA, 1995, J BACTERIOL, V177, P5930, DOI 10.1128/jb.177.20.5930-5936.1995; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4	38	75	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3426	3432		10.1074/jbc.M411210200	http://dx.doi.org/10.1074/jbc.M411210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557327	hybrid, Green Published			2022-12-25	WOS:000226983900037
J	Jansson, A; Koskiniemi, H; Erola, A; Wang, J; Mantsala, P; Schneider, G; Niemi, J				Jansson, A; Koskiniemi, H; Erola, A; Wang, J; Mantsala, P; Schneider, G; Niemi, J			Aclacinomycin 10-hydroxylase is a novel substrate-assisted hydroxylase requiring S-adenosyl-L-methionine as cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRACYCLINE BIOSYNTHESIS; STREPTOMYCES-PURPURASCENS; DAUNORUBICIN BIOSYNTHESIS; CRYSTAL-STRUCTURE; CLONING; GENES; ACLACINOMYCIN-10-HYDROXYLASE; METHYLTRANSFERASE; EXPRESSION; ADENOSYLMETHIONINE	Aclacinomycin 10-hydroxylase is a methyltransferase homologue that catalyzes a S-adenosyl-L-methionine (AdoMet)-dependent hydroxylation of the C-10 carbon atom of 15-demethoxy-epsilon-rhodomycin, a step in the biosynthesis of the polyketide antibiotic beta-rhodomycin. S-Adenosyl-L-homocysteine is an inhibitor of the enzyme, whereas the AdoMet analogue sinefungin can act as cofactor, indicating that a positive charge is required for catalysis. O-18(2) experiments show that the hydroxyl group is derived from molecular oxygen. The reaction further requires thiol reagents such as glutathione or dithiothreitol. Incubation of the enzyme with substrate in the absence of reductant leads to the accumulation of an intermediate with a molecular mass consistent with a perhydroxy compound. This intermediate is turned into product upon addition of glutathione. The crystal structure of an abortive enzyme-AdoMet product ternary complex reveals large conformational changes consisting of a domain rotation leading to active site closure upon binding of the anthracycline ligand. The data suggest a mechanism where decarboxylation of the substrate results in the formation of a carbanion intermediate, which is stabilized by resonance through the aromatic ring system of the anthracycline substrate. The delocalization of the electrons is facilitated by the positive charge of the cofactor AdoMet. The activation of oxygen and formation of a hydroxyperoxide intermediate occurs in a manner similar to that observed in flavoenzymes. Aclacinomycin-10-hydroxylase is the first example of a AdoMet-dependent hydroxylation reaction, a novel function for this cofactor. The enzyme lacks methyltransferase activity due to the positioning of the AdoMet methyl group unfavorable for a S(N)2-type methyl transfer to the substrate.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Turku Univ, Dept Biochem & Food Chem, FIN-20014 Turku, Finland	Karolinska Institutet; University of Turku	Niemi, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jarnie@utu.fi		Schneider, Gunter/0000-0003-0622-5713				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTEL PL, 1990, J BACTERIOL, V172, P4816, DOI 10.1128/jb.172.9.4816-4826.1990; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; Fujii I, 1997, CHEM REV, V97, P2511, DOI 10.1021/cr960019d; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jansson A, 2004, J BIOL CHEM, V279, P41149, DOI 10.1074/jbc.M407081200; Jansson A, 2003, J MOL BIOL, V334, P269, DOI 10.1016/j.jmb.2003.09.061; Jansson A, 2003, ACTA CRYSTALLOGR D, V59, P1637, DOI 10.1107/S0907444903014100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Larsen AK, 2003, PHARMACOL THERAPEUT, V99, P167, DOI 10.1016/S0163-7258(03)00058-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Madduri K, 1998, NAT BIOTECHNOL, V16, P69, DOI 10.1038/nbt0198-69; MADDURI K, 1993, J BACTERIOL, V175, P3900, DOI 10.1128/JB.175.12.3900-3904.1993; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NIEMI J, 1995, J BACTERIOL, V177, P2942, DOI 10.1128/jb.177.10.2942-2945.1995; NIEMI J, 1994, MICROBIOL-UK, V140, P1351, DOI 10.1099/00221287-140-6-1351; OTTEN SL, 1990, J BACTERIOL, V172, P3427, DOI 10.1128/jb.172.6.3427-3434.1990; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Raty K, 2002, GENE, V293, P115, DOI 10.1016/S0378-1119(02)00699-6; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; STROHL WR, 1997, BIOTECHNOLOGY ANTIBI, P577; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torkkell S, 2001, MOL GENET GENOMICS, V266, P276; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Walczak RJ, 1999, J BACTERIOL, V181, P298, DOI 10.1128/JB.181.1.298-304.1999; Wang W, 2001, J CHROMATOGR B, V762, P59, DOI 10.1016/S0378-4347(01)00341-3; Wang YL, 2000, BBA-PROTEIN STRUCT M, V1480, P191, DOI 10.1016/S0167-4838(00)00089-3; Wang YL, 2002, FEMS MICROBIOL LETT, V208, P117, DOI 10.1016/S0378-1097(01)00591-2; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	35	36	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3636	3644		10.1074/jbc.M412095200	http://dx.doi.org/10.1074/jbc.M412095200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548527	hybrid			2022-12-25	WOS:000226983900063
J	Sobczak, K; Krzyzosiak, WJ				Sobczak, K; Krzyzosiak, WJ			CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RNA SECONDARY STRUCTURE; FRAGILE-X PREMUTATION; TRINUCLEOTIDE REPEAT; NEUROLOGICAL DISEASES; EXPANSION; GENE; INSTABILITY; POLYGLUTAMINE; LOCUS	Spinocerebellar ataxia type 2 (SCA2), one of the hereditary human neurodegenerative disorders, is caused by the expansion of the CAG tandem repeats in the translated sequence of the SCA2 gene. In a normal population the CAG repeat is polymorphic not only in length but also in the number and localization of its CAA interruptions. The aim of this study was to determine the structure of the repeat region in the normal and mutant SCA2 transcripts and to reveal the structural basis of its normal function and dysfunction. We show here that the properties of the CAA interruptions are major determinants of the CAG repeat folding in the normal SCA2 transcripts. We also show that the uninterrupted repeats in mutant transcripts form slippery hairpins, whose length is further reduced by the base pairing of the repeat portion with a specific flanking sequence. The structural organization of the repeat interruption systems present in other human transcripts, such as SCA1, TBP, FOXP2, and MAAM2, are also discussed.	Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, PL-61704 Poznan, Poland	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Krzyzosiak, WJ (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Noskowskiego 12-14, PL-61704 Poznan, Poland.	wlodkrzy@ibch.poznan.pl		Sobczak, Krzysztof/0000-0001-8352-9812				Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Broude NE, 2003, EXPERT REV MOL DIAGN, V3, P269, DOI 10.1586/14737159.3.3.269; Choudhry S, 2001, HUM MOL GENET, V10, P2437, DOI 10.1093/hmg/10.21.2437; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; Ciesiolka J, 1998, J MOL BIOL, V275, P211, DOI 10.1006/jmbi.1997.1462; Costanzi-Porrini S, 2000, NEUROLOGY, V54, P491, DOI 10.1212/WNL.54.2.491; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Furtado S, 2002, NEUROLOGY, V59, P1625, DOI 10.1212/01.WNL.0000035625.19871.DC; GIEGE R, 2001, RNA, P71; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; Hagerman PJ, 2004, AM J HUM GENET, V74, P805, DOI 10.1086/386296; Holmes SE, 1999, NAT GENET, V23, P391, DOI 10.1038/70493; Hussey J, 2002, GENET TEST, V6, P217, DOI 10.1089/109065702761403397; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Jasinska A, 2004, FEBS LETT, V567, P136, DOI 10.1016/j.febslet.2004.03.109; Jasinska A, 2003, NUCLEIC ACIDS RES, V31, P5463, DOI 10.1093/nar/gkg767; Jin P, 2003, NEURON, V39, P739, DOI 10.1016/S0896-6273(03)00533-6; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; Krol J, 2004, J BIOL CHEM, V279, P42230, DOI 10.1074/jbc.M404931200; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; La Spada Albert R, 2004, Nat Genet, V36, P667; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, J BIOL CHEM, V272, P27513, DOI 10.1074/jbc.272.44.27513; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Matsuura T, 2000, NAT GENET, V26, P191, DOI 10.1038/79911; McLaughlin BA, 1996, AM J HUM GENET, V59, P561; Michlewski G, 2004, J MOL BIOL, V340, P665, DOI 10.1016/j.jmb.2004.05.021; Miller EK, 2000, IEEE POTENTIALS, V19, P9; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Napierala M, 1997, J BIOL CHEM, V272, P31079, DOI 10.1074/jbc.272.49.31079; Orr HT, 2004, TRENDS NEUROSCI, V27, P233, DOI 10.1016/j.tins.2004.03.003; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Peel AL, 2001, HUM MOL GENET, V10, P1531, DOI 10.1093/hmg/10.15.1531; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Ranum LPW, 2002, CURR OPIN GENET DEV, V12, P266, DOI 10.1016/S0959-437X(02)00297-6; Richards RI, 1997, TRENDS BIOCHEM SCI, V22, P432, DOI 10.1016/S0968-0004(97)01108-0; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Sobczak K, 2004, J BIOL CHEM, V279, P41563, DOI 10.1074/jbc.M405130200; Sobczak K, 2004, HUM MUTAT, V24, P236, DOI 10.1002/humu.20075; Sobczak K, 2003, NUCLEIC ACIDS RES, V31, P5469, DOI 10.1093/nar/gkg766; Tapscott SJ, 2001, SCIENCE, V293, P816, DOI 10.1126/science.1063517; Tian B, 2000, RNA, V6, P79, DOI 10.1017/S1355838200991544; Wrzesinski J, 2000, NUCLEIC ACIDS RES, V28, P1785, DOI 10.1093/nar/28.8.1785; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Zoghbi HY, 1996, NAT GENET, V14, P237, DOI 10.1038/ng1196-237	51	91	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3898	3910		10.1074/jbc.M409984200	http://dx.doi.org/10.1074/jbc.M409984200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15533937	hybrid			2022-12-25	WOS:000226983900092
J	Lanciault, C; Champoux, JJ				Lanciault, C; Champoux, JJ			Effects of unpaired nucleotides within HIV-1 genomic secondary structures on pausing and strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STRONG STOP TRANSFER; RNASE-H ACTIVITY; REVERSE-TRANSCRIPTASE; NUCLEOCAPSID PROTEIN; RETROVIRAL RECOMBINATION; IN-VIVO; DNA-SYNTHESIS; REPEAT DELETION; HIGH-PREVALENCE	Reverse transcriptase-mediated RNA displacement synthesis is required for DNA polymerization through the base-paired stem portions of secondary structures present in retroviral genomes. These regions of RNA duplex often possess single unpaired nucleotides, or "bulges," that disrupt contiguous base pairing. By using well defined secondary structures from the human immunodeficiency virus, type 1 (HIV-1), genome, we demonstrate that removal of these bulges either by deletion or by introducing a complementary base on the opposing strand results in increased pausing at specific positions within the RNA duplex. We also show that the HIV-1 nucleocapsid protein can increase synthesis through the pause sites but not as efficiently as when a bulge residue is present. Finally, we demonstrate that removing a bulge increases the proportion of strand transfer events to an acceptor template that occur prior to complete replication of a donor template secondary structure. Together our data suggest a role for bulge nucleotides in enhancing synthesis through stable secondary structures and reducing strand transfer.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu						Adje-Toure C, 2003, JAIDS-J ACQ IMM DEF, V34, P111, DOI 10.1097/00126334-200309010-00016; Andersen ES, 2003, J VIROL, V77, P3020, DOI 10.1128/JVI.77.5.3020-3030.2003; Anderson JA, 2000, J VIROL, V74, P6953, DOI 10.1128/JVI.74.15.6953-6963.2000; Anderson JA, 1998, J VIROL, V72, P1186, DOI 10.1128/JVI.72.2.1186-1194.1998; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P940, DOI 10.1093/nar/25.5.940; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Brincat JL, 2002, J VIROL, V76, P88, DOI 10.1128/JVI.76.1.88-95.2002; CARLONI G, 1980, P NATL ACAD SCI-BIOL, V77, P3014, DOI 10.1073/pnas.77.5.3014; Castro E, 2003, JAIDS-J ACQ IMM DEF, V32, P338, DOI 10.1097/00126334-200303010-00015; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; Chen Y, 2003, J BIOL CHEM, V278, P8006, DOI 10.1074/jbc.M210959200; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; Cornelissen M, 2000, J GEN VIROL, V81, P515, DOI 10.1099/0022-1317-81-2-515; Derebail SS, 2004, J BIOL CHEM, V279, P47446, DOI 10.1074/jbc.M408927200; Derebail SS, 2003, J BIOL CHEM, V278, P15702, DOI 10.1074/jbc.M211701200; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DESTEFANO JJ, 1994, BBA-GENE STRUCT EXPR, V1219, P380, DOI 10.1016/0167-4781(94)90062-0; Diaz L, 1996, NUCLEIC ACIDS RES, V24, P3086, DOI 10.1093/nar/24.15.3086; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; Drummond JE, 1997, AIDS RES HUM RETROV, V13, P533, DOI 10.1089/aid.1997.13.533; Duch M, 2004, NUCLEIC ACIDS RES, V32, P2039, DOI 10.1093/nar/gkh513; Galetto R, 2004, J BIOL CHEM, V279, P36625, DOI 10.1074/jbc.M405476200; Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Golinelli MP, 2003, BIOCHEMISTRY-US, V42, P8153, DOI 10.1021/bi027039w; Golinelli MP, 2002, VIROLOGY, V294, P122, DOI 10.1006/viro.2001.1322; HARRICH D, 1995, J VIROL, V69, P4906, DOI 10.1128/JVI.69.8.4906-4913.1995; HASELTINE WA, 1976, ICN UCLA S MOLECULAR, V4, P175; Hoelscher M, 2002, AIDS, V16, P2055, DOI 10.1097/00002030-200210180-00011; HOWELL RM, 1991, AIDS RES HUM RETROV, V7, P869, DOI 10.1089/aid.1991.7.869; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Hunter E, 1978, Curr Top Microbiol Immunol, V79, P295; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; JUNGHANS RP, 1982, CELL, V30, P53, DOI 10.1016/0092-8674(82)90011-3; KELLAM P, 1995, J VIROL, V69, P669, DOI 10.1128/JVI.69.2.669-674.1995; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; Klasens BIF, 1999, NUCLEIC ACIDS RES, V27, P446, DOI 10.1093/nar/27.2.446; KLAVER B, 1994, EMBO J, V13, P2650, DOI 10.1002/j.1460-2075.1994.tb06555.x; LAM WC, 1994, BIOCHEMISTRY-US, V33, P10693, DOI 10.1021/bi00201a017; Lanciault C, 2004, J BIOL CHEM, V279, P32252, DOI 10.1074/jbc.M404117200; Li T, 2000, J VIROL, V74, P7646, DOI 10.1128/JVI.74.16.7646-7650.2000; LINIAL M, 1979, J VIROL, V31, P257, DOI 10.1128/JVI.31.1.257-260.1979; Magiorkinis G, 2003, J GEN VIROL, V84, P2715, DOI 10.1099/vir.0.19180-0; Malim MH, 2001, CELL, V104, P469, DOI 10.1016/S0092-8674(01)00234-3; McCutchan FE, 1999, VIROLOGY, V254, P226, DOI 10.1006/viro.1998.9505; Mikkelsen JG, 2004, NUCLEIC ACIDS RES, V32, P102, DOI 10.1093/nar/gkh159; Moumen A, 2003, J BIOL CHEM, V278, P15973, DOI 10.1074/jbc.M212306200; Moumen A, 2001, NUCLEIC ACIDS RES, V29, P3814, DOI 10.1093/nar/29.18.3814; Moutouh L, 1996, P NATL ACAD SCI USA, V93, P6106, DOI 10.1073/pnas.93.12.6106; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; Palaniappan C, 1996, J BIOL CHEM, V271, P22331, DOI 10.1074/jbc.271.37.22331; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Perrin L, 2003, LANCET INFECT DIS, V3, P22, DOI 10.1016/S1473-3099(03)00484-5; Pfeiffer JK, 1999, J VIROL, V73, P8441, DOI 10.1128/JVI.73.10.8441-8447.1999; Pfeiffer JK, 2000, J VIROL, V74, P9629, DOI 10.1128/JVI.74.20.9629-9636.2000; Pollakis G, 2003, AIDS RES HUM RETROV, V19, P999, DOI 10.1089/088922203322588350; Quinones-Mateu ME, 2002, J VIROL, V76, P9600, DOI 10.1128/JVI.76.19.9600-9613.2002; Rhodes T, 2003, J VIROL, V77, P11193, DOI 10.1128/JVI.77.20.11193-11200.2003; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; ROTHBLUM CJ, 1995, J VIROL, V69, P5156, DOI 10.1128/JVI.69.8.5156-5163.1995; Rounseville MP, 1996, VIROLOGY, V216, P411, DOI 10.1006/viro.1996.0077; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; Takebe Y, 2003, AIDS, V17, P2077, DOI 10.1097/00002030-200309260-00009; Takehisa J, 1999, J VIROL, V73, P6810, DOI 10.1128/JVI.73.8.6810-6820.1999; Thomson MM, 2002, LANCET INFECT DIS, V2, P461, DOI 10.1016/S1473-3099(02)00343-2; Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8; Wilbe K, 2002, AIDS RES HUM RETROV, V18, P849, DOI 10.1089/08892220260190326; Wooley DP, 1997, J VIROL, V71, P9650, DOI 10.1128/JVI.71.12.9650-9653.1997; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; YOU JC, 1993, J BIOL CHEM, V268, P16519; Yu H, 1998, J BIOL CHEM, V273, P28384, DOI 10.1074/jbc.273.43.28384; ZHANG JY, 1994, J VIROL, V68, P2409, DOI 10.1128/JVI.68.4.2409-2414.1994; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784; Zhang JY, 2000, J VIROL, V74, P2313, DOI 10.1128/JVI.74.5.2313-2322.2000; ZHANG JY, 1993, J VIROL, V67, P1747, DOI 10.1128/JVI.67.4.1747-1751.1993; Zhang WH, 2002, J VIROL, V76, P7473, DOI 10.1128/JVI.76.15.7473-7484.2002; Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	95	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2413	2423		10.1074/jbc.M410718200	http://dx.doi.org/10.1074/jbc.M410718200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15542863	hybrid			2022-12-25	WOS:000226449100006
J	Cao, S; Fernandez-Zapico, ME; Jin, DZ; Puri, V; Cook, TA; Lerman, LO; Zhu, XY; Urrutia, R; Shah, V				Cao, S; Fernandez-Zapico, ME; Jin, DZ; Puri, V; Cook, TA; Lerman, LO; Zhu, XY; Urrutia, R; Shah, V			KLF11-mediated repression antagonizes Sp1/Sterol-responsive element-binding protein-induced transcriptional activation of caveolin-1 in response to cholesterol signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; LIPOPROTEIN RECEPTOR GENE; INTRACELLULAR CHOLESTEROL; GROWTH-REGULATION; MAP KINASE; CELL-LINES; IN-VITRO; SP1; EXPRESSION; PROMOTER	Cholesterol is a potent regulator of gene expression via a canonical pathway co-regulated by SREBP and Sp1. Here we establish the caveolin-1 gene promoter as a cell type-specific model for SREBP/Sp1 regulation whereby lipoprotein cholesterol depletion activates caveolin-1 transcription in endothelial type cells, but not in fibroblasts, both in vitro and in vivo. By extending this model, we describe a novel pathway distinct from the prototypical SREBP/Sp1 regulatory loop involving the Sp1-like protein, KLF11. Through a combination of RNA interference, chromatin immunoprecipitation assays, electrophoretic mobility shift assays, and reporter assays, we demonstrate that in the presence of cholesterol, KLF11 acts as a dominant repressor of the caveolin-1 gene. Mechanistically, cholesterol depletion results in displacement of KLF11 from an Sp1 site flanking an SRE, indicating that activation by SREBP/Sp1 requires antagonism of KLF11 repression. The displacement of KLF11 results from both a down-regulation of its expression and competition by Sp1 for DNA binding. Therefore, these studies identify a novel pathway whereby KLF11 repression is coordinated with Sp1/SREBP activation of cholesterol-dependent gene expression in a cell type-specific manner and outline the mechanisms by which these functions are achieved.	Mayo Clin Coll Med, Gastroenterol Res Unit, Rochester, MN 55905 USA; Mayo Clin Coll Med, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin Coll Med, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin Coll Med, Dept Mol Biol, Rochester, MN 55905 USA; Mayo Clin Coll Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Shah, V (corresponding author), Mayo Clin & Mayo Fdn, GI Res Unit, A1 2-435,200 1st St SW, Rochester, MN 55905 USA.	shah.vijay@mayo.edu	Lerman, Lilach/M-4962-2017	Cook, Tiffany/0000-0002-3100-5248	NIDDK NIH HHS [R01 DK052913, R01 DK052913-06, DK 52913] Funding Source: Medline; PHS HHS [R01-59388, R01-59615] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, R56DK052913] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cao S, 2003, J BIOL CHEM, V278, P5894, DOI 10.1074/jbc.M212546200; Cao S, 2001, J BIOL CHEM, V276, P14249, DOI 10.1074/jbc.M006258200; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fernandez-Zapico ME, 2003, EMBO J, V22, P4748, DOI 10.1093/emboj/cdg470; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fra AM, 2000, GENE, V243, P75, DOI 10.1016/S0378-1119(99)00559-4; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Herrmann J, 2003, FASEB J, V17, P1730, DOI 10.1096/fj.02-0841fje; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Kathuria H, 2004, J BIOL CHEM, V279, P30028, DOI 10.1074/jbc.M402236200; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Liu Y, 2003, J BIOL CHEM, V278, P48004, DOI 10.1074/jbc.M301902200; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Ou XM, 2004, J BIOL CHEM, V279, P21021, DOI 10.1074/jbc.M312638200; Paxinou E, 2001, P NATL ACAD SCI USA, V98, P11575, DOI 10.1073/pnas.201293198; Peterson TE, 1999, BIOCHEM BIOPH RES CO, V265, P722, DOI 10.1006/bbrc.1999.1738; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Schrick JJ, 1999, GENE, V236, P185, DOI 10.1016/S0378-1119(99)00235-8; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TEALE B, 1992, J BIOL CHEM, V267, P10295; Zhang XL, 2003, J BIOL CHEM, V278, P21474, DOI 10.1074/jbc.M212098200	43	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1901	1910		10.1074/jbc.M407941200	http://dx.doi.org/10.1074/jbc.M407941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15531587	hybrid			2022-12-25	WOS:000226341700024
J	Gerhard, R; Tatge, H; Genth, H; Thum, T; Borlak, J; Fritz, G; Just, I				Gerhard, R; Tatge, H; Genth, H; Thum, T; Borlak, J; Fritz, G; Just, I			Clostridium difficile toxin A induces expression of the stress-induced early gene product RhoB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; CELL-CYCLE PROGRESSION; SORDELLII LETHAL TOXIN; GTP-BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; ACTIN CYTOSKELETON; FAMILY GTPASES; HA-RAS; TRANSFORMATION; ACTIVATION	Clostridium difficile toxin A monoglucosylates the Rho family GTPases Rho, Rac, and Cdc42. Glucosylation leads to the functional inactivation of Rho GTPases and causes disruption of the actin cytoskeleton. A cDNA microarray revealed the immediate early gene rhoB as the gene that was predominantly up-regulated in colonic CaCo-2 cells after treatment with toxin A. This toxin A effect was also detectable in epithelial cells such as HT29 and Madin-Darby canine kidney cells, as well as NIH 3T3 fibroblasts. The expression of RhoB was time-dependent and correlated with the morphological changes of cells. The up-regulation of RhoB was approximately 15-fold and was based on the de novo synthesis of the GTPase because cycloheximide completely inhibited the toxin A effect. After 8 h, a steady state was reached, with no further increase in RhoB. The p38 MAPK inhibitor SB202190 reduced the expression of RhoB, indicating a participation of the p38 MAPK in this stress response. Surprisingly, newly formed RhoB protein was only partially glucosylated by toxin A, sparing a pool of potentially active RhoB, as checked by sequential C3(bot)-catalyzed ADP-ribosylation. A pull-down assay in fact revealed a significant amount of active RhoB in toxin A-treated cells that was not present in control cells. We demonstrate for the first time that toxin A has not only the property to inactivate the GTPases RhoA, Rac1, and Cdc42 by glucosylation, but it also has the property to generate active RhoB that likely contributes to the overall picture of toxin treatment.	Hannover Med Sch, Inst Toxikol, D-30625 Hannover, Germany; Fraunhofer Gessell, Inst Toxicol & Expt Med, D-30625 Hannover, Germany; Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany	Hannover Medical School; Johannes Gutenberg University of Mainz	Gerhard, R (corresponding author), Hannover Med Sch, Inst Toxikol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerhard.ralf@mh-hannover.de	Genth, Harald/HHS-0118-2022	Thum, Thomas/0000-0003-4360-1511				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Ahnert-Hilger G, 2004, J NEUROCHEM, V90, P9, DOI 10.1111/j.1471-4159.2004.02475.x; AKTORIES K, 1997, BACTERIAL TOXINS TOO, P159; Bernhard EJ, 2003, CANCER BIOL THER, V2, P281, DOI 10.4161/cbt.2.3.397; Bodmer D, 2002, HEARING RES, V172, P81, DOI 10.1016/S0378-5955(02)00514-2; BORLAK J, 2002, CRUCIAL ISSUES INHAL; Burger S, 2003, BIOCHEM BIOPH RES CO, V307, P584, DOI 10.1016/S0006-291X(03)01234-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dreikhausen U, 2001, EUR J IMMUNOL, V31, P1610, DOI 10.1002/1521-4141(200105)31:5<1610::AID-IMMU1610>3.0.CO;2-5; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Esteve P, 1995, ONCOGENE, V11, P2657; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gampel A, 2002, BIOCHEM J, V366, P393, DOI 10.1042/BJ20020844; Genth H, 1999, J BIOL CHEM, V274, P29050, DOI 10.1074/jbc.274.41.29050; Geyer M, 2003, BIOCHEMISTRY-US, V42, P11951, DOI 10.1021/bi034529v; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; Hoffmann R, 2004, CELL MICROBIOL, V6, P377, DOI 10.1111/j.1462-5822.2004.00365.x; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; JIMENEZ B, 1995, ONCOGENE, V10, P811; Just I, 2001, INT J MED MICROBIOL, V291, P243, DOI 10.1078/1438-4221-00127; Just I, 2000, CURR TOP MICROBIOL, V250, P55; KRIVAN HC, 1987, INFECT IMMUN, V55, P1873, DOI 10.1128/IAI.55.8.1873-1877.1987; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Malcolm T, 2003, ONCOGENE, V22, P6142, DOI 10.1038/sj.onc.1206638; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nemeth ZH, 2004, J CELL PHYSIOL, V200, P71, DOI 10.1002/jcp.10477; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Singh SP, 2004, ENDOCRINOLOGY, V145, P1003, DOI 10.1210/en.2003-1217; Stamatakis K, 2002, J BIOL CHEM, V277, P49389, DOI 10.1074/jbc.M204049200; Vetter IR, 2000, J MOL BIOL, V301, P1091, DOI 10.1006/jmbi.2000.4045; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zeng PY, 2003, ONCOGENE, V22, P1124, DOI 10.1038/sj.onc.1206181	51	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1499	1505		10.1074/jbc.M406014200	http://dx.doi.org/10.1074/jbc.M406014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15531589	hybrid			2022-12-25	WOS:000226195200079
J	Helt, CE; Cliby, WA; Keng, PC; Bambara, RA; O'Reilly, MA				Helt, CE; Cliby, WA; Keng, PC; Bambara, RA; O'Reilly, MA			Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PHOSPHORYLATION; ACTIVATION; P53; REPLICATION; KINASE; CHK1; CHECKPOINT; BINDING; PATHWAY	The ataxia telangiectasia mutated (ATM) and ATR (ATM and Rad3-related) protein kinases exert cell cycle delay, in part, by phosphorylating Checkpoint kinase (Chk) 1, Chk2, and p53. It is well established that ATR is activated following UV light-induced DNA damage such as pyrimidine dimers and the 6-(1,2)-dihydro-2-oxo-4-pyrimidinyl-5-methyl-2,4-(1H,3H)-pyrimidinediones, whereas ATM is activated in response to double strand DNA breaks. Here we clarify the activation of these kinases in cells exposed to IR, UV, and hyperoxia, a condition of chronic oxidative stress resulting in clastogenic DNA damage. Phosphorylation on Chk1(Ser-345), Chk2(Thr-68), and p53(Ser-15) following oxidative damage by IR involved both ATM and ATR. In response to ultraviolet radiation-induced stalled replication forks, phosphorylation on Chk1 and p53 required ATR, whereas Chk2 required ATM. Cells exposed to hyperoxia exhibited growth delay in G(1), S, and G(2) that was disrupted by wortmannin. Consistent with ATM or ATR activation, hyperoxia induced wortmannin-sensitive phosphorylation of Chk1, Chk2, and p53. By using ATM- and ATR-defective cells, phosphorylation on Chk1, Chk2, and p53 was found to be ATM-dependent, whereas ATR also contributed to Chk1 phosphorylation. These data reveal activated ATM and ATR exhibit selective substrate specificity in response to different genotoxic agents.	Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Obstet Gynecol, Rochester, MN 55905 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Mayo Clinic	O'Reilly, MA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	michael_oreilly@urmc.rochester.edu			NHLBI NIH HHS [HL-58774, HL-66988, HL-67392] Funding Source: Medline; NIEHS NIH HHS [ES-07026, ES-01247] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067392, R01HL058774, T32HL066988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; Das KC, 2004, AM J PHYSIOL-LUNG C, V286, pL87, DOI 10.1152/ajplung.00203.2002; Delia D, 2000, BRIT J CANCER, V82, P1938; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; GERSCHMAN R, 1954, SCIENCE, V119, P623, DOI 10.1126/science.119.3097.623; GILLE JJP, 1993, ENVIRON MOL MUTAGEN, V22, P264, DOI 10.1002/em.2850220414; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hannan MA, 2002, CARCINOGENESIS, V23, P1617, DOI 10.1093/carcin/23.10.1617; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Helt CE, 2004, AM J PHYSIOL-LUNG C, V286, pL506, DOI 10.1152/ajplung.00243.2003; Helt CE, 2001, TOXICOL SCI, V63, P214, DOI 10.1093/toxsci/63.2.214; JOENJE H, 1985, Journal of Free Radicals in Biology and Medicine, V1, P307, DOI 10.1016/0748-5514(85)90136-9; JOENJE H, 1986, HUM GENET, V74, P438, DOI 10.1007/BF00280501; JOENJE H, 1985, LAB INVEST, V52, P420; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Liu QH, 2000, GENE DEV, V14, P1448; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Nur-E-Kamal A, 2003, J BIOL CHEM, V278, P12475, DOI 10.1074/jbc.M212915200; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Rancourt RC, 2002, J CELL PHYSIOL, V193, P26, DOI 10.1002/jcp.10146; Rancourt RC, 2001, AM J PHYSIOL-LUNG C, V280, pL617, DOI 10.1152/ajplung.2001.280.4.L617; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Roper JM, 2004, AM J PHYSIOL-LUNG C, V286, pL1045, DOI 10.1152/ajplung.00376.2003; RUECKERT RR, 1960, CANCER RES, V20, P944; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; Tyrrel R.M., 1991, OXIDATIVE STRESS OXI, P57; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vahteristo P, 2001, CANCER RES, V61, P5718; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; ZWEIER JL, 1989, FEBS LETT, V252, P12, DOI 10.1016/0014-5793(89)80881-6	48	134	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1186	1192		10.1074/jbc.M410873200	http://dx.doi.org/10.1074/jbc.M410873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15533933	hybrid			2022-12-25	WOS:000226195200040
J	Li, WL; Kessler, P; Williams, BRG				Li, WL; Kessler, P; Williams, BRG			Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia	ONCOGENE			English	Article						Wilms tumor; pro. ling; kidney morphogenesis; anaplasia	WOLF-HIRSCHHORN-SYNDROME; P53 GENE-MUTATIONS; N-MYC; MESSENGER-RNA; GROWTH-FACTOR; CELL-LINE; METANEPHRIC MESENCHYME; ONCOGENE EXPRESSION; EMBRYONIC LETHALITY; MULTIPLE-MYELOMA	Anaplasia (unfavorable histology) is associated with therapy resistance and poor prognosis of Wilms tumor, but the molecular basis for this phenotype is unclear. Here, we used a cDNA array with 9240 clones relevant to cancer biology and/or kidney development to examine the expression profiles of 54 Wilms tumors, five normal kidneys and fetal kidney. By linking genes differentially expressed between fetal kidney and Wilms tumors to kidney morphogenesis, we found that genes expressed at a higher level in Wilms tumors tend to be expressed more in uninduced metanephrogenic mesenchyme or blastema than in their differentiated structures. Conversely, genes expressed at a lower level in Wilms tumors tend to be expressed less in uninduced metanephrogenic mesenchyme or blastema. We also identified 97 clones representing 76 Unigenes or unclustered ESTs that clearly separate anaplastic Wilms tumors from tumors with favorable histology. Genes in this set provide insight into the nature of the abnormal nuclear morphology of anaplastic tumors and may facilitate identification of molecular targets to improve their responsiveness to treatment.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Li, Wenliang/A-1022-2010; Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [R01CA089279] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89279] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Alli E, 2002, CANCER RES, V62, P6864; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Bard JBL, 2002, BIOESSAYS, V24, P72, DOI 10.1002/bies.10024; BARDEESY N, 1995, CANCER RES, V55, P215; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Bates CM, 2000, DEV BIOL, V222, P317, DOI 10.1006/dbio.2000.9716; BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BONADIO JF, 1985, J CLIN ONCOL, V3, P513, DOI 10.1200/JCO.1985.3.4.513; Cabello OA, 2001, MOL BIOL CELL, V12, P3527, DOI 10.1091/mbc.12.11.3527; Cancilla B, 1999, KIDNEY INT, V56, P2025, DOI 10.1046/j.1523-1755.1999.00781.x; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Cook DM, 1996, ONCOGENE, V13, P1789; DIAZRUIZ C, 1993, CELL TISSUE RES, V271, P3, DOI 10.1007/BF00297536; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; Gow KW, 2002, J PEDIATR SURG, V37, P823, DOI 10.1053/jpsu.2002.32880; Grisaru S, 2000, PEDIATR NEPHROL, V14, P146, DOI 10.1007/s004670050031; HARDING MA, 1992, KIDNEY INT, V41, P317, DOI 10.1038/ki.1992.44; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Higinbotham KG, 1998, MOL CARCINOGEN, V23, P53, DOI 10.1002/(SICI)1098-2744(199810)23:2<53::AID-MC1>3.0.CO;2-T; Hippo Y, 2001, CANCER RES, V61, P889; Ho R, 2002, CANCER RES, V62, P6462; Jaboin J, 2002, CANCER RES, V62, P6756; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kang DH, 2001, AM J KIDNEY DIS, V37, P601, DOI 10.1053/ajkd.2001.22087; Karavanov AA, 1998, INT J DEV BIOL, V42, P61; Kim IG, 1997, BBA-MOL CELL RES, V1359, P181, DOI 10.1016/S0167-4889(97)00103-1; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kline-Smith SL, 2004, MOL BIOL CELL, V15, P1146, DOI 10.1091/mbc.E03-08-0581; Kooistra R, 1997, MOL CELL BIOL, V17, P6097, DOI 10.1128/MCB.17.10.6097; Kooistra R, 1999, MOL CELL BIOL, V19, P6269; Korkola JE, 2003, CANCER RES, V63, P7167; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; Lahoti C, 1996, AM J PATHOL, V148, P1577; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Malgeri U, 2000, CANCER RES, V60, P4058; MALKIN D, 1994, CANCER RES, V54, P2077; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Niimura F, 1997, AM J PHYSIOL-REG I, V272, pR142, DOI 10.1152/ajpregu.1997.272.1.R142; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; ROTH J, 1988, AM J PATHOL, V133, P596; ROTH J, 1989, VERH DEUT G, V73, P372; Sato N, 2003, CANCER RES, V63, P3735; SAWAI S, 1991, NEW BIOL, V3, P861; Scholl FA, 2000, BRIT J CANCER, V82, P1239; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Skacel M, 2002, APPL IMMUNOHISTO M M, V10, P1, DOI 10.1097/00022744-200203000-00001; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Stanhope-Baker P, 2004, J BIOL CHEM, V279, P33575, DOI 10.1074/jbc.M404787200; STANTON BR, 1992, BRAIN PATHOL, V2, P71; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Stuart RO, 2003, KIDNEY INT, V64, P1997, DOI 10.1046/j.1523-1755.2003.00383.x; Stuart RO, 2001, P NATL ACAD SCI USA, V98, P5649, DOI 10.1073/pnas.091110798; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sugata N, 2000, HUM MOL GENET, V9, P2919, DOI 10.1093/hmg/9.19.2919; Tanaka K, 1999, PEDIATR SURG INT, V15, P243, DOI 10.1007/s003830050567; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021; WANG YQ, 1995, MECH DEVELOP, V52, P275, DOI 10.1016/0925-4773(95)00408-S; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Zhang Hui-Zhong, 2004, Ai Zheng, V23, P493; Zhang XH, 1999, ANTICANCER RES, V19, P1641; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581; ZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7	86	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					457	468		10.1038/sj.onc.1208228	http://dx.doi.org/10.1038/sj.onc.1208228			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531917				2022-12-25	WOS:000226279700016
J	Chang, DY; Lu, AL				Chang, DY; Lu, AL			Interaction of checkpoint proteins Hus1/Rad1/Rad9 with DNA base excision repair enzyme MutY homolog in fission yeast, Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; MISMATCH REPAIR; FUNCTIONAL INTERACTION; DAMAGE RESPONSE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CYCLE CHECKPOINT; REPLICATION FOCI; POLYMERASE DELTA; BUDDING YEAST	The DNA glycosylase MutY homolog (MYH) is responsible for removing adenines misincorporated opposite DNA strands containing guanine or 7,8-dihydro-8-oxoguanine by base excision repair thereby preventing G: C to T: A mutations. MYH has been shown to interact with the proliferating cell nuclear antigen ( PCNA) in both human and fission yeast Schizosaccharomyces pombe systems. Here we show that S. pombe (Sp) MYH physically interacts with all subunits of the PCNA-like checkpoint protein heterotrimer, SpRad9/SpRad1/SpHus1, in yeast extracts and when the individual subunits are expressed in bacteria. The SpHus1 and SpPCNA binding sites are located in discrete regions of SpMYH. Immunoprecipitation assays reveal that the interaction between SpHus1 and SpMYH increases dramatically after hydrogen peroxide treatment, and this increase in the SpHus1-SpMYH interaction correlates with the presence of SpHus1 phosphorylation. In contrast, the interaction between SpPCNA and SpMYH after hydrogen peroxide treatment remains nearly unchanged. SpMYH associates with SpHus1 in a complex of similar to450 kDa, the reported native molecular mass of the SpRad9/SpRad1/SpHus1-MYC complex. A larger portion of SpMYH shifts to the 150-500-kDa regions after hydrogen peroxide treatment in comparison with untreated extracts. SpHus1 phosphorylation is substantially reduced in Sp-MYHDelta cells after hydrogen peroxide treatment. These data suggest that MYH may act as an adaptor to recruit checkpoint proteins to the DNA lesions.	Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Sch Med, 108 N Greene St, Baltimore, MD 21201 USA.	aluchang@umaryland.edu			NATIONAL CANCER INSTITUTE [R56CA078391, R01CA078391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER; NCI NIH HHS [CA/ES78391] Funding Source: Medline; NIGMS NIH HHS [GM 35132] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Carr AM, 2003, SCIENCE, V300, P1512, DOI 10.1126/science.1085689; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chang DY, 2002, J BIOL CHEM, V277, P11853, DOI 10.1074/jbc.M111739200; Chang DY, 2001, MOL GENET GENOMICS, V266, P336, DOI 10.1007/s004380100567; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Gong JG, 1999, NATURE, V399, P806; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hayashi H, 2002, CURR BIOL, V12, P335, DOI 10.1016/S0960-9822(02)00686-3; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; Lu AL, 2001, CELL BIOCHEM BIOPHYS, V35, P141, DOI 10.1385/CBB:35:2:141; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; Melo JA, 2001, GENE DEV, V15, P2809; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Nicolaides NC, 1996, GENOMICS, V31, P395, DOI 10.1006/geno.1996.0067; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Shiomi Y, 2002, GENES CELLS, V7, P861, DOI 10.1046/j.1365-2443.2002.00566.x; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wu JX, 1999, MOL CELL BIOL, V19, P8292; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	59	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					408	417		10.1074/jbc.M406800200	http://dx.doi.org/10.1074/jbc.M406800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15533944	hybrid			2022-12-25	WOS:000226025100050
J	Plaisance, V; Niederhauser, G; Azzouz, F; Lenain, V; Haefliger, JA; Waeber, G; Abderrahmani, A				Plaisance, V; Niederhauser, G; Azzouz, F; Lenain, V; Haefliger, JA; Waeber, G; Abderrahmani, A			The repressor element silencing transcription factor (REST)-mediated transcriptional repression requires the inhibition of Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-RESTRICTIVE SILENCER; PANCREATIC BETA-CELLS; SYNAPSIN-I GENE; HISTONE DEACETYLASE; FACTOR REST; BIOLOGICAL-ACTIVITY; TARGET GENES; DNA-BINDING; SP-FAMILY; EXPRESSION	The terminal differentiation of neuronal and pancreatic beta-cells requires the specific expression of genes that are targets of an important transcriptional repressor named RE-1 silencing transcription factor ( REST). The molecular mechanism by which these REST target genes are expressed only in neuronal and beta-cells and are repressed by REST in other tissues is a central issue in differentiation program of neuronal and beta-cells. Herein, we showed that the transcriptional factor Sp1 was required for expression of most REST target genes both in insulin-secreting cells and neuronal-like cells where REST is absent. Inhibition of REST in a non-beta and a non-neuronal cell model restored the transcriptional activity of Sp1. This activity was also restored by trichostatin A indicating the requirement of histone deacetylases for the REST-mediated silencing of Sp1. Conversely, exogenous introduction of REST blocked Sp1-mediated transcriptional activity. The REST inhibitory effect was mediated through its C-terminal repressor domain, which could interact with Sp1. Taken together, these data show that the inhibition of Sp1 by REST is required for the silencing of its target genes expression in non-neuronal and in non-beta-cells. We conclude that the interplay between REST and Sp1 determines the cell-specific expression of REST target genes.	Univ Lausanne, Inst Cellular Biol & Morphol, CH-1005 Lausanne, Switzerland; Univ Lausanne, Dept Internal Med, CH-1005 Lausanne, Switzerland	University of Lausanne; University of Lausanne	Abderrahmani, A (corresponding author), Univ Lausanne, Inst Cellular Biol & Morphol, CH-1005 Lausanne, Switzerland.	Amar.Abderrahmani@ibcm.unil.ch	Abderrahmani, Amar/O-3124-2017	Abderrahmani, Amar/0000-0003-0752-0343; Haefliger, Jacques-Antoine/0000-0003-2732-1667; Waeber, Gerard/0000-0003-4193-788X				Abderrahmani A, 2004, J CELL SCI, V117, P2239, DOI 10.1242/jcs.01041; Abderrahmani A, 2004, FEBS LETT, V565, P133, DOI 10.1016/j.febslet.2004.04.002; Abderrahmani A, 2001, MOL CELL BIOL, V21, P7256, DOI 10.1128/MCB.21.21.7256-7267.2001; Atouf F, 1997, J BIOL CHEM, V272, P1929, DOI 10.1074/jbc.272.3.1929; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; Chew LJ, 2001, J BIOL CHEM, V276, P42162, DOI 10.1074/jbc.M101895200; CHIANG CMJ, 1994, MED ENG PHYS, V16, P513, DOI 10.1016/1350-4533(94)90078-7; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOWLAND DS, 1991, MOL BRAIN RES, V11, P345, DOI 10.1016/0169-328X(91)90044-X; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Jones FS, 1999, BIOESSAYS, V21, P372, DOI 10.1002/(SICI)1521-1878(199905)21:5<372::AID-BIES3>3.0.CO;2-3; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; Lietz M, 2001, EUR J NEUROSCI, V14, P1303, DOI 10.1046/j.0953-816x.2001.01762.x; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Martin D, 2003, J BIOL CHEM, V278, P53082, DOI 10.1074/jbc.M306861200; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; Murai K, 2004, NUCLEIC ACIDS RES, V32, P3180, DOI 10.1093/nar/gkh550; Myers SJ, 1998, J NEUROSCI, V18, P6723; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Okamoto S, 2002, MOL BRAIN RES, V107, P89, DOI 10.1016/S0169-328X(02)00440-0; Paquette AJ, 2000, P NATL ACAD SCI USA, V97, P12318, DOI 10.1073/pnas.97.22.12318; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Thiel G, 1998, J BIOL CHEM, V273, P26891, DOI 10.1074/jbc.273.41.26891; Yoo JY, 2001, BIOCHEM BIOPH RES CO, V283, P928, DOI 10.1006/bbrc.2001.4857; Zhang XP, 2003, NUCLEIC ACIDS RES, V31, P2900, DOI 10.1093/nar/gkg380; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	49	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					401	407		10.1074/jbc.M411825200	http://dx.doi.org/10.1074/jbc.M411825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15528196	hybrid			2022-12-25	WOS:000226025100049
J	Jones, AM; Douglas, EJ; Halford, SER; Fiegler, H; Gorman, PA; Roylance, RR; Carter, NP; Tomlinson, IPM				Jones, AM; Douglas, EJ; Halford, SER; Fiegler, H; Gorman, PA; Roylance, RR; Carter, NP; Tomlinson, IPM			Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma	ONCOGENE			English	Article						colorectal cancer; CGH; microsatellite; chromosomal instability; genetic pathways	COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RESOLUTION ANALYSIS; PTEN MUTATIONS; AMPLIFICATION; INSTABILITY; MALIGNANCIES; MICROARRAYS; PHENOTYPE; DISTINCT; PATHWAY	Microsatellite-stable, near-diploid (MSI-CIN-) colorectal carcinomas have been reported, but it is not clear as to whether these tumours form a discrete group or represent one end of the distribution of MSI-CIN+ cancers. In order to address this question, we screened 23 MSI-CIN- colorectal cancers for gains and losses using array-based comparative genomic hybridization (aCGH) based on large-insert clones at about 1 Mb density. We compared our findings with those from a small set of MSI+CIN+ cancers, and with our reported data from MSI-CIN+ and MSI+CIN- cancers. We found no evidence of any form of genomic instability in MSI-CIN- cancers. At the level of the chromosome arm, the MSI-CIN- cancers had significantly fewer gains and losses than MSI-CIN+ tumours, but more than the MSI+CIN- and MSI+CIN+ lesions. The chromosomal-scale changes found in MSI-CIN- cancers generally involved the same sites as those in MSI-CIN+ tumours, and in both cancer groups, the best predictor of a specific change was the total number of such changes in that tumour. A few chromosomal-scale changes did, however, differ between the MSI-CIN- and MSI-CIN+ pathways. MSI-CIN- cancers showed: low frequencies of gain of 9p and 19p; infrequent loss of 5q and a high frequency of 20p gain. Overall, our data suggested that the MSI-CIN- group is heterogeneous, one type of MSI-CIN- cancer having few (less than or equal to6) chromosomal-scale changes and the other with more (greater than or equal to10) changes resembling MSI-CIN+ cancers. At the level of individual clones, frequent and/or discrete gains or losses were generally located within regions of chromosomal-scale changes in both MSI-CIN- and MSI-CIN+ cancers, and fewer losses and gains were present in MSI-CIN- than MSI-CIN+ tumours. No changes by clone, which were specific to the MSI-CIN- cancers, were found. In addition to indicating differences among the cancer groups, our results also detected over 50 sites (amplifications, potential homozygous deletion and gains or losses which extended over only a few megabases) which might harbour uncharacterized oncogenes or tumour suppressor loci. In conclusion, our data support the suggestion that some MSI-CIN- carcinomas form a qualitatively different group from the other cancer types, and also suggest that the MSI-CIN- group is itself heterogeneous.	Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; St Marks Hosp, Canc Res UK, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Cancer Research UK; Wellcome Trust Sanger Institute; Cancer Research UK; Imperial College London	Tomlinson, IPM (corresponding author), Canc Res UK, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	ian.tomlinson@cancer.org.uk		Davison, Ellie/0000-0003-0927-932X				Curtis LJ, 2000, J PATHOL, V192, P440; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Giaretti W, 2003, GENE CHROMOSOME CANC, V37, P207, DOI 10.1002/gcc.10203; Gill N, 2002, GASTROENTEROLOGY, V122, P248, DOI 10.1053/gast.2002.30917; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Hawkins NJ, 2001, BRIT J CANCER, V84, P232, DOI 10.1054/bjoc.2000.1554; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; LEACH FS, 1993, CANCER RES, V53, P1986; Lipton L, 2003, CANCER RES, V63, P7595; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059; Pedowitz SD, 2003, GASTROENTEROLOGY, V125, P1915, DOI 10.1053/j.gastro.2003.04.016; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9	20	84	85	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					118	129		10.1038/sj.onc.1208194	http://dx.doi.org/10.1038/sj.onc.1208194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531920				2022-12-25	WOS:000226125800014
J	Xiao, YC; Tang, JZ; Hu, WJ; Xie, JY; Maertens, C; Tytgat, J; Liang, SP				Xiao, YC; Tang, JZ; Hu, WJ; Xie, JY; Maertens, C; Tytgat, J; Liang, SP			Jingzhaotoxin-I, a novel spider neurotoxin preferentially inhibiting cardiac sodium channel inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; CDNA SEQUENCE; TOXIN; ACTIVATION; PEPTIDE; POTASSIUM; BINDING; BRAIN; VENOM	Jingzhaotoxin-I (JZTX-I), a 33-residue polypeptide, is derived from the Chinese tarantula Chilobrachys jing-zhao venom based on its ability to evidently increase the strength and the rate of vertebrate heartbeats. The toxin has three disulfide bonds with the linkage of I-IV, II-V, and III-VI that is a typical pattern found in inhibitor cystine knot molecules. Its cDNA determined by rapid amplification of 3'- and 5'- cDNA ends encoded a 62-residue precursor with a small proregion of eight residues. Whole-cell configuration indicated that JZTX-I was a novel neurotoxin preferentially inhibiting cardiac sodium channel inactivation by binding to receptor site 3. Although JZTX-I also exhibits the interaction with channel isoforms expressing in mammalian and insect sensory neurons, its affinity for tetrodotoxin-resistant subtype in mammalian cardiac myocytes (IC50 = 31.6 nM) is similar to 30-fold higher than that for tetrodotoxin-sensitive subtypes in latter tissues. Not affecting outward delay-rectified potassium channels expressed in Xenopus laevis oocytes and tetrodotoxin-resistant sodium channels in mammal sensory neurons, JZTX-I hopefully represents a potent ligand to discriminate cardiac sodium channels from neuronal tetrodotoxin-resistant isoforms. Furthermore, different from any reported spider toxins, the toxin neither modifies the current-voltage relationships nor shifts the steady-state inactivation of sodium channels. Therefore, JZTX-I defines a new subclass of spider sodium channel toxins. JZTX-I is an alpha-like toxin first reported from spider venoms. The result provides an important witness for a convergent functional evolution between spider and other animal venoms.	Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China; Katholieke Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium	Hunan Normal University; KU Leuven	Liang, SP (corresponding author), Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China.	liangsp@hunnu.edu.cn	Tytgat, Jan/F-1560-2010; Xiao, Yucheng/H-3600-2012	Tytgat, Jan/0000-0003-1778-6022				Benoit E, 2001, NEUROSCIENCE, V104, P551, DOI 10.1016/S0306-4522(01)00073-2; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; Corzo G, 2000, EUR J BIOCHEM, V267, P5783, DOI 10.1046/j.1432-1327.2000.01653.x; Diao JB, 2003, TOXICON, V42, P715, DOI 10.1016/j.toxicon.2003.08.007; Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4; Froy O, 1999, J MOL EVOL, V48, P187, DOI 10.1007/PL00006457; Geffeney S, 2002, SCIENCE, V297, P1336, DOI 10.1126/science.1074310; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Grolleau F, 2001, J EXP BIOL, V204, P711; He Bing-jun, 2001, Acta Entomologica Sinica, V44, P422; Huey RB, 2002, SCIENCE, V297, P1289, DOI 10.1126/science.1075987; Kinoshita E, 2001, MOL PHARMACOL, V59, P1457, DOI 10.1124/mol.59.6.1457; Li DL, 2003, FEBS LETT, V555, P616, DOI 10.1016/S0014-5793(03)01303-6; Li DL, 2004, J BIOL CHEM, V279, P37734, DOI 10.1074/jbc.M405765200; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Maier SKG, 2002, P NATL ACAD SCI USA, V99, P4073, DOI 10.1073/pnas.261705699; Middleton RE, 2002, BIOCHEMISTRY-US, V41, P14734, DOI 10.1021/bi026546a; Nicholson GM, 1998, PFLUG ARCH EUR J PHY, V436, P117, DOI 10.1007/s004240050612; OGATA N, 1993, J PHYSIOL-LONDON, V466, P9; Omecinsky DO, 1996, BIOCHEMISTRY-US, V35, P2836, DOI 10.1021/bi952605r; Ostrow KL, 2003, TOXICON, V42, P263, DOI 10.1016/S0041-0101(03)00141-7; Peng K, 2002, J BIOL CHEM, V277, P47564, DOI 10.1074/jbc.M204063200; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Shon KJ, 1998, J NEUROSCI, V18, P4473; Shu Q, 2002, PROTEIN SCI, V11, P245, DOI 10.1110/ps.30502; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; SU X, 1997, AM J PHYSIOL, V277, P1180; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Xiao XC, 2003, EUR J PHARMACOL, V477, P1, DOI 10.1016/S0014-2999(03)02190-3; Xiao YC, 2004, J BIOL CHEM, V279, P26220, DOI 10.1074/jbc.M401387200; ZETO TH, 2000, FEBS LETT, V470, P293; ZHU MS, 2001, J BAODING TEACHERS C, V14, P1; Zhu SY, 2004, J MOL EVOL, V58, P145, DOI 10.1007/s00239-003-2534-2; Zhu SY, 2003, FASEB J, V17, P1765, DOI 10.1096/fj.02-1044fje	37	62	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12069	12076		10.1074/jbc.M411651200	http://dx.doi.org/10.1074/jbc.M411651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15548530	hybrid			2022-12-25	WOS:000227922000003
J	Drouet, J; Delteil, C; Lefrancois, J; Concannon, P; Salles, B; Calsou, P				Drouet, J; Delteil, C; Lefrancois, J; Concannon, P; Salles, B; Calsou, P			DNA-dependent protein kinase and XRCC4-DNA ligase IV mobilization in the cell in response to DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINED IMMUNE-DEFICIENCY; V(D)J RECOMBINATION; IONIZING-RADIATION; CATALYTIC SUBUNIT; PHOSPHORYLATION SITES; GENOMIC INSTABILITY; MAMMALIAN-CELLS; HISTONE H2AX; KU ENTRY; REPAIR	Repair of DNA double strand breaks (DSBs) by the non-homologous end joining (NHEJ) pathway in mammals requires at least the DNA-dependent protein kinase (DNA-PK) and the DNA ligase IV-XRCC4 protein complexes. DNA-PK comprises the Ku70/Ku8O heterodimer and the catalytic subunit DNA-PKcs. Here we report the first description of the nuclear mobilization of endogenous NHEJ proteins after exposure of human cells to double strand-breaking agents. DSB infliction specifically induced a dose- and time-dependent mobilization of Ku70/80, DNA-PKcs, XRCC4, and DNA ligase IV proteins from a soluble nucleoplasmic compartment to a less extractable nuclear fraction. XRCC4 recruitment was accompanied by its DNA-PK-dependent phosphorylation. The recruited proteins co-immunoprecipitated, indicating that they had assembled into complexes. However, DNA-PK was attached to chromatin, whereas XRCC4-ligase IV resisted solubilization by DNase I. The rates of appearance and dissolution of NHEJ proteins paralleled that of histone variant H2AX phosphorylation and dephosphorylation. We established that under conditions of genomic DSB infliction 1) Ku recruitment was not dependent on the co-recruitment of the other NHEJ proteins, 2) DNA-PKcs was physically required for the mobilization of the XRCC4-ligase IV complex, 3) DNA ligase IV was physically necessary for stable recruitment of XRCC4, and 4) phosphorylation of either H2AX or XRCC4 was unnecessary for DNA-PK or XRCC4-ligase IV recruitment. Altogether these results offer insights into the interplay between key NHEJ proteins during this repair process in the cell.	CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France; Univ Washington, Sch Med, Benaroya Res Inst, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98101 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Benaroya Research Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Salles, B (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse 4, France.	bernard.salles@ipbs.fr	salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806; Concannon, Patrick/0000-0002-5801-1859				Adachi N, 2001, P NATL ACAD SCI USA, V98, P12109, DOI 10.1073/pnas.201271098; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Calsou P, 2003, J MOL BIOL, V326, P93, DOI 10.1016/S0022-2836(02)01328-1; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Frit P, 2000, J BIOL CHEM, V275, P35684, DOI 10.1074/jbc.M004315200; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; HOZAK P, 1995, J CELL SCI, V108, P635; Hsu HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Karanjawala ZE, 2002, DNA REPAIR, V1, P1017, DOI 10.1016/S1568-7864(02)00151-9; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Lee KJ, 2004, DNA REPAIR, V3, P267, DOI 10.1016/j.dnarep.2003.11.005; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; Mauldin SK, 2002, NUCLEIC ACIDS RES, V30, P4075, DOI 10.1093/nar/gkf529; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Remboutsika E, 1999, J CELL SCI, V112, P1671; Rodgers W, 2002, J IMMUNOL, V168, P2348, DOI 10.4049/jimmunol.168.5.2348; Rodrigo G, 2000, MOL CELL BIOL, V20, P2696, DOI 10.1128/MCB.20.8.2696-2705.2000; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sarkaria JN, 1998, CANCER RES, V58, P4375; SHILOH Y, 1983, CARCINOGENESIS, V4, P917, DOI 10.1093/carcin/4.7.917; Smith J, 2003, NUCLEIC ACIDS RES, V31, P2157, DOI 10.1093/nar/gkg317; Soubeyrand S, 2003, CANCER RES, V63, P1198; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Thacker J, 2003, DNA REPAIR, V2, P655, DOI 10.1016/S1568-7864(03)00062-4; Udayakumar D, 2003, J BIOL CHEM, V278, P41631, DOI 10.1074/jbc.M306470200; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yu YP, 2003, DNA REPAIR, V2, P1239, DOI 10.1016/S1568-7864(03)00143-5	64	111	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7060	7069		10.1074/jbc.M410746200	http://dx.doi.org/10.1074/jbc.M410746200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15520013	hybrid			2022-12-25	WOS:000227332700096
J	Hymowitz, SG; Patel, DR; Wallweber, HJA; Runyon, S; Yan, MH; Yin, JP; Shriver, SK; Gordon, NC; Pan, BL; Skelton, NJ; Kelley, RF; Starovasnik, MA				Hymowitz, SG; Patel, DR; Wallweber, HJA; Runyon, S; Yan, MH; Yin, JP; Shriver, SK; Gordon, NC; Pan, BL; Skelton, NJ; Kelley, RF; Starovasnik, MA			Structures of APRIL-receptor complexes - Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR FAMILY; CELL MATURATION ANTIGEN; B-LYMPHOCYTE STIMULATOR; CRYSTAL-STRUCTURE; TNF RECEPTOR; BAFF-R; BLYS RECEPTOR; MEMBER; ACTIVATION; SUPERFAMILY	TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. TACI binds two ligands, APRIL and BAFF, with high affinity and contains two cysteine-rich domains (CRDs) in its extracellular region; in contrast, BCMA and BR3, the other known high affinity receptors for APRIL and BAFF, respectively, contain only a single or partial CRD. However, another form of TACI exists wherein the N-terminal CRD is removed by alternative splicing. We find that this shorter form is capable of ligand-induced cell signaling and that the second CRD alone (TACI_d2) contains full affinity for both ligands. Furthermore, we report the solution structure and alanine-scanning mutagenesis of TACI_d2 along with cocrystal structures of APRIL.TACI_d2 and APRIL.BCMA complexes that together reveal the mechanism by which TACI engages high affinity ligand binding through a single CRD, and we highlight sources of ligand-receptor specificity within the APRIL/BAFF system.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Med Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Starovasnik, MA (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	star@gene.com						BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Cavanagh J., 1995, PROTEIN NMR SPECTROS; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cochran AG, 2001, J AM CHEM SOC, V123, P625, DOI 10.1021/ja003369x; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Gordon NC, 2003, BIOCHEMISTRY-US, V42, P5977, DOI 10.1021/bi034017g; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Karpusas M, 2002, J MOL BIOL, V315, P1145, DOI 10.1006/jmbi.2001.5296; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kim HM, 2003, NAT STRUCT BIOL, V10, P342, DOI 10.1038/nsb925; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Liu YF, 2002, CELL, V108, P383, DOI 10.1016/S0092-8674(02)00631-1; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; Medema JP, 2003, CELL DEATH DIFFER, V10, P1121, DOI 10.1038/sj.cdd.4401291; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Oren DA, 2002, NAT STRUCT BIOL, V9, P288, DOI 10.1038/nsb769; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel DR, 2004, J BIOL CHEM, V279, P16727, DOI 10.1074/jbc.M312316200; Pelletier M, 2003, J BIOL CHEM, V278, P33127, DOI 10.1074/jbc.M305754200; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Skelton NJ, 2003, J BIOL CHEM, V278, P7645, DOI 10.1074/jbc.M209751200; SKELTON NJ, 1993, J MAGN RESON SER B, V102, P253, DOI 10.1006/jmrb.1993.1095; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Wallweber HJA, 2004, J MOL BIOL, V343, P283, DOI 10.1016/j.jmb.2004.08.040; Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Yan MH, 2000, NAT IMMUNOL, V1, P37, DOI 10.1038/76889; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790; Zhang GY, 2004, CURR OPIN STRUC BIOL, V14, P154, DOI 10.1016/j.sbi.2004.03.003	47	130	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7218	7227		10.1074/jbc.M411714200	http://dx.doi.org/10.1074/jbc.M411714200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15542592	hybrid			2022-12-25	WOS:000227332700113
J	Dansithong, W; Paul, S; Comai, L; Reddy, S				Dansithong, W; Paul, S; Comai, L; Reddy, S			MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 UNTRANSLATED REGION; MYOTONIC-DYSTROPHY; TRINUCLEOTIDE REPEAT; MUSCLEBLIND PROTEINS; BINDING PROTEIN; TRIPLET REPEAT; CTG REPEAT; RNA; TRANSCRIPTS; IDENTIFICATION	In myotonic dystrophy 1 (DMI), aggregation of the mutant DMPK RNA into RNA-protein complexes containing MENL1 and MENL2 has been linked to aberrant splicing of the insulin receptor (IR) RNA. In a parallel line of investigation, elevated levels of CUG-binding protein (CUG-BP) have been shown to result in altered IR splicing in DM1. The relative importance of MBNL1, MBNL2, and CUG-BP in DM1 pathogenesis is, however, unclear. Here we have demonstrated that either small interfering RNA-mediated down-regulation of MBNL1 and MBNL2 or the overexpression of CUG-BP in normal myoblasts results in abnormal IR splicing. Our results suggest that CUG-BP regulates the equilibrium of splice site selection by antagonizing the facilitatory activity of MBNL1 and MBNL2 on IR exon 11 splicing in a dose-dependent manner. We have shown that CUG-BP levels are elevated in DM1 cells by mechanisms that are independent of MENL1 and MBN-L2 loss. Importantly, rescue experiments in DM1 myoblasts demonstrated that loss of MBNL1 function is the key event, whereas the overexpression of CUG-BP plays a secondary role in the aberrant alternative splicing of IR RNA in DM1. Small interfering RNA-mediated down-regulation of MBNL1, MBNL2, and CUG-BP in DM1 myoblasts demonstrated that MENL1 plays a critical role in the maintenance of DM1 focus integrity. Thus, these experiments demonstrate that sequestration of MBNLI by the expanded CUG repeats is the primary determinant of both DM1 focus formation and the abnormal splicing of the IR RNA in DMI myoblasts. The data therefore support MBNL1-mediated therapy for DMI.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Inst Med Genet, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Reddy, S (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Inst Med Genet, Los Angeles, CA 90033 USA.	sitaredd@usc.edu	Comai, Lucio/H-9524-2019; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841				Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Ebralidze A, 2004, SCIENCE, V303, P383, DOI 10.1126/science.1088679; Fardaei M, 2002, HUM MOL GENET, V11, P805, DOI 10.1093/hmg/11.7.805; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; Harper P.S., 1989, MYOTONIC DYSTROPHY; Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Kosaki A, 1998, J BIOL CHEM, V273, P10331, DOI 10.1074/jbc.273.17.10331; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Mankodi A, 2002, MOL CELL, V10, P35, DOI 10.1016/S1097-2765(02)00563-4; Michalowski S, 1999, NUCLEIC ACIDS RES, V27, P3534, DOI 10.1093/nar/27.17.3534; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Mutsuddi M, 2004, CURR BIOL, V14, P302, DOI 10.1016/j.cub.2004.01.034; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; Seznec H, 2001, HUM MOL GENET, V10, P2717, DOI 10.1093/hmg/10.23.2717; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660	26	148	157	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5773	5780		10.1074/jbc.M410781200	http://dx.doi.org/10.1074/jbc.M410781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15546872	hybrid			2022-12-25	WOS:000227217100079
J	Murakami, M; Ohba, T; Xu, F; Shida, S; Satoh, E; Ono, K; Miyoshi, I; Watanabe, H; Ito, H; Iijima, T				Murakami, M; Ohba, T; Xu, F; Shida, S; Satoh, E; Ono, K; Miyoshi, I; Watanabe, H; Ito, H; Iijima, T			Genomic organization and functional analysis of murine PKD2L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; CATION CHANNEL; 2ND GENE; PKD1; LOCALIZATION; IDENTIFICATION; HETEROGENEITY; CONDUCTANCE; EXPRESSION; LOCUS	Mutations in genes that encode polycystins 1 or 2 cause polycystic kidney disease (PKD). Here, we report the genomic organization and functional expression of murine orthologue of human polycystin-2L1 (PKD2L1). The murine PY.D2L1 gene comprises 15 exons in chromosome 19C3. Coexpression of PKD2L1 together with polycystin-1 (PKD1) resulted in the expression of PKD2L1 channels on the cell surface, whereas PKD2L1 expressed alone was retained within the endoplasmic reticulum (ER). This suggested that interaction between PKD1 and PKD2L1 is essential for PKD2L1 trafficking and channel formation. Deletion analysis at the cytoplasmic tail of P`KD2L1 revealed that the coiled-coil domain was important for trafficking by PKD1. Mutagenesis within two newly identified ER retention signal-like amino acid sequences caused PKD2L1 to be expressed at the cell surface. This indicated that the coiled-coil domain was responsible for retaining PKD2L1 within the ER. Functional analysis of murine P`KD2L1 expressed in HEK 293 cells was undertaken using calcium imaging. Coexpression of PKD1 and P`KD2L1 resulted in the formation of functional cation channels that were opened by hypo-osmotic stimulation, whereas neither molecule formed functional channels when expressed alone. We conclude that PKD2L1 forms functional cation channels on the plasma membrane by interacting with PKD1. These findings raise the possibility that PKD2L1 represents the third genetic locus that is responsible for PKD.	Akita Univ, Sch Med, Dept Pharmacol, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Internal Med 2, Akita 0108543, Japan; Nagoya City Univ, Grad Sch Med Sci, Ctr Expt Anim Sci, Nagoya, Aichi 4678601, Japan	Akita University; Akita University; Nagoya City University	Murakami, M (corresponding author), Akita Univ, Sch Med, Dept Pharmacol, Akita 0108543, Japan.	manabumurakami@excite.co.jp						Basora N, 2002, J AM SOC NEPHROL, V13, P293, DOI 10.1681/ASN.V132293; BOGDANOVA N, 1995, HUM GENET, V95, P645; Chauvet V, 2002, AM J PATHOL, V160, P973, DOI 10.1016/S0002-9440(10)64919-X; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEALMEIDA S, 1995, HUM GENET, V96, P83, DOI 10.1007/BF00214191; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Guo L, 2000, MAMM GENOME, V11, P46, DOI 10.1007/s003350010009; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Markowitz GS, 1999, AM J PHYSIOL-RENAL, V277, pF17, DOI 10.1152/ajprenal.1999.277.1.F17; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Murakami M, 2003, BIOCHEM BIOPH RES CO, V307, P522, DOI 10.1016/S0006-291X(03)01186-0; Nakao M, 1999, AM J PHYSIOL-CELL PH, V276, pC238, DOI 10.1152/ajpcell.1999.276.1.C238; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Turco AE, 1996, AM J KIDNEY DIS, V28, P759, DOI 10.1016/S0272-6386(96)90261-9; Volk T, 2003, CARDIOVASC RES, V58, P76, DOI 10.1016/S0008-6363(02)00858-1; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724	30	43	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5626	5635		10.1074/jbc.M411496200	http://dx.doi.org/10.1074/jbc.M411496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15548533	hybrid			2022-12-25	WOS:000227217100064
J	Chen, JR; Plotkin, LI; Aguirre, JI; Han, L; Jilka, RL; Kousteni, S; Bellido, T; Manolagas, SC				Chen, JR; Plotkin, LI; Aguirre, JI; Han, L; Jilka, RL; Kousteni, S; Bellido, T; Manolagas, SC			Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLAST SURVIVAL; CYCLIN D1; BONE LOSS; C-JUN; INTERLEUKIN-6 PROMOTER; OSTEOBLAST APOPTOSIS; GENE-EXPRESSION; KAPPA-B; CELL; ACTIVATION	Sex steroids exert anti-apoptotic effects on osteoblasts/osteocytes but exert pro-apoptotic effects on osteoclasts, in both cases requiring activation of the extracellular signal-regulated kinases (ERKs). To explain the mechanistic basis of this divergence, we searched for differences in the kinetics of phosphorylation and/or in the subeellular localization of ERKs in response to 17beta-estradiol in the two cell types. In contrast to its transient effect on ERK phosphorylation in osteocytic cells (return to base line by 30 min), 17beta-estradiol-induced ERK phosphorylation in osteoclasts was sustained for at least 24 h following exposure to the hormone. Conversion of sustained ERK phosphorylation to transient, by means of cholera toxin-induced activation of the adenylate cyclase/cAMP/protein kinase A pathway, abrogated the pro-apoptotic effect of 17beta-estradiol on osteoclasts. Conversely, prolongation of ERK activation in osteocytes, by means of leptomycin B-induced inhibition of ERK export from the nucleus or overexpression of a green fluorescent protein-ERK2 mutant that resides permanently in the nucleus, converted the anti-apoptotic effect of 17beta-estradiol to a pro-apoptotic one. These findings indicate that the kinetics of ERK phosphorylation and the length of time that phospho-ERKs are retained in the nucleus are responsible for pro- versus anti-apoptotic effects of estrogen on different cell types of bone and perhaps their many other target tissues.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Manolagas, SC (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Slot 587,4301 W Markham, Little Rock, AR 72205 USA.	manolagasstavros@uams.edu	Plotkin, Lilian/H-7188-2019	Plotkin, Lilian/0000-0002-9537-4544; Warren, Aaron D./0000-0002-0042-9021	NIAMS NIH HHS [AR46823, KO2-AR02127] Funding Source: Medline; NIA NIH HHS [P01-AG13918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002127, R01AR046823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304; Assoian RK, 2002, NAT CELL BIOL, V4, pE187, DOI 10.1038/ncb0802-e187; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; Boyce BF, 2002, PRINCIPLES BONE BIOL, V1, P151; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Cheng YT, 2004, J MATER RES, V19, P1, DOI 10.1557/jmr.2004.19.1.1; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489; Kanaoka K, 2000, ENDOCRINOLOGY, V141, P2995, DOI 10.1210/en.141.8.2995; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manolagas SC, 2004, KIDNEY INT, V66, pS41, DOI 10.1111/j.1523-1755.2004.09107.x; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198; New LG, 2001, J CELL BIOCHEM, V83, P585, DOI 10.1002/jcb.1253; OURSLER MJ, 1994, P NATL ACAD SCI USA, V91, P5227, DOI 10.1073/pnas.91.12.5227; Pascoe D, 2001, J BONE MINER RES, V16, P1028, DOI 10.1359/jbmr.2001.16.6.1028; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Selander KS, 1996, MOL CELL ENDOCRINOL, V122, P119, DOI 10.1016/0303-7207(96)03870-1; Shevde NK, 1996, BLOOD, V87, P2683, DOI 10.1182/blood.V87.7.2683.bloodjournal8772683; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799	54	132	149	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4632	4638		10.1074/jbc.M411530200	http://dx.doi.org/10.1074/jbc.M411530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557324	hybrid			2022-12-25	WOS:000227096600078
J	Lu, JN; Izvolsky, KI; Qian, J; Cardoso, WV				Lu, JN; Izvolsky, KI; Qian, J; Cardoso, WV			Identification of FGF10 targets in the embryonic lung epithelium during bud morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTORS; BINDING-PROTEIN-ALPHA; BRANCHING MORPHOGENESIS; GENE-EXPRESSION; CELL-PROLIFERATION; TETRASPANIN CO-029; ARACHIDONIC-ACID; CANCER CELLS; MOUSE LUNG; II CELLS	Genetic studies implicate Fgf10-Fgfr2 signaling as a critical regulator of bud morphogenesis in the embryo. However, little is known about the transcriptional targets of Fgf10 during this process. Here we identified global changes in gene expression in lung epithelial explants undergoing FGF10-mediated budding in the absence of other growth factors and mesenchyme. Targets were confirmed by their localization at sites where endogenous Fgf10 signaling is active in embryonic lungs and by demonstrating their induction in intact lungs in response to local application of FGF10 protein. We show that the initial stages of budding are characterized by marked up-regulation of genes associated with cell rearrangement and cell migration, inflammatory process, and lipid metabolism but not cell proliferation. We also found that some genes implicated in tumor invasion and metastatic behavior are epithelial targets of Fgf10 in the lung and other developing organs that depend on Fgf10-Fgfr2 signaling to properly form. Our approach identifies Fgf10 targets that are common to multiple biological processes and provides insights into potential mechanisms by which Fgf signaling regulates epithelial cell behavior.	Boston Univ, Sch Med, Pulm Ctr, Boston, MA 02118 USA	Boston University	Cardoso, WV (corresponding author), Boston Univ, Sch Med, Pulm Ctr, 80 E Concord St,R-304, Boston, MA 02118 USA.	weardoso@lung.bume.bu.edu		Cardoso, Wellington/0000-0002-2550-3697	NHLBI NIH HHS [(P01) HL47049] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047049] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; Asaki T, 2004, MOL CELL ENDOCRINOL, V218, P119, DOI 10.1016/j.mce.2003.12.017; Aubin J, 2002, DEVELOPMENT, V129, P4075; AurrandLions M, 1996, IMMUNITY, V5, P391, DOI 10.1016/S1074-7613(00)80496-3; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bertet C, 2004, NATURE, V429, P667, DOI 10.1038/nature02590; Bhushan A, 2001, DEVELOPMENT, V128, P5109; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Fischer RS, 2003, J CELL BIOL, V161, P371, DOI 10.1083/jcb.200209057; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; Garcia-Montero A, 2001, EUR J CELL BIOL, V80, P720, DOI 10.1078/0171-9335-00209; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X; Grimmond S, 2000, HUM MOL GENET, V9, P1553, DOI 10.1093/hmg/9.10.1553; Harada H, 2002, CONNECT TISSUE RES, V43, P201, DOI 10.1080/030082002900000989; Herlevsen M, 2003, J CELL SCI, V116, P4373, DOI 10.1242/jcs.00760; HSU HY, 1994, J BIOL CHEM, V269, P9213; Huerta S, 2003, INT J ONCOL, V22, P663; Israsena N, 2004, DEV BIOL, V268, P220, DOI 10.1016/j.ydbio.2003.12.024; Jansson I, 2001, PHARMACOGENETICS, V11, P793, DOI 10.1097/00008571-200112000-00007; Kanetaka K, 2003, J GASTROEN HEPATOL, V18, P1309, DOI 10.1046/j.1440-1746.2003.03182.x; Kanetaka K, 2001, J HEPATOL, V35, P637, DOI 10.1016/S0168-8278(01)00183-0; Knoblich JA, 1997, COLD SPRING HARB SYM, V62, P71; Kondo H, 2000, BIOCHEM BIOPH RES CO, V272, P648, DOI 10.1006/bbrc.2000.2790; Lebeche D, 1999, MECH DEVELOP, V86, P125, DOI 10.1016/S0925-4773(99)00124-0; Lu J, 2004, DEV BIOL, V273, P418, DOI 10.1016/j.ydbio.2004.05.035; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Mason RJ, 2003, J CLIN INVEST, V112, P244, DOI 10.1172/JCI200316793; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nogawa H, 1998, DEV DYNAM, V213, P228, DOI 10.1002/(SICI)1097-0177(199810)213:2<228::AID-AJA8>3.0.CO;2-I; Norgaard GA, 2003, DEV BIOL, V264, P323, DOI 10.1016/j.ydbio.2003.08.013; Ohuchi H, 2000, BIOCHEM BIOPH RES CO, V277, P643, DOI 10.1006/bbrc.2000.3721; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Ooshio T, 2004, J BIOL CHEM, V279, P31365, DOI 10.1074/jbc.M401957200; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; Prince LS, 2001, PHYSIOL GENOMICS, V6, P81, DOI 10.1152/physiolgenomics.2001.6.2.81; Qiao J, 2001, MECH DEVELOP, V109, P123, DOI 10.1016/S0925-4773(01)00592-5; Ripani E, 1998, INT J CANCER, V76, P671; Sakaue H, 2002, GENE DEV, V16, P908, DOI 10.1101/gad.983202; Sato M, 2002, DEV CELL, V3, P195, DOI 10.1016/S1534-5807(02)00202-2; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Sugahara K, 2001, CELL TISSUE RES, V306, P57, DOI 10.1007/s004410100420; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tagashira S, 1997, GENE, V197, P399, DOI 10.1016/S0378-1119(97)00187-X; Tao H, 2002, MECH DEVELOP, V116, P39, DOI 10.1016/S0925-4773(02)00131-4; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; Weaver M, 2000, DEVELOPMENT, V127, P2695; Wertz K, 2000, MECH DEVELOP, V98, P51, DOI 10.1016/S0925-4773(00)00452-4; Wertz K, 1999, MECH DEVELOP, V84, P185, DOI 10.1016/S0925-4773(99)00074-X; Williams RL, 1996, STRUCTURE, V4, P1387, DOI 10.1016/S0969-2126(96)00146-3; Zhang CG, 1998, P NATL ACAD SCI USA, V95, P6290, DOI 10.1073/pnas.95.11.6290	56	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4834	4841		10.1074/jbc.M410714200	http://dx.doi.org/10.1074/jbc.M410714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15556938	hybrid			2022-12-25	WOS:000227096600102
J	Zhang, YL; Zhang, JJ; Hara, H; Kato, I; Inouye, M				Zhang, YL; Zhang, JJ; Hara, H; Kato, I; Inouye, M			Insights into the mRNA cleavage mechanism by MazF, an mRNA interferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ESCHERICHIA-COLI; ADDICTION MODULE; TOXIN; RELE; MAINTENANCE; SPECIFICITY; PROTEINS; SEQUENCE; REVERSE	MazF is an Escherichia coli toxin that is highly conserved among the prokaryotes and plays an important role in growth regulation. When MazF is induced, protein synthesis is effectively inhibited. However, the mechanism of MazF action has been controversial. Here we unequivocally demonstrate that MazF is an endoribonuclease that specifically cleaves mRNAs at ACA sequences. We then demonstrate its enzymatic specificity using short RNA substrates. MazF cleaves RNA at the 5'-end of ACA sequences, yielding a 2',3'-cyclic phosphate at one side and a free 5'-OH group at the other. Using DNA-RNA chimeric substrates containing XACA, the 2'-OH group of residue X was found absolutely essential for MazF cleavage, whereas all the other residues may be deoxyriboses. Therefore, MazF exhibits exquisite site specificity and has utility as an RNA-restriction enzyme for RNA structural studies or as an mRNA interferase to regulate cell growth in prokaryotic and eukaryotic cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Takara Bio Inc, Shiga 5202193, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Takara Bio Inc.	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.	inouye@umdnj.edu		Zhang, Junjie/0000-0001-8809-1485				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; Cherny I, 2004, J BIOL CHEM, V279, P8252, DOI 10.1074/jbc.M308263200; Christensen SK, 2004, MOL MICROBIOL, V53, P587, DOI 10.1111/j.1365-2958.2004.04127.x; Christensen SK, 2004, MOL MICROBIOL, V51, P1705, DOI 10.1046/j.1365-2958.2003.03941.x; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; de la Cueva-Mendez G, 2003, EMBO J, V22, P246, DOI 10.1093/emboj/cdg026; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Engelberg-Kulka H, 2004, TRENDS MICROBIOL, V12, P66, DOI 10.1016/j.tim.2003.12.008; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Hayes F, 2003, SCIENCE, V301, P1496, DOI 10.1126/science.1088157; Hazan R, 2004, J BACTERIOL, V186, P3663, DOI 10.1128/JB.186.11.3663-3669.2004; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; MASUDA Y, 1994, J BACTERIOL, V176, P5861, DOI 10.1128/JB.176.18.5861-5863.1994; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; Munoz-Gomez AJ, 2004, FEBS LETT, V567, P316, DOI 10.1016/j.febslet.2004.05.005; NAKAMURA K, 1979, CELL, V18, P1109, DOI 10.1016/0092-8674(79)90224-1; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; SantosSierra S, 1997, FEMS MICROBIOL LETT, V152, P51, DOI 10.1016/S0378-1097(97)00177-8; Smith CM, 1997, VIROLOGY, V229, P437, DOI 10.1006/viro.1997.8454; SMITH JS, 1992, J BIOL CHEM, V267, P15071; Zhang JJ, 2004, J BIOL CHEM, V279, P20678, DOI 10.1074/jbc.M314284200; Zhang JJ, 2003, J BIOL CHEM, V278, P32300, DOI 10.1074/jbc.M304767200; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7	27	186	209	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3143	3150		10.1074/jbc.M411811200	http://dx.doi.org/10.1074/jbc.M411811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15537630	hybrid			2022-12-25	WOS:000226983900005
J	Nagai, T; Abe, A; Sasakawa, C				Nagai, T; Abe, A; Sasakawa, C			Targeting of enteropathogenic Escherichia coli EspF to host mitochondria is essential for bacterial pathogenesis - Critical role of the 16th leucine residue in EspF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION BARRIER; CELL-DEATH; CITROBACTER-RODENTIUM; SECRETED PROTEIN; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; EFFECTOR PROTEIN; MAMMALIAN-CELLS; CACO-2 CELLS; PORIN PORB	The attachment of enteropathogenic Escherichia coli (EPEC) to host cells and the induction of attaching and effacing WE) lesions are prominent pathogenic features. EPEC infection also leads to host cell death and damage to the intestinal mucosa, which is partly dependent upon EspF, one of the effectors. In this study, we demonstrate that EspF is a mitochondrial import protein with a functional mitochondrial targeting signal (MTS), because EspF activity for importing into the mitochondria was abrogated by MTS deletion mutants. Substitution of the 16th leucine with glutamic acid (EspF(L16E)) completely abolished EspF activity. Infection of HeLa cells with wild type but not the espF mutant (DeltaespF) decreased mitochondrial membrane potential (DeltaPsi(m)), leading to cell death. The DeltaPsi(m) decrease and cell death were restored in cells infected with DeltaespF/pEsF but not DeltaespF/pEspF(L16E), suggesting that the 16th leucine in the MTS is a critical amino acid for EspF function. To demonstrate the impact of EspF in vivo, we exploited Citrobacter rodentium by infecting C3H/HeJ mice with DeltaespF(CR), DeltaespF(CR)/pEspF(CR), or DeltaespF(CR)/pEspF(L16E)(CR). These results indicate that EspF activity contributes to bacterial pathogenesis, as judged by murine lethality and intestinal histopathology, and promotion of bacterial colonization of the intestinal mucosa.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immun, Minato Ku, Tokyo 1088639, Japan; Kitasato Univ, Kitasato Inst Life Sci, Lab Bacterial Infect, Minato Ku, Tokyo 1088642, Japan	University of Tokyo; Kitasato University	Sasakawa, C (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immun, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sasakawa@ims.u-tokyo.ac.jp						Abul-Milh M, 2001, INFECT IMMUN, V69, P7356, DOI 10.1128/IAI.69.12.7356-7364.2001; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Berkes J, 2003, GUT, V52, P439, DOI 10.1136/gut.52.3.439; Boya P, 2001, EMBO J, V20, P4325, DOI 10.1093/emboj/20.16.4325; Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; CHU TW, 1987, J BIOL CHEM, V262, P15759; Ciminale V, 1999, ONCOGENE, V18, P4505, DOI 10.1038/sj.onc.1203047; Clarke SC, 2003, CLIN MICROBIOL REV, V16, P365, DOI 10.1128/CMR.16.3.365-378.2003; Crane JK, 2002, AM J PHYSIOL-GASTR L, V283, pG74, DOI 10.1152/ajpgi.00484.2001; Crane JK, 1999, INFECT IMMUN, V67, P2575, DOI 10.1128/IAI.67.5.2575-2584.1999; Crane JK, 2001, CELL MICROBIOL, V3, P197, DOI 10.1046/j.1462-5822.2001.00103.x; Creasey EA, 2003, MICROBIOL-SGM, V149, P3639, DOI 10.1099/mic.0.26735-0; Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101; Dickman KG, 2000, AM J PHYSIOL-GASTR L, V279, pG757, DOI 10.1152/ajpgi.2000.279.4.G757; Elliott SJ, 2001, INFECT IMMUN, V69, P4027, DOI 10.1128/IAI.69.6.4027-4033.2001; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; GROUSELLE M, 1990, BIOCHEM J, V271, P269, DOI 10.1042/bj2710269; Gruenheid S, 2004, MOL MICROBIOL, V51, P1233, DOI 10.1046/j.1365-2958.2003.03911.x; Gruenheid S, 2003, NATURE, V422, P775, DOI 10.1038/nature01603; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; Hernandez LD, 2003, J CELL BIOL, V163, P1123, DOI 10.1083/jcb.200309161; ITOH K, 1988, INFECT IMMUN, V56, P930, DOI 10.1128/IAI.56.4.930-935.1988; Jia J, 2003, INFECT IMMUN, V71, P3361, DOI 10.1128/IAI.71.6.3361-3370.2003; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Kenny B, 2002, MICROBIOL-SGM, V148, P1967, DOI 10.1099/00221287-148-7-1967; Kenny B, 2002, MOL MICROBIOL, V44, P1095, DOI 10.1046/j.1365-2958.2002.02952.x; Kenny B, 2000, CELL MICROBIOL, V2, P579, DOI 10.1046/j.1462-5822.2000.00082.x; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Malish HR, 2003, APOPTOSIS, V8, P179, DOI 10.1023/A:1022974710488; Marches O, 2003, MOL MICROBIOL, V50, P1553, DOI 10.1046/j.1365-2958.2003.03821.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070; Matsuzawa T, 2004, EMBO J, V23, P3570, DOI 10.1038/sj.emboj.7600359; McNamara BP, 1998, FEMS MICROBIOL LETT, V166, P71, DOI 10.1016/S0378-1097(98)00313-9; McNamara BP, 2001, J CLIN INVEST, V107, P621, DOI 10.1172/JCI11138; MENARD R, 1993, J BACTERIOL, V175, P5899; Monack D, 2000, INT J MED MICROBIOL, V290, P7; Muller A, 2000, EMBO J, V19, P5332, DOI 10.1093/emboj/19.20.5332; Mundy R, 2004, INFECT IMMUN, V72, P2288, DOI 10.1128/IAI.72.4.2288-2302.2004; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; Muto T, 2001, J MOL BIOL, V306, P137, DOI 10.1006/jmbi.2000.4397; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nougayrede JP, 2004, CELL MICROBIOL, V6, P1097, DOI 10.1111/j.1462-5822.2004.00421.x; Okutani A, 2001, EXP ANIM TOKYO, V50, P183, DOI 10.1538/expanim.50.183; Simonovic I, 2001, INFECT IMMUN, V69, P5679, DOI 10.1128/IAI.69.9.5679-5688.2001; Stockbauer KE, 2003, CELL MICROBIOL, V5, P123, DOI 10.1046/j.1462-5822.2003.00260.x; Tamano K, 2002, METHOD ENZYMOL, V358, P385; Tatsuno I, 2001, INFECT IMMUN, V69, P6660, DOI 10.1128/IAI.69.11.6660-6669.2001; Tatsuno I, 2000, INFECT IMMUN, V68, P5943, DOI 10.1128/IAI.68.10.5943-5952.2000; Toyotome T, 2001, J BIOL CHEM, V276, P32071, DOI 10.1074/jbc.M101882200; Tu XL, 2003, MOL MICROBIOL, V47, P595, DOI 10.1046/j.1365-2958.2003.03329.x; Vallance BA, 2003, INFECT IMMUN, V71, P3443, DOI 10.1128/IAI.71.6.3443-3453.2003; Viswanathan VK, 2004, CELL MICROBIOL, V6, P987, DOI 10.1111/j.1462-5822.2004.00416.x; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Yoshida S, 2002, EMBO J, V21, P2923, DOI 10.1093/emboj/cdf319	62	120	124	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2998	3011		10.1074/jbc.M411550200	http://dx.doi.org/10.1074/jbc.M411550200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15533930	hybrid			2022-12-25	WOS:000226449100076
J	Rah, SY; Park, KH; Han, MK; Im, MJ; Kim, UH				Rah, SY; Park, KH; Han, MK; Im, MJ; Kim, UH			Activation of CD38 by interleukin-8 signaling regulates intracellular Ca2+ level and motility of lymphokine-activated killer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; RAT CARDIAC MYOCYTES; T-LYMPHOCYTES; CALCIUM MESSENGERS; CYCLASE ACTIVITY; PROTEIN; RELEASE; CHEMOTAXIS; CHEMOKINES; PATHWAYS	CD38 is an ADP-ribosyl cyclase, producing a potent Ca2+ mobilizer cyclic ADP-ribose (cADPR). In this study, we have investigated a role of CD38 and its regulation through interleukin-8 (IL8) signaling in lymphokine-activated killer (LAK) cells. Incubation of IAK cells with IL8 resulted in an increase of cellular cADPR level and a rapid rise of intracellular Ca2+ concentration ([Ca2+](i)), which was sustained for a long period of time (> 10 min). Preincubation of an antagonistic cADPR analog, 8-Br-cADPR (8-bromo-cyclic adenosine diphosphate ribose), abolished the sustained Ca2+ signal only but not the initial Ca2+ rise. An inositol 1,4,5-trisphosphate (IP3) receptor antagonist blocked both Ca2+ signals. Interestingly, the sustained Ca2+ rise was not observed in the absence of extracellular Ca2+. Functional CD38-null (CD38(-)) LAK cells showed the initial rapid increase of [Ca2+](i) but not the sustained Ca2+ rise in response to IL8 treatment. An increase of cellular cADPR level by cGMP analog, 8-pCPT-cGMP (8-(4-chlorophenylthio)guanosine-3',5'-cyclic monophosphate), but not cAMP analog or phorbol 12-myristate 13-acetate was observed. IL8 treatment resulted in the increase of cGMP level that was inhibited by the IP3 receptor blocker but not a protein kinase C inhibitor. cGMP-mediated Ca2+ rise was blocked by 8-Br-cADPR. In addition, IL8-mediated IAK cell migration was inhibited by 8-Br-cADPR and a protein kinase G inhibitor. Consistent with these observations, IL8-induced migration of CD38(-) IAK cells was not observed. However, direct application of cADPR or 8-pCPT-cGMP stimulated migration of CD38- cells. These results demonstrate that CD38 is stimulated by sequential activation of IL8 receptor, IP3-mediated Ca2+ rise, and cGMP/protein kinase G and that CD38 plays an essential role in IL8-induced migration of LAK cells.	Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561182, South Korea; Chonbuk Natl Univ, Sch Med, Inst Cardiovasc Res, Jeonju 561182, South Korea	Jeonbuk National University; Jeonbuk National University	Kim, UH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561182, South Korea.	uhkim@chonbuk.ac.kr		Kim, Uh-Hyun/0000-0003-3304-7190; Han, Myung-Kwan/0000-0003-1931-8898; Rah, So-Young/0000-0002-0255-1960				BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Boittin FX, 2003, J BIOL CHEM, V278, P9602, DOI 10.1074/jbc.M204891200; Cesano A, 1998, J IMMUNOL, V160, P1106; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Graeff RM, 1998, J BIOL CHEM, V273, P118, DOI 10.1074/jbc.273.1.118; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Han MK, 2000, J BIOL CHEM, V275, P20799, DOI 10.1074/jbc.M001189200; Higashida H, 1997, J BIOL CHEM, V272, P31272, DOI 10.1074/jbc.272.50.31272; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Inngjerdingen M, 1999, BIOCHEM BIOPH RES CO, V262, P467, DOI 10.1006/bbrc.1999.1234; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; Maghazachi AA, 2000, INT J BIOCHEM CELL B, V32, P931, DOI 10.1016/S1357-2725(00)00035-2; Mallone R, 2001, INT IMMUNOL, V13, P397, DOI 10.1093/intimm/13.4.397; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; MELDER RJ, 1988, CANCER RES, V48, P3461; Neptune ER, 1999, J BIOL CHEM, V274, P2824, DOI 10.1074/jbc.274.5.2824; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Partida-Sanchez S, 2004, IMMUNITY, V20, P279, DOI 10.1016/S1074-7613(04)00048-2; Schwarzmann N, 2002, J BIOL CHEM, V277, P50636, DOI 10.1074/jbc.M209061200; Sconocchia G, 1999, BLOOD, V94, P3864, DOI 10.1182/blood.V94.11.3864.423k14_3864_3871; SEBOK K, 1993, J IMMUNOL, V150, P1524; Sternfeld L, 2003, J BIOL CHEM, V278, P33629, DOI 10.1074/jbc.M301043200; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Xie GH, 2003, BIOCHEM BIOPH RES CO, V307, P713, DOI 10.1016/S0006-291X(03)01240-3; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; Zubiaur M, 1997, J IMMUNOL, V159, P193	40	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2888	2895		10.1074/jbc.M409592200	http://dx.doi.org/10.1074/jbc.M409592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15556942	hybrid			2022-12-25	WOS:000226449100064
J	Pelman, GR; Morrison, CJ; Overall, CM				Pelman, GR; Morrison, CJ; Overall, CM			Pivotal molecular determinants of peptidic and collagen triple helicase activities reside in the S-3 ' subsite of matrix metalloproteinase 8 (MMP-8) - The role of hydrogen bonding potential of Asn(188) and Tyr(189) and the connecting cis bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; C-TERMINAL DOMAIN; RAT PERIODONTAL TISSUES; SUBSTRATE-SPECIFICITY; GELATINASE-A; FIBROBLAST COLLAGENASE; EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; CRYSTAL-STRUCTURE; HEMOPEXIN DOMAIN	The mechanism of triple helical collagen unwinding and cleavage by collagenases in the matrix metalloproteinase (MMP) family is complex and remains enigmatic. Recent reports show that triple helicase activity is initiated by the hemopexin C domain of membrane type 1-MMP, whereas catalytically inactive full-length interstitial collagenase (MMP-1) exhibits full triple helicase functionality pointing to active site determinants that are needed to complete the triple helicase mechanism. In MMP-8, the neutrophil collagenase, a conserved Gly at the S-3' substrate specificity subsite is replaced by Asn(188) that forms a highly unusual cis bond with Tyr(189), a conserved active site residue in the collagenases. Only in MMP-1 is the S-3' Gly also replaced, and there too a cis configured Glu-Tyr occurs. Thus, this high energy peptide bond coupled to the canonical Tyr may be important in the collagenolytic process. In a systematic mutagenesis investigation of the MMP-8 S-3' subsite we found that introducing an S-3' Gly(188) into MMP-8 reduced collagenolytic efficiency by similar to 30% with a corresponding reduction in cleavage of a synthetic peptide fluorescence resonance energy transfer substrate analogue of the alpha2(I) collagen chain cleavage site. The substitution of Asn(188) to Leu, a hydrophobic residue of similar size to the highly polar Asn and designed to retain the cis bond, revealed the importance of hydrogen bonding to bound substrate with both collagenolytic and peptidic activities reduced similar to3-fold. In contrast, the specificity for type I collagen of the mutant Y189F dropped 3-fold without any significant alteration in general peptidase activity. Therefore, S-3' and in particular the hydrogen bonding potential of Tyr(189) is a specific molecular determinant for MMP-8 triple helicase activity. The cis bond connection to Asn(188) juxtaposes these two side chains for closely spaced hydrogen bonding with substrate that improves collagenolytic and general catalytic efficiency that could be exploited for new collagenase-specific inhibitor drugs.	Univ British Columbia, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Canadian Inst Hlth Res Grp Matrix Dynam, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Ctr Blood Res, 2199 Wesbrook Mall,JB Macdonald Bldg, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca						Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bigg HF, 2001, CANCER RES, V61, P3610; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fingleton B, 2003, EXPERT OPIN THER TAR, V7, P385, DOI 10.1517/14728222.7.3.385; Gioia M, 2002, J BIOL CHEM, V277, P23123, DOI 10.1074/jbc.M110873200; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; GROSS J, 1962, P NATL ACAD SCI USA, V48, P1014, DOI 10.1073/pnas.48.6.1014; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1986, J BIOL CHEM, V261, P5645; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Kadler KE, 1996, BIOCHEM J, V316, P1; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 2000, METH MOL B, V151, P377, DOI 10.1385/1-59259-046-2:377; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Knauper V, 2001, EUR J BIOCHEM, V268, P1888, DOI 10.1046/j.1432-1033.2001.02062.x; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lauer-Fields JL, 2002, BIOPOLYMERS, V66, P19, DOI 10.1002/bip.10201; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; MURPHY G, 1977, BIOCHEM J, V162, P195, DOI 10.1042/bj1620195; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OVERALL CM, 1991, INFECT IMMUN, V59, P4687, DOI 10.1128/IAI.59.12.4687-4692.1991; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; OVERALL CM, 1999, J DENT RES, V78, P458; Patterson ML, 2001, FEBS LETT, V503, P158, DOI 10.1016/S0014-5793(01)02723-5; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SODEK J, 1988, COLLAGEN REL RES, V8, P11; SODEK J, 1977, ARCH ORAL BIOL, V22, P655, DOI 10.1016/0003-9969(77)90095-4; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Sylvia C J, 2003, J Wound Care, V12, P13; Tam EM, 2004, J BIOL CHEM, V279, P43336, DOI 10.1074/jbc.M407186200; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Weiss MS, 1998, NAT STRUCT BIOL, V5, P676, DOI 10.1038/1368; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1980, J BIOL CHEM, V255, P6806; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201; Woessner J.F., 2000, PROTEIN PROFILE SER	60	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2370	2377		10.1074/jbc.M409603200	http://dx.doi.org/10.1074/jbc.M409603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15533938	hybrid			2022-12-25	WOS:000226341700074
J	Reinders, A; Panshyshyn, JA; Ward, JW				Reinders, A; Panshyshyn, JA; Ward, JW			Analysis of transport activity of Arabidopsis sugar alcohol permease homolog AtPLT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOSACCHARIDE TRANSPORTER; GLUCOSE-TRANSPORTER; MOLECULAR-CLONING; H+ SYMPORTER; EXPRESSION; GENE; IDENTIFICATION; PHLOEM; SENESCENCE; ABSCISSION	The transporters responsible for sugar uptake into non-photosynthetic sink tissues in plants, such as roots and flowers, have not been fully identified and analyzed. Plants encode around 100 putative sugar transporters within the major facilitator superfamily, yet only a few have been studied. Here we report the analysis of a sugar alcohol permease homolog (AtPLT5, At3g18830) from Arabidopsis. A wide range of sugars including hexoses, pentoses, tetroses, a sugar acid, and sugar alcohols but not disaccharides induced inward currents in oocytes expressing AtPLT5. AtPLT5 expression also resulted in C-14-labeled substrate uptake in oocytes, indicating that AtPLT5 encodes an ion-coupled uptake transporter. K-0.5 values for glucose and sorbitol were highly dependent on external pH. Expression of AtPLT5 was found primarily in sink tissues: in the elongation zone of roots, in the inflorescence stem, and several floral structures, especially in the floral abscission zone. Expression was induced by mechanical wounding and insect feeding. Analysis of transport properties and expression in Arabidopsis indicate that AtPLT5 functions to transport a wide range of sugars into specific sink tissues in the plant.	Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 250, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Ward, JW (corresponding author), Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 250, 1445 Gortner Ave, St Paul, MN 55108 USA.	jward@tc.umn.edu		Reinders, Anke/0000-0001-5351-3940; Ward, John/0000-0001-8185-0434				BISHOP PD, 1981, P NATL ACAD SCI-BIOL, V78, P3536, DOI 10.1073/pnas.78.6.3536; Bleecker AB, 1997, PLANT CELL, V9, P1169, DOI 10.1105/tpc.9.7.1169; BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Buttner M, 2000, PLANT CELL ENVIRON, V23, P175, DOI 10.1046/j.1365-3040.2000.00538.x; Chaillou S, 1998, APPL ENVIRON MICROB, V64, P4720; Chauhan S, 2000, PLANT J, V24, P511, DOI 10.1046/j.1365-313x.2000.00903.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Diez-Sampedro A, 2003, P NATL ACAD SCI USA, V100, P11753, DOI 10.1073/pnas.1733027100; Ehness R, 1997, PLANT J, V11, P539, DOI 10.1046/j.1365-313X.1997.11030539.x; Fiehn O, 2000, ANAL CHEM, V72, P3573, DOI 10.1021/ac991142i; Fiehn O, 2003, PHYTOCHEMISTRY, V62, P875, DOI 10.1016/S0031-9422(02)00715-X; Gao ZF, 2003, PLANT PHYSIOL, V131, P1566, DOI 10.1104/pp.102.016725; Imlau A, 1999, PLANT CELL, V11, P309, DOI 10.1105/tpc.11.3.309; Kiyosue T, 1998, BBA-BIOMEMBRANES, V1370, P187, DOI 10.1016/S0005-2736(98)00007-8; Leon J, 2001, J EXP BOT, V52, P1, DOI 10.1093/jexbot/52.354.1; Ludewig U, 2002, J BIOL CHEM, V277, P13548, DOI 10.1074/jbc.M200739200; Niederberger C, 1998, CURR GENET, V33, P255, DOI 10.1007/s002940050334; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; Noiraud N, 2000, PLANT PHYSIOL, V122, P1447, DOI 10.1104/pp.122.4.1447; Noiraud N, 2001, PLANT CELL, V13, P695, DOI 10.1105/tpc.13.3.695; Patrick JW, 2001, J EXP BOT, V52, P551, DOI 10.1093/jexbot/52.356.551; Patterson SE, 2001, PLANT PHYSIOL, V126, P494, DOI 10.1104/pp.126.2.494; Quirino BF, 2001, PLANT MOL BIOL, V46, P447, DOI 10.1023/A:1010639015959; Ramsperger-Gleixner M, 2004, PLANT PHYSIOL, V134, P147, DOI 10.1104/pp.103.027136; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; Schneidereit A, 2003, PLANT PHYSIOL, V133, P182, DOI 10.1104/pp.103.026674; Scholz-Starke J, 2003, PLANT PHYSIOL, V131, P70, DOI 10.1104/pp.012666; Simmons CR, 2003, PLANT MOL BIOL, V52, P433, DOI 10.1023/A:1023982704901; Sturm A, 1999, PLANT PHYSIOL, V121, P1, DOI 10.1104/pp.121.1.1; STURM A, 1990, PLANT CELL, V2, P1107, DOI 10.1105/tpc.2.11.1107; Torres GAM, 2003, PLANT MOL BIOL, V51, P341, DOI 10.1023/A:1022014229899; Truernit E, 1996, PLANT CELL, V8, P2169, DOI 10.1105/tpc.8.12.2169; Truernit E, 1999, PLANT J, V17, P191, DOI 10.1046/j.1365-313X.1999.00372.x; Tymowska-Lalanne Z, 1998, PLANTA, V207, P259, DOI 10.1007/s004250050481; VANDERSCHOOT C, 1990, PLANTA, V182, P9, DOI 10.1007/BF00239977; Weber A, 2000, PLANT CELL, V12, P787, DOI 10.1105/tpc.12.5.787; Wieczorke R, 1999, FEBS LETT, V464, P123, DOI 10.1016/S0014-5793(99)01698-1; Williams LE, 2000, TRENDS PLANT SCI, V5, P283, DOI 10.1016/S1360-1385(00)01681-2; Zhang LY, 2004, PLANT PHYSIOL, V135, P574, DOI 10.1104/pp.103.036632	39	59	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1594	1602		10.1074/jbc.M410831200	http://dx.doi.org/10.1074/jbc.M410831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15525644	hybrid			2022-12-25	WOS:000226195200090
J	Shiue, H; Musch, MW; Wang, YM; Chang, EB; Turner, JR				Shiue, H; Musch, MW; Wang, YM; Chang, EB; Turner, JR			Akt2 phosphorylates ezrin to trigger NHE3 translocation and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; CAMP-MEDIATED INHIBITION; APICAL NA+/H+ EXCHANGER; MYOSIN-BINDING SUBUNIT; ERM PROTEINS; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; GROWTH-FACTOR; BRUSH-BORDER; LIPID RAFT	Initiation of Na+-glucose cotransport in intestinal absorptive epithelia causes NHE3 to be translocated to the apical plasma membrane, leading to cytoplasmic alkalinization. We reported recently that this NHE3 translocation requires ezrin phosphorylation. However, the kinase that phosphorylates ezrin in this process has not been identified. Because Akt has also been implicated in NHE3 translocation, we investigated the hypothesis that Akt phosphorylates ezrin. After initiation of Na+-glucose cotransport, Akt is activated with kinetics that parallel those of ezrin phosphorylation. Inhibition of p38 MAP kinase, which blocks ezrin phosphorylation, also prevents Akt activation. Purified Akt directly phosphorylates recombinant ezrin at threonine 567 in vitro in an ATP-dependent manner. This in vitro phosphorylation can be prevented by Akt inhibitors. In intact cells, inhibition of either phosphoinositide 3-kinase, an upstream regulator of Akt, or inhibition of Akt itself using inhibitors validated in vitro prevents ezrin phosphorylation after initiation of Na+-glucose cotransport. Specific small interfering RNA knockdown of Akt2 prevented ezrin phosphorylation in intact cells. Pharmacological Akt inhibition or Akt2 knockdown also prevented NHE3 translocation and activation after initiation of Na+-glucose cotransport, confirming the functional role of Akt2. These studies therefore identify Akt2 as a critical kinase that regulates ezrin phosphorylation and activation. This Akt2-dependent ezrin phosphorylation leads to NHE3 translocation and activation.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Turner, JR (corresponding author), 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.	jturner@bsd.uchicago.edu	Turner, Jerrold R/A-6895-2009; Turner, Jerrold/H-1502-2019	Turner, Jerrold R/0000-0003-0627-9455; 	NCI NIH HHS [P30 CA014599, P30-CA14599] Funding Source: Medline; NIDDK NIH HHS [R01-DK038510, R01 DK061931, R01-DK61931, P30-DK42086, R01 DK038510, P30 DK042086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061931, P30DK042086, R01DK038510] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Brdickova N, 2001, FEBS LETT, V507, P133, DOI 10.1016/S0014-5793(01)02955-6; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Cha BY, 2004, J CELL SCI, V117, P3353, DOI 10.1242/jcs.01180; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Finnerty CM, 2004, J CELL SCI, V117, P1547, DOI 10.1242/jcs.01038; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Hayashi H, 2004, J GEN PHYSIOL, V123, P491, DOI 10.1085/jgp.200308979; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Hou JCQ, 2003, MOL BIOL CELL, V14, P3578, DOI 10.1091/mbc.E03-02-0012; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Lee-Kwon W, 2003, J BIOL CHEM, V278, P16494, DOI 10.1074/jbc.M300580200; Lee-Kwon W, 2001, J BIOL CHEM, V276, P31296, DOI 10.1074/jbc.M103900200; Li X, 2004, GASTROENTEROLOGY, V126, P122, DOI 10.1053/j.gastro.2003.10.061; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Murakami M, 2004, EUR J BIOCHEM, V271, P3330, DOI 10.1111/j.1432-1033.2004.04267.x; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; Taniyama Y, 2004, AM J PHYSIOL-CELL PH, V287, pC494, DOI 10.1152/ajpcell.00439.2003; Turner JR, 2001, AM J PHYSIOL-CELL PH, V281, pC1533, DOI 10.1152/ajpcell.2001.281.5.C1533; Turner JR, 1996, J BIOL CHEM, V271, P7738, DOI 10.1074/jbc.271.13.7738; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; Xu JF, 2004, J BIOL CHEM, V279, P35914, DOI 10.1074/jbc.M402297200; Yonemura S, 2002, J CELL SCI, V115, P2569; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zhang HFM, 2004, J BIOL CHEM, V279, P22539, DOI 10.1074/jbc.M314337200; Zhao HR, 2004, P NATL ACAD SCI USA, V101, P9485, DOI 10.1073/pnas.0308400101; Zhuang SG, 2004, AM J PHYSIOL-RENAL, V287, pF365, DOI 10.1152/ajprenal.00035.2004	61	78	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1688	1695		10.1074/jbc.M409471200	http://dx.doi.org/10.1074/jbc.M409471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15531580	Green Accepted, hybrid			2022-12-25	WOS:000226195200100
J	Zang, H; Harris, TM; Guengerich, FP				Zang, H; Harris, TM; Guengerich, FP			Kinetics of nucleotide incorporation opposite DNA bulky guanine N-2 adducts by processive bacteriophage T7 DNA polymerase (exonuclease(-)) and HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							I KLENOW FRAGMENT; STYRENE OXIDE ADDUCTS; STEADY-STATE KINETICS; TRANSLESION SYNTHESIS; POSTOLIGOMERIZATION SYNTHESIS; DEOXYGUANOSINE ADDUCT; REPLICATION FIDELITY; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; SEQUENCE CONTEXT	Six oligonucleotides with carcinogen derivatives bound at the N2 atom of deoxyguanosine were prepared, including adducts derived from butadiene, acrolein, crotonaldehyde, and styrene, and examined for effects on the replicative enzymes bacteriophage DNA polymerase T7(-) (T7(-)) and HIV-1 reverse transcriptase for comparison with previous work on smaller DNA adducts. All of these adducts strongly blocked dCTP incorporation opposite the adducts. dATP was preferentially incorporated opposite the acrolein and crotonaldehyde adducts, and dTTP incorporation was preferred at the butadiene- and styrene-derived adducts. Steady-state kinetic analysis indicated that the reduced catalytic efficiency with adducted DNA involved both an increased Km and attenuated k(cat). Fluorescence estimates of K-d and pre-steady-state kinetic measurements of k(off) showed no significantly decreased affinity of T7(-) with the adducted oligonucleotides or the dNTP. Pre-steady-state kinetics showed no burst phase kinetics for dNTP incorporation with any of the modified oligonucleotides. These results indicate that phosphodiester bond formation or a conformational change of the enzyme DNA complex is rate-limiting instead of the step involving release of the oligonucleotide. Thio elemental effects for dNTP incorporation were generally relatively small but variable, indicating that the presence of adducts may sometimes make phosphodiester bond formation rate-limiting but not always.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [P01 ES05355, R01 ES10375, P30 ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005355, P30ES000267, R01ES010375] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alekseyev YO, 2000, BIOCHEMISTRY-US, V39, P10431, DOI 10.1021/bi000552u; Alekseyev YO, 2001, BIOCHEMISTRY-US, V40, P2282, DOI 10.1021/bi002245u; BARALE R, 1991, MUTAT RES, V257, P107, DOI 10.1016/0165-1110(91)90021-M; Beard WA, 2003, STRUCTURE, V11, P489, DOI 10.1016/S0969-2126(03)00051-0; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BORER PN, 1975, HDB BIOCH MOL BIOL, P589; BROWN WC, 1991, BIOCHEMISTRY-US, V30, P1342, DOI 10.1021/bi00219a026; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Carmical JR, 2000, ENVIRON MOL MUTAGEN, V35, P48, DOI 10.1002/(SICI)1098-2280(2000)35:1<48::AID-EM7>3.3.CO;2-3; Carmical JR, 2000, CHEM RES TOXICOL, V13, P18, DOI 10.1021/tx9901332; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; Choi JY, 2004, J BIOL CHEM, V279, P19217, DOI 10.1074/jbc.M313759200; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; Cooper MD, 2000, TETRAHEDRON LETT, V41, P3555, DOI 10.1016/S0040-4039(00)00461-5; de los Santos C, 2001, J BIOL CHEM, V276, P9077, DOI 10.1074/jbc.M009028200; DeCorte BL, 1996, CHEM RES TOXICOL, V9, P630, DOI 10.1021/tx9501795; DEMEESTER C, 1988, MUTAT RES, V195, P273, DOI 10.1016/0165-1110(88)90005-X; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; DOSANJH MK, 1990, BIOCHEMISTRY-US, V29, P4698, DOI 10.1021/bi00471a026; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Furge LL, 1999, BIOCHEMISTRY-US, V38, P4818, DOI 10.1021/bi982163u; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; Hays H, 2002, BIOCHEMISTRY-US, V41, P4771, DOI 10.1021/bi0120648; Hemminki K, 1994, DNA ADDUCTS IDENTIFI; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Hughes K, 2003, J TOXICOL ENV HEAL B, V6, P55, DOI 10.1080/10937400306478; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Kanuri M, 2002, J BIOL CHEM, V277, P18257, DOI 10.1074/jbc.M112419200; Kim HYH, 2002, J AM CHEM SOC, V124, P9324, DOI 10.1021/ja020333r; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; KIM SJ, 1992, J AM CHEM SOC, V114, P5480, DOI 10.1021/ja00039a101; KIM SJ, 1991, TETRAHEDRON LETT, V32, P6073; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Kumar JK, 2001, J BIOL CHEM, V276, P34905, DOI 10.1074/jbc.M104151200; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Langouet S, 1998, BIOCHEMISTRY-US, V37, P5184, DOI 10.1021/bi972327r; Langouet S, 1997, BIOCHEMISTRY-US, V36, P6069, DOI 10.1021/bi962526v; LATHAM GJ, 1995, CHEM RES TOXICOL, V8, P422, DOI 10.1021/tx00045a014; Latham GJ, 1996, CHEM RES TOXICOL, V9, P1167, DOI 10.1021/tx9600558; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; LATHAM GJ, 1993, J BIOL CHEM, V268, P23427; LINDSLEY JE, 1994, BIOCHEMISTRY-US, V33, P764, DOI 10.1021/bi00169a018; LOEB LA, 1991, CANCER RES, V51, P3075; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; MANIATIS T, 1989, MOL CLONING LAB MANU, pA1; Minko IG, 2003, J BIOL CHEM, V278, P784, DOI 10.1074/jbc.M207774200; Minko IG, 2001, J BIOL CHEM, V276, P2517, DOI 10.1074/jbc.M007867200; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Nechev LV, 2000, CHEM RES TOXICOL, V13, P421, DOI 10.1021/tx990167+; Nechev LV, 2002, CHEM RES TOXICOL, V15, P607, DOI 10.1021/tx010181y; Nechev LV, 2001, CHEM RES TOXICOL, V14, P379, DOI 10.1021/tx000241k; Nechev LV, 2001, CHEM RES TOXICOL, V14, P1506, DOI 10.1021/tx0100690; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Perlow RA, 2001, J MOL BIOL, V309, P519, DOI 10.1006/jmbi.2001.4674; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Sanchez AM, 2003, CHEM RES TOXICOL, V16, P1019, DOI 10.1021/tx034066u; Searle C. F., 1984, CHEM CARCINOGENS; Selzer RR, 1996, CHEM RES TOXICOL, V9, P126, DOI 10.1021/tx950101o; Selzer RR, 1997, CARCINOGENESIS, V18, P1993, DOI 10.1093/carcin/18.10.1993; Setayesh FR, 1998, CHEM RES TOXICOL, V11, P766, DOI 10.1021/tx9800147; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; Shibutani S, 1997, J BIOL CHEM, V272, P13916, DOI 10.1074/jbc.272.21.13916; SHIBUTANI S, 1993, CHEM RES TOXICOL, V6, P819, DOI 10.1021/tx00036a011; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; Simhadri S, 2002, MUTAT RES-FUND MOL M, V508, P137, DOI 10.1016/S0027-5107(02)00211-7; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; TAN HB, 1994, BIOCHEMISTRY-US, V33, P5335, DOI 10.1021/bi00183a042; Tretyakova N, 1997, CHEM RES TOXICOL, V10, P1171, DOI 10.1021/tx9700681; Tretyakova NY, 1997, CHEM RES TOXICOL, V10, P779, DOI 10.1021/tx970004q; VanderVeen LA, 2001, J BIOL CHEM, V276, P9066, DOI 10.1074/jbc.M008900200; Washington MT, 2003, P NATL ACAD SCI USA, V100, P12093, DOI 10.1073/pnas.2134223100; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1039, DOI 10.1021/bi011496f; Yang IY, 2003, J BIOL CHEM, V278, P13989, DOI 10.1074/jbc.M212535200; Yang IY, 2002, BIOCHEMISTRY-US, V41, P13826, DOI 10.1021/bi0264723; Yun CH, 2000, BIOCHEMISTRY-US, V39, P11319, DOI 10.1021/bi000869u; Zhang YB, 2002, MUTAT RES-FUND MOL M, V510, P23, DOI 10.1016/S0027-5107(02)00249-X; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j; Zhuang P, 2001, BIOCHEMISTRY-US, V40, P6660, DOI 10.1021/bi010005o; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	108	21	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1165	1178		10.1074/jbc.M405996200	http://dx.doi.org/10.1074/jbc.M405996200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15533946	hybrid			2022-12-25	WOS:000226195200038
J	Feinstein, E				Feinstein, E			Ral-GTPases: good chances for a long-lasting fame	ONCOGENE			English	Editorial Material							REQUIREMENT; INVASION		Quark Biotech Inc, Ness Ziona, Israel		Feinstein, E (corresponding author), Quark Biotech Inc, Ness Ziona, Israel.	elenaf@qbi.co.il						Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Malumbres M, 2003, NAT REV CANCER, V3, P708, DOI 10.1038/nrc1193; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003	9	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					326	328		10.1038/sj.onc.1208252	http://dx.doi.org/10.1038/sj.onc.1208252			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531910				2022-12-25	WOS:000226279700003
J	Wei, LH; Lai, KP; Chen, CA; Cheng, CH; Huang, YJ; Chou, CH; Kuo, ML; Hsieh, CY				Wei, LH; Lai, KP; Chen, CA; Cheng, CH; Huang, YJ; Chou, CH; Kuo, ML; Hsieh, CY			Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappa B	ONCOGENE			English	Article						arsenic trioxide; irradiation; matrix metalloproteinase-9; metastasis; nuclear factor kappa B	ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN CERVICAL-CANCER; CELL LUNG-CANCER; MATRIX METALLOPROTEINASES; IONIZING-RADIATION; HUMAN GLIOBLASTOMA; INDUCED APOPTOSIS; CLINICAL-TRIALS; GLIOMA-CELLS; IN-VITRO	Arsenic trioxide (ATO) has been implicated as a promising anticancer agent by inhibiting cell growth and inducing apoptosis in certain types of cancer cells. This study explored the antimetastasis property of arsenic, drew potential link between arsenic use and radiotherapy, and uncovered the specific mechanisms underlying these remarkable responses. Using gelatin invasion assay and intravasation assay, we report the novel finding that low-dose ATO (1 muM) reduced the intrinsic migration ability of HeLa cells and significantly inhibited radiation-promoted tumor invasive potential of CaSki cells without inducing apoptotic cell death. Using the murine Lewis lung carcinoma model, the control animals and ATO treatment animals (1 mg/kg i.p., twice weekly) displayed similar in vivo growth kinetics, where as the radiation (30 Gy in one fraction) and concurrent treatment groups showed considerable growth inhibition. Importantly, although concurrent treatment did not enhance the effectiveness of radiation therapy to the primary tumor, further examination of the lungs revealed that all animals succumbed to radiation-accelerated lung metastases could be effectively treated by combination of ATO and radiation. Radiation-induced matrix metalloproteinase-9 (MMP-9) expression was significantly inhibited by ATO using sequential analysis of the expression of MMPs in xenografts. Supporting this observation, ATO directly downregulates radiation-induced MMP-9 mRNA expression by inhibiting nuclear factor kappaB activity in human cervical cancer cells. In sum, concurrent arsenic radiation therapy not only achieves local tumor control but also inhibits distant metastasis. Experimental results of this study highlight a novel strategy in cancer treatment.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	cyhsieh@ha.mc.ntu.edu.tw	Wei, Lin-Hung/B-1188-2008; Huang, Ruby Yun-Ju/AAE-8854-2019; Kuo, Min-Liang/C-4872-2009	Huang, Ruby Yun-Ju/0000-0001-6376-3185; Wei, Lin-Hung/0000-0001-8789-0859; KUO, MIN-LIANG/0000-0002-7139-0144; CHEN, CHI-AN/0000-0001-6670-7939; CHENG, JASON CHIA-HSIEN/0000-0002-2007-0220				Achanzar WE, 2002, JNCI-J NATL CANCER I, V94, P1888, DOI 10.1093/jnci/94.24.1888; Azria D, 2003, B CANCER, V90, pS202; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Camphausen K, 2001, CANCER RES, V61, P2207; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Choy H, 1998, J CLIN ONCOL, V16, P3316, DOI 10.1200/JCO.1998.16.10.3316; Choy H, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00268-9; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Chun YJ, 2002, FEBS LETT, V519, P195, DOI 10.1016/S0014-5793(02)02765-5; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Didelot C, 2001, INT J RADIAT ONCOL, V51, P1354, DOI 10.1016/S0360-3016(01)02608-6; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eichholtz-Wirth H, 2000, APOPTOSIS, V5, P255, DOI 10.1023/A:1009656513307; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorski DH, 2003, CANCER RES, V63, P308; Hughes MF, 2002, TOXICOL LETT, V133, P1, DOI 10.1016/S0378-4274(02)00084-X; Inanami O, 2002, INT J RADIAT BIOL, V78, P267, DOI 10.1080/09553000110105695; Isaac N, 2002, CANCER, V95, P696, DOI 10.1002/cncr.10744; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kato T, 2000, HEAD NECK-J SCI SPEC, V22, P748, DOI 10.1002/1097-0347(200012)22:8<748::AID-HED2>3.3.CO;2-Y; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kondraganti S, 2000, CANCER RES, V60, P6851; Kwong YL, 1997, BLOOD, V89, P3487, DOI 10.1182/blood.V89.9.3487; Lew YS, 2002, CANCER RES, V62, P4202; LIEBMANN J, 1994, J NATL CANCER I, V86, P441, DOI 10.1093/jnci/86.6.441; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; McGinn CJ, 1996, J NATL CANCER I, V88, P1193, DOI 10.1093/jnci/88.17.1193; Miller WH, 2002, CANCER RES, V62, P3893; Miyamoto S, 2004, CANCER RES, V64, P665, DOI 10.1158/0008-5472.CAN-03-1916; Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6-suppl_2-22; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Qian LW, 2002, CLIN CANCER RES, V8, P1223; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Sienel W, 2003, INT J CANCER, V103, P647, DOI 10.1002/ijc.10841; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Strand S, 2004, ONCOGENE, V23, P3732, DOI 10.1038/sj.onc.1207387; Tanioka Y, 2003, BRIT J CANCER, V89, P2116, DOI 10.1038/sj.bjc.6601372; van Kempen LCL, 2002, CANCER CELL, V2, P251, DOI 10.1016/S1535-6108(02)00157-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Wick W, 2002, CANCER RES, V62, P1915; Wild-Bode C, 2001, CANCER RES, V61, P2744; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	56	58	62	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					390	398		10.1038/sj.onc.1208192	http://dx.doi.org/10.1038/sj.onc.1208192			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531921				2022-12-25	WOS:000226279700010
J	Stoothoff, WH; Cho, JH; McDonald, RP; Johnson, GVW				Stoothoff, WH; Cho, JH; McDonald, RP; Johnson, GVW			FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; DISEASE-LIKE PHOSPHORYLATION; ALZHEIMERS-DISEASE; BETA-CATENIN; PROTEIN-TAU; TYROSINE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; STRUCTURAL BASIS; MAMMALIAN-CELLS; KINASE-3-BETA	Tau is a microtubule-associated protein found primarily in neurons, and its function is regulated by site-specific phosphorylation. Although it is well established that tau is phosphorylated at both primed and unprimed epitopes by glycogen synthase kinase 3beta (GSK3beta), how specific proteins that interact with GSK3beta regulate tau phosphorylation has not been thoroughly examined. Members of the FRAT ( frequently rearranged in advanced T-cell lymphoma) protein family have been shown to interact with GSK3beta, and FRAT-1 has been shown to modulate the activity of GSK3beta toward tau and other substrates. However, the effects of FRAT-2 on GSK3beta activity and tau phosphorylation have not been examined. Therefore in this study the effects of FRAT-2 on GSK3beta activity and tau phosphorylation were examined. In situ, FRAT-2 significantly increased GSK3beta-mediated phosphorylation of tau at a primed epitope while not significantly affecting the phosphorylation of unprimed sites. Co-immunoprecipitation studies revealed that association of FRAT-2 with GSK3beta resulted in a significant increase in phosphorylation of a primed substrate but did not alter phosphorylation of an unprimed substrate. Further, in vitro assays using recombinant proteins directly demonstrated that FRAT-2 enhances GSK3beta-mediated phosphorylation of a primed substrate to a greater extent than an unprimed substrate. In addition, FRAT-2 is phosphorylated by GSK3beta. This is the first demonstration of a protein differentially regulating the activity of GSK3beta toward primed and unprimed epitopes.	Univ Alabama, Dept Psychiat, Sch Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, Sch Med, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404				Abraha A, 2000, J CELL SCI, V113, P3737; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ferkey DM, 2002, J BIOL CHEM, V277, P16147, DOI 10.1074/jbc.M112363200; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Freemantle SJ, 2002, GENE, V291, P17, DOI 10.1016/S0378-1119(02)00594-2; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; MANDELKOW EM, 1993, ANN NY ACAD SCI, V695, P209, DOI 10.1111/j.1749-6632.1993.tb23054.x; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Saitoh T, 2001, INT J ONCOL, V19, P311; Saitoh T, 2001, BIOCHEM BIOPH RES CO, V281, P815, DOI 10.1006/bbrc.2001.4421; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Stoothof WH, 2002, J NEUROCHEM, V83, P904, DOI 10.1046/j.1471-4159.2002.01197.x; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; van Amerongen R, 2004, J BIOL CHEM, V279, P26967, DOI 10.1074/jbc.M400439200; Wagner U, 1996, J CELL SCI, V109, P1537; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	43	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					270	276		10.1074/jbc.M410061200	http://dx.doi.org/10.1074/jbc.M410061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15522877	hybrid			2022-12-25	WOS:000226025100033
J	Burack, WR; Shaw, AS				Burack, WR; Shaw, AS			Live cell imaging of ERK and MEK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; NUCLEAR TRANSLOCATION; MECHANISM; PHOSPHORYLATION; LOCALIZATION; TRANSPORT; SIGNAL; STIMULATION; PATHWAY	In response to epidermal growth factor (EGF), the mitogen-activated protein kinase ERK2 translocates into the nucleus. To probe the mechanisms regulating the subcellular localization of ERK2, we used live cell imaging to examine the interaction between MEK1 and ERK2. Fluorescence resonance energy transfer (FRET) studies show that MEK1 and ERK2 directly interact and demonstrate that this interaction in the cytoplasm is largely responsible for cytoplasmic retention of ERK2. Stimulation with EGF caused loss of FRET as ERK separated from MEK and moved into the nucleus. FRET was recovered as ERK returned to the cytosol, indicating ERK reassociation with MEK in the cytoplasm. The EGF-induced transit of ERK through the nucleus was complete within 20 min, and there was no significant movement of MEK into the nucleus. Fluorescence recovery after photobleaching experiments was used to assess the rate of movement of MEK and ERK. The steady-state rate of ERK entry into the nucleus in resting cells was energy-independent and greater than the rate of ERK entry upon EGF stimulation. This suggests that the rate constant for ERK transport across the nuclear membrane is not limiting nuclear entry. Thus, we suggest that the movement of ERK into and out of the nucleus in response to agonist occurs primarily by diffusion and is controlled by interactions with binding partners in the cytosol and nucleus. No evidence of ERK dimerization was detected by FRET methods; the kinetics for nucleocytoplasmic transport were unaffected by mutations in the ERK putative dimerization domain.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Burack, WR (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid, St Louis, MO 63110 USA.	rburack@path.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA102441] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA102441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Furuno T, 2001, J IMMUNOL, V166, P4416, DOI 10.4049/jimmunol.166.7.4416; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yao Z, 2001, ONCOGENE, V20, P7588, DOI 10.1038/sj.onc.1204963; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	22	87	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3832	3837		10.1074/jbc.M410031200	http://dx.doi.org/10.1074/jbc.M410031200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15546878	hybrid			2022-12-25	WOS:000226983900086
J	Graslund, T; Li, XL; Magnenat, L; Popkov, M; Barbas, CF				Graslund, T; Li, XL; Magnenat, L; Popkov, M; Barbas, CF			Exploring strategies for the design of artificial transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLOBIN GENE; GREEK HEREDITARY PERSISTENCE; ZINC-FINGER DOMAINS; BETA-GLOBIN; FETAL-HEMOGLOBIN; DNA-SEQUENCES; EXPRESSION; PROMOTER; BINDING; ACTIVATION	Artificial transcription factors can be engineered to interact with specific DNA sequences to modulate endogenous gene expression within cells. A significant hurdle to implementation of this approach is the selection of the appropriate DNA sequence for targeting. We reasoned that a good target site should be located in chromatin, where it is accessible to DNA-binding proteins, and it should be, in the close vicinity of known transcriptional regulators of the gene. Here we have explored the efficacy of these criteria to guide our selection of potential regulators of gamma-globin expression. Several zinc finger-based transcriptional activators were designed to target the sites proximal to the -117-position of the gamma-globin promoter. This region is proximal to the binding sites of known and potential natural transcription factors. Design and study of three transcription factors identified the potent transcriptional activator, ggl-VP64-RA. This transcription factor was able to interact directly with the gamma-globin promoter and up-regulate expression of reporter gene constructs as well as the endogenous gene in a selective manner. Transfection of a gg1-VP64-RA expression vector or retroviral delivery of this transcription factor into the erythroleukemia cell line K562 resulted in an increase of fetal hemoglobin. The gamma-globin content of cells expressing gg1-vp64-HA showed up to 16-fold higher levels of fetal hemoglobin than the native K562 cell line. These transcriptional activators constitute a novel class of regulators of the globin locus that may be suitable for treatment of diseases arising from mutations in this locus such as sickle cell disease and thalassemic diseases.	Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Barbas, CF (corresponding author), Skaggs Inst Chem Biol, Dept Mol Biol, BCC-550,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	carlos@scripps.edu			NIDDK NIH HHS [R01 DK61803-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061803] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANAGNOU NP, 1986, EMBO J, V5, P121, DOI 10.1002/j.1460-2075.1986.tb04185.x; Asano H, 1999, MOL CELL BIOL, V19, P3571; Asano H, 2000, BLOOD, V95, P3578, DOI 10.1182/blood.V95.11.3578.011k48_3578_3584; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; Blouin MJ, 2000, NAT MED, V6, P177, DOI 10.1038/72279; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; COLLINS FS, 1985, NATURE, V313, P325, DOI 10.1038/313325a0; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; GELINAS R, 1985, NATURE, V313, P323, DOI 10.1038/313323a0; GUMUCIO DL, 1991, BLOOD, V78, P1853; Haley JD, 2003, BIOCHEM PHARMACOL, V66, P1755, DOI 10.1016/S0006-2952(03)00542-2; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; Langdon SD, 1998, BLOOD, V91, P309, DOI 10.1182/blood.V91.1.309.309_309_318; Laniel MA, 2000, METH MOL B, V148, P13; Li QL, 2002, BLOOD, V100, P3077, DOI 10.1182/blood-2002-04-1104; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Magnenat L, 2004, J MOL BIOL, V341, P635, DOI 10.1016/j.jmb.2004.06.030; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; MURRAY N, 1988, BRIT J HAEMATOL, V69, P89, DOI 10.1111/j.1365-2141.1988.tb07607.x; Peterson KR, 2003, CURR OPIN HEMATOL, V10, P123, DOI 10.1097/00062752-200303000-00004; POWARS DR, 1989, ANN NY ACAD SCI, V565, P262, DOI 10.1111/j.1749-6632.1989.tb24174.x; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Segal DJ, 2004, J BIOL CHEM, V279, P14509, DOI 10.1074/jbc.M400349200; Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Skarpidi E, 2000, BLOOD, V96, P321, DOI 10.1182/blood.V96.1.321.013k48_321_326; Stamatoyannopoulos G., 2001, MOL BASIS BLOOD DIS, Vthird, P135; Swank RA, 1998, CURR OPIN GENET DEV, V8, P366, DOI 10.1016/S0959-437X(98)80095-6; Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Xu D, 2002, J PHARMACOL EXP THER, V302, P963, DOI 10.1124/jpet.102.033639; Xu L, 2001, MOL THER, V3, P262, DOI 10.1006/mthe.2000.0254; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	46	69	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3707	3714		10.1074/jbc.M406809200	http://dx.doi.org/10.1074/jbc.M406809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15537646	Green Submitted, hybrid			2022-12-25	WOS:000226983900070
J	Heinz, U; Kiefer, M; Tholey, A; Adolph, HW				Heinz, U; Kiefer, M; Tholey, A; Adolph, HW			On the competition for available zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; METAL-BINDING; DNA-BINDING; COORDINATION; METALLOTHIONEIN; PROTEIN; REACTIVATION; MUTANTS; SITES; EXAFS	Extended x-ray absorption fine structure (EXAFS) spectroscopy was combined with thermodynamic and kinetic approaches to investigate zinc binding to a zinc finger (C2H2) and a tetrathiolate (C-4) peptide. Both peptides represent structural zinc sites of proteins and rapidly bind a single zinc ion with picomolar dissociation constants. In competition with EDTA the transfer of peptide-bound zinc ions proved to be 6 orders of magnitude faster than predicted for a dissociation-association mechanism thus requiring ligand exchange mechanisms via peptide-zinc-EDTA complexes. EXAFS spectra of C2H2 showed the expected Cys(2)His(2)-ligand geometry when fully loaded with zinc. For a 2-fold excess of peptide, however, the existence of zinc-bridged peptide-peptide complexes with dominating sulfur coordination could be clearly shown. Whereas zinc binding kinetics of C2H2 appeared as a simple second order process, the suggested mechanism for C-4 comprises a zinc-bridged Zn-(C-4)(2) species as well as a Zn-C-4 species with less than 4 metal-bound thiolates, which is supported by EXAFS results. A rapid equilibrium of bound and unbound states of individual ligands might explain the kinetic instability of zinc-peptide complexes, which enables fast ligand exchange during the encounter of occupied and unoccupied acceptor sites. Depending on relative concentrations and stabilities, this results in a rapid transfer of zinc ions in the virtual absence of free zinc ions, as seen for the zinc transfer to EDTA, or in the formation of zinc-bridged complexes, as seen for both peptides with excess of peptides over available zinc.	Univ Saarland, Dept Biochem, D-66041 Saarbrucken, Germany; Univ Saarland, Dept Biochem Engn, D-66041 Saarbrucken, Germany; Univ Saarland, Dept Biochem & Macromol Organ Chem, D-66041 Saarbrucken, Germany	Saarland University; Saarland University; Saarland University	Adolph, HW (corresponding author), Univ Saarland, Dept Biochem, D-66041 Saarbrucken, Germany.	hwadolph@rz.uni-sb.de	Adolph, Hans W/A-2104-2008; Tholey, Andreas/B-3407-2010	Tholey, Andreas/0000-0002-8687-6817				Adolph HW, 2000, BIOCHEMISTRY-US, V39, P12885, DOI 10.1021/bi001376s; AL-KARADAGHI S, 1994, ACTA CRYSTALLOGR D, V50, P793, DOI 10.1107/S0907444994005263; Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Buchsbaum JC, 2000, INORG CHIM ACTA, V297, P217, DOI 10.1016/S0020-1693(99)00313-8; Busenlehner LS, 2001, BIOCHEMISTRY-US, V40, P4426, DOI 10.1021/bi010006g; Clark-Baldwin K, 1998, J AM CHEM SOC, V120, P8401, DOI 10.1021/ja980580o; Collet JF, 2003, J BIOL CHEM, V278, P45325, DOI 10.1074/jbc.M307818200; Cox EH, 2000, CURR OPIN CHEM BIOL, V4, P162, DOI 10.1016/S1367-5931(99)00070-8; Dauter Z, 1996, P NATL ACAD SCI USA, V93, P8836, DOI 10.1073/pnas.93.17.8836; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORMICKAKOZLOWSKA G, 1988, EUR J BIOCHEM, V173, P281, DOI 10.1111/j.1432-1033.1988.tb13996.x; GAN T, 1995, J BIOL CHEM, V270, P5339, DOI 10.1074/jbc.270.10.5339; GERSCHITZ J, 1978, EUR J BIOCHEM, V87, P591, DOI 10.1111/j.1432-1033.1978.tb12411.x; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; Hedin L., 1969, SOLID STATE PHYS, V23, P1, DOI [10.1016/S0081-1947(08)60615-3, DOI 10.1016/S0081-1947(08)60615-3]; JEFFERSON JR, 1990, ANAL BIOCHEM, V187, P328, DOI 10.1016/0003-2697(90)90465-L; JELOKOVA J, 1994, EUR J BIOCHEM, V225, P1015, DOI 10.1111/j.1432-1033.1994.1015b.x; JOYNER RW, 1987, J PHYS C SOLID STATE, V20, P4005, DOI 10.1088/0022-3719/20/25/028; KAEGI JH, 1961, J BIOL CHEM, V236, P2435; Krezel A, 2003, CHEM COMMUN, P704, DOI 10.1039/b300632h; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LEE PA, 1975, PHYS REV B, V11, P2795, DOI 10.1103/PhysRevB.11.2795; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Maret W, 2004, BIOCHEMISTRY-US, V43, P3301, DOI 10.1021/bi036340p; MARET W, 2002, ZINC BIOCH PHYSL HOM; Meijers R, 2001, J BIOL CHEM, V276, P9316, DOI 10.1074/jbc.M010870200; Miura T, 1998, BBA-PROTEIN STRUCT M, V1384, P171, DOI 10.1016/S0167-4838(98)00015-6; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Otvos J. D., 1989, COMMENTS INORG CHEM, V9, P1, DOI DOI 10.1080/02603598908035801; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PETTIFER RF, 1985, J APPL CRYSTALLOGR, V18, P404, DOI 10.1107/S0021889885010627; Roesijadi G, 1998, J BIOL CHEM, V273, P17425, DOI 10.1074/jbc.273.28.17425; RUDOLPH R, 1978, EUR J BIOCHEM, V87, P601, DOI 10.1111/j.1432-1033.1978.tb12412.x; SHI YG, 1993, BIOPHYS J, V64, P749, DOI 10.1016/S0006-3495(93)81435-8; Simonson T, 2002, PROTEINS, V49, P37, DOI 10.1002/prot.10200; Valladares MH, 2000, FEBS LETT, V467, P221, DOI 10.1016/S0014-5793(00)01102-9; Vallee B L, 1995, EXS, V73, P259; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VASAK M, 1981, BIOCHEMISTRY-US, V20, P2852, DOI 10.1021/bi00513a022; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Yang Y, 2001, P NATL ACAD SCI USA, V98, P5556, DOI 10.1073/pnas.101123298; ZEPPEZAUER M, 1986, J PHYS, V47	46	64	64	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3197	3207		10.1074/jbc.M409425200	http://dx.doi.org/10.1074/jbc.M409425200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15536071	hybrid			2022-12-25	WOS:000226983900011
J	Privezentzev, CV; Keeley, A; Sigala, B; Tsaneva, IR				Privezentzev, CV; Keeley, A; Sigala, B; Tsaneva, IR			The role of RuvA octamerization for RuvAB function in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; HOLLIDAY JUNCTION RESOLVASE; MYCOBACTERIUM-LEPRAE RUVA; MIGRATION MOTOR PROTEIN; DNA HELICASE ACTIVITY; BRANCH MIGRATION; CRYSTAL-STRUCTURE; HOMOLOGOUS RECOMBINATION; SCHIZOSACCHAROMYCES-POMBE; RECOGNITION PROTEIN	RuvA plays an essential role in branch migration of the Holliday junction by RuvAB as part of the RuvABC pathway for processing Holliday junctions in Escherichia coli. Two types of RuvA-Holliday junction complexes have been characterized: 1) complex I containing a single RuvA tetramer and 2) complex H in which the junction is sandwiched between two RuvA tetramers. The functional differences between the two forms are still not clear. To investigate the role of RuvA octamerization, we introduced three amino acid substitutions designed to disrupt the E. coli RuvA tetramer-tetramer interface as identified by structural studies. The mutant RuvA was tetrameric and interacted with both RuvB and junction DNA but, as predicted, formed complex I only at protein concentrations up to 500 nm. We present biochemical and surface plasmon resonance evidence for functional and physical interactions of the mutant RuvA with RuvB and RuvC on synthetic junctions. The mutant RuvA with RuvB showed DNA helicase activity and could support branch migration of synthetic four-way and three-way junctions. However, junction binding and the efficiency of branch migration of four-way junctions were affected. The activity of the RuvA mutant was consistent with a RuvAB complex driven by one RuvB hexamer only and lead us to propose that one RuvA tetramer can only support the activity of one RuvB hexamer. Significantly, the mutant failed to complement the UV sensitivity of E. coli DeltaruvA cells. These results indicate strongly that RuvA octamerization is essential for the full biological activity of RuvABC.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London	Tsaneva, IR (corresponding author), UCL, Dept Biochem & Mol Biol, Mortimer St, London WC1E 6BT, England.	tsaneva@biochem.ucl.ac.uk						Arenas-Licea J, 2000, J MOL BIOL, V301, P839, DOI 10.1006/jmbi.2000.4009; Ariyoshi M, 2000, P NATL ACAD SCI USA, V97, P8257, DOI 10.1073/pnas.140212997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chamberlain D, 1998, J MOL BIOL, V284, P385, DOI 10.1006/jmbi.1998.2177; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; Dickman MJ, 2002, EUR J BIOCHEM, V269, P5492, DOI 10.1046/j.1432-1033.2002.03250.x; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; Han YW, 2001, J BIOL CHEM, V276, P35024, DOI 10.1074/jbc.M103611200; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; Hiom K, 1996, GENES CELLS, V1, P443, DOI 10.1046/j.1365-2443.1996.d01-253.x; Hishida T, 1996, GENE, V182, P63, DOI 10.1016/S0378-1119(96)00474-X; Hishida T, 1999, J BIOL CHEM, V274, P25335, DOI 10.1074/jbc.274.36.25335; Ingleston SM, 2000, EMBO J, V19, P6266, DOI 10.1093/emboj/19.22.6266; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; IYPE LE, 1995, J BIOL CHEM, V270, P19473, DOI 10.1074/jbc.270.33.19473; IYPE LE, 1994, J BIOL CHEM, V269, P24967; Kvaratskhelia M, 2000, J MOL BIOL, V297, P923, DOI 10.1006/jmbi.2000.3624; Lee YC, 2003, J MOL BIOL, V333, P677, DOI 10.1016/j.jmb.2003.08.047; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; McGlynn P, 2001, J BIOL CHEM, V276, P41938, DOI 10.1074/jbc.M107945200; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; Miyata T, 2000, J STRUCT BIOL, V131, P83, DOI 10.1006/jsbi.2000.4290; MULLER B, 1993, J BIOL CHEM, V268, P17179; Nishino T, 1998, STRUCTURE, V6, P11, DOI 10.1016/S0969-2126(98)00003-3; Nishino T, 2000, J MOL BIOL, V298, P407, DOI 10.1006/jmbi.2000.3675; Oram M, 1998, NUCLEIC ACIDS RES, V26, P594, DOI 10.1093/nar/26.2.594; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Rice DW, 1997, CURR OPIN STRUC BIOL, V7, P798, DOI 10.1016/S0959-440X(97)80149-2; Roe SM, 1998, MOL CELL, V2, P361, DOI 10.1016/S1097-2765(00)80280-4; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; Speck C, 1999, EMBO J, V18, P6169, DOI 10.1093/emboj/18.21.6169; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1994, J BIOL CHEM, V269, P26552; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; van Gool AJ, 1998, EMBO J, V17, P1838, DOI 10.1093/emboj/17.6.1838; van Gool AJ, 1999, GENE DEV, V13, P1861, DOI 10.1101/gad.13.14.1861; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; Whitby MC, 1998, J BIOL CHEM, V273, P35063, DOI 10.1074/jbc.273.52.35063; Yamada K, 2004, CURR OPIN STRUC BIOL, V14, P130, DOI 10.1016/j.sbi.2004.03.005; Yamada K, 2002, MOL CELL, V10, P671, DOI 10.1016/S1097-2765(02)00641-X; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; Zerbib D, 1998, J MOL BIOL, V281, P621, DOI 10.1006/jmbi.1998.1959	58	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3365	3375		10.1074/jbc.M409256200	http://dx.doi.org/10.1074/jbc.M409256200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15556943	hybrid			2022-12-25	WOS:000226983900030
J	Taupenot, L; Harper, KL; O'Connor, DT				Taupenot, L; Harper, KL; O'Connor, DT			Role of H+-ATPase-mediated acidification in sorting and release of the regulated secretory protein chromogranin A - Evidence for a vesiculogenic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR MONOAMINE TRANSPORTER; CHROMAFFIN GRANULES; CELL-LINE; ATT-20 CELLS; PH; CALCIUM; EXOCYTOSIS; STORAGE; PATHWAY; AGGREGATION	The constitutive and regulated secretory pathways represent the classical routes for secretion of proteins from neuroendocrine cells. Selective aggregation of secretory granule constituents in an acidic, bivalent cation-rich environment is considered to be a prerequisite for sorting to the regulated secretory pathway. The effect of selective vacuolar H-ATPase (V-ATPase) inhibitor bafilomycin A1 on the pH gradient along the secretory pathway was used here to study the role of acidification on the trafficking of the regulated secretory protein chromogranin A (CgA) in PC12 cells. Sorting of CgA was assessed by three-dimensional deconvolution microscopy, subcellular fractionation, and secretagogue-stimulated release, examining a series of full-length or truncated domains of human CgA (CgA-(1-115), CgA-(233-439)) fused to either green fluorescent protein or to a novel form of secreted embryonic alkaline phosphatase (EAP). We show that a full-length CgA/ EAP chimera is sorted to chromaffin granules for exocytosis. Inhibition of V-ATPase by bafilomycin A1 markedly reduced the secretagogue-stimulated release of CgA-EAP by perturbing sorting of the chimera (at the trans-Golgi network or immature secretory granule) rather than the late steps of exocytosis. The effect of bafilomycin A1 on CgA secretion depends on a sorting determinant located within the amino terminus (CgA(1-115)) but not the C-terminal region of the granin. Moreover, examination of chromaffin granule abundance in PC12 cells exposed to bafilomycin A1 reveals a substantial decrease in the number of dense-core vesicles. We propose that a V-ATPase-mediated pH gradient in the secretory pathway is an important factor for the formation of dense-core granules by regulating the ability of CgA to form aggregates, a crucial step that may underlie the granulogenic function of the protein.	Univ Calif San Diego, Dept Med 0838, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Taupenot, L (corresponding author), Univ Calif San Diego, Dept Med 0838, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ltaupenot@ucsd.edu		Taupenot, Laurent/0000-0003-2316-3825	NIDDK NIH HHS [DK59628] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059628] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Axelsson MAB, 2001, GLYCOBIOLOGY, V11, P633, DOI 10.1093/glycob/11.8.633; Barg S, 2001, J CELL SCI, V114, P2145; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Burke NV, 1997, NEURON, V19, P1095, DOI 10.1016/S0896-6273(00)80400-6; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Drose S, 1997, J EXP BIOL, V200, P1; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1989, AM J PHYSIOL, V257, P247; Han WP, 1999, J NEUROSCI, V19, P900; HELDMAN E, 1989, J BIOL CHEM, V264, P7914; HENOMATSU N, 1993, EUR J CELL BIOL, V62, P127; Henry J P, 1998, Adv Pharmacol, V42, P236; Henry JP, 1998, NEUROCHEM INT, V32, P227, DOI 10.1016/S0197-0186(97)00092-2; HOLZ RW, 1983, J BIOL CHEM, V258, P7506; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KNIGHT DE, 1985, J MEMBRANE BIOL, V83, P147, DOI 10.1007/BF01868746; KUIJPERS GAJ, 1989, J BIOL CHEM, V264, P698; Loh YP, 2004, J MOL NEUROSCI, V22, P63, DOI 10.1385/JMN:22:1-2:63; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0; Morel N, 2001, J NEUROCHEM, V79, P485, DOI 10.1046/j.1471-4159.2001.00611.x; ORNBERG RL, 1995, CELL TISSUE RES, V279, P85, DOI 10.1007/BF00300694; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; RODA LG, 1980, EXP CELL RES, V128, P103, DOI 10.1016/0014-4827(80)90392-4; Schoonderwoert VTG, 2000, EUR J BIOCHEM, V267, P5646, DOI 10.1046/j.1432-1327.2000.01648.x; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P5184, DOI 10.1073/pnas.74.11.5184; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; Tabares L, 2001, J BIOL CHEM, V276, P39974, DOI 10.1074/jbc.M106498200; Tanaka S, 1997, J HISTOCHEM CYTOCHEM, V45, P425, DOI 10.1177/002215549704500310; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; Taupenot L, 2002, ANN NY ACAD SCI, V971, P262, DOI 10.1111/j.1749-6632.2002.tb04473.x; Taupenot L, 1999, HYPERTENSION, V34, P1152, DOI 10.1161/01.HYP.34.5.1152; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; WESTERMANN R, 1988, FEBS LETT, V239, P203, DOI 10.1016/0014-5793(88)80917-7; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Wu MM, 2000, CHEM BIOL, V7, P197, DOI 10.1016/S1074-5521(00)00088-0; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012; YOO SH, 1991, J BIOL CHEM, V266, P7740	54	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3885	3897		10.1074/jbc.M408197200	http://dx.doi.org/10.1074/jbc.M408197200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15542860	hybrid			2022-12-25	WOS:000226983900091
J	Hofemeister, H; O'Hare, P				Hofemeister, H; O'Hare, P			Analysis of the localization and topology of nurim, a polytopic protein tightly associated with the inner nuclear membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-B-RECEPTOR; MUSCULAR-DYSTROPHY PHENOTYPE; INTEGRAL PROTEIN; SACCHAROMYCES-CEREVISIAE; ENVELOPE; EMERIN; BINDING; COMPLEX; METHYLTRANSFERASE; ARCHITECTURE	Nurim is an inner nuclear membrane (INM) protein that was first isolated in a visual screen for nuclear envelope-localizing proteins. Nurim lacks an N-terminal domain characteristic of other INM proteins examined to date and may represent a class of proteins that localize to the INM by a distinct mechanism. To further characterize this protein, we constructed nurim-green fluorescent protein fusions and analyzed aspects of localization, biochemistry, and membrane topology. Results from immunoprobing and protease protection assays together with other analyses indicate that nurim (total length of 262 residues) is a six transmembrane-spanning protein and contains a hairpin turn in its C-terminal transmembrane domain, resulting in the N and C termini residing on the same side of the membrane. A loop region between the fourth and fifth transmembrane domains is exposed toward the nucleoplasm and contains a region accessible for site-specific endoproteinase cleavage. In biochemical fractionation, nurim remained extremely tightly bound to nuclear fractions and was released in significant quantities only in the presence of 4 m urea. Under conditions in which nuclear lamins were completely extracted, a significant population of nurim remained resistant to solubilization. This tight binding requires the C-terminal region of the protein. DNase treatment only marginally influenced its retention characteristics in nuclei. Results from consideration of sequence alignments and identification of specific topological features of nurim indicate that it may possess enzymic function. These results are discussed with reference to the retention mechanism and possible nuclear function of nurim.	Marie Curie Res Inst, Surrey RH8 0TL, England		O'Hare, P (corresponding author), Marie Curie Res Inst, Surrey RH8 0TL, England.	P.OHare@mcri.ac.uk		O'Hare, Peter/0000-0003-4508-5602				BIENE S, 1994, NAT GENET, V8, P323; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Clements L, 2000, BIOCHEM BIOPH RES CO, V267, P709, DOI 10.1006/bbrc.1999.2023; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Ellis JA, 1998, J CELL SCI, V111, P781; Fahrenkrog B, 2001, CURR TOP MICROBIOL, V259, P95; Fairley EAL, 1999, J CELL SCI, V112, P2571; FIRMBACHKRAFT L, 1995, J CELL BIOL, V129, P17; Foisner R, 2001, J CELL SCI, V114, P3791; Furukawa K, 1997, BIOCHEM BIOPH RES CO, V238, P240, DOI 10.1006/bbrc.1997.7235; Furukawa K, 1998, EUR J BIOCHEM, V251, P729, DOI 10.1046/j.1432-1327.1998.2510729.x; Furukawa K, 1999, J CELL SCI, V112, P2485; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Georgatos SD, 2001, EMBO J, V20, P2989, DOI 10.1093/emboj/20.12.2989; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; GREAVES R, 1989, J VIROL, V63, P1641, DOI 10.1128/JVI.63.4.1641-1650.1989; HARRIS CA, 1995, GENOMICS, V28, P198, DOI 10.1006/geno.1995.1131; Holmer L, 1998, GENOMICS, V54, P469, DOI 10.1006/geno.1998.5615; Holmer L, 2001, CELL MOL LIFE SCI, V58, P1741, DOI 10.1007/PL00000813; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee KK, 2001, J CELL SCI, V114, P4567; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Marte B, 2001, NAT CELL BIOL, V3, pE135, DOI 10.1038/35078596; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; Monne M, 1999, J MOL BIOL, V293, P807, DOI 10.1006/jmbi.1999.3183; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; Shields DJ, 2003, J BIOL CHEM, V278, P35826, DOI 10.1074/jbc.M306308200; Silve S, 1998, BBA-LIPID LIPID MET, V1392, P233, DOI 10.1016/S0005-2760(98)00041-1; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Wagner N, 2004, J CELL SCI, V117, P2015, DOI 10.1242/jcs.01052; WEBER K, 1986, NATURE, V320, P402, DOI 10.1038/320402a0; Worman HJ, 2000, J MEMBRANE BIOL, V177, P1, DOI 10.1007/s002320001096; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; YE Q, 1994, J BIOL CHEM, V269, P11306; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	49	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2512	2521		10.1074/jbc.M410504200	http://dx.doi.org/10.1074/jbc.M410504200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15542857	hybrid			2022-12-25	WOS:000226449100018
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			The dileucine motif at the COOH terminus of human multidrug resistance P-glycoprotein is important for folding but not activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG-BINDING DOMAIN; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; CYSTEINE-SCANNING MUTAGENESIS; CYSTIC-FIBROSIS; SULFONYLUREA RECEPTOR; PLASMA-MEMBRANE; ATP-BINDING; IDENTIFICATION; TRAFFICKING	P-glycoprotein (P-gp, ABCB1) actively transports a broad range of cytotoxic compounds out of the cell. The COOH terminus of P-gp contains a dileucine motif (Leu(1260)-Leu(1261)) and a conserved phenylalanine (Phe(1268)). Similar residues in SUR1 (ABCC8) were reported to be important plasma membrane-targeting signals (Sharma, N., Crane, A., Clement, J. P. t., Gonzalez, G., Babenko, A. P., Bryan, J., and Aguilar-Bryan, L. (1999) J. Biol. Chem. 274, 20628-20632). Here, we used alanine-scanning mutagenesis to test whether these residues were essential for trafficking of P-gp to the cell surface. Mutant L1260A expressed a 150-kDa immature protein that did not reach the cell surface and was sensitive to digestion by Endo Hp By contrast, mutants L1261A, F1268A, and wild-type P-gps expressed the 170-kDa mature proteins at the cell surface. Mutation of Leu(1260) to Gly, Ile, Trp, Lys, or Glu also resulted in the expression of the 150-kDa immature protein. All of the mutants, however, expressed the 170-kDa protein in the presence of the drug substrate/specific chemical chaperone cyclosporin A. Mutant L1260A P-gp exhibited drug-stimulated ATPase activities similar to that of wild-type enzyme after rescue with cyclosporin A. Deletion of the last 22 amino acids (Q(1259)-Q(1280)) also caused misprocessing. The mutant, however, was rescued by expression in the presence of cyclosporin A and conferred resistance to colchicine in transfected cells. These results show that the dileucine motif is not a plasma membrane targeting signal. The COOH terminus is required for proper folding of P-gp but not for activity.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALLEY MC, 1988, CANCER RES, V48, P589; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen EYJ, 2000, BIOCHEMISTRY-US, V39, P3797, DOI 10.1021/bi992620m; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Haggie PM, 2004, J BIOL CHEM, V279, P5494, DOI 10.1074/jbc.M312445200; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 2004, BIOCHEMISTRY-US, V43, P12081, DOI 10.1021/bi049045t; Loo TW, 2004, J BIOL CHEM, V279, P38395, DOI 10.1074/jbc.M405623200; Loo TW, 1999, FASEB J, V13, P1724, DOI 10.1096/fasebj.13.13.1724; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1994, J BIOL CHEM, V269, P28683; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sauer Brian, 1994, Current Opinion in Biotechnology, V5, P521, DOI 10.1016/0958-1669(94)90068-X; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Westlake CJ, 2004, J BIOL CHEM, V279, P53571, DOI 10.1074/jbc.M402528200; Yan FF, 2004, J BIOL CHEM, V279, P11096, DOI 10.1074/jbc.M312810200	51	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2522	2528		10.1074/jbc.M411483200	http://dx.doi.org/10.1074/jbc.M411483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15542593	hybrid			2022-12-25	WOS:000226449100019
J	Monick, MM; Cameron, K; Staber, J; Powers, LS; Yarovinsky, TO; Koland, JG; Hunninghake, GW				Monick, MM; Cameron, K; Staber, J; Powers, LS; Yarovinsky, TO; Koland, JG; Hunninghake, GW			Activation of the epidermal growth factor receptor by respiratory syncytial virus results in increased inflammation and delayed apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MAMMARY EPITHELIAL-CELLS; PROTEIN-KINASE; POLY(ADP-RIBOSE) POLYMERASE; GENE-EXPRESSION; KAPPA-B; TRANSACTIVATION; INHIBITION; INFECTION; REQUIRES	Respiratory syncytial virus (RSV) preferentially infects lung epithelial cells. Infection by RSV leads to an extended inflammatory response, characterized by the release of interleukin-8 (IL-8). Activation of ERK MAP kinase is required for both RSV-induced inflammation and the extended survival of infected cells. In this study, we analyzed the role of the epidermal growth factor receptor ( EGFR) in RSV activation of ERK. We demonstrate for the first time that RSV activates EGFR in lung epithelial cells. Activation of EGFR results in increased ERK activity, contributing to both the inflammatory response (IL-8 release) and prolonging the survival of RSV-infected cells. Inhibition of EGFR with siRNA decreased both ERK activation and IL-8 production after RSV. In analyzing the effect of EGFR activation on survival of RSV-infected cells, we found that EGFR activation by RSV resulted in ERK-dependent alterations in the balance of pro-versus anti-apoptotic Bcl2 proteins. RSV altered the balance between pro- and anti-apoptotic Bcl2 proteins ( increased BclxL and decreased BimEL) increasing the relative amount of pro- survival proteins. This occurred in an EGFR-dependent manner. This study supports an important role for EGFR activity in the lifespan and inflammatory potential of RSV-infected epithelial cells.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Div Pulm Crit Care & Occupat Med,EMRB, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA; Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	Monick, MM (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Div Pulm Crit Care & Occupat Med,EMRB, Rm 100, Iowa City, IA 52242 USA.	martha-monick@uiowa.edu		Staber, Janice/0000-0002-2738-4206; Koland, John/0000-0002-5028-4297	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077431, P50HL060316] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00059] Funding Source: Medline; NHLBI NIH HHS [HL-60316, HL-077431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad T, 2004, J BIOL CHEM, V279, P1713, DOI 10.1074/jbc.M306156200; Argast GM, 2004, J BIOL CHEM, V279, P34530, DOI 10.1074/jbc.M405703200; BLANCHET S, 2003, AM J RESP CELL MOL B; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Cameron R, 2003, VIRUS RES, V92, P151, DOI 10.1016/S0168-1702(02)00358-1; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; CHEN K, 2004, J BIOL CHEM; Chen WNU, 2004, J BIOL CHEM, V279, P18488, DOI 10.1074/jbc.M310874200; Chen WZ, 2000, EXP LUNG RES, V26, P13, DOI 10.1080/019021400269934; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Eigen H, 1999, J PEDIATR-US, V135, pS1; Eriksson M, 2000, PEDIAT ALLERG IMM-UK, V11, P193, DOI 10.1034/j.1399-3038.2000.00076.x; Hacking D, 2002, J INFECTION, V45, P18, DOI 10.1053/jinf.2002.1015; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Hilgendorf A, 2003, J BIOL CHEM, V278, P51872, DOI 10.1074/jbc.M310038200; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; Joseph TD, 2001, J BIOL CHEM, V276, P47136, DOI 10.1074/jbc.M102030200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leemans JC, 2004, J IMMUNOL, V172, P1125, DOI 10.4049/jimmunol.172.2.1125; Lemen Richard J., 1995, Acta Paediatrica Sinica, V36, P78; Levy BT, 1997, J FAM PRACTICE, V45, P473; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; LEY R, 2003, J BIOL CHEM; MASTRONARDE JG, 1995, AM J RESP CELL MOL, V13, P237, DOI 10.1165/ajrcmb.13.2.7626291; Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; McBride JT, 1999, J PEDIATR-US, V135, pS28; MENZO S, 1993, VIROLOGY, V196, P878, DOI 10.1006/viro.1993.1550; Miller WE, 1999, TRENDS MICROBIOL, V7, P453, DOI 10.1016/S0966-842X(99)01605-4; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; Monick MM, 2001, J IMMUNOL, V166, P2681, DOI 10.4049/jimmunol.166.4.2681; Monick MM, 2003, J BIOL CHEM, V278, P53035, DOI 10.1074/jbc.M308093200; MONICK MM, 2003, FRONT BIOSCI, V8, pS28; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sah JF, 2004, J BIOL CHEM, V279, P12755, DOI 10.1074/jbc.M312333200; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Satoh M, 2001, STROKE, V32, P225, DOI 10.1161/01.STR.32.1.225; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; SIGURS N, 1995, PEDIATRICS, V95, P500; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stoorvogel W, 2004, J BIOL CHEM, V279, P11562, DOI 10.1074/jbc.M308449200; Thomas KW, 2002, J BIOL CHEM, V277, P492, DOI 10.1074/jbc.M108107200; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; TSCHUMPERLIN DJ, 2004, NATURE; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zanardi TA, 2003, J VIROL, V77, P11685, DOI 10.1128/JVI.77.21.11685-11696.2003	58	74	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2147	2158		10.1074/jbc.M408745200	http://dx.doi.org/10.1074/jbc.M408745200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542601	hybrid			2022-12-25	WOS:000226341700050
J	Song, HH; Shi, W; Xiang, YY; Filmus, J				Song, HH; Shi, W; Xiang, YY; Filmus, J			The loss of glypican-3 induces alterations in wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CONVERGENT EXTENSION MOVEMENTS; CONTROLS CELLULAR-RESPONSES; BEHMEL OVERGROWTH SYNDROME; WNT/BETA-CATENIN; CYCLIN D1; GASTRULATION MOVEMENTS; GROWTH-RETARDATION; INSULIN-RESISTANCE; TRANSGENIC MICE	Loss-of-function mutations of the GPC3 gene are the cause of the human Simpson-Golabi-Behmel syndrome. Based on the overgrowth phenotype of the Simpson-Golabi-Behmel syndrome patients and the key role played by the insulin-like growth factor (IGF) signaling system in regulating embryonic growth, it was speculated that GPC3 regulates IGF signaling. In order to test the validity of this hypothesis, we mated GPC3 knockout mice with insulin receptor substrate-1 (IRS-1) nullizygous mice. We found that GPC3 regulates organism growth independent of IRS-1, suggesting that GPC3 does not modulate IGF signaling. Instead, we found that GPC3 knockout mice exhibit alterations in the Wnt signaling pathway, which is also associated with the regulation of cell proliferation. In particular, the loss of GPC3 led to the inhibition of the non-canonical Wnt/JNK signaling pathway, while concomitantly causing the activation of canonical Wnt/beta-catenin signaling. These in vivo findings were confirmed in vitro upon the ectopic overexpression of GPC3 in mesothelioma cells. In these cells, the GPC3-induced increase in JNK activity was associated with an enhanced response to Wnt5a. Most interestingly, the heparan sulfate chains of GPC3 were not required for its stimulatory activity on Wnt5a signaling and for the formation of GPC3-Wnt5a complexes. We propose that at least in some cell types GPC3 serves as a selective regulator of Wnt signaling, by potentiating non-canonical Wnt signaling, while inhibiting the canonical Wnt signaling pathway.	Univ Toronto, Div Mol & Cellular Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Filmus, J (corresponding author), Univ Toronto, Div Mol & Cellular Biol Res, Res Bldg,S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	jorge.filmus@swchsc.on.ca						Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Borello U, 1999, DEVELOPMENT, V126, P4247; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chiao E, 2002, DEV BIOL, V243, P185, DOI 10.1006/dbio.2001.0554; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; De Cat B, 2003, J CELL BIOL, V163, P625, DOI 10.1083/jcb.200302152; Desbordes SC, 2003, DEVELOPMENT, V130, P6245, DOI 10.1242/dev.00874; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Filmus J, 2002, GLYCOCONJUGATE J, V19, P319, DOI 10.1023/A:1025312819804; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; FILMUS J, 2000, PROTEOGLYCANS, P161; Fransson LA, 2003, INT J BIOCHEM CELL B, V35, P125, DOI 10.1016/S1357-2725(02)00095-X; Fujise M, 2003, DEVELOPMENT, V130, P1515, DOI 10.1242/dev.00379; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Han C, 2004, DEVELOPMENT, V131, P601, DOI 10.1242/dev.00958; Heller RS, 2002, DEV DYNAM, V225, P260, DOI 10.1002/dvdy.10157; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kirkpatrick CA, 2004, DEV CELL, V7, P513, DOI 10.1016/j.devcel.2004.08.004; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Kreuger J, 2004, DEV CELL, V7, P503, DOI 10.1016/j.devcel.2004.08.005; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuhl M, 2001, MECH DEVELOP, V106, P61, DOI 10.1016/S0925-4773(01)00416-6; LANDER AD, 1998, PERSPECT DEV NEUROBI, V1, P1; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Maye P, 2004, J BIOL CHEM, V279, P24659, DOI 10.1074/jbc.M311724200; Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Nakato H, 2002, BBA-GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304-4165(02)00398-7; Ohkawara B, 2003, DEVELOPMENT, V130, P2129, DOI 10.1242/dev.00435; Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Song HH, 2002, BBA-GEN SUBJECTS, V1573, P241, DOI 10.1016/S0304-4165(02)00390-2; Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Tada M, 2002, SEMIN CELL DEV BIOL, V13, P251, DOI 10.1016/S1084-9521(02)00052-6; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Veugelers M, 1999, J BIOL CHEM, V274, P26968, DOI 10.1074/jbc.274.38.26968; Veugelers M, 1998, TRENDS GLYCOSCI GLYC, V10, P145, DOI 10.4052/tigg.10.145; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Weidinger G, 2003, J CELL BIOL, V162, P753, DOI 10.1083/jcb.200307181; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	71	175	184	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2116	2125		10.1074/jbc.M410090200	http://dx.doi.org/10.1074/jbc.M410090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537637	hybrid			2022-12-25	WOS:000226341700046
J	Vetter, M; Blumenthal, SG; Lindemann, RK; Manns, J; Wesselborg, S; Dittmer, J				Vetter, M; Blumenthal, SG; Lindemann, RK; Manns, J; Wesselborg, S; Dittmer, J			Ets1 is an effector of protein kinase Ca in cancer cells	ONCOGENE			English	Article						Ets transcription factors; protein kinase C; breast cancer; RNA interference	HORMONE-RELATED PROTEIN; BREAST-CARCINOMA CELLS; TRANSCRIPTION FACTOR; PKC-ALPHA; INDUCED APOPTOSIS; GENE-EXPRESSION; PROMOTER; GROWTH; PHOSPHORYLATION; INVOLVEMENT	PKCalpha and Ets1 are both associated with breast cancer progression. Our previous studies suggested that these proteins are likely to functionally interact with one another. Here, we show that attenuation of endogenous PKCalpha expression (siPalpha) by RNA interference leads to reduced Ets1 protein expression in a variety of cancer cells. Pulse-chase experiments and treatment with proteasome inhibitor MG-132 revealed that siPa interferes with both Ets1 protein synthesis and stability. The effect of siPalpha on Ets1 expression could be partially prevented by KN-93, suggesting that calcium/calmodulin-dependent kinase II ( CaMKII), a modulator of Ets1 activity, may play a role in PKCalpha-dependent Ets1 regulation. In contrast, Ets1-regulating kinases ERK1/ 2 were not found to be involved in this process. To assess the importance of the PKCalpha/Ets1 interaction, we compared the biological responses of MDA-MB-231 cells to PKCalpha- and Ets1-specific siRNAs (siE1). While only siPalpha induced changes in cellular morphology and anchorage-independent growth, both siRNAs similarly affected cellular responses to the antitumor drug mithramycin A and to UV light. Microarray analyses further showed that the expression of a certain set of genes was equally affected by siPa and siE1. The data suggest that Ets1 serves as an effector for PKCalpha to fulfil certain functions in cancer cells.	Univ Halle Wittenberg, Univ Klin & Poliklin Gynakol, D-06097 Halle Saale, Saale, Germany; Univ Tubingen, Innere Med Abt 1, Med Klin, D-72076 Tubingen, Germany	Martin Luther University Halle Wittenberg; Eberhard Karls University of Tubingen	Dittmer, J (corresponding author), Univ Halle Wittenberg, Univ Klin & Poliklin Gynakol, Ernst Grube Str 40, D-06097 Halle Saale, Saale, Germany.	dittmer@medizin.uni-halle.de	Dittmer, Juergen/G-1160-2011; Manns, J/AAA-4986-2020	Wesselborg, Sebastian/0000-0002-5236-942X				Anilkumar N, 2003, EMBO J, V22, P5390, DOI 10.1093/emboj/cdg521; Asher G, 2003, P NATL ACAD SCI USA, V100, P15065, DOI 10.1073/pnas.2436329100; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Ballschmieter P, 2003, INT J ONCOL, V22, P849; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Budworth J, 1997, BRIT J CANCER, V75, P1330, DOI 10.1038/bjc.1997.225; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Cowley DO, 2000, GENE DEV, V14, P366; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Foos G, 2004, HANDB EXP PHARM, V166, P259; Gardoni F, 2001, J BIOL CHEM, V276, P7609, DOI 10.1074/jbc.M009922200; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Goldstein AS, 2002, J BIOMED MATER RES, V59, P665, DOI 10.1002/jbm.1276; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Jiang Y, 2002, CANCER RES, V62, P1910; Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464; Lee MP, 1998, CANCER RES, V58, P1052; Lin Q, 2003, CURR BIOL, V13, P1469, DOI 10.1016/S0960-9822(03)00613-4; Lindemann RK, 2003, INT J ONCOL, V22, P799; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Okabe H, 2003, CANCER RES, V63, P3043; Orlandi L, 2003, PROSTATE, V54, P133, DOI 10.1002/pros.10181; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Remsing LL, 2003, J AM CHEM SOC, V125, P5745, DOI 10.1021/ja034162h; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Samatar AA, 2002, J BIOL CHEM, V277, P28118, DOI 10.1074/jbc.M203686200; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sioud M, 1998, NAT BIOTECHNOL, V16, P556, DOI 10.1038/nbt0698-556; Soh Jae-Won, 2003, J Exp Ther Oncol, V3, P115, DOI 10.1046/j.1359-4117.2003.01087.x; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Song JC, 2002, AM J PHYSIOL-CELL PH, V283, pC1548, DOI 10.1152/ajpcell.00105.2002; Sunaga N, 2002, CANCER EPIDEM BIOMAR, V11, P730; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yordy JS, 2004, ONCOGENE, V23, P6654, DOI 10.1038/sj.onc.1207891; Zhou JN, 1998, MOL CARCINOGEN, V21, P234, DOI 10.1002/(SICI)1098-2744(199804)21:4<234::AID-MC2>3.0.CO;2-K	54	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					650	661		10.1038/sj.onc.1208234	http://dx.doi.org/10.1038/sj.onc.1208234			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15531915				2022-12-25	WOS:000226420400012
J	Li, YQ; Sedwick, CE; Hu, JR; Altman, A				Li, YQ; Sedwick, CE; Hu, JR; Altman, A			Role for protein kinase C theta (PKC theta) in TCR/CD28-mediated signaling through the canonical but not the non-canonical pathway for NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; NF-KAPPA-B2 P100; IKK-ALPHA; BETA; COSTIMULATION; LYMPHOTOXIN; P52; PHOSPHORYLATION; AUTOREGULATION; EXPRESSION	NF-kappaB is a family of essential transcription factors involved in both embryonic development and inflammatory responses of the immune system. NF-kappaB can be activated by two pathways, i.e. the canonical (NF-kappaB1) pathway, which acts through the catalytic components of the IkappaB kinase complex and leads to IkappaB phosphorylation, degradation, and subsequent NF-kappaB nuclear translocation, or the non-canonical (NF-kappaB2) pathway, which involves NF-kappaB-induced kinase-dependent proteolytic processing of p100/p52 to yield translocation-competent p52-containing NF-kappaB complexes. We examined the relative roles of the NF-kappaB1 and NF-kappaB2 pathways in TCR/CD28 costimulation. We found that TCR/CD28 costimulation activates the canonical but not the non-canonical NF-kappaB pathway and that the serine/threonine kinase protein kinase Ctheta (PKCtheta) is essential for TCR/CD28-mediated canonical NF-kappaB activation in T cells. Importantly, TCR/CD28 costimulation induces higher p52 protein levels in T cells, but this effect is secondary to enhanced de novo synthesis of p100, not to enhanced processing of extant p100; PKCtheta deficiency impairs signal-dependent p52 accumulation because of defects in p100 production. Finally, we found that TCR/CD28 costimulation induces IkappaBalpha, IkappaBbeta, and IkappaBepsilon degradation, and PKCtheta is required for IkappaBalpha and IkappaBepsilon but not IkappaBbeta degradation. PKCtheta acts solely within the canonical pathway to activate NF-kappaB, and PKCtheta deficiency impacts upon p100/p52 processing in a manner that is independent of NF-kappaB-induced kinase.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Sun Yat Sen Univ, Coll Life Sci, State Key Lab Biocontrol, Guangzhou 510275, Peoples R China	La Jolla Institute for Immunology; Sun Yat Sen University	Altman, A (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	amnon@liai.org			NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049888, F32AI051909] Funding Source: NIH RePORTER; NCI NIH HHS [CA35299] Funding Source: Medline; NIAID NIH HHS [AI49888, AI51909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; KahnPerles B, 1997, J BIOL CHEM, V272, P21774, DOI 10.1074/jbc.272.35.21774; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li YQ, 2004, EMBO J, V23, P1112, DOI 10.1038/sj.emboj.7600125; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Maier HJ, 2003, J BIOL CHEM, V278, P39242, DOI 10.1074/jbc.M301521200; Marinari B, 2004, P NATL ACAD SCI USA, V101, P6098, DOI 10.1073/pnas.0308688101; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Sedwick CE, 2004, MOL IMMUNOL, V41, P675, DOI 10.1016/j.molimm.2004.01.007; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	30	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1217	1223		10.1074/jbc.M409492200	http://dx.doi.org/10.1074/jbc.M409492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15536066	hybrid			2022-12-25	WOS:000226195200044
J	Phung-Koskas, T; Pilon, A; Pous, C; Betzina, C; Sturm, M; Bourguet-Kondracki, ML; Durand, G; Drechou, A				Phung-Koskas, T; Pilon, A; Pous, C; Betzina, C; Sturm, M; Bourguet-Kondracki, ML; Durand, G; Drechou, A			STAT5B-mediated growth hormone signaling is organized by highly dynamic microtubules in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETYROSINATED GLU MICROTUBULES; ACTIVATED PROTEIN-KINASE; KINESIN-RELATED PROTEIN; GLUCOCORTICOID-RECEPTOR; TYROSINE PHOSPHORYLATION; INTERMEDIATE-FILAMENTS; STABLE MICROTUBULES; GENE-EXPRESSION; TGF-BETA; ASSOCIATION	In the last decade, the notion that microtubules are critical to the spatial organization of signal transduction and contribute to the transmission of signals to downstream targets has been proposed. Because the STAT5B transduction and transcription factor is the major STAT protein activated by growth hormone stimulation in hepatocytes and is a crossroads between many signaling pathways, we studied the involvement of microtubules in STAT5B-mediated growth hormone signaling pathway in the highly differentiated and polarized WIF-B hepatic cell line. We showed that depolymerization of the microtubule network impaired STAT5B translocation to the nucleus upon growth hormone treatment. A significant amount of STAT5B binds to microtubules, while STAT5A and STAT3 are exclusively compartmentalized in the cytosol. Moreover, taxol-induced stabilization of microtubules released STAT5B from its binding, and we show that STAT5B binds specifically to the highly dynamic microtubules and is absent of the stable microtubule subpopulation. The specific involvement of dynamic microtubule subpopulation in growth hormone signaling pathway was confirmed by the inhibition of growth hormone-induced STAT5B nuclear translocation after stabilization of microtubules or specific disruption of highly dynamic microtubules. Upon growth hormone treatment, MT-bound STAT5B was rapidly released from microtubules by a dynein-dependent transport to the nucleus. Altogether, our findings indicate that the labile microtubule subpopulation specifically and dynamically organizes STAT5B-mediated growth hormone signaling in hepatic cells.	Univ Paris 11, Fac Pharm, Lab Biochim & Biol Cellulaire, F-92296 Chatenay Malabry, France; Museum Natl Hist Nat, CNRS, UMR 5154, Chim Lab, F-75005 Paris, France	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN)	Drechou, A (corresponding author), Univ Paris 11, Fac Pharm, Lab Biochim & Biol Cellulaire, EA 1595,5 Rue JB Clement, F-92296 Chatenay Malabry, France.	anne.drechou@cep.u-psud.fr	POÜS, Christian/R-5089-2018; Pilon, Antoine/S-5585-2018	POUS, Christian/0000-0002-2502-7854				AKNER G, 1995, J STEROID BIOCHEM, V52, P1, DOI 10.1016/0960-0760(94)00155-F; AKNER G, 1991, J STEROID BIOCHEM, V39, P419, DOI 10.1016/0960-0760(91)90235-W; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Cambiazo V, 1999, FEBS LETT, V457, P343, DOI 10.1016/S0014-5793(99)01070-4; CASSIO D, 1991, J CELL BIOL, V115, P1397, DOI 10.1083/jcb.115.5.1397; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; Dinerstein-Cali H, 2000, MOL CELL ENDOCRINOL, V166, P89, DOI 10.1016/S0303-7207(00)00277-X; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Doppler W, 2000, ADV EXP MED BIOL, V480, P139; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Galigniana M. D., 2004, J BIOL CHEM; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Goh ELK, 1998, ENDOCRINOLOGY, V139, P4364, DOI 10.1210/en.139.10.4364; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; GUNDERSEN GG, 1994, J CELL SCI, V107, P645; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GURLAND G, 1995, J CELL BIOL, V131, P1275, DOI 10.1083/jcb.131.5.1275; Infante AS, 2000, J CELL SCI, V113, P3907; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; KONDRACKI ML, 1989, TETRAHEDRON, V45, P1995, DOI 10.1016/S0040-4020(01)80062-4; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; LIAO GJ, 1995, J CELL SCI, V108, P3473; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Lim RWL, 2000, J BIOL CHEM, V275, P20578, DOI 10.1074/jbc.M001887200; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; Minin AA, 1997, J CELL SCI, V110, P2495; MIZUNO M, 1994, J CELL SCI, V107, P1321; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Pircher TJ, 1999, MOL ENDOCRINOL, V13, P555, DOI 10.1210/mend.13.4.0263; Pous C, 1998, J CELL BIOL, V142, P153, DOI 10.1083/jcb.142.1.153; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SHANKS MR, 1994, J CELL SCI, V107, P813; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; Vasilenko K P, 1998, Tsitologiia, V40, P1063; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wadsworth P, 1996, CELL MOTIL CYTOSKEL, V35, P225, DOI 10.1002/(SICI)1097-0169(1996)35:3<225::AID-CM5>3.0.CO;2-7; Wang GL, 2004, DEV BIOL, V268, P493, DOI 10.1016/j.ydbio.2004.01.008; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xi SC, 2003, CANCER RES, V63, P6763	58	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1123	1131		10.1074/jbc.M409918200	http://dx.doi.org/10.1074/jbc.M409918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528207	hybrid			2022-12-25	WOS:000226195200033
J	Shi, T; Giannakopoulos, B; Iverson, GM; Cockerill, KA; Linnik, MD; Krilis, SA				Shi, T; Giannakopoulos, B; Iverson, GM; Cockerill, KA; Linnik, MD; Krilis, SA			Domain v of beta(2)-Glycoprotein I binds factor XI/XIa and is cleaved at Lys(317)-Thr(318)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) GLYCOPROTEIN-I; AMINO-ACID-SEQUENCE; FACTOR-XI; PHOSPHOLIPID-BINDING; ANTIPHOSPHOLIPID ANTIBODIES; 5TH DOMAIN; HUMAN BETA-2-GLYCOPROTEIN-I; ANTICARDIOLIPIN ANTIBODIES; ENDOTHELIAL-CELLS; PLATELET SURFACE	The fifth domain (DV) of beta(2)-glycoprotein I (beta(2)GPI) is important for binding a number of ligands including phospholipids and factor XI (FXI). beta(2)GPI is proteolytically cleaved in DV by plasmin but not by thrombin, VIIa, tissue plasminogen activator, or uPA. Following proteolytic cleavage of DV by plasmin, beta(2)GPI retains binding to FXI but not to phospholipids. Native beta(2)GPI, but not cleaved beta(2)GPI, inhibits activation of FXI by thrombin and factor XIIa, attenuating a positive feedback mechanism for additional thrombin generation. In this report, we have defined the FXI/FXIa binding site on beta(2)GPI using site-directed mutagenesis. We show that the positively charged residues Lys(284), Lys(286), and Lys(287) in DV are essential for the interaction of beta(2)GPI with FXI/FXIa. We also demonstrate that FXIa proteolytically cleaves beta(2)GPI at Lys(317)- Thr(318) in DV. Thus, FXIa cleavage of beta(2)GPI in vivo during thrombus formation may accelerate FXI activation by decreasing the inhibitory effect of beta(2)GPI.	Univ New S Wales, St George Hosp, Dept Med, Dept Immunol Allergy & Infect Dis, Sydney, NSW 2217, Australia; La Jolla Pharmaceut Corp, San Diego, CA 92121 USA	St George Hospital; University of New South Wales Sydney; La Jolla Pharmaceutical Company	Krilis, SA (corresponding author), Univ New S Wales, St George Hosp, Dept Med, Dept Immunol Allergy & Infect Dis, 2 South St, Sydney, NSW 2217, Australia.	s.Krilis@unsw.edu.au						Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; Baird TR, 2002, J BIOL CHEM, V277, P28498, DOI 10.1074/jbc.M203427200; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; Bouma BN, 1999, THROMB HAEMOSTASIS, V82, P243; Del Papa N, 1998, J IMMUNOL, V160, P5572; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117; Galli M, 2003, BLOOD, V101, P1827, DOI 10.1182/blood-2002-02-0441; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Guerin J, 2002, J BIOL CHEM, V277, P2644, DOI 10.1074/jbc.M110176200; Hagihara Y, 1997, J BIOCHEM-TOKYO, V121, P128; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; Horbach DA, 1999, THROMB HAEMOSTASIS, V81, P87; Hoshino M, 2000, J MOL BIOL, V304, P927, DOI 10.1006/jmbi.2000.4243; HUNT J, 1994, J IMMUNOL, V152, P653; HUNT JE, 1993, LUPUS, V2, P285, DOI 10.1177/096120339300200501; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; Itoh Y, 2000, J BIOCHEM-TOKYO, V128, P1017, DOI 10.1093/oxfordjournals.jbchem.a022829; Iverson GM, 2002, J IMMUNOL, V169, P7097, DOI 10.4049/jimmunol.169.12.7097; Iverson GM, 1998, P NATL ACAD SCI USA, V95, P15542, DOI 10.1073/pnas.95.26.15542; Kandiah DA, 1998, ADV IMMUNOL, V70, P507, DOI 10.1016/S0065-2776(08)60393-4; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; Lutters BCH, 2003, J BIOL CHEM, V278, P33831, DOI 10.1074/jbc.M212655200; Ma KY, 2000, J BIOL CHEM, V275, P15541, DOI 10.1074/jbc.275.20.15541; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Mehdi H, 2000, EUR J BIOCHEM, V267, P1770, DOI 10.1046/j.1432-1327.2000.01174.x; Meroni PL, 1998, LUPUS, V7, pS44, DOI 10.1177/096120339800700211; Ohkura N, 1998, BLOOD, V91, P4173, DOI 10.1182/blood.V91.11.4173.411k35_4173_4179; POLZ E, 1981, ARTERY, V9, P305; Raschi E, 2003, BLOOD, V101, P3495, DOI 10.1182/blood-2002-08-2349; Reddel S. W., 2002, MOL PATHOLOGY AUTOIM, P325; Reddel SW, 2000, J AUTOIMMUN, V15, P91, DOI 10.1006/jaut.2000.0427; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Renne T, 2002, J BIOL CHEM, V277, P4892, DOI 10.1074/jbc.M105221200; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Sheng YH, 1996, J IMMUNOL, V157, P3744; Shi T, 2004, P NATL ACAD SCI USA, V101, P3939, DOI 10.1073/pnas.0400281101; SIMANTOV R, 1995, J CLIN INVEST, V96, P2211, DOI 10.1172/JCI118276; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; STEINKASSERER A, 1992, FEBS LETT, V313, P193, DOI 10.1016/0014-5793(92)81442-O; STEINKASSERER A, 1991, BIOCHEM J, V277, P387, DOI 10.1042/bj2770387; VONDEMBORNE PAK, 1995, BLOOD, V86, P3035; Yasuda S, 2004, BLOOD, V103, P3766, DOI 10.1182/blood-2003-08-2712	48	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					907	912		10.1074/jbc.M410291200	http://dx.doi.org/10.1074/jbc.M410291200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522884	hybrid			2022-12-25	WOS:000226195200009
J	Spagnuolo, MS; Cigliano, L; D'Andrea, LD; Pedone, C; Abrescia, P				Spagnuolo, MS; Cigliano, L; D'Andrea, LD; Pedone, C; Abrescia, P			Assignment of the binding site for haptoglobin on apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; SCAVENGER RECEPTOR; APOA-I; SR-BI; CELLULAR CHOLESTEROL; ALPHA-HELICES; CELLS; TRANSPORT; ESTERIFICATION	Haptoglobin (Hpt) was previously found to bind the high density lipoprotein (HDL) apolipoprotein A-I (ApoA-I) and able to inhibit the ApoA-I-dependent activity of the enzyme lecithin: cholesterol acyltransferase (LCAT), which plays a major role in the reverse cholesterol transport. The ApoA-I structure was analyzed to detect the site bound by Hpt. ApoA-I was treated by cyanogen bromide or hydroxylamine; the resulting fragments, separated by electrophoresis or gel filtration, were tested by Western blotting or enzyme-linked immunosorbent assay for their ability to bind Hpt. The ApoA-I sequence from Glu(113) to Asn(184) harbored the binding site for Hpt. Biotinylated peptides were synthesized overlapping such a sequence, and their Hpt binding activity was determined by avidin-linked peroxidase. The highest activity was exhibited by the peptide P2a, containing the ApoA-I sequence from Leu(141) to Ala(164). Such a sequence contains an ApoA-I domain required for binding cells, promoting cholesterol efflux, and stimulating LCAT. The peptide P2a effectively prevented both binding of Hpt to HDL-coated plastic wells and Hpt-dependent inhibition of LCAT, measured by anti-Hpt antibodies and cholesterol esterification activity, respectively. The enzyme activity was not influenced, in the absence of Hpt, by P2a. Differently from ApoA-I or HDL, the peptide did not compete with hemoglobin for Hpt binding in enzyme-linked immunosorbent assay experiments. The results suggest that Hpt might mask the ApoA-I domain required for LCAT stimulation, thus impairing the HDL function. Synthetic peptides, able to displace Hpt from ApoA-I without altering its property of binding hemoglobin, might be used for treatment of diseases associated with defective LCAT function.	Univ Naples Federico II, Dipartimento Fisiol Gen & Ambientale, I-80134 Naples, Italy; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy; Univ Naples Federico II, Dipartimento Chim Biol, I-80134 Naples, Italy; CNR, Ist Genet & Biofis A Buzzati Traverso, I-80125 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Abrescia, P (corresponding author), Univ Naples Federico II, Dipartimento Fisiol Gen & Ambientale, Via Mezzocannone 8, I-80134 Naples, Italy.	abrescia@biol.dgbm.unina.it	Spagnuolo, Maria Stefania/B-7661-2015	Spagnuolo, Maria Stefania/0000-0001-6980-0661; D'ANDREA, LUCA DOMENICO/0000-0002-2589-216X				Abplanalp W, 2000, EUR J ENDOCRINOL, V142, P79, DOI 10.1530/eje.0.1420079; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Balestrieri M, 2001, MOL REPROD DEV, V59, P186, DOI 10.1002/mrd.1021; Bielicki JK, 1999, J LIPID RES, V40, P85; BORNSTEIN P, 1970, BIOCHEMISTRY-US, V9, P2408, DOI 10.1021/bi00814a004; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; CERDA S, 1990, J IMMUNOL METHODS, V134, P51, DOI 10.1016/0022-1759(90)90111-8; Chan WC, 2000, FMOC SOLID PHASE PEP; CHAPELLE JP, 1982, NEW ENGL J MED, V307, P457, DOI 10.1056/NEJM198208193070801; CHEN CH, 1982, J LIPID RES, V23, P680; Cigliano L, 2003, ARCH BIOCHEM BIOPHYS, V416, P227, DOI 10.1016/S0003-9861(03)00318-7; Cigliano L, 2001, STEROIDS, V66, P889, DOI 10.1016/S0039-128X(01)00124-6; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; Delanghe J, 1997, ATHEROSCLEROSIS, V132, P215, DOI 10.1016/S0021-9150(97)00089-0; FIELDING CJ, 1995, J LIPID RES, V36, P211; Frank PG, 2000, J LIPID RES, V41, P853; Frank PG, 1998, BIOCHEMISTRY-US, V37, P13902, DOI 10.1021/bi981205b; FUNKE H, 1984, ARTERIOSCLEROSIS, V4, P452, DOI 10.1161/01.ATV.4.5.452; GIBLETT E, 1974, STRUCTURE FUNCTION P, P55; GIBLETT ELOISE R., 1968, SER HAEMATOL, V1, P3; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GORDON V, 1983, J BIOL CHEM, V258, P6202; GUTTERIDGE JMC, 1987, BIOCHIM BIOPHYS ACTA, V917, P219, DOI 10.1016/0005-2760(87)90125-1; Hochberg RB, 1998, ENDOCR REV, V19, P331, DOI 10.1210/er.19.3.331; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; KOO C, 1985, J BIOL CHEM, V260, P1934; KUNITAKE ST, 1994, BIOCHEMISTRY-US, V33, P1988, DOI 10.1021/bi00174a003; Langlois MR, 1996, CLIN CHEM, V42, P1589; LARNER JM, 1992, J CLIN ENDOCR METAB, V75, P195, DOI 10.1210/jc.75.1.195; LARNER JM, 1985, ENDOCRINOLOGY, V117, P1209, DOI 10.1210/endo-117-3-1209; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lindholm EM, 1998, BIOCHEMISTRY-US, V37, P4863, DOI 10.1021/bi972888i; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Martin-Campos JM, 2002, J LIPID RES, V43, P115; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; OHTA T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P119, DOI 10.1016/0005-2760(92)90083-8; Oram JF, 1996, J LIPID RES, V37, P2473; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Porta A, 1999, ZYGOTE, V7, P67, DOI 10.1017/S0967199499000416; RADEMACHER BE, 1987, ANAL BIOCHEM, V160, P119, DOI 10.1016/0003-2697(87)90621-X; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; Sorci-Thomas MG, 2002, TRENDS CARDIOVAS MED, V12, P121, DOI 10.1016/S1050-1738(01)00163-3; Sorci-Thomas MG, 2000, J BIOL CHEM, V275, P12156, DOI 10.1074/jbc.275.16.12156; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; Spagnuolo MS, 2003, BIOL CHEM, V384, P1593, DOI 10.1515/BC.2003.176; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Steinberg D, 1996, SCIENCE, V271, P460, DOI 10.1126/science.271.5248.460; Subbaiah PV, 1997, LIPIDS, V32, P157, DOI 10.1007/s11745-997-0020-5; SUTTON HE, 1970, PROG MED GENET, V7, P163; TALAVERA F, 1989, ENDOCRINOLOGY, V125, P2015, DOI 10.1210/endo-125-4-2015; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; vonEckardstein A, 1996, CURR OPIN LIPIDOL, V7, P308, DOI 10.1097/00041433-199610000-00009; Xu SZ, 1997, J LIPID RES, V38, P1289	61	68	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1193	1198		10.1074/jbc.M411390200	http://dx.doi.org/10.1074/jbc.M411390200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15533931	hybrid			2022-12-25	WOS:000226195200041
J	Suenaga, A; Takada, N; Hatakeyama, M; Ichikawa, M; Yu, XM; Tomii, K; Okimoto, N; Futatsugi, N; Narumi, T; Shirouzu, M; Yokoyama, S; Konagaya, A; Taiji, M				Suenaga, A; Takada, N; Hatakeyama, M; Ichikawa, M; Yu, XM; Tomii, K; Okimoto, N; Futatsugi, N; Narumi, T; Shirouzu, M; Yokoyama, S; Konagaya, A; Taiji, M			Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-ENERGY CALCULATIONS; MOLECULAR-DYNAMICS; SH2 DOMAINS; PHOSPHOINOSITIDE 3-KINASE; CONTINUUM SOLVENT; MM-PBSA; BINDING; ACTIVATION; HEREGULIN; AFFINITY	Ligand-activated and tyrosine-phosphorylated ErbB3 receptor binds to the SH2 domain of the p85 subunit of phosphatidylinositol 3-kinase and initiates intracellular signaling. Here, we studied the interactions between the N- (N-SH2) and C- (C-SH2) terminal SH2 domains of the p85 subunit of the phosphatidylinositol 3-kinase and eight ErbB3 receptor-derived phosphotyrosyl peptides (P-peptides) by using molecular dynamics, free energy, and surface plasmon resonance (SPR) analyses. In SPR analysis, these P-peptides showed no binding to the C-SH2 domain, but P-peptides containing a phospho-YXXM or a non-phospho-YXXM motif did bind to the N- SH2 domain. The N- SH2 domain has two phosphotyrosine binding sites in its N- (N1) and C- (N2) terminal regions. Interestingly, we found that P-peptides of pY1180 and pY1241 favored to bind to the N2 site, although all other P-peptides showed favorable binding to the N1 site. Remarkably, two phosphotyrosines, pY1178 and pY1243, which are just 63 amino acids apart from the pY1241 and pY1180, respectively, showed favorable binding to the N1 site. These findings indicate a possibility that the pair of phosphotyrosines, pY1178-pY1241 or pY1243-pY1180, will fold into an appropriate configuration for binding to the N1 and N2 sites simultaneously. Our model structures of the cytoplasmic C- terminal domain of ErbB3 receptor also strongly supported the speculation. The calculated binding free energies between the N- SH2 domain and P-peptides showed excellent qualitative agreement with SPR data with a correlation coefficient of 0.91. The total electrostatic solvation energy between the N- SH2 domain and P-peptide was the dominant factor for its binding affinity.	RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, Kanagawa 2300045, Japan; RIKEN Genom Sci Ctr, Prot Res Grp, Tsurumi Ku, Kanagawa 2300045, Japan; Natl Inst Adv Ind Sci & Technol, CBRC, Koutou Ku, Tokyo 1350064, Japan; SPring8, RIKEN Harima Inst, Mikazuki, Sayo Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; RIKEN; National Institute of Advanced Industrial Science & Technology (AIST); Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo	Hatakeyama, M (corresponding author), RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Kanagawa 2300045, Japan.	marikoh@gsc.riken.jp	Yokoyama, Shigeyuki/N-6911-2015; Tomii, Kentaro/B-1135-2017; Konagaya, Akihiko/F-9302-2014; Taiji, Makoto/N-1077-2014; Shirouzu, Mikako/A-6521-2016; Okimoto, Noriaki/AAI-4656-2020; Tomii, Kentaro/AAK-6940-2021; Okada, Mariko/N-6933-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Tomii, Kentaro/0000-0002-4567-4768; Taiji, Makoto/0000-0002-5317-0500; Okimoto, Noriaki/0000-0002-2956-1317; Tomii, Kentaro/0000-0002-4567-4768; 				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E; Bashford D, 1997, LECT NOTES COMPUTER, P233, DOI [10.1007/3-540-63827-X, DOI 10.1007/3-540-63827-X_66]; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BROOKS BR, 1995, J COMPUT CHEM, V16, P1522, DOI 10.1002/jcc.540161209; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE DA, 1999, AMBER 6 0; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chong LT, 1999, P NATL ACAD SCI USA, V96, P14330, DOI 10.1073/pnas.96.25.14330; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Folmer RHA, 2002, BIOCHEMISTRY-US, V41, P14176, DOI 10.1021/bi026465e; Fu Z, 2003, P NATL ACAD SCI USA, V100, P3275, DOI 10.1073/pnas.0535975100; Fujii Y, 2003, J PHYS CHEM B, V107, P10274, DOI 10.1021/jp034536t; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; Gohlke H, 2004, J COMPUT CHEM, V25, P238, DOI 10.1022/jcc.10379; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Huo SH, 2002, J MED CHEM, V45, P1412, DOI 10.1021/jm010338j; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KOLLMAN P, 1997, COMP SIM BIOMOL SYST, V3, P83; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; Kuhn B, 2000, J MED CHEM, V43, P3786, DOI 10.1021/jm000241h; Laitinen T, 2004, PROTEINS, V55, P34, DOI 10.1002/prot.10399; Luo HB, 2002, P NATL ACAD SCI USA, V99, P10399, DOI 10.1073/pnas.162365999; Masukawa KM, 2003, J MED CHEM, V46, P5628, DOI 10.1021/jm030060q; Narumi E, 1999, MOL SIMULAT, V21, P401; Okimoto N, 2004, J AM CHEM SOC, V126, P13132, DOI 10.1021/ja048053u; OKIMOTO N, 2003, CHEM BIO INFORMATICS, V3, P1; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Rocchia W, 2002, J COMPUT CHEM, V23, P128, DOI 10.1002/jcc.1161; Rocchia W, 2001, J PHYS CHEM B, V105, P6507, DOI 10.1021/jp010454y; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLER C, 1994, J BIOL CHEM, V269, P12320; Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+; Suenaga A, 2004, J BIOL CHEM, V279, P4657, DOI 10.1074/jbc.M310598200; Suenaga A, 2003, BIOCHEMISTRY-US, V42, P5195, DOI 10.1021/bi034113h; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Tomii K, 2004, BIOINFORMATICS, V20, P594, DOI 10.1093/bioinformatics/btg474; Vadlamudi R, 1999, CANCER RES, V59, P2843; Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q; Wang W, 2001, J AM CHEM SOC, V123, P3986, DOI 10.1021/ja003164o; Weber T, 2000, BIOCHEMISTRY-US, V39, P15860, DOI 10.1021/bi001474d; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang K, 1996, J BIOL CHEM, V271, P3884	56	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1321	1326		10.1074/jbc.M410436200	http://dx.doi.org/10.1074/jbc.M410436200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15520002	hybrid			2022-12-25	WOS:000226195200057
J	Yin, D; Zhou, H; Kumagai, T; Liu, GT; Ong, JM; Black, KL; Koeffler, HP				Yin, D; Zhou, H; Kumagai, T; Liu, GT; Ong, JM; Black, KL; Koeffler, HP			Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)	ONCOGENE			English	Article						proteasome inhibitor; glioblastoma multiforme; PS-341; apoptosis; NF-kappa B	FACTOR-KAPPA-B; HUMAN GLIOMA-CELLS; MULTIPLE-MYELOMA CELLS; DRUG-RESISTANCE; C-MYC; CANCER; INDUCTION; P53; ANGIOGENESIS; ACTIVATION	The proteasome plays a pivotal role in controlling cell proliferation, apoptosis, and differentiation in a variety of normal and tumor cells. PS-341, a novel boronic acid dipeptide that inhibits 26S proteasome activity, has prominent effects in vitro and in vivo against several solid tumors. We examined its antiproliferation, proapoptotic effects using three human glioblastoma multiforme (GBM) cell lines and five primary GBM explants. PS-341 markedly inhibited proliferation of GBM cell lines and explants in liquid and soft agar culture. These cells developed a G2/M cell cycle arrest with a concomitant decreased percentage of cells in S phase (approximate to2-fold), associated with an increased expression of p21(WAF1), p27(KIP1), as well as cyclin B1 and decreased levels of CDK2, CDK4, and E2F4. About 35-40% of the cells became apoptotic when exposed to PS-341 (10(-7) M, 24-48 h) as shown by Annexin V analysis; in concert with these findings, immunobloting showed a C-terminal 85 kDa apoptotic fragment of poly ADP-ribose polymerase (PARP), and a decreased level of Bcl2 and Bcl-xl. PS-341 downregulated the expression of Bcl-2 and Bcl-xl in protein levels at an early time of treatment. These changes occurred irrespective of the p53 mutational status of the cells. PS-341 activated JNK/c-Jun signaling in GBM cells, and the JNK inhibitor SP600125 blocked the JNK signaling to reverse partially the PS-341 growth inhibition. PS-341 (10(-7) M, 24 h) decreased nuclear NF-kappaB levels as shown by Western blot, and reduced transcriptional activity of NF-kappaB as measured by reporter assays in these transformed cells. Also, PS-341 enhanced TRAIL (TNF-related apoptosis-inducing ligand) and TNFalpha (tumor necrosis factor alpha) induced cell death and apoptosis (two-to-five-fold) in GBM cells. In summary, PS-341 has profound effects on growth and apoptosis of GBM cells, suggesting that PS-341 maybe an effective therapy for patients with gliomas.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol & Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, D (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol & Oncol, 8700 Beverly Blvd,Davis Bldg 5022 Room, Los Angeles, CA 90048 USA.	Dong.Yin@cshs.org		Black, Keith/0000-0002-0546-4934				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; An JB, 2003, CLIN CANCER RES, V9, P4537; Cusack JC, 2001, CANCER RES, V61, P3535; Dai Y, 2003, ONCOGENE, V22, P7108, DOI 10.1038/sj.onc.1206863; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Hayashi S, 2001, NEUROL MED-CHIR, V41, P187, DOI 10.2176/nmc.41.187; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; IMAI Y, 1994, MODERN PATHOL, V7, P766; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LeBlanc R, 2002, CANCER RES, V62, P4996; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Ling YH, 2002, MOL CANCER THER, V1, P841; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nawrocki ST, 2002, MOL CANCER THER, V1, P1243; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Tani E, 2001, FEBS LETT, V504, P53, DOI 10.1016/S0014-5793(01)02770-3; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang Y, 2004, CANCER SCI, V95, P176, DOI 10.1111/j.1349-7006.2004.tb03200.x	33	205	211	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2005	24	3					344	354		10.1038/sj.onc.1208225	http://dx.doi.org/10.1038/sj.onc.1208225			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531918				2022-12-25	WOS:000226279700006
J	Aksoy, E; Zouain, CS; Vanhoutte, F; Fontaine, J; Pavelka, N; Thieblemont, N; Willems, F; Ricciardi-Castagnoli, P; Goldman, M; Capron, M; Ryffel, B; Trottein, F				Aksoy, E; Zouain, CS; Vanhoutte, F; Fontaine, J; Pavelka, N; Thieblemont, N; Willems, F; Ricciardi-Castagnoli, P; Goldman, M; Capron, M; Ryffel, B; Trottein, F			Double-stranded RNAs from the helminth parasite Schistosoma activate TLR3 in dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-3; NF-KAPPA-B; GENE-EXPRESSION; CAENORHABDITIS-ELEGANS; REGULATORY FACTOR-3; SIGNALING PATHWAY; TH2 RESPONSES; CUTTING EDGE; INNATE; MANSONI	Stimulation of dendritic cells (DCs) by the egg stage of the helminth parasite Schistosoma mansoni activates a signaling pathway resulting in type I interferon (IFN) and IFN-stimulated gene (ISG) expression. Here, we demonstrate that S. mansoni eggs disjointedly activate myeloid differentiation factor 88 (MyD88)-dependent and MyD88-independent pathways in DCs. Inflammatory cytokine expression and NF-kappaB activation in DCs from MyD88-deficient mice were impaired, whereas signaling transducer activator of transcription ( STAT) 1((Tyr701)) phosphorylation and ISG expression were intact in MyD88 or Toll-like receptor (TLR)4-deficient counterparts. Accordingly, we analyzed distinct TLR members for their ability to respond to schistosome eggs and established that TLR3 resulted in the activation of NF-kappaB and the positive regulatory domain III-I site from IFN-beta promoter. Unexpectedly, egg-derived RNA possessed RNase A-resistant and RNase III-sensitive structures capable of triggering TLR3 activation, suggesting the involvement of double-stranded (ds) structures. Moreover, DCs from TLR3-deficient mice displayed a complete loss of signaling transducer activator of transcription 1 phosphorylation and ISG expression in response to egg-derived dsRNA. Finally, TLR3-deficient DCs showed a reduced response to schistosome eggs relative to wild-type cells. Collectively, our data suggest for the first time that dsRNA from a non-viral pathogen may act as an inducer of the innate immune system through TLR3.	Inst Pasteur, Ctr Immunol & Biol Parasitaire, INSERM, U547, F-59019 Lille, France; Univ Libre Brussels, Inst Med Immunol, B-1070 Brussels, Belgium; Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; Univ Paris 05, Hop Necker, F-75743 Paris, France; CNRS, F-75743 Paris, France; CNRS, Lab Genet Expt & Mol GEM2358, F-41500 Orleans, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite Libre de Bruxelles; University of Milano-Bicocca; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Trottein, F (corresponding author), Inst Pasteur, Ctr Immunol & Biol Parasitaire, INSERM, U547, 1 Rue Prof Calmette, F-59019 Lille, France.	francois.trottein@pasteurlille.fr	Castagnoli, Paola/E-8288-2010; Thieblemont, Nathalie/P-1329-2017; Aksoy, Ezra/ABH-1337-2021; TROTTEIN, Francois/C-2405-2018; Capron, monique/Z-2207-2019; Pavelka, Norman/G-4577-2018	Thieblemont, Nathalie/0000-0002-8898-9217; Aksoy, Ezra/0000-0002-6962-1572; TROTTEIN, Francois/0000-0003-3373-1814; Capron, monique/0000-0001-5625-5158; Pavelka, Norman/0000-0003-4542-9970				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Boyle JP, 2003, INT J PARASITOL, V33, P1259, DOI 10.1016/S0020-7519(03)00159-0; Cervi L, 2004, J IMMUNOL, V172, P2016, DOI 10.4049/jimmunol.172.4.2016; Chiu BC, 2004, AM J PATHOL, V164, P1021, DOI 10.1016/S0002-9440(10)63189-6; Danin-Kreiselman M, 2003, MOL CELL, V11, P1279, DOI 10.1016/S1097-2765(03)00137-0; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Ferbeyre G, 1998, MOL CELL BIOL, V18, P3880, DOI 10.1128/MCB.18.7.3880; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gao JJ, 1998, J IMMUNOL, V161, P4803; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; LIBONATI M, 1992, MOL CELL BIOCHEM, V117, P139; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Nicholson AW, 1999, FEMS MICROBIOL REV, V23, P371, DOI 10.1016/S0168-6445(99)00013-3; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Sakaguchi S, 2003, BIOCHEM BIOPH RES CO, V306, P860, DOI 10.1016/S0006-291X(03)01049-0; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Sousa CRE, 2004, CURR OPIN IMMUNOL, V16, P21, DOI 10.1016/j.coi.2003.11.007; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Straw AD, 2003, J IMMUNOL, V170, P727, DOI 10.4049/jimmunol.170.2.727; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thomas PG, 2003, J IMMUNOL, V171, P5837, DOI 10.4049/jimmunol.171.11.5837; Tijsterman M, 2004, CURR BIOL, V14, P111, DOI 10.1016/j.cub.2003.12.029; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Trottein F, 2004, J IMMUNOL, V172, P3011, DOI 10.4049/jimmunol.172.5.3011; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; VanLint C, 1997, J VIROL, V71, P6113, DOI 10.1128/JVI.71.8.6113-6127.1997; Vazquez-Tello A, 2002, NUCLEIC ACIDS RES, V30, P1606, DOI 10.1093/nar/30.7.1606; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zaccone P, 2003, EUR J IMMUNOL, V33, P1439, DOI 10.1002/eji.200323910	54	127	137	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					277	283		10.1074/jbc.M411223200	http://dx.doi.org/10.1074/jbc.M411223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15519998	hybrid			2022-12-25	WOS:000226025100034
J	Azam, L; Dowell, C; Watkins, M; Stitzel, JA; Olivera, BM; McIntosh, JM				Azam, L; Dowell, C; Watkins, M; Stitzel, JA; Olivera, BM; McIntosh, JM			alpha-conotoxin BuIA, a novel peptide from Conus bullatus, distinguishes among neuronal nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 BETA 2; MESSENGER-RNAS; BINDING-SITES; A-SUPERFAMILY; SUBUNIT; DETERMINANTS; SENSITIVITY; ANTAGONIST; SPECIFICITY; INHIBITION	Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels. alpha Subunits, together with beta2 and/or beta4 subunits, form ligand-binding sites at alpha/beta subunit interfaces. Predatory marine snails of the genus Conus are a rich source of nAChR-targeted peptides. Using conserved features of the alpha-conotoxin signal sequence and 3'-untranslated sequence region, we have cloned a novel gene from the fish-eating snail, Conus bullatus; the gene codes for a previously unreported alpha-conotoxin with unusual 4/4 spacing of amino acids in the two disulfide loops. Chemical synthesis of the predicted mature toxin was performed. The resulting peptide, alpha-conotoxin BuIA, was tested on cloned nAChRs expressed in Xenopus oocytes. The peptide potently blocks numerous rat nAChR subtypes, with highest potency for alpha3- and chimeric alpha6-containing nAChRs; BuIA blocks alpha6/alpha3beta2 nAChRs with a 40,000-fold lower IC50 than alpha4beta2 nAChRs. The kinetics of toxin unblock are dependent on the beta subunit. nAChRs with a beta4 subunit have very slow off-times, compared with the corresponding beta2 subunit-containing nAChR. In each instance, rat alphaxbeta4 may be distinguished from rat alphaxbeta2 by the large difference in time to recover from toxin block. Similar results are obtained when comparing mouse alpha3beta2 to mouse alpha3beta4, and human alpha3beta2 to human alpha3beta4, indicating that the beta subunit dependence extends across species. Thus, alpha-conotoxin BuIA also represents a novel probe for distinguishing between beta2- and beta4-containing nAChRs.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	McIntosh, JM (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.	mcintosh@biology.utah.edu		STITZEL, JERRY/0000-0001-8161-6525	NIDA NIH HHS [DA 14369, DA 016835] Funding Source: Medline; NIGMS NIH HHS [GM 48677] Funding Source: Medline; NIMH NIH HHS [MH 53631] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053631, R29MH053631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014369, F32DA016835] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bibevski S, 2000, J NEUROSCI, V20, P5076; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; ChavezNoriega LE, 1997, J PHARMACOL EXP THER, V280, P346; Colquhoun LM, 1997, J NEUROCHEM, V69, P2355; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; De Biasi M, 2002, J NEUROBIOL, V53, P568, DOI 10.1002/neu.10145; Dowell C, 2003, J NEUROSCI, V23, P8445; Ellison M, 2003, J BIOL CHEM, V278, P757, DOI 10.1074/jbc.M204565200; Everhart D, 2003, J PHARMACOL EXP THER, V306, P664, DOI 10.1124/jpet.103.051656; FIGL A, 1992, FEBS LETT, V308, P245, DOI 10.1016/0014-5793(92)81284-S; Francis MM, 2000, MOL PHARMACOL, V58, P109, DOI 10.1124/mol.58.1.109; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; Hann RM, 1997, BIOCHEMISTRY-US, V36, P9051, DOI 10.1021/bi970807c; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; Harvey SC, 1996, J NEUROCHEM, V67, P1953; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; Harvey SC, 1996, J NEUROSCI, V16, P3798; Jacobsen R, 1998, J PEPT RES, V51, P173; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Jones S, 1999, TRENDS NEUROSCI, V22, P555, DOI 10.1016/S0166-2236(99)01471-X; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; LUETJE CW, 1991, J NEUROSCI, V11, P837; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; McIntosh J M, 1999, Methods Enzymol, V294, P605; McIntosh JM, 2002, J BIOL CHEM, V277, P33610, DOI 10.1074/jbc.M205102200; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; Parker MJ, 1998, MOL PHARMACOL, V54, P1132, DOI 10.1124/mol.54.6.1132; Quik M, 2004, J NEUROCHEM, V88, P668, DOI 10.1111/j.1471-4159.2004.02177.x; Quik M, 2001, J NEUROSCI, V21, P5494, DOI 10.1523/JNEUROSCI.21-15-05494.2001; ROCKEL D, 1995, MANUAL LIVING CONIDA, V1, P214; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; RUST G, 1994, EUR J NEUROSCI, V6, P478, DOI 10.1111/j.1460-9568.1994.tb00290.x; Santos AD, 2004, J BIOL CHEM, V279, P17596, DOI 10.1074/jbc.M309654200; Schoenfeld R.A., 1999, THESIS U UTAH SALT L; STAFFORD GA, 1994, MOL PHARMACOL, V45, P758; Stitzel JA, 2001, PHARMACOGENETICS, V11, P331, DOI 10.1097/00008571-200106000-00008; Vailati S, 1999, MOL PHARMACOL, V56, P11, DOI 10.1124/mol.56.1.11; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; Wang CZ, 2003, TOXICON, V42, P613, DOI 10.1016/j.toxicon.2003.08.005; Wang NS, 2002, PROG NEUROBIOL, V68, P341, DOI 10.1016/S0301-0082(02)00106-5; Wang NS, 2003, MOL PHARMACOL, V63, P574, DOI 10.1124/mol.63.3.574; WinzerSerhan UH, 1997, J COMP NEUROL, V386, P540, DOI 10.1002/(SICI)1096-9861(19971006)386:4<540::AID-CNE2>3.0.CO;2-2; Xu W, 1999, J NEUROSCI, V19, P9298	51	98	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					80	87		10.1074/jbc.M406281200	http://dx.doi.org/10.1074/jbc.M406281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15520009	hybrid			2022-12-25	WOS:000226025100011
J	Holla, VR; Wang, DZ; Brown, JR; Mann, JR; Katkuri, S; Dubois, RN				Holla, VR; Wang, DZ; Brown, JR; Mann, JR; Katkuri, S; Dubois, RN			Prostaglandin E-2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; INTESTINAL EPITHELIAL-CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; TUMOR-NECROSIS-FACTOR; COLON-CANCER; CARCINOMA-CELLS; FACTOR EXPRESSION; GENE-EXPRESSION; CD55	Cyclooxygenase-derived prostaglandin E-2 (PGE(2)) stimulates tumor progression by modulating several proneoplastic pathways. The mechanisms by which PGE(2) promotes tumor growth and metastasis through stimulation of cell migration, invasion, and angiogenesis have been fairly well characterized. Much less is known, however, about the molecular mechanisms responsible for the immunosuppressive effects of PGE(2). We identified PGE(2) target genes and subsequently studied their biologic role in colorectal cancer cells. The complement regulatory protein decay-accelerating factor (DAF or CD55) was induced following PGE(2) treatment of LS174T colon cancer cells. Analysis of PGE(2)-mediated activation of the DAF promoter employing 5'-deletion luciferase constructs suggests that regulation occurs at the transcriptional level via a cyclic AMP/protein kinase A-dependent pathway. Nonsteroidal anti-inflammatory drugs blocked DAF expression in HCA-7 colon cancer cells, which could be restored by the addition of exogenous PGE(2). Finally, we observed an increase in DAF expression in the intestinal mucosa of Apc(Min+/-) mice treated with PGE(2) in vivo. In summary, these results indicate a novel immunosuppressive role for PGE(2) in the development of colorectal carcinomas.	Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Dubois, RN (corresponding author), Vanderbilt Ingram Canc Ctr, Dept Canc Biol, 691 Preston Bldg,2300 Pierce Ave, Nashville, TN 37232 USA.	raymond.dubois@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [P0-CA-77839] Funding Source: Medline; NIDDK NIH HHS [R0-DK-62112, R37-DK47297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062112, R37DK047297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andoh A, 1997, IMMUNOLOGY, V90, P358, DOI 10.1111/j.1365-2567.1997.00358.x; Andoh A, 2002, CANCER IMMUNOL IMMUN, V50, P663, DOI 10.1007/s262-001-0239-1; Andoh A, 2001, J IMMUNOL, V167, P3887, DOI 10.4049/jimmunol.167.7.3887; BAXEVANIS CN, 1993, CANCER-AM CANCER SOC, V72, P491, DOI 10.1002/1097-0142(19930715)72:2<491::AID-CNCR2820720227>3.0.CO;2-1; Bremers AJA, 2000, CRIT REV ONCOL HEMAT, V34, P1, DOI 10.1016/S1040-8428(99)00059-1; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Chan TA, 2002, LANCET ONCOL, V3, P166, DOI 10.1016/S1470-2045(02)00680-0; Chouaib S, 1997, IMMUNOL TODAY, V18, P493, DOI 10.1016/S0167-5699(97)01115-8; DeLong P, 2003, CANCER RES, V63, P7845; Donin N, 2003, CLIN EXP IMMUNOL, V131, P254, DOI 10.1046/j.1365-2249.2003.02066.x; DuBois RN, 2003, PROG EXP TUMOR RES, V37, P124; Durrant LG, 2003, CANCER IMMUNOL IMMUN, V52, P638, DOI 10.1007/s00262-003-0402-y; Gelderman KA, 2002, LAB INVEST, V82, P483, DOI 10.1038/labinvest.3780441; GOODWIN JS, 1983, SEMIN ARTHRITIS RHEU, V13, P134, DOI 10.1016/0049-0172(83)90033-1; Gorter A, 1999, IMMUNOL TODAY, V20, P576, DOI 10.1016/S0167-5699(99)01537-6; Gorter A, 1996, LAB INVEST, V74, P1039; Gupta RA, 2003, CANCER RES, V63, P906; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Harndahl L, 2002, J BIOL CHEM, V277, P37446, DOI 10.1074/jbc.M205401200; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Heine H, 2003, EUR J IMMUNOL, V33, P1399, DOI 10.1002/eji.200323381; Hilkens C M, 1996, Eur Respir J Suppl, V22, p90s; Inoue T, 2002, J CLIN PATHOL-MOL PA, V55, P193, DOI 10.1136/mp.55.3.193; Jurianz K, 1999, MOL IMMUNOL, V36, P929, DOI 10.1016/S0161-5890(99)00115-7; Kettunen HL, 2003, CANCER RES, V63, P5136; Kirschfink M, 2001, Expert Opin Pharmacother, V2, P1073, DOI 10.1517/14656566.2.7.1073; Kirschfink M, 2001, IMMUNOL REV, V180, P177, DOI 10.1034/j.1600-065X.2001.1800116.x; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KLINGEMANN HG, 1986, BLOOD, V68, P102; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; Li L, 2001, BRIT J CANCER, V84, P80, DOI 10.1054/bjoc.2000.1570; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; Mason JC, 2002, AM J PHYSIOL-CELL PH, V282, pC578, DOI 10.1152/ajpcell.00339.2001; Mastellos D, 2003, IMMUNOL RES, V27, P367, DOI 10.1385/IR:27:2-3:367; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; Nakashima M, 1999, NAT MED, V5, P938, DOI 10.1038/11383; Nasu J, 1998, CLIN EXP IMMUNOL, V113, P379; NICHOLSONWELLER A, 1983, P NATL ACAD SCI-BIOL, V80, P5066, DOI 10.1073/pnas.80.16.5066; O'Connell J, 1999, NAT MED, V5, P267, DOI 10.1038/6477; PANGBURN MK, 1983, P NATL ACAD SCI-BIOL, V80, P5430, DOI 10.1073/pnas.80.17.5430; Pawelec G, 2004, CANCER IMMUNOL IMMUN, V53, P262, DOI 10.1007/s00262-003-0469-5; PHIPPS RP, 1990, IMMUNOL REV, V117, P135, DOI 10.1111/j.1600-065X.1990.tb00571.x; Ristimaki A, 2004, NOVART FDN SYMP, V256, P259; Ristimaki Ari, 2004, Novartis Found Symp, V256, P215; Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001; Roth W, 2001, CANCER RES, V61, P2759; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; SCALES WE, 1989, J LEUKOCYTE BIOL, V45, P416, DOI 10.1002/jlb.45.5.416; Schmoeckel M, 1997, TRANSPLANT P, V29, P3157, DOI 10.1016/S0041-1345(97)00823-3; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 1998, CANCER RES, V58, P362; Sogabe H, 2001, J IMMUNOL, V167, P2791, DOI 10.4049/jimmunol.167.5.2791; STAHL RAK, 1987, KIDNEY INT, V31, P1126, DOI 10.1038/ki.1987.118; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Suny XJ, 1999, P NATL ACAD SCI USA, V96, P628, DOI 10.1073/pnas.96.2.628; THOMAS DJ, 1993, J IMMUNOL, V150, P151; Thorsteinsson L, 1998, APMIS, V106, P869, DOI 10.1111/j.1699-0463.1998.tb00233.x; Thun Michael J, 2004, Novartis Found Symp, V256, P6; Thun MJ, 2004, NOVART FDN SYMP, V256, P22; THUN MJ, 2004, NOVART FDN SYMP, V256, P49; Turnberg D, 2003, MOL IMMUNOL, V40, P145, DOI 10.1016/S0161-5890(03)00110-X; Varsano S, 1998, AM J RESP CELL MOL, V19, P522, DOI 10.1165/ajrcmb.19.3.3181; Yakar I, 2003, ANN SURG ONCOL, V10, P469, DOI 10.1245/ASO.2003.08.017	67	50	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					476	483		10.1074/jbc.M407403200	http://dx.doi.org/10.1074/jbc.M407403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15520008	hybrid			2022-12-25	WOS:000226025100057
J	Rigby, SEJ; Hynson, RMG; Ramsay, RR; Munro, AW; Scrutton, NS				Rigby, SEJ; Hynson, RMG; Ramsay, RR; Munro, AW; Scrutton, NS			A stable tyrosyl radical in monoamine oxidase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; BENZYLAMINE ANALOGS; FLAVIN SEMIQUINONE; INHIBITORS ALTER; REDOX PROPERTIES; HUMAN LIVER; OXIDATION; MECHANISM; CATALYSIS; AMINE	We present spectroscopic evidence consistent with the presence of a stable tyrosyl radical in partially reduced human monoamine oxidase (MAO) A. The radical forms following single electron donation to MAO A and exists in equilibrium with the FAD flavosemiquinone. Oxidative formation of the tyrosyl radical in MAO is not reliant on neighboring metal centers and uniquely requires reduction of the active site flavin to facilitate oxidation of a tyrosyl side chain. The identified tyrosyl radical provides the key missing link in support of the single electron transfer mechanism for amine oxidation by MAO enzymes.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ London Queen Mary Coll, Dept Biol Sci, London E1 4NS, England; Univ St Andrews, Ctr Biomol Sci, St Andrews KY19 9ST, Fife, Scotland	University of Leicester; University of London; Queen Mary University London; University of St Andrews	Munro, AW (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	awm9@le.ac.uk; nss4@le.ac.uk	Ramsay, Rona/A-4065-2009; Ramsay, Rona R./A-6681-2008; Munro, Andrew/G-5639-2019	Ramsay, Rona R./0000-0003-1535-4904; Munro, Andrew/0000-0002-4642-180X				Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; Boulton A. A., 1998, CATACHOLAMINES BRIDG, P308; BROWN LE, 1970, J AM CHEM SOC, V92, P7225; Candeias LP, 1998, BBA-BIOENERGETICS, V1363, P1, DOI 10.1016/S0005-2728(97)00077-7; Cesura A M, 1992, Prog Drug Res, V38, P171; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; DeRose VJ, 1996, BIOCHEMISTRY-US, V35, P11085, DOI 10.1021/bi960749f; EDMONDSON DE, 1985, BIOCHEM SOC T, V13, P593, DOI 10.1042/bst0130593; EDMONDSON DE, 1995, XENOBIOTICA, V25, P735, DOI 10.3109/00498259509061889; EDMONDSON DE, 1996, FLAVINS FLAVOPROTEIN, P23; Geha RM, 2002, J BIOL CHEM, V277, P17209, DOI 10.1074/jbc.M110920200; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; Hoegy SE, 1997, TETRAHEDRON, V53, P5027, DOI 10.1016/S0040-4020(97)00206-8; Hynson RMG, 2004, BBA-GEN SUBJECTS, V1672, P60, DOI 10.1016/j.bbagen.2004.02.011; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KIM JM, 1993, J AM CHEM SOC, V115, P10591, DOI 10.1021/ja00076a017; Ma JC, 2004, J MOL BIOL, V338, P103, DOI 10.1016/j.jmb.2004.02.032; Maruyama W, 2003, NEUROSCI LETT, V341, P233, DOI 10.1016/S0304-3940(03)00211-8; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Mezzetti A, 1999, J PHYS CHEM A, V103, P9636, DOI 10.1021/jp9903763; Miller JR, 1999, BIOCHEMISTRY-US, V38, P13670, DOI 10.1021/bi990920y; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Ramsay RR, 2002, BBA-PROTEINS PROTEOM, V1601, P178, DOI 10.1016/S1570-9639(02)00466-1; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P1734, DOI 10.1021/bi00173a016; Sablin SO, 2001, ANTIOXID REDOX SIGN, V3, P723, DOI 10.1089/15230860152664920; SAURA J, 1994, NEUROSCIENCE, V62, P15, DOI 10.1016/0306-4522(94)90311-5; Silverman RB, 1995, PROG BRAIN RES, V106, P23; SILVERMAN RB, 1995, ACCOUNTS CHEM RES, V28, P335, DOI 10.1021/ar00056a003; SILVERMAN RB, 1980, J AM CHEM SOC, V102, P7126, DOI 10.1021/ja00543a052; TAN AK, 1991, BIOCHEM BIOPH RES CO, V181, P1084, DOI 10.1016/0006-291X(91)92048-O; Vindis C, 2000, BIOCHEM BIOPH RES CO, V271, P181, DOI 10.1006/bbrc.2000.2524; WALKER MC, 1994, BIOCHEMISTRY-US, V33, P7088, DOI 10.1021/bi00189a011; WEIL JA, 1994, ELECT PARAMAGNETIC R, P498; WEYLER W, 1985, J BIOL CHEM, V260, P3199; YUE KT, 1993, ARCH BIOCHEM BIOPHYS, V300, P178, DOI 10.1006/abbi.1993.1025	36	39	39	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4627	4631		10.1074/jbc.M410596200	http://dx.doi.org/10.1074/jbc.M410596200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15556933	hybrid			2022-12-25	WOS:000227096600077
J	Zambelli, B; Stola, M; Musiani, F; De Vriendt, K; Samyn, B; Devreese, B; Van Beeumen, J; Turano, P; Dikiy, A; Bryant, DA; Ciurli, S				Zambelli, B; Stola, M; Musiani, F; De Vriendt, K; Samyn, B; Devreese, B; Van Beeumen, J; Turano, P; Dikiy, A; Bryant, DA; Ciurli, S			UreG, a chaperone in the urease assembly process, is an intrinsically unstructured GTPase that specifically binds Zn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-AEROGENES UREASE; PROTEUS-MIRABILIS UREASE; CARBON-MONOXIDE DEHYDROGENASE; SIGNAL RECOGNITION PARTICLE; CIRCULAR-DICHROISM SPECTRA; CRYSTAL-STRUCTURE; HELICOBACTER-PYLORI; ACCESSORY PROTEINS; NUCLEOTIDE-BINDING; METAL-BINDING	Bacillus pasteurii UreG, a chaperone involved in the urease active site assembly, was overexpressed in Escherichia coli BL21 (DE3) and purified to homogeneity. The identity of the recombinant protein was confirmed by SDS-PAGE, protein sequencing, and mass spectrometry. A combination of size exclusion chromatography and multiangle and dynamic laser light scattering established that BpUreG is present in solution as a dimer. Analysis of circular dichroism spectra indicated that the protein contains large portions of helices (15%) and strands (29%), whereas NMR spectroscopy indicated the presence of conformational fluxionality of the protein backbone in solution. BpUreG catalyzes the hydrolysis of GTP with a k(cat) = 0.04 min(-1), confirming a role for this class of proteins in coupling energy requirements and nickel incorporation into the urease active site. BpUreG binds two Zn2+ ions per dimer, with a K-D = 42 +/- 3 mum, and has a 10-fold lower affinity for Ni2+. A structural model for BpUreG was calculated by using threading algorithms. The protein, in the fully folded state, features the typical structural architecture of GTPases, with an open beta-barrel surrounded by alpha-helices and a P-loop at the N terminus. The protein dynamic behavior observed in solution is critically discussed relative to the structural model, using algorithms for disorder predictions. The results suggest that UreG proteins belong to the class of intrinsically unstructured proteins that need the interaction with cofactors or other protein partners to perform their function. It is also proposed that metal ions such as Zn2+ could have important structural roles in the urease activation process.	Univ Bologna, Dept Agroenvironm Sci & Technol, Lab Biooorgan Chem, I-40127 Bologna, Italy; Univ Ghent, Dept Biochem Physiol & Microbiol, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; Univ Florence, Dept Chem, I-50019 Florence, Italy; Univ Florence, Magnet Resonance Ctr, I-50019 Florence, Italy; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Bologna; Ghent University; University of Florence; University of Florence; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ciurli, S (corresponding author), Univ Bologna, Dept Agroenvironm Sci & Technol, Lab Biooorgan Chem, Viale Giuseppe Fanin 40, I-40127 Bologna, Italy.	stefano.ciurli@unibo.it	Samyn, Bart/F-4149-2014; Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019; Turano, Paola/F-9089-2011; Musiani, Francesco/A-7410-2016; Musiani, Francesco/AAA-2385-2021; Ciurli, Stefano/K-4355-2014	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581; Turano, Paola/0000-0002-7683-8614; Musiani, Francesco/0000-0003-0200-1712; Musiani, Francesco/0000-0003-0200-1712; Ciurli, Stefano/0000-0001-9557-926X; Zambelli, Barbara/0000-0002-3876-0051				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Blokesch M, 2004, J BACTERIOL, V186, P2603, DOI 10.1128/JB.186.9.2603-2611.2004; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYD VL, 1992, ANAL BIOCHEM, V206, P344, DOI 10.1016/0003-2697(92)90376-I; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brayman TG, 1996, J BACTERIOL, V178, P5410, DOI 10.1128/jb.178.18.5410-5416.1996; Chang ZZ, 2004, J BIOL CHEM, V279, P15305, DOI 10.1074/jbc.M312979200; Chen X, 1999, P NATL ACAD SCI USA, V96, P8396, DOI 10.1073/pnas.96.15.8396; Ciurli S, 2002, J BIOL INORG CHEM, V7, P623, DOI 10.1007/s00775-002-0341-7; Ciurli S, 2001, HANDBOOK ON METALLOPROTEINS, P669; Colpas GJ, 1998, J BIOL INORG CHEM, V3, P150, DOI 10.1007/s007750050216; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; Colpas GJ, 2000, J BIOL CHEM, V275, P10731, DOI 10.1074/jbc.275.15.10731; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dupont DR, 2000, EXS, V88, P119; ESNOUF BM, 1997, J MOL GRAPHICS, V15, P133; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Freyermuth SK, 2000, PLANT J, V21, P53, DOI 10.1046/j.1365-313x.2000.00655.x; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; Ginalski K, 2003, NUCLEIC ACIDS RES, V31, P3291, DOI 10.1093/nar/gkg503; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Ha NC, 2001, NAT STRUCT BIOL, V8, P505, DOI 10.1038/88563; Hausinger R.P., 2001, HDB METALLOPROTEINS, P867; Heimer SR, 2001, J BACTERIOL, V183, P1423, DOI 10.1128/JB.183.4.1423-1433.2001; ISLAND MD, 1995, J BACTERIOL, V177, P5653, DOI 10.1128/jb.177.19.5653-5660.1995; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Jeon WB, 2001, J BIOL CHEM, V276, P38602, DOI 10.1074/jbc.M104945200; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; JONES BD, 1988, J BACTERIOL, V170, P3342, DOI 10.1128/jb.170.8.3342-3349.1988; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; Khil PP, 2004, PROTEINS, V54, P371, DOI 10.1002/prot.10430; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; LEE MH, 1990, J BACTERIOL, V172, P4427, DOI 10.1128/jb.172.8.4427-4431.1990; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Mehta N, 2003, J BACTERIOL, V185, P726, DOI 10.1128/JB.185.3.726-734.2003; Mehta N, 2003, MICROB PATHOGENESIS, V35, P229, DOI 10.1016/S0882-4010(03)00151-7; Michalopoulos I, 2004, NUCLEIC ACIDS RES, V32, pD251, DOI 10.1093/nar/gkh060; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Moncrief MBC, 1996, J BACTERIOL, V178, P5417, DOI 10.1128/jb.178.18.5417-5421.1996; Moncrief MBC, 1997, J BACTERIOL, V179, P4081, DOI 10.1128/jb.179.13.4081-4086.1997; Montoya G, 1997, PROTEINS, V28, P285, DOI 10.1002/(SICI)1097-0134(199706)28:2<285::AID-PROT15>3.0.CO;2-E; Montoya G, 2000, STRUCTURE, V8, P515, DOI 10.1016/S0969-2126(00)00131-3; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Musiani F, 2004, J INORG BIOCHEM, V98, P803, DOI 10.1016/j.jinorgbio.2003.12.012; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson JW, 2001, MOL MICROBIOL, V39, P176, DOI 10.1046/j.1365-2958.2001.02244.x; Padmanabhan S, 2001, STRUCTURE, V9, P859, DOI 10.1016/S0969-2126(01)00641-4; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Park IS, 1996, BIOCHEMISTRY-US, V35, P5345, DOI 10.1021/bi952894j; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; PARK IS, 1995, J BACTERIOL, V177, P1947, DOI 10.1128/jb.177.8.1947-1951.1995; PARK IS, 1995, SCIENCE, V267, P1156, DOI 10.1126/science.7855593; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Ramirez UD, 2002, J MOL BIOL, V320, P783, DOI 10.1016/S0022-2836(02)00476-X; Remaut H, 2001, J BIOL CHEM, V276, P49365, DOI 10.1074/jbc.M108304200; REY L, 1994, J BACTERIOL, V176, P6066, DOI 10.1128/jb.176.19.6066-6073.1994; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samyn B, 2000, ANAL CHEM, V72, P1389, DOI 10.1021/ac991049u; Scheidig AJ, 1999, STRUCTURE, V7, P1311, DOI 10.1016/S0969-2126(00)80021-0; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Song HK, 2001, J BIOL CHEM, V276, P49359, DOI 10.1074/jbc.M108619200; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sternberg M.J.E., 1996, PROTEIN STRUCTURE PR, P1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Tramontano A, 2003, NAT STRUCT BIOL, V10, P87, DOI 10.1038/nsb0203-87; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Voland P, 2003, AM J PHYSIOL-GASTR L, V284, pG96, DOI 10.1152/ajpgi.00160.2002; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; Witte CP, 2001, PLANT MOL BIOL, V45, P169, DOI 10.1023/A:1006429315851; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Zhu GY, 2003, J BIOL CHEM, V278, P2452, DOI 10.1074/jbc.M211042200	95	86	89	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4684	4695		10.1074/jbc.M408483200	http://dx.doi.org/10.1074/jbc.M408483200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15542602	hybrid			2022-12-25	WOS:000227096600084
J	Schmidt, MHH; Dikic, I; Bogler, O				Schmidt, MHH; Dikic, I; Bogler, O			Src phosphorylation of Alix/AIP1 modulates its interaction with binding partners and antagonizes its activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; C-SRC; DOWN-REGULATION; SH3 DOMAINS; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; FAMILY KINASES; HELA-CELLS; APOPTOSIS; ALIX	Alix/AIP1 is an adaptor protein involved in regulating the function of receptor and cytoskeleton-associated tyrosine kinases. Here, we investigated its interaction with and regulation by Src. Tyr(319) of Alix bound the isolated Src homology-2 (SH2) domain and was necessary for interaction with intact Src. A proline-rich region in the C terminus of Alix bound the Src SH3 domain, but this interaction was dependent on the release of the Src SH2 domain from its Src internal ligand either by interaction with Alix Tyr(319) or by mutation of Src Tyr(527). Src phosphorylated Alix at a C-terminal region rich in tyrosines, an activity that was stimulated by the presence of the Alix binding partner SETA/CIN85. Phosphorylation of Alix by Src caused it to translocate from the membrane and cytoskeleton to the cytoplasm and reduced its interaction with binding partners SETA/CIN85, epidermal growth factor receptor, and Pyk2. As a consequence of this, Src antagonized the negative regulation of receptor tyrosine kinase internalization and cell adhesion by Alix. We propose a model whereby Src antagonizes the effects of Alix by phosphorylation of its C terminus, leading to the disruption of interactions with target proteins.	Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, William & Karen Davidson Lab Brain Tumor Biol, Detroit, MI 48202 USA; Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany	Henry Ford Health System; Henry Ford Hospital; Goethe University Frankfurt	Bogler, O (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, William & Karen Davidson Lab Brain Tumor Biol, E&R 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	oliver@bogler.net	Schmidt, Mirko H. H./ABI-6650-2020; Dikic, Ivan/O-4650-2015	Schmidt, Mirko H. H./0000-0001-7411-8835; Dikic, Ivan/0000-0001-8156-9511; Bogler, Oliver/0000-0002-3700-0480	NATIONAL CANCER INSTITUTE [R01CA108500, R01CA084109] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084109, CA-R01-84109, R01 CA108500, CA-R01-108500] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Dikic I, 2004, BIOESSAYS, V26, P604, DOI 10.1002/bies.20068; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Harlow E., 1988, ANTIBODIES LAB MANUA; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Katoh K, 2003, J BIOL CHEM, V278, P39104, DOI 10.1074/jbc.M301604200; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Schmidt MHH, 2003, J CELL SCI, V116, P2845, DOI 10.1242/jcs.00522; Schmidt MHH, 2004, MOL CELL BIOL, V24, P8981, DOI 10.1128/MCB.24.20.8981-8993.2004; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wu Y, 2001, DIFFERENTIATION, V67, P139, DOI 10.1046/j.1432-0436.2001.670406.x; Wu Y, 2002, ONCOGENE, V21, P6801, DOI 10.1038/sj.onc.1205849; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	41	56	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3414	3425		10.1074/jbc.M409839200	http://dx.doi.org/10.1074/jbc.M409839200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557335	hybrid, Green Accepted			2022-12-25	WOS:000226983900036
J	Alphey, MS; Yu, WH; Byres, E; Li, D; Hunter, WN				Alphey, MS; Yu, WH; Byres, E; Li, D; Hunter, WN			Structure and reactivity of human mitochondrial 2,4-dienoyl-CoA reductase - Enzyme-ligand interactions in a distinctive short-chain reductase active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENOYL-ACP REDUCTASE; CRYSTAL-STRUCTURE; BETA-OXIDATION; PTERIDINE REDUCTASE; MOLECULAR-CLONING; MECHANISM; DEHYDROGENASE; SPECIFICITY; EXPRESSION; PROGRAM	Fatty acid catabolism by beta-oxidation mainly occurs in mitochondria and to a lesser degree in peroxisomes. Polyunsaturated fatty acids are problematic for beta-oxidation, because the enzymes directly involved are unable to process all the different double bond conformations and combinations that occur naturally. In mammals, three accessory proteins circumvent this problem by catalyzing specific isomerization and reduction reactions. Central to this process is the NADPH-dependent 2,4-dienoyl-CoA reductase. We present high resolution crystal structures of human mitochondrial 2,4-dienoyl-CoA reductase in binary complex with cofactor, and the ternary complex with NADP(+) and substrate trans-2,trans-4-dienoyl-CoA at 2.1 and 1.75 Angstrom resolution, respectively. The enzyme, a homotetramer, is a short-chain dehydrogenase/reductase with a distinctive catalytic center. Close structural similarity between the binary and ternary complexes suggests an absence of large conformational changes during binding and processing of substrate. The site of catalysis is relatively open and placed beside a flexible loop thereby allowing the enzyme to accommodate and process a wide range of fatty acids. Seven single mutants were constructed, by site-directed mutagenesis, to investigate the function of selected residues in the active site thought likely to either contribute to the architecture of the active site or to catalysis. The mutant proteins were overexpressed, purified to homogeneity, and then characterized. The structural and kinetic data are consistent and support a mechanism that derives one reducing equivalent from the cofactor, and one from solvent. Key to the acquisition of a solvent-derived proton is the orientation of substrate and stabilization of a dienolate intermediate by Tyr-199, Asn-148, and the oxidized nicotinamide.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee, Scotland; City Univ Hong Kong, Div Biol & Chem, Kowloon, Hong Kong, Peoples R China	University of Dundee; City University of Hong Kong	Hunter, WN (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee, Scotland.	w.n.hunter@dundee.ac.uk	Hunter, William/AAE-3947-2019					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Chu XS, 2003, PROTEIN EXPRES PURIF, V31, P292, DOI 10.1016/S1046-5928(03)00191-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CVETANOVIC M, 1985, BIOCHEM J, V227, P9; Das AK, 2000, J BIOL CHEM, V275, P24333, DOI 10.1074/jbc.M001168200; De Nys K, 2001, BBA-MOL CELL BIOL L, V1533, P66, DOI 10.1016/S1388-1981(01)00141-X; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Duax WL, 2003, PROTEINS, V53, P931, DOI 10.1002/prot.10512; Fillgrove KL, 2001, BIOCHEMISTRY-US, V40, P12412, DOI 10.1021/bi0111606; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Geisbrecht BV, 1999, J BIOL CHEM, V274, P25814, DOI 10.1074/jbc.274.36.25814; Gourley DG, 2001, NAT STRUCT BIOL, V8, P521, DOI 10.1038/88584; Gurr MI, 1991, LIPID BIOCH INTRO; Gurvitz A, 1999, BIOCHEM J, V344, P903, DOI 10.1042/0264-6021:3440903; HAKKOLA EH, 1993, EUR J BIOCHEM, V215, P199, DOI 10.1111/j.1432-1033.1993.tb18023.x; Helander HM, 1997, GENOMICS, V46, P112, DOI 10.1006/geno.1997.5004; HILTUNEN JK, 2000, BIOCHIM BIOPHYS ACTA, V1482, P117; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hubbard PA, 2003, J BIOL CHEM, V278, P37553, DOI 10.1074/jbc.M304642200; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kim JJP, 2002, CURR OPIN STRUC BIOL, V12, P721, DOI 10.1016/S0959-440X(02)00390-1; KOIVURANTA KT, 1994, BIOCHEM J, V304, P787, DOI 10.1042/bj3040787; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEONARD GA, 1995, ACTA CRYSTALLOGR D, V51, P136, DOI 10.1107/S0907444994004713; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; McLuskey K, 2004, ACTA CRYSTALLOGR D, V60, P1780, DOI 10.1107/S0907444904018955; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Powell AJ, 2000, J MOL BIOL, V303, P311, DOI 10.1006/jmbi.2000.4139; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; ROE CR, 1990, J CLIN INVEST, V85, P1703, DOI 10.1172/JCI114624; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; Shi R, 2004, J BIOL CHEM, V279, P16778, DOI 10.1074/jbc.M313156200; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072	47	37	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3068	3077		10.1074/jbc.M411069200	http://dx.doi.org/10.1074/jbc.M411069200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15531764	hybrid			2022-12-25	WOS:000226449100083
J	Bullerwell, CE; Gray, MW				Bullerwell, CE; Gray, MW			In vitro characterization of a tRNA editing activity in the mitochondria of Spizellomyces punctatus, a chytridiomycete fungus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE TRANSFER-RNA; ACANTHAMOEBA-CASTELLANII; DICTYOSTELIUM-DISCOIDEUM; TRYPANOSOME MITOCHONDRIA; PHYSARUM-POLYCEPHALUM; MESSENGER-RNAS; RIBOSOMAL-RNA; DNA; MECHANISM; EVOLUTION	In the chytridiomycete fungus, Spizellomyces punctatus, all eight of the mitochondrially encoded tRNAs are predicted to have one or more base pair mismatches at the first three positions of their aminoacyl acceptor stems. These tRNAs are edited post-transcriptionally by replacement of the 5'-nucleotide in each mismatched pair with a nucleotide that can form a standard Watson-Crick base pair with its counterpart in the 3'-half of the stem. The type of mitochondrial tRNA editing found in S. punctatus also occurs in Acanthamoeba castellanii, a distantly related amoeboid protist. Using an S. punctatus mitochondrial extract, we have developed an in vitro assay of tRNA editing in which nucleotides are incorporated into various tRNA substrates. Experiments employing synthetic transcripts revealed that the S. punctatus tRNA editing activity incorporates nucleotides on the 5'-side of substrate tRNAs, uses the W-sequence as a template for incorporation, and adds nucleotides in a 3'-to-5' direction. This activity can add nucleotides to a triphosphorylated 5'-end in the absence of ATP but requires ATP to add nucleotides to a monophosphorylated 5'-end; moreover, it functions independently of the state of tRNA 3' processing. These data parallel results obtained in a previous in vitro study of A. castellanii tRNA editing, suggesting that remarkably similar activities function in the mitochondria of these two organisms. The evolutionary origins of these activities are discussed.	Dalhousie Univ, Dept Biochem & Mol Biol, Canadian Inst Adv Res, Program Evolutionary Biol, Halifax, NS B3H 1X5, Canada	Canadian Institute for Advanced Research (CIFAR); Dalhousie University	Gray, MW (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Canadian Inst Adv Res, Program Evolutionary Biol, Rm 8F-2,Sir Charles Tupper Med Bldg,5850 Coll St, Halifax, NS B3H 1X5, Canada.	m.w.gray@dal.ca		Gray, Michael/0000-0001-7125-2625				Alfonzo JD, 1999, EMBO J, V18, P7056, DOI 10.1093/emboj/18.24.7056; Antes T, 1998, MOL CELL BIOL, V18, P7521, DOI 10.1128/MCB.18.12.7521; Barth C, 1999, CURR GENET, V36, P55, DOI 10.1007/s002940050472; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BINDER S, 1994, MOL GEN GENET, V244, P67, DOI 10.1007/BF00280188; BOCK R, 2001, RNA EDITING, P38; Borner GV, 1996, EMBO J, V15, P5949, DOI 10.1002/j.1460-2075.1996.tb00981.x; Bullerwell CE, 2003, NUCLEIC ACIDS RES, V31, P1614, DOI 10.1093/nar/gkg264; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Driscoll DM, 2001, RNA EDITING, P61; Fey J, 2002, GENE, V286, P21, DOI 10.1016/S0378-1119(01)00817-4; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; GOTT JM, 2001, RNA EDITING, P20; Gray MW, 2003, IUBMB LIFE, V55, P227, DOI 10.1080/1521654031000119425; Gu WF, 2003, GENE DEV, V17, P2889, DOI 10.1101/gad.1148603; HAUSMANN S, 2001, RNA EDITING, P139; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Horton TL, 2002, CURR OPIN MICROBIOL, V5, P620, DOI 10.1016/S1369-5274(02)00379-X; Hough R.F., 2001, RNA EDITING, P77; JAHN D, 1991, J BIOL CHEM, V266, P22832; JANKE A, 1993, NUCLEIC ACIDS RES, V21, P1523, DOI 10.1093/nar/21.7.1523; Laforest MJ, 2004, RNA, V10, P1191, DOI 10.1261/rna.7330504; Laforest MJ, 1997, NUCLEIC ACIDS RES, V25, P626, DOI 10.1093/nar/25.3.626; LANE BG, 1963, BIOCHIM BIOPHYS ACTA, V72, P110; Lavrov DV, 2000, P NATL ACAD SCI USA, V97, P13738, DOI 10.1073/pnas.250402997; Leigh J, 2004, RNA, V10, P615, DOI 10.1261/rna.5195504; Lin SJ, 2002, J MOL BIOL, V320, P727, DOI 10.1016/S0022-2836(02)00468-0; LONERGAN KM, 1993, SCIENCE, V259, P812, DOI 10.1126/science.8430334; MAHENDRAN R, 1994, EMBO J, V13, P232, DOI 10.1002/j.1460-2075.1994.tb06253.x; MarechalDrouard L, 1996, MOL CELL BIOL, V16, P3504; MarechalDrouard L, 1996, NUCLEIC ACIDS RES, V24, P3229, DOI 10.1093/nar/24.16.3229; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORL M, 1995, NUCLEIC ACIDS RES, V23, P3380, DOI 10.1093/nar/23.17.3380; Ogawa S, 2000, MOL GEN GENET, V263, P514, DOI 10.1007/PL00008685; ORELLANA O, 1986, MOL CELL BIOL, V6, P525, DOI 10.1128/MCB.6.2.525; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; Price DH, 1999, CURR GENET, V35, P23, DOI 10.1007/s002940050428; PRICE DH, 1998, MODIFICATION EDITING, P285; SCHNARE MN, 1985, CURR GENET, V9, P389, DOI 10.1007/BF00421610; SCHUSTER W, 1991, CURR GENET, V20, P397, DOI 10.1007/BF00317068; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; SPENCER DF, 1992, MOD METHOD PLANT, V4, P347; STUART KD, 2001, RNA EDITING, P1; Tomita K, 1996, NUCLEIC ACIDS RES, V24, P4987, DOI 10.1093/nar/24.24.4987; WILLIAMS JB, 1990, METHOD ENZYMOL, V181, P451; YOKOBORI S, 1995, NATURE, V377, P490, DOI 10.1038/377490a0; YOKOBORI S, 1995, P NATL ACAD SCI USA, V92, P10432, DOI 10.1073/pnas.92.22.10432	48	37	38	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2463	2470		10.1074/jbc.M411273200	http://dx.doi.org/10.1074/jbc.M411273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15546859	hybrid			2022-12-25	WOS:000226449100012
J	Gao, XL; Du, ZY; Patel, TB				Gao, XL; Du, ZY; Patel, TB			Copper and zinc inhibit G alpha(s) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; CRYSTAL-STRUCTURE; G-PROTEINS; GTP; BINDING; GDP; STIMULATION; ACTIVATION; DEFICIENT; MUTATIONS	The stimulatory GTP-binding protein of adenylyl cyclase (AC) regulates hormone-stimulated production of cAMP. Here, we demonstrate that Cu2+ and Zn2+ inhibit the steady-state GTPase activity of the a subunit of GTP-binding protein (Galpha(s)) but do not alter its intrinsic GTPase activity. Cu2+ and Zn2+ decrease steady-state GTPase activity by inhibiting the binding of GTP to Galpha(s). Moreover, Cu2+ and Zn2+ increase GDP dissociation from Galpha(s) and render the G protein in a nucleotide-free state. However, these cations do not alter the dissociation of the guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) that is already bound to the Galpha(s). Because of their ability to inhibit GTPgammaS binding, preincubation of Cu2+ or Zn2+ with Galpha(s) does not permit GTPgammaS to activate Galpha(s) and stimulate AC activity. However, preincubation of Galpha(s) with GTPgammaS followed by addition Of Cu2+ or Zn2+ did not alter the ability of Galpha(s) to stimulate AC activity. Interestingly, AlF4- partially restored the ability of Galpha(s), which had been preincubated with Cu2+ or Zn2+, to stimulate AC; AlF4- does not permit the re-association of unbound GDP with Galpha(s). Thus, the interaction of AlF4- with the nucleotide-free Galpha(s) is sufficient to activate AC. Using antibodies to the N and C termini of Galpha(s), we show that the Cu2+ interaction site on the G protein is in the C terminus. We conclude that Cu2+ and Zn2+ generate a nucleotide-free state of Galpha(s) and that, in the absence of any nucleotide, the gamma-phosphate mimic of GTP, AlF4-, alters Galpha(s) structure sufficiently to permit stimulation of AC activity. Moreover, our finding that isoproterenol-stimulated AC activity was more sensitive to inhibition by Cu2+ and Zn2+ as compared with forskolin-stimulated activity is consistent with Galpha(s) being a primary target of these cations in regulating the signaling from receptor to AC.	Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA	Loyola University Chicago	Patel, TB (corresponding author), Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, 2160 S 1st Ave, Maywood, IL 60153 USA.	tpatel7@lumc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abudu N, 1998, EUR J BIOCHEM, V257, P622, DOI 10.1046/j.1432-1327.1998.2570622.x; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Chen YB, 2001, J BIOL CHEM, V276, P45751, DOI 10.1074/jbc.M107191200; Chin KV, 2002, ANN NY ACAD SCI, V968, P49, DOI 10.1111/j.1749-6632.2002.tb04326.x; Chu YF, 1996, J BIOL CHEM, V271, P2574, DOI 10.1074/jbc.271.5.2574; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Gennis RB, 1998, SCIENCE, V280, P1712, DOI 10.1126/science.280.5370.1712; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; GILMAN AG, 1991, HARVEY LECT, V85, P153; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Klein C, 2002, J BIOL CHEM, V277, P11859, DOI 10.1074/jbc.M108808200; Kocaturk, 2000, Pathophysiology, V7, P63, DOI 10.1016/S0928-4680(00)00030-4; KONINGSBERGER JC, 1994, CLIN CHIM ACTA, V230, P51, DOI 10.1016/0009-8981(94)90088-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MARX G, 1986, BIOCHEM J, V236, P397, DOI 10.1042/bj2360397; Moir RD, 1999, EUR J CLIN INVEST, V29, P569; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Patel TB, 2001, GENE, V269, P13, DOI 10.1016/S0378-1119(01)00448-6; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; Rathbun JK, 1996, INT J NEUROSCI, V85, P221, DOI 10.3109/00207459608986684; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; THOLEY G, 1988, NEUROCHEM RES, V13, P45, DOI 10.1007/BF00971853; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; Wittpoth C, 2000, J BIOL CHEM, V275, P25915, DOI 10.1074/jbc.M001687200	41	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2579	2586		10.1074/jbc.M409791200	http://dx.doi.org/10.1074/jbc.M409791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15546818	hybrid			2022-12-25	WOS:000226449100026
J	Brandts, CH; Bilanges, B; Hare, G; McCormick, F; Stokoe, D				Brandts, CH; Bilanges, B; Hare, G; McCormick, F; Stokoe, D			Phosphorylation-independent stabilization of p27(kip1) by the phosphoinositide 3-kinase pathway in glioblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; G(1) GROWTH ARREST; TUMOR-SUPPRESSOR; CYCLE ARREST; CYTOPLASMIC LOCALIZATION; PHOSPHATASE-ACTIVITY; INHIBITOR P27(KIP1); PTEN; DEGRADATION; P27	The PTEN tumor suppressor gene is a frequent target of somatic mutation, particularly in glioblastoma multiform and prostate cancer. The expression of PTEN in PTEN-mutant glioblastoma cells leads to a cell cycle arrest in G(0)/G(1) that is mediated at least partially by increased p27(kip1) levels. Here we show that p27(kip1) is not regulated by transcriptional control but that p27kip1 protein shows increased stability after inhibition of the phosphoinositide (PI) 3-kinase pathway. Because p27(kip1) protein stability is known to be regulated by phosphorylation, we have examined modifications in the phosphorylation pattern after PI 3-kinase inhibition. Biochemical evidence suggests that p27kip1 is phosphorylated on several serine residues, including Ser-10 and Ser-178, but that phosphorylation is unaltered by PI 3-kinase activity. This is further confirmed by the inducible expression of p27(kip1) phosphorylation site mutants, suggesting that p27(kip1) is destabilized in a phosphorylation-independent manner by the PI 3-kinase pathway at the G(1)/S transition.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Stokoe, D (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94115 USA.	dstokoe@cc.ucsf.edu	Bilanges, Benoit/AAP-6078-2020	Bilanges, Benoit/0000-0003-4400-3716; Brandts, Christian H./0000-0003-1732-2535	NCI NIH HHS [P50CA97257, R01CA79548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097257, R01CA079548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furnari FB, 1998, CANCER RES, V58, P5002; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; Gottschalk AR, 2001, CANCER RES, V61, P2105; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762	30	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2012	2019		10.1074/jbc.M408348200	http://dx.doi.org/10.1074/jbc.M408348200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542603	hybrid			2022-12-25	WOS:000226341700035
J	Kim, SH; Sisodia, SS				Kim, SH; Sisodia, SS			A sequence within the first transmembrane domain of PEN-2 is critical for PEN-2-mediated endoproteolysis of presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE COMPLEX; AMYLOID PRECURSOR PROTEIN; COORDINATED EXPRESSION; NICASTRIN; APH-1; BETA; RECONSTITUTION; ACCUMULATION; SUBCOMPLEX; COMPONENT	Macromolecular complexes containing presenilins (PS), nicastrin (NCT), APH-1, and PEN-2 mediate the beta-secretase cleavage of the gamma-amyloid precursor protein and Notch. APH-1 and NCT stabilize the PS1 holoprotein, whereas PEN-2 is critical for endoproteolysis of PS1. To define the structural domains of PEN-2 that are necessary for mediating PS1 endoproteolysis and gamma-secretase activity, we coexpressed APH-1, NCT, and PS1 together with a series of PEN-2 mutants, which harbored deletions in hydrophilic segments, or chimeric PEN-2 molecules that contained heterologous transmembrane domains (TMDs). We now report that with the exception of the PEN-2 variants with deletions proximal to the TMDs, the vast majority of the deletion variants were functional. Mutants that were nonfunctional were also unstable but were rescued by transposition of a heterologous sequence containing conservative amino acid substitutions into the deleted region. Notably, the carboxyl-terminal hydrophilic domain of PEN-2 was dispensable for promoting PS1 endoproteolysis but was critical for stabilizing the resulting PS1 derivatives. More importantly, we demonstrated that a chimeric PEN-2 with a replacement of the TMD2 with the TMD1 from sterol regulatory element binding protein 1 (SREBP-1) is fully functional but that a chimeric PEN-2 with a replacement of the TMD1 with the TMD2 from SREBP-1 is not. The function of this latter chimera was rescued by the replacement of the proximal two-thirds of the SREBP-1 TMD2 with the proximal two-thirds of the authentic TMD1 from PEN-2. These results suggest that the proximal two-thirds of the PEN-2 TMD1 is functionally important for endoproteolysis of PS1 holoproteins and the generation of PS1 fragments, essential components of the gamma-secretase complex.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.	ssisodia@drugs.bsd.uchicago.edu			NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER; NIA NIH HHS [AG021494] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Hasegawa H, 2004, J BIOL CHEM, V279, P46455, DOI 10.1074/jbc.M406289200; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390	25	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1992	2001		10.1074/jbc.M412404200	http://dx.doi.org/10.1074/jbc.M412404200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537629	hybrid			2022-12-25	WOS:000226341700033
J	Price, NE; Price, NC; Kelly, SM; McDonnell, JM				Price, NE; Price, NC; Kelly, SM; McDonnell, JM			The key role of protein flexibility in modulating IgE interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; MOLTEN-GLOBULE; IMMUNOGLOBULIN E; BINDING; DOMAIN; ALPHA; C-EPSILON-3; CONFORMATION; RESIDUES	The interaction between IgE and its high affinity receptor (FcepsilonRI) is a critical step in the development of allergic responses. Detailed characterization of the IgE-FcepsilonRI interaction may offer insights into possible modes of inhibiting the interaction, which could thereby act as a potential therapy for allergy. In this study, NMR, CD, and fluorescence spectroscopies have been used to characterize structurally the Cepsilon3 domain of IgE and its interaction with other protein ligands, namely, Cepsilon2, Cepsilon4, sFcepsilonRIalpha, and CD23. We have shown that the recombinant Cepsilon3 domain exists alone in solution as a "molten globule." On interaction with sFcepsilonRIalpha, Cepsilon3 adopts a folded tertiary structure, as shown by the release of the fluorescent probe 8-anilinonaphthalene-1-sulfonate and by characteristic changes in the H-1, N-15 heteronuclear single quantum coherence NMR spectrum. However, the interactions between the Cepsilon3 domain and Cepsilon2, Cepsilon4, or CD23 do not induce such folding and would therefore be expected to involve only local interaction surfaces. The conformational flexibility of the Cepsilon3 domain of the whole IgE molecule may play a role in allowing fine tuning of the affinity and specificity of IgE for a variety of different physiological ligands and may be involved in the conformational change of IgE postulated to occur on interaction with FcepsilonRI.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Oxford; University of Glasgow	McDonnell, JM (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Pks Rd, Oxford OX1 3QU, England.	jim@biop.ox.ac.uk	Kelly, Sharon/K-4611-2013	McDonnell, James/0000-0001-9037-2980; Kelly, Sharon/0000-0002-3516-1387	Medical Research Council [G0001352, G0200486] Funding Source: Medline; MRC [G0200486, G0001352] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BASU M, 1993, J BIOL CHEM, V268, P13118; BEAVIL AJ, 1995, BIOCHEMISTRY-US, V34, P14449, DOI 10.1021/bi00044a023; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; CREIGHTON TE, 1984, ADV BIOPHYS, V18, P1, DOI 10.1016/0065-227X(84)90004-2; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; Henry AJ, 2000, BIOCHEMISTRY-US, V39, P7406, DOI 10.1021/bi9928391; HORNBY DP, 1994, FEBS LETT, V355, P57, DOI 10.1016/0014-5793(94)01171-0; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; LEE KM, 1995, J BIOMOL NMR, V5, P93, DOI 10.1007/BF00227474; Luque I, 2000, PROTEINS, P63; Mackay GA, 2002, J IMMUNOL, V168, P1787, DOI 10.4049/jimmunol.168.4.1787; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Novak N, 2002, NAT IMMUNOL, V3, P607, DOI 10.1038/ni0702-607; Nozaki Y, 1972, Methods Enzymol, V26, P43; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; Shi JG, 1997, BIOCHEMISTRY-US, V36, P2112, DOI 10.1021/bi961231e; Sondermann P, 2002, IMMUNOL LETT, V82, P51, DOI 10.1016/S0165-2478(02)00018-4; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TAYLOR MAJ, 1992, PROTEIN ENG, V5, P455, DOI 10.1093/protein/5.5.455; Vangelista L, 1999, J CLIN INVEST, V103, P1571, DOI 10.1172/JCI6551; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002	38	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2324	2330		10.1074/jbc.M409458200	http://dx.doi.org/10.1074/jbc.M409458200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15520005	hybrid			2022-12-25	WOS:000226341700069
J	Horenstein, J; Riegelhaupt, P; Akabas, MH				Horenstein, J; Riegelhaupt, P; Akabas, MH			Differential protein mobility of the gamma-aminobutyric acid, type A, receptor alpha and beta subunit channel-lining segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-BINDING SITES; NICOTINIC ACETYLCHOLINE-RECEPTORS; AFFINITY ZN2+ BINDING; GATED ION-CHANNEL; SHAKER K+ CHANNEL; GABA(A) RECEPTOR; SECONDARY STRUCTURE; CRYSTAL-STRUCTURES; GENERAL-METHOD; M2 SEGMENT	The gamma-aminobutyric acid, type A (GABA(A)), receptor ion channel is lined by the second membrane-spanning (M2) segments from each of five homologous subunits that assemble to form the receptor. Gating presumably involves movement of the M2 segments. We assayed protein mobility near the M2 segment extracellular ends by measuring the ability of engineered cysteines to form disulfide bonds and high affinity Zn2+-binding sites. Disulfide bonds formed in alpha(1)beta(1)E270Cgamma(2) but not in alpha(1)N275Cbeta(1)gamma(2) or alpha(1)beta(1)gamma(2)K285C. Diazepam potentiation and Zn2+ inhibition demonstrated that expressed receptors contained a gamma subunit. Therefore, the disulfide bond in alpha(1)beta(1)E270Cgamma(2) formed between non-adjacent subunits. In the homologous acetylcholine receptor 4-Angstrom resolution structure, the distance between alpha carbon atoms of 20' aligned positions in non-adjacent subunits is similar to19 Angstrom. Because disulfide trapping involves covalent bond formation, it indicates the extent of movement but does not provide an indication of the energetics of protein deformation. Pairs of cysteines can form high affinity Zn2+-binding sites whose affinity depends on the energetics of forming a bidentate-binding site. The Zn2+ inhibition IC50 for alpha(1)beta(1)E270Cgamma(2) was 34 nM. In contrast, it was greater than 100 muM in alpha(1)N275Cbeta(1)gamma(2) and alpha(1)beta(1)gamma(2)K285C receptors. The high Zn2+ affinity in alpha(1)beta(1)E270Cgamma(2) implies that this region in the beta subunit has a high protein mobility with a low energy barrier to translational motions that bring the positions into close proximity. The differential mobility of the extracellular ends of the beta and alphaM2 segments may have important implications for GABA-induced conformational changes during channel gating.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Akabas, MH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	makabas@aecom.yu.edu		Akabas, Myles/0000-0001-8781-7846	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM061925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030808] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61925] Funding Source: Medline; NINDS NIH HHS [NS30808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; AUERBACH A, 2003, SCI STKE; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Choi YB, 2001, J NEUROSCI, V21, P392, DOI 10.1523/JNEUROSCI.21-02-00392.2001; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Collet JF, 2003, J BIOL CHEM, V278, P45325, DOI 10.1074/jbc.M307818200; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Dolinska B, 2001, FARMACO, V56, P737, DOI 10.1016/S0014-827X(01)01129-6; England PM, 1999, CELL, V96, P89, DOI 10.1016/S0092-8674(00)80962-9; Fayyazuddin A, 2000, NEURON, V25, P683, DOI 10.1016/S0896-6273(00)81070-3; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Gether U, 2001, LIFE SCI, V68, P2187, DOI 10.1016/S0024-3205(01)01005-0; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; Halle B, 2002, P NATL ACAD SCI USA, V99, P1274, DOI 10.1073/pnas.032522499; Hevers W, 1998, MOL NEUROBIOL, V18, P35, DOI 10.1007/BF02741459; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kash TL, 2004, J BIOL CHEM, V279, P4887, DOI 10.1074/jbc.M311441200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Panicker S, 2004, J BIOL CHEM, V279, P28149, DOI 10.1074/jbc.M403545200; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Paoletti P, 1997, J NEUROSCI, V17, P5711; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; REGAN L, 1994, PROTEIN SCI, V3, P2419, DOI 10.1002/pro.5560031225; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; Shapovalov G, 2003, BIOPHYS J, V84, P2357, DOI 10.1016/S0006-3495(03)75041-3; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Starace DM, 2001, J GEN PHYSIOL, V117, P469, DOI 10.1085/jgp.117.5.469; Tretter V, 1997, J NEUROSCI, V17, P2728; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; Whiting PJ, 2003, CURR OPIN DRUG DISC, V6, P648; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Wooltorton JRA, 1997, J PHYSIOL-LONDON, V505, P633, DOI 10.1111/j.1469-7793.1997.633ba.x; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	63	21	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1573	1581		10.1074/jbc.M410881200	http://dx.doi.org/10.1074/jbc.M410881200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522864	hybrid			2022-12-25	WOS:000226195200088
J	Martinez-Pinna, J; Gurung, IS; Vial, C; Leon, C; Gachet, C; Evans, RJ; Mahaut-Smith, MP				Martinez-Pinna, J; Gurung, IS; Vial, C; Leon, C; Gachet, C; Evans, RJ; Mahaut-Smith, MP			Direct voltage control of signaling via P2Y(1) and other G alpha(q)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CYTOPLASMIC CA2+ OSCILLATION; INOSITOL 1,4,5-TRISPHOSPHATE; PLATELET-AGGREGATION; MOLECULAR-MECHANISMS; DEPENDENT INHIBITION; CALCIUM-CHANNELS; P2X(1) RECEPTORS; ACTIVATION; ADP	Emerging evidence suggests that Ca2+ release evoked by certain G-protein-coupled receptors can be voltage-dependent; however, the relative contribution of different components of the signaling cascade to this response remains unclear. Using the electrically inexcitable megakaryocyte as a model system, we demonstrate that inositol 1,4,5-trisphosphate-dependent Ca2+ mobilization stimulated by several agonists acting via Galpha(q)-coupled receptors is potentiated by depolarization and that this effect is most pronounced for ADP. Voltage-dependent Ca2+ release was not induced by direct elevation of inositol 1,4,5-trisphosphate, by agents mimicking diacylglycerol actions, or by activation of phospholipase Cgamma-coupled receptors. The response to voltage did not require voltage-gated Ca2+ channels as it persisted in the presence of nifedipine and was only weakly affected by the holding potential. Strong predepolarizations failed to affect the voltage-dependent Ca2+ increase; thus, an alteration of G-protein betagamma subunit binding is also not involved. Megakaryocytes from P2Y(1)(-/-) mice lacked voltage-dependent Ca2+ release during the application of ADP but retained this response after stimulation of other Galpha(q)-coupled receptors. Although depolarization enhanced Ca2+ mobilization resulting from GTPgammaS dialysis and to a lesser extent during AlF4- or thimerosal, these effects all required the presence of P2Y(1) receptors. Taken together, the voltage dependence to Ca2+ release via Galpha(q)-coupled receptors is not due to control of G-proteins or downstream signals but, rather, can be explained by a voltage sensitivity at the level of the receptor itself. This effect, which is particularly robust for P2Y(1) receptors, has widespread implications for cell signaling.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; EFS Alsace 10, INSERM, U311, F-67065 Strasbourg, France	University of Cambridge; University of Leicester; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mahaut-Smith, MP (corresponding author), Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England.	mpm11@cam.ac.uk	Léon, Catherine/G-6473-2015; Gachet, Christian/H-9156-2016; leon, catherine/ABB-5242-2020; Martinez-Pinna, Juan/T-9271-2017	Léon, Catherine/0000-0002-8597-9929; leon, catherine/0000-0002-8597-9929; Martinez-Pinna, Juan/0000-0003-0777-2049	Medical Research Council [G0301031] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Araya R, 2003, J GEN PHYSIOL, V121, P3, DOI 10.1085/jgp.20028671; Ben-Chaim Y, 2003, J BIOL CHEM, V278, P22482, DOI 10.1074/jbc.M301146200; BERVEN LA, 1994, FEBS LETT, V346, P235, DOI 10.1016/0014-5793(94)00481-1; BEST L, 1986, N-S ARCH PHARMACOL, V333, P78, DOI 10.1007/BF00569664; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOLTON TB, 2003, SCI STKE; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; DECLERCK F, 1982, AGENTS ACTIONS, V12, P388; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Fowler CJ, 1998, CELL SIGNAL, V10, P561, DOI 10.1016/S0898-6568(97)00192-7; GANITKEVICH VY, 1993, J PHYSIOL-LONDON, V470, P35, DOI 10.1113/jphysiol.1993.sp019845; Ganitkevich VY, 1996, CIRC RES, V78, P717, DOI 10.1161/01.RES.78.4.717; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLARD A, 1993, J NEUROSCI, V13, P3884; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; HALL DA, 1993, BRIT J PHARMACOL, V108, P728, DOI 10.1111/j.1476-5381.1993.tb12869.x; Hardy AR, 2004, BLOOD, V104, P1745, DOI 10.1182/blood-2004-02-0534; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Hassock SR, 2002, BLOOD, V100, P2801, DOI 10.1182/blood-2002-03-0723; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hussain JF, 1999, J PHYSIOL-LONDON, V514, P713, DOI 10.1111/j.1469-7793.1999.713ad.x; ITOH T, 1992, J PHYSIOL-LONDON, V451, P307, DOI 10.1113/jphysiol.1992.sp019166; Jiang QL, 1997, MOL PHARMACOL, V52, P499, DOI 10.1124/mol.52.3.499; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Kawa K, 2004, AM J PHYSIOL-CELL PH, V286, pC119, DOI 10.1152/ajpcell.00014.2003; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Mahaut-Smith Martyn P, 2004, Methods Mol Biol, V273, P277; Mahaut-Smith MP, 2000, BRIT J PHARMACOL, V131, P108, DOI 10.1038/sj.bjp.0703517; Mahaut-Smith MP, 1998, J MICROSC-OXFORD, V191, P60; Mahaut-Smith MP, 2004, PLATELETS, V15, P131, DOI 10.1080/09537100410001682788; Mahaut-Smith MP, 1999, J PHYSIOL-LONDON, V515, P385, DOI 10.1111/j.1469-7793.1999.385ac.x; Martinez-Pinna J, 2004, J PHYSIOL-LONDON, V555, P61, DOI 10.1113/jphysiol.2003.056846; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; Mason Michael J, 2004, Methods Mol Biol, V273, P251; Mason MJ, 2000, J PHYSIOL-LONDON, V524, P437, DOI 10.1111/j.1469-7793.2000.00437.x; Mason MJ, 2001, J PHYSIOL-LONDON, V533, P175, DOI 10.1111/j.1469-7793.2001.0175b.x; MURRAY R, 1989, P NATL ACAD SCI USA, V86, P124, DOI 10.1073/pnas.86.1.124; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; Randall AD, 1998, J MEMBRANE BIOL, V161, P207, DOI 10.1007/s002329900327; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; Roth BL, 1998, PHARMACOL THERAPEUT, V79, P231, DOI 10.1016/S0163-7258(98)00019-9; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Sage SO, 2000, CELL CALCIUM, V28, P119, DOI 10.1054/ceca.2000.0139; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SOMASUNDARAM B, 1994, J PHYSIOL-LONDON, V480, P225, DOI 10.1113/jphysiol.1994.sp020355; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; Storey RF, 2000, BRIT J HAEMATOL, V110, P925, DOI 10.1046/j.1365-2141.2000.02208.x; Tertyshnikova S, 2000, J GEN PHYSIOL, V115, P481, DOI 10.1085/jgp.115.4.481; Thomas D, 2001, J PHYSIOL-LONDON, V537, P371, DOI 10.1111/j.1469-7793.2001.00371.x; UNEYAMA C, 1993, J PHYSIOL-LONDON, V470, P731, DOI 10.1113/jphysiol.1993.sp019885; UNEYAMA H, 1993, J BIOL CHEM, V268, P168; VALLERODRIGUEZ A, 2003, EMBO J, V22, P4337; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; Woulfe Donna, 2004, Methods Mol Biol, V273, P3; Yang M, 1997, THROMB HAEMOSTASIS, V78, P892; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035	70	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1490	1498		10.1074/jbc.M407783200	http://dx.doi.org/10.1074/jbc.M407783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528188	hybrid			2022-12-25	WOS:000226195200078
J	Scheuring, S; Busselez, J; Levy, D				Scheuring, S; Busselez, J; Levy, D			Structure of the dimeric PufX-containing core complex of Rhodobacter blasticus by in situ atomic force microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; PHOTOSYNTHETIC REACTION CENTER; CYTOCHROME BC(1) COMPLEX; CRYSTAL-STRUCTURE; RHODOPSEUDOMONAS-VIRIDIS; RHODOSPIRILLUM-RUBRUM; SUPRAMOLECULAR ORGANIZATION; RUBRIVIVAX-GELATINOSUS; RESOLUTION CRITERION; NATIVE MEMBRANES	We have studied photosynthetic membranes of wild type Rhodobacter blasticus, a closely related strain to the well studied Rhodobacter sphaeroides, using atomic force microscopy. High-resolution atomic force microscopy topographs of both cytoplasmic and periplasmic surfaces of LH2 and RC-LH1-PufX ( RC, reaction center) complexes were acquired in situ. The LH2 is a nonameric ring inserted into the membrane with the 9-fold axis perpendicular to the plane. The core complex is an S-shaped dimer composed of two RCs, each encircled by 13 LH1 alpha/beta-heterodimers, and two PufXs. The LH1 assembly is an open ellipse with a topography-free gap of similar to25 Angstrom. The two PufXs, one of each core, are located at the dimer center. Based on our data, we propose a model of the core complex, which provides explanation for the PufX-induced dimerization of the Rhodobacter core complex. The Q(B) site is located facing a similar to25-Angstrom wide gap within LH1, explaining the PufX-favored quinone passage in and out of the core complex.	Inst Curie, CNRS, Unite Mixte Rech 168, F-75231 Paris 05, France; Commiss Energie Atom 34V, Lab Rech Correspondant, F-75231 Paris, France	UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CEA	Scheuring, S (corresponding author), Inst Curie, CNRS, Unite Mixte Rech 168, 11 Rue Pierre & Marie Curie, F-75231 Paris 05, France.	simon.scheuring@curie.fr	Scheuring, Simon/L-9843-2018	Scheuring, Simon/0000-0003-3534-069X; levy, daniel/0000-0002-8949-4072				ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; Bahatyrova S, 2004, NATURE, V430, P1058, DOI 10.1038/nature02823; BARZ WP, 1995, BIOCHEMISTRY-US, V34, P15248, DOI 10.1021/bi00046a033; BARZ WP, 1995, BIOCHEMISTRY-US, V34, P15235, DOI 10.1021/bi00046a032; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; FARCHAUS JW, 1992, EMBO J, V11, P2779, DOI 10.1002/j.1460-2075.1992.tb05345.x; Fotiadis D, 2004, J BIOL CHEM, V279, P2063, DOI 10.1074/jbc.M310382200; Francia F, 1999, BIOCHEMISTRY-US, V38, P6834, DOI 10.1021/bi982891h; Francia F, 2002, EUR J BIOCHEM, V269, P1877, DOI 10.1046/j.1432-1033.2002.02834.x; Frese RN, 2000, P NATL ACAD SCI USA, V97, P5197, DOI 10.1073/pnas.090083797; GONCALVES RP, 2004, IN PRESS J STRUCT BI; Hu XC, 2002, Q REV BIOPHYS, V35, P1, DOI 10.1017/S0033583501003754; Jamieson SJ, 2002, EMBO J, V21, P3927, DOI 10.1093/emboj/cdf410; JOLIOT P, 1989, BIOCHIM BIOPHYS ACTA, V975, P336, DOI 10.1016/S0005-2728(89)80341-X; Jungas C, 1999, EMBO J, V18, P534, DOI 10.1093/emboj/18.3.534; KARRASCH S, 1995, EMBO J, V14, P631, DOI 10.1002/j.1460-2075.1995.tb07041.x; Koepke J, 1996, STRUCTURE, V4, P581, DOI 10.1016/S0969-2126(96)00063-9; LILBURN TG, 1992, BIOCHIM BIOPHYS ACTA, V1100, P160; Loach PA, 2000, P NATL ACAD SCI USA, V97, P5016, DOI 10.1073/pnas.97.10.5016; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MCGLYNN P, 1994, FEBS LETT, V349, P349, DOI 10.1016/0014-5793(94)00701-2; MONTOYA G, 1995, J MOL BIOL, V250, P1, DOI 10.1006/jmbi.1995.0353; Parkes-Loach PS, 2001, BIOCHEMISTRY-US, V40, P5593, DOI 10.1021/bi002580i; Pugh RJ, 1998, BBA-BIOENERGETICS, V1366, P301, DOI 10.1016/S0005-2728(98)00131-5; Ranck JL, 2001, BBA-BIOENERGETICS, V1506, P67, DOI 10.1016/S0005-2728(01)00185-2; Recchia PA, 1998, BIOCHEMISTRY-US, V37, P11055, DOI 10.1021/bi980657l; Roszak AW, 2003, SCIENCE, V302, P1969, DOI 10.1126/science.1088892; SCHABERT FA, 1994, BIOPHYS J, V67, P2394, DOI 10.1016/S0006-3495(94)80726-X; Scheuring S, 2004, J BIOL CHEM, V279, P3620, DOI 10.1074/jbc.M310050200; Scheuring S, 2004, P NATL ACAD SCI USA, V101, P11293, DOI 10.1073/pnas.0404350101; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; Scheuring S, 2003, J MOL BIOL, V325, P569, DOI 10.1016/S0022-2836(02)01241-X; Scheuring S, 2001, EMBO J, V20, P3029, DOI 10.1093/emboj/20.12.3029; Siebert CA, 2004, EMBO J, V23, P690, DOI 10.1038/sj.emboj.7600092; Tsukatani Y, 2004, PHOTOSYNTH RES, V79, P83, DOI 10.1023/B:PRES.0000011922.56394.92; Uchino Y, 2003, MOL BIOL EVOL, V20, P821, DOI 10.1093/molbev/msg100; UNSER M, 1989, ULTRAMICROSCOPY, V30, P429, DOI 10.1016/0304-3991(89)90074-0; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; Vermeglio A, 1999, TRENDS MICROBIOL, V7, P435, DOI 10.1016/S0966-842X(99)01625-X; VERMEGLIO A, 1993, BIOCHIM BIOPHYS ACTA, V1183, P352, DOI 10.1016/0005-2728(93)90239-C; Vermeglio A, 2002, BBA-BIOENERGETICS, V1555, P60, DOI 10.1016/S0005-2728(02)00255-4; Walz T, 1998, J MOL BIOL, V282, P833, DOI 10.1006/jmbi.1998.2050; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	44	95	102	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1426	1431		10.1074/jbc.M411334200	http://dx.doi.org/10.1074/jbc.M411334200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522874	hybrid			2022-12-25	WOS:000226195200070
J	Elchuri, S; Oberley, TD; Qi, WB; Eisenstein, RS; Roberts, LJ; Van Remmen, H; Jepstein, CJ; Huang, TT				Elchuri, S; Oberley, TD; Qi, WB; Eisenstein, RS; Roberts, LJ; Van Remmen, H; Jepstein, CJ; Huang, TT			CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life	ONCOGENE			English	Article						CuZnSOD; hepatocellular carcinoma; aconitase; 8-oxo dG; cyclin D1; APEX1; Met	CARBONIC-ANHYDRASE-III; ZINC SUPEROXIDE-DISMUTASE; IRON REGULATORY PROTEINS; HEPATOCELLULAR-CARCINOMA; ANTIOXIDANT ENZYMES; GLUTATHIONE-PEROXIDASE; MITOCHONDRIAL-DNA; CYCLIN D1; LIVER; OVEREXPRESSION	Mice deficient in CuZn superoxide dismutase (CuZn-SOD) showed no overt abnormalities during development and early adulthood, but had a reduced lifespan and increased incidence of neoplastic changes in the liver. Greater than 70% of Sod1-/- mice developed liver nodules that were either nodular hyperplasia or hepatocellular carcinoma (HCC). Cross-sectional studies with livers collected from Sod1-/- and age-matched +/+ controls revealed extensive oxidative damage in the cytoplasm and, to a lesser extent, in the nucleus and mitochondria from as early as 3 months of age. A marked reduction in cytosolic aconitase, increased levels of 8-oxo dG and F2-isoprostanes, and a moderate reduction in glutathione peroxidase activities and porin levels were observed in all age groups of Sod1-/- mice examined. There were also age-related reductions in Mn superoxide dismutase activities and carbonic anhydrase III. Parallel to the biochemical changes, there were progressive increases in the DNA repair enzyme APEX1, the cell cycle control proteins cyclin D1 and D3, and the hepatocyte growth factor receptor Met. Increased cell proliferation in the presence of persistent oxidative damage to macromolecules likely contributes to hepatocarcinogenesis later in life.	Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA; VA Hosp, Pathol Serv, Madison, WI 53705 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Audie L Murphy Mem Vet Adm Med Ctr, GRECC, San Antonio, TX 78229 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94341 USA; Palo Alto VA Hlth Care Syst, GRECC, Palo Alto, CA 94304 USA	Stanford University; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Health San Antonio; University of Wisconsin System; University of Wisconsin Madison; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of California System; University of California San Francisco; Geriatric Research Education & Clinical Center	Huang, TT (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, 3801 Miranda Ave,Bldg 100,Room D3-101,Mail Stop 1, Palo Alto, CA 94304 USA.	tthuang@stanford.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, R01DK047219, R29DK047219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, R01GM042056, P50GM015431, R37GM042056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016998, R01AG016633] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Anzenbacher P, 2001, CELL MOL LIFE SCI, V58, P737, DOI 10.1007/PL00000897; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Bai JX, 1998, CHINESE MED J-PEKING, V111, P789; Blum HE, 2002, DIGEST DIS, V20, P81, DOI 10.1159/000063163; Bobola MS, 2001, CLIN CANCER RES, V7, P3510; Bonkovsky H L, 2000, Clin Liver Dis, V4, P409, DOI 10.1016/S1089-3261(05)70116-1; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CASARIL M, 1994, INT J CLIN LAB RES, V24, P94, DOI 10.1007/BF02593907; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Court FG, 2002, BRIT J SURG, V89, P1089, DOI 10.1046/j.1365-2168.2002.02166.x; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Crawford DHG, 1998, BAILLIERE CLIN GASTR, V12, P209, DOI 10.1016/S0950-3528(98)90131-2; Crichton RR, 2002, J INORG BIOCHEM, V91, P9, DOI 10.1016/S0162-0134(02)00461-0; Deane NG, 2001, CANCER RES, V61, P5389; Diehl AM, 2002, FRONT BIOSCI-LANDMRK, V7, pE301, DOI 10.2741/diehl; Dominguez-Malagon H, 2001, ULTRASTRUCT PATHOL, V25, P497, DOI 10.1080/019131201753343539; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fletcher LM, 2002, J INTERN MED, V251, P181, DOI 10.1046/j.1365-2796.2002.00945.x; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Haddow JE, 2003, J MED SCREEN, V10, P11, DOI 10.1258/096914103321610743; Hamilton ML, 2001, NUCLEIC ACIDS RES, V29, P2117, DOI 10.1093/nar/29.10.2117; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; Huang C, 1990, Zhonghua Yi Xue Za Zhi, V70, P138; HUANG C, 1990, ZHONGHUA YI XUE ZA Z, V70, P12; Huang TT, 2002, METHOD ENZYMOL, V349, P191, DOI 10.1016/S0076-6879(02)49335-4; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; INAGAKI T, 1992, GASTROENTEROL JPN, V27, P382; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kruidenier L, 2003, FREE RADICAL BIO MED, V34, P753, DOI 10.1016/S0891-5849(02)01426-0; Kuo WH, 2003, LIFE SCI, V73, P2211, DOI 10.1016/S0024-3205(03)00597-6; LEE GH, 1991, CANCER RES, V51, P3257; LEE GH, 1989, CARCINOGENESIS, V10, P2227, DOI 10.1093/carcin/10.12.2227; Lee HC, 2004, MUTAT RES-FUND MOL M, V547, P71, DOI 10.1016/j.mrfmmm.2003.12.011; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; Levy L, 2002, ANN NY ACAD SCI, V963, P21; Liaw KY, 1997, AM J GASTROENTEROL, V92, P2260; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; Lin MT, 2001, HEPATO-GASTROENTEROL, V48, P1102; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Liu YL, 2004, BIOCHEM PHARMACOL, V67, P777, DOI 10.1016/j.bcp.2003.09.025; LOEB LA, 1991, CANCER RES, V51, P3075; Missirlis F, 2003, J BIOL CHEM, V278, P47365, DOI 10.1074/jbc.M307700200; Moriya K, 2001, CANCER RES, V61, P4365; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; MUSE KE, 1994, HISTOCHEM J, V26, P734, DOI 10.1007/BF00158205; Neonaki M, 2002, BIOCHEM SOC T, V30, P726, DOI 10.1042/BST0300726; NOWELL PC, 1979, CLIN IMMUNOL IMMUNOP, V12, P323, DOI 10.1016/0090-1229(79)90035-7; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Oberley TD, 1999, FREE RADICAL BIO MED, V27, P695, DOI 10.1016/S0891-5849(99)00117-3; Oberley TD, 2000, PROSTATE, V44, P144, DOI 10.1002/1097-0045(20000701)44:2<144::AID-PROS7>3.0.CO;2-G; Olinski R, 2002, FREE RADICAL BIO MED, V33, P192, DOI 10.1016/S0891-5849(02)00878-X; Ozaki M, 2002, FASEB J, V16, P889, DOI 10.1096/fj.01-0664fje; Perlmutter D H, 2000, Clin Liver Dis, V4, P387, DOI 10.1016/S1089-3261(05)70115-X; PIGEOLET E, 1990, MECH AGEING DEV, V51, P283, DOI 10.1016/0047-6374(90)90078-T; PUGH TD, 1992, CANCER RES, V52, P280; Puglisi F, 2001, ANTICANCER RES, V21, P4041; Raisanen SR, 1999, FASEB J, V13, P513, DOI 10.1096/fasebj.13.3.513; Robertson KA, 2001, CANCER RES, V61, P2220; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Sauer H, 2004, EXP CELL RES, V294, P313, DOI 10.1016/j.yexcr.2003.10.032; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; Sola B, 1999, INT J CANCER, V83, P230, DOI 10.1002/(SICI)1097-0215(19991008)83:2<230::AID-IJC14>3.0.CO;2-J; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; SUN Y, 1993, CARCINOGENESIS, V14, P1457, DOI 10.1093/carcin/14.7.1457; Takahashi K, 2002, TOXICOL PATHOL, V30, P599, DOI 10.1080/01926230290105776; Valgimigli M, 2002, FREE RADICAL RES, V36, P939, DOI 10.1080/107156021000006653; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zhang Y, 2002, CANCER RES, V62, P1205; Zimmermann Artur, 2002, Med Sci Monit, V8, pRA53	89	454	473	1	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					367	380		10.1038/sj.onc.1208207	http://dx.doi.org/10.1038/sj.onc.1208207			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531919				2022-12-25	WOS:000226279700008
J	Buensuceso, CS; Obergfell, A; Soriani, A; Eto, K; Kiosses, WB; Arias-Salgado, EG; Kawakami, T; Shattil, SJ				Buensuceso, CS; Obergfell, A; Soriani, A; Eto, K; Kiosses, WB; Arias-Salgado, EG; Kawakami, T; Shattil, SJ			Regulation of outside-in signaling in platelets by integrin-associated protein kinase C beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN PLATELETS; FOCAL ADHESION FORMATION; CYTOPLASMIC DOMAIN; LIVING CELLS; TYROSINE KINASES; PKC-EPSILON; RACK1; PHOSPHORYLATION; SRC; ALPHA(IIB)BETA(3)	Studies with inhibitors have implicated protein kinase C (PKC) in the adhesive functions of integrin alpha(IIb)beta(3) in platelets, but the responsible PKC isoforms and mechanisms are unknown. alpha(IIb)beta(3) interacts directly with tyrosine kinases c-Src and Syk. Therefore, we asked whether alpha(IIb)beta(3) might also interact with PKC. Of the several PKC isoforms expressed in platelets, only PKCbeta co-immunoprecipitated with alpha(IIb)beta(3) in response to the interaction of platelets with soluble or immobilized fibrinogen. PKCbeta recruitment to alpha(IIb)beta(3) was accompanied by a 9-fold increase in PKC activity in alpha(IIb)beta(3) immunoprecipitates. RACK1, an intracellular adapter for activated PKCbeta, also co-immunoprecipitated with alphaIIbbeta3, but in this case, the interaction was constitutive. Broad spectrum PKC inhibitors blocked both PKCbeta recruitment to alpha(IIb)beta(3) and the spread of platelets on fibrinogen. Similarly, mouse platelets that are genetically deficient in PKCbeta spread poorly on fibrinogen, despite normal agonist-induced fibrinogen binding. In a Chinese hamster ovary cell model system, adhesion to fibrinogen caused green fluorescent protein-PKCbetaI to associate with alpha(IIb)beta(3) and to co-localize with it at lamellipodial edges. These responses, as well as Chinese hamster ovary cell migration on fibrinogen, were blocked by the deletion of the beta(3) cytoplasmic tail or by co-expression of a RACK1 mutant incapable of binding to beta(3). These studies demonstrate that the interaction of alpha(IIb)beta(3) with activated PKCbeta is regulated by integrin occupancy and can be mediated by RACK1 and that the interaction is required for platelet spreading triggered through alpha(IIb)beta(3). Furthermore, the studies extend the concept of alpha(IIb)beta(3) as a scaffold for multiple protein kinases that regulate the platelet actin cytoskeleton.	Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	University of California System; University of California San Diego; Scripps Research Institute; La Jolla Institute for Immunology	Shattil, SJ (corresponding author), Univ Calif San Diego, Dept Med, Div Hematol Oncol, Leichtag Biomed Res Bldg,Rm 180,9500 Gilman Dr,Ma, La Jolla, CA 92093 USA.	sshattil@ucsd.edu	Kawakami, Toshiaki/O-1616-2015	Garcia Arias-Salgado, Elena/0000-0002-3612-5791; SORIANI, Alessandra/0000-0001-5461-9026	NHLBI NIH HHS [HL57900, HL56595] Funding Source: Medline; NIAID NIH HHS [AI38343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595, P01HL057900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arias-Salgado EG, 2004, BLOOD, V104, p98A, DOI 10.1182/blood.V104.11.330.330; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; BRASS LF, 2005, IN PRESS HEMATOLOGY; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Buensuceso C, 2003, J BIOL CHEM, V278, P15217, DOI 10.1074/jbc.M213234200; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Cristea IM, 2004, BLOOD, V103, P3624, DOI 10.1182/blood-2003-09-3295; Crosby D, 2003, J BIOL CHEM, V278, P24533, DOI 10.1074/jbc.M301847200; Crosby D, 2002, J BIOL CHEM, V277, P9958, DOI 10.1074/jbc.M108965200; de Virgilio M, 2004, J CELL BIOL, V165, P305, DOI 10.1083/jcb.200402064; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; Hartwig JH, 1999, THROMB HAEMOSTASIS, V82, P392; Hillen TJ, 2001, BIOCHEM BIOPH RES CO, V280, P259, DOI 10.1006/bbrc.2000.4083; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Ivaska J, 2003, BIOCHEM SOC T, V31, P90, DOI 10.1042/bst0310090; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Kawakami T, 2002, J BIOCHEM, V132, P677, DOI 10.1093/oxfordjournals.jbchem.a003273; KHAN WA, 1993, J BIOL CHEM, V268, P5063; Kirk RI, 2000, J BIOL CHEM, V275, P30901, DOI 10.1074/jbc.M001908200; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Litvinov RI, 2004, BLOOD, V104, P3979, DOI 10.1182/blood-2004-04-1411; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miller LD, 2004, ONCOGENE, V23, P5682, DOI 10.1038/sj.onc.1207735; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Naik UP, 2003, BLOOD, V102, P1355, DOI 10.1182/blood-2003-02-0591; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Parsons M, 2002, MOL CELL BIOL, V22, P5897, DOI 10.1128/MCB.22.16.5897-5911.2002; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Saito Naoaki, 2003, Methods Mol Biol, V233, P93; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; Shattil SJ, 2004, BLOOD, V104, P1606, DOI 10.1182/blood-2004-04-1257; Stafford MJ, 2003, BLOOD, V101, P1392, DOI 10.1182/blood-2002-08-2384; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Tabuchi A, 2003, J BIOL CHEM, V278, P26374, DOI 10.1074/jbc.M212407200; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Toker Alex, 2003, Methods Mol Biol, V233, P475; WANG FS, 1995, BIOCHEM J, V311, P401, DOI 10.1042/bj3110401; WOODS A, 1992, J CELL SCI, V101, P277; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	59	100	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					644	653		10.1074/jbc.M410229200	http://dx.doi.org/10.1074/jbc.M410229200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15536078	hybrid			2022-12-25	WOS:000226025100076
J	Jung, SW; Akabas, MH; Harris, RA				Jung, SW; Akabas, MH; Harris, RA			Functional and structural analysis of the GABA(A) receptor alpha(1) subunit during channel gating and alcohol modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; MEMBRANE-SPANNING SEGMENT; RECEPTOR M2-M3 LOOP; GLYCINE RECEPTORS; BINDING-SITE; ACETYLCHOLINE-RECEPTOR; ANESTHETIC POTENCIES; ETHANOL ACTIONS; NERVOUS-SYSTEM; ALPHA-SUBUNIT	The substituted cysteine accessibility method has proven useful for investigating structural changes of the gamma-aminobutyric acid type A (GABA(A)) receptor during channel gating and allosteric modulation. In the present study, the surface accessibility and reaction rate of propyl- and hexyl-methanethiosulfonate to cysteine residues introduced into the third transmembrane segment of the GABA(A) receptor alpha(1) subunit were examined. GABA-induced currents in Xenopus oocytes expressing wild type and cysteine mutant GABA(A) receptors were recorded before and after application of methanethiosulfonate (MTS) reagents in the resting, GABA- or alcohol-bound ( ethanol or hexanol) states. Our results indicate that a water-filled cavity exists around the Ala(291) and Tyr(294) residues of the third transmembrane segment, in agreement with previous results. Furthermore, our data indicate that a conformational change produced by alcohols (200 mM ethanol or 0.5 mM hexanol) exposure induces the water cavity around the A291C and Y294C residues to extend deeper, causing the A295C and F296C residues to become accessible to the MTS reagents. In addition, exposure of the A291C, Y294C, F296C, and V297C mutants to MTS reagents in the presence of GABA had significant effects on their GABA-induced currents, indicating that the water cavity around A291C and Y294C residues expanded to F296C and V297C by a structural movement caused by GABA binding. Our data show that GABA(A) receptor is a dynamic protein during alcohol modulation and channel gating.	Univ Texas, Cell & Mol Biol Program, Austin, TX 78712 USA; Univ Texas, Waggoner Ctr Alcohol & Addict Res, Austin, TX 78712 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Jung, SW (corresponding author), Univ Texas, Cell & Mol Biol Program, Austin, TX 78712 USA.	sangwook@mail.utexas.edu		Akabas, Myles/0000-0001-8781-7846	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, R37AA006399] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06399] Funding Source: Medline; NIADDK NIH HHS [AM61925] Funding Source: Medline; NIGMS NIH HHS [GM47818] Funding Source: Medline; NINDS NIH HHS [NS30808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; Chang YC, 1996, J NEUROSCI, V16, P5415; DEITRICH RA, 1989, PHARMACOL REV, V41, P489; Fang Z, 1997, ANESTH ANALG, V84, P1042, DOI 10.1097/00000539-199705000-00017; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; Harris RA, 1999, ALCOHOL CLIN EXP RES, V23, P1563, DOI 10.1097/00000374-199910000-00001; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kruse SW, 2003, NAT STRUCT BIOL, V10, P694, DOI 10.1038/nsb960; Lobo IA, 2004, J BIOL CHEM, V279, P33919, DOI 10.1074/jbc.M313941200; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mascia MP, 2000, ANESTH ANALG, V91, P1289, DOI 10.1097/00000539-200011000-00044; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Peoples RW, 1996, ANNU REV PHARMACOL, V36, P185, DOI 10.1146/annurev.pa.36.040196.001153; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728; Trudell JR, 2004, ALCOHOL CLIN EXP RES, V28, P1, DOI 10.1097/01.ALC.0000108648.32241.BD; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; Ueno S, 1999, BRIT J PHARMACOL, V127, P377, DOI 10.1038/sj.bjp.0702563; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Wallner M, 2003, P NATL ACAD SCI USA, V100, P15218, DOI 10.1073/pnas.2435171100; Whiting PJ, 2003, DRUG DISCOV TODAY, V8, P445, DOI 10.1016/S1359-6446(03)02703-X; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Williams DB, 2000, MOL PHARMACOL, V58, P1129, DOI 10.1124/mol.58.5.1129; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Williams DB, 2002, J NEUROSCI, V22, P7417; Williams DB, 2001, NEUROPHARMACOLOGY, V41, P539, DOI 10.1016/S0028-3908(01)00099-5; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	38	38	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					308	316		10.1074/jbc.M409871200	http://dx.doi.org/10.1074/jbc.M409871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15522868	hybrid			2022-12-25	WOS:000226025100038
J	Ost, A; Ortegren, U; Gustavsson, J; Nystrom, FH; Stralfors, P				Ost, A; Ortegren, U; Gustavsson, J; Nystrom, FH; Stralfors, P			Triacylglycerol is synthesized in a specific subclass of caveolae in primary adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; PLASMA-MEMBRANE; INSULIN-RECEPTOR; LIPID DROPLETS; RAT ADIPOCYTES; FATTY-ACID; CAVEOLIN-1-DEFICIENT MICE; SIGNAL-TRANSDUCTION; PROTEIN; LOCALIZATION	A principal metabolic function of adipocytes is to synthesize triacylglycerol (TG) from exogenous fatty acids. The level of fatty acids has to be tightly controlled in the adipocyte, as they can act as detergents that rapidly dissolve the plasma membrane, causing cell lysis if allowed to accumulate. Fatty acids therefore have to be efficiently converted to TG and stored in the central lipid droplet. We report that in intact primary adipocytes exogenous oleic acid was taken up and directly converted to TG in the plasma membrane, in a novel subclass of caveolae that specifically contains the protein perilipin. Isolated caveolae catalyzed de novo TG synthesis from oleic acid and glycerol 3-phosphate. Electron microscopy revealed the presence of caveolin and perilipin in caveolae and in lipid-laden bulbs in the plasma membrane, and fluorescence microscopy demonstrated colocalization of fatty acids/TG with caveolin and perilipin at the plasma membrane. A second caveolae fraction was isolated, which lacked perilipin and the triacylglycerol synthesizing enzymes. Both caveolae fractions contained caveolin-1 and the insulin receptor. The findings demonstrate that specific subclasses of caveolae carry out specific functions in cell metabolism. In particular, triacylglycerol is synthesized at the site of fatty acid entry in one of these caveolae classes.	Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Ctr Diabet Res, SE-58185 Linkoping, Sweden; Linkoping Univ, Dept Med & Care, SE-58185 Linkoping, Sweden	Linkoping University; Linkoping University; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden.	peter.stralfors@ibk.liu.se		Stralfors, Peter/0000-0002-1196-1806; Nystrom, Fredrik/0000-0002-1680-1000				Aboulaich N, 2004, BIOCHEM J, V383, P237, DOI 10.1042/BJ20040647; Belfrage P., 1984, P365; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; Czech MP, 2002, MOL CELL, V9, P695, DOI 10.1016/S1097-2765(02)00509-9; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Gargiulo CE, 1999, J LIPID RES, V40, P881; GOLDRICK RB, 1967, J LIPID RES, V8, P581; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; GUSTAVSSON J, 1995, EXP CELL RES, V221, P443, DOI 10.1006/excr.1995.1395; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Isshiki M, 2003, TRAFFIC, V4, P717, DOI 10.1034/j.1600-0854.2003.00130.x; Karlsson M, 2004, EUR J BIOCHEM, V271, P2471, DOI 10.1111/j.1432-1033.2004.04177.x; KARSLSSON M, 2001, FASEB J, V16, P249; KASURINEN J, 1992, BIOCHEM BIOPH RES CO, V187, P1594, DOI 10.1016/0006-291X(92)90485-4; KATES M, 1986, LAB TECHNIQUES BIOCH, V3, P326; LINDROTH M, 1991, J MICROSC-OXFORD, V161, P229, DOI 10.1111/j.1365-2818.1991.tb03086.x; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Marchesan D, 2003, J BIOL CHEM, V278, P27293, DOI 10.1074/jbc.M301430200; Ortegren U, 2004, EUR J BIOCHEM, V271, P2028, DOI 10.1111/j.1432-1033.2004.04117.x; Pohl J, 2004, BIOCHEMISTRY-US, V43, P4179, DOI 10.1021/bi035743m; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STRALFORS P, 1990, FEBS LETT, V263, P153, DOI 10.1016/0014-5793(90)80726-Y; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; Thorn H, 2003, MOL BIOL CELL, V14, P3967, DOI 10.1091/mbc.E03-01-0050; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615	32	95	98	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					5	8		10.1074/jbc.C400429200	http://dx.doi.org/10.1074/jbc.C400429200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15537657	hybrid			2022-12-25	WOS:000226025100002
J	Di Giovanni, S; Faden, AI; Yakovlev, A; Duke-Cohan, JS; Finn, T; Thouin, M; Knoblach, S; De Biase, A; Bregman, BS; Hoffman, EP				Di Giovanni, S; Faden, AI; Yakovlev, A; Duke-Cohan, JS; Finn, T; Thouin, M; Knoblach, S; De Biase, A; Bregman, BS; Hoffman, EP			Neuronal plasticity after spinal cord injury: identification of a gene cluster driving neurite outgrowth	FASEB JOURNAL			English	Article						SCI; microtubule-associated proteins; GAP-43	PROTEIN 1A; FUNCTIONAL RECOVERY; AXONAL PLASTICITY; GLYCOPROTEIN MOG; NERVOUS-SYSTEM; ADULT-RAT; GROWTH; REGENERATION; EXPRESSION; CPG15	Functional recovery after spinal cord injury (SCI) may result in part from axon outgrowth and related plasticity through coordinated changes at the molecular level. We employed microarray analysis to identify a subset of genes the expression patterns of which were temporally coregulated and correlated to functional recovery after SCI. Steady-state mRNA levels of this synchronously regulated gene cluster were depressed in both ventral and dorsal horn neurons within 24 h after injury, followed by strong re-induction during the following 2 wk, which paralleled functional recovery. The identified cluster includes neuritin, attractin, microtubule-associated protein 1a, and myelin oligodendrocyte protein genes. Transcriptional and protein regulation of this novel gene cluster was also evaluated in spinal cord tissue and in single neurons and was shown to play a role in axonal plasticity. Finally, in vitro transfection experiments in primary dorsal root ganglion cells showed that cluster members act synergistically to drive neurite outgrowth.	Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC 20057 USA; Childrens Natl Med Ctr, Ctr Genet Med, Washington, DC 20010 USA; Dana Farber Canc Inst D1526, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Georgetown University; Children's National Health System; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Faden, AI (corresponding author), Georgetown Univ, Sch Med, Dept Neurosci, 3900 Reservoir Rd NW, Washington, DC 20057 USA.	fadena@georgetown.edu	Duke-Cohan, Jonathan/A-5812-2010	Duke-Cohan, Jonathan/0000-0002-9478-9609; Hoffman, Eric/0000-0001-6470-5139	NHLBI NIH HHS [U01 HL66614] Funding Source: Medline; NINDS NIH HHS [NS-1-2339] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONSO G, 1995, EXP NEUROL, V134, P35, DOI 10.1006/exnr.1995.1034; AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625, DOI 10.1016/0959-4388(95)80068-9; Azmitia EC, 2002, PROG BRAIN RES, V136, P87; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; Bulsara KR, 2002, SPINE, V27, P1946, DOI 10.1097/00007632-200209010-00030; Cantallops I, 2000, NAT NEUROSCI, V3, P1004, DOI 10.1038/79823; Coffey JC, 1997, J NEUROCYTOL, V26, P149, DOI 10.1023/A:1018579912831; Condic ML, 2002, NEUROREPORT, V13, pA37, DOI 10.1097/00001756-200203040-00002; Cornea-Hebert V, 2002, NEUROSCIENCE, V113, P23, DOI 10.1016/S0306-4522(02)00146-X; Corriveau RA, 1999, J NEUROSCI, V19, P7999, DOI 10.1523/jneurosci.19-18-07999.1999; Dewar D, 1997, ACTA NEUROPATHOL, V93, P71, DOI 10.1007/s004010050584; DEWAR J, 1997, BIOCHIM BIOPHYS ACTA, V9, P71; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; FEDOROFF S, 2001, PROTOCOLS NEURAL CEL, P95; Gavazzi I, 2001, CELL TISSUE RES, V305, P275, DOI 10.1007/s004410100365; Gregersen R, 2001, EXP BRAIN RES, V138, P384, DOI 10.1007/s002210100715; Hill CE, 2001, EXP NEUROL, V171, P153, DOI 10.1006/exnr.2001.7734; Kalb RG, 2000, CONT NEUROS, pV; KALB RK, 2000, NEUROBIOLOGY SPINAL, P113; Karim F, 2001, BRAIN RES REV, V36, P204, DOI 10.1016/S0165-0173(01)00096-0; Kawasaki T, 2001, NEUROSCI RES, V39, P347, DOI 10.1016/S0168-0102(00)00234-0; Kikukawa S, 1998, NEUROSCI LETT, V249, P135, DOI 10.1016/S0304-3940(98)00406-6; Kuramoto T, 2001, P NATL ACAD SCI USA, V98, P559, DOI 10.1073/pnas.98.2.559; Kuwamura M, 2002, LAB INVEST, V82, P1279, DOI 10.1097/01.LAB.0000032375.70196.26; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lee WCA, 2002, J NEUROSCI, V22, P1807, DOI 10.1523/JNEUROSCI.22-05-01807.2002; Li GL, 2002, BRAIN PATHOL, V12, P463; Lu XY, 1999, FEBS LETT, V462, P101, DOI 10.1016/S0014-5793(99)01494-5; MARCUS J, 2002, BIOCHIM BIOPHYS ACTA, V19, P406; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; Nedivi E, 1998, SCIENCE, V281, P1863, DOI 10.1126/science.281.5384.1863; Nedivi E, 2001, J COMP NEUROL, V435, P464, DOI 10.1002/cne.1044; Nicholls J, 1996, TRENDS NEUROSCI, V19, P229, DOI 10.1016/0166-2236(96)10021-7; Noiges R, 2002, J NEUROSCI, V22, P2106, DOI 10.1523/JNEUROSCI.22-06-02106.2002; Nunez J, 1997, J MOL NEUROSCI, V8, P207, DOI 10.1007/BF02736834; Oudega M, 1998, NEUROSCI LETT, V246, P81, DOI 10.1016/S0304-3940(98)00232-8; Pellier-Monnin V, 2001, J COMP NEUROL, V433, P239, DOI 10.1002/cne.1138; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; SEO J, 2003, IEEE ICME, V3, P461; Solly SK, 1996, GLIA, V18, P39, DOI 10.1002/(SICI)1098-1136(199609)18:1<39::AID-GLIA4>3.3.CO;2-T; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; Tang W, 2000, P NATL ACAD SCI USA, V97, P6025, DOI 10.1073/pnas.110139897; Tang W, 2002, J NEUROPATH EXP NEUR, V61, P767, DOI 10.1093/jnen/61.9.767; Turnley AM, 1998, NEUROREPORT, V9, P1987, DOI 10.1097/00001756-199806220-00013; Uchida K, 2002, SPINE, V27, P480, DOI 10.1097/00007632-200203010-00008; Vaillant AR, 1998, J BIOL CHEM, V273, P13973, DOI 10.1074/jbc.273.22.13973; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	56	65	66	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					153	+		10.1096/fj.04-2694fje	http://dx.doi.org/10.1096/fj.04-2694fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522907				2022-12-25	WOS:000225482100026
J	Herzog, A; Siler, U; Spitzer, V; Seifert, N; Denelavas, A; Hunziker, PB; Hunziker, W; Goralczyk, R; Wertz, K				Herzog, A; Siler, U; Spitzer, V; Seifert, N; Denelavas, A; Hunziker, PB; Hunziker, W; Goralczyk, R; Wertz, K			Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate	FASEB JOURNAL			English	Article						DHT; 3 beta-adiol; IGF-I	ESTROGEN RECEPTOR-BETA; EPITHELIAL-CELLS; TISSUE DISTRIBUTION; TRANS-LYCOPENE; GROWTH-FACTORS; CANCER CELLS; HUMAN SERUM; VITAMIN-E; ER-BETA; INTERLEUKIN-6	Epidemiological evidence links consumption of lycopene, the red carotenoid of tomato, to reduced prostate cancer risk. We investigated the effect of lycopene in normal prostate tissue to gain insight into the mechanisms, by which lycopene can contribute to primary prostate cancer prevention. We supplemented young rats with 200 ppm lycopene for up to 8 wk, measured the uptake into individual prostate lobes, and analyzed lycopene-induced gene regulations in dorsal and lateral lobes after 8 wk of supplementation. Lycopene accumulated in all four prostate lobes over time, with all-trans lycopene being the predominant isoform. The lateral lobe showed a significantly higher total lycopene content than the other prostate lobes. Transcriptomics analysis revealed that lycopene treatment mildly but significantly reduced gene expression of androgen-metabolizing enzymes and androgen targets. Moreover, local expression of IGF-I was decreased in the lateral lobe. Lycopene also consistently reduced transcript levels of proinflammatory cytokines, immunoglobulins, and immunoglobulin receptors in the lateral lobe. This indicates that lycopene reduced inflammatory signals in the lateral prostate lobe. In summary, we show for the first time that lycopene reduced local prostatic androgen signaling, IGF-I expression, and basal inflammatory signals in normal prostate tissue. All of these mechanisms can contribute to the epidemiologically observed prostate cancer risk reduction by lycopene.	DSM Nutr Prod, Carotenoid Sect, CH-4002 Basel, Switzerland	DSM NV	Wertz, K (corresponding author), DSM Nutr Prod, Carotenoid Sect, POB 3255, CH-4002 Basel, Switzerland.	karin.wertz@dsm.com		Siler, Ulrich/0000-0002-2458-2629				Albrecht M, 2004, PROSTATE, V58, P82, DOI 10.1002/pros.10288; Aumuller G, 1996, ACTA ANAT, V156, P241; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Belanger A, 2003, TRENDS ENDOCRIN MET, V14, P473, DOI 10.1016/j.tem.2003.10.005; Boileau TWM, 2000, J NUTR, V130, P1613, DOI 10.1093/jn/130.6.1613; Bollito E, 2001, ANN ONCOL, V12, pS159, DOI 10.1093/annonc/12.suppl_2.S159; Boue SM, 2003, J AGR FOOD CHEM, V51, P2193, DOI 10.1021/jf021114s; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chang WY, 1999, PROSTATE, V40, P115; Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Etminan M, 2004, CANCER EPIDEM BIOMAR, V13, P340; FENWICK, 2003, PHYTOCHEMICALS HLTH, P285; Ford ES, 2002, AM J CLIN NUTR, V76, P818, DOI 10.1093/ajcn/76.4.818; FREVERT CW, 1995, INFLAMMATION, V19, P133, DOI 10.1007/BF01534386; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Gann PH, 1999, CANCER RES, V59, P1225; GEMZIK B, 1992, ARCH BIOCHEM BIOPHYS, V296, P355, DOI 10.1016/0003-9861(92)90585-K; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Haddad JJ, 2002, EUR CYTOKINE NETW, V13, P250; Hansson J, 2001, ANN ONCOL, V12, pS145, DOI 10.1093/annonc/12.suppl_2.S145; Harris J, 2000, VET IMMUNOL IMMUNOP, V77, P163, DOI 10.1016/S0165-2427(00)00235-X; HAYASHI N, 1991, BIOL REPROD, V45, P308, DOI 10.1095/biolreprod45.2.308; Hobisch A, 1998, CANCER RES, V58, P4640; Hoosein Naseema M., 1998, Frontiers in Bioscience, V3, pD1274; IMPERATOMCGINLEY J, 1992, ENDOCRINOLOGY, V131, P1149, DOI 10.1210/en.131.3.1149; ISAACS JT, 1980, STEROIDS, V35, P139, DOI 10.1016/0039-128X(80)90099-9; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Keith IM, 2001, J UROLOGY, V166, P323, DOI 10.1016/S0022-5347(05)66153-8; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383; Kim IY, 2002, CANCER RES, V62, P5365; Klein T, 2001, BRIT J PHARMACOL, V133, P643, DOI 10.1038/sj.bjp.0704111; Konig JE, 2004, PROSTATE, V58, P121, DOI 10.1002/pros.10317; Korytko PJ, 2003, J NUTR, V133, P2788, DOI 10.1093/jn/133.9.2788; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lau KM, 2000, CANCER RES, V60, P3175; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Maliner-Stratton MS, 2001, NEOPLASIA, V3, P509, DOI 10.1038/sj.neo.7900178; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; NASLUND MJ, 1988, J UROLOGY, V140, P1049, DOI 10.1016/S0022-5347(17)41924-0; Obermuller-Jevic UC, 2003, J NUTR, V133, P3356, DOI 10.1093/jn/133.11.3356; Okamoto M, 1998, PROSTATE, V35, P255, DOI 10.1002/(SICI)1097-0045(19980601)35:4<255::AID-PROS4>3.0.CO;2-F; Pelletier G, 1998, J UROLOGY, V160, P577, DOI 10.1016/S0022-5347(01)62961-6; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; PRICE DOROTHY, 1963, NATL CANCER INST MONOGR, V12, P1; Prins GS, 1998, ENDOCRINOLOGY, V139, P874, DOI 10.1210/en.139.3.874; ROBINETTE CL, 1988, PROSTATE, V12, P271; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIES H, 1995, AM J CLIN NUTR, V62, P1315; Siler U, 2004, FASEB J, V18, P1019, DOI 10.1096/fj.03-1116fje; STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N; Stoker TE, 1999, BIOL REPROD, V61, P1636, DOI 10.1095/biolreprod61.6.1636; SUNDIN M, 1987, J BIOL CHEM, V262, P12293; THIEULANT ML, 1981, ENDOCRINOLOGY, V108, P1552, DOI 10.1210/endo-108-4-1552; Thornton DJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1118, DOI 10.1152/ajplung.2000.278.6.L1118; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; van Breemen RB, 2002, J AGR FOOD CHEM, V50, P2214, DOI 10.1021/jf0110351; van Ommen B, 2002, CURR OPIN BIOTECH, V13, P517, DOI 10.1016/S0958-1669(02)00349-X; VANZUPTEN L, 1993, PRINCIPLES LAB SCI; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walfisch Y, 2003, BRIT J NUTR, V90, P759, DOI 10.1079/BJN2003955; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898	67	97	102	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					272	+		10.1096/fj.04-1905fje	http://dx.doi.org/10.1096/fj.04-1905fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545302				2022-12-25	WOS:000225482100022
J	Khakh, BS; Egan, TM				Khakh, BS; Egan, TM			Contribution of transmembrane regions to ATP-gated P2X(2) channel permeability dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CHANNEL; MOLECULAR PHYSIOLOGY; DEPENDENT CHANGES; STRUCTURAL MOTIF; GATING MECHANISM; CATION CHANNELS; PORE FORMATION; AMINO-ACIDS; RECEPTOR; DOMAIN	ATP-gated P2X(2) channels undergo activation-dependent permeability increases as they proceed from the selective I-1 state to the I-2 state that is readily permeable to organic cations. There are two main models about how permeability changes may occur. The first proposes that permeability change-competent P2X channels are clustered or redistribute to form such regions in response to ATP. The second proposes that permeability changes occur because of an intrinsic conformational change in P2X channels. In the present study we experimentally tested these views with total internal reflection fluorescence microscopy, electrophysiology, and mutational perturbation analysis. We found no evidence for clusters of P2X(2) channels within the plasma membrane or for cluster formation in response to ATP, suggesting that channel clustering is not an obligatory requirement for permeability changes. We next sought to identify determinants of putative intrinsic conformational changes in P2X(2) channels by mapping the transmembrane domain regions involved in the transition from the relatively selective I-1 state to the dilated I-2 state. Initial channel opening to the I-1 state was only weakly affected by Ala substitutions, whereas dramatic effects were observed for the higher permeability I-2 state. Ten residues appeared to perturb only the I-1-I-2 transition (Phe(31), Arg(34), Gln(37), Lys(53), Ile(32)8, Ile(332), Ser(340), Gly(342), Trp(350), Leu(352)), The data favor the hypothesis that permeability changes occur because of permissive motions at the interface between first and second transmembrane domains of neighboring subunits in pre-existing P2X(2) channels.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	MRC Laboratory Molecular Biology; Saint Louis University	Khakh, BS (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	bsk@mrc-lmb.cam.ac.uk		Egan, Terrance/0000-0002-7249-3161				Aschrafi A, 2004, J MOL BIOL, V342, P333, DOI 10.1016/j.jmb.2004.06.092; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; Collins A, 1997, P NATL ACAD SCI USA, V94, P5456, DOI 10.1073/pnas.94.10.5456; Dahan DS, 2004, P NATL ACAD SCI USA, V101, P10195, DOI 10.1073/pnas.0301885101; Doyle DA, 2004, TRENDS NEUROSCI, V27, P298, DOI 10.1016/j.tins.2004.04.004; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; Egan TM, 1998, J NEUROSCI, V18, P2350; Egan TM, 2004, J NEUROSCI, V24, P3413, DOI 10.1523/JNEUROSCI.5429-03.2004; Eickhorst AN, 2002, J GEN PHYSIOL, V120, P119, DOI 10.1085/jgp.20028535; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Fisher JA, 2004, J NEUROSCI, V24, P10475, DOI 10.1523/JNEUROSCI.3250-04.2004; Fujiwara Y, 2004, J PHYSIOL-LONDON, V558, P31, DOI 10.1113/jphysiol.2004.064568; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Haines WR, 2001, J NEUROSCI, V21, P5885, DOI 10.1523/JNEUROSCI.21-16-05885.2001; Haines WR, 2001, J BIOL CHEM, V276, P32793, DOI 10.1074/jbc.M104216200; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Jiang LH, 2001, J BIOL CHEM, V276, P14902, DOI 10.1074/jbc.M011327200; Jiang LH, 2003, J NEUROSCI, V23, P8903; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Khakh BS, 2001, P NATL ACAD SCI USA, V98, P5288, DOI 10.1073/pnas.081089198; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KORTEMME T, 2004, SCI STKE, V219, P12; Leite JF, 2003, P NATL ACAD SCI USA, V100, P13054, DOI 10.1073/pnas.2133028100; Li ZY, 2004, J NEUROSCI, V24, P7378, DOI 10.1523/JNEUROSCI.1423-04.2004; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Migita K, 2001, J BIOL CHEM, V276, P30934, DOI 10.1074/jbc.M103366200; NAKAZAWA K, 1991, J PHYSIOL-LONDON, V434, P647, DOI 10.1113/jphysiol.1991.sp018491; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 2003, MOL PHARMACOL, V63, P243, DOI 10.1124/mol.63.1.243; Norenberg W, 2000, N-S ARCH PHARMACOL, V362, P324, DOI 10.1007/s002100000311; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Pankratov YV, 2002, J NEUROSCI, V22, P8363; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Riven I, 2003, NEURON, V38, P225, DOI 10.1016/S0896-6273(03)00193-4; Roberts JA, 2004, J BIOL CHEM, V279, P9043, DOI 10.1074/jbc.M308964200; SCHLICHTER R, 2002, FENS ABSTR, V1; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Smart ML, 2002, AM J PHYSIOL-CELL PH, V283, pC77, DOI 10.1152/ajpcell.00456.2001; Spelta V, 2003, BRIT J PHARMACOL, V138, P131, DOI 10.1038/sj.bjp.0705018; Spencer RH, 2002, ANNU REV BIOPH BIOM, V31, P207, DOI 10.1146/annurev.biophys.31.082901.134329; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9	60	53	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6118	6129		10.1074/jbc.M411324200	http://dx.doi.org/10.1074/jbc.M411324200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15556949	hybrid			2022-12-25	WOS:000227217100119
J	Chae, YC; Lee, HY; Heo, K; Kim, JH; Kim, JH; Suh, PG; Ryu, SH				Chae, YC; Lee, HY; Heo, K; Kim, JH; Kim, JH; Suh, PG; Ryu, SH			Inhibition of muscarinic receptor-linked phospholipase D activation by association with tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; FACTOR-REVERSIBLE MANNER; PROTEIN-KINASE-C; ACETYLCHOLINE-RECEPTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DIRECTLY INTERACTS; MEMBRANE TUBULIN; PLASMA-MEMBRANE; CELL BIOLOGY; D ISOENZYMES	Mammalian phospholipase D (PLD) is considered a key enzyme in the transmission signals from various receptors including muscarinic receptors. PLD activation is a rapid and transient process, but a negative regulator has not been found that inhibits signal-dependent PLD activation. Here, for the first time, we report that tubulin binding to PLD2 is an inhibition mechanism for muscarinic receptor-linked PLD2 activation. Tubulin was identified in an immunoprecipitated PLD2 complex from COS-7 cells by peptide mass fingerprinting. The direct interaction between PLD2 and tubulin was found to be mediated by a specific region of PLD2 (amino acids 476-612). PLD2 was potently inhibited (lC(50) < 10 nm) by tubulin binding in vitro. In cells, the interaction between PLD2 and tubulin was increased by the microtubule disrupting agent nocodazole and reduced by the microtubule stabilizing agent Taxol. Moreover, PLD2 activity was found to be inversely correlated with the level of monomeric tubulin. In addition, we found that interaction with and the inhibition of PLD2 by monomeric tubulin is important for the muscarinic receptor-linked PLD signaling pathway. Interaction between PLD2 and tubulin was increased only after 1-2 min of carbachol stimulation when carbachol-stimulated PLD2 activity was decreased. The expression of the tubulin binding region of PLD2 blocked the later decrease in carbachol-induced PLD activity by masking tubulin binding. Taken together, these results indicate that an increase in local membrane monomeric tubulin concentration inhibits PLD2 activity, and provides a novel mechanism for the inhibition of muscarinic receptor-induced PLD2 activation by interaction with tubulin.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Ryu, SH (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea.	sungho@postech.ac.kr	Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Kim, Jung Hwan/0000-0001-8548-4435				BHATTACHARYYA B, 1976, NATURE, V264, P576, DOI 10.1038/264576a0; BoyanoAdanez MC, 1997, NEUROPHARMACOLOGY, V36, P295, DOI 10.1016/S0028-3908(96)00178-5; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CARON JM, 1987, BIOCHEMISTRY-US, V26, P3681, DOI 10.1021/bi00386a063; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DANNIEL LW, 1999, BIOCHIM BIOPHYS ACTA, V1439, P265; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; KANOH H, 1992, J NEUROCHEM, V59, P1786, DOI 10.1111/j.1471-4159.1992.tb11011.x; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kim JH, 1999, J IMMUNOL, V163, P5462; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee C, 2000, J BIOL CHEM, V275, P18751, DOI 10.1074/jbc.M001695200; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; Lee HY, 2004, J BIOL CHEM, V279, P16339, DOI 10.1074/jbc.M310976200; Lee S, 2002, J BIOL CHEM, V277, P6542, DOI 10.1074/jbc.M108047200; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; Lee SD, 2000, J NEUROCHEM, V75, P1053, DOI 10.1046/j.1471-4159.2000.0751053.x; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Mitchell R, 2003, J BIOL CHEM, V278, P33818, DOI 10.1074/jbc.M305825200; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Molina-Holgado E, 2003, BRIT J PHARMACOL, V138, P47, DOI 10.1038/sj.bjp.0705002; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pochet S, 2003, CELL SIGNAL, V15, P103, DOI 10.1016/S0898-6568(02)00059-1; Popova JS, 2000, J NEUROSCI, V20, P2774; Popova JS, 2002, J NEUROSCI, V22, P1668, DOI 10.1523/JNEUROSCI.22-05-01668.2002; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; REGULA CS, 1986, ANN NY ACAD SCI, V466, P832, DOI 10.1111/j.1749-6632.1986.tb38466.x; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; SERRANO L, 1986, J BIOL CHEM, V261, P7076; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; STEPHENS RE, 1977, BIOCHEMISTRY-US, V16, P2047, DOI 10.1021/bi00629a001; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Szekeres PG, 1998, J NEUROCHEM, V70, P1694; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; Wess J, 2004, ANNU REV PHARMACOL, V44, P423, DOI 10.1146/annurev.pharmtox.44.101802.121622; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836	61	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3723	3730		10.1074/jbc.M406987200	http://dx.doi.org/10.1074/jbc.M406987200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548524	hybrid			2022-12-25	WOS:000226983900072
J	Leonardi, R; Chohnan, S; Zhang, YM; Virga, KG; Lee, RE; Rock, CO; Jackowski, S				Leonardi, R; Chohnan, S; Zhang, YM; Virga, KG; Lee, RE; Rock, CO; Jackowski, S			A pantothenate kinase from Staphylococcus aureus refractory to feedback regulation by coenzyme A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANYL CARRIER PROTEIN; ESCHERICHIA-COLI; DISULFIDE REDUCTASE; LIPOTEICHOIC ACID; FATTY-ACID; TEICHOIC-ACIDS; BIOSYNTHESIS; ANTIMETABOLITES; METABOLISM; EXPRESSION	The key regulatory step in CoA biosynthesis in bacteria and mammals is pantothenate kinase (CoaA), which governs the intracellular concentration of CoA through feedback regulation by CoA and its thioesters. CoaA from Staphylococcus aureus (SaCoaA) has a distinct primary sequence that is more similar to the mammalian pantothenate kinases than the prototypical bacterial CoaA of Escherichia coli. In contrast to all known pantothenate kinases, SaCoaA activity is not feedback-regulated by CoA or CoA thioesters. Metabolic labeling of S. aureus confirms that CoA levels are not controlled by CoaA or at steps downstream from CoaA. The pantothenic acid antimetabolite N-heptylpantothenamide (N7-Pan) possesses potent antimicrobial activity against S. aureus and has multiple cellular targets. N7-Pan is a substrate for SaCoaA and is converted to the inactive butyldethia-CoA analog by the downstream pathway enzymes. The analog is also incorporated into acyl carrier protein and D-alanyl carrier protein, the prosthetic groups of which are derived from CoA. The inactivation of acyl carrier protein and the cessation of fatty acid synthesis are the most critical causes of growth inhibition by N7-Pan because the toxicity of the drug is ameliorated by supplementing the growth medium with fatty acids. The absence of feedback regulation at the pantothenate kinase step allows the accumulation of high concentrations of intracellular CoA, consistent with the physiology of S. aureus, which lacks glutathione and relies on the CoA/CoA disulfide reductase redox system for protection from oxidative damage.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	Suzanne.jackowski@stjude.org	Lee, Richard/AAX-3996-2021; Lee, Richard/J-4997-2013; Chohnan, Shigeru/W-1580-2019; Chohnan, Shigeru/AAS-8040-2020; Jackowski, Suzanne/N-8168-2018	Lee, Richard/0000-0002-2397-0443; Lee, Richard/0000-0002-2397-0443; Jackowski, Suzanne/0000-0002-6855-1429; Chohnan_, Shigeru/0000-0002-4624-927X	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 62896, GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062896, R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABIKO Y, 1967, J BIOCHEM, V61, P290, DOI 10.1093/oxfordjournals.jbchem.a128547; ALTENBERN RA, 1977, ANTIMICROB AGENTS CH, V11, P574, DOI 10.1128/AAC.11.3.574; Boyd DA, 2000, J BACTERIOL, V182, P6055, DOI 10.1128/JB.182.21.6055-6065.2000; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003; CLIFTON G, 1970, ARCH BIOCHEM BIOPHYS, V137, P523, DOI 10.1016/0003-9861(70)90470-4; Debabov DV, 1996, J BACTERIOL, V178, P3869, DOI 10.1128/jb.178.13.3869-3876.1996; delCardayre SB, 1998, J BIOL CHEM, V273, P5752, DOI 10.1074/jbc.273.10.5752; delCardayre SB, 1998, J BIOL CHEM, V273, P5744, DOI 10.1074/jbc.273.10.5744; FALK KL, 1993, ARCH BIOCHEM BIOPHYS, V301, P424, DOI 10.1006/abbi.1993.1166; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; Ivey RA, 2004, J BIOL CHEM, V279, P35622, DOI 10.1074/jbc.M403152200; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; Kiriukhin MY, 2001, J BACTERIOL, V183, P2051, DOI 10.1128/JB.183.6.2051-2058.2001; Kleinkauf Horst, 2000, Biofactors, V11, P91; Lambalot RH, 1997, METHOD ENZYMOL, V279, P254; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Luba J, 1999, BIOCHEMISTRY-US, V38, P2725, DOI 10.1021/bi9825899; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1994, CANCER RES, V54, pS1969; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Peschel A, 2000, ANTIMICROB AGENTS CH, V44, P2845, DOI 10.1128/AAC.44.10.2845-2847.2000; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Strauss E, 2002, J BIOL CHEM, V277, P48205, DOI 10.1074/jbc.M204560200; VALLARI DS, 1987, J BACTERIOL, V169, P5795, DOI 10.1128/jb.169.12.5795-5800.1987; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; Yun M, 2000, J BIOL CHEM, V275, P28093; Zhang YM, 2004, J BIOL CHEM, V279, P50969, DOI 10.1074/jbc.M409607200	47	79	85	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3314	3322		10.1074/jbc.M411608200	http://dx.doi.org/10.1074/jbc.M411608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548531	hybrid			2022-12-25	WOS:000226983900024
J	Huang, YT; Huang, DM; Guh, JH; Chen, IL; Tzeng, CC; Teng, CM				Huang, YT; Huang, DM; Guh, JH; Chen, IL; Tzeng, CC; Teng, CM			CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in the human prostate cancer PC-3 cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTAMNUS-DASYCARPUS TURCZ; AGGREGATION CONSTITUENTS; PHOSPHORYLATION; SURVIVIN; BCL-2; AGENTS; DEATH; CHEMOTHERAPY; ACTIVATION; DIVISION	There have been no therapeutic agents that provide a survival advantage in hormone-refractory prostate cancer. Recently, the Food and Drug Administration approved docetaxel combined with prednisone for the treatment of patients with advanced metastatic prostate cancer, and it does show a survival benefit. Hence, anti-microtubule drugs might be of benefit in chemotherapy of hormone-refractory prostate cancer. We used metastatic hormone-refractory prostate cancer PC-3 cells to investigate potential molecular mechanisms for CIL-102, a semisynthetic alkaloid derivative. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide and sulforhodamine B assays indicated that CIL-102 inhibits cell growth dose-dependently. Immunofluorescence microscopy and in vitro tubulin assembly assays indicated that CIL-102 binds to tubulin and disrupts microtubule organization. Flow cytometry showed that CIL-102 causes cells to accumulate in G(2)/M phase and sub-G(0)/G(1) phase. CIL-102-induced apoptosis was also characterized by immunofluorescence microscopy. Western blotting and kinase assays showed that CIL-102 exposure induced up-regulation of cyclin B1 and p34(cdc2) kinase activity and olomoucine, a p34(cdc2) inhibitor, profoundly reduced the number of cells accumulated in mitotic phase. Moreover, Bcl-2 phosphorylation, Cdc25C phosphorylation, and survivin expression were increased. CIL-102-induced apoptosis was associated with activation of caspase-3, but a noncaspase pathway may also be involved, since benzyloxy-carbonyl-VAD-fluoromethyl ketone, a pancaspase inhibitor, only partially inhibited the apoptosis, and apoptosis-inducing factor was translocated from mitochondria to cytosol. We conclude that CIL-102 induces mitotic arrest and apoptosis by binding to tubulin and inhibiting tubulin polymerization. CIL-102 causes mitotic arrest, at least partly, by modulating cyclin-dependent kinases and then apoptosis executed by caspase and noncaspase pathways.	Natl Taiwan Univ, Inst Pharmacol, Taipei 100, Taiwan; Natl Taiwan Univ, Sch Pharm, Coll Med, Taipei 100, Taiwan; Tajen Inst Technol, Dept Pharm, Pingtung 907, Taiwan; Kaohsiung Med Univ, Sch Med & Appl Chem, Coll Life Sci, Kaohsiung 807, Taiwan	National Taiwan University; National Taiwan University; Kaohsiung Medical University	Teng, CM (corresponding author), Natl Taiwan Univ, Inst Pharmacol, Taipei 100, Taiwan.	cmteng@ntumc.org	Huang, Dong-Ming/E-3663-2010; Tzeng, Cherng-Chyi/C-9637-2009	Huang, Yao-Ting/0000-0001-5912-8090; TENG, CHE-MING/0000-0002-9719-7334; GUH, JIH-HWA/0000-0002-6738-6054				Ahn HJ, 2004, J CELL BIOCHEM, V91, P1043, DOI 10.1002/jcb.20006; Akay C, 2004, CELL CYCLE, V3, P324; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Blagosklonny MV, 1997, CANCER RES, V57, P130; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Carter BZ, 2003, BLOOD, V102, P4179, DOI 10.1182/blood-2003-03-0960; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen IL, 2002, HELV CHIM ACTA, V85, P2214, DOI 10.1002/1522-2675(200207)85:7<2214::AID-HLCA2214>3.0.CO;2-W; CHEN IS, 1994, PHYTOCHEMISTRY, V36, P237, DOI 10.1016/S0031-9422(00)97045-6; CHEN IS, 1995, PHYTOCHEMISTRY, V39, P1091, DOI 10.1016/0031-9422(95)00054-B; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dixon SC, 2001, PHARMACOL REV, V53, P73; Earhart RH, 1999, SEMIN ONCOL, V26, P8; Guh JH, 1998, MOL PHARMACOL, V53, P467, DOI 10.1124/mol.53.3.467; Haldar S, 1996, CANCER RES, V56, P1253; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Huang DM, 2002, J BIOMED SCI, V9, P443, DOI 10.1007/BF02256539; Huang YT, 2004, BIOCHEM PHARMACOL, V67, P727, DOI 10.1016/j.bcp.2003.10.013; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Liu ZL, 2002, J AGR FOOD CHEM, V50, P1447, DOI 10.1021/jf010838l; Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Pratesi G, 2001, BIOCHEM PHARMACOL, V61, P381, DOI 10.1016/S0006-2952(00)00538-4; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Su TL, 1998, PHYTOTHER RES, V12, pS74, DOI 10.1002/(SICI)1099-1573(1998)12:1+<S74::AID-PTR255>3.0.CO;2-V; Tang WC, 2003, PLANTA MED, V69, P97, DOI 10.1055/s-2003-37718; Wall NR, 2003, CANCER RES, V63, P230; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Wu TS, 2003, J CHIN CHEM SOC-TAIP, V50, P171, DOI 10.1002/jccs.200300024; YU SM, 1992, N-S ARCH PHARMACOL, V345, P349	39	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2771	2779		10.1074/jbc.M408850200	http://dx.doi.org/10.1074/jbc.M408850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15536083	hybrid			2022-12-25	WOS:000226449100050
J	Justino, MC; Vicente, JB; Teixeira, M; Saraiva, LM				Justino, MC; Vicente, JB; Teixeira, M; Saraiva, LM			New genes implicated in the protection of anaerobically grown Escherichia coli against nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOID-ASSOCIATED PROTEIN; TRANSCRIPTIONAL REGULATOR; NITROSATIVE STRESS; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; MICROARRAY DATA; EXPRESSION; BINDING; IRON; FLAVOHEMOGLOBIN	Nitric oxide produced by activated macrophages plays a key role as one of the immune system's weapons against pathogens. Because the lifetime of nitric oxide is short in aerobic conditions, whereas in anaerobic conditions the cytotoxic effects of nitric oxide are greatly increased as in the infection/inflammation processes, it is important to establish which systems are able to detoxify nitric oxide under anaerobic conditions. In the present work a new set of Escherichia coli K-12 genes conferring anaerobic resistance to nitric oxide is presented, namely the gene product of YtfE and a potential transcriptional regulator of the helix-turn-helix LysR-type (YidZ). The crucial role of flavohemoglobin for anaerobic nitric oxide protection is also demonstrated. Furthermore, nitric oxide is shown to cause a significant alteration of the global E. coli gene transcription profile that includes the increase of the transcript level of genes encoding for detoxification enzymes, iron-sulfur cluster assembly systems, DNA-repairing enzymes, and stress response regulators.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal	Universidade Nova de Lisboa	Saraiva, LM (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Apartado 127,Ave Republ EAN, P-2781901 Oeiras, Portugal.	lst@itqb.unl.pt	Vicente, Joao B/L-8732-2016; Teixeira, Miguel/M-1509-2019; Vicente, João B/B-9623-2014; Saraiva, Ligia M/H-8537-2012; Teixeira, Miguel/A-9098-2011	Teixeira, Miguel/0000-0003-4124-6237; Vicente, João B/0000-0003-3919-8280; Saraiva, Ligia M/0000-0002-0675-129X; Teixeira, Miguel/0000-0003-4124-6237; Vicente, Joao/0000-0001-5244-8059; Justino, Marta/0000-0002-9310-9456				Andersson JO, 2003, CURR BIOL, V13, P94, DOI 10.1016/S0960-9822(03)00003-4; Badger JL, 1998, INFECT IMMUN, V66, P5692, DOI 10.1128/IAI.66.12.5692-5697.1998; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; Brunskill EW, 1997, MICROBIOL-UK, V143, P2877, DOI 10.1099/00221287-143-9-2877; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; D'Autreaux B, 2002, P NATL ACAD SCI USA, V99, P16619, DOI 10.1073/pnas.252591299; da Costa PN, 2003, FEMS MICROBIOL LETT, V218, P385, DOI 10.1016/S0378-1097(02)01186-2; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Demple B, 2002, MOL CELL BIOCHEM, V234, P11, DOI 10.1023/A:1015933216079; Falconi M, 2001, MOL MICROBIOL, V42, P439, DOI 10.1046/j.1365-2958.2001.02646.x; Feng HM, 2000, INFECT IMMUN, V68, P6729, DOI 10.1128/IAI.68.12.6729-6736.2000; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Goldberg MD, 2001, MOL MICROBIOL, V41, P549, DOI 10.1046/j.1365-2958.2001.02526.x; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Huffman LJ, 2003, J BIOSCIENCES, V28, P29, DOI 10.1007/BF02970129; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Kanamaru K, 2000, MOL MICROBIOL, V38, P805, DOI 10.1046/j.1365-2958.2000.02171.x; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Khil PP, 2002, MOL MICROBIOL, V44, P89, DOI 10.1046/j.1365-2958.2002.02878.x; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Kim CC, 2003, INFECT IMMUN, V71, P3196, DOI 10.1128/IAI.71.6.3196-3205.2003; Kim S, 2000, J BIOL CHEM, V275, P6220, DOI 10.1074/jbc.275.9.6220; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Krieglstein CF, 2001, J EXP MED, V194, P1207, DOI 10.1084/jem.194.9.1207; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; McLeod SM, 2001, CURR OPIN MICROBIOL, V4, P152, DOI 10.1016/S1369-5274(00)00181-8; Meier TI, 2000, MICROBIOL-UK, V146, P1071, DOI 10.1099/00221287-146-5-1071; Monje-Casas F, 2001, J BIOL CHEM, V276, P18031, DOI 10.1074/jbc.M011728200; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Muraoka S, 2003, J MOL BIOL, V328, P555, DOI 10.1016/S0022-2836(03)00312-7; Phadtare S, 2002, J BACTERIOL, V184, P6725, DOI 10.1128/JB.184.23.6725-6729.2002; Pohlmann A, 2000, MOL MICROBIOL, V38, P626, DOI 10.1046/j.1365-2958.2000.02157.x; Pomposiello PJ, 2001, TRENDS BIOTECHNOL, V19, P109, DOI 10.1016/S0167-7799(00)01542-0; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Saarinen M, 2002, J MED MICROBIOL, V51, P13, DOI 10.1099/0022-1317-51-1-13; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saraiva LM, 2004, ADV MICROB PHYSIOL, V49, P77, DOI 10.1016/S0065-2911(04)49002-X; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Smirnova IA, 2004, J MOL BIOL, V340, P405, DOI 10.1016/j.jmb.2004.04.071; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Spek EJ, 2001, J BACTERIOL, V183, P131, DOI 10.1128/JB.183.1.131-138.2001; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tucker NP, 2004, J BACTERIOL, V186, P6656, DOI 10.1128/JB.186.19.6656-6660.2004; Vollack KU, 2001, J BACTERIOL, V183, P2516, DOI 10.1128/JB.183.8.2516-2526.2001; WALTER EG, 1992, PLASMID, V27, P52, DOI 10.1016/0147-619X(92)90006-V; Wilson RL, 2001, MOL MICROBIOL, V39, P79, DOI 10.1046/j.1365-2958.2001.02192.x; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yang YH, 2002, NAT REV GENET, V3, P579, DOI 10.1038/nrg863; Zaim J, 2003, NUCLEIC ACIDS RES, V31, P1444, DOI 10.1093/nar/gkg234; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	57	160	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2636	2643		10.1074/jbc.M411070200	http://dx.doi.org/10.1074/jbc.M411070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15546870	hybrid			2022-12-25	WOS:000226449100033
J	Nixon, RR				Nixon, RR			Prion-associated increases in Src-family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; TRANSGENIC MICE; SIGNAL-TRANSDUCTION; AMYLOID PLAQUES; SCRAPIE; PRP; ACCUMULATION; EXPRESSION	The prion diseases result from the generation and propagation of an abnormal conformer of the prion protein. It is unclear how this molecular event disrupts neuronal function and viability. Current evidence argues it is not due to loss of normal prion protein activity or direct toxic effects of the abnormal conformer. Both the normal and abnormal prion proteins are glycosylphosphatidylinositol-linked membrane proteins. Conversion to the abnormal isoform results in the formation and accumulation of prion protein aggregates. Because aggregation of glycosylphosphatidylinositol-linked proteins activates Src-family kinases, the activation status and levels of the Src-family kinases in prion disease were investigated. Elevations of Src-family kinases were found in a cell culture model and two separate animal models of prion disease. The elevations in Src kinases preceded the onset of symptoms and occurred concurrently with the appearance of detergent-insoluble prion protein. In addition, the total level of kinases phosphorylated at tyrosine residues associated with activation was increased. Similar alterations were not present in brain homogenates from presymptomatic animals early in the disease course, prion protein-ablated animals, or end-stage Tg2576 mice overexpressing mutant amyloid precursor protein. Identification of similar elevations in cell culture and animal model systems suggests the elevations are a specific response to the presence of the disease-associated conformer. Abnormal regulation of these signal transduction cascades may be a key element in the cellular pathology of the prion diseases.	Oregon Hlth & Sci Univ, Dept Pathol, Neuropathol Sect, Portland, OR 97201 USA	Oregon Health & Science University	Nixon, RR (corresponding author), Oregon Hlth & Sci Univ, Dept Pathol, Neuropathol Sect, L-113,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	nixonr@ohsu.edu			NATIONAL INSTITUTE ON AGING [P30AG008017, R03AG020310] Funding Source: NIH RePORTER; NIA NIH HHS [5P30-AG08017-12, R03AG20310] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Combs CK, 1999, J NEUROSCI, V19, P928; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; Doh-ura K, 2000, J NEUROPATH EXP NEUR, V59, P774, DOI 10.1093/jnen/59.9.774; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Harlow E, 1999, USING ANTIBODIES LAB, P321; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jeffrey M, 2000, NEUROPATH APPL NEURO, V26, P41, DOI 10.1046/j.1365-2990.2000.00216.x; Jeffrey M, 2001, J COMP PATHOL, V124, P20, DOI 10.1053/jcpa.2000.0423; Johnston AR, 1998, EXP NEUROL, V151, P326, DOI 10.1006/exnr.1998.6817; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KIM JH, 1986, ACTA NEUROPATHOL, V69, P81, DOI 10.1007/BF00687042; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LASZLO L, 1992, J PATHOL, V166, P333, DOI 10.1002/path.1711660404; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MacFarlane SN, 2000, J NEUROSCI, V20, P5245, DOI 10.1523/JNEUROSCI.20-14-05245.2000; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Mattson MP, 2000, BRAIN PATHOL, V10, P300, DOI 10.1111/j.1750-3639.2000.tb00264.x; Morel E, 2004, J BIOL CHEM, V279, P1499, DOI 10.1074/jbc.M308578200; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Ostlund P, 2001, MOL BRAIN RES, V97, P161, DOI 10.1016/S0169-328X(01)00316-3; Peel AL, 2003, NEUROBIOL DIS, V14, P52, DOI 10.1016/S0969-9961(03)00086-X; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Quinn J, 2001, EXP NEUROL, V168, P203, DOI 10.1006/exnr.2000.7598; Rossner S, 2001, EUR J NEUROSCI, V13, P269, DOI 10.1046/j.1460-9568.2001.01388.x; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006-2952(98)00124-5; Savage MJ, 2002, J NEUROSCI, V22, P3376; Schroder HC, 1998, NEUROTOXICOLOGY, V19, P683; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SHIRAZI SK, 1993, NEUROREPORT, V4, P435, DOI 10.1097/00001756-199304000-00024; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Tatzelt J, 1999, J NEUROPATH EXP NEUR, V58, P1244, DOI 10.1097/00005072-199912000-00005; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Williams R, 2002, MATER WORLD, V10, P20; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Wong K, 1996, NEUROLOGY, V47, P741, DOI 10.1212/WNL.47.3.741; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhang C, 1996, NEUROSCI LETT, V211, P187, DOI 10.1016/0304-3940(96)12761-0	62	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2455	2462		10.1074/jbc.M410883200	http://dx.doi.org/10.1074/jbc.M410883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15546860	hybrid			2022-12-25	WOS:000226449100011
J	Kimura, Y; Mizusawa, N; Yamanari, T; Ishii, A; Ono, T				Kimura, Y; Mizusawa, N; Yamanari, T; Ishii, A; Ono, T			Structural changes of D1 C-terminal alpha-carboxylate during S-state cycling in photosynthetic oxygen evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-OXIDIZING COMPLEX; AMINO-ACID-RESIDUES; FTIR DIFFERENCE SPECTRA; PHOTOSYSTEM-II; MANGANESE CLUSTER; EVOLVING COMPLEX; VIBRATIONAL-MODES; OXIDATION; ALANINE; POLYPEPTIDE-D1	Changes in the chemical structure of alpha-carboxylate of the D1 C-terminal Ala-344 during S-state cycling of photosynthetic oxygen-evolving complex were selectively measured using light-induced Fourier transform infrared (FTIR) difference spectroscopy in combination with specific [C-13]alanine labeling and site-directed mutagenesis in photosystem II core particles from Synechocystis sp. PCC 6803. Several bands for carboxylate symmetric stretching modes in an S-2/S-1 FTIR difference spectrum were affected by selective C-13 labeling of the alpha-carboxylate of Ala with L-[1-C-13] alanine, whereas most of the isotopic effects failed to be induced in a site-directed mutant in which Ala-344 was replaced with Gly. Labeling of the alpha-methyl of Ala with L-[3-C-13] alanine had much smaller effects on the spectrum to induce isotopic bands due to a symmetric CH3 deformation coupled with the alpha-carboxylate. The isotopic bands for the alpha-carboxylate of Ala-344 showed characteristic changes during S-state cycling. The bands appeared prominently upon the S-1-to-S-2 transition and to a lesser extent upon the S-2-to-S-3 transition but reappeared at slightly upshifted frequencies with the opposite sign upon the S-3-to-S-0 transition. No obvious isotopic band appeared upon the S-0-to-S-1 transition. These results indicate that the alpha-carboxylate of C-terminal Ala-344 is structurally associated with a manganese ion that becomes oxidized upon the S-1-to-S-2 transition and reduced reversely upon the S-3-to-S-0 transition but is not associated with manganese ion(s) oxidized during the S-0-to-S-1 (and S-2-to-S-3) transition(s). Consistently, L-[1-C-13] alanine labeling also induced spectral changes in the low frequency (670-350 cm(-1)) S-2/S-1 FTIR difference spectrum.	Inst Phys & Chem Res, RIKEN Photodynam Res Ctr, Lab Photobiol 1, Aoba Ku, Sendai, Miyagi 9800845, Japan; Hiroshima Univ, Fac Integrated Arts & Sci, Higashihiroshima 7398521, Japan	RIKEN; Hiroshima University	Ono, T (corresponding author), Inst Phys & Chem Res, RIKEN Photodynam Res Ctr, Lab Photobiol 1, Aoba Ku, 519-1399 Aoba, Sendai, Miyagi 9800845, Japan.	takaaki@riken.jp						Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815; CANNON RD, 1993, J CHEM SOC DALTON, P2005, DOI 10.1039/dt9930002005; Chu HA, 2004, BIOCHEMISTRY-US, V43, P3152, DOI 10.1021/bi035915f; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fromme P, 2002, PHILOS T R SOC B, V357, P1337, DOI 10.1098/rstb.2002.1143; Goussias C, 2002, PHILOS T R SOC B, V357, P1369, DOI 10.1098/rstb.2002.1134; Hillier W, 2001, BIOCHEMISTRY-US, V40, P1503, DOI 10.1021/bi002436x; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; Kimura Y, 2003, BIOCHEMISTRY-US, V42, P13170, DOI 10.1021/bi035420q; Kimura Y, 2002, BIOCHEMISTRY-US, V41, P5844, DOI 10.1021/bi016093u; Kimura Y, 2001, BIOCHEMISTRY-US, V40, P14061, DOI 10.1021/bi011216w; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; Liang WC, 2000, J AM CHEM SOC, V122, P3399, DOI 10.1021/ja992501u; MARDER JB, 1984, J BIOL CHEM, V259, P3900; Mizusawa N, 2004, J BIOL CHEM, V279, P29622, DOI 10.1074/jbc.M402397200; Mrozek R, 1999, POLYHEDRON, V18, P2321, DOI 10.1016/S0277-5387(99)00140-0; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1994, BIOCHEM SOC T, V22, P338, DOI 10.1042/bst0220338; Noguchi T, 2003, BIOCHEMISTRY-US, V42, P6035, DOI 10.1021/bi0341612; Noguchi T, 2002, BIOCHEMISTRY-US, V41, P2322, DOI 10.1021/bi011954k; Noguchi T, 2001, BIOCHEMISTRY-US, V40, P1497, DOI 10.1021/bi0023807; PERCY GC, 1976, J CHEM SOC DALTON, P2429, DOI 10.1039/dt9760002429; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; Yamanari T, 2004, BIOCHEMISTRY-US, V43, P7479, DOI 10.1021/bi0362323; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	31	63	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2078	2083		10.1074/jbc.M410627200	http://dx.doi.org/10.1074/jbc.M410627200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542597	hybrid			2022-12-25	WOS:000226341700042
J	Stasinopoulos, IA; Mironchik, Y; Raman, A; Wildes, F; Winnard, P; Raman, V				Stasinopoulos, IA; Mironchik, Y; Raman, A; Wildes, F; Winnard, P; Raman, V			HOXA5-Twist interaction alters p53 homeostasis in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HOMEOTIC GENES; HOMEOBOX GENES; DNA-DAMAGE; TWIST GENE; PROTEIN; MUTATIONS; DEGRADATION; DIFFERENTIATION; EVOLUTION	The homeotic gene HOXA5 has been shown to play an important role in breast tumorigenesis. We have shown that loss of p53 correlated with loss of a developmentally regulated transcription factor, HOXA5, in primary breast cancer. Searching for potential protein interacting partners we found that HOXA5 binds to an antiapoptotic protein, Twist. Furthermore, Twist-overexpressing MCF-7 cells displayed a deregulated p53 response to gamma-radiation and decreased regulation of downstream target genes. Using a p53-promoter-reporter system, we demonstrated that HOXA5 could partially restore the inhibitory effects of Twist on p53 target genes. These effects are likely mediated through both the transcriptional up-regulation of p53 and the protein-protein interaction between HOXA5 and Twist. Thus, the loss of HOXA5 expression could lead to the functional activation of Twist resulting in aberrant cell cycle regulation and promoting breast carcinogenesis.	Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21250 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore County	Raman, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol, 340 Traylor Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	vraman2@jhmi.edu			NCI NIH HHS [1R01 CA097226] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097226] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bate Michael, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1047; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buske C, 2000, INT J HEMATOL, V71, P301; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Castanon I, 2002, GENE, V287, P11, DOI 10.1016/S0378-1119(01)00893-9; Cho JW, 2001, CELL PROLIFERAT, V34, P267, DOI 10.1046/j.0960-7722.2001.00208.x; Chun K, 2002, AM J MED GENET, V110, P136, DOI 10.1002/ajmg.10400; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813; ElGhouzzi V, 1997, NAT GENET, V15, P42; Feldman BJ, 2000, BLOOD, V96, P1906, DOI 10.1182/blood.V96.5.1906.h8001906_1906_1913; Fujino T, 2002, BLOOD, V99, P1428, DOI 10.1182/blood.V99.4.1428; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; Goodman FR, 2001, CLIN GENET, V59, P1, DOI 10.1034/j.1399-0004.2001.590101.x; Gripp KW, 2000, HUM MUTAT, V15, P150, DOI 10.1002/(SICI)1098-1004(200002)15:2<150::AID-HUMU3>3.0.CO;2-D; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Naora H, 2001, P NATL ACAD SCI USA, V98, P15209, DOI 10.1073/pnas.011503998; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reichert H, 1999, CURR OPIN NEUROBIOL, V9, P589, DOI 10.1016/S0959-4388(99)00002-1; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sherr CJ, 2000, CANCER RES, V60, P3689; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Westphal CH, 1997, CANCER RES, V57, P1664; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	36	85	99	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2294	2299		10.1074/jbc.M411018200	http://dx.doi.org/10.1074/jbc.M411018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15545268	hybrid			2022-12-25	WOS:000226341700066
J	Lin, MJ; Tang, LY; Reddy, MN; Shen, CKJ				Lin, MJ; Tang, LY; Reddy, MN; Shen, CKJ			DNA methyltransferase gene dDnmt2 and longevity of Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; MELANOGASTER; METHYLATION; PROTEIN; SYSTEM; EXPRESSION; DNMT2	The DNA methylation program of the fruit fly Drosophila melanogaster is carried out by the single DNA methyltransferase gene dDnmt2, the function of which is unknown before. We present evidence that intactness of the gene is required for maintenance of the normal life span of the fruit flies. In contrast, overexpression of dDnmt2 could extend Drosophila life span. The study links the Drosophila DNA methylation program with the small heatshock proteins and longevity/ aging and has interesting implication on the eukaryotic DNA methylation programs in general.	Natl Taiwan Univ, Inst Mol Med, Taipei 11529, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	National Taiwan University; Academia Sinica - Taiwan	Shen, CKJ (corresponding author), Natl Taiwan Univ, Inst Mol Med, Taipei 11529, Taiwan.	ckshen@ccvax.sinica.edu.tw	shen, Che-Kun James/L-1343-2015					Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Helfand SL, 2003, ANNU REV GENET, V37, P329, DOI 10.1146/annurev.genet.37.040103.095211; Hermann A, 2003, J BIOL CHEM, V278, P31717, DOI 10.1074/jbc.M305448200; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; King V, 1999, DEV BIOL, V207, P107, DOI 10.1006/dbio.1998.9147; Kunert N, 2003, DEVELOPMENT, V130, P5083, DOI 10.1242/dev.00716; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Morrow G, 2004, J BIOL CHEM, V279, P43382, DOI 10.1074/jbc.C400357200; Morrow G, 2004, FASEB J, V18, P598, DOI 10.1096/fj.03-0860fje; Morrow G, 2003, SEMIN CELL DEV BIOL, V14, P291, DOI 10.1016/j.semcdb.2003.09.023; Reddy MN, 2003, ONCOGENE, V22, P6301, DOI 10.1038/sj.onc.1206650; Seong KH, 2001, BIOGERONTOLOGY, V2, P209, DOI 10.1023/A:1011517325711; Tang LY, 2003, J BIOL CHEM, V278, P33613, DOI 10.1074/jbc.C300255200; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; Wang HD, 2004, P NATL ACAD SCI USA, V101, P12610, DOI 10.1073/pnas.0404648101; Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697	25	85	95	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					861	864		10.1074/jbc.C400477200	http://dx.doi.org/10.1074/jbc.C400477200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15533947	Green Published, hybrid			2022-12-25	WOS:000226195200003
J	Shan, B; Zhuo, Y; Chin, D; Morris, CA; Morris, GF; Lasky, JA				Shan, B; Zhuo, Y; Chin, D; Morris, CA; Morris, GF; Lasky, JA			Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; P-TEFB KINASE; ELONGATION-FACTOR-B; IV COLLAGENASE; TNF-ALPHA; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; IN-VIVO; GENE; INDUCTION	The proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) promotes tumor progression through activation of matrix metalloproteinase (MMP) activity. MMP-9 is a gelatinase secreted by both cancer cells and surrounding stromal cells, and it contributes to TNF-alpha-stimulated tumor invasion and metastasis. Cyclin-dependent kinase 9 (CDK9), the catalytic component of positive transcription elongation factor-b, phosphorylates serine 2 residues in the C-terminal domain of RNA polymerase II for productive transcription elongation and is up-regulated upon exposure to various stresses. This study investigated roles of CDK9 in TNF-alpha-stimulated MMP-9 expression in human lung adenocarcinoma cells. CDK9 activity was inhibited using three different strategies, including the CDK9 pharmacological inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), a dominant-negative CDK9, and a CDK9-specific small interfering RNA. All three approaches reduced TNF-alpha-mediated accumulation of MMP-9 in the conditioned media as demonstrated by gelatin zymography. In contrast, transforming growth factor-beta1-induced accumulation of MMP-2 was unaffected by DRB. Expression of the MMP-9 gene was examined using reverse transcription real time PCR and using a transient transfection assay to evaluate MMP-9 promoter activity. DRB reduced the TNF-alpha-induced increase in MMP-9 mRNA levels but did not effect transforming growth factor-beta1-induced MMP-2 mRNA expression. Consistently DRB and dominant-negative CDK9 completely abrogated TNF-alpha-stimulated human MMP-9 promoter activity. TNF-alpha did not regulate expression or localization of CDK9 or its regulatory partner Cyclin T. However, TNF-alpha stimulated CDK9 binding to Cyclin T and MMP-9 gene occupancy by both CDK9 and the serine 2-phosphorylated form of RNA polymerase II. Our findings indicate that CDK9 mediates TNF-alpha-induced MMP-9 transcription. Disruption of TNF-alpha signaling using CDK9 inhibitors could serve as a potential therapeutic strategy against tumor invasion and metastasis.	Tulane Univ, Hlth Sci Ctr, Dept Med, Pulm & Crit Care Sect, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Microbiol, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Pathol, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Program Lung Biol, New Orleans, LA 70112 USA	Tulane University; Tulane University; Tulane University; Tulane University; Tulane University	Lasky, JA (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Med, Pulm Sect, SL-9,1430 Tulane Ave, New Orleans, LA 70112 USA.	jlasky@tulane.edu		Shan, Bin/0000-0002-6869-2678	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061934] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnott CH, 2002, ONCOGENE, V21, P4728, DOI 10.1038/sj.onc.1205588; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Becerril C, 1999, AM J RESP CELL MOL, V20, P1020, DOI 10.1165/ajrcmb.20.5.3288; Boehm AK, 2003, MOL CELL BIOL, V23, P7628, DOI 10.1128/MCB.23.21.7628-7637.2003; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; De Falco G, 2002, CANCER BIOL THER, V1, P342; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; Ghose R, 2001, J VIROL, V75, P11336, DOI 10.1128/JVI.75.23.11336-11343.2001; Giannelli G, 2002, HISTOL HISTOPATHOL, V17, P339, DOI 10.14670/HH-17.339; Haaland RE, 2003, AIDS, V17, P2429, DOI 10.1097/00002030-200311210-00004; Hah N, 2003, BIOCHEM BIOPH RES CO, V305, P428, DOI 10.1016/S0006-291X(03)00788-5; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harimaya K, 2000, CLIN EXP METASTAS, V18, P121, DOI 10.1023/A:1006791723233; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kanazawa S, 2003, ONCOGENE, V22, P5707, DOI 10.1038/sj.onc.1206800; Kanazawa S, 2001, INT IMMUNOL, V13, P951, DOI 10.1093/intimm/13.7.951; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Katerinaki E, 2003, BRIT J CANCER, V89, P1123, DOI 10.1038/sj.bjc.6601257; KAWASHIMA A, 1994, VIRCHOWS ARCH, V424, P547; Kubota S, 1996, CANCER LETT, V98, P233; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAURICELLALEFEBVRE MA, 1993, INVAS METAST, V13, P289; Lis JT, 2000, GENE DEV, V14, P792; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Rao VH, 1999, INT J ONCOL, V14, P291; ROSEN EM, 1991, CANCER RES, V51, P5315; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; SATO H, 1993, ONCOGENE, V8, P395; Scott KA, 2003, MOL CANCER THER, V2, P445; Shan B, 2003, J BIOL CHEM, V278, P44009, DOI 10.1074/jbc.M302671200; Shore SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	54	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1103	1111		10.1074/jbc.M406293200	http://dx.doi.org/10.1074/jbc.M406293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528190	hybrid			2022-12-25	WOS:000226195200031
J	Schwarz, M; Rottgen, P; Takada, Y; Le Gall, F; Knackmuss, S; Bassler, N; Buttner, C; Little, M; Bode, C; Peter, K				Schwarz, M; Rottgen, P; Takada, Y; Le Gall, F; Knackmuss, S; Bassler, N; Buttner, C; Little, M; Bode, C; Peter, K			Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alpha(IIb)beta(3) designed by subtractive selection from naive human phage libraries	FASEB JOURNAL			English	Article						fibrinogen; phage-display	ACUTE CORONARY SYNDROME; GLYCOPROTEIN-IIB-IIIA; INTEGRIN ALPHA(IIB)BETA(3); LIGAND-BINDING; ADHESION RECEPTORS; FIBRINOGEN BINDING; CELL-ADHESION; GPIIB-IIIA; IIB/IIIA; INHIBITORS	Binding of fibrinogen to platelet integrin alpha(II)beta(3) mediates platelet aggregation, and thus inhibition of alpha(IIb)beta(3) represents a powerful therapeutic strategy in cardiovascular medicine. However, the currently used inhibitors of a(IIb)beta(3) demonstrate several adverse effects like thrombocytopenia and bleeding, which are associated with their property to bind to non-activated alpha(IIb)beta(3). To circumvent these problems, we designed blocking single-chain antibody-fragments (scFv) that bind to alpha(IIb)beta(3) exclusively in its activated conformation. Two nave phage libraries were created: a natural phage library, based on human lymphocyte cDNA, and a synthetic library, with randomized V(H)CDR3. We performed serial rounds of subtractive panning with depletion on non-activated and selection on activated aIIbbeta3, which were provided on resting and ADP-stimulated platelets and CHO cells, expressing wild-type or mutated and thereby activated alpha(IIb)beta(3). In contrast to isolated, immobilized targets, as generally used for phage display, this unique cell-based approach for panning allowed the preservation of functional integrin conformation. Thereby, we obtained several scFv-clones that demonstrated exclusive binding to activated platelets and complete inhibition of fibrinogen binding and platelet aggregation. Interestingly, all activation-specific clones contained an RXD pattern in the HCDR3. Binding studies on transiently expressed point mutants and mouse-human domain-switch mutants of alphaIIbbeta3 indicate a binding site similar to fibrinogen. In conclusion, we generated human activation-specific scFvs against alpha(IIb)beta(3), which bind selectively to activated alpha(IIb)beta(3) and thereby potently inhibit fibrinogen binding to alpha(IIb)beta(3) and platelet aggregation.	Univ Freiburg, Dept Cardiol, D-79106 Freiburg, Germany; Scripps Res Inst, La Jolla, CA 92037 USA; Affimed Therapeut AG, D-69120 Heidelberg, Germany; Univ N Carolina, Chapel Hill, NC USA	University of Freiburg; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill	Schwarz, M (corresponding author), Univ Freiburg, Dept Cardiol, Breisacherstr 33, D-79106 Freiburg, Germany.	schwarz@med1.ukl.uni-freiburg.de	/S-2765-2019; Peter, Karlheinz/E-8772-2010	/0000-0002-8040-2258; Peter, Karlheinz/0000-0002-8040-2258; takada, yoshikazu/0000-0001-5481-9589				ABRAMS C, 1994, J BIOL CHEM, V269, P18781; Bennett JS, 2001, ANN NY ACAD SCI, V936, P340; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Billheimer JT, 2002, BLOOD, V99, P3540, DOI 10.1182/blood.V99.10.3540; Borrebaeck CAK, 2002, NAT BIOTECHNOL, V20, P1189, DOI 10.1038/nbt1202-1189; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Chung L, 2004, FASEB J, V18, pA345, DOI 10.1096/fj.03-0586fje; Curtis BR, 2002, BLOOD, V99, P2054, DOI 10.1182/blood.V99.6.2054; Dasgupta H, 2000, AM HEART J, V140, P206, DOI 10.1067/mhj.2000.107554; Dorsam H, 1997, FEBS LETT, V414, P7, DOI 10.1016/S0014-5793(97)00966-6; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; Francisco JA, 1997, BLOOD, V89, P4493, DOI 10.1182/blood.V89.12.4493; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; Hamm CW, 2001, LANCET, V358, P1533, DOI 10.1016/S0140-6736(01)06585-0; Holmes MB, 2000, AM J CARDIOL, V85, P491, DOI 10.1016/S0002-9149(99)00778-X; Hoogenboom Hennie R, 2002, Methods Mol Biol, V178, P1; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; Kipriyanov SM, 1996, J IMMUNOL METHODS, V196, P51, DOI 10.1016/0022-1759(96)00115-9; Kunicki TJ, 1996, J BIOL CHEM, V271, P20315, DOI 10.1074/jbc.271.34.20315; LERNER RA, 1992, SCIENCE, V258, P1313, DOI 10.1126/science.1455226; Little M, 1999, J IMMUNOL METHODS, V231, P3, DOI 10.1016/S0022-1759(99)00164-7; Madan M, 1999, AM HEART J, V138, pS317, DOI 10.1053/hj.1999.v138.a100465; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Peter K, 1998, BLOOD, V92, P3240, DOI 10.1182/blood.V92.9.3240.421k21_3240_3249; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Peter K, 2000, CIRCULATION, V101, P1158, DOI 10.1161/01.CIR.101.10.1158; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Quinn MJ, 2003, ARTERIOSCL THROM VAS, V23, P945, DOI 10.1161/01.ATV.0000066686.46338.F1; Quinn MJ, 2002, CIRCULATION, V106, P379, DOI 10.1161/01.CIR.0000019581.22812.B2; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Schneider DJ, 2000, CARDIOVASC RES, V45, P437, DOI 10.1016/S0008-6363(99)00253-9; Schwarz M, 2004, J PHARMACOL EXP THER, V308, P1002, DOI 10.1124/jpet.103.058883; Schwentker A, 2002, NITRIC OXIDE-BIOL CH, V7, P1, DOI 10.1016/S1089-8603(02)00002-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; Tur MK, 2001, BIOTECHNIQUES, V30, P404, DOI 10.2144/01302rr04; Welschof M, 1997, P NATL ACAD SCI USA, V94, P1902, DOI 10.1073/pnas.94.5.1902	40	69	77	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1704	+		10.1096/fj.04-1513fje	http://dx.doi.org/10.1096/fj.04-1513fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15522915				2022-12-25	WOS:000224243200021
J	Brusselmans, K; Vrolix, R; Verhoeven, G; Swinnen, JV				Brusselmans, K; Vrolix, R; Verhoeven, G; Swinnen, JV			Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; BREAST-CANCER; OLIVE OIL; DIETARY FLAVONOIDS; RNA INTERFERENCE; GREEN TEA; RISK; PROGRESSION; ABSORPTION; ALCOHOL	The consumption of food products containing high amounts of flavonoids has been reported to lower the risk of various cancers. The mechanisms underlying the cancer-protective effects of these naturally occurring polyphenolic compounds, however, remain elusive. Based on our previous finding that the cytotoxic effect of the flavanol epigallocatechin-3-gallate on prostate cancer cells correlates with its ability to inhibit fatty acid synthase (FAS, a key lipogenic enzyme overexpressed in many human cancers), we examined the antilipogenic effects of a panel of 18 naturally occurring polyphenolic compounds. In addition to epigallocatechin-3-gallate, five other flavonoids, more particularly luteolin, quercetin, kaempferol, apigenin, and taxifolin, also markedly inhibited cancer cell lipogenesis. Interestingly, in both prostate and breast cancer cells, a remarkable dose-response parallelism was observed between flavonoid-induced inhibition of fatty acid synthesis, inhibition of cell growth, and induction of apoptosis. In support for a role of fatty acid synthesis in these effects, the addition of exogenous palmitate, the end product of FAS, markedly suppressed the cytotoxic effects of flavonoids. Taken together, these findings indicate that the potential of flavonoids to induce apoptosis in cancer cells is strongly associated with their FAS inhibitory properties, thereby providing a new mechanism by which polyphenolic compounds may exert their cancer-preventive and antineoplastic effects.	Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Gasthuisberg O&N, Dept Dev Biol, B-3000 Leuven, Belgium	KU Leuven	Swinnen, JV (corresponding author), Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Gasthuisberg O&N, Dept Dev Biol, Bus 902,Herestr 49, B-3000 Leuven, Belgium.	johan.swinnen@med.kuleuven.ac.be	Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077				Beecher GR, 2003, J NUTR, V133, p3248S; Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; Boege F, 1996, J BIOL CHEM, V271, P2262, DOI 10.1074/jbc.271.4.2262; Bosetti C, 2002, CANCER CAUSE CONTROL, V13, P465, DOI 10.1023/A:1015760004130; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Brown M D, 1999, Altern Med Rev, V4, P360; Brusselmans K, 2003, INT J CANCER, V106, P856, DOI 10.1002/ijc.11317; Bushman JL, 1998, NUTR CANCER, V31, P151, DOI 10.1080/01635589809514697; Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006-2952(01)00583-4; Challier B, 1998, EUR J EPIDEMIOL, V14, P737, DOI 10.1023/A:1007512825851; Choi JA, 2001, INT J ONCOL, V19, P837; Chowdhury AR, 2002, BIOCHEM J, V366, P653, DOI 10.1042/BJ20020098; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Schrijver E, 2003, CANCER RES, V63, P3799; Dorant E, 1996, GASTROENTEROLOGY, V110, P12, DOI 10.1053/gast.1996.v110.pm8536847; DuPont MS, 2004, EUR J CLIN NUTR, V58, P947, DOI 10.1038/sj.ejcn.1601916; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gammon MD, 1997, J NATL CANCER I, V89, P1277, DOI 10.1093/jnci/89.17.1277; GOLDFINE H, 1978, BIOCHIM BIOPHYS ACTA, V512, P229, DOI 10.1016/0005-2736(78)90249-3; Graefe EU, 2001, J CLIN PHARMACOL, V41, P492, DOI 10.1177/00912700122010366; Hollman PCH, 1996, FREE RADICAL BIO MED, V21, P703, DOI 10.1016/0891-5849(96)00129-3; Hollman PCH, 1999, FREE RADICAL RES, V31, P569, DOI 10.1080/10715769900301141; Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648; IKUTA K, 1986, VIROLOGY, V154, P195, DOI 10.1016/0042-6822(86)90441-1; Knekt P, 2002, AM J CLIN NUTR, V76, P560, DOI 10.1093/ajcn/76.3.560; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Lamson D W, 2000, Altern Med Rev, V5, P196; Le Marchand L, 2000, JNCI-J NATL CANCER I, V92, P154, DOI 10.1093/jnci/92.2.154; Li BH, 2004, J BIOCHEM, V135, P85, DOI 10.1093/jb/mvh010; Li BH, 2003, J ENZYM INHIB MED CH, V18, P349, DOI 10.1080/1475636031000118419; Mukhtar H, 2000, AM J CLIN NUTR, V71, p1698S, DOI 10.1093/ajcn/71.6.1698S; Myhrstad MCW, 2002, FREE RADICAL BIO MED, V32, P386, DOI 10.1016/S0891-5849(01)00812-7; Newmark HL, 1999, ANN NY ACAD SCI, V889, P193, DOI 10.1111/j.1749-6632.1999.tb08735.x; Olthof MR, 2000, J NUTR, V130, P1200, DOI 10.1093/jn/130.5.1200; Paul H W, 2001, Clio Med, V64, P269; Pedersen A, 2003, GUT, V52, P861, DOI 10.1136/gut.52.6.861; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Prescott E, 1999, AM J EPIDEMIOL, V149, P463, DOI 10.1093/oxfordjournals.aje.a009834; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stoneham M, 2000, J EPIDEMIOL COMMUN H, V54, P756, DOI 10.1136/jech.54.10.756; Suganuma M, 1998, CARCINOGENESIS, V19, P1771, DOI 10.1093/carcin/19.10.1771; SWANSON CA, 1993, EPIDEMIOLOGY, V4, P530, DOI 10.1097/00001648-199311000-00009; Swinnen JV, 2003, BIOCHEM BIOPH RES CO, V302, P898, DOI 10.1016/S0006-291X(03)00265-1; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Uda Y, 1997, CANCER LETT, V120, P213, DOI 10.1016/S0304-3835(97)00311-X; Van de Sande T, 2002, CANCER RES, V62, P642; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Wang X, 2003, BIOCHEM PHARMACOL, V66, P2039, DOI 10.1016/S0006-2952(03)00585-9; Waterhouse AL, 2002, ANN NY ACAD SCI, V957, P21, DOI 10.1111/j.1749-6632.2002.tb02903.x; WOHLMUTH H, BOT PATHWAYS, V10, P2; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381	59	327	354	4	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5636	5645		10.1074/jbc.M408177200	http://dx.doi.org/10.1074/jbc.M408177200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15533929	hybrid			2022-12-25	WOS:000227217100065
J	Czerwinski, EW; Midoro-Horiuti, T; White, MA; Brooks, EG; Goldblum, RM				Czerwinski, EW; Midoro-Horiuti, T; White, MA; Brooks, EG; Goldblum, RM			Crystal structure of Jun a 1, the major cedar pollen allergen from Juniperus ashei, reveals a parallel beta-helical core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PECTATE LYASE-E; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; PECTIC ENZYMES; JUN; IGE; IDENTIFICATION; MUTATIONS; PROTEINS	Pollen from cedar and cypress trees is a major cause of seasonal hypersensitivity in humans in several regions of the Northern Hemisphere. We report the first crystal structure of a cedar allergen, Jun a 1, from the pollen of the mountain cedar Juniperus ashei (Cupressaceae). The core of the structure consists primarily of a parallel beta-helix, which is nearly identical to that found in the pectin/pectate lyases from several plant pathogenic microorganisms. Four IgE epitopes mapped to the surface of the protein are accessible to the solvent. The conserved vWiDH sequence is covered by the first 30 residues of the N terminus. The potential reactive arginine, analogous to the pectin/pectate lyase reaction site, is accessible to the solvent, but the substrate binding groove is blocked by a histidine-aspartate salt bridge, a glutamine, and an alpha-helix, all of which are unique to Jun a 1. These observations suggest that steric hindrance in Jun a 1 precludes enzyme activity. The overall results suggest that it is the structure of Jun a 1 that makes it a potent allergen.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Czerwinski, EW (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Sealy Ctr Struct Biol, Galveston, TX 77555 USA.	edcz@xray.utmb.edu	White, Mark Andrew/B-1723-2012	White, Mark Andrew/0000-0003-1057-4203	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI052428] Funding Source: Medline; NICHD NIH HHS [P30 HD027841-08, P30 HD27841] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676, ES006676] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aceituno E, 2000, CLIN EXP ALLERGY, V30, P1750, DOI 10.1046/j.1365-2222.2000.00949.x; Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARRAS F, 1994, ANNU REV PHYTOPATHOL, V32, P201, DOI 10.1146/annurev.py.32.090194.001221; Boutselakis H, 2003, NUCLEIC ACIDS RES, V31, P458, DOI 10.1093/nar/gkg065; BREANDAEN CI, 1999, INTRO PROTEIN STRUCT, P84; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carpita N., 2000, BIOCH MOL BIOL PLANT, P52; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; HENRISSAT B, 1995, PLANT PHYSIOL, V107, P963, DOI 10.1104/pp.107.3.963; Herron SR, 2000, P NATL ACAD SCI USA, V97, P8762, DOI 10.1073/pnas.97.16.8762; Kita N, 1996, J BIOL CHEM, V271, P26529, DOI 10.1074/jbc.271.43.26529; Krissinel E., 2003, P 5 INT C MOL STRUCT, P88; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lietzke SE, 1996, PLANT PHYSIOL, V111, P73, DOI 10.1104/pp.111.1.73; LIETZKE SE, 1994, PLANT PHYSIOL, V106, P849, DOI 10.1104/pp.106.3.849; Liu DQ, 2003, ACTA CRYSTALLOGR D, V59, P1052, DOI 10.1107/S0907444903005778; Marin-Rodriguez MC, 2003, PLANT MOL BIOL, V51, P851, DOI 10.1023/A:1023057202847; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Midoro-Horiuti T, 1999, J ALLERGY CLIN IMMUN, V104, P613, DOI 10.1016/S0091-6749(99)70332-5; Midoro-Horiuti T, 1999, J ALLERGY CLIN IMMUN, V104, P608, DOI 10.1016/S0091-6749(99)70331-3; Midoro-Horiuti T, 2003, MOL IMMUNOL, V40, P555, DOI 10.1016/S0161-5890(03)00168-8; Midoro-Horiuti T, 2001, CLIN EXP ALLERGY, V31, P771, DOI 10.1046/j.1365-2222.2001.01079.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pilnik W., 1981, ENZYMES FOOD PROCESS, P105; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; RING CS, 1992, J MOL BIOL, V224, P685, DOI 10.1016/0022-2836(92)90553-V; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Sato K, 1997, ANN ALLERG ASTHMA IM, V79, P57, DOI 10.1016/S1081-1206(10)63085-2; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Schwietz LA, 2000, ANN ALLERG ASTHMA IM, V84, P87, DOI 10.1016/S1081-1206(10)62746-9; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; Suzuki M, 1996, MOL IMMUNOL, V33, P451, DOI 10.1016/0161-5890(95)00147-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thomas LM, 2002, ACTA CRYSTALLOGR D, V58, P1008, DOI 10.1107/S0907444902005851; Vitali J, 1998, PLANT PHYSIOL, V116, P69, DOI 10.1104/pp.116.1.69; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	43	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3740	3746		10.1074/jbc.M409655200	http://dx.doi.org/10.1074/jbc.M409655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15539389	hybrid, Green Accepted			2022-12-25	WOS:000226983900074
J	Hall, JA; Maloney, PC				Hall, JA; Maloney, PC			Altered oxyanion selectivity in mutants of UhpT, the P-i-linked sugar phosphate carrier of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE PERMEASE MUTANTS; SUBSTRATE SELECTIVITY; TRANSPORT; IDENTIFICATION; SPECIFICITY; SUPERFAMILY; MECHANISM; ANTIPORT; MALTOSE; SYSTEM	In Escherichia coli, the UhpT transporter catalyzes the electroneutral accumulation of sugar 6-phosphate by exchange with internal inorganic phosphate (P-i). The substrate specificity of UhpT is regulated at least in part by constituents of an Asp(388)-Lys(391) intrahelical salt bridge, and mutations that remove one but not both of these residues alter UhpT preference for organophosphate substrates. Using site-directed mutagenesis, we examined the role played by these two positions in the selection of the oxyanion countersubstrate. We show that derivatives having aliphatic or polar residues at positions 388 and 391 are gain-of-function mutants capable of transporting SO4 as well as P-i. These oxyanions share similar structures but differ significantly in the presence of a proton(s) on Pi. Our findings therefore lead us to suggest that the Asp(388)-Lys(391) ion pair acts normally as a filter that prevents substrates lacking a proton that can be donated from occupying the UhpT active site.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	pmaloney@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024195, R56GM024195] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Fann MC, 1998, J MEMBRANE BIOL, V164, P187, DOI 10.1007/s002329900404; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GOSWITZ VC, 1993, MEMBRANE BIOCHEM, V10, P61, DOI 10.3109/09687689309150253; Hall JA, 1999, J BIOL CHEM, V274, P6148, DOI 10.1074/jbc.274.10.6148; Hall JA, 2002, J BACTERIOL, V184, P3756, DOI 10.1128/JB.184.13.3756-3758.2002; Hall JA, 2001, J BIOL CHEM, V276, P25107, DOI 10.1074/jbc.M102017200; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KING SC, 1990, J BIOL CHEM, V265, P9638; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MALONEY PC, 1984, J BACTERIOL, V158, P238, DOI 10.1128/JB.158.1.238-245.1984; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Miller J. H., 1972, EXPT MOL GENETICS, P431; OLSEN SG, 1993, J BACTERIOL, V175, P6269, DOI 10.1128/JB.175.19.6269-6275.1993; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Quiocho FA, 1996, KIDNEY INT, V49, P943, DOI 10.1038/ki.1996.132; Rosenberg H., 1987, ION TRANSPORT PROKAR, P205; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Segel IH, 1975, ENZYME KINETICS, P210; Shimamoto T, 1996, BIOCHEM BIOPH RES CO, V226, P481, DOI 10.1006/bbrc.1996.1381; Shinnick SG, 2003, J BACTERIOL, V185, P3672, DOI 10.1128/JB.185.12.3672-3677.2003; SONNA LA, 1988, J MEMBRANE BIOL, V101, P267, DOI 10.1007/BF01872841; SONNA LA, 1988, J BIOL CHEM, V263, P6625; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987	32	6	6	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3376	3381		10.1074/jbc.M409965200	http://dx.doi.org/10.1074/jbc.M409965200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15556940	hybrid			2022-12-25	WOS:000226983900031
J	Chen, X; Dai, JC; Orellana, SA; Greenfield, EM				Chen, X; Dai, JC; Orellana, SA; Greenfield, EM			Endogenous protein kinase inhibitor gamma terminates immediate-early gene expression induced by cAMP-dependent protein kinase (PKA) signaling - Termination depends on PKA inactivation rather than PKA export from the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; C-FOS GENE; PARATHYROID-HORMONE; MAMMALIAN-CELLS; CATALYTIC SUBUNIT; PHOSPHORYLATION; STIMULATION; SYSTEM; ALPHA; DIFFERENTIATION	Expression of many genes induced by cAMP-dependent protein kinase (PKA) signaling is rapidly terminated. Although many mechanisms contribute to regulation of PKA signaling, members of the endogenous protein kinase inhibitor (PKI) family may be particularly important for terminating nuclear PKA activity and gene expression. Here we used both siRNA and antisense knockdown strategies to examine PKA signaling activated by parathyroid hormone or the beta-adrenergic agonist, isoproterenol. We found that endogenous PKIgamma is required for efficient termination of nuclear PKA activity, transcription factor phosphorylation, and immediate-early genes. Moreover, PKIgamma is required for export of PKA catalytic subunits from the nucleus back to the cytoplasm following activation of PKA signaling because this is also inhibited by PKIgamma knockdown. Leptomycin B blocks PKA nuclear export but has little or no effect on nuclear PKA activity or immediate-early gene expression. Thus, inactivation of PKA activity in the nucleus is sufficient to terminate signaling, and nuclear export is not required. These results were the first in any cell type showing that endogenous levels of PKI regulate PKA signaling.	Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Greenfield, EM (corresponding author), Case Western Reserve Univ, Dept Orthopaed, 2109 Adelbert Rd,BRB1028, Cleveland, OH 44106 USA.	emg3@po.cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064963] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK064963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Belyamani M, 2001, MOL CELL BIOL, V21, P3959, DOI 10.1128/MCB.21.12.3959-3963.2001; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chen X, 2002, AM J PHYSIOL-CELL PH, V283, pC1432, DOI 10.1152/ajpcell.00221.2002; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; de Lecea L, 1998, J NEUROSCI RES, V53, P269, DOI 10.1002/(SICI)1097-4547(19980801)53:3<269::AID-JNR1>3.0.CO;2-8; Efthymiadis A, 1998, ARCH BIOCHEM BIOPHYS, V355, P254, DOI 10.1006/abbi.1998.0719; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Evans DB, 1996, J BONE MINER RES, V11, P1066; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gangolli EA, 2000, MOL CELL BIOL, V20, P3442, DOI 10.1128/MCB.20.10.3442-3448.2000; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greenfield EM, 1996, J BIOL CHEM, V271, P10984, DOI 10.1074/jbc.271.18.10984; GREENFIELD EM, 1993, J BONE MINER RES, V8, P1163; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Harborth J, 2001, J CELL SCI, V114, P4557; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Kawakami M, 2001, DEVELOPMENT, V128, P2509; Kellenberger S, 1998, BONE, V22, P471, DOI 10.1016/S8756-3282(98)00026-X; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lum H, 2002, AM J PHYSIOL-CELL PH, V282, pC59, DOI 10.1152/ajpcell.00256.2001; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; McCauley LK, 1997, ENDOCRINOLOGY, V138, P5427, DOI 10.1210/en.138.12.5427; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Murray EJB, 1998, EXP CELL RES, V242, P460, DOI 10.1006/excr.1998.4090; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Ragab AA, 1999, J ORTHOPAED RES, V17, P803, DOI 10.1002/jor.1100170603; Seeman E, 2001, TRENDS ENDOCRIN MET, V12, P281, DOI 10.1016/S1043-2760(01)00460-X; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Takeuchi T, 2001, BIOCHEM PHARMACOL, V61, P579, DOI 10.1016/S0006-2952(00)00591-8; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Tetradis S, 1998, J BONE MINER RES, V13, P1846, DOI 10.1359/jbmr.1998.13.12.1846; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yu JQ, 2002, MOL BRAIN RES, V99, P145, DOI 10.1016/S0169-328X(02)00104-3; Zheng LH, 2000, BIOCHEM J, V349, P403, DOI 10.1042/0264-6021:3490403	52	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2700	2707		10.1074/jbc.M412558200	http://dx.doi.org/10.1074/jbc.M412558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15557275	hybrid			2022-12-25	WOS:000226449100041
J	Tsukimoto, M; Harada, H; Ikari, A; Takagi, K				Tsukimoto, M; Harada, H; Ikari, A; Takagi, K			Involvement of chloride in apoptotic cell death induced by activation of ATP-sensitive P2X(7) purinoceptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; LYMPHOCYTES; RELEASE; K+; CHANNELS; KINETICS; CLONING; ROLES; LINE	The ATP-gated P2X(7) receptor is a plasma membrane receptor belonging to the family of P2X purinoceptors. Its activation leads to multiple downstream events including influx of ions, pore formation to allow the passage of larger molecular weight species, and cell death by apoptosis and/or necrosis. The cell death is thought to be correlated with the pore formation but does not directly result from the dilatation of pores. We have generated and characterized a clone of chicken DT40 lymphocytes stably transfected with the rat P2X(7) receptor. In this study, we investigated the mechanism of P2X(7) receptor-induced cell death using this clone. Treatment with P2X(7) receptor agonist, 2'-3'-O-(4-benzoylbenzoyl)-ATP induced depolarization of membrane potential, pore formation, and cell shrinkage, an early hallmark of apoptosis in the buffer containing physiological concentrations of ions. Analysis by flow cytometry revealed that the activity of pore formation in shrunk cells was much higher than in non-shrunk cells. The activation of P2X(7) receptor also caused the release of lactate dehydrogenase from cells. The P2X(7) receptor-mediated cell shrinkage and lactate dehydrogenase release were blocked when media Cl- was replaced with gluconate. However, removal of extracellular Cl- did not affect plasma membrane depolarization and pore formation by treatment with 2'-3'-O-(4-benzoylbenzoyl)-ATP. Therefore we concluded that pore formation plays a critical role in the P2X(7) receptor-induced apoptotic cell death and that this is mediated by extracellular Cl- influx.	Univ Shizuoka, Sch Pharmaceut Sci, Dept Environm Biochem & Toxicol, Shizuoka 4228526, Japan	University of Shizuoka	Harada, H (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Environm Biochem & Toxicol, 52-1 Yada, Shizuoka 4228526, Japan.	harada@u-shizuoka-ken.ac.jp						Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Bortner CD, 2004, PFLUG ARCH EUR J PHY, V448, P313, DOI 10.1007/s00424-004-1266-5; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; Burnstock G, 2004, CURR TOP MED CHEM, V4, P793, DOI 10.2174/1568026043451014; Chessell IP, 1998, FEBS LETT, V439, P26, DOI 10.1016/S0014-5793(98)01332-5; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Chow SC, 1997, NEUROPHARMACOLOGY, V36, P1149, DOI 10.1016/S0028-3908(97)00123-8; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Di Virgilio F, 2002, LANCET, V360, P1898, DOI 10.1016/S0140-6736(02)11933-7; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; EPPS DE, 1994, CHEM PHYS LIPIDS, V69, P137, DOI 10.1016/0009-3084(94)90035-3; GARCIASOTO JJ, 1990, AM J PHYSIOL, V258, pC1108, DOI 10.1152/ajpcell.1990.258.6.C1108; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Hillman KA, 2003, BIOCHEM PHARMACOL, V66, P415, DOI 10.1016/S0006-2952(03)00286-7; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Kahlenberg JM, 2004, AM J PHYSIOL-CELL PH, V286, pC1100, DOI 10.1152/ajpcell.00494.2003; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lundy PM, 2004, EUR J PHARMACOL, V487, P17, DOI 10.1016/j.ejphar.2004.01.010; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Okada Y, 2004, PFLUG ARCH EUR J PHY, V448, P287, DOI 10.1007/s00424-004-1276-3; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Pilas B, 1997, CYTOMETRY, V28, P316, DOI 10.1002/(SICI)1097-0320(19970801)28:4<316::AID-CYTO7>3.3.CO;2-J; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Remillard CV, 2004, AM J PHYSIOL-LUNG C, V286, pL49, DOI 10.1152/ajplung.00041.2003; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Sluyter R, 2001, CELL TISSUE RES, V304, P231, DOI 10.1007/s004410100372; Solini A, 1999, J CELL SCI, V112, P297; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Thompson GJ, 2001, BIOCHEM J, V357, P137, DOI 10.1042/0264-6021:3570137; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; Wang CM, 2002, GLIA, V37, P8, DOI 10.1002/glia.10004; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yasuda Tomoharu, 2004, Methods Mol Biol, V271, P261	39	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2653	2658		10.1074/jbc.M411072200	http://dx.doi.org/10.1074/jbc.M411072200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15550367	hybrid			2022-12-25	WOS:000226449100035
J	Briaud, I; Dickson, LM; Lingohr, MK; McCuaig, JF; Lawrence, JC; Rhodes, CJ				Briaud, I; Dickson, LM; Lingohr, MK; McCuaig, JF; Lawrence, JC; Rhodes, CJ			Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SERINE/THREONINE PHOSPHORYLATION; DIFFERENTIAL ACTIVATION; PSAMMOMYS-OBESUS; UP-REGULATION; FATTY-ACIDS; GLUCOSE; APOPTOSIS; GROWTH; RESISTANCE	Regulation of insulin receptor substrate (IRS)-2 expression is critical to beta-cell survival, but the mechanisms that control this are complex and undefined. Here in pancreatic beta-cells (INS-1), chronic exposure (> 8 h) to 15 mM glucose and/or 5 nM IGF-1, increased Ser/Thr phosphorylation of IRS-2, which correlated with decreased IRS-2 levels. This glucose/IGF-1-induced decrease in IRS-2 levels was prevented by the proteasomal inhibitor, lactacystin. In addition, the glucose/IGF-1-induced increase in Ser/Thr phosphorylation of IRS-2 and the subsequent decrease in INS-1 cell IRS-2 protein levels was thwarted by the mammalian target of rapamycin( mTOR) inhibitor, rapamycin. Moreover, adenoviral-mediated expression of constitutively active mTOR (mTORDelta) further increased glucose/IGF-1-induced Ser/Thr phosphorylation of IRS-2 and decreased IRS-2 protein levels, whereas adenoviral-mediated expression of "kinase-dead" mTOR (mTOR-KD) conversely reduced Ser/Thr phosphorylation of IRS-2 and maintained IRS-2 protein levels. In adenoviral-infected beta-cells expressing mTORDelta, the decrease in IRS-2 protein levels was also prevented by rapamycin or lactacystin, further indicating a proteasomal mediated degradation of IRS-2 mediated via mTOR-induced Ser/Thr phosphorylation of IRS-2. Finally, we found that chronic activation of mTOR leading to decreased levels of IRS-2 in INS-1 cells led to a significant decrease in PKB activation and consequently increased beta-cell apoptosis. Thus, chronic activation of mTOR by glucose (and/or IGF-1) in beta-cells leads to increased Ser/Thr phosphorylation of IRS-2 that targets it for proteasomal degradation, resulting in decreased IRS-2 expression and increased beta-cell apoptosis. This may be a contributing mechanism as to how beta-cell mass is decreased by chronic hyperglycemia in the pathogenesis of type-2 diabetes.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA; Univ Virginia, Sch Med, Dept Med & Pharmacol, Charlottesville, VA 22908 USA	University of Washington; University of Washington Seattle; University of Virginia	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	cjr@pnri.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK060266, R01DK052753] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-60266, DK-55269, DK-52753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; Cousin SP, 2001, ENDOCRINOLOGY, V142, P229, DOI 10.1210/en.142.1.229; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Dickson LM, 2004, AM J PHYSIOL-ENDOC M, V287, pE192, DOI 10.1152/ajpendo.00031.2004; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harris TE, 2003, SCI STKE, V2003, pr; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Ikeda Y, 2001, DIABETES, V50, P584, DOI 10.2337/diabetes.50.3.584; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V209, P17, DOI 10.1016/j.mce.2003.08.003; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V204, P85, DOI 10.1016/S0303-7207(03)00124-2; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Lingohr MK, 2002, TRENDS MOL MED, V8, P375, DOI 10.1016/S1471-4914(02)02377-8; Maedler K, 2003, DIABETES, V52, P726, DOI 10.2337/diabetes.52.3.726; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; McDaniel ML, 2002, DIABETES, V51, P2877, DOI 10.2337/diabetes.51.10.2877; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Sekulic A, 2000, CANCER RES, V60, P3504; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200; Xu G, 2001, DIABETES, V50, P353, DOI 10.2337/diabetes.50.2.353; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	59	116	124	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2282	2293		10.1074/jbc.M412179200	http://dx.doi.org/10.1074/jbc.M412179200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537654	hybrid			2022-12-25	WOS:000226341700065
J	Voronina, SG; Gryshchenko, OV; Gerasimenko, OV; Green, AK; Petersen, OH; Tepikin, AV				Voronina, SG; Gryshchenko, OV; Gerasimenko, OV; Green, AK; Petersen, OH; Tepikin, AV			Bile acids induce a cationic current, depolarizing pancreatic acinar cells and increasing the intracellular Na+ concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-REGULATORY MECHANISMS; CALCIUM SIGNALS; DUCT; CHANNELS; ACTIVATION; SECRETION; SALTS; CA2+; H+	Biliary disease is a major cause of acute pancreatitis. In this study we investigated the electrophysiological effects of bile acids on pancreatic acinar cells. In perforated patch clamp experiments we found that taurolithocholic acid 3-sulfate depolarized pancreatic acinar cells. At low bile acid concentrations this occurred without rise in the cytosolic calcium concentration. Measurements of the intracellular Na+ concentration with the fluorescent probe Sodium Green revealed a substantial increase upon application of the bile acid. We found that bile acids induce Ca2+-dependent and Ca2+-independent components of the Na+ concentration increase. The Ca2+-independent component was resolved in conditions when the cytosolic Ca2+ level was buffered with a high concentration of the calcium chelator 1,2- bis(o-aminophenoxy) ethane-N, N, N', N'-tetraacetic acid (BAPTA). The Ca2+-dependent component of intracellular Na+ increase was clearly seen during stimulation with the calcium-releasing agonist acetylcholine. During acetylcholine-induced Ca2+ oscillations the recovery of cytosolic Na+ was much slower than the recovery of Ca2+, creating a possibility for the summation of Na+ transients. The bile-induced Ca2+-independent current was found to be carried primarily by Na+ and K+, with only small Ca2+ and Cl- contributions. Measurable activation of such a cationic current could be produced by a very low concentration of taurolithocholic acid 3-sulfate (10 muM). This bile acid induced a cationic current even when applied in sodium- and bicarbonate-free solution. Other bile acids, taurochenodeoxycholic acid, taurocholic acid, and bile itself also induced cationic currents. Bile-induced depolarization of acinar cells should have a profound effect on acinar fluid secretion and, consequently, on transport of secreted zymogens.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Tepikin, AV (corresponding author), Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England.	a.tepikin@liv.ac.uk	Gerasimenko, Oleg/A-6622-2010; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Tepikin, Alexei/0000-0002-8172-7513; Petersen, Ole/0000-0002-6998-0380				ARMSTRONG CP, 1987, DIGEST DIS SCI, V32, P861, DOI 10.1007/BF01296710; Blackstone M, 2003, GASTROENTEROLOGY, V124, P863, DOI 10.1053/gast.2003.50126; Brown DA, 2003, AM J PHYSIOL-GASTR L, V285, pG804, DOI 10.1152/ajpgi.00150.2003; COWEN AE, 1977, J LIPID RES, V18, P698; COWEN AE, 1975, GASTROENTEROLOGY, V69, P67; DEVOR DC, 1993, J CLIN INVEST, V92, P2173, DOI 10.1172/JCI116819; FARMER RC, 1984, DIGEST DIS SCI, V29, P740, DOI 10.1007/BF01312948; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; Hofmann A F, 1976, Adv Intern Med, V21, P501; IWATSUKI N, 1980, PFLUG ARCH EUR J PHY, V386, P153, DOI 10.1007/BF00584203; IWATSUKI N, 1977, NATURE, V268, P147, DOI 10.1038/268147a0; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kidd JF, 2001, PFLUG ARCH EUR J PHY, V441, P489, DOI 10.1007/s004240000451; Kim JY, 2002, GASTROENTEROLOGY, V122, P1941, DOI 10.1053/gast.2002.33617; Kim JY, 2003, GASTROENTEROLOGY, V124, P864, DOI 10.1053/gast.2003.50127; KUIPERS F, 1985, SCAND J GASTROENTERO, V20, P1255, DOI 10.3109/00365528509089286; LERCH MM, 1993, GASTROENTEROLOGY, V104, P853, DOI 10.1016/0016-5085(93)91022-A; LIDOFSKY SD, 1993, AM J PHYSIOL, V264, pG478, DOI 10.1152/ajpgi.1993.264.3.G478; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MATTHEWS EK, 1973, J PHYSIOL-LONDON, V231, P283, DOI 10.1113/jphysiol.1973.sp010233; Mauricio AC, 1999, EXP PHYSIOL, V84, P489; Mauricio AC, 2000, PFLUG ARCH EUR J PHY, V439, P532, DOI 10.1007/s004240050974; MOODY FG, 1993, GASTROENTEROLOGY, V104, P927, DOI 10.1016/0016-5085(93)91034-F; MUALLEM S, 1990, J BIOL CHEM, V265, P12813; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; Opie EL, 1901, B JOHNS HOPKINS HOSP, V12, P182; Park MK, 2004, CELL CALCIUM, V35, P367, DOI 10.1016/j.ceca.2003.10.003; Park MK, 2001, P NATL ACAD SCI USA, V98, P10948, DOI 10.1073/pnas.181353798; PETERSEN OH, 1973, PROC R SOC SER B-BIO, V184, P115, DOI 10.1098/rspb.1973.0037; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; REBER HA, 1980, BRIT J SURG, V67, P59, DOI 10.1002/bjs.1800670119; Thorn P, 1993, EXS, V66, P185; Voronina S, 2002, J PHYSIOL-LONDON, V540, P49, DOI 10.1113/jphysiol.2002.017525; Voronina SG, 2004, J BIOL CHEM, V279, P27327, DOI 10.1074/jbc.M311698200; Weinman SA, 1998, J BIOL CHEM, V273, P34691, DOI 10.1074/jbc.273.52.34691	35	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1764	1770		10.1074/jbc.M410230200	http://dx.doi.org/10.1074/jbc.M410230200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15536077	hybrid			2022-12-25	WOS:000226341700009
J	Nagata, E; Luo, HBR; Saiardi, A; Bae, BI; Suzuki, N; Snyder, SH				Nagata, E; Luo, HBR; Saiardi, A; Bae, BI; Suzuki, N; Snyder, SH			Inositol hexakisphosphate kinase-2, a physiologic mediator of cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CARCINOMA CELLS; PROTEIN; PYROPHOSPHATES; PATHWAY; BAX; POLYPHOSPHATES; MITOCHONDRIA; APOPTOSIS; CYTOSOL; FAMILY	Diphosphoinositol pentakisphosphate (InsP7) and bis-diphosphoinositol tetrakisphosphate contain pyrophosphate bonds. InsP7 is formed from inositol hexakisphosphate (InsP6) by a family of three inositol hexakisphosphate kinases (InsP6K). In this study we establish one of the InsP6Ks, InsP6K2, as a physiologic mediator of cell death. Overexpression of wild-type InsP6K2 augments the cytotoxic actions of multiple cell stressors in diverse cell lines, whereas transfection with a dominant negative InsP6K2 decreases cell death. During cell death, InsP6 kinase activity is enhanced, and intracellular InsP7 level is augmented. Deletion of InsP6K2 but not the other forms of InsP6K diminishes cell death, suggesting that InsP6K2 is the major InsP6 kinase involved in cell death. Cytotoxicity is associated with a translocation of InsP6K2 from nuclei to mitochondria, whereas the intracellular localization of the other isoforms of the enzyme does not change. The present study provides compelling evidence that endogenous InsP6K2, by generating InsP7, provides physiologic regulation of the apoptotic process.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Keio Univ, Sch Med, Dept Neurol, Shinjuku Ku, Tokyo 1608582, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Keio University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	ssnyder@bs.jhmi.edu	Suzuki, Norihiro/J-5125-2013	Suzuki, Norihiro/0000-0002-0399-6590; BAE, BYOUNG-IL/0000-0002-9958-678X	NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantrell DA, 2001, J CELL SCI, V114, P1439; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; HUANG KN, 1995, GENETICS, V141, P1275; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100; Luo HR, 2001, NEURON, V31, P439, DOI 10.1016/S0896-6273(01)00384-1; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	28	97	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1634	1640		10.1074/jbc.M409416200	http://dx.doi.org/10.1074/jbc.M409416200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15533939	hybrid			2022-12-25	WOS:000226195200094
J	Nakamaru-Ogiso, E; Yano, T; Yagi, T; Ohnishi, T				Nakamaru-Ogiso, E; Yano, T; Yagi, T; Ohnishi, T			Characterization of the iron-sulfur cluster N7 (N1c) in the subunit NuoG of the proton-translocating NADH-quinone oxidoreductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS HB-8; DEHYDROGENASE COMPLEX-I; UBIQUINONE OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; FORMATE DEHYDROGENASE; PERIPHERAL SUBUNITS; RESPIRATORY-CHAIN; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; NQO2 SUBUNIT	The proton-pumping NADH-quinone oxidoreductase from Escherichia coli houses nine iron-sulfur clusters, eight of which are found in its mitochondrial counterpart, complex I. The extra putative iron-sulfur cluster binding site with a CXXCXXXCX27C motif in the NuoG subunit has been assigned to ligate a [2Fe-2S] (N1c). However, we have shown previously that the Thermus thermophilus N1c fragment containing this motif ligates a [4Fe-4S] (Nakamaru-Ogiso, E., Yano, T., Ohnishi, T., and Yagi, T. (2002) J. Biol. Chem. 277, 1680-1688). In the current study, we individually inactivated four sets of the iron-sulfur binding motifs in the E. coli NuoG subunit by replacing all four ligands with Ala. Each mutant subunit, designated DeltaN1b, DeltaN1c, DeltaN4, and DeltaN5, was expressed as maltose-binding protein fusion proteins. After in vitro reconstitution, all mutant subunits were characterized by EPR. Although EPR signals from cluster N1b were not detected in any preparations, we detected two [4Fe-4S] EPR signals with g values of g(x,y,z) = 1.89, 1.94, and 2.06, and g(x,y,z) = 1.91, 1.94, and 2.05 at 6-20 K in wild type, DeltaN1b, and DeltaN5. The former signal was assigned to cluster N4, and the latter signal was assigned to cluster N1c because of their disappearance in DeltaN4 and DeltaN1c. Confirming that a [4Fe-4S] cluster ligates to the N1c motif, we propose to replace its misleading [2Fe-2S] name, N1c, with "cluster N7." In addition, because these mutations differently affected the assembly of peripheral subunits by in trans complementation analysis with the nuoG knock-out strain, the implicated structural importance of the iron-sulfur binding domains is discussed.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA; Fukuoka Prefectural Univ, Fac Nursing, Dept Expt Nursing, Fukuoka 8258585, Japan	Scripps Research Institute; University of Pennsylvania	Yagi, T (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	yagi@scripps.edu; ohnishi@mail.med.upenn.edu			NIGMS NIH HHS [R01GM30736, R01GM33712] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712, R01GM030736] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, BIOCHIM BIOPHYS ACTA, V391, P259, DOI 10.1016/0005-2744(75)90249-1; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Butler CS, 1999, BIOCHEMISTRY-US, V38, P9000, DOI 10.1021/bi990402n; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; DOEG KA, 1962, ARCH BIOCHEM BIOPHYS, V97, P37, DOI 10.1016/0003-9861(62)90041-3; Dupuis A, 1998, BBA-BIOENERGETICS, V1364, P147, DOI 10.1016/S0005-2728(98)00025-5; Falk-Krzesinski HJ, 1998, J BACTERIOL, V180, P1174, DOI 10.1128/JB.180.5.1174-1184.1998; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; Kao MC, 2004, BIOCHEMISTRY-US, V43, P3750, DOI 10.1021/bi049927s; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURPHY E, 1985, EMBO J, V4, P3357, DOI 10.1002/j.1460-2075.1985.tb04089.x; Nakamaru-Ogiso E, 2002, J BIOL CHEM, V277, P1680, DOI 10.1074/jbc.M108796200; Oh JI, 1998, J BIOL CHEM, V273, P26349, DOI 10.1074/jbc.273.41.26349; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; YAMAGUCHI M, 1993, BIOCHEMISTRY-US, V32, P1935, DOI 10.1021/bi00059a008; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; Yano T, 1999, J BIOL CHEM, V274, P28606, DOI 10.1074/jbc.274.40.28606; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; Yano T, 2003, J BIOL CHEM, V278, P15514, DOI 10.1074/jbc.M212275200; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014; Yano T, 2002, MOL ASPECTS MED, V23, P345, DOI 10.1016/S0098-2997(02)00011-0; Zu YB, 2002, BIOCHEMISTRY-US, V41, P10056, DOI 10.1021/bi026026f	46	47	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					301	307		10.1074/jbc.M410377200	http://dx.doi.org/10.1074/jbc.M410377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15520003	hybrid			2022-12-25	WOS:000226025100037
J	Klopfer, A; Hasenjager, A; Belka, C; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Klopfer, A; Hasenjager, A; Belka, C; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway	ONCOGENE			English	Article						2CdA; FAraA; apoptosis; FADD; CD95/Fas; caspase-8; Bcl-2	DRUG-RESISTANCE; LEUKEMIA-CELLS; WILD-TYPE; BCL-2; CASPASE; LIGAND; DNA; SENSITIVITY; DOXORUBICIN; RADIATION	The adenine deoxynucleosides cladribine (2CdA) and fludarabine (FAraA) are DNA-damaging agents that interfere with DNA repair and induce apoptosis in nonproliferating lymphoid cells. Although both drugs are clinically used for the treatment of indolent lymphoproliferative diseases, the pathways of apoptosis induction remain largely unknown. In the present work, we demonstrate that both drugs induce apoptosis independently of death receptor signaling but activate the mitochondrial cell death pathway. To dissect the signaling pathways, we employed Jurkat cells either deficient for FADD or caspase-8 or overexpressing Bcl-2. In Bcl-2 overexpressing cells, apoptosis and cytochrome c release were blocked whereas processing of caspase-9, -3 and -8 was partially inhibited. In contrast, neither the deficiency of FADD or caspase-8 nor the interference with death receptor signaling by neutralizing anti-CD95/Fas antibodies affected cell death. Inhibitor experiments revealed that caspase-8 is processed by caspase-3- like caspases. Moreover, cytochrome c release and processing of caspase-9 and - 3 occurred to an equal extent in wild-type FADD -/- and caspase-8 -/- Jurkat cells. Likewise, apoptosis induction by cladribine or fludarabine was not hampered upon inhibition of caspase-8 in MOLT-3 and MOLT-4 cells or overexpression of a dominant-negative FADD mutant in BJAB cells. Thus, we conclude that apoptosis induced by nucleoside analogues is independent from death receptor signaling as well as from a proposed direct effect on APAF-1, but rather follows the mitochondrial signaling pathway of cytochrome c release and subsequent processing of caspase-9 and -3.	Humboldt Univ, Univ Med Ctr Charite, Dpet Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Med Sch, Dept Radiat Oncol, Tubingen, Germany; Univ Med Sch, Inst Mol Med, Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dpet Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bosanquet AG, 1996, BLOOD, V87, P1962; Bosanquet AG, 1999, BRIT J HAEMATOL, V106, P71, DOI 10.1046/j.1365-2141.1999.01516.x; BROMIDGE TJ, 1995, CYTOMETRY, V20, P257, DOI 10.1002/cyto.990200309; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DHEIN J, 1992, J IMMUNOL, V149, P3166; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Huang P, 1995, CLIN CANCER RES, V1, P1005; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marzo I, 2001, BIOCHEM J, V359, P537, DOI 10.1042/0264-6021:3590537; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	29	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9408	9418		10.1038/sj.onc.1207975	http://dx.doi.org/10.1038/sj.onc.1207975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516989				2022-12-25	WOS:000225764100012
J	del Rincon, SV; Guo, Q; Morelli, C; Shiu, HY; Surmacz, E; Miller, WH				del Rincon, SV; Guo, Q; Morelli, C; Shiu, HY; Surmacz, E; Miller, WH			Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism	ONCOGENE			English	Article						retinoic acid; IRS-1; ubiquitin; PKC; breast cancer	INSULIN-RECEPTOR SUBSTRATE-1; BREAST-CANCER CELLS; PROTEIN-KINASE-C; ACUTE PROMYELOCYTIC LEUKEMIA; BRONCHIAL EPITHELIAL-CELLS; GROWTH-FACTOR; CYCLIN D1; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; 3T3-L1 ADIPOCYTES	Insulin receptor substrate-1 (IRS-1) mediates signaling from the insulin-like growth factor type-I receptor. We found that all-trans retinoic acid ( RA) decreases IRS-1 protein levels in MCF-7, T47-D, and ZR75.1 breast cancer cells, which are growth arrested by RA, but not in the RA-resistant MDA-MB-231 and MDA-MB-468 cells. Based on prior reports of ubiquitin-mediated degradation of IRS-1, we investigated the ubiquitination of IRS-1 in RA-treated breast cancer cells. Two proteasome inhibitors, MG-132 and lactacystin, blocked the RA-mediated degradation of IRS-1, and RA increased ubiquitination of IRS-1 in the RA-sensitive breast cancer cells. In addition, we found that RA increases serine phosphorylation of IRS-1. To elucidate the signaling pathway responsible for this phosphorylation event, pharmacologic inhibitors were used. Two PKC inhibitors, but not a MAPK inhibitor, blocked the RA-induced degradation and serine phosphorylation of IRS-1. We demonstrate that RA activates PKC-delta in the sensitive, but not in the resistant cells, with a time course that is consistent with the RA-induced decrease of IRS-1. We also show that: ( 1) RA-activated PKC-delta phosphorylates IRS-1 in vitro, ( 2) PKC-delta and IRS-1 interact in RA-treated cells, and ( 3) mutation of three PKC-delta serine sites in IRS-1 to alanines results in no RA-induced in vitro phosphorylation of IRS-1. Together, these results indicate that RA regulates IRS-1 levels by the ubiquitin - proteasome pathway, involving a PKC-sensitive mechanism.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Calabria, Postgrad Sch Clin Pathol, I-87036 Cosenza, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Lady Davis Institute; McGill University; McGill University; McGill University; University of Calabria; Jefferson University	Miller, WH (corresponding author), Lady Davis Inst, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	wmiller@ldi.jgh.mcgill.ca	Morelli, Catia/AAE-1886-2019	Morelli, Catia/0000-0002-9407-0805				Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Boylan JM, 2002, ENDOCRINOLOGY, V143, P4178, DOI 10.1210/en.2002-220321; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Brouillard F, 2003, J BIOL CHEM, V278, P39509, DOI 10.1074/jbc.M307123200; Buren J, 2002, EUR J ENDOCRINOL, V146, P419, DOI 10.1530/eje.0.1460419; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chan TW, 2001, CLIN CANCER RES, V7, P2545; Chang Q, 2002, CANCER RES, V62, P6035; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Gonzalez C, 2001, JOP, V2, P140; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hirashima Y, 2003, J ENDOCRINOL, V179, P253, DOI 10.1677/joe.0.1790253; Huang XD, 2002, J CLIN ENDOCR METAB, V87, P255, DOI 10.1210/jc.87.1.255; Ito T, 1996, MOL CELL BIOL, V16, P943; IWAO K, 1999, NUCL ACIDS S SER, V42, P207; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kim HJ, 2004, CANCER RES, V64, P2439, DOI 10.1158/0008-5472.CAN-03-2643; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lindahl T, 2004, CARCINOGENESIS, V25, P375, DOI 10.1093/carcin/bgh019; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Rosenauer A, 1998, CANCER RES, V58, P5110; Salerno M, 1999, INT J CANCER, V81, P299; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SMITH LK, 1993, BIOCHEM BIOPH RES CO, V196, P767, DOI 10.1006/bbrc.1993.2315; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Yoshida H, 1996, CANCER RES, V56, P2945; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200	55	51	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9269	9279		10.1038/sj.onc.1208104	http://dx.doi.org/10.1038/sj.onc.1208104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516986				2022-12-25	WOS:000225638000012
J	Lauth, X; Babon, JJ; Stannard, JA; Singh, S; Nizet, V; Carlberg, JM; Ostland, VE; Pennington, MW; Norton, RS; Westerman, ME				Lauth, X; Babon, JJ; Stannard, JA; Singh, S; Nizet, V; Carlberg, JM; Ostland, VE; Pennington, MW; Norton, RS; Westerman, ME			Bass hepcidin synthesis, solution structure, antimicrobial activities and synergism, and in vivo hepatic response to bacterial infections	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE ANTIBIOTICS; HEREDITARY HEMOCHROMATOSIS; ACTIVE-SITE; JUVENILE HEMOCHROMATOSIS; METHANOL DEHYDROGENASE; DISULFIDE BRIDGE; SELF-ASSOCIATION; GENE-EXPRESSION; CHRONIC DISEASE; IRON OVERLOAD	Bass hepcidin was purified from the gill of hybrid striped bass ( Morone chrysops x Morone saxatilis) based on antimicrobial activity against Escherichia coli. This 21-amino acid peptide has 8 cysteines engaged in 4 disulfide bonds and is very similar to human hepcidin, an antimicrobial peptide with iron regulatory properties. To gain insight into potential role(s) of bass hepcidin in innate immunity in fish, we synthesized the peptide, characterized its antimicrobial activities in vitro, determined its solution structure by NMR, and quantified hepatic gene expression in vivo following infection of bass with the fish pathogens, Streptococcus iniae or Aeromonas salmonicida. Its structure is very similar to that of human hepcidin, including the presence of an antiparallel beta-sheet, a conserved disulfide-bonding pattern, and a rare vicinal disulfide bond. Synthetic bass hepcidin was active in vitro against Gram- negative pathogens and fungi but showed no activity against key Gram- positive pathogens and a single yeast strain tested. Hepcidin was non-hemolytic at microbicidal concentrations and had lower specific activity than moronecidin, a broad spectrum, amphipathic, alpha-helical, antimicrobial peptide constitutively expressed in bass gill tissue. Good synergism between the bacterial killing activities of hepcidin and moronecidin was observed in vitro. Hepcidin gene expression in bass liver increased significantly within hours of infection with Gram- positive ( S. iniae) or Gram- negative ( A. salmonicida) pathogens and was 4 - 5 orders of magnitude above base-line 24-48 h post-infection. Our results suggest that hepcidin plays a key role in the antimicrobial defenses of bass and that its functions are potentially conserved between fish and human.	Kent SeaTech Corp, San Diego, CA 92121 USA; BACHEM Biosci Inc, King Of Prussia, PA 19406 USA; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA	Walter & Eliza Hall Institute; University of California System; University of California San Diego	Westerman, ME (corresponding author), Kent SeaTech Corp, 11125 Flintkote Ave,Ste J, San Diego, CA 92121 USA.	mwesterman@kentseatech.com	Nizet, Victor/AAF-3190-2019; babon, jeffrey j/B-9170-2013	babon, jeffrey j/0000-0002-5408-6239; Norton, Raymond/0000-0001-8893-0584; Nizet, Victor/0000-0003-3847-0422; pennington, michael/0000-0001-5446-3447				Amsterdam D, 1996, ANTIBIOTICS LAB MED, V4, P52; Anderson GJ, 2002, BIOCHEM SOC T, V30, P724, DOI 10.1042/bst0300724; Ashrafian H, 2003, INFECT IMMUN, V71, P6693, DOI 10.1128/IAI.71.12.6693-6700.2003; Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; Barnham KJ, 1997, BIOCHEMISTRY-US, V36, P5970, DOI 10.1021/bi9629945; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bengoechea JA, 2000, MOL MICROBIOL, V37, P67, DOI 10.1046/j.1365-2958.2000.01956.x; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; BORRIELLO F, 1995, BIOTECHNIQUES, V19, P580; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; Carugo O, 2003, PROTEIN ENG, V16, P637, DOI 10.1093/protein/gzg088; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; Chen MF, 2000, DIS AQUAT ORGAN, V43, P117, DOI 10.3354/dao043117; CONGLETON JL, 1991, COMP BIOCHEM PHYS A, V98, P195, DOI 10.1016/0300-9629(91)90519-I; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delatycki MB, 2004, CLIN GENET, V65, P378, DOI 10.1111/j.0009-9163.2004.00254.x; DINGLEY AJ, 1995, J BIOMOL NMR, V6, P321; Engst S, 1999, BIOCHEMISTRY-US, V38, P3519, DOI 10.1021/bi982680c; Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Ganz T, 2002, ISRAEL MED ASSOC J, V4, P1043; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hetru C, 1997, Methods Mol Biol, V78, P35; Hunter HN, 2002, J BIOL CHEM, V277, P37597, DOI 10.1074/jbc.M205305200; Hwang PM, 1998, BIOCHEMISTRY-US, V37, P4288, DOI 10.1021/bi972323m; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Laederach A, 2002, BIOCHEMISTRY-US, V41, P12359, DOI 10.1021/bi026185z; Langston AL, 2001, FISH SHELLFISH IMMUN, V11, P333, DOI 10.1006/fsim.2000.0319; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lauth X, 2002, J BIOL CHEM, V277, P5030, DOI 10.1074/jbc.M109173200; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Mandard N, 1998, EUR J BIOCHEM, V256, P404, DOI 10.1046/j.1432-1327.1998.2560404.x; Mandard N, 2002, EUR J BIOCHEM, V269, P1190, DOI 10.1046/j.0014-2956.2002.02760.x; MOR A, 1994, J BIOL CHEM, V269, P31635; Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Patrzykat A, 2001, ANTIMICROB AGENTS CH, V45, P1337, DOI 10.1128/AAC.45.5.1337-1342.2001; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Powers JPS, 2003, PEPTIDES, V24, P1681, DOI 10.1016/j.peptides.2003.08.023; RIVIER J, 1983, J CHROMATOGR, V268, P112, DOI 10.1016/S0021-9673(01)95395-6; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; Saint N, 2002, BBA-BIOMEMBRANES, V1564, P359, DOI 10.1016/S0005-2736(02)00470-4; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Shike H, 2002, EUR J BIOCHEM, V269, P2232, DOI 10.1046/j.1432-1033.2002.02881.x; Silphaduang U, 2001, NATURE, V414, P268, DOI 10.1038/35104690; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tossi A, 2000, BIOPOLYMERS, V55, P4; Trabi M, 2001, BIOCHEMISTRY-US, V40, P4211, DOI 10.1021/bi002028t; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Xia ZX, 1999, BIOCHEMISTRY-US, V38, P1214, DOI 10.1021/bi9822574; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001; Yao SG, 2000, J BIOMOL NMR, V16, P109, DOI 10.1023/A:1008382624724; Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000	69	163	185	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9272	9282		10.1074/jbc.M411154200	http://dx.doi.org/10.1074/jbc.M411154200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15546886	hybrid			2022-12-25	WOS:000227453100078
J	Leppanen, A; Stowell, S; Blixt, O; Cummings, RD				Leppanen, A; Stowell, S; Blixt, O; Cummings, RD			Dimeric galectin-1 binds with high affinity to alpha 2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL DEATH; SELECTIN GLYCOPROTEIN LIGAND-1; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; NORMAL HUMAN-LEUKOCYTES; HAMSTER OVARY CELLS; BOVINE HEART-MUSCLE; LEUKEMIA HL60 CELLS; S-TYPE LECTIN; P-SELECTIN; O-GLYCANS	Galectin-1 is a member of the galectin family of glycan-binding proteins and occurs as an similar to29.5-kDa noncovalent homodimer (dGal-1) that is widely expressed in many tissues. Here, we report that human recombinant dGal-1 bound preferentially and with high affinity (apparent K-d similar to 2-4 mum) to immobilized extended glycans containing terminal N-acetyllactosamine (LN; Galbeta1-4GlcNAc) sequences on poly-N-acetyllactosamine (PL; (-3Galbeta1-4GlcNAcbeta1-)(n)) sequences, complex-type bi-antennary N-glycans, or novel chitin-derived glycans modified to contain terminal LN. Although terminal Gal residues are important for dGal-1 recognition, dGal-1 bound similarly to alpha3-sialylated and alpha2-fucosylated terminal LN, but not to alpha6-sialylated and alpha3-fucosylated terminal LN. The binding specificity of human recombinant dGal-1 was similar to that observed with purified bovine heart-derived dGal-1. Unexpectedly, dGal-1 bound free ligands in solution with relatively low affinity and displayed no preference for extended glycans, indicating that dGal-1 preferentially recognizes extended glycans only when they are surface-bound, such as found on cell surfaces. Human dGal-l also bound to both native and desialylated human promyelocytic HL-60 cells with similar affinity as observed for immobilized long chain PL. Binding to these cells was reduced upon treatment with endo-beta-galactosidase, which cleaves PL sequences, indicating that cell-surface PLs are ligands. To test the role of dimerization in dGal-1 binding, we examined the binding of a mutated form of dGal-1 that weakly dimerizes (monomeric Gal-1 (mGal-1)) and a covalently dimerized (chemically cross-linked) form of mGal-1 (cd-mGal-1). dGal-1 and cd-mGal-1 had similar affinities that were both similar to3.5-fold higher for immobilized PL than observed for mGal-1, suggesting that dGal-1 acts as a dimer to cross-link terminal LN units on immobilized PL. These results indicate that dGal-1 functions as a dimer to recognize LN units on extended PLs on cell surfaces.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Scripps Res Inst, Dept Mol Biol, Consortium Funct Glycom, La Jolla, CA 92037 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Scripps Research Institute	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, BRC417,975 NE 10th St, Oklahoma City, OK 73104 USA.	richard-cummings@ouhsc.edu		Blixt, Ola/0000-0003-4143-6276	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48075] Funding Source: Medline; NIGMS NIH HHS [GM62116] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; Ackers G K, 1973, Methods Enzymol, V27, P441; Aeed PA, 2001, CELL RES, V11, P28, DOI 10.1038/sj.cr.7290063; Ahmad N, 2004, GLYCOBIOLOGY, V14, P817, DOI 10.1093/glycob/cwh095; Amano M, 2003, J BIOL CHEM, V278, P7469, DOI 10.1074/jbc.M209595200; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Battig P, 2004, MOL IMMUNOL, V41, P9, DOI 10.1016/j.molimm.2004.02.004; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Blixt O, 2001, J ORG CHEM, V66, P2442, DOI 10.1021/jo0057809; BOURNE Y, 1994, J MOL BIOL, V235, P787, DOI 10.1006/jmbi.1994.1034; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; Brewer CF, 2002, BBA-GEN SUBJECTS, V1572, P255, DOI 10.1016/S0304-4165(02)00312-4; BRILES EB, 1979, J CELL BIOL, V81, P528, DOI 10.1083/jcb.81.3.528; Carlow DA, 2003, J IMMUNOL, V171, P5100, DOI 10.4049/jimmunol.171.10.5100; Cho M, 1996, BIOCHEMISTRY-US, V35, P13081, DOI 10.1021/bi961181d; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Colnot C, 1996, BIOCHEM SOC T, V24, P141, DOI 10.1042/bst0240141; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DEWAARD A, 1976, J BIOL CHEM, V251, P7581; Di Virgilio S, 1999, GLYCOBIOLOGY, V9, P353, DOI 10.1093/glycob/9.4.353; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0; Gabius HJ, 2002, ANTICANCER RES, V22, P405; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; Gauthier L, 2002, P NATL ACAD SCI USA, V99, P13014, DOI 10.1073/pnas.202323999; Giudicelli V, 1997, GLYCOBIOLOGY, V7, pR8; GU MJ, 1994, J CELL SCI, V107, P175; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ITO M, 1986, J BIOCHEM-TOKYO, V100, P773, DOI 10.1093/oxfordjournals.jbchem.a121770; La M, 2003, AM J PATHOL, V163, P1505, DOI 10.1016/S0002-9440(10)63507-9; LEE N, 1990, J BIOL CHEM, V265, P20476; LEFFLER H, 1986, J BIOL CHEM, V261, P119; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Leppanen A, 2003, J BIOL CHEM, V278, P26391, DOI 10.1074/jbc.M303551200; Leppanen A, 2002, J BIOL CHEM, V277, P39749, DOI 10.1074/jbc.M206281200; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LI SC, 1975, J BIOL CHEM, V250, P6786; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Liebmann C, 2004, CURR PHARM DESIGN, V10, P1937, DOI 10.2174/1381612043384367; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; Lyer P N, 1976, Arch Biochem Biophys, V177, P330; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Martinez VG, 2004, GLYCOBIOLOGY, V14, P127, DOI 10.1093/glycob/cwh025; Mellado M, 2001, CELL MOL BIOL, V47, P575; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; Miura T, 2004, CELL DEATH DIFFER, V11, P1076, DOI 10.1038/sj.cdd.4401462; Moiseeva EP, 2003, BIOCHEM BIOPH RES CO, V310, P1010, DOI 10.1016/j.bbrc.2003.09.112; NAKAGAWA H, 1980, J BIOL CHEM, V255, P5955; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; OHANNESIAN DW, 1994, CANCER RES, V54, P5992; Ozaki K, 2004, NATURE, V429, P72, DOI 10.1038/nature02502; OZEKI Y, 1995, GLYCOBIOLOGY, V5, P255, DOI 10.1093/glycob/5.2.255; Pace KE, 1999, J IMMUNOL, V163, P3801; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; Patterson RJ, 2002, GLYCOCONJUGATE J, V19, P499, DOI 10.1023/B:GLYC.0000014079.87862.c7; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Poirier F, 2002, BIOCHEM SOC SYMP, V69, P95; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Rubinstein N, 2004, TISSUE ANTIGENS, V64, P1, DOI 10.1111/j.0001-2815.2004.00278.x; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; Stowell SR, 2004, GLYCOBIOLOGY, V14, P157, DOI 10.1093/glycob/cwh018; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; Unverzagt C, 2002, J MED CHEM, V45, P478, DOI 10.1021/jm0110237; Van Brocklyn JR, 2002, BBA-MOL CELL BIOL L, V1582, P89, DOI 10.1016/S1388-1981(02)00141-5; van den Brule F, 2002, GLYCOCONJUGATE J, V19, P537, DOI 10.1023/B:GLYC.0000014083.48508.6a; WANG WC, 1991, J BIOL CHEM, V266, P23185; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	88	128	129	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5549	5562		10.1074/jbc.m412019200	http://dx.doi.org/10.1074/jbc.m412019200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15556936	hybrid			2022-12-25	WOS:000227217100055
J	Deng, XB; Ewton, DZ; Mercer, SE; Friedman, E				Deng, XB; Ewton, DZ; Mercer, SE; Friedman, E			Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIRK PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATOR; LOCALIZATION; BINDING; MEF2; PHOSPHORYLATION; SPECIFICITY; MYOGENESIS; INHIBITOR; SUBSTRATE	Mirk/dyrk1B is a member of the dyrk/minibrain family of serine/threonine kinases that mediate the transition from growth to differentiation in lower eukaryotes and mammals. Depletion of endogenous Mirk from C2C12 myoblasts by RNA interference blocks skeletal muscle differentiation (Deng, X., Ewton, D., Pawlikowski, B., Maimone, M., and Friedman, E. (2003) J. Biol. Chem. 278, 41347-41354). We now demonstrate that knockdown of Mirk blocks transcription of the muscle regulatory factor myogenin. Co-expression of Mirk with MEF2C, but not MyoD or Myf5, enhanced activation of the myogenin promoter in a Mirk kinase-dependent manner. Mirk activated MEF2 not through direct phosphorylation of MEF2 but by phosphorylation of its inhibitors, the class II histone deacetylases (HDACs). MEF2 is sequestered by class II HDACs such as HDAC5 and MEF2-interacting transcriptional repressor (MITR). Mirk antagonized the inhibition of MEF2C by MITR, whereas kinase-inactive Mirk was ineffective. Mirk phosphorylates class II HDACs at a conserved site within the nuclear localization region, reducing their nuclear accumulation in a dose-dependent and kinase-dependent manner. Moreover, less mutant MITR phosphomimetic at the Mirk phosphorylation site localized in the nucleus than wildtype MITR. Regulation of class II HDACs occurs by multiple mechanisms. Others have shown that calcium signaling leads to phosphorylation of HDACs at 14-3-3-binding sites, blocking their association with MEF2 within the nucleus. Mirk provides another level of regulation. Mirk is induced within the initial 24 h of myogenic differentiation and enables MEF2 to transcribe the myogenin gene by decreasing the nuclear accumulation of class II HDACs.	SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), SUNY Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.	friedmae@upstate.edu			NCI NIH HHS [R01 CA67405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Borghi S, 2001, J CELL SCI, V114, P4477; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Friday BB, 2003, DIFFERENTIATION, V71, P217, DOI 10.1046/j.1432-0436.2003.710303.x; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 2000, CANCER RES, V60, P3631; Lee K.-M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P273; Lim S, 2002, J BIOL CHEM, V277, P49438, DOI 10.1074/jbc.M206840200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200; Zou YL, 2003, J BIOL CHEM, V278, P49573, DOI 10.1074/jbc.M307556200	34	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4894	4905		10.1074/jbc.M411894200	http://dx.doi.org/10.1074/jbc.M411894200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15546868	hybrid			2022-12-25	WOS:000227096600110
J	Yang, J; Holman, GD				Yang, J; Holman, GD			Insulin and contraction stimulate exocytosis, but increased AMP-activated protein kinase activity resulting from oxidative metabolism stress slows endocytosis of GLUT4 in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; SUBCELLULAR TRAFFICKING; TRANSFERRIN RECEPTORS; TRANSLOCATION; HEART; ADIPOCYTES; FUSION; MECHANISMS	Stimulations of glucose transport produced by insulin action, contraction, or through a change in cell energy status are mediated by separate signaling pathways. These are the wortmannin-sensitive phosphatidylinositol 3-kinase pathway leading to the intermediate Akt and the wortmannin-insensitive AMP-activated protein kinase (AMPK) pathway. Electrical stimulation of cardiomyocytes produced a rapid, insulin-like, wortmannin-sensitive stimulation of glucose transport activity, but this occurred without extensive activation of Akt. Although AMPK phosphorylation was increased by contraction, this response was not wortmannin-inhibitable and consequently did not correlate with the wortmannin sensitivity of the transport stimulation. Oxidative metabolism stress due to hypoxia or treatment with oligomycin led to increased AMPK activity with a corresponding increase in glucose transport activity. We show here that these separate signaling pathways converge on GLUT4 trafficking at separate steps. The rate of exocytosis of GLUT4 was rapidly stimulated by insulin, but insulin treatment did not alter the endocytosis rate. Like insulin stimulation, electrical stimulation of contraction led to a stimulation of GLUT4 exocytosis without any marked change in endocytosis. By contrast, after oxidative metabolism stress, no stimulation of GLUT4 exocytosis occurred; instead, this treatment led to a reduction in GLUT4 endocytosis.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Bath	Holman, GD (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	g.d.holman@bath.ac.uk		Holman, Geoffrey/0000-0001-7045-1358	British Heart Foundation [PG/03/096/15794] Funding Source: Medline; Medical Research Council [G0300415, G9225018, G9225018(63350), MR/J003417/1] Funding Source: Medline; MRC [G9225018, G0300415] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abel ED, 2004, FRONT BIOSCI-LANDMRK, V9, P201, DOI 10.2741/1216; Barnes BR, 2002, DIABETES, V51, P2703, DOI 10.2337/diabetes.51.9.2703; Barnes K, 2002, J CELL SCI, V115, P2433; Becker C, 2001, ENDOCRINOLOGY, V142, P5267, DOI 10.1210/en.142.12.5267; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; CHUNQIU HJ, 2003, MOL BIOL CELL, V14, P3578; Coven DL, 2003, AM J PHYSIOL-ENDOC M, V285, pE629, DOI 10.1152/ajpendo.00171.2003; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Desrois M, 2004, CARDIOVASC RES, V61, P288, DOI 10.1016/j.cardiores.2003.11.021; ECKEL J, 1980, BIOCHIM BIOPHYS ACTA, V629, P510, DOI 10.1016/0304-4165(80)90156-7; Fischer Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1204, DOI 10.1152/ajpcell.1996.270.4.C1204; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hashimoto M, 2001, CHEMBIOCHEM, V2, P52, DOI 10.1002/1439-7633(20010105)2:1<52::AID-CBIC52>3.0.CO;2-F; HOLMAN GD, 1988, BIOCHIM BIOPHYS ACTA, V946, P75, DOI 10.1016/0005-2736(88)90459-2; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Koistinen HA, 2003, DIABETES, V52, P1066, DOI 10.2337/diabetes.52.5.1066; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Li J, 2004, AM J PHYSIOL-ENDOC M, V287, pE834, DOI 10.1152/ajpendo.00234.2004; Lund S, 1998, FEBS LETT, V425, P472, DOI 10.1016/S0014-5793(98)00293-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Pryor PR, 2000, BIOCHEM J, V348, P83, DOI 10.1042/0264-6021:3480083; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Sakamoto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1081, DOI 10.1152/ajpendo.00228.2003; Sakamoto K, 2002, J BIOL CHEM, V277, P11910, DOI 10.1074/jbc.M112410200; Sakamoto K, 2002, J APPL PHYSIOL, V93, P369, DOI 10.1152/japplphysiol.00167.2002; SATOH S, 1993, J BIOL CHEM, V268, P17820; Scheuermann-Freestone M, 2003, CIRCULATION, V107, P3040, DOI 10.1161/01.CIR.0000072789.89096.10; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; Taegtmeyer H, 2002, CIRCULATION, V105, P1727, DOI 10.1161/01.CIR.0000012466.50373.E8; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Till M, 2000, BIOCHEM J, V346, P841, DOI 10.1042/0264-6021:3460841; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Wright DC, 2004, DIABETES, V53, P330, DOI 10.2337/diabetes.53.2.330; Yang J, 2002, J BIOL CHEM, V277, P6559, DOI 10.1074/jbc.M108610200; YANG J, 1993, J BIOL CHEM, V268, P4600; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	50	89	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4070	4078		10.1074/jbc.M410213200	http://dx.doi.org/10.1074/jbc.M410213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15557332	hybrid			2022-12-25	WOS:000227096600011
J	Deval, J; Alvarez, K; Selmi, B; Bermond, M; Boretto, J; Guerreiro, C; Mulard, L; Canard, B				Deval, J; Alvarez, K; Selmi, B; Bermond, M; Boretto, J; Guerreiro, C; Mulard, L; Canard, B			Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AB-INITIO CALCULATIONS; DNA-POLYMERASE-I; NUCLEOTIDE ANALOGS; TERNARY COMPLEXES; STRUCTURAL BASIS; FIDELITY; HIV; REPLICATION; PHOSPHONATES; DIPHOSPHATE	A class of amino acid substitutions in drug-resistant HIV-1 reverse transcriptase (RT) is responsible for the selectively impaired incorporation of the nucleotide analog inhibitor into DNA. We have shown previously that a-boranophosphate nucleoside analogs suppress RT-mediated resistance when the catalytic rate is responsible for drug resistance such as in the case of K65R and dideoxy (dd)NTPs, and Q151M toward AZTTP and ddNTPs. Here, we extend this property to BH3-d4TTP and BH3-3TCTP toward their clinically relevant mutants Q151M and M184V, respectively. Pre-steady-state kinetics on mutants of the Q151M RT family reveal a 3-5-fold resistance to d4TTP. This resistance is suppressed using BH3-d4TTP. Likewise, resistance to 3TCTP by M184V RT (30-fold) and K65R/M184V RT (180-fold) is suppressed using BH3-3TCTP because of a 160-fold acceleration of the catalytic constant k(pol). Mechanistic insights into the rate enhancement were obtained using various a-boranophosphate nucleotides. The presence of the BH3 group renders k(pol) independent of amino acid substitutions present in RT. Indeed, the similar to100-fold decrease in polymerase activity caused by the R72A substitution is restored to wild-type levels using BH3-dTTP. Metal ion titration studies show that a-boranophosphate nucleoside analogs enhance 3-8-fold the binding of Mg2+ ions to the active site of the RT-DNA-dNTP complex and alleviate the requirement of critical amino acids involved in phosphodiester bond formation. To our knowledge, this is the first example of rescue of polymerase activity by means of a nucleotide analog.	Univ Aix Marseille 1, CNRS, UMR 6098, ESIL, F-13288 Marseille 9, France; Univ Aix Marseille 2, CNRS, UMR 6098, F-13288 Marseille 9, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Canard, B (corresponding author), Univ Aix Marseille 1, CNRS, UMR 6098, ESIL, Case 925,163 Ave Luminy, F-13288 Marseille 9, France.	bruno@afmb.cnrs-mrs.fr	ALVAREZ, Karine/T-6326-2017	Canard, Bruno/0000-0003-4924-1991				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; BARTH RF, 1992, CANCER-AM CANCER SOC, V70, P2995; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; Boretto J, 2001, ANAL BIOCHEM, V292, P139, DOI 10.1006/abio.2001.5045; Crabtree RH, 1996, ACCOUNTS CHEM RES, V29, P348, DOI 10.1021/ar950150s; Cramer CJ, 1997, INORG CHEM, V36, P5358, DOI 10.1021/ic970211d; De Clercq E, 2001, J CLIN VIROL, V22, P73, DOI 10.1016/S1386-6532(01)00167-6; Deval J, 2002, J BIOL CHEM, V277, P42097, DOI 10.1074/jbc.M206725200; Deval J, 2004, J BIOL CHEM, V279, P509, DOI 10.1074/jbc.M308806200; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; FREEMAN GA, 1992, J MED CHEM, V35, P3192, DOI 10.1021/jm00095a014; HALL IH, 1993, BIOMED PHARMACOTHER, V47, P79, DOI 10.1016/0753-3322(93)90295-V; HALL IH, 1992, ANTICANCER RES, V12, P1091; He KZ, 1999, NUCLEIC ACIDS RES, V27, P1788, DOI 10.1093/nar/27.8.1788; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Imamoto T, 1997, J AM CHEM SOC, V119, P9925, DOI 10.1021/ja972276l; KATI WM, 1992, J BIOL CHEM, V267, P25988; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Menendez-Arias L, 2002, TRENDS PHARMACOL SCI, V23, P381, DOI 10.1016/S0165-6147(02)02054-0; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Miller V, 2001, ANTIVIR THER, V6, P25; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Porter KW, 1997, NUCLEIC ACIDS RES, V25, P1611, DOI 10.1093/nar/25.8.1611; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; Schneider B, 2001, NUCLEOS NUCLEOT NUCL, V20, P297, DOI 10.1081/NCN-100002300; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; Shaw BR, 2003, ANN NY ACAD SCI, V1002, P12, DOI 10.1196/annals.1281.004; Shaw BR, 2000, METHOD ENZYMOL, V313, P226; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; Summers JS, 1998, INORG CHEM, V37, P4158, DOI 10.1021/ic971435z; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; THATCHER GRJ, 1993, J ORG CHEM, V58, P2272, DOI 10.1021/jo00060a050; Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000; VICTOROVA LS, 1992, NUCLEIC ACIDS RES, V20, P783, DOI 10.1093/nar/20.4.783	41	34	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3838	3846		10.1074/jbc.M411559200	http://dx.doi.org/10.1074/jbc.M411559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550379	hybrid			2022-12-25	WOS:000226983900087
J	Wiwi, CA; Waxman, DJ				Wiwi, CA; Waxman, DJ			Role of hepatocyte nuclear factors in transcriptional regulation of male-specific CYP2A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA GROWTH-HORMONE; LIVER GENE-EXPRESSION; 3A10/LITHOCHOLIC ACID 6-BETA-HYDROXYLASE; SEXUALLY DIMORPHIC EXPRESSION; RAT-LIVER; HEPATIC CYTOCHROME-P450; MOUSE-LIVER; GENDER-DIFFERENCES; BINDING PROTEIN; FACTOR 4-ALPHA	Cytochrome P450 2A2 (CYP2A2) is an adult male-specific rat liver steroid hydroxylase whose sex-dependent expression is regulated at the transcriptional level by sexually dimorphic pituitary growth hormone (GH) secretory patterns. In contrast to CYP2C11 and other male-specific, plasma GH pulse-inducible liver genes, CYP2A2 is highly expressed in hypophysectomized rat liver, despite the absence of GH stimulation. CYP2A2 promoter fragments 0.9-6.2 kb long exhibited unusually high basal promoter activity when transfected into the liver cell line HepG2. A further similar to2.5-fold increase in activity was obtained by cotransfection of hepatocyte nuclear factor (HNF) 3gamma or HNF4alpha. CYP2A2 promoter activity was inhibited similar to85% by transfection of HNF3beta or HNF6, both of which are more highly expressed in female than male liver and can strongly trans-activate the female-specific CYP2C12 promoter. The male GH pulse-activated transcription factor STAT5b had no effect on CYP2A2 promoter activity, either alone or in combination with HNF3gamma and HNF4alpha, consistent with the GH pulse-independence of CYP2A2 expression. By contrast, STAT5b synergistically enhanced the transcriptional activity of HNF4alpha toward two other male-specific liver target genes, Cyp2d9 and CYP8B1. Furthermore, STAT5b in combination with the HNF4alpha coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha strongly enhanced the transcriptional activity of HNF4alpha toward CYP8B1 but not toward CYP2A2. These findings support the hypothesis that sex-dependent HNFs contribute to the sexually dimorphic expression of CYP2A2 and other liver CYPs and highlight the ability of STAT5b to act in concert with HNF4alpha to regulate select male-specific liver CYP genes.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bu.edu		Waxman, David/0000-0001-7982-9206	NIDDK NIH HHS [DK33765, R01 DK033765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agrawal AK, 2000, J PHARMACOL EXP THER, V292, P228; Ahluwalia A, 2004, MOL ENDOCRINOL, V18, P747, DOI 10.1210/me.2003-0138; Akiyama TE, 2003, BBA-GEN SUBJECTS, V1619, P223, DOI 10.1016/S0304-4165(02)00480-4; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Delesque-Touchard N, 2000, J BIOL CHEM, V275, P34173, DOI 10.1074/jbc.M004027200; Frith MC, 2003, NUCLEIC ACIDS RES, V31, P3666, DOI 10.1093/nar/gkg540; Gonzalez FJ, 1996, FASEB J, V10, P1112, DOI 10.1096/fasebj.10.10.8751713; Halees AS, 2003, NUCLEIC ACIDS RES, V31, P3554, DOI 10.1093/nar/gkg549; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P503, DOI 10.1089/dna.1.1989.8.503; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; Lamba V, 2003, J PHARMACOL EXP THER, V307, P906, DOI 10.1124/jpet.103.054866; LEGRAVEREND C, 1992, FASEB J, V6, P711, DOI 10.1096/fasebj.6.2.1537461; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; MATSUNAGA T, 1990, BIOCHEMISTRY-US, V29, P1329, DOI 10.1021/bi00457a032; NOSHIRO M, 1986, J BIOL CHEM, V261, P5923; Pampori NA, 1999, ENDOCRINOLOGY, V140, P1245, DOI 10.1210/en.140.3.1245; Pampori NA, 1996, MOL PHARMACOL, V50, P1148; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Park SH, 2001, J BIOL CHEM, V276, P43031, DOI 10.1074/jbc.M107597200; SHAPIRO BH, 1995, INT J BIOCHEM CELL B, V27, P9, DOI 10.1016/1357-2725(94)00056-5; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; Sueyoshi T, 1999, MOL PHARMACOL, V56, P473, DOI 10.1124/mol.56.3.473; Tannenbaum GS, 2001, ENDOCRINOLOGY, V142, P4599, DOI 10.1210/en.142.11.4599; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Varin-Blank N, 1998, P NATL ACAD SCI USA, V95, P8750, DOI 10.1073/pnas.95.15.8750; Waxman D J, 2000, Novartis Found Symp, V227, P61; WAXMAN DJ, 1988, J BIOL CHEM, V263, P11396; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WAXMAN DJ, 2004, CYTOCHROME P450 STRU, P347; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Wiwi CA, 2004, MOL ENDOCRINOL, V18, P1975, DOI 10.1210/me.2004-0129; Wiwi CA, 2004, GROWTH FACTORS, V22, P79, DOI 10.1080/08977190410001715172; Wolbold R, 2003, HEPATOLOGY, V38, P978, DOI 10.1053/jhep.2003.50393; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200	46	27	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3259	3268		10.1074/jbc.M409294200	http://dx.doi.org/10.1074/jbc.M409294200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15539409	hybrid			2022-12-25	WOS:000226983900018
J	Yamamoto, A; Friedlein, A; Imai, Y; Takahashi, R; Kahle, PJ; Haass, C				Yamamoto, A; Friedlein, A; Imai, Y; Takahashi, R; Kahle, PJ; Haass, C			Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; DISEASE GENE-PRODUCT; CELL-DEATH; ALPHA-SYNUCLEIN; MOLECULAR PATHWAYS; BINDING-PROTEIN; S-NITROSYLATION; MUTATIONS; SUBSTRATE; COMPLEX	Mutations in the PARKIN gene are the most common cause of hereditary parkinsonism. The parkin protein comprises an N-terminal ubiquitin-like domain, a linker region containing caspase cleavage sites, a unique domain in the central portion, and a special zinc finger configuration termed RING-IBR-RING. Parkin has E3 ubiquitin-protein ligase activity and is believed to mediate proteasomal degradation of aggregation-prone proteins. Whereas the effects of mutations on the structure and function of parkin have been intensely studied, post-translational modifications of parkin and the regulation of its enzymatic activity are poorly understood. Here we report that parkin is phosphorylated both in human embryonic kidney HEK293 cells and human neuroblastoma SH-SY5Y cells. The turnover of parkin phosphorylation was rapid, because inhibition of phosphatases with okadaic acid was necessary to stabilize phosphoparkin. Phosphoamino acid analysis revealed that phosphorylation occurred mainly on serine residues under these conditions. At least five phosphorylation sites were identified, including Ser(101), Ser(131), and Ser(136) (located in the linker region) as well as Ser(296) and Ser(378) (located in the RING-IBR-RING motif). Casein kinase-1, protein kinase X and protein kinase C phosphorylated parkin in vitro, and inhibition of casein kinase-1 caused a dramatic reduction of parkin phosphorylation in cell lysates. Induction of protein folding stress in cells reduced parkin phosphorylation, and unphosphorylated parkin had slightly but significantly elevated autoubiquitination activity. Thus, complex regulation of the phosphorylation state of parkin may contribute to the unfolded protein response in stressed cells.	Univ Munich, Dept Metab Chem, Lab Alzheimer & Parkinsons Dis Res, D-80336 Munich, Germany; F Hoffmann La Roche & Co Ltd, Roche Ctr Med Genom, CH-4070 Basel, Switzerland; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan	University of Munich; Roche Holding; RIKEN	Kahle, PJ (corresponding author), Univ Munich, Dept Metab Chem, Lab Alzheimer & Parkinsons Dis Res, D-80336 Munich, Germany.	Philipp.Kahle@med.uni-muenchen.de	Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231				CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; Choi P, 2003, MOL BRAIN RES, V117, P179, DOI 10.1016/S0169-328X(03)00318-8; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cookson MR, 2003, NEUROMOL MED, V3, P1, DOI 10.1385/NMM:3:1:1; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Giasson BI, 2001, NEURON, V31, P885, DOI 10.1016/S0896-6273(01)00439-1; Higashi Y, 2004, J NEUROCHEM, V89, P1490, DOI 10.1111/j.1471-4159.2004.02445.x; Huynh DP, 2003, HUM MOL GENET, V12, P2587, DOI 10.1093/hmg/ddg269; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; Kahle PJ, 2004, EMBO REP, V5, P681, DOI 10.1038/sj.embor.7400188; Kahns S, 2003, J BIOL CHEM, V278, P23376, DOI 10.1074/jbc.M300495200; Kahns S, 2002, J BIOL CHEM, V277, P15303, DOI 10.1074/jbc.M111534200; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Pawlyk AC, 2003, J BIOL CHEM, V278, P48120, DOI 10.1074/jbc.M306889200; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Ren Y, 2003, J NEUROSCI, V23, P3316; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	39	96	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3390	3399		10.1074/jbc.M407724200	http://dx.doi.org/10.1074/jbc.M407724200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557340	hybrid			2022-12-25	WOS:000226983900033
J	Carter, WJ; Cama, E; Huntington, JA				Carter, WJ; Cama, E; Huntington, JA			Crystal structure of thrombin bound to heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; TERNARY COMPLEX; MUTAGENESIS; INHIBITION; ACTIVATION; MECHANISMS; RESIDUES; REVEALS; EXOSITE	Thrombin is the final protease in the blood coagulation cascade and serves both pro- and anticoagulant functions through the cleavage of several targets. The ability of thrombin to specifically recognize a wide range of substrates derives from interactions that occur outside of the active site of thrombin. Thrombin possesses two anion binding exosites, which mediate many of its interactions with cofactors and substrates, and although many structures of thrombin have been solved, few such interactions have been described in molecular detail. Glycosaminoglycan binding to exosite II of thrombin plays a major role in switching off the procoagulant functions of thrombin by mediating its irreversible inhibition by circulating serpins and by its binding to the endothelial cell surface receptor thrombomodulin. Here we report the 1.85-Angstrom structure of human a-thrombin bound to a heparin fragment of eight monosaccharide units in length. The asymmetric unit is composed of two thrombin dimers, each sharing a single heparin octasaccharide chain. The observed interactions are fully consistent with previous mutagenesis studies and illustrate on a molecular level the cofactor interaction that is critical for the restriction of clotting to the site of blood vessel injury.	Univ Cambridge, Dept Haematol, Div Struct Med,Wellcome Trust, Thrombosis Res Unit,Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge; Wellcome Trust Sanger Institute	Huntington, JA (corresponding author), Univ Cambridge, Dept Haematol, Div Struct Med,Wellcome Trust, Thrombosis Res Unit,Cambridge Inst Med Res, MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			Medical Research Council [G117/444] Funding Source: Medline; NHLBI NIH HHS [R01 HL68629] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068629] Funding Source: NIH RePORTER; MRC [G117/444] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; ESNOUF RM, 1997, J MOL GRAPH MODEL, V15, P112; GAN ZR, 1994, J BIOL CHEM, V269, P1301; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2003, TRENDS PHARMACOL SCI, V24, P589, DOI 10.1016/j.tips.2003.09.002; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Leung LLK, 2000, TRENDS CARDIOVAS MED, V10, P89, DOI 10.1016/S1050-1738(00)00047-5; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; OLSON ST, 1991, J BIOL CHEM, V266, P6342; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Rezaie AR, 2003, TRENDS CARDIOVAS MED, V13, P8, DOI 10.1016/S1050-1738(02)00191-3; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Tsiang M, 1997, J BIOL CHEM, V272, P12024, DOI 10.1074/jbc.272.18.12024; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; YE J, 1994, J BIOL CHEM, V269, P17965	29	122	127	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2745	2749		10.1074/jbc.M411606200	http://dx.doi.org/10.1074/jbc.M411606200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548541	hybrid			2022-12-25	WOS:000226449100047
J	Liu, CJ; Chang, E; Yu, J; Carlson, CS; Prazak, L; Yu, XP; Ding, B; Lengyel, P; Di Cesare, PE				Liu, CJ; Chang, E; Yu, J; Carlson, CS; Prazak, L; Yu, XP; Ding, B; Lengyel, P; Di Cesare, PE			The interferon-inducible p204 protein acts as a transcriptional coactivator of Cbfa1 and enhances osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; BONE MORPHOGENETIC PROTEIN-2; LOOP-HELIX PROTEINS; CLEIDOCRANIAL DYSPLASIA; GENE-EXPRESSION; MYOBLAST DIFFERENTIATION; RETINOBLASTOMA PROTEIN; CELL-DIFFERENTIATION; DEPENDENT INDUCTION; OSTEOCALCIN GENE	The differentiation of uncommitted mesenchymal cells into osteoblasts is a fundamental molecular event governing both embryonic development and bone repair. The bone morphogenetic proteins (BMPs) are important regulators of this process; they function by binding to cell surface receptors and signaling by means of Smad proteins. Core binding factor alpha-1 (Cbfa1), a member of the runt family of transcription factors, is an essential transcriptional regulator of osteoblast differentiation and bone formation, and this process is positively or negatively regulated by a variety of coactivators and corepressors. We report that p204, an interferon-inducible protein that was previously shown to inhibit cell proliferation and promote the differentiation of myoblasts to myotubes, is a novel regulator in the course of osteogenesis. p204 is expressed in embryonic osteoblasts and hypertrophic chondrocytes in the growth plate as well as in the calvaria osteoblasts of neonatal mice. Its level is increased in the course of the BMP-2-triggered osteoblast differentiation of pluripotent C2C12 cells. This increase is probably due to the activation of the gene encoding 204 (Ifi2O4) by Smad transcription factor, including Smad1, -4, and -5. Overexpression of p204 enhances the BMP-2-induced osteoblast differentiation in vitro, as revealed by elevated alkaline phosphatase activity and osteocalcin production. p204 acts as a cofactor of Cbfa1: 1) high levels of p204 augment, whereas the lowering of p204 level decreases, the Cbfa1-dependent transcription, and 2) p204 associates with Cbfa1 both in vitro and in vivo. Two nonoverlapping segments in p204 bind to Cbfa1, and the N-terminal 88-amino acid segment of Cbfa1 is required for binding to p204. p204, which is the first interferon-inducible protein found to associate with Cbfa1, functions as a novel regulator of osteoblast differentiation.	NYU, Dept Orthopaed Surg & Cell Biol, Hosp Joint Dis, New York, NY 10003 USA; NYU, Musculoskeletal Res Ctr, Hosp Joint Dis, New York, NY 10003 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA; Shandong Univ, Sch Med, Inst Pathogen Biol, Shandong 250012, Peoples R China; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; University of Minnesota System; University of Minnesota Twin Cities; Shandong University; Yale University	Liu, CJ (corresponding author), NYU, Dept Orthopaed Surg & Cell Biol, Hosp Joint Dis, 301 E 17th St, New York, NY 10003 USA.	Chuanju.liu@med.nyu.edu		liu, chuanju/0000-0002-7181-8032	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045612] Funding Source: NIH RePORTER; NCRR NIH HHS [RR14099] Funding Source: Medline; NIAMS NIH HHS [R01-AR45612-01A2] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alliston T, 2002, NATURE, V416, P686, DOI 10.1038/416686a; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1990, ANN NY ACAD SCI, V599, P1; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GLACKIN CA, 1992, BIOCHEM INT, V28, P67; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Guo CS, 2003, J BIOL CHEM, V278, P22615, DOI 10.1074/jbc.M301943200; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; JONES KL, 1997, SMITHS RECOGNIZABLE, P204; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Munz B, 2002, MOL CELL BIOL, V22, P5879, DOI 10.1128/MCB.22.16.5879-5886.2002; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756-3282(02)00826-8; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xie WF, 2000, MATRIX BIOL, V19, P501, DOI 10.1016/S0945-053X(00)00087-1; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	64	52	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2788	2796		10.1074/jbc.M412604200	http://dx.doi.org/10.1074/jbc.M412604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15557274	hybrid			2022-12-25	WOS:000226449100052
J	Wang, JL; Lad, L; Poulos, TL; de Montellano, PRO				Wang, JL; Lad, L; Poulos, TL; de Montellano, PRO			Regiospecificity determinants of human heme oxygenase - Differential NADPH- and ascorbate-dependent heme cleavage by the R183E mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; FERROUS-NO FORMS; CRYSTAL-STRUCTURE; CORYNEBACTERIUM-DIPHTHERIAE; ELECTRONIC CONTROL; RAT HEME; OXIDATION; COMPLEX; PROTEIN; GENE	The ability of the human heme oxygenase-1 (hHO-1) R183E mutant to oxidize heme in reactions supported by either NADPH-cytochrome P450 reductase or ascorbic acid has been compared. The NADPH-dependent reaction, like that of wild-type hHO-1, yields exclusively biliverdin IXalpha. In contrast, the R183E mutant with ascorbic acid as the reductant produces biliverdin IXalpha (79 +/- 4%), IXdelta (19 +/- 3%), and a trace of IXbeta. In the presence of superoxide dismutase and catalase, the yield of biliverdin IXdelta is decreased to 8 +/- 1% with a corresponding increase in biliverdin IXalpha. Spectroscopic analysis of the NADPH-dependent reaction shows that the R183E ferric biliverdin complex accumulates, because reduction of the iron, which is required for sequential iron and biliverdin release, is impaired. Reversal of the charge at position 183 makes reduction of the iron more difficult. The crystal structure of the R183E mutant, determined in the ferric and ferrous-NO bound forms, shows that the heme primarily adopts the same orientation as in wild-type hHO-1. The structure of the Fe(II).NO complex suggests that an altered active site hydrogen bonding network supports catalysis in the R183E mutant. Furthermore, Arg-183 contributes to the regiospecificity of the wild-type enzyme, but its contribution is not critical. The results indicate that the ascorbate-dependent reaction is subject to a lower degree of regiochemical control than the NADPH-dependent reaction. Ascorbate may be able to reduce the R183E ferric and ferrous dioxygen complexes in active site conformations that cannot be reduced by NADPH-cytochrome P450 reductase.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Chem & Struct Biol, Irvine, CA 92697 USA	University of California System; University of California San Francisco; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St,N572D, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM33688] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUCLAIR K, 2002, PORPHYRIN HDB, V12, P183; Avila L, 2003, J AM CHEM SOC, V125, P4103, DOI 10.1021/ja029311v; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caignan GA, 2002, J AM CHEM SOC, V124, P14879, DOI 10.1021/ja0274960; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; CORNEJO J, 1988, J BIOL CHEM, V263, P11915; Dolphin, 1979, PORPHYRINS, VVI, P257; Fang J, 2004, INT J CANCER, V109, P1, DOI 10.1002/ijc.11644; Friedman J, 2004, BIOCHEMISTRY-US, V43, P5239, DOI 10.1021/bi049687g; Fujii H, 2004, J AM CHEM SOC, V126, P4466, DOI 10.1021/ja031791i; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lad L, 2004, J INORG BIOCHEM, V98, P1686, DOI 10.1016/j.jinorgbio.2004.07.004; Lad L, 2004, BIOCHEMISTRY-US, V43, P3793, DOI 10.1021/bi035451l; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Maines MD, 1992, HEME OXYGENASE CLIN, P145; McCarter SD, 2003, GENE THER, V10, P1629, DOI 10.1038/sj.gt.3302063; MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Migita CT, 2003, EUR J BIOCHEM, V270, P687, DOI 10.1046/j.1432-1033.2003.03421.x; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; Schuller DJ, 1998, PROTEIN SCI, V7, P1836, DOI 10.1002/pro.5560070820; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; SHEN AL, 1991, J BIOL CHEM, V266, P19976; Sigman JA, 2001, J AM CHEM SOC, V123, P6945, DOI 10.1021/ja015776u; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2003, J BIOL CHEM, V278, P32352, DOI 10.1074/jbc.M303682200; TEHUNEN R, 1969, J BIOL CHEM, V244, P6388; Torpey J, 1997, J BIOL CHEM, V272, P22008, DOI 10.1074/jbc.272.35.22008; Torpey J, 1996, J BIOL CHEM, V271, P26067, DOI 10.1074/jbc.271.42.26067; Unno M, 2004, J BIOL CHEM, V279, P21055, DOI 10.1074/jbc.M400491200; Uzel C, 1998, SEMIN HEMATOL, V35, P27; Visner GA, 2003, TRANSPLANTATION, V76, P650, DOI 10.1097/01.TP.0000080069.61917.18; Wilks A, 1998, BIOCHEMISTRY-US, V37, P2889, DOI 10.1021/bi972720x; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; Zeng YH, 2004, BIOCHEMISTRY-US, V43, P5222, DOI 10.1021/bi035970o; Zhou H, 2000, J AM CHEM SOC, V122, P8311, DOI 10.1021/ja0002868; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	50	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2797	2806		10.1074/jbc.M411229200	http://dx.doi.org/10.1074/jbc.M411229200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15525643	hybrid			2022-12-25	WOS:000226449100053
J	Li, CY; Zhu, JY; Wang, JYJ				Li, CY; Zhu, JY; Wang, JYJ			Ectopic expression of p73 alpha, but not p73 beta, suppresses myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; MYOD FAMILY; TRANSCRIPTION FACTORS; APOPTOTIC RESPONSE; P73 EXPRESSION; ACTIN PROMOTER; REGULATES P73; P53; GENE; SKELETAL	The TRP73 gene, a member of the p53 family, encodes several variants through differential splicing and use of alternative promoters. At the N terminus, two different promoters generate the full-length and the DeltaN isoforms, with or without the transactivating domain. At the C terminus, seven isoforms generated through alternative splicing have been cloned. Previous studies have demonstrated that DeltaN-p73 interferes with p73-induced apoptosis. However, there has been no evidence for functional diversity of the C-terminal p73 variants. In this study, we found that p73alpha and p73beta exerted differential effect on the differentiation of C2C12 myoblasts. Although p73beta lacked any detectable effect on differentiation, p73alpha caused a substantial delay in the expression of muscle-specific genes. In co-transfection experiments p73alpha, but not p73beta, attenuated the transcriptional activity of MyoD. Microarray-based gene profiling confirmed the protraction of MyoD-dependent gene expression in C2C12 cells stably expressing p73alpha. Notwithstanding the differential effect on differentiation, p73alpha and p73beta showed similar activity in sensitizing C2C12 myoblasts to cisplatin-induced cell death. These results demonstrated a functional diversity between the two C-terminal variants of p73 and suggested that p73alpha can regulate cellular differentiation in addition to its role in stimulating cell death.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	jywang@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; ASAKURA A, 1993, MOL CELL BIOL, V13, P7153, DOI 10.1128/MCB.13.11.7153; Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Dasgupta P, 2004, J BIOL CHEM, V279, P38762, DOI 10.1074/jbc.M312273200; Davis J, 2003, PROF ENG, V16, P23; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guan M, 2003, JPN J CLIN ONCOL, V33, P215, DOI 10.1093/jjco/hyg045; GUTTRIDGE DC, 2000, SCIENCE, V289, P2363, DOI [10.1126/sci-ence.289.5488.2363, DOI 10.1126/SCI-ENCE.289.5488.2363, DOI 10.1126/science.289.5488.2363, DOI 10.1126/SCIENCE.289.5488.2363]; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Liu T, 2000, J MOL EVOL, V50, P22, DOI 10.1007/s002399910003; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Marsh DR, 1998, J MUSCLE RES CELL M, V19, P897, DOI 10.1023/A:1005485400448; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Puri PL, 2000, GENE DEV, V14, P574; Rentzsch F, 2003, GENE, V323, P19, DOI 10.1016/j.gene.2003.10.002; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200; Szalay K, 1997, EUR J CELL BIOL, V74, P391; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Vella V, 2003, J BIOL CHEM, V278, P25151, DOI 10.1074/jbc.M301962200; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Wheeler MT, 1999, AM J PHYSIOL-CELL PH, V276, pC1069, DOI 10.1152/ajpcell.1999.276.5.C1069; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	55	9	9	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2159	2164		10.1074/jbc.M411194200	http://dx.doi.org/10.1074/jbc.M411194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15545283	hybrid			2022-12-25	WOS:000226341700051
J	Sedelnikova, A; Smith, CD; Zakharkin, SO; Davis, D; Weiss, DS; Chang, YC				Sedelnikova, A; Smith, CD; Zakharkin, SO; Davis, D; Weiss, DS; Chang, YC			Mapping the rho(1) GABA(C) receptor agonist binding pocket - Constructing a complete model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; ACTIVATION MECHANISM; SITE; IDENTIFICATION; RESIDUES; CHANNELS; INSIGHTS; SUBUNIT; REVEALS; SEGMENT	gamma-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain. The GABA receptor type C (GABA(C)) is a ligand-gated ion channel with pharmacological properties distinct from the GABA(A) receptor. To date, only three binding domains in the recombinant rho(1) GABA(C) receptor have been recognized among six potential regions. In this report, using the substituted cysteine accessibility method, we scanned three potential regions previously unexplored in the rho(1) GABA(C) receptor, corresponding to the binding loops A, E, and F in the structural model for ligand-gated ion channels. The cysteine accessibility scanning and agonist/antagonist protection tests have resulted in the identification of residues in loops A and E, but not F, involved in forming the GABA(C) receptor agonist binding pocket. Three of these newly identified residues are in a novel region corresponding to the extended stretch of loop E. In addition, the cysteine accessibility pattern suggests that part of loop A and part of loop E have a beta-strand structure, whereas loop F is a random coil. Finally, when all of the identified ligand binding residues are mapped onto a three-dimensional homology model of the amino-terminal domain of the rho(1) GABA(C) receptor, they are facing toward the putative binding pocket. Combined with previous findings, a complete model of the GABA(C) receptor binding pocket was proposed and discussed in comparison with the GABA(A) receptor binding pocket.	Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chang, YC (corresponding author), Barrow Neurol Inst, Div Neurobiol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	yongchang.chang@chw.edu		Zakharkin, Stanislav/0000-0001-9816-510X	NIDDK NIH HHS [DK07545] Funding Source: Medline; NINDS NIH HHS [NS35291] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS035291, R01NS035291] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Amin J, 1996, P ROY SOC B-BIOL SCI, V263, P273, DOI 10.1098/rspb.1996.0042; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; AMIN J, 1994, RECEPTOR CHANNEL, V2, P227; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang YC, 2000, MOL PHARMACOL, V58, P1375, DOI 10.1124/mol.58.6.1375; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; Chang YC, 1996, J NEUROSCI, V16, P5415; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Chang YC, 2002, NAT NEUROSCI, V5, P1163, DOI 10.1038/nn926; Chang YC, 2002, J NEUROSCI, V22, P7982; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; HOLDEN J, 2003, SOC NEUR 33 ANN M NE; Holden JH, 2002, J BIOL CHEM, V277, P18785, DOI 10.1074/jbc.M111778200; Johnston GAR, 1996, TRENDS PHARMACOL SCI, V17, P319, DOI 10.1016/S0165-6147(96)10038-9; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Sullivan D, 2002, MOL PHARMACOL, V61, P463, DOI 10.1124/mol.61.2.463; Sullivan DA, 2000, J BIOL CHEM, V275, P12651, DOI 10.1074/jbc.275.17.12651; Torres VI, 2002, J BIOL CHEM, V277, P43741, DOI 10.1074/jbc.M202007200; Ueno S, 1997, J NEUROSCI, V17, P625; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195	32	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1535	1542		10.1074/jbc.M409908200	http://dx.doi.org/10.1074/jbc.M409908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15548535	hybrid, Green Submitted			2022-12-25	WOS:000226195200084
J	Vitavska, O; Merzendorfer, H; Wieczorek, H				Vitavska, O; Merzendorfer, H; Wieczorek, H			The V-ATPase subunit C binds to polymeric F-actin as well as to monomeric G-actin and induces cross-linking of actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM MIDGUT; ANIMAL PLASMA-MEMBRANE; BUNDLING ACTIVITY; IN-VIVO; PURIFICATION; CYTOSKELETON; TWINFILIN; PROTEINS; SITE	Previously, we have shown that the V-ATPase holoenzyme as well as the V-1 complex isolated from the midgut of the tobacco hornworm ( Manduca sexta) exhibits the ability of binding to actin filaments via the V-1 subunits B and C (Vitavska, O., Wieczorek, H., and Merzendorfer, H. (2003) J. Biol. Chem. 278, 18499 - 18505). Since the recombinant subunit C not only enhances actin binding of the V-1 complex but also can bind separately to F-actin, we analyzed the interaction of recombinant subunit C with actin. We demonstrate that it binds not only to F-actin but also to monomeric G-actin. With dissociation constants of similar to 50 nM, the interaction exhibits a high affinity, and no difference could be observed between binding to ATP-G-actin or ADP-G-actin, respectively. Unlike other proteins such as members of the ADF/cofilin family, which also bind to G- as well as to F-actin, subunit C does not destabilize actin filaments. On the contrary, under conditions where the disassembly of F-actin into G- actin usually occurred, subunit C stabilized F-actin. In addition, it increased the initial rate of actin polymerization in a concentration-dependent manner and was shown to cross-link actin filaments to bundles of varying thickness. Apparently bundling is enabled by the existence of at least two actin-binding sites present in the N- and in the C-terminal halves of subunits C, respectively. Since subunit C has the possibility to dimerize or even to oligomerize, spacing between actin filaments could be variable in size.	Univ Osnabruck, Dept Biol Chem, Div Anim Physiol, D-49069 Osnabruck, Germany	University Osnabruck	Wieczorek, H (corresponding author), Univ Osnabruck, Dept Biol Chem, Div Anim Physiol, D-49069 Osnabruck, Germany.	wieczorek@biologie.uni-osnabrueck.de						Armbruster A, 2004, FEBS LETT, V570, P119, DOI 10.1016/j.febslet.2004.06.029; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BONFANTI P, 1992, EUR J CELL BIOL, V57, P298; Burg MB, 2000, CELL PHYSIOL BIOCHEM, V10, P251, DOI 10.1159/000016371; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Chen SH, 2004, J BIOL CHEM, V279, P7988, DOI 10.1074/jbc.M305351200; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; DETMERS P, 1981, J BIOL CHEM, V256, P99; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; KOCH A, 1987, J EXP BIOL, V133, P199; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Merzendorfer H, 2000, BBA-BIOMEMBRANES, V1467, P369, DOI 10.1016/S0005-2736(00)00233-9; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Ojala PJ, 2002, MOL BIOL CELL, V13, P3811, DOI 10.1091/mbc.E02-03-0157; Palmgren S, 2002, J CELL SCI, V115, P881; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pfannstiel J, 2001, J BIOL CHEM, V276, P49476, DOI 10.1074/jbc.M104760200; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Robinson DN, 2002, J BIOL CHEM, V277, P9088, DOI 10.1074/jbc.M112144200; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; Vartiainen MK, 2002, MOL BIOL CELL, V13, P183, DOI 10.1091/mbc.01-07-0331; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; Wieczorek H, 1999, J BIOENERG BIOMEMBR, V31, P67, DOI 10.1023/A:1005448614450	37	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1070	1076		10.1074/jbc.M406797200	http://dx.doi.org/10.1074/jbc.M406797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15525650	hybrid			2022-12-25	WOS:000226195200027
J	Yamazaki, S; Muta, T; Matsuo, S; Takeshige, K				Yamazaki, S; Muta, T; Matsuo, S; Takeshige, K			Stimulus-specific induction of a novel nuclear factor-kappa B regulator, I kappa B-zeta, via toll/interleukin-1 receptor is mediated by mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AU-RICH ELEMENT; GENE-EXPRESSION; FACTOR-ALPHA; 3'-UNTRANSLATED REGION; BINDING PROTEIN; ESSENTIAL ROLES; CODING REGION; TNF-ALPHA; IL-17	We have recently identified an inducible nuclear factor-kappaB (NF-kappaB) regulator, IkappaB-zeta, which is induced by microbial ligands for Toll-like receptors such as lipopolysaccharide and the proinflammatory cytokine interleukin (IL)-1beta but not by tumor necrosis factor (TNF)-alpha. In the present study, we examined mechanisms for stimulus-specific induction of IkappaB-zeta. The analysis of the IkappaB-zeta promoter revealed an essential role for an NF-kappaB binding sequence in transcriptional activation. The activation, however, did not account for the Toll-like receptor/IL-1 receptor-specific induction of IkappaB-zeta, because the promoter analysis and nuclear run-on analysis indicated that its transcription was similarly induced by TNF-alpha. To examine post-transcriptional regulation, we analyzed the decay of IkappaB-zeta mRNA, and we found that it was specifically stabilized by lipopolysaccharide or IL-1beta but not by TNF-alpha. Furthermore, we found that costimulation with TNF-alpha and another proinflammatory cytokine, IL-17, elicited the IkappaB-zeta induction. Stimulation with IL-17 alone did not induce IkappaB-zeta but stabilized its mRNA. Therefore, IkappaB-zeta induction requires both NF-kappaB activation and stimulus-specific stabilization of its mRNA. Because IkappaB-zeta is essential for expression of a subset of NF-kappaB target genes, the stimulus-specific induction of IkappaB-zeta may be of great significance in regulation of inflammatory reactions.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan; Japan Sci & Technol Agcy, PRESTO, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Muta, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan.	tmuta@mailserver.med.kyushu-u.ac.jp		Yamazaki, Soh/0000-0001-5038-1567				Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Almawi WY, 2002, J MOL ENDOCRINOL, V28, P69, DOI 10.1677/jme.0.0280069; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Awane M, 1999, J IMMUNOL, V162, P5337; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Chabaud M, 2001, J IMMUNOL, V167, P6015, DOI 10.4049/jimmunol.167.10.6015; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cowland JB, 2003, J IMMUNOL, V171, P6630, DOI 10.4049/jimmunol.171.12.6630; Davis CA, 2001, J BIOL CHEM, V276, P37317, DOI 10.1074/jbc.M104378200; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; ELIAS JA, 1990, J IMMUNOL, V145, P161; Eto A, 2003, BIOCHEM BIOPH RES CO, V301, P495, DOI 10.1016/S0006-291X(02)03082-6; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fossiez F, 1998, Int Rev Immunol, V16, P541, DOI 10.3109/08830189809043008; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; KATZ Y, 1989, J IMMUNOL, V142, P3862; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; NG SB, 1994, J BIOL CHEM, V269, P19021; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OHMORI Y, 1994, BIOCHEM BIOPH RES CO, V198, P590, DOI 10.1006/bbrc.1994.1086; Paste M, 2003, EUR J BIOCHEM, V270, P1590, DOI 10.1046/j.1432-1033.2003.03530.x; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Shiina T, 2001, IMMUNOGENETICS, V53, P649, DOI 10.1007/s00251-001-0376-x; Shim J, 2002, MOL CELLS, V14, P323; Shimada M, 2002, J IMMUNOL, V168, P861, DOI 10.4049/jimmunol.168.2.861; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Tebo JM, 2000, J BIOL CHEM, V275, P12987, DOI 10.1074/jbc.275.17.12987; Tierney MJ, 2001, J BIOL CHEM, V276, P13675, DOI 10.1074/jbc.M010627200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Witowski J, 2000, J IMMUNOL, V165, P5814, DOI 10.4049/jimmunol.165.10.5814; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	53	97	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1678	1687		10.1074/jbc.M409983200	http://dx.doi.org/10.1074/jbc.M409983200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15522867	hybrid			2022-12-25	WOS:000226195200099
J	Westmark, CJ; Bartleson, VB; Malter, JS				Westmark, CJ; Bartleson, VB; Malter, JS			RhoB mRNA is stabilized by HuR after UV light	ONCOGENE			English	Article						RhoB; HuR; ARE; mRNA stability; UVL	ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; P38 SIGNALING CASCADE; AU-RICH ELEMENTS; BINDING-PROTEIN; GTPASE RHOB; DOWN-REGULATION; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ULTRAVIOLET-IRRADIATION	RhoB is a small GTP-binding protein that is involved in apoptotic signal transduction. We have cloned the mouse RhoB mRNA including a 1377 nucleotide 3'-untranslated region (UTR) that contains six AU-rich elements (AREs) as well as several uridine-rich stretches. There is 94% homology overall between the mouse and rat RhoB genes and 92% homology between the mouse and a putative human clone. Ultraviolet light (UVL) induces RhoB production through regulated changes in gene transcription and mRNA stabilization although the latter mechanism is unknown. We observed that UVL increased the half-life of RhoB mRNA from 63 min to 3.3 h in NIH/3T3 cells and from 87 min to 2.7 h in normal human keratinocyte cells. In vitro mobility shift assays demonstrated that HuR bound the 3'-UTR of RhoB at three distinct locations (nucleotides 1342-1696, 1765-1920 and 1897-1977) suggesting a regulatory role for this RNA-binding protein. HuR immunoprecipitations were positive for RhoB mRNA indicating an in vivo association, and Western blot analysis and immunofluorescence demonstrated that HuR rapidly partitions from the nucleus to the cytoplasm after UVL. Therefore, we propose a model in which UVL induces stress-activated signal transduction leading to nuclear/cytoplasmic shuttling of HuR and subsequent stabilization of RhoB mRNA.	Univ Wisconsin, Waisman Ctr Dev Disabil, Dept Pathol & Lab Med, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Malter, JS (corresponding author), Univ Wisconsin, Waisman Ctr Dev Disabil, Dept Pathol & Lab Med, Waisman Ctr Rm T509,1500 Highland Ave, Madison, WI 53705 USA.	jsmalter@facstaff.wisc.edu	Westmark, Cara J/L-4647-2019; Westmark, Cara/AAX-4408-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061666] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH61666] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adnane J, 2002, CLIN CANCER RES, V8, P2225; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carninci P, 1999, METHOD ENZYMOL, V303, P19; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Delarue FL, 2001, ONCOGENE, V20, P6531, DOI 10.1038/sj.onc.1204801; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, ANTICANCER RES, V19, P1681; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kasashima K, 2002, NUCLEIC ACIDS RES, V30, P4519, DOI 10.1093/nar/gkf567; Kirigiti P, 2001, MOL PHARMACOL, V60, P1308, DOI 10.1124/mol.60.6.1308; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Malcolm T, 2003, ONCOGENE, V22, P6142, DOI 10.1038/sj.onc.1206638; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; Montero L, 1999, CANCER RES, V59, P5286; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Park-Lee S, 2003, J BIOL CHEM, V278, P39801, DOI 10.1074/jbc.M307105200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Westmark CJ, 2001, MOL BRAIN RES, V90, P193, DOI 10.1016/S0169-328X(01)00112-7; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; 1998, GENOME RES, V8, P1097	63	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					502	511		10.1038/sj.onc.1208224	http://dx.doi.org/10.1038/sj.onc.1208224			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543229				2022-12-25	WOS:000226279700020
J	Kumar, PR; Singhal, PK; Rao, MRKS; Mahalingam, S				Kumar, PR; Singhal, PK; Rao, MRKS; Mahalingam, S			Phosphorylation by MAPK regulates simian immunodeficiency virus Vpx protein nuclear import and virus infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL DNA FLAP; VIRAL MATRIX PROTEIN; CELL-CYCLE ARREST; TYPE-1 VPR; NONDIVIDING CELLS; VIRION INCORPORATION; TYROSINE PHOSPHORYLATION; KINASE PHOSPHORYLATION; LOCALIZATION SIGNAL; MUTATIONAL ANALYSIS	Transport of the viral genome into the nucleus required phosphorylation of components in the preintegration complex by virion-associated host cellular kinases. In this study, we showed that ERK-2/MAPK is associated with simian immunodeficiency virus (SIV) virions and regulated the nuclear transport of Vpx and virus replication in non-proliferating target cells by phosphorylating Vpx. Suppression of the virion-associated ERK-2 activity by MAPK pathway inhibitors impaired both Vpx nuclear import and viral infectivity without affecting virus particle maturation and release. In addition, mutation analysis indicated that the inactivation of Vpx phosphorylation precluded nuclear import and reduced virus replication in macrophage cultures, even when functional integrase and Gag matrix proteins implicated in viral preintegration complex nuclear import are present. In this study, we also showed that co-localization of Vpx with Gag precursor in the cytoplasm is a prerequisite for Vpx incorporation into virus particles. Substitution of hydrophobic Leu-74 and Ile-75 with serines in the helical domain abrogated Vpx nuclear import, and its incorporation into virus particles, despite its localization in the cytoplasm, suggested that the structural integrity of helical domains is critical for Vpx functions. Taken together, these studies demonstrated that the host cell MAPK signal transduction pathway regulated an early step in SIV infection.	Ctr DNA Fingerprinting & Diagnost, Mol Virol Lab, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Mahalingam, S (corresponding author), Ctr DNA Fingerprinting & Diagnost, Mol Virol Lab, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.	maha@cdfd.org.in	Malireddi, RKSubbarao/C-5804-2013	Malireddi, RKSubbarao/0000-0001-8855-9447; Mahalingam, Sundarasamy/0000-0003-4460-3949				Accola MA, 1999, J VIROL, V73, P9992, DOI 10.1128/JVI.73.12.9992-9999.1999; Belshan M, 2003, VIROLOGY, V311, P7, DOI 10.1016/S0042-6822(03)00093-X; Bresnahan PA, 1999, J IMMUNOL, V163, P2977; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Camaur D, 1997, J VIROL, V71, P6834, DOI 10.1128/JVI.71.9.6834-6841.1997; Cartier C, 2003, J BIOL CHEM, V278, P35211, DOI 10.1074/jbc.M301257200; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Dvorin JD, 2002, J VIROL, V76, P12087, DOI 10.1128/JVI.76.23.12087-12096.2002; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; Fridell RA, 1997, J CELL SCI, V110, P1325; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Harty RN, 1999, J VIROL, V73, P2921, DOI 10.1128/JVI.73.4.2921-2929.1999; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hemonnot B, 2004, J BIOL CHEM, V279, P32426, DOI 10.1074/jbc.M313137200; HENDERSON LE, 1988, SCIENCE, V241, P199, DOI 10.1126/science.3388031; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jenkins Y, 2001, J VIROL, V75, P8348, DOI 10.1128/JVI.75.17.8348-8352.2001; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; KAPPES JC, 1988, J VIROL, V62, P3501, DOI 10.1128/JVI.62.9.3501-3505.1988; KAPPES JC, 1993, VIROLOGY, V193, P222, DOI 10.1006/viro.1993.1118; Kewalramani VN, 1996, VIROLOGY, V218, P159, DOI 10.1006/viro.1996.0176; Kumar PR, 2003, J MOL BIOL, V331, P1141, DOI 10.1016/s0022-2836(03)00853-3; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Limon A, 2002, J VIROL, V76, P12078, DOI 10.1128/JVI.76.23.12078-12086.2002; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; Luo TC, 1997, J VIROL, V71, P2535, DOI 10.1128/JVI.71.3.2535-2539.1997; Mahalingam S, 2001, J VIROL, V75, P362, DOI 10.1128/JVI.75.1.362-374.2001; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; MAHALINGAM S, 1995, VIROLOGY, V207, P297, DOI 10.1006/viro.1995.1081; Pancio HA, 2000, J VIROL, V74, P6162, DOI 10.1128/JVI.74.13.6162-6167.2000; Paul M, 1997, VIROLOGY, V232, P207, DOI 10.1006/viro.1997.8541; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SAIER MH, 1988, J BACTERIOL, V170, P2296, DOI 10.1128/jb.170.5.2296-2300.1988; Shackney SE, 1999, CYTOMETRY, V35, P97, DOI 10.1002/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.3.CO;2-X; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Subbramanian RA, 1998, J MOL BIOL, V278, P13, DOI 10.1006/jmbi.1998.1685; TACKE E, 1993, VIROLOGY, V197, P274, DOI 10.1006/viro.1993.1588; Trono D, 1998, NAT MED, V4, P1368, DOI 10.1038/3953; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; WU XY, 1994, J VIROL, V68, P6161, DOI 10.1128/JVI.68.10.6161-6169.1994; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	59	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8553	8563		10.1074/jbc.M407863200	http://dx.doi.org/10.1074/jbc.M407863200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15556948	hybrid			2022-12-25	WOS:000227395700132
J	Brailoiu, E; Hoard, JL; Filipeanu, CM; Brailoiu, GC; Dun, SL; Patel, S; Dun, NJ				Brailoiu, E; Hoard, JL; Filipeanu, CM; Brailoiu, GC; Dun, SL; Patel, S; Dun, NJ			Nicotinic acid adenine dinucleotide phosphate potentiates neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FROG NEUROMUSCULAR-JUNCTION; NAADP MOBILIZES CA2+; GROWTH CONE BEHAVIOR; RAT SPINAL-CORD; NERVE GROWTH; CA2+-MOBILIZING MESSENGER; INTRACELLULAR CALCIUM; INOSITOL TRISPHOSPHATE; TRANSMITTER RELEASE; PANCREATIC ACINAR	Ca2+ regulates a spectrum of cellular processes including many aspects of neuronal function. Ca2+-sensitive events such as neurite extension and axonal guidance are driven by Ca2+ signals that are precisely organized in both time and space. These complex cues result from both Ca2+ influx across the plasma membrane and the mobilization of intracellular Ca2+ stores. In the present study, using rat cortical neurons, we have examined the effects of the novel intracellular Ca2+- mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) on neurite length and cytosolic Ca2+ levels. We show that NAADP potentiates neurite extension in response to serum and nerve growth factor and stimulates increases in cytosolic Ca2+ from bafilomycin-sensitive Ca2+ stores. Simultaneous blockade of inositol trisphosphate and ryanodine receptors abolished the effects of NAADP on neurite length and reduced the magnitude of NAADP-mediated Ca2+ signals. This is the first report demonstrating functional NAADP receptors in a mammalian neuron. Interplay between NAADP receptors and more established intracellular Ca2+ channels may therefore play important signaling roles in the nervous system.	UCL, Dept Physiol, London WC1E 6BT, England; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; E Tennessee State Univ, Coll Med, Dept Pharmacol, Johnson City, TN 37614 USA; Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	University of London; University College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; East Tennessee State University; Louisiana State University System	Patel, S (corresponding author), UCL, Dept Physiol, Old Squash Courts,Gower St, London WC1E 6BT, England.	patel.s@ucl.ac.uk	Patel, Sandip/O-9591-2015	Patel, Sandip/0000-0001-7247-2013; Filipeanu, Catalin/0000-0002-7298-9327	NINDS NIH HHS [NS 18170] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018170] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; Berridge G, 2002, BIOCHEM J, V365, P295, DOI 10.1042/BJ20020180; Berridge G, 2002, J BIOL CHEM, V277, P43717, DOI 10.1074/jbc.M203224200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Boittin FX, 2002, CIRC RES, V91, P1168, DOI 10.1161/01.RES.0000047507.22487.85; Brailoiu E, 2004, NEUROSCI LETT, V365, P10, DOI 10.1016/j.neulet.2004.03.092; Brailoiu E, 2003, BIOCHEM J, V373, P313, DOI 10.1042/BJ20030472; Brailoiu E, 2001, MOL PHARMACOL, V60, P718; Brailoiu E, 2000, NEUROSCIENCE, V95, P927; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Ceni C, 2003, BIOCHEM J, V370, P175, DOI 10.1042/BJ20020604; Chameau P, 2001, PFLUG ARCH EUR J PHY, V443, P289, DOI 10.1007/s004240100691; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Filipeanu CM, 2002, J NEUROCHEM, V83, P879, DOI 10.1046/j.1471-4159.2002.01196.x; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; Genazzani AA, 2002, TRENDS PHARMACOL SCI, V23, P165, DOI 10.1016/S0165-6147(00)01990-8; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; Gomez TM, 2000, J NEUROBIOL, V44, P174, DOI 10.1002/1097-4695(200008)44:2<174::AID-NEU7>3.3.CO;2-I; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; KATER SB, 1991, J NEUROSCI, V11, P891; Kinnear NP, 2004, J BIOL CHEM, V279, P54319, DOI 10.1074/jbc.M406132200; Lee HC, 2000, CHEM IMMUNOL, V75, P39; Lee HC, 2003, CURR BIOL, V13, pR186, DOI 10.1016/S0960-9822(03)00120-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Morikawa H, 2003, J NEUROSCI, V23, P149; Patel S, 2000, J BIOL CHEM, V275, P36495, DOI 10.1074/jbc.C000458200; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 2004, BIOL CELL, V96, P19, DOI 10.1016/j.biolcel.2003.12.001; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Song JX, 2004, PHARM STAT, V3, P81, DOI 10.1002/pst.95; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Xiang Y, 2002, NAT NEUROSCI, V5, P843, DOI 10.1038/nn899; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501	45	86	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5646	5650		10.1074/jbc.M408746200	http://dx.doi.org/10.1074/jbc.M408746200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15528210	hybrid, Green Published			2022-12-25	WOS:000227217100066
J	Relogio, A; Ben-Dov, C; Baum, M; Ruggiu, M; Gemund, C; Benes, V; Darnell, RB; Valcarcel, J				Relogio, A; Ben-Dov, C; Baum, M; Ruggiu, M; Gemund, C; Benes, V; Darnell, RB; Valcarcel, J			Alternative splicing microarrays reveal functional expression of neuron-specific regulators in Hodgkin lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; IDENTIFICATION; NOVA	Alternative splicing provides a versatile mechanism of gene regulation, which is often subverted in disease. We have used customized oligonucleotide microarrays to interrogate simultaneously the levels of expression of splicing factors and the patterns of alternative splicing of genes involved in tumor progression. Analysis of RNAs isolated from cell lines derived from Hodgkin lymphoma tumors indicate that the relative abundance of alternatively spliced isoforms correlates with transformation and tumor grade. Changes in expression of regulators were also detected, and a subset sample was confirmed at the protein level. Ectopic expression of neuron-specific splicing regulatory proteins of the Nova family was observed in some cell lines and tumor samples, correlating with expression of a neuron-specific mRNA isoform of JNK2 kinase. This microarray design can help assess the role of alternative splicing in a variety of biological and medical problems and potentially serve as a diagnostic tool.	Ctr Regulacio Genom, Barcelona 08003, Spain; European Mol Biol Lab, D-69117 Heidelberg, Germany; Rockefeller Univ, New York, NY 10021 USA; Febit AG, D-68167 Mannheim, Germany	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); European Molecular Biology Laboratory (EMBL); Rockefeller University	Valcarcel, J (corresponding author), Ctr Regulacio Genom, Passeig Maritim 37-49, Barcelona 08003, Spain.	juan.valcarcel@crg.es	Valcarcel, Juan/O-9814-2014; Darnell, Robert B/B-9022-2008; Relógio, Angela/M-4959-2016	Valcarcel, Juan/0000-0001-5398-3571; Darnell, Robert B/0000-0002-5134-8088; Relógio, Angela/0000-0002-9165-2439; Benes, Vladimir/0000-0002-0352-2547; Ruggiu, Matteo/0000-0002-6404-1210				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baum M, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng151; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Darnell RB, 2004, ARCH NEUROL-CHICAGO, V61, P30, DOI 10.1001/archneur.61.1.30; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hanamura A, 1998, RNA, V4, P430; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KAY CL, 1993, J NEUROL NEUROSUR PS, V56, P831, DOI 10.1136/jnnp.56.7.831; Kuppers R, 2003, J CLIN INVEST, V111, P529, DOI 10.1172/JC1200316624; Lee C, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-231; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Schwab P, 2002, EUR PHYS J B, V30, P5, DOI 10.1140/epjb/e2002-00335-2; Schwaenen C, 2003, ANN HEMATOL, V82, P323, DOI 10.1007/s00277-003-0649-6; Schwering I, 2003, MOL MED, V9, P85, DOI 10.1007/BF03402041; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Sturzenhofecker B, 2003, LEUKEMIA LYMPHOMA, V44, P1587, DOI 10.1080/1042819031000103962; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; Wang H, 2003, BIOINFORMATICS, V19, pi315, DOI 10.1093/bioinformatics/btg1044; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254; Yeakley JM, 2002, NAT BIOTECHNOL, V20, P353, DOI 10.1038/nbt0402-353; Zhou YY, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-3	35	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4779	4784		10.1074/jbc.M411976200	http://dx.doi.org/10.1074/jbc.M411976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15546866	hybrid			2022-12-25	WOS:000227096600095
J	Yin, F; Herring, BP				Yin, F; Herring, BP			GATA-6 can act as a positive or negative regulator of smooth muscle-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; HEAVY-CHAIN GENE; TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; MOUSE EMBRYOGENESIS; HOMEODOMAIN PROTEIN; TELOKIN EXPRESSION; MYOCARDIN; LINEAGES; PROMOTER	The GATA-4/5/6 family of transcription factors is important for the development of the cardiovascular system and the visceral endoderm. GATA-6 is the only family member expressed in vascular smooth muscle cells and has been shown to be important for controlling the phenotype of these cells following vascular injury. To clarify further the role of GATA-6 in regulating vascular smooth muscle differentiation, we directly examined its ability to regulate the promoters of smooth muscle-specific genes. This analysis revealed that GATA-6 strongly repressed telokin promoter activity. In contrast, GATA-6 activated the smooth muscle myosin heavy chain and smooth muscle alpha-actin promoters and had no significant effect on the SM22alpha promoter. Gel mobility shift assays demonstrate that GATA-6 binds to a consensus site adjacent to the CArG box in the telokin promoter. GATA-6 did not interfere with the serum-response factor-stimulated promoter activity but blocked myocardin-induced activation of the telokin promoter. In contrast, GATA-6 and myocardin resulted in synergistic activation of the smooth muscle myosin heavy chain promoter. Consistent with these findings, overexpression of GATA-6 in smooth muscle cells selectively inhibited expression of endogenous telokin, while simultaneously increasing expression of other smooth muscle proteins. These data suggest that GATA-6 selectively inhibits telokin expression by triggering the displacement of myocardin from the serum-response factor. As GATA-6 is expressed at high levels in vascular smooth muscle, this finding may explain the relatively low levels of telokin expression in the vascular system. These data also reveal a novel transcription regulatory mechanism by which GATA-6 can modulate the activity of the myocardin-serum-response factor complexes.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.	pherring@iupui.edu	YIN, FENG/AAM-3823-2020; Yin, Feng/F-6052-2010	YIN, FENG/0000-0002-8444-1123; 	NHLBI NIH HHS [HL58571] Funding Source: Medline; NIDDK NIH HHS [DK61130, DK65644] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065644, R01DK061130] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Carson JA, 2000, J BIOL CHEM, V275, P39061, DOI 10.1074/jbc.M006532200; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Herring BP, 2001, AM J PHYSIOL-CELL PH, V280, pC12, DOI 10.1152/ajpcell.2001.280.1.C12; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; Hoggatt AM, 2002, CIRC RES, V91, P1151, DOI 10.1161/01.RES.0000047508.30800.4F; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; MA JT, 1994, BIOCHEM BIOPH RES CO, V200, P1742, DOI 10.1006/bbrc.1994.1654; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Narita N, 1996, GENOMICS, V36, P345, DOI 10.1006/geno.1996.0472; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; Oh J, 2004, MOL CELL BIOL, V24, P8519, DOI 10.1128/MCB.24.19.8519-8528.2004; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Tanaka M, 1998, DEV GENET, V22, P239, DOI 10.1002/(SICI)1520-6408(1998)22:3<239::AID-DVG6>3.3.CO;2-G; Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Yoshida T, 2004, ARTERIOSCL THROM VAS, V24, P1596, DOI 10.1161/01.ATV.0000137190.63214.c5; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhou JL, 2004, J BIOL CHEM, V279, P15929, DOI 10.1074/jbc.M313822200	42	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4745	4752		10.1074/jbc.M411585200	http://dx.doi.org/10.1074/jbc.M411585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15550397	hybrid			2022-12-25	WOS:000227096600091
J	Zaas, DW; Duncan, MJ; Li, GJ; Wright, JR; Abraham, SN				Zaas, DW; Duncan, MJ; Li, GJ; Wright, JR; Abraham, SN			Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; EPITHELIAL-CELLS; SHOW EVIDENCE; LIPID RAFTS; ENDOCYTOSIS; TRANSPORT; PATHOGENESIS; REGULATOR; PROTEINS; PORTALS	Pseudomonas aeruginosa is a major cause of pneumonia in patients with cystic fibrosis and other immuncompromising conditions. Here we showed that P. aeruginosa invades type I pneumocytes via a lipid raft-mediated mechanism. P. aeruginosa invasion of rat primary type I-like pneumocytes as well as a murine lung epithelial cell line 12 (MLE-12) is inhibited by drugs that remove membrane cholesterol and disrupt lipid rafts. Confocal microscopy demonstrated co-localization of intracellular P. aeruginosa with lipid raft components including caveolin-1 and -2. We generated caveolin-1 and -2 knockdowns in MLE-12 cells by using RNA interference techniques. Decreased expression of caveolin-2 significantly impaired the ability of P. aeruginosa to invade MLE-12 cells. In addition, the lipid raft-dependent tyrosine phosphorylation of caveolin-2 appeared to be a critical regulator of P. aeruginosa invasion.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Abraham, SN (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Box 3020, Durham, NC 27710 USA.	soman.abraham@duke.edu			NHLBI NIH HHS [5 R01 HL68072] Funding Source: Medline; NIAID NIH HHS [5R01 AI150021-03, 1 R21 AI056101-01A1] Funding Source: Medline; NIDDK NIH HHS [1F32-DK065412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK065412] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; CIANCIOTTO NP, 1995, CURR MICROBIOL, V30, P247, DOI 10.1007/BF00293641; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Dahlin K, 2004, AM J RESP CELL MOL, V31, P309, DOI 10.1165/rcmb.2003-0423OC; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DOBBS LG, 1985, BIOCHIM BIOPHYS ACTA, V846, P155, DOI 10.1016/0167-4889(85)90121-1; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; Duncan MJ, 2004, J BIOL CHEM, V279, P18944, DOI 10.1074/jbc.M400769200; Duncan MJ, 2002, CELL MICROBIOL, V4, P783, DOI 10.1046/j.1462-5822.2002.00230.x; Fang XH, 2004, AM J PHYSIOL-LUNG C, V287, pL104, DOI 10.1152/ajplung.00176.2003; Garau J, 2003, CURR OPIN INFECT DIS, V16, P135, DOI 10.1097/00001432-200304000-00010; GOVAN JRW, 1992, BRIT MED BULL, V48, P912, DOI 10.1093/oxfordjournals.bmb.a072585; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Hutchison ML, 1999, MICROBES INFECT, V1, P1005, DOI 10.1016/S1286-4579(99)80518-8; Johnson MD, 2002, P NATL ACAD SCI USA, V99, P1966, DOI 10.1073/pnas.042689399; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; Kurahashi K, 1999, J CLIN INVEST, V104, P743, DOI 10.1172/JCI7124; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; Lillehoj EP, 2004, AM J PHYSIOL-LUNG C, V287, pL809, DOI 10.1152/ajplung.00385.2003; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Mora R, 1999, J BIOL CHEM, V274, P25708, DOI 10.1074/jbc.274.36.25708; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Nanjundan M, 2001, BIOCHEM J, V358, P637, DOI 10.1042/0264-6021:3580637; Newman GR, 1999, CELL TISSUE RES, V295, P111, DOI 10.1007/s004410051217; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Razani B, 2001, J BIOL CHEM, V276, P38121; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Schneeberger EE., 1997, LUNG SCI FDN, V2, P535; Schroeder F, 2001, EXP BIOL MED, V226, P873, DOI 10.1177/153537020122601002; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shin JS, 2001, MICROBES INFECT, V3, P755, DOI 10.1016/S1286-4579(01)01423-X; Shin JS, 2001, IMMUNOLOGY, V102, P2, DOI 10.1046/j.1365-2567.2001.01173.x; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; Vazquez-Boland JA, 2001, CLIN MICROBIOL REV, V14, P584, DOI 10.1128/CMR.14.3.584-640.2001; WIENERKRONISH JP, 1993, J APPL PHYSIOL, V75, P1661, DOI 10.1152/jappl.1993.75.4.1661; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Williams MC, 2003, ANNU REV PHYSIOL, V65, P669, DOI 10.1146/annurev.physiol.65.092101.142446; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Yang F, 2003, J BIOL CHEM, V278, P32173, DOI 10.1074/jbc.M305149200	49	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4864	4872		10.1074/jbc.M411702200	http://dx.doi.org/10.1074/jbc.M411702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15545264	hybrid			2022-12-25	WOS:000227096600106
J	Benedito, AB; Lehtinen, M; Massol, R; Lopes, UG; Kirchhausen, T; Rao, A; Bonni, A				Benedito, AB; Lehtinen, M; Massol, R; Lopes, UG; Kirchhausen, T; Rao, A; Bonni, A			The transcription factor NFAT3 mediates neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; GLYCOGEN-SYNTHASE KINASE-3; CELL-DEATH MACHINERY; SIGNALING PATHWAY; GENE-TRANSCRIPTION; INDUCED APOPTOSIS; GROWTH-FACTOR; NF-ATC; C-JUN; LITHIUM	Neuronal apoptosis is critical for normal development of the mammalian nervous system and also contributes to the pathogenesis of ischemic and degenerative diseases of the brain. Apoptosis of neurons is tightly regulated by extrinsic signals including growth factors and neuronal activity, but the intracellular mechanisms by which these signals promote neuronal survival are incompletely understood. We report that the transcription factor NFAT3 plays a critical role in mediating survival of granule neurons of the developing cerebellum. NFAT3 accumulated in the nucleus of primary granule neurons under survival conditions of serum growth factors and neuronal activity that was elicited by depolarization with high K+. In contrast, deprivation of serum and K+, which leads to neuronal apoptosis, triggered NFAT3 nuclear export. Treatment of granule neurons with Li+, an inhibitor of the NFAT export kinase GSK3, prevented the nuclear export of NFAT3 and increased granule cell survival even under pro-apoptotic conditions. Thus, the nuclear localization of NFAT3 correlated tightly with granule neuron survival. Consistent with a pro-survival function for NFAT3, genetic knockdown of NFAT3 by RNA interference in primary granule neurons led to increased apoptosis even in neurons cultured under survival conditions. Conversely, expression of a constitutively active form of NFAT protected neurons against apoptosis induced by serum withdrawal and low K+. Taken together, these results reveal an essential function for NFAT3-mediated transcription in neuronal survival that may play important roles in the developing and mature brain.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-22790 Rio De Janeiro, Brazil	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Universidade Federal do Rio de Janeiro	Rao, A (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.	arao@cbr.med.harvard.edu; azad_bonni@hms.harvard.edu	Lopes, Ulisses Gazos/T-6634-2019		FOGARTY INTERNATIONAL CENTER [R03TW001323] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041021] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW 01323] Funding Source: Medline; NCI NIH HHS [R01 CA42471] Funding Source: Medline; NIAID NIH HHS [R01 AI41027] Funding Source: Medline; NINDS NIH HHS [R01 NS41021] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Konishi Y, 2003, J NEUROSCI, V23, P1649; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lopez-Coronado JM, 1999, J BIOL CHEM, V274, P16034, DOI 10.1074/jbc.274.23.16034; LOWENSTEIN DH, 1991, EPILEPSY RES, V10, P49, DOI 10.1016/0920-1211(91)90094-V; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Miller TM, 1996, J NEUROSCI, V16, P7487; Monticelli S, 2004, J BIOL CHEM, V279, P36210, DOI 10.1074/jbc.M406354200; Monticelli S, 2002, EUR J IMMUNOL, V32, P2971, DOI 10.1002/1521-4141(2002010)32:10<2971::AID-IMMU2971>3.0.CO;2-G; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Patel S, 2002, J MOL BIOL, V315, P677, DOI 10.1006/jmbi.2001.5271; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; Shalizi A, 2003, J NEUROSCI, V23, P7326; Spiegelberg BD, 1999, J BIOL CHEM, V274, P13619, DOI 10.1074/jbc.274.19.13619; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Watson A, 1998, J NEUROSCI, V18, P751; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149	55	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2818	2825		10.1074/jbc.M408741200	http://dx.doi.org/10.1074/jbc.M408741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15537643	hybrid			2022-12-25	WOS:000226449100055
J	Buschbeck, M; Ullrich, A				Buschbeck, M; Ullrich, A			The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MAP-KINASE; NUCLEOCYTOPLASMIC TRANSPORT; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PATHWAY; CELLS; MICE; IDENTIFICATION; TRANSCRIPTION	ERK5 is unique among mitogen-activated protein kinases (MAPKs) in that it contains a large C-terminal tail. We addressed the question of how this tail could affect the signaling capacity of ERK5. Gradual deletion of the C-terminal domains resulted in a drastic increase of ERK5 kinase activity, which was dependent on the upstream MAPK cascade, thus indicating a possible auto-inhibitory function of the tail. It is interesting that ERK5 was able to autophosphorylate its own tail. Moreover, ERK5, which was found to be expressed in virtually all kinds of cell lines, localized to nuclear as well as cytoplasmic compartments. The localization of ERK5 was determined by its C-terminal domains, which were also required for appropriate nucleocytoplasmic shuttling. Taken together, these results indicate that ERK5 signaling is directed by the presence of its unique C-terminal tail, which might be the key to understanding the key role of ERK5 in MAPK signaling.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Am Klopferspitz 18A, D-82152 Martinsried, Germany.	marcus.buschbeck@crg.es; ullrich@biochem.mpg.de	Buschbeck, Marcus/J-8204-2017	Buschbeck, Marcus/0000-0002-3218-4567				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Buschbeck M, 2002, J BIOL CHEM, V277, P29503, DOI 10.1074/jbc.M202149200; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kato Y, 2000, IMMUNOL RES, V21, P233, DOI 10.1385/IR:21:2-3:233; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Raviv Z, 2004, J CELL SCI, V117, P1773, DOI 10.1242/jcs.01040; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Selcher JC, 2001, LEARN MEMORY, V8, P11, DOI 10.1101/lm.37001; Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	41	89	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2659	2667		10.1074/jbc.M412599200	http://dx.doi.org/10.1074/jbc.M412599200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548525	hybrid			2022-12-25	WOS:000226449100036
J	He, ZW; Cho, YY; Ma, WY; Choi, HS; Bode, AM; Dong, ZG				He, ZW; Cho, YY; Ma, WY; Choi, HS; Bode, AM; Dong, ZG			Regulation of ultraviolet B-induced phosphorylation of histone H3 at serine 10 by Fyn kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED MOUSE FIBROBLASTS; KERATINOCYTE CELL-LINE; SRC-FAMILY KINASES; NF-KAPPA-B; C-FOS; UVB IRRADIATION; TYROSINE KINASE; GENE-EXPRESSION; SER-10 PHOSPHORYLATION; GROWTH-FACTOR	Ultraviolet B (UVB) induces phosphorylation of histone H3 at serine 10, and mitogen-activated protein kinases are involved in this signal transduction pathway. Here we provide evidence that Fyn kinase, a member of the Src kinase family, is involved in the UVB-induced phosphorylation of histone H3 at serine 10. UVB distinctly increased Fyn kinase activity and phosphorylation. Fyn kinase inhibitors 4-amino-5-(4-chlorophenyl)7(t-butyl)pyrazol(3,4-d)pyramide and leflunomide, an Sre kinase inhibitor, suppressed both UVB-induced phosphorylation of histone H3 at serine 10 and Fyn kinase activity and phosphorylation. UVB-induced phosphorylation of histone H3 at serine 10 was blocked by either a dominant-negative mutant of Fyn (DNM-Fyn) kinase or small interfering RNA of Fyn kinase. UVB-induced phosphorylation and activities of ERKs and protein kinase B/Akt were markedly inhibited by DNM-Fyn kinase. However, DNM-Fyn kinase did not inhibit UVB-induced phosphorylation of p38 MAPK or c-Jun N-terminal kinases. Active Fyn kinase phosphorylated histone H3 at serine 10 in vitro, and the phosphorylated Fyn kinase could translocate into the nucleus of HaCaT cells. These results indicate that Fyn kinase plays a key role in the UVB-induced phosphorylation of histone H3 at serine 10.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Cho, Yong-Yeon/AAD-4263-2020	Cho, Yong-Yeon/0000-0003-1107-2651	NATIONAL CANCER INSTITUTE [P01CA027502, R01CA077646] Funding Source: NIH RePORTER; NCI NIH HHS [CA27502, CA77646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Beissert S, 1996, J INVEST DERMATOL, V107, P553, DOI 10.1111/1523-1747.ep12582809; Bhat NR, 1995, DEV NEUROSCI-BASEL, V17, P267, DOI 10.1159/000111296; BODE AM, 2003, SCI STKE; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chazal M, 2002, ONCOGENE, V21, P2652, DOI 10.1038/sj.onc.1205349; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Gonzales M, 2002, GENE, V293, P169, DOI 10.1016/S0378-1119(02)00723-0; Gonzales M, 2002, ONCOGENE, V21, P2721, DOI 10.1038/sj.onc.1205366; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; KLEINSZANTO AJP, 1994, CANCER RES, V54, P4569; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; MANESS PF, 1992, DEV NEUROSCI-BASEL, V14, P257, DOI 10.1159/000111670; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Mildner M, 2002, J BIOL CHEM, V277, P14146, DOI 10.1074/jbc.M110687200; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Paitel E, 2003, J BIOL CHEM, V278, P10061, DOI 10.1074/jbc.M211580200; Pedeux R, 2002, INT J CANCER, V98, P811, DOI 10.1002/ijc.10275; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Strelkov IS, 2002, CANCER RES, V62, P75; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Wang YX, 2004, AM J PHYSIOL-HEART C, V286, pH685, DOI 10.1152/ajpheart.00237.2003; XU XL, 1995, J BIOL CHEM, V270, P12398, DOI 10.1074/jbc.270.21.12398; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamoyska R, 2003, IMMUNOL REV, V191, P107, DOI 10.1034/j.1600-065X.2003.00015.x; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	50	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2446	2454		10.1074/jbc.M402053200	http://dx.doi.org/10.1074/jbc.M402053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15537652	hybrid			2022-12-25	WOS:000226449100010
J	Meurer, SK; Tihaa, L; Lahme, B; Gressner, AM; Weiskirchen, R				Meurer, SK; Tihaa, L; Lahme, B; Gressner, AM; Weiskirchen, R			Identification of endoglin in rat hepatic stellate cells - New insights into transforming growth factor beta receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; RECOMBINANT SOLUBLE BETAGLYCAN; HUMAN ENDOTHELIAL-CELLS; MICE LACKING ENDOGLIN; TGF-BETA; II RECEPTOR; GENE-EXPRESSION; DOMAIN PROTEIN; REGULATED EXPRESSION; HETEROMERIC COMPLEX	Transforming growth factor beta (TGF-beta) signaling is mediated by the cell surface TGF-beta type I (ALK5), type II, and the accessory type III receptors endoglin and betaglycan. Hepatic stellate cells (HSC), the most profibrogenic cell type in the liver, express ALK5, TbetaRII, and betaglycan. To monitor the expression of betaglycan in HSC, we used the commercially available antibody sc-6199 in Western blot analysis. This antibody, raised against a peptide mapping at the carboxyl terminus of the human betaglycan, is claimed to be specific for betaglycan, although it is known that the C-terminal domain is highly conserved in type III receptors. Proteins recognized in HSC by sc-6199 did not match the characteristic migration pattern of betaglycan. Moreover, the determined molecular weight (M-r 160) and the observed reductant sensitivity after treatment with dithiothreitol resemble those of a closely related type III receptor, endoglin (CD105). Endoglin, a disulfide-linked homodimer, is an accessory component of the TGF-beta receptor complex and mainly expressed on endothelial cells. The presence of endoglin in HSC of rat liver was confirmed by molecular cloning of the endoglin cDNA and immunocytochemistry. The reactivity of sc-6199 with both auxiliary TGF-beta receptors (betaglycan and endoglin) from rats was demonstrated by Western blot and immunocytochemical analysis of cells heterologously expressing these proteins. Furthermore, Northern and Western blotting revealed that both betaglycan and endoglin genes are differentially regulated in HSC and in trans-differentiated myofibroblasts (MFB). By surface labeling and immunoprecipitation experiments, we show that endoglin is found in significant amounts exposed at the plasma membrane of HSC and MFB, which is a pivotal prerequisite for binding of and signaling in response to TGF-beta. In conclusion, we hypothesize that TGF-beta signals in HSC and MFB are tuned by two different interconnected signaling pathways, as it was previously demonstrated for endothelial cells.	RWTH Univ Hosp, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Weiskirchen, R (corresponding author), RWTH Univ Hosp, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany.	rweiskirchen@ukaachen.de	Weiskirchen, Ralf/O-1734-2018	Weiskirchen, Ralf/0000-0003-3888-0931				Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Bandyopadhyay A, 2002, CANCER RES, V62, P4690; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bataller R, 2001, SEMIN LIVER DIS, V21, P437, DOI 10.1055/s-2001-17558; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Fehrenbach H, 2001, HEPATOLOGY, V34, P943, DOI 10.1053/jhep.2001.28788; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Gressner AM, 1998, CELL TISSUE RES, V292, P447, DOI 10.1007/s004410051073; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; GRESSNER AM, 1996, KIDNEY INT, V49, P39; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Hirai R, 1996, EXP CELL RES, V223, P135, DOI 10.1006/excr.1996.0066; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Moustakas A, 2001, J CELL SCI, V114, P4359; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Philip A, 1999, EUR J BIOCHEM, V261, P618, DOI 10.1046/j.1432-1327.1999.00298.x; PONCECASTANEDA MV, 1998, BIOCHIM BIOPHYS ACTA, V384, P189; Rius C, 1998, BLOOD, V92, P4677; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Robledo MM, 1996, BRIT J HAEMATOL, V93, P507, DOI 10.1046/j.1365-2141.1996.d01-1698.x; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Rotzer D, 2001, EMBO J, V20, P480, DOI 10.1093/emboj/20.3.480; Roulot D, 1999, HEPATOLOGY, V29, P1730, DOI 10.1002/hep.510290622; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; SCHAFER S, 1987, HEPATOLOGY, V7, P680, DOI 10.1002/hep.1840070411; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; Shen H, 2003, AM J PHYSIOL-GASTR L, V285, pG539, DOI 10.1152/ajpgi.00436.2002; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sorensen LK, 2003, DEV BIOL, V261, P235, DOI 10.1016/S0012-1606(03)00158-1; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Weiner OH, 1996, CELL TISSUE RES, V285, P11, DOI 10.1007/s004410050615; Weiskirchen R, 2000, BIOCHEM BIOPH RES CO, V274, P655, DOI 10.1006/bbrc.2000.3187; Weiskirchen R, 2001, BIOCHEM J, V359, P485, DOI 10.1042/0264-6021:3590485; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995	83	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3078	3087		10.1074/jbc.M405411200	http://dx.doi.org/10.1074/jbc.M405411200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15537649	hybrid			2022-12-25	WOS:000226449100084
J	Panopoulos, A; Harraz, M; Engelhardt, JF; Zandi, E				Panopoulos, A; Harraz, M; Engelhardt, JF; Zandi, E			Iron-mediated H2O2 production as a mechanism for cell type-specific inhibition of tumor necrosis factor alpha-induced but not interleukin-1 beta-induced I kappa B kinase complex/nuclear factor-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; RESPIRATORY BURST; IKK; APOPTOSIS; OVEREXPRESSION; ANTIOXIDANTS; MACROPHAGES; PATHWAYS	Coordinated and specific regulation of tumor necrosis factor (TNF) and interleukin (IL)-1 signaling pathways and how and whether they are modified by different agents are key events for proper immune responses. The IkappaB kinase complex (IKK)/NF-kappaB and JNK/AP-1 pathways are central mediators of TNF and IL-1 during inflammatory responses. Here we show that L-minosine, a toxic non-protein amino acid that has been shown to reduce serum TNFalpha levels and affect inflammatory responses, specifically inhibits TNF-induced IKK but not JNK in a cell type-specific manner. L-Mimosine did not affect IKK and NF-kappaB activation by IL-1beta. L-Mimosine caused cell cycle arrest at G(1)-S phase, but inhibition of IKK was found to be independent of cell cycle arrest. Treatment of cells with L-mimosine resulted in production of H2O2. Addition of FeSO4 restored IKK activation by TNFa as did ectopic expression of catalase or pretreatment of cells with N-aceltyl-L-cysteine, indicating a role for intracellular H2O2 as a mediator of inhibition. Cleavage and degradation of TNF pathway components TNFR1, RIP, and Hsp90 were observed in L-mimosine and H2O2 treated cells indicating a putative mechanism for selective inhibition of TNF but not IL-1beta-induced IKK activation.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of Southern California; University of Iowa	Zandi, E (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Mol Microbiol & Immunol, 1441 Eastlake Ave,Norris 6429, Los Angeles, CA 90033 USA.	Zandi@usc.edu	Harraz, Maged M/P-4777-2014	Harraz, Maged M/0000-0003-4353-4216; Engelhardt, John/0000-0003-2389-9277	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R24AA012885] Funding Source: NIH RePORTER; NIAAA NIH HHS [R24AA12885] Funding Source: Medline; NIAID NIH HHS [2T32AI07078-21A1] Funding Source: Medline; NIGMS NIH HHS [R01GM065325] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Bowlus CL, 2003, AUTOIMMUN REV, V2, P73, DOI 10.1016/S1568-9972(02)00143-X; Brigelius-Flohe R, 2004, ARCH BIOCHEM BIOPHYS, V423, P66, DOI 10.1016/j.abb.2003.12.008; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; Burchiel SW, 2004, TOXICOL APPL PHARM, V196, P337, DOI 10.1016/j.taap.2004.01.011; Byun MS, 2002, EXP MOL MED, V34, P332, DOI 10.1038/emm.2002.47; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fiers W, 1996, J INFLAMM, V47, P67; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; Forman HJ, 2001, IUBMB LIFE, V51, P365; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Haddad JJ, 2004, BIOCHEM BIOPH RES CO, V316, P969, DOI 10.1016/j.bbrc.2004.02.162; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Kaul N, 1996, FREE RADICAL BIO MED, V21, P401, DOI 10.1016/0891-5849(96)00178-5; KONTOGHIORGHES GJ, 1987, BIOCHEM J, V241, P87, DOI 10.1042/bj2410087; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MANNING LS, 1991, CLIN EXP IMMUNOL, V83, P85; MAY JM, 1979, J BIOL CHEM, V254, P9017; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Mikhailov I, 2000, MUTAT RES-DNA REPAIR, V459, P299, DOI 10.1016/S0921-8777(00)00007-0; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Murata Y, 2002, INT IMMUNOL, V14, P201, DOI 10.1093/intimm/14.2.201; Neyens E, 2003, J HAZARD MATER, V98, P33, DOI 10.1016/S0304-3894(02)00282-0; ODWYER PJ, 1994, CANCER RES, V54, P724; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pantano C, 2003, J BIOL CHEM, V278, P44091, DOI 10.1074/jbc.M308487200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reddy MB, 2004, NUTR REV, V62, P120, DOI 10.1301/nr.2004.mar.120-124; ROSEN V, 1994, J BONE MINER RES, V9, P1759; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shrivastava A, 1999, ANTIOXID REDOX SIGN, V1, P181, DOI 10.1089/ars.1999.1.2-181; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tsai W C, 1974, Taiwan Yi Xue Hui Za Zhi, V73, P543; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Vazquez-Torres A, 2001, P NATL ACAD SCI USA, V98, P2561, DOI 10.1073/pnas.041618998; Vega VL, 2003, MOL BIOL CELL, V14, P764, DOI 10.1091/mbc.E02-08-0498; Wilson MR, 2002, TOXICOL APPL PHARM, V184, P172, DOI 10.1006/taap.2002.9501; Xiong SG, 2003, J BIOL CHEM, V278, P17646, DOI 10.1074/jbc.M210905200; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	57	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2912	2923		10.1074/jbc.M409524200	http://dx.doi.org/10.1074/jbc.M409524200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15550384	hybrid			2022-12-25	WOS:000226449100067
J	Kim, EH; Kim, SU; Choi, KS				Kim, EH; Kim, SU; Choi, KS			Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; rottlerin; apoptosis; glioma	PROTEIN-KINASE-C; LIGAND-INDUCED APOPTOSIS; X-LINKED INHIBITOR; PROSTATE-CANCER CELLS; MEDIATED APOPTOSIS; GLIAL-CELLS; EXPRESSION; DELTA; FAMILY; DEATH	In the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant glioma cells, treatment with TRAIL in combination with subtoxic doses of rottlerin induced rapid apoptosis. While the proteolytic processing of procaspase-3 by TRAIL was partially blocked in these cells, treatment with rottlerin efficiently recovered TRAIL-induced activation of caspases. Treatment with rottlerin significantly decreased Cdc2 activity through the downregulation of cyclin A, cyclin B, and Cdc2 proteins, whereas the sensitizing effect of rottlerin on TRAIL-induced apoptosis was independent of PKCdelta activity. Furthermore, treatment with rottlerin downregulated the protein levels of survivin and X-chromosome-linked IAP (XIAP), two major caspase inhibitors. Forced expression of Cdc2 together with cyclin B attenuated rottlerin-potentiated TRAIL-induced apoptosis by over-riding the rottlerin-mediated downregulation of survivin and XIAP protein levels. Taken together, inhibition of Cdc2 activity and the subsequent downregulation of survivin and XIAP by subtoxic doses of rottlerin contribute to amplification of caspase cascades, thereby overcoming resistance of glioma cells to TRAIL-mediated apoptosis. Since rottlerin can sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells but not human astrocytes to TRAIL-induced apoptosis, this combined treatment may offer an attractive strategy for safely treating resistant gliomas.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea	Ajou University; Ajou University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Griffith TS, 2002, CANCER RES, V62, P3093; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hao CH, 2001, CANCER RES, V61, P1162; Harper N, 2003, J BIOL CHEM, V278, P44338, DOI 10.1074/jbc.M307376200; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lavia P, 1999, BIOESSAYS, V21, P221; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Mandil R, 2001, CANCER RES, V61, P4612; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shingu T, 2003, J NEUROSURG, V98, P154, DOI 10.3171/jns.2003.98.1.0154; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Susarla BTS, 2003, J NEUROCHEM, V86, P635, DOI 10.1046/j.1471-4159.2003.01886.x; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Tillman DM, 2003, CANCER RES, V63, P5118; Toth R, 1999, EUR J IMMUNOL, V29, P383, DOI 10.1002/(SICI)1521-4141(199902)29:02<383::AID-IMMU383>3.0.CO;2-A; Trauzold A, 2003, ONCOGENE, V22, P8939, DOI 10.1038/sj.onc.1207001; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Welters HJ, 2004, J MOL ENDOCRINOL, V32, P227, DOI 10.1677/jme.0.0320227; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2001, CANCER RES, V61, P7339; Zhao HY, 2002, AM J PHYSIOL-RENAL, V282, pF710, DOI 10.1152/ajprenal.00303.2001; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	64	36	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					838	849		10.1038/sj.onc.1208241	http://dx.doi.org/10.1038/sj.onc.1208241			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15531913				2022-12-25	WOS:000226577100010
J	Foltyn, VN; Bendikov, I; De Miranda, J; Panizzutti, R; Dumin, E; Shleper, M; Li, P; Toney, MD; Kartvelishvily, E; Wolosker, H				Foltyn, VN; Bendikov, I; De Miranda, J; Panizzutti, R; Dumin, E; Shleper, M; Li, P; Toney, MD; Kartvelishvily, E; Wolosker, H			Serine racemase modulates intracellular D-serine levels through an alpha,beta-elimination activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMODULATOR D-SERINE; D-ASPARTATE RECEPTOR; RAT-BRAIN; IN-VIVO; THREONINE DEAMINASE; ALANINE; MECHANISM; IDENTIFICATION; METABOLISM; ASTROCYTES	Mammalian brain contains high levels of D-serine, an endogenous co-agonist of N-methyl D-aspartate type of glutamate receptors. D-Serine is synthesized by serine racemase, a brain enriched enzyme converting L- to D-serine. Degradation of D-serine is achieved by D-amino acid oxidase, but this enzyme is not present in forebrain areas that are highly enriched in D-serine. We now report that serine racemase catalyzes the degradation of cellular D-serine itself, through the alpha,beta-elimination of water. The enzyme also catalyzes water alpha,beta-elimination with L-serine and L-threonine. alpha,beta-Elimination with these substrates is observed both in vitro and in vivo. To investigate further the role of alpha,beta-elimination in regulating cellular D-serine, we generated a serine racemase mutant displaying selective impairment of alpha,beta-elimination activity (Q155D). Levels of D-serine synthesized by the Q155D mutant are several-fold higher than the wildtype both in vitro and in vivo. This suggests that the alpha,beta-elimination reaction limits the achievable D-serine concentration in vivo. Additional mutants in vicinal residues (H152S, P153S, and N154F) similarly altered the partition between the alpha, beta-elimination and racemization reactions. alpha,beta-Elimination also competes with the reverse serine racemase reaction in vivo. Although the formation of L- from D-serine is readily detected in Q155D mutant-expressing cells incubated with physiological D-serine concentrations, reversal with wild-type serine racemase-expressing cells required much higher D-serine concentration. We propose that alpha,beta-elimination provides a novel mechanism for regulating intracellular D-serine levels, especially in brain areas that do not possess D-amino acid oxidase activity. Extracellular D-serine is more stable toward alpha,beta-elimination, likely due to physical separation from serine racemase and its elimination activity.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Univ Fed Rio de Janeiro, Dept Biochem, BR-21941590 Rio De Janeiro, Brazil; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Universidade Federal do Rio de Janeiro; University of California System; University of California Davis	Wolosker, H (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.	hwolosker@tx.technion.ac.il		Wolosker, Herman/0000-0001-5508-9194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054779, R56GM054779] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54779] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Danysz W, 1998, PHARMACOL REV, V50, P597; De Miranda J, 2000, GENE, V256, P183, DOI 10.1016/S0378-1119(00)00356-5; de Miranda J, 2002, P NATL ACAD SCI USA, V99, P14542, DOI 10.1073/pnas.222421299; Dunlop DS, 1997, BIOCHEM BIOPH RES CO, V235, P26, DOI 10.1006/bbrc.1997.6724; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; FISHER KE, 1993, J BACTERIOL, V175, P6605, DOI 10.1128/jb.175.20.6605-6613.1993; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Hashimoto A, 1997, PROG NEUROBIOL, V52, P325, DOI 10.1016/S0301-0082(97)00019-1; HASHIMOTO A, 1992, J CHROMATOGR-BIOMED, V582, P41, DOI 10.1016/0378-4347(92)80300-F; HASHIMOTO A, 1993, NEUROSCI LETT, V152, P33, DOI 10.1016/0304-3940(93)90476-2; HASHIMOTO A, 1995, NEUROSCIENCE, V66, P635, DOI 10.1016/0306-4522(94)00597-X; HASHIMOTO A, 1993, J NEUROCHEM, V60, P783, DOI 10.1111/j.1471-4159.1993.tb03219.x; Hayashi F, 1997, NEUROSCI LETT, V239, P85, DOI 10.1016/S0304-3940(97)00892-6; Helboe L, 2003, EUR J NEUROSCI, V18, P2227, DOI 10.1046/j.1460-9568.2003.02966.x; Huang Y, 1998, BIOL PHARM BULL, V21, P156, DOI 10.1248/bpb.21.156; JOHN RA, 1993, ENZYME ASSAYS PRACTI, P76; KATSUKI H, 1971, ANAL BIOCHEM, V43, P349, DOI 10.1016/0003-2697(71)90263-6; MORINO Y, 1967, J BIOL CHEM, V242, P2800; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Neidle A, 2002, NEUROCHEM RES, V27, P1719, DOI 10.1023/A:1021607715824; Panizzutti R, 2001, P NATL ACAD SCI USA, V98, P5294, DOI 10.1073/pnas.091002298; PAXTON R, 1986, BIOCHEM J, V234, P295, DOI 10.1042/bj2340295; Ribeiro CS, 2002, BRAIN RES, V929, P202, DOI 10.1016/S0006-8993(01)03390-X; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SCHWARTZENBACH G, 1957, HELV CHIM ACTA, V40, P1186; Silbernagl S, 1999, AM J PHYSIOL-RENAL, V276, pF857, DOI 10.1152/ajprenal.1999.276.6.F857; Stevens ER, 2003, P NATL ACAD SCI USA, V100, P6789, DOI 10.1073/pnas.1237052100; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Strisovsky K, 2003, FEBS LETT, V535, P44, DOI 10.1016/S0014-5793(02)03855-3; Sun SX, 1999, BIOCHEMISTRY-US, V38, P4058, DOI 10.1021/bi982924t; Takahashi K, 1997, J NEUROCHEM, V69, P1286; Tsai GC, 1998, BIOL PSYCHIAT, V44, P1081, DOI 10.1016/S0006-3223(98)00279-0; WAKO K, 1995, NEUROSCI LETT, V185, P171, DOI 10.1016/0304-3940(95)11253-S; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 2002, NEUROCHEM INT, V41, P327, DOI 10.1016/S0197-0186(02)00055-4; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	41	162	167	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1754	1763		10.1074/jbc.M405726200	http://dx.doi.org/10.1074/jbc.M405726200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15536068	hybrid			2022-12-25	WOS:000226341700008
J	Vernochet, C; Azoulay, S; Duval, D; Guedj, R; Cottrez, F; Vidal, H; Ailhaud, G; Dani, C				Vernochet, C; Azoulay, S; Duval, D; Guedj, R; Cottrez, F; Vidal, H; Ailhaud, G; Dani, C			Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; HIV-INFECTED SUBJECTS; EMBRYONIC STEM-CELLS; DIFFERENTIATION; PLASMA; LIPODYSTROPHY; ADIPONECTIN; RITONAVIR; PHARMACOKINETICS; DISPOSITION	Lipodystrophic syndrome is a major side effect of highly active antiviral therapy. Fat tissue redistribution is associated with changes in adipocyte gene expression and in circulating levels of adipocytokines involved in the development of insulin resistance. However, the evidence that HIV drugs accumulate into human adipocytes and have a direct effect on the expression of adipocyte-specific genes is still lacking. To address these questions, we used adipocytes derived from adult stem (hMADS) cells isolated from human adipose tissue. We showed by ELISA that two inhibitors of the HIV protease, lopinavir and ritonavir, accumulated at similar levels during the development of hMADS cells in adipocytes, whereas a non-nucleoside reverse transcriptase inhibitor, the nevirapine, accumulated at lower levels. Two fluorescent protease inhibitors then have been generated to investigate their subcellular localization. The data showed that HIV drugs accumulated into adipocytes and displayed various effects on hMADS cell-derived adipocytes. Indinavir, amprenavir, and nevirapine did not alter differentiation of precursor cells. In contrast, lopinavir, saquinavir, and ritonavir inhibited the development of preadipocytes into adipocytes. In adipocytes, amprenavir increased leptin expression and ritonavir was able to up-regulate tumor necrosis factor-alpha, interleukin 6, and leptin expression and downregulate the expression of peroxisome proliferator-activated receptor gamma and adiponectin. Intracellular accumulation and localization of HIV drugs into human adipocytes strongly suggest that adipose tissues store these drugs. Because ritonavir can alter the expression of insulin resistance-related cytokines in human adipocytes in a way parallel to the situation observed in vivo upon treatment of HIV-infected patients, we propose that protease inhibitors participate in insulin resistance through a direct effect on adipocytes.	Ctr Biochim, Inst Signalisat Biol Dev & Canc, CNRS, UMR 6543, F-06108 Nice, France; Chim Bioorgan Lab, CNRS, UMR 6001, F-06108 Nice, France; Hop Archet, INSERM, U343, F-06202 Nice, France; Fac Med R Laennec, INSERM, U449, F-69372 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm)	Dani, C (corresponding author), Ctr Biochim, Inst Signalisat Biol Dev & Canc, CNRS, UMR 6543, F-06108 Nice, France.	dani@unice.fr	DANI, Christian/G-3639-2014; Vidal, Hubert/M-6674-2017	DANI, Christian/0000-0003-3228-0230; Vidal, Hubert/0000-0002-9467-0317; Ailhaud, Gerard/0000-0003-0596-2906; AZOULAY, Stephane/0000-0002-1125-9291				Akeb F, 2002, J IMMUNOL METHODS, V263, P1, DOI 10.1016/S0022-1759(02)00026-1; Azoulay S, 2004, ANTIMICROB AGENTS CH, V48, P104, DOI 10.1128/AAC.48.1.104-109.2004; Balani SK, 1996, DRUG METAB DISPOS, V24, P1389; Barreiro P, 2000, AIDS, V14, P807, DOI 10.1097/00002030-200005050-00006; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Boffito M, 2004, ANTIVIR THER, V9, P423; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Dani C, 1997, J CELL SCI, V110, P1279; Dani C, 2002, Methods Mol Biol, V185, P107; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Dupin N, 2002, AIDS, V16, P2419, DOI 10.1097/00002030-200212060-00006; El Hadri K, 2004, J BIOL CHEM, V279, P15130, DOI 10.1074/jbc.M312875200; Fasshauer M, 2003, BIOCHEM BIOPH RES CO, V301, P1045, DOI 10.1016/S0006-291X(03)00090-1; FRIEDMAN JM, 2002, NUTR REV, V84, P85; Hotamisligil GS, 2000, INT J OBESITY, V24, pS23, DOI 10.1038/sj.ijo.0801497; Hsu A, 1997, ANTIMICROB AGENTS CH, V41, P898, DOI 10.1128/AAC.41.5.898; Imai T, 2004, P NATL ACAD SCI USA, V101, P4543, DOI 10.1073/pnas.0400356101; Jain RG, 2002, J BIOL CHEM, V277, P19247, DOI 10.1074/jbc.C200069200; Janneh O, 2003, ANTIVIR THER, V8, P417; Khoo SH, 2002, ANTIMICROB AGENTS CH, V46, P3228, DOI 10.1128/AAC.46.10.3228-3235.2002; Kinlaw WB, 2004, ENDOCRINOLOGY, V145, P484, DOI 10.1210/en.2003-1513; Lihn AS, 2003, AM J PHYSIOL-ENDOC M, V285, pE1072, DOI 10.1152/ajpendo.00206.2003; Pai VB, 1999, ANN PHARMACOTHER, V33, P325, DOI 10.1345/aph.18089; Perrey S, 2001, METABOLISM, V50, P36, DOI 10.1053/meta.2001.19505; Roche R, 2002, AIDS, V16, P13, DOI 10.1097/00002030-200201040-00003; Rodriguez AM, 2004, BIOCHEM BIOPH RES CO, V315, P255, DOI 10.1016/j.bbrc.2004.01.053; VASSAUX G, 1994, J CELL PHYSIOL, V161, P249, DOI 10.1002/jcp.1041610209; Vernochet C, 2003, AIDS, V17, P2177, DOI 10.1097/00002030-200310170-00005; Vigouroux C, 2003, AIDS, V17, P1503, DOI 10.1097/00002030-200307040-00011; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274	30	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2238	2243		10.1074/jbc.M408687200	http://dx.doi.org/10.1074/jbc.M408687200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15525648	Green Published, hybrid			2022-12-25	WOS:000226341700060
J	Kasza, A; O'Donnell, A; Gascoigne, K; Zeef, LAH; Hayes, A; Sharrocks, AD				Kasza, A; O'Donnell, A; Gascoigne, K; Zeef, LAH; Hayes, A; Sharrocks, AD			The ETS domain transcription factor Elk-1 regulates the expression of its partner protein, SRF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; TERNARY COMPLEX FACTORS; C-FOS PROMOTER; GENE-EXPRESSION; DNA-BINDING; ACTIVATION; COACTIVATOR; MYOCARDIN; PHOSPHORYLATION; TARGET	The ternary complex factors (TCF) are a subfamily of ETS domain transcription factors that bind and activate serum response elements (SREs) in the promoters of target genes in a ternary complex with a second transcription factor, serum response factor (SRF). Here, we have identified the SRF gene as a target for the TCFs, thereby providing a positive feedback loop whereby TCF activation leads to the enhancement of the expression of its partner protein SRF. The binding of the TCF Elk-1 to the SRF promoter and subsequent regulation of SRF expression occurs in a ternary complex-dependent manner. Our data therefore reveal that SRF is an important target for the ERK and Rho signaling pathways that converge on a ternary TCF-SRF complex at the SRE on the SRF promoter.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Sharrocks, AD (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	a.d.sharrocks@man.ac.uk	Zeef, Leo/D-6922-2011	Hayes, Andy/0000-0002-9525-0306; O'Donnell, Amanda/0000-0003-3655-6126				Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Cesari F, 2004, MOL CELL BIOL, V24, P294, DOI 10.1128/MCB.24.1.294-305.2004; Costello PS, 2004, NAT IMMUNOL, V5, P289, DOI 10.1038/ni1038; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; Latinkic BV, 1996, NUCLEIC ACIDS RES, V24, P1345, DOI 10.1093/nar/24.7.1345; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Li QJ, 2000, BLOOD, V96, P3696, DOI 10.1182/blood.V96.12.3696.h8003696_3696_3706; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Murai K, 2002, MOL CELL BIOL, V22, P7083, DOI 10.1128/MCB.22.20.7083-7092.2002; OHagan RC, 1996, ONCOGENE, V13, P1323; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Selvaraj A, 2003, J BIOL CHEM, V278, P41977, DOI 10.1074/jbc.M305679200; Sharrocks AD, 2002, BIOCHEM SOC T, V30, P1; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Vickers ER, 2004, MOL CELL BIOL, V24, P10340, DOI 10.1128/MCB.24.23.10340-10351.2004; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	40	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1149	1155		10.1074/jbc.M411161200	http://dx.doi.org/10.1074/jbc.M411161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15531578	hybrid			2022-12-25	WOS:000226195200036
J	Sandberg, MK; Low, P				Sandberg, MK; Low, P			Altered interaction and expression of proteins involved in neurosecretion in scrapie-infected GT1-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; CENTRAL-NERVOUS-SYSTEM; CALCIUM-CHANNELS; N-TYPE; NEUROTRANSMITTER RELEASE; PRION PROTEIN; DIFFERENTIAL EXPRESSION; CA2+ CHANNELS; MOLECULAR DETERMINANTS; FUNCTIONAL INTERACTION	Prions cause transmissible and fatal diseases that are associated with spongiform degeneration, astrogliosis, and loss of axon terminals in the brains. To determine the expression of proteins involved in neurosecretion and synaptic functions after prion infection, gonadotropin-releasing hormone neuronal cell line subclone (GT1-1) was infected with the RML scrapie strain and analyzed by Western blotting, real time PCR, and immunohistochemistry. As revealed by Western blotting of lysates exposed to different temperatures, the levels of complexed SNAP-25, syntaxin 1A, and synaptophysin were decreased in scrapie-infected GT1-1 cells (ScGT1-1), whereas the level of monomeric forms of these proteins was increased and correlated to the level of scrapie prion protein (PrPSc). However, when complex formation was prevented by prolonged heating of samples in SDS, the levels of monomeric SNAP-25, syntaxin 1A and synaptophysin in ScGT1-1 cells were decreased in comparison to GT1-1 cells. The reduced level of SNAP-25 was observed as early as 32 days postinfection. Increased mRNA levels of both splice variants SNAP-25a and -b in ScGT1-1 cells were seen. No difference in the morphology, neuritic outgrowth or distribution of SNAP-25, syntaxin 1A, or synaptophysin could be observed in ScGT1-1 cells. Treatment with quinacrine or pentosan polysulfate cleared the PrPSc from the ScGT1-1 cell cultures, and the increase in levels of monomeric SNAP-25 and synaptophysin was reversible. These results indicate that a scrapie infection can cause changes in the expression of proteins involved in neuronal secretion, which may be of pathogenetic relevance for the axon terminal changes seen in prion-infected brains.	Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden	Karolinska Institutet	Sandberg, MK (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Vag 8 B2-5, S-17177 Stockholm, Sweden.	malin.sandberg@neuro.ki.se						Aguado F, 1999, NEUROSCIENCE, V93, P275, DOI 10.1016/S0306-4522(99)00103-7; Ahnert-Hilger G, 1998, EUR J NEUROSCI, V10, P1145, DOI 10.1046/j.1460-9568.1998.00129.x; ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BARK IC, 1995, P NATL ACAD SCI USA, V92, P1510, DOI 10.1073/pnas.92.5.1510; Becher A, 1999, J NEUROSCI, V19, P1922; Bergsman JB, 2000, J NEUROSCI, V20, P4368, DOI 10.1523/JNEUROSCI.20-12-04368.2000; Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Boschert U, 1996, J COMP NEUROL, V367, P177, DOI 10.1002/(SICI)1096-9861(19960401)367:2<177::AID-CNE2>3.0.CO;2-2; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CLINTON J, 1993, NEUROREPORT, V4, P65, DOI 10.1097/00001756-199301000-00017; Cunningham C, 2003, EUR J NEUROSCI, V17, P2147, DOI 10.1046/j.1460-9568.2003.02662.x; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Ferrer I, 1999, NEUROBIOL DIS, V6, P92, DOI 10.1006/nbdi.1998.0226; Ferrer I, 2000, NEUROSCIENCE, V97, P715, DOI 10.1016/S0306-4522(00)00045-2; GEDDES JW, 1990, NEUROSCIENCE, V38, P515, DOI 10.1016/0306-4522(90)90047-8; Gonelle-Gispert C, 1999, BIOCHEM J, V339, P159, DOI 10.1042/0264-6021:3390159; Grant NJ, 1999, J NEUROCHEM, V72, P363, DOI 10.1046/j.1471-4159.1999.0720363.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; JEFFREY M, 1995, NEUROPATH APPL NEURO, V21, P41, DOI 10.1111/j.1365-2990.1995.tb01027.x; Jeffrey M, 1997, NEUROPATH APPL NEURO, V23, P93, DOI 10.1111/j.1365-2990.1997.tb01191.x; Jeffrey M, 2000, NEUROPATH APPL NEURO, V26, P41, DOI 10.1046/j.1365-2990.2000.00216.x; Jeffrey M, 2001, J COMP PATHOL, V124, P20, DOI 10.1053/jcpa.2000.0423; KITAMOTO T, 1992, AM J PATHOL, V141, P271; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; LANDIS DMD, 1981, NEUROLOGY, V31, P538, DOI 10.1212/WNL.31.5.538; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Low P, 1999, EUR J CELL BIOL, V78, P787, DOI 10.1016/S0171-9335(99)80029-6; Marti E, 1999, NEUROSCIENCE, V90, P1421, DOI 10.1016/S0306-4522(98)00522-3; MCKINLEY MP, 1991, LAB INVEST, V65, P622; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; Patanow CM, 1997, NEUROSCIENCE, V76, P187; PRUSINER SB, 1999, PRION BIOL DIS, P585; Sandberg MK, 2004, NEUROBIOL DIS, V15, P143, DOI 10.1016/j.nbd.2003.09.006; Sanders JD, 1998, J NEUROSCI RES, V53, P670, DOI 10.1002/(SICI)1097-4547(19980915)53:6<670::AID-JNR5>3.3.CO;2-H; SANNA PP, 1991, DEV BRAIN RES, V59, P104, DOI 10.1016/0165-3806(91)90035-H; Schatzl HM, 1997, J VIROL, V71, P8821; Siso S, 2002, ACTA NEUROPATHOL, V103, P615, DOI 10.1007/s00401-001-0512-6; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; Spafford JD, 2003, CURR OPIN NEUROBIOL, V13, P308, DOI 10.1016/S0959-4388(03)00061-8; Vazquez-Martinez R, 2001, ENDOCRINOLOGY, V142, P5364, DOI 10.1210/en.142.12.5364; Verderio C, 2004, NEURON, V41, P599, DOI 10.1016/S0896-6273(04)00077-7; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WIEDENMANN B, 1986, P NATL ACAD SCI USA, V83, P3500, DOI 10.1073/pnas.83.10.3500; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Xiao JN, 2004, J NEUROSCI RES, V75, P143, DOI 10.1002/jnr.10840; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721	56	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1264	1271		10.1074/jbc.M411439200	http://dx.doi.org/10.1074/jbc.M411439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528199	hybrid			2022-12-25	WOS:000226195200051
J	Jurek, D; Udilova, N; Jozkowicz, A; Nohl, H; Marian, B; Schulte-Hermann, R				Jurek, D; Udilova, N; Jozkowicz, A; Nohl, H; Marian, B; Schulte-Hermann, R			Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells	FASEB JOURNAL			English	Article						colon carcinogenesis; dietary fat; fatty acid hydroperoxides; cyclooxygenase-2	PROTEIN-KINASE-C; INTESTINAL POLYPOSIS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; PROSTATE-CANCER; UP-REGULATION; COLON-CANCER; CARCINOGENESIS; BREAST; RISK	Fatty acid hydroperoxides arise from unsaturated fatty acids in the presence of oxygen and elevated temperature during processing of food. Here we have studied their effects on gene expression in colorectal tumor cells using linoleic acid hydroperoxide (LOOH) as a model compound. Its addition to the medium of LT97 human adenoma cells and SW480 human carcinoma cells enhanced the production of intracellular hydrogen peroxide. Furthermore, in both cell lines, increases in VEGF mRNA and protein were observed. Unoxidized linoleic acid had little or no activity. Concomitantly, COX-2 expression was up-regulated. In the LT97 cells, the COX inhibitors SC58560 and SC58236 completely prevented the VEGF induction, suggesting that the effect was dependent on prostaglandin synthesis. In vivo prostaglandin-mediated induction of VEGF secretion is known to be essential for the growth of adenomatous polyps and their progression to carcinomas. Therefore, our results for the first time implicate dietary lipid hydroperoxide as a key risk factor in colon carcinogenesis.	Med Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Vet Univ Vienna, Res Inst Pharmacol & Toxicol, Vienna, Austria; Jagiellonian Univ, Fac Biotechnol, Krakow, Poland	Medical University of Vienna; University of Veterinary Medicine Vienna; Jagiellonian University	Marian, B (corresponding author), Med Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	brigitte.marian@meduniwien.ac.at	Rohr-Udilova, Nataliya/J-6751-2015	Rohr-Udilova, Nataliya/0000-0003-2432-3632				Bartsch H, 1999, CARCINOGENESIS, V20, P2209, DOI 10.1093/carcin/20.12.2209; Bartsch H, 2002, CANCER DETECT PREV, V26, P308, DOI 10.1016/S0361-090X(02)00093-4; Bird RP, 2000, TOXICOL LETT, V112, P395, DOI 10.1016/S0378-4274(99)00261-1; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEDMAN E, 1989, CANCER RES, V49, P544; Furstenberger G, 2002, PROSTAG OTH LIPID M, V68-9, P235, DOI 10.1016/S0090-6980(02)00033-3; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; HIETANEN E, 1994, EUR J CLIN NUTR, V48, P575; Jiang WG, 2003, PROSTAG LEUKOTR ESS, V69, P275, DOI 10.1016/S0952-3278(03)00110-8; Jozkowicz A, 2001, CARDIOVASC RES, V51, P773, DOI 10.1016/S0008-6363(01)00344-3; KahlRainer P, 1996, GASTROENTEROLOGY, V110, P1753, DOI 10.1053/gast.1996.v110.pm8964400; Kanazawa K, 1998, BBA-LIPID LIPID MET, V1393, P349, DOI 10.1016/S0005-2760(98)00089-7; Kanner J, 2001, FREE RADICAL BIO MED, V31, P1388, DOI 10.1016/S0891-5849(01)00718-3; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Liu ZH, 2001, INT J ONCOL, V19, P1009; Mason Joel B, 2002, Semin Gastrointest Dis, V13, P143; Matsuyama M, 2004, INT J ONCOL, V24, P821; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Paul S, 1997, CRIT REV FOOD SCI, V37, P635, DOI 10.1080/10408399709527793; Rao CV, 2001, CANCER RES, V61, P1927; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Rota C, 1997, BIOCHEM J, V328, P565, DOI 10.1042/bj3280565; Schulte-Hermann R, 1999, TOXICOLOGY, P179; Seno H, 2002, CANCER RES, V62, P506; SNYDERWINE EG, 2002, MUTAT RES, V506, P215; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stamp DH, 2002, MED HYPOTHESES, V59, P398, DOI 10.1016/S0306-9877(02)00125-1; Stolze K, 2000, FREE RADICAL BIO MED, V29, P1005, DOI 10.1016/S0891-5849(00)00401-9; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Udilova N, 2003, FOOD CHEM TOXICOL, V41, P1481, DOI 10.1016/S0278-6915(03)00164-9; Urata Y, 2002, FREE RADICAL BIO MED, V32, P688, DOI 10.1016/S0891-5849(01)00823-1; WEINSTEIN IB, 1991, ENVIRON HEALTH PERSP, V93, P175, DOI 10.2307/3431186; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; Winer I, 2002, MELANOMA RES, V12, P429, DOI 10.1097/00008390-200209000-00003; Yoshimura R, 2003, J UROLOGY, V170, P1994, DOI 10.1097/01.ju.0000080296.54262.c8; Zhu JW, 2002, WORLD J GASTROENTERO, V8, P153, DOI 10.3748/wjg.v8.i1.153	40	30	30	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					97	+		10.1096/fj.04-2111fje	http://dx.doi.org/10.1096/fj.04-2111fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522906				2022-12-25	WOS:000225482100028
J	Lecca, MR; Wagner, U; Patrignani, A; Berger, EG; Hennet, T				Lecca, MR; Wagner, U; Patrignani, A; Berger, EG; Hennet, T			Genome-wide analysis of the unfolded protein response in fibroblasts from congenital disorders of glycosylation type-I patients	FASEB JOURNAL			English	Article						disease; stress; oligonucleotide array; transcriptome	ENDOPLASMIC-RETICULUM STRESS; ER-ASSOCIATED DEGRADATION; MOLECULAR CHAPERONE; GENE-EXPRESSION; TRANSCRIPTIONAL INDUCTION; MISFOLDED GLYCOPROTEINS; TRANSMEMBRANE PROTEIN; MAMMALIAN-CELLS; KINASE-ACTIVITY; REQUIRES	Congenital disorders of glycosylation (CDG) are a family of diseases characterized by defects of N-linked glycosylation. In CDG-I, several genetic defects cause a shortage of dolichol-linked oligosaccharides, which leads to underglycosylation of nascent glycoproteins. N-linked glycosylation is important for proper folding and trafficking of glycoproteins. Inhibition of glycosylation results in the buildup of misfolded proteins in the endoplasmic reticulum, which induces a protective reaction known as the unfolded protein response (UPR). To investigate whether UPR components are induced in CDG, we have performed a transcriptome analysis of primary fibroblasts from unaffected control subjects and from CDG-I patients using oligonucleotide gene expression arrays. The stress imposed by CDG was also compared with the stress induced by tunicamycin and glucose deprivation. Whereas tunicamycin elicited a strong transcriptional response typical for the UPR, CDG fibroblasts displayed a qualitatively similar yet moderate induction of genes encoding components of the UPR. Among these genes, the PERK kinase inhibitor DNAJC3/P58(IPK) gene showed the highest induction throughout all CDG-I types tested. This was paralleled by elevated expression of genes involved in amino acid biosynthesis and transport, which defined a new component of the cellular response to glycosylation stress.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Funct Genom Ctr Zurich, Zurich, Switzerland	University of Zurich	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	thennet@access.unizh.ch		Partigiani, Andrea/0000-0001-8019-3911				Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; Aebi M, 1999, Glycoconj J, V16, P669; Baek JY, 2003, BIOCHEM J, V373, P191, DOI 10.1042/BJ20030144; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERGER EG, 1993, J CELL BIOCHEM, V52, P275, DOI 10.1002/jcb.240520304; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gill A, 2002, J BIOL CHEM, V277, P44747, DOI 10.1074/jbc.M205001200; Grubenmann CE, 2002, HUM MOL GENET, V11, P2331, DOI 10.1093/hmg/11.19.2331; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Imbach T, 2000, HUM GENET, V106, P538, DOI 10.1007/s004390050022; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Imbach T, 1999, P NATL ACAD SCI USA, V96, P6982, DOI 10.1073/pnas.96.12.6982; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim BI, 2000, MAX PLANCK SERIES, V1, P105; Klebl B, 2001, BIOCHEM BIOPH RES CO, V286, P714, DOI 10.1006/bbrc.2001.5457; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; MORI K, 1993, CELL, V74, P743; Mote PL, 1998, MECH AGEING DEV, V104, P149, DOI 10.1016/S0047-6374(98)00064-5; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yang YH, 2002, NAT REV GENET, V3, P579, DOI 10.1038/nrg863; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200	46	41	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					240	+		10.1096/fj.04-2397fje	http://dx.doi.org/10.1096/fj.04-2397fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545299				2022-12-25	WOS:000225482100019
J	Martinez-Rico, C; Pincet, F; Perez, E; Thiery, JP; Shimizu, K; Takai, Y; Dufour, S				Martinez-Rico, C; Pincet, F; Perez, E; Thiery, JP; Shimizu, K; Takai, Y; Dufour, S			Separation force measurements reveal different types of modulation of E-cadherin-based adhesion by nectin-1 and-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; POLIOVIRUS RECEPTOR; ADHERENS JUNCTIONS; ALPHA-CATENIN; PROTEIN INTERACTIONS; CYTOPLASMIC DOMAIN; BINDING PROTEIN; SENSORY NEURONS; TIGHT JUNCTIONS; MOLECULAR-BASIS	Nectins are Ca2+-independent cell adhesion molecules found at cadherin-based adherens junctions. We used a,dual pipette assay that measures the forces required to separate cell doublets to determine how nectins affect the formation and strength of cell-cell adhesion. Less force was required to separate doublets of L cells expressing nectin-1 or nectin-3 than to separate doublets of E-cadherin-expressing cells. Heterodimers formed between cells expressing nectin-1 or nectin-3 adhered more strongly than homodimers. Nectin-3 that does not trans-interact with nectin-1 inhibited E-cadherin-mediated adhesion. However, the extracellular fragment of nectin-1 did not have an agonistic effect on E-cadherindependent cell adhesion when it trans-interacted with nectin-3, expressed at high levels in cells. In contrast, the extracellular fragment of nectin-3 had a significant agonistic effect on cadherin-based adhesion when it interacted with endogenous nectin-1, expressed at low levels in cells. Our results indicate that E-cadherin is the key molecule involved in cell adhesion and that the regulation of E-cadherin-based adhesion involving cellular nectin-1 trans-interacting with nectin-3 is qualitatively different from that involving cellular nectin-3 trans-interacting with nectin-1 and depends on the nectin levels expressed by cells.	CNRS, Inst Curie, UMR 144, F-75248 Paris 05, France; CNRS, ENS, UMR 8550, F-75248 Paris 05, France; Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Osaka University	Dufour, S (corresponding author), CNRS, Inst Curie, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.	Sylvie.Dufour@curie.fr	DUFOUR, Sylvie/G-2253-2019; Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Dufour, Sylvie/0000-0002-6663-0676; Thiery, Jean Paul/0000-0003-0478-5020; PINCET, FREDERIC/0000-0002-4243-2157				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; BEAUVAIS A, 1995, J CELL BIOL, V128, P699, DOI 10.1083/jcb.128.4.699; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Chu YS, 2004, J CELL BIOL, V167, P1183, DOI 10.1083/jcb.200403043; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Daoudi M, 2004, J BIOL CHEM, V279, P19649, DOI 10.1074/jbc.M313457200; Dufour S, 1999, J CELL BIOL, V146, P501, DOI 10.1083/jcb.146.2.501; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haarr L, 2001, VIROLOGY, V287, P301, DOI 10.1006/viro.2001.1041; HERRENKNECHT K, 1996, MOL MED SCI, P45; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kemler R, 1992, Semin Cell Biol, V3, P149; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mata M, 2001, J NEUROVIROL, V7, P476, DOI 10.1080/135502801753170336; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Richart SM, 2003, J VIROL, V77, P3307, DOI 10.1128/JVI.77.5.3307-3311.2003; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P6791, DOI 10.1073/pnas.96.12.6791; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; SUNG KLP, 1986, SCIENCE, V234, P1405, DOI 10.1126/science.3491426; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TAKEICHI M, 1988, CELL DIFFER DEV    S, V9, P1; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wheelock MJ, 1996, CURR TOP MEMBR, V43, P169; Yagi T, 2000, GENE DEV, V14, P1169; Yasumi M, 2003, BIOCHEM BIOPH RES CO, V302, P61, DOI 10.1016/S0006-291X(03)00106-2	58	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4753	4760		10.1074/jbc.M412544200	http://dx.doi.org/10.1074/jbc.M412544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15550395	hybrid			2022-12-25	WOS:000227096600092
J	Backlund, MG; Mann, JR; Holla, VR; Buchanan, FG; Tai, HH; Musiek, ES; Milne, GL; Katkuri, S; DuBois, RN				Backlund, MG; Mann, JR; Holla, VR; Buchanan, FG; Tai, HH; Musiek, ES; Milne, GL; Katkuri, S; DuBois, RN			15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CANCER; PROSTAGLANDIN E-2; CYCLOOXYGENASE INHIBITORS; CELL-MIGRATION; GROWTH; EXPRESSION; RECEPTOR; 15-PGDH; INDOMETHACIN; EGF	Prostaglandin E-2 (PGE(2)) can stimulate tumor progression by modulating several proneoplastic pathways, including proliferation, angiogenesis, cell migration, invasion, and apoptosis. Although steady-state tissue levels of PGE(2) stem from relative rates of biosynthesis and breakdown, most reports examining PGE(2) have focused solely on the cyclooxygenase-dependent formation of this bioactive lipid. Enzymatic degradation of PGE(2) involves the NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The present study examined a range of normal tissues in the human and mouse and found high levels of 15-PGDH in the large intestine. By contrast, the expression of 15-PGDH is decreased in several colorectal carcinoma cell lines and in other human malignancies such as breast and lung carcinomas. Consistent with these findings, we observe diminished 15-Pgdh expression in Ape(Min+/-) mouse adenomas. Enzymatic activity of 15-PGDH correlates with expression levels and the genetic disruption of 15-Pgdh completely blocks production of the urinary PGE(2) metabolite. Finally, 15-PGDH expression and activity are significantly down-regulated in human colorectal carcinomas relative to matched normal tissue. In summary, these results suggest a novel tumor suppressive role for 15-PGDH due to loss of expression during colorectal tumor progression.	Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Kentucky	DuBois, RN (corresponding author), Vanderbilt Ingram Canc Ctr, 691 Preston Res Bldg,2300 Pierce Ave, Nashville, TN 37232 USA.	raymond.dubois@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020; Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X; Musiek, Erik/0000-0002-8873-0360	NCI NIH HHS [P0-CA77839, P01 CA077839] Funding Source: Medline; NIDDK NIH HHS [R37-DK47297, R01 DK062112, T32 DK007673, R37 DK047297, R0-DK-62112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062112, R37DK047297, T32DK007673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Cho H, 2002, PROSTAG LEUKOTR ESS, V67, P461, DOI 10.1054/plef.2002.0457; Cho H, 2002, ARCH BIOCHEM BIOPHYS, V405, P247, DOI 10.1016/S0003-9861(02)00352-1; Coggins KG, 2002, NAT MED, V8, P91, DOI 10.1038/nm0202-91; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; DeLong P, 2003, CANCER RES, V63, P7845; DuBois RN, 2003, PROG EXP TUMOR RES, V37, P124; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; Frenkian M, 2001, PROSTAG OTH LIPID M, V65, P11, DOI 10.1016/S0090-6980(01)00116-2; Frenkian M, 2001, PROSTAG LEUKOTR ESS, V64, P87, DOI 10.1054/plef.2001.0246; Gee JR, 2003, UROL ONCOL-SEMIN O I, V21, P266, DOI 10.1016/S1078-1439(02)00271-5; Giardiello FM, 2004, GASTROENTEROLOGY, V126, P425, DOI 10.1053/j.gastro.2003.11.013; Ivanov AI, 2004, FRONT BIOSCI-LANDMRK, V9, P1977, DOI 10.2741/1383; Kettunen HL, 2003, CANCER RES, V63, P5136; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595; Moran AE, 2004, J BIOL CHEM, V279, P43261, DOI 10.1074/jbc.M404276200; Murphey LJ, 2004, ANAL BIOCHEM, V334, P266, DOI 10.1016/j.ab.2004.08.019; Nandy A, 2003, J MOL ENDOCRINOL, V31, P105, DOI 10.1677/jme.0.0310105; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pichaud F, 1997, HUM GENET, V99, P279, DOI 10.1007/s004390050354; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675; Quidville V, 2004, ENDOCRINOLOGY, V145, P2561, DOI 10.1210/en.2003-0915; Rao CV, 1997, CANCER RES, V57, P3717; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Sabichi AL, 2003, CANCER RES, V63, P5649; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Sheng HM, 1998, CANCER RES, V58, P362; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Tai HH, 2002, PROSTAG OTH LIPID M, V68-9, P483, DOI 10.1016/S0090-6980(02)00050-3; TAI HH, 1976, BIOCHEMISTRY-US, V15, P4586, DOI 10.1021/bi00666a007; Tong M, 2004, ENDOCRINOLOGY, V145, P2141, DOI 10.1210/en.2003-1229; Tong M, 2000, BIOCHEM BIOPH RES CO, V276, P77, DOI 10.1006/bbrc.2000.3437; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011	40	227	239	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3217	3223		10.1074/jbc.M411221200	http://dx.doi.org/10.1074/jbc.M411221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15542609	hybrid, Green Accepted			2022-12-25	WOS:000226983900013
J	Datta, S; Osborne, TF				Datta, S; Osborne, TF			Activation domains from both monomers contribute to transcriptional stimulation by sterol regulatory element-binding protein dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TRANSGENIC MICE; DNA-BINDING; GENE-EXPRESSION; ADIPOSE-TISSUE; CULTURED-CELLS; CHOLESTEROL; SPECIFICITY; LIVER; ACID	Sterol regulatory element-binding proteins (SREBPs) are basic helix-loop-helix leucine zipper proteins that act as dimers to activate genes in lipid metabolism. Three SREBP isoforms, 1a, 1c, and 2, are expressed at varying levels in different tissues. Thus, homo- and heterodimers probably contribute to overall SREBP activity. No studies have directly evaluated the formation or activation properties of SREBP homo- and heterodimers. Studies with overexpressed SREBP monomers are inconclusive regarding the function of a particular SREBP dimer because of potential dimerization with endogenous proteins. To assess activation by a particular SREBP dimer, we fused DNA encoding individual monomers together via a predicted flexible polypeptide tether. Tethered SREBP dimers bound DNA equivalently to the monomeric proteins and were resistant to dominant negative SREBP-1 inhibition, confirming preferential formation of intramolecular dimers. Tethered SREBP-1a and -2 homodimers, similar to the monomeric forms, activated target genes more robustly than tethered SREBP-1c homodimers. A forced SREBP1a/2 heterodimer had similar activity to the respective homodimers. However, SREBP-1c in a heterodimer with either SREBP-1a or -2 attenuated the activity relative to the SREBP-1a or -2 homodimers. These experiments provide some of the first data showing that the integrity of both activation domains in a dimeric transcription factor is required for maximal activity. In addition, the results support a model where changes in SREBP-1c protein expression that occur in response to insulin signaling and liver X receptor signaling would be predicted to increase or decrease overall SREBP activity in a tissue-specific fashion depending on the initial fractional contribution of SREBP-1c to total cellular levels of SREBP.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3244 McGaugh Hall, Irvine, CA 92697 USA.	tfosborn@uci.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bennett MK, 2004, J BIOL CHEM, V279, P37360, DOI 10.1074/jbc.M404693200; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; Horton JD, 2003, J BIOL CHEM, V278, P36652, DOI 10.1074/jbc.M306540200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Osborne TF, 1998, METHODS, V16, P42, DOI 10.1006/meth.1998.0643; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rishi V, 2004, J BIOL CHEM, V279, P11863, DOI 10.1074/jbc.M308000200; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; VALLETT SM, 1994, NUCLEIC ACIDS RES, V22, P5184, DOI 10.1093/nar/22.24.5184; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102	32	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3338	3345		10.1074/jbc.M411222200	http://dx.doi.org/10.1074/jbc.M411222200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550381	hybrid			2022-12-25	WOS:000226983900027
J	Eschemann, A; Galkin, A; Oettmeier, W; Brandt, U; Kerscher, S				Eschemann, A; Galkin, A; Oettmeier, W; Brandt, U; Kerscher, S			HDQ (1-hydroxy-2-dodecyl-4(1H)quinolone), a high affinity inhibitor for mitochondrial alternative NADH dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA-CRASSA MITOCHONDRIA; ROTENONE-INSENSITIVE NADH; REFINED CRYSTAL-STRUCTURE; RESPIRATORY-CHAIN; UBIQUINONE OXIDOREDUCTASE; YARROWIA-LIPOLYTICA; SACCHAROMYCES-CEREVISIAE; LIPOAMIDE DEHYDROGENASE; ACIDIANUS-AMBIVALENS; INNER MEMBRANE	Alternative NADH dehydrogenases (NADH:ubiquinone oxidoreductases) are single subunit respiratory chain enzymes found in plant and fungal mitochondria and in many bacteria. It is unclear how these peripheral membrane proteins interact with their hydrophobic substrate ubiquinone. Known inhibitors of alternative NADH dehydrogenases bind with rather low affinities. We have identified 1-hydroxy-2-dodecyl-4(1H)quinolone as a high affinity inhibitor of alternative NADH dehydrogenase from Yarrowia lipolytica. Using this compound, we have analyzed the bisubstrate and inhibition kinetics for NADH and decylubiquinone. We found that the kinetics of alternative NADH dehydrogenase follow a ping-pong mechanism. This suggests that NADH and the ubiquinone headgroup interact with the same binding pocket in an alternating fashion.	Univ Frankfurt, Fachbereich Med, Inst Biochem 1, D-60590 Frankfurt, Germany; Ruhr Univ Bochum, Lehrstuhl Biochem Pflanzen, D-47780 Bochum, Germany	Goethe University Frankfurt; Ruhr University Bochum	Kerscher, S (corresponding author), Univ Frankfurt, Fachbereich Med, Inst Biochem 1, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.	kerscher@zbc.kgu.de	Brandt, Ulrich/C-4406-2008; Brandt, Ulrich/GLV-1242-2022	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				Bandeiras TM, 2003, BBA-BIOENERGETICS, V1557, P13, DOI 10.1016/S0005-2728(02)00374-2; Bandeiras TM, 2002, FEBS LETT, V531, P273, DOI 10.1016/S0014-5793(02)03514-7; Bjorklof K, 2000, FEBS LETT, V467, P105, DOI 10.1016/S0014-5793(00)01130-3; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; Faig M, 2000, P NATL ACAD SCI USA, V97, P3177, DOI 10.1073/pnas.050585797; Gomes CM, 2001, J BIOENERG BIOMEMBR, V33, P1, DOI 10.1023/A:1005630221892; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; Kerscher S, 2002, BBA-BIOENERGETICS, V1555, P83, DOI 10.1016/S0005-2728(02)00259-1; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kerscher SJ, 2001, J CELL SCI, V114, P3915; Kerscher SJ, 2000, BBA-BIOENERGETICS, V1459, P274, DOI 10.1016/S0005-2728(00)00162-6; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; Matsushita K, 2001, FEMS MICROBIOL LETT, V204, P271, DOI 10.1016/S0378-1097(01)00417-7; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; Melo AMP, 1999, BBA-BIOENERGETICS, V1412, P282, DOI 10.1016/S0005-2728(99)00072-9; Melo AMP, 2001, J BIOL CHEM, V276, P3947, DOI 10.1074/jbc.M008199200; OETTMEIER W, 1994, BIOCHEM SOC T, V22, P213, DOI 10.1042/bst0220213; Rasmusson AG, 1999, PLANT J, V20, P79, DOI 10.1046/j.1365-313X.1999.00576.x; Velazquez I, 2001, ARCH BIOCHEM BIOPHYS, V389, P7, DOI 10.1006/abbi.2001.2293	23	55	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3138	3142		10.1074/jbc.M411217200	http://dx.doi.org/10.1074/jbc.M411217200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15533932	hybrid			2022-12-25	WOS:000226983900004
J	Ohyagi, Y; Asahara, H; Chui, DH; Tsuruta, Y; Sakae, N; Miyoshi, K; Yamada, T; Kikuchi, H; Taniwaki, T; Murai, H; Ikezoe, K; Furuya, H; Kawarabayashi, T; Shoji, M; Checler, F; Iwaki, T; Makifuchi, T; Takeda, K; Kira, JI; Tabira, T				Ohyagi, Y; Asahara, H; Chui, DH; Tsuruta, Y; Sakae, N; Miyoshi, K; Yamada, T; Kikuchi, H; Taniwaki, T; Murai, H; Ikezoe, K; Furuya, H; Kawarabayashi, T; Shoji, M; Checler, F; Iwaki, T; Makifuchi, T; Takeda, K; Kira, JI; Tabira, T			Intracellular A beta 42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease	FASEB JOURNAL			English	Article									Kyushu Univ, Dept Neurol, Grad Sch Med Sci,Neurol Inst, Higashi-ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Neuropathol, Grad Sch Med Sci, Neurol Inst, Fukuoka, Japan; NCNP, Natl Inst Neurosci, Div Demyelinating Dis & Aging, Tokyo, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Neurol, Okayama, Japan; Inst Pharmacol Mol & Cellulaire, Valbonne, France; Natl Saigata Hosp, Dept Clin Res, Niigata, Japan; Natl Inst Longev Sci, Aichi, Japan	Kyushu University; Kyushu University; National Center for Neurology & Psychiatry - Japan; Okayama University; UDICE-French Research Universities; Universite Cote d'Azur	Ohyagi, Y (corresponding author), Kyushu Univ, Dept Neurol, Grad Sch Med Sci,Neurol Inst, Higashi-ku, 311 Maidashi, Fukuoka 8128582, Japan.	ohyagi@neuro.med.kyushu-u.ac.jp	Checler, Frederic/C-1241-2009	Checler, Frederic/0000-0003-2098-1750; Shoji, Mikio/0000-0003-1027-1712					0	210	228	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					255	257		10.1096/fj.04-2637fje	http://dx.doi.org/10.1096/fj.04-2637fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15548589				2022-12-25	WOS:000227591900029
J	Shitaka, Y; Kimura, C; Miki, M				Shitaka, Y; Kimura, C; Miki, M			The rates of switching movement of troponin T between three states of skeletal muscle thin filaments determined by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER SPECTROSCOPY; S1-INDUCED MOVEMENT; REGULATORY SITES; CARDIAC TROPONIN; ACTIN; TROPOMYOSIN; KINETICS; COMPLEX; BINDING; MODEL	Troponin (Tn) plays the key roles in the regulation of striated muscle contraction. Tn consists of three sub-units (TnT, TnC, and TnI). In combination with the stopped-flow method, fluorescence resonance energy transfer between probes attached to Cys-60 or Cys-250 of TnT and Cys-374 of actin was measured to determine the rates of switching movement of the troponin tail domain (Cys-60) and of the TnT-TnI coiled-coil C terminus (Cys-250) between three states (relaxed, closed, and open) of the thin filament. When the free Ca2+ concentration was rapidly changed, these domains moved with rates of similar to450 and similar to85 s(-1) at pH 7.0 on Ca2+ up and down, respectively. When myosin subfragment 1 (S1) was dissociated from thin filaments by rapid mixing with ATP, these domains moved with a single rate constant of similar to400 s(-1) in the presence and absence of Ca2+. The light scattering measurements showed that ATP-induced S1 dissociation occurred with a rate constant >800 s(-1). When S1 was rapidly mixed with the thin filament, these domains moved with almost the same or slightly faster rates than those of S1 binding measured by light scattering. In most but not all aspects, the rates of movement of the troponin tail domain and of the TnT-TnI coiled-coil C terminus were very similar to those of certain TnI sites (N terminus, Cys-133, and C terminus) previously characterized (Shitaka, Y., Kimura, C., Iio, T., and Miki, M. (2004) Biochemistry 43, 10739-10747), suggesting that a series of conformational changes in the Tn complex during switching on or off process occurs synchronously.	Univ Fukui, Dept Appl Chem & Biotechnol, Fukui 9108507, Japan	University of Fukui	Miki, M (corresponding author), Univ Fukui, Dept Appl Chem & Biotechnol, 3-9-1 Bunkyo, Fukui 9108507, Japan.	masao@acbio2.acbio.fukui-u.ac.jp						Dong WJ, 2003, J BIOL CHEM, V278, P42394, DOI 10.1074/jbc.M304858200; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; ELSALEH SC, 1988, J BIOL CHEM, V263, P3274; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GULATI J, 1989, FEBS LETT, V245, P279, DOI 10.1016/0014-5793(89)80237-6; Hai H, 2002, J BIOCHEM, V131, P407, DOI 10.1093/oxfordjournals.jbchem.a003116; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLMES KC, 1995, BIOPHYS J S, V68, P2; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kimura C, 2002, J BIOCHEM, V132, P345, DOI 10.1093/oxfordjournals.jbchem.a003229; Kimura C, 2002, J BIOCHEM, V132, P93, DOI 10.1093/oxfordjournals.jbchem.a003204; Kobayashi T, 2001, BBA-PROTEIN STRUCT M, V1549, P148, DOI 10.1016/S0167-4838(01)00254-0; LAMKIN M, 1983, BIOCHEMISTRY-US, V22, P3053, DOI 10.1021/bi00282a005; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Maytum R, 2002, J BIOL CHEM, V277, P29774, DOI 10.1074/jbc.M201761200; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MIKI M, 1993, J BIOL CHEM, V268, P7101; MIKI M, 1990, EUR J BIOCHEM, V187, P155, DOI 10.1111/j.1432-1033.1990.tb15289.x; Miki M, 1998, J BIOCHEM-TOKYO, V123, P324; Morimoto S, 2001, BIOCHEM BIOPH RES CO, V282, P811, DOI 10.1006/bbrc.2001.4647; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; ONOYAMA Y, 1986, J BIOCHEM-TOKYO, V100, P517, DOI 10.1093/oxfordjournals.jbchem.a121742; Resetar AM, 2002, BIOPHYS J, V83, P1039, DOI 10.1016/S0006-3495(02)75229-6; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; Shitaka Y, 2004, BIOCHEMISTRY-US, V43, P10739, DOI 10.1021/bi0492713; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; Zhou X, 2000, BIOCHEMISTRY-US, V39, P1128, DOI 10.1021/bi992327m	36	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2613	2619		10.1074/jbc.M408553200	http://dx.doi.org/10.1074/jbc.M408553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15548522	hybrid			2022-12-25	WOS:000226449100030
J	Turner, JE; Greville, K; Murphy, EC; Hooks, MA				Turner, JE; Greville, K; Murphy, EC; Hooks, MA			Characterization of Arabidopsis fluoroacetate-resistant mutants reveals the principal mechanism of acetate activation for entry into the glyoxylate cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA SYNTHETASE; NONUTILIZING MUTANTS; ASPERGILLUS-NIDULANS; COENZYME-A; DIAUXIC GROWTH; GENE; ENCODES; TRANSCRIPTION; CARBOHYDRATE; SELECTION	The toxic acetate analogue monofluoroacetic acid was employed to isolate Arabidopsis tDNA-tagged plants deficient in their ability to utilize or sense acetate. Several tDNA-tagged lines were isolated, including two that were determined to be allelic to an EMS-mutagenized line denoted acn1 for ac non-utilizing. Following conventions, the tDNA-tagged mutants were designated acn1-2 and acn1-3. Both mutants displayed identical behavior to acn1-1 on a variety of fluorinated and nonfluorinated organic acids, indicating that resistance was specific to fluoroacetate. Thermal asymmetric interlaced PCR identified the sites of tDNA insertion in both mutants to be within different exons in a gene, which encoded a protein containing an AMP-binding motif. Reverse transcription-PCR confirmed that the gene was not expressed in the mutants, and quantitative reverse transcription-PCR showed that the gene is expressed in imbibed seeds and increases in amount during establishment. The wild type AMP-binding protein cDNA was cloned and expressed in Escherichia coli, and the expressed protein was purified by nickel chelate chromatography. The enzyme was identified as an acyl-CoA synthetase that was more active with acetate than butyrate and was not active with fatty acids longer than C-4. The enzyme was localized to peroxisomes by enzymatic analysis of organellar fractions isolated by sucrose density gradient centrifugation. Labeling studies with [C-14]acetate showed that acn1 seedlings, like those of the isocitrate lyase mutant icl-1 (isocitrate lyase), are compromised in carbohydrate synthesis, indicating that this enzyme is responsible for activating exogenous acetate to the coenzyme A form for entry into the glyoxylate cycle.	Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales	Bangor University	Hooks, MA (corresponding author), Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.	m.a.hooks@bangor.ac.uk						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APIRION D, 1965, GENET RES, V6, P317, DOI 10.1017/S0016672300004213; Bao XM, 2000, PLANT J, V22, P39, DOI 10.1046/j.1365-313x.2000.00712.x; BEEVERS H, 1980, BIOCH PLANTS, V4, P117; BRADBEER C, 1959, J BIOL CHEM, V234, P498; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANVIN DT, 1961, J BIOL CHEM, V236, P988; De Lucas JR, 1999, ARCH MICROBIOL, V171, P386, DOI 10.1007/s002030050725; De Lucas JR, 1997, ARCH MICROBIOL, V168, P504; Eastmond PJ, 2000, P NATL ACAD SCI USA, V97, P5669, DOI 10.1073/pnas.97.10.5669; Eastmond PJ, 2001, TRENDS PLANT SCI, V6, P72, DOI 10.1016/S1360-1385(00)01835-5; ERHARD B, 1993, LIPID METABOLISM PLA, P527; Fatland BL, 2002, PLANT PHYSIOL, V130, P740, DOI 10.1104/pp.008110; FLAVELL RB, 1968, J BACTERIOL, V95, P1056, DOI 10.1128/JB.95.3.1056-1062.1968; Fukao Y, 2003, PLANT CELL PHYSIOL, V44, P1002, DOI 10.1093/pcp/pcg145; FULDA M, 1994, MOL GEN GENET, V242, P241, DOI 10.1007/BF00280412; GRAHAM IA, 1992, PLANT CELL, V4, P349, DOI 10.1105/tpc.4.3.349; Hooks MA, 2004, MOL GENET GENOMICS, V271, P249, DOI 10.1007/s00438-004-0985-9; Hooks MA, 2002, PLANT PEROXISOMES, P19; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; HUANG KP, 1970, ANAL BIOCHEM, V37, P98, DOI 10.1016/0003-2697(70)90263-0; Karan D, 2001, GENE, V265, P95, DOI 10.1016/S0378-1119(01)00358-4; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kim BR, 2003, BIOTECHNOL LETT, V25, P1869, DOI 10.1023/A:1026298032009; KUDIELKA RA, 1983, PLANT SCI LETT, V31, P237, DOI 10.1016/0304-4211(83)90061-5; KUHN DN, 1981, ARCH BIOCHEM BIOPHYS, V209, P441, DOI 10.1016/0003-9861(81)90301-5; Lawand S, 2002, PLANT CELL, V14, P2161, DOI 10.1105/tpc.002485; Lee TK, 1996, PLANT PHYSIOL, V110, P465, DOI 10.1104/pp.110.2.465; Lee TK, 1999, PLANT CELL PHYSIOL, V40, P1046, DOI 10.1093/oxfordjournals.pcp.a029486; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; MILLERD A, 1954, ARCH BIOCHEM BIOPHYS, V49, P343, DOI 10.1016/0003-9861(54)90204-0; MINKOV IN, 1993, J PLANT PHYSIOL, V141, P708, DOI 10.1016/S0176-1617(11)81579-8; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OWEN NE, 1992, J GEN MICROBIOL, V138, P2599, DOI 10.1099/00221287-138-12-2599; Penfield S, 2004, PLANT CELL, V16, P2705, DOI 10.1105/tpc.104.024711; ROUGHAN PG, 1994, ANAL BIOCHEM, V216, P77, DOI 10.1006/abio.1994.1010; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; Shockey JM, 2003, PLANT PHYSIOL, V132, P1065, DOI 10.1104/pp.103.020552; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; Smith SM, 2002, TRENDS PLANT SCI, V7, P12, DOI 10.1016/S1360-1385(01)02189-6; Todd RB, 1997, MOL GEN GENET, V254, P495, DOI 10.1007/s004380050444; Tolbert N E, 1974, Methods Enzymol, V31, P734; Tumaney AW, 2004, J PLANT PHYSIOL, V161, P485, DOI 10.1078/0176-1617-01258; Walker DA, 1971, METHOD ENZYMOL, V23, P211, DOI 10.1016/S0076-6879(71)23094-9; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; Zhang Q, 2003, GROUND WATER, V41, P391, DOI 10.1111/j.1745-6584.2003.tb02609.x	48	37	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2780	2787		10.1074/jbc.M407291200	http://dx.doi.org/10.1074/jbc.M407291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15533942	hybrid			2022-12-25	WOS:000226449100051
J	Jiang, YF; Cronan, JE				Jiang, YF; Cronan, JE			Expression cloning and demonstration of Enterococcus faecalis lipoamidase (pyruvate dehydrogenase inactivase) as a Ser-Ser-Lys triad amidohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOIC ACID METABOLISM; ACETYL-COA CARBOXYLASE; LIPOATE-PROTEIN LIGASE; ACYL CARRIER PROTEIN; T7 RNA-POLYMERASE; ESCHERICHIA-COLI; MULTIFUNCTIONAL ENZYMES; MOLECULAR-CLONING; CATALYTIC TRIAD; SWINGING ARMS	Enterococcus faecalis lipoamidase was discovered almost 50 years ago ( Reed, L. J., Koike, M., Levitch, M. E., and Leach, F. R. ( 1958) J. Biol. Chem. 232, 143 - 158) as an enzyme activity that cleaved lipoic acid from small lipoylated molecules and from pyruvate dehydrogenase thereby inactivating the enzyme. Although the partially purified enzyme was a key reagent in proving the crucial role of protein-bound lipoic acid in the reaction mechanism of the 2-oxoacid dehydrogenases, the identity of the lipoamidase protein and the encoding gene remained unknown. We report isolation of the lipoamidase gene by screening an expression library made in an unusual cosmid vector in which the copy number of the vector is readily varied from 1 - 2 to 40 - 80 in an appropriate Escherichia coli host. Although designed for manipulation of large genome segments, the vector was also ideally suited to isolation of the gene encoding the extremely toxic lipoamidase. The gene encoding lipoamidase was isolated by screening for expression in E. coli and proved to encode an unexpectedly large protein (80 kDa) that contained the sequence signature of the Ser-Ser-Lys triad amidohydrolase family. The hexahistidine-tagged protein was expressed in E. coli and purified to near-homogeneity. The purified enzyme was found to cleave both small molecule lipoylated and biotinylated substrates as well as lipoic acid from two 2-oxoacid dehydrogenases and an isolated lipoylated lipoyl domain derived from the pyruvate dehydrogenase E2 subunit. Lipoamidase-mediated inactivation of the 2-oxoacid dehydrogenases was observed both in vivo and in vitro. Mutagenesis studies showed that the residues of the Ser-Ser-Lys triad were required for activity on both small molecule and protein substrates and confirmed that lipoamidase is a member of the Ser-Ser-Lys triad amidohydrolase family.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; BACKMANGULLERS B, 1990, CLIN CHIM ACTA, V191, P49, DOI 10.1016/0009-8981(90)90057-Y; BERMAN JN, 1981, BIOCHEM J, V199, P513, DOI 10.1042/bj1990513; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Chebrou H, 1996, BBA-PROTEIN STRUCT M, V1298, P285, DOI 10.1016/S0167-4838(96)00145-8; Choi-Rhee E, 2003, J BIOL CHEM, V278, P30806, DOI 10.1074/jbc.M302507200; Cicchillo RM, 2004, BIOCHEMISTRY-US, V43, P6378, DOI 10.1021/bi049528x; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; DEIBEL RH, 1964, BACTERIOL REV, V28, P330, DOI 10.1128/MMBR.28.3.330-366.1964; GARGANTA CL, 1990, CLIN CHIM ACTA, V189, P313, DOI 10.1016/0009-8981(90)90313-H; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; GUNSALUS IC, 1952, J BIOL CHEM, V194, P849; HALE G, 1992, P ROY SOC B-BIOL SCI, V248, P247, DOI 10.1098/rspb.1992.0069; HUI DY, 1993, BIOCHEM J, V291, P65, DOI 10.1042/bj2910065; JENG ST, 1990, J BIOL CHEM, V265, P3823; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; Jordan SW, 2003, J BACTERIOL, V185, P1582, DOI 10.1128/JB.185.5.1582-1589.2003; Koike K, 1998, HEPATOLOGY, V27, P1467, DOI 10.1002/hep.510270602; KOIKE M, 1960, J BIOL CHEM, V235, P1931; KOIVUSALO M, 1963, J BIOL CHEM, V238, P1038; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; OIZUMI J, 1989, BIOCHEM BIOPH RES CO, V162, P658, DOI 10.1016/0006-291X(89)92361-9; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; REED LJ, 1958, J BIOL CHEM, V232, P143; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REED LJ, 1958, J BIOL CHEM, V232, P123; REED LJ, 1951, SCIENCE, V114, P93, DOI 10.1126/science.114.2952.93; SEAMAN GR, 1959, J BIOL CHEM, V234, P161; Shin S, 2002, EMBO J, V21, P2509, DOI 10.1093/emboj/21.11.2509; Shin S, 2003, J BIOL CHEM, V278, P24937, DOI 10.1074/jbc.M302156200; SNELL EE, 1989, ANNU REV NUTR, V9, P1, DOI 10.1146/annurev.nu.09.070189.000245; STEPP LR, 1981, BIOCHEMISTRY-US, V20, P4555, DOI 10.1021/bi00519a007; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI K, 1963, J BIOL CHEM, V238, P4021; TATE R, 1998, THESIS OKLAHOMA STAT; VANDENBOOM TJ, 1991, J BACTERIOL, V173, P6411, DOI 10.1128/jb.173.20.6411-6420.1991; Wild J, 2002, GENOME RES, V12, P1434, DOI 10.1101/gr.130502; Wycuff DR, 2000, ANAL BIOCHEM, V277, P67, DOI 10.1006/abio.1999.4385; Zhao X, 2003, CHEM BIOL, V10, P1293, DOI 10.1016/j.chembiol.2003.11.016	48	27	31	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2244	2256		10.1074/jbc.M408612200	http://dx.doi.org/10.1074/jbc.M408612200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15528186	hybrid			2022-12-25	WOS:000226341700061
J	Segawa, H; Soares, RP; Kawakita, M; Beverley, SM; Turco, SJ				Segawa, H; Soares, RP; Kawakita, M; Beverley, SM; Turco, SJ			Reconstitution of GDP-mannose transport activity with purified Leishmania LPG2 protein in liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; NUCLEOTIDE-SUGAR TRANSPORTER; UDP-GALACTOSE TRANSPORTER; SIALIC-ACID TRANSPORTER; PROTOZOAN PARASITE LEISHMANIA; GOLGI-APPARATUS; MOLECULAR-CLONING; ENDOPLASMIC-RETICULUM; ACETYLGALACTOSAMINE TRANSPORTER; SACCHAROMYCES-CEREVISIAE	Activated nucleotide sugars required for the synthesis of glycoconjugates within the secretory pathway of eukaryotes are provided by the action of nucleotide sugar transporters (NSTs). Typically, NSTs are studied in microsomal preparations from wild-type or mutant lines; however, in this setting it can be difficult to assess NST properties because of the presence of glycosyltransferases and other interfering activities. Here we have engineered Leishmania donovani to express high levels of an active LPG2 Golgi GDP-Man transporter bearing a C-terminal polyhistidine tag. The functional LPG2-HIS was solubilized, purified by metal affinity chromatography, and reconstituted into phosphatidylcholine-containing liposomes using polystyrene SM-2 beads. The proteoliposomes exhibited robust GDP-Man transport activity with an apparent K-m of 6.6 muM. Transport activity was enhanced by preloading of GMP and showed specificity for multiple substrates (GDP-Ara and GDP-Fuc). In contrast to the activity in crude microsomes, transport was not dependent on the presence of divalent cations. Thus, reconstitution of transport activity using purified LPG2 protein in liposomes provides firm experimental evidence that a single polypeptide is solely required for NST activity and is able to mediate the uptake of multiple substrates. These studies are relevant to the study of NST structure and function in both protozoan parasites as well as their higher eukaryotic hosts.	Univ Kentucky, Med Ctr, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Kogakuin Univ, Dept Appl Chem, Shinjuku Ku, Tokyo 1638677, Japan; Washington Univ, Sch Med, Dept Mol Microbiol & Mol Genet, St Louis, MO 63110 USA	University of Kentucky; Kogakuin University; Washington University (WUSTL)	Turco, SJ (corresponding author), Univ Kentucky, Med Ctr, Coll Med, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.	turco@uky.edu	Soares, Rodrigo/S-5191-2019	Soares, Rodrigo/0000-0002-7966-3629; Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI020941] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020941, R01AI020941] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; Baldwin TC, 2001, PLANT CELL, V13, P2283, DOI 10.1105/tpc.13.10.2283; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Chiaramonte M, 2001, BIOCHEMISTRY-US, V40, P14260, DOI 10.1021/bi011262w; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DESCOTEAUX A, 1994, METH MOL G, V3, P22; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Gao XD, 2001, J BIOL CHEM, V276, P4424, DOI 10.1074/jbc.M009114200; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; Ishida N, 1996, J BIOCHEM, V120, P1074; Ishida N, 1998, J BIOCHEM, V124, P171, DOI 10.1093/oxfordjournals.jbchem.a022076; Ishida N, 1999, J BIOCHEM, V126, P68, DOI 10.1093/oxfordjournals.jbchem.a022437; Kawakita M, 1998, J BIOCHEM, V123, P777; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Kumamoto K, 2001, CANCER RES, V61, P4620; Lopez-Avalos MD, 2001, GLYCOBIOLOGY, V11, P413, DOI 10.1093/glycob/11.5.413; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; Martinez-Duncker I, 2003, BIOCHIMIE, V85, P245, DOI 10.1016/S0300-9084(03)00046-4; Mengeling BJ, 1999, ANAL BIOCHEM, V267, P227, DOI 10.1006/abio.1998.3011; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Nishikawa A, 2002, J BACTERIOL, V184, P29, DOI 10.1128/JB.184.1.29-42.2002; Norambuena L, 2002, J BIOL CHEM, V277, P32923, DOI 10.1074/jbc.M204081200; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3685, DOI 10.1021/bi951302u; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Segawa H, 1999, FEBS LETT, V451, P295, DOI 10.1016/S0014-5793(99)00596-7; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239	47	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2028	2035		10.1074/jbc.M404915200	http://dx.doi.org/10.1074/jbc.M404915200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542612	hybrid			2022-12-25	WOS:000226341700037
J	Kotake, Y; Nakayama, K; Ishida, N; Nakayama, KI				Kotake, Y; Nakayama, K; Ishida, N; Nakayama, KI			Role of serine 10 phosphorylation in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; UBIQUITIN-MEDIATED DEGRADATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL-CYCLE; BREAST-CANCER; P27(KIP1) GENE; CDK INHIBITORS; MOLECULAR ANALYSIS; NUCLEAR EXPORT; S-PHASE	The inhibition of cyclin-dependent kinase activity by p27 contributes to regulation of cell cycle progression. Serine 10 is the major phosphorylation site of p27, and its phosphorylation has been shown to affect the stability and nuclear export of p27 at the G(0)-G(1) transition in transfected cultured cells. To investigate the physiological relevance of p27 phosphorylation on Ser(10), we generated p27 "knock-in" mice that harbor an S10A mutation in this protein. Mice homozygous for the mutation (p27(S10A/S10A) mice) were normal in body size, but the abundance of p27 was decreased in many organs, including brain, thymus, spleen, and testis. The stability of p27 in G(0) phase was markedly reduced in lymphocytes of p27(S10A/S10A) mice compared with that in wild-type cells, whereas p27 stability in S phase was similar in cells of the two genotypes. The degradation of p27 in cells of the mutant mice at G(0) phase was prevented by a proteasome inhibitor. These data indicate that the physiological role of p27 phosphorylation on Ser(10) is to stabilize the protein in G(0) phase. Unexpectedly, the nuclear export of p27 at the G(0)-G(1) transition occurred normally in p27(S10A/S10A) mouse embryonic fibroblasts, indicating that phosphorylation of Ser(10) is dispensable for this process.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Tohoku Univ, Sch Med, Div Dev Genet, Ctr Translat & Adv Anim Res Human Dis, Sendai, Miyagi 9808575, Japan	Kyushu University; Japan Science & Technology Agency (JST); Tohoku University	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp						Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ferrando AA, 1996, HUM GENET, V97, P91; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kawamata N, 1996, CANCER, V77, P570; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; Nagahama H, 2001, ANAT EMBRYOL, V203, P77, DOI 10.1007/s004290000146; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Seriu T, 1996, LEUKEMIA, V10, P345; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Spirin KS, 1996, CANCER RES, V56, P2400; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stegmaier K, 1996, CANCER RES, V56, P1413; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan P, 1997, CANCER RES, V57, P1259; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	54	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1095	1102		10.1074/jbc.M406117200	http://dx.doi.org/10.1074/jbc.M406117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528185	hybrid			2022-12-25	WOS:000226195200030
J	Vaque, JP; Navascues, J; Shiio, Y; Laiho, M; Ajenjo, N; Mauleon, I; Matallanas, D; Crespo, P; Leon, J				Vaque, JP; Navascues, J; Shiio, Y; Laiho, M; Ajenjo, N; Mauleon, I; Matallanas, D; Crespo, P; Leon, J			Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21(Cip1) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; MAP KINASE PATHWAYS; C-MYC; N-RAS; ENDOPLASMIC-RETICULUM; INDUCED PROLIFERATION; NEGATIVE REGULATION; ONCOGENIC RAS; CYCLE ARREST; P53 GENE	Even though RAS usually acts as a dominant transforming oncogene, in primary fibroblasts and some established cell lines Ras inhibits proliferation. This can explain the virtual absence of RAS mutations in some types of tumors, such as chronic myeloid leukemia (CML). We report that in the CML cell line K562 Ras induces p21(Cip1) expression through the Raf-MEK-ERK pathway. Because K562 cells are deficient for p15(INK4b), p16(INK4a), p14(ARF), and p53, this would be the main mechanism whereby Ras up-regulates p21 expression in these cells. Accordingly, we also found that Ras suppresses K562 growth by signaling through the Raf-ERK pathway. Because c-Myc and Ras cooperate in cell transformation and c-Myc is up-regulated in CML, we investigated the effect of c-Myc on Ras activity in K562 cells. c-Myc antagonized the induction of p21(Cip1) mediated by oncogenic H-, K-, and N-Ras and by constitutively activated Raf and ERK2. Activation of the p21(Cip1) promoter by Ras was dependent on Sp1/3 binding sites in K562. However, mutational analysis of the p21 promoter and the use of a Gal4-Sp1 chimeric protein strongly suggest that c-Myc affects Sp1 transcriptional activity but not the binding of Sp1 to the p21 promoter. c-Myc-mediated impairment of Ras activity on p21 expression required a transactivation domain, a DNA binding region, and a Max binding region. Moreover, the effect was independent of Miz1 binding to c-Myc. Consistent with its effect on p21(Cip1) expression, c-Myc rescued cell growth inhibition induced by Ras. The data suggest that in particular tumor types, such as those associated with CML, c-Myc contributes to tumorigenesis by inhibiting Ras antiproliferative activity.	Univ Cantabria, Fac Med, CSIC, Dept Biol Mol,Grp Biol Mol Canc, Santander 39011, Spain; Univ Cantabria, Fac Med, CSIC, Unidad Biomed, Santander 39011, Spain; Fred Hutchinson Canc Res Ctr, Basic Sci Program, Seattle, WA 98109 USA; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Fred Hutchinson Cancer Center; University of Helsinki; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Leon, J (corresponding author), Univ Cantabria, Fac Med, CSIC, Dept Biol Mol,Grp Biol Mol Canc, Avda Cardenal Herrera Oria S-N, Santander 39011, Spain.	leonj@unican.es	Leon, Javier/K-4615-2014; Vaqué, José P/H-8413-2015; gomez, david/U-9465-2019; Crespo, Piero/M-3273-2014	Vaqué, José P/0000-0002-3913-2495; gomez, david/0000-0002-2360-3141; Leon, Javier/0000-0001-5803-0112; Ajenjo Diez, Nuria/0000-0002-9435-6467; Crespo, Piero/0000-0003-2825-7783				Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Ajenjo N, 2004, J BIOL CHEM, V279, P32813, DOI 10.1074/jbc.M313656200; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Beaupre DM, 1999, J CLIN ONCOL, V17, P1071, DOI 10.1200/JCO.1999.17.3.1071; Beck Z, 1998, LEUKEMIA LYMPHOMA, V30, P293, DOI 10.3109/10428199809057542; Benito A, 1997, LEUKEMIA, V11, P940, DOI 10.1038/sj.leu.2400699; BLICK M, 1987, CANCER GENET CYTOGEN, V27, P349, DOI 10.1016/0165-4608(87)90018-5; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; CARNERO A, 2004, ONCOGENE; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; COLLINS SJ, 1989, BLOOD, V73, P1028; COMPERE SJ, 1989, P NATL ACAD SCI USA, V86, P2224, DOI 10.1073/pnas.86.7.2224; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cortez D, 1996, ONCOGENE, V13, P2589; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Garicochea B, 1998, LEUKEMIA RES, V22, P1003, DOI 10.1016/S0145-2126(98)00076-9; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Herman JG, 1996, CANCER RES, V56, P722; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jennings BA, 1998, LEUKEMIA RES, V22, P899, DOI 10.1016/S0145-2126(98)00097-6; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liu A, 2001, J BIOL CHEM, V276, P45372, DOI 10.1074/jbc.M105399200; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; OTSUKI T, 1995, CANCER RES, V55, P1436; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perez de Castro I, 1999, CARCINOGENESIS, V20, P1675; PREISLER HD, 1990, BLOOD, V75, P1587; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; WANG Z, 1990, EUR J CANCER, V26, P694, DOI 10.1016/0277-5379(90)90119-E; WATZINGER F, 1994, CANCER RES, V54, P3934; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145	91	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1112	1122		10.1074/jbc.M409503200	http://dx.doi.org/10.1074/jbc.M409503200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528212	hybrid			2022-12-25	WOS:000226195200032
J	Zhu, H; Shuman, S				Zhu, H; Shuman, S			A primer-dependent polymerase function of pseudomonas aeruginosa ATP-dependent DNA ligase (LigD)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; REVERSE-TRANSCRIPTASE; NUCLEOTIDE ADDITION; BACTERIAL HOMOLOGS; END; PRIMASE; MECHANISM; RNA; KU; IDENTIFICATION	Pseudomonas aeruginosa encodes two putative DNA ligases: a classical NAD(+)-dependent DNA ligase (LigA) plus an ATP-dependent DNA ligase (LigD). LigD exemplifies a family of bacterial proteins that consist of a ligase domain fused to flanking domains that resemble nucleases and/or polymerases. Here we purify LigD and show that it possesses an intrinsic polymerase function resident within an autonomous C-terminal polymerase domain, LigD-(533-840), that flanks an autonomous DNA ligase domain, LigD-(188-527). Native LigD and the polymerase domain are both monomeric proteins. The polymerase activity is manifest in three ways: (i) nontemplated nucleotide addition to a blunt-ended duplex DNA primer; (ii) non-templated addition to a single-stranded DNA primer; and (iii) templated extension of a 5'-tailed duplex DNA primer-template. The divalent cation cofactor requirement for non-templated and templated polymerase activity is satisfied by manganese or cobalt. rNTPs are preferred over dNTPs as substrates for non-templated blunt-end addition, which typically entails the incorporation of only 1 or 2 nucleotides at the primer terminus. Templated dNMP addition to a 5'-tailed substrate is efficient with respect to dNTP utilization; the primer is elongated to the end of the template strand and is then further extended with a non-templated nucleotide. The polymerase activity is abolished by alanine substitution for two aspartates (Asp-669 and Asp-671) within the putative metal-binding site. We speculate that polymerase activity is relevant to LigD function in nonhomologous end-joining.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org						Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Augustin MA, 2001, NAT STRUCT BIOL, V8, P57, DOI 10.1038/83060; Cheng CH, 1997, NUCLEIC ACIDS RES, V25, P1369, DOI 10.1093/nar/25.7.1369; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Doherty AJ, 2001, FEBS LETT, V500, P186, DOI 10.1016/S0014-5793(01)02589-3; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Golinelli MP, 2002, BIOCHEMISTRY-US, V41, P5894, DOI 10.1021/bi0160415; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Ito N, 2003, GENES CELLS, V8, P913, DOI 10.1111/j.1365-2443.2003.00693.x; Koonin EV, 2000, J MOL MICROB BIOTECH, V2, P509; LEHMAN IR, 1974, SCIENCE, V186, P790; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lipps G, 2004, NAT STRUCT MOL BIOL, V11, P157, DOI 10.1038/nsmb723; Magnet S, 2004, BIOCHEMISTRY-US, V43, P710, DOI 10.1021/bi0355387; Nandakumar J, 2004, MOL CELL, V16, P211, DOI 10.1016/j.molcel.2004.09.022; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; SHEAFF RJ, 1994, J BIOL CHEM, V269, P19225; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Weller GR, 2001, FEBS LETT, V505, P340, DOI 10.1016/S0014-5793(01)02831-9; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599	26	53	65	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					418	427		10.1074/jbc.M410110200	http://dx.doi.org/10.1074/jbc.M410110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15520014	hybrid			2022-12-25	WOS:000226025100051
J	Haviernik, P; Lahoda, C; Bradley, HL; Hawley, TS; Ramezani, A; Hawley, RG; Stetler-Stevenson, M; Stetler-Stevenson, WG; Bunting, KD				Haviernik, P; Lahoda, C; Bradley, HL; Hawley, TS; Ramezani, A; Hawley, RG; Stetler-Stevenson, M; Stetler-Stevenson, WG; Bunting, KD			Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation	ONCOGENE			English	Article						tissue inhibitor of matrix metalloproteinase; myeloid leukemia; signal transducer and activator of transcription; retroviral vector	ERYTHROID-POTENTIATING ACTIVITY; PANCREATIC-CANCER; GROWTH-FACTOR; TUMOR-GROWTH; BONE-MARROW; CELL-DEATH; IN-VIVO; TIMP-1; EXPRESSION; LEUKEMIA	The balance between matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinase ( TIMP) is important for extracellular matrix interactions of hematopoietic cells. MMP-independent growth modulating activity for TIMP-1 on B lymphocytes and erythroid progenitors has also been described, but a role for TIMP-1 in myelomonocytic differentiation has not been previously reported. In this study, we demonstrate that TIMP-1 overexpression impairs differentiation of the myeloblastic M1 cell line following interleukin (IL)-6 stimulation. We generated retroviral vectors coexpressing human TIMP-1 and the green fluorescent protein (GFP) and stably transduced murine M1 myeloid cells. TIMP-1 expressing cells showed a large reduction in IL-6-induced macrophage differentiation in vitro that was reversible with a specific monoclonal antibody. The differentiation delay in M1/TIMP-1 cells was also specifically reversible by pharmacologic phosphatidylinositol-3 kinase (PI3-K) inhibition. Additionally, overexpression of a TIMP-1/GFP fusion protein also impaired M1 differentiation and this protein was localized to the cell surface, consistent with an autocrine receptor-mediated mechanism. Surprisingly, TIMP-1 transduced cells had a selective advantage for growth in IL-6, indicating that functional effects on growth and differentiation of M1 cells were primarily through an autocrine mechanism. Intrinsic TIMP-1 expression in myeloid leukemia cells might thus impact upon survival or differentiation.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Hematopoiesis Dept, Rockville, MD 20855 USA; George Washington Univ, Inst Biomed Sci, Genet Program, Washington, DC 20037 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Flow Cytometry Facil, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA; NIH, Flow Cytometry Unit, Pathol Lab, Div Clin Sci, Bethesda, MD 20892 USA; NIH, Extracellular Matrix Sect, Pathol Lab, Div Clin Sci, Bethesda, MD 20892 USA	American Red Cross; George Washington University; American Red Cross; George Washington University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Bunting, KD (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, 10900 Euclid Ave WRB2, Cleveland, OH 44106 USA.	kevin.bunting@case.edu	Stetler-Stevenson, William G/H-6956-2012; Stetler-Stevenson, Maryalice/AAV-7393-2020; Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William G/0000-0002-5500-5808; Stetler-Stevenson, William/0000-0002-5500-5808; Bradley, Heath/0000-0001-5796-7595; Hawley, Robert/0000-0003-3512-5818	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC009373] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIASC009179, Z01SC009179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL071171, R01HL073738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059380] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL073738, R21HL071171] Funding Source: Medline; NIDDK NIH HHS [R01DK059380] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVALOS BR, 1988, BLOOD, V71, P1720; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Bloomston M, 2002, J SURG RES, V102, P39, DOI 10.1006/jsre.2001.6318; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; de Bont ESJM, 2001, BRIT J HAEMATOL, V113, P296, DOI 10.1046/j.1365-2141.2001.02722.x; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; Gronning LM, 2000, BIOL REPROD, V62, P1040, DOI 10.1095/biolreprod62.4.1040; Guedez L, 1996, CRIT REV ONCOGENESIS, V7, P205, DOI 10.1615/CritRevOncog.v7.i3-4.40; Guedez L, 2001, BLOOD, V97, P1796, DOI 10.1182/blood.V97.6.1796; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Ismair MG, 1998, LEUKEMIA, V12, P1136, DOI 10.1038/sj.leu.2401042; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KOOP S, 1994, CANCER RES, V54, P4791; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; Li GY, 1999, CANCER RES, V59, P6267; Lin LI, 2002, BRIT J HAEMATOL, V117, P835, DOI 10.1046/j.1365-2141.2002.03510.x; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NISKANEN E, 1988, BLOOD, V72, P806; NISKANEN E, 1990, EUR J HAEMATOL, V45, P267; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Ries C, 1999, CLIN CANCER RES, V5, P1115; Rigg AS, 2001, CANCER GENE THER, V8, P869, DOI 10.1038/sj.cgt.7700387; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Soloway PD, 1996, ONCOGENE, V13, P2307; STRIFE A, 1987, BLOOD, V69, P1508; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; Yamauchi K, 2001, SURG TODAY, V31, P791, DOI 10.1007/s005950170049; Zhang JY, 2001, LEUKEMIA RES, V25, P463, DOI 10.1016/S0145-2126(00)00157-0; Zhao WQ, 1998, J CELL SCI, V111, P1147	44	12	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9212	9219		10.1038/sj.onc.1208096	http://dx.doi.org/10.1038/sj.onc.1208096			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516987				2022-12-25	WOS:000225638000006
J	Chung, TW; Moon, SK; Chang, YC; Ko, JH; Lee, YC; Cho, G; Kim, SH; Kim, JG; Kim, CH				Chung, TW; Moon, SK; Chang, YC; Ko, JH; Lee, YC; Cho, G; Kim, SH; Kim, JG; Kim, CH			Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism	FASEB JOURNAL			English	Article						hepatocellular carcinoma; tumor regression; Euonymus alatus; MMP-9; NF-kappa B; CAPE; xenograft	NF-KAPPA-B; MATRIX-METALLOPROTEINASE INHIBITOR; ACTIVATED PROTEIN-KINASE; PHENETHYL ESTER; HEPATOCELLULAR-CARCINOMA; TUMOR ANGIOGENESIS; BINDING-ACTIVITY; EXPRESSION; CANCER; MATRIX-METALLOPROTEINASE-9	Our previous studies have clearly shown that the angiogenic enzymes, matrix metalloproteinase (MMP) -2/9, are directly involved in human hepatic tumorigenesis and metastasis and suggest that the MMP-2/9 inhibitors, which have dual inhibitory activities on enzyme activity and transcription, represent the best candidates for achieving tumor regression. Many anti-cancer drugs have strong cellular cytotoxicity and side effects, indicating that strong anti-cancer drugs that have no or minimal cytotoxicity and side effects need to be developed. The specific aim of the present study was to develop powerful anti-cancer drugs with specific tumor regression and anti-metastatic potential having the dual inhibitory activities of specific MMP-2 and -9 enzyme activities and gene transcription at the molecular level. Caffeic acid (CA), a strong and selective MMP-9 activity and transcription inhibitor, was isolated from the plant Euonymus alatus and its derivative, caffeic acid phenethyl ester (CAPE), was synthesized. CA and CAPE selectively inhibited MMP-2 and -9 but not -1, -3, -7, or cathepsin K. Treatment of HepG2 cells with CA (100 mug/mL) and CAPE (5 mug/mL) suppressed phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression by inhibiting the function of NF-kappaB, but not AP-1. We confirmed that CA and CAPE suppressed the growth of HepG2 tumor xenografts in nude mice in vivo. The subcutaneous and oral administrations of CA and CAPE significantly reduced the liver metastasis. These results confirm the therapeutic potential of the compounds and suggest that the anti-metastatic and anti-tumor effects of CA and CAPE are mediated through the selective suppression of MMP-9 enzyme activity and transcriptional down-regulation by the dual inhibition of NF-kappaB as well as MMP-9 catalytic activity.	Dongguk Univ, Natl Res Lab Glycobiol, Coll Oriental Med, Kyungju 780714, Kyungbuk, South Korea; Dongguk Univ, Dept Biochem & Mol Biol, Coll Oriental Med, Kyungju 780714, Kyungbuk, South Korea; Daegu Catholic Univ, Dept Pathol, Coll Med, Taegu, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon, South Korea; Dong A Univ, Fac Biotechnol, Pusan, South Korea; Korea Basic Sci Res Inst, Proteome Anal Team, Taejon, South Korea; Kyungpook Natl Univ, Dept Microbiol, Taegu, South Korea	Dongguk University; Dongguk University; Catholic University of Daegu; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Dong A University; Korea Basic Science Institute (KBSI); Kyungpook National University	Kim, CH (corresponding author), Dongguk Univ, Natl Res Lab Glycobiol, Coll Oriental Med, Sukjang Dong 707, Kyungju 780714, Kyungbuk, South Korea.	chkimbio@dongguk.ac.kr	Ko, Jae-Hyeon/I-4133-2019	Ko, Jae-Hyeon/0000-0001-7766-2385; Chung, Tae-Wook/0000-0001-5243-5020; Kim, Cheorl-Ho/0000-0002-6323-0714				Abiru S, 2002, HEPATOLOGY, V35, P1117, DOI 10.1053/jhep.2002.32676; Arai K, 2003, GLIA, V43, P254, DOI 10.1002/glia.10255; Arii S, 1996, HEPATOLOGY, V24, P316; Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Cha BY, 2003, J ETHNOPHARMACOL, V85, P163, DOI 10.1016/S0378-8741(02)00373-2; CHAN WS, 1995, ANTICANCER RES, V15, P703; Chung TW, 2002, ARCH BIOCHEM BIOPHYS, V408, P147, DOI 10.1016/S0003-9861(02)00522-2; Chung TW, 2003, CANCER RES, V63, P3453; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Demeule M, 2000, BBA-PROTEIN STRUCT M, V1478, P51, DOI 10.1016/S0167-4838(00)00009-1; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Fernandez MA, 1998, J PHARM PHARMACOL, V50, P1183, DOI 10.1111/j.2042-7158.1998.tb03332.x; FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRENKEL K, 1993, CANCER RES, V53, P1255; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gatto C, 1999, CLIN CANCER RES, V5, P3603; GRUNBERGER D, 1988, EXPERIENTIA, V44, P230, DOI 10.1007/BF01941717; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hah N, 2003, BIOCHEM BIOPH RES CO, V305, P428, DOI 10.1016/S0006-291X(03)00788-5; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003; Kaegi E, 1998, CAN MED ASSOC J, V158, P1033; KASHIWADA Y, 1995, J NAT PRODUCTS, V58, P392, DOI 10.1021/np50117a007; Katori H, 2002, CANCER LETT, V178, P151, DOI 10.1016/S0304-3835(01)00837-0; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KOHN EC, 1995, CANCER RES, V55, P1856; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; Lochter A, 1999, APMIS, V107, P128, DOI 10.1111/j.1699-0463.1999.tb01535.x; Lozonschi L, 1999, CANCER RES, V59, P1252; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Maekawa R, 1999, CANCER RES, V59, P1231; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; Michaluart P, 1999, CANCER RES, V59, P2347; Mirzoeva OK, 1996, FEBS LETT, V396, P266, DOI 10.1016/0014-5793(96)01111-8; Nagaoka T, 2003, BIOL PHARM BULL, V26, P638; Nagaoka T, 2002, BIOORGAN MED CHEM, V10, P3351, DOI 10.1016/S0968-0896(02)00138-4; Nardini M, 2001, FREE RADICAL BIO MED, V30, P722, DOI 10.1016/S0891-5849(00)00515-3; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PLOEMEN JHTM, 1993, FOOD CHEM TOXICOL, V31, P475, DOI 10.1016/0278-6915(93)90106-9; Sakamoto Y, 2000, INT J ONCOL, V17, P237; Sato T, 2002, CANCER RES, V62, P1025; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Shahidi F., 1995, FOOD PHENOLICS SOURC; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Sugita K, 1999, IDrugs, V2, P327; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; TANAKA T, 1993, CARCINOGENESIS, V14, P1321, DOI 10.1093/carcin/14.7.1321; Tonn JC, 1999, INT J CANCER, V80, P764, DOI 10.1002/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0.CO;2-J; Vieira O, 1998, BIOCHEM PHARMACOL, V55, P333, DOI 10.1016/S0006-2952(97)00470-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wojtowicz-Praga S, 1999, Drugs R D, V1, P117, DOI 10.2165/00126839-199901020-00001; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	65	306	323	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1670	1681		10.1096/fj.04-2126com	http://dx.doi.org/10.1096/fj.04-2126com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522912				2022-12-25	WOS:000225482100035
J	Ahmed, N; Dobler, D; Dean, M; Thornalley, PJ				Ahmed, N; Dobler, D; Dean, M; Thornalley, PJ			Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED GLYCATION ENDPRODUCTS; EPSILON-CARBOXYMETHYL-LYSINE; ARGININE RESIDUES; CRYSTAL-STRUCTURE; CHROMATOGRAPHIC ASSAY; WARFARIN-BINDING; END-PRODUCTS; FATTY-ACIDS; IN-VITRO; PROTEIN	Methylglyoxal is a potent glycating agent under physiological conditions. Human serum albumin is modified by methylglyoxal in vivo. The glycation adducts formed and structural and functional changes induced by methylglyoxal modification have not been fully disclosed. Methylglyoxal reacted with human serum albumin under physiological conditions to form mainly the hydroimidazolone N-delta-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (92% of total modification) with a minor formation of argpyrimidine, N-is an element of-(1-carboxyethyl)lysine, and methylglyoxal lysine dimer. When human serum albumin was modified minimally with methylglyoxal, tryptic peptide mapping indicated a hotspot of modification at Arg-410 located in drug-binding site II and the active site of albumin-associated esterase activity. Modification of Arg-410 by methylglyoxal was found in albumin glycated in vivo. Other sites of minor modification were: Arg-114, Arg-186, Arg-218, and Arg-428. Hydroimidazolone formation at Arg-410 inhibited ketoprofen binding and esterase activity; correspondingly, glycation in the presence of ketoprofen inhibited Arg-410 modification and loss of esterase activity. The pH dependence of esterase activity indicated a catalytic group with pK(a) = 7.9 +/- 0.1, assigned to the catalytic base Tyr-411 with the conjugate base stabilized by interaction with the guanidinium group of Arg-410. Modification by methylglyoxal destabilized Tyr-411 and increased the pK, to 8.8 +/- 0.1. Molecular dynamics and modeling studies indicated that hydroimidazolone formation caused structural distortion leading to disruption of arginine-directed hydrogen bonding and loss of electrostatic interactions. Methylglyoxal modification of critical arginine residues, therefore, whether experimental or physiological, is expected to disrupt protein-ligand interactions and inactivate enzyme activity by hydroimidazolone formation.	Univ Essex, Dept Sci Biol, Colchester CO4 3SQ, Essex, England	University of Essex	Thornalley, PJ (corresponding author), Univ Essex, Dept Sci Biol, Colchester CO4 3SQ, Essex, England.	thorp@essex.ac.uk		Thornalley, Paul/0000-0001-7659-443X				Ahmed N, 2002, BIOCHEM J, V364, P15, DOI 10.1042/bj3640015; Ahmed N, 2002, BIOCHEM J, V364, P1; Ahmed N, 2003, INVEST OPHTH VIS SCI, V44, P5287, DOI 10.1167/iovs.03-0573; Ahmed N, 2004, J HEPATOL, V41, P913, DOI 10.1016/j.jhep.2004.08.007; Ahmed N, 2003, DIABETES, V52, pA441; Arvinte T, 2004, ANAL BIOCHEM, V332, P46, DOI 10.1016/j.ab.2004.05.045; Bashford D, 2000, ANNU REV PHYS CHEM, V51, P129, DOI 10.1146/annurev.physchem.51.1.129; Bergman DL, 1997, J MOL GRAPH MODEL, V15, P301, DOI 10.1016/S1093-3263(98)00003-5; Bhattacharya AA, 2000, J MOL BIOL, V303, P721, DOI 10.1006/jmbi.2000.4158; BRIGGS JM, 1989, BROWNIAN DYNAMICS CO; CASE DA, 2002, AMBER 7 COMPUTER PRO; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DAVIS ME, 1991, METHOD ENZYMOL, V202, P473; Dockal M, 1999, J BIOL CHEM, V274, P29303, DOI 10.1074/jbc.274.41.29303; Dockal M, 2000, PROTEIN SCI, V9, P1455, DOI 10.1110/ps.9.8.1455; Fan X, 2003, ARCH BIOCHEM BIOPHYS, V409, P274, DOI 10.1016/S0003-9861(02)00599-4; Gallet X, 2000, J MOL BIOL, V302, P917, DOI 10.1006/jmbi.2000.4092; GARLICK RL, 1983, J BIOL CHEM, V258, P6142; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Kragh-Hansen U, 2002, BIOL PHARM BULL, V25, P695, DOI 10.1248/bpb.25.695; Lee C, 1998, J BIOL CHEM, V273, P25272, DOI 10.1074/jbc.273.39.25272; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; MCLELLAN AC, 1992, ANAL CHIM ACTA, V263, P137, DOI 10.1016/0003-2670(92)85435-9; Ng R, 2002, INT CONGR SER, V1245, P77, DOI 10.1016/S0531-5131(02)00925-1; Paul RG, 1998, BIOCHEM J, V330, P1241, DOI 10.1042/bj3301241; PETERS T, 1996, ALL ALBUMIN BIOCH GE, P25; Petersen CE, 1997, BIOCHEMISTRY-US, V36, P7012, DOI 10.1021/bi970225v; Petitpas I, 2001, J BIOL CHEM, V276, P22804, DOI 10.1074/jbc.M100575200; Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2000.5208; Simard JR, 2004, BIOPHYS J, V86, p75A; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; Thornalley PJ, 2000, KIDNEY INT, V58, P2228; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Thornalley PJ, 2003, BIOCHEM J, V375, P581, DOI 10.1042/BJ20030763; TURNER M, 1988, BIOCHEM BIOPH RES CO, V156, P830, DOI 10.1016/S0006-291X(88)80919-7; Watanabe H, 2000, BIOCHEM J, V349, P813, DOI 10.1042/bj3490813; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; Westwood ME, 1997, BBA-MOL CELL RES, V1356, P84, DOI 10.1016/S0167-4889(96)00154-1	42	244	266	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5724	5732		10.1074/jbc.M410973200	http://dx.doi.org/10.1074/jbc.M410973200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15557329	hybrid			2022-12-25	WOS:000227217100074
J	Banerjee, DK; Carrasquillo, EA; Hughey, P; Schutzbach, JS; Martinez, JA; Baksi, K				Banerjee, DK; Carrasquillo, EA; Hughey, P; Schutzbach, JS; Martinez, JA; Baksi, K			In vitro phosphorylation by cAMP-dependent protein kinase up-regulates recombinant Saccharomyces cerevisiae mannosylphosphodolichol synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOLICHOL-PHOSPHATE-MANNOSE; HAMSTER OVARY CELLS; P-MAN SYNTHASE; POLYACRYLAMIDE GELS; TRYPANOSOMA-BRUCEI; MAMMALIAN-CELLS; N-GLYCOSYLATION; YEAST GENE; BIOSYNTHESIS; EXPRESSION	DPM1 is the structural gene for mannosylphosphodolichol synthase (i.e. Dol-P-Man synthase, DPMS) in Saccharomyces cerevisiae. Earlier studies with cDNA cloning and sequence analysis have established that 31kDa DPMS of S. cerevisiae contains a consensus sequence (YRRVIS141) that can be phosphorylated by cAMP-dependent protein kinase (PKA). We have been studying the up-regulation of DPMS activity by protein kinase A-mediated phosphorylation in higher eukaryotes, and used the recombinant DPMS from S. cerevisiae in this study to advance our knowledge further. DPMS catalytic activity was indeed enhanced severalfold when the recombinant protein was phosphorylated in vitro. The rate as well as the magnitude of catalysis was higher with the phosphorylated enzyme. A similar increase in the catalytic activity was also observed when the in vitro phosphorylated recombinant DPMS was assayed as a function of increasing concentrations of exogenous dolichylmonophosphate (Dol-P). Kinetic studies indicated that there was no change in the K-m for GDPmannose between the in vitro phosphorylated and control recombinant DPMS, but the V-max. was increased by 6-fold with the phosphorylated enzyme. In vitro phosphorylated recombinant DPMS also exhibited higher enzyme turnover (k(cat)) and enzyme efficiency (k(cat)K(m)). SDS-PAGE followed by autoradiography of the "P-labeled DPMS detected a 31-kDa phosphoprotein, and immunoblotting with anti-phosphoserine antibody established the presence of a phosphoserine residue in in vitro phosphorylated recombinant DPMS. To confirm the phosphorylation activation of recombinant DPMS, serine 141 in the consensus sequence was replaced with alanine by PCR site-directed mutagenesis. The S141A DPMS mutant exhibited more than half-a-fold reduction in catalytic activity compared with the wild type when both were analyzed after in vitro phosphorylation. Thus, confirming that S. cerevisiae DPMS activity is indeed regulated by the cAMP-dependent protein phosphorylation signal, and the phosphorylation target is serine 141.	Univ Puerto Rico, Sch Med, Dept Biochem, San Juan, PR 00936 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Univ Cent Caribe, Dept Anat & Cell Biol, Bayamon, PR 00960 USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Alabama System; University of Alabama Birmingham	Banerjee, DK (corresponding author), Univ Puerto Rico, Sch Med, Dept Biochem, San Juan, PR 00936 USA.	dbanerjee@rcm.upr.edu	Martinez, Juan/GXM-4393-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM050695, R01GM038643, F31GM017177] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38643, GM47492, 2S07 GM50695, F31 GM17177] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BANERJEE DK, 1989, J BIOL CHEM, V264, P2024; BANERJEE DK, 1985, BIOCHEM BIOPH RES CO, V126, P123, DOI 10.1016/0006-291X(85)90580-7; Banerjee DK, 2004, GLYCOCONJUGATE J, V21, P479, DOI 10.1007/s10719-004-5538-2; BANERJEE DK, 1992, FEBS LETT, V306, P33, DOI 10.1016/0014-5793(92)80831-Z; Banerjee DK, 1999, BIOSCIENCE REP, V19, P169, DOI 10.1023/A:1020221602373; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BANERJEE DK, 1987, P NATL ACAD SCI USA, V84, P6389, DOI 10.1073/pnas.84.18.6389; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BECK PJ, 1990, SOMAT CELL MOLEC GEN, V16, P539, DOI 10.1007/BF01233094; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CLARKE BL, 1989, CHEM PHYS LIPIDS, V51, P239, DOI 10.1016/0009-3084(89)90011-X; Colussi PA, 1997, P NATL ACAD SCI USA, V94, P7873, DOI 10.1073/pnas.94.15.7873; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; HASELBECK A, 1989, EUR J BIOCHEM, V181, P663, DOI 10.1111/j.1432-1033.1989.tb14774.x; HEIFETZ A, 1977, J BIOL CHEM, V252, P3057; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; JENSEN JW, 1985, EUR J BIOCHEM, V153, P41, DOI 10.1111/j.1432-1033.1985.tb09264.x; JENSEN JW, 1986, BIOCHEMISTRY-US, V27, P6315; Kim S, 2000, J CLIN INVEST, V105, P191, DOI 10.1172/JCI7302; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maeda Y, 2000, EMBO J, V19, P2475, DOI 10.1093/emboj/19.11.2475; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; Marquardt T, 2003, EUR J PEDIATR, V162, P359, DOI 10.1007/s00431-002-1136-0; MazhariTabrizi R, 1996, BIOCHEM J, V316, P853, DOI 10.1042/bj3160853; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; Nozaki M, 1999, LAB INVEST, V79, P293; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHUTZBACH JS, 1993, J BIOL CHEM, V268, P24190; SHANKARAPPA B, 1992, BIOTECHNIQUES, V12, P882; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tempone AJ, 2002, COMP BIOCHEM PHYS B, V131, P465, DOI 10.1016/S1096-4959(01)00513-9; Tomita S, 1998, J BIOL CHEM, V273, P9249, DOI 10.1074/jbc.273.15.9249; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Xing J, 2000, BIOCHEMISTRY-US, V39, P7886, DOI 10.1021/bi0003240; Zimmerman JW, 1996, YEAST, V12, P765, DOI 10.1002/(SICI)1097-0061(19960630)12:8<765::AID-YEA974>3.0.CO;2-A	48	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4174	4181		10.1074/jbc.M406962200	http://dx.doi.org/10.1074/jbc.M406962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15548536	hybrid			2022-12-25	WOS:000227096600023
J	de Mendonca, FL; da Fonseca, PCA; Phillips, RM; Saldanha, JW; Williams, TJ; Pease, JE				de Mendonca, FL; da Fonseca, PCA; Phillips, RM; Saldanha, JW; Williams, TJ; Pease, JE			Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; EXTRACELLULAR DOMAINS; FUNCTIONAL EXPRESSION; TRANSMEMBRANE HELICES; LIGAND-BINDING; BETA-CHEMOKINE; HIV-1 ENTRY; TXP MOTIF; POTENT; IDENTIFICATION	The chemokine receptor CCR1 and its principal ligand, CCL3/MIP-1alpha, have been implicated in the pathology of several inflammatory diseases including rheumatoid arthritis, multiple sclerosis, and asthma. As such, these molecules are the focus of much research with the ultimate aim of developing novel therapies. We have described previously a non-competitive small molecule antagonist of CCR1 (UCB 35625), which we hypothesized interacted with amino acids located within the receptor transmembrane (TM) helices (Sabroe, I., Peck, M. J., Jan Van Keulen, B., Jorritsma, A., Simmons, G., Clapham, P. R., Williams, T. J., and Pease, J. E. (2000) J. Biol Chem. 275, 25985-25992). Here we describe an approach to identifying the mechanism by which the molecule antagonizes CCR1. Thirty-three point mutants of CCR1 were expressed transiently in L1.2 cells, and the cells were assessed for their capacity to migrate in response to CCL3 in the presence or absence of UCB 35625. Cells expressing the mutant constructs Y41A (TM helix 1, or TM1), Y113A (TM3), and E287A (TM7) were responsive to CCL3 but resistant to the antagonist, consistent with a role for the TM helices in CCR1 interactions with UCB 35625. Subsequent molecular modeling successfully docked the compound with CCR1 and suggests that the antagonist ligates TM1, 2, and 7 of CCR1 and severely impedes access to TM2 and TM3, a region thought to be perturbed by the chemokine amino terminus during the process of receptor activation. Insights into the mechanism of action of these compounds may facilitate the development of more potent antagonists that show promise as future therapeutic agents in the treatment of inflammatory disease.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Biomed Sci Div, Leukocyte Biol Sect, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Biomed Sci Div, Biol Struct & Funct Sect, London SW7 2AZ, England; Natl Inst Med Res, Med Res Council, Div Math Biol, London NW7 1AA, England	Imperial College London; Imperial College London; MRC National Institute for Medical Research; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Pease, JE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Biomed Sci Div, Leukocyte Biol Sect, London SW7 2AZ, England.	j.pease@imperial.ac.uk	Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341; da Fonseca, Paula/0000-0001-8656-5747	Medical Research Council [MC_U117581331] Funding Source: Medline; MRC [MC_U117581331] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arias DA, 2003, J BIOL CHEM, V278, P36513, DOI 10.1074/jbc.M303739200; Auger GA, 2002, EUR J IMMUNOL, V32, P1052, DOI 10.1002/1521-4141(200204)32:4<1052::AID-IMMU1052>3.0.CO;2-L; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Broxmeyer HE, 1999, J EXP MED, V189, P1987, DOI 10.1084/jem.189.12.1987; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Gerard C, 1997, J CLIN INVEST, V100, P2022, DOI 10.1172/JCI119734; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200; Govaerts C, 2001, J BIOL CHEM, V276, P13217, DOI 10.1074/jbc.M011670200; Halks-Miller M, 2003, ANN NEUROL, V54, P638, DOI 10.1002/ana.10733; Haringman JJ, 2003, ANN RHEUM DIS, V62, P715, DOI 10.1136/ard.62.8.715; Horuk R, 2004, E SCHERING RES FDN W, V44, P169; Horuk R, 2001, J BIOL CHEM, V276, P4199, DOI 10.1074/jbc.M007457200; Liang M, 2000, J BIOL CHEM, V275, P19000, DOI 10.1074/jbc.M001222200; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Naya A, 2001, J MED CHEM, V44, P1429, DOI 10.1021/jm0004244; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Onuffer J, 2003, J IMMUNOL, V170, P1910, DOI 10.4049/jimmunol.170.4.1910; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Paterlini MG, 2002, BIOPHYS J, V83, P3012, DOI 10.1016/S0006-3495(02)75307-1; Phillips RM, 2003, J IMMUNOL, V170, P6190, DOI 10.4049/jimmunol.170.12.6190; Rosenkilde MM, 2004, J BIOL CHEM, V279, P3033, DOI 10.1074/jbc.M309546200; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sabroe I, 1999, J IMMUNOL, V162, P2946; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sarau HM, 1997, J PHARMACOL EXP THER, V283, P411; Sussman JL, 1998, ACTA CRYSTALLOGR D, V54, P1078, DOI 10.1107/S0907444998009378; Weber C, 2001, BLOOD, V97, P1144, DOI 10.1182/blood.V97.4.1144; Xanthou G, 2003, EUR J IMMUNOL, V33, P2927, DOI 10.1002/eji.200324235; Xanthou G, 2003, EUR J IMMUNOL, V33, P2241, DOI 10.1002/eji.200323787; Youn BS, 1997, J IMMUNOL, V159, P5201; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	43	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4808	4816		10.1074/jbc.M412267200	http://dx.doi.org/10.1074/jbc.M412267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15548526	hybrid			2022-12-25	WOS:000227096600099
J	Jason, LJM; Finn, RM; Lindsey, G; Ausio, J				Jason, LJM; Finn, RM; Lindsey, G; Ausio, J			Histone H2A ubiquitination does not preclude histone H1 binding, but it facilitates its association with the nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENE; HIGHER-ORDER STRUCTURE; LINKER HISTONE; GLOBULAR DOMAIN; CORE PARTICLE; POSITIONED NUCLEOSOMES; THERMAL-DENATURATION; ANGSTROM RESOLUTION; CHROMATIN-STRUCTURE; CIRCULAR-DICHROISM	Histone H2A ubiquitination is a bulky posttranslational modification that occurs at the vicinity of the binding site for linker histones in the nucleosome.Therefore, we took several experimental approaches to investigate the role of ubiquitinated H2A (uH2A) in the binding of linker histones. Our results showed that uH2A was present in situ in histone H1-containing nucleo-cleosomes. Notably in vitro experiments using nucleosomes reconstituted onto 167-bp random sequence and 208-bp (5 S rRNA gene) DNA fragments showed that ubiquitination of H2A did not prevent binding of histone H1 but it rather enhanced the binding of this histone to the nucleosome. We also showed that ubiquitination of H2A did not affect the positioning of the histone octamer in the nucleosome in either the absence or the presence of linker histones.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 396, Canada; Univ Cape Town, Dept Mol & Cell Biol, ZA-7701 Rondebosch, South Africa; Biacore Inc, Piscataway, NJ 08854 USA	University of Victoria; University of Cape Town	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, Petch Bldg,Rm 220, Victoria, BC V8N 5Y2, Canada.	jausio@uvic.ca						ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; An WJ, 1998, NUCLEIC ACIDS RES, V26, P4042, DOI 10.1093/nar/26.17.4042; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Ausio J, 1998, METHODS, V15, P333, DOI 10.1006/meth.1998.0637; AUSIO J, 2004, CHROMATIN STRUCTURE, V39, P249; Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155; BALLAL NR, 1975, J BIOL CHEM, V250, P5921; BARSOUM J, 1985, J BIOL CHEM, V260, P7688; BONNER WM, 1979, P NATL ACAD SCI USA, V76, P2190, DOI 10.1073/pnas.76.5.2190; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; CERF C, 1993, BIOCHEMISTRY-US, V32, P11345, DOI 10.1021/bi00093a011; CLORE GM, 1987, EMBO J, V6, P1833, DOI 10.1002/j.1460-2075.1987.tb02438.x; COWMAN MK, 1980, BIOCHEMISTRY-US, V19, P532, DOI 10.1021/bi00544a022; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DAVIE JR, 1987, BIOCHIM BIOPHYS ACTA, V909, P183, DOI 10.1016/0167-4781(87)90076-5; DAVIES N, 1994, BBA-GENE STRUCT EXPR, V1218, P187, DOI 10.1016/0167-4781(94)90009-4; DAVIES N, 1991, BIOCHIM BIOPHYS ACTA, V1129, P57, DOI 10.1016/0167-4781(91)90212-5; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; GARCIA-RAMIREZ M, 1990, Protein Expression and Purification, V1, P40, DOI 10.1016/1046-5928(90)90043-X; Guschin D, 1998, BIOCHEMISTRY-US, V37, P8629, DOI 10.1021/bi9805846; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jason LJM, 2001, J BIOL CHEM, V276, P14597, DOI 10.1074/jbc.M011153200; KAPLAN LJ, 1984, J BIOL CHEM, V259, P8777; KLEINSCHMIDT AM, 1981, NUCLEIC ACIDS RES, V9, P2423, DOI 10.1093/nar/9.11.2423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee KM, 1998, BIOCHEMISTRY-US, V37, P8622, DOI 10.1021/bi980499y; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LEVINGER L, 1985, J BIOL CHEM, V260, P1799; LINDSEY GG, 1989, BIOCHIM BIOPHYS ACTA, V1009, P257, DOI 10.1016/0167-4781(89)90111-5; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; NELSON PP, 1979, J BIOL CHEM, V254, P1751; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; Osley MA, 2004, BBA-GENE STRUCT EXPR, V1677, P74, DOI 10.1016/j.bbaexp.2003.10.013; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; SUGARMAN BJ, 1983, J BIOL CHEM, V258, P9005; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THORNE AW, 1987, EMBO J, V6, P1005, DOI 10.1002/j.1460-2075.1987.tb04852.x; Travers A, 1999, TRENDS BIOCHEM SCI, V24, P4, DOI 10.1016/S0968-0004(98)01339-5; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Turner BM, 2003, NAT CELL BIOL, V5, P390, DOI 10.1038/ncb0503-390; URA K, 1994, J BIOL CHEM, V269, P27171; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; van Holde K.E., 1988, CHROMATIN; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; WEISCHET WO, 1979, NUCLEIC ACIDS RES, V6, P1843, DOI 10.1093/nar/6.5.1843; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; YAGER TD, 1984, J BIOL CHEM, V259, P4212; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhou YB, 1998, NATURE, V395, P402, DOI 10.1038/26521; ZLATANOVA J, 1992, J CELL SCI, V103, P889	75	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4975	4982		10.1074/jbc.M410203200	http://dx.doi.org/10.1074/jbc.M410203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15546875	hybrid			2022-12-25	WOS:000227096600119
J	Ohsugi, M; Cras-Meneur, C; Zhou, YY; Bernal-Mizrachi, E; Johnson, JD; Luciani, DS; Polonsky, KS; Permutt, MA				Ohsugi, M; Cras-Meneur, C; Zhou, YY; Bernal-Mizrachi, E; Johnson, JD; Luciani, DS; Polonsky, KS; Permutt, MA			Reduced expression of the insulin receptor in mouse insulinoma (MIN6) cells reveals multiple roles of insulin signaling in gene expression, proliferation, insulin content, and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; CYTOSOLIC CA2+; IN-SITU; GLUCOSE; TRANSCRIPTION; ACTIVATION; FEEDBACK; KINASE; GROWTH; TRANSDUCTION	The role of insulin signaling in pancreatic beta cells has become increasingly apparent. Stably transformed insulinoma cell lines (MIN6) were created with small interfering RNA resulting in the reduction of insulin receptor (IR) expression up to 80% (insulin receptor knockdown, IRKDDelta80). Functionally perturbed IR signaling was confirmed with the absence of insulin-stimulated insulin receptor substrate 1 tyrosine phosphorylation. Additionally, Akt phosphorylation was reduced and responded poorly to glucose stimulation. Gene expression profiling revealed that reduced IR expression was associated with alterations in expression of > 1,500 genes with diverse functions. IRKD cells exhibited low rate of proliferation due to delay in transition from G(0)/G(1) to S phase, whereas susceptibility to apoptosis did not differ from that of control cells. Insulin content was reduced in proportion to the reduction of IR. IRKD cells maintained glucose responsiveness as measured by NAD(P)H generation, whereas Ca2+ responses and insulin secretion were enhanced. IRKDDelta80 and control cells were treated with glucose (25 mm) or insulin (100 nM) for 45 min, and gene expression profiles were assessed. Transcriptional activation of several hundred early response genes common to both glucose and insulin stimulation was observed in control cells. In IRKDDelta80 cells' insulin failed to activate any genes as anticipated. Importantly, glucose stimulation of gene expression in IRKDDelta80 cells showed that most genes previously activated by glucose were no longer activated, suggesting a major autocrine/paracrine effect of insulin on glucose-regulated gene expression. On the other hand, there were a number of glucose-regulated genes in the IRKDDelta80 cells that were not previously observed in control cells, suggesting a feedback regulation of insulin signaling on glucose-regulated gene expression. These results demonstrate important roles of the insulin receptor in islet beta cell gene expression and function and may serve to elucidate molecular defects in animal models with diminished beta cell insulin signaling.	Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA	Washington University (WUSTL)	Permutt, MA (corresponding author), Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, 660 S Euclid Ave,Campus Box 8127, St Louis, MO 63110 USA.	apermutt@im.wustl.edu	Cras-Meneur, Corentin/K-7728-2019; Cras-Méneur, Corentin/A-2628-2008	Cras-Meneur, Corentin/0000-0001-8921-8927; Cras-Méneur, Corentin/0000-0001-8921-8927; Johnson, James/0000-0002-7523-9433; Luciani, Dan/0000-0002-4318-4159	NIDDK NIH HHS [DK99007, DK56954, DK16746] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016746, R37DK016746, R24DK056954] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Aspinwall CA, 1999, ANAL CHEM, V71, P5551, DOI 10.1021/ac990817e; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; Cousin SP, 1999, BIOCHEM J, V344, P649, DOI 10.1042/0264-6021:3440649; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; Dunckley T, 2003, J BIOL CHEM, V278, P15633, DOI 10.1074/jbc.M210389200; ELAHI D, 1982, NEW ENGL J MED, V306, P1196, DOI 10.1056/NEJM198205203062002; Eto K, 2002, DIABETES, V51, P87, DOI 10.2337/diabetes.51.1.87; Ferrante AW, 2001, DIABETES, V50, P2268, DOI 10.2337/diabetes.50.10.2268; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Johnson JD, 1999, GEN COMP ENDOCR, V116, P178, DOI 10.1006/gcen.1999.7349; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Kaestner KH, 2003, DIABETES, V52, P1604, DOI 10.2337/diabetes.52.7.1604; Kahn SE, 2001, J CLIN ENDOCR METAB, V86, P4047, DOI 10.1210/jc.86.9.4047; Khan FA, 2001, DIABETES, V50, P2192, DOI 10.2337/diabetes.50.10.2192; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 2002, FEBS LETT, V532, P1, DOI 10.1016/S0014-5793(02)03627-X; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Manduchi E, 2002, PHYSIOL GENOMICS, V10, P169, DOI 10.1152/physiolgenomics.00120.2001; Mauvais-Jarvis F, 2000, DIABETES, V49, P2126, DOI 10.2337/diabetes.49.12.2126; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Ohsugi M, 2004, DIABETES, V53, P1496, DOI 10.2337/diabetes.53.6.1496; Otani K, 2004, AM J PHYSIOL-ENDOC M, V286, pE41, DOI 10.1152/ajpendo.00533.2001; Persaud SJ, 2002, FEBS LETT, V510, P225, DOI 10.1016/S0014-5793(01)03268-9; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rachdi L, 2001, DIABETES, V50, P2021, DOI 10.2337/diabetes.50.9.2021; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Span LFR, 2002, CYTOMETRY, V47, P24, DOI 10.1002/cyto.10028; Srinivasan S, 2002, AM J PHYSIOL-ENDOC M, V283, pE784, DOI 10.1152/ajpendo.00177.2002; Srivastava S, 2003, DIABETES, V52, P2049, DOI 10.2337/diabetes.52.8.2049; STAGNER J, 1986, J CLIN INVEST, V78, P1193, DOI 10.1172/JCI112702; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13; Wice BM, 2001, DIABETOLOGIA, V44, P453, DOI 10.1007/s001250051643; Wicksteed B, 2003, J BIOL CHEM, V278, P42080, DOI 10.1074/jbc.M303509200; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Woo AL, 2002, J BIOL CHEM, V277, P49036, DOI 10.1074/jbc.M205288200; Wu H, 1999, BIOCHEM J, V344, P813, DOI 10.1042/0264-6021:3440813; Xavier GD, 2000, J BIOL CHEM, V275, P36269, DOI 10.1074/jbc.M006597200; Xavier GD, 2004, BIOCHEM J, V377, P149, DOI 10.1042/BJ20031260; Xu GG, 2000, BIOCHEMISTRY-US, V39, P14912, DOI 10.1021/bi001260w; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; Yang IV, 2002, GENOME BIOL, V3	62	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4992	5003		10.1074/jbc.M411727200	http://dx.doi.org/10.1074/jbc.M411727200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15546857	hybrid			2022-12-25	WOS:000227096600121
J	Pengt, B; Hodge, DR; Thomas, SB; Cherry, JM; Munroe, DJ; Pompeia, C; Xiao, WH; Farrar, WL				Pengt, B; Hodge, DR; Thomas, SB; Cherry, JM; Munroe, DJ; Pompeia, C; Xiao, WH; Farrar, WL			Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; REPRESSES TRANSCRIPTION; XERODERMA-PIGMENTOSUM; P53 GENE; PROMOTER; CANCER; DAMAGE; METHYLTRANSFERASE; CARCINOGENESIS; EXPRESSION	During tumorigenesis, selective proliferative advantage in certain cell subsets is associated with accumulation of multiple genetic alterations. For instance, multiple myeloma is characterized by frequent karyotypic instability at the earliest stage, progressing to extreme genetic abnormalities as the disease progresses. These successive genetic alterations can be attributed, in part, to defects in DNA repair pathways, perhaps based on epigenetic gene silencing of proteins involved in DNA damage repair. Here we report epigenetic hypermethylation of the hHR23B gene, a key component of the nucleotide excision repair in response to DNA damage, in interleukin-6 (IL-6)-responsive myeloma KAS-6/1 cells. This hypermethylation was significantly abated by Zebularine, a potent demethylating agent, with a consequent increase in the hHR23B mRNA level. Subsequent removal of this drug and supplementation with IL-6 in the culture medium re-established DNA hypermethylation of the hHR23B gene and silencing of mRNA expression levels. The inclination of DNA to be remethylated, at least within the hHR23B gene promoter region, reflects an epigenetic driving force by the cytogenetic/ tumorigenic status of KAS-6/1 myeloma. The IL-6 response of V.AS-6/1 myeloma also raises a question of whether the proneoplastic growth factor, such as IL-6, supports the epigenetic silencing of important DNA repair genes via promoter hypermethylation during the development of multiple myeloma.	NCI, Frederick Canc Res & Dev Ctr, Cytokine Mol Mech Sect, Mol Immunoregulat Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, Sci Applicat Int Corp, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Mol Technol, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Gene Express Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Farrar, WL (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Cytokine Mol Mech Sect, Mol Immunoregulat Lab, 1050 Boyles St,Bldg 560,Rm 31-68, Frederick, MD 21702 USA.	farrar@mail.ncifcrf.gov	Xiao, Weihua/N-2775-2013; Pompeia, Celine/D-1593-2012	Xiao, Weihua/0000-0001-9102-6326; Pompeia, Celine/0000-0002-7595-8702	NCI NIH HHS [N01-CO-5600] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010253] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMLAK MG, 2002, BIOCHEM BIOPH RES CO, V297, P760; Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Emmert S, 2002, J INVEST DERMATOL, V118, P972, DOI 10.1046/j.1523-1747.2002.01782.x; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hodge DR, 2002, BIOCHEM BIOPH RES CO, V292, P287, DOI 10.1006/bbrc.2002.6652; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kaina B, 2003, BIOCHEM PHARMACOL, V66, P1547, DOI 10.1016/S0006-2952(03)00510-0; Kallen KJ, 2002, BBA-MOL CELL RES, V1592, P323, DOI 10.1016/S0167-4889(02)00325-7; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Kopantzev Y, 2002, ONCOGENE, V21, P6791, DOI 10.1038/sj.onc.1205815; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Lorincz MC, 2001, P NATL ACAD SCI USA, V98, P10034, DOI 10.1073/pnas.201392598; Melki JR, 2002, SEMIN CANCER BIOL, V12, P347, DOI 10.1016/S1044-579X(02)00055-X; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0; Pratt G, 2002, J CLIN PATHOL-MOL PA, V55, P273, DOI 10.1136/mp.55.5.273; Qiao YW, 2002, MUTAT RES-FUND MOL M, V509, P165, DOI 10.1016/S0027-5107(02)00219-1; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rossi D, 2003, BRIT J HAEMATOL, V123, P475, DOI 10.1046/j.1365-2141.2003.04644.x; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Thoma BS, 2003, MOL CARCINOGEN, V38, P1, DOI 10.1002/mc.10143; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; WESTENDORF JJ, 1996, LEUKEMIA BALTIMORE, V5, P866	32	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4182	4187		10.1074/jbc.M412566200	http://dx.doi.org/10.1074/jbc.M412566200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15550378	hybrid			2022-12-25	WOS:000227096600024
J	Kaur, R; Liu, X; Gjoerup, O; Zhang, AH; Yuan, X; Balk, SP; Schneider, MC; Lu, ML				Kaur, R; Liu, X; Gjoerup, O; Zhang, AH; Yuan, X; Balk, SP; Schneider, MC; Lu, ML			Activation of p21-activated kinase 6 by MAP kinase kinase 6 and p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; PROTEIN-KINASE; PAK ACTIVATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION; DOMAIN; IDENTIFICATION; MECHANISM; PATHWAY; SWITCH	The p21-activated kinases (PAKs) contain an N-terminal Cdc42/Rac interactive binding domain, which in the group 1 PAKs (PAK1, 2, and 3) regulates the activity of an adjacent conserved autoinhibitory domain. In contrast, the group 2 PAKs (PAK4, 5, and 6) lack this autoinhibitory domain and are not activated by Cdc42/Rac binding, and the mechanisms that regulate their kinase activity have been unclear. This study found that basal PAK6 kinase activity was repressed by a p38 mitogen-activated protein (MAP) kinase antagonist and could be strongly stimulated by constitutively active MAP kinase kinase 6 (MKK6), an upstream activator of p38 MAP kinases. Mutation of a consensus p38 MAP kinase target site at serine 165 decreased PAK6 kinase activity. Moreover, PAK6 was directly activated by MKK6, and mutation of tyrosine 566 in a consensus MKK6 site (threonine-proline-tyrosine, TPY) in the activation loop of the PAK6 kinase domain prevented activation by MKK6. PAK6 activation by MKK6 was also blocked by mutation of an autophosphorylated serine (serine 560) in the PAK6 activation loop, indicating that phosphorylation of this site is necessary for MKK6-mediated activation. PAK4 and PAK5 were similarly activated by MKK6, consistent with a conserved TPY motif in their activation domains. The activation of PAK6 by both p38 MAP kinase and MKK6 suggests that PAK6 plays a role in the cellular response to stress-related signals.	Brigham & Womens Hosp, Urol Res Lab, Dept Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Lu, ML (corresponding author), Brigham & Womens Hosp, Urol Res Lab, Dept Surg, LMRC-BLI-143,221 Longwood Ave, Boston, MA 02115 USA.	mlu@rics.bwh.harvard.edu			NCI NIH HHS [CA8799701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Ching YP, 2003, J BIOL CHEM, V278, P33621, DOI 10.1074/jbc.C300234200; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Clark AR, 2003, J ENDOCRINOL, V178, P5, DOI 10.1677/joe.0.1780005; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jiang Y, 1997, J BIOL CHEM, V272, P11096; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Lee SR, 2002, MOL ENDOCRINOL, V16, P85, DOI 10.1210/me.16.1.85; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Schrantz N, 2004, J BIOL CHEM, V279, P1922, DOI 10.1074/jbc.M311145200; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565	24	41	47	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3323	3330		10.1074/jbc.M406701200	http://dx.doi.org/10.1074/jbc.M406701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550393	hybrid			2022-12-25	WOS:000226983900025
J	Mayer, KM; Shanklin, J				Mayer, KM; Shanklin, J			A structural model of the plant acyl-acyl carrier protein thioesterase FatB comprises two helix/4-stranded sheet domains, the N-terminal domain containing residues that affect specificity and the C-terminal domain containing catalytic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-HYDROXYBENZOYL-COA THIOESTERASE; ACP THIOESTERASES; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; ACID BIOSYNTHESIS; CRYSTAL-STRUCTURE; ACTIVE-SITE; PURIFICATION; PREDICTIONS; EXPRESSION	Plant acyl-acyl carrier protein thioesterases (TEs) terminate the acyl-acyl carrier protein track of fatty acid biosynthesis and play an essential role in determining the amount and composition of fatty acids entering the storage lipid pool. A combination of bioinformatics tools was used to predict a three-dimensional model for Arabidopsis FatB (AtFatB), which comprises a fold similar to that of Escherichia coli TEII, an enzyme that is functionally similar to plant TEs but lacks significant sequence similarity and displays different inhibitor sensitivity. The catalytic residues in AtFatB, Cys-264 and His-229, localize to the same region of the model as catalytic residues found in other enzymes with helix/multi-stranded sheet motifs (hot dog folds). Based on the model, we identified Asn-227 as a possible third member of the proposed papain-like catalytic triad. The conversion of Asn-227 to Ala resulted in a loss of detectable activity (>200-fold reduction), similar to the result seen for the equivalent mutation in papain. Mapping of plant TE specificity-affecting mutations onto the structural model showed that these mutations all cluster around the catalytic triad. Also, superposition of the crystallographically determined structures of the complexes of 4-hydroxybenzoyl-CoA TE with substrate and beta-hydroxydecanoyl thiol ester dehydrase with inhibitor onto the AtFatB model showed that the substrate and inhibitor localize to the same region as the AtFatB catalytic triad in their respective structures. Together these data corroborate the structural model and show that the hot dog fold is common to enzymes from both prokaryotes and eukaryotes and that this fold supports at least three different catalytic mechanisms.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Shanklin, J (corresponding author), Brookhaven Natl Lab, Dept Biol, Biol Bldg 463,50 Bell Ave, Upton, NY 11973 USA.	shanklin@bnl.gov		Shanklin, John/0000-0002-6774-8043				Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; Brody SS, 1999, PROTEINS, V37, P485, DOI 10.1002/(SICI)1097-0134(19991115)37:3<485::AID-PROT15>3.0.CO;2-G; Bromme D, 1996, BIOCHEMISTRY-US, V35, P3970, DOI 10.1021/bi9523015; Das AK, 2003, BIOCHEM BIOPH RES CO, V302, P442, DOI 10.1016/S0006-291X(03)00116-5; DAVIES HM, 1991, ARCH BIOCHEM BIOPHYS, V290, P37, DOI 10.1016/0003-9861(91)90588-A; Dillon SC, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-109; DORMANN P, 1995, ARCH BIOCHEM BIOPHYS, V316, P612, DOI 10.1006/abbi.1995.1081; Facciotti MT, 1999, NAT BIOTECHNOL, V17, P593, DOI 10.1038/9909; Facciotti MT, 1998, FETT-LIPID, V100, P167; Ginalski K, 2003, NUCLEIC ACIDS RES, V31, P3291, DOI 10.1093/nar/gkg503; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HELLYER A, 1992, PLANT MOL BIOL, V20, P763, DOI 10.1007/BF00027148; Hills MJ, 1999, TRENDS PLANT SCI, V4, P421, DOI 10.1016/S1360-1385(99)01483-1; Hisano T, 2003, J BIOL CHEM, V278, P617, DOI 10.1074/jbc.M205484200; JONES A, 1995, PLANT CELL, V7, P359, DOI 10.1105/tpc.7.3.359; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KANEKO T, 1995, DNA RES, V2, P191, DOI DOI 10.1093/DNARES/2.4.191; Lambert C, 2002, BIOINFORMATICS, V18, P1250, DOI 10.1093/bioinformatics/18.9.1250; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Li J, 2000, NAT STRUCT BIOL, V7, P555; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Marrakchi H, 2002, BIOCHEM SOC T, V30, P1050, DOI 10.1042/bst0301050; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; Patthy L, 2003, GENETICA, V118, P217, DOI 10.1023/A:1024182432483; Salas JJ, 2002, ARCH BIOCHEM BIOPHYS, V403, P25, DOI 10.1016/S0003-9861(02)00017-6; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Thoden JB, 2002, J BIOL CHEM, V277, P27468, DOI 10.1074/jbc.M203904200; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; Voelker T, 1996, Genet Eng (N Y), V18, P111; VOELKER TA, 1994, J BACTERIOL, V176, P7320, DOI 10.1128/JB.176.23.7320-7327.1994; VOELKER TA, 1992, SCIENCE, V257, P72, DOI 10.1126/science.1621095; Vogel C, 2004, CURR OPIN STRUC BIOL, V14, P208, DOI 10.1016/j.sbi.2004.03.011; VONGROTTHAUSS M, 2003, PROTEIN-STRUCT FUNCT, V3, P418; Yuan L, 1996, SCIENCE, V271, P17, DOI 10.1126/science.271.5245.17a; YUAN L, 1995, P NATL ACAD SCI USA, V92, P10639, DOI 10.1073/pnas.92.23.10639; Zhuang ZH, 2002, BIOCHEMISTRY-US, V41, P11152, DOI 10.1021/bi0262303	38	43	76	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3621	3627		10.1074/jbc.M411351200	http://dx.doi.org/10.1074/jbc.M411351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15531590	hybrid			2022-12-25	WOS:000226983900061
J	Middaugh, J; Hamel, R; Jean-Baptiste, G; Beriault, R; Chenier, D; Appanna, VD				Middaugh, J; Hamel, R; Jean-Baptiste, G; Beriault, R; Chenier, D; Appanna, VD			Aluminum triggers decreased aconitase activity via Fe-S cluster disruption and the overexpression of isocitrate dehydrogenase and isocitrate lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON REGULATORY PROTEINS; ATP CITRATE-LYASE; PSEUDOMONAS-FLUORESCENS; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; BINDING-PROTEIN; SULFUR CLUSTER; RNA-BINDING; OXALIC-ACID; ADAPTATION	Although aluminum is known to be toxic to most organisms, its precise biochemical interactions are not fully understood. In the present study, we demonstrate that aluminum promotes the inhibition of aconitase (Acn) activity via the perturbation of the Fe-S cluster in Pseudomonas fluorescens. Despite the significant decrease in citrate isomerization activity, cellular survival is assured by the overexpression of isocitrate lyase and isocitrate dehydrogenase (IDH)-NADP(+). C-13 NMR spectroscopic studies, Blue Native PAGE, and Western blot analyses indicated that although the decrease in Acn activity is concomitant with the increase of aluminum in the culture, the amount of Acn expressed is not sensitive to the concentration of the trivalent metal. A 6-fold decrease in Acn activity and no discernable change in protein content in aluminum-stressed cultures were observed. The addition of Fe(NH4)(2)(SO4)(2) in a reducing environment led to a significant recovery in Acn activity. This enzymatic activity reverted to normal levels when aluminum-stressed cells were transferred to either a control or an iron-supplemented medium. The overexpression of the two isocitrate-metabolizing enzymes isocitrate lyase and IDH-NADP(+) appears to mitigate the deficit in Acn activity. The levels of these enzymes are dependent on the aluminum content of the culture and appear to be under transcriptional control. Hence, the regulation of the enzymes involved in the homeostasis of isocitrate constitutes a pivotal component of the global metabolic strategy that ensures the survival of this organism in an aluminum citrate environment.	Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3C 2C6, Canada; No Ctr Biotechnol & Clin Res, Sudbury, ON P3E 6B4, Canada	Laurentian University	Appanna, VD (corresponding author), Laurentian Univ, Dept Chem & Biochem, 935 Ramsey Lake Rd, Sudbury, ON P3C 2C6, Canada.	vappanna@laurentian.ca		Appanna, Vasu/0000-0002-0138-5665				Adams IP, 2002, BBA-PROTEIN STRUCT M, V1597, P36, DOI 10.1016/S0167-4838(02)00276-5; Alen C, 1999, P NATL ACAD SCI USA, V96, P10412, DOI 10.1073/pnas.96.18.10412; APPANNA VD, 1995, BIOTECHNOL PROGR, V11, P159, DOI 10.1021/bp00032a007; APPANNA VD, 1999, RRD MICROBIOL 2, V3, P615; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Berndt C, 2004, J BIOL CHEM, V279, P7850, DOI 10.1074/jbc.M309332200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairo G, 2002, FREE RADICAL BIO MED, V32, P1237, DOI 10.1016/S0891-5849(02)00825-0; CLARK DP, 1990, FEMS MICROBIOL LETT, V67, P245, DOI 10.1016/0378-1097(90)90003-9; CONOVER WW, 1984, TOPICS CARBON 13 NMR, V4, P4; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; Exley C, 2004, FREE RADICAL BIO MED, V36, P380, DOI 10.1016/j.freeradbiomed.2003.11.017; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Goodacre Royston, 2004, Drug Discov Today, V9, P260, DOI 10.1016/S1359-6446(04)03027-2; GRUER MJ, 1994, MICROBIOL-SGM, V140, P2531, DOI 10.1099/00221287-140-10-2531; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hamel R, 2003, BBA-GEN SUBJECTS, V1619, P70, DOI 10.1016/S0304-4165(02)00444-0; Hamel R, 1999, J INORG BIOCHEM, V76, P99, DOI 10.1016/S0162-0134(99)00120-8; Hamel R, 2004, BIOCHEM BIOPH RES CO, V317, P1189, DOI 10.1016/j.bbrc.2004.03.157; HAMEL R, 2003, ENHANCED LIPOGENESIS; Hamel RD, 2001, J INORG BIOCHEM, V87, P1, DOI 10.1016/S0162-0134(01)00307-5; HENSON CP, 1967, J BIOL CHEM, V242, P3833; Kayashima T, 2002, BBA-GEN SUBJECTS, V1573, P1, DOI 10.1016/S0304-4165(02)00338-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma JF, 1997, NATURE, V390, P569, DOI 10.1038/37518; Nayak P, 2002, ENVIRON RES, V89, P101, DOI 10.1006/enrs.2002.4352; Romanov V, 1999, ANAL BIOCHEM, V268, P49, DOI 10.1006/abio.1998.3033; Sanford K, 2002, CURR OPIN MICROBIOL, V5, P318, DOI 10.1016/S1369-5274(02)00318-1; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schneider K, 2000, FEBS LETT, V483, P165, DOI 10.1016/S0014-5793(00)02105-0; Soum E, 2003, BIOCHEMISTRY-US, V42, P7648, DOI 10.1021/bi030041i; Tuhackova Z, 1996, BIOCHEM BIOPH RES CO, V218, P61, DOI 10.1006/bbrc.1996.0012; Varghese S, 2003, J BACTERIOL, V185, P221, DOI 10.1128/JB.185.1.221-230.2003; WARREN WA, 1970, BIOCHIM BIOPHYS ACTA, V212, P503, DOI 10.1016/0005-2744(70)90257-3	35	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3159	3165		10.1074/jbc.M411979200	http://dx.doi.org/10.1074/jbc.M411979200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548528	hybrid			2022-12-25	WOS:000226983900007
J	Qian, CN; Knol, J; Igarashi, P; Lin, FM; Zylstra, U; Teh, BT; Williams, BO				Qian, CN; Knol, J; Igarashi, P; Lin, FM; Zylstra, U; Teh, BT; Williams, BO			Cystic renal neoplasia following conditional inactivation of Apc in mouse renal tubular epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS-POLYPOSIS-COLI; POLYCYSTIC KIDNEY-DISEASE; BETA-CATENIN; TUMOR-SUPPRESSOR; GENE-PRODUCT; E-CADHERIN; EXPRESSION; PROMOTER; PROTEIN; WNT	Alterations in Wnt/beta-catenin signaling have been linked to abnormal kidney development and tumorigenesis. To gain more insights into the effects of these alterations, we created mice carrying a conditional deletion of the Apc tumor suppressor gene specifically in the renal epithelium. As expected, the loss of Apc leads to increased levels of beta-catenin protein in renal epithelium. Most of these mice die shortly after birth, and multiple kidney cysts were found upon, histological. examination. Only rarely did these animals survive to adulthood. Analysis of these adults revealed severely cystic kidneys associated with the presence of renal adenomas. Our results confirm an important role for proper regulation of Wnt/beta-catenin signaling in renal development and provide evidence that dysregulation of the pathway can initiate tumorigenesis in the kidney.	Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI 49503 USA; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Basic Sci, Dallas, TX 75390 USA; Calvin Coll, Dept Biol, Grand Rapids, MI 49546 USA	Van Andel Institute; Van Andel Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Calvin University	Williams, BO (corresponding author), Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	bart.williams@vai.org	Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301; Igarashi, Peter/0000-0001-8698-1185; Teh, Bin Tean/0000-0003-1514-1124	NIDDK NIH HHS [P50 DK057328, R01 DK067565, DK-57328, DK-42921, DK-67565, R01 DK042921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057328, R01DK067565, R01DK042921, R37DK042921] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham SC, 2002, HUM PATHOL, V33, P39, DOI 10.1053/hupa.2002.30196; Abraham SC, 2002, AM J PATHOL, V160, P953, DOI 10.1016/S0002-9440(10)64917-6; Battagli C, 2003, CANCER RES, V63, P8695; Bingham C, 2001, AM J HUM GENET, V68, P219, DOI 10.1086/316945; Chen TA, 2003, CANCER RES, V63, P4368; Delmas P, 2004, CELL, V118, P145, DOI 10.1016/j.cell.2004.07.007; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Gresh L, 2004, EMBO J, V23, P1657, DOI 10.1038/sj.emboj.7600160; Hasegawa S, 2002, P NATL ACAD SCI USA, V99, P297, DOI 10.1073/pnas.012264999; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; *K DQQI, 2002, AM J KID DIS, V39, pS1; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim GH, 1998, P NATL ACAD SCI USA, V95, P14552, DOI 10.1073/pnas.95.24.14552; Kim YS, 2000, PATHOL INT, V50, P725, DOI 10.1046/j.1440-1827.2000.01111.x; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koesters R, 1999, CANCER RES, V59, P3880; Kok SH, 2002, J ORAL PATHOL MED, V31, P395, DOI 10.1034/j.1600-0714.2002.00118.x; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; Mache CJ, 2002, PEDIATR NEPHROL, V17, P1021, DOI 10.1007/s00467-002-0975-2; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Muto S, 2002, HUM MOL GENET, V11, P1731, DOI 10.1093/hmg/11.15.1731; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ong ACM, 2003, LANCET, V361, P774, DOI 10.1016/S0140-6736(03)12662-1; Rodova M, 2002, J BIOL CHEM, V277, P29577, DOI 10.1074/jbc.M203570200; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Shao XL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016443.50138.CD; Shao XL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016444.90348.50; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Usadel H, 2002, CANCER RES, V62, P371; Vainio SJ, 2000, PEDIATR NEPHROL, V15, P151, DOI 10.1007/s004670000404; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; Wilson PD, 2001, J AM SOC NEPHROL, V12, P834, DOI 10.1681/ASN.V124834; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Wyse B, 2002, AM J PHYSIOL-RENAL, V282, pF424, DOI 10.1152/ajprenal.0028.2001; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; ZERRES K, 1996, POLYCYSTIC KIDNEY DI, P167; Zhu XD, 2000, PATHOL INT, V50, P945, DOI 10.1046/j.1440-1827.2000.01139.x; Zolotnitskaya A, 1999, AM J PHYSIOL-RENAL, V276, pF825, DOI 10.1152/ajprenal.1999.276.6.F825	49	112	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3938	3945		10.1074/jbc.M410697200	http://dx.doi.org/10.1074/jbc.M410697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550389	hybrid			2022-12-25	WOS:000226983900096
J	Pang, JH; Kraemer, A; Stehbens, SJ; Frame, MC; Yap, AS				Pang, JH; Kraemer, A; Stehbens, SJ; Frame, MC; Yap, AS			Recruitment of phosphoinositide 3-kinase defines a positive contribution of tyrosine kinase signaling to E-cadherin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; SRC-FAMILY; ADHERENS JUNCTIONS; CONTACT FORMATION; PROTEIN-KINASE; BETA-CATENIN; P85 SUBUNIT; ACTIVATION; PHOSPHORYLATION	Classical cadherin adhesion molecules can function as adhesion-activated cell-signaling receptors. One key target for cadherin signaling is the lipid kinase phosphoinositide (PI) 3-kinase, which is recruited to cell-cell contacts and activated by E-cadherin. In this study, we sought to identify upstream factors necessary for E-cadherin to activate PI 3-kinase signaling. We found that inhibition of tyrosine kinase signaling blocked recruitment of PI 3-kinase to E-cadherin contacts and abolished the ability of E-cadherin to activate PI 3-kinase signaling. Tyrosine kinase inhibitors further perturbed several parameters of cadherin function, including cell adhesion and the ability of cells to productively extend nascent cadherin-adhesive contacts. Notably, the functional effects of tyrosine kinase blockade were rescued by expression of a constitutively active form of PI 3-kinase that restores PI 3-kinase signaling. Finally, using dominant negative Src mutants and Src-null cells, we identified Src as one key upstream kinase in the E-cadherin/PI 3-kinase-signaling pathway. Taken together, our findings indicate that tyrosine kinase activity, notably Src signaling, can contribute positively to cadherin function by supporting E-cadherin signaling to PI 3-kinase.	Univ Queensland, Inst Mol Biosci, Div Mol Cell Biol, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Queensland; University of Queensland; Beatson Institute	Yap, AS (corresponding author), Univ Queensland, Inst Mol Biosci, Div Mol Cell Biol, Brisbane, Qld 4072, Australia.	a.yap@imb.uq.edu.au	Stehbens, Samantha/AAH-4145-2019; Yap, Alpha S./J-1554-2014; Stehbens, Samantha/D-3512-2019	Stehbens, Samantha/0000-0002-8145-2708; Yap, Alpha S./0000-0002-1038-8956; Stehbens, Samantha/0000-0002-8145-2708; Frame, Margaret/0000-0001-5882-1942				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Cantrell DA, 2001, J CELL SCI, V114, P1439; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; El Sayegh TY, 2004, J CELL SCI, V117, P5117, DOI 10.1242/jcs.01385; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Helwani FM, 2004, J CELL BIOL, V164, P899, DOI 10.1083/jcb.200309034; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Verma S, 2004, J BIOL CHEM, V279, P34062, DOI 10.1074/jbc.M404814200; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	39	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3043	3050		10.1074/jbc.M412148200	http://dx.doi.org/10.1074/jbc.M412148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15556934	hybrid			2022-12-25	WOS:000226449100080
J	Baldus, SE; Schwarz, E; Lohrey, C; Zapatka, M; Landsberg, S; Hahn, SA; Schmidt, D; Dienes, HP; Schmiegel, WH; Schwarte-Waldhoff, I				Baldus, SE; Schwarz, E; Lohrey, C; Zapatka, M; Landsberg, S; Hahn, SA; Schmidt, D; Dienes, HP; Schmiegel, WH; Schwarte-Waldhoff, I			Smad4 deffiency in cervical carcinoma cells	ONCOGENE			English	Article						tumor suppressor gene; TGF-beta; multistep carcinogenesis; CIN lesion	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; UTERINE CERVIX; PAPILLOMAVIRUS INFECTIONS; INTRAEPITHELIAL NEOPLASIA; GENOMIC INSTABILITY; COLORECTAL-CANCER; DPC4 INACTIVATION; TGF-BETA; EXPRESSION	Squamous cell carcinoma of the uterine cervix is one of the most frequent cancers affecting women worldwide. Carcinomas arise from cervical intraepithelial lesions, in which infection with high-risk human papillomavirus types has led to deregulated growth control through the actions of the viral E6 and E7 oncoproteins. The molecular mechanisms underlying progression to invasive tumor growth are poorly understood. One important feature, however, is the escape from growth inhibition by transforming growth factor beta (TGF-beta). Loss of chromosomal arm 18q is among the most frequent cytogenetic alterations in cervical cancers and has been associated with poor prognosis. Since the TGF-beta response is mediated by Smad proteins and the tumor suppressor gene Smad4 resides at 18q21, we have analysed the Smad4 gene for cervical cancer-associated alterations in cell lines and primary carcinomas. Here, we report Smad4 deficiency in four out of 13 cervical cancer cell lines which is due to an intronic rearrangement or deletions of 30 exons. All cell lines, however, showed either absent or moderate responsiveness to TGF-beta irrespective of their Smad4 status. In 41 primary squamous cervical carcinomas analysed, 10 samples showed loss of Smad4 protein expression and 26 samples a reduced expression. Altogether, our results strongly suggest that Smad4 gene alterations are involved in cervical carcinogenesis.	Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, IMBL,Dept Internal Med, D-44892 Bochum, Germany; Univ Cologne, Inst Pathol, D-50931 Cologne, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany; Inst Pathol, D-68159 Mannheim, Germany; Ruhr Univ Bochum, Dept Gastroenterol & Hepatol, D-44892 Bochum, Germany	Ruhr University Bochum; University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ); Ruhr University Bochum	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, IMBL,Dept Internal Med, Schornau 23-25, D-44892 Bochum, Germany.	irmgard.schwarte-waldhoff@ruhr-uni-bochum.de	Zapatka, Marc/G-9896-2013; Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Zapatka, Marc/0000-0001-8287-5967; Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741				AUERSPERG N, 1989, CANCER RES, V49, P3007; Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO;2-U; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.3.CO;2-5; Dellas A, 1999, CANCER RES, V59, P3475; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Einstein MH, 2002, CLIN CANCER RES, V8, P549; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Harima Y, 2001, INT J CANCER, V96, P286, DOI 10.1002/ijc.1027; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Iacobuzio-Donahue CA, 2004, CLIN CANCER RES, V10, P1597, DOI 10.1158/1078-0432.CCR-1121-3; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.3.CO;2-5; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.0.CO;2-7; Kersemaekers AMF, 1998, BRIT J CANCER, V77, P192, DOI 10.1038/bjc.1998.33; Klaes R, 1999, CANCER RES, V59, P6132; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee SH, 2001, INT J CANCER, V94, P500, DOI 10.1002/ijc.1494; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Maliekal TT, 2003, ONCOGENE, V22, P4889, DOI 10.1038/sj.onc.1206806; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Minami R, 1998, BBA-GENE STRUCT EXPR, V1443, P182, DOI 10.1016/S0167-4781(98)00217-6; MITRA AB, 1994, CANCER RES, V54, P4481; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Muliokandov MR, 1996, CANCER RES, V56, P197; Rader JS, 1996, ONCOGENE, V13, P2737; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Reyes G, 1996, CANCER RES, V56, P5713; Roth S, 2000, BRIT J CANCER, V83, P1015, DOI 10.1054/bjoc.2000.1387; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Slebos RJC, 1998, CANCER RES, V58, P5333; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wilentz RE, 2000, CANCER RES, V60, P2002; Zhou Y, 1999, MOL CARCINOGEN, V25, P64, DOI 10.1002/(SICI)1098-2744(199905)25:1<64::AID-MC8>3.0.CO;2-Z; ZURHAUSEN H, 1995, INT J CANCER, V63, P315; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	44	26	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					810	819		10.1038/sj.onc.1208235	http://dx.doi.org/10.1038/sj.onc.1208235			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15531914				2022-12-25	WOS:000226577100007
J	Hupfeld, CJ; Resnik, JL; Ugi, S; Olefsky, JM				Hupfeld, CJ; Resnik, JL; Ugi, S; Olefsky, JM			Insulin-induced beta-Arrestin1 Ser-412 phosphorylation is a mechanism for desensitization of ERK activation by G alpha(i)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; PROTEIN PHOSPHATASE 2A; SIGNAL-REGULATED KINASES; BETA-ARRESTIN; DEPENDENT ENDOCYTOSIS; ADRENERGIC-RECEPTOR; FEEDBACK-REGULATION; COUPLED RECEPTOR; DOWN-REGULATION; GROWTH	beta-Arrestin1 is an adapter/scaffold for many G protein-coupled receptors during mitogen-activated protein kinase signaling. Phosphorylation of beta-arrestin1 at position Ser-412 is a regulator of beta-arrestin1 function, and in the present study, we showed that insulin led to a time- and dose-dependent increase in beta-arrestin1 Ser-412 phosphorylation, which blocked isoproterenol- and lysophosphatidic acid-induced Ser-412 dephosphorylation and impaired ERK signaling by these G protein-coupled receptor ligands. Insulin treatment also led to accumulation of Ser-412-phosphorylated beta-arrestin1 at the insulin-like growth factor 1 receptor and prevented insulin-like growth factor 1/Src association. Insulin-induced Ser-412 phosphorylation was partially dependent on ERK as treatment with the MEK inhibitor PD98059 inhibited the insulin effect (62% reduction, p = 0.03). Inhibition of phosphatidylinositol 3-kinase by wortmannin did not have a significant effect (9% reduction, p = 0.41). We also found that the protein phosphatase 2A (PP2A) was in a molecular complex with beta-arrestin1 and that the PP2A inhibitor okadaic acid increased Ser-412 phosphorylation. Concomitant addition of insulin and okadaic acid did not produce an additive effect on Ser-412 phosphorylation, suggesting a common mechanism. Small t antigen specifically inhibited PP2A, and in HIRcB cells expressing small t antigen, beta-arrestin1 Ser-412 phosphorylation was increased, and insulin had no further effect. Insulin treatment caused increased beta-arrestin1 Ser-412 phosphorylation, which blocked mitogen-activated protein kinase signaling and internalization by beta-arrestin1-dependent receptors with no effect on beta-adrenergic receptor G(s)-mediated cAMP production. These findings provide a new mechanism for insulin-induced desensitization of ERK activation by Galpha(i)-coupled receptors.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Reprod Med, La Jolla, CA 92093 USA; Vet Affairs Hosp, Res Serv, San Diego, CA 92161 USA; Whittier Diabet Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu			NIDDK NIH HHS [K08 DK65127-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK065127] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; BEJUM N, 1996, J BIOL CHEM, V271, P31166; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; Cammisotto PG, 2002, AM J PHYSIOL-CELL PH, V283, pC244, DOI 10.1152/ajpcell.00033.2002; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dalle S, 2002, MOL CELL BIOL, V22, P6272, DOI 10.1128/MCB.22.17.6272-6285.2002; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Hupfeld CJ, 2003, P NATL ACAD SCI USA, V100, P161, DOI 10.1073/pnas.0235674100; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kreuzer OJ, 2001, J NEUROENDOCRINOL, V13, P279, DOI 10.1046/j.1365-2826.2001.00630.x; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lindquist JM, 1998, J BIOL CHEM, V273, P30147, DOI 10.1074/jbc.273.46.30147; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Wu JH, 2003, J BIOL CHEM, V278, P44238, DOI 10.1074/jbc.M309450200	38	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1016	1023		10.1074/jbc.M403674200	http://dx.doi.org/10.1074/jbc.M403674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15520010	hybrid			2022-12-25	WOS:000226195200021
J	Shin, OH; Han, WP; Wang, Y; Sudhof, TC				Shin, OH; Han, WP; Wang, Y; Sudhof, TC			Evolutionarily conserved multiple C-2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOTAGMIN-I; PHOSPHOLIPID-BINDING; C2 DOMAIN; CALMODULIN; RELEASE; FAMILY; FORMS; RIM	C-2 domains are primarily found in signal transduction proteins such as protein kinase C, which generally contain a single C-2 domain, and in membrane trafficking proteins such as synaptotagmins, which generally contain multiple C-2 domains. In both classes of proteins, C-2 domains usually regulate the respective protein's function by forming Ca2+-dependent or Ca2+-independent phospholipid complexes. We now describe MCTPs ( multiple C-2 domain and transmembrane region proteins), a novel family of evolutionarily conserved C-2 domain proteins with unusual Ca2+-dependent properties. MCTPs are composed of a variable N-terminal sequence, three C-2 domains, two transmembrane regions, and a short C-terminal sequence. The invertebrate organisms Caenorhabditis elegans and Drosophila melanogaster express a single MCTP gene, whereas vertebrates express two MCTP genes (MCTP1 and MCTP2) whose primary transcripts are extensively alternatively spliced. Most of the MCTP sequences, in particular the C-2 domains, are highly conserved. All MCTP C-2 domains except for the second C-2 domain of MCTP2 include a perfect Ca2+/phospholipid-binding consensus sequence. To determine whether the C-2 domains of MCTPs actually function as Ca2+/phospholipid-binding modules, we analyzed their Ca2+ and phospholipid binding properties. Surprisingly, we found that none of the three MCTP1 C-2 domains interacted with negatively charged or neutral phospholipids in the presence or absence of Ca2+. However, Ca2+ titrations monitored via intrinsic tryptophan fluorescence revealed that all three C-2 domains bound Ca2+ in the absence of phospholipids with a high apparent affinity (EC50 of similar to1.3-2.3 muM). Our data thus reveal that MCTPs are evolutionarily conserved C-2 domain proteins that are unusual in that the C-2 domains are anchored in the membrane by two closely spaced transmembrane regions and represent Ca2+-binding but not phospholipid-binding modules.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu						Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Dai H, 2004, NAT STRUCT MOL BIOL, V11, P844, DOI 10.1038/nsmb817; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Morris NJ, 1999, BBA-PROTEIN STRUCT M, V1431, P525, DOI 10.1016/S0167-4838(99)00068-0; Nakayama N, 2000, TOP BIOL INORG CHEM, V3, P29; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Pucharcos C, 2001, BBA-GENE STRUCT EXPR, V1521, P1, DOI 10.1016/S0167-4781(01)00276-7; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Toutenhoofd SL, 2000, CELL CALCIUM, V28, P83, DOI 10.1054/ceca.2000.0136; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 2003, GENOMICS, V81, P126, DOI 10.1016/S0888-7543(02)00024-1	33	76	79	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1641	1651		10.1074/jbc.M407305200	http://dx.doi.org/10.1074/jbc.M407305200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15528213	hybrid			2022-12-25	WOS:000226195200095
J	Cho, HS; Kim, DU; Kehrl, JH				Cho, HS; Kim, DU; Kehrl, JH			RGS14 is a centrosomal and nuclear cytoplasmic shuttling protein that traffics to promyelocytic leukemia nuclear bodies following heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; G-ALPHA; LOCALIZATION; TRANSCRIPTION; REGULATOR; DOMAIN; EXPRESSION; FEATURES; CELLS; MOTIF	RGS14, a member of the regulator of G-protein signaling (RGS) protein family, possesses an N-terminal RGS domain, two Raf-like Ras-binding domains, and a GoLoco motif, which has GDP dissociation inhibitor activity. In this study we show that unique among the known mammalian RGS proteins, RGS14 localizes in centrosomes. Its first Ras-binding domain is sufficient to target RGS14 to centrosomes. RGS14 also shuttles between the cytoplasm and nucleus, and its nuclear export depends on the CRM-1 nuclear export receptor. Mutation of a nuclear export signal or treatment with leptomycin B causes nuclear accumulation of RGS14 and its association with promyelocytic leukemia protein nuclear bodies. Furthermore, a point mutant defective in nuclear export fails to target to centrosomes, suggesting that nuclear cytoplasmic shuttling is necessary for its proper localization. Mild heat stress, but not proteotoxic or transcription-linked stresses, re-localizes the RGS14 from the cytoplasm to promyelocytic leukemia nuclear bodies. Expression of RGS14, but not point mutants that disrupt the functional activity of its RGS domain or GoLoco motif, enhances the reporter gene activity. The multifunctional domains and the dynamic subcellular localization of RGS14 implicate it in a diverse set of cellular processes including centrosome and nuclear functions and stress-induced signaling pathways.	NIAID, Immunoregulat Lab, NIH, B Cell Mol Immunol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, NIH, B Cell Mol Immunol Sect, Bldg 10,Rm 11B08,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.	jkehrl@niaid.nih.gov	Kehrl, John/AAE-6292-2019	Cho, Hyeseon/0000-0001-7512-1980; Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000738, ZIAAI000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bouhamdan M, 2004, BBA-MOL CELL RES, V1691, P141, DOI 10.1016/j.bbamcr.2004.01.005; Burchett SA, 2003, J NEUROCHEM, V87, P551, DOI 10.1046/j.1471-4159.2003.02047.x; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 2003, J BIOL CHEM, V278, P30272, DOI 10.1074/jbc.M212688200; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Cho H., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P107, DOI 10.2174/1568008043339938; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hess HA, 2004, CELL, V119, P209, DOI 10.1016/j.cell.2004.09.025; Hollinger S, 2003, BIOCHEMISTRY-US, V42, P811, DOI 10.1021/bi026664y; Keryer G, 2003, MOL BIOL CELL, V14, P4260, DOI 10.1091/mbc.E02-11-0773; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lamond AI, 2003, CURR BIOL, V13, pR825, DOI 10.1016/j.cub.2003.10.012; Nair R, 2003, NUCLEIC ACIDS RES, V31, P397, DOI 10.1093/nar/gkg001; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Stukenberg PT, 2004, J CELL BIOL, V165, P607, DOI 10.1083/jcb.200405089; Suico MA, 2004, J BIOL CHEM, V279, P19091, DOI 10.1074/jbc.M312439200; Tashiro S, 2004, MOL CELL BIOL, V24, P3473, DOI 10.1128/MCB.24.8.3473-3484.2004; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Traver S, 2004, BIOCHEM J, V379, P627, DOI 10.1042/BJ20031889; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wang L, 2001, P NATL ACAD SCI USA, V98, P3220, DOI 10.1073/pnas.051633398; Willard FS, 2004, ANNU REV BIOCHEM, V73, P925, DOI 10.1146/annurev.biochem.73.011303.073756; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796	39	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					805	814		10.1074/jbc.M408163200	http://dx.doi.org/10.1074/jbc.M408163200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15520006	hybrid			2022-12-25	WOS:000226025100094
J	Corvol, JC; Valjent, E; Toutant, M; Enslen, H; Irinopoulou, T; Lev, S; Herve, D; Girault, JA				Corvol, JC; Valjent, E; Toutant, M; Enslen, H; Irinopoulou, T; Lev, S; Herve, D; Girault, JA			Depolarization activates ERK and proline-rich tyrosine kinase 2 (PYK2) independently in different cellular compartments in hippocampal slices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SIGNAL-REGULATED KINASE; TRANSIENT CEREBRAL-ISCHEMIA; SYNAPSIN-I PHOSPHORYLATION; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE; MAP KINASE; NMDA-RECEPTOR; RAT HIPPOCAMPUS; ELECTROCONVULSIVE SHOCK	In the hippocampus, extracellular signal-regulated kinase (ERK) and the non-receptor protein proline-rich tyrosine kinase 2 (PYK2) are activated by depolarization and involved in synaptic plasticity. Both are also activated under pathological conditions following ischemia, convulsions, or electroconvulsive shock. Although in non-neuronal cells PYK2 activates ERK through the recruitment of Src-family kinases (SFKs), the link between these pathways in the hippocampus is not known. We addressed this question using K+-depolarized rat hippocampal slices. Depolarization increased the phosphorylation of PYK2, SFKs, and ERK. These effects resulted from Ca2+ influx through voltage-gated Ca2+ channels and were diminished by GF109203X, a protein kinase C inhibitor. Inhibition of SFKs with PP2 decreased PYK2 tyrosine phosphorylation dramatically, but not its autophosphorylation on Tyr-402. Moreover, PYK2 autophosphorylation and total tyrosine phosphorylation were profoundly altered in fyn(-/-) mice, revealing an important functional relationship between Fyn and PYK2 in the hippocampus. In contrast, ERK activation was unaltered by PP2, Fyn knock-out, or LY294002, a phosphatidyl-inositol-3-kinase inhibitor. ERK activation was prevented by MEK inhibitors that had no effect on PYK2. Immunofluorescence of hippocampal slices showed that PYK2 and ERK were activated in distinct cellular compartments in somatodendritic regions and nerve terminals, respectively, with virtually no overlap. Activation of ERK was critical for the rephosphorylation of a synaptic vesicle protein, synapsin I, following depolarization, underlining its functional importance in nerve terminals. Thus, in hippocampal slices, in contrast to cell lines, depolarization-induced activation of non-receptor tyrosine kinases and ERK occurs independently in distinct cellular compartments in which they appear to have different functional roles.	Univ Paris 06, Inst Fer Moulin, INSERM, Signal Transduct & Plast Nervous Syst Unit,U536, F-75005 Paris, France; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Weizmann Institute of Science	Girault, JA (corresponding author), Univ Paris 06, Inst Fer Moulin, INSERM, Signal Transduct & Plast Nervous Syst Unit,U536, 17 Rue Fer Moulin, F-75005 Paris, France.	girault@fer-a-moulin.inserm.fr	Enslen, Hervé/AAH-4492-2021; Lev, Sima/AAP-7880-2020; Girault, Jean-Antoine/F-7518-2013; HERVE, Denis/E-2929-2017; corvol, jean-christophe/I-6387-2012; Enslen, Hervé/M-3400-2017; Corvol, Jean-Christophe/F-2124-2017	Enslen, Hervé/0000-0001-9741-5293; Lev, Sima/0000-0002-2108-3330; Girault, Jean-Antoine/0000-0002-7900-1705; HERVE, Denis/0000-0003-1376-1522; corvol, jean-christophe/0000-0001-7325-0199; Enslen, Hervé/0000-0001-9741-5293; Corvol, Jean-Christophe/0000-0001-7325-0199; Valjent, Emmanuel/0000-0002-1034-606X				Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BARABAN JM, 1993, J NEUROCHEM, V60, P330, DOI 10.1111/j.1471-4159.1993.tb05855.x; Baron C, 1996, J NEUROCHEM, V66, P1005; Barsacchi R, 1999, FEBS LETT, V461, P273, DOI 10.1016/S0014-5793(99)01468-4; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; CAMPOSGONZALEZ R, 1992, J NEUROCHEM, V59, P1955, DOI 10.1111/j.1471-4159.1992.tb11032.x; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Cheung HH, 2000, J CEREBR BLOOD F MET, V20, P505, DOI 10.1097/00004647-200003000-00009; Chi P, 2003, NEURON, V38, P69, DOI 10.1016/S0896-6273(03)00151-X; Combs CK, 1999, J NEUROSCI, V19, P928; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; Derkinderen P, 1999, NEUROREPORT, V10, pR24; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Derkinderen P, 1998, EUR J NEUROSCI, V10, P1667, DOI 10.1046/j.1460-9568.1998.00174.x; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Flood DG, 1998, J COMP NEUROL, V398, P373, DOI 10.1002/(SICI)1096-9861(19980831)398:3<373::AID-CNE6>3.0.CO;2-X; Giovannardi S, 2002, J BIOL CHEM, V277, P12158, DOI 10.1074/jbc.M110466200; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Henley JM, 2001, NEURON, V29, P312, DOI 10.1016/S0896-6273(01)00204-5; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Jeon SH, 2001, BIOCHEM BIOPH RES CO, V282, P1026, DOI 10.1006/bbrc.2001.4686; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Jovanovic JN, 2001, J NEUROSCI, V21, P7944, DOI 10.1523/JNEUROSCI.21-20-07944.2001; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Krapivinsky G, 2003, NEURON, V40, P775, DOI 10.1016/S0896-6273(03)00645-7; KURINO M, 1995, J NEUROCHEM, V65, P1282; Lauri SE, 2000, NEUROREPORT, V11, P997, DOI 10.1097/00001756-200004070-00020; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Liu Y, 2003, NEUROSCI LETT, V348, P127, DOI 10.1016/S0304-3940(03)00618-9; Liu Y, 2003, BRAIN RES, V972, P142, DOI 10.1016/S0006-8993(03)02519-8; Liu Y, 2001, BRAIN RES, V909, P51, DOI 10.1016/S0006-8993(01)02619-1; Menegon A, 1999, EUR J NEUROSCI, V11, P3777, DOI 10.1046/j.1460-9568.1999.00798.x; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; Omri B, 1996, J NEUROCHEM, V67, P1360; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park SY, 2004, J BIOL CHEM, V279, P33315, DOI 10.1074/jbc.M313527200; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Seabold GK, 2003, J BIOL CHEM, V278, P15040, DOI 10.1074/jbc.M212825200; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; Tian DH, 2000, J NEUROSCI, V20, P6478, DOI 10.1523/JNEUROSCI.20-17-06478.2000; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Toutant M, 2002, MOL CELL BIOL, V22, P7731, DOI 10.1128/MCB.22.22.7731-7743.2002; Valjent E, 2000, J NEUROSCI, V20, P8701; Valjent Emmanuel, 2003, Current Neuropharmacology, V1, P165, DOI 10.2174/1570159033477198; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yamagata Y, 2002, J NEUROCHEM, V80, P835, DOI 10.1046/j.0022-3042.2001.00753.x; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	75	37	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					660	668		10.1074/jbc.M411312200	http://dx.doi.org/10.1074/jbc.M411312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15537634	hybrid			2022-12-25	WOS:000226025100078
J	Wang, YQ; Marotti, LA; Lee, MJ; Dohlman, HG				Wang, YQ; Marotti, LA; Lee, MJ; Dohlman, HG			Differential regulation of G protein alpha subunit trafficking by mono- and polyubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; DOA4 DEUBIQUITINATING ENZYME; A-FACTOR RECEPTOR; END RULE PATHWAY; VACUOLAR DEGRADATION; SIGNAL-TRANSDUCTION; N-MYRISTOYLATION; 26S PROTEASOME; UBIQUITINATION; CHAINS	Previously we used mass spectrometry to show that the yeast G protein alpha subunit Gpa1 is ubiquitinated at Lys-165, located within a subdomain not present in other Galpha proteins (Marotti, L. A., Jr., Newitt, R., Wang, Y., Aebersold, R., and Dohlman, H. G. ( 2002) Biochemistry 41, 5067-5074). Here we describe the functional role of Gpa1 ubiquitination. We find that Gpa1 expression is elevated in mutants deficient in either proteasomal or vacuolar protease function. Vacuolar protease pep4 mutants accumulate monoubiquitinated Gpa1, and much of the protein is localized within the vacuolar compartment. In contrast, proteasome-defective rpt6/cim3 mutants accumulate polyubiquitinated Gpa1, and in this case the protein exhibits cytoplasmic localization. Cells that lack Ubp12 ubiquitin-processing protease activity accumulate both mono- and polyubiquitinated forms of Gpa1. In this case, Gpa1 accumulates in both the cytoplasm and vacuole. Finally, a Gpa1 mutant that lacks the ubiquitinated subdomain remains unmodified and is predominantly localized at the plasma membrane. These data reveal a strong relationship between the extent of ubiquitination and trafficking of the G protein alpha subunit to its site of degradation.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Yale Univ, Sch Med, Interdept Neurosci Program, New Haven, CT 06536 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Yale University	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 405 Mary Ellen Jones Bldg,Campus Box 7260, Chapel Hill, NC 27599 USA.	henrik_dohlman@med.unc.edu		Dohlman, Henrik/0000-0003-2443-0729; Lee, Michael/0000-0003-3378-6196	NIGMS NIH HHS [R01 GM055316, R01 GM059167, GM055316, GM059167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055316, R29GM055316, R01GM059167] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Amerik AY, 1997, EMBO J, V16, P4826; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Cohen M, 2003, J BIOL CHEM, V278, P51989, DOI 10.1074/jbc.C300451200; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Dohlman HG, 2002, ANNU REV PHYSIOL, V64, P129, DOI 10.1146/annurev.physiol.64.081701.133448; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Esch RK, 2002, P NATL ACAD SCI USA, V99, P9160, DOI 10.1073/pnas.142034399; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Guo M, 2003, MOL CELL, V12, P517, DOI 10.1016/S1097-2765(03)00307-1; HADARI T, 1992, J BIOL CHEM, V267, P719; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; Hao N, 2003, J BIOL CHEM, V278, P46506, DOI 10.1074/jbc.M308432200; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoffman GA, 2002, METHOD ENZYMOL, V344, P617; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Lindsey DF, 1998, J BIOL CHEM, V273, P29178, DOI 10.1074/jbc.273.44.29178; Loayza D, 1998, MOL CELL BIOL, V18, P779, DOI 10.1128/MCB.18.2.779; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marotti LA, 2002, BIOCHEMISTRY-US, V41, P5067, DOI 10.1021/bi015940q; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NAKAFUKU M, 1987, P NATL ACAD SCI USA, V84, P2140, DOI 10.1073/pnas.84.8.2140; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Obin M, 2002, J BIOL CHEM, V277, P44566, DOI 10.1074/jbc.M205308200; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SIKORSKI RS, 1989, GENETICS, V122, P19; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Springael JY, 1999, J CELL SCI, V112, P1375; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang YQ, 2003, J BIOL CHEM, V278, P22284, DOI 10.1074/jbc.M301272200; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	62	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					284	291		10.1074/jbc.M411624200	http://dx.doi.org/10.1074/jbc.M411624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15519996	hybrid, Green Published			2022-12-25	WOS:000226025100035
J	Arispe, N; Doh, M; Simakova, O; Kurganov, B; De Maio, A				Arispe, N; Doh, M; Simakova, O; Kurganov, B; De Maio, A			Hsc70 and Hsp70 interact with phosphatidylserine on the surface of PC12 cells resulting in a decrease of viability	FASEB JOURNAL			English	Article						heat shock proteins; polypeptide; lipid bilayer; apoptosis	HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; THERMOTOLERANT CELLS; RIBOSOMAL-SUBUNITS; SELF-ASSOCIATION; SERUM-LEVELS; BINDING; RECEPTOR; EXPRESSION; PEPTIDES	Heat shock proteins ( hsps) are involved in multiple cellular processes during normal and stress conditions, particularly in the folding of polypeptides. A newly recognized property of the members of the Hsp70 family is their ability to interact with lipids, opening ion conductance pathways in artificial membranes, and integrating into natural membranes. The formation of Hsp70 channels in biological membranes and their function is still elusive. In this study, we showed that Hsp70 and Hsc70 display a highly selective interaction with phosphatidylserine moieties on membranes, followed by rapid incorporation into the lipid bilayer. Addition of Hsp70 or Hsc70 into the extracellular medium resulted in a viability decrease of cells beading PS on the exterior surface, such as PC12 cells. This toxic effect is modulated by the presence of ATP or ADP and can be blocked by screening PS moieties with annexin 5. These observations suggest that the presence of Hsp70 in the extracellular medium may be an accelerator of apoptosis since the presence of PS on the surface is an early indicator of this process. These findings may also explain the toxicity observed in cells overexpressing Hsp70s and provide a rational for the tight regulation of Hsp70 expression.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; Russian Acad Sci, AN Bach Inst Biochem, Moscow, Russia; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Uniformed Services University of the Health Sciences - USA; Research Center of Biotechnology RAS; Russian Academy of Sciences; Johns Hopkins University	Arispe, N (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	narispe@usuhs.mil	Kurganov, Boris/M-1286-2019	Kurganov, Boris/0000-0002-2930-2286				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; Arispe N, 2000, J BIOL CHEM, V275, P30839, DOI 10.1074/jbc.M005226200; Arispe N, 2002, CELL STRESS CHAPERON, V7, P330, DOI 10.1379/1466-1268(2002)007<0330:LIDTCA>2.0.CO;2; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2003, EXERC IMMUNOL REV, V9, P25; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu-Modak S., 2001, COMP PHOTO, V3, P303; BECK SC, 1994, J BIOL CHEM, V269, P21803; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; Cornivelli L, 2003, SHOCK, V20, P320, DOI 10.1097/01.shk.0000082443.66379.d9; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; GUIDON PT, 1986, BIOCHEMISTRY-US, V25, P3231, DOI 10.1021/bi00359a023; GUIDON PT, 1986, J CELL PHYSIOL, V128, P239, DOI 10.1002/jcp.1041280215; Kurganov B, 2004, PEPTIDES, V25, P217, DOI 10.1016/j.peptides.2004.01.001; Kurucz I, 1999, CELL STRESS CHAPERON, V4, P139; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TAIT JF, 1989, J BIOL CHEM, V264, P7944; Theodorakis NG, 1999, J BIOL CHEM, V274, P12081, DOI 10.1074/jbc.274.17.12081; Tsvetkova NM, 2002, P NATL ACAD SCI USA, V99, P13504, DOI 10.1073/pnas.192468399; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; WELCH WJ, 1985, J CELL BIOL, V101, P1198, DOI 10.1083/jcb.101.4.1198; Zhu JH, 2003, ARTERIOSCL THROM VAS, V23, P1055, DOI 10.1161/01.ATV.0000074899.60898.FD	37	115	121	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1636	1645		10.1096/fj.04-2088com	http://dx.doi.org/10.1096/fj.04-2088com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522909				2022-12-25	WOS:000225482100032
J	Baum, B; Craig, G				Baum, B; Craig, G			RNAi in a postmodern, postgenomic era	ONCOGENE			English	Article						functional genomics; RNAi; cell culture; post-modernism	DROSOPHILA CULTURED-CELLS; IDENTIFICATION; INTERFERENCE; GENOME; COMPONENTS; PROTEINS; PATHWAY; SCREEN	As dsRNA-mediated interference (RNAi) libraries become more widely available, genome-wide loss of function experiments in cell culture are likely to become a routine laboratory tool. RNAi screens can then be conducted to test gene functions in different assays in a variety of cell types and across species. In comparing these large phenotypic data sets, researchers will gain a new perspective, enabling them to see each gene as part of a fluid network that is remodelled in response to changes in environmental and developmental context, and with the passage of evolutionary time.	Ludwig Inst Canc Res, UCL Branch, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London	Baum, B (corresponding author), Ludwig Inst Canc Res, UCL Branch, London W1W 7BS, England.	buzz@ludwig.ucl.ac.uk		Baum, Buzz/0000-0002-9201-6186				Agaisse H, 2003, DEV CELL, V5, P441, DOI 10.1016/S1534-5807(03)00244-2; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Chou TB, 1996, GENETICS, V144, P1673; Forler D, 2003, NAT BIOTECHNOL, V21, P89, DOI 10.1038/nbt773; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Grosshans H, 2002, J CELL BIOL, V156, P17, DOI 10.1083/jcb.200111033; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hartwell L, 2004, SCIENCE, V303, P774, DOI 10.1126/science.1094731; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Karim FD, 1996, GENETICS, V143, P315; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Stowers RS, 1999, GENETICS, V152, P1631; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982	21	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8336	8339		10.1038/sj.onc.1208009	http://dx.doi.org/10.1038/sj.onc.1208009			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517013				2022-12-25	WOS:000224815900002
J	Malki, A; Caldas, T; Abdallah, J; Kern, R; Eckey, V; Kim, SJ; Cha, SS; Mori, H; Richarme, G				Malki, A; Caldas, T; Abdallah, J; Kern, R; Eckey, V; Kim, SJ; Cha, SS; Mori, H; Richarme, G			Peptidase activity of the Escherichia coli Hsp31 chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CRYSTAL-STRUCTURE; DEGRADATION; REVEALS; PEPN	Hsp31, the Escherichia coli hcha gene product, is a molecular chaperone whose activity is inhibited by ATP at high temperature. Its crystal structure reveals a putative Cys(184), His(185), and Asp(213) catalytic triad similar to that of the Pyrococcus horikoshii protease PH1704, suggesting that it should display a proteolytic activity. A preliminary report has shown that Hsp31 has an exceedingly weak proteolytic activity toward bovine serum albumin and a peptidase activity toward two peptide substrates with small amino acids at their N terminus ( alanine or glycine), but the physiological significance of this observation remains unclear. In this study, we report that Hsp31 does not diplay any significant proteolytic activity but has peptidolytic activity. The aminopeptidase cleavage preference of Hsp31 is Ala > Lys > Arg > His, suggesting that Hsp31 is an aminopeptidase of broad specificity. Its aminopeptidase activity is inhibited by the thiol reagent iodoacetamide and is completely abolished in a C185A mutant, which is consistent with Hsp31 being a cysteine peptidase. The aminopeptidase activity of Hsp31 is also inhibited by EDTA and 1,10-phenanthroline, in concordance with the importance of the putative His(85), His(122), and Glu(90) metal-binding site revealed by crystallographic studies. An Hsp31-deficient mutant accumulates more 8 - 12-mer peptides than its parental strain, and purified Hsp31 can transform these peptides into smaller peptides, suggesting that Hsp31 has an important peptidase function both in vivo and in vitro. Proteins interacting with Hsp31 have been identified by reverse purification of a crude E. coli extract on an Hsp31-affinity column, followed by SDS-polyacrylamide electrophoresis and mass spectrometry. The ClpA component of the ClpAP protease.	Univ Paris 07, Inst Jacques Monod, F-75005 Paris, France; Pohang Accelerator Lab, Beamline Div, Pohang 790784, South Korea; Nara Inst Sci & Technol, Nara 6300101, Japan	UDICE-French Research Universities; Universite Paris Cite; Pohang University of Science & Technology (POSTECH); Nara Institute of Science & Technology	Richarme, G (corresponding author), Univ Paris 07, Inst Jacques Monod, 2 Pl Jussieu, F-75005 Paris, France.	richarme@ccr.jussieu.fr	Abdallah, Jad/AAD-3595-2020; Cha, Sun Shin/B-7370-2009	Abdallah, Jad/0000-0001-5267-4953; Cha, Sun-Shin/0000-0002-0913-8706				Blankenhorn D, 1999, J BACTERIOL, V181, P2209, DOI 10.1128/JB.181.7.2209-2216.1999; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; Chandu D, 2003, MICROBIOL-SGM, V149, P3437, DOI 10.1099/mic.0.26518-0; Chandu D, 2003, J BIOL CHEM, V278, P5548, DOI 10.1074/jbc.M207926200; Cho JH, 2001, BIOCHEMISTRY-US, V40, P10197, DOI 10.1021/bi010807j; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Fukiage C, 2002, J BIOL CHEM, V277, P20678, DOI 10.1074/jbc.M200697200; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hotokezaka Y, 2002, J BIOL CHEM, V277, P18545, DOI 10.1074/jbc.M201022200; Kim KI, 1999, J MOL BIOL, V294, P1363, DOI 10.1006/jmbi.1999.3320; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kudlicki W, 1997, J BIOL CHEM, V272, P32206, DOI 10.1074/jbc.272.51.32206; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Malki A, 2003, BIOCHEM BIOPH RES CO, V301, P430, DOI 10.1016/S0006-291X(02)03053-X; MILLER CG, 1983, J BACTERIOL, V153, P350, DOI 10.1128/JB.153.1.350-356.1983; Mujacic M, 2004, MOL MICROBIOL, V51, P849, DOI 10.1046/j.1365-2958.2003.03871.x; Quigley PM, 2004, PROTEIN SCI, V13, P269, DOI 10.1110/ps.03399604; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; Sastry MSR, 2002, J BIOL CHEM, V277, P46026, DOI 10.1074/jbc.M205800200; SCHROEDER U, 1994, FEMS MICROBIOL LETT, V123, P153, DOI 10.1111/j.1574-6968.1994.tb07215.x; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; YEN C, 1980, J MOL BIOL, V143, P21, DOI 10.1016/0022-2836(80)90122-9; Zhao YH, 2003, PROTEIN SCI, V12, P2303, DOI 10.1110/ps.03121403	27	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14420	14426		10.1074/jbc.M408296200	http://dx.doi.org/10.1074/jbc.M408296200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15550391	hybrid			2022-12-25	WOS:000228236800010
J	Day, CL; Chen, L; Richardson, SJ; Harrison, PJ; Huang, DCS; Hinds, MG				Day, CL; Chen, L; Richardson, SJ; Harrison, PJ; Huang, DCS; Hinds, MG			Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR STRUCTURE CALCULATION; CELL-DEATH; BCL-2 FAMILY; DEFICIENT MICE; IN-VIVO; APOPTOSIS; PROTEINS; SURVIVAL; PROGRAM; COMPLEX	The B cell lymphoma-2 (Bcl-2) homologs myeloid cell leukemia-1 (Mcl-1) and A1 are prosurvival factors that selectively bind a subset of proapoptotic Bcl homology (BH) 3-only proteins. To investigate the molecular basis of the selectivity, we determined the solution structure of the C-terminal Bcl-2-like domain of Mcl-1. This domain shares features expected of a prosurvival Bcl-2 protein, having a helical fold centered on a core hydrophobic helix and a surface-exposed hydrophobic groove for binding its cognate partners. A number of residues in the binding groove differentiate Mcl-1 from its homologs, and in contrast to other Bcl-2 homologs, Mcl-1 has a binding groove in a conformation intermediate between the open structures characterized by peptide complexes and the closed state observed in unliganded structures. Mutagenesis of potential binding site residues was used to probe the contributions of groove residues to the binding properties of Mcl-1. Although mutations in Mcl-1 had little impact on binding, a single mutation in the BH3-only ligand Bad enabled it to bind both Mcl-1 and A1 while retaining its binding to Bcl-2, Bcl-x(L), and Bcl-w. Elucidating the selective action of certain BH3-only ligands is required for delineating their mode of action and will aid the search for effective BH3-mimetic drugs.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Otago, Dept Biochem, Dunedin 9001, New Zealand	Walter & Eliza Hall Institute; University of Otago	Hinds, MG (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	mhinds@wehi.edu.au	Hinds, Mark Gavin/AAD-3653-2020; Huang, David C. S./C-7586-2013	Hinds, Mark Gavin/0000-0002-2856-5375; Huang, David C. S./0000-0002-3101-4873; Richardson, Sarah/0000-0002-1160-6062; Day, Catherine/0000-0003-1571-4367				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; Denisov AY, 2003, J BIOL CHEM, V278, P21124, DOI 10.1074/jbc.M301798200; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rinkenberger JL, 2000, GENE DEV, V14, P23; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Woo JS, 2003, CELL DEATH DIFFER, V10, P1310, DOI 10.1038/sj.cdd.4401303; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	45	176	190	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4738	4744		10.1074/jbc.M411434200	http://dx.doi.org/10.1074/jbc.M411434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15550399	hybrid			2022-12-25	WOS:000227096600090
J	Nesmelova, IV; Sham, Y; Dudek, AZ; van Eijk, LI; Wu, GP; Slungaard, A; Mortari, F; Griffioen, AW; Mayo, KH				Nesmelova, IV; Sham, Y; Dudek, AZ; van Eijk, LI; Wu, GP; Slungaard, A; Mortari, F; Griffioen, AW; Mayo, KH			Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-IV; NEUTROPHIL-ACTIVATING PEPTIDE; 3-DIMENSIONAL STRUCTURE; NMR-SPECTROSCOPY; PROGENITOR CELLS; SELF-ASSOCIATION; IL-8 BINDING; ELR-MOTIF; DYNAMICS; DIMER	The apparent complexity of biology increases as more biomolecular interactions that mediate function become known. We have used NMR spectroscopy and molecular modeling to provide direct evidence that tetrameric platelet factor-4 (PF4) and dimeric inter-leukin-8 (IL8), two members of the CXC chemokine family, readily interact by exchanging subunits and forming heterodimers via extension of their antiparallel beta-sheet domains. We further demonstrate using functional assays that PF4/IL8 heterodimerization has a direct and significant consequence on the biological activity of both chemokines. Formation of heterodimers enhances the anti-proliferative effect of PF4 on endothelial cells in culture, as well as the IL8-induced migration of CXCR2 vector-transfected Baf3 cells. These results suggest that CXC chemokine biology, and perhaps cytokine biology in general, may be functionally modulated at the molecular level by formation of heterodimers. This concept, in turn, has implications for designing chemokine/cytokine variants with modified biological properties.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Supercomp, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA; Univ Hosp Maastricht, Angiogenesis Lab, Dept Pathol, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Angiogenesis Lab, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands; R&D Syst Inc, Minneapolis, MN 55413 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Mayo, KH (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St, Minneapolis, MN 55455 USA.	mayox001@umn.edu	Dudek, Arkadiusz Zbigniew/HGD-1339-2022; Sham, Yuk Y/A-6472-2011; Nesmelova, Irina/D-6033-2015	Dudek, Arkadiusz Zbigniew/0000-0002-9114-8945; Sham, Yuk Y/0000-0003-2601-8930; Nesmelova, Irina/0000-0002-1835-1533				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROXMEYER HE, 1993, J IMMUNOL, V150, P3448; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CHEN MJ, 1991, BIOCHEMISTRY-US, V30, P6402, DOI 10.1021/bi00240a009; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DINGLEY AJ, 1995, J BIOMOL NMR, V6, P321; Dudek AZ, 2003, BLOOD, V101, P4687, DOI 10.1182/blood-2002-08-2363; Fernando H, 2004, J BIOL CHEM, V279, P36175, DOI 10.1074/jbc.C400283200; Griffioen AW, 2001, BIOCHEM J, V354, P233, DOI 10.1042/0264-6021:3540233; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; Ilyina E, 1997, BIOCHEMISTRY-US, V36, P3383, DOI 10.1021/bi9622229; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KIM KS, 1994, J BIOL CHEM, V269, P32909; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEONARD EJ, 1993, CURRENT PROTOCOLS IM, V1, P6; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MAYO KH, 1994, BIOCHEM J, V304, P371, DOI 10.1042/bj3040371; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P925, DOI 10.1021/bi00218a007; MAYO KH, 1995, BIOCHEMISTRY-US, V34, P11399, DOI 10.1021/bi00036a012; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; Mikhailov D, 1999, J BIOL CHEM, V274, P25317, DOI 10.1074/jbc.274.36.25317; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOORE S, 1975, BIOCHIM BIOPHYS ACTA, V379, P370, DOI 10.1016/0005-2795(75)90144-0; Nesmelova IV, 2004, J MAGN RESON, V166, P129, DOI 10.1016/j.jmr.2003.09.004; Nesmelova IV, 1998, BBA-PROTEIN STRUCT M, V1383, P311, DOI 10.1016/S0167-4838(97)00224-0; PAOLETTI S, 2004, IN PRESS BLOOD; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Price W. S., 2000, ANNU REP PROG CHEM C, V96, P3, DOI DOI 10.1039/B000773K; Qian YQ, 1999, J MOL BIOL, V294, P1065, DOI 10.1006/jmbi.1999.3333; Rajagopalan L, 2004, J BIOL CHEM, V279, P30000, DOI 10.1074/jbc.M313883200; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SCHNITZEL W, 1994, J LEUKOCYTE BIOL, V55, P763, DOI 10.1002/jlb.55.6.763; Schwartzkopff F, 2002, J INTERF CYTOK RES, V22, P257, DOI 10.1089/107999002753536239; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Young H, 1999, BIOCHEM J, V338, P591, DOI 10.1042/0264-6021:3380591	48	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4948	4958		10.1074/jbc.M405364200	http://dx.doi.org/10.1074/jbc.M405364200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15531763	hybrid			2022-12-25	WOS:000227096600116
J	Laurents, DV; Gorman, PM; Guo, M; Rico, M; Chakrabartty, A; Bruix, M				Laurents, DV; Gorman, PM; Guo, M; Rico, M; Chakrabartty, A; Bruix, M			Alzheimer's A beta 40 studied by NMR at low pH reveals that sodium 4,4-dimethyl-4-silapentane-1-sulfonate (DSS) binds and promotes beta-ball oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						10.1074/jbc.M409507200d	PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; AMYLOID PEPTIDE; COMPLETE SEQUENCE; COMMON MECHANISM; AGGREGATION; FRAGMENTS; C-13; IDENTIFICATION; A-BETA(1-40)	The Alzheimer's Abeta40 peptide forms soluble oligomers that are extremely potent neurotoxins and strongly impede synapses function. In this study the formation and structure of the large, soluble, neurotoxic Abeta40 oligomer called "beta-ball' were characterized by two-dimensional NMR, circular dichroism, fluorescence spectroscopy, hydrogen exchange, and equilibrium sedimentation. In acidic aqueous solution, half the Abeta40 molecules are in the beta-ball state; the remainder are monomeric. The equilibrium between the two states is slow as judged by NMR linewidths and is stable for months. The kinetics of beta-ball formation from monomer are biphasic with tau(1) = 7 min and tau(2) = 80 min with no transient helix formation. Monomeric Abeta40 is essentially devoid of stable secondary structure, although the central, Leu(17) -Ala(21), and C-terminal, Gly(29)-Val(40), hydrophobic regions show propensity toward adopting extended structure, and residues 22-25 tended to form a turn. We found that sodium 4,4-dimethyl-4-silapentane-1-sulfonate (DSS) binds to the central hydrophobic region of monomeric Abeta40. DSS binds beta-balls more strongly and caused them to double in size. Plausible micelle-like models for the beta-ball structure with and without bound DSS are presented.	Univ Toronto, Dept Med Biophys, Toronto, ON M59 2M9, Canada; CSIC, Inst Quim Fis Rocasolano, Madrid 28006, Spain	University of Toronto; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Chakrabartty, A (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON M59 2M9, Canada.	chakrab@uhnres.utoronto.ca; mbruix@iqfr.csic.es	Laurents, Douglas V/E-7527-2015; Bruix, Marta/H-4161-2011	Laurents, Douglas V/0000-0002-4187-165X; Bruix, Marta/0000-0002-0096-3558; Chakrabartty, Avi/0000-0001-7002-8381				BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Bateman DA, 2004, BIOPOLYMERS, V76, P4, DOI 10.1002/bip.10561; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; Crescenzi O, 2002, EUR J BIOCHEM, V269, P5642, DOI 10.1046/j.1432-1033.2002.03271.x; Danielsson J, 2004, BIOCHEMISTRY-US, V43, P6261, DOI 10.1021/bi036254p; Ditaranto K, 2001, NEUROBIOL DIS, V8, P19, DOI 10.1006/nbdi.2000.0364; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Frost D, 2003, EUR J BIOCHEM, V270, P654, DOI 10.1046/j.1432-1033.2003.03415.x; Gorman PM, 2003, J MOL BIOL, V325, P743, DOI 10.1016/S0022-2836(02)01279-2; Gorman PM, 2001, BIOPOLYMERS, V60, P381, DOI 10.1002/1097-0282(2001)60:5<381::AID-BIP10173>3.0.CO;2-U; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hou LM, 2004, J AM CHEM SOC, V126, P1992, DOI 10.1021/ja036813f; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Hughes E, 2000, J BIOL CHEM, V275, P25109, DOI 10.1074/jbc.M003554200; Jayawickrama DA, 1999, ANAL CHEM, V71, P2117, DOI 10.1021/ac980989w; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kohno T, 1996, BIOCHEMISTRY-US, V35, P16094, DOI 10.1021/bi961598j; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Laurents DV, 1998, J MOL BIOL, V283, P669, DOI 10.1006/jmbi.1998.2118; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; Ma K, 1999, J AM CHEM SOC, V121, P8698, DOI 10.1021/ja990864o; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Nowick JS, 2003, ORG LETT, V5, P3511, DOI 10.1021/ol035347w; Pace CN, 2000, PROTEIN SCI, V9, P1395; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Riek R, 2001, EUR J BIOCHEM, V268, P5930, DOI 10.1046/j.0014-2956.2001.02537.x; Riek R, 1999, P NATL ACAD SCI USA, V96, P4918, DOI 10.1073/pnas.96.9.4918; Santiveri CM, 2001, J BIOMOL NMR, V19, P331, DOI 10.1023/A:1011224625129; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; SORIMACHI K, 1994, EUR J BIOCHEM, V219, P237, DOI 10.1111/j.1432-1033.1994.tb19935.x; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; TALAFOUS J, 1994, BIOCHEMISTRY-US, V33, P7788, DOI 10.1021/bi00191a006; TANFORD C, 1972, J PHYS CHEM-US, V76, P3020, DOI 10.1021/j100665a018; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang YJ, 2002, PROTEIN SCI, V11, P852, DOI 10.1110/ps.3180102; Westlind-Danielsson A, 2001, BIOCHEMISTRY-US, V40, P14736, DOI 10.1021/bi010375c; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Yong W, 2002, P NATL ACAD SCI USA, V99, P150, DOI 10.1073/pnas.012584899; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288	61	32	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3675	3685		10.1074/jbc.M409507200	http://dx.doi.org/10.1074/jbc.M409507200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557279	hybrid			2022-12-25	WOS:000226983900067
J	Sidhaye, V; Hoffert, JD; King, LS				Sidhaye, V; Hoffert, JD; King, LS			cAMP has distinct acute and chronic effects on Aquaporin-5 in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL PLASMA-MEMBRANE; CILIARY BEAT FREQUENCY; PAROTID ACINAR-CELLS; NA+-K+-ATPASE; CYCLIC-AMP; WATER PERMEABILITY; SALIVARY-GLANDS; MOUSE LUNG; EXPRESSION; PROTEIN	Aquaporin-5 (AQP5) is present on the apical membrane of epithelial cells in various secretory glands as well as on the apical membrane of the airway epithelium, airway submucosal glands, and type 1 pneumocytes, where it can participate in respiratory tract water homeostasis. We examined the effects of cAMP on AQP5 distribution and abundance. When AQP5-expressing mouse lung epithelial cells were treated with cAMP or the beta-adrenergic agonist terbutaline, a biphasic AQP5 response was observed. Short term (minutes) exposure to cAMP produced internalization of AQP5 off of the membrane and a decrease in protein abundance. Both of these responses were blocked by inhibition of protein kinase A and the decrease in abundance was blocked by chloroquine, indicating lysosome-mediated degradation. Sustained cAMP exposure (hours) produced an increase in membrane localization and increased abundance; these effects were also blocked by protein kinase A inhibition. The beta-adrenergic agonist terbutaline produced changes in AQP5 abundance in mouse trachea and lung, consistent with our findings in cultured epithelial cells. Purified AQP5 protein was phosphorylated by protein kinase A but not protein kinase C or casein kinase II, and aquaporin-5 was phosphorylated in cultured cells after long term (but not short term) exposure to cAMP. These studies indicate that cAMP and beta-adrenergic agonists produce distinct short and long term effects on AQP5 distribution and abundance that may contribute to regulation of lung water homeostasis.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21224 USA; NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	King, LS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 4B-64,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	lsking@jhmi.edu	Sidhaye, Venkataramana/AAC-3930-2019	Sidhaye, Venkataramana/0000-0002-4506-8549	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL074515, R01HL070217, K08HL085763] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL074515, F32-HL074515, R01 HL070217, K08 HL085763, R01-HL70217] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boucher RC, 2003, PFLUG ARCH EUR J PHY, V445, P495, DOI 10.1007/s00424-002-0955-1; Bredenbroker D, 2001, EUR J PHARMACOL, V411, P319, DOI 10.1016/S0014-2999(00)00918-3; Burghardt B, 2003, GUT, V52, P1008, DOI 10.1136/gut.52.7.1008; Cheng XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1981, DOI 10.1152/ajpcell.1997.273.6.C1981; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; Dobbs LG, 1998, P NATL ACAD SCI USA, V95, P2991, DOI 10.1073/pnas.95.6.2991; Ecelbarger CA, 1997, J CLIN INVEST, V99, P1852, DOI 10.1172/JCI119352; Feschenko MS, 2000, J BIOL CHEM, V275, P34693, DOI 10.1074/jbc.M005869200; Gresz V, 2004, AM J PHYSIOL-GASTR L, V287, pG151, DOI 10.1152/ajpgi.00480.2003; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V265, P94, DOI 10.1006/bbrc.1999.1630; Ishikawa Y, 2000, FEBS LETT, V477, P253, DOI 10.1016/S0014-5793(00)01763-4; Ishikawa Y, 2002, MOL PHARMACOL, V61, P1423, DOI 10.1124/mol.61.6.1423; Ishikawa Y, 1998, BIOCHEM BIOPH RES CO, V245, P835, DOI 10.1006/bbrc.1998.8395; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; LANSLEY AB, 1992, AM J PHYSIOL, V263, pL232, DOI 10.1152/ajplung.1992.263.2.L232; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; Matthay MA, 2002, J APPL PHYSIOL, V93, P1533, DOI 10.1152/japplphysiol.01210.2001; Moore A, 2001, EMBO REP, V2, P8, DOI 10.1093/embo-reports/kve004; Nejsum LN, 2002, P NATL ACAD SCI USA, V99, P511, DOI 10.1073/pnas.012588099; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; PYERIN W, 1994, ADV ENZYME REGUL, V34, P225, DOI 10.1016/0065-2571(94)90018-3; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Salathe Matthias, 2002, Journal of Allergy and Clinical Immunology, V110, pS275, DOI 10.1067/mai.2002.129412; SANDERSON MJ, 1989, AM REV RESPIR DIS, V139, P432, DOI 10.1164/ajrccm/139.2.432; SANDERSON MJ, 1992, CHEST, V101, pS69, DOI 10.1378/chest.101.3.69S; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; SATOH T, 1992, J CLIN INVEST, V89, P1496, DOI 10.1172/JCI115740; SATOH T, 1993, AM J PHYSIOL, V265, pF399, DOI 10.1152/ajprenal.1993.265.3.F399; Scott MGH, 1999, BRIT J PHARMACOL, V128, P721, DOI 10.1038/sj.bjp.0702829; Song YL, 2001, J BIOL CHEM, V276, P41288, DOI 10.1074/jbc.M107257200; Steinfeld S, 2001, LAB INVEST, V81, P143, DOI 10.1038/labinvest.3780221; Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818; Towne JE, 2001, J BIOL CHEM, V276, P18657, DOI 10.1074/jbc.M100322200; Tsubota K, 2001, LANCET, V357, P688, DOI 10.1016/S0140-6736(00)04140-4; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Yang F, 2003, J BIOL CHEM, V278, P32173, DOI 10.1074/jbc.M305149200; Yasui M, 1997, AM J PHYSIOL-RENAL, V272, pF443, DOI 10.1152/ajprenal.1997.272.4.F443	50	84	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3590	3596		10.1074/jbc.M411038200	http://dx.doi.org/10.1074/jbc.M411038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15536076	Green Accepted, hybrid			2022-12-25	WOS:000226983900057
J	Kojima, H; Uemura, T				Kojima, H; Uemura, T			Strong and rapid induction of osteoblast differentiation by Cbfa1/Til-1 overexpression for bone regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; IN-VITRO; C-MYC; TRANSCRIPTION FACTOR; GENE-THERAPY; MORPHOGENETIC PROTEIN-2; CLEIDOCRANIAL DYSPLASIA; POROUS HYDROXYAPATITE; HUMAN OSTEOSARCOMA; CBFA1	Core binding factor alpha-1 (Cbfa1), known as an essential transcription factor for osteogenic lineage, has two major N-terminal isoforms: Pebp2a.A and Til-1. To study the roles of these isoforms in bone regeneration, we applied an adenoviral vector carrying their genes to transduce primary osteoprogenitor cells in vitro and in vivo. Overexpression of the two isoforms induced rapid and marked osteoblast differentiation, with Til-1 being more effective in vitro, by examination of the alkaline phosphatase activity, calcium content, and Alizarin red staining. Til-1 overexpressing cells/ porous ceramic composites were transplanted into subcutaneous and bone defect sites in Fischer rats (cultured bone transplantation model) and markedly affected in vivo bone formation and osteoblast markers. The results demonstrated that the reconstitution of bone tissues, such as cortical bone and trabecular bone was accelerated by implantation of Til-1 overexpressing cells/porous ceramic composites. Moreover, the new bone formation by Til-1 overexpression appeared to reflect replacement of new bone within the implant boundaries. To ascertain whether implanted Cbfa1 overexpressing cells could differentiate into osteogenic cells to create bone or whether it stimulated the surrounding recipient tissue to regenerate bone, implanted male donor cells were visualized by fluorescent in situ hybridization analysis. The proportion of implanted cells in the presumptive bone forming region was over 80% and did not change throughout from 3 days to 8 weeks after implantation. These findings suggested that the newly formed bone in the porous area of the scaffold is mostly produced by the implanted donor cells or their derived cells, effectively by Til-1 overexpression.	Natl Inst Adv Ind Sci & Technol AIST, ADRC, Tsukuba, Ibaraki 3058566, Japan; Japan Sci & Technol Agcy, Chiyoda Ku, Tokyo 1028666, Japan; Tokyo Med & Dent Univ, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138519, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Uemura, T (corresponding author), Natl Inst Adv Ind Sci & Technol AIST, ADRC, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	t.uemura@aist.go.jp						Acampora D, 1999, DEVELOPMENT, V126, P3795; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; BARRIOS C, 1993, J ORTHOPAED RES, V11, P556, DOI 10.1002/jor.1100110410; BOGENMANN E, 1987, CANCER RES, V47, P3808; Breitbart AS, 1999, ANN PLAS SURG, V42, P488, DOI 10.1097/00000637-199905000-00005; Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931; Caplan A., 1997, PRINCIPLES TISSUE EN, P603; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Cheng SL, 2001, CALCIFIED TISSUE INT, V68, P87, DOI 10.1007/BF02678146; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Dong J, 2002, BIO-MED MATER ENG, V12, P203; Dong J, 2001, J BIOMED MATER RES, V57, P208, DOI 10.1002/1097-4636(200111)57:2<208::AID-JBM1160>3.0.CO;2-N; Dong JA, 2002, BIOMATERIALS, V23, P4493, DOI 10.1016/S0142-9612(02)00193-X; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097-4644(20000901)78:3<476::AID-JCB12>3.0.CO;2-5; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gamberi G, 1998, J ORTHOP RES, V16, P1, DOI 10.1002/jor.1100160102; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317; Mehrara BJ, 1999, J BONE MINER RES, V14, P1290, DOI 10.1359/jbmr.1999.14.8.1290; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Ohgushi H, 1999, J BIOMED MATER RES, V48, P913, DOI 10.1002/(SICI)1097-4636(1999)48:6<913::AID-JBM22>3.0.CO;2-0; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shafritz AB, 1998, CLIN ORTHOP RELAT R, P46; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Tanaka J, 2000, Tanpakushitsu Kakusan Koso, V45, P2150; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Uemura T, 2003, BIOMATERIALS, V24, P2277, DOI 10.1016/S0142-9612(03)00039-5; Wang YC, 2003, TISSUE ENG, V9, P1205, DOI 10.1089/10763270360728116; Wu NX, 2000, CURR OPIN BIOTECH, V11, P205, DOI 10.1016/S0958-1669(00)00080-X; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705	41	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2944	2953		10.1074/jbc.M311598200	http://dx.doi.org/10.1074/jbc.M311598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15537653	hybrid			2022-12-25	WOS:000226449100070
J	Wu, A; Tu, XA; Prisco, M; Baserga, R				Wu, A; Tu, XA; Prisco, M; Baserga, R			Regulation of upstream binding factor 1 activity by insulin-like growth factor I receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; RIBOSOMAL GENE-TRANSCRIPTION; NUCLEAR TRANSLOCATION; T-ANTIGEN; CELL-SIZE; IGF-I; PHOSPHORYLATION; SUBSTRATE-1; DIFFERENTIATION; ACTIVATION	The upstream binding factor 1 (UBF1) is one of the proteins in a complex that regulates the activity of RNA polymerase 1, which controls the rate of ribosomal RNA (rRNA) synthesis. We have shown previously that insulin receptor substrate-1 (IRS-1) can translocate to the nuclei and nucleoli of cells and bind UBF1. We report here that activation of the type I insulin-like growth factor receptor (IGF-IR) by IGF-I increases transcription from the ribosomal DNA (rDNA) promoter in both myeloid cells and mouse fibroblasts. The increased activity of the rDNA promoter is accompanied by increased phosphorylation of UBF1, a requirement for UBF1 activation. Phosphorylation occurs on a number of UBF1 peptides, most prominently on the highly acidic, serine-rich C terminus. In myeloid cells (but not in mouse embryo fibroblasts) IRS-1 signaling stabilizes the levels of UBF1 protein. These findings demonstrate that IGF-IR signaling can increase the activity of UBF1 and transcription from the rDNA promoter, providing one explanation for the reported effects of the IGF/ IRS-1 axis on cell and body size in animals and cells in culture.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 Bluemle Life Sci Bldg, Philadelphia, PA 19107 USA.	b_lupo@mail.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA089640, P01CA078890] Funding Source: NIH RePORTER; NCI NIH HHS [CA 89640, CA78890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; Baserga R, 2003, MED INTELL UNIT, P104; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Boylan JM, 2002, ENDOCRINOLOGY, V143, P4178, DOI 10.1210/en.2002-220321; Brandenburger Y, 2001, FASEB J, V15, P2051, DOI 10.1096/fj.00-0853fje; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; Comai L, 2000, CELL GROWTH DIFFER, V11, P63; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Donahue AC, 2004, SEMIN CELL DEV BIOL, V15, P183, DOI 10.1016/j.semcdb.2003.12.024; Drakas R, 2004, P NATL ACAD SCI USA, V101, P9272, DOI 10.1073/pnas.0403328101; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Grueneberg DA, 2003, MOL CELL BIOL, V23, P3936, DOI 10.1128/MCB.23.11.3936-3950.2003; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Guo L, 2003, J AM SOC MASS SPECTR, V14, P1022, DOI 10.1016/S1044-0305(03)00206-X; Hannan KM, 1998, AM J PHYSIOL-CELL PH, V275, pC130, DOI 10.1152/ajpcell.1998.275.1.C130; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Knight ZA, 2003, NAT BIOTECHNOL, V21, P1047, DOI 10.1038/nbt863; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Ringertz Nils R., 1976, CELL HYBRIDS; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Soon L, 1999, MOL CELL BIOL, V19, P3816; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SOPRANO KJ, 1979, P NATL ACAD SCI USA, V76, P3885, DOI 10.1073/pnas.76.8.3885; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; SURMACZ E, 1987, MOL CELL BIOL, V7, P657, DOI 10.1128/MCB.7.2.657; Tu X, 2003, EXP CELL RES, V288, P119, DOI 10.1016/S0014-4827(03)00178-2; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White Robert J., 2004, VVolume 42, P371; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	70	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2863	2872		10.1074/jbc.M406138200	http://dx.doi.org/10.1074/jbc.M406138200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15533945	hybrid			2022-12-25	WOS:000226449100061
J	Wu, RY; Skaar, EP; Zhang, RG; Joachimiak, G; Gornicki, P; Schneewind, O; Joachimiak, A				Wu, RY; Skaar, EP; Zhang, RG; Joachimiak, G; Gornicki, P; Schneewind, O; Joachimiak, A			Staphylococcus aureus IsdG and IsdI, heme-degrading enzymes with structural similarity to monooxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-DIPHTHERIAE; OXYGENASE; IRON; EXPRESSION; GENE; BIOSYNTHESIS; ACQUISITION; PROTEINS; PRODUCT	Heme-degrading enzymes are involved in human diseases ranging from stroke, cancer, and multiple sclerosis to infectious diseases such as malaria, diphtheria, and meningitis. All mammalian and microbial enzymes identified to date are members of the heme oxygenase superfamily and assume similar monomeric structures with an all a-helical fold. Here we describe the crystal structures of IsdG and IsdI, two heme-degrading enzymes from Staphylococcus aureus. The structures of both enzymes resemble the ferredoxin-like fold and form a beta-barrel at the dimer interface. Two large pockets found on the outside of the barrel contain the putative active sites. Sequence homologs of IsdG and IsdI were identified in multiple Gram-positive pathogens. Substitution of conserved IsdG amino acid residues either reduced or abolished heme degradation, suggesting a common catalytic mechanism. This mechanism of IsdG-mediated heme degradation may be similar to that of the structurally related monooxygenases, enzymes involved in the synthesis of antibiotics in Streptomyces. Our results imply the evolutionary adaptation of microbial enzymes to unique environments.	Argonne Natl Lab, Struct Biol Ctr, Biosci Div, Argonne, IL 60439 USA; Argonne Natl Lab, Midwest Ctr Struct Genom, Biosci Div, Argonne, IL 60439 USA; Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago; University of Chicago; University of Chicago	Schneewind, O (corresponding author), Argonne Natl Lab, Struct Biol Ctr, Biosci Div, 9700 S Cass Ave,Bldg 202, Argonne, IL 60439 USA.	oschnee@bsd.uchicago.edu; andrzejj@anl.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897, R01AI052474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38897, R01 AI052474, AI52474, R01 AI038897] Funding Source: Medline; NIGMS NIH HHS [P50 GM062414, GM62414, P50 GM062414-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Kim Youngchang, 2004, Journal of Structural and Functional Genomics, V5, P111, DOI 10.1023/B:JSFG.0000029206.07778.fc; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mack J, 2004, BIOCHEM BIOPH RES CO, V320, P781, DOI 10.1016/j.bbrc.2004.06.025; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paoli M, 2002, DNA CELL BIOL, V21, P271, DOI 10.1089/104454902753759690; Rafanan ER, 2001, J NAT PROD, V64, P444; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; Skaar EP, 2004, MICROBES INFECT, V6, P390, DOI 10.1016/j.micinf.2003.12.008; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; Unno M, 2004, J BIOL CHEM, V279, P21055, DOI 10.1074/jbc.M400491200; vonEiff C, 1997, J BACTERIOL, V179, P4706, DOI 10.1128/jb.179.15.4706-4712.1997; Walsh MA, 1999, ACTA CRYSTALLOGR D, V55, P1168, DOI 10.1107/S0907444999003698; Wilks A, 1998, BIOCHEMISTRY-US, V37, P2889, DOI 10.1021/bi972720x; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; Wilks A, 2002, ANTIOXID REDOX SIGN, V4, P603, DOI 10.1089/15230860260220102; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	23	113	119	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2840	2846		10.1074/jbc.M409526200	http://dx.doi.org/10.1074/jbc.M409526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15520015	Green Accepted, hybrid			2022-12-25	WOS:000226449100058
J	Iwata, K; Luo, JS; Penn, RB; Benovic, JL				Iwata, K; Luo, JS; Penn, RB; Benovic, JL			Bimodal regulation of the human H1 histamine receptor by G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; AIRWAY SMOOTH-MUSCLE; MG ASTROCYTOMA-CELLS; H-1 RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; INDUCED DESENSITIZATION; CARBOXYL-TERMINUS; CA2+/CALMODULIN-MEDIATED REGULATION; PHOSPHORYLATION SITES; SELECTIVE REGULATION	The H1 histamine receptor (H1HR) is a member of the G protein-coupled receptor superfamily and regulates numerous cellular functions through its activation of the G(q/11) subfamily of heterotrimeric G proteins. Although the H1HR has been shown to undergo desensitization in multiple cell types, the mechanisms underlying the regulation of H1HR signaling are poorly defined. To address this issue, we examined the effects of wild type and mutant G protein-coupled receptor kinases (GRKs) on the phosphorylation and signaling of human H1HR in HEK293 cells. Overexpression of GRK2 promoted H1HR phosphorylation in intact HEK293 cells and completely inhibited inositol phosphate production stimulated by H1HR, whereas GRK5 and GRK6 had lesser effects on H1HR phosphorylation and signaling. Interestingly, catalytically inactive GRK2 (GRK2-K220R) also significantly attenuated H1HR-mediated inositol phosphate production, as did an N-terminal fragment of GRK2 previously characterized as a regulator of G protein signaling (RGS) protein for Galpha(q/11). Disruption of this RGS function in holo-GRK2 by mutation (GRK2-D110A) partially reversed the quenching effect of GRK2, whereas deletion of both the kinase activity and RGS function (GRK2-D110A/K220R) effectively relieved the inhibition of inositol phosphate generation. To evaluate the role of endogenous GRKs on H1HR regulation, we used small interfering RNAs to selectively target GRK2 and GRK5, two of the primary GRKs expressed in HEK293 cells. A GRK2-specific small interfering RNA effectively reduced GRK2 expression and resulted in a significant increase in histamine-promoted calcium flux. In contrast, knockdown of GRK5 expression was without effect on H1HR signaling. These findings demonstrate that GRK2 is the principal kinase mediating H1 histamine receptor desensitization in HEK293 cells and suggest that rapid termination of H1HR signaling is mediated by both the kinase activity and RGS function of GRK2.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Wake Forest Univ, Dept Med, Winston Salem, NC 27157 USA	Jefferson University; Wake Forest University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@mail.jci.tju.edu			NHLBI NIH HHS [HL67663] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067663, P50HL067663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnes PJ, 1998, PHARMACOL REV, V50, P515; Billington CK, 2003, RESP RES, V4; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fujimoto K, 1999, MOL PHARMACOL, V55, P735; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTH PH, 1983, MICROVASC RES, V25, P322, DOI 10.1016/0026-2862(83)90022-5; HILL SJ, 1977, NATURE, V270, P361, DOI 10.1038/270361a0; Hill SJ, 1997, PHARMACOL REV, V49, P253; Hishinuma S, 2000, J NEUROCHEM, V75, P772, DOI 10.1046/j.1471-4159.2000.0750772.x; Hishinuma S, 1998, J NEUROCHEM, V71, P2626; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KILLACKEY JJF, 1986, AM J PATHOL, V122, P50; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; Marley PD, 2003, PHARMACOL THERAPEUT, V98, P1, DOI 10.1016/S0163-7258(03)00002-0; MATSUMOTO T, 1986, BIOCHEM BIOPH RES CO, V140, P195; MCCREATH G, 1994, BRIT J PHARMACOL, V113, P823, DOI 10.1111/j.1476-5381.1994.tb17067.x; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MURRAY RK, 1989, AM J PHYSIOL, V267, pL209; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Pronin AN, 1998, J BIOL CHEM, V273, P31510, DOI 10.1074/jbc.273.47.31510; Pype JL, 1998, BRIT J PHARMACOL, V125, P1477, DOI 10.1038/sj.bjp.0702222; Sallese M, 2000, BBA-MOL CELL RES, V1498, P112, DOI 10.1016/S0167-4889(00)00088-4; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Schulz R, 2002, MOL PHARMACOL, V61, P1444, DOI 10.1124/mol.61.6.1444; SMIT MJ, 1992, BRIT J PHARMACOL, V107, P448, DOI 10.1111/j.1476-5381.1992.tb12766.x; Smit MJ, 1996, BRIT J PHARMACOL, V117, P1071, DOI 10.1111/j.1476-5381.1996.tb16699.x; STADEL JM, 1983, P NATL ACAD SCI-BIOL, V80, P3173, DOI 10.1073/pnas.80.11.3173; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Usui K, 2000, INT J MOL MED, V5, P335; Wieland K, 1999, J BIOL CHEM, V274, P29994, DOI 10.1074/jbc.274.42.29994	46	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2197	2204		10.1074/jbc.M408834200	http://dx.doi.org/10.1074/jbc.M408834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542600	hybrid			2022-12-25	WOS:000226341700055
J	Liu, XM; Peyton, KJ; Ensenat, D; Wang, H; Schafer, AI; Alam, J; Durante, W				Liu, XM; Peyton, KJ; Ensenat, D; Wang, H; Schafer, AI; Alam, J; Durante, W			Endoplasmic reticulum stress stimulates heme oxygenase-1 gene expression in vascular smooth muscle - Role in cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; CARBON-MONOXIDE PRODUCTION; ENDOTHELIAL-CELLS; SKIN FIBROBLASTS; OXIDATIVE STRESS; KINASE PATHWAY; ACTIVATION; APOPTOSIS; NRF2; RAT	Heme oxygenase-1 (HO-1) is a cytoprotective protein that catalyzes the degradation of heme to biliverdin, iron, and carbon monoxide ( CO). In the present study, we found that endoplasmic reticulum ( ER) stress induced by a variety of experimental agents stimulated a time- and concentration-dependent increase in HO-1 mRNA and protein in vascular smooth muscle cells (SMC). The induction of HO-1 by ER stress was blocked by actinomycin D or cycloheximide and was independent of any changes in HO-1 mRNA stability. Luciferase reporter assays indicated that ER stress stimulated HO-1 promoter activity via the antioxidant response element. Moreover, ER stress induced the nuclear import of Nrf2 and the binding of Nrf2 to the HO-1 antioxidant response element. Interestingly, ER stress stimulated SMC apoptosis, as demonstrated by annexin V binding, caspase-3 activation, and DNA laddering. The induction of apoptosis by ER stress was potentiated by HO inhibition, whereas it was prevented by addition of HO substrate. In addition, exposure of SMC to exogenously administered CO inhibited ER stress-mediated apoptosis, and this was associated with a decrease in the expression of the proapoptotic protein, GADD153. In contrast, the other HO- 1 products failed to block apoptosis or GADD153 expression during ER stress. These results demonstrated that ER stress is an inducer of HO-1 gene expression in vascular SMC and that HO-1-derived CO acts in an autocrine fashion to inhibit SMC apoptosis. The capacity of ER stress to stimulate the HO-1/CO system provides a novel mechanism by which this organelle regulates cell survival.	Vet Affairs Med Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Ochsner Clin Fdn, Dept Mol Genet, New Orleans, LA 70121 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Baylor College of Medicine; University of Pennsylvania; Ochsner Health System	Durante, W (corresponding author), Vet Affairs Med Ctr, Rm 130,Bldg 109,2002 Holcombe Blvd, Houston, TX 77030 USA.	wdurante@bcm.tmc.edu	Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062467, R01HL036045, R01HL059976] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36045, HL59976, HL62467] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alam J, 2000, J BIOL CHEM, V275, P27694; ALAM J, 1994, J BIOL CHEM, V269, P25049; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chang SH, 2002, J BIOL CHEM, V277, P1933, DOI 10.1074/jbc.M108921200; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Durante W, 1999, ARTERIOSCL THROM VAS, V19, P2666, DOI 10.1161/01.ATV.19.11.2666; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Hayashi S, 2004, GENE, V336, P241, DOI 10.1016/j.gene.2004.04.002; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kudo T, 2002, ANN NY ACAD SCI, V977, P349, DOI 10.1111/j.1749-6632.2002.tb04837.x; Linden T, 1998, NEUROSCI LETT, V247, P103, DOI 10.1016/S0304-3940(98)00278-X; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; MOTTERLINI R, 1996, AM J PHYSIOL, V270, P107; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Paschen W, 1998, MOL BRAIN RES, V60, P115, DOI 10.1016/S0169-328X(98)00180-6; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Robert K, 2003, J BIOL CHEM, V278, P31504, DOI 10.1074/jbc.M213036200; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Ryu EJ, 2002, J NEUROSCI, V22, P10690; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TENHUNEN R, 1968, P NATL ACAD SCI USA, V244, P6388; Tian W, 2001, AM J PHYSIOL-RENAL, V281, pF983, DOI 10.1152/ajprenal.0358.2000; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; VILE GF, 1993, J BIOL CHEM, V268, P14678; Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97	56	109	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					872	877		10.1074/jbc.M410413200	http://dx.doi.org/10.1074/jbc.M410413200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15546873	hybrid			2022-12-25	WOS:000226195200005
J	Misaghi, S; Galardy, PJ; Meester, WJN; Ovaa, H; Ploegh, HL; Gaudet, R				Misaghi, S; Galardy, PJ; Meester, WJN; Ovaa, H; Ploegh, HL; Gaudet, R			Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HYDROLASES; DEUBIQUITINATING ENZYMES; CRYSTAL-STRUCTURE; SPECIFICITY; SITE; MONOUBIQUITIN; PROTEINS; REVEALS; PATHWAY; BINDING	Ubiquitin C-terminal hydrolases (UCHs) comprise a family of small ubiquitin-specific proteases of uncertain function. Although no cellular substrates have been identified for UCHs, their highly tissue-specific expression patterns and the association of UCH-L1 mutations with human disease strongly suggest a critical role. The structure of the yeast UCH Yuh1-ubiquitin aldehyde complex identified an active site crossover loop predicted to limit the size of suitable substrates. We report the 1.45 resolution crystal structure of human UCH-L3 in complex with the inhibitor ubiquitin vinylmethylester, an inhibitor that forms a covalent adduct with the active site cysteine of ubiquitin-specific proteases. This structure confirms the predicted mechanism of the inhibitor and allows the direct comparison of a UCH family enzyme in the free and ligand-bound state. We also show the efficient hydrolysis by human UCH-L3 of a 13-residue peptide in isopeptide linkage with ubiquitin, consistent with considerable flexibility in UCH substrate size. We propose a model for the catalytic cycle of UCH family members which accounts for the hydrolysis of larger ubiquitin conjugates.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,NRB RM 836, Boston, MA 02115 USA.	hidde_ploegh@hms.harvard.edu; gaudet@mcb.harvard.edu	Gaudet, Rachelle/I-4133-2014; Gaudet, Rachelle/Y-3985-2019; Galardy, Paul/AAE-9297-2019; ovaa, huib/M-2334-2016	Gaudet, Rachelle/0000-0002-9177-054X; Gaudet, Rachelle/0000-0002-9177-054X; Misaghi, Shahram/0000-0002-4376-1876; ovaa, huib/0000-0002-0068-054X; Meester, Wim/0000-0001-9350-3448	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-15301] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Baek SH, 1999, BIOCHEM BIOPH RES CO, V264, P235, DOI 10.1006/bbrc.1999.1492; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Layfield R, 1999, ANAL BIOCHEM, V274, P40, DOI 10.1006/abio.1999.4234; Mason DE, 2004, BIOCHEMISTRY-US, V43, P6535, DOI 10.1021/bi049722j; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Ovaa H, 2004, P NATL ACAD SCI USA, V101, P2253, DOI 10.1073/pnas.0308411100; PICKART CM, 1985, J BIOL CHEM, V260, P7903; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wilkinson KD, 1999, J MOL BIOL, V291, P1067; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8	29	156	161	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1512	1520		10.1074/jbc.M410770200	http://dx.doi.org/10.1074/jbc.M410770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15531586	hybrid, Green Published			2022-12-25	WOS:000226195200081
J	Koshikawa, N; Minegishi, T; Sharabi, A; Quaranta, V; Seiki, M				Koshikawa, N; Minegishi, T; Sharabi, A; Quaranta, V; Seiki, M			Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-2 CHAIN; CELL-MIGRATION; STABILITY	Processing of the laminin-5 (Ln-5) gamma2 chain by membrane-type-1 matrix metalloproteinases (MT1-MMP) promotes migration and invasion of epithelial and tumor cells. We previously demonstrated that MT1-MMP cleaves the rat gamma2 chain at two sites, producing two major C-terminal fragments of 100 (gamma2') and 80 (gamma2x) kDa and releasing a 30-kDa fragment containing epidermal growth factor (EGF)-like motifs (domain III (DIII) fragment). The DIII fragment bound the EGF receptor (EGF-R) and stimulated cell scattering and migration. However, it is not yet clear whether human Ln-5 is processed in a similar fashion to rat Ln-5 because one of the two MT1-MMP cleavage sites present in rat gamma2 is not found in human gamma2. To identify the exact cleavage site for MT1-MMP in human Ln-5, we purified both the whole molecule as well as a monomeric form of human gamma2 that is frequently expressed by malignant tumor cells. Like rat Ln-5, both the monomer of gamma2, as well as the gamma2 derived from intact Ln-5, were cleaved by MT1-MMP in vitro, generating C-terminal gamma2' (100 kDa) and gamma2x (85 kDa) fragments and releasing DIII fragments (25 and 27k Da). In addition to the conserved first cleavage site used to generate gamma2', two adjacent cleavage sites (Gly(559)-Asp(560) and Gly(579)-Ser(580)) were found that could generate the gamma2x and DIII fragments. Two of the three EGF-like motifs present in the rat DIII fragment are present in the 27-kDa human fragment, and like the rat DIII, this fragment can promote breast carcinoma cell migration by engaging the EGF-R. These results suggest that MT1-MMP processing of Ln-5 in human tumors may stimulate the EGF-R, resulting in increased tumor cell scattering and migration that could possibly increase their metastatic potential.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Vanderbilt Univ, Sch Med, Ctr Matrix Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA	University of Tokyo; Scripps Research Institute; Vanderbilt University; Vanderbilt University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Quaranta, Vito/G-6512-2016; Seiki, Motoharu/K-9443-2015; Koshikawa, Naohiko/S-7306-2017	Quaranta, Vito/0000-0001-7491-8672; Koshikawa, Naohiko/0000-0002-4539-888X; Sharabi, Andrew/0000-0003-2075-1197	NATIONAL CANCER INSTITUTE [R01CA047858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046902] Funding Source: NIH RePORTER; NCI NIH HHS [CA47858] Funding Source: Medline; NIGMS NIH HHS [GM46902] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Baker SE, 1996, J CELL SCI, V109, P2509; CARTER BZ, 1991, LAB INVEST, V65, P610; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gilles C, 2001, J CELL SCI, V114, P2967; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; Koshikawa N, 1999, CANCER RES, V59, P5596; Koshikawa N, 2003, FASEB J, V17, P364, DOI 10.1096/fj.03-0584fje; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Niki T, 2002, AM J PATHOL, V160, P1129, DOI 10.1016/S0002-9440(10)64933-4; Plopper G, 1996, J CELL SCI, V109, P1965; Schenk S, 2003, TRENDS CELL BIOL, V13, P366, DOI 10.1016/S0962-8924(03)00129-6; Schenk S, 2003, J CELL BIOL, V161, P197, DOI 10.1083/jcb.200208145; Seftor REB, 2001, CANCER RES, V61, P6322; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200	18	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					88	93		10.1074/jbc.M411824200	http://dx.doi.org/10.1074/jbc.M411824200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15525652	hybrid			2022-12-25	WOS:000226025100012
J	Chen, XL; Jhee, KH; Kruger, WD				Chen, XL; Jhee, KH; Kruger, WD			Production of the neuromodulator H2S by cystathionine beta-synthase via the condensation of cysteine and homocysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-SULFIDE; PLASMA HOMOCYSTEINE; ALZHEIMERS-DISEASE; N-ACETYLCYSTEINE; BRAIN-TISSUE; CYCLIC-AMP; LIVER; CHROMATOGRAPHY; MODULATION; MUTATIONS	Hydrogen sulfide (H2S) has been observed in relatively high concentrations in the mammalian brain and has been shown to act as a neuromodulator. However, there is confusion in the literature regarding the actual source of H2S production. Reactions catalyzed by the cystathionine beta-synthase enzyme (CBS) are one possible source for the production of H2S. Here we show that the CBS enzyme can efficiently produce H2S via a beta-replacement reaction in which cysteine is condensed with homocysteine to form cystathionine and H2S. The production of H2S by this reaction is at least 50 times more efficient than that produced by hydrolysis of cysteine alone via beta-elimination. Kinetic studies demonstrate that the K-m and K-cat for cysteine is 3-fold higher and 2-fold lower, respectively, than that for serine. Consistent with these data, in vitro reconstitution studies show that at physiologically relevant concentrations of serine, homocysteine, and cysteine, about 5% of the cystathionine formed is from cysteine. We also show that AdoMet stimulates this H2S producing reaction but that there is no evidence for stimulation by calcium and calmodulin as reported previously. In summary, these results confirm the ability of CBS to produce H2S, but show in contrast to prior reports that the major mechanism is via beta-replacement and not cysteine hydrolysis. In addition, these studies provide a biochemical explanation for the previously inexplicable homocysteine-lowering effects of N-acetylcysteine treatments in humans.	Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA; Kumoh Natl Inst Technol, Dept Appl Chem, Gumi 730701, South Korea	Fox Chase Cancer Center; Kumoh National University Technology	Kruger, WD (corresponding author), Fox Chase Canc Ctr, Div Populat Sci, 333 Cottman Ave, Philadelphia, PA 19111 USA.	warren.kruger@fccc.edu	kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NCI NIH HHS [CA06927] Funding Source: Medline; NHLBI NIH HHS [HL5299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 1996, J NEUROSCI, V16, P1066; BLOMMAART PJE, 1993, J BIOL CHEM, V268, P1610; BRAUNSTE.AE, 1971, BIOCHIM BIOPHYS ACTA, V242, P247, DOI 10.1016/0005-2744(71)90105-7; BRAUNSTEIN AE, 1969, BIOCHIM BIOPHYS ACTA, V171, P366, DOI 10.1016/0005-2744(69)90173-9; Eto K, 2002, BIOCHEM BIOPH RES CO, V293, P1485, DOI 10.1016/S0006-291X(02)00422-9; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; Jhee KH, 2000, BIOCHEMISTRY-US, V39, P10548, DOI 10.1021/bi001020g; Kimura H, 2002, MOL NEUROBIOL, V26, P13, DOI 10.1385/MN:26:1:013; Kimura H, 2000, BIOCHEM BIOPH RES CO, V267, P129, DOI 10.1006/bbrc.1999.1915; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; McLean RR, 2004, NEW ENGL J MED, V350, P2042, DOI 10.1056/NEJMoa032739; MILES EW, 1986, PYRIDOXAL PHOSPHAT B, P235; Ovrebo KK, 2000, PHARMACOL TOXICOL, V87, P103, DOI 10.1111/j.0901-9928.2000.870301.x; Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634; ROBERTS E, 1962, AMINO ACID POOLS, P284; Roes EM, 2002, CLIN CHEM LAB MED, V40, P496, DOI 10.1515/CCLM.2002.086; SAVAGE JC, 1990, J CHROMATOGR-BIOMED, V526, P540, DOI 10.1016/S0378-4347(00)82537-2; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; Shan XY, 2001, HUM MOL GENET, V10, P635, DOI 10.1093/hmg/10.6.635; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; van Meurs JBJ, 2004, NEW ENGL J MED, V350, P2033, DOI 10.1056/NEJMoa032546; Wang LQ, 2004, CIRC RES, V94, P1318, DOI 10.1161/01.RES.0000129182.46440.4a; WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8; Wiklund O, 1996, ATHEROSCLEROSIS, V119, P99, DOI 10.1016/0021-9150(95)05635-1; WILLHARDT I, 1975, ANAL BIOCHEM, V63, P263, DOI 10.1016/0003-2697(75)90213-4; Yamagata S, 2002, BIOSCI BIOTECH BIOCH, V66, P2706, DOI 10.1271/bbb.66.2706; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	28	245	267	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52082	52086		10.1074/jbc.C400481200	http://dx.doi.org/10.1074/jbc.C400481200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15520012	hybrid			2022-12-25	WOS:000225493400046
J	Shashidharamurthy, R; Koteiche, HA; Dong, JH; Mchaourab, HS				Shashidharamurthy, R; Koteiche, HA; Dong, JH; Mchaourab, HS			Mechanism of chaperone function in small heat shock proteins - Dissociation of the Hsp27 oligomer is required for recognition and binding of destabilized T4 lysozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-A-CRYSTALLIN; SUBUNIT EXCHANGE; B-CRYSTALLIN; UNFOLDING PROTEINS; HYDROGEN-EXCHANGE; MASS-SPECTROMETRY; TERMINAL DOMAIN; EXCITED-STATES; 2-MODE BINDING; IN-VITRO	Mammalian small heat shock proteins (sHSP) form polydisperse and dynamic oligomers that undergo equilibrium subunit exchange. Current models of their chaperone activity hypothesize that recognition and binding of protein non-native states involve changes in the oligomeric state. The equivalent thermodynamic representation is a set of three coupled equilibria that includes the sHSP oligomeric equilibrium, the substrate folding equilibrium, and the equilibrium binding between the sHSP and the substrate non-native states. To test this hypothesis and define the binding-competent oligomeric state of human Hsp27, we have perturbed the two former equilibria and quantitatively determined the consequences on binding. The substrate is a set of T4 lysozyme (T4L) mutants that bind under conditions that favor the folded state over the unfolded state by 10(2)-10(4)- fold. The concentration-dependent oligomer equilibrium of Hsp27 was perturbed by mutations that alter the relative stability of two major oligomeric states including phosphorylation-mimicking mutations that result in the dissociation to a small multimer over a wide range of concentrations. Correlation of binding isotherms with size exclusion chromatography analysis of the Hsp27 oligomer equilibrium demonstrates that the multimer is the binding-competent state. Binding occurs through two modes, each characterized by different affinity and number of binding sites, and results in T4L.Hsp27 complexes of different hydrodynamic properties. Mutants of the Hsp27 phosphorylation mimic that reverse the reduction in oligomer size also reduce the extent of T4L binding. Taken together, these results suggest a central role for the oligomeric equilibrium in regulating the chaperone activity of sHSP. The mutants identify sequence features important for modulating this equilibrium.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, 741 Light Hall, Nashville, TN 37232 USA.	hassane.mchaourab@vanderbilt.edu		Dong, Jinhui/0000-0003-4542-7756	NATIONAL EYE INSTITUTE [R01EY012018] Funding Source: NIH RePORTER; NEI NIH HHS [EY-R0112018] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Berengian AR, 1999, J BIOL CHEM, V274, P6305, DOI 10.1074/jbc.274.10.6305; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 2000, METH MOL B, V99, P421; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Englander SW, 1998, TRENDS BIOCHEM SCI, V23, P378, DOI 10.1016/S0968-0004(98)01281-X; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Koteiche HA, 2002, FEBS LETT, V519, P16, DOI 10.1016/S0014-5793(02)02688-1; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P14627, DOI 10.1021/bi971700s; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; Morrison LE, 2003, CIRC RES, V92, P203, DOI 10.1161/01.RES.0000052989.83995.A5; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Pace CN, 2000, PROTEINS, P1; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Sathish HA, 2004, J BIOL CHEM, V279, P16425, DOI 10.1074/jbc.M313402200; Sathish HA, 2003, J BIOL CHEM, V278, P44214, DOI 10.1074/jbc.M307578200; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Stromer T, 2004, J BIOL CHEM, V279, P11222, DOI 10.1074/jbc.M310149200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Wintrode PL, 2003, BIOCHEMISTRY-US, V42, P10667, DOI 10.1021/bi034117m; Xi JH, 2003, J CELL SCI, V116, P1073, DOI 10.1242/jcs.00325	49	137	142	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5281	5289		10.1074/jbc.M407236200	http://dx.doi.org/10.1074/jbc.M407236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15542604	hybrid			2022-12-25	WOS:000227217100023
J	Aminova, LR; Chavez, JC; Lee, J; Ryu, H; Kung, A; LaManna, JC; Ratan, RR				Aminova, LR; Chavez, JC; Lee, J; Ryu, H; Kung, A; LaManna, JC; Ratan, RR			Prosurvival and prodeath effects of hypoxia-inducible factor-1 alpha stabilization in a murine hippocampal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; FOCAL CEREBRAL-ISCHEMIA; FACTOR 1-ALPHA; IN-VITRO; TRANSCRIPTIONAL REGULATION; ENDOPLASMIC-RETICULUM; GLYCOLYTIC-ENZYMES; CORTICAL-NEURONS; PROTEIN BNIP3	Hypoxia-inducible factor-1 (HIF-1) is a transcriptional activator involved in adaptation to hypoxic stress. Previous studies, from our laboratory demonstrated that pharmacological activators of HIF-1 (e.g. deferoxamine, cobalt chloride) could also protect cultured primary neurons or an immortalized hippocampal neuroblast line (HT22) from oxidative stress-induced death. However, whether HIF-1 activation is sufficient to abrogate neuronal death resulting from oxidative stress or other hypoxia-independent death inducers remains unclear. To address this question we utilized a HIF-1alpha fusion protein that partially lacks the domain required for oxygen-dependent degradation of HIF-1a and that has a VP16 transcriptional activation domain from herpes simplex virus. HT22 cells were infected with a retrovirus encoding either the HIF-1alpha-VP16 fusion protein or the activation domain of the VP16 protein alone as a control. Expression of HIF-1alpha-VIP16, but not VP16 alone, increased luciferase activity driven by a canonical hypoxia response element, increased mRNA of established HIF-1 target genes, and increased activity of one of these HIF-1 target genes. Unexpectedly, enhanced HIF-1 activity in HT22 cells enhanced sensitivity to oxidative death induced by glutathione depletion. Accordingly, suppression of HIF-1alpha expression using RNA interference prevented oxidative death. By contrast, HIF-1alpha-VP16-expressing HT22 cells were more resistant to DNA damage (induced by camptothecin) or endoplasmic reticulum stress (induced by thapsigargin and tunicamycin) than were VP16-expressing cells, and suppression of HIF-1alpha expression using RNA interference rendered HT22 cells more sensitive to death induced by DNA damage or endoplasmic reticulum stress. Together, these data demonstrate that HIF-1 can mediate prodeath or prosurvival responses in the same cell type depending on the injury stimulus.	Burke Cornell Med Res Inst, White Plains, NY 10605 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Case Western Reserve Univ, Dept Anat & Neurol, Cleveland, OH 44106 USA; Cornell Univ, Wiell Med Coll, Dept Neurol, New York, NY 10021 USA; Cornell Univ, Wiell Med Coll, Dept Neurosci, New York, NY 10021 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Case Western Reserve University; Cornell University; Cornell University	Ratan, RR (corresponding author), Burke Cornell Med Res Inst, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	rratan@burke.org	LaManna, Joseph C/C-3347-2012; Kung, Andrew L/AEU-0826-2022; Kung, Andrew/AAL-2384-2020; LaManna, Joseph/D-3860-2013	LaManna, Joseph C/0000-0002-0159-4512; Kung, Andrew L/0000-0002-9091-488X; LaManna, Joseph/0000-0002-0159-4512; Ryu, Hoon/0000-0001-6544-3732	NINDS NIH HHS [NS46239, NS40591, NS39170] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040591, F32NS046239, R01NS039170] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Greenberg DA, 2004, TRENDS MOL MED, V10, P1, DOI 10.1016/j.molmed.2003.11.006; Halterman MW, 1999, EXP NEUROL, V159, P65, DOI 10.1006/exnr.1999.7160; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V7, P6341; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shibata M, 2002, J CEREBR BLOOD F MET, V22, P810, DOI 10.1097/00004647-200207000-00006; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Tan SL, 1998, J NEUROCHEM, V71, P95; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Wang G L, 1996, Curr Opin Hematol, V3, P156; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Zaman K, 1999, J NEUROSCI, V19, P9821; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	49	94	100	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3996	4003		10.1074/jbc.M409223200	http://dx.doi.org/10.1074/jbc.M409223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15557337	hybrid			2022-12-25	WOS:000226983900103
J	Gage, RM; Matveeva, EA; Whiteheart, SW; von Zastrow, M				Gage, RM; Matveeva, EA; Whiteheart, SW; von Zastrow, M			Type IPDZ ligands are sufficient to promote rapid recycling of G protein-coupled receptors independent of binding to N-ethylmaleimide-sensitive factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; DOMAIN INTERACTION CONTROLS; INDUCED DOWN-REGULATION; KAPPA-OPIOID RECEPTORS; D-ASPARTATE RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; MEMBRANE TRAFFICKING; PDZ DOMAINS	Molecular sorting of G protein-coupled receptors (GPCRs) between divergent recycling and lysosomal pathways determines the functional consequences of agonist-induced endocytosis. The carboxyl-terminal cytoplasmic domain of the beta(2) adrenergic receptor (beta(2)AR) mediates both PDZ binding to Na+/H+ exchanger regulatory factor/ezrin/radixin/moesin-binding phosphoprotein of 50 kDa (NHERF/EBP50) family proteins and non-PDZ binding to the N-ethylmaleimide-sensitive factor (NSF). We have investigated whether PDZ interaction(s) are actually sufficient to promote rapid recycling of endocytosed receptors and, if so, whether PDZ-mediated sorting is restricted to the B(2)AR tail or to sequences that bind NHERF/EBP50. The trafficking effects of short (10 residue) sequences differing in PDZ and NSF binding properties were examined using chimeric mutant receptors. The recycling activity of the B(2)AR-derived tail sequence was not blocked by a point mutation that selectively disrupts binding to NSF, and naturally occurring PDZ ligand sequences were identified that do not bind detectably to NSF yet function as strong recycling signals. The carboxyl-terminal cytoplasmic domain of the beta(1)-adrenergic receptor, which does not bind either to NSF or NHERF/EBP50 and interacts selectively with a distinct group of PDZ proteins, promoted rapid recycling of chimeric mutant receptors with efficiency similarly high as that of the beta(2)AR tail. These results indicate that PDZ domain-mediated protein interactions are sufficient to promote rapid recycling of GPCRs, independent of binding to NSF. They also suggest that PDZ-directed recycling is a rather general mechanism of GPCR regulation, which is not restricted to a single GPCR, and may involve additional PDZ domain-containing protein(s) besides NHERF/EBP50.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Kentucky; University of California System; University of California San Francisco; University of California System; University of California San Francisco	von Zastrow, M (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Gentechy Hall,600 16th St,Box 2140,2nd Floor,N-21, San Francisco, CA 94143 USA.	zastrow@itsa.ucsf.edu		Whiteheart, Sidney/0000-0001-5577-0473				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman O B Jr, 1998, Adv Pharmacol, V42, P429; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KURZ JB, 1992, MOL PHARMACOL, V41, P375; Ladias JAA, 2003, J MEMBRANE BIOL, V192, P79, DOI 10.1007/s00232-002-1065-x; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Liu-Chen LY, 2004, LIFE SCI, V75, P511, DOI 10.1016/j.lfs.2003.10.041; Mashima J, 2000, BIOCHEM BIOPH RES CO, V274, P559, DOI 10.1006/bbrc.2000.3162; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; VON ZM, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	57	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3305	3313		10.1074/jbc.M406934200	http://dx.doi.org/10.1074/jbc.M406934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15548537	hybrid			2022-12-25	WOS:000226983900023
J	Mukudai, Y; Kubota, S; Eguchi, T; Kondo, S; Nakao, K; Takigawa, M				Mukudai, Y; Kubota, S; Eguchi, T; Kondo, S; Nakao, K; Takigawa, M			Regulation of chicken ccn2 gene by interaction between RNA cis-element and putative trans-factor during differentiation of chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; VASCULAR ENDOTHELIAL-CELLS; 3' UNTRANSLATED REGION; ELASTIN MESSENGER-RNA; 3'-UNTRANSLATED REGION; PARATHYROID-HORMONE; CTGF/HCS24 GENE; BONE-FORMATION; COLLAGEN GENE; FACTOR-BETA	CCN2/CTGF is a multifunctional growth factor. Our previous studies have revealed that CCN2 plays important roles in both growth and differentiation of chondrocytes and that the 3'-untranslated region (3'-UTR) of ccn2 mRNA contains a cis-repressive element of gene expression. In the present study, we found that the stability of chicken ccn2 mRNA is regulated in a differentiation stage-dependent manner in chondrocytes. We also found that stimulation by bone morphogenetic protein 2, platelet-derived growth factor, and CCN2 stabilized ccn2 mRNA in proliferating chondrocytes but that it destabilized the mRNA in prehypertrophic-hypertrophic chondrocytes. The results of a reporter gene assay revealed that the minimal repressive cis-element of the 3'-UTR of chicken ccn2 mRNA was located within the area between 100 and 150 bases from the polyadenylation tail. Moreover, the stability of ccn2 mRNA was correlated with the interaction between this cis-element and a putative 40-kDa trans-factor in nuclei and cytoplasm. In fact, the binding between them was prominent in proliferating chondrocytes and attenuated in (pre)hypertrophic chondrocytes. Stimulation by the growth factors repressed the binding in proliferating chondrocytes; however, it enhanced it in (pre)hypertrophic chondrocytes. Therefore, gene expression of ccn2 mRNA during endochondral ossification is properly regulated, at least in part, by changing the stability of the mRNA, which arises from the interaction between the RNA cis-element and putative trans-factor.	Okayama Univ, Sch Dent, Biodent Res Ctr, Okayama 7008525, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Biochem & Mol Dent, Okayama 7008525, Japan; Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1028471, Japan	Okayama University; Okayama University; Japan Society for the Promotion of Science	Takigawa, M (corresponding author), Okayama Univ, Sch Dent, Biodent Res Ctr, Okayama 7008525, Japan.	takigawa@md.okayama-u.ac.jp	Mukudai, Yoshiki/L-4459-2019; Kondo, Seiji/I-4332-2017; Kondo, Seiji/ABD-3982-2020	Mukudai, Yoshiki/0000-0002-9600-4430; Kondo, Seiji/0000-0001-9341-5069; Kondo, Seiji/0000-0001-9341-5069; Eguchi, Takanori/0000-0002-3297-6126				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; Babic AM, 1999, MOL CELL BIOL, V19, P2958; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Eguchi T, 2001, J BIOCHEM, V130, P79, DOI 10.1093/oxfordjournals.jbchem.a002965; Enomoto-Iwamoto M, 1998, J CELL BIOL, V140, P409, DOI 10.1083/jcb.140.2.409; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Fujii H, 1999, HISTOCHEM CELL BIOL, V112, P131, DOI 10.1007/s004180050399; GITELMAN SE, 1994, J CELL BIOL, V126, P1595, DOI 10.1083/jcb.126.6.1595; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hew Y, 1999, J BIOL CHEM, V274, P14415, DOI 10.1074/jbc.274.20.14415; Hew Y, 2000, J BIOL CHEM, V275, P24857, DOI 10.1074/jbc.M002776200; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KARAPLIS A, 2002, PRINCIPLES BONE BIOL, P38; KATO Y, 1988, P NATL ACAD SCI USA, V85, P9552, DOI 10.1073/pnas.85.24.9552; KATO Y, 1990, J BIOL CHEM, V265, P5903; Kieswetter K, 1997, ENDOCRINE, V6, P257, DOI 10.1007/BF02820501; KIKUCHI K, 1995, J INVEST DERMATOL, V105, P128, DOI 10.1111/1523-1747.ep12313452; Kilav R, 2001, J BIOL CHEM, V276, P8727, DOI 10.1074/jbc.M005471200; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; Kondo S, 2000, BIOCHEM BIOPH RES CO, V278, P119, DOI 10.1006/bbrc.2000.3780; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kubota S, 2000, ONCOGENE, V19, P4773, DOI 10.1038/sj.onc.1203835; Kubota S, 1999, FEBS LETT, V450, P84, DOI 10.1016/S0014-5793(99)00480-9; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; Minina E, 2001, DEVELOPMENT, V128, P4523; Mukudai Y, 2003, BIOL CHEM, V384, P1, DOI 10.1515/BC.2003.001; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nakanishi T, 1997, BIOCHEM BIOPH RES CO, V234, P206, DOI 10.1006/bbrc.1997.6528; Nakanishi T, 2001, BIOCHEM BIOPH RES CO, V281, P678, DOI 10.1006/bbrc.2001.4379; NAKATA K, 1992, FEBS LETT, V299, P278, DOI 10.1016/0014-5793(92)80131-Y; NINOMIYA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3014, DOI 10.1073/pnas.81.10.3014; Nishida T, 2002, J CELL PHYSIOL, V192, P55, DOI 10.1002/jcp.10113; Nishida T, 2000, J CELL PHYSIOL, V184, P197, DOI 10.1002/1097-4652(200008)184:2<197::AID-JCP7>3.0.CO;2-R; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; RAJAGOPALAN LE, 1995, BLOOD, V86, P2551; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Takigawa M, 2003, DRUG NEWS PERSPECT, V16, P11, DOI 10.1358/dnp.2003.16.1.829302; TAKIGAWA M, 1988, ENDOCRINOLOGY, V122, P831, DOI 10.1210/endo-122-3-831; TAKIGAWA M, 1981, J CELL PHYSIOL, V106, P259, DOI 10.1002/jcp.1041060212; Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206; van Tuinen M, 2000, MOL BIOL EVOL, V17, P451, DOI 10.1093/oxfordjournals.molbev.a026324; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	67	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3166	3177		10.1074/jbc.M411632200	http://dx.doi.org/10.1074/jbc.M411632200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550387	hybrid, Green Published			2022-12-25	WOS:000226983900008
J	Suzuki, R; Tobe, K; Aoyama, M; Sakamoto, K; Ohsugi, M; Kamei, N; Nemoto, S; Inoue, A; Ito, Y; Uchida, S; Hara, K; Yamauchi, T; Kubota, N; Terauchi, Y; Kadowaki, T				Suzuki, R; Tobe, K; Aoyama, M; Sakamoto, K; Ohsugi, M; Kamei, N; Nemoto, S; Inoue, A; Ito, Y; Uchida, S; Hara, K; Yamauchi, T; Kubota, N; Terauchi, Y; Kadowaki, T			Expression of DGAT2 in white adipose tissue is regulated by central leptin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; COA-DIACYLGLYCEROL ACYLTRANSFERASE-1; INSULIN-RESISTANCE; MICE; OBESITY; GENE; IRS-2; SENSITIVITY; DISRUPTION; MECHANISMS	Acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes catalyze the final step in mammalian triglyceride synthesis, and their functions are considered to be involved in the mechanisms of obesity, insulin resistance, and leptin resistance. Insulin receptor substrate-2 (IRS-2)-deficient mice exhibit obesity-associated with hypertrophic adipocytes and leptin resistance. Screening for transcripts of genes involved in fatty acid and triglyceride synthesis to investigate the mechanism of the hypertrophic change in the adipocytes showed that expression of DGAT2 mRNA was up-regulated in the white adipose tissue (WAT) of Irs2(-/-) mice, whereas that of DGAT1 was down-regulated. This reciprocal expression of DGAT1 and DGAT2 was also observed in WAT of leptin-deficient ob/ob mice. A high fat diet also resulted in increased DGAT2 and reduced DGAT1 in the WAT of C57BL/6 mice. Induction of adipocyte hypertrophy in vitro up-regulated both DGAT1 and DGAT2 expression in 3T3-L1 cells, suggesting that adipocyte non-autonomous mechanism in vivo is required for the reciprocal changes in expression of DGAT1 and DGAT2. In fact, intracerebroventricular infusion of leptin reduced DGAT2 expression in WAT of Irs2(-/-) mice and ob/ob mice, independently of DGAT1 expression. We propose the hypothesis that leptin regulates adipocyte size by altering expression patterns of DGAT via central nervous system to determine the levels of triglyceride synthesis.	Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Kubota, Naoto/N-7892-2015; Terauchi, Yasuo/AAO-4347-2020; Suzuki, Ryo/AAA-2736-2019	Suzuki, Ryo/0000-0002-2965-6906; Kamei, Nozomu/0000-0002-7686-437X				Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2004, DIABETES, V53, P1445, DOI 10.2337/diabetes.53.6.1445; Chen HC, 2002, J CLIN INVEST, V109, P175, DOI 10.1172/JCI0213880; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; Masaki T, 2004, OBES RES, V12, P878, DOI 10.1038/oby.2004.106; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Soukas A, 2000, GENE DEV, V14, P963; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Suzuki R, 2004, J BIOL CHEM, V279, P25039, DOI 10.1074/jbc.M311956200; Suzuki R, 2003, J BIOL CHEM, V278, P43691, DOI 10.1074/jbc.M307004200; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; Uchida SK, 2002, DIABETES, V51, pA465; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wakimoto K, 2003, BIOCHEM BIOPH RES CO, V310, P296, DOI 10.1016/j.bbrc.2003.09.015; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200	30	44	55	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3331	3337		10.1074/jbc.M410955200	http://dx.doi.org/10.1074/jbc.M410955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15550388	hybrid			2022-12-25	WOS:000226983900026
J	Takahashi, S; Zhao, YX; O'Maille, PE; Greenhagen, BT; Noel, JP; Coates, RM; Chappell, J				Takahashi, S; Zhao, YX; O'Maille, PE; Greenhagen, BT; Noel, JP; Coates, RM; Chappell, J			Kinetic and molecular analysis of 5-epiaristolochene 1,3-dihydroxylase, a cytochrome P450 enzyme catalyzing successive hydroxylations of sesquiterpenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE RECOGNITION SITES; ARABIDOPSIS-THALIANA; ACTIVE-SITE; AMINO-ACID; HETEROLOGOUS EXPRESSION; GIBBERELLIN 20-OXIDASE; PLANT CYTOCHROME-P450; FUNCTIONAL EXPRESSION; GENETIC ALGORITHM; CRYSTAL-STRUCTURE	The final step of capsidiol biosynthesis is catalyzed by 5-epiaristolochene dihydroxylase (EAH), a cytochrome P450 enzyme that catalyzes the regio- and stereospecific insertion of two hydroxyl moieties into the bicyclic sesquiterpene 5-epiaristolochene (EA). Detailed kinetic studies using EA and the two possible monohydroxylated intermediates demonstrated the release of 1beta-hydroxy-EA ((OH)EA) at high EA concentrations and a 10-fold catalytic preference for 1beta(OH)EA versus 3alpha(OH)EA, indicative of a preferred reaction order of hydroxylation at C-1, followed by that at C-3. Sequence alignments and homology modeling identified active-site residues tested for their contribution to substrate specificity and overall enzymatic activity. Mutants EAH-S368C and EAH-S368V exhibited wild-type catalytic efficiencies for 1beta(OH)EA biosynthesis, but were devoid of the successive hydroxylation activity for capsidiol biosynthesis. In contrast to EAH-S368C, EAH-S368V catalyzed the relative equal biosynthesis of 1beta(OH)EA, 2beta(OH)EA, and 3beta(OH)EA from EA with wild-type efficiency. Moreover, EAH-S368V converted similar to1.5% of these monohydroxylated products to their respective ketone forms. Alanine and threonine mutations at position 368 were significantly compromised in their conversion rates of EA to capsidiol and correlated with 3.6- and 5.7-fold increases in their K-m values for the 1beta(OH)EA intermediate, respectively. A role for Ile(486) in the successive hydroxylations of EA was also suggested by the EAH-I468A mutant, which produced significant amounts 1beta(OH)EA, but negligible amounts of capsidiol from EA. The altered product profile of the EAH-I486A mutant correlated with a 3.6-fold higher K-m for EA and a 4.4-fold slower turnover rate (k(cat)) for 1beta(OH)EA. These kinetic and mutational studies were correlated with substrate docking predictions to suggest how Ser(368) and Ile(486) might contribute to active-site topology, substrate binding, and substrate presentation to the oxo-Fe-heme reaction center.	Univ Kentucky, Dept Agron, Plant Physiol Biochem & Mol Biol Program, Lexington, KY 40546 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	University of Kentucky; University of Illinois System; University of Illinois Urbana-Champaign; Salk Institute	Chappell, J (corresponding author), Univ Kentucky, Dept Agron, Plant Physiol Biochem & Mol Biol Program, 301B Plant Sci Bldg,1405 Vet Dr, Lexington, KY 40546 USA.	chappell@uky.edu	Takahashi, Shunji/N-6921-2015; Noel, Joseph P/A-9459-2009; Takahashi, Shunji/GLT-3245-2022	Takahashi, Shunji/0000-0003-1684-9298; Takahashi, Shunji/0000-0003-1684-9298	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [GM54029, GM13956, R01 GM013956, R01 GM054029] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054029, R01GM013956] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAPPELL J, 1987, PHYTOCHEMISTRY, V26, P2259, DOI 10.1016/S0031-9422(00)84695-6; CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1, DOI 10.1145/224057.224059; Choe SW, 1998, PLANT CELL, V10, P231, DOI 10.1105/tpc.10.2.231; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Frey M, 1997, SCIENCE, V277, P696, DOI 10.1126/science.277.5326.696; GIBSON RW, 1983, NATURE, V302, P608, DOI 10.1038/302608a0; GOTOH O, 1992, J BIOL CHEM, V267, P83; Greenhagen BT, 2003, ARCH BIOCHEM BIOPHYS, V409, P385, DOI 10.1016/S0003-9861(02)00613-6; GUEDES MEM, 1982, PHYTOCHEMISTRY, V21, P2987, DOI 10.1016/0031-9422(80)85086-2; HASLER JA, 1994, MOL PHARMACOL, V46, P338; He YA, 1997, BIOCHEMISTRY-US, V36, P8831, DOI 10.1021/bi970182i; HE YA, 1992, BIOCHEMISTRY-US, V31, P9220, DOI 10.1021/bi00153a015; HE YA, 1994, BIOCHEMISTRY-US, V33, P4419, DOI 10.1021/bi00180a040; Helliwell CA, 1999, PLANT PHYSIOL, V119, P507, DOI 10.1104/pp.119.2.507; Helliwell CA, 2001, P NATL ACAD SCI USA, V98, P2065, DOI 10.1073/pnas.041588998; Humphreys JM, 1999, P NATL ACAD SCI USA, V96, P10045, DOI 10.1073/pnas.96.18.10045; Imai T, 1998, BIOCHEMISTRY-US, V37, P8097, DOI 10.1021/bi9802768; Jennewein S, 2003, ARCH BIOCHEM BIOPHYS, V413, P262, DOI 10.1016/S0003-9861(03)00090-0; Jennewein S, 2001, P NATL ACAD SCI USA, V98, P13595, DOI 10.1073/pnas.251539398; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kahn RA, 2001, ARCH BIOCHEM BIOPHYS, V391, P180, DOI 10.1006/abbi.2001.2415; Kaltenbach M, 1999, PLANT J, V19, P183, DOI 10.1046/j.1365-313X.1999.00524.x; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; Kessler A, 2001, SCIENCE, V291, P2141, DOI 10.1126/science.291.5511.2141; Khan KK, 2000, ARCH BIOCHEM BIOPHYS, V373, P335, DOI 10.1006/abbi.1999.1578; KOCH BM, 1995, ARCH BIOCHEM BIOPHYS, V323, P177; Kumar S, 2003, J BIOL CHEM, V278, P17178, DOI 10.1074/jbc.M212515200; Lewis DFV, 2002, J INORG BIOCHEM, V91, P502, DOI 10.1016/S0162-0134(02)00429-4; Lupien S, 1999, ARCH BIOCHEM BIOPHYS, V368, P181, DOI 10.1006/abbi.1999.1298; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MENTING JGT, 1994, PLANT PHYSIOL, V106, P633, DOI 10.1104/pp.106.2.643; Meyer K, 1996, P NATL ACAD SCI USA, V93, P6869, DOI 10.1073/pnas.93.14.6869; Nissink JWM, 2002, PROTEINS, V49, P457, DOI 10.1002/prot.10232; Nomura T, 2002, MOL GENET GENOMICS, V267, P210, DOI 10.1007/s00438-002-0653-x; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pelkonen P, 1997, CHEM RES TOXICOL, V10, P85, DOI 10.1021/tx960078m; PHILLIPS AL, 1995, PLANT PHYSIOL, V108, P1049, DOI 10.1104/pp.108.3.1049; Pikuleva I, 2003, ARCH BIOCHEM BIOPHYS, V420, P35, DOI 10.1016/j.abb.2003.09.028; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Ralston L, 2001, ARCH BIOCHEM BIOPHYS, V393, P222, DOI 10.1006/abbi.2001.2483; Rising KA, 2000, J AM CHEM SOC, V122, P1861, DOI 10.1021/ja993584h; Rupasinghe S, 2003, PROTEIN ENG, V16, P721, DOI 10.1093/protein/gzg094; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sawada N, 2000, BIOCHEM BIOPH RES CO, V273, P977, DOI 10.1006/bbrc.2000.3050; Schalk M, 2000, P NATL ACAD SCI USA, V97, P11948, DOI 10.1073/pnas.97.22.11948; Schoch GA, 2003, EUR J BIOCHEM, V270, P3684, DOI 10.1046/j.1432-1033.2003.03739.x; Schoendorf A, 2001, P NATL ACAD SCI USA, V98, P1501, DOI 10.1073/pnas.98.4.1501; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; STEVENS KL, 1984, ISOPENTENOIDS PLANTS, P63; STOESSL A, 1976, PHYTOCHEMISTRY, V15, P855, DOI 10.1016/S0031-9422(00)84361-7; STOESSL A, 1973, PHYTOPATHOLOGY, V63, P1225, DOI 10.1094/Phyto-63-1225; STOESSL A, 1972, Phytopathologische Zeitschrift, V74, P141; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; TEUTSCH HG, 1993, P NATL ACAD SCI USA, V90, P4102, DOI 10.1073/pnas.90.9.4102; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; VOGELI U, 1988, PLANT PHYSIOL, V88, P1291, DOI 10.1104/pp.88.4.1291; Wang EM, 2001, NAT BIOTECHNOL, V19, P371, DOI 10.1038/86770; WARD EWB, 1973, PHYTOPATHOLOGY, V63, P1537, DOI 10.1094/Phyto-63-1537; WATSON DG, 1985, PHYTOCHEMISTRY, V24, P2195, DOI 10.1016/S0031-9422(00)83009-5; WATSON DG, 1983, BIOCHEM SOC T, V11, P589; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; WHITEHEAD IM, 1989, PHYTOCHEMISTRY, V28, P775, DOI 10.1016/0031-9422(89)80114-1; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; Wust M, 2001, ARCH BIOCHEM BIOPHYS, V387, P125, DOI 10.1006/abbi.2000.2248; XU YL, 1995, P NATL ACAD SCI USA, V92, P6640, DOI 10.1073/pnas.92.14.6640; Yamazaki T, 1998, BIOCHEMISTRY-US, V37, P2800, DOI 10.1021/bi9715066; Zhao YX, 2004, J ORG CHEM, V69, P7428, DOI 10.1021/jo049058c	72	34	39	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3686	3696		10.1074/jbc.M411870200	http://dx.doi.org/10.1074/jbc.M411870200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15522862	Green Accepted, hybrid			2022-12-25	WOS:000226983900068
J	Kodding, J; Killig, F; Polzer, P; Howard, SP; Diederichs, K; Welte, W				Kodding, J; Killig, F; Polzer, P; Howard, SP; Diederichs, K; Welte, W			Crystal structure of a 92-residue C-terminal fragment of TonB from Escherichia coli reveals significant conformational changes compared to structures of smaller TonB fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE TRANSPORTER; IN-VIVO EVIDENCE; SALMONELLA-TYPHIMURIUM; DIFFRACTION DATA; RECEPTOR FHUA; PROTEIN; COBALAMIN; BINDING; DOMAIN; FEPA	Uptake of siderophores and vitamin B,, through the outer membrane of Escherichia coli is effected by an active transport system consisting of several outer membrane receptors and a protein complex of the inner membrane. The link between these is TonB, a protein associated with the cytoplasmic membrane, which forms a large periplasmic domain capable of interacting with several outer membrane receptors, e.g. FhuA, FecA, and FepA for siderophores and BtuB for vitamin B-12. The active transport across the outer membrane is driven by the chemiosmotic gradient of the inner membrane and is mediated by the TonB protein. The receptor-binding domain of TonB appears to be formed by a highly conserved C-terminal amino acid sequence of similar to100 residues. Crystal structures of two C-terminal TonB fragments composed of 85 (TonB-85) and 77 (TonB-77) amino acid residues, respectively, have been previously determined (Chang, C., Mooser, A., Pluckthun, A., and Wlodawer, A. (2001) J. Biol. Chem. 276,27535-27540 and Koedding, J., Howard, S. P., Kaufmann, L., Polzer, P., Lustig, A., and Welte, W. (2004) J. Biol. Chem. 279, 9978-9986). In both cases the TonB fragments form dimers in solution and crystallize as dimers consisting of monomers tightly engaged with one another by the exchange of a beta-hairpin and a C-terminal beta-strand. Here we present the crystal structure of a 92-residue fragment of TonB (TonB-92), which is monomeric in solution. The structure, determined at 1.13-Angstrom resolution, shows a dimer with considerably reduced intermolecular interaction compared with the other known TonB structures, in particular lacking the beta-hairpin exchange.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada	University of Konstanz; University of Saskatchewan	Welte, W (corresponding author), Univ Konstanz, Dept Biol, Univ Str 10, D-78457 Constance, Germany.	wolfram.welte@uni-konstanz.de						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blandl T, 2003, PROTEIN SCI, V12, P237, DOI 10.1110/ps.0228603; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Cascales E, 2001, MOL MICROBIOL, V42, P795, DOI 10.1046/j.1365-2958.2001.02673.x; Chang CS, 2001, J BIOL CHEM, V276, P27535, DOI 10.1074/jbc.M102778200; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; Fanucci GE, 2003, BIOCHEMISTRY-US, V42, P1391, DOI 10.1021/bi027120z; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ghosh J, 2004, MOL MICROBIOL, V51, P203, DOI 10.1046/j.1365-2958.2003.03816.x; Gunasekaran K, 1997, PROTEIN ENG, V10, P1131, DOI 10.1093/protein/10.10.1131; GUNTER K, 1990, FEBS LETT, V274, P85, DOI 10.1016/0014-5793(90)81335-L; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; HELLER KJ, 1988, GENE, V64, P147, DOI 10.1016/0378-1119(88)90488-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Khursigara CM, 2004, J BIOL CHEM, V279, P7405, DOI 10.1074/jbc.M311784200; Killmann H, 2002, MICROBIOL-SGM, V148, P3497, DOI 10.1099/00221287-148-11-3497; Koedding J, 2004, ACTA CRYSTALLOGR D, V60, P1281, DOI 10.1107/S0907444904009722; Koedding J, 2004, J BIOL CHEM, V279, P9978, DOI 10.1074/jbc.M311720200; LARSEN RA, 1993, MOL MICROBIOL, V10, P943, DOI 10.1111/j.1365-2958.1993.tb00966.x; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Larsen RA, 2001, J BIOL CHEM, V276, P8111, DOI 10.1074/jbc.M007479200; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; Merianos HJ, 2000, NAT STRUCT BIOL, V7, P205; MILLER JH, 1972, EXPT MOL GENETICS, P218; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ogierman M, 2003, J BACTERIOL, V185, P1870, DOI 10.1128/JB.185.6.1870-1885.2003; POSTLE K, 1988, J BIOL CHEM, V263, P11000; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Sauter A, 2003, J BACTERIOL, V185, P5747, DOI 10.1128/JB.185.19.5747-5754.2003; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TRAUB I, 1993, MOL MICROBIOL, V8, P409, DOI 10.1111/j.1365-2958.1993.tb01584.x; Witty M, 2002, EMBO J, V21, P4207, DOI 10.1093/emboj/cdf417	49	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3022	3028		10.1074/jbc.M411155200	http://dx.doi.org/10.1074/jbc.M411155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15522863	Green Published, hybrid			2022-12-25	WOS:000226449100078
J	Li, Q; Ishikawa, T; Miyoshi, H; Oshima, M; Taketo, MM				Li, Q; Ishikawa, T; Miyoshi, H; Oshima, M; Taketo, MM			A targeted mutation of Nkd1 impairs mouse spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE GERM-CELLS; MESSENGER-RIBONUCLEIC-ACID; NAKED-CUTICLE; INTESTINAL POLYPOSIS; PROTOONCOGENE INT-1; MOLECULAR-CLONING; RAT TESTIS; EXPRESSION; GENE; MICE	Nkd1 is an antagonist of the canonical Wnt/beta-catenin signaling pathway. The EF-hand motif of Nkd1 is required for its inhibitory function. Early studies suggested that Nkd1 might play important roles in mouse embryonic development and tumorigenesis. We constructed Nkd1(-/-) mice whose Nkd1 protein lacked the EF-hand and was unable to inhibit Wnt/beta-catenin signaling. The homozygotes were viable and grew normally, but their fertility in males was reduced. In wild-type adult testes, Nkd1 mRNA was expressed more abundantly in the elongating spermatids than in the round spermatids. Lack of EF-hand caused reductions in the testis weight and sperm count by 30 and 60%, respectively. During testis development, Nkd1 mRNA expression started at the 25th day after birth, coincident with the onset of Wnt1 expression. Nuclear localization of beta-catenin increased in the elongating spermatids, suggesting that the mutant Nkd1 failed to inhibit the Wnt/ beta-catenin pathway. These results suggest that deletion of the EF-hand from Nkd1 reduces the number of the elongating spermatids at haploid stage. In contrast, the mutant Nkd1 did not affect intestinal polyposis in Apc(Delta716) mice.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Miyoshi, Hiroyuki/0000-0001-7400-0714				Feige E, 2002, MECH DEVELOP, V117, P369, DOI 10.1016/S0925-4773(02)00217-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Irla M, 2003, GENE EXPR PATTERNS, V3, P135, DOI 10.1016/S1567-133X(03)00024-3; Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9; Katoh M, 2001, INT J ONCOL, V19, P963; Katoh M, 2001, INT J ONCOL, V19, P977; Kirikoshi H, 2002, INT J ONCOL, V21, P895; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; Lee NPY, 2003, BIOL REPROD, V68, P489, DOI 10.1095/biolreprod.102.005793; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MORI C, 1992, BIOL REPROD, V46, P859, DOI 10.1095/biolreprod46.5.859; Ogawa T, 1999, BIOL REPROD, V60, P515, DOI 10.1095/biolreprod60.2.515; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Oshima H, 1997, CANCER RES, V57, P1644; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; PEIFER M, 1994, DEVELOPMENT, V120, P369; Polakis P, 2000, GENE DEV, V14, P1837; QUINN P, 1985, FERTIL STERIL, V44, P493; Rousset R, 2002, J BIOL CHEM, V277, P49019, DOI 10.1074/jbc.M203246200; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Tanaka SS, 2000, GENE DEV, V14, P841; Valentin M, 2000, EUR J BIOCHEM, V267, P5438, DOI 10.1046/j.1432-1327.2000.01603.x; Wang YK, 1999, GENOMICS, V57, P235, DOI 10.1006/geno.1999.5773; Wharton KA, 2001, DEV BIOL, V234, P93, DOI 10.1006/dbio.2001.0238; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615	37	32	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2831	2839		10.1074/jbc.M405680200	http://dx.doi.org/10.1074/jbc.M405680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15546883	hybrid			2022-12-25	WOS:000226449100057
J	Luo, NG; Kaguni, LS				Luo, NG; Kaguni, LS			Mutations in the Spacer region of Drosophila mitochondrial DNA polymerase affect DNA binding, processivity, and the balance between Pol and Exo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CRYSTAL-STRUCTURE; BIOCHEMICAL-CHARACTERIZATION; FRAMESHIFT FIDELITY; ACCESSORY SUBUNIT; CATALYTIC SUBUNIT; 3'-5' EXONUCLEASE; THUMB SUBDOMAIN; ACTIVE-SITE	The catalytic subunit (alpha) of mitochondrial DNA polymerase (poly) shares conserved DNA polymerase and 3'-5' exonuclease active site motifs with Escherichia coli DNA polymerase I and bacteriophage T7 DNA polymerase. A major difference between the prokaryotic and mitochondrial proteins is the size and sequence of the region between the exonuclease and DNA polymerase domains, referred to as the spacer in pol gamma-alpha. Four gamma-specific conserved sequence elements are located within the spacer region of the catalytic subunit in eukaryotic species from yeast to humans. To elucidate the functional roles of the spacer region, we pursued deletion and site-directed mutagenesis of Drosophila poly. Mutant proteins were expressed from baculovirus constructs in insect cells, purified to near homogeneity, and analyzed biochemically. We find that mutations in three of the four conserved sequence elements within the spacer alter enzyme activity, processivity, and/or DNA binding affinity. In addition, several mutations affect differentially DNA polymerase and exonuclease activity and/or functional interactions with mitochondrial single-stranded DNA-binding protein. Based on these results and crystallographic evidence showing that the template-primer binds in a cleft between the exonuclease and DNA polymerase domains in family A DNA polymerases, we propose that conserved sequences within the spacer of pol gamma may position the substrate with respect to the enzyme catalytic domains.	Michigan State Univ, Grad Program Genet, E Lansing, MI 48823 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48823 USA	Michigan State University; Michigan State University	Kaguni, LS (corresponding author), Michigan State Univ, Grad Program Genet, E Lansing, MI 48823 USA.	lskaguni@msu.edu			NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey MF, 2004, J MOL BIOL, V336, P673, DOI 10.1016/j.jmb.2003.11.023; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h; Fansler B S, 1974, Methods Enzymol, V29, P53; Farr Carol L, 2002, Methods Mol Biol, V197, P273, DOI 10.1385/1-59259-284-8:273; Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779; Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Iyengar B, 1999, GENETICS, V153, P1809; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; JOYCE CM, 1982, J BIOL CHEM, V257, P1958; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; Lam WC, 2002, BIOCHEMISTRY-US, V41, P3943, DOI 10.1021/bi0120603; Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278; Lewis DL, 1996, J BIOL CHEM, V271, P23389, DOI 10.1074/jbc.271.38.23389; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tuske S, 2000, J BIOL CHEM, V275, P23759, DOI 10.1074/jbc.M001804200; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang YX, 1999, J BIOL CHEM, V274, P28972, DOI 10.1074/jbc.274.41.28972; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2491	2497		10.1074/jbc.M411447200	http://dx.doi.org/10.1074/jbc.M411447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15537632	hybrid			2022-12-25	WOS:000226449100015
J	Orban-Nemeth, Z; Simader, H; Badurek, S; Trancikova, A; Propst, F				Orban-Nemeth, Z; Simader, H; Badurek, S; Trancikova, A; Propst, F			Microtubule-associated protein 1S, a short and ubiquitously expressed member of the microtubule-associated protein 1 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL NERVOUS-SYSTEM; BINDING DOMAIN; MAP1B; MICE; 1B; CELLS; IDENTIFICATION; STABILIZATION; POLYPROTEIN; DYNAMICS	The related high molecular mass microtubule-associated proteins (MAPs) MAP1A and MAP1B are predominantly expressed in the nervous system and are involved in axon guidance and synaptic function. MAP1B is implicated in fragile X mental retardation, giant axonal neuropathy, and ataxia type 1. We report the functional characterization of a novel member of the microtubule-associated protein 1 family, which we termed MAP1S ( corresponding to sequence data bank entries for VCY2IP1 and C19ORF5). MAP1S contains the three hallmark domains of the microtubule-associated protein 1 family but hardly any additional sequences. It decorates neuronal microtubules and copurifies with tubulin from brain. MAP1S is synthesized as a precursor protein that is partially cleaved into heavy and light chains in a tissue-specific manner. Heavy and light chains interact to form the MAP1S complex. The light chain binds, bundles, and stabilizes microtubules and binds to actin. The heavy chain appears to regulate light chain activity. In contrast to MAP1A and MAP1B, MAP1S is expressed in a wide range of tissues in addition to neurons and represents the non-neuronal counterpart of this cytolinker family.	Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Cell Biol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Propst, F (corresponding author), Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Cell Biol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	friedrich.propst@univie.ac.at	Trancikova, Alzbeta Kralova/X-7402-2018	Trancikova, Alzbeta Kralova/0000-0002-4743-4952; Badurek, Sylvia/0000-0003-0808-2920				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREU JM, 1982, P NATL ACAD SCI-BIOL, V79, P6753, DOI 10.1073/pnas.79.22.6753; Billups D, 2000, J NEUROSCI, V20, P8643; CRAVCHIK A, 1994, J CELL SCI, V107, P661; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; Franzen R, 2001, J CELL BIOL, V155, P893, DOI 10.1083/jcb.200108137; Gonzalez-Billault C, 2000, MOL CELL NEUROSCI, V16, P408, DOI 10.1006/mcne.2000.0880; Gonzalez-Billault C, 2002, BRAIN RES, V943, P56, DOI 10.1016/S0006-8993(02)02534-9; Gonzalez-Billault C, 2001, MOL BIOL CELL, V12, P2087, DOI 10.1091/mbc.12.7.2087; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; Hummel T, 2000, NEURON, V26, P357, DOI 10.1016/S0896-6273(00)81169-1; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Liu LY, 2002, IN VITRO CELL DEV-AN, V38, P582; Lucas FR, 1998, J CELL SCI, V111, P1351; Mack TGA, 2000, MOL CELL NEUROSCI, V15, P51, DOI 10.1006/mcne.1999.0802; Meixner A, 2000, J CELL BIOL, V151, P1169, DOI 10.1083/jcb.151.6.1169; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Noiges R, 2002, J NEUROSCI, V22, P2106, DOI 10.1523/JNEUROSCI.22-06-02106.2002; Pedrotti B, 1996, FEBS LETT, V388, P131, DOI 10.1016/0014-5793(96)00520-0; Pigino G, 1997, J CELL SCI, V110, P257; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; Takei Y, 1997, J CELL BIOL, V137, P1615, DOI 10.1083/jcb.137.7.1615; Togel M, 1999, FEBS LETT, V451, P15, DOI 10.1016/S0014-5793(99)00523-2; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Vaillant AR, 1998, J BIOL CHEM, V273, P13973, DOI 10.1074/jbc.273.22.13973; Wong EYM, 2004, BIOL REPROD, V70, P775, DOI 10.1095/biolreprod.103.018531	32	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2257	2265		10.1074/jbc.M408984200	http://dx.doi.org/10.1074/jbc.M408984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15528209	hybrid			2022-12-25	WOS:000226341700062
J	Robert, J; Clauser, E; Petit, PX; Ventura, MA				Robert, J; Clauser, E; Petit, PX; Ventura, MA			A novel C-terminal motif is necessary for the export of the vasopressin V1b/V3 receptor to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NEPHROGENIC DIABETES-INSIPIDUS; CELL-SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; MOLECULAR-CLONING; QUALITY-CONTROL; ARGININE-VASOPRESSIN; CARBOXYL-TERMINUS; BETA-ARRESTIN	Little is known about endoplasmic reticulum ( ER) export signals, particularly those of members of the G-protein-coupled receptor family. We investigated the structural motifs involved in membrane export of the human pituitary vasopressin V1b/V3 receptor. A series of V3 receptors carrying deletions and point mutations were expressed in AtT20 corticotroph cells. We analyzed the export of these receptors by monitoring radioligand binding and by analysis of a V3 receptor tagged with both green fluorescent protein and Myc epitopes by a novel flow cytometry-based method. This novel method allowed us to quantify total and membrane-bound receptor expression. Receptors lacking the C terminus were not expressed at the cell surface, suggesting the presence of an export motif in this domain. The distal C terminus contains two di-acidic (DXE) ER export motifs; however, mutating both these motifs had no effect on the V3 receptor export. The proximal C terminus contains a di-leucine (LL346)-L-345 motif surrounded by the hydrophobic residues Phe(341), Asn(342), and Leu(350). The mutation of one or more of these five residues abolished up to 100% of the receptor export. In addition, these mutants colocalized with calnexin, demonstrating that they were retained in the ER. Finally, this motif was sufficient to confer export properties on a CD8alpha glycoprotein-V3 receptor chimera. In conclusion, we have identified a novel export motif, FN(X)(2)LL(X)(3)L, in the C terminus of the V3 receptor.	Univ Paris 05, Inst Cochin Genet Mol, INSERM U567, CNRS UMR8104,Dept Endocrinol, F-75014 Paris, France; Univ Paris 05, Inst Cochin Genet Mol, INSERM U567, CNRS UMR8104,Dept Genet Dev & Pathol Mol, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ventura, MA (corresponding author), Univ Paris 05, Inst Cochin Genet Mol, INSERM U567, CNRS UMR8104,Dept Endocrinol, F-75014 Paris, France.	ventura@cochin.inserm.fr	PETIT, Patrice/A-4453-2008; Petit, patrice/AAF-6774-2020; Petit, Patrice X./A-3692-2009	Petit, Patrice X./0000-0002-5038-9101				Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Berrada K, 2000, J BIOL CHEM, V275, P27229; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; Birnbaumer M, 2000, TRENDS ENDOCRIN MET, V11, P406, DOI 10.1016/S1043-2760(00)00304-0; Chen JX, 2003, J HUM GENET, V48, P217, DOI 10.1007/s10038-003-0012-8; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DEKEYZER Y, 1994, FEBS LETT, V356, P215, DOI 10.1016/0014-5793(94)01268-7; Derick S, 2002, ENDOCRINOLOGY, V143, P4655, DOI 10.1210/en.2002-220363; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Duvernay MT, 2004, J BIOL CHEM, V279, P30741, DOI 10.1074/jbc.M313881200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Erdtmann L, 2000, TRAFFIC, V1, P871, DOI 10.1034/j.1600-0854.2000.011106.x; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Heymann JAW, 1997, P NATL ACAD SCI USA, V94, P4966, DOI 10.1073/pnas.94.10.4966; Houry WA, 2001, CURR PROTEIN PEPT SC, V2, P227, DOI 10.2174/1389203013381134; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Iodice L, 2001, J BIOL CHEM, V276, P28920, DOI 10.1074/jbc.M103558200; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Krause G, 2000, MOL PHARMACOL, V57, P232; Liang ZM, 2004, BIOCHEM J, V380, P43, DOI 10.1042/BJ20031788; Luttrell LM, 2002, J CELL SCI, V115, P455; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pankevych H, 2003, J BIOL CHEM, V278, P30283, DOI 10.1074/jbc.M212918200; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Sadeghi HM, 1997, MOL ENDOCRINOL, V11, P706, DOI 10.1210/me.11.6.706; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; Tanoue A, 2004, J CLIN INVEST, V113, P302, DOI 10.1172/JCI200419656; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Thibonnier M, 2001, AM J PHYSIOL-ENDOC M, V281, pE81, DOI 10.1152/ajpendo.2001.281.1.E81; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Ventura MA, 1999, J MOL ENDOCRINOL, V22, P251, DOI 10.1677/jme.0.0220251	47	65	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2300	2308		10.1074/jbc.M410655200	http://dx.doi.org/10.1074/jbc.M410655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15528211	hybrid			2022-12-25	WOS:000226341700067
J	Suto, K; Yamazaki, Y; Morita, T; Mizuno, H				Suto, K; Yamazaki, Y; Morita, T; Mizuno, H			Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms - Insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; KDR; PROGRAM; COMPLEX	Vascular endothelial growth factor-A (VEGF-A(165)) exerts multiple effects upon binding to the fms-like tyrosine kinase-1 (Flt-1) and the kinase insert domain-containing receptor (KDR). We recently identified two novel snake venom VEGFs (vammin and VR-1) having unique properties. These VEGFs, designated VEGF-Fs, are highly specific ligands for the kinase insert domain-containing receptor and exhibit potent biological activity both in vitro and in vivo when compared with VEGF-A(165). Here, we solved the crystal structures of vammin and VR-1 at 1.9 and 2.0 Angstrom resolutions, respectively. Both structures are very similar to each other, and these structures exhibit similar but significantly different features from the known structures of other VEGFs. These differences include a conformational difference in receptor-binding loop 3 caused by an amino acid residue insertion and a difference in surface potential on the possible binding surface for domain 3 of the receptor. These structural differences may be related to the highly selective ligand properties of VEGF-F.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan; Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan	Meiji Pharmaceutical University; National Institute of Agrobiological Sciences - Japan	Morita, T (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, 2-522-1 Noshio, Tokyo 2048588, Japan.	tmorita@my-pharm.ac.jp; mizuno@affrc.go.jp		Yamazaki, Yasuo/0000-0001-5297-9837				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kiba A, 2003, J BIOL CHEM, V278, P13453, DOI 10.1074/jbc.M210931200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 2003, J BIOL CHEM, V278, P38004, DOI 10.1074/jbc.M301194200; Yamazaki Y, 2003, J BIOL CHEM, V278, P51985, DOI 10.1074/jbc.C300454200	22	78	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2126	2131		10.1074/jbc.M411395200	http://dx.doi.org/10.1074/jbc.M411395200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15542594	hybrid			2022-12-25	WOS:000226341700047
J	Uren, RT; Dewson, G; Bonzon, C; Lithgow, T; Newmeyer, DD; Kluck, RM				Uren, RT; Dewson, G; Bonzon, C; Lithgow, T; Newmeyer, DD; Kluck, RM			Mitochondrial release of pro-apoptotic proteins - Electrostatic interactions can hold cytochrome c but not Smac/DIABLO to mitochondrial membranes*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE APOPTOSIS; CASPASE ACTIVATION; OUTER-MEMBRANE; IONIC-STRENGTH; YEAST MITOCHONDRIA; EGG EXTRACTS; BINDING; BAX; CARDIOLIPIN; IMPORT	A key step in the initiation of apoptosis is the release from the mitochondrial intermembrane space of cytochrome c and other pro-apoptotic proteins such as Smac/DIABLO, Omi/HtrA2, apoptosis-inducing factor (AIF), and endonuclease G (EndoG). Discrepancies have arisen, however, as to whether all these proteins are released in different systems. Our results suggest that failure to observe cytochrome c release may be due to the use of different buffers because after permeabilization by caspase-8 cleaved human Bid (tBid), cytochrome c dissociation from mitochondria was highly dependent on ionic strength and required 50 - 80 mM KCl, NaCl, or LiCl. In addition, mitochondria isolated from apoptotic cells using low ionic strength buffer bound a greater proportion of endogenous cytochrome c. In contrast to cytochrome c, Smac/DIABLO and Omi/HtrA2 were released independent of ionic strength, and AIF and EndoG behaved as if they are exposed to the intermembrane space but tethered to or within the inner membrane. AIF and EndoG were also not released by active caspases, which suggests their involvement in apoptosis may be limited. In summary, whereas tBid permeabilizes the outer membrane to cytochrome c, Smac/DIABLO, and Omi/HtrA2, the release of cytochrome c during apoptosis will be underestimated unless sufficient ionic strength is maintained to overcome the electrostatic association of cytochrome c with membranes.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Melbourne, Vic 3010, Australia	Walter & Eliza Hall Institute; La Jolla Institute for Immunology; University of Melbourne	Kluck, RM (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	kluck@wehi.edu.au	dewson, grant/C-7646-2013; Kluck, Ruth M/C-8413-2013; Lithgow, Trevor J/H-5925-2017	dewson, grant/0000-0003-4251-8898; Kluck, Ruth M/0000-0002-7101-1925; Lithgow, Trevor J/0000-0002-0102-7884; Uren, Rachel/0000-0001-7456-478X				Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2003, CELL DEATH DIFFER, V10, P845, DOI 10.1038/sj.cdd.4401240; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; BOYER CS, 1994, BBA-BIOMEMBRANES, V1190, P304, DOI 10.1016/0005-2736(94)90088-4; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; CORTESE JD, 1991, J CELL BIOL, V113, P1331, DOI 10.1083/jcb.113.6.1331; Cozzolino M, 2004, CELL DEATH DIFFER, V11, P1179, DOI 10.1038/sj.cdd.4401476; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; EILENBERG H, 1989, J LIPID RES, V30, P1127; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GONI FM, 1985, BIOCHIM BIOPHYS ACTA, V835, P549, DOI 10.1016/0005-2760(85)90124-9; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; Hampton MB, 1998, BIOCHEM J, V329, P95; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; JACOBS EE, 1960, J BIOL CHEM, V235, P531; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KOPPENOL WH, 1978, BIOCHIM BIOPHYS ACTA, V503, P499, DOI 10.1016/0005-2728(78)90149-4; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LITHGOW T, 1993, FEBS LETT, V332, P277, DOI 10.1016/0014-5793(93)80649-F; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; MOCHAN E, 1972, BIOCHIM BIOPHYS ACTA, V267, P309, DOI 10.1016/0005-2728(72)90119-3; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Purring-Koch C, 2000, P NATL ACAD SCI USA, V97, P11928, DOI 10.1073/pnas.220416197; Robertson JD, 2003, CELL DEATH DIFFER, V10, P485, DOI 10.1038/sj.cdd.4401218; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; von Ahsen O, 2000, METHOD ENZYMOL, V322, P183; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Waterhouse Nigel J, 2004, Methods Mol Biol, V284, P307; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Waterhouse NJ, 2001, METHOD CELL BIOL, V66, P365; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhang XD, 2001, CANCER RES, V61, P7339	54	134	139	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2266	2274		10.1074/jbc.M411106200	http://dx.doi.org/10.1074/jbc.M411106200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15537572	hybrid			2022-12-25	WOS:000226341700063
J	Zhang, YW; Su, YL; Lanning, N; Gustafson, M; Shinomiya, N; Zhao, P; Cao, B; Tsarfaty, G; Wang, LM; Hay, R; Vande Woude, GF				Zhang, YW; Su, YL; Lanning, N; Gustafson, M; Shinomiya, N; Zhao, P; Cao, B; Tsarfaty, G; Wang, LM; Hay, R; Vande Woude, GF			Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor	ONCOGENE			English	Article						human HGF/SF; met; transgenic; SCID; tumor xenograft	SCATTER-FACTOR; ANTITUMOR-ACTIVITY; METASTASIS; MOTILITY; INVASION; CELLS; TUMORIGENICITY; NETWORK; MOUSE	Downstream signaling that results from the interaction of hepatocyte growth factor/scatter factor (HGF/SF) with the receptor tyrosine kinase Met plays critical roles in tumor development, progression, and metastasis. This ligand-receptor pair is an attractive target for new diagnostic and therapeutic agents, preclinical development of which requires suitable animal models. The growth of heterotopic and orthotopic Met-expressing human tumor xenografts in conventional strains of immunocompromised mice inadequately replicates the paracrine stimulation by human HGF/SF (hHGF/SF) that occurs in humans with cancer. We have therefore generated a mouse strain transgenic for hHGF/SF (designated hHGF-Tg) on a severe combined immunodeficiency (SCID) background. We report here that the presence of ectopically expressed hHGF/SF ligand significantly enhances growth of heterotopic subcutaneous xenografts derived from human Met-expressing cancer cells, including the lines SK-LMS-1 (human leiomyosarcoma), U118 (human glioblastoma), and DU145 (human prostate carcinoma), but not that of M14-Mel xenografts (human melanoma that expresses insignificant levels of Met). Our results indicate that ectopic hHGF/SF can specifically activate Met in human tumor xenografts. This new hHGF-Tg strain of mice should provide a powerful tool for evaluating drugs and diagnostic agents that target the various pathways influenced by Met activity.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Van Andel Res Inst, Lab Antibody Technol, Grand Rapids, MI 49503 USA; Chaim Sheba Med Ctr, Tel Aviv, Israel; Vita Genom Inc, Taipei, Taiwan	Van Andel Institute; Van Andel Institute; Chaim Sheba Medical Center; Vita Genomics Incorporated	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	george.vandewoude@vai.org	Lanning, Nathan/AAI-2532-2019; Shinomiya, Nariyoshi/I-9666-2014	Lanning, Nathan/0000-0002-0983-7451; 				Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BOCK TA, 1995, J EXP MED, V182, P2037, DOI 10.1084/jem.182.6.2037; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Christensen JG, 2003, CANCER RES, V63, P7345; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kerbel RS, 2003, CANCER BIOL THER, V2, pS134; Koochekpour S, 1997, CANCER RES, V57, P5391; MUELLER BM, 1991, CANCER METAST REV, V10, P193, DOI 10.1007/BF00050791; Qian CN, 2003, J UROLOGY, V170, P994, DOI 10.1097/01.ju.0000080321.99119.df; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Webb CP, 2000, CANCER RES, V60, P342; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	21	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					101	106		10.1038/sj.onc.1208181	http://dx.doi.org/10.1038/sj.onc.1208181			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531925				2022-12-25	WOS:000226125800012
J	Nyberg, P; Rasmussen, M; Bjorck, L				Nyberg, P; Rasmussen, M; Bjorck, L			alpha(2)-macroglobulin-proteinase complexes protect Streptococcus pyogenes from killing by the antimicrobial peptide LL-37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CYSTEINE PROTEASE; COMMON PATHOGENIC BACTERIA; PROTEINASES; PROTEOLYSIS; SURFACE; SPECIFICITY; VIRULENCE; CLEAVAGE; SEQUENCE; BINDING	The significant human bacterial pathogen Streptococcus pyogenes expresses GRAB, a surface protein that binds alpha(2)-macroglobulin (alpha(2)M), a major proteinase inhibitor of human plasma. alpha(2)M inhibits proteolysis by trapping the proteinase, which, however, still remains proteolytically active against smaller peptides that can penetrate the alpha(2)M-proteinase complex. Here we report that SpeB, a cysteine proteinase secreted by S. pyogenes, is trapped by alpha(2)M bound to protein GRAB. As a consequence, SpeB is retained at the bacterial surface and protects S. pyogenes against killing by the antibacterial peptide LL-37.	Lund Univ, BMC, Dept Cell & Mol Biol, Sect Clin & Expt Infect Med, S-22184 Lund, Sweden	Lund University	Nyberg, P (corresponding author), Lund Univ, BMC, Dept Cell & Mol Biol, Sect Clin & Expt Infect Med, B14,Tornavagen 10, S-22184 Lund, Sweden.	Patrik.Nyberg@medkem.lu.se		Rasmussen, Magnus/0000-0003-1588-5473				Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Budd A, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r38; Collin M, 2001, INFECT IMMUN, V69, P7187, DOI 10.1128/IAI.69.11.7187-7189.2001; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; ELLIOTT SD, 1945, J EXP MED, V81, P573, DOI 10.1084/jem.81.6.573; Frick IM, 2003, J BIOL CHEM, V278, P16561, DOI 10.1074/jbc.M301995200; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; KAPUR V, 1993, P NATL ACAD SCI USA, V90, P7676, DOI 10.1073/pnas.90.16.7676; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; MULLER HP, 1995, INFECT IMMUN, V63, P2833; Musser JM, 1996, INFECT IMMUN, V64, P1913, DOI 10.1128/IAI.64.6.1913-1917.1996; Nomizu M, 2001, J BIOL CHEM, V276, P44551, DOI 10.1074/jbc.M106306200; Nyberg P, 2004, MICROBIOL-SGM, V150, P1559, DOI 10.1099/mic.0.27076-0; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Rasmussen M, 2002, MOL MICROBIOL, V43, P537, DOI 10.1046/j.1365-2958.2002.02766.x; Rasmussen M, 1999, J BIOL CHEM, V274, P15336, DOI 10.1074/jbc.274.22.15336; Schmidtchen A, 2002, MOL MICROBIOL, V46, P157, DOI 10.1046/j.1365-2958.2002.03146.x; Schmidtchen A, 2001, MOL MICROBIOL, V39, P708, DOI 10.1046/j.1365-2958.2001.02251.x; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Toppel AW, 2003, J INFECT DIS, V187, P1694, DOI 10.1086/375029; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147	27	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52820	52823		10.1074/jbc.C400485200	http://dx.doi.org/10.1074/jbc.C400485200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15520011	hybrid			2022-12-25	WOS:000225680600005
J	Kilic, E; Kilic, U; Soliz, J; Bassetti, CL; Gassmann, M; Hermann, DM				Kilic, E; Kilic, U; Soliz, J; Bassetti, CL; Gassmann, M; Hermann, DM			Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways	FASEB JOURNAL			English	Article						neuroprotection; mitogen-activated protein kinase; phosphatidyl inositol-3 kinase; NO synthase	MICE OVEREXPRESSING ERYTHROPOIETIN; ARTERY-OCCLUSION; RETINAL DEGENERATION; NEURONAL APOPTOSIS; NITRIC-OXIDE; CELL-DEATH; INJURY; KINASE; NEUROPROTECTION; EXPRESSION	Apart from its hematopoietic function, erythropoietin (Epo) exerts neuroprotective functions in brain hypoxia and ischemia. To examine the mechanisms mediating Epo's neuroprotective activity in vivo, we made use of our transgenic mouse line tg21 that constitutively expresses human Epo in brain without inducing excessive erythrocytosis. We show that human Epo is expressed in tg21 brains and that cortical and striatal neurons carry the Epo receptor. After middle cerebral artery occlusion, human Epo potently protected brains of tg21 mice against ischemic injury, both when severe (90 min) and mild (30 min) ischemia was imposed. Histochemical studies revealed that Epo induced an activation of JAK-2, ERK-1/-2, and Akt pathways in the ischemic brain. This activation was associated with elevated Bcl-X-L and decreased NO synthase-1 and -2 levels in neurons. Intracerebroventricular injections of selective inhibitors of ERK-1/-2 (PD98059) or Akt (wortmannin) pathways revealed that both ERK-1/-2 and Akt were required for Epo's neuroprotective function, antagonization of either pathway completely abolishing tissue protection. On the other hand, ERK-1/-2 and Akt blockade did not reverse the neuronal NO synthase-1/-2 inhibition, indicating that Epo down-regulates these NO synthases in an ERK-1/-2 and Akt independent manner. On the basis of our data, the dual activation of ERK-1/-2 and Akt is crucial for Epo's neuroprotective activity.	Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich	Kilic, E (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	ertugrul.kilic@usz.ch	Hermann, Dirk/GZB-9350-2022; Hermann, Dirk M/AAP-5538-2020; Hermann, Dirk M./AAT-3652-2021; Soliz, Jorge/AAA-9752-2022; Kilic, Ertugrul/W-4563-2018	Hermann, Dirk M./0000-0003-0198-3152; Kilic, Ertugrul/0000-0001-6494-8923; Soliz, Jorge/0000-0002-2335-5862; Bassetti, Claudio/0000-0002-4535-0245; Gassmann, Max/0000-0003-2750-8878				Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2005, SEMIN CELL DEV BIOL, V16, P531, DOI 10.1016/j.semcdb.2005.03.004; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hermann DM, 2001, NEUROBIOL DIS, V8, P655, DOI 10.1006/nbdi.2001.0399; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Hudson JQ, 2002, PHARMACOTHERAPY, V22, p141S, DOI 10.1592/phco.22.14.141S.33397; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Macdougall Iain C, 2003, Curr Hematol Rep, V2, P459; Maeda K, 1999, NEUROBIOL DIS, V6, P101, DOI 10.1006/nbdi.1998.0235; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Wang YM, 2005, BRAIN, V128, P52, DOI 10.1093/brain/awh325; Wenger RH, 1998, INT J MOL MED, V2, P317; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011	37	239	269	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2026	+		10.1096/fj.05-3941fje	http://dx.doi.org/10.1096/fj.05-3941fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	15556972				2022-12-25	WOS:000232991100027
J	Nunes, AF; Saraiva, MJ; Sousa, MM				Nunes, AF; Saraiva, MJ; Sousa, MM			Transthyretin knockouts are a new mouse model for increased neuropeptide Y	FASEB JOURNAL			English	Article						lipoprotein lipase; peptidylglycine alpha-amidating monooxygenase; peripheral nerve; depression	VASOACTIVE INTESTINAL POLYPEPTIDE; DORSAL-ROOT GANGLIA; MESSENGER-RNA; LIPOPROTEIN-LIPASE; EXPRESSION; PEPTIDE; CELLS; MONOOXYGENASE; RECEPTOR; BEHAVIOR	Transthyretin (TTR) has access to the brain and nerve through the blood and cerebrospinal fluid. To investigate TTR function in nervous system homeostasis, differential gene expression in wild-type (WT) and TTR knockout ( KO) mice was assessed. Peptidylglycine alpha-amidating monooxygenase (PAM), the rate-limiting enzyme in neuropeptide maturation, is overexpressed in the peripheral (PNS) and central nervous system (CNS) of TTR KOs that, consequently, display increased neuropeptide Y (NPY) levels. NPY acts on energy homeostasis by increasing white adipose tissue lipoprotein lipase (LPL) and decreasing thermogenesis; accordingly, we show increased LPL expression and activity in white adipose tissue, PNS, and CNS as well as decreased body temperature in TTR KOs. Associated to increased NPY levels, TTR KOs display increased carbohydrate consumption and preference. In neuronal cells, absence of TTR is related to increased PAM activity, NPY levels and LPL expression, reinforcing that TTR is involved in neuropeptide maturation and that increased NPY correlates with LPL overexpression in the nervous system. Furthermore, we provide molecular insights to the reduced depressive behavior of TTR KOs, as NPY is anti-depressant. Our findings demonstrate that TTR KOs are a model for increased NPY and that TTR plays a role in nervous system physiology.	Inst Mol & Cellular Biol, Mol Neurobiol Grp, P-4150180 Oporto, Portugal; Univ Porto, ICBAS, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Sousa, MM (corresponding author), Inst Mol & Cellular Biol, Mol Neurobiol Grp, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	msousa@ibmc.up.pt	Sousa, Monica/K-4367-2013; Saraiva, Maria João/K-3907-2013	Sousa, Monica/0000-0002-4524-2260; Saraiva, Maria João/0000-0002-3360-6899				BILLINGTON CJ, 1994, AM J PHYSIOL, V266, pR1765, DOI 10.1152/ajpregu.1994.266.6.R1765; Chen XL, 1997, AM J PHYSIOL-HEART C, V273, pH1737, DOI 10.1152/ajpheart.1997.273.4.H1737; Cougnon-Aptel N, 1999, NEUROSCI LETT, V259, P45, DOI 10.1016/S0304-3940(98)00900-8; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; ERNSTROM U, 1995, FEBS LETT, V360, P177, DOI 10.1016/0014-5793(95)00095-Q; ESTEBAN J, 1989, LIFE SCI, V45, P2395, DOI 10.1016/0024-3205(89)90002-7; FORD TA, 1993, J MOL NEUROSCI, V4, P97, DOI 10.1007/BF02782122; Fraboulet S, 1996, ENDOCRINOLOGY, V137, P5493, DOI 10.1210/en.137.12.5493; Heilig M, 2004, NEUROPEPTIDES, V38, P213, DOI 10.1016/j.npep.2004.05.002; HEILIG M, 1988, EUR J PHARMACOL, V147, P465, DOI 10.1016/0014-2999(88)90182-3; Herzog H, 2003, EUR J PHARMACOL, V480, P21, DOI 10.1016/j.ejphar.2003.08.089; Hiruma H, 2000, BRAIN RES, V883, P184, DOI 10.1016/S0006-8993(00)02892-4; Huey PU, 2002, J LIPID RES, V43, P19; Huey PU, 1998, J LIPID RES, V39, P2135; Inui A, 1998, P ASSOC AM PHYSICIAN, V110, P171; Kohno K, 1997, AM J PATHOL, V150, P1497; Liz MA, 2004, J BIOL CHEM, V279, P21431, DOI 10.1074/jbc.M402212200; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; Pedrazzini T, 2003, CELL MOL LIFE SCI, V60, P350, DOI 10.1007/s000180300029; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; PULFORD D, 2002, SOC NEUR 32 ANN M WA; RAZ A, 1969, J BIOL CHEM, V244, P3230; Redrobe JP, 2002, NEUROPSYCHOPHARMACOL, V26, P615, DOI 10.1016/S0893-133X(01)00403-1; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; Saegusa T, 2003, J VET MED SCI, V65, P1365, DOI 10.1292/jvms.65.1365; Serot JM, 1997, J NEUROL NEUROSUR PS, V63, P506, DOI 10.1136/jnnp.63.4.506; Shi TJS, 1999, NEUROSCIENCE, V93, P741; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; Sousa JC, 2004, J NEUROCHEM, V88, P1052, DOI 10.1046/j.1471-4159.2003.02309.x; Sousa MM, 2003, PROG NEUROBIOL, V71, P385, DOI 10.1016/j.pneurobio.2003.11.002; Sousa MM, 2000, J LIPID RES, V41, P58; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; SPINDEL ER, 1987, GEN COMP ENDOCR, V67, P67, DOI 10.1016/0016-6480(87)90206-1; STENFORS C, 1989, J NEUROSCI RES, V24, P445, DOI 10.1002/jnr.490240315; Stogner KA, 2000, EUR J PHARMACOL, V387, pR9, DOI 10.1016/S0014-2999(99)00800-6; Sunman JA, 2004, MOL CARCINOGEN, V41, P231, DOI 10.1002/mc.20060; THEODORSSONNORHEIM E, 1987, LIFE SCI, V41, P845, DOI 10.1016/0024-3205(87)90177-9; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Thorsell A, 2000, P NATL ACAD SCI USA, V97, P12852, DOI 10.1073/pnas.220232997; Valenzuela RF, 2000, J NEUROL SCI, V173, P140, DOI 10.1016/S0022-510X(99)00316-0; Vasquez PAJ, 2000, BEHAV BRAIN RES, V111, P115, DOI 10.1016/S0166-4328(00)00142-X; White DM, 1996, NEUROSCIENCE, V73, P881, DOI 10.1016/0306-4522(96)00055-3; WIDDOWSON PS, 1992, J NEUROCHEM, V59, P73, DOI 10.1111/j.1471-4159.1992.tb08877.x; WIDERLOV E, 1988, J PSYCHIATR RES, V22, P69, DOI 10.1016/0022-3956(88)90030-1; ZACHRISSON O, 1995, NEUROSCI LETT, V194, P89, DOI 10.1016/0304-3940(95)11735-F	45	64	70	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					166	+		10.1096/fj.05-4106fje	http://dx.doi.org/10.1096/fj.05-4106fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16263939				2022-12-25	WOS:000234053100022
